<SEC-DOCUMENT>0001213900-22-057479.txt : 20221031
<SEC-HEADER>0001213900-22-057479.hdr.sgml : 20221031
<ACCEPTANCE-DATETIME>20220920172901
ACCESSION NUMBER:		0001213900-22-057479
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		83
FILED AS OF DATE:		20220920
DATE AS OF CHANGE:		20220920

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Silo Pharma, Inc.
		CENTRAL INDEX KEY:			0001514183
		STANDARD INDUSTRIAL CLASSIFICATION:	APPAREL & OTHER FINISHED PRODS OF FABRICS & SIMILAR MATERIAL [2300]
		IRS NUMBER:				462137136
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-261532
		FILM NUMBER:		221254570

	BUSINESS ADDRESS:	
		STREET 1:		560 SYLVAN AVE
		STREET 2:		SUITE 3160
		CITY:			ENGLEWOOD CLIFFS
		STATE:			NJ
		ZIP:			07632
		BUSINESS PHONE:		(718) 400-9031

	MAIL ADDRESS:	
		STREET 1:		560 SYLVAN AVE
		STREET 2:		SUITE 3160
		CITY:			ENGLEWOOD CLIFFS
		STATE:			NJ
		ZIP:			07632

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Uppercut Brands, Inc.
		DATE OF NAME CHANGE:	20190808

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Point Capital, Inc.
		DATE OF NAME CHANGE:	20130130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Gold Swap Inc
		DATE OF NAME CHANGE:	20110301
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>ea165987-s1a4_silopharma.htm
<DESCRIPTION>AMENDMENT NO. 4 TO FORM S-1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:silo="http://silopharma.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml"><head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">As filed with the Securities and Exchange
Commission on September 20, 2022.</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><b>Registration Statement
No. 333-261532</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>WASHINGTON, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:AmendmentDescription"><b style="-keep: true">AMENDMENT No. 4</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>to</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <span style="-sec-ix-hidden: hidden-fact-0">S-1</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>REGISTRATION STATEMENT
UNDER<br/>
THE SECURITIES ACT OF 1933</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><b>SILO PHARMA, INC.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>(Exact name of Registrant
as specified in its charter)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 2%; text-align: center">&#160;</td> <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b>2834</b></span></td> <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 2%; text-align: center">&#160;</td> <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b>27-3046338</b></span></td></tr> <tr> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><i>(State or other jurisdiction of&#160;<br/> incorporation or organization)</i></span></td> <td style="vertical-align: bottom; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><i>(Primary Standard Industrial<br/> Classification Code Number)</i></span></td> <td style="vertical-align: bottom; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><i>(I.R.S. Employer<br/> Identification No.)</i></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>560 Sylvan Avenue,
Suite 3160</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Englewood Cliffs,
NJ 07632</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(718) 400-9031</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>(Address and telephone
number of principal executive offices)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Eric Weisblum</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Chief Executive Officer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>560 Sylvan Avenue,
Suite 3160</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Englewood Cliffs,
NJ 07632</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(718) 400-9031</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>(Name, address and
telephone number of agent for service)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Copies to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 51%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Richard A. Friedman,
                           Esq.</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Gregory R. Carney, Esq.</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Sheppard, Mullin, Richter &amp; Hampton
    LLP</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>30 Rockefeller Plaza</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>New York, NY 10112</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(212) 653-8700</b></p></td>
    <td style="width: 1%; font-size: 10pt; text-align: center">&#160;</td>
    <td style="width: 48%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Barrett DiPaolo,
                           Esq.</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Sichenzia Ross Ference LLP</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>1185 Avenue of the Americas</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>New York, NY 10036</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(212) 930-9700</b></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Approximate Date of Commencement of Proposed
Sale to the Public:</b>&#160;As soon as practicable after the effective date of this registration statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the securities being registered
on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following
box. <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment
filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number
of the earlier effective registration statement for the same offering. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment
filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number
of the earlier effective registration statement for the same offering. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%">&#160;</td> <td style="text-align: justify; width: 25%"><span style="font-size: 10pt">Large accelerated filer</span></td> <td style="width: 10%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 30%; text-align: justify"><span style="font-size: 10pt">Accelerated filer</span></td> <td style="width: 30%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory"><span style="font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Smaller reporting company</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td colspan="2">&#160;</td> <td style="text-align: justify"><span style="font-size: 10pt">Emerging growth company</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities Act <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file&#160;a further amendment
which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of
the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and
Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The information in this preliminary
prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities
and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an
offer to buy these securities in any state or jurisdiction where the offer or sale is not permitted.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">SUBJECT TO COMPLETION, DATED SEPTEMBER 20,
2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>PRELIMINARY PROSPECTUS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Silo Pharma, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">588,236 Shares of Common Stock</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">This prospectus relates to the sale by Silo
Pharma, Inc. (the &#8220;Company&#8221; or &#8220;Silo Pharma&#8221;) of 588,236&#160;shares of common stock of (the &#8220;Common Stock&#8221;),
at an assumed public offering price of $8.50 per share of common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have applied to list our common stock on
the Nasdaq Capital Market upon our satisfaction of the exchange&#8217;s initial listing criteria. If our common stock is not approved
for listing on the Nasdaq Capital Market, we will not consummate this offering. No assurance can be given that our application will be
approved.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Our common stock is currently trading on the
OTCQB Venture Market (the &#8220;OTCQB&#8221;) under the symbol &#8220;SILO.&#8221; The last reported sale price for our common stock
as reported on the OTCQB on September 16, 2022 was $8.50 per share. For the purposes of this prospectus, we have assumed a public offering
price of $8.50 per share. The actual public offering price per share will be determined between us and the underwriter at the time of
pricing and may be at a discount to the current market price. Therefore, the assumed public offering price used throughout this prospectus
may not be indicative of the final offering price.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The public offering price per share of our
common stock will be determined between us, the underwriter and investors based on market conditions at the time of pricing, and may
be at a discount to the current market price of our common stock. Therefore, the recent market price used throughout this prospectus
may not be indicative of the actual combined public offering price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Investing in our securities is highly speculative
and involves a high degree of risk. You should carefully consider the risks and uncertainties described under the heading &#8220;Risk
Factors&#8221; beginning on page 5 of this prospectus before making a decision to purchase our securities.</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NEITHER THE SECURITIES AND EXCHANGE COMMISSION
NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS.
ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Per Share</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Total</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%"><span style="font-size: 10pt">Public offering price</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right">&#160;&#160;&#160;&#160;&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Underwriting discounts and commissions (1)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td/></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Proceeds to us, Inc. before expenses</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.25in">(1)</td><td style="text-align: justify">Reflects underwriting discounts
                                            and commissions to the underwriter of $___, or eight percent (8.0%) per share. We have also
                                            agreed to issue the representative of the underwriters or its designees five-year warrants
                                            to purchase a number of shares of common stock equal to 5.0% of the shares of common stock
                                            sold in this offering and to reimburse the underwriters for certain offering-related expenses.
                                            In addition, we have agreed to pay a management fee to the Representative equal to 1% of
                                            the gross proceeds received in this offering (excluding proceeds received from exercise of
                                            the underwriters&#8217; over-allotment option) which is not included in the underwriting
                                            discounts and commission.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company has granted a 45&#160;day option to
the underwriter to purchase up to an additional 88,236 shares of common stock, from us at the public offering price, less the underwriting
discount, to cover over-allotments, if any.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter expects to deliver the shares
to purchasers in the offering on or about&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Laidlaw &amp; Company (UK) Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The date of this prospectus is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2022.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ABOUT THIS PROSPECTUS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this prospectus, unless the context suggests
otherwise, references to &#8220;the Company,&#8221; &#8220;Silo Pharma,&#8221; &#8220;SILO,&#8221; &#8220;we,&#8221; &#8220;us,&#8221;
and &#8220;our&#8221; refer to Silo Pharma, Inc. and its consolidated subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus describes the specific details
regarding this offering, the terms and conditions of the common stock being offered hereby and the risks of investing in the Company&#8217;s
common stock. You should read this prospectus and the additional information about the Company described in the section entitled &#8220;Where
You Can Find More Information&#8221; before making your investment decision.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither the Company, nor any of its officers,
directors, agents, representatives or underwriters, make any representation to you about the legality of an investment in the Company&#8217;s
common stock. You should not interpret the contents of this prospectus to be legal, business, investment or tax advice. You should consult
with your own advisors for that type of advice and consult with them about the legal, tax, business, financial and other issues that
you should consider before investing in the Company&#8217;s common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ADDITIONAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information contained
in this prospectus and in any accompanying prospectus supplement. No one has been authorized to provide you with different or additional
information. The shares of common stock are not being offered in any jurisdiction where the offer is not permitted. You should not assume
that the information in this prospectus or any prospectus supplement is accurate as of any date other than the date on the front of such
documents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TRADEMARKS AND TRADE NAMES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus includes trademarks that are
protected under applicable intellectual property laws and are the Company&#8217;s property or the property of one of the Company&#8217;s
subsidiaries. This prospectus also contains trademarks, service marks, trade names and/or copyrights of other companies, which are the
property of&#160;their respective owners. Solely for convenience, trademarks and trade names referred to in this prospectus may appear
without the &#174; or TM symbols, but such references are not intended to indicate, in any way, that the Company will not assert, to the
fullest extent under applicable law, its rights or the right of the applicable licensor to these trademarks and trade names.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDUSTRY AND MARKET DATA</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, information contained
in this prospectus concerning the Company&#8217;s industry and the markets in which it operates, including market position and market
opportunity, is based on information from management&#8217;s estimates, as well as from industry publications and research, surveys and
studies conducted by third parties. The third-party sources from which the Company has obtained information generally state that the
information contained therein has been obtained from sources believed to be reliable, but the Company cannot assure you that this information
is accurate or complete. The Company has not independently verified any of the data from third-party sources nor has it verified the
underlying economic assumptions relied upon by those third parties. Similarly, internal company surveys, industry forecasts and market
research, which the Company believes to be reliable, based upon management&#8217;s knowledge of the industry, have not been verified
by any independent sources. The Company&#8217;s internal surveys are based on data it has collected over the past several years, which
it believes to be reliable. Management estimates are derived from publicly available information, its knowledge of the industry, and
assumptions based on such information and knowledge, which management believes to be reasonable and appropriate. However, assumptions
and estimates of the Company&#8217;s future performance, and the future performance of its industry, are subject to numerous known and
unknown risks and uncertainties, including those described under the heading &#8220;Risk Factors&#8221; in this prospectus and those
described elsewhere in this prospectus, and the other documents the Company files with the Securities and Exchange Commission, or SEC,
from time to time. These and other important factors could result in its estimates and assumptions being materially different from future
results. You should read the information contained in this prospectus completely and with the understanding that future results may be
materially different and worse from what the Company expects. See the information included under the heading &#8220;Forward-Looking Statements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; width: 90%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center"><span style="font-size: 10pt"><b>Page
    No.</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-size: 10pt"><a href="#a_001">PROSPECTUS
    SUMMARY</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_002"><span style="font-size: 10pt">RISK
    FACTORS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">5</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_003"><span style="font-size: 10pt">USE
    OF PROCEEDS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">30</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_004"><span style="font-size: 10pt">DIVIDEND
    POLICY</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">30</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_005"><span style="font-size: 10pt">CAPITALIZATION</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">31</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_006"><span style="font-size: 10pt">DILUTION</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">32</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_007"><span style="font-size: 10pt">MANAGEMENT&#8217;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">33</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_008"><span style="font-size: 10pt">BUSINESS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">48</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_009"><span style="font-size: 10pt">MANAGEMENT</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">57</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_010"><span style="font-size: 10pt">EXECUTIVE
    COMPENSATION</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">63</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_011"><span style="font-size: 10pt">MATERIAL
    U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF THE COMPANY&#8217;S COMMON STOCK</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">65</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_012"><span style="font-size: 10pt">SECURITY
    OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">69</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_013"><span style="font-size: 10pt">CERTAIN
    RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">70</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_014"><span style="font-size: 10pt">UNDERWRITING</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">71</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_015"><span style="font-size: 10pt">DESCRIPTION
    OF SECURITIES</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">79</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_016"><span style="font-size: 10pt">LEGAL
    MATTERS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">86</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_017"><span style="font-size: 10pt">EXPERTS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">86</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_018"><span style="font-size: 10pt">WHERE
    YOU CAN FIND MORE INFORMATION</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">86</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_019"><span style="font-size: 10pt">INDEX
    TO CONSOLIDATED FINANCIAL STATEMENTS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-1</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<a id="a_001"></a><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROSPECTUS SUMMARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The following summary highlights selected
information contained elsewhere in this prospectus and is qualified in its entirety by the more detailed information and financial statements
included elsewhere in this prospectus. It does not contain all the information that may be important to you and your investment decision.
You should carefully read this entire prospectus, including the matters set forth under &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and our financial statements and related notes included
elsewhere in this prospectus. In this prospectus, unless context requires otherwise, references to &#8220;we,&#8221; &#8220;us,&#8221;
&#8220;our,&#8221; &#8220;Silo&#8221; or &#8220;the Company&#8221; refer to Silo Pharma, Inc. and its subsidiary. </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">On September 15, 2022, we effected a 1-for-50
reverse split of our outstanding shares of common stock No fractional shares were issued in connection with the reverse stock split and
all such fractional interests were rounded up to the nearest whole number of shares of common stock. The conversion and/or exercise prices
of our issued and outstanding convertible securities, including shares issuable upon exercise of outstanding stock options and warrants,
conversion of our outstanding convertible notes and conversions of preferred stock have been adjusted accordingly. All information presented
in this prospectus have been retrospectively restated to give effect to our 1-for-50 reverse split of our outstanding shares of common
stock, and unless otherwise indicated, all such amounts and corresponding conversion price and/or exercise price data set forth in this
prospectus have been adjusted to give effect to such reverse stock split.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a developmental stage biopharmaceutical
company focused on merging traditional therapeutics with psychedelic research. We are committed to developing innovative solutions to
address a variety of underserved conditions. In these uncertain times, the mental health of the nation and beyond is being put to the
test. More than ever, creative new therapies are needed to address the health challenges of today. Combining our resources with world-class
medical research partners, we hope to make significant advances in the medical and psychedelic space.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rare Disease Therapeutics</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We seek to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. We are focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as
depression, post-traumatic stress disorder (&#8220;PTSD&#8221;), Parkinson&#8217;s, and other rare neurological disorders. Our mission
is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the
health care industry.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Psilocybin is considered a serotonergic hallucinogen
and is an active ingredient in some species of mushrooms. Recent industry studies using psychedelics, such as psilocybin, have been promising,
and we believe there is a large unmet need with many people suffering from depression, mental health issues and neurological disorders.
While classified as a Schedule I substance under the Controlled Substances Act (&#8220;CSA&#8221;), there is an accumulating body of
evidence that psilocybin may have beneficial effects on depression and other mental health conditions. Therefore, the U.S. Food and Drug
Administration (&#8220;FDA&#8221;) and U.S. Drug Enforcement Agency (&#8220;DEA&#8221;) have permitted the use of psilocybin in clinical
studies for the treatment of a range of psychiatric conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The potential of psilocybin therapy in mental
health conditions has been demonstrated in a number of academic-sponsored studies over the last decade. In these early studies, it was
observed that psilocybin therapy provided rapid reductions in depression symptoms after a single high dose, with antidepressant effects
lasting for up to at least six months for a number of patients. These studies assessed symptoms related to depression and anxiety through
a number of widely used and validated scales. The data generated by these studies suggest that psilocybin is generally well-tolerated
and has the potential to treat depression when administered with psychological support.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have engaged in discussions with a number
of world-renowned educational institutions and advisors regarding potential opportunities and have formed a scientific advisory board
that is intended to help advise management regarding potential acquisition and development of products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, as more fully described below,
we have entered into a license agreement with the University of Baltimore, Maryland, and have entered into a joint venture with Zylo
Therapeutics, Inc., with respect to certain intellectual property and technology that may be used for targeted delivery of potential
novel treatments. In addition, we have recently entered into a sponsored research agreement with Columbia University pursuant to which
we have been granted an option to license certain patents and inventions relating to the treatment of Alzheimer&#8217;s disease and stress-induced
affective disorders using Ketamine in combination with certain other compounds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to actively pursue the acquisition
and/or development of intellectual property or technology rights to treat rare diseases, and to ultimately expand our business to focus
on this new line of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.9pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.9pt; text-align: justify"><span style="font-size: 6pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 6.9pt; margin-bottom: 0pt; text-align: left"><b>Risks
Associated with Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.9pt; text-align: justify"><span style="font-size: 6pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We
                                            will require additional financing in the future to fund our operations, and raising additional
                                            capital may cause dilution to holders of our stockholders, restrict our operations or require
                                            us to relinquish certain rights.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Clinical
                                            drug development is a lengthy and expensive process with uncertain timelines and uncertain
                                            outcomes. If clinical trials of any future therapeutic candidates are prolonged or delayed,
                                            we or our current or future collaborators may be unable to obtain required regulatory approvals,
                                            and therefore we will be unable to commercialize our future therapeutic candidates on a timely
                                            basis or at all, which will adversely affect our business.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Any
                                            therapeutic candidates we may develop in the future may be subject to controlled substance
                                            laws and regulations in the territories where the product will be marketed, and failure to
                                            comply with these laws and regulations, or the cost of compliance with these laws and regulations,
                                            may adversely affect the results of our business operations and our financial condition.
                                            Specifically, psilocybin and psilocin are listed as Schedule I controlled substances under
                                            the Controlled Substances Act in the U.S., and similar controlled substance legislation in
                                            other countries and any significant breaches in our compliance with these laws and regulations,
                                            or changes in the laws and regulations may result in interruptions to our development activity
                                            or business continuity.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our
                                            product candidates may contain controlled substances, the use of which may generate public
                                            controversy. Adverse publicity or public perception regarding psilocybin or our current or
                                            future investigational therapies using psilocybin may negatively influence the success of
                                            these therapies.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Even
                                            if any of our future therapeutic candidates obtain regulatory approval, we will be subject
                                            to ongoing obligations and continued regulatory review, which may result in significant additional
                                            expense or penalties if we fail to comply with regulatory requirements.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">If
                                            we are unable to enroll patients in our clinical trials, our research and development efforts
                                            and business, financial condition and results of operations could be materially adversely
                                            affected.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We
                                            have never commercialized a therapeutic candidate before and may lack the necessary expertise,
                                            personnel and resources to successfully commercialize our therapies on our own or with suitable
                                            collaborators.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            future commercial success of our future therapeutic candidates will depend on the degree
                                            of market access and acceptance of our potential therapies as well as the extent to which
                                            governmental authorities and health insurers establish adequate reimbursement levels and
                                            pricing policies.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We
                                            may become exposed to costly and damaging liability claims, and our product liability insurance
                                            may not cover all damages from such claims.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Enacted
                                            and future legislation may increase the difficulty and cost for us to obtain marketing approval
                                            of and commercialize any of our future therapeutic candidates and could have a material adverse
                                            effect on our business.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our
                                            business operations and current and future relationships with investigators, health care
                                            professionals, consultants, third-party payors and customers may be subject, directly or
                                            indirectly, to U.S. federal and state healthcare fraud and abuse laws, false claims laws,
                                            health information privacy and security laws, other healthcare laws and regulations and other
                                            foreign privacy and security laws. If we are unable to comply, or have not fully complied,
                                            with such laws, we could face substantial penalties.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The
                                            failure to obtain or maintain patents, licensing agreements and other intellectual property
                                            could materially impact our ability to compete effectively.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">If
                                            we fail to comply with our obligations in the agreements under which we may license intellectual
                                            property rights from third parties or otherwise experience disruptions to our business relationships
                                            with our licensors, we could lose rights that are important to our business.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We
                                            have never paid cash dividends and have no plans to pay cash dividends in the future.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">If
                                            we fail to remain current in our reporting requirements, we could be removed from the OTCQB
                                            which would limit the ability of broker-dealers to sell our securities and the ability of
                                            stockholders to sell their securities in the secondary market.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our
                                            common stock could be subject to extreme volatility. Market and economic conditions may negatively
                                            impact our business, financial condition and share price.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Future
                                            sales and issuances of our securities could result in additional dilution of the percentage
                                            ownership of our stockholders and could cause our share price to fall.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.9pt; text-align: justify"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.9pt; text-align: justify"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were incorporated in the State of New York
on July 13, 2010. On January 24, 2013, we changed our state of incorporation from New York to Delaware. Our principal executive offices
are located at 560 Sylvan Avenue, Suite 3160, Englewood Cliffs, NJ 07632 and our telephone number is (718) 400-9031.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center"><b>THE OFFERING</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 30%; padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">Common stock offered
    by us</span></td>
    <td style="vertical-align: top; width: 1%; padding: 0.25pt"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; width: 69%; padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">588,236 shares</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt"><span style="font-size: 10pt">Common stock to be outstanding immediately after this offering </span></td>
    <td style="padding: 0.25pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">2,576,142 shares (2,664,378 shares if the underwriters
    exercise their option to purchase additional shares in full).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; text-align: justify">&#160;</td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">Over-allotment option</span></td>
    <td style="padding: 0.25pt"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">The underwriters have an
    option for a period of 45 days to acquire up to an additional 88,236 shares of common stock at the public offering price, less the
    underwriting discount, solely for the purpose of covering over-allotments, if any.</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding: 0.25pt; text-align: justify">&#160;</td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="vertical-align: bottom; padding: 0.25pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">Use of Proceeds</span></td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="vertical-align: bottom; padding: 0.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We
                                            estimate that the net proceeds from this offering will be approximately $4.15 million, or
                                            approximately $4.83 million if the underwriters exercise their over-allotment option in full,
                                            after deducting the underwriting discounts and commissions and estimated offering expenses
                                            payable by us.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company intends to use the net proceeds
    from this offering for product development, marketing and working capital and general corporate purposes. Additionally, we may use
    a portion of the proceeds to us for acquisitions of complementary businesses, technologies, or other assets. However, we have no
    commitments to use the proceeds from this Offering for any such acquisitions or investments at this time.&#160;See &#8220;Use of
    Proceeds&#8221; for a more complete description of the intended use of proceeds from this offering.</p></td></tr>
  <tr>
    <td style="vertical-align: top; padding: 0.25pt; text-align: justify">&#160;</td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="vertical-align: bottom; padding: 0.25pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">Dividend Policy</span></td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">The Company has never declared any cash dividends
    on its common stock.&#160;The Company currently intends to use all available funds and any future earnings for use in financing the
    growth of its business and does not anticipate paying any cash dividends for the foreseeable future. &#160;See &#8220;Dividend Policy.&#8221;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">Trading Symbol</span></td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have applied to list our common stock on
    the Nasdaq Capital Market upon our satisfaction of the exchange&#8217;s initial listing criteria.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock is currently trading on the
    OTCQB under the symbol of &#8220;SILO.&#8221;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt"><span style="font-size: 10pt">Reverse Stock Split</span></td>
    <td style="padding: 0.25pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding: 0.25pt; text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">On March 11,
                                            2022, the Company&#8217;s stockholders approved a reverse stock split at a ratio of between
                                            1-for 5 and 1-for-50, with discretion for the exact ratio to be approved by the Company&#8217;s
                                            board of directors. On September 15, 2022, we effected a 1-for-50 reverse split of our outstanding
                                            shares of common stock. No fractional shares were issued in connection with the reverse stock
                                            split and all such fractional interests have been rounded up to the nearest whole number
                                            of shares of common stock. The conversion and/or exercise prices of our issued and outstanding
                                            convertible securities, including shares issuable upon exercise of outstanding stock options
                                            and warrants, conversion of our outstanding convertible notes, and conversions of convertible
                                            preferred stock have been adjusted accordingly. All information presented in this prospectus
                                            has been retrospectively restated to give effect to our 1-for-50 reverse split of our outstanding
                                            shares of common stock, and unless otherwise indicated, all such amounts and corresponding
                                            conversion price and/or exercise price data set forth in this prospectus have been adjusted
                                            to give effect to our reverse stock split.</span></p></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">Risk Factors</span></td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">You should carefully consider the information set
    forth in this prospectus and, in particular, the specific factors set forth in the &#8220;Risk Factors&#8221; section beginning on
    page 5 of this prospectus before deciding whether or not to invest in the Company&#8217;s common stock.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; text-align: justify">&#160;</td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">Lock-up</span></td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">We and our directors, officers and principal stockholders
    have agreed with the underwriters not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our
    common stock or securities convertible into common stock for a period of&#160;6-months after the date of this prospectus. See &#8220;Underwriting&#8221;
    section on page 71.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.9pt; text-align: justify">&#160;</p>

</div><div>



</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.9pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.9pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="-keep: true">The number of shares of common stock to be outstanding
immediately after this offering is based on 1,987,906 shares of common stock outstanding as of September 19, 2022 and excludes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.9pt 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.9pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">347,080 shares
                                            of common stock issuable upon exercise of warrants with a weighted average exercise price
                                            of $15.5 per share; and</span></p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.9pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">28,849 shares
                                            of common stock issuable upon exercise of options.</span></p></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.9pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 6.5pt; margin-bottom: 0pt; text-align: left">Except
as otherwise indicated herein, all information in this prospectus reflects or assumes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: justify; text-indent: 40.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">a
                                            one-for-fifty reverse stock split of our common stock effected on September 15, 2022.</span></p></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: justify; text-indent: 40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    exercise of the outstanding options or warrants described above; and</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    exercise of the underwriters&#8217; option to purchase up to an additional 88,236 shares of common stock to cover over-allotments,
    if any.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

</div><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>Any investment
in our common stock involves a high degree of risk. Before deciding whether to purchase our common stock, investors should carefully
consider the risks described below. Our business, financial condition, operating results and prospects are subject to the following material
risks. Additional risks and uncertainties not presently foreseeable to us may also impair our business operations. If any of the following
risks actually occurs, our business, financial condition or operating results could be materially adversely affected. In such case, the
trading price of our common stock could decline, and our stockholders may lose all or part of their investment in the shares of our common
stock.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Risks Related to Our Financial Position
and Need for Capital</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have only a limited history upon
which an evaluation of our prospects and future performance can be made and have no history of profitable operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We commenced operations in 2010 and have a
limited history upon which an evaluation of our prospects and future performance can be made and have no history of profitable operations.
We may sustain losses in the future as we implement our business plan. We have not yet achieved positive cash flow on a monthly basis
during any fiscal year including the fiscal year ended December 31, 2021, and there can be no assurance that we will ever generate revenues
or operate profitably.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will require additional financing
in the future to fund our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will need additional capital in the future
to continue to execute our business plan. Therefore, we will be dependent upon additional capital in the form of either debt or equity
to continue our operations. At the present time, we do not have arrangements to raise all of the needed additional capital, and we will
need to identify potential investors and negotiate appropriate arrangements with them. Our ability to obtain additional financing will
be subject to a number of factors, including market conditions, our operating performance and investor sentiment. If we are unable to
raise additional capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Raising additional capital may cause
dilution to our stockholders, restrict our operations or require us to relinquish certain rights.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may seek additional capital through a combination
of equity offerings, debt financings, strategic collaborations and alliances or licensing arrangements. To the extent that we raise additional
capital through the sale of equity, convertible debt securities or other equity-based derivative securities, your ownership interest
will be diluted and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Any indebtedness
we incur could involve restrictive covenants, such as limitations on our ability to incur additional debt, acquire or license intellectual
property rights, declare dividends, make capital expenditures and other operating restrictions that could adversely impact our ability
to conduct our business. Furthermore, the issuance of additional securities, whether equity or debt, by us, or the possibility of such
issuance, may cause the market price of our common stock to decline. If we raise additional funds through strategic collaborations and
alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to future therapeutic candidates or
otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.
Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise additional funds when
needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant
rights to develop and market our future therapeutic candidates that we would otherwise prefer to develop and market ourselves.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Risks Related to our Rare Disease Therapeutics
Business</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Clinical drug
development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of any future therapeutic
candidates are prolonged or delayed, we or our current or future collaborators may be unable to obtain required regulatory approvals,
and therefore we will be unable to commercialize our future therapeutic candidates on a timely basis or at all, which will adversely
affect our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical testing is expensive and can take
many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process and
our future clinical trial results may not be successful. We may experience delays in initiating or completing our clinical trials. We
may also experience numerous unforeseen events during our clinical trials that could delay or prevent our ability to receive marketing
approval or commercialize any future therapeutic candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We cannot provide any assurance that
any product candidates will successfully complete clinical trials or receive regulatory approval, which is necessary before they can
be commercialized.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have no therapies that are approved
for commercial sale and may never be able to develop marketable therapies. We entered into the Option Agreement with University of Maryland,
Baltimore (&#8220;UMB&#8221;) pursuant to which, UMB has granted us an exclusive, non-sublicensable, non-transferable license with respect
to the exploration of the potential use of central nervous system-homing peptides in vivo and their use for the investigation and treatment
of MS and other neuroinflammatory pathology. Accordingly, our business may depend on the successful regulatory approval of potential
in-licensed product candidates. We cannot be certain that any of our product candidates will receive regulatory approval or that our
therapies will be successfully commercialized even if we receive regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The research, testing, manufacturing, safety,
efficacy, labeling, approval, sale, marketing, and distribution of any in-licensed product is, and will remain, subject to comprehensive
regulation by the FDA, the DEA, the European Medicines Agency (&#8220;EMA&#8221;), the Medicines and Healthcare Products Regulatory Agency
(&#8220;MHRA&#8221;) and foreign regulatory authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Any therapeutic candidates we may develop
in the future may be subject to controlled substance laws and regulations in the territories where the product will be marketed, and
failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, may adversely affect the
results of our business operations and our financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, psychedelics, or psilocybin,
and its active metabolite, psilocin, are listed by the DEA as a Schedule I substance under the CSA. The DEA regulates chemical compounds
as Schedule I, II, III, IV or V substances. Schedule I substances by definition have a high potential for abuse, have no currently &#8220;accepted
medical use&#8221; in the United States, lack accepted safety for use under medical supervision, and may not be prescribed marketed or
sold in the United States. Pharmaceutical products approved for use in the United States may be listed as Schedule II, III, IV or V,
with Schedule II substances considered to present the highest potential for abuse or dependence and Schedule V substances the lowest
relative risk of abuse among such substances. Schedule I and II substances are subject to the strictest controls under the CSA, including
manufacturing and procurement quotas, security requirements and criteria for importation. In addition, dispensing of Schedule II substances
is further restricted. For example, they may not be refilled without a new prescription and may have a black box warning. Further, most,
if not all, state laws in the United States classify psilocybin and psilocin as Schedule I controlled substances. For any product containing
psilocybin to be available for commercial marketing in the United States, psilocybin and psilocin must be rescheduled, or the product
itself must be scheduled, by the DEA to Schedule II, III, IV or V. Commercial marketing in the United States will also require scheduling-related
legislative or administrative action.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Scheduling determinations by the DEA are dependent
on FDA approval of a substance or a specific formulation of a substance. Therefore, while psilocybin and psilocin are Schedule I controlled
substances, products approved by the FDA for medical use in the United States that contain psilocybin or psilocin should be placed in
Schedules II-V, since approval by the FDA satisfies the &#8220;accepted medical use&#8221; requirement. If one of our product candidates
receives FDA approval, we anticipate that the DEA will make a scheduling determination and place it in a schedule other than Schedule
I in order for it to be prescribed to patients in the United States. This scheduling determination will be dependent on FDA approval
and the FDA&#8217;s recommendation as to the appropriate schedule. During the review process, and prior to approval, the FDA may determine
that it requires additional data, either from non-clinical or clinical studies, including with respect to whether, or to what extent,
the substance has abuse potential. This may introduce a delay into the approval and any potential rescheduling process. That delay would
be dependent on the quantity of additional data required by the FDA. This scheduling determination will require DEA to conduct notice
and comment rule making including issuing an interim final rule. Such action will be subject to public comment and requests for hearing
which could affect the scheduling of these substances. There can be no assurance that the DEA will make a favorable scheduling decision.
Even assuming categorization as a Schedule II or lower controlled substance (i.e., Schedule III, IV or V), at the federal level, such
substances would also require scheduling determinations under state laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, therapeutic candidates containing
controlled substances are subject to DEA regulations relating to manufacturing, storage, distribution and physician prescription procedures,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>DEA
                                            registration and inspection of facilities.</b> Facilities conducting research, manufacturing,
                                            distributing, importing or exporting, or dispensing controlled substances must be registered
                                            (licensed) to perform these activities and have the security, control, recordkeeping, reporting
                                            and inventory mechanisms required by the DEA to prevent drug loss and diversion. All these
                                            facilities must renew their registrations annually, except dispensing facilities, which must
                                            renew every three years. The DEA conducts periodic inspections of certain registered establishments
                                            that handle controlled substances. Obtaining and maintaining the necessary registrations
                                            may result in delay of the importation, manufacturing or distribution of product candidates.
                                            Furthermore, failure to maintain compliance with the CSA, particularly non-compliance resulting
                                            in loss or diversion, can result in regulatory action that could have a material adverse
                                            effect on our business, financial condition and results of operations. The DEA may seek civil
                                            penalties, refuse to renew necessary registrations, or initiate proceedings to restrict,
                                            suspend or revoke those registrations. In certain circumstances, violations could lead to
                                            criminal proceedings.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>State-controlled
                                            substances laws.</b> Individual U.S. states have also established controlled substance laws
                                            and regulations. Though state-controlled substances laws often mirror federal law, because
                                            the states are separate jurisdictions, they may separately schedule product candidates. While
                                            some states automatically schedule a drug based on federal action, other states schedule
                                            drugs through rule making or a legislative action. State scheduling may delay commercial
                                            sale of any product for which we obtain federal regulatory approval and adverse scheduling
                                            could have a material adverse effect on the commercial attractiveness of such product. We
                                            or any partners must also obtain separate state registrations, permits or licenses in order
                                            to be able to obtain, handle, and distribute controlled substances for clinical trials or
                                            commercial sale, and failure to meet applicable regulatory requirements could lead to enforcement
                                            and sanctions by the states in addition to those from the DEA or otherwise arising under
                                            federal law.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Clinical
                                            trials.</b> Because any product candidates may contain psilocybin, to conduct clinical trials
                                            in the United States prior to approval, each of our research sites must submit a research
                                            protocol to the DEA and obtain and maintain a DEA researcher registration that will allow
                                            those sites to handle and dispense such product candidates and to obtain the product from
                                            our importer. If the DEA delays or denies the grant of a researcher registration to one or
                                            more research sites, the clinical trial could be significantly delayed, and we could lose
                                            clinical trial sites.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Importation.
                                            </b>If any of our product candidates is approved and classified as a Schedule II, III or
                                            IV substance, an importer can import it for commercial purposes if it obtains an importer
                                            registration and files an application for an import permit for each import. The DEA provides
                                            annual assessments/estimates to the International Narcotics Control Board, which guides the
                                            DEA in the amounts of controlled substances that the DEA authorizes to be imported. The failure
                                            to identify an importer or obtain the necessary import authority, including specific quantities,
                                            could affect the availability of our product candidates and have a material adverse effect
                                            on our business, results of operations and financial condition. In addition, an application
                                            for a Schedule II importer registration must be published in the Federal Register, and there
                                            is a waiting period for third-party comments to be submitted. It is always possible that
                                            adverse comments may delay the grant of an importer registration.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Manufacture.
                                            </b>If, because of a Schedule II classification or voluntarily, we were to conduct manufacturing
                                            or repackaging/relabeling in the United States, our contract manufacturers would be subject
                                            to the DEA&#8217;s annual manufacturing and procurement quota requirements.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Distribution.
                                            </b>If any of our product candidates is scheduled as Schedule II, III or IV, we would also
                                            need to identify wholesale distributors with the appropriate DEA registrations and authority
                                            to distribute any future therapeutic candidates. These distributors would need to obtain
                                            Schedule II, III or IV distribution registrations.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The potential reclassification of psilocybin
and psilocin in the United States could create additional regulatory burdens on our operations and negatively affect our results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If psilocybin and/or psilocin, other than
the FDA-approved formulation, is rescheduled under the CSA as a Schedule II or lower controlled substance (i.e., Schedule III, IV or
V), the ability to conduct research on psilocybin and psilocin would most likely be improved. However, rescheduling psilocybin and psilocin
may materially alter enforcement policies across many federal agencies, primarily the FDA and DEA. The FDA is responsible for ensuring
public health and safety through regulation of food, drugs, supplements, and cosmetics, among other products, through its enforcement
authority pursuant to the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;). The FDA&#8217;s responsibilities include regulating
the ingredients as well as the marketing and labeling of drugs sold in interstate commerce. Because it is currently illegal under federal
law to produce and sell psilocybin and psilocin, and because there are no federally recognized medical uses, the FDA has historically
deferred enforcement related to psilocybin and psilocin to the DEA. If psilocybin and psilocin were to be rescheduled to a federally
controlled, yet legal, substance, the FDA would likely play a more active regulatory role. The DEA would continue to be active in regulating
manufacturing, distribution and dispensing of such substances. The potential for multi-agency enforcement post-rescheduling could threaten
or have a materially adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Psilocybin and psilocin are listed as
Schedule I controlled substances under the CSA in the U.S., and similar controlled substance legislation in other countries and any significant
breaches in our compliance with these laws and regulations, or changes in the laws and regulations may result in interruptions to our
development activity or business continuity.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Psilocybin and psilocin are categorized as
Schedule I controlled substances under the CSA, and are similarly categorized by most states and foreign governments. Even assuming any
future therapeutic candidates containing psilocybin or psilocin are approved and scheduled by regulatory authorities to allow their commercial
marketing, the ingredients in such therapeutic candidates would likely continue to be Schedule I, or the state or foreign equivalent.
Violations of any federal, state or foreign laws and regulations could result in significant fines, penalties, administrative sanctions,
convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal
charges and penalties, including, but not limited to, disgorgement of profits, cessation of business activities, divestiture or prison
time. This could have a material adverse effect on us, including on our reputation and ability to conduct business, our financial position,
operating results, profitability or liquidity, the potential listing of our shares or the market price of our shares. In addition, it
is difficult for us to estimate the time or resources that would be needed for the investigation or defense of any such matters or our
final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information
requested by the applicable authorities involved, and such time or resources could be substantial. It is also illegal to aid or abet
such activities or to conspire or attempt to engage in such activities. An investor&#8217;s contribution to and involvement in such activities
may result in federal civil and/or criminal prosecution, including, but not limited to, forfeiture of his, her or its entire investment,
fines and/or imprisonment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Various federal, state, provincial and local
laws govern our business in any jurisdictions in which we may operate, and to which we may export our products, including laws relating
to health and safety, the conduct of our operations, and the production, storage, sale and distribution of our products. Complying with
these laws requires that we comply concurrently with complex federal, state, provincial and/or local laws. These laws change frequently
and may be difficult to interpret and apply. To ensure our compliance with these laws, we will need to invest significant financial and
managerial resources. It is impossible for us to predict the cost of such laws or the effect they may have on our future operations.
A failure to comply with these laws could negatively affect our business and harm our reputation. Changes to these laws could negatively
affect our competitive position and the markets in which we operate, and there is no assurance that various levels of government in the
jurisdictions in which we operate will not pass legislation or regulation that adversely impacts our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, even if we or third parties were
to conduct activities in compliance with U.S. state or local laws or the laws of other countries and regions in which we conduct activities,
potential enforcement proceedings could involve significant restrictions being imposed upon us or third parties, while diverting the
attention of key executives. Such proceedings could have a material adverse effect on our business, revenue, operating results and financial
condition as well as on our reputation and prospects, even if such proceedings conclude successfully in our favor. In the extreme case,
such proceedings could ultimately involve the criminal prosecution of our key executives, the seizure of corporate assets, and consequently,
our inability to continue business operations. Strict compliance with state and local laws with respect to psilocybin and psilocin does
not absolve us of potential liability under U.S. federal law or EU law, nor provide a defense to any proceeding which may be brought
against us. Any such proceedings brought against us may adversely affect our operations and financial performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Despite the current status of psilocybin and
psilocin as Schedule I controlled substances in the United States, there may be changes in the status of psilocybin or psilocin under
the laws of certain U.S. cities or states. For instance, the city of Denver voted to decriminalize the possession of psilocybin in 2019
and five other cities have decriminalized psilocybin since (Oakland, California; Santa Cruz, California; Ann Arbor, Michigan; Cambridge,
Massachusetts; and Somerville, Massachusetts). Moreover, in the November 2020 election, Oregon passed Measure 109 which legalizes medical
use of &#8220;psilocybin products,&#8221; including magic mushrooms, to treat mental health conditions in licensed facilities with registered
therapists.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The legalization of psilocybin without regulatory
oversight may lead to the setup of clinics without proper therapeutic infrastructure or adequate clinical research, which could put patients
at risk and bring reputational and regulatory risk to the entire industry, making it harder for us to achieve regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may contain controlled
substances, the use of which may generate public controversy. Adverse publicity or public perception regarding psilocybin or our current
or future investigational therapies using psilocybin may negatively influence the success of these therapies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Therapies containing controlled substances
may generate public controversy. Political and social pressures and adverse publicity could lead to delays in approval of, and increased
expenses for any future therapeutic candidates we may develop. Opponents of these therapies may seek restrictions on marketing and withdrawal
of any regulatory approvals. In addition, these opponents may seek to generate negative publicity in an effort to persuade the medical
community to reject these therapies. For example, we may face media-communicated criticism directed at our clinical development program.
Adverse publicity from psilocybin misuse may adversely affect the commercial success or market penetration achievable by our product
candidates. Anti-psychedelic protests have historically occurred and may occur in the future and generate media coverage. Political pressures
and adverse publicity could lead to delays in, and increased expenses for, and limit or restrict the introduction and marketing of any
future therapeutic candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our clinical trials may fail to demonstrate
substantial evidence of the safety and effectiveness of future product candidates that we may identify and pursue, which would prevent,
delay or limit the scope of regulatory approval and commercialization.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before obtaining regulatory approvals for
the commercial sale of future therapeutic candidates, we must demonstrate through lengthy, complex and expensive nonclinical studies,
preclinical studies and clinical trials that the applicable therapeutic candidate is both safe and effective for use in each target indication.
A therapeutic candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended
use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical testing is expensive and can take
many years to complete, and its outcome is inherently uncertain. Most product candidates that begin clinical trials are never approved
by regulatory authorities for commercialization. We have limited experience in designing clinical trials and may be unable to design
and execute a clinical trial to support marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot be certain that any clinical trials
will be successful. In some instances, there can be significant variability in safety or efficacy results between different clinical
trials of the same therapeutic candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences
in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among
clinical trial participants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if any of our future therapeutic
candidates obtain regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in
significant additional expense. Additionally, any such therapeutic candidates, if approved, could be subject to labeling and other restrictions
and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated
problems with any of our future therapeutic candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the FDA, the EMA, the MHRA or a comparable
foreign regulatory authority approves any of our future therapeutic candidates, the manufacturing processes, labeling, packaging, distribution,
adverse event reporting, storage, advertising, promotion and recordkeeping for the therapy and underlying therapeutic substance will
be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing
information and reports, registration, as well as continued compliance with current good manufacturing practice (&#8220;cGMP&#8221;)
and with good clinical practice (&#8220;GCP&#8221;) for any clinical trials that we conduct post-approval, all of which may result in
significant expense and limit our ability to commercialize such therapies. Later discovery of previously unknown problems with any approved
therapeutic candidate, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing
processes, or failure to comply with regulatory requirements, may result in, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">restrictions
                                            on the labeling, distribution, marketing or manufacturing of our future therapeutic candidates,
                                            withdrawal of the product from the market, or product recalls;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">untitled
                                            and warning letters, or holds on clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">refusal
                                            by the FDA, the EMA, the MHRA or other foreign regulatory body to approve pending applications
                                            or supplements to approved applications we filed or suspension or revocation of license approvals;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">requirements
                                            to conduct post-marketing studies or clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">restrictions
                                            on coverage by third-party payors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">fines,
                                            restitution or disgorgement of profits or revenue;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">suspension
                                            or withdrawal of marketing approvals;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">product
                                            seizure or detention, or refusal to permit the import or export of the product; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">injunctions
                                            or the imposition of civil or criminal penalties.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, any regulatory approvals that
we receive for our future therapeutic candidates may also be subject to limitations on the approved indicated uses for which the therapy
may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase
IV clinical trials, and surveillance to monitor the safety and efficacy of such therapeutic candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If there are changes in the application of
legislation, regulations or regulatory policies or if we or one of our distributors, licensees or co-marketers fails to comply with regulatory
requirements, the regulators could take various actions. These include imposing fines on us, imposing restrictions on the therapeutic
or its manufacture and requiring us to recall or remove the therapeutic from the market. The regulators could also suspend or withdraw
our marketing authorizations, requiring us to conduct additional clinical trials, change our therapeutic labeling or submit additional
applications for marketing authorization. If any of these events occurs, our ability to sell such therapy may be impaired, and we may
incur substantial additional expense to comply with regulatory requirements, which could materially adversely affect our business, financial
condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and development of drugs targeting
the central nervous system is particularly difficult, which makes it difficult to predict and understand why the drug has a positive
effect on some patients but not others.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Discovery and development of new drugs targeting
central nervous system disorders are particularly difficult and time-consuming, evidenced by the higher failure rate for new drugs for
central nervous system disorders compared with most other areas of drug discovery. For example, in 2019, both Rapastinel and SAGE-217,
two new drugs targeting major depressive disorder (&#8220;MDD&#8221;), failed to meet their primary endpoints in Phase III trials. ALKS
5461, another new drug targeting MDD, was rejected by FDA in 2019 after its Phase III trials as FDA required additional clinical data
to provide substantial evidence of effectiveness. Any such setbacks in our clinical development could have a material adverse effect
on our business and operating results. In addition, our later stage clinical trials may present challenges related to conducting adequate
and well-controlled clinical trials, including designing an appropriate comparator arm in trials given the potential difficulties related
to maintaining the blinding during the trial or placebo or nocebo effects. Due to the complexity of the human brain and the central nervous
system, it can be difficult to predict and understand why a drug may have a positive effect on some patients but not others and why some
individuals may react to the drug differently from others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The results of preclinical studies and
early-stage clinical trials of our future therapeutic candidates may not be predictive of the results of later stage clinical trials.
Initial success in our ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later
stage trials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Therapeutic candidates in later stages of
clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial
clinical trials. Furthermore, there can be no assurance that any of our clinical trials will ultimately be successful or support further
clinical development of any of our future therapeutic candidates. There is a high failure rate for drugs proceeding through clinical
trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in clinical development even after achieving
promising results in earlier studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will depend on enrollment of patients
in our clinical trials for our future therapeutic candidates. If we are unable to enroll patients in our clinical trials, our research
and development efforts and business, financial condition and results of operations could be materially adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Identifying and qualifying patients to participate
in our clinical trials will be critical to our success. Patient enrollment depends on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the
                                            size of the patient population required for analysis of the trial&#8217;s primary endpoints
                                            and the process for identifying patients;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">identifying
                                            and enrolling eligible patients, including those willing to discontinue use of their existing
                                            medications;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the
                                            design of the clinical protocol and the patient eligibility and exclusion criteria for the
                                            trial;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">safety
                                            profile, to date, of the therapeutic candidate under study;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the
                                            willingness or availability of patients to participate in our trials, including due to the
                                            perceived risks and benefits, stigma or other side effects of use of a controlled substance;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">perceived
                                            risks and benefits of our approach to treatment of indication;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the
                                            proximity of patients to clinical sites;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our
                                            ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the
                                            availability of competing clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the
                                            availability of new drugs approved for the indication the clinical trial is investigating;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">clinicians&#8217;
                                            and patients&#8217; perceptions of the potential advantages of the drug being studied in
                                            relation to other available therapies, including any new therapies that may be approved for
                                            the indications we are investigating; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our
                                            ability to obtain and maintain patient informed consents.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Even once enrolled, we may be unable to retain a sufficient number
of patients to complete any of our trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, any negative results we may report
in clinical trials may make it difficult or impossible to recruit and retain patients in other clinical trials of that same therapeutic
candidate. Delays in the enrollment for any clinical trial will likely increase our costs, slow down the approval process and delay or
potentially jeopardize our ability to commence sales of our future therapeutic candidates and generate revenue. In addition, some of
the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial
of regulatory approval of any future therapeutic candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have never commercialized a therapeutic
candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize our therapies on our own
or with suitable collaborators.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have limited organizational experience
in the sale or marketing of therapeutic candidates. To achieve commercial success for any approved therapy, we must develop or acquire
a sales and marketing organization, outsource these functions to third parties or enter into partnerships.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we enter into arrangements with third parties
to perform market access and commercial services for any approved therapies, the revenue or the profitability of these revenue to us
could be lower than if we were to commercialize any therapies that we develop ourselves. Such collaborative arrangements may place the
commercialization of any approved therapies outside of our control and would make us subject to a number of risks including that we may
not be able to control the amount or timing of resources that our collaborative partner devotes to our therapies or that our collaborator&#8217;s
willingness or ability to complete its obligations, and our obligations under our arrangements may be adversely affected by business
combinations or significant changes in our collaborator&#8217;s business strategy. We may not be successful in entering into arrangements
with third parties to commercialize our therapies or may be unable to do so on terms that are favorable to us. Acceptable third parties
may fail to devote the necessary resources and attention to commercialize our therapies effectively, to set up sufficient number of treatment
centers in third-party therapy sites, or to recruit, train and retain adequate number of therapists to administer our therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we do not establish commercial capabilities
successfully, either on our own or in collaboration with third parties, we may not be successful in commercializing our therapies, which
in turn would have a material adverse effect on our business, prospects, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The future commercial success of our
future therapeutic candidates will depend on the degree of market access and acceptance of our potential therapies among healthcare professionals,
patients, healthcare payors, health technology assessment bodies and the medical community at large.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may never have a therapy that is commercially
successful. To date, we have no therapy authorized for marketing. Furthermore, if approved, our future therapies may not achieve an adequate
level of acceptance by payors, health technology assessment bodies, healthcare professionals, patients and the medical community at large,
and we may not become profitable. The level of acceptance we ultimately achieve may be affected by negative public perceptions and historic
media coverage of psychedelic substances, including psilocybin. Because of this history, efforts to educate the medical community and
third-party payors and health technologies assessment bodies on the benefits of our future therapies may require significant resources
and may never be successful, which would prevent us from generating significant revenue or becoming profitable. Market acceptance of
our future therapies by healthcare professionals, patients, healthcare payors and health technology assessment bodies will depend on
a number of factors, many of which are beyond our control, including, but not limited to, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">acceptance
                                            by healthcare professionals, patients and healthcare payors of each therapy as safe, effective
                                            and cost-effective;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">changes
                                            in the standard of care for the targeted indications for any therapeutic candidate;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the
                                            strength of sales, marketing and distribution support;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">potential
                                            product liability claims;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the
                                            therapeutic candidate&#8217;s relative convenience, ease of use, ease of administration and
                                            other perceived advantages over alternative therapies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the
                                            prevalence and severity of adverse events or publicity;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">limitations,
                                            precautions or warnings listed in the summary of therapeutic characteristics, patient information
                                            leaflet, package labeling or instructions for use;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the
                                            cost of treatment with our therapy in relation to alternative treatments;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the
                                            ability to manufacture our product in sufficient quantities and yields;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the availability and amount of coverage and reimbursement from healthcare
    payors, and the willingness of patients to pay out of pocket in the absence of healthcare payor coverage or adequate reimbursement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the
                                            willingness of the target patient population to try, and of healthcare professionals to prescribe,
                                            the therapy;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">any
                                            potential unfavorable publicity, including negative publicity associated with recreational
                                            use or abuse of psilocybin;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the
                                            extent to which therapies are approved for inclusion and reimbursed on formularies of hospitals
                                            and managed care organizations; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">whether
                                            our therapies are designated under physician treatment guidelines or under reimbursement
                                            guidelines as a first-line, second-line, third-line or last-line therapy.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our future therapeutic candidates fail
to gain market access and acceptance, this will have a material adverse impact on our ability to generate revenue to provide a satisfactory,
or any, return on our investments. Even if some therapies achieve market access and acceptance, the market may prove not to be large
enough to allow us to generate significant revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in methods of therapeutic candidate
manufacturing or formulation may result in additional costs or delay.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As therapeutic candidates are developed through
preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects
of the development program, such as manufacturing methods and formulation, may be altered along the way in an effort to optimize processes
and results. Any of these changes could cause any of our future therapeutic candidates to perform differently and affect the results
of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes
may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the conduct
of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of any of
our future therapeutic candidates and jeopardize our ability to commence product sales and generate revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may become exposed to costly and
damaging liability claims, either when testing our future therapeutic candidates in the clinic or at the commercial stage, and our product
liability insurance may not cover all damages from such claims.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will be exposed to potential product liability
and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of therapeutic substances.
Currently, we have no therapies that have been approved for commercial sale; however, any future therapeutic candidates by us and our
corporate collaborators in clinical trials, and the potential sale of any approved therapies in the future, may expose us to liability
claims. These claims might be made by patients who use our therapies, healthcare providers, pharmaceutical companies, our corporate collaborators
or other third parties that sell our therapies. Any claims against us, regardless of their merit, could be difficult and costly to defend
and could materially adversely affect the market for our future therapeutic candidates or any prospects for commercialization of our
future therapeutic candidates. Although the clinical trial process is designed to identify and assess potential side effects, it is always
possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If any of our future therapeutic candidates
causes adverse side effects during clinical trials or after regulatory approval, we may be exposed to substantial liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Physicians and patients may not comply with
warnings that identify known potential adverse effects and describe which patients should not use any of our future therapeutic candidates.
Regardless of the merits or eventual outcome, liability claims may cause, among other things, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">decreased
                                            demand for our therapies due to negative public perception;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">injury
                                            to our reputation;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">withdrawal
                                            of clinical trial participants or difficulties in recruiting new trial participants;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">initiation
                                            of investigations by regulators;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">costs
                                            to defend or settle the related litigation;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">a
                                            diversion of management&#8217;s time and our resources;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">substantial
                                            monetary awards to trial participants or patients;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">recalls,
                                            withdrawals or labeling, marketing or promotional restrictions;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">loss
                                            of revenue from therapeutic sales; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our
                                            inability to commercialize any of our future therapeutic candidates, if approved.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition we may not be able to obtain or
maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may
arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured
liabilities, our assets may not be sufficient to cover such claims and our business, financial condition and results of operations could
be materially adversely affected. Liability claims resulting from any of the events described above could have a material adverse effect
on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Enacted and future legislation may increase
the difficulty and cost for us to obtain marketing approval of and commercialize any of our future therapeutic candidates and could have
a material adverse effect on our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, there have been a number
of legislative and regulatory changes to the healthcare system that could affect our future results of operations. In particular, there
have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve
the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care
and Education Reconciliation Act of 2010 (collectively, &#8220;ACA&#8221;), substantially changed the way healthcare is financed by both
governmental and private insurers, and significantly impacted the U.S. biopharmaceutical industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Among the provisions of the ACA of importance
to our potential therapeutic candidates are the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">an
                                            annual, nondeductible fee on any entity that manufactures or imports specified branded prescription
                                            drugs, apportioned among these entities according to their market share in certain government
                                            healthcare programs, although this fee would not apply to sales of certain products approved
                                            exclusively for orphan indications;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">expansion
                                            of eligibility criteria for Medicaid programs, a Federal and state program which extends
                                            healthcare to low-income individuals and other groups, by, among other things, allowing states
                                            to offer Medicaid coverage to certain individuals and adding new eligibility categories for
                                            certain individuals with income at or below 133% of the federal poverty level, thereby potentially
                                            increasing a manufacturer&#8217;s Medicaid rebate liability;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">expansion
                                            of manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program, which requires
                                            that drug manufacturers provide rebates to states in exchange for state Medicaid coverage
                                            for most of the manufacturers&#8217; drugs by increasing the minimum rebate for both branded
                                            and generic drugs and revising the definition of &#8220;average manufacturer price,&#8221;
                                            for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices
                                            and extending rebate liability to prescriptions for individuals enrolled in Medicare Advantage
                                            plans (i.e., a type of Medicare healthcare plan offered by private companies);</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">a
                                            new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program
                                            are calculated for products that are inhaled, infused, instilled, implanted or injected;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">expansion
                                            of the types of entities eligible for the 340B drug discount program, which requires drug
                                            manufacturers to provide outpatient drugs to eligible healthcare organizations and covered
                                            entities at significantly reduced prices;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">establishment
                                            of the Medicare Part D coverage gap discount program, which requires manufacturers to provide
                                            a 50% point-of-sale-discount (increased to 70% pursuant to the Bipartisan Budget Act of 2018,
                                            or BBA, effective as of January 1, 2019) off the negotiated price of applicable products
                                            to eligible beneficiaries during their coverage gap period as a condition for the manufacturers&#8217;
                                            outpatient products to be covered under Medicare Part D;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">creation
                                            of a new non-profit, nongovernmental institute, called the Patient-Centered Outcomes Research
                                            Institute, to oversee, identify priorities in and conduct comparative clinical effectiveness
                                            research, along with funding for such research; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">establishment
                                            of the Center for Medicare and Medicaid Innovation within Centers for Medicare &amp; Medicaid
                                            to test innovative payment and service delivery models to lower Medicare and Medicaid spending,
                                            potentially including prescription product spending.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since its enactment, there have been numerous
judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional
challenges and amendments to the ACA in the future. It is unclear whether the ACA will be overturned, repealed, replaced, or further
amended. We cannot predict what affect further changes to the ACA would have on our business. This uncertainty is heightened by President
Biden&#8217;s January 28, 2021 Executive Order on Strengthening Medicaid and the Affordable Care Act which indicates that the incoming
Biden Administration may significantly modify the ACA and potentially revoke any changes implemented by the Trump Administration. It
is also possible that President Biden will further reform the ACA and other federal programs in manner that may impact our operations.
The Biden Administration has indicated that a goal of its administration is to expand and support Medicaid and the ACA and to make high-quality
healthcare accessible and affordable. The potential increase in patients covered by government funded insurance may impact our pricing.
Further, it is possible that the Biden Administration may further increase the scrutiny on drug pricing. <span>Additionally,
on December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the tax penalty
on certain individuals who fail to maintain qualifying health coverage for all or part of a year, commonly referred to as the &#8220;individual
mandate.&#8221; Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit ruled that the individual mandate was
unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid
as well. The United States Supreme Court is currently reviewing this case, but it is unclear when a decision will be</span> made. It
is also unclear how the Supreme Court ruling, other such litigation and the healthcare reform measures of the Biden administration will
impact the ACA. We cannot predict the likelihood, nature or extent of government regulation <span>that
may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional
state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state
governments will pay for health care products and services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Third-party payors
are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in
addition to their safety and efficacy. To obtain coverage and reimbursement for any product that might be approved for marketing, we
may need to conduct expensive studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would
be in addition to the costs expended to obtain regulatory approvals. Third-party payors may not consider our product or product candidates
to be medically necessary or cost-effective compared to other available therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Additionally, the
containment of healthcare costs (including drug prices) has become a priority of federal and state governments. The U.S. government,
state legislatures, and foreign governments have shown significant interest in implementing cost-containment programs, including price
controls, restrictions on reimbursement, and requirements for substitution by generic products. For example, the Biden Administration,
including his nominee for Secretary of the Department of Health and Human Services, has indicated that lowering prescription drug prices
is a priority, but we do not yet know what steps the administration will take or whether such steps will be successful. Adoption of price
controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures,
could limit our net revenue and results. If these third-party payors do not consider our products to be cost-effective compared to other
therapies, they may not cover our products or product candidates if approved as a benefit under their plans or, if they do, the level
of reimbursement may not be sufficient to allow us to sell our products on a profitable basis. Decreases in third-party reimbursement
for our products once approved or a decision by a third-party payor to not cover our products could reduce or eliminate utilization of
our products and have an adverse effect on our sales, results of operations, and financial condition. In addition, state and federal
healthcare reform measures have been and will be adopted in the future, any of which could limit the amounts that federal and state governments
will pay for healthcare products and services, which could result in reduced demand for our products or product candidates once approved
or additional pricing pressures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, new laws and additional health
reform measures may result in additional reductions in Medicare and other healthcare funding, which may adversely affect customer demand
and affordability for our future therapeutic candidates and, accordingly, the results of our financial operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business operations and current
and future relationships with investigators, health care professionals, consultants, third-party payors and customers may be subject,
directly or indirectly, to U.S. federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and
security laws, other healthcare laws and regulations and other foreign privacy and security laws. If we are unable to comply, or have
not fully complied, with such laws, we could face substantial penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Although
we do not currently have any therapies on the market, our current and future operations may be directly, or indirectly through our relationships
with investigators, health care professionals, customers and third-party payors, subject to various U.S. federal and state healthcare
laws and regulations, including, without limitation, the U.S. federal Anti-Kickback Statute or the federal Anti-Kickback Statute. Healthcare
providers, physicians and others play a primary role in the recommendation and prescription of any therapies for which we obtain marketing
approval. These laws impact, among other things, our research activities and proposed sales, marketing and education programs and constrain
our business and financial arrangements and relationships with third-party payors, healthcare professionals who participate in our clinical
research program, healthcare professionals and others who recommend, purchase, or provide our approved therapies, and other parties through
which we market, sell and distribute our therapies for which we obtain marketing approval. In addition, we may be subject to patient
data privacy and security regulation by both the U.S. federal government and the states in which we conduct our business, along with
foreign regulators (including European data protection authorities). Finally, our current and future operations will be subject to additional
healthcare-related statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which
we conduct our business. These laws include, but are not limited to, the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt; ">the federal Anti-Kickback
    Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or
    paying any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash
    or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any
    good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs
    such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate
    it in order to have committed a violation. Violations are subject to significant civil and criminal fines and penalties for each
    violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In
    addition, the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback
    Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act (&#8220;FCA&#8221;). The definition of
    the &#8220;remuneration&#8221; under the federal Anti-Kickback Statute has been interpreted to include anything of value. Further,
    courts have found that if &#8220;one purpose&#8221; of remuneration is to induce referrals, the federal Anti-Kickback Statute is
    violated. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one
    hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory
    safe harbors protecting some common activities from prosecution; but the exceptions and safe harbors are drawn narrowly and require
    strict compliance in order to offer protection;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt; ">the federal civil and
    criminal false claims laws, such as the FCA, which prohibits individuals or entities from, among other things, knowingly presenting,
    or causing to be presented, false or fraudulent claims for payment to, or approval by Medicare, Medicaid, or other federal healthcare
    programs, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim
    or an obligation to pay or transmit money to the federal government, or knowingly concealing or knowingly and improperly avoiding
    or decreasing or concealing an obligation to pay money to the U.S. federal government. Manufacturers can be held liable under the
    FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of
    false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on
    behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined
    to have violated the FCA, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude
    the entity from participation in Medicare, Medicaid and other federal healthcare programs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt; ">the federal civil monetary
    penalties laws, which impose civil fines for, among other things, the offering or transfer or remuneration to a Medicare or state
    healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of
    a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception
    applies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt; ">The Health Insurance Portability
    and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and
    their implementing regulations (collectively referred to as &#8220;HIPAA&#8221;) as well as numerous other federal and state laws
    and regulations, govern the collection, dissemination, use, privacy, security, confidentiality, integrity and availability of personally
    identifiable information (&#8220;PII&#8221;), including protected health information (&#8220;PHI&#8221;). HIPAA applies national
    privacy and security standards for PHI to covered entities, including certain types of health care entities and their service providers
    that access PHI, known as business associates. HIPAA requires covered entities and business associates to maintain policies and procedures
    governing PHI that is used or disclosed, and to implement administrative, physical and technical safeguards to protect PHI, including
    PHI maintained, used and disclosed in electronic form. These safeguards include employee training, identifying business associates
    with whom covered entities need to enter into HIPAA-compliant contractual arrangements and various other measures. While we shall
    undertake substantial efforts to secure the PHI we maintain, use and disclose in electronic form, a cyber-attack or other intrusion
    that bypasses our information security systems causing an information security breach, loss of PHI, PII or other data subject to
    privacy laws or a material disruption of our operational systems could result in a material adverse impact on our business, along
    with potentially substantial fines and penalties. Ongoing implementation and oversight of these security measures involves significant
    time, effort and expense. HIPAA requires covered entities and their business associates to report breaches of unsecured PHI to affected
    individuals without unreasonable delay and in no case later than 60 days after the discovery of the breach by the covered entity
    or its agents. Notification must also be made to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and, in certain
    situations involving large breaches, to the media. The HIPAA rules created a presumption that all non-permitted uses or disclosures
    of unsecured PHI are breaches unless the covered entity establishes that there is a low probability the information has been compromised.
    A data breach affecting sensitive personal information, including health information, also could result in significant legal and
    financial exposure and reputational damages that could potentially have an adverse effect on our business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the FDCA, which prohibits, among other things,
    the adulteration or misbranding of drugs, biologics and medical devices;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt; ">the U.S. federal legislation
    commonly referred to as Physician Payments Sunshine Act, and its implementing regulations, which requires certain manufacturers of
    drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance
    Program to report annually to the CMS information related to certain payments and other transfers of value to physicians (defined
    to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, as well as ownership and investment
    interests held by physicians and their immediate family members. Effective January 1, 2022, these reporting obligations will extend
    to include transfers of value made during the previous year to certain non-physician providers such as physician assistants and nurse
    practitioners; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt; ">analogous state laws and
    regulations, including the following: state anti-kickback and false claims laws, which may be broader in scope than their federal
    equivalents, and which may apply to our business practices, including research, distribution, sales and marketing arrangements and
    claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require
    pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance
    guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and
    other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing
    and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals
    and entities; state and local laws that require the registration of pharmaceutical sales representatives and state laws governing
    the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways
    and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The distribution
of pharmaceutical products is subject to additional requirements and regulations, including licensing, extensive record-keeping, storage
and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The scope and enforcement
of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of
the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions
between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements
in the healthcare industry. Even if precautions are taken, it is possible that governmental authorities will conclude that our business
practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare
laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that
may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment,
exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight
if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws,
reputational harm and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities
with whom we expect to do business is found not to be in compliance with applicable laws, that person or entity may be subject to significant
criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Prohibitions or restrictions
on sales or withdrawal of future marketed products could materially affect business in an adverse way.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Efforts to ensure
that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial
costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant
legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and
the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting
requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to comply with health and data
protection laws and regulations could lead to U.S. federal and state government enforcement actions, including civil or criminal penalties,
private litigation, and adverse publicity and could negatively affect our operating results and business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We and any potential collaborators may be
subject to U.S. federal and state data protection laws and regulations, such as laws and regulations that address privacy and data security.
In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information
privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of health-related
and other personal information. In addition, we may obtain health information from third parties, including research institutions from
which we obtain clinical trial data, which are subject to privacy and security requirements under HIPAA, as amended by the Health Information
Technology for Economic and Clinical Health (&#8220;HITECH&#8221;). To the extent that we act as a business associate to a healthcare
provider engaging in electronic transactions, we may also be subject to the privacy and security provisions of HIPAA, as amended by HITECH,
which restricts the use and disclosure of patient-identifiable health information, mandates the adoption of standards relating to the
privacy and security of patient-identifiable health information, and requires the reporting of certain security breaches to healthcare
provider customers with respect to such information. Additionally, many states have enacted similar laws that may impose more stringent
requirements on entities like ours. Depending on the facts and circumstances, we could be subject to significant civil, criminal, and
administrative penalties if we obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity
in a manner that is not authorized or permitted by HIPAA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compliance with U.S. and foreign privacy and
data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect,
use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and
regulations could result in government enforcement actions (which could include civil, criminal and administrative penalties), private
litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects,
employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who
share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#8217;
privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable,
could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The successful commercialization of
any of our future therapeutic candidates will depend in part on the extent to which governmental authorities and health insurers establish
adequate reimbursement levels and pricing policies. Failure to obtain or maintain adequate coverage and reimbursement for any of our
future therapeutic candidates, if approved, could limit our ability to market those therapies and decrease our ability to generate revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The availability and adequacy of coverage
and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors
are essential for most patients to be able to afford therapies. As Schedule I substances under the CSA, psilocybin and psilocin are deemed
to have no accepted medical use and therapies that use psilocybin or psilocin are precluded from reimbursement in the United States.
Our products must be scheduled as a Schedule II or lower controlled substance (i.e., Schedule III, IV or V) before they can be commercially
marketed. Our ability to achieve acceptable levels of coverage and reimbursement for therapies by governmental authorities, private health
insurers and other organizations will have an effect on our ability to successfully commercialize, and attract additional collaboration
partners to invest in the development of our future therapeutic candidates. Even if we obtain coverage for a given therapy by third-party
payors, the resulting reimbursement payment rates may not be adequate or may require patient out-of-pocket costs that patients may find
unacceptably high. We cannot be sure that coverage and reimbursement in the United States or elsewhere will be available for any therapy
that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, third-party payors are increasingly
challenging prices charged for therapeutic substances and services, and many third-party payors may refuse to provide coverage and reimbursement
for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor
may consider our future therapeutic candidates as substitutable and only offer to reimburse patients for the less expensive therapy.
These payors may deny or revoke the reimbursement status of a given drug product or establish prices for new or existing marketed therapies
at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is
not available or is available only at limited levels, we may not be able to successfully commercialize our future therapeutic candidates,
and may not be able to obtain a satisfactory financial return on therapeutic candidates that we may develop.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is significant uncertainty related to
the insurance coverage and reimbursement of newly approved therapies. In the United States, third-party payors, including private and
governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs
will be covered. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors
develop their coverage and reimbursement policies for drugs. Some third-party payors may require pre-approval of coverage for new or
innovative devices or drug therapies before they will reimburse health care providers who use such therapies. It is difficult to predict
at this time what third-party payors will decide with respect to the coverage and reimbursement for our future therapeutic candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, obtaining and maintaining reimbursement
status is time-consuming and costly. No uniform policy for coverage and reimbursement for drug therapies exists among third-party payors
in the United States. Therefore, coverage and reimbursement for drug therapies can differ significantly from payor to payor. As a result,
the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical
support for the use of our therapies to each payor separately, with no assurance that coverage and adequate reimbursement will be applied
consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some
cases at short notice, and we believe that changes in these rules and regulations are likely.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Outside the United States, international operations
are generally subject to extensive governmental price controls and other market regulations. Other countries allow companies to fix their
own prices for medical therapies, but monitor and control company profits. Additional foreign price controls or other changes in pricing
regulation could restrict the amount that we are able to charge for our future therapeutic candidates. Accordingly, in markets outside
the United States, the reimbursement for our therapies may be reduced compared with the United States and may be insufficient to generate
commercially reasonable revenue and profits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will be subject to environmental,
health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental
compliance or remediation activities which may adversely affect our business and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operations, including our research, development,
testing and manufacturing activities, will be subject to numerous foreign, federal, state and local environmental, health and safety
laws and regulations. These laws and regulations govern, among other things, the controlled use, manufacture, handling, release and disposal
of and the maintenance of a registry for, hazardous materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic
compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may incur significant costs to comply with
these current or future environmental and health and safety laws and regulations. Furthermore, if we fail to comply with such laws and
regulations, we could be subject to fines or other sanctions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Risks Relating to Our Intellectual Property
Rights</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The failure to obtain or maintain patents,
licensing agreements and other intellectual property could materially impact our ability to compete effectively.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order for our business to be viable and
to compete effectively, we need to develop and maintain, and we will heavily rely on, a proprietary position with respect to our intellectual
property. However, there are significant risks associated with our actual or proposed intellectual property. The risks and uncertainties
that we face with respect to our rights principally include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">pending patent applications we have filed or will
    file may not result in issued patents or may take longer than we expect to result in issued patents;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">we may be subject to interference proceedings;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">we may be subject to reexamination proceedings;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">we may be subject to post grant review proceedings;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">we may be subject to <i>inter partes </i>review
    proceedings;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">we may be subject to derivation proceedings;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">we may be subject to opposition proceedings in
    the U.S. or in foreign countries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">any patents that are issued or licensed to us may
    not provide us with any competitive advantages or meaningful protection;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">we may not be able to develop additional proprietary
    technologies that are patentable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">other companies may challenge patents licensed
    or issued to us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">other companies may have independently developed
    and patented (or may in the future independently develop and patent) similar or alternative technologies, or duplicate our technologies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">other companies may design around technologies
    we have licensed or developed;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">enforcement of patents is complex, uncertain and
    very expensive and we may not be able to secure, enforce and defend our patents; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">in the event that we were to ever seek to enforce
    our patents in ligation, there is some risk that they could be deemed invalid, not infringed, or unenforceable; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the patents of others may have an adverse effect
    on our business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot be certain that any patents will
be issued as a result of any pending or future applications, or that any patents, once issued, will provide us with adequate protection
from competing products. For example, issued patents may be circumvented or challenged, declared invalid or unenforceable, or narrowed
in scope. In addition, since publication of discoveries in scientific or patent literature often lags behind actual discoveries, we cannot
be certain that we or our licensors were the first to invent or to file patent applications covering them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is also possible that others may have or
may obtain issued patents that could prevent us from commercializing our products or require us to obtain licenses requiring the payment
of significant fees or royalties in order to enable us to conduct our business. There is no guarantee that such licenses will be available
based on commercially reasonable terms. As to those patents that we have licensed, our rights depend on maintaining our obligations to
the licensor under the applicable license agreement, and we may be unable to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to obtain and maintain
patent protection for our products, or if the scope of the patent protection obtained is not sufficiently broad, competitors could develop
and commercialize products similar or identical to ours, and our ability to successfully commercialize our products could be impaired.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent prosecution process is expensive
and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost,
in a timely manner, or in all jurisdictions. It is also possible that we will fail to identify patentable aspects of our development
output before it is too late to obtain patent protection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent position of life science companies
generally is highly uncertain, involves complex legal and factual questions and has in past years been the subject of much litigation.
In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States and we may
fail to seek or obtain patent protection in all major markets. For example, unlike the U.S., European patent law restricts the patentability
of methods of treatment of the human body. Our pending and future patent applications may not result in patents being issued which protect
our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and
products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish
the value of our patents or narrow the scope of our patent protection, even post-grant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recent patent reform legislation has increased
the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. On September
16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of
significant changes to United States patent law. These include provisions that affect the way patent applications are prosecuted and
may also affect patent litigation. The U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) recently developed new regulations and
procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith
Act, and in particular, the first to file provisions, only became effective on March 16, 2013. Accordingly, it is not clear what, if
any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could
increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued
patents, all of which could have a material adverse effect on our business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, we may be subject to a third-party
pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, reexamination, <i>inter partes </i>review,
post-grant review or interference proceedings challenging our patent rights (whether licensed or otherwise held) or the patent rights
of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent
rights (whether licensed or otherwise held), allow third parties to commercialize our products and compete directly with us, without
payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition,
if the breadth or strength of protection provided by our patents and patent applications (whether licensed or otherwise held) is threatened,
it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if our patent applications (whether licensed
or otherwise held) result in the issuance of patents, they may not issue in a form that will provide us with any meaningful protection,
prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent
our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The issuance of a patent is not conclusive
as to its inventorship, scope, validity or enforceability, and our licensed or owned patents may be challenged in the courts or patent
offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims
being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing
similar or identical products, or limit the duration of the patent protection of our products. Given the amount of time required for
the development, testing and regulatory review of new life science product candidates, patents protecting such candidates might expire
before or shortly after such candidates are commercialized. As a result, our intellectual property rights portfolio may not provide us
with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may become involved in lawsuits to
protect or enforce our intellectual property rights, which could be expensive, time-consuming and ultimately unsuccessful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Competitors may infringe our intellectual
property. To counter infringement or unauthorized use, we may be required to sue a third party, or otherwise make a claim, alleging infringement
or other violation of patents, trademarks, trade dress, copyrights, trade secrets, domain names or other intellectual property rights
that we either own or license from a third party. If we do not prevail in enforcing our intellectual property rights in this type of
litigation, we may be subject to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">paying monetary damages related to the legal expenses
    of the third party;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">facing additional competition that may have a significant
    adverse effect on our product pricing, market share, business operations, financial condition, and the commercial viability of our
    product; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">restructuring our Company or delaying or terminating
    select business opportunities, including, but not limited to, research and development, clinical trial, and commercialization activities,
    due to a potential deterioration of our financial condition or market competitiveness.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any claims we assert against perceived infringers
could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property or that our intellectual
property is invalid or unenforceable. The result of these challenges may narrow the scope or claims of or invalidate or found unenforceable
patents that are integral to our product or product candidate. In addition, in a patent infringement proceeding, a court may decide that
a licensed or owned patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse
to stop the other party from using the technology at issue on the grounds that our patents do not cover that technology. Moreover, lawsuits
to protect or enforce our intellectual property rights could be expensive, time-consuming and ultimately unsuccessful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third parties may initiate legal proceedings
alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our commercial success depends upon our ability
to develop, manufacture, market and sell our product candidates without infringing the proprietary rights of third parties. There is
considerable intellectual property litigation in the life sciences industry. We cannot guarantee that our product candidates will not
infringe third-party patents or other proprietary rights. We may become party to, or threatened with, future adversarial proceedings
or litigation regarding intellectual property rights with respect to our products and technology, including <i>inter partes </i>review,
interference, or derivation proceedings before the USPTO and similar bodies in other countries. Third parties may assert infringement
claims against us based on existing intellectual property rights and intellectual property rights that may be granted in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are found to infringe a third party&#8217;s
intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our
products. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able
to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could
be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable
for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding
of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which
could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties
could have a similar negative impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Obtaining and maintaining our patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent
agencies, and our own patent protection could be reduced or eliminated for noncompliance with these requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Periodic maintenance fees and annuities on
any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The
USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other
similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late
fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment
or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance
events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond
to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents.
In such an event, our competitors might be able to enter our markets, which could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims by third
parties asserting that our employees or we have misappropriated their intellectual property or claiming ownership of what we regard as
our own intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may retain employees and contractors that
were previously employed at universities or other companies, including potential competitors. Although we will try to ensure that our
employees and contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims
that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of
any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims, and any such litigation could
have an unfavorable outcome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, while it is our policy to require
our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual
property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that
we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring
claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual
property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail in prosecuting or defending any
such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful
in prosecuting or defending against such claims, litigation could result in substantial costs and adverse results, and be a distraction
to management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with our obligations
in the agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our
business relationships with our licensors, we could lose rights that are important to our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have licensed and may be required to enter
into intellectual property license agreements that are important to our business. These license agreements may impose various diligence,
milestone payment, royalty and other obligations on us. For example, we may enter into exclusive license agreements with various universities
and research institutions, we may be required to use commercially reasonable efforts to engage in various development and commercialization
activities with respect to licensed products, and may need to satisfy specified milestone and royalty payment obligations. If we fail
to comply with any obligations under our agreements with any of these licensors, we may be subject to termination of the license agreement
in whole or in part, increased financial obligations to our licensors or loss of exclusivity in a particular field or territory, in which
case our ability to develop or commercialize products covered by the license agreement will be impaired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, disputes may arise regarding
intellectual property subject to a license agreement, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the scope of rights granted under the license agreement
    and other interpretation-related issues;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the extent to which our processes infringe on intellectual
    property of the licensor that is not subject to the licensing agreement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">our diligence obligations under the license agreement
    and what activities satisfy those obligations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">if a third-party expresses interest in an area
    under a license that we are not pursuing, under the terms of certain of our license agreements, we may be required to sublicense
    rights in that area to a third party, and that sublicense could harm our business; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the ownership of inventions and know-how resulting
    from the joint creation or use of intellectual property by our licensors and us.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Disputes over intellectual property that we
have licensed may prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, and we may be unable
to successfully develop and commercialize our product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intellectual property litigation could
cause us to spend substantial resources and distract our personnel from their normal responsibilities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if resolved in our favor, litigation
or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our
technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results
of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be
negative, it could have an adverse effect on the price of our common stock. Such litigation or proceedings could increase our operating
losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may
not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be
able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources.
Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to
compete in the marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may spend considerable resources
developing and maintaining patents, licensing agreements and other intellectual property that may later be abandoned or may otherwise
never result in products brought to market.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not all technologies and candidate products
that initially show potential as the basis for future products will ultimately meet the rigors of our development process and as a result
may be abandoned and/or never otherwise result in products brought to market. In some cases, prior to abandonment we may be required
to incur significant costs developing and maintaining intellectual property and/or maintaining license agreements and our business could
be harmed by such costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are not able to adequately prevent
disclosure of trade secrets and other proprietary information, the value of our technology and product could be significantly diminished.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on trade secrets to protect our proprietary
technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult
to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored
researchers and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent
disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential
information. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part
of its transparency initiative, is currently considering whether to make additional information publicly available on a routine basis,
including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time
how the FDA&#8217;s disclosure policies may change in the future, if at all. Costly and time-consuming litigation could be necessary
to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely
affect our competitive business position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on information technology, and
if we are unable to protect against service interruptions, data corruption, cyber-based attacks or network security breaches, our operations
could be disrupted, and our business could be negatively affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on information technology networks
and systems to process, transmit and store electronic and financial information; to coordinate our business; and to communicate within
our Company and with customers, suppliers, partners and other third-parties. These information technology systems may be susceptible
to damage, disruptions or shutdowns, hardware or software failures, power outages, computer viruses, cyber-attacks, telecommunication
failures, user errors or catastrophic events. If our information technology systems suffer severe damage, disruption or shutdown, and
our business continuity plans do not effectively resolve the issues in a timely manner, our operations could be disrupted, and our business
could be negatively affected. In addition, cyber-attacks could lead to potential unauthorized access and disclosure of confidential information,
and data loss and corruption. There is no assurance that we will not experience these service interruptions or cyber-attacks in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Other Risks Related to Our Business</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be successful in hiring and
retaining key employees, including executive officers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success materially depends upon the expertise,
experience and continued service of our management and other key personnel, including, but not limited to, Eric Weisblum, our Chief Executive
Officer. If we lose the services of Mr. Weisblum or any of other member of management, our business would be materially and adversely
affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our future success also depends upon our ability
to attract and retain highly qualified management personnel and other employees. There can be no assurance that these professionals will
be available in the market, or that we will be able to retain existing professionals or to meet or to continue to meet their compensation
requirements. Furthermore, the cost base in relation to such compensation, which may include equity compensation, may increase significantly,
which could have a material adverse effect on us. Failure to establish and maintain an effective management team and work force could
adversely affect our ability to operate, grow and manage our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Unfavorable global economic, business
or political conditions could adversely affect our business, financial condition or results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our results of operations could be adversely
affected by general conditions in the global economy and in the global financial markets, including conditions that are outside of our
control, including the impact of health and safety concerns, such as those relating to the current COVID-19 outbreak. The most recent
global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn
could result in a variety of risks to our business, including weakened demand for our products and our ability to raise additional capital
when needed on acceptable terms, if at all. A weak or declining economy could strain our domestic and international customers, possibly
resulting in delays in customer payments. Any of the foregoing could harm our business and we cannot anticipate all the ways in which
the current economic climate and financial market conditions could adversely impact our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Risks Relating to Our Securities</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Certificate of Incorporation grants
our board of directors, without any action or approval by our stockholders, the power to designate and issue preferred stock with rights,
preferences and privileges that may be adverse to the rights of the holders of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The
total number of preferred stock that we are authorized to issue is 5,000,000 shares of which 1,000,000 shares have been&#160; designated
as Series A Preferred Stock, none of which are issued and outstanding as of September 19, 2022, 2,000 shares have been designated as
Series B Preferred Stock, none of which are issued and outstanding as of September 19, 2022 and 4,280 shares have been designated as
Series C Preferred Stock, of which no shares are issued and outstanding as of September 19, 2022. Pursuant to authority granted by our
Certificate of Incorporation, our board of directors, without any action or approval by our stockholders, may issue&#160;preferred stock
in one or more series, the terms of which may be determined at the time of issuance by our board of directors without further action
by stockholders. The terms of any series of preferred stock may include voting rights (including the right to vote as a series on particular
matters), preferences as to dividend, liquidation, conversion and redemption rights and sinking fund provisions.&#160;The rights of holders
of other classes or series of capital stock, including preferred stock that may be issued could be superior to the rights of the holders
of shares of our common stock. The designation and issuance of shares of capital stock having preferential rights could materially adversely
affect&#160;the rights of the holders of our&#160;common stock.&#160;In addition, any issuances of additional capital stock (common or
preferred) will dilute the percentage of ownership interest of our stockholders.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our common stock is subject to the &#8220;penny
stock&#8221; rules of the SEC and the trading market in the securities is limited, which makes transactions in the stock cumbersome and
may reduce the value of an investment in the stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rule 15g-9 under the Securities Exchange Act
of 1934, as amended (the &#8220;Exchange Act&#8221;) establishes the definition of a &#8220;penny stock,&#8221; for the purposes relevant
to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share,
subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require: (a) that a broker or dealer
approve a person&#8217;s account for transactions in penny stocks; and (b) the broker or dealer receive from the investor a written agreement
to the transaction, setting forth the identity and quantity of the penny stock to be purchased.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to approve a person&#8217;s account
for transactions in penny stocks, the broker or dealer must: (a) obtain financial information and investment experience objectives of
the person and (b) make a reasonable determination that the transactions in penny stocks are suitable for that person and the person
has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The broker or dealer must also deliver, prior
to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight
form: (a) sets forth the basis on which the broker or dealer made the suitability determination; and (b) confirms that the broker or
dealer received a signed, written agreement from the investor prior to the transaction. Generally, brokers may be less willing to execute
transactions in securities subject to the &#8220;penny stock&#8221; rules. This may make it more difficult for investors to dispose of
our common stock and cause a decline in the market value of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Disclosure also has to be made about the risks
of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker or
dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor
in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the
penny stock held in the account and information on the limited market in penny stocks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have never paid cash dividends and
have no plans to pay cash dividends in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of shares of our common stock are
entitled to receive such dividends as may be declared by our board of directors. To date, we have paid no cash dividends on our capital
stock and we do not expect to pay cash dividends in the foreseeable future. We intend to retain future earnings, if any, to provide funds
for operations of our business. Therefore, any return investors in our capital stock may have will be in the form of appreciation, if
any, in the market value of their shares of common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our compliance with complicated U.S.
regulations concerning corporate governance and public disclosure is expensive and diverts management&#8217;s attention from our core
business, which could adversely affect our business, results of operations, and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a publicly reporting company, we are faced
with expensive, complicated and evolving disclosure, governance and compliance laws, regulations and standards relating to corporate
governance and public disclosure, including the Sarbanes-Oxley Act and the Dodd-Frank Act, and, following this offering, Nasdaq rules.
As a result of the complexity involved in complying with the applicable rules and regulations, our management&#8217;s attention may be
diverted from other business concerns, which could harm our business, results of operations and financial condition. We may need to hire
more personnel in the future or engage outside consultants, which will increase our operating expenses, to assist us in complying with
these requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, changing laws, regulations and
standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and
financial compliance costs, and making some activities more time-consuming. These laws, regulations and standards are subject to varying
interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time
as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters
and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest substantial resources
to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses
and a diversion of management&#8217;s time and attention from business operations to compliance activities. If our efforts to comply
with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related
to their application and practice, regulatory authorities may initiate legal proceedings against us, and our business may be harmed.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Our common
stock could be subject to extreme volatility.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trading price of our common stock may
be affected by a number of factors, including events described in the risk factors set forth herein and in our other reports filed with
the SEC from time to time, as well as our operating results, financial condition and other events or factors. In addition to the uncertainties
relating to future operating performance and the profitability of operations, factors such as variations in interim financial results
or various, and unpredictable, factors, many of which are beyond our control, may have a negative effect on the market price of our common
stock. In recent years, broad stock market indices, in general, and smaller capitalization companies, in particular, have experienced
substantial price fluctuations. In a volatile market, we may experience wide fluctuations in the market price of our common stock and
wide bid-ask spreads. These fluctuations may have a negative effect on the market price of our common stock. In addition, the securities
market has, from time to time, experienced significant price and volume fluctuations that are not related to the operating performance
of particular companies. These market fluctuations may have a material adverse effect the market price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Market and
economic conditions may negatively impact our business, financial condition and share price.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Concerns over inflation,
energy costs, geopolitical issues, the U.S. mortgage market and a declining real estate market, unstable global credit markets and financial
conditions, and volatile oil prices have led to periods of significant economic instability, diminished liquidity and credit availability,
declines in consumer confidence and discretionary spending, diminished expectations for the global economy and expectations of slower
global economic growth going forward, increased unemployment rates, and increased credit defaults in recent years. Our general business
strategy may be adversely affected by any such economic downturns, volatile business environments and continued unstable or unpredictable
economic and market conditions. If these conditions continue to deteriorate or do not improve, it may make any necessary debt or equity
financing more difficult to complete, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and
on favorable terms could have a material adverse effect on our growth strategy, financial performance, and share price and could require
us to delay or abandon development or commercialization plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Future sales
and issuances of our securities could result in additional dilution of the percentage ownership of our stockholders and could cause our
share price to fall.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">We expect that significant
additional capital will be needed in the future to continue our planned operations, including research and development, increased marketing,
hiring new personnel, commercializing our products, and continuing activities as an operating public company. To the extent we raise
additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible
securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell
common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by
subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior
to our existing stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>We may be at risk of securities
class action litigation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">We may be at risk
of securities class action litigation. In the past, biotechnology and pharmaceutical companies have experienced significant stock price
volatility, particularly when associated with binary events such as clinical trials and product approvals. If we face such litigation,
it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business and
results in a decline in the market price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Financial reporting
obligations of being a public company in the United States are expensive and time-consuming, and our management will be required to devote
substantial time to compliance matters.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">As a publicly traded
company we incur significant legal, accounting and other expenses. The obligations of being a public company in the United States require
significant expenditures and places significant demands on our management and other personnel, including costs resulting from public
company reporting obligations under the Exchange Act and the rules and regulations regarding corporate governance practices, including
those under the Sarbanes-Oxley Act of 2002, as amended (&#8220;Sarbanes-Oxley&#8221;) and the Dodd-Frank Wall Street Reform and Consumer
Protection Act. These rules require the establishment and maintenance of effective disclosure and financial controls and procedures,
internal control over financial reporting and changes in corporate governance practices, among many other complex rules that are often
difficult to implement, monitor and maintain compliance with. Our management and other personnel will need to devote a substantial amount
of time to ensure that we comply with all of these requirements and to keep pace with new regulations, otherwise we may fall out of compliance
and risk becoming subject to litigation among other potential problems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Failure to
maintain effective internal control over our financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could cause
our financial reports to be inaccurate.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">We are required pursuant
to Section 404 of the Sarbanes-Oxley Act, or Section 404, to maintain internal control over financial reporting and to assess and report
on the effectiveness of those controls. This assessment includes disclosure of any material weaknesses identified by our management in
our internal control over financial reporting. Although we prepare our financial statements in accordance with accounting principles
generally accepted in the United States, our internal accounting controls may not meet all standards applicable to companies with publicly
traded securities. If we fail to implement any required improvements to our disclosure controls and procedures, we may be obligated to
report control deficiencies and our independent registered public accounting firm may not be able to certify the effectiveness of our
internal controls over financial reporting. In either case, we could become subject to regulatory sanction or investigation. Further,
these outcomes could damage investor confidence in the accuracy and reliability of our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management has concluded that our internal
controls over financial reporting were, and continue to be, ineffective, as December 31, 2021 as a result of the following: (i) we lacked
segregation of duties within accounting functions duties and lacked monitoring control as a result of our limited financial resources
to support hiring of personnel; and (ii) we not have not implemented adequate system and manual controls. While management intends to
remediate the material weakness, there is no assurance that such changes, when economically feasible and sustainable, will remediate
the identified material weaknesses or that the controls will prevent or detect future material weaknesses. If we are not able to maintain
effective internal control over financial reporting, our financial statements, including related disclosures, may be inaccurate, which
could have a material adverse effect on our business.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to this Offering</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Company will have broad discretion
in the use of the net proceeds from this offering and may fail to apply these proceeds effectively.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s management will have broad
discretion in the application of the net proceeds of this offering, including using the proceeds to conduct operations, expand the Company&#8217;s
business lines and for general working capital. The Company may also use the net proceeds of this offering to acquire or invest in complementary
businesses, products, or technologies, or to obtain the right to use such complementary technologies. We have no commitments with respect
to any acquisition or investment; however, we seek opportunities and transactions that management believes will be advantageous to the
Company and its operations or prospects. We cannot specify with certainty the actual uses of the net proceeds of this offering. You may
not agree with the manner in which our management chooses to allocate and spend the net proceeds. We may invest the net proceeds from
this offering in a manner that does not produce income or that loses value. The failure by our management to apply these funds effectively
could harm our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There is no guarantee that we will successfully
have our common stock listed on the Nasdaq Capital Market. Even if our common stock is accepted for listing on the Nasdaq Capital Market,
upon our satisfaction of the exchange&#8217;s initial listing criteria, the exchange may subsequently delist our common stock if we fail
to comply with ongoing listing standards.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event we are able to list our common
stock on the Nasdaq Capital Market upon our satisfaction of the exchange&#8217;s initial listing criteria, the exchange will require
us to meet certain financial, public float, bid price and liquidity standards on an ongoing basis in order to continue the listing of
our common stock. If we fail to meet these continued listing requirements, our common stock may be subject to delisting. If our common
stock are delisted and we are not able to list such common stock or warrants on another national securities exchange, we expect our securities
would be quoted on an over-the-counter market; However, if this were to occur, our stockholders could face significant material adverse
consequences, including limited availability of market quotations for our common stock and reduced liquidity for the trading of our securities.
In addition, in the event of such delisting, we could experience a decreased ability to issue additional securities and obtain additional
financing in the future. Even if our common stock is listed on the Nasdaq Capital Market, there can be no assurance that an active trading
market for our common stock will develop or be sustained after our initial listing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>You will experience immediate and substantial dilution as
a result of this offering and may experience additional dilution in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">If you purchase shares of common stock in
this offering, the value of your shares based on our actual book value will immediately be less than the price you paid. This reduction
in the value of your equity is known as dilution. This dilution occurs in large part because our existing stockholders paid less than
the assumed public offering price when they acquired their shares of common stock. Based upon the issuance and sale of&#160;588,236 shares
of common stock by us in this offering at an assumed public offering price of $8.50 per share, you will incur immediate dilution of $3.83
in the net tangible book value per share of common stock. If the underwriters exercise their over-allotment option, or if outstanding
options to purchase our common shares are exercised, investors will experience additional dilution. For more information, see &#8220;Dilution.&#8221;</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus contains forward-looking statements
that involve risks and uncertainties. You should not place undue reliance on these forward-looking statements. All statements other than
statements of historical facts contained in this prospectus are forward-looking statements. The forward-looking statements in this prospectus
are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future
events and financial trends that we believe may affect our business, financial condition and results of operations. In some cases, you
can identify these forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221;
&#8220;could,&#8221; &#8220;depends,&#8221; &#8220;estimate,&#8221; &#8220;expects,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;ongoing,&#8221;
&#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221;
&#8220;would&#8221; or the negative of those terms or other similar expressions, although not all forward-looking statements contain
those words. We have based these forward-looking statements on our current expectations and projections about future events and trends
that we believe may affect our financial condition, results of operations, strategy, short-term and long-term business operations and
objectives and financial needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These forward-looking statements are subject
to a number of risks, uncertainties and assumptions, including those described in &#8220;Risk Factors.&#8221; Moreover, we operate in
a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict
all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors,
may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks,
uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur and actual results
could differ materially and adversely from those anticipated or implied in the forward-looking statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should not rely upon forward-looking statements
as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable,
we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking
statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for
the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements
for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should read this prospectus and the documents
that we reference in this prospectus and have filed with the SEC as exhibits to the registration statement of which this prospectus is
a part with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially
different from what we expect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>USE OF PROCEEDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Assuming the sale of all of the 588,236 shares
of common stock in this offering at an assumed offering price of $8.50 per share, the Company estimates that the net proceeds from the
sale of shares it is offering will be approximately $4.15 million. If the underwriters fully exercise the over-allotment option, the
net proceeds will be approximately $4.83 million. &#8220;Net proceeds&#8221; is what the Company expects to receive after deducting the
underwriting discount and commission and estimated offering expenses payable by the Company.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company intends to use the net proceeds
from this offering for product development, marketing and working capital and general corporate purposes.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may also use a portion of the
net proceeds of this offering to acquire or invest in complementary businesses, products, or technologies, or to obtain the right to
use such complementary technologies. The Company has no commitments with respect to any acquisition or investment and is not currently
involved in any negotiations with respect to any such transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus, the Company
cannot specify with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering. The
amounts and timing of its actual expenditures will depend on numerous factors, including the status of its product development efforts,
sales and marketing activities, technological advances, amount of cash generated or used by its operations and competition. Accordingly,
the Company&#8217;s management will have broad discretion in the application of the net proceeds and investors will be relying on the
judgment of its management regarding the application of the proceeds of this offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DIVIDEND POLICY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has not declared nor paid any
cash dividend on its common stock, and it currently intends to retain future earnings, if any, to finance the expansion of its business,
and the Company does not expect to pay any cash dividends in the foreseeable future. &#160;The decision whether to pay cash dividends
on its common stock will be made by its board of directors, in their discretion, and will depend on the Company&#8217;s financial condition,
results of operations, capital requirements and other factors that its board of directors considers significant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAPITALIZATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the Company&#8217;s
cash and capitalization as of June 30, 2022 on:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; padding: 0.25pt; font-size: 10pt">&#160;</td>
    <td style="width: 24px; padding: 0.25pt; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">an actual basis; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; padding: 0.25pt; font-size: 10pt">&#160;</td>
    <td style="width: 24px; padding: 0.25pt; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt; font-size: 10pt; text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">on
                                            a pro forma basis to give effect to the sale and issuance by the Company of 588,236 shares
                                            of common stock being sold in this offering at an assumed public offering price of $8.50
                                            per share, resulting in net proceeds to the Company of approximately $4.15 million after
                                            deducting underwriting discounts and commissions and estimated offering expenses payable
                                            by the Company.</span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this table is unaudited
and is illustrative only and the Company&#8217;s capitalization following the completion of this offering will be adjusted based on the
actual public offering price and other terms of this offering determined at pricing. You should read this table in conjunction with the
information contained in &#8220;Use of Proceeds,&#8221; &#8220;Summary Financial Information&#8221; and &#8220;Management&#8217;s Discussion
and Analysis of Financial Condition and Results of Operation,&#8221; as well as the financial statements and the notes included elsewhere
in this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">June 30,<br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Net<br/>
    Proceeds</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Adjusted</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: right"><span style="-keep: true">(Unaudited)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%"><span style="-keep: true">Cash</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">8,734,434</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">4,146,130</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">12,880,564</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="-keep: true">Stockholders&#8217; Equity</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="-keep: true">Common stock par value $0.0001: 500,000,000 shares authorized; 1,987,906
    shares issued and outstanding as of June 30, 2022</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">199</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">59</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">258</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="-keep: true">Additional paid in capital</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">12,398,889</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,146,071</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">16,544,960</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="-keep: true">Accumulated deficit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(4,525,051</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(4,525,051</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="-keep: true">Total Stockholders&#8217; Equity</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,874,037</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,146,130</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">12,020,167</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="-keep: true">Total Liabilities and Stockholders&#8217; Equity</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">9,044,715</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,146,130</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">13,190,845</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Each $1.00 increase (decrease) in the assumed
public offering price of $8.50 per share would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents,
working capital, total assets and total stockholders&#8217; equity (deficit) by approximately $541,200 ($541,200), assuming that the
number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting
discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 100,000 shares in the
number of shares offered by us at the assumed public offering price of $8.50 per share would increase (decrease) the pro forma as adjusted
amount of each of cash and cash equivalents, working capital, total assets and total stockholders&#8217; equity (deficit) by approximately
$782,000 ($782,000).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of common stock outstanding
is based on 1,987,906 shares of common stock issued and outstanding as of June 30, 2022, and excludes the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">347,080 shares
                                            of common stock issuable upon exercise of warrants with a weighted average exercise price
                                            of $15.50 per share; and</span></p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.9pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">28,849 shares
                                            of common stock issuable upon exercise of options.</span></p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt -0.5in; text-align: justify; text-indent: 48px">Except as
otherwise indicated herein, all information in this prospectus reflects or assumes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.5pt; text-align: justify; text-indent: 40.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; padding: 0.25pt">&#160;</td>
    <td style="width: 24px; padding: 0.25pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt; text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">a one-for-fifty
                                            reverse stock split of our common stock effected on September 15, 2022;</span></p></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; width: 24px">&#160;</td>
    <td style="padding: 0.25pt; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">no exercise of the outstanding options or warrants
    described above; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0.25pt; text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">no exercise
                                            of the underwriters&#8217; option to purchase up to an additional 88,236 shares of common
                                            stock to cover over-allotments, if any.</span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DILUTION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you invest in the Company&#8217;s common
stock in this offering, your ownership interest will be diluted to the extent of the difference between the assumed offering price per
share of its common stock and the as adjusted net tangible book value per share of its common stock immediately after the offering. Historical
net tangible book value per share represents the amount of the Company&#8217;s total tangible assets less total liabilities, divided
by the number of shares of its common stock outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The historical net tangible book value (deficit)
of the Company&#8217;s common stock as of June 30, 2022 was approximately $7,874,037 or $3.96 per share based upon shares of common stock
outstanding on such date. Historical net tangible book value (deficit) per share represents the amount of its total tangible assets reduced
by the amount of its total liabilities, divided by the total number of shares of common stock outstanding. After giving effect to the
Company&#8217;s sale of all of the 588,236 shares offered in this offering at an assumed public offering price of $8.50 per share after
deducting estimated underwriting discounts and commissions and the Company&#8217;s estimated offering expenses, the Company&#8217;s pro
forma as adjusted net tangible book value as of June 30, 2022 would have been $12,020,167 or $4.67&#160;per share. This represents an
immediate increase in net tangible book value of $0.71 per share to the Company&#8217;s existing stockholders, and an immediate dilution
in net tangible book value of $3.83 per share to new investors. The following table illustrates this per share dilution:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-keep: true">Assumed public offering price per share</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"/><td style="width: 9%; text-align: right"/><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">8.50</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">Pro forma net tangible book value per share as of June 30, 2022</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">3.96</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">Increase in net tangible book value per share attributable to new investors
    in this offering</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">0.71</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">Pro forma, as adjusted net tangible book value, after this offering</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">4.67</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">Dilution per share to new investors in this offering</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">3.83</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The information discussed above is illustrative
only, and the dilution information following this offering will be adjusted based on the actual public offering price and other terms
of this offering determined at pricing. A $1.00 increase (decrease) in the assumed public offering price of $8.50 per share would increase
(decrease) the pro forma as adjusted net tangible book value by $0.21 per share and increase (decrease) the dilution to new investors
by $0.79 per share, assuming the number of shares offered by the Company, as set forth on the cover page of this prospectus, remains
the same, and after deducting the estimated underwriting discounts and commissions and estimated expenses payable by the Company. The
Company may also increase or decrease the number of shares it is offering. An increase of 100,000 shares offered by it would increase
the pro forma as adjusted net tangible book value by $0.11 per share and decrease the dilution to new investors by $0.11 per share, assuming
the assumed public offering price of $8.50 per share remains the same and after deducting the estimated underwriting discounts and commissions
and estimated expenses payable by the Company. Similarly, a decrease of 100,000 shares offered by the Company would decrease the pro
forma as adjusted net tangible book value by $0.13 per share and increase the dilution to new investors by $0.13 per share, assuming
the assumed public offering price of $8.50 per share remains the same and after deducting the estimated underwriting discounts and commissions
and estimated expenses payable by the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">If the underwriters&#8217; over-allotment
option to purchase additional shares from the Company is exercised in full, and based on the assumed public offering price of $8.50 per
share, the pro forma as adjusted net tangible book value per share after this offering would be $4.77 per share, the increase in as adjusted
net tangible book value per share to existing stockholders would be $0.81 per share and the dilution to new investors purchasing shares
in this offering would be $3.73 per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of common stock outstanding
is based on 1,987,906 shares of common stock issued and outstanding as of June 30, 2022, and excludes the following:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">347,080 shares
                                            of common stock issuable upon exercise of warrants with a weighted average exercise price
                                            of $15.50 per share; and</span></p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">28,849 shares
                                            of common stock issuable upon exercise of options.</span></p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt -0.5in; text-align: justify; text-indent: 48px">Except as
otherwise indicated herein, all information in this prospectus reflects or assumes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.5pt; text-align: justify; text-indent: 40.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&#160;</td>
    <td style="width: 24px; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><span style="-keep: true">a
                                            one-for-fifty reverse stock split of our common stock effected September 15, 2022;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 24px">&#160;</td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    exercise of the outstanding options or warrants described above; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&#160;</td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&#160;</td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&#160;</td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">no
                                            exercise of the underwriters&#8217; option to purchase up to an additional 88,236 shares
                                            of common stock to cover over-allotments, if any.</span></p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.5pt; text-align: justify; text-indent: 40.5pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>MANAGEMENT&#8217;S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>You should read the following discussion
of our financial condition and results of operations in conjunction with financial statements and notes thereto, as well as the &#8220;Risk
Factors&#8221; and &#8220;Description of Business&#8221; sections included elsewhere in this prospectus. The following discussion contains
forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed
in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere
in this prospectus, particularly in &#8220;Risk Factors.&#8221;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a developmental stage biopharmaceutical
company focused on merging traditional therapeutics with psychedelic research. We are committed to developing innovative solutions to
address a variety of underserved conditions.&#160;In these uncertain times, the mental health of the nation and beyond is being put to
the test. More than ever, creative new therapies are needed to address the health challenges of today. Combining our resources with world-class
medical research partners, we hope to make significant advances in the medical and psychedelic space.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Rare Disease Therapeutics</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We seek to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. We are&#160;focused on merging traditional therapeutics with psychedelic research for people suffering from indications such
as depression, post-traumatic stress disorder (&#8220;PTSD&#8221;), Parkinson&#8217;s, and other rare neurological disorders. Our mission
is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the
health care industry.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Psilocybin is considered a serotonergic hallucinogen
and is an active ingredient in some species of mushrooms. Recent industry studies using psychedelics, such as psilocybin, have been promising,
and we believe there is a large unmet need with many people suffering from depression, mental health issues and neurological disorders.
While classified as a Schedule I substance under the Controlled Substances Act (&#8220;CSA&#8221;), there is an accumulating body of
evidence that psilocybin may have beneficial effects on depression and other mental health conditions. Therefore, the U.S. Food and Drug
Administration (&#8220;FDA&#8221;) and U.S. Drug Enforcement Agency (&#8220;DEA&#8221;) have permitted the use of psilocybin in clinical
studies for the treatment of a range of psychiatric conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The potential of psilocybin therapy in mental
health conditions has been demonstrated in a number of academic-sponsored studies over the last decade. In these early studies, it was
observed that psilocybin therapy provided rapid reductions in depression symptoms after a single high dose, with antidepressant effects
lasting for up to at least six months for a number of patients. These studies assessed symptoms related to depression and anxiety through
a number of widely used and validated scales. The data generated by these studies suggest that psilocybin is generally well-tolerated
and has the potential to treat depression when administered with psychological support.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have engaged in discussions with a number
of world-renowned educational institutions and advisors regarding potential opportunities and have formed a scientific advisory board
that is intended to help advise management regarding potential acquisition and development of products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, as more fully described below,
we have entered into a license agreement with the University of Baltimore, Maryland, and have entered into a joint venture with Zylo
Therapeutics, Inc., with respect to certain intellectual property and technology that may be used for targeted delivery of potential
novel treatments. In addition, we have recently entered into a sponsored research agreement with Columbia University pursuant to which
we have been granted an option to license certain patents and inventions relating to the treatment of Alzheimer&#8217;s disease and stress-induced
affective disorders using Ketamine in combination with certain other compounds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to actively pursue the acquisition
and/or development of intellectual property or technology rights to treat rare diseases, and to ultimately expand our business to focus
on this new line of business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License Agreements between the Company
and a Vendor</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Vendor License Agreement with the University
of Baltimore, Maryland for CNS Homing Peptide</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 12, 2021, we entered into a Master
License Agreement (the &#8220;UMB License Agreement&#8221;) with the University of Maryland, Baltimore (&#8220;UMB&#8221;) pursuant to
which UMB granted us an exclusive, worldwide, sublicensable, royalty-bearing license to certain intellectual property (i) to make, have
made, use, sell, offer to sell, and import certain licensed products and (ii) to use the invention titled, &#8220;Central nervous system-homing
peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology&#8221;
(the &#8220;Invention&#8221;) and UMB&#8217;s confidential information to develop and perform certain licensed processes for the therapeutic
treatment of neuroinflammatory disease. The term of the License Agreement shall commence on the UMB Effective Date and shall continue
until the latest of (i) ten years from the date of First Commercial Sale (as defined in the Sublicense Agreement) of the Licensed Product
in such country and (ii) the date of expiration of the last to expire claim of the Patent Rights (as defined in the UMB License Agreement)
covering such Licensed Product in such country, or (iii) the expiration of data protection, new chemical entity, orphan drug exclusivity,
regulatory exclusivity, or other legally enforceable market exclusivity, if applicable, unless terminated earlier pursuant to the terms
of the agreement. Pursuant to the UMB License Agreement, we agreed to pay UMB (i) a license fee of $75,000, (ii) certain event-based
milestone payments, (iii) royalty payments, depending on net revenues, (iv) minimum royalty payments, and (v) a tiered percentage of
sublicense income. The UMB License Agreement will remain in effect until the later of: (a) the last patent covered under the UMB License
Agreement expires, (b) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other
legally enforceable market exclusivity, if applicable, or (c) ten years after the first commercial sale of a licensed product in that
country, unless earlier terminated in accordance with the provisions of the UMB License Agreement. The term of the UMB License Agreement
shall expire 15 year after the effective date in which (a) there were never any patent rights, (b) there was never any data protection,
new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally enforceable market exclusivity or (c) there was
never a first commercial sale of a licensed product. On January 28, 2022, the Company and University of Maryland, Baltimore (&#8220;UMB&#8221;)
entered into a second amendment to the commercial evaluation and license agreement dated February 26, 2021 (&#8220;Second Amendment&#8221;).
The Second Amendment to extend the term of the original license agreement until December 31, 2022. However, if the Company exercises
the Exclusive Option, the License Agreement shall expire at the end of the negotiation period (as defined in the License Agreement) or
upon execution of a master license agreement, whichever occurs first.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As described below, the Company has entered
into an investigator sponsored research agreement with UMB related to a clinical study to examine a novel peptide-guided drug delivery
approach for the treatment of Multiple Sclerosis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Commercial Evaluation License and Option Agreement with UMB
for Joint Homing Peptide</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of February 26, 2021, the Company,
through its wholly-subsidiary, Silo Pharma, Inc., and University of Maryland, Baltimore (&#8220;UMB&#8221;), entered into a commercial
evaluation license and option agreement (&#8220;License Agreement&#8221;), which granted the Company an exclusive, non-sublicensable,
non-transferable license to with respect to the exploration of the potential use of joint-homing peptides for use in the investigation
and treatment of arthritogenic processes. The License Agreement also granted the Company an exclusive option to negotiate and obtain
an exclusive, sublicensable, royalty-bearing license (&#8220;Exclusive Option&#8221;) to with respect to the subject technology. The
License Agreement had a term of six months from the effective date. Both parties could have terminated the License Agreement within thirty
days by giving a written notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, the Company entered into
a First Amendment Agreement (&#8220;Amended License Agreement&#8221;) with UMB to extend the term of the original License Agreement by
an additional six months such that the Amended License Agreement was effective until February 25, 2022 however, if the Company exercises
the Exclusive Option, the License Agreement shall expire at the end of the negotiation period (as defined in the License Agreement) or
upon execution of a master license agreement, whichever occurs first. The Company paid a license fee of $10,000 to UMB in March 2021
pursuant to the License Agreement, which was expensed, since the Company could not conclude that such costs would be recoverable for
this early-stage venture.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2022, the Company and University
of Maryland, Baltimore (&#8220;UMB&#8221;) entered into a second amendment to the commercial evaluation and license agreement dated February
26, 2021 (&#8220;Second Amendment&#8221;). The Second Amendment to extend the term of the original license agreement until December 31,
2022. However, if the Company exercises the Exclusive Option, the License Agreement shall expire at the end of the negotiation period
(as defined in the License Agreement) or upon execution of a master license agreement, whichever occurs first.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2022, the Parties entered into
a third amendment to the commercial evaluation and license agreement dated February 26, 2021 (&#8220;Third Amendment&#8221;). The Third
Amendment expands the scope of the license granted in the License Agreement to add additional patent rights with respect to an invention
generally known as <i>Peptide-Targeted Liposomal Delivery for Treatment Diagnosis, and Imaging of Diseases and Disorders</i>. In consideration
of the licenses granted under this Third Amendment, Company agreed to pay a one-time, non-refundable fee of $2,500 which was recorded
as research and development expense in the condensed consolidated statement of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>


</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Joint Venture Agreement with Zyl&#246; Therapeutics, Inc. for
Z-pod&#8482; Technology</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 22, 2021, the Company entered into
a Joint Venture Agreement with Zyl&#246; Therapeutics, Inc. (&#8220;ZTI&#8221;) pursuant to which the parties agreed to form a joint
venture entity, to be named Ketamine Joint Venture, LLC, to, among other things, focus on the clinical development of ketamine using
ZTI&#8217;s Z-pod&#8482; technology. Pursuant to the Joint Venture Agreement, the Company shall act as the manager of the Joint Venture.
The Venture shall terminate if the development program does not meet certain specifications and milestones as set forth in the Joint
Venture Agreement within 30 days of the date set forth in the Joint Venture Agreement. Notwithstanding the foregoing, the Manager may,
in its sole discretion, terminate the Venture at any time. As of the current date of this registration statement, the joint venture entity
has not been formed yet.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Joint Venture
Agreement,&#160;(A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and
(B) ZTI shall contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to
the know-how and trade secrets with respect to its Z-pod&#8482; technology for the loading and release of ketamine, (3) ketamine to be
used for clinical purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the Joint
Venture Agreement, 51% of the interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint
Venture shall initially be owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding
the foregoing, in no event shall either party own more than 60% of the interest in the Joint Venture.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, pursuant to the terms of the
JV Agreement, ZTI shall grant the Joint Venture a sublicense pursuant to its license agreement (the &#8220;License Agreement&#8221;)
with Albert Einstein College of Medicine dated November 27, 2017, in the event that the Company or a third party makes a request indicating
that the patented technology (the &#8220;Patented Technology&#8221;) licensed to ZTI pursuant to the License Agreement is needed to advance
the development of the Joint Venture or it is contemplated or determined that the Patented Technology will be sold. Furthermore, pursuant
to the JV Agreement, ZTI granted the Company an exclusive option to enter into a separate joint venture for the clinical development
of psilocybin using ZTI&#8217;s Z-pod&#8482; technology on the same terms and conditions set forth in the JV Agreement, which option
shall expire 24 months after the JV Effective Date. As of the current date of this registration statement, the joint venture entity has
not yet been formed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Investigator-Sponsored Study Agreements
between the Company and Vendors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sponsored Research Agreement with Columbia
University for the Study of Ketamine in Combination with Other Drugs for Treatment of Alzheimer&#8217;s and Depression Disorders</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2021, the Company entered into
a sponsored research agreement with The Trustees of Columbia University in the City of New York (&#8220;Columbia&#8221;) pursuant to
which Columbia shall conduct two different studies related to all uses of Ketamine or its metabolites in combination with Prucalopride,
one of which is related to Alzheimer&#8217;s and the other of which is related to Depression, PTSD and Stress Projects.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, Company has been granted an option
to license certain assets currently under development, including Alzheimer&#8217;s disease. The term of the option will commence on the
effective date of this agreement and will expire upon the earlier of (i) 90 days after the date of the Company&#8217;s receipt of a final
research report for each specific research proposal as defined in the agreement or (ii) termination of the research. If the Company elects
to exercise the option, both parties will commence negotiation of a license agreement and will execute a license agreement no later than
3 months after the dated of the exercise of the option. Columbia University and the Company will work towards developing a therapeutic
treatment for patients suffering from Alzheimer&#8217;s disease to posttraumatic stress disorder. During a one-year period from the date
of this agreement, the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the
payment schedule as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months
after the start of the project and, (iv)10% at completion of the project. The Company paid the first payment of $430,825 in November
2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sponsored Research Agreement with University
of Maryland, Baltimore for the Study of Targeted liposomal drug delivery for rheumatoid arthritis</i></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, we entered into a sponsored
research agreement (the &#8220;July 2021 Sponsored Research Agreement&#8221;) with UMB pursuant to which UMB shall&#160;evaluate the
pharmacokinetics of dexamethasone delivered to arthritic rats via liposome.&#160; The research pursuant to the July 2021 Sponsored Research
Agreement commenced on September 1, 2021 and will continue until the substantial completion thereof, subject to renewal upon written
consent of the parties with a project timeline of twelve months. The July 2021 Sponsored Research Agreement may be terminated by either
party upon 30 days&#8217; prior written notice to the other party. In addition, if either party commits any material breach of or defaults
with respect to any terms or conditions of the July 2021 Sponsored Research Agreement and fails to remedy such default or breach within
10 business days after written notice from the other party, the party giving notice may terminate the July 2021 Sponsored Research Agreement
as of the date of receipt of such notice by the other party. If the Company terminates the July 2021 Sponsored Research Agreement for
any reason other than an uncured material breach by UMB, we shall relinquish any and all rights it may have in the Results (as defined
in the July 2021 Sponsored Research Agreement) to UMB. In addition, if the July 2021 Sponsored Research Agreement is terminated early,
we, among other things, will pay all costs incurred and accrued by UMB as of the date of termination. Pursuant to the terms of the July
2021 Sponsored Research Agreement, UMB granted us an option (the &#8220;Option&#8221;) to negotiate and obtain an exclusive license to
any UMB Arising IP (as defined in the July 2021 Sponsored Research Agreement) and UMB&#8217;s rights in any Joint Arising IP (as defined
in the July 2021 Sponsored Research Agreement) (collectively, the &#8220;UMB IP&#8221;). We may exercise the Option by giving UMB written
notice within 60 days after it receives notice from UMB of the UMB IP. We shall pay total fees of $276,285 as set forth in the July 2021
Sponsored Research Agreement. The Company paid the first payment of $92,095 on September 1, 2021 and partial of the second payment of
$50,000 on February 1, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 7, 2022, the Company and UMB amended
the July 2021 Sponsored Research Agreement whereby both parties agreed to make changes to the original project work and budget.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sponsored Research Agreement with The Regents
of the University of California for the Effect of Psilocybin on Inflammation in the Blood</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021, the Company entered into
a sponsored research agreement with The Regents of the University of California, on behalf of its San Francisco Campus (&#8220;UCSF&#8221;)
pursuant to which UCSF shall conduct a study to examine psilocybin&#8217;s effect on inflammatory activity in humans to accelerate its
implementation as a potential treatment for Parkinson&#8217;s Disease, chronic pain, and bipolar disorder. The purpose of this is to
show what effect psilocybin has on inflammation in the blood. The Company believe that this study will help support the UMB homing peptide
study. Pursuant to the Agreement, we shall pay UCSF a total fee of $342,850 to conduct the research over the two-year period. The Agreement
shall be effective for a period of two years from the effective date, subject to renewal or earlier termination as set forth in the Sponsored
Research Agreement. The Company paid the first payment of $40,000 pursuant to the payment schedule on the Sponsored Research Agreement
on June 15, 2021, second payment of $40,000 on September 9, 2021 and $20,570 on November 18, 2021 and third payment of $60,570 on March
1, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investigator-Sponsored Study Agreement
with UMB for CNS Homing Peptide</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, we entered into an investigator-sponsored
study agreement with UMB. The research project is a clinical study to examine a novel peptide-guided drug delivery approach for the treatment
of Multiple Sclerosis (&#8220;MS&#8221;). More specifically, the study is designed to evaluate (1) whether MS-1-displaying liposomes
can effectively deliver dexamethasone to the central nervous system and (2) whether MS-1-displaying liposomes are superior to plain liposomes,
also known as free drug, in inhibiting the relapses and progression of Experimental Autoimmune Encephalomyelitis. Pursuant to the agreement,
the research commenced on March 1, 2021 and will continue until substantial completion, subject to renewal upon mutual written consent
of the parties.&#160;The total cost under the S investigator-sponsored study agreement shall not exceed $81,474, which is payable in
two equal installments of $40,737 upon execution of the Sponsored Study Agreement and $40,737 upon completion of the project with an
estimated project timeline of nine months. The Company paid $40,737 on January 13, 2021. Currently, the project has not been completed
due to the delays cause by the Covid-19 pandemic.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investigator-Sponsored Study Agreement
with Maastricht University of the Netherlands</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 1, 2020, we entered into an investigator-sponsored
study agreement with Maastricht University of the Netherlands. The research project is a clinical study to examine the effects of repeated
low doses of psilocybin and&#160;lysergic acid diethylamide on cognitive and emotional dysfunctions in Parkinson&#8217;s disease and
to understand its mechanism of action. The agreement shall terminate on October 31, 2024, unless earlier terminated pursuant to the terms
thereof. We shall pay a total fee of 433,885 Euros ($507,602 USD) exclusive of value added tax based on a payment schedule set forth
in the agreement. In December 2020, the Company paid the first payment of $101,520. In September 2021, we notified Maastricht University
of Netherlands for an early termination of this agreement. Maastricht University of Netherlands has not reached the second phase which
is to obtain approval from ethical committee. We have no further obligation after the termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other License Agreements between the Company
and a Customer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Customer Patent License Agreement with
AIkido Pharma Inc.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, we entered into a Patent
License Agreement (the &#8220;AIkido License Agreement&#8221;) with our wholly-owned subsidiary, Silo Pharma, Inc., and AIkido Pharma
Inc. (&#8220;AIkido&#8221;) pursuant to which we granted AIkido an exclusive, worldwide, sublicensable, royalty-bearing license to certain
intellectual property (i) to make, have made, use, provide, import, export, lease, distribute, sell, offer for sale, develop and advertise
certain licensed products and (ii) to develop and perform certain licensed processes for the treatment of cancer and symptoms caused
by cancer. The AIkido License Agreement relates to the rights which we had obtained under the UMB Option Agreement. Pursuant to the AIkido
License Agreement, we agreed that if we exercised the UMB Option, we would grant AIkido a non-exclusive sublicense to certain UMB patent
rights in the field of neuroinflammatory diseases occurring in patients diagnosed with cancer. The UMB Option was exercised on January
13, 2021. Accordingly, on April 6, 2021, we entered into a sublicense agreement with AIkido pursuant to which we granted AIkido a worldwide
exclusive sublicense to our licensed patents under the UMB License Agreement. (See &#8220;<i>Sublicense&#160;with AIkido Pharma Inc.</i>&#8221;).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Customer Sublicense Agreement&#160;with
AIkido Pharma Inc.</i></p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2021 (&#8220;Effective Date&#8221;),
we entered into a sublicense agreement (the &#8220;Sublicense Agreement&#8221;) with AIkido pursuant to which we granted AIkido an exclusive
worldwide sublicense to (i) make, have made, use, sell, offer to sell and import the Licensed Products (as defined below) and (ii) in
connection therewith to (A) use the Invention that was sublicensed to us pursuant to the UMB License Agreement and (B) practice certain
patent rights as set forth in the Sublicense Agreement (the &#8220;Patent Rights&#8221;) for the therapeutic treatment of neuroinflammatory
disease in cancer patients. &#8220;Licensed Products&#8221; means any product, service, or process, the development, making, use, offer
for sale, sale, importation, or providing of which: (i) is covered by one or more claims of the Patent Rights; or (ii) contains, comprises,
utilizes, incorporates, or is derived from the Invention or any technology disclosed in the Patent Rights. Pursuant to the Sublicense
Agreement, AIkido shall agree to pay the Company (i) an upfront license fee of $50,000, (ii)&#160;the same sales-based royalty payments
that we are subject to under the UMB License Agreement and (iii) total milestone payments of up to $1.9 million. The Sublicense Agreement
shall continue on a Licensed Product-by-Licensed Product and country-by-country basis until the later of (i) the date of expiration of
the last to expire claim of the Patent Rights covering such Licensed Product in such country, (ii) the expiration of data protection,
new chemical entity, orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity, if applicable and
(iii) 10 years after the first commercial sale of a Licensed Product in that country, unless terminated earlier pursuant to the terms
of the Sublicense Agreement. Furthermore, the Sublicense Agreement shall expire 15 years after the Effective Date with respect to any
country in which (i) there were never any Patent Rights, (ii) there was never any data protection, new chemical entity, orphan drug exclusivity,
regulatory exclusivity or other legally enforceable market exclusivity with respect to a Licensed Product and (ii) there was never a
commercial sale of a Licensed Product, unless such agreement is earlier terminated pursuant to its terms. The Company collected the upfront
license fee of $50,000 in April 2021.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>COVID-19</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The outbreak of the novel Coronavirus (COVID-19)
evolved into a global pandemic. The Coronavirus has spread to many regions of the world. The extent to which the Coronavirus impacts
the Company&#8217;s business and operating results will depend on future developments that are highly uncertain and cannot be accurately
predicted, including new information that may emerge concerning the Coronavirus and the actions to contain the Coronavirus or treat its
impact, among others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the continuing spread of the
Coronavirus, certain aspects of the Company&#8217;s business operations may be delayed or subject to interruptions. Specifically, as
a result of the shelter-in-place orders and other mandated local travel restrictions, among other things, the research and development
activities of certain of the Company&#8217;s partners may be affected, which may result in delays to the Company&#8217;s clinical trials,
and the Company can provide no assurance as to when such trials, if delayed, will resume at this time or the revised timeline to complete
trials once resumed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, site initiation, participant
recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis may be delayed
due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic
efforts, or other reasons related to the pandemic. If the Coronavirus continues to spread, some participants and clinical investigators
may not be able to comply with clinical trial protocols. For example, quarantines or other travel limitations (whether voluntary or required)
may impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, and the Company may be unable
to conduct its clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Infections and deaths related to the pandemic
may disrupt the United States&#8217; healthcare and healthcare regulatory systems. Such disruptions could divert healthcare resources
away from, or materially delay U.S. Food and Drug Administration review and/or approval with respect to the Company&#8217;s clinical
trials. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of the Company&#8217;s
clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of the
Company&#8217;s product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The spread of the Coronavirus, which has caused
a broad impact globally, including restrictions on travel and quarantine policies put into place by businesses and governments, may have
a material economic effect on the Company&#8217;s business. While the potential economic impact brought by and the duration of the pandemic
may be difficult to assess or predict, it has already caused, and is likely to result in further, significant disruption of global financial
markets, which may negatively impact the Company&#8217;s ability to access capital on favorable terms, if at all. In addition, a recession,
depression or other sustained adverse market event resulting from the spread of the Coronavirus could materially and adversely affect
the Company&#8217;s business and the value of its common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ultimate impact of the current pandemic,
or any other health epidemic, is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays
or impacts on its business, its clinical trials, its research programs, healthcare systems or the global economy as a whole. However,
these effects could have a material impact on the Company&#8217;s operations, and the Company will continue to monitor the situation
closely.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2022 and December 31, 2021, equity
investments, at fair value of $113,012 and $419,995, respectively, comprised mainly of marketable common stock are recorded at fair value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Comparison of Our Results of Operations
for the Three and Six Months Ended June 30, 2022 and 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the results
of operations for the three and six months ended June 30, 2022 and 2021 based primarily on the comparative condensed consolidated financial
statements, footnotes and related information for the periods identified, and should be read in conjunction with our condensed consolidated
financial statements and the notes to those statements that are included elsewhere in this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Six Months</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,026</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,051</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">35,213</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,459</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,460</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,919</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,085</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,566</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,566</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,132</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,128</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(510,851</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(453,415</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,054,676</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,371,113</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating loss from continuing operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(494,285</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(436,849</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,021,544</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,337,985</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(164,117</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,042</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(239,767</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,443</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss from discontinued operations, net of tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(73,183</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,163</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(140,150</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(658,402</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(461,990</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,262,474</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,392,692</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenues </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30, 2022
and 2021, revenues consisted of revenues on licensing fees related to our biopharmaceutical operation of $18,025 and $18,026, respectively.
Such revenues are primarily related to the Aikido License and Sublicense Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended June 30, 2022
and 2021, revenues consisted of revenues on licensing fees related to our biopharmaceutical operation of $36,051 and $35,313, respectively.
Such revenues are primarily related to the Aikido License and Sublicense Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cost of Revenues</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30, 2022
and 2021, cost of revenues on license fees related to our biopharmaceutical operation amounted to $1,459 and $1,460, respectively. The
primary components of cost of revenues on license fees include the cost of the license fees primarily related to the UMB License and
Sublicense Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended June 30, 2022
and 2021, cost of revenues on license fees related to our biopharmaceutical operation amounted to $2,919 and $2,085, respectively. The
primary components of cost of revenues on license fees include the cost of the license fees primarily related to the UMB License and
Sublicense Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and six months ended June
30, 2022 and 2021, total operating expenses consisted of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Six Months</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Compensation expense</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">100,212</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">54,942</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">227,393</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">164,234</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">248,179</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">270,906</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">444,427</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">942,475</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98,846</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">275,955</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">147,448</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Insurance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,866</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,015</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,158</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,721</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bad debt recovery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(46,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(53,500</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Selling, general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,918</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,706</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62,743</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">116,735</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total operating expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">510,851</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">453,415</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,054,676</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,371,113</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Compensation
    Expense</span>:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="text-align: justify; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0">During the three months ended June 30, 2022 and 2021,
                                    compensation expense were $100,212 and $54,942, respectively, an increase of $45,270 or 82%. This
                                    increase resulted from an increase in stock-based compensation of $29,236, an increase in BOD fees
                                    of $11,000, an increase payroll expense of $5,400 offset by a decrease in other payroll related expenses
                                    of $366.</p>
                                    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                    <p style="margin-top: 0; margin-bottom: 0">During the six months ended June 30, 2022 and 2021,
                                    compensation expense were $227,393 and $164,234, respectively, an increase of $63,159 or 36%. This
                                    increase resulted from an increase in stock-based compensation of $74,245, an increase in BOD fees
                                    of $22,000, an increase payroll expense of $15,400 and an increase in other payroll related expenses
                                    of $10,014 offset by a decrease in bonus of $61,500. &#160;</p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Professional
    Fees</span>:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="text-align: justify; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0">During the three months ended June 30, 2022 and 2021,
                                    professional fees were $248,179 and $270,906, respectively, a decrease of $22,727 or 8%. The decrease
                                    was attributable to a decrease in stock-based consulting fees of $6,748 related to the issuance of
                                    shares to consultants, a decrease in consulting fees of $67,781 and a decrease in accounting fees
                                    of $7,345 offset by an increase in investor relation fees of $36,443 and increase of legal fees of
                                    $22,704.</p>
                                    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                    <p style="margin-top: 0; margin-bottom: 0">During the six months ended June 30, 2022 and 2021,
                                    professional fees were $444,427 and $942,475, respectively, a decrease of $498,048 or 53%. The decrease
                                    was attributable to a decrease in stock-based consulting fees of $107,970 related to the issuance
                                    of shares to consultants, a decrease in consulting fees of $181,865, a decrease in investor relation
                                    fees of $104,496 and a decrease of legal fees of $104,922 offset by increase in accounting fees of
                                    $1,205. &#160;</p></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Research
    and Development</span>:</i></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="text-align: justify; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0">During the three months ended June 30, 2022 and 2021,
                                    research and development were $105,676 and $98,846, respectively, an increase of $6,830 or 7%. The
                                    increase was primarily attributable to research and development costs in connection with the investigator-sponsored
                                    study agreement with University of Columbia, UCSF and UMB.</p>
                                    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                    <p style="margin-top: 0; margin-bottom: 0">During the six months ended June 30, 2022 and 2021,
                                    research and development were $275,955 and $147,448, respectively, an increase of $128,507 or 82%.
                                    The increase was primarily attributable to research and development costs in connection with the
                                    investigator-sponsored study agreement with University of Columbia, UCSF and UMB.</p></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Insurance
    Expense</span>:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="text-align: justify; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0">During the three months ended June 30, 2022 and 2021,
                                    insurance expense were $30,866 and $29,015, respectively, an increase of $1,851 or 6%. This increase
                                    was a result of increase in the cost of renewal of D&amp;O insurance policy.</p>
                                    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                    <p style="margin-top: 0; margin-bottom: 0">During the six months ended June 30, 2022 and 2021,
                                    insurance expense were $64,158 and $50,721, respectively, an increase of $13,437 or 27%. This increase
                                    was a result of increase in the cost of renewal of D&amp;O insurance policy.</p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Bad
    Debt Recovery</span>:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="text-align: justify; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0">During the three months ended June 30, 2022 and 2021,
                                    bad debt recovery were $0 and $46,000, respectively, a decrease of $46,000 or 100%. We recorded bad
                                    debt recovery from the collection of a previously written off note receivable deemed uncollectible.</p>
                                    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                    <p style="margin-top: 0; margin-bottom: 0">During the six months ended June 30, 2022 and 2021,
                                    bad debt recovery were $20,000 and $53,500, respectively, a decrease of $33,500 or 63%. We recorded
                                    bad debt recovery from the collection of a previously written off note receivable deemed uncollectible.</p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Selling,
    General and Administrative Expenses</span>:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="text-align: justify; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0">Selling, general and administrative expenses consist
                                    of advertising and promotion, patent related expenses, transfer agent fees, custodian fees, bank
                                    service charges, travel, and other fees and expenses.</p>
                                    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                    <p style="margin-top: 0; margin-bottom: 0">During the three months ended June 30, 2022 and 2021,
                                    selling, general and administrative expenses were $25,918 and $45,706, respectively, a decrease of
                                    $19,788 or 43%. The decrease was primarily attributable to a decrease in filing fees of $10,644,
                                    a decrease in transfer agent fees of $10,471, offset by an increase in other administrative expenses
                                    of $1,347</p>
                                    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                    <p style="margin-top: 0; margin-bottom: 0">During the six months ended June 30, 2022 and 2021,
                                    selling, general and administrative expenses were $62,743 and $116,735, respectively, a decrease
                                    of $53,992 or 46%. The decrease was primarily attributable to a decrease in filing fees of $22,840,
                                    a decrease in patent expense of $17,230 and a decrease in proxy meeting expense of $19,863, offset
                                    by an increase in insurance expense of $13,437 and an increase in other administrative expenses of
                                    $7,496. .</p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Loss from Continuing Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30, 2022
and 2021, operating loss from continuing operations&#160;amounted to $494,285 and $436,849, respectively, an increase of $57,436 or 13%.
The increase was primarily a result of the changes in operating expenses discussed above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended June 30, 2022
and 2021, operating loss from continuing operations&#160;amounted to $1,021,544 and $1,337,985, respectively, a decrease of $316,441
or 24%. The increase was primarily a result of the changes in operating expenses discussed above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Income (Expenses), net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30, 2022
and 2021, other (expense), net amounted to $(164,117) and other income, net amounted to $48,042, respectively, an increase in other (expense),
net of $(212,159) or 442%. The increase in other (expense), net was primarily due to an increase in net unrealized (loss) on equity investment
of $(89,511), an increase in net realized (loss) on equity investment of $(104,700) from the sale of equity investment, increase in net
interest income of $1,417 resulting from the interest on note receivable, an increase in other expense of $(283) offset by a decrease
in gain on forgiveness of PPP notes payable from 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended June 30, 2022
and 2021, other (expense), net amounted to $(239,767) and other income, net amounted to $85,443, respectively, an increase in other (expense),
net of $(352,210) or 381%. The increase in other (expense), net was primarily due to an increase in net unrealized (loss) on equity investment
of $(290,059), an increase in net realized (loss) on equity investment of $(104,700) from the sale of equity investment, increase in
net interest income of $3,181 resulting from the interest on note receivable and an increase in other expense of $(283) and an increase
in other income of $85,733 resulting from the grant date fair value of Home Bistro, Inc common stock received in exchange for entering
into a lock up agreement with Home Bistro, Inc and a decrease in gain on forgiveness of PPP notes payable from 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Loss from Discontinued Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30, 2022
and 2021, loss from discontinued operations amounted to $0 and $73,183, respectively, a decrease of $73,183 or 100%. The decrease was
primarily due to a sale of the Company&#8217;s NFID business in September 2021. (NFID was a streetwear apparel brand featuring lifestyles
graphic designs that we originally acquired in 2018.)</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended June 30, 2022
and 2021, loss from discontinued operations amounted to $1,163 and $140,150, respectively, a decrease of $138,987 or 99%. The decrease
was primarily due to a sale of the Company&#8217;s NFID business in September 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preferred Stock Dividend</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30, 2022
and 2021, there were no deemed dividends.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended June 30, 2022
and 2021, dividends amounted to $0 and $1,403,997 respectively, a decrease of $1,403,997 or 100%. In 2021, the Company recorded $1,403,997
of deemed dividends resulting from the beneficial conversion feature in connection with the issuance of Series C Convertible Preferred
Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Loss Available to Common Stockholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the three months ended June 30, 2022
and 2021, net loss available to common stockholders amounted to $658,402 or $(0.33) per common share (basic and diluted), and $461,990
or $(0.24) per common share (basic and diluted), respectively, an increase of $196,412 or 43%. The increase was primarily a result of
the changes discussed above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="-keep: true">During the six months ended June 30, 2022
and 2021, net loss available to common stockholders amounted to $1,262,474 or $(0.64) per common share (basic and diluted), and $2,796,689
or $(1.54) per common share (basic and diluted), respectively, a decrease of $1,534,215 or 55%. The decrease was primarily a result of
the changes discussed above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Comparison of Our Results of Operations for the Years Ended
December 31, 2021 and 2020</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the results
of operations for the years ending December 31, 2021 and 2020 and were based primarily on the comparative audited financial statements,
footnotes and related information for the periods identified and should be read in conjunction with the consolidated financial statements
and the notes to those statements that are included elsewhere in this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">71,264</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,004</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,260</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,810,603</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,201,719</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating loss from continuing operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,744,343</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,201,719</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,926,327</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(464,550</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Provision for income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(24,876</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss from discontinued operations, net of tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(253,367</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(371,248</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Net income (loss)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,903,741</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(3,037,517</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenues </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2021 and
2020, we generated minimal revenues from operations. For the year ended December 31, 2021, revenues consisted of revenues on licensing
fees related to our biopharmaceutical operation of $71,264, as compared to $0 for the year ended December 31, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cost of Revenues</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2021, cost
of revenues on license fees related to our biopharmaceutical operation amounted to $5,004, as compared to $0 for the year ended December
31, 2020. The primary components of cost of revenues on license fees include the cost of the license fees primarily related to the UMB
License and Sublicense Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2021 and
2020, total operating expenses consisted of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended<br/> December
    31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Compensation expense</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">395,123</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">755,993</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,598,367</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,173,717</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">693,910</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Insurance expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,191</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bad debt (recovery) expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(148,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165,376</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Selling, general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">162,953</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,192</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,810,603</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,201,719</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Compensation
    Expense</span>:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended
    December 31, 2021 and 2020, compensation expense was $395,123 and $755,993, respectively, a decreased of $360,870 or 48%. This decrease
    was primarily attributable to a decrease in stock-based compensation related to the issuance of stock to our chief executive officer
    for his employment agreement of $610,476 in 2020 offset by an increase of our Chief Executive Officer&#8217;s compensation and related
    benefits expense of $63,605, increase in other compensation expense of $4,500 and bonuses paid to our Chief Executive Officer and
    directors of an aggregate amount of $181,500.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Professional
    Fees</span>:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended
    December 31, 2021 and 2020, professional fees were $1,598,367 and $1,173,717, respectively, an increase of $424,650 or 36%. The increase
    was primarily attributable to an increase other consulting fees of $565,720, an increase in legal fees of $122,412, an increase in
    investor relation fees of $170,652, an increase in option fees of $10,000, and an increase in accounting fees of $46,362 offset by
    a decrease in auditing fees of $19,542 and a decrease in stock-based consulting fees of $470,954 related to the issuance of shares
    to consultants for business advisory and strategic planning services.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Research
    and Development:</span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December
    31, 2021 and 2020, we incurred $693,910 and $26,250, respectively, an increase of $667,660 or 2,544%. The increase was a result of
    increase in research and development costs in connection with the Investigator-sponsored Study Agreement with Maastricht University,
    UCSF, UMB and Columbia University.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Insurance
    Expense</span>:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December
    31, 2021 and 2020, insurance expense was $108,750 and $30,191, respectively, increased by $78,559 or 260%. The increase was a result
    of increases in the cost of renewal of certain insurance policies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Bad
    Debt (Recovery) Expense, net:</span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December
    31, 2021 and 2020, we recorded bad debt recovery (expense) of $148,500 and ($165,376). For the year ended December 31, 2021, we recorded
    bad debt recovery of $148,500 from the collection of a previously written off notes receivable deemed uncollectible. For the year
    ended December 31, 2020, the Company recorded bad debt (expense) of ($174,376) and bad debt recovery of $9,000 for a net recorded
    bad debt (expense) of ($165,376). </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Selling,
    General and Administrative Expenses</span>:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling, general and
    administrative expenses include advertising and promotion, patent related expenses, public company expenses, custodian fees, bank
    service charges, travel, and other office expenses. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December
    31, 2021 and 2020, selling, general and administrative expenses were $162,953 and $50,192, respectively, an increase of $112,761,
    or 225%. The increase was primarily attributed to an increase in public company expenses of $62,908, an increase in annual meeting
    proxy expense of $20,000, an increase in patent related expenses of $21,015 and an increase in other office expenses of $8,838.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Loss from Continuing Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2021 and
2020, operating loss from continuing operations&#160;amounted to $2,744,343 and $2,201,719, respectively, an increase of $542,624 or
25%. The increase was primarily a result of the changes in operating expenses discussed above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Income (Expenses), net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2021 and 2020,
other income, net amounted to $6,926,327 and other (expenses), net amounted to ($464,550), respectively, an increase of $7,390,877 or
1,591%. The change in other income (expenses), net was primarily due to an increase in gain on forgiveness of PPP note payable of $19,082,
an increase in net realized gain on equity investments of $6,660,483 resulting from sale of our equity investments and an increase in
net unrealized gain of $257,782 offset by a decrease of net interest expense of $255,898 resulting from the increase in fair value of
our equity investments, offset by a decrease in other income of $3,000, a decrease of foreign exchange loss of $2,950 and a decrease
in loss on debt extinguishment of $197,682 incurred in 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Loss from Discontinued Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2021 and 2020,
loss from discontinued operations amounted to $253,367 and $371,248, respectively, a decrease of $117,881 or 32%. The decrease was primarily
due to a sale of the Company&#8217;s NFID business in September 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preferred Stock Dividend</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2021 and 2020,
dividends amounted to $1,403,997 and $69,000, respectively, an increase of $1,334,997 or 1,935%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">For the year ended December 31, 2020, the
Company recorded $69,000 of deemed dividends in connection with exchange agreement dated April 15, 2020 whereby shares of Series B preferred
stock and accompanying warrants were converted at a rate of $4.00 instead of the original rate of $10.00 resulting in the issuance of
additional shares of common stock valued at $69,000 which was recorded as deemed dividends.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2021, the
Company recorded $1,403,997 of deemed dividends resulting from the beneficial conversion feature in connection with the issuance of these
Series C Convertible Preferred Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Income (Loss) Available to Common
Stockholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">For the years ended December 31, 2021 and
2020, net income available to common stockholders amounted to $2,499,744 or $1.32 per common share (basic) and $1.30 per common share
(diluted), and net (loss) $(3,106,517), or $(2.07) per common share (basic and diluted), respectively, a change of $5,606,261, or 180%.
The increase was primarily a result of the increase in operating expenses, and offset by other income, net discussed above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Liquidity and
Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liquidity is the ability of an enterprise
to generate adequate amounts of cash to meet its needs for cash requirements. We had a working capital of $8,678,540 and $8,734,434 in
cash and cash equivalents as of June 30, 2022 and working capital of $9,912,281 and $9,837,001 in cash and cash equivalents as of December
31, 2021</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Working Capital<br/> Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage<br/> Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Working capital:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt">Total current assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,947,385</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,402,320</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,454,935</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">14</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(268,845</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(490,039</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">221,194</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">45</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Working capital:</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,678,540</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,912,281</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,233,741</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">12</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The decrease in working capital of $1,233,741
was primarily attributable to a decrease in current assets of $1,454,936 primarily due to decrease in cash of approximately $1,102,567,
decrease in equity investments of $306,983 and a decrease in accounts payable of $262,013.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We had a working capital of $9,912,281 and
$9,837,001 in cash and cash equivalents as of December 31, 2021 and working capital of $1,284,941 and $1,128,389 in cash and cash equivalents
as of December 31, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Working<br/> Capital<br/> Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage<br/> Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Working capital:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Total current assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,402,320</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,426,664</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,975,656</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">629</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(490,039</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(141,723</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(348,316</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">246</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Working capital:</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,912,281</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,284,941</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,627,340</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">671</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The increase in working capital of $8,627,340
was primarily attributable to an increase in current assets of $8,975,656 primarily due to increase in cash of $8.7 million and an increase
in current liabilities of $348,316.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><i><span style="text-decoration:underline">Cash Flows</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">A summary of cash flow activities is summarized
as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Six months <br/> Ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Six months<br/> Ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Cash (used in) operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,189,274</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(841,063</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,278,016</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(1,156,996</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Cash provided by investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86,707</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,192,526</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,794,102</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,794,102</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,134,663</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Net (decrease) increase in cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,102,567</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,022,539</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,708,612</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,016,637</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="text-decoration:underline">Net Cash (Used in) Operating Activities</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in operating activities for
the six months ended June 30, 2022 and 2021 were $1,189,274 and $841,063, respectively, an increase of $348,211 or 41%. Net cash used
in operating activities for the years ended December 31, 2021 and 2020 were $2,278,016 and $1,156,996, respectively, an increase of $1,121,020
or 97%.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Net
                                            cash used in operating activities for the six months ended June 30, 2022 primarily reflected
                                            a net loss of $1,262,474 adjusted for the add-back of non-cash items such as bad debt recovery
                                            of $20,000, stock-based compensation of $74,245, net realized loss on equity investments
                                            of $104,700, net unrealized loss on equity investments of $221,309, non-cash income from
                                            equity investment of $85,733 and changes in operating asset and liabilities primarily consisting
                                            of an increase of interest receivable of $2,380, an increase in insurance payable of $40,819
                                            offset by a decrease in prepaid expenses and other current assets of $38,304, a decrease
                                            in accounts payable and accrued expenses of $262,013 and decrease in deferred revenue of
                                            $36,051. Net cash used in operating activities for the year ended December 31, 2021 primarily
                                            reflected a net income of $3,903,741 adjusted for the add-back of non-cash items such net
                                            realized gain on equity investments of $6,660,483, net unrealized gain on equity investments
                                            of $248,588, bad debt recovery of $148,500, amortization of prepaid stock-based compensation
                                            of $107,970, stock-based compensation of $83,728, gain on forgiveness of PPP note payable
                                            of $19,082, gain on disposal of assets from discontinued operations of $1,553 and changes
                                            in operating asset and liabilities primarily consisting of an increase in prepaid expenses
                                            and other current assets of $38,862, an increase in assets of discontinued operations of
                                            $24,963, an increase of interest receivable of $1,210, an increase in accounts payable and
                                            accrued expenses of $291,050 and an increase in deferred revenue of $478,736.</p></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Net
                                            cash used in operating activities for the six months ended June 30, 2021 primarily reflected
                                            a net loss of $1,392,692 adjusted for the add-back of non-cash items such bad debt recovery
                                            of $46,000, net unrealized gain on equity investments of $68,750, stock-based compensation
                                            of $83,728, amortization of prepaid stock-based compensation of $107,970, gain on forgiveness
                                            of PPP note payable of $19,082 and changes in operating asset and liabilities primarily consisting
                                            of an increase in prepaid expenses and other current assets of $64,047, an increase in assets
                                            of discontinued operations of $22,123, an increase in accounts payable and accrued expenses
                                            of $65,146 and an increase in deferred revenue of $514,787. Net cash used in operating activities
                                            for the year ended December 31, 2020 primarily reflected a net loss of $3,037,517 adjusted
                                            for the add-back of non-cash items such as net bad debt expense of $165,376, total stock-based
                                            compensation of $610,476, amortization of debt discount of $268,125, inventory write-down
                                            of $137,947, net unrealized loss of $9,194, loss from debt extinguishment of $197,682 and
                                            changes in operating asset and liabilities primarily consisting of an increase in prepaid
                                            expenses and other current assets of $144,663, an increase in inventory of $15,065 and an
                                            increase in accounts payable and accrued expenses of $72,525.</p></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="text-decoration:underline">Net Cash Provided by Investing Activities</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net
                                            cash provided by investing activities for the six months ended June 30, 2022 and 2021 were
                                            $86,707 and $69,500, respectively, an increase of $17,207 or 25%. Net cash provided by investing
                                            activities for the six months ended June 30, 2022 was $20,000 from proceeds from notes receivable
                                            collection and $66,707 net proceeds from sale of equity investment. Net cash provided by
                                            investing activities for the six months ended June 30, 2021 was $69,500 which consisted of
                                            proceeds from collection of previously written off notes receivable of $7,500 and proceeds
                                            from notes receivable collection of $62,000. Net cash provided by investing activities for
                                            the year ended December 31, 2021 was $7,192,526 which consisted of aggregate proceeds from
                                            sale of equity investments in Aikido and DatChat, Inc. of $7,020,526, proceeds from collection
                                            of previously written off notes receivable of $7,500 and proceeds from notes receivable collection
                                            of $164,500. Net cash provided by investing activities for the year ended December 31, 2020
                                            was $39,000 from collection notes receivable</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="text-decoration:underline">Net Cash Provided by Financing Activities</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by financing activities
for the six months ended June 30, 2022 and 2021 were $0 and $3,794,102, respectively, an increase of $3,794,102 or 100%. Net cash provided
by financing activities for the six months ended June 30, 2021 was $3,794,102 which consisted of net proceeds from sale of preferred
stock of $3,794,102, proceeds from a related party advance of $2,366 offset by a related party advance repayment of $2,366. Net cash
provided by financing activities for the year ended December 31, 2021 was $3,794,102 which consisted of net proceeds from sale of preferred
stock of $3,794,102, proceeds from a related party advance of $2,366 offset by repayment of the related party advance of $2,366. Net
cash provided by financing activities for the year ended December 31, 2020 was $2,134,633 which consisted of proceeds from note payable
&#8211; related party of $35,000, proceeds from note payable of $18,900. Proceeds from sale of common stock of $2,115,733 offset by repayment
of note payable &#8211; related party of $35,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Cash Requirements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company believes
that the proceeds from the sale of our equity investments of $7,020,526 and the proceeds from the sale of our preferred stock of $3,794,102
amounting to aggregate proceeds of $10,814,628, during the year ended December 31, 2021, will provide sufficient cash required to meet
our obligations for a minimum of twelve months from the date of this filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">We currently have
no material commitments for any capital expenditures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Liquidity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">As reflected in the
accompanying consolidated financial statements, the Company generated a net income of $3,903,741 and used cash in operations of $2,278,016,
for the year ended December 31, 2021. Additionally, the Company has an accumulated deficit of $3,262,577 at December 31, 2021. During
the year ended December 31, 2021, the Company has received gross proceeds of approximately $7,020,526 from the sale of equity investments.
As of December 31, 2021, the Company had working capital of $9,912,281.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">These events served to mitigate the conditions
that historically raised substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company believes the
proceeds received during the year ended December 31, 2021 will provide sufficient cash flows to meet its obligations for a minimum of
twelve months from the date of this filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>


</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Off-Balance
Sheet Arrangements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">As of December 31,
2021 and June 30, 2022, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K or any
commitments or contractual obligations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Critical Accounting
Policies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Basis of Presentation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The accompanying
condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America, (&#8220;U.S. GAAP&#8221;).</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Cash and Cash
Equivalents</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">We consider all highly
liquid instruments purchased with an original maturity of three months or less and money market accounts to be cash equivalents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Equity Investments,
at fair value</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Equity investments
are carried at fair value with unrealized gains or losses included in income (expense).&#160;Realized gains and losses are determined
on a specific identification basis and are included in other income (expense). We review equity investments, at fair value for impairment
whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recovered.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Equity Investments, at Cost</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Equity investments,
at cost are comprised mainly of non-marketable capital stock and stock warrants, are recorded at cost, as adjusted for other than temporary
impairment write-downs and are evaluated for impairment periodically.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Fair Value
of Financial Instruments and Fair Value Measurements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">We use the guidance
of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 820 for fair value measurements which clarifies the definition of fair
value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair
value as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Level 1-Inputs are
unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Level 2-Inputs are
unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities
in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable
market data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>


</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Level 3-Inputs are
unobservable inputs which reflect the reporting entity&#8217;s own assumptions on what assumptions the market participants would use
in pricing the asset or liability based on the best available information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The carrying amounts
reported in the balance sheets for cash, prepaid expenses and other current assets, and accounts payable and accrued expenses approximate
their fair market value based on the short-term maturity of these instruments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Revenue Recognition</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">We apply ASC Topic
606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). ASC 606 establishes a single comprehensive model for entities to
use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance.
This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount
that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires
certain additional disclosures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">We record interest
and dividend income on an accrual basis to the extent that we expect to collect such amounts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">For license and royalty
income, revenue is recognized when we satisfy the performance obligation based on the related license agreement. Payments received from
licensee that are related to future periods are recorded as deferred revenue to be recognized as revenues over the term of the related
license agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Product sales were
recognized when the NFID products were shipped to the customer and title was transferred and were recorded net of any discounts or allowances
which are separately reported as &#8220;discontinued operations&#8221; on the condensed consolidated statements of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Stock-based
Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Stock-based compensation
is accounted for based on the requirements of ASC 718 &#8211; &#8220;Compensation &#8211;Stock Compensation&#8221;, which requires recognition
in the financial statements of the cost of employee, director, and non-employee services received in exchange for an award of equity
instruments over the period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively,
the vesting period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange
for an award based on the grant-date fair value of the award. We have elected to recognize forfeitures as they occur as permitted under
Accounting Standards Update 2016-09 Improvements to Employee Share-Based Payment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Income Taxes</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Deferred income tax
assets and liabilities arise from temporary differences between the financial statements and tax basis of assets and liabilities, as
measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities
are classified as current or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred
tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in
which the temporary differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets
to the amount expected to be realized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">We follow the provisions
of Financial Accounting Standards Board ASC 740-10, &#8220;Uncertainty in Income Taxes&#8221;. Certain recognition thresholds must be
met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax positions
that meet a &#8220;more-likely-than-not&#8221; threshold. We do not believe we have any uncertain tax positions as of June 30, 2022 that
would require either recognition or disclosure in the accompanying financial statements.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BUSINESS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a developmental stage biopharmaceutical
company focused on merging traditional therapeutics with psychedelic research. We are committed to developing innovative solutions to
address a variety of underserved conditions.&#160;In these uncertain times, the mental health of the nation and beyond is being put to
the test. More than ever, creative new therapies are needed to address the health challenges of today. Combining our resources with world-class
medical research partners, we hope to make significant advances in the medical and psychedelic space.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Rare Disease Therapeutics</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We seek to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. We are&#160;focused on merging traditional therapeutics with psychedelic research for people suffering from indications such
as depression, post-traumatic stress disorder (&#8220;PTSD&#8221;), Parkinson&#8217;s, and other rare neurological disorders. Our mission
is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the
health care industry.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Psilocybin is considered a serotonergic hallucinogen
and is an active ingredient in some species of mushrooms. Recent industry studies using psychedelics, such as psilocybin, have been promising,
and we believe there is a large unmet need with many people suffering from depression, mental health issues and neurological disorders.
While classified as a Schedule I substance under the Controlled Substances Act (&#8220;CSA&#8221;), there is an accumulating body of
evidence that psilocybin may have beneficial effects on depression and other mental health conditions. Therefore, the U.S. Food and Drug
Administration (&#8220;FDA&#8221;) and U.S. Drug Enforcement Agency (&#8220;DEA&#8221;) have permitted the use of psilocybin in clinical
studies for the treatment of a range of psychiatric conditions.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The potential of psilocybin therapy in mental
health conditions has been demonstrated in a number of academic-sponsored studies over the last decade. In these early studies, it was
observed that psilocybin therapy provided rapid reductions in depression symptoms after a single high dose, with antidepressant effects
lasting for up to at least six months for a number of patients. These studies assessed symptoms related to depression and anxiety through
a number of widely used and validated scales. The data generated by these studies suggest that psilocybin is generally well-tolerated
and has the potential to treat depression when administered with psychological support.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have engaged in discussions with a number
of world-renowned educational institutions and advisors regarding potential opportunities and have formed a scientific advisory board
that is intended to help advise management regarding potential acquisition and development of products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, as more fully described below,
we have entered into a license agreement with the University of Baltimore, Maryland, and have entered into a joint venture with Zylo
Therapeutics, Inc., with respect to certain intellectual property and technology that may be used for targeted delivery of potential
novel treatments. In addition, we have recently entered into a sponsored research agreement with Columbia University pursuant to which
we have been granted an option to license certain patents and inventions relating to the treatment of Alzheimer&#8217;s disease and stress-induced
affective disorders using Ketamine in combination with certain other compounds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to actively pursue the acquisition
and/or development of intellectual property or technology rights to treat rare diseases, and to ultimately expand our business to focus
on this new line of business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License Agreements between the Company
and a Vendor</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Vendor License Agreement with the University
of Baltimore, Maryland for CNS Homing Peptide</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 12, 2021, we entered into a Master
License Agreement (the &#8220;UMB License Agreement&#8221;) with the University of Maryland, Baltimore (&#8220;UMB&#8221;) pursuant to
which UMB granted us an exclusive, worldwide, sublicensable, royalty-bearing license to certain intellectual property (i) to make, have
made, use, sell, offer to sell, and import certain licensed products and (ii) to use the invention titled, &#8220;Central nervous system-homing
peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology&#8221;
(the &#8220;Invention&#8221;) and UMB&#8217;s confidential information to develop and perform certain licensed processes for the therapeutic
treatment of neuroinflammatory disease. The term of the License Agreement shall commence on the UMB Effective Date and shall continue
until the latest of (i) ten years from the date of First Commercial Sale (as defined in the Sublicense Agreement) of the Licensed Product
in such country and (ii) the date of expiration of the last to expire claim of the Patent Rights (as defined in the UMB License Agreement)
covering such Licensed Product in such country, or (iii) the expiration of data protection, new chemical entity, orphan drug exclusivity,
regulatory exclusivity, or other legally enforceable market exclusivity, if applicable, unless terminated earlier pursuant to the terms
of the agreement. Pursuant to the UMB License Agreement, we agreed to pay UMB (i) a license fee of $75,000, (ii) certain event-based
milestone payments, (iii) royalty payments, depending on net revenues, (iv) minimum royalty payments, and (v) a tiered percentage of
sublicense income. The UMB License Agreement will remain in effect until the later of: (a) the last patent covered under the UMB License
Agreement expires, (b) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other
legally enforceable market exclusivity, if applicable, or (c) ten years after the first commercial sale of a licensed product in that
country, unless earlier terminated in accordance with the provisions of the UMB License Agreement. The term of the UMB License Agreement
shall expire 15 year after the effective date in which (a) there were never any patent rights, (b) there was never any data protection,
new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally enforceable market exclusivity or (c) there was
never a first commercial sale of a licensed product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2022, the Company and University
of Maryland, Baltimore (&#8220;UMB&#8221;) entered into a second amendment to the commercial evaluation and license agreement dated February
26, 2021 (&#8220;Second Amendment&#8221;). The Second Amendment to extend the term of the original license agreement until December 31,
2022. However, if the Company exercises the Exclusive Option, the License Agreement shall expire at the end of the negotiation period
(as defined in the License Agreement) or upon execution of a master license agreement, whichever occurs first.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As described below, the Company has entered
into an investigator sponsored research agreement with UMB related to a clinical study to examine a novel peptide-guided drug delivery
approach for the treatment of Multiple Sclerosis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Commercial Evaluation License and Option
Agreement with UMB for Joint Homing Peptide</i></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective
                                            as of February 26, 2021, the Company, through the Company&#8217;s wholly-subsidiary, Silo
                                            Pharma, Inc and University of Maryland Baltimore (&#8220;UMB&#8221;), entered into a commercial
                                            evaluation license and option agreement (the &#8220;License Agreement&#8221;), which granted
                                            the Company an exclusive non-sublicensable, non-transferable license with respect to the
                                            exploration of the potential use of joint-homing peptides for use in the investigation and
                                            treatment of arthritogenic processes. The License Agreement also granted the Company an exclusive,
                                            option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license (the
                                            &#8220;Exclusive Option&#8221;) with respect to the subject technology. The License Agreement
                                            had a term of six months from the effective date. Both parties could have terminated the
                                            License Agreement within thirty days by giving a written notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On July 6, 2021,
the Company entered into a First Amendment Agreement (&#8220;Amended License Agreement&#8221;) with UMB to extend the term of the original
License Agreement by an additional six months such that the Amended License Agreement was effective until February 25, 2022 however,
if the Company exercises the Exclusive Option, the License Agreement shall expire at the end of the negotiation period (as defined in
the License Agreement) or upon execution of a master license agreement, whichever occurs first. The Company paid a license fee of $10,000
to UMB in March 2021 pursuant to the License Agreement, which was expensed, since the Company could not conclude that such costs would
be recoverable for this early-stage venture.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On January 28, 2022,
the Company and University of Maryland, Baltimore (&#8220;UMB&#8221;) entered into a second amendment to the commercial evaluation and
license agreement dated February 26, 2021 (&#8220;Second Amendment&#8221;). The Second Amendment to extend the term of the original license
agreement until December 31, 2022. However, if the Company exercises the Exclusive Option, the License Agreement shall expire at the
end of the negotiation period (as defined in the License Agreement) or upon execution of a master license agreement, whichever occurs
first.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On June 30, 2022, the Parties entered into
a third amendment to the commercial evaluation and license agreement dated February 26, 2021 (&#8220;Third Amendment&#8221;). The Third
Amendment expands the scope of the license granted in the License Agreement to add additional patent rights with respect to an invention
generally known as <i>Peptide-Targeted Liposomal Delivery for Treatment Diagnosis, and Imaging of Diseases and Disorders</i>. In consideration
of the licenses granted under this Third Amendment, Company agreed to pay a one-time, non-refundable fee of $2,500 which was recorded
as research and development expense in the condensed consolidated statement of operations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Joint Venture Agreement with Zyl&#246;
Therapeutics, Inc. for Z-pod&#8482; Technology</i></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 22, 2021, the Company entered into
a Joint Venture Agreement with Zyl&#246; Therapeutics, Inc. (&#8220;ZTI&#8221;) pursuant to which the parties agreed to form a joint
venture entity, to be named Ketamine Joint Venture, LLC, to, among other things, focus on the clinical development of ketamine using
ZTI&#8217;s Z-pod&#8482; technology. Pursuant to the Joint Venture Agreement, the Company shall act as the manager of the Joint Venture.
The Joint Venture shall terminate if the development program does not meet certain specifications and milestones as set forth in the
Joint Venture Agreement within 30 days of the date set forth in the Joint Venture Agreement. Notwithstanding the foregoing, the Manager
may, in its sole discretion, terminate the Venture at any time.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Joint Venture
Agreement,&#160;(A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and
(B) ZTI shall contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to
the know-how and trade secrets with respect to its Z-pod&#8482; technology for the loading and release of ketamine, (3) ketamine to be
used for clinical purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the Joint
Venture Agreement, 51% of the interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint
Venture shall initially be owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding
the foregoing, in no event shall either party own more than 60% of the interest in the Joint Venture. As of the current date of this
registration statement, the joint venture entity has not been formed yet.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, pursuant to the terms of the
JV Agreement, ZTI shall grant the Joint Venture a sublicense pursuant to its license agreement (the &#8220;License Agreement&#8221;)
with Albert Einstein College of Medicine dated November 27, 2017, in the event that the Company or a third party makes a request indicating
that the patented technology (the &#8220;Patented Technology&#8221;) licensed to ZTI pursuant to the License Agreement is needed to advance
the development of the Joint Venture or it is contemplated or determined that the Patented Technology will be sold. Furthermore, pursuant
to the JV Agreement, ZTI granted the Company an exclusive option to enter into a separate joint venture for the clinical development
of psilocybin using ZTI&#8217;s Z-pod&#8482; technology on the same terms and conditions set forth in the JV Agreement, which option
shall expire 24 months after the JV Effective Date. As of the current date of this registration statement, the joint venture entity has
not yet been formed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Investigator-Sponsored Study Agreements
between the Company and Vendors</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sponsored Research Agreement with Columbia
University for the Study of Ketamine in Combination with Other Drugs for Treatment of Alzheimer&#8217;s and Depression Disorders</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2021, the Company entered into
a sponsored research agreement with The Trustees of Columbia University in the City of New York (&#8220;Columbia&#8221;) pursuant to
which Columbia shall conduct two different studies related to all uses of Ketamine or its metabolites in combination with Prucalopride,
one of which is related to Alzheimer&#8217;s and the other of which is related to Depression, PTSD and Stress Projects. <span>In
addition, Company has been granted an option to license certain assets currently under development, including Alzheimer&#8217;s disease.
The term of the option will commence on the effective date of this agreement and will expire upon the earlier of (i) 90 days after the
date of the Company&#8217;s receipt of a final research report for each specific research proposal as defined in the agreement or (ii)
termination of the research. If the Company elects to exercise the option, both parties will commence negotiation of a license agreement
and will execute a license agreement no later than 3 months after the dated of the exercise of the option. Columbia University and the
Company will work towards developing a therapeutic treatment for patients suffering from Alzheimer&#8217;s disease to posttraumatic stress
disorder. During a one-year period from the date of this agreement, the Company shall pay a total of $1,436,082 to Columbia University
for the support of the research according to the payment schedule as follows: (i) 30% at signing, (ii) 30% at four and half months after
the start of the project, (iii) 30% at nine months after the start of the project and, (iv)10% at completion of the project. The Company
paid the first payment of $430,825 in November 2021. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sponsored Research Agreement with University
of Maryland, Baltimore for the Study of Targeted liposomal drug delivery for rheumatoid arthritis</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, we entered into a sponsored
research agreement (the &#8220;July 2021 Sponsored Research Agreement&#8221;) with UMB pursuant to which UMB shall&#160;evaluate the
pharmacokinetics of dexamethasone delivered to arthritic rats via liposome.&#160; The research pursuant to the July 2021 Sponsored Research
Agreement commenced on September 1, 2021 and will continue until the substantial completion thereof, subject to renewal upon written
consent of the parties with a project timeline of twelve months. The July 2021 Sponsored Research Agreement may be terminated by either
party upon 30 days&#8217; prior written notice to the other party. In addition, if either party commits any material breach of or defaults
with respect to any terms or conditions of the July 2021 Sponsored Research Agreement and fails to remedy such default or breach within
10 business days after written notice from the other party, the party giving notice may terminate the July 2021 Sponsored Research Agreement
as of the date of receipt of such notice by the other party. If the Company terminates the July 2021 Sponsored Research Agreement for
any reason other than an uncured material breach by UMB, we shall relinquish any and all rights it may have in the Results (as defined
in the July 2021 Sponsored Research Agreement) to UMB. In addition, if the July 2021 Sponsored Research Agreement is terminated early,
we, among other things, will pay all costs incurred and accrued by UMB as of the date of termination. Pursuant to the terms of the July
2021 Sponsored Research Agreement, UMB granted us an option (the &#8220;Option&#8221;) to negotiate and obtain an exclusive license to
any UMB Arising IP (as defined in the July 2021 Sponsored Research Agreement) and UMB&#8217;s rights in any Joint Arising IP (as defined
in the July 2021 Sponsored Research Agreement) (collectively, the &#8220;UMB IP&#8221;). We may exercise the Option by giving UMB written
notice within 60 days after it receives notice from UMB of the UMB IP. We shall pay total fees of $276,285 as set forth in the July 2021
Sponsored Research Agreement.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid the first payment of $92,095
on September 1, 2021 and partial of the second payment of $50,000 on February 1, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 7, 2022, the Company and UMB amended
the July 2021 Sponsored Research Agreement whereby both parties agreed to make changes to the original project work and budget.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Sponsored Research Agreement with The Regents
of the University of California for the Effect of Psilocybin on Inflammation in the Blood</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On June 1, 2021, the Company entered into
a sponsored research agreement with The Regents of the University of California, on behalf of its San Francisco Campus (&#8220;UCSF&#8221;)
pursuant to which UCSF shall conduct a study to examine psilocybin&#8217;s effect on inflammatory activity in humans to accelerate its
implementation as a potential treatment for Parkinson&#8217;s Disease, chronic pain, and bipolar disorder. The purpose of this is to
show what effect psilocybin has on inflammation in the blood. The Company believe that this study will help support the UMB homing peptide
study. Pursuant to the Agreement, we shall pay UCSF a total fee of $342,850 to conduct the research over the two-year period. The Agreement
shall be effective for a period of two years from the effective date, subject to renewal or earlier termination as set forth in the Sponsored
Research Agreement. The Company paid the first payment of $40,000 pursuant to the payment schedule on the Sponsored Research Agreement
on June 15, 2021, second payment of $40,000 on September 9, 2021 and $20,570 on November 18, 2021 and third payment of $60,570 on March
1, 2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investigator-Sponsored Study Agreement
with UMB for CNS Homing Peptide</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, we entered into an investigator-sponsored
study agreement with UMB. The research project is a clinical study to examine a novel peptide-guided drug delivery approach for the treatment
of Multiple Sclerosis (&#8220;MS&#8221;). More specifically, the study is designed to evaluate (1) whether MS-1-displaying liposomes
can effectively deliver dexamethasone to the central nervous system and (2) whether MS-1-displaying liposomes are superior to plain liposomes,
also known as free drug, in inhibiting the relapses and progression of Experimental Autoimmune Encephalomyelitis. Pursuant to the agreement,
the research commenced on March 1, 2021 and will continue until substantial completion, subject to renewal upon mutual written consent
of the parties.&#160;The total cost under the S investigator-sponsored study agreement shall not exceed $81,474. which is payable in
two equal installments of $40,737 upon execution of the Sponsored Study Agreement and $40,737 upon completion of the project with an
estimated project timeline of nine months. The Company paid $40,737 on January 13, 2021. Currently, the project has not been completed
due to the delays cause by the Covid-19 pandemic.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Investigator-Sponsored Study Agreement
with Maastricht University of the Netherlands</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 1, 2020, we entered into an investigator-sponsored
study agreement with Maastricht University of the Netherlands. The research project is a clinical study to examine the effects of repeated
low doses of psilocybin and&#160;lysergic acid diethylamide on cognitive and emotional dysfunctions in Parkinson&#8217;s disease and
to understand its mechanism of action. The agreement shall terminate on October 31, 2024, unless earlier terminated pursuant to the terms
thereof. We shall pay a total fee of 433,885 Euros ($507,602 USD) exclusive of value added tax based on a payment schedule set forth
in the agreement. In September 2021, we notified Maastricht University of Netherlands for an early termination of this agreement. Maastricht
University of Netherlands has not reached the second phase which is to obtain approval from ethical committee. We have no further obligation
after the termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other License Agreements between the Company
and a Customer</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Customer Patent License Agreement with
AIkido Pharma Inc.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, we entered into a Patent
License Agreement (the &#8220;AIkido License Agreement&#8221;) with our wholly-owned subsidiary, Silo Pharma, Inc., and AIkido Pharma
Inc. (&#8220;AIkido&#8221;) pursuant to which we granted AIkido an exclusive, worldwide, sublicensable, royalty-bearing license to certain
intellectual property (i) to make, have made, use, provide, import, export, lease, distribute, sell, offer for sale, develop and advertise
certain licensed products and (ii) to develop and perform certain licensed processes for the treatment of cancer and symptoms caused
by cancer. The AIkido License Agreement relates to the rights which we had obtained under the UMB Option Agreement. Pursuant to the AIkido
License Agreement, we agreed that if we exercised the UMB Option, we would grant AIkido a non-exclusive sublicense to certain UMB patent
rights in the field of neuroinflammatory diseases occurring in patients diagnosed with cancer. The UMB Option was exercised on January
13, 2021. Accordingly, on April 6, 2021, we entered into a sublicense agreement with AIkido pursuant to which we granted AIkido a worldwide
exclusive sublicense to our licensed patents under the UMB License Agreement. (See &#8220;<i>Sublicense&#160;with AIkido Pharma Inc.</i>&#8221;).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Customer Sublicense Agreement&#160;with
AIkido Pharma Inc.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2021 (&#8220;Effective Date&#8221;),
we entered into a sublicense agreement (the &#8220;Sublicense Agreement&#8221;) with AIkido pursuant to which we granted AIkido an exclusive
worldwide sublicense to (i) make, have made, use, sell, offer to sell and import the Licensed Products (as defined below) and (ii) in
connection therewith to (A) use the Invention that was sublicensed to us pursuant to the UMB License Agreement and (B) practice certain
patent rights as set forth in the Sublicense Agreement (the &#8220;Patent Rights&#8221;) for the therapeutic treatment of neuroinflammatory
disease in cancer patients. &#8220;Licensed Products&#8221; means any product, service, or process, the development, making, use, offer
for sale, sale, importation, or providing of which: (i) is covered by one or more claims of the Patent Rights; or (ii) contains, comprises,
utilizes, incorporates, or is derived from the Invention or any technology disclosed in the Patent Rights. Pursuant to the Sublicense
Agreement, AIkido shall agree to pay the Company (i) an upfront license fee of $50,000, (ii)&#160;the same sales-based royalty payments
that we are subject to under the UMB License Agreement and (iii) total milestone payments of up to $1.9 million. The Sublicense Agreement
shall continue on a Licensed Product-by-Licensed Product and country-by-country basis until the later of (i) the date of expiration of
the last to expire claim of the Patent Rights covering such Licensed Product in such country, (ii) the expiration of data protection,
new chemical entity, orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity, if applicable and
(iii) 10 years after the first commercial sale of a Licensed Product in that country, unless terminated earlier pursuant to the terms
of the Sublicense Agreement. Furthermore, the Sublicense Agreement shall expire 15 years after the Effective Date with respect to any
country in which (i) there were never any Patent Rights, (ii) there was never any data protection, new chemical entity, orphan drug exclusivity,
regulatory exclusivity or other legally enforceable market exclusivity with respect to a Licensed Product and (ii) there was never a
commercial sale of a Licensed Product, unless such agreement is earlier terminated pursuant to its terms. The Company collected the upfront
license fee of $50,000 in April 2021.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>COVID-19</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The outbreak of the novel Coronavirus (COVID-19)
evolved into a global pandemic. The Coronavirus has spread to many regions of the world. The extent to which the Coronavirus impacts
the Company&#8217;s business and operating results will depend on future developments that are highly uncertain and cannot be accurately
predicted, including new information that may emerge concerning the Coronavirus and the actions to contain the Coronavirus or treat its
impact, among others.</p><div>




</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the continuing spread of the
Coronavirus, certain aspects of the Company&#8217;s business operations may be delayed or subject to interruptions. Specifically, as
a result of the shelter-in-place orders and other mandated local travel restrictions, among other things, the research and development
activities of certain of the Company&#8217;s partners may be affected, which may result in delays to the Company&#8217;s clinical trials,
and the Company can provide no assurance as to when such trials, if delayed, will resume at this time or the revised timeline to complete
trials once resumed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, site initiation, participant
recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis may be delayed
due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic
efforts, or other reasons related to the pandemic. If the Coronavirus continues to spread, some participants and clinical investigators
may not be able to comply with clinical trial protocols. For example, quarantines or other travel limitations (whether voluntary or required)
may impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, and the Company may be unable
to conduct its clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Infections and deaths related to the pandemic
may disrupt the United States&#8217; healthcare and healthcare regulatory systems. Such disruptions could divert healthcare resources
away from, or materially delay U.S. Food and Drug Administration review and/or approval with respect to the Company&#8217;s clinical
trials. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of the Company&#8217;s
clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of the
Company&#8217;s product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The spread of the Coronavirus, which has caused
a broad impact globally, including restrictions on travel and quarantine policies put into place by businesses and governments, may have
a material economic effect on the Company&#8217;s business. While the potential economic impact brought by and the duration of the pandemic
may be difficult to assess or predict, it has already caused, and is likely to result in further, significant disruption of global financial
markets, which may negatively impact the Company&#8217;s ability to access capital on favorable terms, if at all. In addition, a recession,
depression or other sustained adverse market event resulting from the spread of the Coronavirus could materially and adversely affect
the Company&#8217;s business and the value of its common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ultimate impact of the current pandemic,
or any other health epidemic, is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays
or impacts on its business, its clinical trials, its research programs, healthcare systems or the global economy as a whole. However,
these effects could have a material impact on the Company&#8217;s operations, and the Company will continue to monitor the situation
closely.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Our
goal is to obtain, maintain and enforce patent protection for our products, formulations, processes, methods and other proprietary technologies,
preserve our trade secrets, and operate without infringing on the proprietary rights of other parties. Our policy is to actively seek
the broadest intellectual property protection possible for our products, proprietary information and proprietary technology through a
combination of contractual arrangements and patents. Specifically, we try to </span>ensure that we own intellectual property created
for us by signing agreements with employees, independent contractors, consultants, companies, and any other third party that create intellectual
property for us or that assign any intellectual property rights to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we have established business
procedures designed to maintain the confidentiality of our proprietary information, including the use of confidentiality agreements with
employees, independent contractors, consultants and entities with which we conduct business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have filed four provisional patent
applications related to the use of the central nervous system-homing peptides covered by the UMB Option Agreement to deliver certain
compounds, including a nonsteroidal anti-inflammatory drug and/or psilocybin, for the treatment of arthritis, central nervous system
diseases ,neuroinflammatory diseases as well as cancer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to the rare disease therapeutics
segment of our business, our industry is characterized by many newly emerging and innovative technologies, intense competition and a
strong emphasis on proprietary product rights. We face potential competition from many different sources, including major pharmaceutical,
specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and medical research organizations.
Any product candidates that we may successfully develop and commercialize will compete with the standard of care and new therapies that
may become available in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of the pharmaceutical, biopharmaceutical
and biotechnology companies with whom we may compete have established markets for their therapies and have substantially greater financial,
technical, human and other resources than we do and may be better equipped to develop, manufacture and market superior products or therapies.
In addition, many of these potential competitors have significantly greater experience than we have in undertaking non-clinical studies
and human clinical trials of new therapeutic substances and in obtaining regulatory approvals of human therapeutic products. Accordingly,
our competitors may succeed in obtaining regulatory approvals for alternative or superior products. In addition, many competitors have
greater name recognition and more extensive collaborative relationships. Smaller and earlier-stage companies may also prove to be significant
competitors, particularly through collaborative arrangements with large, established companies. An increasing number of companies are
increasing their efforts in discovery of new psychedelic compounds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA and other regulatory authorities at
federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development,
testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, recordkeeping,
approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drugs. We, along with any potential
our vendors, contract research organizations and contract manufacturers, will be required to navigate the various preclinical, clinical,
manufacturing and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct
studies or seek approval of our product candidates. The process of obtaining regulatory approvals of drugs and ensuring subsequent compliance
with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial
resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, the FDA regulates drug
products under the FDCA, its implementing regulations and other laws. If we fail to comply with applicable FDA or other requirements
at any time with respect to product development, clinical testing, approval or any other legal requirements relating to product manufacture,
processing, handling, storage, quality control, safety, marketing, advertising, promotion, packaging, labeling, export, import, distribution,
or sale, we may become subject to administrative or judicial sanctions or other legal consequences. These sanctions or consequences could
include, among other things, the FDA&#8217;s refusal to approve pending applications, issuance of clinical holds for ongoing studies,
suspension or revocation of approved applications, warning or untitled letters, product withdrawals or recalls, product seizures, relabeling
or repackaging, total or partial suspensions of manufacturing or distribution, injunctions, fines, civil penalties or criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The process required by the FDA before any
product candidates are approved as drugs for therapeutic indications and may be marketed in the United States generally involves the
following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Completion of extensive preclinical studies in
    accordance with applicable regulations, including studies conducted in accordance with good laboratory practice requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Completion of the manufacture, under cGMP requirements
    of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and
    stability testing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Submission to the FDA of an investigational new
    drug application (&#8220;IND&#8221;) which must become effective before clinical trials may begin;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Approval by an institutional review board or independent
    ethics committee at each clinical trial site before each trial may be initiated;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Performance of adequate and well-controlled clinical
    trials in accordance with applicable IND regulations, GCP requirements and other clinical trial-related regulations to establish
    the safety and efficacy of the investigational product for each proposed indication;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Submission to the FDA of a New Drug Application
    (&#8220;NDA&#8221;);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Payment of user fees for FDA review of the NDA;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">A determination by the FDA within 60 days of its
    receipt of an NDA, to accept the filing for review;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Satisfactory completion of one or more FDA pre-approval
    inspections of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP requirements
    to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Potentially, satisfactory completion of FDA audit
    of the clinical trial sites that generated the data in support of the NDA; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">FDA review and approval of the NDA, including consideration
    of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the United States.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Controlled Substances</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The federal CSA and its implementing regulations
establish a &#8220;closed system&#8221; of regulations for controlled substances. The CSA imposes registration, security, recordkeeping
and reporting, storage, manufacturing, distribution, importation and other requirements under the oversight of the DEA. The DEA is the
federal agency responsible for regulating controlled substances, and requires those individuals or entities that manufacture, import,
export, distribute, research, or dispense controlled substances to comply with the regulatory requirements in order to prevent the diversion
of controlled substances to illicit channels of commerce.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The DEA categorizes controlled substances
into one of five schedules&#8201;&#8212;&#8201;Schedule I, II, III, IV or V&#8201;&#8212;&#8201;with varying qualifications for listing
in each schedule. Schedule I substances by definition have a high potential for abuse, have no currently accepted medical use in treatment
in the United States and lack accepted safety for use under medical supervision. Pharmaceutical products having a currently accepted
medical use that are otherwise approved for marketing may be listed as Schedule II, III, IV or V substances, with Schedule II substances
presenting the highest potential for abuse and physical or psychological dependence, and Schedule V substances presenting the lowest
relative potential for abuse and dependence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Facilities that manufacture, distribute, import
or export any controlled substance must register annually with the DEA. The DEA registration is specific to the particular location,
activity(ies) and controlled substance schedule(s).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The DEA inspects all manufacturing facilities
to review security, recordkeeping, reporting and handling prior to issuing a controlled substance registration. The specific security
requirements vary by the type of business activity and the schedule and quantity of controlled substances handled. The most stringent
requirements apply to manufacturers of Schedule I and Schedule II substances. Required security measures commonly include background
checks on employees and physical control of controlled substances through storage in approved vaults, safes and cages, and through use
of alarm systems and surveillance cameras. Once registered, manufacturing facilities must maintain records documenting the manufacture,
receipt and distribution of all controlled substances. Manufacturers must submit periodic reports to the DEA of the distribution of Schedule
I and II controlled substances, Schedule III narcotic substances, and other designated substances. Registrants must also report any controlled
substance thefts or significant losses, and must obtain authorization to destroy or dispose of controlled substances. Imports of Schedule
I and II controlled substances for commercial purposes are generally restricted to substances not already available from a domestic supplier
or where there is not adequate competition among domestic suppliers. In addition to an importer or exporter registration, importers and
exporters must obtain a permit for every import or export of a Schedule I and II substance or Schedule III, IV and V narcotic, and submit
import or export declarations for Schedule III, IV and V non-narcotics. In some cases, Schedule III non-narcotic substances may be subject
to the import/export permit requirement, if necessary, to ensure that the United States complies with its obligations under international
drug control treaties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For drugs manufactured in the United States,
the DEA establishes annually an aggregate quota for the amount of substances within Schedules I and II that may be manufactured or produced
in the United States based on the DEA&#8217;s estimate of the quantity needed to meet legitimate medical, scientific, research and industrial
needs. The quotas apply equally to the manufacturing of the active pharmaceutical ingredient and production of dosage forms. The DEA
may adjust aggregate production quotas a few times per year, and individual manufacturing or procurement quotas from time to time during
the year, although the DEA has substantial discretion in whether or not to make such adjustments for individual companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The states also maintain separate controlled
substance laws and regulations, including licensing, recordkeeping, security, distribution, and dispensing requirements. State authorities,
including boards of pharmacy, regulate use of controlled substances in each state. Failure to maintain compliance with applicable requirements,
particularly as manifested in the loss or diversion of controlled substances, can result in enforcement action that could have a material
adverse effect on our business, operations and financial condition. The DEA may seek civil penalties, refuse to renew necessary registrations,
or initiate proceedings to revoke those registrations. In certain circumstances, violations could lead to criminal prosecution.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of July 12, 2022, we employed three full-time
employees. We are not a party to any collective bargaining agreements. We believe that we maintain a good relationship with our employees.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate History</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We were incorporated as Gold Swap, Inc. (&#8220;Gold
Swap&#8221;) under the laws of the State of New York on July 13, 2010.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 11, 2012, stockholders approved
changing our state of incorporation from New York to Delaware via the merger of Gold Swap with and into our wholly-owned subsidiary,
Point Capital, Inc., and to change our name from &#8220;Gold Swap Inc.&#8221; to &#8220;Point Capital, Inc.&#8221; The merger was effective
on January 24, 2013.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 21, 2019, we amended our Certificate
of Incorporation to change our name to &#8220;Uppercut Brands, Inc,&#8221; and on September 24, 2020, we amended our Certificate of Incorporation
to change our name to &#8220;Silo Pharma, Inc.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through September 28, 2018, we were a closed-end,
non-diversified investment company that had elected to be regulated as a business development company under the Investment Company Act
of 1940 (the &#8220;Investment Company Act&#8221;). As a business development company, we were required to comply with certain regulatory
requirements. For instance, we generally had to invest at least 70% of our total assets in &#8220;qualifying assets,&#8221; including
securities of private U.S. companies, cash, cash equivalents, U.S. government securities and high-quality debt investments that mature
in one year or less.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 29, 2018, we filed Form N-54C,
Notification of Withdrawal of election to be Subject to Section 55 through 65 of the Investment Company Act, because we changed the nature
of our business so as to cease to be a business development company. Accordingly, as of December 31, 2018, our consolidated financial
statements of have been prepared in accordance with accounting principles generally accepted in the United States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of this change in status, we discontinued
applying the guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standard Codification (&#8220;ASC&#8221;)
Topic 946 - Financial Services &#8211; Investment Company and account for the change in our status prospectively by accounting for our
equity investments in accordance with ASC Topics 320 - Investments&#8212;Debt and Equity Securities as of the date of the change in status.
In addition, the presentation of the financial statements are that of a commercial company rather than that of an investment company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 946, we made this change
to our financial reporting prospectively, and did not restate periods prior to our change in status to a non-investment company effective
September 29, 2018. Accordingly, we may refer to both accounting in accordance with U.S. generally accepted accounting principles applicable
to corporations (&#8220;Corporation Accounting&#8221;), which applied commencing September 29, 2018 and to that applicable to investment
companies under the Investment Company Act (&#8220;Investment Company Accounting&#8221;) which applied to prior periods. We determined
that there is no cumulative effect of the change from Investment Company Accounting to Corporation Accounting on periods prior to those
presented, and that there is no effect on our financial position or results of operations as a result of this change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to maintain our status as a non-investment
company, we will continue to operate so as to fall outside the definition of an &#8220;investment company&#8221; or within an applicable
exception. We expect to continue to operate outside the definition of an &#8220;investment company&#8221; as a developmental stage company
primarily engaged in merging traditional therapeutics with psychedelic research.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through March 31, 2017, we elected to be treated
as a regulated investment company (&#8220;RIC&#8221;) under Subchapter M of the Internal Revenue Code of 1986, as amended, and operated
in a manner so as to qualify for the tax treatment applicable to RICs. At March 31, 2017, we failed the diversification test since our
investment in Ipsidy Inc. accounted for over 25% of our total assets. We did not cure our failure to retain our status as a RIC and we
will not seek to obtain RIC status again. Accordingly, beginning in 2017, we became subject to income taxes at corporate tax rates. The
loss of our status as a RIC did not have any impact on our financial position or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, we are not making any new equity
investments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 29, 2018, we entered into an
Asset Purchase Agreement with Blind Faith Concepts Holdings, Inc. pursuant to which we completed the acquisition of 100% of the assets
of NFID from the seller which consisted of three trademarks related to the NFID brand, the NFID website, shoe designs and samples, and
the assumption of a one-year Brand Ambassador Agreement in exchange for 40,000 shares of our common stock. NFID is a recently developed
unisex clothing brand. We plan on continuing product development to fully launch the product. Our acquisition of the NFID assets gives
us access to the growing market for unisex products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 5, 2018, we entered into 14 separate
Return to Treasury Agreements, whereby certain stockholders holding an aggregate of 574,698 shares of our common stock agreed to return
a portion of their respective holdings to treasury in exchange for cash payments aggregating $2,872. As a result, the total issued and
outstanding number of our common stock was reduced by 574,698 shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 8, 2020, we incorporated a wholly-owned
subsidiary, Silo Pharma Inc., in the State of Florida.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Corporate Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were incorporated as in the State of New
York on July 13, 2010. On January 24, 2013, we changed our state of incorporation from New York to Delaware. Our principal executive
offices are located at 560 Sylvan Avenue, Suite 3160, Englewood Cliffs, NJ 07632 and our telephone number is (718) 400-9031.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>MANAGEMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the name, age
and positions of our executive officers and directors. Each director of the Company serves for a term of one year or until the successor
is elected at the Company&#8217;s annual shareholders&#8217; meeting and is qualified, subject to removal by the Company&#8217;s shareholders.
Each officer serves, at the pleasure of the board of directors, for a term of one year and until the successor is elected at the annual
meeting of the board of directors and is qualified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    and Business Address</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric Weisblum </span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 58%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman,
    Chief Executive Officer, Chief Financial Officer and President </span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel Ryweck</span></td>
    <td>&#160;</td>
    <td style="text-align: center">57</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer
    Nominee</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wayne D. Linsley &#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Kevin Mu&#241;oz</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeff Pavell (1), (2), (3)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">55</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director Nominee</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Will be a member of
                                            our Audit Committee upon appointment to our Board of Directors.</td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Will be a member of
                                            our Compensation Committee upon appointment to our Board of Directors.</td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">Will be a member of
                                            our Nominating and Corporate Governance Committee upon appointment to our Board of Directors.</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">The
following is a brief account of the education and business experience of each director and executive officer of our Company, indicating
the person&#8217;s principal occupation during that period, and the name and principal business of the organization in which such occupation
and employment were carried out.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Eric Weisblum &#8211; Chief Executive Officer
and Chairman</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eric Weisblum has been our Chief Executive
Officer and Chairman of the board of directors since November 2015, and our President and a member of the board of directors since January
2013. Mr. Weisblum has over 20 years of experience in structuring and trading financial instruments. From December 2016 to April 2020,
Mr. Weisblum, served as a director of Aikido Pharma, Inc. (NASDAQ: AIKI), a biotechnology company that develops anti-cancer therapeutics.
Mr. Weisblum holds a Bachelor of Art degree from the University of Hartford&#8217;s Barney School of Business. We believe that Mr. Weisblum
is qualified to serve as a member of our board of directors because of his extensive experience in senior leadership roles and background
in finance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Daniel Ryweck &#8211; Chief Financial Officer
Nominee </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Ryweck has agreed to become Chief Financial
Officer upon consummation of this offering. Since January 2020, Mr. Ryweck has served as Controller at Mill City Ventures III Ltd. (NASDAQ:
MCVT), a non-bank lender and specialty finance company. From. June 2014 to December 2019, he served as Chief Compliance Officer of Mill
City Ventures III Ltd. From July 2016 to September 2017, Mr. Ryweck served as a director of KonaTel Inc. (NASDAQ: KTEL), a Software-as-a-Service
(SaaS) cloud based voice and data telecommunications company formerly known as Dala Petroleum Corp. Mr. Ryweck holds a Bachelor of Science
degree in Accounting from the Carlson School of Management at the University of Minnesota.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Wayne D. Linsley - Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Wayne D. Linsley has served as a director
of the Company since January 2020. Mr. Linsley has over 40 years of experience in business management. Since April 2020, Mr. Linsley
has served as a member of the board of directors of Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company.
Since August 2021, Mr. Linsley has served as a member of the board of directors of DatChat, Inc. (NASDAQ: DATS), a communication software
company. From 2014 to September 2021, Mr. Linsley served as the Vice President of Operations at CFO Oncall, Inc., a company that provides
financial reporting and controller services on an outsourced basis and previously, from 2012 to 2014, Mr. Linsley worked at CFO Oncall,
Inc. as an independent contractor. Mr. Linsley holds Bachelor of Science degree in Business Administration from Siena College. We believe
that Mr. Linsley is qualified to serve as a member of our board of directors because of his experience as a director of public companies
and background in financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dr. Kevin Mu&#241;oz &#8211; Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Kevin Mu&#241;oz has served as a director
of the Company since October 2020. Since December 2021, Dr. Mu&#241;oz has taught Biomedical Science and Medical Intervention at Passaic
County Technical Institute. Since June 2008, Dr. Mu&#241;oz has served as the Director of Operations and Medical Assistant at The Physical
Medicine and Rehabilitation Center, P.A., a diagnostic and treatment facility that specializes in treating sports, spine, orthopedic
and neuromuscular conditions. Dr. Mu&#241;oz holds Doctor of Medicine degree from Xavier University School of Medicine and a Bachelor
of Science degree in Kinesiology from the University of Michigan. We believe that Dr. Mu&#241;oz is qualified to serve as a member
of our board of directors because of his medical background and experience in business operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dr. Jeff Pavell &#8211; Director Nominee
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Dr. Pavell has agreed to become a director
upon consummation of this offering. Dr. Pavell has over 20 years of medical experience. Since January 2021, Dr. Pavell has served as
a director of FoxWayne Enterprises Acquisition Corp. (NASDAQ: FOXW), a blank check company incorporated for the purpose of effecting
a business combination. Since October 1999, Dr. Pavell has served as an Attending Physician at the Physical Medicine and Rehabilitation
Center, P.A., a diagnostic and treatment facility that specializes in treating sports, spine, orthopedic and neuromuscular conditions.
Since January 2000, Dr. Pavell has served as the Chief of Rehabilitation Medicine at Englewood Hospital and Medical Center. Since April
2002, Dr. Pavell has served as the Associate Director of Pain Medicine at the Center for Advanced Surgery in Paramus, New Jersey. Since
April 2002, Dr. Pavell has been an Instructor in Clinical Rehabilitation at Columbia University&#8217;s College of Physicians &amp; Surgeons.
Dr. Pavell holds a Doctor of Medicine degree from the New York College of Osteopathic Medicine and a Bachelor of Art degree in Political
Science from John Hopkins University. We believe that Dr. Pavell is qualified to serve as a member of our board of directors due to his
medical background and experience practicing in the healthcare industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Family Relationships</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no family relationships among any
of our executive officers or directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Arrangements between Officers and Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as set forth herein, to our knowledge,
there is no arrangement or understanding between any of our officers or directors and any other person pursuant to which the officer
or director was selected to serve as an officer or director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Involvement in Certain Legal Proceedings</b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not aware of any of our directors or
officers being involved in any legal proceedings in the past ten years relating to any matters in bankruptcy, insolvency, criminal proceedings
(other than traffic and other minor offenses), or being subject to any of the items set forth under Item 401(f) of Regulation S-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Scientific Advisory Board</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">We have formed a scientific advisory board
that is intended to help advise management regarding potential acquisition and development of products. The members of such board are
as follows.; Dr. Josh Woolley MD/Ph.D.and Dr. Charles Nemeroff.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Josh Woolley MD/Ph.D. is an Associate
Professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco (&#8220;UCSF&#8221;).
He is also a licensed psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He received both his MD and his Ph.D.
in Neuroscience from UCSF and completed his psychiatry residency training at UCSF. Dr. Woolley is the director and founder of the Bonding
and Attunement in Neuropsychiatric Disorders (&#8220;BAND&#8221;) Laboratory. The mission of the BAND Lab is to understand why people
with mental illnesses, including schizophrenia, posttraumatic stress disorder, mood disorders, and substance use disorders, have trouble
with social connection, and to develop and test novel treatments for these deficits. His laboratory is actively investigating psilocybin
therapy for multiple disorders including major depressive disorder, bipolar depression, chronic pain, and mood symptoms associated with
Parkinson&#8217;s Disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Charles Nemeroff is chair and professor
with the Department of Psychiatry and Behavioral Sciences. He also directs the Institute for Early Life Adversity Research within the
Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. Prior to joining Dell Med, Dr. Nemeroff
was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami
Miller School of Medicine in Miami, Florida. He received his medical degree and doctorate degrees in neurobiology from the University
of North Carolina (&#8220;UNC&#8221;) School of Medicine. After psychiatry residency training at UNC and Duke University, he held faculty
positions at Duke University Medical Center and at Emory University School of Medicine before relocating to the University of Miami in
2009. He has served as president of the American College of Psychiatrists and the American College of Neuropsychopharmacology, and sits
on the Scientific Advisory Board of the Brain and Behavior Research Foundation. He is President-elect of the Anxiety and Depression Association
of America and a member of the National Academy of Medicine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Director Terms; Qualifications</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Members of our board of directors serve until
the next annual meeting of stockholders, or until their successors have been duly elected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When considering whether directors and nominees
have the experience, qualifications, attributes and skills to enable the board of directors to satisfy its oversight responsibilities
effectively in light of the Company&#8217;s business and structure, the board of directors focuses primarily on the industry and transactional
experience, and other background, in addition to any unique skills or attributes associated with a director.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Directors and Officers Liability Insurance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has directors&#8217; and officers&#8217;
liability insurance insuring its directors and officers against liability for acts or omissions in their capacities as directors or officers,
subject to certain exclusions. Such insurance also insures the Company against losses, which it may incur in indemnifying its officers
and directors. In addition, officers and directors also have indemnification rights under applicable laws, and the Company&#8217;s Certificates
of Incorporation, as amended and Bylaws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Director Independence</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The listing rules
of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) require that independent directors must comprise a majority of a listed company&#8217;s
board of directors. In addition, the rules of Nasdaq require that, subject to specified exceptions, each member of a listed company&#8217;s
audit, compensation, and nominating and governance committees be independent. Audit committee members must also satisfy the independence
criteria set forth in Rule 10A-3 under the Exchange Act. Under the rules of Nasdaq, a director will only qualify as an &#8220;independent
director&#8221; if, in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere
with the exercise of independent judgment in carrying out the responsibilities of a director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors has undertaken a review
of the independence of our directors and considered whether any director has a material relationship with it that could compromise his
or her ability to exercise independent judgment in carrying out his or her responsibilities. Based upon information requested from and
provided by each director concerning his background, employment and affiliations, including family relationships, the board of directors
has determined that Wayne Linsley, Kevin Munoz and Jeff Pavell are &#8220;independent&#8221; as that term is defined under the applicable
rules and regulations of the SEC and the listing standards of Nasdaq. In making these determinations, our board of directors considered
the current and prior relationships that each&#160;non-employee&#160;director has with the Company and all other facts and circumstances
our board of directors deemed relevant in determining their independence, including the beneficial ownership of the Company&#8217;s capital
stock by each&#160;non-employee&#160;director, and any transactions involving them described in the section captioned &#8220;&#8212;Certain
relationships and related transactions and director independence.&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Committees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the consummation of this Offering, the
Company&#8217;s Board will establish three standing committees: Audit, Compensation, and Nominating and Corporate Governance. Each of
the committees will operate pursuant to its charter. The committee charters will be reviewed annually by the Nominating and Corporate
Governance Committee. If appropriate, and in consultation with the chairs of the other committees, the Nominating and Corporate Governance
Committee may propose revisions to the charters. The responsibilities of each committee are described in more detail below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nasdaq permits a phase-in period of up to
one year for an issuer registering securities in an initial public offering to meet the Audit Committee, Compensation Committee and Nominating
and Corporate Governance Committee independence requirements. Under the initial public offering phase-in period, only one member of each
committee is required to satisfy the heightened independence requirements at the time our registration statement becomes effective, a
majority of the members of each committee must satisfy the heightened independence requirements within 90 days following the effectiveness
of our registration statement, and all members of each committee must satisfy the heightened independence requirements within one year
from the effectiveness of our registration statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee, among other things, will
be responsible for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">appointing; approving the compensation of; overseeing
    the work of; and assessing the independence, qualifications, and performance of the independent auditor;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">reviewing the internal audit function, including
    its independence, plans, and budget;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">approving, in advance, audit and any permissible
    non-audit services performed by our independent auditor;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">reviewing our internal controls with the independent
    auditor, the internal auditor, and management;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">reviewing the adequacy of our accounting and financial
    controls as reported by the independent auditor, the internal auditor, and management;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">overseeing our financial compliance system; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">overseeing our major risk exposures regarding the
    Company&#8217;s accounting and financial reporting policies, the activities of our internal audit function, and information technology.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The board of directors has affirmatively determined
that each member of the Audit Committee meets the additional independence criteria applicable to audit committee members under SEC rules
and Nasdaq listing rules. Effective upon the completion of this offering the board of directors will adopt a written charter setting
forth the authority and responsibilities of the Audit Committee. The Board has affirmatively determined that each member of the Audit
Committee is financially literate, and that Mr. Linsley meets the qualifications of an Audit Committee financial expert.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee will consist of Wayne
Linsley, Kevin Munoz and Jeff Pavell. Mr. Linsley will chair the Audit Committee. We believe that, after consummation of this offering,
the functioning of the Audit Committee will comply with the applicable requirements of the rules and regulations of the Nasdaq listing
rules and the SEC.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee will be responsible
for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">reviewing and making recommendations to the Board
    with respect to the compensation of our officers and directors, including the CEO;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">overseeing and administering the Company&#8217;s
    executive compensation plans, including equity-based awards;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">negotiating and overseeing employment agreements
    with officers and directors; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">overseeing how the Company&#8217;s compensation
    policies and practices may affect the Company&#8217;s risk management practices and/or risk-taking incentives.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective upon the completion of this offering,
the board of directors will adopt a written charter setting forth the authority and responsibilities of the Compensation Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee will consist of
Wayne Linsley, Kevin Munoz and Jeff Pavell. Dr. Munoz will serve as chairman of the Compensation Committee. The board of directors has
affirmatively determined that each member of the Compensation Committee meets the independence criteria applicable to compensation committee
members under SEC rules and Nasdaq listing rules. The Company believes that, after the consummation of the offering, the composition
of the Compensation Committee will meet the requirements for independence under, and the functioning of such Compensation Committee will
comply with, any applicable requirements of the rules and regulations of Nasdaq listing rules and the SEC.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nominating and Corporate Governance
Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Nominating and Corporate Governance Committee,
among other things, will be responsible for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">reviewing and assessing the development of the
    executive officers and considering and making recommendations to the Board regarding promotion and succession issues;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">evaluating and reporting to the Board on the performance
    and effectiveness of the directors, committees and the Board as a whole;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">working with the Board to determine the appropriate
    and desirable mix of characteristics, skills, expertise and experience, including diversity considerations, for the full Board and
    each committee;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">annually presenting to the Board a list of individuals
    recommended to be nominated for election to the Board;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">reviewing, evaluating, and recommending changes
    to the Company&#8217;s Corporate Governance Principles and Committee Charters;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">recommending to the Board individuals to be elected to fill vacancies
    and newly created directorships;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">overseeing the Company&#8217;s compliance program, including the
    Code of Conduct; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">overseeing and evaluating how the Company&#8217;s corporate governance
    and legal and regulatory compliance policies and practices, including leadership, structure, and succession planning, may affect
    the Company&#8217;s major risk exposures.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective upon completion of this offering.,
the board of directors will adopt a written charter setting forth the authority and responsibilities of the Corporate Governance/Nominating
Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Nominating and Corporate Governance Committee
will consist of Wayne Linsley, Kevin Munoz and Jeff Pavell. Ms. Pavell will serve as chairman. The Company&#8217;s board of directors
has determined that each member of the Nominating and Corporate Governance Committee is independent within the meaning of the independent
director guidelines of Nasdaq listing rules.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Compensation Committee Interlocks
and Insider Participation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">None of the Company&#8217;s
executive officers serves, or in the past has served, as a member of the board of directors or compensation committee, or other committee
serving an equivalent function, of any entity that has one or more executive officers who serve as members of the Company&#8217;s board
of directors or its compensation committee. None of the members of the Company&#8217;s compensation committee is, or has ever been, an
officer or employee of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Code of Business Conduct and Ethics</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Prior to the completion
of this offering, the Company&#8217;s Board of Directors will adopt a code of business conduct and ethics applicable to its employees,
directors and officers, in accordance with applicable U.S. federal securities laws and the corporate governance rules of Nasdaq. The
code of business conduct and ethics will be publicly available on the Company&#8217;s website. Any substantive amendments or waivers
of the code of business conduct and ethics or code of ethics for senior financial officers may be made only by the Company&#8217;s board
of directors and will be promptly disclosed as required by applicable U.S. federal securities laws and the corporate governance rules
of Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Corporate Governance Guidelines</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the completion of this offering,
the Company&#8217;s board of directors will adopt corporate governance guidelines in accordance with the corporate governance rules of
Nasdaq.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXECUTIVE COMPENSATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides certain information
regarding compensation awarded to, earned by or paid to persons serving as our principal executive officer and our principal financial
officer during the year ended December 31, 2021 and 2020 (each a &#8220;named executive officer&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Summary Compensation Table</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    and<br/>
    Principal&#160;Position</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fiscal<br/>
    Year</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary<br/>
    Paid<br/>
    ($)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus<br/>
    ($)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock<br/>
    Awards<br/>
    ($)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br/>
    Awards<br/>
    ($)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Equity<br/>
    Incentive<br/>
    Plan<br/>
    Compensation<br/>
    ($)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-<br/>
    Qualified<br/>
    Deferred<br/>
    Compensation<br/>
    Earnings<br/>
    ($)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other<br/>
    Compensation<br/>
    ($)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<br/>
    ($)</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 14%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
    Weisblum, Chief Executive</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">175,000 </span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">170,000 </span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">345,000</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer
    and Chief Financial Officer</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115,000 </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">610,476 </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">725,476</span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 18, 2021,
    the Company and Mr. Weisblum entered into the first amendment (the &#8220;Amendment&#8221;) to the Employment Agreement, effective
    as of January 1, 2021. Pursuant to the Amendment Mr. Weisblum&#8217;s base salary was increased from $120,000 per year to $180,000
    per year and all the terms and provisions of the Employment Agreement shall remain in full force and effect.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to Mr. Weisblum&#8217;s
    Employment Agreement dated April 17, 2020 he was eligible to earn a bonus in an amount of up to $120,000. On December 29, 2021, the
    Company&#8217;s Board of Directors (&#8220;Board&#8221;) approved bonus of $120,000 which was recorded as accrued liability as of
    December 31, 2021 and was paid out in January 2022. In addition, Mr. Weisblum also received in 2021, a cash bonus of $50,000 for
    his services in 2020. </span></td></tr>

<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; font-size: 10pt; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="padding-right: 0.8pt; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    April 17, 2020, the Company entered into an Employment Agreement with Mr. Weisblum, the Company&#8217;s Chief Executive Officer,
    pursuant to which Mr. Weisblum will continue to serve as Chief Executive Officer and Chief Financial Officer of the Company. Mr.
    Weisblum&#8217;s base salary was $120,000, and he shall be eligible to earn a bonus in an amount of up to $120,000, subject to the
    sole discretion of the Company&#8217;s board of directors. In addition, Mr. Weisblum was granted 152,619 shares of the Company&#8217;s
    common stock. These shares were valued at $610,476, or $4.00 per common share, based on contemporaneous common share sales. Such
    employment agreement was amended in January 2021.</span></td></tr>
  </table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Outstanding Equity Awards at Fiscal Year-End Table</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-style: normal; font-weight: normal">The
following table provides information regarding option and restricted stock unit awards held by each of our named executive officers that
were outstanding as of December 31, 2021. There were no stock awards or other equity awards to named executive officers outstanding as
of December 31, 2021.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td colspan="16" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
    Awards</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td colspan="13" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
    Awards</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of<br/>
    Securities<br/>
    Underlying<br/>
    Unexercised<br/>
    Options (#)<br/>
    (Exercisable)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of<br/>
    Securities<br/>
    Underlying<br/>
    Unexercised<br/>
    Options (#)<br/>
    (Unexercisable)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity<br/>
    Incentive<br/>
    Plan<br/>
    Awards:<br/>
    Number of<br/>
    Securities<br/>
    Underlying<br/>
    Unexercised<br/>
    Unearned<br/>
    Options (#)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br/>
    Exercise<br/>
    Price<br/>
    ($)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br/>
    Expiration<br/>
    Date</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of<br/>
    Shares or<br/>
    Units of<br/>
    Stock That<br/>
    Have Not<br/>
    Vested<br/>
    (#)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market<br/>
    Value of<br/>
    Shares or<br/>
    Units of<br/>
    Stock That<br/>
    Have Not<br/>
    Vested (#)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity<br/>
    Incentive<br/>
    Plan Awards:<br/>
    Number of<br/>
    Unearned<br/>
    Shares, Units<br/>
    or Other<br/>
    Rights that<br/>
    Have Not<br/>
    Vested<br/>
    (#)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity<br/>
    Incentive<br/>
    Plan Awards:<br/>
    Market or<br/>
    Payout Value&#160;of Unearned<br/>
    Shares, Units<br/>
    or Other<br/>
    Rights that<br/>
    Have Not<br/>
    Vested<br/>
    ($)</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 10%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
    Weisblum</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.005</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;04/15/2024</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer&#160;and</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.005</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;07/15/2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.005</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/15/2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment Agreement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 17, 2020, the Company entered into
an employment agreement (&#8220;Employment Agreement&#8221;) with Eric Weisblum to serve as Chief Executive Officer and Chief Financial
Officer of the Company. The term of the Employment Agreement will continue for a period of one year from the date of execution date thereof
and automatically renews for successive one-year periods at the end of each term until either party delivers written notice of their
intent not to review at least six months prior to the expiration of the then effective term. The Employment Agreement provided for a
base salary of $120,000 and 152,619 of vested shares of the Company&#8217;s common stock in April 2020. In addition, Mr. Weisblum shall
be eligible to earn a bonus, subject to the sole discretion of the Company&#8217;s Board of Directors (&#8220;Board&#8221;). The Employment
Agreement may be terminated by either the Company or Mr. Weisblum at any time and for any reason upon 60 days prior written notice. Upon
termination of the Employment Agreement, Mr. Weisblum shall be entitled to (i) any equity award that has vested prior to the termination
date, (ii) reimbursement of expenses incurred on or prior to such termination date and (iii) such employee benefits to which he may be
entitled as of the termination date (collectively, the &#8220;Accrued Amounts&#8221;). Mr. Weisblum employment may also be terminated
by the Company at any time, with cause, death or disability (as defined in the Employment Agreement). Upon the termination of the Employment
Agreement for death or disability, Mr. Weisblum shall be entitled to receive the Accrued Amounts. The Employment Agreement also contains
covenants prohibiting Mr. Weisblum from disclosing confidential information with respect to the Company.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 18, 2021, the Company and Mr. Weisblum
entered into the first amendment (the &#8220;Amendment&#8221;) to the Employment Agreement, effective as of January 1, 2021. Pursuant
to the Amendment Mr. Weisblum&#8217;s base salary was increased from $120,000 per year to $180,000 per year and all the terms and provisions
of the Employment Agreement shall remain in full force and effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt"><b>Non-Employee Director Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents the total compensation
for each person who served as a non-employee member of our board of directors and received compensation for such service during the fiscal
year ended December&#160;31, 2021. Other than as set forth in the table and described more fully below, we did not pay any compensation,
make any equity awards or non-equity awards to, or pay any other compensation to any of the non-employee members of our board of directors
in 2021.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fees<br/>
    earned or<br/>
    paid in<br/>
    cash</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock<br/>
    awards</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br/>
    awards</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-equity<br/>
    incentive<br/>
    plan<br/>
    compensation</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nonqualified<br/>
    deferred<br/>
    compensation<br/>
    earnings</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All
    other<br/>
    compensation</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wayne Linsley</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,000</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,000</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Kevin Mu&#241;oz</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,500</span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents: (i) $5,000
    quarterly board fee of Mr. Linsley, for a total of $20,000 and (ii) $1,500 quarterly board fee of Dr. Kevin Munoz, for a total of
    $6,000.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents $10,000 bonus
    for Mr. Linsley and $1,500 bonus for Dr. Mu&#241;oz.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>MATERIAL U.S. FEDERAL&#160;INCOME
TAX CONSEQUENCES TO NON-U.S. HOLDERS OF THE COMPANY&#8217;S COMMON STOCK</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the material
U.S. federal income tax consequences to non-U.S. holders (as defined below) of the ownership and disposition of the Company&#8217;s common
stock but does not purport to be a complete analysis of all the potential tax considerations relating thereto. This summary is based
upon the provisions of the&#160;Internal Revenue Code of 1986, as amended, or the Internal Revenue Code, Treasury regulations promulgated
thereunder, administrative rulings and judicial decisions, all as of the date hereof. These authorities may be changed, possibly retroactively,
so as to result in U.S. federal income tax consequences different from those set forth below. No ruling on the U.S. federal, state, or
local tax considerations relevant to the Company&#8217;s operations or to the purchase, ownership or disposition of its shares, has been
requested from the&#160;IRS or other tax authority. No assurance can be given that the&#160;IRS would not assert, or that a court would
not sustain, a position contrary to any of the tax consequences described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary also does not address the tax
considerations arising under the laws of any non-U.S., state or local jurisdiction, or under U.S. federal gift and estate tax laws, except
to the limited extent set forth below.&#160;In addition, this discussion does not address tax considerations applicable to an investor&#8217;s
particular circumstances or to investors that may be subject to special tax rules, including, without limitation:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">banks, insurance companies or other financial institutions,
    regulated investment companies or real estate investment trusts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">persons subject to the alternative minimum tax
    or Medicare contribution tax on net investment income;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">tax-exempt organizations or governmental organizations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">controlled foreign corporations, passive foreign
    investment companies and corporations that accumulate earnings to avoid U.S. federal income tax;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">brokers or dealers in securities or currencies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">traders in securities that elect to use a mark-to-market
    method of accounting for their securities holdings;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">persons that own, or are deemed to own, more than
    five percent of the Company&#8217;s capital stock (except to the extent specifically set forth below);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">U.S. expatriates and certain former citizens or
    long-term residents of the United States;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">partnerships or entities classified as partnerships
    for U.S. federal income tax purposes or other pass-through entities (and investors therein);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">persons who hold the Company&#8217;s common stock
    as a position in a hedging transaction, &#8220;straddle,&#8221; &#8220;conversion transaction&#8221; or other risk reduction transaction
    or integrated investment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">persons who hold or receive the Company&#8217;s
    common stock pursuant to the exercise of any employee stock option or otherwise as compensation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">persons who do not hold the Company&#8217;s common
    stock as a capital asset within the meaning of Section&#160;1221 of the Internal Revenue Code; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">persons deemed to sell the Company&#8217;s common
    stock under the constructive sale provisions of the Internal Revenue Code.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, if a partnership or entity classified
as a partnership for U.S. federal income tax purposes holds the Company&#8217;s common stock, the tax treatment of a partner generally
will depend on the status of the partner and upon the activities of the partnership. Accordingly, partnerships that hold the Company&#8217;s
common stock, and partners in such partnerships, should consult their tax advisors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>You are urged to consult your tax advisor
with respect to the application of the U.S. federal income tax laws to your particular situation, as well as any tax consequences of
the purchase, ownership and disposition of the Company&#8217;s common stock arising under the U.S. federal estate or gift tax rules or
under the laws of any state, local, non-U.S., or other taxing jurisdiction or under any applicable tax treaty.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Non-U.S. Holder Defined</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this discussion, you are a
non-U.S. holder (other than a partnership) if you are any holder other than:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">an individual citizen or resident of the United
    States (for U.S. federal income tax purposes);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a corporation or other entity taxable as a corporation
    created or organized in the United States or under the laws of the United States, any state thereof, or the District of Columbia,
    or other entity treated as such for U.S. federal income tax purposes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">an estate whose income is subject to U.S. federal
    income tax regardless of its source; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a trust (x)&#160;whose administration is subject
    to the primary supervision of a U.S. court and which has one or more &#8220;U.S. persons&#8221; (within the meaning of Section&#160;7701(a)(30)
    of the Internal Revenue Code) who have the authority to control all substantial decisions of the trust or (y)&#160;which has made
    a valid election to be treated as a U.S. person.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Distributions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As described in &#8220;Dividend Policy,&#8221;
the Company has never declared or paid cash dividends on its common stock and do not anticipate paying any dividends on its common stock
in the foreseeable future. However, if the Company does make distributions on its common stock, those payments will constitute dividends
for U.S. tax purposes to the extent paid from the Company&#8217;s current or accumulated earnings and profits, as determined under U.S.
federal income tax principles. To the extent those distributions exceed both the Company&#8217;s current and its accumulated earnings
and profits, they will constitute a return of capital and will first reduce your basis in the Company&#8217;s common stock, but not below
zero, and then will be treated as gain from the sale of stock as described below under &#8220;&#8212; Gain on Disposition of common stock.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the discussion below on effectively
connected income, backup withholding and foreign accounts, any dividend paid to you generally will be subject to U.S. withholding tax
either at a rate of 30% of the gross amount of the dividend or such lower rate as may be specified by an applicable income tax treaty.&#160;In
order to receive a reduced treaty rate, you must provide us with an&#160;IRS Form W-8BEN, IRS Form W-8BEN-E, or other appropriate version
of&#160;IRS Form W-8 certifying qualification for the reduced rate. A non-U.S. holder of shares of the Company&#8217;s common stock eligible
for a reduced rate of U.S. withholding tax pursuant to an income tax treaty may obtain a refund of any excess amounts withheld by timely
filing an appropriate claim for refund with the&#160;IRS.&#160;If the non-U.S. holder holds the stock through a financial institution
or other agent acting on the non-U.S. holder&#8217;s behalf, the non-U.S. holder will be required to provide appropriate documentation
to the agent, which then will be required to provide certification to the Company or its paying agent, either directly or through other
intermediaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dividends received by you that are effectively
connected with your conduct of a U.S. trade or business (and, if required by an applicable income tax treaty, attributable to a permanent
establishment maintained by you in the United States) are generally exempt from the withholding tax described above.&#160;In order to
obtain this exemption, you must provide us with an&#160;IRS Form W-8ECI or other applicable&#160;IRS Form W-8 properly certifying such
exemption. Such effectively connected dividends, although not subject to withholding tax, are taxed at the same graduated rates applicable
to U.S. persons, net of certain deductions and credits.&#160;In addition, if you are a corporate non-U.S. holder, dividends you receive
that are effectively connected with your conduct of a U.S. trade or business may also be subject to a branch profits tax at a rate of
30% or such lower rate as may be specified by an applicable income tax treaty. You should consult your tax advisor regarding any applicable
tax treaties that may provide for different rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Gain on Disposition of Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the discussion below regarding
backup withholding and foreign accounts, you generally will not be required to pay U.S. federal income tax on any gain realized upon
the sale or other disposition of the Company&#8217;s common stock unless:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the gain is effectively connected with your conduct
    of a U.S. trade or business (and, if required by an applicable income tax treaty, the gain is attributable to a permanent establishment
    maintained by you in the United States);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">you are a non-resident alien individual who is
    present in the United States for a period or periods aggregating 183 days or more during the taxable year in which the sale or disposition
    occurs and certain other conditions are met; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the Company&#8217;s common stock constitutes a
    United States real property interest by reason of its status as a &#8220;United&#160;States real property holding corporation,&#8221;
    or USRPHC, for U.S. federal income tax purposes at any time within the shorter of (i)&#160;the five-year period preceding your disposition
    of the Company&#8217;s common stock, or (ii)&#160;your holding period for its common stock.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that it is not currently
and will not become a USRPHC for U.S. federal income tax purposes, and the remainder of this discussion so assumes. However, because
the determination of whether it is a USRPHC depends on the fair market value of its U.S. real property relative to the fair market value
of its other business assets, there can be no assurance that the Company will not become a USRPHC in the future. Even if it becomes a
USRPHC, however, as long as the Company&#8217;s common stock is regularly traded on an established securities market, such common stock
will be treated as U.S. real property interests only if you actually or constructively hold more than five percent of such regularly
traded common stock at any time during the shorter of (i) the five-year period preceding your disposition of the Company&#8217;s common
stock, or (ii) your holding period for the Company&#8217;s common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you are a non-U.S. holder described in
the first bullet above, you will be required to pay tax on the net gain derived from the sale under regular graduated U.S. federal income
tax rates, and a corporate non-U.S. holder described in the first bullet above also may be subject to the branch profits tax at a 30%
rate, or such lower rate as may be specified by an applicable income tax treaty.&#160;If you are an individual non-U.S. holder described
in the second bullet above, you will be required to pay a flat 30% tax (or such lower rate specified by an applicable income tax treaty)
on the gain derived from the sale, which gain may be offset by U.S. source capital losses for the year (provided you have timely filed
U.S. federal income tax returns with respect to such losses). You should consult any applicable income tax or other treaties that may
provide for different rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Backup Withholding and&#160;Information Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, the Company must report annually
to the&#160;IRS, regardless of whether any tax was withheld, the amount of dividends paid to you, your name and address and the amount
of tax withheld, if any. A similar report will be sent to you. Pursuant to applicable income tax treaties or other agreements, the&#160;IRS
may make these reports available to tax authorities in your country of residence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payments of dividends or of proceeds on the
disposition of stock made to you may be subject to information reporting and backup withholding at a current rate of 24% unless you establish
an exemption, for example, by properly certifying your non-U.S. status on an&#160;IRS Form W-8BEN, IRS Form W-8BEN-E, or another appropriate
version of&#160;IRS Form W-8.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Backup withholding is not an additional tax;
rather, the U.S. federal income tax liability of persons subject to backup withholding will be reduced by the amount of tax withheld.&#160;If
withholding results in an overpayment of taxes, a refund or credit may generally be obtained from the&#160;IRS, provided that the required
information is furnished to the&#160;IRS in a timely manner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Foreign Account Tax Compliance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Foreign Account Tax Compliance Act, or
FATCA, imposes withholding tax at a rate of 30% on dividends on and gross proceeds from the sale or other disposition of the Company&#8217;s
common stock paid to &#8220;foreign financial institutions&#8221; (as specially defined under these rules), unless such institution enters
into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial
information regarding the U.S. account holders of such institution (which includes certain equity and debt holders of such institution,
as well as certain account holders that are foreign entities with U.S. owners) or otherwise establishes an exemption. FATCA also generally
imposes a U.S. federal withholding tax of 30% on dividends on and gross proceeds from the sale or other disposition of the Company&#8217;s
common stock paid to a &#8220;non-financial foreign entity&#8221; (as specially defined for purposes of these rules) unless such entity
provides the withholding agent with a certification identifying certain substantial direct and indirect U.S. owners of the entity, certifies
that there are none or otherwise establishes an exemption. The withholding provisions under FATCA generally apply to dividends on our
common stock, and under current transition rules, are expected to apply with respect to the gross proceeds from the sale or other disposition
of the Company&#8217;s common stock on or after January&#160;1, 2019. An intergovernmental agreement between the United States and an
applicable foreign country may modify the requirements described in this paragraph. Non-U.S. holders should consult their own tax advisors
regarding the possible implications of this legislation on their investment in the Company&#8217;s common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Each prospective investor should consult
its own tax advisor regarding the particular U.S. federal, state and local and non-U.S. tax consequences of purchasing, holding and disposing
of the Company&#8217;s common stock, including the consequences of any proposed change in applicable laws.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITY OWNERSHIP OF
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 5pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The following table sets forth certain information
regarding beneficial ownership of shares of our common stock as of September 19, 2022 by (i) each person known to beneficially own more
than 5% of our outstanding common stock, (ii) each of our directors, (iii) each of our named executive officers and (iv) all of our directors
and named executive officers as a group.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">The percentage ownership information is based on (i) 1,987,906
shares of common stock outstanding as of September 19, 2022 before the Offering and (ii) 2,576,142 shares of common stock outstanding
after the offering to reflect the assumed sale of shares of common stock but without giving effect to the exercise of the Representative&#8217;s
Warrants or the exercise of the Representative&#8217;s over-allotment option. Information with respect to beneficial ownership has been
furnished by each director, officer or beneficial owner of more than 5% of our common stock. We have determined beneficial ownership
in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole
or shared voting power or investment power with respect to those securities. In addition, the rules attribute beneficial ownership of
securities as of a particular date to persons who hold convertible preferred stock, options or warrants to purchase shares of common
stock and that are exercisable within 60 days of such date. These shares are deemed to be outstanding and beneficially owned by the person
holding those convertible preferred stock, options or warrants for the purpose of computing the percentage ownership of that person,
but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Except as otherwise
indicated, the persons named in the table below have sole voting and investment power with respect to all shares beneficially owned,
subject to community property laws, where applicable.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 5pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise noted below, the address
for each person or entity listed in the table is c/o Silo Pharma, Inc., 560 Sylvan Avenue, Suite 3160, Englewood Cliffs, NJ 07632.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 5pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">Name and Address of Beneficial Owner</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number of<br/> shares<br/> beneficially<br/>
    owned</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Percentage<br/> of&#160;shares<br/>
    beneficially<br/> owned <br/>
    before <br/>
    Offering</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage
    <br/>
    of shares <br/>
    beneficially <br/>
    owned after <span style="text-decoration: none"><br/>
    Offering</span></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-keep: true">5% or greater shareholders:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott
    Wilfong <sup>(1)</sup></span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">107,876</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">5.42</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">%</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">4.19</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt"><span style="font-size: 5pt">&#160;</span></td><td><span style="font-size: 5pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 5pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 5pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 5pt">&#160;</span></td><td><span style="font-size: 5pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 5pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 5pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 5pt">&#160;</span></td><td><span style="font-size: 5pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 5pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 5pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 5pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0.25pt"><span style="-keep: true">Directors and Named Executive Officers:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt"><span style="-keep: true">Eric Weisblum</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">160,221</span></td><td style="vertical-align: super; text-align: left"><sup style="-keep: true">(2)</sup></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">8.03</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6.20</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wayne
    D. Linsley <sup>(3)</sup></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin
    Munoz <sup>(3)</sup></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0.25pt"><span style="-keep: true">All executive officers and directors as a group (3 persons)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">160,221</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">8.03</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6.20</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 5pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents beneficial
    ownership of less than 1% of the outstanding shares of our common stock.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 5pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The address is 6427
    Lake Washington Blvd. NE, Kirkland, WA 98033.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 6,000 shares
    of common stock issuable upon exercise of presently exercisable options.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reporting person also owns options to purchase
    3,425 shares of common stock, none of which are presently exercisable.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 5pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION
PLANS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 5pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table shows information regarding our equity compensation
plans as of December 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 5pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Plan
    Category</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of<br/>
    securities<br/>
    to be<br/>
    issued upon<br/>
    exercise of<br/>
    outstanding<br/>
    options,<br/>
    warrants<br/>
    and<br/>
    rights (a)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/>
    average<br/>
    exercise<br/>
    price of<br/>
    outstanding<br/>
    options,<br/>
    warrants<br/>
    and<br/>
    rights (b)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of<br/>
    securities<br/>
    remaining<br/>
    available for<br/>
    future<br/>
    issuance<br/>
    under&#160;equity<br/>
    compensation<br/>
    plans<br/>
    (excluding<br/>
    securities<br/>
    reflected&#160;in<br/>
    column (c)</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 68%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans approved
    by security holders <sup>(1)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: right">&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans not approved by security
    holders</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 5pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020 Omnibus Equity
    Incentive Plan</b>. On January 18, 2021, the board of directors of the Company approved the Silo Pharma, Inc. 2020 Omnibus Equity
    Incentive Plan (the &#8220;2020 Plan&#8221;) to incentivize employees, officers, directors and consultants of the Company and its
    affiliates. The number of shares of common stock that are reserved and available for issuance under the 2020 Plan shall be equal
    to 170,000 shares provided that with respect to exempt awards as defined in the 2020 Plan, shall not count against such share limit.
    The 2020 Plan provides for the grant, from time to time, at the discretion of the Board or a committee thereof, of cash, stock options,
    including incentive stock options and nonqualified stock options, restricted stock, dividend equivalents, restricted stock units,
    stock appreciation units and other stock or cash-based awards. The Plan shall terminate on the tenth anniversary of the date of adoption
    by the Board of Directors. Subject to certain restrictions, the Board of Directors may amend or terminate the Plan at any time and
    for any reason. An amendment of the Plan shall be subject to the approval of the Company&#8217;s stockholders only to the extent
    required by applicable laws, rules or regulations. On March 10, 2021, the stockholders of the Company approved the Plan.</span></td></tr>
  </table><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTAIN RELATIONSHIPS
AND RELATED PARTY TRANSACTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Except as set forth
below, there were no transactions during our fiscal years ended December 31, 2021 and 2020 to which we were a party, including transactions
in which the amount involved in the transaction exceeds the lesser of $120,000 or 1% of the average of our total assets at year-end for
the last two completed fiscal years, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of
more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or
indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are
described elsewhere in this registration statement. We are not otherwise a party to a current related party transaction, and no transaction
is currently proposed, in which the amount of the transaction exceeds the lesser of $120,000 or 1% of the average of our total assets
at year-end for the last two completed fiscal years and in which a related person had or will have a direct or indirect material interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 11, 2020, we issued a promissory
note in the principal amount of $15,000 to our Chief Executive Officer. The note accrued interest at a rate of 6% per annum, was unsecured
and matured on April 10, 2020. For the years ended December 31, 2020 and 2019, interest expense related to this note amounted to $126
and $0, respectively. In April, we repaid the promissory note in full, or an aggregate of $15,126 (which includes accrued interest).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On April 1, 2020,
we issued a promissory note in the principal amount of $20,000 to our Chief Executive Officer. The note accrued interest at a rate of
6% per annum, was unsecured and matured on September 30, 2020. For the years ended December 31, 2020 and 2019, interest expense related
to this note amounted to $99 and $0, respectively. On April 30, 2020, we repaid the promissory note in full, or an aggregate of $20,099
(which includes accrued interest).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>


</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNDERWRITING</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; ">Laidlaw &amp; Company
(U.K.) Ltd. is acting as lead book-running manager of the offering and as representative of the underwriters named below. Subject to
the terms and conditions stated in the underwriting agreement among us and the underwriters dated the date of this prospectus, each underwriter
named below has severally and not jointly agreed to purchase, and we have agreed to sell to that underwriter, the number of shares of
common stock set forth opposite the underwriter&#8217;s name.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font-size: 10pt"><span style="font-size: 10pt"><b>Underwriter</b></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>Number
    of Shares</b></span></td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 88%; font-size: 10pt">Laidlaw &amp; Company (U.K.) Ltd.</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 9%; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font-size: 10pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt"><span style="font-size: 10pt"><b>Total</b></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double; font-size: 10pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double; font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The underwriters
are offering the shares, subject to prior sale, when, as and if issued to and accepted by them. The underwriting agreement provides that
the obligations of the underwriters to purchase the shares of common stock included in this offering are subject to approval of legal
matters by counsel and to other conditions. The underwriters are obligated to purchase all the shares of common stock (other than those
covered by the over-allotment option described below) if they purchase any of the shares of common stock and warrants. The underwriters
reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Shares of common
stock sold by the underwriters to the public will initially be offered at the initial public offering price set forth on the cover of
this prospectus. Any shares of common stock sold by the underwriters to securities dealers may be sold at a discount from the initial
public offering price not to exceed $	 per share. If all the shares of common stock are not sold at the initial offering price, the
underwriters may change the offering price and the other selling terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We have granted to the underwriter an option,
exercisable no later than 45 calendar days after the closing of this offering, to purchase up to an additional 115,030 shares of common
stock from us to cover over-allotments, if any. If the underwriter exercises all or any part of this option, it will purchase&#160;shares
or warrants covered by the option at the public offering price per share, less the underwriting discount. If this option is exercised
in full, the total offering price to the public will be $___________ and the total net proceeds, before expenses, to us will be $_________.
We will pay the expenses associated with the exercise of the over-allotment option.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Underwriting discounts and commissions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The following table
shows the underwriting discounts and commissions that we are to pay to the underwriters in connection with this offering. These amounts
are shown assuming both no exercise and full exercise of the underwriters&#8217; over-allotment option.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><b>Per Share</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total
    Without Over-Allotment Option</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total
    With Over Allotment Option</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public offering price</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting discount (8%)(1)</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds, before expenses, to us</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
                                            underwriting discounts and commissions to the underwriter of $___, or eight percent (8.0%)
                                            per share. We have also agreed to issue the representative of the underwriters or its designees
                                            warrants to purchase a number of shares of common stock equal to 5.0% of the shares of common
                                            stock sold in this offering and to reimburse the underwriters for certain offering-related
                                            expenses. In addition, we have agreed to pay a management fee to the representative equal
                                            to 1% of the gross proceeds received in this offering, which is not included in the underwriting
                                            discounts and commissions.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; ">&#160;</p><div>






</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have also agreed to reimburse the underwriter
for its expenses in connection with this offering, up to $&#160; , including fees of underwriter counsel of up to $100,000. We estimate
the total expenses of this offering which will be payable by us, excluding the underwriting discount and the underwriter&#8217;s expenses
payable by us, will be approximately $&#160; .</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Indemnification</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">We have agreed to
indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments
the underwriters may be required to make because of any of those liabilities.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Representative&#8217;s
Warrants</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">We have also agreed to issue to the representative
or its designees warrants to purchase a number of our shares of common stock equal to&#160;5% of the common stock sold in this offering.
The representative&#8217;s warrant will have an exercise price equal to 125% of the public offering price of the shares set forth on
the cover of this prospectus. The representative&#8217;s warrants will be exercisable six&#160;months from the effective date of this
registration statement and will expire five&#160;years from the effective date thereof, will have customary one-time demand registration
rights and &#8220;piggyback&#8221; registration rights in respect of the underlying shares of common stock, and may be exercised on a
cashless basis. The representative&#8217;s warrant is not redeemable by us. This prospectus also covers the sale of the representative&#8217;s
warrant and the shares of common stock underlying such warrant. The representative&#8217;s warrant and the underlying securities have
been deemed compensation by FINRA, and are therefore subject to FINRA Rule 5110(e)(1). In accordance with FINRA Rule 5110(e)(1), neither
the representative&#8217;s warrant nor any securities issued upon exercise of the representative&#8217;s warrant may be sold, transferred,
assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result
in the effective economic disposition of such securities by any person for a period of 180 days immediately following the date of effectiveness
or commencement of sales of the offering pursuant to which the representative&#8217;s warrant is being issued, except the transfer of
any security: (i) by operation of law or by reason of reorganization of our company; (ii) to any FINRA member firm participating in this
offering and the officers or partners thereof, if all securities so transferred remain subject to the lock-up restriction described above
for the remainder of the time period; (iii) if the aggregate amount of our securities held by beneficially owned by the representative
does not exceed 1% of the securities being offered; (iv) that is beneficially owned on a pro-rata basis by all equity owners of an investment
fund, provided that no participating member manages or otherwise directs investments by the fund, and participating members in the aggregate
do not own more than 10% of the equity in the fund; (v) the exercise or conversion of any security, if all securities received remain
subject to the lock-up restriction set forth above for the remainder of the time period; or (vi) the transfer or sale of the security
back to us in a transaction exempt from registration with the SEC. In accordance with FINRA Rule 5110(g)(8)(C), the demand registration
rights will have a duration of 5 (five) years from the commencement of sales of the public offering and the unlimited piggyback registration
right provided will not be greater than seven&#160;years from the effective date of the registration statement in compliance with FINRA
Rule&#160;5110(g)(8)(D). We will bear all fees and expenses attendant to registering the securities issuable on exercise of the warrants
other than underwriting commissions incurred and payable by the holders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>No Sales of Similar Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except for the shares of common stock to be
sold hereunder, we have agreed, for a period of 180 days after the date of the final prospectus supplement for this offering (the &#8220;Lock-Up
Period&#8221;), not to, directly or indirectly, without the prior written consent of the representative on behalf of the underwriters
(1) offer for sale, sell, issue, contract to sell, pledge or otherwise dispose of (or enter into any transaction or device that is designed
to, or could be expected to, result in the disposition by any person at any time in the future of) any shares of common stock or other
equity securities of the Company (or securities of the Company convertible into or exercisable or exchangeable for common stock or other
equity securities of the Company (collectively, &#8220;Lock-Up Securities&#8221;), or sell or grant options, rights or warrants with
respect to any shares of common stock or securities convertible into or exchangeable for common stock (other than the grant of options
or other equity awards in the ordinary course of business pursuant to incentive plans described in the registration statement of which
this prospectus forms a part), (2) enter into any swap or other derivatives transaction that transfers to another, in whole or in part,
any of the economic benefits or risks of ownership of such shares of common stock, whether any such transaction described in clause (1)
or (2) above is to be settled by delivery of common stock or other securities, in cash or otherwise, (3) offer to purchase, purchase
or contract to purchase or grant any option, right or warrant to purchase any Lock-Up Securities, (4) file or cause to be filed a registration
statement, including any amendments, with respect to the registration of any Lock-Up Securities, (5) establish or increase a put equivalent
position or liquidate or decrease a call equivalent position in Lock-Up Securities or (6) agree to or publicly disclose the intention
to do any of the foregoing; provided, however, that the following shall not be prohibited by the foregoing: (i) the adoption of an equity
incentive plan approved by ours independent directors, and the grant of awards or equity pursuant to any such equity incentive plan or
existing plan disclosed in the registration statement of which this prospectus forms a part to officers, directors, employees or consultants
of the Company or any of its subsidiaries, and the filing of a registration statement on Form S-8 relating thereto; (ii) the issuance
of equity securities in connection with an acquisition or a strategic relationship, which may include the sale of Lock-Up Securities,
and the filing of a registration statement on Form S-4 relating thereto, provided that any such issuance shall only be to an entity (or
to the equity holders of an entity) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business
synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds,
but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an
entity whose primary business is investing in securities; provided, further, that none of such Lock-Up Securities described in (i) and
(ii) above shall be saleable in the public market until the expiration of the Lock-Up Period, and in no event may any issuance of Lock-Up
Securities described in (i) and (ii) above be at a price less than the public offering price of the shares of common stock in this offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Our executive officers and directors have
entered into lock-up agreements with the underwriters pursuant to which each of these persons or entities, with limited exceptions, may
not, directly or indirectly, for a period of 180 days after the date of the final prospectus supplement for this offering (subject to
extension in certain circumstances), without the prior written consent of representative on behalf of the underwriters: (1) offer, pledge,
sell or contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or
warrant for the sale of, or otherwise dispose of or transfer any common stock or any securities convertible into or exchangeable or exercisable
for common stock, whether now owned or hereafter acquired by the officer or director or with respect to which the officer or director
has or hereafter acquires the power of disposition, or file, make any demand with respect to, cause to be filed, or exercise any right
with respect to any registration statement under the Securities Act, with respect to any of the foregoing, (2)&#160;enter into any swap
or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership
of any such securities, whether any such swap or transaction is to be settled by delivery of common stock or other securities, in cash
or otherwise or (3) engage in any short selling of the common stock. Notwithstanding the foregoing, our executive officers and directors
may transfer any such securities provided that (1)&#160;representative on behalf of the underwriters receives a signed lock-up agreement
for the balance of the lockup period from each donee, trustee, distributee, or transferee, as the case may be, (2)&#160;any such transfer
shall not involve a disposition for value, (3)&#160;such transfers are not required to be reported with the SEC in accordance with the
Exchange Act under Section 16 or otherwise, and (4)&#160;neither the officer or director nor any donee, trustee, distributee or transferee,
as the case may be, otherwise voluntarily effects any public filing or report or other public notice regarding such transfers: (i) as
a&#160;<i>bona fide</i>&#160;gift or gifts; or (ii) to any trust for the direct or indirect benefit of the officer or director or the
immediate family of the officer or director; or (iii) transfers by will, other testamentary document or intestate succession to the legal
representative, heir, beneficiary or a member of the immediate family of the officer or director. In addition, the lock-up will not restrict
the delivery of common stock to the officer or director upon vesting and settlement of restricted share units or exercise of options
outstanding on the date hereof in accordance with their terms; provided, that the common stock delivered upon any such vesting, settlement
or exercise shall be subject to the foregoing restrictions. Furthermore, the officer or director may sell shares of common stock purchased
by the officer or director on the open market following this offering if and only if (i)&#160;such sales are not required to be reported
in any public report or filing with the SEC in accordance with the Exchange Act under Section 16 or otherwise and (ii)&#160;neither the
officer or director nor any purchaser of the common stock otherwise voluntarily effects any public filing or report or other public notice
regarding such sales.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 5pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stabilization, Short Positions and Penalty
Bids</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 5pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The representatives may engage in stabilizing
transactions, short sales and purchases to cover positions created by short sales, and penalty bids or purchases for the purpose of pegging,
fixing or maintaining the price of the common stock, in accordance with Regulation M under the Exchange Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 5pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Stabilizing transactions permit bids to purchase the underlying
    security so long as the stabilizing bids do not exceed a specified maximum.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 5pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">A short position involves a sale by the underwriters of shares in
    excess of the number of shares the underwriters are obligated to purchase in the offering, which creates the syndicate short position.
    This short position may be either a covered short position or a naked short position. In a covered short position, the number of
    shares involved in the sales made by the underwriters in excess of the number of shares they are obligated to purchase is not greater
    than the number of shares that they may purchase by exercising their option to purchase additional shares. In a naked short position,
    the number of shares involved is greater than the number of shares in their option to purchase additional shares. The underwriters
    may close out any short position by either exercising their option to purchase additional shares and/or purchasing shares in the
    open market. In determining the source of shares to close out the short position, the underwriters will consider, among other things,
    the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through
    their option to purchase additional shares. A naked short position is more likely to be created if the underwriters are concerned
    that there could be downward pressure on the price of the shares in the open market after pricing that could adversely affect investors
    who purchase in the offering.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 5pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Syndicate covering transactions involve purchases of the common
    stock in the open market after the distribution has been completed in order to cover syndicate short positions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 5pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Penalty bids permit the representatives to reclaim a selling concession
    from a syndicate member when the common stock originally sold by the syndicate member is purchased in a stabilizing or syndicate
    covering transaction to cover syndicate short positions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 5pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These stabilizing transactions, syndicate
covering transactions and penalty bids may have the effect of raising or maintaining the market price of our common stock or preventing
or retarding a decline in the market price of the common stock. As a result, the price of the common stock may be higher than the price
that might otherwise exist in the open market. These transactions may be effected on the Nasdaq Capital Market or otherwise and, if commenced,
may be discontinued at any time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 5pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither we nor any of the underwriters make
any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the
price of the common stock. In addition, neither we nor any of the underwriters make any representation that the representatives will
engage in these stabilizing transactions or that any transaction, once commenced, will not be discontinued without notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 5pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Nasdaq Passive Market Making</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 5pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this offering, underwriters
and selling group members may engage in passive market making transactions in the common stock on the Nasdaq Capital Market in accordance
with Rule 103 of Regulation M under the Exchange Act during a period before the commencement of offers or sales of common stock and extending
through the completion of distribution. A passive market maker must display its bid at a price not in excess of the highest independent
bid of that security. However, if all independent bids are lowered below the passive market maker&#8217;s bid, that bid must then be
lowered when specified purchase limits are exceeded. Passive market making may cause the price of our common stock to be higher than
the price that otherwise would exist in the open market in the absence of those transactions. The underwriters and dealers are not required
to engage in passive market making and may end passive market making activities at any time.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Electronic Distribution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A prospectus in electronic format may be made
available on the Internet sites or through other online services maintained by one or more of the underwriters and/or selling group members
participating in this offering, or by their affiliates. In those cases, prospective investors may view offering terms online and, depending
upon the particular underwriter or selling group member, prospective investors may be allowed to place orders online. The underwriters
may agree with us to allocate a specific number of shares for sale to online brokerage account holders. Any such allocation for online
distributions will be made by the representatives on the same basis as other allocations.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than the prospectus in electronic format,
the information on any underwriter&#8217;s or selling group member&#8217;s web site and any information contained in any other web site
maintained by an underwriter or selling group member is not part of the prospectus or the registration statement of which this prospectus
forms&#160;a part, has not been approved and/or endorsed by us or any underwriter or selling group member in its capacity as underwriter
or selling group member and should not be relied upon by investors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Listing on the Nasdaq Capital Market</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have applied to list our common stock on
the Nasdaq Capital Market upon our satisfaction of the exchange&#8217;s initial listing criteria. If our common stock is not approved
for listing on the Nasdaq Capital Market, we will not consummate this offering. No assurance can be given that our application will be
approved. We do not intend to apply for any listing of the representative&#8217;s warrants on the Nasdaq Capital Market or any other
securities exchange or nationally recognized trading system, and we do not expect a market to develop for such warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other Relationships</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriters and certain of their affiliates
are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment
banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities.
The underwriters and certain of their affiliates have, from time to time, performed, and may in the future perform, various commercial
and investment banking and financial advisory services for the issuer and its affiliates, for which they received or may in the future
receive customary fees and expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the ordinary course of their various business
activities, the underwriters and certain of their affiliates may make or hold a broad array of investments and actively trade debt and
equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the
accounts of their customers, and such investment and securities activities may involve securities and/or instruments of the issuer or
its affiliates. If the underwriters or their affiliates have a lending relationship with us, they routinely hedge their credit exposure
to us consistent with their customary risk management policies. The underwriters and their affiliates may hedge such exposure by entering
into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities or
the securities of our affiliates, including potentially the shares of common stock offered hereby. Any such credit default swaps or short
positions could adversely affect future trading prices of the shares of common stock offered hereby. The underwriters and certain of
their affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express
independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire,
long and/or short positions in such securities and instruments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Selling Restrictions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus does not constitute an offer
to sell to, or a solicitation of an offer to buy from, anyone in any country or jurisdiction (i)&#160;in which such an offer or solicitation
is not authorized, (ii)&#160;in which any person making such offer or solicitation is not qualified to do so or (iii)&#160;in which any
such offer or solicitation would otherwise be unlawful. No action has been taken that would, or is intended to, permit a public offer
of the shares of common stock or possession or distribution of this prospectus or any other offering or publicity material relating to
the shares of common stock in any country or jurisdiction (other than the United States) where any such action for that purpose is required.
Accordingly, each underwriter has undertaken that it will not, directly or indirectly, offer or sell any shares of common stock or have
in its possession, distribute or publish any prospectus, form of application, advertisement or other document or information in any country
or jurisdiction except under circumstances that will, to the best of its knowledge and belief, result in compliance with any applicable
laws and regulations and all offers and sales of shares of common stock by it will be made on the same terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>European Economic Area</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In relation to each Member State of the European
Economic Area which has implemented the prospectus Directive (each, a &#8220;Relevant Member State&#8221;) an offer to the public of
any common stock which are the subject of the offering contemplated herein may not be made in that Relevant Member State, except that
an offer to the public in that Relevant Member State of any common stock may be made at any time under the following exemptions under
the prospectus Directive, if they have been implemented in that Relevant Member State:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">to legal entities which are qualified investors as defined under
    the prospectus Directive;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">by the underwriters to fewer than 100, or, if the Relevant Member
    State has implemented the relevant provisions of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified
    investors as defined in the prospectus Directive), as permitted under the prospectus Directive, subject to obtaining the prior consent
    of the representatives of the underwriters for any such offer; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">in any other circumstances falling within Article&#160;3(2) of the
    prospectus Directive, provided that no such offer of common stock shall result in a requirement for us or any underwriter to publish
    a prospectus pursuant to Article 3 of the prospectus Directive or supplement a prospectus pursuant to Article&#160;16 of the prospectus
    Directive.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each person in a Relevant Member State who
receives any communication in respect of, or who acquires any common stock under, the offers contemplated here in this prospectus will
be deemed to have represented, warranted and agreed to and with each underwriter and us that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">it is a qualified investor as defined under the prospectus Directive;
    and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">in the case of any common stock acquired by it as a financial intermediary,
    as that term is used in Article&#160;3(2) of the prospectus Directive, (i)&#160;the common stock acquired by it in the offering have
    not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Relevant Member
    State other than qualified investors, as that term is defined in the prospectus Directive, or in the circumstances in which the prior
    consent of the representatives of the underwriters has been given to the offer or resale or (ii)&#160;where common stock have been
    acquired by it on behalf of persons in any Relevant Member State other than qualified investors, the offer of such common stock to
    it is not treated under the prospectus Directive as having been made to such persons.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the purposes of this representation and
the provision above, the expression an &#8220;offer of common stock to the public&#8221; in relation to any common stock in any Relevant
Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any common
stock to be offered so as to enable an investor to decide to purchase or subscribe for the common stock, as the same may be varied in
that Relevant Member State by any measure implementing the prospectus Directive in that Relevant Member State, the expression &#8220;prospectus
Directive&#8221; means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented
in the Relevant Member State), and includes any relevant implementing measure in each Relevant Member State and the expression &#8220;2010
PD Amending Directive&#8221; means Directive 2010/73/EU.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>United Kingdom</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus has only been communicated
or caused to have been communicated and will only be communicated or caused to be communicated as an invitation or inducement to engage
in investment activity (within the meaning of Section&#160;21 of the Financial Services and Markets Act of 2000 (the &#8220;FSMA&#8221;))
as received in connection with the issue or sale of the common stock in circumstances in which Section&#160;21(1) of the FSMA does not
apply to us. All applicable provisions of the FSMA will be complied with in respect to anything done in relation to the common stock
in, from or otherwise involving the United Kingdom.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Notice to Residents of Canada</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities may be sold only to purchasers
purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument&#160;45-106 prospectus
Exemptions or subsection&#160;73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument&#160;31-103
Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with
an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities legislation in certain provinces
or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment
thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the
time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any
applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or
consult with a legal advisor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to section&#160;3A.3 (or, in the
case of securities issued or guaranteed by the government of a non-Canadian jurisdiction, section&#160;3A.4) of National Instrument&#160;33-105
Underwriting Conflicts (NI&#160;33-105), the underwriters are not required to comply with the disclosure requirements of NI&#160;33-105
regarding underwriter conflicts of interest in connection with this offering.&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Notice to Prospective Investors in the Dubai International
Financial Centre</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This document relates to an Exempt Offer in
accordance with the Markets Rules 2012 of the Dubai Financial Services Authority (&#8220;DFSA&#8221;). This document is intended for
distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by,
any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA
has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for
this document. The shares to which this document relates may be illiquid and/or subject to restrictions on their resale. Prospective
purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this
document you should consult an authorized financial advisor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In relation to its use in the DIFC, this document
is strictly private and confidential and is being distributed to a limited number of investors and must not be provided to any person
other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the shares may not be offered
or sold directly or indirectly to the public in the DIFC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Notice to Prospective Investors in Australia</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No placement document, prospectus, product
disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission (&#8220;ASIC&#8221;),
in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document
under the Corporations Act 2001 (the &#8220;Corporations Act&#8221;), and does not purport to include the information required for a
prospectus, product disclosure statement or other disclosure document under the Corporations Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any offer in Australia of the shares may only
be made to persons (the &#8220;Exempt Investors&#8221;) who are &#8220;sophisticated investors&#8221; (within the meaning of section
708(8) of the Corporations Act), &#8220;professional investors&#8221; (within the meaning of section 708(11) of the Corporations Act)
or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the shares
without disclosure to investors under Chapter 6D of the Corporations Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares applied for by Exempt Investors
in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except
in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption
under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter
6D of the Corporations Act. Any person acquiring shares must observe such Australian on-sale restrictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus contains general information
only and does not take account of the investment objectives, financial situation or particular needs of any particular person. It does
not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider
whether the information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert
advice on those matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Notice to Prospective Investors in Hong Kong</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares have not been offered or sold and
will not be offered or sold in Hong Kong, by means of any document, other than (a) to &#8220;professional investors&#8221; as defined
in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong (the &#8220;SFO&#8221;)) of Hong Kong and any rules made thereunder;
or (b) in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies (Winding
Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong (the &#8220;CO&#8221;) or which do not constitute an offer to the public
within the meaning of the CO. No advertisement, invitation or document relating to the shares has been or may be issued or has been or
may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents
of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong
Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional
investors&#8221; as defined in the SFO and any rules made thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Belgium</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering is exclusively conducted under
applicable private placement exemptions and therefore it has not been and will not be notified to, and this document or any other offering
material relating to the shares of common stock has not been and will not be approved by, the Belgian Banking, Finance and Insurance
Commission (&#8220;Commission bancaire, financi&#232;re et des assurances/Commissie voor het Bank, Financie en Assurantiewezen&#8221;).
Any representation to the contrary is unlawful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each underwriter has undertaken not to offer
sell, resell, transfer or deliver directly or indirectly, any shares of common stock, or to take any steps relating/ancillary thereto,
and not to distribute or publish this document or any other material relating to the shares of common stock or to the offering in a manner
which would be construed as: (a) a public offering under the Belgian Royal Decree of 7 July 1999 on the public character of financial
transactions; or (b) an offering of securities to the public under Directive 2003/71/EC which triggers an obligation to publish a prospectus
in Belgium. Any action contrary to these restrictions will cause the recipient and the company to be in violation of the Belgian securities
laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>France</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither this prospectus nor any other offering
material relating to the shares of common stock has been submitted to the clearance procedures of the Autorit&#233; des march&#233;s
financiers in France. The shares of common stock have not been offered or sold and will not be offered or sold, directly or indirectly,
to the public in France. Neither this prospectus nor any other offering material relating to the shares of common stock has been or will
be: (a) released, issued, distributed or caused to be released, issued or distributed to the public in France; or (b) used in connection
with any offer for subscription or sale of the shares of common stock to the public in France. Such offers, sales and distributions will
be made in France only: (i) to qualified investors (investisseurs qualifi&#233;s) and/or to a restricted circle of investors (cercle
restreint d&#8217;investisseurs), in each case investing for their own account, all as defined in and in accordance with Articles L.411-2,
D.411-1, D.411-2, D.734-1, D.744-1, D.754-1 and D.764-1 of the French Code mon&#233;taire et financier; (ii) to investment services
providers authorised to engage in portfolio management on behalf of third parties; or (iii) in a transaction that, in accordance with
article L.411-2-II-1&#176;-or-2&#176;-or 3&#176; of the French Code mon&#233;taire et financier and article 211-2 of the General Regulations
(R&#232;glement G&#233;n&#233;ral) of the Autorit&#233; des march&#233;s financiers, does not constitute a public offer (appel
public &#224; l&#8217;&#233;pargne). Such shares of common stock may be resold only in compliance with Articles L.411-1, L.411-2,
L.412-1 and L.621-8 through L.621-8-3 of the French Code mon&#233;taire et financier.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Israel</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus does not constitute a prospectus
under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities
Authority. In the State of Israel, this document is being distributed only to, and is directed only at, and any offer of the shares of
common stock is directed only at, investors listed in the first addendum to the Israeli Securities Law, or the Addendum, consisting primarily
of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of
the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50 million and &#8220;qualified
individuals&#8221;, each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors
(in each case purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors
listed in the Addendum). Qualified investors will be required to submit written confirmation that they fall within the scope of the Addendum,
are aware of the meaning of same and agree to it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Italy</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering of the shares of common stock
offered hereby in Italy has not been registered with the Commissione Nazionale per la Societ&#224; e la Borsa, or CONSOB, pursuant
to Italian securities legislation and, accordingly, the shares of common stock offered hereby cannot be offered, sold or delivered in
the Republic of Italy, or Italy, nor may any copy of this prospectus or any other document relating to the shares of common stock offered
hereby be distributed in Italy other than to professional investors (operatori qualificati) as defined in Article 31, second paragraph,
of CONSOB Regulation No. 11522 of 1 July, 1998 as subsequently amended. Any offer, sale or delivery of the shares of common stock offered
hereby or distribution of copies of this prospectus or any other document relating to the shares of common stock offered hereby in Italy
must be made:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    an investment firm, bank or intermediary permitted to conduct such activities in Italy in accordance with Legislative Decree No.
    58 of 24 February 1998 and Legislative Decree No. 385 of 1 September 1993, or the Banking Act;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in compliance with Article
    129 of the Banking Act and the implementing guidelines of the Bank of Italy; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in compliance with any
    other applicable laws and regulations and other possible requirements or limitations which may be imposed by Italian authorities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Sweden</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus has not been nor will it be
registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority). Accordingly, this prospectus may not
be made available, nor may the shares of common stock offered hereunder be marketed and offered for sale in Sweden, other than under
circumstances which are deemed not to require a prospectus under the Financial Instruments Trading Act (1991: 980).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Switzerland</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares of common stock offered pursuant
to this prospectus will not be offered, directly or indirectly, to the public in Switzerland and this prospectus does not constitute
a public offering prospectus as that term is understood pursuant to art. 652a or art. 1156 of the Swiss Federal Code of Obligations.
The company has not applied for a listing of the shares of common stock being offered pursuant to this prospectus on the SWX Swiss Exchange
or on any other regulated securities market, and consequently, the information presented in this prospectus does not necessarily comply
with the information standards set out in the relevant listing rules. The shares of common stock being offered pursuant to this prospectus
have not been registered with the Swiss Federal Banking Commission as foreign investment funds, and the investor protection afforded
to acquirers of investment fund certificates does not extend to acquirers of shares of common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Investors are advised to contact their legal,
financial or tax advisers to obtain an independent assessment of the financial and tax consequences of an investment in shares of common
stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DESCRIPTION OF SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The following description of the Company&#8217;s
capital stock and provisions of its Certificate of Incorporation and Bylaws are summaries and are qualified by reference to the Company&#8217;s
Certificate of Incorporation and Bylaws.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Our Certificate of Incorporation authorizes
the issuance of 505,000,000 shares of capital stock, 500,000,000 shares of which are designated as common stock, par value $0.0001 per
share, and 5,000,000 of which are designated as preferred stock, par value $0.0001 per share. As of September 19, 2022, we have 1,987,906
shares of common stock issued and outstanding and no shares of preferred stock issued or outstanding.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each stockholder of our common stock is entitled
to a pro rata share of cash distributions made to stockholders, including dividend payments. The holders of our common stock are entitled
to one vote for each share of record on all matters to be voted on by stockholders. There is no cumulative voting with respect to the
election of our directors or any other matter. Therefore, the holders of more than 50% of the shares voted for the election of those
directors can elect all of the directors. The holders of our common stock are entitled to receive dividends when and if declared by our
board of directors from funds legally available therefore. Cash dividends are at the sole discretion of our board of directors. In the
event of our liquidation, dissolution or winding up, the holders of common stock are entitled to share ratably in all assets remaining
available for distribution to them after payment of our liabilities and after provision has been made for each class of stock, if any,
having any preference in relation to our common stockholders of shares of our common stock have no conversion, preemptive or other subscription
rights, and there are no redemption provisions applicable to our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Preferred Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Series C Preferred Stock </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 9, 2021, we filed a Certificate
of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the &#8220;Certificate of Designations&#8221;)
with the Delaware Secretary of State, designating 4,280 shares of preferred stock as Series C Convertible Preferred Stock. The following
is only a summary of the Certificate of Designations and is qualified in its entirety by reference to the full text of the Certificate
of Designations which is filed as an exhibit to this registration statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Designation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have designated 4,280 shares of preferred
stock as Series C Preferred Stock. Each share of Series C Preferred Stock has a par value of $0.0001 per share and a stated value of
$1,000 (the &#8220;Stated Value&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dividends</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of Series C Preferred Stock shall
be entitled to receive dividends (on an as-if-converted-to-common-stock basis) in the same form as dividends actually paid on shares
of the common stock when, as and if such dividends are paid on shares of the common stock. No other dividends shall be paid on shares
of Series C Preferred Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Liquidation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon any liquidation, dissolution or winding-up
of the Company, whether voluntary or involuntary, the holders of Series C Preferred Stock shall be entitled to receive the same amount
that a holder of common stock would receive if the Series C Preferred Stock were fully converted into common stock (disregarding any
conversion limitations) which amounts shall be paid pari passu with all holders of common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Voting Rights</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise provided in the Certificate
of Designations or as otherwise required by law, the Series C Preferred Stock shall have no voting rights. However, as long as any shares
of Series C Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of a majority of the then outstanding
shares of the Series C Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series C Preferred
Stock or alter or amend the Certificate of Designations, (b) amend our Certificate of Incorporation or other charter documents in any
manner that adversely affects any rights of the holders of the Series C Preferred Stock, (c) increase the number of authorized shares
of Series C Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Conversion</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Each share of Series C Preferred Stock is
convertible, at any time and from time to time after the issuance date, at the option of the holder, into such number of shares of common
stock determined by dividing the Stated Value by the Conversion Price. &#8220;Conversion Price&#8221; means $15.00, subject to adjustment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Forced Conversion</span>. Notwithstanding
anything herein to the contrary, after the date that the Company&#8217;s stockholder approval is obtained and deemed effective, the Company
may deliver a written notice to all holders (the &#8220;Forced Conversion Notice Date&#8221;) to cause each holder to convert all or
part of such holder&#8217;s Series C Convertible Preferred Stock pursuant to Section 6 (&#8220;Forced Conversion&#8221;), it being agreed
that the &#8220;Conversion Date&#8221; shall be deemed to occur no later than the earlier of (i) two (2) trading days and (ii) the number
of trading days comprising the standard settlement period following the Forced Conversion Notice Date; provided, however, a holder shall
only be required to convert pursuant to a Forced Conversion to the extent that such conversion would not cause a holder to exceed its
beneficial ownership limitation. On March 10, 2021, the Company obtained the stockholders&#8217; approval forcing the conversion of all
the Series C Convertible Preferred Stock. On April 12, 2021, the Company notified holders of its Series C Convertible Preferred Stock
of its election to force the conversion to its Series C Convertible Preferred Stock into shares of the Company&#8217;s common stock.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On April
12, 2021, the Company notified holders of its Series C Convertible Preferred Stock of its election to force the conversion to its Series
C Convertible Preferred Stock into shares of the Company&#8217;s common stock pursuant to the Certificate of Designations unless such
conversion would cause the holder to exceed its beneficial ownership limitation pursuant to the Certificate of Designations. On April
14, 2021, the Company converted 4,049 Series C Convertible Preferred Stock into 269,900 shares of common stock. On March 31, 2022, the
Company notified holders of its Series C Convertible preferred stock of its election to force the conversion to its Series C Convertible
preferred stock into shares of the Company&#8217;s common stock pursuant to the Certificate of Designations unless such conversion would
cause the holder to exceed its beneficial ownership limitation pursuant to the Certificate of Designations. On March 31, 2022, the Company
converted 227 Series C Convertible preferred stock into 15,167 shares of common stock. As of March 31, 2022, there were no shares of
Series C Convertible preferred stock issued and outstanding.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Exercisability</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A holder of Series C Preferred Stock may not
convert any portion of the Series C Preferred Stock to the extent that the holder, together with its affiliates and any other person
or entity acting as a group, would own more than 4.99% (or, upon election by a holder prior to issuance, 9.99%) of the outstanding shares
of common stock after conversion, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 12, 2021, we issued Warrants to
purchase up to 285,066 shares of our common stock in a private offering. The Warrants are exercisable for a period of five years from
the date of issuance at an exercise price of $15.00 per share. If, after a period of 180 days after the date of issuance of the Warrants,
a registration statement covering the resale of the Warrant Shares is not effective, the holders may exercise the Warrants by means of
a cashless exercise. We are prohibited from effecting an exercise of the Warrants to the extent that, as a result of such exercise, the
holder of the Warrant together with the holder&#8217;s affiliates, would beneficially own more than 4.99% of the number of shares of
common stock outstanding immediately after giving effect to the issuance of the Warrant Shares, which beneficial ownership limitation
may be increased by the holder up to, but not exceeding, 9.99%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the private placement of
the Warrant, we issued the placement agents warrants to purchase up to an aggregate of 57,013 shares of our common stock. The placement
agent warrants are exercisable for a period of five years from the closing date of the offering at an exercise price of $17.50 per share,
subject to adjustment.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of September 19, 2022 we have warrants
to purchase up to 347,080 shares of our common stock issued and outstanding at a weighted average exercise price of $15.00 per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Options</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of September 19, 2022, we have options
to purchase up to 28,649 shares of our common stock issued and outstanding at an exercise price of $0.01 per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Registration Rights </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 9, 2021, in connection with the
Purchase Agreements, we entered into Registration Rights Agreements (&#8220;RRAs&#8221;) with the Investors pursuant to which we agreed
to file a registration statement to register the resale of the Conversion Shares and the Warrant Shares. Pursuant to the RRA, we shall
use our best efforts to cause the registration to be declared effective no later than the 60<sup>th</sup> calendar day following February
9, 2021, or in the event of a full review by the SEC, the 90<sup>th</sup> calendar day following February 9, 2021, and to maintain the
effectiveness of the registration statement until all of the Conversion Shares and Warrant Shares have been sold or are otherwise able
to be sold pursuant to Rule 144 under the Securities Act. If we fail to file the registration statement or have it declared effective
by the dates set forth above, amongst other things, we will be obligated to pay the investors damages in the amount of 1% of their subscription
amount, per month, until such events are satisfied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Anti-Takeover Provisions of our Certificate
of Incorporation and our Bylaws</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Set forth below is a summary of the provisions
of our Certificate of Incorporation, Bylaws and the Delaware General Corporation Law that could have the effect of delaying or preventing
a change in control of our Company. The following description is only a summary, and it is qualified by reference to the Certificate
of Incorporation and Bylaws which are incorporated by reference herein and relevant provisions of the Delaware General Corporation Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Board of Directors Vacancies</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Bylaws authorize only our board of directors
to fill vacant directorships. In addition, the number of directors constituting our board of directors may be set only by resolution
of the majority of the incumbent directors; provided, however, the number of directors shall not be less than three.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Special Meeting of Stockholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Bylaws provide that special meetings of
our stockholders may be called by our President or our board of directors and our <span>Secretary at
the request in writing of our stockholders owning a majority of our voting capital.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Authorized but Unissued Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized but unissued shares of common
stock and preferred stock are available for future issuance without stockholder approval and may be utilized for a variety of corporate
purposes, including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence
of authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain
control of us by means of a proxy contest, tender offer, merger or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Section 203 of the Delaware General
Corporation Law</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not subject to the provisions of Section
203 of the Delaware General Corporation Law regulating corporate takeovers. This statute prevents certain Delaware corporations, under
certain circumstances, from engaging in a &#8220;business combination&#8221; with:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a stockholder who owns 15% or more of our outstanding voting stock
    (otherwise known as an &#8220;interested stockholder&#8221;);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">an affiliate of an interested stockholder; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">an associate of an interested stockholder, for three years following
    the date that the stockholder became an interested stockholder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A &#8220;business combination&#8221; includes
a merger or sale of more than 10% of our assets. However, the above provisions of Section 203 will not apply to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transfer Agent and Registrar</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our transfer agent and registrar is West Coast Stock Transfer,
Inc. whose address is 721 N. Vulcan Avenue, Suite 106, Encinitas, CA 92024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Listing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">Our shares of common stock are currently quoted on The OTCQB Venture
Market, operated by OTC Markets Group, under the temporary symbol of &#8220;SILOD&#8221; and the fifth character &#8220;D&#8221; will
remain appended to our symbol for 20 business days following our September 15, 2022 reverse stock split or until the Company is listed
on Nasdaq, whichever comes first, at which point the Company&#8217;s trading symbol will revert back to &#8220;SILO.&#8221; We have applied
to list our common stock on the Nasdaq Capital Market upon our satisfaction of the exchange&#8217;s initial listing criteria. No assurance
can be given that our application will be approved. If our common stock is not approved for listing on the Nasdaq Capital Market, we
will not consummate this offering.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2020 Omnibus Equity Incentive Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On January 18, 2021,
the board of directors of the Company approved the Silo Pharma, Inc. 2020 Omnibus Equity Incentive Plan (the &#8220;2020 Plan&#8221;)
to incentivize employees, officers, directors and consultants of the Company and its affiliates. The number of shares of common stock
that are reserved and available for issuance under the 2020 Plan shall be equal to 170,000 shares provided that with respect to exempt
awards as defined in the 2020 Plan, shall not count against such share limit. The 2020 Plan provides for the grant, from time to time,
at the discretion of the Board or a committee thereof, of cash, stock options, including incentive stock options and nonqualified stock
options, restricted stock, dividend equivalents, restricted stock units, stock appreciation units and other stock or cash-based awards.
The Plan shall terminate on the tenth anniversary of the date of adoption by the Board of Directors. Subject to certain restrictions,
the Board of Directors may amend or terminate the Plan at any time and for any reason. An amendment of the Plan shall be subject to the
approval of the Company&#8217;s stockholders only to the extent required by applicable laws, rules or regulations. On March 10, 2021,
the stockholders of the Company approved the Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Description of 2020 Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the material
features of the 2020 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Types of Awards</i>. The 2020 Plan provides
for the issuance of incentive stock options, non-statutory stock options, stock appreciation rights (&#8220;SARs&#8221;), restricted
stock, restricted stock units (&#8220;RSUs&#8221;), and other stock-based awards. Items described above in the Section called &#8220;Shares
Available; Certain Limitations&#8221; are incorporated herein by reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Administration</i>. The 2020 Plan will
be administered by our Board of Directors, or if our Board of Directors does not administer the 2020 Plan, a committee or subcommittee
of our Board of Directors that complies with the applicable requirements of Section 16 of the Exchange Act and any other applicable legal
or stock exchange listing requirements (each of our Board of Directors or such committee or subcommittee, the &#8220;plan administrator&#8221;).
The plan administrator may interpret the 2020 Plan and may prescribe, amend and rescind rules and make all other determinations necessary
or desirable for the administration of the 2020 Plan, provided that, subject to the equitable adjustment provisions described below,
the plan administrator will not have the authority to reprice or cancel and re-grant any award at a lower exercise, base or purchase
price or cancel any award with an exercise, base or purchase price in exchange for cash, property or other awards without first obtaining
the approval of our stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2020 Plan permits the plan administrator
to select the eligible recipients who will receive awards, to determine the terms and conditions of those awards, including, but not
limited to, the exercise price or other purchase price of an award, the number of shares of common stock or cash or other property subject
to an award, the term of an award and the vesting schedule applicable to an award, and to amend the terms and conditions of outstanding
awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock and Restricted Stock Units</i>.
Restricted stock and RSUs may be granted under the 2020 Plan. The plan administrator will determine the purchase price, vesting schedule
and performance goals, if any, and any other conditions that apply to a grant of restricted stock and RSUs. If the restrictions, performance
goals or other conditions determined by the plan administrator are not satisfied, the restricted stock and RSUs will be forfeited. Subject
to the provisions of the 2020 Plan and the applicable award agreement, the plan administrator has the sole discretion to provide for
the lapse of restrictions in installments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless the applicable award agreement provides
otherwise, participants with restricted stock will generally have all of the rights of a stockholder; provided that dividends will only
be paid if and when the underlying restricted stock vests. RSUs will not be entitled to dividends prior to vesting, but may be entitled
to receive dividend equivalents if the award agreement provides for them. The rights of participants granted restricted stock or RSUs
upon the termination of employment or service to us will be set forth in the award agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Options.&#160;</i>Incentive stock options
and non-statutory stock options may be granted under the 2020 Plan. An &#8220;incentive stock option&#8221; means an option intended
to qualify for tax treatment applicable to incentive stock options under Section 422 of the Code. A &#8220;non-statutory stock option&#8221;
is an option that is not subject to statutory requirements and limitations required for certain tax advantages that are allowed under
specific provisions of the Code. A non-statutory stock option under the 2020 Plan is referred to for federal income tax purposes as a
&#8220;non-qualified&#8221; stock option. Each option granted under the 2020 Plan will be designated as a non-qualified stock option
or an incentive stock option. At the discretion of the plan administrator, incentive stock options may be granted only to our employees,
employees of our &#8220;parent corporation&#8221; (as such term is defined in Section 424(e) of the Code) or employees of our subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The exercise period of an option may not exceed
ten years from the date of grant and the exercise price may not be less than 100% of the fair market value of a share of common stock
on the date the option is granted (110% of fair market value in the case of incentive stock options granted to ten percent stockholders).
The exercise price for shares of common stock subject to an option may be paid in cash, or as determined by the plan administrator in
its sole discretion, (i) through any cashless exercise procedure approved by the plan administrator (including the withholding of shares
of common stock otherwise issuable upon exercise), (ii) by tendering unrestricted shares of common stock owned by the participant, (iii)
with any other form of consideration approved by the plan administrator and permitted by applicable law or (iv) by any combination of
these methods. The option holder will have no rights to dividends or distributions or other rights of a stockholder with respect to the
shares of common stock subject to an option until the option holder has given written notice of exercise and paid the exercise price
and applicable withholding taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a participant&#8217;s termination
of employment or service, the participant may exercise his or her option (to the extent vested as of such date of termination) for such
period of time as specified in his or her option agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stock Appreciation Rights</i>. SARs may
be granted either alone (a &#8220;free-standing SAR&#8221;) or in conjunction with all or part of any option granted under the 2020 Plan
(a &#8220;tandem SAR&#8221;). A free-standing SAR will entitle its holder to receive, at the time of exercise, an amount per share up
to the excess of the fair market value (at the date of exercise) of a share of common stock over the base price of the free-standing
SAR (which shall be no less than 100% of the fair market value of the related shares of common stock on the date of grant) multiplied
by the number of shares in respect of which the SAR is being exercised. A tandem SAR will entitle its holder to receive, at the time
of exercise of the SAR and surrender of the applicable portion of the related option, an amount per share up to the excess of the fair
market value (at the date of exercise) of a share of common stock over the exercise price of the related option multiplied by the number
of shares in respect of which the SAR is being exercised. The exercise period of a free-standing SAR may not exceed ten years from the
date of grant. The exercise period of a tandem SAR will also expire upon the expiration of its related option.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holder of a SAR will have no rights to
dividends or any other rights of a stockholder with respect to the shares of common stock subject to the SAR until the holder has given
written notice of exercise and paid the exercise price and applicable withholding taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a participant&#8217;s termination
of employment or service, the holder of a SAR may exercise his or her SAR (to the extent vested as of such date of termination) for such
period of time as specified in his or her SAR agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other Stock-Based Awards</i>. The plan
administrator may grant other stock-based awards under the 2020 Plan, valued in whole or in part by reference to, or otherwise based
on, shares of common stock. The plan administrator will determine the terms and conditions of these awards, including the number of shares
of common stock to be granted pursuant to each award, the manner in which the award will be settled, and the conditions to the vesting
and payment of the award (including the achievement of performance goals). The rights of participants granted other stock-based awards
upon the termination of employment or service to us will be set forth in the applicable award agreement. In the event that a bonus is
granted in the form of shares of common stock, the shares of common stock constituting such bonus shall, as determined by the plan administrator,
be evidenced in uncertificated form or by a book entry record or a certificate issued in the name of the participant to whom such grant
was made and delivered to such participant as soon as practicable after the date on which such bonus is payable. Any dividend or dividend
equivalent award issued hereunder shall be subject to the same restrictions, conditions and risks of forfeiture as apply to the underlying
award.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Equitable Adjustment and Treatment of
Outstanding Awards Upon a Change in Control</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Equitable Adjustments</i>. In the event
of a merger, consolidation, reclassification, recapitalization, spin-off, spin-out, repurchase, reorganization, special or extraordinary
dividend or other extraordinary distribution (whether in the form of common stock, cash or other property), combination, exchange of
shares, or other change in corporate structure affecting our common stock, an equitable substitution or proportionate adjustment shall
be made in (i) the aggregate number and kind of securities reserved for issuance under the 2020 Plan, (ii) the kind and number of securities
subject to, and the exercise price of, any outstanding options and SARs granted under the 2020 Plan, (iii) the kind, number and purchase
price of shares of common stock, or the amount of cash or amount or type of property, subject to outstanding restricted stock, RSUs and
other stock-based awards granted under the 2020 Plan and (iv) the terms and conditions of any outstanding awards (including any applicable
performance targets). Equitable substitutions or adjustments other than those listed above may also be made as determined by the plan
administrator. In addition, the plan administrator may terminate all outstanding awards for the payment of cash or in-kind consideration
having an aggregate fair market value equal to the excess of the fair market value of the shares of common stock, cash or other property
covered by such awards over the aggregate exercise price, if any, of such awards, but if the exercise price of any outstanding award
is equal to or greater than the fair market value of the shares of common stock, cash or other property covered by such award, the plan
administrator may cancel the award without the payment of any consideration to the participant. With respect to awards subject to foreign
laws, adjustments will be made in compliance with applicable requirements. Except to the extent determined by the plan administrator,
adjustments to incentive stock options will be made only to the extent not constituting a &#8220;modification&#8221; within the meaning
of Section 424(h)(3) of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Change in Control</i>. The 2020 Plan provides
that, unless otherwise determined by the plan administrator and evidenced in an award agreement, if a &#8220;change in control&#8221;
(as defined below) occurs and a participant is employed by us or any of our affiliates immediately prior to the consummation of the change
in control, then the plan administrator, in its sole and absolute discretion, may (i) provide that any unvested or unexercisable portion
of an award carrying a right to exercise will become fully vested and exercisable; and (ii) cause the restrictions, deferral limitations,
payment conditions and forfeiture conditions applicable to any award granted under the 2020 Plan to lapse, and the awards will be deemed
fully vested and any performance conditions imposed with respect to such awards will be deemed to be fully achieved at target performance
levels. The plan administrator shall have discretion in connection with such change in control to provide that all outstanding and unexercised
options and SARs shall expire upon the consummation of such change in control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the 2020 Plan, a &#8220;change
in control&#8221; means, in summary, the first to occur of the following events: (i) a person or entity becomes the beneficial owner
of more than 50% of our voting power; (ii) an unapproved change in the majority membership of our Board of Directors; (iii) a merger
or consolidation of us or any of our subsidiaries, other than (A) a merger or consolidation that results in our voting securities continuing
to represent 50% or more of the combined voting power of the surviving entity or its parent and our Board of Directors immediately prior
to the merger or consolidation continuing to represent at least a majority of the Board of Directors of the surviving entity or its parent
or (B) a merger or consolidation effected to implement a recapitalization in which no person is or becomes the beneficial owner of our
voting securities representing more than 50% of our combined voting power; or (iv) stockholder approval of a plan of our complete liquidation
or dissolution or the consummation of an agreement for the sale or disposition of substantially all of our assets, other than (A) a sale
or disposition to an entity, more than 50% of the combined voting power of which is owned by our stockholders in substantially the same
proportions as their ownership of us immediately prior to such sale or (B) a sale or disposition to an entity controlled by our Board
of Directors. However, a change in control will not be deemed to have occurred as a result of any transaction or series of integrated
transactions following which our stockholders, immediately prior thereto, hold immediately afterward the same proportionate equity interests
in the entity that owns all or substantially all of our assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Tax Withholding</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each participant will be required to make
arrangements satisfactory to the plan administrator regarding payment of up to the maximum statutory tax rates in the participant&#8217;s
applicable jurisdiction with respect to any award granted under the 2020 Plan, as determined by us. We have the right, to the extent
permitted by applicable law, to deduct any such taxes from any payment of any kind otherwise due to the participant. With the approval
of the plan administrator, the participant may satisfy the foregoing requirement by either electing to have us withhold from delivery
of shares of common stock, cash or other property, as applicable, or by delivering already owned unrestricted shares of common stock,
in each case, having a value not exceeding the applicable taxes to be withheld and applied to the tax obligations. We may also use any
other method of obtaining the necessary payment or proceeds, as permitted by applicable law, to satisfy our withholding obligation with
respect to any award.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Amendment and Termination of the 2020
Plan</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2020 Plan provides our Board of Directors
with authority to amend, alter or terminate the 2020 Plan, but no such action impair the rights of any participant with respect to outstanding
awards without the participant&#8217;s consent. The plan administrator may amend an award, prospectively or retroactively, but no such
amendment may materially impair the rights of any participant without the participant&#8217;s consent. Stockholder approval of any such
action will be obtained if required to comply with applicable law. The 2020 Plan will terminate on the tenth anniversary of the Effective
Date (although awards granted before that time will remain outstanding in accordance with their terms).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Clawback</i>. If we are required to prepare
a financial restatement due to the material non-compliance with any financial reporting requirement, then the plan administrator may
require any Section 16 officer to repay or forfeit to us that part of the cash or equity incentive compensation received by that Section
16 officer during the preceding three years that the plan administrator determines was in excess of the amount that such Section 16 officer
would have received had such cash or equity incentive compensation been calculated based on the financial results reported in the restated
financial statement. The plan administrator may take into account any factors it deems reasonable in determining whether to seek recoupment
of previously paid cash or equity incentive compensation and how much of such compensation to recoup from each Section 16 officer (which
need not be the same amount or proportion for each Section 16 officer). The amount and form of the incentive compensation to be recouped
shall be determined by the plan administrator in its sole and absolute discretion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>LEGAL MATTERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The validity of the issuance of the common
stock offered by us in this offering will be passed upon for us by Sheppard, Mullin, Richter &amp; Hampton LLP, New York, New York. Certain
legal matters will be passed upon for the underwriters by Sichenzia Ross Ference LLP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXPERTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements of Silo
Pharma, Inc. (f/k/a Uppercut Brands, Inc.) for the years ended December 31, 2021 and December 31, 2020 have been included herein in reliance
upon the reports of Salberg &amp; Company, P.A., independent registered public accounting firm, upon the authority of said firm as experts
in accounting and auditing.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WHERE YOU CAN FIND MORE
INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company files annual, quarterly and current
reports, proxy statements and other information with the SEC. The Company has filed with the SEC a registration statement on Form&#160;S-1
under the Securities Act, with respect to the common stock being offered under this prospectus. This prospectus does not contain all
of the information set forth in the registration statement and the exhibits to the registration statement. For further information with
respect to the Company and the securities being offered under this prospectus, please refer to the complete registration statement and
the exhibits and schedules filed as a part of the registration statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may read and copy the registration statement,
as well as the Company&#8217;s reports, proxy statements and other information, at the SEC&#8217;s Public Reference Room at 100&#160;F
Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the Public Reference
Room. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers
that file electronically with the SEC. The SEC&#8217;s Internet site can be found at&#160;<i>http://www.sec.gov</i>. You may access our
annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other reports filed or furnished pursuant
to Section&#160;13(a) or 15(d) of the Exchange Act with the SEC free of charge on the SEC&#8217;s website.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>SILO
PHARMA, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>FINANCIAL
STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">AUDITED FINANCIAL STATEMENTS&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 91%"><a href="#f_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
    of Independent Registered Public Accounting Firm</span></a></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#f_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Balance Sheets as of December 31, 2021 and 2020</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#f_003"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Operations for the Years Ended December 31, 2021 and 2020</span> </a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>4</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#f_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Changes in Stockholders&#8217; Equity for the Years Ended December 31, 2021 and 2020</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>5</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#f_005"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Cash Flows for the Years Ended December 31, 2021 and 2020</span> </a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>6</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#f_006"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    to Consolidated Financial Statements</span> </a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>7</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 91%"><span style="font-size: 10pt">UNAUDITED FINANCIAL STATEMENTS</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: center; vertical-align: bottom; width: 8%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-size: 10pt"><a href="#S_001">Condensed
    Consolidated Balance Sheets as of June 30, 2022 (Unaudited) and December 31, 2021</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-30</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-size: 10pt"><a href="#S_002">Condensed
    Consolidated Statements of Operations for the three and six months ended&#160;June 30, 2022 and 2021 (Unaudited)</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-31</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-size: 10pt"><a href="#S_003">Condensed
    Consolidated Statement of Changes in Stockholders&#8217; Equity (Deficiency) for the Three Months Ended June 30, 2022 and 2021 (Unaudited)</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-32</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-size: 10pt"><a href="#S_004">Condensed
    Consolidated Statement of Cash Flows for the six months ended&#160;June 30, 2022 and 2021 (Unaudited)</a></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-</span>33</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-size: 10pt"><a href="#S_005">Notes
    to Condensed Consolidated Financial Statements (Unaudited)</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center">F-34</td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 91; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="fin_001.jpg" style="width: 670px; height: 81px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Report of Independent
Registered Public Accounting Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Shareholders and the Board of Directors
of:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Silo Pharma, Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Opinion on the Financial Statements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of SILO Pharma, Inc. (f/k/a Uppercut Brands, Inc.) (the &#8220;Company&#8221;) as of December 31, 2021, and 2020, the
related consolidated statements of operations, changes in stockholders&#8217; equity (deficit) and cash flows for each of the two years
in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;).
In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of
the Company as of December 31, 2021, and 2020, and the consolidated results of its operations and its cash flows for each of the two
years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Basis for Opinion</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements are
the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether
the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of internal control over financial reporting. As part of our audits, we are required to
obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures
to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates
made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits
provide a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Critical Audit Matters</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The critical audit matters communicated below
are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated
to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and
(2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">/s/ Salberg&#160;&amp;
Company, P.A.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">SALBERG&#160;&amp;
COMPANY, P.A.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">We have served as
the Company&#8217;s auditor since 2019<i>.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Boca Raton, Florida</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="-keep: true">March 28, 2022 (Except
for the reverse stock split as discussed</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="-keep: true">in the last paragraph
of footnote 11 as to which the date is</span></p><div>

</div><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">September 20, 2022)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">2295 NW Corporate Blvd.,
Suite 240 &#8226; Boca Raton, FL 33431-7328</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Phone: (561) 995-8270
&#8226; Toll Free: (866) CPA-8500 &#8226; Fax: (561) 995-1920</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">www.salbergco.com &#8226;
info@salbergco.com</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>Member National Association
of Certified Valuation Analysts &#8226; Registered with the PCAOB</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>Member CPAConnect
with Affiliated Offices Worldwide &#8226; Member AICPA Center for Audit Quality</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>SILO PHARMA, INC.
AND SUBSIDIARY</b></p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>CONSOLIDATED
BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="-keep: true">ASSETS</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">CURRENT ASSETS:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left; text-indent: 10pt"><span style="-keep: true">Cash and cash equivalents</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 6%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">9,837,001</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 6%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">1,128,389</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 10pt"><span style="-keep: true">Equity investments</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="silo:EquityInvestmentsAtCost" scale="0" unitRef="usd">419,995</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="silo:EquityInvestmentsAtCost" scale="0" unitRef="usd">200</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt"><span style="-keep: true">Notes receivable, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="0" unitRef="usd">23,500</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 10pt"><span style="-keep: true">Prepaid expenses and other current assets - current</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">145,324</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">241,091</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt"><span style="-keep: true">Assets of discontinued operations</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-2"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" unitRef="usd">33,484</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Total Current Assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">10,402,320</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">1,426,664</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Note receivable - non-current, including interest receivable of $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivableNoncurrent" scale="0" unitRef="usd">1,210</ix:nonFraction></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd">61,210</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-keep: true">Prepaid expenses - non-current</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" unitRef="usd">26,659</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-4"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Total Assets</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">10,490,189</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">1,426,664</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: center"><span style="-keep: true">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">CURRENT LIABILITIES:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 10pt"><span style="-keep: true">Accounts payable and accrued expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">417,937</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">127,069</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt"><span style="-keep: true">Note payable - current portion</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">14,654</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt"><span style="-keep: true">Deferred revenue - current portion</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="0" unitRef="usd">72,102</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-6"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Current Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">490,039</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">141,723</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">LONG TERM LIABILITIES:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt"><span style="-keep: true">Deferred revenue - long-term portion</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="0" unitRef="usd">937,884</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt"><span style="-keep: true">Note payable - long-term portion</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermNotesPayable" scale="0" unitRef="usd">4,246</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Long Term Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd">937,884</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd">4,246</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">1,427,923</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">145,969</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Commitment and Contingencies (see Note 10)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9"><span style="-keep: true">&#160;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10"><span style="-keep: true">&#160;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">STOCKHOLDERS&#8217; EQUITY:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt"><span style="-keep: true">Preferred stock, $<ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11"><span style="-keep: true">&#160;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12"><span style="-keep: true">&#160;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in"><span style="-keep: true">Series B convertible preferred stock, $<ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">2,000</ix:nonFraction></ix:nonFraction> shares designated; <span style="-sec-ix-hidden: hidden-fact-15"><span style="-sec-ix-hidden: hidden-fact-16"><span style="-sec-ix-hidden: hidden-fact-17"><span style="-sec-ix-hidden: hidden-fact-18">no</span></span></span></span> shares issued and outstanding at December 31, 2021 and 2020, respectively ($<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" unitRef="usdPershares">1,000</ix:nonFraction></ix:nonFraction> per share liquidation value)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in"><span style="-keep: true">Series C convertible preferred stock, $<ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c6" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">4,280</ix:nonFraction></ix:nonFraction> shares designated; <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">227</ix:nonFraction></ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-21"><span style="-sec-ix-hidden: hidden-fact-22">no</span></span> shares issued and outstanding at December 31, 2021 and 2020, respectively ($<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" unitRef="usdPershares">1,000</ix:nonFraction></ix:nonFraction> per share liquidation value)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in"><p style="margin-left: -0.25in; padding-left: 0.25in; text-align: left; text-indent: -0.125in"><span style="-keep: true">Common stock, $<ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">1,972,739</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">1,702,839</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2021 and 2020, respectively</span></p></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">197</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">170</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt"><span style="-keep: true">Additional paid-in capital</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">12,324,646</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">7,042,846</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt"><span style="-keep: true">Accumulated deficit</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">3,262,577</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">5,762,321</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Stockholders&#8217; Equity</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">9,062,266</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">1,280,695</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Total Liabilities and Stockholders&#8217; Equity</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">10,490,189</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">1,426,664</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">See accompanying notes
to consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>SILO PHARMA, INC.
AND SUBSIDIARY</b></p><div>

</div><div><a id="f_003"></a></div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></p><div>

</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="-keep: true">For the Years Ended</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">LICENSE FEE REVENUES:</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:LicenseFees" scale="0" unitRef="usd">71,264</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">COST OF REVENUES</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">5,004</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">GROSS PROFIT</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">66,260</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">OPERATING EXPENSES:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 20pt"><span style="-keep: true">Compensation expense</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">395,123</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">755,993</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 20pt"><span style="-keep: true">Professional fees</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd">1,598,367</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd">1,173,717</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 20pt"><span style="-keep: true">Research and development</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">693,910</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">26,250</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 20pt"><span style="-keep: true">Insurance expense</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="0" unitRef="usd">108,750</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="0" unitRef="usd">30,191</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 20pt"><span style="-keep: true">Bad debt (recovery) expense, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:BadDebtRecoveryExpense" scale="0" sign="-" unitRef="usd">148,500</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:BadDebtRecoveryExpense" scale="0" unitRef="usd">165,376</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt"><span style="-keep: true">Selling, general and administrative expenses</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">162,953</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">50,192</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt"><span style="-keep: true">Total operating expenses</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">2,810,603</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">2,201,719</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">OPERATING LOSS FROM CONTINUING OPERATIONS</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">2,744,343</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">2,201,719</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">OTHER INCOME (EXPENSE):</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 20pt"><span style="-keep: true">Interest income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" unitRef="usd">1,210</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" unitRef="usd">11,543</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 20pt"><span style="-keep: true">Other income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd">3,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 20pt"><span style="-keep: true">Gain on forgiveness of PPP note payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="0" unitRef="usd">19,082</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 20pt"><span style="-keep: true">Interest expense</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd">3,036</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd">269,043</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 20pt"><span style="-keep: true">Interest expense - related party</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseRelatedParty" scale="0" unitRef="usd">224</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 20pt"><span style="-keep: true">Foreign exchange loss</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" sign="-" unitRef="usd">2,950</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 20pt"><span style="-keep: true">Loss on debt extinguishment</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" sign="-" unitRef="usd">197,682</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 20pt"><span style="-keep: true">Net realized gain on equity investments</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="0" unitRef="usd">6,660,483</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt"><span style="-keep: true">Net unrealized gain (loss) on equity investments</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:UnrealizedGainLossOnEquityInvestments" scale="0" unitRef="usd">248,588</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:UnrealizedGainLossOnEquityInvestments" scale="0" sign="-" unitRef="usd">9,194</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt"><span style="-keep: true">Total other income (expense)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd">6,926,327</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd">464,550</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-align: left; text-indent: -10pt"><span style="-keep: true">INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE PROVISION
    FOR INCOME TAXES</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" unitRef="usd">4,181,984</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">2,666,269</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-keep: true">Provision for income taxes</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">24,876</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">INCOME (LOSS) FROM CONTINUING OPERATIONS</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="0" unitRef="usd">4,157,108</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="0" sign="-" unitRef="usd">2,666,269</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">DISCONTINUED OPERATIONS:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Gain from sale of assets of discontinued operations, net of tax</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" scale="0" unitRef="usd">1,553</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-keep: true">Loss from discontinued operations, net of tax</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="0" sign="-" unitRef="usd">254,920</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="0" sign="-" unitRef="usd">371,248</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">LOSS FROM DISCONTINUED OPERATIONS</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="0" sign="-" unitRef="usd">253,367</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="0" sign="-" unitRef="usd">371,248</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">NET INCOME (LOSS)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" unitRef="usd">3,903,741</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">3,037,517</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Deemed dividend</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="0" unitRef="usd">1,403,997</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="0" unitRef="usd">69,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">NET INCOME (LOSS) AVAILABLE TO COMMON STOCKHOLDERS</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="0" unitRef="usd">2,499,744</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="0" sign="-" unitRef="usd">3,106,517</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">NET INCOME (LOSS) PER COMMON SHARE AVAILABLE TO COMMON STOCKHOLDERS:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 20pt"><div style="-sec-ix-hidden: hidden-fact-48; -sec-ix-hidden: hidden-fact-47"><span style="-keep: true">Continuing operations - basic</span></div></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares">1.45</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">2.07</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 20pt"><span style="-keep: true">Continuing operations - diluted</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1.43</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(2.07</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 20pt"><div style="-sec-ix-hidden: hidden-fact-50; -sec-ix-hidden: hidden-fact-49"><span style="-keep: true">Discontinued operations - basic and diluted</span></div></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" sign="-" unitRef="usdPershares">0.13</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" sign="-" unitRef="usdPershares">0.28</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: 20pt"><div style="-sec-ix-hidden: hidden-fact-52; -sec-ix-hidden: hidden-fact-51"><span style="-keep: true">Basic</span></div></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">1,897,315</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">1,319,094</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: 20pt"><span style="-keep: true">Diluted</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1,918,444</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1,319,094</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">See accompanying notes
to consolidated financial statements.</p><div>

</div><p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>SILO PHARMA, INC.
AND SUBSIDIARY</b></p><div>

</div><div><a id="f_004"></a></div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>FOR THE YEARS ENDED
DECEMBER 31, 2021 AND 2020</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Series B<br/> Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Series C<br/> Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Common Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">Additional<br/> Paid In</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">Accumulated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">Total<br/> Stockholders&#8217;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Equity</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt; width: 10%"><span style="-keep: true">Balance, December 31, 2019</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">115</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">472,084</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 7%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">47</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 7%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">2,632,865</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 7%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">2,655,804</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 7%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">22,892</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Common Stock issued for cash, net of offering cost</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">755,162</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">76</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">2,115,657</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">2,115,733</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Common Stock issued for future services</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="silo:CommonStockIssuedForFutureServicesShares" scale="0" unitRef="shares">171,724</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="silo:CommonStockIssuedForFutureServices" scale="0" unitRef="usd">17</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="silo:CommonStockIssuedForFutureServices" scale="0" unitRef="usd">686,878</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:CommonStockIssuedForFutureServices" scale="0" unitRef="usd">686,895</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Preferred Shares Exchanged for Common Stock</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="silo:PreferredSharesExchangedForCommonStockShares" scale="0" sign="-" unitRef="shares">115</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-99"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="silo:PreferredSharesExchangedForCommonStockShares" scale="0" unitRef="shares">28,750</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="silo:PreferredSharesExchangedForCommonStock" scale="0" unitRef="usd">3</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="silo:PreferredSharesExchangedForCommonStock" scale="0" sign="-" unitRef="usd">3</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Common Stock issued in connection with employment agreement</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" scale="0" unitRef="shares">152,619</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="0" unitRef="usd">15</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="0" unitRef="usd">610,461</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="0" unitRef="usd">610,476</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Common Stock issued for Exchange of Notes</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="silo:CommonStockIssuedForExchangeOfNotesShares" scale="0" unitRef="shares">82,500</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="silo:CommonStockIssuedForExchangeOfNotes" scale="0" unitRef="usd">8</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="silo:CommonStockIssuedForExchangeOfNotes" scale="0" unitRef="usd">527,992</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:CommonStockIssuedForExchangeOfNotes" scale="0" unitRef="usd">528,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Common Stock issued for conversion of Redeemable Series A Preferred
    stock</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares" scale="0" unitRef="shares">40,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock" scale="0" unitRef="usd">4</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock" scale="0" unitRef="usd">399,996</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock" scale="0" unitRef="usd">400,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Deemed dividend on Preferred Stock Exchange</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="silo:DeemedDividendOnPreferredStockExchange" scale="0" unitRef="usd">69,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="silo:DeemedDividendOnPreferredStockExchange" scale="0" sign="-" unitRef="usd">69,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Net loss</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">3,037,517</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">3,037,517</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Balance, December 31, 2020</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">1,702,839</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">170</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">7,042,846</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">5,762,321</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">1,280,695</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Series C preferred stock issued for cash, net of offering cost</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">4,276</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">3,794,102</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">3,794,102</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Deemed dividend upon issuance of preferred stock</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" unitRef="usd">1,403,997</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" sign="-" unitRef="usd">1,403,997</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Common stock warrants granted for services</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-140"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">83,728</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">83,728</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Issuance of common stock for conversion of preferred stock</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-144"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-145"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="silo:IssuanceOfCommonSharesForConversionOfPreferredStockinShares" scale="0" sign="-" unitRef="shares">4,049</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="silo:IssuanceOfCommonSharesForConversionOfPreferredStockinShares" scale="0" unitRef="shares">269,900</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="silo:IssuanceOfCommonStockForConversionOfPreferredStock" scale="0" unitRef="usd">27</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="silo:IssuanceOfCommonStockForConversionOfPreferredStock" scale="0" sign="-" unitRef="usd">27</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Net income</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" unitRef="usd">3,903,741</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" unitRef="usd">3,903,741</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Balance, December 31, 2021</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">227</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">1,972,739</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">197</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">12,324,646</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">3,262,577</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">9,062,266</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">See accompanying notes
to consolidated financial statements.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>SILO PHARMA, INC.
AND SUBSIDIARY</b></p><div>

</div><div><a id="f_005"></a></div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Net income (loss)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" unitRef="usd">3,903,741</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">3,037,517</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Adjustments&#160;to&#160;reconcile&#160;net&#160;loss
    to&#160;net&#160;cash used in operating&#160;activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Bad debt (recovery) expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd">148,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd">165,376</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd">83,728</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd">610,476</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Amortization of debt discount to interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-217">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd">268,125</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Amortization of prepaid stock-based expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:AmortizationOfPrepaidStockbasedExpense" scale="0" unitRef="usd">107,970</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:AmortizationOfPrepaidStockbasedExpense" scale="0" unitRef="usd">578,924</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Inventory write-down</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-218">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="0" unitRef="usd">137,947</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Net realized gain on equity investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd">6,660,483</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-219">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Net unrealized (gain) loss on equity investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" unitRef="usd">248,588</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" sign="-" unitRef="usd">9,194</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Gain on forgiveness of PPP note payable and accrued
    interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnRestructuringOfDebt" scale="0" unitRef="usd">19,082</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-220">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Gain from disposal of assets from discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets" scale="0" unitRef="usd">1,553</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-221">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Loss from debt extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-222">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:LossFromDebtExtinguishment" scale="0" sign="-" unitRef="usd">197,682</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Change in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" unitRef="usd">38,862</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" unitRef="usd">144,663</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Assets of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:IncreaseDecreaseInAssetsOfDiscontinuedOperation" scale="0" sign="-" unitRef="usd">24,963</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:IncreaseDecreaseInAssetsOfDiscontinuedOperation" scale="0" sign="-" unitRef="usd">15,065</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Interest receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInReceivables" scale="0" unitRef="usd">1,210</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-223">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">291,050</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">72,525</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Deferred revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="0" unitRef="usd">478,736</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-224">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">NET&#160;CASH&#160;USED IN OPERATING&#160;ACTIVITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">2,278,016</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">1,156,996</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Net proceeds from sale of equity investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="0" unitRef="usd">7,020,526</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-225">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Collection on note receivable written off prior to 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" scale="0" unitRef="usd">7,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-226">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Collection on note receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:CollectionOnNoteReceivable" scale="0" unitRef="usd">164,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:CollectionOnNoteReceivable" scale="0" unitRef="usd">39,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">NET&#160;CASH&#160;PROVIDED
    BY INVESTING ACTIVITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" unitRef="usd">7,192,526</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" unitRef="usd">39,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Proceeds from note payable - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Proceeds from note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-228">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="0" unitRef="usd">18,900</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Repayment of note payable - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-229">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" sign="-" unitRef="usd">35,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Net proceeds from sale of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-230">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">2,115,733</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Net proceeds from sale of preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="0" unitRef="usd">3,794,102</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-231">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Advance from a related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:AdvanceFromARelatedParty" scale="0" unitRef="usd">2,366</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-232">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Repayment of advance from a related
    party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd">2,366</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-233">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">NET&#160;CASH&#160;PROVIDED
    BY FINANCING ACTIVITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">3,794,102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">2,134,633</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 7pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">NET&#160;INCREASE IN&#160;CASH:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" unitRef="usd">8,708,612</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" unitRef="usd">1,016,637</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">CASH AND CASH EQUIVALENTS -
    beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">1,128,389</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">111,752</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">CASH AND CASH EQUIVALENTS - end
    of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">9,837,001</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">1,128,389</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Supplemental Disclosure of Cash Flow Information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.5in; padding-bottom: 4pt">Interest paid</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-234">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; padding-bottom: 4pt">Taxes paid</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-237">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">SUPPLEMENTAL&#160;DISCLOSURE&#160;OF&#160;CASH&#160;FLOW&#160;INFORMATION:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash&#160;paid&#160;during&#160;the&#160;period&#160;for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; padding-bottom: 4pt">Interest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-238">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd">224</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 4pt">Income&#160;taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-240">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 4pt">Common stock issued for prepaid
    services</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-241">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:StockIssuedForFutureServices" scale="0" unitRef="usd">686,895</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 4pt">Common stock issued for Exchange
    of Notes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-242">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:CommonStockIssuedForPrepaidServices" scale="0" unitRef="usd">528,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 4pt">Common stock issued for conversion
    of Redeemable Series A Preferred Stock</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-243">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock" scale="0" unitRef="usd">400,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 4pt">Increase in equity investments recorded
    as deferred revenue pursuant to a patent license agreement</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree" scale="0" unitRef="usd">531,250</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-244">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 4pt">Note receivable issued in connection
    with asset purchase agreement</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement" scale="0" unitRef="usd">60,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-245">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>
</div><p style="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 6.5pt"><b>&#160;</b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">See accompanying notes
to consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND
SUBSIDIARY<br/>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c10" continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c10_cont_1" escape="true" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 &#8211; <span style="text-decoration:underline">ORGANIZATION AND BUSINESS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c10_cont_2" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Silo Pharma, Inc. (formerly Uppercut Brands,
Inc.) (the &#8220;Company&#8221;) was incorporated in the State of New York on July 13, 2010 under the name Gold Swap, Inc. On January
24, 2013, the Company changed its state of incorporation from New York to Delaware.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c10_cont_3" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c10_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a developmental stage biopharmaceutical
company focused on merging traditional therapeutics with psychedelic research.&#160;The Company seeks to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. The Company is focused on merging traditional therapeutics with psychedelic research for people suffering from indications
such as depression, post-traumatic stress disorder (&#8220;PTSD&#8221;), Alzheimer&#8217;s, Parkinson&#8217;s, and other rare neurological
disorders. The Company&#8217;s mission is to identify assets to license and fund the research which the Company&#8217;s believes will
be transformative to the well-being of patients and the health care industry.&#160;The Company was engaged in the development of a streetwear
apparel brand, NFID (see below).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c10_cont_4" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c10_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 4, 2013, the Company filed a Form
N-54A and elected to become a business development company (&#8220;BDC&#8221;) under the Investment Company Act of 1940, as amended (the
&#8220;1940 Act&#8221;). In addition, the Company previously elected to be treated for federal income tax purpose as a regulated investment
company, (&#8220;RIC&#8221;) under Subchapter M of the Internal Revenue Code of 1986, as amended, (the &#8220;Code&#8221;). Through September
29, 2018, the Company met the definition of RIC in accordance with the guidance under Accounting Standards Codification (&#8220;ASC&#8221;)
Topic 946 &#8220;Financial Services &#8211; Investment Companies&#8221;. On September 29, 2018, the Company filed Form N-54C, Notification
of Withdrawal of Election to be Subject to Section 55 through 65 of the 1940 Act, as the Company changed the nature of its business so
as to cease to be a business development company (see Note 2 &#8211; <i>Basis of Presentation</i>). Additionally, since 2017, the Company
has been subject to income taxes at corporate tax rates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c10_cont_5" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c10_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 21, 2019, the Company filed an amendment
to its Certificate of Incorporation with the State of Delaware to change its name from Point Capital, Inc. to Uppercut Brands, Inc. thereafter,
on September 24, 2020, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to change its name
from Uppercut Brands, Inc. to Silo Pharma, Inc.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c10_cont_6" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c10_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 8, 2020, the Company incorporated
a new wholly-owned subsidiary, Silo Pharma Inc.,&#160;in the State of Florida. The Company has also secured the domain name <i>www.silopharma.com</i>.
The Company has been exploring opportunities to expand the Company&#8217;s business by seeking to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. In July 2020, through the Company&#8217;s newly formed subsidiary, the Company entered into a commercial evaluation license
and option agreement with University of Maryland, Baltimore (&#8220;UMB&#8221;) (see Note 10) pursuant to which, among other things,
UMB granted the Company an exclusive, option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license to with respect
to certain technology. The option was extended and exercised on January 13, 2021. On February 12, 2021, the Company entered into a Master
License Agreement with UMB (see Note 10). The Company plans to actively pursue the acquisition and/or development of intellectual property
or technology rights to treat rare diseases, and to ultimately expand the Company&#8217;s business to focus on this new line of business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c10_cont_7" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c10_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2021, the Company entered
into and closed on an Asset Purchase Agreement (&#8220;Asset Purchase Agreement) with NFID, LLC, a Florida limited liability company
(&#8220;Buyer&#8221;), whereby the Buyer purchased from the Company certain assets, properties, and rights in connection with the Company&#8217;s
NFID trademark name, logos, domain, and apparel clothing and accessories for a purchase price of $<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SupplementalDeferredPurchasePrice" scale="0" unitRef="usd">60,000</ix:nonFraction> in the form of a promissory
note amounting to $<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="silo:promissoryNoteAmount" scale="0" unitRef="usd">60,000</ix:nonFraction>. The promissory note bears <ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRate" scale="-2" unitRef="pure">8</ix:nonFraction>% interest per annum and matures on <ix:nonNumeric contextRef="c87" format="ixt:date-monthname-day-year-en" name="us-gaap:InvestmentMaturityDate">October 1, 2023</ix:nonNumeric>. Accordingly, the results of
operations of this component, for all periods presented, are separately reported as &#8220;discontinued operations&#8221; on the accompanying
consolidated statements of operations (see Note 4).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c10_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On September 14, 2022, the Company filed a
Certificate of Amendment to the Amended and Restated Articles of Incorporation (the &#8220;Certificate of Amendment&#8221;) with the
Secretary of State of the State of Nevada to effect a 1-for-50 reverse stock split (the &#8220;Reverse Stock Split&#8221;) with respect
to the outstanding shares of the Company&#8217;s common stock. The Certificate of Amendment became effective on September 14, 2022. The
Reverse Stock Split was previously approved by the sole director and the majority of stockholders of the Company. The Reverse Stock Split
was deemed effective at the open of business on September 15, 2022. All share and per share data in the accompanying consolidated financial
statements have been retroactively restated to reflect the effect of the reverse stock split.</span></p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c10" continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 &#8211; <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_2" id="_SignificantAccountingPoliciesTextBlock-c10_cont_1"><ix:nonNumeric contextRef="c10" continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c10_cont_1" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation and Principles of
Consolidation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_3" id="_SignificantAccountingPoliciesTextBlock-c10_cont_2"><ix:continuation continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c10_cont_2" id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S.
GAAP&#8221;), the instructions to Form 10-K, and the rules and regulations of the United States Securities and Exchange Commission (the
&#8220;SEC&#8221;) for financial information. The Company&#8217;s consolidated financial statements include financial statements for
Silo Pharma, Inc and its inactive wholly-owned subsidiary with the same name as the parent entity, Silo Pharma, Inc, as of December 31,
2021 and during the years ended December 31, 2021 and 2020. All intercompany transactions and balances have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_4" id="_SignificantAccountingPoliciesTextBlock-c10_cont_3"><ix:continuation id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c10_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with, ASC 205-20 &#8220;Discontinued
Operations&#8221; establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should
be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity&#8217;s
operations and financial results. As a result, the NFID, LLC component&#8217;s results of operations have been classified as discontinued
operations on a retrospective basis for all periods presented. Accordingly, the results of operations of this component, for all periods,
are separately reported as &#8220;discontinued operations&#8221; on the consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_5" id="_SignificantAccountingPoliciesTextBlock-c10_cont_4"><ix:nonNumeric contextRef="c10" continuedAt="_LiquidityPolicyTextBlock-c10_cont_1" escape="true" name="silo:LiquidityPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_6" id="_SignificantAccountingPoliciesTextBlock-c10_cont_5"><ix:continuation continuedAt="_LiquidityPolicyTextBlock-c10_cont_2" id="_LiquidityPolicyTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As reflected in the accompanying consolidated
financial statements, the Company generated a net income of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" unitRef="usd">3,903,741</ix:nonFraction> and used cash in operations of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInContinuingOperations" scale="0" unitRef="usd">2,278,016</ix:nonFraction>, for the year ended
December 31, 2021. Additionally, the Company has an accumulated deficit of $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">3,262,577</ix:nonFraction> at December 31, 2021. During the year ended December
31, 2021, the Company has received gross proceeds of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" unitRef="usd">7,020,526</ix:nonFraction> from the sale of equity investments. As of December 31, 2021, the Company
had working capital of $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnits" scale="0" unitRef="usd">9,912,281</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_7" id="_SignificantAccountingPoliciesTextBlock-c10_cont_6"><ix:continuation id="_LiquidityPolicyTextBlock-c10_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These events served to mitigate the conditions
that historically raised substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company believes the
proceeds received during the year ended December 31, 2021 will provide sufficient cash flows to meet its obligations for a minimum of
<ix:nonFraction contextRef="c1" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:SharesIssued" scale="0" unitRef="shares">twelve</ix:nonFraction> months from the date of this filing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_8" id="_SignificantAccountingPoliciesTextBlock-c10_cont_7"><ix:nonNumeric contextRef="c10" continuedAt="_UseOfEstimates-c10_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_9" id="_SignificantAccountingPoliciesTextBlock-c10_cont_8"><ix:continuation id="_UseOfEstimates-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at
least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date
of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more
future events. Accordingly, the actual results could differ significantly from estimates. Significant estimates during the years ended
December 31, 2021 and 2020 include the collectability of notes receivable, the valuation of equity investments, estimates for obsolete
and slow-moving inventory, estimates of the deemed dividend, valuation allowances for deferred tax assets, the fair value of warrants
issued with debt and for services, and the fair value of shares issued for services and in settlements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_10" id="_SignificantAccountingPoliciesTextBlock-c10_cont_9"><ix:nonNumeric contextRef="c10" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c10_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash and Cash Equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_11" id="_SignificantAccountingPoliciesTextBlock-c10_cont_10"><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid investments
with a maturity of three months or less when acquired to be cash equivalents. The Company places its cash with high credit quality financial
institutions. The Company&#8217;s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)
up to $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashFDICInsuredAmount" scale="0" unitRef="usd">250,000</ix:nonFraction> and by the Securities Investor Protection Corporation (&#8220;SIPC&#8221;) up to $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="silo:CashSPICInsuredAmount" scale="0" unitRef="usd">250,000</ix:nonFraction>. To reduce its risk associated
with the failure of such financial institutions, the Company evaluates, at least annually, the rating of the financial institutions in
which it holds deposits. At December 31, 2021 and 2020, the Company had cash in excess of FDIC and SIPC limits of approximately $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FDICIndemnificationAssetCashPaymentsReceived" scale="0" unitRef="usd">9,100,000</ix:nonFraction>
and $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FDICIndemnificationAssetCashPaymentsReceived" scale="0" unitRef="usd">880,000</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_12" id="_SignificantAccountingPoliciesTextBlock-c10_cont_11"><ix:nonNumeric contextRef="c10" continuedAt="_TradeAndOtherAccountsReceivablePolicy-c10_cont_1" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Notes Receivable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_13" id="_SignificantAccountingPoliciesTextBlock-c10_cont_12"><ix:continuation id="_TradeAndOtherAccountsReceivablePolicy-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes an allowance for losses
on notes receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical
bad debt experience, current note receivable aging, and expected future write-offs, as well as an assessment of specific identifiable
accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recognized as general
and administrative expense.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_14" id="_SignificantAccountingPoliciesTextBlock-c10_cont_13"><ix:nonNumeric contextRef="c10" continuedAt="_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-c10_cont_1" escape="true" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Prepaid Expenses and Other Current Assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.65pt; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_15" id="_SignificantAccountingPoliciesTextBlock-c10_cont_14"><ix:continuation id="_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prepaid expenses and other current assets
- current of $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="0" unitRef="usd">145,324</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="0" unitRef="usd">241,091</ix:nonFraction> at December 31, 2021 and 2020, respectively, consist primarily of costs paid for future services which
will occur within a year. Prepaid expenses and other current assets &#8211; non-current of $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" unitRef="usd">26,659</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" unitRef="usd">0</ix:nonFraction> at December 31, 2021 and 2020,
respectively, consist primarily of costs paid for license fees and future services which will occur after a year. Prepaid expenses may
include prepayments in cash and equity instruments for consulting, business advisory, legal services, license fees, research and development
fees, and insurance which are being amortized over the terms of their respective agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_16" id="_SignificantAccountingPoliciesTextBlock-c10_cont_15"><ix:nonNumeric contextRef="c10" continuedAt="_EquityInvestmentsAtFairValuePolicyTextBlock-c10_cont_1" escape="true" name="silo:EquityInvestmentsAtFairValuePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments, at Fair Value</b></p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_17" id="_SignificantAccountingPoliciesTextBlock-c10_cont_16"><ix:continuation id="_EquityInvestmentsAtFairValuePolicyTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Realized gain or loss is recognized when an
investment is disposed of and is computed as the difference between the Company&#8217;s carrying value and the net proceeds received
from such disposition.&#160;&#160;Realized gains and losses on investment transactions are determined by specific identification. Net
unrealized appreciation or depreciation is computed as the difference between the fair value of the investment and the cost basis of
such investment. Net unrealized gains or losses for equity investments are recognized in operations as the difference between the carrying
value at the beginning of the period and the fair value at the end of the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b>SILO
PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b>DECEMBER
31, 2021 AND 2020</b></span></p><div>


</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_18" id="_SignificantAccountingPoliciesTextBlock-c10_cont_17"><ix:nonNumeric contextRef="c10" continuedAt="_EquityInvestmentsAtCostPolicyTextBlock-c10_cont_1" escape="true" name="silo:EquityInvestmentsAtCostPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Equity Investments, at Cost</b></p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_19" id="_SignificantAccountingPoliciesTextBlock-c10_cont_18"><ix:continuation id="_EquityInvestmentsAtCostPolicyTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equity investments, at cost are comprised
mainly of non-marketable capital stock and stock warrants, are recorded at cost, as adjusted for other than temporary impairment write-downs
and are evaluated for impairment periodically.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_20" id="_SignificantAccountingPoliciesTextBlock-c10_cont_19"><ix:nonNumeric contextRef="c10" continuedAt="_RevenueRecognitionPolicyTextBlock-c10_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Recognition</b></p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_21" id="_SignificantAccountingPoliciesTextBlock-c10_cont_20"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c10_cont_2" id="_RevenueRecognitionPolicyTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies ASC Topic 606, Revenue
from Contracts with Customers (&#8220;ASC 606&#8221;). ASC 606 establishes a single comprehensive model for entities to use in accounting
for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires
an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_22" id="_SignificantAccountingPoliciesTextBlock-c10_cont_21"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c10_cont_3" id="_RevenueRecognitionPolicyTextBlock-c10_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records interest and dividend
income on an accrual basis to the extent that the Company expects to collect such amounts.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_23" id="_SignificantAccountingPoliciesTextBlock-c10_cont_22"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c10_cont_4" id="_RevenueRecognitionPolicyTextBlock-c10_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the license and royalty income, revenue
is recognized when the Company satisfies the performance obligation based on the related license agreement. Payments received from the
licensee that are related to future periods are recorded as deferred revenue to be recognized as revenues over the term of the related
license agreement (see Note 10).</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_24" id="_SignificantAccountingPoliciesTextBlock-c10_cont_23"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c10_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Product sales were recognized when the NFID
products were shipped to the customer and title was transferred and were recorded net of any discounts or allowances which are separately
reported as &#8220;discontinued operations&#8221; on the consolidated statements of operations.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_25" id="_SignificantAccountingPoliciesTextBlock-c10_cont_24"><ix:nonNumeric contextRef="c10" continuedAt="_CostOfRevenuesPolicyTextBlock-c10_cont_1" escape="true" name="silo:CostOfRevenuesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cost of Revenues</b></p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.05pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_26" id="_SignificantAccountingPoliciesTextBlock-c10_cont_25"><ix:continuation continuedAt="_CostOfRevenuesPolicyTextBlock-c10_cont_2" id="_CostOfRevenuesPolicyTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary components of cost of revenues
on license fees included the cost of the license fees. Payments made to the licensor that are related to future periods are recorded
as prepaid expense to be amortized over the term of the related license agreement (see Note 10).</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_27" id="_SignificantAccountingPoliciesTextBlock-c10_cont_26"><ix:continuation id="_CostOfRevenuesPolicyTextBlock-c10_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary components of cost of revenues
on NFID apparel include the cost of the product, production costs, warehouse storage costs and shipping fees which are separately reported
as &#8220;discontinued operations&#8221; on the consolidated statements of operations.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_28" id="_SignificantAccountingPoliciesTextBlock-c10_cont_27"><ix:nonNumeric contextRef="c10" continuedAt="_ShareBasedCompensationForfeituresPolicyTextBlock-c10_cont_1" escape="true" name="us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_29" id="_SignificantAccountingPoliciesTextBlock-c10_cont_28"><ix:continuation id="_ShareBasedCompensationForfeituresPolicyTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation is accounted for
based on the requirements of ASC 718 &#8211; &#8220;Compensation &#8211; Stock Compensation&#8221;, which requires recognition in the
financial statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments
over the period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively,
the vesting period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange
for an award based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted
under Accounting Standards Update (&#8220;ASU&#8221;) 2016-09 Improvements to Employee Share-Based Payment.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_30" id="_SignificantAccountingPoliciesTextBlock-c10_cont_29"><ix:nonNumeric contextRef="c10" continuedAt="_IncomeTaxPolicyTextBlock-c10_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Income Taxes</b></p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_31" id="_SignificantAccountingPoliciesTextBlock-c10_cont_30"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c10_cont_2" id="_IncomeTaxPolicyTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income tax assets and liabilities
arise from temporary differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted
tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current
or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities
not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences
are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to
be realized.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_32" id="_SignificantAccountingPoliciesTextBlock-c10_cont_31"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c10_cont_3" id="_IncomeTaxPolicyTextBlock-c10_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the provisions of Financial
Accounting Standards Board (&#8220;FASB&#8221;) ASC 740-10, &#8220;Uncertainty in Income Taxes&#8221;. Certain recognition thresholds
must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax
positions that meet a &#8220;more-likely-than-not&#8221; threshold. The Company does not believe it has any uncertain tax positions as
of December 31, 2021 and 2020 that would require either recognition or disclosure in the accompanying consolidated financial statements.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_33" id="_SignificantAccountingPoliciesTextBlock-c10_cont_32"><ix:continuation id="_IncomeTaxPolicyTextBlock-c10_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognized income tax expense
of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" unitRef="usd">24,876</ix:nonFraction> and $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" unitRef="usd">0</ix:nonFraction> for the years ended December 31, 2021 and 2020 (see Note 8).</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_34" id="_SignificantAccountingPoliciesTextBlock-c10_cont_33"><ix:nonNumeric contextRef="c10" continuedAt="_ResearchAndDevelopmentExpensePolicy-c10_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_35" id="_SignificantAccountingPoliciesTextBlock-c10_cont_34"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 730-10, &#8220;Research
and Development-Overall,&#8221; research and development costs are expensed when incurred. During the years ended December 31, 2021 and
2020, research and development costs were $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd">693,910</ix:nonFraction> and $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd">26,250</ix:nonFraction>, respectively.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO
                                            PHARMA, INC. AND SUBSIDIARY<br/>
                                            NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_36" id="_SignificantAccountingPoliciesTextBlock-c10_cont_35"><ix:nonNumeric contextRef="c10" continuedAt="_EarningsPerSharePolicyTextBlock-c10_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Net Income (Loss) per Common Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_37" id="_SignificantAccountingPoliciesTextBlock-c10_cont_36"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c10_cont_2" id="_EarningsPerSharePolicyTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net income (loss) per share is computed
by dividing net income (loss) allocable to common shareholders by the weighted average number of shares of common stock outstanding during
each period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted average number
of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period using the as-if
converted method. Potentially dilutive securities which include convertible preferred shares and stock options are excluded from the
computation of diluted shares outstanding if they would have an anti-dilutive impact on the Company&#8217;s net income or (loss). The
following are the potentially dilutive shares for the years ended December 31, 2021 and 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_38" id="_SignificantAccountingPoliciesTextBlock-c10_cont_37"><ix:nonNumeric contextRef="c10" escape="true" name="silo:ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c10_cont_3" id="_EarningsPerSharePolicyTextBlock-c10_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">December&#160;31,<br/> 2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">December&#160;31,<br/> 2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left"><span style="-keep: true">Series C convertible preferred stock</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c88" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">15,133</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-263"><span style="-keep: true">&#8212;</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Stock options</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c90" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">6,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c91" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">6,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Warrants</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c92" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">347,080</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-264"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">368,213</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">6,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_39" id="_SignificantAccountingPoliciesTextBlock-c10_cont_38"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c10_cont_4" id="_EarningsPerSharePolicyTextBlock-c10_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents a reconciliation
of basic and diluted net loss per share:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_40" id="_SignificantAccountingPoliciesTextBlock-c10_cont_39"><ix:nonNumeric contextRef="c10" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c10_cont_4"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the Years Ended<br/> December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="-keep: true">Income (loss) per common share &#8212; basic:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="-keep: true">Income (loss) from continuing operations</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:IncomelossFromContinuingOperation" scale="0" unitRef="usd">4,157,108</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:IncomelossFromContinuingOperation" scale="0" sign="-" unitRef="usd">2,666,269</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-keep: true">Loss from discontinued operations</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:IncomeLossFromDiscontinuedOperations" scale="0" sign="-" unitRef="usd">253,367</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:IncomeLossFromDiscontinuedOperations" scale="0" sign="-" unitRef="usd">371,248</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Net income (loss)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" unitRef="usd">3,903,741</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd">3,037,517</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Weighted average common shares outstanding &#8212; basic</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">1,897,315</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">1,319,094</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">Net income (loss) per common share available to common stockholders&#8211; basic:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 9pt"><span style="-keep: true">From continuing operations</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" unitRef="usdPershares">1.45</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" sign="-" unitRef="usdPershares">2.07</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"><span style="-keep: true">From discontinued operations</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" sign="-" unitRef="usdPershares">0.13</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" sign="-" unitRef="usdPershares">0.28</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="-keep: true">Income (loss) per common share &#8212; diluted:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Income (loss) from continuing operations</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:IncomelossFromContinuingOperation" scale="0" unitRef="usd">4,157,108</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:IncomelossFromContinuingOperation" scale="0" sign="-" unitRef="usd">2,666,269</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">Add: interest expense, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="0" sign="-" unitRef="usd">3,036</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-265"><span style="-keep: true">&#8212;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Numerator for loss from continuing operations per common share &#8212; diluted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:NumeratorForLossFromContinuingOperationsPerCommonShareDiluted" scale="0" unitRef="usd">4,154,072</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:NumeratorForLossFromContinuingOperationsPerCommonShareDiluted" scale="0" sign="-" unitRef="usd">2,666,269</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-keep: true">Numerator for loss from discontinuing operations per common share &#8212;
    diluted</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted" scale="0" sign="-" unitRef="usd">253,367</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted" scale="0" sign="-" unitRef="usd">371,248</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Net loss per common share &#8211; diluted</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAllocatedToGeneralPartners" scale="0" unitRef="usd">3,900,705</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAllocatedToGeneralPartners" scale="0" sign="-" unitRef="usd">3,037,517</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Weighted average common shares outstanding &#8212; basic</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">1,897,315</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">1,319,094</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">Effect of dilutive securities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt"><span style="-keep: true">Options</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" unitRef="shares">5,996</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-266"><span style="-keep: true">&#8212;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt"><span style="-keep: true">Preferred shares</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AuctionMarketPreferredSecuritiesSharesOutstanding" scale="0" unitRef="shares">15,133</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-267"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Weighted average common shares outstanding &#8211; diluted</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268"><span style="-keep: true">1,918,4448</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">1,319,094</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Net loss per common share available to common stockholders &#8211; diluted:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"><span style="-keep: true">From continuing operations</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" unitRef="usdPershares">1.43</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" sign="-" unitRef="usdPershares">2.07</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"><span style="-keep: true">From discontinued operations</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" sign="-" unitRef="usdPershares">0.13</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" sign="-" unitRef="usdPershares">0.28</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_41" id="_SignificantAccountingPoliciesTextBlock-c10_cont_40"><ix:nonNumeric contextRef="c10" continuedAt="_LesseeLeasesPolicyTextBlock-c10_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_42" id="_SignificantAccountingPoliciesTextBlock-c10_cont_41"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c10_cont_2" id="_LesseeLeasesPolicyTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company accounts
for its leases using the method prescribed by ASC 842 &#8211; <i>Lease Accounting</i>. The Company assess whether the contract is, or
contains, a lease at the inception of a contract which is based on (i) whether the contract involves the use of a distinct identified
asset, (ii) whether the Company obtain the right to substantially all the economic benefit from the use of the asset throughout the period,
and (iii) whether the Company has the right to direct the use of the asset. The Company allocates the consideration in the contract to
each lease component based on its relative stand-alone price to determine the lease payments. The Company has elected not to recognize
right-of-use (&#8220;ROU&#8221;) assets and lease liabilities for short-term leases that have a term of 12 months or less.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_43" id="_SignificantAccountingPoliciesTextBlock-c10_cont_42"><ix:continuation id="_LesseeLeasesPolicyTextBlock-c10_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Operating lease ROU
assets represents the right to use the leased asset for the lease term. Operating lease liabilities are recognized based on the present
value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate,
the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value
of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included
in general and administrative expenses in the consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_44" id="_SignificantAccountingPoliciesTextBlock-c10_cont_43"><ix:nonNumeric contextRef="c10" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c10_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_45" id="_SignificantAccountingPoliciesTextBlock-c10_cont_44"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c10_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, the FASB issued ASU 2020-06&#8212;<i>Debt&#8212;Debt
with Conversion and Other Options (Subtopic 470-20) and Derivatives and edging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic
815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;)</i> to simplify
the accounting for convertible instruments by removing certain separation models in Subtopic 470- 20, <i>Debt with Conversion and Other
Options</i>, for convertible instruments. Under the amendments in ASU 2020-06, the embedded conversion features no longer are separated
from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives
under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently,
a convertible debt instrument will be accounted for as a single liability measured at its amortized cost and a convertible preferred
stock will be accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation
and recognition as derivatives. By removing those separation models, the interest rate of convertible debt instruments typically will
be closer to the coupon interest rate when applying the guidance in Topic 835, Interest. The amendments in ASU 2020-06 provide financial
statement users with a simpler and more consistent starting point to perform analyses across entities. The amendments also improve the
operability of the guidance and reduce, to a large extent, the complexities in the accounting for convertible instruments and the difficulties
with the interpretation and application of the relevant guidance. To further improve the decision usefulness and relevance of the information
being provided to users of financial statements, amendments in ASU 2020-06 increased information transparency by making the following
amendments to the disclosure for convertible instruments:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_46" id="_SignificantAccountingPoliciesTextBlock-c10_cont_45"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c10_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c10_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Add a disclosure objective</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Add information about
    events or conditions that occur during the reporting period that cause conversion contingencies to be met or conversion terms to
    be significantly changed</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Add information on which
    party controls the conversion rights</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Align disclosure requirements
    for contingently convertible instruments with disclosure requirements for other convertible instruments</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Require that existing
    fair value disclosures in Topic 825, Financial Instruments, be provided at the individual convertible instrument level rather than
    in the aggregate.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_47" id="_SignificantAccountingPoliciesTextBlock-c10_cont_46"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c10_cont_4" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c10_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, for convertible debt instruments
with substantial premiums accounted for as paid-in capital, amendments in ASU 2020-06 added disclosures about (1) the fair value amount
and the level of fair value hierarchy of the entire instrument for public business entities and (2) the premium amount recorded as paid-in
capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_48" id="_SignificantAccountingPoliciesTextBlock-c10_cont_47"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c10_cont_5" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c10_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The amendments in
ASU 2020-06 are effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the
SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities,
the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years.
Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those
fiscal years. Entities should adopt the guidance as of the beginning of its annual fiscal year and are allowed to adopt the guidance
through either a modified retrospective method of transition or a fully retrospective method of transition. In applying the modified
retrospective method, entities should apply the guidance to transactions outstanding as of the beginning of the fiscal year in which
the amendments are adopted. Transactions that were settled (or expired) during prior reporting periods are unaffected. The cumulative
effect of the change should be recognized as an adjustment to the opening balance of retained earnings at the date of adoption. If an
entity elects the fully retrospective method of transition, the cumulative effect of the change should be recognized as an adjustment
to the opening balance of retained earnings in the first comparative period presented. The Company is evaluating the impact of the revised
guidance and believes that it will not have a significant impact on its consolidated financial statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c10_cont_49" id="_SignificantAccountingPoliciesTextBlock-c10_cont_48"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c10_cont_6" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c10_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, the FASB issued ASU 2021-04,
Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718),
and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40). The new ASU addresses issuer&#8217;s accounting
for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities,
for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted.
The Company is evaluating the impact of the revised guidance and believes that it will not have a significant impact on its consolidated
financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c10_cont_49"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c10_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management does not believe that any other
recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company&#8217;s consolidated
financial statements.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO
                                            PHARMA, INC. AND SUBSIDIARY<br/>
                                            NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020</b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c10" continuedAt="_FairValueDisclosuresTextBlock-c10_cont_1" escape="true" name="us-gaap:FairValueDisclosuresTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 &#8211; <span style="text-decoration:underline">FAIR VALUE OF FINANCIAL
INSTRUMENTS AND FAIR VALUE MEASUREMENTS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c10_cont_2" id="_FairValueDisclosuresTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 820 - Fair Value Measurements and
Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments,
whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent
information available to the Company on December 31, 2021. Accordingly, the estimates presented in these financial statements are not
necessarily indicative of the amounts that could be realized on disposition of the financial instruments. FASB ASC 820 specifies a hierarchy
of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect
market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest
priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority
to unobservable inputs (Level 3 measurement).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c10_cont_3" id="_FairValueDisclosuresTextBlock-c10_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.6in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1-&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unadjusted
    quoted prices in active markets for identical assets or liabilities available at the measurement date.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unadjusted
    quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities
    in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable
    market data.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unobservable
    inputs which reflect the reporting entity&#8217;s own assumptions on what assumptions the market participants would use in pricing
    the asset or liability based on the best available information.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c10_cont_4" id="_FairValueDisclosuresTextBlock-c10_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company analyzes all financial instruments
with features of both liabilities and equity under the FASB&#8217;s accounting standard for such instruments. Under this standard, financial
assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c10_cont_5" id="_FairValueDisclosuresTextBlock-c10_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts reported in the consolidated
balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair market
value based on the short-term maturity of these instruments.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c10_cont_6" id="_FairValueDisclosuresTextBlock-c10_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments at Fair Value</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c10_cont_7" id="_FairValueDisclosuresTextBlock-c10_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounted for certain equity investments
at fair value using level 1, level 2 and level 3 valuations. Assets and liabilities measured at fair value on a recurring basis are as
follows at December 31, 2021 and 2020:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c10_cont_8" id="_FairValueDisclosuresTextBlock-c10_cont_7"><ix:nonNumeric contextRef="c10" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At December 31, 2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding-left: 0.125in; text-indent: -0.125in; text-align: left; font-weight: bold">Description</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 28%; text-align: left">Equity investments consisting of common
    stock, at fair value</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="silo:EquityInvestmentsAtFairValue" scale="0" unitRef="usd">419,995</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-269">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-272">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-273">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c10_cont_9" id="_FairValueDisclosuresTextBlock-c10_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes activity in
the Company&#8217;s equity investments, at fair value for the periods presented:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c10_cont_10" id="_FairValueDisclosuresTextBlock-c10_cont_9"><ix:nonNumeric contextRef="c10" escape="true" name="silo:ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Balance, beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-274">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-275">&#160;&#160;&#160;&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; width: 76%">Additions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:AdditionsofEquitySecurities" scale="0" unitRef="usd">531,250</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-276">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" unitRef="usd">359,843</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-277">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Unrealized gain</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="0" unitRef="usd">248,588</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-278">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Balance, end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd">419,995</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-279">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c10_cont_11" id="_FairValueDisclosuresTextBlock-c10_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2021, equity investments,
at fair value consisted of common equity securities of two entities, Home Bistro, Inc and Aikido Pharma, Inc. (see Note 10).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c10_cont_12" id="_FairValueDisclosuresTextBlock-c10_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equity investments are carried at fair value
with unrealized gains or losses which is recorded as net unrealized gain (loss) on equity investments in the accompanying consolidated
statement of operations.&#160;Realized gains and losses are determined on a specific identification basis which is recorded as net realized
gain (loss) on equity investments in the accompanying consolidated statement of operations. The Company reviews equity investments, at
fair value for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may
not be recovered.&#160;For the year ended December 31, 2021, we recorded a net realized gain on equity investments of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="0" unitRef="usd">6,660,483</ix:nonFraction> primarily
attributed to a gain from the sale of the Company&#8217;s equity investment in DatChat, Inc. of $<ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="0" unitRef="usd">6,657,120</ix:nonFraction> and Aikido Pharma, Inc. of
$<ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="0" unitRef="usd">3,363</ix:nonFraction>. DatChat, Inc. was a cost basis investment carried at $<ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedAtCost" scale="0" unitRef="usd">200</ix:nonFraction> at December 31, 2020 (see below). The Company paid a commission on
the sale of DatChat, Inc. totaling $<ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredSalesCommission" scale="0" unitRef="usd">578,880</ix:nonFraction> which was netted with the proceeds.</p><p style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020</b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c10_cont_13" id="_FairValueDisclosuresTextBlock-c10_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 825-10 &#8220;Financial Instruments&#8221;
allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair
value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value
option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent
reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c10_cont_14" id="_FairValueDisclosuresTextBlock-c10_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Equity Investments at Cost</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_FairValueDisclosuresTextBlock-c10_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2021 and 2020, equity investments,
at cost of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:EquityInvestmentsCost" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:EquityInvestmentsCost" scale="0" unitRef="usd">200</ix:nonFraction>, respectively, comprised mainly of non-marketable capital stock and stock warrants, are recorded at cost, as adjusted
for other than temporary impairment write-downs and are evaluated for impairment periodically.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c10" continuedAt="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c10_cont_1" escape="true" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8211; <span style="text-decoration:underline">DISPOSAL OF THE DISCONTINUED
OPERATIONS OF THE NFID BUSINESS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c10_cont_2" id="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2021, the Company entered
into and closed on an Asset Purchase Agreement (see Note 1) with NFID, LLC, an unrelated party, a Florida limited liability company,
whereby the Company sold certain assets, properties, and rights in connection with its NFID trademark name, logos, domain, and apparel
clothing and accessories for a purchase price of $<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="silo:PurchasePrice" scale="0" unitRef="usd">60,000</ix:nonFraction> in the form of a promissory note for the same amount (&#8220;Note&#8221;). The
Note bears <ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" scale="-2" unitRef="pure">8</ix:nonFraction>% interest per annum and matures on <ix:nonNumeric contextRef="c87" format="ixt:date-monthname-day-year-en" name="us-gaap:LongTermDebtMaturityDate">October 1, 2023</ix:nonNumeric>. As of December 31, 2021, the Note had principal balance of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:PrincipalBalance" scale="0" unitRef="usd">60,000</ix:nonFraction> and
accrued interest receivable of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:AccruedInterestReceivable" scale="0" unitRef="usd">1,210</ix:nonFraction> for a total outstanding receivable balance of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:TotalOutstandingBalanceReceivable" scale="0" unitRef="usd">61,210</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c10_cont_3" id="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c10_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 205-20 &#8220;Discontinued Operations&#8221;
establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should be reported in
discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity&#8217;s operations
and financial results. As a result, the component&#8217;s results of operations have been classified as discontinued operations on a
retrospective basis for all periods presented. Accordingly, the results of operations of this component, for all periods, are separately
reported as &#8220;discontinued operations&#8221; in the accompanying consolidated statements of operations.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c10_cont_4" id="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c10_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2021 and 2020, assets of
discontinued operations amounted $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" scale="0" unitRef="usd">33,484</ix:nonFraction>, respectively, which primarily consisted of NFID inventory.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c10_cont_5" id="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c10_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table set forth the selected
financial data of the Company&#8217;s gain from sale of the NFID business on September 30, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c10_cont_6" id="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c10_cont_5"><ix:nonNumeric contextRef="c10" escape="true" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September&#160;30,<br/>
    2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 1.5pt">Inventory, net</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">58,447</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="0" unitRef="usd">58,447</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-280">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net asset of NFID business disposed</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="silo:NetAssetOfNFIDBusinessDisposed" scale="0" unitRef="usd">58,447</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Consideration in the form of a note receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="silo:ConsiderationInTheFormOfANoteReceivable" scale="0" sign="-" unitRef="usd">60,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Gain from sale of NFID business</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfOtherAssets" scale="0" sign="-" unitRef="usd">1,553</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c10_cont_7" id="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c10_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The summarized operating result of discontinued
operations of the NFID Business included in the Company&#8217;s consolidated statements of operations for the years ended December 31,
2021 and 2020 is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c10_cont_7"><ix:nonNumeric contextRef="c10" escape="true" name="srt:ScheduleOfCondensedIncomeStatementTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Year Ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Product sales, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="0" unitRef="usd">119,405</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="0" unitRef="usd">40,923</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="0" unitRef="usd">103,824</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="0" unitRef="usd">182,426</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="0" unitRef="usd">15,581</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="0" sign="-" unitRef="usd">141,503</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total operating and other non-operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd">270,501</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd">229,745</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain from sale of NFID business</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:GainFromSaleOfNFIDBusiness" scale="0" unitRef="usd">1,533</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-281">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Loss from discontinued operations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" sign="-" unitRef="usd">253,367</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" sign="-" unitRef="usd">371,248</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SILO PHARMA, INC.
AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>DECEMBER 31, 2021
AND 2020 </b></p><div>

</div><p style="margin: 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c10" continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c10_cont_1" escape="true" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>NOTE 5 &#8211; <span style="text-decoration:underline">NOTES RECEIVABLE</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c10_cont_2" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 28, 2018, the Company and Blind
Faith Concepts Holdings, Inc. (the &#8220;Seller&#8221;) executed a two-year promissory note receivable agreement with a principal balance
of $<ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="0" unitRef="usd">200,000</ix:nonFraction> of which $<ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="0" unitRef="usd">100,000</ix:nonFraction> was funded to the Seller in September 2018 and the remaining $<ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="silo:RemainingBalanceOfPromissoryNoteReceivable" scale="0" unitRef="usd">100,000</ix:nonFraction> was funded in October 2018. The promissory
note accrued interest at a rate of <ix:nonFraction contextRef="c103" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure">6</ix:nonFraction>% per annum, and the Company was repaid in interest only payments on a quarterly basis, until the
maturity date of <ix:nonNumeric contextRef="c106" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate">September 27, 2020</ix:nonNumeric>, at which time the full principal and any interest payments was due to the Company. At the time the
promissory note receivable agreement was executed, the Company also executed a security interest and pledge agreement with the borrower
pursuant to which the borrower pledged all of the assets of its company as security for the performance of the note obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c10_cont_3" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c10_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 2, 2018, the Company and Blind
Faith Concepts Holdings, Inc. (the &#8220;Debtor&#8221;) entered into a promissory note agreement for the sale of a promissory note with
a principal balance of $<ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="0" unitRef="usd">50,000</ix:nonFraction> (&#8220;Note&#8221;). The Note bore an interest rate of <ix:nonFraction contextRef="c108" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure">10</ix:nonFraction>% per annum and <ix:nonFraction contextRef="c109" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure">18</ix:nonFraction>% per annum in the event of
default, payable on a monthly basis. The terms of the Note also provides for the principal balance of $<ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="0" unitRef="usd">50,000</ix:nonFraction> to be used by the Debtor
for an asset purchase transaction (&#8220;Transaction&#8221;) which is not related to the Company and for the Transaction to close within
thirty days from the issuance date of the Note otherwise the Note becomes immediately due. In December 2018, the Company determined that
the Note was not collectible and accordingly recorded an allowance for doubtful account and bad debt expense of $<ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd">50,000</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c10_cont_4" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c10_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2019, the Company and a third
party entity (&#8220;Purchaser&#8221;) entered into two separate claim purchase agreements (&#8220;Purchase Agreements&#8221;), whereby
the Company sold and the Purchaser assumed the promissory notes: (i) dated September 28, 2018 with a principal balance of $<ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="0" unitRef="usd">200,000</ix:nonFraction> and
related accrued interest and: (ii) dated November 2, 2018 with a principal balance of $<ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="0" unitRef="usd">50,000</ix:nonFraction> and related accrued interest (discussed
above) (collectively as &#8220;Notes&#8221;), for an aggregate purchase price of $<ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SupplementalDeferredPurchasePrice" scale="0" unitRef="usd">277,305</ix:nonFraction>. Pursuant to the Purchase Agreements, the purchase
price is payable on the earlier of the payment of six-monthly installments or upon the liquidation of the Blind Faith Concepts Holdings,
Inc settlement securities pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended. During the year ended December 31,
2020, the Company collected an aggregate amount of $<ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="silo:NotesReceivablePurchasePrice" scale="0" unitRef="usd">30,000</ix:nonFraction> of the Notes.&#160;During the year ended December 31, 2020, the Company recorded
an allowance for doubtful account and bad debt expense of $<ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="0" unitRef="usd">146,500</ix:nonFraction> related to the principal balance of the Notes and wrote off $<ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivable" scale="0" unitRef="usd">27,876</ix:nonFraction>
of the accrued interest receivable related to the Notes, for a total bad debt expense of $<ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd">174,376</ix:nonFraction>, due to slow collection of the installment
payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c10_cont_5" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c10_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2020,
the Company recorded an aggregate bad debt expense in the amount of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="0" unitRef="usd">174,376</ix:nonFraction> and recovered an aggregate of $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForLoanAndLeaseLossRecoveryOfBadDebts" scale="0" unitRef="usd">9,000</ix:nonFraction> bad debt previously
written off during the periods between 2018 to 2020, resulting in net bad debt expense of $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:NetBadDebtExpense" scale="0" unitRef="usd">165,376</ix:nonFraction> recorded in the accompanying consolidated
statement of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c10_cont_6" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c10_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2021,
the Company recovered $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForLoanAndLeaseLossRecoveryOfBadDebts" scale="0" unitRef="usd">148,500</ix:nonFraction> of the bad debt that was previously written off during the periods between 2018 to 2020, recorded as bad
debt recovery in the accompanying consolidated statement of operations. <ix:nonNumeric contextRef="c116" name="silo:BadDebtRecoveryCashPayment">On June 7, 2021, the Company and the investor, entered into a
settlement agreement whereby both parties agreed to settle the remaining balance of this note receivable which was previously written
off in year 2020 for a total settlement amount of $196,000 to be paid as follows; (i) an initial payment of $46,000 upon execution of
the settlement agreement and (ii) $10,000 per month for fifteen months.</ix:nonNumeric> During the year ended, $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:CollectedSettlementAgreement" scale="0" unitRef="usd">148,500</ix:nonFraction> was collected under this settlement
agreement and $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:RemainsCollectibleSettlementAgreement" scale="0" unitRef="usd">47,500</ix:nonFraction> remains collectible under this settlement agreement and such amount has been fully reserved as of December 31,
2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c10_cont_7" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c10_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2021, the Company executed
a note receivable agreement with NFID, LLC in connection with an Asset Purchase Agreement (see Note 4). The promissory note bears <ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="silo:PromissoryNote" scale="-2" unitRef="pure">8</ix:nonFraction>%
interest per annum and matures on October 1, 2023. The outstanding principal and accrued interest shall be due and payable on maturity.
As of December 31, 2021, this note receivable had outstanding principal receivable of $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="silo:NoteReceivableNonCurrentAmount" scale="0" unitRef="usd">60,000</ix:nonFraction> and accrued interest receivable of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:DebtInstrumentIncreasesAccruedInterest" scale="0" unitRef="usd">1,210</ix:nonFraction>
for a total receivable balance of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireReceivables" scale="0" unitRef="usd">61,210</ix:nonFraction> which is reflected in the accompanying consolidated balance sheet as note receivable &#8211;
non-current.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c10_cont_8" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c10_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2021 and 2020, notes receivable,
net, consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c10_cont_8"><ix:nonNumeric contextRef="c10" escape="true" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Principal amounts of notes receivable at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableGross" scale="0" unitRef="usd">220,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableGross" scale="0" unitRef="usd">250,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify">Additional notes receivable in 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="silo:AdditionalNotesReceivableIn2021" scale="0" unitRef="usd">60,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-282">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Collections on notes receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="silo:CollectionsOnNotesReceivable" scale="0" unitRef="usd">148,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="silo:CollectionsOnNotesReceivable" scale="0" unitRef="usd">30,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" scale="0" unitRef="usd">71,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" scale="0" unitRef="usd">196,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total Notes receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd">60,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd">23,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">Less: notes receivable, net &#8211; current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-283">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="silo:LessNotesReceivableNetCurrentPortion" scale="0" sign="-" unitRef="usd">23,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Notes receivable &#8211; non-current</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableNet" scale="0" unitRef="usd">60,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-284">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c10" continuedAt="_DebtDisclosureTextBlock-c10_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>NOTE 6 - <span style="text-decoration:underline">NOTE PAYABLE</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c10_cont_2" id="_DebtDisclosureTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>Paycheck Protection Program Funding</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c10_cont_3" id="_DebtDisclosureTextBlock-c10_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 30, 2020, the Company received federal
funding in the amount of $<ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="0" unitRef="usd">18,900</ix:nonFraction> through the Paycheck Protection Program (the &#8220;PPP&#8221;). PPP funds had certain restrictions
on use of the funding proceeds, and generally must be repaid within two years and accrued interest at a rate of <ix:nonFraction contextRef="c119" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure">1</ix:nonFraction>% per annum. The PPP
loan may, under circumstances, be forgiven. No payment was due by the Company during the nine months period beginning on the date of
this note (&#8220;Deferral Period&#8221;). Commencing one month after the expiration of the Deferral Period, the Company was to pay the
lender monthly payments of principal and interest, each in equal amount required to fully amortize by the maturity date. If a payment
on this note was more than ten days late, the lender would charge a late fee of up to <ix:nonFraction contextRef="c118" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableInterestBearingInterestRate" scale="-2" unitRef="pure">5</ix:nonFraction>% of the unpaid portion of the regularly scheduled
payment. As of December 31, 2020, the principal balance of this note amounted to $<ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">18,900</ix:nonFraction> and accrued interest of $<ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd">174</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c10_cont_4" id="_DebtDisclosureTextBlock-c10_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2021, the Company was notified by
the Small Business Administration that the principal and accrued interest under the PPP loan has been forgiven in full. Accordingly,
during the year ended December 31, 2021, the Company recorded a total gain on forgiveness of PPP note payable of $<ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNotesPayable" scale="0" unitRef="usd">19,082</ix:nonFraction> which consisted
of the principal balance of $<ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">18,900</ix:nonFraction> and accrued interest of $<ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd">182</ix:nonFraction>. As of December 31, 2021, the PPP note had no outstanding balance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c10_cont_5" id="_DebtDisclosureTextBlock-c10_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2021 and
2020, the Company recognized $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">54</ix:nonFraction> and $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">80</ix:nonFraction> of interest expense, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c10_cont_6" id="_DebtDisclosureTextBlock-c10_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2021 and 2020, notes payable
consisted of the following:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c10_cont_6"><ix:nonNumeric contextRef="c10" escape="true" name="us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Principal amount</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-285">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="silo:DebtInstrumentsFaceAmount" scale="0" unitRef="usd">18,900</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-286">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="silo:NotrPayableLessCurrentPortion" scale="0" unitRef="usd">14,654</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Note payable - long term portion</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-287">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="silo:NotePayableLongTermPortion" scale="0" unitRef="usd">4,246</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c10" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7 &#8211; <span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Shares Authorized</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has authorized the issuance of
<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">5,000,000</ix:nonFraction> shares of preferred stock, $<ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.0001</ix:nonFraction> par value. The Company&#8217;s board of directors is authorized, at any time, and from time
to time, to provide for the issuance of shares of preferred stock in one or more series, and to determine the designations, preferences,
limitations and relative or other rights of the preferred stock or any series thereof.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 10, 2021, the Company filed an amendment
to its Certificate of Incorporation with the Secretary of State of Delaware to increase the authorized number of shares of common stock
of the Company from <ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" scale="0" unitRef="shares">100,000,000</ix:nonFraction>&#160;shares to <ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" scale="0" unitRef="shares">500,000,000</ix:nonFraction> shares.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>Preferred Stock</b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2013, <ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">1,000,000</ix:nonFraction> shares of preferred
stock were designated as Series A Convertible Preferred Stock, and in November 2019, <ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">2,000</ix:nonFraction> shares of preferred stock were designated
as Series B Convertible Preferred Stock. On February 9, 2021, <ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">4,280</ix:nonFraction> shares of preferred stock were designated as Series C Convertible
Preferred Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Conversion of Series A Redeemable Preferred
Stock into Common Shares</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On August 3, 2020, at the request of the investor,
the Company converted <ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="silo:ConvertablePreferredStock" scale="0" unitRef="shares">4,000</ix:nonFraction> Series A Preferred Stock into <ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares">40,000</ix:nonFraction> shares of common stock. After such conversion, the Company reclassified
the $<ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" unitRef="usd">400,000</ix:nonFraction> redemption value of the Series A Preferred Stock to additional paid in capital. Accordingly, there are no shares of Series
A Preferred Stock issued and outstanding as of December 31, 2021 and 2020. &#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SILO PHARMA, INC.
AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b><i>Conversion of Series B Convertible Preferred
Stock into Common Shares </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><ix:nonNumeric contextRef="c130" name="silo:ExchangeAgreementsDescription">On April 15, 2020, the Company entered into
Exchange Agreements with the holders of its Series B Preferred Stock, which shares of Series B Preferred Stock were originally issued
in November 2019. Pursuant to the Exchange Agreements, the holders agreed to exchange their 115 shares of Series B Preferred Stock with
a stated value of $115,000 and 11,500 warrants issued in connection with the Series B Preferred Stock for an aggregate of 28,750 shares
of the Company&#8217;s common stock at a price of $4.00 per share. After the exchanges, there are no shares of the Company&#8217;s Series
B Preferred Stock outstanding. The Company issued 28,750 shares of common stock which was more than the shares that would have been issued
at the original conversion price of $10.00 per share or 11,500 shares of common stock, an excess of 17,250 shares of common stock. The
excess shares were valued at a price of $4.00 per share. Consequently, in connection with this share exchange, the Company recorded a
deemed dividend on this extinguishment of $69,000 during the year ended December 31, 2020. Accordingly, there are no shares of Series
B Preferred Stock issued and outstanding as of December 31, 2021 and 2020.</ix:nonNumeric> &#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Series C Convertible Preferred Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 9, 2021, the Company filed a Certificate
of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the &#8220;Certificate of Designations&#8221;)
with the Delaware Secretary of State, designating <ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">4,280</ix:nonFraction> shares of preferred stock as Series C Convertible Preferred Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Designation</span>. The Company has designated <ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">4,280</ix:nonFraction> shares of preferred stock as Series C Convertible Preferred Stock. Each share of Series C Convertible Preferred Stock has a par value of $<ix:nonFraction contextRef="c132" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.0001</ix:nonFraction> per share and a stated value of $<ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="silo:CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares" scale="0" unitRef="shares">1,000</ix:nonFraction> (the &#8220;Series C Stated Value&#8221;).</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Dividends</span><i>.&#160;</i>Holders
                                            of Series C Convertible Preferred Stock shall be entitled to receive dividends (on an as-if-converted-to-common-stock
                                            basis) in the same form as dividends actually paid on shares of the common stock when, as
                                            and if such dividends are paid on shares of the common stock. No other dividends shall be
                                            paid on shares of the Series C Convertible Preferred Stock.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_15" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_14"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Liquidation</span>.
                                            Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary,
                                            the holders of Series C Convertible Preferred Stock shall be entitled to receive the same
                                            amount that a holder of common stock would receive if the Series C Convertible Preferred
                                            Stock were fully converted (disregarding any conversion limitations) which amounts shall
                                            be paid&#160;pari passu&#160;with all holders of common stock.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_16" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_15"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Voting
                                            Rights</span>. Except as otherwise provided in the Certificate of Designations or as otherwise
                                            required by law, the Series C Convertible Preferred Stock shall have no voting rights. However,
                                            as long as any shares of Series C Convertible Preferred Stock are outstanding, the Company
                                            shall not, without the affirmative vote of the holders of a majority of the then outstanding
                                            shares of the Series C Convertible Preferred Stock, (a) alter or change adversely the powers,
                                            preferences or rights given to the Series C Convertible Preferred Stock or alter or amend
                                            the Certificate of Designations, (b) amend its Certificate of Incorporation or other charter
                                            documents in any manner that adversely affects any rights of the holders of the Series C
                                            Convertible Preferred Stock, (c) increase the number of authorized shares of Series C Convertible
                                            Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt"></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_17" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_16"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Conversion</span>. Each share of Series C Convertible Preferred Stock is convertible, at any time and from time to time after the issuance date, at the option of the holder, into such number of shares of common stock determined by dividing the Series C Stated Value by the Series C Conversion Price. &#8220;Series C Conversion Price&#8221; means $<ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares">15.00</ix:nonFraction>, subject to adjustment in the event of stock split, stock dividends, subsequent right offerings and similar recapitalization transactions.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_18" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_17"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Forced
                                            Conversion</span>. Notwithstanding anything herein to the contrary, after the date that the
                                            Company&#8217;s stockholder approval is obtained and deemed effective, the Company may deliver
                                            a written notice to all holders (the &#8220;Forced Conversion Notice Date&#8221;) to cause
                                            each holder to convert all or part of such holder&#8217;s Series C Convertible Preferred
                                            Stock pursuant to Section 6 (&#8220;Forced Conversion&#8221;), it being agreed that the &#8220;Conversion
                                            Date&#8221; shall be deemed to occur no later than the earlier of (i) two (2) trading days
                                            and (ii) the number of trading days comprising the standard settlement period following the
                                            Forced Conversion Notice Date; provided, however, a holder shall only be required to convert
                                            pursuant to a Forced Conversion to the extent that such conversion would not cause a holder
                                            to exceed its beneficial ownership limitation. On March 10, 2021, the Company obtained the
                                            stockholders&#8217; approval forcing the conversion of all the Series C Convertible Preferred
                                            Stock. On April 12, 2021, the Company notified holders of its Series C Convertible Preferred
                                            Stock of its election to force the conversion to its Series C Convertible Preferred Stock
                                            into shares of the Company&#8217;s common stock (see below).</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_19" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_18"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Exercisability</span><i>.&#160;</i><ix:nonNumeric contextRef="c133" name="silo:PreferredStockOutstandingDescription">A holder of Series C Convertible Preferred Stock may not convert any portion of the Series C Convertible Preferred Stock to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, upon election by a holder prior to issuance, 9.99%) of the outstanding shares of the Company&#8217;s common stock after conversion, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%.</ix:nonNumeric></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_20" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Series C Convertible Preferred Stock
Financing</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:nonNumeric contextRef="c135" name="us-gaap:PreferredStockConversionBasis"><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_21" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On February 9, 2021 (the &#8220;Effectiveness
Date&#8221;), the Company entered into securities purchase agreements (collectively, the &#8220;Series C Purchase Agreements&#8221;)
with certain institutional and accredited investors for the sale of an aggregate of 4,276 shares of the Company&#8217;s Series C Convertible
Preferred Stock and warrants (the &#8220;February Warrants&#8221;) to purchase up to 285,066 shares (the &#8220;February Warrant Shares&#8221;)
of the Company&#8217;s common stock for gross proceeds of approximately $4,276,000, before deducting placement agent and other offering
expenses of $481,898 which are offset against the proceeds in additional paid in capital. The offering closed on February 12, 2021. Accordingly,
the Company recognized a total deemed dividend of $1,403,997 for the beneficial conversion feature in connection with the issuance of
these Series C Convertible Preferred Stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_22" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The February Warrants are exercisable for
a period of <ix:nonNumeric contextRef="c10" format="ixt-sec:durwordsen" name="silo:WarrantsTerm">five years</ix:nonNumeric> from the date of issuance at an exercise price of $<ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">15.00</ix:nonFraction> per share. If, after a period of 180 days after the date
of issuance of the February Warrants, a registration statement covering the resale of the February Warrant Shares is not effective, the
holders may exercise the February Warrants by means of a cashless exercise.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:nonNumeric contextRef="c10" name="us-gaap:PreferredStockConversionBasis"><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_23" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series C Convertible Preferred Stock and
the February Warrants each contain a beneficial ownership limitation that restricts each of the investor&#8217;s ability to exercise
the February Warrants and convert the Series C Convertible Preferred Stock such that the number of shares of the Company common stock
held by each of them and their affiliates after such conversion or exercise does not exceed 4.99% (or, at the election of the Investor,
9.99%) of the Company&#8217;s then issued and outstanding shares of common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_24" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series C Purchase Agreement also provides
that until the 18 month anniversary of the Effectiveness Date, in the event of a subsequent financing (except for certain exempt issuances
as provided in the Series C Purchase Agreement) by the Company, each investor will have the right to participate in such subsequent financing
up to an amount equal to the investor&#8217;s proportionate share of the subsequent financing based on such investor&#8217;s participation
in the offering on the same terms, conditions and price provided for in the subsequent financing up to an amount equal to <ix:nonFraction contextRef="c136" decimals="2" format="ixt:num-dot-decimal" name="silo:SubsequentFinancingPercentage" scale="-2" unitRef="pure">50</ix:nonFraction>% of the
subsequent financing. In addition, pursuant to the Series C Purchase Agreement, the Company has agreed that neither it nor its subsidiaries
will enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common stock equivalents
to file any registration statement other than as contemplated pursuant to the Registration Rights Agreement (as defined below) for a
period of 90 days from the Effectiveness Date. Furthermore, subject to certain exceptions, the Company is prohibited from effecting or
entering into an agreement to effect any issuance by the Company or any of its subsidiaries of common stock or common stock equivalents
involving a Variable Rate Transaction (as defined in the Series C Purchase Agreement).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_25" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the offering, the Company
entered into separate registration rights agreements (&#8220;Registration Rights Agreements&#8221;) with the investors pursuant to which
the Company agreed to undertake to file a registration statement (the &#8220;Registration Statement&#8221;) to register the resale of
the Registrable Securities (as defined in the Registration Rights Agreement) within ten calendar days following the Effectiveness Date.
The Company agreed to use its best efforts to cause the Registration Statement covering the Registrable Securities to be declared effective
no later than the 60<sup>th</sup>&#160;calendar day following the Effectiveness Date, or in the event of a full review by the Securities
and Exchange Commission, the 90<sup>th</sup>&#160;calendar day following the Effectiveness Date, and to maintain the effectiveness of
the Registration Statement until all of the Registrable Securities have been sold or are otherwise able to be sold pursuant to Rule 144
under the Securities Act of 1933, as amended. If the Company fails to file the Registration Statement or have it declared effective by
the dates set forth above, amongst other things, the Company will be obligated to pay the investors damages in the amount of <ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="silo:ObligationPercentage" scale="-2" unitRef="pure">1</ix:nonFraction>% of their
subscription amount, per month, until such events are satisfied. The Registration Statement was filed and declared effective in April
2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_26" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><ix:nonNumeric contextRef="c10" name="silo:PlacementAgentWarrantsDescriptoin">In addition, pursuant to the terms of the
offering, the Company issued Bradley Woods &amp; Co, Ltd. and Katalyst Securities LLC warrants (the &#8220;Placement Agent Warrants&#8221;)
to purchase up to an aggregate of 57,013 shares of common stock, or 10% of the shares of common stock issuable upon conversion of the
Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period
of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment.</ix:nonNumeric> The Placement Agent
Warrants were valued at the grant date using a Black-Scholes option pricing model with the following assumptions: risk-free interest
rate of <ix:nonFraction contextRef="c10" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.50</ix:nonFraction>%, expected dividend yield of <ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction>%, expected term of <ix:nonNumeric contextRef="c10" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric> years using the simplified method and expected volatility of $<ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">169</ix:nonFraction>% based
on comparable and calculated volatility. The aggregate grant date fair value of these Placement Agent Warrants amounted to approximately
$<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:AggregateGrantDateFairValueOfPlacementAgentWarrants" scale="0" unitRef="usd">1,106,000</ix:nonFraction> and was recorded against the proceeds with no net effect on the consolidated financials.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_27" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net proceeds of the offering are expected
to be used for working capital purposes and to further execute on the Company&#8217;s existing business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_28" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_27"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Conversion of Series C Convertible Preferred
Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_29" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_28"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 12, 2021, the Company notified holders
of its Series C Convertible Preferred Stock of its election to force the conversion to its Series C Convertible Preferred Stock into
shares of the Company&#8217;s common stock pursuant to the Certificate of Designations unless such conversion would cause the holder
to exceed its beneficial ownership limitation pursuant to the Certificate of Designations. On April 14, 2021, the Company converted <ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="silo:ConvertablePreferredStock" scale="0" unitRef="shares">4,049</ix:nonFraction>
Series C Convertible Preferred Stock into <ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares">269,900</ix:nonFraction> shares of common stock. As of December 31, 2021, there were <ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">227</ix:nonFraction> shares of the Company&#8217;s
Series C Convertible Preferred Stock issued and outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020 </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_30" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_29"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_31" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_30"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sale of Common Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_32" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_31"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Between April 9, 2020 to April 18, 2020, the
Company entered into subscription agreements with certain accredited investors pursuant to which it issued an aggregate of <ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">155,287</ix:nonFraction> shares
of the Company&#8217;s common stock for proceeds of $<ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">75,644</ix:nonFraction>, and subscription receivable of $<ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" scale="0" unitRef="usd">2,000</ix:nonFraction> or $<ix:nonFraction contextRef="c138" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares">0.50</ix:nonFraction> per share, for a total of
$<ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="silo:TotalSubscriptionReceivableValue" scale="0" unitRef="usd">77,644</ix:nonFraction>. The Company collected the subscription receivable of $<ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" scale="0" unitRef="usd">2,000</ix:nonFraction> on July 6, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_33" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_32"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 28, 2020, the Company entered into
securities purchase agreements (collectively, the &#8220;April Purchase Agreements&#8221;) with certain institutions and accredited investors
for the sale of an aggregate <ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">599,875</ix:nonFraction> shares of the Company&#8217;s common stock at a price of $<ix:nonFraction contextRef="c142" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">4.00</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">2,399,500</ix:nonFraction>,
before deducting placement agent fees of $<ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="silo:PlacementAgentFees" scale="0" unitRef="usd">242,950</ix:nonFraction> and other offering expenses of $<ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOwnershipInterestsOfferingCosts" scale="0" unitRef="usd">118,460</ix:nonFraction> (the &#8220;Private Placement&#8221;) for total
net proceeds of $<ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="0" unitRef="usd">2,038,090</ix:nonFraction>. The April Purchase Agreements contains customary representations, warranties and covenants of the parties,
and the closing was subject to customary closing conditions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_34" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_33"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The April Purchase Agreements also provides
that until the six month anniversary of the date of the April Purchase Agreements, in the event of a subsequent financing (except for
certain exempt issuances as provided in the April Purchase Agreements) by the Company, each investor that invested over $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:InvestorInvestedAmount" scale="0" unitRef="usd">100,000</ix:nonFraction> pursuant
to the April Purchase Agreements will have the right to participate in such subsequent financing up to an amount equal to <ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="silo:SubsequentFinancingPercentage" scale="-2" unitRef="pure">50</ix:nonFraction>% of the
subsequent financing on the same terms, conditions and price provided for in the subsequent financing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_35" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_34"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Private Placement,
the Company entered into separate Registration Rights Agreements with the investors, pursuant to which the Company agreed to undertake
to file a registration statement to register the resale of the shares underlying the Registrable Securities (as defined therein) within
30 calendar days following the closing date, and to maintain the effectiveness of the registration statement until all of such shares
of common stock have been sold or are otherwise able to be sold pursuant to Rule 144. <ix:nonNumeric contextRef="c10" name="us-gaap:ConstructionContractorLiquidityCharacteristic">If the Company fails to file the registration statement
or have it declared effective by the dates set forth above, amongst other things, the Company is obligated to pay the investors liquidated
damages in the amount of 1% of their subscription amount, per month, until such events are satisfied, subject to a cap of 6%.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_36" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_35"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In conjunction with the Private Placement,
all officers and directors of the Company have entered into lock-up agreements pursuant to which they have agreed not to sell their shares
of common stock or common stock equivalents in the Company until the twelve-month anniversary of the closing date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_37" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_36"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock Issued for Future Services&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_38" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_37"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 17, 2020, the Company entered into
one-year advisory agreements with certain accredited investors pursuant to which it agreed to issue an aggregate of <ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">102,347</ix:nonFraction> shares of
the Company&#8217;s common stock to the advisors for advisory services to be rendered. These shares were valued at $<ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">409,387</ix:nonFraction>, or $<ix:nonFraction contextRef="c144" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">4.00</ix:nonFraction>
per common share, based on contemporaneous common share sales which are being amortized over the term of the agreements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_39" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_38"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 17, 2020, the Company entered into
a six-month consulting agreement with an accredited investor pursuant to which it agreed to issue an aggregate of <ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">69,377</ix:nonFraction> shares of the
Company&#8217;s common stock to the consultant for consulting services to be rendered. These shares were valued at $<ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">277,508</ix:nonFraction>, or $<ix:nonFraction contextRef="c146" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">4.00</ix:nonFraction>
per common share, based on contemporaneous common share sales which is being amortized over the term of the agreement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_40" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_39"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2021 and
2020, the Company recognized stock-based consulting fees of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:AmortizationOfPrepaidStockbasedExpense" scale="0" unitRef="usd">107,970</ix:nonFraction> and $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:AmortizationOfPrepaidStockbasedExpense" scale="0" unitRef="usd">578,924</ix:nonFraction>, respectively, with a remaining prepaid expense included
in prepaid expenses and other current assets of $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" unitRef="usd">107,970</ix:nonFraction> at December 31, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO
                                            PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020 </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_41" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_40"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock Issued for Employment Agreement</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_42" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_41"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 17, 2020, the Company entered into
an Employment Agreement with the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;) pursuant to which CEO will continue to serve
as Chief Executive Officer and Chief Financial Officer of the Company. In connection with this employment agreement, the CEO was granted
<ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">152,619</ix:nonFraction> shares of the Company&#8217;s common stock. These shares were valued at $<ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">610,476</ix:nonFraction>, or $<ix:nonFraction contextRef="c148" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">4.00</ix:nonFraction> per common share, based on contemporaneous
common share sales. During the year ended December 31, 2020, the Company recognized stock-based compensation of $<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="silo:AmortizationOfPrepaidStockbasedExpense" scale="0" unitRef="usd">610,476</ix:nonFraction>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_43" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_42"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock Issued for Conversion of
Series A and B Preferred Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_44" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_43"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On August 3, 2020, at the request of the investor,
the Company converted <ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="silo:ConvertablePreferredStock" scale="0" unitRef="shares">4,000</ix:nonFraction> Series A Preferred Stock into <ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares">40,000</ix:nonFraction> shares of common stock. After such conversion, the Company reclassed
the $<ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd">400,000</ix:nonFraction> redemption value of the Series A Preferred Stock to additional paid in capital.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_45" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_44"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><ix:nonNumeric contextRef="c153" name="us-gaap:PreferredStockConversionBasis">On April 15, 2020, the Company entered into
Exchange Agreements with the holders of its Series B Preferred Stock whereby the holders agreed to exchange their 115 shares of Series
B Preferred Stock with a stated value of $115,000 and 11,500 warrants issued in connection with the Series B Preferred Stock for an aggregate
of 28,750 shares of the Company&#8217;s common stock at a price of $4.00 per share.</ix:nonNumeric> In connection with this share exchange, the Company
recorded a deemed dividend on this extinguishment of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="silo:DeemedDividend" scale="0" unitRef="usd">69,000</ix:nonFraction> during the year ended December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_46" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_45"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock Issued for Exchange of
Notes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:nonNumeric contextRef="c154" name="us-gaap:DebtInstrumentDescription"><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_47" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_46"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 15, 2020, the Company entered into
Exchange Agreements with the holders of certain convertible promissory notes. Pursuant to these Exchange Agreements, the holders agreed
to exchange their convertible promissory notes of $330,000 and 33,000 warrants issued in connection with this debt for an aggregate of
82,500 shares of the Company&#8217;s common stock at a price of $4.00 per share. Consequently, the Company recorded a loss on debt extinguishment
of $<ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" unitRef="usd">198,000</ix:nonFraction> during the year ended December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_48" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_47"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Options</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_49" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_48"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 18, 2021, the Company&#8217;s board
of directors (&#8220;Board&#8221;) approved the Silo Pharma, Inc. 2020 Omnibus Equity Incentive Plan (the &#8220;Plan&#8221;) to incentivize
employees, officers, directors and consultants of the Company and its affiliates. <ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">170,000</ix:nonFraction> shares of common stock are reserved and available
for issuance under the Plan, provided that certain exempt awards (as defined in the Plan), shall not count against such share limit.
The Plan provides for the grant, from time to time, at the discretion of the Board or a committee thereof, of cash, stock options, including
incentive stock options and nonqualified stock options, restricted stock, dividend equivalents, restricted stock units, stock appreciation
units and other stock or cash-based awards.&#160;The Plan shall terminate on the tenth anniversary of the date of adoption by the Board.
Subject to certain restrictions, the Board may amend or terminate the Plan at any time and for any reason. An amendment of the Plan shall
be subject to the approval of the Company&#8217;s stockholders only to the extent required by applicable laws, rules or regulations.
On March 10, 2021, the Plan was approved by the stockholders.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_50" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_49"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock option activities for the years ended
December 31, 2021 and 2020 are summarized as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_51" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_50"><ix:nonNumeric contextRef="c10" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number<br/> of Options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted<br/> Average<br/> Exercise<br/>
    Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted<br/> Average<br/> Remaining<br/>
    Contractual<br/> Term<br/> (Years)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Aggregate<br/> Intrinsic<br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%"><span style="-keep: true">Balance Outstanding, December 31, 2019</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c162" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares">6,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c162" decimals="3" format="ixt:num-dot-decimal" name="silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" scale="0" unitRef="usdPershares">0.005</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c163" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="-keep: true">4.5</span></ix:nonNumeric></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="0" unitRef="usd">104,970</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Granted/Issued/ Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-288"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-289"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-290"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-291"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Balance Outstanding, December 31, 2020</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c164" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares">6,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c164" decimals="3" format="ixt:num-dot-decimal" name="silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" scale="0" unitRef="usdPershares">0.005</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><ix:nonNumeric contextRef="c163" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"><span style="-keep: true">3.5</span></ix:nonNumeric></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="0" unitRef="usd">127,290</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Granted/Issued/ Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-292"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-293"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-294"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-295"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Balance Outstanding, December 31, 2021</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c166" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares">6,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c166" decimals="3" format="ixt:num-dot-decimal" name="silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" scale="0" unitRef="usdPershares">0.005</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c165" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"><span style="-keep: true">2.5</span></ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c166" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="0" unitRef="usd">42,870</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Exercisable, December 31, 2021</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c166" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">6,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c166" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.005</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c165" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"><span style="-keep: true">2.5</span></ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c166" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" unitRef="usd">42,870</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_52" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_51"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Warrants</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_53" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_52"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warrant activities for the years ended December
31, 2021 and 2020 are summarized as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_54" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_53"><ix:nonNumeric contextRef="c10" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of Warrants</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
    Average Exercise Price</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
    Average Remaining Contractual Term (Years)</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/>
    Intrinsic<br/>
    Value</b></span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Outstanding, December
    31, 2019</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c167" decimals="INF" format="ixt:num-dot-decimal" name="silo:NumberOfWarrant" scale="0" unitRef="shares">44,500</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c167" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">10.00</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c93" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.80</span></ix:nonNumeric></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue" scale="0" unitRef="usd">337,750</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c93" decimals="INF" format="ixt:num-dot-decimal" name="silo:ShareBasedComponsationNumberOfWarrantsForfeited" scale="0" sign="-" unitRef="shares">44,500</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c93" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">10.00</ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-296"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-297"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Outstanding, December 31, 2020</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-298"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-299"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-300"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-301"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c92" decimals="INF" format="ixt:num-dot-decimal" name="silo:ShareBasedComponsationNumberOfWarrantsGranted" scale="0" unitRef="shares">347,080</ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c92" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">15.50</ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c92" format="ixt-sec:duryear" name="silo:ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></ix:nonNumeric></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-302"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Outstanding, December 31, 2021</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c169" decimals="INF" format="ixt:num-dot-decimal" name="silo:NumberOfWarrant" scale="0" unitRef="shares">347,080</ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c169" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">15.50</ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c92" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></ix:nonNumeric></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-303"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, December 31, 2021</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c92" decimals="INF" format="ixt:num-dot-decimal" name="silo:ShareBasedComponsationNumberOfWarrantsExercisableinDollars" scale="0" unitRef="shares">347,080</ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c169" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">15.50</ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c92" format="ixt-sec:duryear" name="silo:ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></ix:nonNumeric></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-304"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_55" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_54"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 15, 2020, the Company entered into
Exchange Agreements with the holders of convertible promissory notes (see Note 5). Pursuant to these Exchange Agreements, the noteholders
agreed to exchange their convertible promissory notes of $<ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="silo:ConvertibleLongTermNotesPayables" scale="0" unitRef="usd">330,000</ix:nonFraction> and <ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="silo:WarrantIssued" scale="0" unitRef="shares">33,000</ix:nonFraction> warrants issued in connection with this debt for an aggregate
of <ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" scale="0" unitRef="shares">82,500</ix:nonFraction> shares of the Company&#8217;s common stock at a price of $<ix:nonFraction contextRef="c158" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">4.00</ix:nonFraction> per share. After the exchanges, there are no convertible notes
outstanding. <ix:nonNumeric contextRef="c159" name="us-gaap:DebtInstrumentDescription">The Company issued 82,500 shares of common stock which was more than the shares that would have been issued at the original
conversion price of $4.00 per share or 33,000 shares of common stock, an excess of 49,500 shares of common stock. The excess shares were
valued at a price of $4.00 per share.</ix:nonNumeric> Consequently, the Company recorded a loss on debt extinguishment of $<ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" unitRef="usd">198,000</ix:nonFraction> during the year ended
December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_56" id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_55"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 18, 2021, the Company granted warrants
to purchase up to <ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">5,000</ix:nonFraction> shares of the Company&#8217;s common stock in exchange for legal services rendered. The warrants have a term
of <ix:nonNumeric contextRef="c161" format="ixt-sec:durwordsen" name="silo:WarrantsTerm">five years</ix:nonNumeric> from the date of grant and are exercisable at an exercise price of $<ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">10.00</ix:nonFraction> per share. <ix:nonNumeric contextRef="c92" name="silo:CommonStockServiceDescription">The warrants were valued on the grant
date at approximately $16.50 per warrant for a total of $83,728 using a Black-Scholes option pricing model with the following assumptions:
stock price of $17.50 per share (based on the quoted trading price on the date of grant), volatility of 169%, expected term of five year,
and a risk-free interest rate of 0.46%.</ix:nonNumeric> During the year ended December 31, 2021, the Company recorded stock-based compensation of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="0" unitRef="usd">83,728</ix:nonFraction>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:nonNumeric contextRef="c131" name="silo:PurchaseAgreementsDescription"><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c10_cont_56"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On February 9, 2021, the Company entered into
pursuant to securities purchase agreements with certain investors pursuant to which it sold warrants to purchase up to 285,067 shares
of the Company&#8217;s common stock and 4,276 shares of the Company&#8217;s Series C Convertible Preferred Stock. The February Warrants
are exercisable for a period of five years from the date of issuance at an exercise price of $15.00 per share, subject to adjustment.
If, after a period of 180 days after the date of issuance of the February Warrants, a registration statement covering the resale of the
February Warrant Shares is not effective, the holders may exercise the February Warrants by means of a cashless exercise. In addition,
pursuant to the terms of the offering, the Company issued the Placement Agent Warrants to purchase up to an aggregate of 57,013 shares
of common stock to its placement agents, or 10% of the shares of common stock issuable upon conversion of the Series C Preferred Stock
and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing
date of the offering at an exercise price of $17.50 per share, subject to adjustment (see Series C Convertible Preferred Stock Financing
above). Such warrants issued to various investors and to the placement agents were recorded as additional paid in capital with an offsetting
debit applied against additional paid in capital, thus these warrants have no further accounting effect within the equity section.</span></p></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020 </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c10" continuedAt="_IncomeTaxDisclosureTextBlock-c10_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 - <span style="text-decoration:underline">INCOME TAXES</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c10_cont_2" id="_IncomeTaxDisclosureTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains deferred tax assets
and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for
financial reporting purposes and the amounts used for income tax purposes. The deferred tax assets on December 31, 2021 and 2020 consist
of net operating loss carry-forwards. The net deferred tax asset has been fully offset by a valuation allowance because of the uncertainty
of the attainment of future taxable income. As of December 31, 2021 and 2020, the Company had not recorded a liability for any unrecognized
tax positions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c10_cont_3" id="_IncomeTaxDisclosureTextBlock-c10_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The items accounting for the difference between
income taxes at the effective statutory rate and the provision for income taxes for the years ended December 31, 2021 and 2020 was as
follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c10_cont_4" id="_IncomeTaxDisclosureTextBlock-c10_cont_3"><ix:nonNumeric contextRef="c10" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Income tax (benefit) liability at U.S. statutory rate of <ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" unitRef="pure">21</ix:nonFraction></ix:nonFraction>%&#8239;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" unitRef="usd">819,786</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" sign="-" unitRef="usd">637,879</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Income tax (benefit) liability &#8211; state</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" unitRef="usd">253,743</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" sign="-" unitRef="usd">197,439</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:AvailableForSalesEquitySecuritiesGrossUnrealizedGain" scale="0" sign="-" unitRef="usd">20,893</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="silo:AvailableForSalesEquitySecuritiesGrossUnrealizedGain" scale="0" unitRef="usd">457,798</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" sign="-" unitRef="usd">1,027,760</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">377,520</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total provision for income tax</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">24,876</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-305">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c10_cont_5" id="_IncomeTaxDisclosureTextBlock-c10_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s approximate net deferred
tax asset as of December 31, 2021 and 2020 was as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c10_cont_6" id="_IncomeTaxDisclosureTextBlock-c10_cont_5"><ix:nonNumeric contextRef="c10" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Net operating loss carryforward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd">1,647,335</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd">868,338</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Net capital loss carryforward</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="silo:DeferredTaxAssetsCapitalLossCarryforward" scale="0" sign="-" unitRef="usd">1,707,701</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="silo:DeferredTaxAssetsCapitalLossCarryforward" scale="0" unitRef="usd">123,932</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total deferred tax asset (liability) before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="silo:DeferredTaxAssetGross" scale="0" sign="-" unitRef="usd">60,366</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="silo:DeferredTaxAssetGross" scale="0" unitRef="usd">992,271</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="silo:DeferredTaxAssetsValuationAllowances" scale="0" unitRef="usd">35,490</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="silo:DeferredTaxAssetsValuationAllowances" scale="0" sign="-" unitRef="usd">992,271</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Provision for income tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">24,876</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-306">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Net deferred tax asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-307">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-308">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c10_cont_7" id="_IncomeTaxDisclosureTextBlock-c10_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">At December 31, 2021,
the Company had a capital gain of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:VentureCapitalGainsLossesNet" scale="0" unitRef="usd">6,660,483</ix:nonFraction> which offset the prior year net capital loss carryforward $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="silo:NetCapitalLossCarryForward" scale="0" unitRef="usd">450,663</ix:nonFraction> for a capital gain of
$<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:GainLossOnSaleOfCapitalLeaseNet" scale="0" unitRef="usd">6,209,820</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c10_cont_8" id="_IncomeTaxDisclosureTextBlock-c10_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Due to the loss of
its Regulated Investment Company (&#8220;RIC&#8221;) tax status in 2017, any net tax operating losses generated as a RIC cannot be used
to offset any future taxable income. As of December 31, 2021, the Company had an aggregate estimated net operating loss carryforwards
of approximately $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:AggregateEstimatedNetOperatingLoss" scale="0" unitRef="usd">5,990,308</ix:nonFraction> for income taxes. These net operating loss carries forwards may be available to reduce future years&#8217;
taxable income. <ix:nonNumeric contextRef="c10" name="silo:DescriptionOfIncomeTaxDescription">The net loss carryforward up until 2017 in the amount of $470,204, will expire in 2037. Net loss carryforwards in the
amount of $5,520,104 from 2018 onwards can be carried over indefinitely, subject to annual usage limits.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c10_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Management believes
that it appears more likely than not that the Company will not realize these tax benefits due to the Company&#8217;s continuing losses
for income taxes purposes. <ix:nonNumeric contextRef="c10" name="us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange">Accordingly, the Company has provided a 100% valuation allowance on the deferred tax asset benefit related
to the U.S. net operating loss and capital loss carry forwards to reduce the asset to zero.</ix:nonNumeric> Management will review this valuation allowance
periodically and will make adjustments as necessary.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO
                                            PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020 </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c10" continuedAt="_ConcentrationRiskDisclosureTextBlock-c10_cont_1" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9 &#8211; <span style="text-decoration:underline">CONCENTRATIONS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c10_cont_2" id="_ConcentrationRiskDisclosureTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Customer Concentration</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c10_cont_3" id="_ConcentrationRiskDisclosureTextBlock-c10_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 30, 2021 and
2020, no customer accounted for over <ix:nonFraction contextRef="c170" decimals="2" format="ixt:num-dot-decimal" name="silo:ConcentrationsRiskPercentage1" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c171" decimals="2" format="ixt:num-dot-decimal" name="silo:ConcentrationsRiskPercentage1" scale="-2" unitRef="pure">10</ix:nonFraction></ix:nonFraction>% of total revenues from apparel sales included in discontinued operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c10_cont_4" id="_ConcentrationRiskDisclosureTextBlock-c10_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Vendor Concentrations</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c10_cont_5" id="_ConcentrationRiskDisclosureTextBlock-c10_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2021, one
licensor accounted for <ix:nonFraction contextRef="c172" decimals="2" format="ixt:num-dot-decimal" name="silo:ConcentrationsRiskPercentage1" scale="-2" unitRef="pure">100</ix:nonFraction>% of the Company&#8217;s vendor license agreements (see Note 10) related to the Company&#8217;s biopharmaceutical
operation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_ConcentrationRiskDisclosureTextBlock-c10_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2020, the
Company did not have any licensor.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c10" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10 &#8211; <span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment Agreement</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 17, 2020, the Company entered into
an employment agreement (&#8220;Employment Agreement&#8221;) with Eric Weisblum to serve as Chief Executive Officer and Chief Financial
Officer of the Company. The term of the Employment Agreement will continue for a period of one year from the date of execution date thereof
and automatically renews for successive one-year periods at the end of each term until either party delivers written notice of their
intent not to review at least six months prior to the expiration of the then effective term. <ix:nonNumeric contextRef="c173" name="silo:EmploymentAgreementDescription">The Employment Agreement provided for a
base salary of $120,000 and 152,619 of vested shares of the Company&#8217;s common stock in April 2020. In addition, Mr. Weisblum shall
be eligible to earn a bonus, subject to the sole discretion of the Company&#8217;s Board of Directors (&#8220;Board&#8221;).</ix:nonNumeric> The Employment
Agreement may be terminated by either the Company or Mr. Weisblum at any time and for any reason upon 60 days prior written notice. Upon
termination of the Employment Agreement, Mr. Weisblum shall be entitled to (i) any equity award that has vested prior to the termination
date, (ii) reimbursement of expenses incurred on or prior to such termination date and (iii) such employee benefits to which he may be
entitled as of the termination date (collectively, the &#8220;Accrued Amounts&#8221;). Mr. Weisblum employment may also be terminated
by the Company at any time, with cause, death or disability (as defined in the Employment Agreement). Upon the termination of the Employment
Agreement for death or disability, Mr. Weisblum shall be entitled to receive the Accrued Amounts. The Employment Agreement also contains
covenants prohibiting Mr. Weisblum from disclosing confidential information with respect to the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 18, 2021, the Company and Mr. Weisblum
entered into the first amendment (the &#8220;Amendment&#8221;) to the Employment Agreement, effective as of January 1, 2021. Pursuant
to the Amendment Mr. Weisblum&#8217;s base salary was increased from $<ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SupplementalUnemploymentBenefitsSalaryContinuation" scale="0" unitRef="usd">120,000</ix:nonFraction> per year to $<ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SupplementalUnemploymentBenefitsSalaryContinuation" scale="0" unitRef="usd">180,000</ix:nonFraction> per year and all the terms and provisions
of the Employment Agreement shall remain in full force and effect.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020 </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License Agreements between the Company
and Vendors </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_6" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>University of Maryland, Baltimore -
License Agreement for Development and Use of Central Nervous System-Homing Peptides</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_7" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Commercial Evaluation License and Option
Agreement with the University of Maryland, Baltimore</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_8" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of July 15, 2020, the Company,
through its wholly-owned subsidiary, Silo Pharma, Inc. (see Note 1) and University of Maryland, Baltimore (&#8220;UMB&#8221;), entered
into a commercial evaluation license and option agreement (&#8220;License Agreement&#8221;), granting the Company an exclusive, non-sublicensable,
non-transferable license to with respect to the exploration of the potential use of central nervous system-homing peptides in vivo and
their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology. The License Agreement also
granted the Company an exclusive option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license (&#8220;Exclusive
Option&#8221;) to with respect to the subject technology. The License Agreement had a term of six months from the effective date however
if the Company exercises the Exclusive Option, the License Agreement shall expire at the end of the negotiation period (as defined in
the License Agreement) or upon execution of a master license agreement, whichever occurs first. The Company exercised its Exclusive Option
on January 13, 2021 and entered into a Master License Agreement on February 12, 2021. Both parties may terminate this agreement within
thirty days by giving a written notice. In July 2020, the Company paid a license fee of $<ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="silo:LicenseFee" scale="0" unitRef="usd">10,000</ix:nonFraction> to UMB pursuant to the License Agreement
which was recorded in professional fees during the year ended December 31, 2020 since the Company could not conclude that such costs
would be recoverable for this early-stage venture.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_9" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Master License Agreement with the University
of Maryland, Baltimore</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_10" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As disclosed above, effective as of February
12, 2021, the Company and University of Maryland, Baltimore (&#8220;UMB&#8221;), entered into the Master License Agreement (&#8220;Master
License Agreement&#8221;) which grants the Company an exclusive, worldwide, sublicensable, royalty-bearing license to certain intellectual
property: (i) to make, have made, use, sell, offer to sell, and import certain licensed products and: (ii) to use the invention titled,
&#8220;Central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other
neuroinflammatory pathology&#8221; and UMB&#8217;s confidential information to develop and perform certain licensed processes for the
therapeutic treatment of neuroinflammatory disease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_11" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Master License Agreement will remain in
effect on a Licensed Product-by-Licensed Product basis and country-by-country basis until the later of: (a) the last patent covered under
the Master License Agreement expires, (b) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory
exclusivity, or other legally enforceable market exclusivity, if applicable, or (c) <ix:nonNumeric contextRef="c10" format="ixt-sec:duryear" name="silo:CommercialSaleTerm">10</ix:nonNumeric> years after the first commercial sale of a Licensed
Product in that country, unless earlier terminated in accordance with the provisions of the Master License Agreement. The term of the
Master License Agreement shall expire <ix:nonNumeric contextRef="c10" format="ixt-sec:duryear" name="silo:LicenseAgreementExpire">15</ix:nonNumeric> years after the Master License Agreement Effective Date in which (a) there were never any patent
rights, (b) there was never any data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally
enforceable market exclusivity or (c) there was never a first commercial sale of a Licensed Product.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_12" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may assign, sublicense, grant,
or otherwise convey any rights or obligations under the Master License Agreement to a Company affiliate, without obtaining prior written
consent from UMB provided that it meets the terms defined in the Master License Agreement. The Company may grant sublicenses of some
or all of the rights granted by the Master License Agreement, provided that there is no uncured default or breach of any material term
or condition under the Master License Agreement, by Company, at the time of the grant, and that the grant complies with the terms and
conditions of the Master License Agreement. The Company shall be and shall remain responsible for the performance by each of the Company&#8217;s
sublicensee. Any sublicense shall be consistent with and subject to the terms and conditions of the Master License Agreement and shall
incorporate terms and conditions sufficient to enable Company to comply with the Master License Agreement. <ix:nonNumeric contextRef="c10" name="silo:SublicenseIncomeDescription">The Company or Company affiliates
shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company&#8217;s sublicense income
which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first
licensed product; and (b) 15% of the Company&#8217;s sublicense income which is receivable with respect to any sublicense that is executed
after the filing of an NDA (or foreign equivalent) for the first licensed product.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020 </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_13" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Master License Agreement,
<ix:nonNumeric contextRef="c10" name="silo:LicenseAgreementDescription">the Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty
payments depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company shall
pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the effective date; and (b)
$50,000 on or before the first anniversary of the effective date. The license fee is non-refundable and is not creditable against any
other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing,
prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid $25,000 license fee on
February 17, 2021 which was recorded as prepaid expense and is being amortized over the 15-year term. The Company recognized amortization
expense of $4,375 during the year ended December 31, 2021. At December 31, 2021, prepaid expense and other current assets &#8211; current
amounted $5,000 and prepaid expense &#8211; non-current amounts $15,625 as reflected in the accompanying consolidated balance sheets.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_14" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Milestone Payment Terms:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_15" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_14"><ix:nonNumeric contextRef="c10" escape="true" name="silo:ScheduleOfMilestonePayments"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Milestone</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><ix:nonNumeric contextRef="c190" name="silo:Milestone">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="silo:MilestonePayment" scale="0" unitRef="usd">50,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><ix:nonNumeric contextRef="c191" name="silo:Milestone">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="silo:MilestonePayment" scale="0" unitRef="usd">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><ix:nonNumeric contextRef="c192" name="silo:Milestone">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="silo:MilestonePayment" scale="0" unitRef="usd">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><ix:nonNumeric contextRef="c193" name="silo:Milestone">Receipt of New Drug Application (&#8220;NDA&#8221;) (or foreign equivalent) approval for a Licensed Product</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="silo:MilestonePayment" scale="0" unitRef="usd">500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><ix:nonNumeric contextRef="c194" name="silo:Milestone">Achievement of First Commercial Sale of Licensed Product</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="silo:MilestonePayment" scale="0" unitRef="usd">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_16" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Royalty Payments Terms:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_17" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_16"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><ix:nonNumeric contextRef="c10" continuedAt="_RoyaltyPaymentsDescription-c10_cont_1" name="silo:RoyaltyPaymentsDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></ix:nonNumeric></td> <td style="text-align: justify"><ix:continuation id="_RoyaltyPaymentsDescription-c10_cont_1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3% on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and</span></ix:continuation></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5% on sales of licensed products during the applicable calendar year for sales greater than $50,000,000; and</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_18" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_17"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(iii)</td><td style="text-align: justify">a minimum annual
                                            royalty payments, as follows:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_19" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_18"><ix:nonNumeric contextRef="c10" escape="true" name="silo:ScheduleOfUMBMinimumRoyaltyPayments"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Minimum Annual Royalty</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c190" name="silo:UMBYearDescription">Prior to First Commercial Sale</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-309; font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c191" name="silo:UMBYearDescription">Year of First Commercial Sale</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-310; font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify"><ix:nonNumeric contextRef="c192" name="silo:UMBYearDescription">First calendar year following the First Commercial Sale</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="silo:UMBPayment" scale="0" unitRef="usd">25,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c193" name="silo:UMBYearDescription">Second calendar year following the First Commercial Sale</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="silo:UMBPayment" scale="0" unitRef="usd">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c194" name="silo:UMBYearDescription">Third calendar year following the First Commercial Sale</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="silo:UMBPayment" scale="0" unitRef="usd">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_20" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2021, in connection with the Company&#8217;s
Sublicense Agreement with Aikido Pharma Inc. (see below - <i>Patent License Agreement with Aikido Pharma Inc.</i>), the Company paid
<ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="silo:SublicenseIncomePercentage" scale="-2" unitRef="pure">25</ix:nonFraction>% of its sublicense income to UMB, pursuant to the Master License Agreement, which amounted to $<ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="silo:SublicenseAgreementAmountPaid" scale="0" unitRef="usd">12,500</ix:nonFraction>. The Company recognized amortization
expense of $<ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="silo:OtherDepreciationsAndAmortization" scale="0" unitRef="usd">628</ix:nonFraction> during the year ended December 31, 2021. At December 31, 2021, prepaid expense and other current assets &#8211; current
amounted $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:PaymentOfSponsoredResearchAmount" scale="0" unitRef="usd">838</ix:nonFraction> and prepaid expenses &#8211; non-current amounts $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="silo:PrepaidExpenses" scale="0" unitRef="usd">11,034</ix:nonFraction> as reflected in the accompanying consolidated balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO
                                            PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020 </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_21" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>University of Maryland, Baltimore -
License Agreement for Development and Use of Joint-Homing Peptides</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_22" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Commercial Evaluation License and Option
Agreement with the University of Maryland, Baltimore</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_23" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of February 26, 2021, the Company,
through its wholly-subsidiary, Silo Pharma, Inc., and University of Maryland, Baltimore (&#8220;UMB&#8221;), entered into a commercial
evaluation license and option agreement (&#8220;License Agreement&#8221;), which granted the Company an exclusive, non-sublicensable,
non-transferable license to with respect to the exploration of the potential use of joint-homing peptides for use in the investigation
and treatment of arthritogenic processes. The License Agreement also granted the Company an exclusive option to negotiate and obtain
an exclusive, sublicensable, royalty-bearing license (&#8220;Exclusive Option&#8221;) to with respect to the subject technology. The
License Agreement had a term of six months from the effective date. Both parties could have terminated the License Agreement within thirty
days by giving a written notice.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_24" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, the Company entered into
a First Amendment Agreement (&#8220;Amended License Agreement&#8221;) with UMB to extend the term of the original License Agreement by
an additional six months such that the Amended License Agreement was effective until February 25, 2022 however, if the Company exercises
the Exclusive Option, the License Agreement shall expire at the end of the negotiation period (as defined in the License Agreement) or
upon execution of a master license agreement, whichever occurs first. The Company paid a license fee of $<ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="silo:LicenseFee" scale="0" unitRef="usd">10,000</ix:nonFraction> to UMB in March 2021
pursuant to the License Agreement which was recorded in professional fees during the year ended December 31, 2021, since the Company
could not conclude that such costs would be recoverable for this early-stage venture. Subsequent to December 31, 2021, the Company and
UMB entered into a Second Amendment Agreement (see Note 11).</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_25" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License Agreements between the Company
and Customer</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_26" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Customer Patent License Agreement with
Aikido Pharma Inc.</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_27" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, the Company and its subsidiary
Silo Pharma, Inc., a Florida corporation, entered into a patent license agreement (&#8220;License Agreement&#8221;) (collectively, the
&#8220;Licensor&#8221;) and Aikido Pharma Inc. (&#8220;Aikido&#8221; or the &#8220;Customer&#8221;), as amended on April 12, 2021, pursuant
to which the Licensor granted Aikido an exclusive, worldwide (&#8220;Territory&#8221;), sublicensable, royalty-bearing license to certain
intellectual property: (i) to make, have made, use, provide, import, export, lease, distribute, sell, offer for sale, develop and advertise
certain licensed products and (ii) to develop and perform certain licensed processes for the treatment of cancer and symptoms caused
by cancer (&#8220;Field of Use&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_28" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_27"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The License Agreement also provided that,
if the Licensor exercised the option granted to it pursuant to its commercial evaluation license and option agreement with UMB, effective
as of July 15, 2020, it would grant Aikido a non-exclusive sublicense (&#8220;Right&#8221;) to certain UMB patent rights in the field
of neuroinflammatory diseases occurring in patients diagnosed with cancer (&#8220;Field&#8221;). Pursuant to the License Agreement, Aikido
agreed to pay the Licensor, among other things, (i) a one-time non-refundable cash payment of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:NonrefundableCashPayment" scale="0" unitRef="usd">500,000</ix:nonFraction> and (ii) royalty payments equal
to <ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="silo:NetSalePercentage" scale="-2" unitRef="pure">2</ix:nonFraction>% of net sales (as defined in the License Agreement) in the Field of Use in the Territory. In addition, Aikido agreed to issue the
Licensor <ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:LicensorShare" scale="0" unitRef="shares">500</ix:nonFraction> shares of Aikido&#8217;s newly designated Series M Convertible Preferred Stock which were to be converted into an aggregate
of <ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:AggregateOfConvertedShares" scale="0" unitRef="shares">625,000</ix:nonFraction> shares of the Aikido&#8217;s common stock. On April 12, 2021, the Company entered into an amendment to the License Agreement
(&#8220;Amended License Agreement&#8221;) with Aikido dated January 5, 2021 whereby Aikido issued an aggregate of <ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" name="silo:AggregateOfConvertedShares" scale="0" unitRef="shares">625,000</ix:nonFraction> restricted
shares of Aikido&#8217;s common stock instead of the <ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" name="silo:LicensorShare" scale="0" unitRef="shares">500</ix:nonFraction> shares of the Series M Convertible Preferred Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_29" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_28"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the License Agreement, the Company
is required to prepare file, prosecute, and maintain the licensed patents. Unless earlier terminated, the term of the license to the
licensed patents will continue until the expiration or abandonment of all issued patents and filed patent applications within the licensed
patents. The Company may terminate the License Agreement upon 30 day written notice if Aikido fails to pay any amounts due and payable
to the Company or if Aikido or any of its affiliates brings a patent challenge against the Company, assists others in bringing a legal
or administrative challenge to the validity, scope, or enforceability of or opposes any of the licensed patents (&#8220;Patent Challenge&#8221;)
against the Company (except as required under a court order or subpoena). Aikido may terminate the Agreement at any time without cause,
and without incurring any additional penalty, (i) by providing at least 30 days&#8217; prior written notice and paying the Company all
amounts due to it through such termination effective date. Either party may terminate the Agreement for material breaches that have failed
to be cured within 60 days after receiving written notice. The Company collected the non-refundable cash payment of $<ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="silo:NonrefundableCashPayment" scale="0" unitRef="usd">500,000</ix:nonFraction> on January
5, 2021 which was recorded as deferred revenue to be recognized as revenues over the <ix:nonNumeric contextRef="c181" format="ixt-sec:duryear" name="silo:RevenueTerm">15</ix:nonNumeric> year term of the License Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_30" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_29"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to a vote of Aikido&#8217;s stockholders
to approve a reverse split of its common stock no later than December 31, 2021 only (&#8220;Reverse Stock Split Vote&#8221;), each share
of the Series M Convertible Preferred Stock shall be entitled to such number of votes equal to <ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:NumberOfVotingShares" scale="0" unitRef="shares">20,000</ix:nonFraction> shares of Aikido&#8217;s common
stock. <ix:nonNumeric contextRef="c10" continuedAt="_ReverseStockSplitVoteDescription-c10_cont_1" name="silo:ReverseStockSplitVoteDescription">In addition, each share of the Series M Convertible Preferred Stock shall be convertible, at any time after the earlier of (i)
the date that the Reverse Stock Split Vote is approved by Aikido&#8217;s stockholders and (ii) December 31, 2021, at the option of the
holder, into such number of shares of Aikido&#8217;s common stock determined by dividing the Stated Value by the Conversion Price. &#8220;Stated
Value&#8221; means $1,000. &#8220;Conversion Price&#8221; means $0.80, subject to adjustment.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020 </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_31" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_30"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:continuation id="_ReverseStockSplitVoteDescription-c10_cont_1">Prior to the April 12, 2021 issuance of the
common stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible
Preferred stock which was equivalent into Aikido&#8217;s 625,000 shares of common stock at a fair value of $0.85 per common share or
$531,250 based quoted trading price of Aikido&#8217;s common stock on the date of grant. The Company recorded an equity investment of
$531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license.</ix:continuation> Accordingly, the Company
recorded a total deferred revenue of $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenue" scale="0" unitRef="usd">1,031,250</ix:nonFraction> ($<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="silo:CashReceived" scale="0" unitRef="usd">500,000</ix:nonFraction> cash received and $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="silo:SecuritiesReceived" scale="0" unitRef="usd">531,250</ix:nonFraction> value of equity securities received) to be recognized
as revenues over the <ix:nonNumeric contextRef="c10" format="ixt-sec:duryear" name="silo:RevenueTerm">15</ix:nonNumeric>-year term. The Company recognized revenue of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueRevenueRecognized1" scale="0" unitRef="usd">68,750</ix:nonFraction> during the year ended December 31, 2021. At December 31,
2021, deferred revenue &#8211; current portion amounted $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InsuranceServicesRevenue" scale="0" unitRef="usd">68,750</ix:nonFraction> and deferred revenue &#8211; long-term portion amounted $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="silo:DeferredRevenueLongtermPortion" scale="0" unitRef="usd">893,750</ix:nonFraction> as reflected
in the accompanying consolidated balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_32" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_31"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Right shall be to the full extent permitted
by and on terms and conditions required by UMB for a term consistent with the term of patent and technology licenses that UMB normally
grants. In the event that the Company exercises its option and executes a license with UMB to the UMB patent rights within 40 days after
the execution of such UMB license, for consideration to be agreed upon and paid by Aikido, which consideration shall in no event exceed
<ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="silo:ConsiderationFeePayablePercentage" scale="-2" unitRef="pure">110</ix:nonFraction>% of any fee payable by the Company to UMB for the right to sublicense the UMB patent rights. The Company shall grant Aikido a nonexclusive
sublicense in the United States to the UMB patent rights in the Field, subject to the terms of any UMB license Licensor obtains, including
any royalty obligations on sublicensees required under any such sublicense. The option was exercised on January 13, 2021. Accordingly,
on April 6, 2021, the Company entered into the Sublicense Agreement with Aikido pursuant to which it granted Aikido a worldwide exclusive
sublicense to its licensed patents under the Master License Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_33" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_32"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Customer Sublicense&#160;Agreement with
Aikido Pharma Inc.</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_34" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_33"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2021 (the &#8220;Sublicense Agreement
Effective Date&#8221;), the Company entered into the Sublicense Agreement with Aikido pursuant to which the Company granted Aikido an
exclusive worldwide sublicense to (i) make, have made, use, sell, offer to sell and import the Licensed Products (as defined below) and
(ii) in connection therewith to (A) use an invention known as &#8220;Central nervous system-homing peptides in vivo and their use for
the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology&#8221; which was sublicensed to the Company
pursuant to the Master License Agreement&#160;and (B) practice certain patent rights (&#8220;Patent Rights&#8221;) for the therapeutic
treatment of neuroinflammatory disease in cancer patients. &#8220;Licensed Products&#8221; means any product, service, or process, the
development, making, use, offer for sale, sale, importation, or providing of which: (i) is covered by one or more claims of the Patent
Rights; or (ii) contains, comprises, utilizes, incorporates, or is derived from the Invention or any technology disclosed in the Patent
Rights.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_35" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_34"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Sublicense Agreement, Aikido
agreed to pay the Company (i) an upfront license fee of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:UpfrontLicenseFees" scale="0" unitRef="usd">50,000</ix:nonFraction>, (ii)&#160;the same sales-based royalty payments that the Company is
subject to under the Master License Agreement and (iii) total milestone payments of up to $<ix:nonFraction contextRef="c182" decimals="-5" format="ixt:num-dot-decimal" name="silo:UpfrontLicenseFees" scale="6" unitRef="usd">1.9</ix:nonFraction> million. The Sublicense Agreement shall
continue on a Licensed Product-by-Licensed Product and country-by-country basis until the later of (i) the date of expiration of the
last to expire claim of the Patent Rights covering such Licensed Product in such country, (ii) the expiration of data protection, new
chemical entity, orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity, if applicable and (iii)
<ix:nonNumeric contextRef="c10" format="ixt-sec:duryear" name="silo:FirstCommercialSale">10</ix:nonNumeric> years after the first commercial sale of a Licensed Product in that country, unless terminated earlier pursuant to the terms of the
Sublicense Agreement. Furthermore, the Sublicense Agreement shall expire <ix:nonNumeric contextRef="c10" format="ixt-sec:duryear" name="silo:AgreementShallExpire">15</ix:nonNumeric> years after the Sublicense Agreement Effective Date with
respect to any country in which (i) there were never any Patent Rights, (ii) there was never any data protection, new chemical entity,
orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity with respect to a Licensed Product and
(ii) there was never a commercial sale of a Licensed Product, unless such agreement is earlier terminated pursuant to its terms. The
Company collected the upfront license fee of $<ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="silo:UpfrontLicenseFees" scale="0" unitRef="usd">50,000</ix:nonFraction> in April 2021. The Company recognized revenue of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:RecognizedRevenues" scale="0" unitRef="usd">2,514</ix:nonFraction> during the year ended December
31, 2021. At December 31, 2021, deferred revenue &#8211; current portion amounted $<ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="0" unitRef="usd">3,352</ix:nonFraction> and deferred revenue &#8211; long-term portion
amounted $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLongTermDebt" scale="0" unitRef="usd">44,134</ix:nonFraction> as reflected in the accompanying consolidated balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_36" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_35"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sponsored Study and Research Agreements
between the Company and Vendors</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_37" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_36"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investigator-Sponsored Study Agreement
with Maastricht University of the Netherlands</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_38" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_37"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 1, 2020, the Company entered into
an investigator-sponsored study agreement (&#8220;Study Agreement&#8221;) with Maastricht University of the Netherlands. The research
project is a clinical study to examine the effects of repeated low doses of psilocybin and lysergic acid diethylamide on cognitive and
emotional dysfunctions in Parkinson&#8217;s disease and to understand its mechanism of action. The Study Agreement shall terminate on
October 31, 2024, unless earlier terminated pursuant to the terms thereof. The Company shall pay a total fee of <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ManagementFeePayable" scale="0" unitRef="eur">433,885</ix:nonFraction> Euros ($<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ManagementFeePayable" scale="0" unitRef="usd">507,602</ix:nonFraction>
USD) exclusive of value added tax to be amortized over the four-year term and payment schedule as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_39" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_38"><ix:nonNumeric contextRef="c10" escape="true" name="silo:ScheduleOfExclusiveOfValueAddedTaxToBeAmortized"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="width: 24%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="silo:Payment" scale="0" unitRef="eur">86,777</ix:nonFraction> Euros ($<ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="silo:Payment" scale="0" unitRef="usd">101,520</ix:nonFraction> USD)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 69%"><ix:nonNumeric contextRef="c195" name="silo:PaymentDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon signing the Study Agreement and was paid in December 2020</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="silo:Payment" scale="0" unitRef="eur">86,777</ix:nonFraction> Euros ($<ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="silo:Payment" scale="0" unitRef="usd">101,520</ix:nonFraction> USD)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><ix:nonNumeric contextRef="c196" name="silo:PaymentDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtained approval from ethical committee</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="silo:Payment" scale="0" unitRef="eur">86,777</ix:nonFraction> Euros ($<ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="silo:Payment" scale="0" unitRef="usd">101,520</ix:nonFraction> USD)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><ix:nonNumeric contextRef="c197" name="silo:PaymentDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data collection has commenced</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="silo:Payment" scale="0" unitRef="eur">130,166</ix:nonFraction> Euros ($<ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="silo:Payment" scale="0" unitRef="usd">152,281</ix:nonFraction> USD)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><ix:nonNumeric contextRef="c198" name="silo:PaymentDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First half of the participants are tested</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="silo:Payment" scale="0" unitRef="eur">43,885</ix:nonFraction> Euros ($<ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="silo:Payment" scale="0" unitRef="usd">50,760</ix:nonFraction> USD)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><ix:nonNumeric contextRef="c199" name="silo:PaymentDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of data collection and delivery of final report</span></ix:nonNumeric></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.4pt">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020 </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c185" name="silo:PaymentDescription"><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_40" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_39"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2020, the Company paid the first
payment of $101,520 which was recorded to prepaid expense and other current assets &#8211; current of which approximately $22,318 was
amortized in fiscal 2020. In September 2021, the Company notified Maastricht University of Netherlands for an early termination of this
agreement. Maastricht University of Netherlands has not reached the second phase which is to obtain approval from ethical committee.
The Company has no further obligation after the termination. During the year ended December 31, 2021, the Company amortized the remaining
prepaid expense of $79,202.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_41" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_40"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investigator-Sponsored Study Agreement
with University of Maryland, Baltimore </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_42" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_41"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, the Company entered into
an investigator-sponsored study agreement (&#8220;Sponsored Study Agreement&#8221;) with the University of Maryland, Baltimore. The research
project is a clinical study to examine a novel peptide-guided drug delivery approach for the treatment of multiple sclerosis (&#8220;MS&#8221;).
More specifically, the study is designed to evaluate (1) whether MS-1-displaying liposomes can effectively deliver dexamethasone to the
CNS and (2) whether MS-1-displaying liposomes are superior to plain liposomes, also known as free drug, in inhibiting the relapses and
progression of experimental autoimmune encephalomyelitis. Pursuant to the Sponsored Study Agreement, the research shall commence on March
1, 2021 and will continue until substantial completion, subject to renewal upon mutual written consent of the parties. <ix:nonNumeric contextRef="c181" name="silo:SponsoredStudyAgreementDescription">The total cost
under the Sponsored Study Agreement shall not exceed $81,474 which is payable in two equal installments of $40,737 upon execution of
the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. The Company
paid $40,737 on January 13, 2021 which was recorded in prepaid expense to be amortized over the nine-month period. Currently, the project
has not been completed due to the delays cause by the Covid-19 pandemic. During the year ended December 31, 2021, the Company fully amortized
the prepaid expense of $40,737.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_43" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_42"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sponsored Research Agreement with The
Regents of the University of California</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_44" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_43"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021 (the &#8220;Effective Date&#8221;),
the Company entered into a sponsored research agreement (the &#8220;Sponsored Research Agreement&#8221;) with The Regents of the University
of California, on behalf of its San Francisco Campus (&#8220;UCSF&#8221;) pursuant to which UCSF shall conduct a study to examine psilocybin&#8217;s
effect on inflammatory activity in humans to accelerate its implementation as a potential treatment for Parkinson&#8217;s Disease, chronic
pain, and bipolar disorder. Pursuant to the Agreement, the Company shall pay UCSF a total fee of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:SublicenseAmountPaid" scale="0" unitRef="usd">342,850</ix:nonFraction> to conduct the research over
the two-year period. The Agreement shall be effective for a period of two years from the Effective Date, subject to renewal or earlier
termination as set forth in the Sponsored Research Agreement. <ix:nonNumeric contextRef="c10" name="silo:SponsoredResearchAgreementDescription">The Company paid the first payment of $40,000 pursuant to the payment schedule
on the Sponsored Research Agreement on June 15, 2021, second payment of $40,000 on September 9, 2021 and $20,570 on November 18, 2021
which were recorded to prepaid expense and other current assets &#8211; current to be amortized over the two-year period. During the
year ended December 31, 2021, the Company amortized $92,855 of the prepaid expense leaving a prepaid asset of $<ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">7,715</ix:nonFraction> at December 31,
2021.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_45" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_44"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sponsored Research Agreement with University
of Maryland, Baltimore</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_46" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_45"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, the Company and University
of Maryland, Baltimore (&#8220;UMB&#8221;) entered into a sponsored research agreement (&#8220;July 2021 Sponsored Research Agreement&#8221;)
pursuant to which UMB shall&#160;evaluate the pharmacokinetics of dexamethasone delivered to arthritic rats via liposome.&#160;The research
pursuant to the July 2021 Sponsored Research Agreement shall commence on September 1, 2021 and will continue until the substantial completion
thereof, subject to renewal upon written consent of the parties. The July 2021 Sponsored Research Agreement may be terminated by either
party upon 30 days&#8217; prior written notice to the other party. In addition, if either party commits any material breach of or defaults
with respect to any terms or conditions of the July 2021 Sponsored Research Agreement and fails to remedy such default or breach within
10 business days after written notice from the other party, the party giving notice may terminate the July 2021 Sponsored Research Agreement
as of the date of receipt of such notice by the other party. If the Company terminates the July 2021 Sponsored Research Agreement for
any reason other than an uncured material breach by UMB, the Company shall relinquish any and all rights it may have in the Results (as
defined in the July 2021 Sponsored Research Agreement) to UMB. In addition, if the July 2021 Sponsored Research Agreement is terminated
early, the Company, among other things, will pay all costs incurred and accrued by UMB as of the date of termination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_47" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_46"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the July 2021 Sponsored
Research Agreement, UMB granted the Company an option (the &#8220;Option&#8221;) to negotiate and obtain an exclusive license to any
UMB Arising IP (as defined in the July 2021 Sponsored Research Agreement) and UMB&#8217;s rights in any Joint Arising IP (as defined
in the July 2021 Sponsored Research Agreement) (collectively, the &#8220;UMB IP&#8221;). The Company may exercise the Option by giving
UMB written notice within 60 days after it receives notice from UMB of the UMB IP. Pursuant to the July 2021 Sponsored Research Agreement,
the Company shall pay UMB the fees below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_48" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_47"><ix:nonNumeric contextRef="c10" escape="true" name="silo:ScheduleOfShallPayUMB"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="5" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="silo:SponsoredPayment" scale="0" unitRef="usd">92,095</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 84%"><ix:nonNumeric contextRef="c200" name="silo:PaymentDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon execution of the July 2021 Sponsored Research Agreement</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="silo:SponsoredPayment" scale="0" unitRef="usd">92,095</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><ix:nonNumeric contextRef="c201" name="silo:PaymentDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="silo:SponsoredPayment" scale="0" unitRef="usd">92,095</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><ix:nonNumeric contextRef="c202" name="silo:PaymentDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement</span></ix:nonNumeric></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_49" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_48"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid the first payment of $<ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="silo:CompanyPaidCash" scale="0" unitRef="usd">92,095</ix:nonFraction>
on September 1, 2021 which was recorded to prepaid expense and other current assets &#8211; current to be amortized over the estimated
project timeline of twelve months. During the year ended December 31, 2021, the Company fully amortized the prepaid expense of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:OtherDepreciationsAndAmortization" scale="0" unitRef="usd">92,095</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020 </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_50" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_49"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sponsored Research Agreement with Columbia
University</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_51" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_50"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2021, the Company entered into
a sponsored research agreement with Columbia University pursuant to which the Company has been granted an option to license certain assets
currently under development, including Alzheimer&#8217;s disease. The term of the option will commence on the effective date of this
agreement and will expire upon the earlier of (i) 90 days after the date of the Company&#8217;s receipt of a final research report for
each specific research proposal as defined in the agreement or (ii) termination of the research. <ix:nonNumeric contextRef="c188" name="silo:SponsoredResearchAgreementDescription">If the Company elects to exercise the
option, both parties will commence negotiation of a license agreement and will execute a license agreement no later than 3 months after
the dated of the exercise of the option. Columbia University and the Company will work towards developing a therapeutic treatment for
patients suffering from Alzheimer&#8217;s disease to post-traumatic stress disorder. During a one-year period from the date of this agreement,
the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the payment schedule
as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months after the start
of the project and, (iv)10% at completion of the project. The Company paid the first payment of $430,825 in November 2021 which was recorded
to prepaid expense and other current assets &#8211; current to be amortized over the estimated project timeline of twelve months. During
the year ended December 31, 2021, the Company amortized $359,021 of the prepaid expense. As of December 31, 2021, prepaid expense related
to the sponsored research agreement was $71,804.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_52" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_51"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Joint Venture Agreement with Zyl&#246; Therapeutics, Inc.</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_53" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_52"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 22, 2021 (&#8220;Effective Date&#8221;),
the Company entered into a Joint Venture Agreement (&#8220;JV Agreement&#8221;) with Zyl&#246; Therapeutics, Inc. (&#8220;ZTI&#8221;)
pursuant to which the parties agreed to form a joint venture entity, to be named Ketamine Joint Venture, LLC (&#8220;Joint Venture&#8221;),
to, among other things, focus on the clinical development of ketamine using ZTI&#8217;s Z-pod&#8482; technology (&#8220;Venture&#8221;).
Pursuant to the JV Agreement, the Company shall act as the manager (&#8220;Manager&#8221;) of the Joint Venture. The Joint Venture shall
terminate if the development program does not meet certain specifications and milestones as set forth in the JV Agreement within 30 days
of the date set forth in the JV Agreement. Notwithstanding the foregoing, the Manager may, in its sole discretion, terminate the Joint
Venture at any time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_54" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_53"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c189" name="silo:PursuantTerms">Pursuant to the terms of the JV Agreement,
(A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall
contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and
trade secrets with respect to its Z-pod&#8482; technology for the loading and release of ketamine, (3) ketamine to be used for clinical
purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the
interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be
owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event
shall either party own more than 60% of the interest in the Joint Venture.</ix:nonNumeric> As of December 31, 2021 and as of the current date of this
report, the joint venture entity has not been formed yet.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_55" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_54"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, pursuant to the terms of the
JV Agreement, ZTI shall grant the Joint Venture a sublicense pursuant to its license agreement (the &#8220;License Agreement&#8221;)
with Albert Einstein College of Medicine dated November 27, 2017, in the event that the Company or a third party makes a request indicating
that the patented technology (the &#8220;Patented Technology&#8221;) licensed to ZTI pursuant to the License Agreement is needed to advance
the development of the Joint Venture or it is contemplated or determined that the Patented Technology will be sold. Furthermore, pursuant
to the JV Agreement, ZTI granted the Company an exclusive option to enter into a separate joint venture for the clinical development
of psilocybin using ZTI&#8217;s Z-pod&#8482; technology on the same terms and conditions set forth in the JV Agreement, which option
shall expire 24 months after the JV Effective Date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2021 AND 2020 </b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_56" id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_55"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Amended Service Agreement</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c10_cont_56"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 10, 2021 (&#8220;Effective Date&#8221;),
the Company entered into an Amendment Agreement (&#8220;Amended Service Agreement&#8221;) to a certain service agreement dated on September
8, 2020 with the University of Texas (&#8220;University&#8221;) at Austin whereby the University will provide advisory service and assist
the Company on identifying license and sponsored research opportunities for the Company. The Company shall pay the University $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:PaymentOfUniversity" scale="0" unitRef="usd">5,000</ix:nonFraction>
per quarter starting on the Effective Date. Any cost incurred will be reimbursed only after prior written consent by the Company. The
term of the Amended Service Agreement is for 36 months unless earlier terminated by either party upon giving a written notice as defined
in the agreement. During the year ended December 31, 2021, the Company paid $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:CompanyPaidCash" scale="0" unitRef="usd">5,000</ix:nonFraction> related to this agreement.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c10" continuedAt="_SubsequentEventsTextBlock-c10_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11 &#8211; <span style="text-decoration:underline">SUBSEQUENT EVENTS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c10_cont_2" id="_SubsequentEventsTextBlock-c10_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 27, 2022, the Company and Dr. James
Kuo entered into an employment agreement (&#8220;Kuo Employment Agreement&#8221;) for Dr. Kuo to serve as the Vice President of Research
&amp; Development. The Kuo Employment Agreement shall be effective as of the date of the agreement and shall automatically renew for
a period of one year at every anniversary of the effective date, with the same terms and conditions, unless either party provides written
notice of its intention not to extend the term of the Kuo Employment Agreement at least thirty days&#8217; prior to the applicable renewal
date. Dr. Kuo shall be paid an annual base salary of $<ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="silo:AnnualBaseSalary" scale="0" unitRef="usd">30,000</ix:nonFraction>. <ix:nonNumeric contextRef="c203" name="us-gaap:SubsequentEventDescription">For each twelve-month period of his employment, Dr. Kuo shall be entitled
to a bonus whereby amount and terms shall be in the sole and absolute discretion of the Board of Directors (&#8220;Board&#8221;) and
shall be payable at the Company&#8217;s sole option in stock or in cash. In addition, an aggregate of 16,000 incentive stock options
was granted to Dr. Kou, at an exercise price equal to the closing price of the Company&#8217;s common stock on the date of grant (&#8220;ISOs&#8221;)
as follows: (i) 6,000 ISOs (&#8220;Initial Options&#8221;), issued under the Company&#8217;s 2020 Equity Incentive Plan (&#8220;2020
Plan&#8221;) which vest immediately, and (ii) an additional 10,000 ISOs (&#8220;Additional Options&#8221;), issued under the 2020 Plan
which shall vest ratably over two successive equal quarterly installments over the subsequent one year period as follows: 5,000 ISOs
shall vest at 9 months, and 12 months following the effective date of the Kuo Employment Agreement, which underlying Additional Options
shall be exercisable immediately upon the applicable vesting date.</ix:nonNumeric></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c10_cont_3" id="_SubsequentEventsTextBlock-c10_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2022, the Company and University
of Maryland, Baltimore (&#8220;UMB&#8221;) entered into a second amendment to the commercial evaluation and license agreement dated February
26, 2021 (&#8220;Second Amendment&#8221;) (see Note 10 - <i>University of Maryland, Baltimore - License Agreement for Development and
Use of Joint-Homing Peptides</i>). The Second Amendment to extend the term of the original license agreement until December 31, 2022.
However, if the Company exercises the Exclusive Option, the License Agreement shall expire at the end of the negotiation period (as defined
in the License Agreement) or upon execution of a master license agreement, whichever occurs first.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c10_cont_4" id="_SubsequentEventsTextBlock-c10_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On March 11, 2022, the Company held its special
meeting of stockholders (&#8220;Special Meeting&#8221;). A total of <ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="silo:TotalOfSharesOfCommonStock" scale="0" unitRef="shares">1,077,199</ix:nonFraction> shares of common stock constituting a quorum were represented
in person or by valid proxies at the Special Meeting. The final results for of the matter submitted to a vote of stockholders at the
Special Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on February 14, 2022,
is as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c10_cont_5" id="_SubsequentEventsTextBlock-c10_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Proposal 1. <ix:nonNumeric contextRef="c205" name="us-gaap:StockholdersEquityReverseStockSplit">At the Special Meeting, the stockholders
approved granting discretionary authority to the Company&#8217;s Board of Directors to amend the Company&#8217;s Certificate of Incorporation
to effect one or more consolidations of the Company&#8217;s issued and outstanding shares of common stock, pursuant to which the shares
of common stock would be combined and reclassified into one share of common stock at a ratio within the range from 1-for-5 up to 1-for-50
(the &#8220;Reverse Stock Split&#8221;), provided that, (X) that the Company shall not effect Reverse Stock Splits that, in the aggregate,
exceeds 1-for-50, and (Y) any Reverse Stock Split is completed no later than the first anniversary of the record date of the Special
Meeting, or February 8, 2023.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c10_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On September 14, 2022, the Company filed a
Certificate of Amendment to the Amended and Restated Articles of Incorporation (the &#8220;Certificate of Amendment&#8221;) with the
Secretary of State of the State of Nevada to effect a 1-for-50 reverse stock split (the &#8220;Reverse Stock Split&#8221;) with respect
to the outstanding shares of the Company&#8217;s common stock. The Certificate of Amendment became effective on September 14, 2022. The
Reverse Stock Split was previously approved by the sole director and the majority of stockholders of the Company. The Reverse Stock Split
was deemed effective at the open of business on September 15, 2022. All share and per share data in the accompanying consolidated financial
statements have been retroactively restated to reflect the effect of the reverse stock split.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="S_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SILO
PHARMA, INC. AND SUBSIDIARY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED BALANCE SHEETS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">June 30,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December 31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">(Unaudited)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="-keep: true">ASSETS</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">CURRENT ASSETS:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Cash and cash equivalents</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">8,734,434</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">9,837,001</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Equity investments</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="silo:EquityInvestmentsAtCost" scale="0" unitRef="usd">113,012</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="silo:EquityInvestmentsAtCost" scale="0" unitRef="usd">419,995</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Prepaid expenses and other current
    assets - current</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">99,939</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">145,324</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">Total Current Assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">8,947,385</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">10,402,320</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">Note receivable - non-current, including interest receivable of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivableNoncurrent" scale="0" unitRef="usd">3,590</ix:nonFraction></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd">63,590</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd">61,210</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">Prepaid expenses - non-current</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" unitRef="usd">33,740</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" unitRef="usd">26,659</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">Total Assets</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">9,044,715</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">10,490,189</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center; text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">LIABILITIES AND STOCKHOLDERS&#8217;
    EQUITY</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">CURRENT LIABILITIES:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Accounts payable and accrued expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">155,924</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">417,937</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Insurance payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableCurrent" scale="0" unitRef="usd">40,819</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Deferred revenue - current portion</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="0" unitRef="usd">72,102</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="0" unitRef="usd">72,102</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">Total Current Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">268,845</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">490,039</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">LONG TERM LIABILITIES:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Deferred revenue - long-term portion</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="0" unitRef="usd">901,833</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="0" unitRef="usd">937,884</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total
    Long Term Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd">901,833</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd">937,884</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">Total Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">1,170,678</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">1,427,923</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">Commitment and Contingencies (see Note 8)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24"><span style="-keep: true">&#160;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25"><span style="-keep: true">&#160;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">STOCKHOLDERS&#8217; EQUITY:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Preferred stock, $<ix:nonFraction contextRef="c7" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26"><span style="-keep: true">&#160;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27"><span style="-keep: true">&#160;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Series B convertible preferred stock, $<ix:nonFraction contextRef="c8" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">2,000</ix:nonFraction></ix:nonFraction> shares designated; <span style="-sec-ix-hidden: hidden-fact-30"><span style="-sec-ix-hidden: hidden-fact-31"><span style="-sec-ix-hidden: hidden-fact-32"><span style="-sec-ix-hidden: hidden-fact-33">no</span></span></span></span> shares issued and outstanding at June 30, 2022 and December 31, 2021 ($<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" unitRef="usdPershares">1,000</ix:nonFraction></ix:nonFraction> per share liquidation value)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Series C convertible preferred stock, $<ix:nonFraction contextRef="c9" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">4,280</ix:nonFraction></ix:nonFraction> shares designated; <ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">0</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">227</ix:nonFraction></ix:nonFraction> shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively ($<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" unitRef="usdPershares">1,000</ix:nonFraction></ix:nonFraction> per share liquidation value)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Common stock, $<ix:nonFraction contextRef="c7" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">1,987,906</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">1,972,739</ix:nonFraction></ix:nonFraction> shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">199</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">197</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Additional paid-in capital</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">12,398,889</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">12,324,646</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Accumulated deficit</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">4,525,051</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">3,262,577</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">Total Stockholders&#8217; Equity</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">7,874,037</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">9,062,266</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in"><span style="-keep: true">Total Liabilities and Stockholders&#8217;
    Equity</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">9,044,715</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">10,490,189</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying condensed notes to unaudited consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="S_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SILO
PHARMA, INC. AND SUBSIDIARY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)
</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="-keep: true">For the Three Months Ended</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="-keep: true">For the Six Months Ended</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">June 30,</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">June 30,</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2022</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2021</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2022</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2021</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left"><span style="-keep: true">LICENSE FEE REVENUES:</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="silo:LicenseFees" scale="0" unitRef="usd">18,025</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="silo:LicenseFees" scale="0" unitRef="usd">18,026</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:LicenseFees" scale="0" unitRef="usd">36,051</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="silo:LicenseFees" scale="0" unitRef="usd">35,213</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt"><span style="-keep: true">COST OF REVENUES</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">1,459</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">1,460</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">2,919</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">2,085</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">GROSS PROFIT</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">16,566</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">16,566</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">33,132</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">33,128</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">OPERATING EXPENSES:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-align: left; text-indent: 0.125in"><span style="-keep: true">Compensation expense</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">100,212</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">54,942</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">227,393</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">167,234</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; text-indent: 0.125in"><span style="-keep: true">Professional fees</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd">248,179</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd">270,906</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd">444,427</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd">942,475</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-align: left; text-indent: 0.125in"><span style="-keep: true">Research and development</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">105,676</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">98,846</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">275,955</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">147,448</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; text-indent: 0.125in"><span style="-keep: true">Insurance expense</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="0" unitRef="usd">30,866</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="0" unitRef="usd">29,015</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="0" unitRef="usd">64,158</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="0" unitRef="usd">50,721</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-align: left; text-indent: 0.125in"><span style="-keep: true">Bad debt recovery</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="silo:BadDebtRecoveryExpense" scale="0" sign="-" unitRef="usd">46,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:BadDebtRecoveryExpense" scale="0" sign="-" unitRef="usd">20,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="silo:BadDebtRecoveryExpense" scale="0" sign="-" unitRef="usd">53,500</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; text-indent: 0.125in"><span style="-keep: true">Selling, general and administrative
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">25,918</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">45,706</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">62,743</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">116,735</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; text-indent: 0in"><span style="-keep: true">Total operating expenses</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">510,851</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">453,415</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">1,054,676</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">1,371,113</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">OPERATING LOSS FROM CONTINUING
    OPERATIONS</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">494,285</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">436,849</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">1,021,544</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">1,337,985</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">OTHER INCOME (EXPENSE):</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-align: left; text-indent: 0.125in"><span style="-keep: true">Interest income (expense), net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" unitRef="usd">377</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" sign="-" unitRef="usd">1,040</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" unitRef="usd">792</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" sign="-" unitRef="usd">2,389</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; text-indent: 0.125in"><span style="-keep: true">Other income from equity shares earned for lock up agreement</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:OtherIncomeFromEquitySharesEarnedForServices" scale="0" unitRef="usd">85,733</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-align: left; text-indent: 0.125in"><span style="-keep: true">Gain on forgiveness of PPP note payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="0" unitRef="usd">19,082</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="0" unitRef="usd">19,082</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; text-indent: 0.125in"><span style="-keep: true">Net realized loss on equity investments</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="0" sign="-" unitRef="usd">104,700</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="0" sign="-" unitRef="usd">104,700</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-align: left; text-indent: 0.125in"><span style="-keep: true">Net unrealized gain (loss) on equity investments</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="silo:UnrealizedGainLossOnEquityInvestments" scale="0" sign="-" unitRef="usd">59,511</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="silo:UnrealizedGainLossOnEquityInvestments" scale="0" unitRef="usd">30,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:UnrealizedGainLossOnEquityInvestments" scale="0" sign="-" unitRef="usd">221,309</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="silo:UnrealizedGainLossOnEquityInvestments" scale="0" unitRef="usd">68,750</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; text-indent: 0.125in"><span style="-keep: true">Other expense</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd">283</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd">283</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; text-indent: 0in"><span style="-keep: true">Total other income (expense)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd">164,117</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd">48,042</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd">239,767</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd">85,443</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">LOSS FROM CONTINUING OPERATIONS BEFORE PROVISION FOR
    INCOME TAXES</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">658,402</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">388,807</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">1,261,311</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">1,252,542</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Provision for income taxes</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">LOSS FROM CONTINUING OPERATIONS</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="0" sign="-" unitRef="usd">658,402</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="0" sign="-" unitRef="usd">388,807</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="0" sign="-" unitRef="usd">1,261,311</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="0" sign="-" unitRef="usd">1,252,542</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">DISCONTINUED OPERATIONS:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Loss from discontinued operations,
    net of tax</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="0" sign="-" unitRef="usd">73,183</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="0" sign="-" unitRef="usd">1,163</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="0" sign="-" unitRef="usd">140,150</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">LOSS FROM DISCONTINUED OPERATIONS</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="0" sign="-" unitRef="usd">73,183</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="0" sign="-" unitRef="usd">1,163</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="0" sign="-" unitRef="usd">140,150</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="-keep: true">NET LOSS</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">658,402</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">461,990</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">1,262,474</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">1,392,692</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Deemed dividend</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="0" unitRef="usd">1,403,997</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt"><span style="-keep: true">NET LOSS AVAILABLE TO COMMON STOCKHOLDERS</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="0" sign="-" unitRef="usd">658,402</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="0" sign="-" unitRef="usd">461,990</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="0" sign="-" unitRef="usd">1,262,474</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="0" sign="-" unitRef="usd">2,796,689</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">NET LOSS PER COMMON SHARE AVAILABLE TO COMMON STOCKHOLDERS:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt; text-indent: 0.125in"><div style="-sec-ix-hidden: hidden-fact-75; -sec-ix-hidden: hidden-fact-74; -sec-ix-hidden: hidden-fact-73; -sec-ix-hidden: hidden-fact-72"><span style="-keep: true">Continuing operations - basic and diluted</span></div></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c12" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.33</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c13" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.20</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.64</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c14" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">1.46</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt; text-indent: 0.125in"><div style="-sec-ix-hidden: hidden-fact-80; -sec-ix-hidden: hidden-fact-79; -sec-ix-hidden: hidden-fact-78"><span style="-keep: true">Discontinued operations <span style="-sec-ix-hidden: hidden-fact-77">-</span> basic and diluted</span></div></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c13" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" sign="-" unitRef="usdPershares">0.04</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" unitRef="usdPershares">0.00</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c14" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" sign="-" unitRef="usdPershares">0.08</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt; text-indent: 0.125in"><div style="-sec-ix-hidden: hidden-fact-84; -sec-ix-hidden: hidden-fact-83; -sec-ix-hidden: hidden-fact-82; -sec-ix-hidden: hidden-fact-81"><span style="-keep: true">Basic and diluted</span></div></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c12" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">1,987,906</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">1,937,148</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">1,980,365</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">1,820,641</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying condensed notes to unaudited consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><div><a id="S_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SILO
PHARMA, INC. AND SUBSIDIARY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Series B<br/> Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Series C<br/> Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Common Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">Additional</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">Paid
                                            In</b></p></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">Accumulated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">Total</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">Stockholders&#8217;</b></p></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Equity</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt; width: 19%"><span style="-keep: true">Balance, December 31, 2021</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 6%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 6%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 6%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">227</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 6%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 6%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">1,972,739</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 6%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">197</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 6%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">12,324,646</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 6%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">3,262,577</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 6%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">9,062,266</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Stock options issued as stock based compensation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">45,009</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">45,009</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Common stock issued for conversion of Series C preferred stock</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-163"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" sign="-" unitRef="shares">227</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares">15,167</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">2</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" sign="-" unitRef="usd">2</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Net loss</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-166"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-167"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-169"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">604,072</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">604,072</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Balance, March 31, 2022</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">1,987,906</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">199</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">12,369,653</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">3,866,649</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">8,503,203</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Stock options issued as stock based compensation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-172"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-173"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">15,112</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">15,112</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Amortization of prepaid stock-based compensation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-178"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" unitRef="usd">14,124</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-179"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" unitRef="usd">14,124</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Net loss</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-181"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-182"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-183"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">658,402</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">658,402</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Balance, June 30, 2022</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right">&#160;&#160;&#160;<span style="-keep: true">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-185"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">1,987,906</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">199</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">12,398,889</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">4,525,051</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">7,874,037</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="margin: 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Series B<br/> Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Series C<br/> Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Common Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">Additional</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">Paid
                                            In</b></p></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="-keep: true">Accumulated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">Total</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">Stockholders&#8217;</b></p></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Equity</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt; width: 19%"><span style="-keep: true">Balance, December 31, 2020</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 6%; text-align: right"><span style="-keep: true">-</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 6%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-186"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 6%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-187"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 6%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-188"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 6%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">1,702,839</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 6%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">170</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 6%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">7,042,846</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 6%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">5,762,321</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 6%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">1,280,695</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Series C preferred stock issued for cash, net of offering cost</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-189"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">4,276</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-190"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-191"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">3,794,102</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-192"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">3,794,102</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Deemed dividend upon issuance of preferred stock</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-193"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-195"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" unitRef="usd">1,403,997</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" sign="-" unitRef="usd">1,403,997</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Common stock warrants granted for services</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-197"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-198"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-199"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">83,728</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-200"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">83,728</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Net loss</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-201"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-202"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-203"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-204"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">930,702</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">930,702</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Balance, March 31, 2021</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-205"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">4,276</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-206"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">1,702,839</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">170</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">12,324,673</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">8,097,020</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">4,227,823</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Common stock issued for conversion of Series C preferred stock</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" sign="-" unitRef="shares">4,049</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-208"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares">269,900</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">27</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" sign="-" unitRef="usd">27</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-210"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Net loss</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-211"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-212"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-213"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-214"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">461,990</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">461,990</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Balance, June 30, 2021</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">&#160;&#160;&#160;-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-215"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">227</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-216"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">1,972,739</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">197</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">12,324,646</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">8,559,010</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">3,765,833</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="margin: 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying condensed notes to unaudited consolidated financial statements. </span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><div><a id="S_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SILO
PHARMA, INC. AND SUBSIDIARY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr>
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr>
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">1,262,474</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">1,392,692</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Adjustments&#160;to&#160;reconcile&#160;net&#160;loss
    to&#160;net&#160;cash used in operating&#160;activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Bad debt recovery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd">20,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd">46,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd">74,245</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd">83,728</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Amortization of prepaid stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-246">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="silo:AmortizationOfPrepaidStockbasedExpense" scale="0" unitRef="usd">107,970</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Net realized gain on equity investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" sign="-" unitRef="usd">104,700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Net unrealized loss (gain) loss on equity investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" sign="-" unitRef="usd">221,309</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" unitRef="usd">68,750</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Equity shares earned for lock up agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfDerivatives" scale="0" unitRef="usd">85,733</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-247">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Gain on forgiveness of PPP note payable&#160;and accrued
    interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-248">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnRestructuringOfDebt" scale="0" unitRef="usd">19,082</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Change in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" sign="-" unitRef="usd">38,304</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" unitRef="usd">64,047</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Assets of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-249">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="silo:IncreaseDecreaseInAssetsOfDiscontinuedOperation" scale="0" sign="-" unitRef="usd">22,123</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Interest receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInReceivables" scale="0" unitRef="usd">2,380</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-250">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" sign="-" unitRef="usd">262,013</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">65,146</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Insurance payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPayablesToBrokerDealers" scale="0" unitRef="usd">40,819</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-251">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Deferred revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="0" sign="-" unitRef="usd">36,051</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="0" unitRef="usd">514,787</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">NET&#160;CASH&#160;USED IN OPERATING&#160;ACTIVITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">1,189,274</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">841,063</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Net proceeds from sale of equity investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="0" unitRef="usd">66,707</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-252">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Collection on note receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:CollectionOnNoteReceivable" scale="0" unitRef="usd">20,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="silo:CollectionOnNoteReceivable" scale="0" unitRef="usd">69,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">NET&#160;CASH&#160;PROVIDED
    BY INVESTING ACTIVITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" unitRef="usd">86,707</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" unitRef="usd">69,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Net proceeds from sale of preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-253">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="0" unitRef="usd">3,794,102</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Advance from a related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-254">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="silo:AdvanceFromARelatedParty" scale="0" unitRef="usd">2,366</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Repayment of advance from a
    related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd">2,366</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">NET&#160;CASH&#160;PROVIDED
    BY FINANCING ACTIVITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">3,794,102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">NET&#160;CHANGE IN&#160;CASH AND CASH EQUIVALENTS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" sign="-" unitRef="usd">1,102,567</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" unitRef="usd">3,022,539</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">CASH AND CASH EQUIVALENTS -
    beginning of the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">9,837,001</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">1,128,389</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">CASH AND CASH EQUIVALENTS - end
    of the period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">8,734,434</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">4,150,928</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">SUPPLEMENTAL&#160;DISCLOSURE&#160;OF&#160;CASH&#160;FLOW&#160;INFORMATION:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash&#160;paid&#160;during&#160;the&#160;period&#160;for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; padding-bottom: 4pt">Interest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-257">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd">224</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Income&#160;taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" unitRef="usd">25,159</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-258">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Common stock issued for conversion
    of Series C preferred stock</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd">76</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-259">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Initial fair value of stock options
    issued as stock-based compensation recorded as deferred compensation</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp" scale="0" unitRef="usd">89,546</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-260">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Common stock warrants granted
    for services</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-261">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="0" unitRef="usd">83,728</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Increase in equity investments
    recorded as deferred revenue pursuant to a patent license agreement</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="silo:IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree" scale="0" unitRef="usd">531,250</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying condensed notes to unaudited consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="S_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND
SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 &#8211; <span style="text-decoration:underline">ORGANIZATION AND BUSINESS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_2" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Silo Pharma, Inc. (formerly Uppercut Brands,
Inc.) (the &#8220;Company&#8221;) was incorporated in the State of New York on July 13, 2010, under the name Gold Swap, Inc. On January
24, 2013, the Company changed its state of incorporation from New York to Delaware.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_3" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a developmental stage biopharmaceutical
company focused on merging traditional therapeutics with psychedelic research.&#160;The Company seeks to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. The Company is focused on merging traditional therapeutics with psychedelic research for people suffering from indications
such as depression, post-traumatic stress disorder (&#8220;PTSD&#8221;), Alzheimer&#8217;s, Parkinson&#8217;s, and other rare neurological
disorders. The Company&#8217;s mission is to identify assets to license and fund the research which the Company&#8217;s believes will
be transformative to the well-being of patients and the health care industry.&#160;The Company was engaged in the development of a streetwear
apparel brand, NFID (see below).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_4" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 4, 2013, the Company filed a Form
N-54A and elected to become a business development company (&#8220;BDC&#8221;) under the Investment Company Act of 1940, as amended (the
&#8220;1940 Act&#8221;). In addition, the Company previously elected to be treated for federal income tax purpose as a regulated investment
company, (&#8220;RIC&#8221;) under Subchapter M of the Internal Revenue Code of 1986, as amended, (the &#8220;Code&#8221;). Through September
29, 2018, the Company met the definition of RIC in accordance with the guidance under Accounting Standards Codification (&#8220;ASC&#8221;)
Topic 946 &#8220;Financial Services &#8211; Investment Companies&#8221;. On September 29, 2018, the Company filed Form N-54C, Notification
of Withdrawal of Election to be Subject to Section 55 through 65 of the 1940 Act, as the Company changed the nature of its business so
as to cease to be a business development company (See Note 2 &#8211; Basis of Presentation). Additionally, since 2017, the Company has
been subject to income taxes at corporate tax rates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_5" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 21, 2019, the Company filed an amendment
to its Certificate of Incorporation with the State of Delaware to change its name from Point Capital, Inc. to Uppercut Brands, Inc. Thereafter,
on September 24, 2020, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to change its name
from Uppercut Brands, Inc. to Silo Pharma, Inc.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_6" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 8, 2020, the Company incorporated
a new wholly-owned subsidiary, Silo Pharma Inc.,&#160;in the State of Florida. The Company has also secured the domain name www.silopharma.com.
The Company has been exploring opportunities to expand the Company&#8217;s business by seeking to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. In July 2020, through the Company&#8217;s newly formed subsidiary, the Company entered into a commercial evaluation license
and option agreement with University of Maryland, Baltimore (&#8220;UMB&#8221;) (see Note 8) pursuant to which, among other things, UMB
granted the Company an exclusive, option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license to with respect
to certain technology. The option was extended and exercised on January 13, 2021. On February 12, 2021, the Company entered into a Master
License Agreement with UMB (see Note 8). The Company plans to actively pursue the acquisition and/or development of intellectual property
or technology rights to treat rare diseases, and to ultimately expand the Company&#8217;s business to focus on this new line of business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:nonNumeric contextRef="c0" name="silo:AssetPurchaseAgreementDescription"><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_7" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2021, the Company entered
into and closed on an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement) with NFID, LLC, a Florida limited liability company
(the &#8220;Buyer&#8221;), whereby the Buyer purchased from the Company certain assets, properties, and rights in connection with the
Company&#8217;s NFID trademark name, logos, domain, and apparel clothing and accessories for a purchase price of $60,000 in the form
of a promissory note amounting to $60,000. The promissory note bears 8% interest per annum and matures on October 1, 2023. Accordingly,
the results of operations of this component, for all periods presented, are separately reported as &#8220;discontinued operations&#8221;
on the condensed consolidated statements of operations (see Note 4).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_8" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 11, 2022, the Company stockholders
approved granting discretionary authority to the Company&#8217;s Board of Directors to amend the Company&#8217;s Certificate of Incorporation
to effect one or more consolidations of the Company&#8217;s issued and outstanding shares of common stock, pursuant to which the shares
of common stock would be combined and reclassified into one share of common stock at a ratio within the range from 1-for-5 up to 1-for-50
(the &#8220;Reverse Stock Split&#8221;), provided that, (X) that the Company shall not effect Reverse Stock Splits that, in the aggregate,
exceeds 1-for-50, and (Y) any Reverse Stock Split is completed no later than February 8, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On September 14, 2022, the Company filed a
Certificate of Amendment to the Amended and Restated Articles of Incorporation (the &#8220;Certificate of Amendment&#8221;) with the
Secretary of State of the State of Nevada to effect a 1-for-50 reverse stock split (the &#8220;Reverse Stock Split&#8221;) with respect
to the outstanding shares of the Company&#8217;s common stock. The Certificate of Amendment became effective on September 14, 2022. The
Reverse Stock Split was previously approved by the sole director and the majority of stockholders of the Company. The Reverse Stock Split
was deemed effective at the open of business on September 15, 2022. All share and per share data in the accompanying consolidated financial
statements have been retroactively restated to reflect the effect of the reverse stock split.</span></p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 &#8211; <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation and Principles of
Consolidation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s consolidated financial statements
include financial statements for Silo Pharma, Inc and its inactive wholly-owned subsidiary with the same name as the parent entity, Silo
Pharma, Inc, as of June 30, 2022 and during the three and nine months ended June 30, 2022. All intercompany balances and transactions
have been eliminated in consolidation. Management acknowledges its responsibility for the preparation of the accompanying unaudited condensed
consolidated financial statements which reflect all adjustments, consisting of normal recurring and non-recurring adjustments, considered
necessary in its opinion for a fair statement of its consolidated financial position and the consolidated results of its operations for
the periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_3" id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America (the &#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions Article 8-03 of Regulation S-X.
Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole.
Certain information and note disclosure normally included in financial statements prepared in accordance with U.S. GAAP has been condensed
or omitted from these statements pursuant to such accounting principles and, accordingly, they do not include all the information and
notes necessary for comprehensive financial statements. These unaudited condensed consolidated financial statements should be read in
conjunction with the summary of significant accounting policies and notes to the financial statements for the year ended December 31,
2021 included in the Company&#8217;s Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 28, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with, ASC 205-20 &#8220;Discontinued
Operations&#8221; establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should
be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity&#8217;s
operations and financial results. As a result, the NFID, LLC component&#8217;s results of operations have been classified as discontinued
operations on a retrospective basis for all periods presented. Accordingly, the results of operations of this component, for all periods,
are separately reported as &#8220;discontinued operations&#8221; on the condensed consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_LiquidityPolicyTextBlock-c0_cont_1" escape="true" name="silo:LiquidityPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation continuedAt="_LiquidityPolicyTextBlock-c0_cont_2" id="_LiquidityPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As reflected in the accompanying condensed
consolidated financial statements, the Company generated a net loss of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" unitRef="usd">1,262,474</ix:nonFraction> and used cash in operations of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInContinuingOperations" scale="0" unitRef="usd">1,189,274</ix:nonFraction> during the
six months ended June 30, 2022. Additionally, the Company has an accumulated deficit of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsUnappropriated" scale="0" unitRef="usd">4,525,051</ix:nonFraction> at June 30, 2022. However, as of June
30, 2022, the Company had working capital of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="silo:WorkingCapital" scale="0" unitRef="usd">8,678,540</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation id="_LiquidityPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The positive worthy capital serves to mitigate
the conditions that historically raised substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company
believes that the Company has sufficient cash to meet its obligations for a minimum of twelve months from the date of this filing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of unaudited condensed consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment.
It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at
the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one
or more future events. Accordingly, the actual results could differ significantly from estimates. Significant estimates during the six
months ended June 30, 2022 and year ended December 31, 2021 include the collectability of notes receivable, valuation of equity investments,
estimates for obsolete and slow-moving inventory, estimates of the deemed dividend, valuation allowances for deferred tax assets, the
fair value of warrants issued with debt and for services, and the fair value of shares issued for services and in settlements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash and Cash Equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid investments
with a maturity of three months or less when acquired to be cash equivalents. The Company places its cash with high credit quality financial
institutions. The Company&#8217;s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)
up to $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashFDICInsuredAmount" scale="0" unitRef="usd">250,000</ix:nonFraction> or by the Securities Investor Protection Corporation up to $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="silo:CashSPICInsuredAmount" scale="0" unitRef="usd">250,000</ix:nonFraction>. To reduce its risk associated with the failure of
such financial institutions, the Company evaluates, at least annually, the rating of the financial institutions in which it holds deposits.
At June 30, 2022 and December 31, 2021, the Company had cash in excess of FDIC limits of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FDICIndemnificationAssetCashPaymentsReceived" scale="0" unitRef="usd">8,240,000</ix:nonFraction>, and approximately
$<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FDICIndemnificationAssetCashPaymentsReceived" scale="0" unitRef="usd">9,100,000</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:nonNumeric contextRef="c0" continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Notes Receivable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:continuation id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes an allowance for losses
on notes receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical
bad debt experience, current note receivable aging, and expected future write-offs, as well as an assessment of specific identifiable
accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recognized as general
and administrative expense.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" continuedAt="_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Prepaid Expenses and Other Current Assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:continuation id="_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prepaid expenses and other current assets
- current of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="0" unitRef="usd">99,939</ix:nonFraction> and $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="0" unitRef="usd">145,324</ix:nonFraction> at June 30, 2022 and December 31, 2021, respectively, consist primarily of costs paid for future services
which will occur within a year. Prepaid expenses and other current assets &#8211; non-current of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="0" unitRef="usd">33,740</ix:nonFraction> and $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="0" unitRef="usd">26,659</ix:nonFraction> at June 30, 2022
and December 31, 2021, respectively, consist primarily of costs paid for license fees and future services which will occur after a year.
Prepaid expenses may include prepayments in cash and equity instruments for consulting, business advisory, legal services, license fees,
research and development fees, and insurance which are being amortized over the terms of their respective agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:nonNumeric contextRef="c0" continuedAt="_EquityInvestmentsAtFairValuePolicyTextBlock-c0_cont_1" escape="true" name="silo:EquityInvestmentsAtFairValuePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments, at Fair Value</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:continuation id="_EquityInvestmentsAtFairValuePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Realized gain or loss is recognized when an
investment is disposed of and is computed as the difference between the Company&#8217;s carrying value and the net proceeds received
from such disposition. Realized gains and losses on investment transactions are determined by specific identification. Net unrealized
appreciation or depreciation is computed as the difference between the fair value of the investment and the cost basis of such investment.
Net unrealized gains or losses for equity investments are recognized in operations as the difference between the carrying value at the
beginning of the period and the fair value at the end of the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:nonNumeric contextRef="c0" continuedAt="_EquityInvestmentsAtCostPolicyTextBlock-c0_cont_1" escape="true" name="silo:EquityInvestmentsAtCostPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments, at Cost</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:continuation id="_EquityInvestmentsAtCostPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equity investments, at cost are comprised
mainly of non-marketable capital stock and stock warrants, are recorded at cost, as adjusted for other than temporary impairment write-downs
and are evaluated for impairment periodically.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Recognition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies ASC Topic 606, Revenue
from Contracts with Customers (&#8220;ASC 606&#8221;). ASC 606 establishes a single comprehensive model for entities to use in accounting
for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires
an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records interest and dividend
income on an accrual basis to the extent that the Company expects to collect such amounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_4" id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the license and royalty income, revenue
is recognized when the Company satisfies the performance obligation based on the related license agreement. Payments received from the
licensee that are related to future periods are recorded as deferred revenue to be recognized as revenues over the term of the related
license agreement (see Note 8).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Product sales were recognized when the NFID
products were shipped to the customer and title was transferred and were recorded net of any discounts or allowances which are separately
reported as &#8220;discontinued operations&#8221; on the condensed consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:nonNumeric contextRef="c0" continuedAt="_CostOfRevenuesPolicyTextBlock-c0_cont_1" escape="true" name="silo:CostOfRevenuesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cost of Revenues</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:continuation continuedAt="_CostOfRevenuesPolicyTextBlock-c0_cont_2" id="_CostOfRevenuesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary components of cost of revenues
on license fees included the cost of the license fees. Payments made to the licensor that are related to future periods are recorded
as prepaid expense to be amortized over the term of the related license agreement (see Note 8).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:continuation id="_CostOfRevenuesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary components of cost of revenues
on NFID apparel include the cost of the product, production costs, warehouse storage costs and shipping fees which are separately reported
as &#8220;discontinued operations&#8221; on the condensed consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationForfeituresPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_30" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:continuation id="_ShareBasedCompensationForfeituresPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation is accounted for
based on the requirements of ASC 718 &#8211; &#8220;Compensation &#8211; Stock Compensation&#8221;, which requires recognition in the
financial statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments
over the period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively,
the vesting period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange
for an award based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted
under Accounting Standards Update (&#8220;ASU&#8221;) 2016-09 Improvements to Employee Share-Based Payment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_31" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_32" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income tax assets and liabilities
arise from temporary differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted
tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current
or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities
not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences
are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to
be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_33" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the provisions of Financial
Accounting Standards Board (&#8220;FASB&#8221;) ASC 740-10, &#8220;Uncertainty in Income Taxes&#8221;. Certain recognition thresholds
must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax
positions that meet a &#8220;more-likely-than-not&#8221; threshold. The Company does not believe it has any uncertain tax positions as
of June 30, 2022 and December 31, 2021 that would require either recognition or disclosure in the accompanying condensed consolidated
financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_34" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_35" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 730-10, &#8220;Research
and Development-Overall,&#8221; <ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy">research and development costs are expensed when incurred. During the six months ended June 30, 2022
and 2021, research and development costs were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">275,955</ix:nonFraction> and $<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">147,448</ix:nonFraction>, respectively. During the three months ended June 30, 2022 and 2021,
research and development costs were $<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">105,676</ix:nonFraction> and $<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">98,846</ix:nonFraction>, respectively.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_36" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Net Loss per Common Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_37" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per share is computed by dividing
net loss allocable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Diluted
earnings per share is computed by dividing net income available to common shareholders by the weighted average number of shares of common
stock, common stock equivalents and potentially dilutive securities outstanding during the period using the as-if converted method. Potentially
dilutive securities which included convertible preferred shares and stock options are excluded from the computation of diluted shares
outstanding if they would have an anti-dilutive impact on the Company&#8217;s net losses. The following are the potentially dilutive
shares for the six months ended June 30, 2022 and 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_38" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37"><ix:nonNumeric contextRef="c0" escape="true" name="silo:ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Series C convertible preferred stock</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-311"><span style="-keep: true">&#8212;</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c207" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">15,133</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Stock options</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c208" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">28,849</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c209" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">6,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Warrants</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c210" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">347,080</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c211" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">347,080</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">375,929</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">368,213</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_39" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_40" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, the FASB issued ASU 2020-06&#8212;<i>Debt&#8212;Debt
with Conversion and Other Options (Subtopic 470-20) and Derivatives and edging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic
815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;)</i> to simplify
the accounting for convertible instruments by removing certain separation models in Subtopic 470- 20, <i>Debt with Conversion and Other
Options</i>, for convertible instruments. Under the amendments in ASU 2020-06, the embedded conversion features no longer are separated
from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives
under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently,
a convertible debt instrument will be accounted for as a single liability measured at its amortized cost and a convertible preferred
stock will be accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation
and recognition as derivatives. By removing those separation models, the interest rate of convertible debt instruments typically will
be closer to the coupon interest rate when applying the guidance in Topic 835, Interest. The amendments in ASU 2020-06 provide financial
statement users with a simpler and more consistent starting point to perform analyses across entities. The amendments also improve the
operability of the guidance and reduce, to a large extent, the complexities in the accounting for convertible instruments and the difficulties
with the interpretation and application of the relevant guidance. To further improve the decision usefulness and relevance of the information
being provided to users of financial statements, amendments in ASU 2020-06 increased information transparency by making the following
amendments to the disclosure for convertible instruments:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_41" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Add a disclosure objective</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Add information about events or conditions that occur during the
    reporting period that cause conversion contingencies to be met or conversion terms to be significantly changed</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Add information on which party controls the conversion rights</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Align disclosure requirements for contingently convertible instruments
    with disclosure requirements for other convertible instruments</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Require that existing fair value disclosures in Topic 825, Financial
    Instruments, be provided at the individual convertible instrument level rather than in the aggregate.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_42" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, for convertible debt instruments
with substantial premiums accounted for as paid-in capital, amendments in ASU 2020-06 added disclosures about (1) the fair value amount
and the level of fair value hierarchy of the entire instrument for public business entities and (2) the premium amount recorded as paid-in
capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_43" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amendments in ASU 2020-06 are effective
for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning
after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for
fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but
no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Entities should
adopt the guidance as of the beginning of its annual fiscal year and are allowed to adopt the guidance through either a modified retrospective
method of transition or a fully retrospective method of transition. In applying the modified retrospective method, entities should apply
the guidance to transactions outstanding as of the beginning of the fiscal year in which the amendments are adopted. Transactions that
were settled (or expired) during prior reporting periods are unaffected. The cumulative effect of the change should be recognized as
an adjustment to the opening balance of retained earnings at the date of adoption. If an entity elects the fully retrospective method
of transition, the cumulative effect of the change should be recognized as an adjustment to the opening balance of retained earnings
in the first comparative period presented. The Company adopted ASU 2020-06 during the three months ended March 31, 2022 and it did not
have material impact on its condensed consolidated financial statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_44" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_6" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, the FASB issued ASU 2021-04,
Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718),
and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40). The new ASU addresses issuer&#8217;s accounting
for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities,
for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted.
The Company adopted ASU 2020-06 during the three months ended March 31, 2022 and did not have material impact on its condensed consolidated
financial statements</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_44"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management does not believe that any other
recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company&#8217;s consolidated
financial statements.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_FairValueDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueDisclosuresTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 &#8211; <span style="text-decoration:underline">FAIR VALUE OF FINANCIAL
INSTRUMENTS AND FAIR VALUE MEASUREMENTS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_2" id="_FairValueDisclosuresTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 820 - Fair Value Measurements and
Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments,
whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent
information available to the Company on June 30, 2022. Accordingly, the estimates presented in these financial statements are not necessarily
indicative of the amounts that could be realized on disposition of the financial instruments. FASB ASC 820 specifies a hierarchy of valuation
techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market
data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority
to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable
inputs (Level 3 measurement).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_3" id="_FairValueDisclosuresTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px">&#160;</td>
    <td style="width: 58px; text-align: justify"><span style="font-size: 10pt">Level 1 -</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inputs are unadjusted quoted prices in active markets for identical
    assets or liabilities available at the measurement date.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 2 -</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inputs are unadjusted quoted prices for similar assets and liabilities
    in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than
    quoted prices that are observable, and inputs derived from or corroborated by observable market data.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 3 -</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inputs are unobservable inputs which reflect the reporting entity&#8217;s
    own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available
    information.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_4" id="_FairValueDisclosuresTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company analyzes all financial instruments
with features of both liabilities and equity under the FASB&#8217;s accounting standard for such instruments. Under this standard, financial
assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_5" id="_FairValueDisclosuresTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts reported in the consolidated
balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair market
value based on the short-term maturity of these instruments.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_6" id="_FairValueDisclosuresTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments at Fair Value</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_7" id="_FairValueDisclosuresTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounted for certain equity investments
at fair value using level 1, level 2 and level 3 valuations. Assets and liabilities measured at fair value on a recurring basis are as
follows at June 30, 2022 and December 31, 2021:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_8" id="_FairValueDisclosuresTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At June 30, 2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At December 31, 2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; text-align: left">Equity investments consisting of common
    stock, at fair value</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="silo:EquityInvestmentsAtFairValue" scale="0" unitRef="usd">113,012</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-312">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-313">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="silo:EquityInvestmentsAtFairValue" scale="0" unitRef="usd">419,995</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-314">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-315">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_9" id="_FairValueDisclosuresTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes activity in
the Company&#8217;s equity investments, at fair value for the periods presented:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_10" id="_FairValueDisclosuresTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" escape="true" name="silo:ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance, beginning</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities" scale="0" unitRef="usd">419,995</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-316">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:AdditionsofEquitySecurities" scale="0" unitRef="usd">85,733</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:AdditionsofEquitySecurities" scale="0" unitRef="usd">531,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Sales at original cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" unitRef="usd">171,407</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" unitRef="usd">359,843</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Unrealized (loss) gain</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="0" sign="-" unitRef="usd">221,309</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="0" unitRef="usd">248,588</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance as of June 30, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities" scale="0" unitRef="usd">113,012</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities" scale="0" unitRef="usd">419,995</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_11" id="_FairValueDisclosuresTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended June 30, 2022,
the Company received <ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="silo:CompanyReceivedShares" scale="0" unitRef="shares">77,939</ix:nonFraction> shares of Home Bistro, Inc. common stock with grant date fair value of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet" scale="0" unitRef="usd">85,733</ix:nonFraction> or $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="silo:CommonStockGrantDateFairValuePerShare" scale="0" unitRef="usdPershares">1.10</ix:nonFraction> per share, in exchange
for entering into a lock up and leak out agreement which was recorded as other income from equity shares earned for services in the accompanying
condensed consolidated statement of operations. The Company measures equity securities received for services at fair value on the date
of receipt.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_12" id="_FairValueDisclosuresTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended June 30, 2022,
the Company sold its equity investments in Aikido Pharma, Inc. with cost of $<ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainOnSaleOfInvestments" scale="0" unitRef="usd">171,407</ix:nonFraction> for gross proceeds of $<ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="silo:GrossProceeds" scale="0" unitRef="usd">66,707</ix:nonFraction> and the Company recorded
a net realized loss on equity investments amounting to $<ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="silo:EquityMethodInvestment" scale="0" unitRef="usd">104,700</ix:nonFraction> as reflected in the accompanying condensed consolidated statement of
operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_13" id="_FairValueDisclosuresTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2022 and December 31, 2021, equity
investments, at fair value consisted of common equity securities of two entities, Home Bistro, Inc. and Aikido Pharma, Inc. (see Note
8).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_14" id="_FairValueDisclosuresTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equity investments are carried at fair value
with unrealized gains or losses which is recorded as net unrealized gain (loss) on equity investments in the accompanying condensed consolidated
statement of operations.&#160;Realized gains and losses are determined on a specific identification basis which is recorded as net realized
gain (loss) on equity investments in the consolidated statement of operations. The Company reviews equity investments, at fair value
for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recovered.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_15" id="_FairValueDisclosuresTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 825-10 &#8220;Financial Instruments&#8221;
allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair
value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value
option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent
reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_16" id="_FairValueDisclosuresTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments at Cost</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_FairValueDisclosuresTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2022 and December 31, 2021, the
Company did not have non-marketable capital stock and stock warrants, recorded at cost.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8211; <span style="text-decoration:underline">DISPOSAL OF THE DISCONTINUED
OPERATIONS OF THE NFID BUSINESS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c0_cont_2" id="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2021, the Company entered
into and closed on an Asset Purchase Agreement (see Note 1) with NFID, LLC, an unrelated party, a Florida limited liability company,
whereby the Company sold certain assets, properties, and rights in connection with its NFID trademark name, logos, domain, and apparel
clothing and accessories for a purchase price of $<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="silo:PurchasePrice" scale="0" unitRef="usd">60,000</ix:nonFraction> in the form of a promissory note amounting to $<ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="silo:PromissoryNotes" scale="0" unitRef="usd">60,000</ix:nonFraction>. The promissory note bears
<ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" scale="-2" unitRef="pure">8</ix:nonFraction>% interest per annum and matures on <ix:nonNumeric contextRef="c87" format="ixt:date-monthname-day-year-en" name="us-gaap:LongTermDebtMaturityDate">October 1, 2023</ix:nonNumeric>. Note receivable &#8211; non-current amounted to $<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="silo:PrincipalBalance" scale="0" unitRef="usd">60,000</ix:nonFraction> as of September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c0_cont_3" id="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 205-20 &#8220;Discontinued Operations&#8221;
establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should be reported in
discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity&#8217;s operations
and financial results. As a result, the component&#8217;s results of operations have been classified as discontinued operations on a
retrospective basis for all periods presented. Accordingly, the results of operations of this component, for all periods, are separately
reported as &#8220;discontinued operations&#8221; on the condensed consolidated statements of operations.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c0_cont_4" id="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table set forth the selected
financial data of the Company&#8217;s gain from sale of the NFID business on September 30, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c0_cont_5" id="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September&#160;30, <br/>
    2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 1.5pt">Inventory, net</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">58,447</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="0" unitRef="usd">58,447</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-317">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net asset of NFID business disposed</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="silo:NetAssetOfNFIDBusinessDisposed" scale="0" unitRef="usd">58,447</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Consideration in the form of a note receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="silo:ConsiderationInTheFormOfANoteReceivable" scale="0" sign="-" unitRef="usd">60,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Gain from sale of NFID business</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfOtherAssets" scale="0" sign="-" unitRef="usd">1,553</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c0_cont_6" id="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The summarized operating result of discontinued
operations of the NFID Business included in the Company&#8217;s condensed consolidated statements of operations for the six months ended
June 30, 2022 and 2021 is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="srt:ScheduleOfCondensedIncomeStatementTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Product sales, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-318">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="0" unitRef="usd">80,305</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="0" unitRef="usd">1,079</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="0" unitRef="usd">68,360</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="0" sign="-" unitRef="usd">1,079</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="0" unitRef="usd">11,945</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating and other non-operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd">84</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd">152,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Loss from discontinued operations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="0" sign="-" unitRef="usd">1,163</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="0" sign="-" unitRef="usd">140,150</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5 &#8211; <span style="text-decoration:underline">NOTES RECEIVABLE</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_2" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022 and December 31, 2021,
notes receivable, net, consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_3" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Principal amounts of notes receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableGross" scale="0" unitRef="usd">115,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableGross" scale="0" unitRef="usd">220,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Additional notes receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-319">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="silo:AdditionalNotesReceivableIn2021" scale="0" unitRef="usd">60,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Collections on notes receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="silo:CollectionsOnNotesReceivables" scale="0" unitRef="usd">20,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="silo:CollectionsOnNotesReceivables" scale="0" unitRef="usd">164,500</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" scale="0" unitRef="usd">35,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" scale="0" unitRef="usd">55,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Notes receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd">60,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd">60,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: notes receivable, net &#8211; current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-320">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-321">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Notes receivable &#8211; non-current</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableNet" scale="0" unitRef="usd">60,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableNet" scale="0" unitRef="usd">60,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_4" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 28, 2018, the Company and Blind
Faith Concepts Holdings, Inc. (the &#8220;Seller&#8221;) executed a two-year promissory note receivable agreement with a principal balance
of $<ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">200,000</ix:nonFraction> of which $<ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">100,000</ix:nonFraction> was funded to the Seller in September 2018 and the remaining $<ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">100,000</ix:nonFraction> was funded in October 2018. The promissory
note accrued interest at a rate of <ix:nonFraction contextRef="c103" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure">6</ix:nonFraction>% per annum, and the Company was repaid in interest only payments on a quarterly basis, until the
maturity date of <ix:nonNumeric contextRef="c106" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate">September 27, 2020</ix:nonNumeric>, at which time the full principal and any interest payments was due to the Company. At the time the
promissory note receivable agreement was executed, the Company also executed a security interest and pledge agreement with the borrower
pursuant to which the borrower pledged all of the assets of its company as security for the performance of the note obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_5" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 2, 2018, the Company and Seller
entered into a promissory note agreement (&#8220;Promissory Note Agreement&#8221;) with a principal balance of $<ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="0" unitRef="usd">50,000</ix:nonFraction>. Pursuant to the
Promissory Note Agreement, the $<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="silo:PromissoryNoteAgreement" scale="0" unitRef="usd">50,000</ix:nonFraction> note was a deposit and credit towards the acquisition of the assets of Lust for Life Group such
as inventory, trademarks and logos. Pursuant to the Promissory Note Agreement, since the purchase did not close within 30 days from date
of the Promissory Note, the note receivable became immediately due. Through the date of default, the outstanding principal balance accrued
interest at an interest rate of <ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFixedInterestRate" scale="-2" unitRef="pure">10</ix:nonFraction>% per annum payable on a monthly basis. Upon default, the interest rate increased to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" scale="-2" unitRef="pure">18</ix:nonFraction>% per annum.
As of December 31, 2018, the Company determined that this note receivable was doubtful and accordingly, recorded an allowance for doubtful
account and bad debt expense of $<ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd">50,000</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_6" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, pursuant to claim purchase
agreements (&#8220;Claim Purchase Agreements&#8221;), the Company sold its notes receivable and related interest receivable balances
in the aggregate amount of $<ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SupplementalDeferredPurchasePrice" scale="0" unitRef="usd">277,305</ix:nonFraction> to an investor. Pursuant to the Claim Purchase Agreements, the investor agreed to pay the Company
the purchase price of $<ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SupplementalDeferredPurchasePrice" scale="0" unitRef="usd">277,305</ix:nonFraction> on the earlier of the payment of six-monthly installments or upon the liquidation of settlement securities
of the Seller pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended. The first installment was be made following entry
and full effectuation of a court order approving the settlement of the claim which occurred on March 6, 2020 in the United States District
Court for the District of Maryland Northern Division. Additionally, on January 6, 2020, the Company and the Seller entered into a settlement
agreement related to notes receivable. In lieu of the Company seeking default and foreclosure against the Seller pursuant to the note
agreements, the Company received <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:ReceivedShares" scale="0" unitRef="shares">10,420</ix:nonFraction> shares of the Seller&#8217;s convertible Series B Preferred Stock. Since the shares of Series
B Preferred Stock have limited marketability, no value was placed on these shares. Between April 2020 and December 2020, the Company
collected an aggregate of $<ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" name="silo:AggregateOfNotesReceivablePurchasePrice" scale="0" unitRef="usd"><ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="silo:AggregateOfNotesReceivablePurchasePrice" scale="0" unitRef="usd">30,000</ix:nonFraction></ix:nonFraction> on the notes receivable balance.&#160;During the year ended December 31, 2020, the Company recorded
a total allowance for doubtful account and bad debt expense of $<ix:nonFraction contextRef="c223" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd">174,376</ix:nonFraction> (consisting of the principal balance of $<ix:nonFraction contextRef="c223" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="0" unitRef="usd">146,500</ix:nonFraction> and interest
receivable of $<ix:nonFraction contextRef="c223" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivable" scale="0" unitRef="usd">27,876</ix:nonFraction>) due to slow collection of the installment payments pursuant to the Claim Purchase Agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_7" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2021,
the Company recovered an aggregate of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:RecoveredAggregateBadDebt" scale="0" unitRef="usd">7,500</ix:nonFraction> bad debt previously written off during the periods between 2018 to 2020, recorded as bad
debt recovery in the accompanying consolidated statement of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_8" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2021, the
Company received $<ix:nonFraction contextRef="c224" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForLoanAndLeaseLossRecoveryOfBadDebts" scale="0" unitRef="usd">23,500</ix:nonFraction> of payment and recovered $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:RecoveredBadDebt" scale="0" unitRef="usd">141,000</ix:nonFraction> of the of the $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease" scale="0" unitRef="usd">196,500</ix:nonFraction> bad debt allowance. <ix:nonNumeric contextRef="c116" name="silo:BadDebtRecoveryCashPayment">On June 7, 2021, the Company and
the investor, entered into a settlement agreement whereby both parties agreed to settle the remaining balance of this note receivable
which was previously written off in year 2020 for a total settlement amount of $196,000 to be paid as follows; (i) an initial payment
of $46,000 upon execution of the settlement agreement and (ii) $10,000 per month for fifteen months.</ix:nonNumeric> During the six months ended June
30, 2022, $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:RemainsCollectibleSettlementAgreement" scale="0" unitRef="usd">20,000</ix:nonFraction> was collected under this settlement agreement and $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:RemainsCollectibleSettlementAgreementAmountReserved" scale="0" unitRef="usd">35,500</ix:nonFraction> remains collectible under this settlement agreement and such
amount has been fully reserved as of June 30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2021, the Company executed
a note receivable agreement with NFID, LLC in connection with an Asset Purchase Agreement (see Note 4). The promissory note bears <ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="silo:PromissoryNote" scale="-2" unitRef="pure">8</ix:nonFraction>%
interest per annum and matures on <ix:nonNumeric contextRef="c87" format="ixt:date-monthname-day-year-en" name="us-gaap:LongTermDebtMaturityDate">October 1, 2023</ix:nonNumeric>. The outstanding principal and accrued interest shall be due and payable on maturity.
As of December 31, 2021, this note receivable had outstanding principal receivable of $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="0" unitRef="usd">60,000</ix:nonFraction> and accrued interest receivable of $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivable" scale="0" unitRef="usd">1,210</ix:nonFraction>
for a total receivable balance of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireReceivables" scale="0" unitRef="usd">61,210</ix:nonFraction>. As of June 30, 2022, this note receivable had outstanding principal receivable of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="0" unitRef="usd">60,000</ix:nonFraction>
and accrued interest receivable of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivable" scale="0" unitRef="usd">3,590</ix:nonFraction> for a total receivable balance of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireReceivables" scale="0" unitRef="usd">63,590</ix:nonFraction> which is reflected in the accompanying consolidated
balance sheet as note receivable &#8211; non-current.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6 &#8211; <span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Shares Authorized</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesAuthorized" scale="0" unitRef="shares">505,000,000</ix:nonFraction> shares authorized
which consist of <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">500,000,000</ix:nonFraction> shares of common stock and <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">5,000,000</ix:nonFraction> shares of preferred stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Preferred Stock</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2013, the Company designated <ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares">1,000,000</ix:nonFraction>
shares of preferred stock as Series A Convertible Preferred Stock and in November 2019, the Company designated <ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares">2,000</ix:nonFraction> shares of preferred
stock as Series B Convertible Preferred Stock. As of June 30, 2022 and December 31, 2021, there were <ix:nonFraction contextRef="c225" decimals="0" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c225" decimals="0" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">no</ix:nonFraction></ix:nonFraction> shares of the Series A and Series
B preferred stock issued and outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Series C Convertible Preferred Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 9, 2021, the Company filed a Certificate
of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the &#8220;Certificate of Designations&#8221;)
with the Delaware Secretary of State, designating <ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares">4,280</ix:nonFraction> shares of preferred stock as Series C Convertible preferred stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Designation</span>. The Company has designated <ix:nonFraction contextRef="c226" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares">4,280</ix:nonFraction> shares of preferred stock as Series C Convertible preferred stock. Each share of Series C Convertible Preferred Stock has a par value of $<ix:nonFraction contextRef="c226" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.0001</ix:nonFraction> per share and a stated value of $<ix:nonFraction contextRef="c227" decimals="0" format="ixt:num-dot-decimal" name="silo:PreferredStockStatedValue" scale="0" unitRef="usd">1,000</ix:nonFraction> (the &#8220;Series C Stated Value&#8221;).</span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Dividends</span><i>.&#160;</i>Holders
                                            of Series C Convertible preferred stock shall be entitled to receive dividends (on an as-if-converted-to-common-stock
                                            basis) in the same form as dividends actually paid on shares of the common stock when, as
                                            and if such dividends are paid on shares of the common stock. No other dividends shall be
                                            paid on shares of the Series C Convertible preferred stock.</span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Liquidation</span>.
                                            Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary,
                                            the holders of Series C Convertible preferred stock shall be entitled to receive the same
                                            amount that a holder of common stock would receive if the Series C Convertible preferred
                                            stock were fully converted (disregarding any conversion limitations) which amounts shall
                                            be paid&#160;pari passu&#160;with all holders of common stock.</span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Voting
                                            Rights</span>. Except as otherwise provided in the Certificate of Designations or as otherwise
                                            required by law, the Series C Convertible preferred stock shall have no voting rights. However,
                                            as long as any shares of Series C Convertible preferred stock are outstanding, the Company
                                            shall not, without the affirmative vote of the holders of a majority of the then outstanding
                                            shares of the Series C Convertible preferred stock, (a) alter or change adversely the powers,
                                            preferences or rights given to the Series C Convertible preferred stock or alter or amend
                                            the Certificate of Designations, (b) amend its Certificate of Incorporation or other charter
                                            documents in any manner that adversely affects any rights of the holders of the Series C
                                            Convertible preferred stock, (c) increase the number of authorized shares of Series C Convertible
                                            preferred stock, or (d) enter into any agreement with respect to any of the foregoing.</span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-keep: true">&#160;</span></td> <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Conversion</span>. Each share of Series C Convertible preferred stock is convertible, at any time and from time to time after the issuance date, at the option of the holder, into such number of shares of common stock determined by dividing the Series C Stated Value by the Series C Conversion Price. &#8220;Series C Conversion Price&#8221; means $<ix:nonFraction contextRef="c228" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares">15.00</ix:nonFraction>, subject to adjustment in the event of stock split, stock dividends, subsequent right offerings and similar recapitalization transactions.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Forced
                                            Conversion</span>. Notwithstanding anything herein to the contrary, after the date that the
                                            Company&#8217;s stockholder approval is obtained and deemed effective, the Company may deliver
                                            a written notice to all holders (the &#8220;Forced Conversion Notice Date&#8221;) to cause
                                            each holder to convert all or part of such holder&#8217;s Series C Convertible preferred
                                            stock pursuant to Section 6 (&#8220;Forced Conversion&#8221;), it being agreed that the &#8220;Conversion
                                            Date&#8221; shall be deemed to occur no later than the earlier of (i) two (2) trading days
                                            and (ii) the number of trading days comprising the standard settlement period following the
                                            Forced Conversion Notice Date; provided, however, a holder shall only be required to convert
                                            pursuant to a Forced Conversion to the extent that such conversion would not cause a holder
                                            to exceed its beneficial ownership limitation. On March 10, 2021, the Company obtained the
                                            stockholders&#8217; approval forcing the conversion of all the Series C Convertible preferred
                                            stock. On April 12, 2021, the Company notified holders of its Series C Convertible preferred
                                            stock of its election to force the conversion to its Series C Convertible preferred stock
                                            into shares of the Company&#8217;s common stock (see below for additional conversions in
                                            2022).</span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Exercisability</span><i>.&#160;</i><ix:nonNumeric contextRef="c227" name="us-gaap:ConvertiblePreferredStockTermsOfConversion">A holder of Series C Convertible preferred stock may not convert any portion of the Series C Convertible preferred stock to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, upon election by a holder prior to issuance, 9.99%) of the outstanding shares of the Company&#8217;s common stock after conversion, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%.</ix:nonNumeric></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Series C Convertible Preferred Stock
Financing</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On February 9, 2021 (the &#8220;Effectiveness
Date&#8221;), the Company entered into securities purchase agreements (collectively, the &#8220;Series C Purchase Agreements&#8221;)
with certain institutional and accredited investors for the sale of an aggregate of <ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">4,276</ix:nonFraction> shares of the Company&#8217;s Series C Convertible
Preferred Stock and warrants (the &#8220;February Warrants&#8221;) to purchase up to <ix:nonFraction contextRef="c229" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares">285,066</ix:nonFraction> shares (the &#8220;February Warrant Shares&#8221;)
of the Company&#8217;s common stock for gross proceeds of approximately $<ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" unitRef="usd">4,276,000</ix:nonFraction>, before deducting placement agent and other offering
expenses of $<ix:nonFraction contextRef="c229" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="0" unitRef="usd">481,898</ix:nonFraction> which are offset against the proceeds in additional paid in capital. The offering closed on February 12, 2021. Accordingly,
the Company recognized a total deemed dividend of $<ix:nonFraction contextRef="c230" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DividendsPreferredStockCash" scale="0" unitRef="usd">1,403,997</ix:nonFraction> for the beneficial conversion feature in connection with the issuance of
these Series C Convertible preferred stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The February Warrants are exercisable for
a period of <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="silo:WarrantsTerm">five years</ix:nonNumeric> from the date of issuance at an exercise price of $<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">15.00</ix:nonFraction> per share. If, after a period of 180 days after the date
of issuance of the February Warrants, a registration statement covering the resale of the February Warrant Shares is not effective, the
holders may exercise the February Warrants by means of a cashless exercise.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:nonNumeric contextRef="c0" name="us-gaap:PreferredStockConversionBasis"><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series C Convertible preferred stock and
the February Warrants each contain a beneficial ownership limitation that restricts each of the investor&#8217;s ability to exercise
the February Warrants and convert the Series C Convertible preferred stock such that the number of shares of the Company common stock
held by each of them and their affiliates after such conversion or exercise does not exceed 4.99% (or, at the election of the Investor,
9.99%) of the Company&#8217;s then issued and outstanding shares of common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series C Purchase Agreement also provides
that until the 18 month anniversary of the Effectiveness Date, in the event of a subsequent financing (except for certain exempt issuances
as provided in the Series C Purchase Agreement) by the Company, each investor will have the right to participate in such subsequent financing
up to an amount equal to the investor&#8217;s proportionate share of the subsequent financing based on such investor&#8217;s participation
in the offering on the same terms, conditions and price provided for in the subsequent financing up to an amount equal to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="silo:InvestorInvestedAmountPercentage" scale="-2" unitRef="pure">50</ix:nonFraction>% of the
subsequent financing. In addition, pursuant to the Series C Purchase Agreement, the Company has agreed that neither it nor its subsidiaries
will enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common stock equivalents
to file any registration statement other than as contemplated pursuant to the Registration Rights Agreement (as defined below) for a
period of 90 days from the Effectiveness Date. Furthermore, subject to certain exceptions, the Company is prohibited from effecting or
entering into an agreement to effect any issuance by the Company or any of its subsidiaries of common stock or common stock equivalents
involving a Variable Rate Transaction (as defined in the Series C Purchase Agreement).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the offering, the Company
entered into separate registration rights agreements (&#8220;Registration Rights Agreements&#8221;) with the investors pursuant to which
the Company agreed to undertake to file a registration statement (the &#8220;Registration Statement&#8221;) to register the resale of
the Registrable Securities (as defined in the Registration Rights Agreement) within ten calendar days following the Effectiveness Date.
The Company agreed to use its best efforts to cause the Registration Statement covering the Registrable Securities to be declared effective
no later than the 60<sup>th</sup>&#160;calendar day following the Effectiveness Date, or in the event of a full review by the Securities
and Exchange Commission, the 90<sup>th</sup>&#160;calendar day following the Effectiveness Date, and to maintain the effectiveness of
the Registration Statement until all of the Registrable Securities have been sold or are otherwise able to be sold pursuant to Rule 144
under the Securities Act of 1933, as amended. <ix:nonNumeric contextRef="c0" name="us-gaap:ConstructionContractorLiquidityCharacteristic">If the Company fails to file the Registration Statement or have it declared effective by
the dates set forth above, amongst other things, the Company will be obligated to pay the investors damages in the amount of 1% of their
subscription amount, per month, until such events are satisfied.</ix:nonNumeric> The Registration Statement was filed and declared effective in April
2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><ix:nonNumeric contextRef="c0" name="silo:PlacementAgentWarrantsDescriptoin">In addition, pursuant to the terms of the
offering, the Company issued Bradley Woods &amp; Co, Ltd. and Katalyst Securities LLC warrants (the &#8220;Placement Agent Warrants&#8221;)
to purchase up to an aggregate of 57,013 shares of common stock, or 10% of the shares of common stock issuable upon conversion of the
Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period
of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment.</ix:nonNumeric> The Placement Agent
Warrants were valued at the grant date using a Black-Scholes option pricing model with the following assumptions: risk-free interest
rate of <ix:nonFraction contextRef="c231" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.50</ix:nonFraction>%, expected dividend yield of <ix:nonFraction contextRef="c231" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction>%, expected term of <ix:nonNumeric contextRef="c231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric> years using the simplified method and expected volatility of <ix:nonFraction contextRef="c231" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">169</ix:nonFraction>% based
on comparable and calculated volatility. The aggregate grant date fair value of these Placement Agent Warrants amounted to approximately
$<ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" name="silo:AggregateGrantDateFairValueOfPlacementAgentWarrants" scale="0" unitRef="usd">1,106,000</ix:nonFraction> and was recorded against the proceeds with no net effect on the consolidated financials.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net proceeds of the offering are expected
to be used for working capital purposes and to further execute on the Company&#8217;s existing business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Conversion of Series C Convertible Preferred
Stock into Common Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On March 31, 2022, the Company notified holders
of its Series C Convertible preferred stock of its election to force the conversion to its Series C Convertible preferred stock into
shares of the Company&#8217;s common stock pursuant to the Certificate of Designations unless such conversion would cause the holder
to exceed its beneficial ownership limitation pursuant to the Certificate of Designations. On March 31, 2022, the Company converted <ix:nonFraction contextRef="c232" decimals="0" format="ixt:num-dot-decimal" name="silo:ConvertablePreferredStock" scale="0" unitRef="shares">227</ix:nonFraction>
Series C Convertible preferred stock into <ix:nonFraction contextRef="c232" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares">15,167</ix:nonFraction> shares of common stock. As of June 30, 2022, there were no shares of Series C Convertible
preferred stock issued and outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_25" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Options</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_26" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 18, 2021, the Company&#8217;s board
of directors (&#8220;Board&#8221;) approved the Silo Pharma, Inc. 2020 Omnibus Equity Incentive Plan (the &#8220;2020 Plan&#8221;) to
incentivize employees, officers, directors and consultants of the Company and its affiliates. <ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">170,000</ix:nonFraction> shares of common stock are reserved
and available for issuance under the 2020 Plan, provided that certain exempt awards (as defined in the 2020 Plan), shall not count against
such share limit. The 2020 Plan provides for the grant, from time to time, at the discretion of the Board or a committee thereof, of
cash, stock options, including incentive stock options and nonqualified stock options, restricted stock, dividend equivalents, restricted
stock units, stock appreciation units and other stock or cash-based awards.&#160;The 2020 Plan shall terminate on the tenth anniversary
of the date of adoption by the Board. Subject to certain restrictions, the Board may amend or terminate the Plan at any time and for
any reason. An amendment of the 2020 Plan shall be subject to the approval of the Company&#8217;s stockholders only to the extent required
by applicable laws, rules or regulations. On March 10, 2021, the 2020 Plan was approved by the stockholders.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_27" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On December 29, 2021, the Board granted an
aggregate of <ix:nonFraction contextRef="c234" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">6,849</ix:nonFraction> incentive stock options under the 2020 Plan, to two non-employee board members, exercisable at $<ix:nonFraction contextRef="c235" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">7.30</ix:nonFraction> per share which
expire on <ix:nonNumeric contextRef="c236" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate">December 26, 2026</ix:nonNumeric> and vest on the first anniversary date of the grant date. These options were valued at $<ix:nonFraction contextRef="c234" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">30,224</ix:nonFraction> on the grant
date using a Binomial Lattice option pricing model with the following assumptions: risk-free interest rate of <ix:nonFraction contextRef="c234" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.75</ix:nonFraction>%, expected dividend
yield of <ix:nonFraction contextRef="c234" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">0</ix:nonFraction>%, expected term of <ix:nonNumeric contextRef="c234" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2</ix:nonNumeric> years using the simplified method and expected volatility of <ix:nonFraction contextRef="c234" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" scale="-2" unitRef="pure">115</ix:nonFraction>% based on historical volatility. The
Company recorded the fair value of the unvested stock options, in the amount of $<ix:nonFraction contextRef="c234" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares">30,224</ix:nonFraction>, as deferred compensation which is being amortized
over the vesting period. During the six months ended June 30, 2022, the Company amortized $<ix:nonFraction contextRef="c237" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" scale="0" unitRef="usd">15,122</ix:nonFraction> of the deferred compensation which
was recorded as compensation expenses in the accompanying condensed consolidated statement of operations. As of June 30, 2022, the deferred
compensation related to this issuance had a balance of $$<ix:nonFraction contextRef="c238" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" scale="0" unitRef="usd">15,122</ix:nonFraction>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_28" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_27"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 31, 2022, pursuant to an Employment
Agreement (see Note 8), an aggregate of 16,000 incentive stock options were issued under the 2020 Plan, to Dr. <ix:nonNumeric contextRef="c239" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">Kou, exercisable at $10.00
per share and expires on January 31, 2032. The stock options vest as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests
on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023.</ix:nonNumeric> The <ix:nonFraction contextRef="c240" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" unitRef="shares">16,000</ix:nonFraction> stock options had a fair value of $<ix:nonFraction contextRef="c240" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" unitRef="usd">94,915</ix:nonFraction> which were valued
at the grant date using a Binomial Lattice option pricing model with the following assumptions: risk-free interest rate of <ix:nonFraction contextRef="c240" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.18</ix:nonFraction>%, expected
dividend yield of <ix:nonFraction contextRef="c240" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction>%, expected term of <ix:nonNumeric contextRef="c240" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2</ix:nonNumeric> years using the simplified method and expected volatility of <ix:nonFraction contextRef="c240" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">117</ix:nonFraction>% based on historical volatility.
The Company recorded the fair value of the unvested stock options, in the amount of $<ix:nonFraction contextRef="c240" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" scale="0" unitRef="usd">59,322</ix:nonFraction>, as deferred compensation which is being
amortized over the vesting period. During the six months ended June 30, 2022, the Company amortized $<ix:nonFraction contextRef="c240" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">23,540</ix:nonFraction> of the deferred compensation
which was recorded as compensation expenses in the accompanying condensed consolidated statement of operations. As of June 30, 2022,
the deferred compensation related to his employment agreement had a balance of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">35,782</ix:nonFraction>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_29" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_28"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock option activities for the six months
ended June 30, 2022 are summarized as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_30" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_29"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number of<br/> Options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted Average<br/> Exercise<br/>
    Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted Average<br/> Remaining<br/>
    Contractual Term<br/> (Years)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Aggregate<br/> Intrinsic<br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%"><span style="-keep: true">Balance Outstanding, December 31, 2021</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c166" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">6,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c166" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.005</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c242" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="-keep: true">2.5</span></ix:nonNumeric></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-322"><span style="-keep: true">&#8212;</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">Granted as incentives</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c242" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">6,849</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c242" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">7.30</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><ix:nonNumeric contextRef="c242" format="ixt-sec:duryear" name="silo:GrantedAsIncentivesWeightedAverageRemainingContractualTermYears"><span style="-keep: true">4.5</span></ix:nonNumeric></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-323"><span style="-keep: true">&#8212;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Granted pursuant to employment agreement (see Note 8)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c242" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" unitRef="shares">16,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c242" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">10.00</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><ix:nonNumeric contextRef="c242" format="ixt-sec:duryear" name="silo:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"><span style="-keep: true">9.6</span></ix:nonNumeric></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-324"><span style="-keep: true">&#8212;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-325"><span style="-keep: true">&#160;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-326"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-327"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-328"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Balance Outstanding, June 30, 2022</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c243" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">28,849</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c243" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">7.50</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c242" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"><span style="-keep: true">7.5</span></ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-329"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Exercisable, June 30, 2022</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c243" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">12,000</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c243" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.00</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c242" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"><span style="-keep: true">5.8</span></ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" unitRef="usd">6,030</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_31" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_30"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Warrants</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_32" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_31"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 18, 2021, the Company granted warrants
to purchase up to <ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">5,000</ix:nonFraction> shares of the Company&#8217;s common stock in exchange for legal services rendered. The warrants have a term
of <ix:nonNumeric contextRef="c161" format="ixt-sec:durwordsen" name="silo:WarrantsTerm">five years</ix:nonNumeric> from the date of grant and are exercisable at an exercise price of $<ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">10.00</ix:nonFraction> per share. The warrants were valued on the grant
date at approximately $<ix:nonFraction contextRef="c161" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">16.50</ix:nonFraction> per warrant for a total of $<ix:nonFraction contextRef="c161" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" unitRef="usd">83,728</ix:nonFraction> using a Black-Scholes option pricing model with the following assumptions:
stock price of $<ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">17.50</ix:nonFraction> per share (based on the quoted trading price on the date of grant), volatility of <ix:nonFraction contextRef="c161" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">169</ix:nonFraction>%, expected term of <ix:nonNumeric contextRef="c161" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">five year</ix:nonNumeric>,
and a risk-free interest rate of <ix:nonFraction contextRef="c161" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.46</ix:nonFraction>%. During the year ended December 31, 2021, the Company recorded stock-based compensation of $<ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">83,728</ix:nonFraction>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:nonNumeric contextRef="c241" name="silo:PurchaseAgreementsDescription"><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_33" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_32"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On February 9, 2021, the Company entered into
pursuant to securities purchase agreements with certain investors pursuant to which it sold warrants to purchase up to 285,066 shares
of the Company&#8217;s common stock and 4,276 shares of the Company&#8217;s Series C Convertible preferred stock. The February Warrants
are exercisable for a period of five years from the date of issuance at an exercise price of $15.00 per share, subject to adjustment.
If, after a period of 180 days after the date of issuance of the February Warrants, a registration statement covering the resale of the
February Warrant Shares is not effective, the holders may exercise the February Warrants by means of a cashless exercise. In addition,
pursuant to the terms of the offering, the Company issued the Placement Agent Warrants to purchase up to an aggregate of 57,013 shares
of common stock to its placement agents, or 10% of the shares of common stock issuable upon conversion of the Series C preferred stock
and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing
date of the offering at an exercise price of $17.50 per share, subject to adjustment (see Series C Convertible Preferred Stock Financing
above). Such warrants issued to various investors and to the placement agents were recorded as additional paid in capital with an offsetting
debit applied against additional paid in capital, thus these warrants have no further accounting effect within the equity section.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation></ix:nonNumeric><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_34" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_33"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warrant activities for the six months ended
June 30, 2022 are summarized as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_34"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of<br/>
    Warrants</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
    Average<br/>
    Exercise<br/>
    Price</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
    Average<br/>
    Remaining<br/>
    Contractual Term<br/>
    (Years)</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/>
    Intrinsic<br/>
    Value</b></span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Outstanding, December
    31, 2021</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c169" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares">347,080</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c169" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">15.50</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: center"><ix:nonNumeric contextRef="c244" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></ix:nonNumeric></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-330"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted/Forfeited</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-331"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-332"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-333"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-334"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Outstanding, June 30, 2022</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c245" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares">347,080</ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c245" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">15.50</ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c244" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></ix:nonNumeric></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-335"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, June 30, 2022</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c244" decimals="INF" format="ixt:num-dot-decimal" name="silo:ShareBasedComponsationNumberOfWarrantsExercisableinDollars" scale="0" unitRef="shares">347,080</ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c245" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">15.50</ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c244" format="ixt-sec:duryear" name="silo:ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></ix:nonNumeric></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-336"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7 &#8211; <span style="text-decoration:underline">CONCENTRATIONS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_2" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Customer Concentration</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_3" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2022 and
2021, no customer accounted for over <ix:nonFraction contextRef="c246" decimals="2" format="ixt:num-dot-decimal" name="silo:ConcentrationsRiskPercentage1" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c251" decimals="2" format="ixt:num-dot-decimal" name="silo:ConcentrationsRiskPercentage1" scale="-2" unitRef="pure">10</ix:nonFraction></ix:nonFraction>% of total revenues from apparel sales included in discontinued operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_4" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2022 and
2021, one licensee accounted for <ix:nonFraction contextRef="c247" decimals="2" format="ixt:num-dot-decimal" name="silo:ConcentrationsRiskPercentage1" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c248" decimals="2" format="ixt:num-dot-decimal" name="silo:ConcentrationsRiskPercentage1" scale="-2" unitRef="pure">100</ix:nonFraction></ix:nonFraction>% total revenues from customer license fee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_5" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Vendor Concentrations</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_ConcentrationRiskDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2022 and
2021, one licensor accounted for <ix:nonFraction contextRef="c249" decimals="2" format="ixt:num-dot-decimal" name="silo:ConcentrationsRiskPercentage1" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c250" decimals="2" format="ixt:num-dot-decimal" name="silo:ConcentrationsRiskPercentage1" scale="-2" unitRef="pure">100</ix:nonFraction></ix:nonFraction>% of the Company&#8217;s vendor license agreements (see below) related to the Company&#8217;s biopharmaceutical
operation.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 &#8211; <span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment Agreement</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Eric Weisblum</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 17, 2020, the Company entered into
an employment agreement (&#8220;Employment Agreement&#8221;) with Eric Weisblum to serve as Chief Executive Officer and Chief Financial
Officer of the Company. The term of the Employment Agreement will continue for a period of one year from the date of execution date thereof
and automatically renews for successive one-year periods at the end of each term until either party delivers written notice of their
intent not to review at least six months prior to the expiration of the then effective term. <ix:nonNumeric contextRef="c173" name="silo:EmploymentAgreementDescription">The Employment Agreement provided for a
base salary of $120,000 and 152,619 of vested shares of the Company&#8217;s common stock in April 2020. In addition, Mr. Weisblum shall
be eligible to earn a bonus, subject to the sole discretion of the Company&#8217;s Board of Directors (&#8220;Board&#8221;).</ix:nonNumeric> The Employment
Agreement may be terminated by either the Company or Mr. Weisblum at any time and for any reason upon 60 days prior written notice. Upon
termination of the Employment Agreement, Mr. Weisblum shall be entitled to (i) any equity award that has vested prior to the termination
date, (ii) reimbursement of expenses incurred on or prior to such termination date and (iii) such employee benefits to which he may be
entitled as of the termination date (collectively, the &#8220;Accrued Amounts&#8221;). Mr. Weisblum employment may also be terminated
by the Company at any time, with cause, death or disability (as defined in the Employment Agreement). Upon the termination of the Employment
Agreement for death or disability, Mr. Weisblum shall be entitled to receive the Accrued Amounts. The Employment Agreement also contains
covenants prohibiting Mr. Weisblum from disclosing confidential information with respect to the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 18, 2021, the Company and Mr. Weisblum
entered into the first amendment (the &#8220;Amendment&#8221;) to the Employment Agreement, effective as of January 1, 2021. Pursuant
to the Amendment Mr. Weisblum&#8217;s base salary was increased from $<ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SupplementalUnemploymentBenefitsSalaryContinuation" scale="0" unitRef="usd">120,000</ix:nonFraction> per year to $<ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SupplementalUnemploymentBenefitsSalaryContinuation" scale="0" unitRef="usd">180,000</ix:nonFraction> per year and all the terms and provisions
of the Employment Agreement shall remain in full force and effect.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Dr. James Kuo </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 27, 2022, the Company and Dr. <ix:nonNumeric contextRef="c254" name="silo:EmploymentAgreementDescription">James
Kuo entered into an employment agreement (&#8220;Kuo Employment Agreement&#8221;) for Dr. Kuo to serve as the Vice President of Research
&amp; Development. The Kuo Employment Agreement shall be effective as of the date of the agreement and shall automatically renew for
a period of one year at every anniversary of the effective date, with the same terms and conditions, unless either party provides written
notice of its intention not to extend the term of the Kuo Employment Agreement at least thirty days&#8217; prior to the applicable renewal
date. Dr. Kuo shall be paid an annual base salary of $30,000. For each twelve-month period of his employment, Dr. Kuo shall be entitled
to a bonus whereby amount and terms shall be in the sole and absolute discretion of the Board of Directors (&#8220;Board&#8221;) and
shall be payable at the Company&#8217;s sole option in stock or in cash. In addition, an aggregate of 16,000 incentive stock options
were granted under the 2020 Plan to Dr. Kou, exercisable at $10.00 per share and expires on January 31, 2032. The stock options vest
as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023.</ix:nonNumeric> The
<ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" unitRef="shares">16,000</ix:nonFraction> stock options had a fair value of $<ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" unitRef="usd">94,914</ix:nonFraction> which valued at grant date using Binomial Lattice option pricing model with the following
assumptions: risk-free interest rate of <ix:nonFraction contextRef="c255" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.18</ix:nonFraction>%, expected dividend yield of <ix:nonFraction contextRef="c255" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction>%, expected term of <ix:nonNumeric contextRef="c255" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2</ix:nonNumeric> years using the simplified method and
expected volatility of <ix:nonFraction contextRef="c255" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">117</ix:nonFraction>% based on calculated volatility. The Company recorded the fair value of the unvested stock options, in the
amount of $<ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" scale="0" unitRef="usd">59,322</ix:nonFraction>, as deferred compensation which is being amortized over the vesting period. During the six months ended June 30, 2022,
the Company amortized $<ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">23,540</ix:nonFraction> of the deferred compensation which was recorded as compensation expenses in the accompanying condensed
consolidated statement of operations. As of June 30, 2022, the deferred compensation had a balance of $<ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">35,782</ix:nonFraction> (see Note 6).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License Agreements between the Company
and Vendors </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>University of Maryland, Baltimore -
License Agreement for Development and Use of Central Nervous System-Homing Peptides</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Commercial Evaluation License and Option
Agreement with the University of Maryland, Baltimore</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_11" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of July 15, 2020, the Company,
through its wholly-owned subsidiary, Silo Pharma, Inc. (see Note 1) and University of Maryland, Baltimore (&#8220;UMB&#8221;) (collectively
as &#8220;Parties&#8221;), entered into a commercial evaluation license and option agreement (&#8220;License Agreement&#8221;), granting
the Company an exclusive, non-sublicensable, non-transferable license to with respect to the exploration of the potential use of central
nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory
pathology. The License Agreement also granted the Company an exclusive option to negotiate and obtain an exclusive, sublicensable, royalty-bearing
license (&#8220;Exclusive Option&#8221;) to with respect to the subject technology. The License Agreement had a term of six months from
the effective date however if the Company exercises the Exclusive Option, the License Agreement shall expire at the end of the negotiation
period (as defined in the License Agreement) or upon execution of a master license agreement, whichever occurs first. The Company exercised
its Exclusive Option on January 13, 2021 and entered into a Master License Agreement on February 12, 2021. Both parties may terminate
this agreement within thirty days by giving a written notice. In July 2020, the Company paid a license fee of $<ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="silo:LicenseFee" scale="0" unitRef="usd">10,000</ix:nonFraction> to UMB pursuant
to the License Agreement which was recorded in professional fees during the year ended December 31, 2020 since the Company could not
conclude that such costs would be recoverable for this early-stage venture.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_12" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Master License Agreement with the University
of Maryland, Baltimore</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_13" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As disclosed above, effective as of February
12, 2021, the Company and University of Maryland, Baltimore (&#8220;UMB&#8221;), entered into the Master License Agreement (&#8220;Master
License Agreement&#8221;) which grants the Company an exclusive, worldwide, sublicensable, royalty-bearing license to certain intellectual
property: (i) to make, have made, use, sell, offer to sell, and import certain licensed products and: (ii) to use the invention titled,
&#8220;Central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other
neuroinflammatory pathology&#8221; and UMB&#8217;s confidential information to develop and perform certain licensed processes for the
therapeutic treatment of neuroinflammatory disease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_14" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Master License Agreement will remain in
effect on a Licensed Product-by-Licensed Product basis and country-by-country basis until the later of: (a) the last patent covered under
the Master License Agreement expires, (b) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory
exclusivity, or other legally enforceable market exclusivity, if applicable, or (c) <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="silo:CommercialSaleTerm">10</ix:nonNumeric> years after the first commercial sale of a Licensed
Product in that country, unless earlier terminated in accordance with the provisions of the Master License Agreement. The term of the
Master License Agreement shall expire <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="silo:LicenseAgreementExpire">15</ix:nonNumeric> years after the Master License Agreement Effective Date in which (a) there were never any patent
rights, (b) there was never any data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally
enforceable market exclusivity or (c) there was never a first commercial sale of a Licensed Product.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_15" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may assign, sublicense, grant,
or otherwise convey any rights or obligations under the Master License Agreement to a Company affiliate, without obtaining prior written
consent from UMB provided that it meets the terms defined in the Master License Agreement. The Company may grant sublicenses of some
or all of the rights granted by the Master License Agreement, provided that there is no uncured default or breach of any material term
or condition under the Master License Agreement, by Company, at the time of the grant, and that the grant complies with the terms and
conditions of the Master License Agreement. The Company shall be and shall remain responsible for the performance by each of the Company&#8217;s
sublicensee. Any sublicense shall be consistent with and subject to the terms and conditions of the Master License Agreement and shall
incorporate terms and conditions sufficient to enable Company to comply with the Master License Agreement. <ix:nonNumeric contextRef="c0" name="silo:SublicenseIncomeDescription">The Company or Company affiliates
shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company&#8217;s sublicense income
which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first
licensed product; and (b) 15% of the Company&#8217;s sublicense income which is receivable with respect to any sublicense that is executed
after the filing of an NDA (or foreign equivalent) for the first licensed product.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_16" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Master License Agreement,
<ix:nonNumeric contextRef="c0" name="silo:LicenseAgreementDescription">the Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty
payments depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company shall
pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the effective date; and (b)
$50,000 on or before the first anniversary of the effective date. The license fee is non-refundable and is not creditable against any
other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing,
prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid $25,000 license fee on
February 17, 2021 which was recorded as prepaid expense and is being amortized over the 15-year term. The Company recognized amortization
expense of $4,375 in 2021. During the six months ended June 30, 2022, the Company recognized amortization expense of $2,500. At December
31, 2021, prepaid expense and other current assets &#8211; current amounted $5,000 and prepaid expense &#8211; non-current amounts $15,625.
At June 30, 2022, prepaid expense and other current assets &#8211; current amounted $5,000 and prepaid expense &#8211; non-current amounts
$13,125 as reflected in the accompanying condensed consolidated balance sheets.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_17" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Milestone Payment Terms</span>:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_18" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_17"><ix:nonNumeric contextRef="c0" escape="true" name="silo:ScheduleOfMilestonePayments"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Milestone</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><ix:nonNumeric contextRef="c262" name="silo:Milestone">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c262" decimals="0" format="ixt:num-dot-decimal" name="silo:MilestonePayment" scale="0" unitRef="usd">50,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><ix:nonNumeric contextRef="c263" name="silo:Milestone">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c263" decimals="0" format="ixt:num-dot-decimal" name="silo:MilestonePayment" scale="0" unitRef="usd">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><ix:nonNumeric contextRef="c264" name="silo:Milestone">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c264" decimals="0" format="ixt:num-dot-decimal" name="silo:MilestonePayment" scale="0" unitRef="usd">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><ix:nonNumeric contextRef="c265" name="silo:Milestone">Receipt of New Drug Application (&#8220;NDA&#8221;) (or foreign equivalent) approval for a Licensed Product</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c265" decimals="0" format="ixt:num-dot-decimal" name="silo:MilestonePayment" scale="0" unitRef="usd">500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><ix:nonNumeric contextRef="c266" name="silo:Milestone">Achievement of First Commercial Sale of Licensed Product</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c266" decimals="0" format="ixt:num-dot-decimal" name="silo:MilestonePayment" scale="0" unitRef="usd">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_19" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_18"><ix:nonNumeric contextRef="c0" continuedAt="_RoyaltyPaymentsDescription-c0_cont_1" name="silo:RoyaltyPaymentsDescription"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Royalty Payments Terms</span>:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_20" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_19"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.25in"><ix:continuation continuedAt="_RoyaltyPaymentsDescription-c0_cont_2" id="_RoyaltyPaymentsDescription-c0_cont_1">&#160;</ix:continuation></td> <td style="width: 0.25in; text-align: justify"><ix:continuation continuedAt="_RoyaltyPaymentsDescription-c0_cont_3" id="_RoyaltyPaymentsDescription-c0_cont_2"><span style="font-size: 10pt">(i)</span></ix:continuation></td> <td style="text-align: justify"><ix:continuation continuedAt="_RoyaltyPaymentsDescription-c0_cont_4" id="_RoyaltyPaymentsDescription-c0_cont_3"><span style="font-size: 10pt">3% on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and</span></ix:continuation></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><ix:continuation continuedAt="_RoyaltyPaymentsDescription-c0_cont_5" id="_RoyaltyPaymentsDescription-c0_cont_4">&#160;</ix:continuation></td> <td style="text-align: justify"><ix:continuation continuedAt="_RoyaltyPaymentsDescription-c0_cont_6" id="_RoyaltyPaymentsDescription-c0_cont_5">&#160;</ix:continuation></td> <td style="text-align: justify"><ix:continuation continuedAt="_RoyaltyPaymentsDescription-c0_cont_7" id="_RoyaltyPaymentsDescription-c0_cont_6">&#160;</ix:continuation></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><ix:continuation continuedAt="_RoyaltyPaymentsDescription-c0_cont_8" id="_RoyaltyPaymentsDescription-c0_cont_7">&#160;</ix:continuation></td> <td style="text-align: justify"><ix:continuation continuedAt="_RoyaltyPaymentsDescription-c0_cont_9" id="_RoyaltyPaymentsDescription-c0_cont_8"><span style="font-size: 10pt">(ii)</span></ix:continuation></td> <td style="text-align: justify"><ix:continuation id="_RoyaltyPaymentsDescription-c0_cont_9"><span style="font-size: 10pt">5% on sales of licensed products during the applicable calendar year for sales greater than $50,000,000; and</span></ix:continuation></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-size: 10pt">(iii)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">a minimum annual royalty payments, as follows:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_21" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_20"><ix:nonNumeric contextRef="c0" escape="true" name="silo:ScheduleOfUMBMinimumRoyaltyPayments"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Years</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Minimum Annual Royalty</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><ix:nonNumeric contextRef="c262" name="silo:YearsDescription">Prior to First Commercial Sale</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-337; font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><ix:nonNumeric contextRef="c263" name="silo:YearsDescription">Year of First Commercial Sale</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-338; font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><ix:nonNumeric contextRef="c264" name="silo:YearsDescription">First calendar year following the First Commercial Sale</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c264" decimals="0" format="ixt:num-dot-decimal" name="silo:MinimumAnnualRoyalty" scale="0" unitRef="usd">25,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><ix:nonNumeric contextRef="c265" name="silo:YearsDescription">Second calendar year following the First Commercial Sale</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c265" decimals="0" format="ixt:num-dot-decimal" name="silo:MinimumAnnualRoyalty" scale="0" unitRef="usd">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><ix:nonNumeric contextRef="c266" name="silo:YearsDescription">Third calendar year following the First Commercial Sale</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c266" decimals="0" format="ixt:num-dot-decimal" name="silo:MinimumAnnualRoyalty" scale="0" unitRef="usd">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_22" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2021, in connection with the Company&#8217;s
Sublicense Agreement with Aikido Pharma Inc. (see below - <i>Patent License Agreement with Aikido Pharma Inc.</i>), the Company paid
<ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="silo:SublicenseIncomePercentage" scale="-2" unitRef="pure">25</ix:nonFraction>% of its sublicense income to UMB, pursuant to the Master License Agreement, which amounted to $<ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="silo:SublicenseAgreementAmountPaid" scale="0" unitRef="usd">12,500</ix:nonFraction>. The Company recognized amortization
expense of $<ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="silo:OtherDepreciationsAndAmortization" scale="0" unitRef="usd">628</ix:nonFraction> in 2021. During the six months ended June 30, 2022, the Company recognized amortization expense of $<ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UtilitiesOperatingExpenseDepreciationAndAmortization" scale="0" unitRef="usd">419</ix:nonFraction>. At December
31, 2021, prepaid expense and other current assets &#8211; current amounted $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd">838</ix:nonFraction> and prepaid expenses &#8211; non-current amounts $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseOtherNoncurrent" scale="0" unitRef="usd">11,034</ix:nonFraction>.
At June 30, 2022, prepaid expense and other current assets &#8211; current amounted $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd">838</ix:nonFraction> and prepaid expenses &#8211; non-current amounts
$<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseOtherNoncurrent" scale="0" unitRef="usd">10,615</ix:nonFraction> as reflected in the accompanying condensed consolidated balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_23" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>University of Maryland, Baltimore -
License Agreement for Development and Use of Joint-Homing Peptides</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_24" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Commercial Evaluation License and Option
Agreement with the University of Maryland, Baltimore</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_25" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of February 26, 2021, the Company,
through its wholly-subsidiary, Silo Pharma, Inc., and University of Maryland, Baltimore (&#8220;UMB&#8221;) (collectively as &#8220;Parties&#8221;),
entered into a commercial evaluation license and option agreement (&#8220;License Agreement&#8221;), which granted the Company an exclusive,
non-sublicensable, non-transferable license to with respect to the exploration of the potential use of joint-homing peptides for use
in the investigation and treatment of arthritogenic processes. The License Agreement also granted the Company an exclusive option to
negotiate and obtain an exclusive, sublicensable, royalty-bearing license (&#8220;Exclusive Option&#8221;) to with respect to the subject
technology. The License Agreement had a term of six months from the effective date. Both parties could have terminated the License Agreement
within thirty days by giving a written notice.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_26" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, the Company entered into
a First Amendment Agreement (&#8220;First Amendment&#8221;) with UMB to extend the term of the original License Agreement by an additional
six months such that the First Amendment was effective until February 25, 2022 however, if the Company exercises the Exclusive Option,
the License Agreement shall expire at the end of the negotiation period (as defined in the License Agreement) or upon execution of a
master license agreement, whichever occurs first. The Company paid a license fee of $<ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="silo:LicenseFee" scale="0" unitRef="usd">10,000</ix:nonFraction> to UMB in March 2021 pursuant to the License
Agreement which was recorded in professional fees during the year ended December 31, 2021, since the Company could not conclude that
such costs would be recoverable for this early-stage venture.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_27" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2022, the Parties entered into
a second amendment to the commercial evaluation and license agreement dated February 26, 2021 (&#8220;Second Amendment&#8221;). The Second
Amendment extends the term of the original license agreement until December 31, 2022. However, if the Company exercises the Exclusive
Option, the License Agreement shall expire at the end of the negotiation period (as defined in the License Agreement) or upon execution
of a master license agreement, whichever occurs first.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_28" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_27"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2022, the Parties entered into
a third amendment to the commercial evaluation and license agreement dated February 26, 2021 (&#8220;Third Amendment&#8221;). The Third
Amendment expands the scope of the license granted in the License Agreement to add additional patent rights with respect to an invention
generally known as <i>Peptide-Targeted Liposomal Delivery for Treatment Diagnosis, and Imaging of Diseases and Disorders</i>. In consideration
of the licenses granted under this Third Amendment, Company agreed to pay a one-time, non-refundable fee of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CustomerRefundableFeesProceeds" scale="0" unitRef="usd">2,500</ix:nonFraction> which was recorded
as research and development expense in the condensed consolidated statement of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_29" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_28"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License Agreements between the Company
and Customer</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_30" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_29"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Customer Patent License Agreement with
Aikido Pharma Inc.</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_31" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_30"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, the Company and its subsidiary
Silo Pharma, Inc., a Florida corporation, entered into a patent license agreement (&#8220;License Agreement&#8221;) (collectively, the
&#8220;Licensor&#8221;) and Aikido Pharma Inc. (&#8220;Aikido&#8221; or the &#8220;Customer&#8221;), as amended on April 12, 2021, pursuant
to which the Licensor granted Aikido an exclusive, worldwide (&#8220;Territory&#8221;), sublicensable, royalty-bearing license to certain
intellectual property: (i) to make, have made, use, provide, import, export, lease, distribute, sell, offer for sale, develop and advertise
certain licensed products and (ii) to develop and perform certain licensed processes for the treatment of cancer and symptoms caused
by cancer (&#8220;Field of Use&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_32" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_31"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The License Agreement also provided that,
if the Licensor exercised the option granted to it pursuant to its commercial evaluation license and option agreement with UMB, effective
as of July 15, 2020, it would grant Aikido a non-exclusive sublicense (&#8220;Right&#8221;) to certain UMB patent rights in the field
of neuroinflammatory diseases occurring in patients diagnosed with cancer (&#8220;Field&#8221;). Pursuant to the License Agreement, Aikido
agreed to pay the Licensor, among other things, (i) a one-time non-refundable cash payment of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:NonrefundableCashPayment" scale="0" unitRef="usd">500,000</ix:nonFraction> and (ii) royalty payments equal
to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="silo:NetSalePercentage" scale="-2" unitRef="pure">2</ix:nonFraction>% of net sales (as defined in the License Agreement) in the Field of Use in the Territory. In addition, Aikido agreed to issue the
Licensor <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:LicensorShare" scale="0" unitRef="shares">500</ix:nonFraction> shares of Aikido&#8217;s newly designated Series M Convertible Preferred Stock which were to be converted into an aggregate
of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:AggregateOfConvertedShares" scale="0" unitRef="shares">625,000</ix:nonFraction> shares of the Aikido&#8217;s common stock. On April 12, 2021, the Company entered into an amendment to the License Agreement
(&#8220;Amended License Agreement&#8221;) with Aikido dated January 5, 2021 whereby Aikido issued an aggregate of <ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="silo:AggregateOfConvertedShares" scale="0" unitRef="shares">625,000</ix:nonFraction> restricted
shares of Aikido&#8217;s common stock instead of the <ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="silo:LicensorShare" scale="0" unitRef="shares">500</ix:nonFraction> shares of the Series M Convertible Preferred Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>







</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_33" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_32"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the License Agreement, the Company
is required to prepare file, prosecute, and maintain the licensed patents. Unless earlier terminated, the term of the license to the
licensed patents will continue until the expiration or abandonment of all issued patents and filed patent applications within the licensed
patents. The Company may terminate the License Agreement upon 30 day written notice if Aikido fails to pay any amounts due and payable
to the Company or if Aikido or any of its affiliates brings a patent challenge against the Company, assists others in bringing a legal
or administrative challenge to the validity, scope, or enforceability of or opposes any of the licensed patents (&#8220;Patent Challenge&#8221;)
against the Company (except as required under a court order or subpoena). Aikido may terminate the Agreement at any time without cause,
and without incurring any additional penalty, (i) by providing at least 30 days&#8217; prior written notice and paying the Company all
amounts due to it through such termination effective date. Either party may terminate the Agreement for material breaches that have failed
to be cured within 60 days after receiving written notice. The Company collected the non-refundable cash payment of $<ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="silo:NonrefundableCashPayment" scale="0" unitRef="usd">500,000</ix:nonFraction> on January
5, 2021 which was recorded as deferred revenue to be recognized as revenues over the <ix:nonNumeric contextRef="c181" format="ixt-sec:duryear" name="silo:RevenueTerm">15</ix:nonNumeric> year term of the License Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_34" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_33"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to a vote of Aikido&#8217;s stockholders
to approve a reverse split of its common stock no later than December 31, 2021 (&#8220;Reverse Stock Split Vote&#8221;), each share of
the Series M Convertible Preferred Stock shall be entitled to such number of votes equal to <ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:NumberOfVotingShares" scale="0" unitRef="shares">20,000</ix:nonFraction> shares of Aikido&#8217;s common stock.
<ix:nonNumeric contextRef="c0" continuedAt="_ReverseStockSplitVoteDescription-c0_cont_1" name="silo:ReverseStockSplitVoteDescription">In addition, each share of the Series M Convertible Preferred Stock shall be convertible, at any time after the earlier of (i) the date
that the Reverse Stock Split Vote is approved by Aikido&#8217;s stockholders and (ii) December 31, 2021, at the option of the holder,
into such number of shares of Aikido&#8217;s common stock determined by dividing the Stated Value by the Conversion Price. &#8220;Stated
Value&#8221; means $1,000. &#8220;Conversion Price&#8221; means $0.80, subject to adjustment.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_35" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_34"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:continuation id="_ReverseStockSplitVoteDescription-c0_cont_1">Prior to the April 12, 2021, issuance of the
common stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible
Preferred stock which was equivalent into Aikido&#8217;s 625,000 shares of common stock at a fair value of $0.85 per common share or
$531,250 based quoted trading price of Aikido&#8217;s common stock on the date of grant. The Company recorded an equity investment of
$531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license.</ix:continuation> Accordingly, the Company
recorded a total deferred revenue of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenue" scale="0" unitRef="usd">1,031,250</ix:nonFraction> ($<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="silo:CashReceived" scale="0" unitRef="usd">500,000</ix:nonFraction> cash received and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="silo:SecuritiesReceived" scale="0" unitRef="usd">531,250</ix:nonFraction> value of equity securities received) to be recognized
as revenues over the <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="silo:RevenueTerm">15</ix:nonNumeric>-year term. The Company recognized revenue of $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueRevenueRecognized1" scale="0" unitRef="usd">68,750</ix:nonFraction> in 2021. During the six months ended June 30, 2022, the
Company recognized revenue of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueRevenueRecognized1" scale="0" unitRef="usd">34,375</ix:nonFraction>. At December 31, 2021, deferred revenue &#8211; current portion amounted $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RecognitionOfDeferredRevenue" scale="0" unitRef="usd">68,750</ix:nonFraction> and deferred revenue
&#8211; long-term portion amounted $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="silo:DeferredRevenueLongtermPortionAmounted" scale="0" unitRef="usd">893,750</ix:nonFraction>. At June 30, 2022, deferred revenue &#8211; current portion amounted $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RecognitionOfDeferredRevenue" scale="0" unitRef="usd">68,750</ix:nonFraction> and deferred
revenue &#8211; long-term portion amounted $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="silo:DeferredRevenueLongtermPortion" scale="0" unitRef="usd">859,375</ix:nonFraction> as reflected in the accompanying condensed consolidated balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_36" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_35"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Right shall be to the full extent permitted
by and on terms and conditions required by UMB for a term consistent with the term of patent and technology licenses that UMB normally
grants. In the event that the Company exercises its option and executes a license with UMB to the UMB patent rights within 40 days after
the execution of such UMB license, for consideration to be agreed upon and paid by Aikido, which consideration shall in no event exceed
<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="silo:ConsiderationFeePayablePercentage" scale="-2" unitRef="pure">110</ix:nonFraction>% of any fee payable by the Company to UMB for the right to sublicense the UMB patent rights. The Company shall grant Aikido a nonexclusive
sublicense in the United States to the UMB patent rights in the Field, subject to the terms of any UMB license Licensor obtains, including
any royalty obligations on sublicensees required under any such sublicense. The option was exercised on January 13, 2021. Accordingly,
on April 6, 2021, the Company entered into the Sublicense Agreement with Aikido pursuant to which it granted Aikido a worldwide exclusive
sublicense to its licensed patents under the Master License Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_37" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_36"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Customer Sublicense&#160;Agreement with
Aikido Pharma Inc.</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_38" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_37"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2021 (the &#8220;Sublicense Agreement
Effective Date&#8221;), the Company entered into the Sublicense Agreement with Aikido pursuant to which the Company granted Aikido an
exclusive worldwide sublicense to (i) make, have made, use, sell, offer to sell and import the Licensed Products (as defined below) and
(ii) in connection therewith to (A) use an invention known as &#8220;Central nervous system-homing peptides in vivo and their use for
the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology&#8221; which was sublicensed to the Company
pursuant to the Master License Agreement&#160;and (B) practice certain patent rights (&#8220;Patent Rights&#8221;) for the therapeutic
treatment of neuroinflammatory disease in cancer patients. &#8220;Licensed Products&#8221; means any product, service, or process, the
development, making, use, offer for sale, sale, importation, or providing of which: (i) is covered by one or more claims of the Patent
Rights; or (ii) contains, comprises, utilizes, incorporates, or is derived from the Invention or any technology disclosed in the Patent
Rights.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>







</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_39" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_38"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Sublicense Agreement, Aikido
agreed to pay the Company (i) an upfront license fee of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:UpfrontLicenseFees" scale="0" unitRef="usd">50,000</ix:nonFraction>, (ii)&#160;the same sales-based royalty payments that the Company is
subject to under the Master License Agreement and (iii) total milestone payments of up to $<ix:nonFraction contextRef="c257" decimals="-5" format="ixt:num-dot-decimal" name="silo:UpfrontLicenseFees" scale="6" unitRef="usd">1.9</ix:nonFraction> million. The Sublicense Agreement shall
continue on a Licensed Product-by-Licensed Product and country-by-country basis until the later of (i) the date of expiration of the
last to expire claim of the Patent Rights covering such Licensed Product in such country, (ii) the expiration of data protection, new
chemical entity, orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity, if applicable and (iii)
<ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="silo:FirstCommercialSale">10</ix:nonNumeric> years after the first commercial sale of a Licensed Product in that country, unless terminated earlier pursuant to the terms of the
Sublicense Agreement. Furthermore, the Sublicense Agreement shall expire <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="silo:AgreementShallExpire">15</ix:nonNumeric> years after the Sublicense Agreement Effective Date with
respect to any country in which (i) there were never any Patent Rights, (ii) there was never any data protection, new chemical entity,
orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity with respect to a Licensed Product and
(ii) there was never a commercial sale of a Licensed Product, unless such agreement is earlier terminated pursuant to its terms. The
Company collected the upfront license fee of $<ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="silo:UpfrontLicenseFees" scale="0" unitRef="usd">50,000</ix:nonFraction> in April 2021. The Company recognized revenue of $<ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="silo:RecognizedRevenues" scale="0" unitRef="usd">2,514</ix:nonFraction> in 2021. During the six
months ended June 30, 2022, the Company recognized revenue of $<ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="silo:RecognizedRevenues" scale="0" unitRef="usd">1,676</ix:nonFraction>. At December 31, 2021, deferred revenue &#8211; current portion
amounted $<ix:nonFraction contextRef="c258" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RecognitionOfDeferredRevenue" scale="0" unitRef="usd">3,352</ix:nonFraction> and deferred revenue &#8211; long-term portion amounted $<ix:nonFraction contextRef="c258" decimals="0" format="ixt:num-dot-decimal" name="silo:DeferredRevenueLongtermPortionAmounted" scale="0" unitRef="usd">44,134</ix:nonFraction>. At June 30, 2022, deferred revenue &#8211; current portion
amounted $<ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RecognitionOfDeferredRevenue" scale="0" unitRef="usd">3,352</ix:nonFraction> and deferred revenue &#8211; long-term portion amounted $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:DeferredRevenueLongtermPortionAmounted" scale="0" unitRef="usd">42,458</ix:nonFraction> as reflected in the accompanying condensed consolidated
balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_40" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_39"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sponsored Study and Research Agreements
between the Company and Vendors</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_41" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_40"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investigator-Sponsored Study Agreement
with University of Maryland, Baltimore </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_42" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_41"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, the Company entered into
an investigator-sponsored study agreement (&#8220;Sponsored Study Agreement&#8221;) with the University of Maryland, Baltimore. The research
project is a clinical study to examine a novel peptide-guided drug delivery approach for the treatment of multiple sclerosis (&#8220;MS&#8221;).
More specifically, the study is designed to evaluate (1) whether MS-1-displaying liposomes can effectively deliver dexamethasone to the
CNS and (2) whether MS-1-displaying liposomes are superior to plain liposomes, also known as free drug, in inhibiting the relapses and
progression of experimental autoimmune encephalomyelitis. Pursuant to the Sponsored Study Agreement, the research shall commence on March
1, 2021 and will continue until substantial completion, subject to renewal upon mutual written consent of the parties. <ix:nonNumeric contextRef="c181" name="silo:SponsoredStudyAgreementDescription">The total cost
under the Sponsored Study Agreement shall not exceed $81,474 which is payable in two equal installments of $40,737 upon execution of
the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. The Company
paid $40,737 on January 13, 2021 which was recorded in prepaid expense to be amortized over the nine-month period. Currently, the project
has not been completed due to the delays cause by the Covid-19 pandemic. During the year ended December 31, 2021, the Company fully amortized
the prepaid expense of $40,737.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_43" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_42"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sponsored Research Agreement with The
Regents of the University of California</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_44" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_43"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021 (the &#8220;Effective Date&#8221;),
the Company entered into a sponsored research agreement (the &#8220;Sponsored Research Agreement&#8221;) with The Regents of the University
of California, on behalf of its San Francisco Campus (&#8220;UCSF&#8221;) pursuant to which UCSF shall conduct a study to examine psilocybin&#8217;s
effect on inflammatory activity in humans to accelerate its implementation as a potential treatment for Parkinson&#8217;s Disease, chronic
pain, and bipolar disorder. Pursuant to the Agreement, the Company shall pay UCSF a total fee of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:SublicenseAmountPaid" scale="0" unitRef="usd">342,850</ix:nonFraction> to conduct the research over
the two-year period. The Agreement shall be effective for a period of two years from the Effective Date, subject to renewal or earlier
termination as set forth in the Sponsored Research Agreement. <ix:nonNumeric contextRef="c0" name="silo:SponsoredResearchAgreementDescription">The Company paid the first payment of $40,000 pursuant to the payment schedule
on the Sponsored Research Agreement on June 15, 2021, second payment of $40,000 on September 9, 2021 and $20,570 on November 18, 2021,
third payment of $60,570 on March 1, 2022, which were recorded to prepaid expense and other current assets &#8211; current to be amortized
over the two-year period. In 2021, the Company amortized $92,855 of the prepaid expense. During the six months ended June 30, 2022, the
Company amortized $68,285 of the prepaid expense leaving a prepaid asset of $0 at June 30, 2022.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>







</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_45" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_44"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sponsored Research Agreement with University
of Maryland, Baltimore</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_46" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_45"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, the Company and University
of Maryland, Baltimore (&#8220;UMB&#8221;) entered into a sponsored research agreement (&#8220;July 2021 Sponsored Research Agreement&#8221;)
pursuant to which UMB shall&#160;evaluate the pharmacokinetics of dexamethasone delivered to arthritic rats via liposome. The research
pursuant to the July 2021 Sponsored Research Agreement shall commence on September 1, 2021 and will continue until the substantial completion
thereof, subject to renewal upon written consent of the parties. The July 2021 Sponsored Research Agreement may be terminated by either
party upon 30 days&#8217; prior written notice to the other party. In addition, if either party commits any material breach of or defaults
with respect to any terms or conditions of the July 2021 Sponsored Research Agreement and fails to remedy such default or breach within
10 business days after written notice from the other party, the party giving notice may terminate the July 2021 Sponsored Research Agreement
as of the date of receipt of such notice by the other party. If the Company terminates the July 2021 Sponsored Research Agreement for
any reason other than an uncured material breach by UMB, the Company shall relinquish any and all rights it may have in the Results (as
defined in the July 2021 Sponsored Research Agreement) to UMB. In addition, if the July 2021 Sponsored Research Agreement is terminated
early, the Company, among other things, will pay all costs incurred and accrued by UMB as of the date of termination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_47" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_46"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the July 2021 Sponsored
Research Agreement, UMB granted the Company an option (the &#8220;Option&#8221;) to negotiate and obtain an exclusive license to any
UMB Arising IP (as defined in the July 2021 Sponsored Research Agreement) and UMB&#8217;s rights in any Joint Arising IP (as defined
in the July 2021 Sponsored Research Agreement) (collectively, the &#8220;UMB IP&#8221;). The Company may exercise the Option by giving
UMB written notice within 60 days after it receives notice from UMB of the UMB IP. Pursuant to the July 2021 Sponsored Research Agreement,
the Company shall pay UMB the fees below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_48" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_47"><ix:nonNumeric contextRef="c0" escape="true" name="silo:ScheduleOfShallPayUMB"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Payment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 2%; text-align: center"><span style="font-size: 10pt">1</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c267" decimals="0" format="ixt:num-dot-decimal" name="silo:SponsoredPayment" scale="0" unitRef="usd">92,095</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 83%"><ix:nonNumeric contextRef="c267" name="silo:PaymentDescription"><span style="font-size: 10pt">Upon execution of the July 2021 Sponsored Research Agreement</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center"><span style="font-size: 10pt">2</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="silo:SponsoredPayment" scale="0" unitRef="usd">92,095</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><ix:nonNumeric contextRef="c268" name="silo:PaymentDescription"><span style="font-size: 10pt">Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-size: 10pt">3</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c269" decimals="0" format="ixt:num-dot-decimal" name="silo:SponsoredPayment" scale="0" unitRef="usd">92,095</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><ix:nonNumeric contextRef="c269" name="silo:PaymentDescription"><span style="font-size: 10pt">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement</span></ix:nonNumeric></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_49" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_48"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid the first payment of $<ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="silo:CompanyPaidCash" scale="0" unitRef="usd">92,095</ix:nonFraction>
on September 1, 2021 which was recorded to prepaid expense and other current assets &#8211; current and was amortized during the year
ended December 31, 2021. The Company paid the second payment of $<ix:nonFraction contextRef="c259" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear" scale="0" unitRef="usd">50,000</ix:nonFraction> on February 1, 2022 which was recorded as research and development
expense in the accompanying condensed consolidated statement of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_50" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_49"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 7, 2022, the Company and UMB amended
the July 2021 Sponsored Research Agreement whereby both parties agreed to make changes to the original project work and budget. The amendment
had no effect on the consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_51" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_50"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sponsored Research Agreement with Columbia
University</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_52" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_51"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2021, the Company entered into
a sponsored research agreement with Columbia University pursuant to which the Company has been granted an option to license certain assets
currently under development, including Alzheimer&#8217;s disease. The term of the option will commence on the effective date of this
agreement and will expire upon the earlier of (i) 90 days after the date of the Company&#8217;s receipt of a final research report for
each specific research proposal as defined in the agreement or (ii) termination of the research. <ix:nonNumeric contextRef="c260" name="silo:SponsoredResearchAgreementDescription">If the Company elects to exercise the
option, both parties will commence negotiation of a license agreement and will execute a license agreement no later than 3 months after
the dated of the exercise of the option. Columbia University and the Company will work towards developing a therapeutic treatment for
patients suffering from Alzheimer&#8217;s disease to post-traumatic stress disorder. During a one-year period from the date of this agreement,
the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the payment schedule
as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months after the start
of the project and, (iv)10% at completion of the project. The Company paid the first payment of $430,825 in November 2021 which was recorded
to prepaid expense and other current assets &#8211; current to be amortized over the estimated project timeline of twelve months. In
2021, the Company amortized $359,021 of the prepaid expense. During the six months ended June 30, 2022, the Company amortized the remaining
prepaid expense of $71,804. As of June 30, 2022 and December 31, 2021, prepaid expense related to the sponsored research agreement were
$0 and $71,804, respectively.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SILO PHARMA, INC. AND SUBSIDIARY<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
JUNE 30, 2022<br/>
(UNAUDITED)</b></p><div>







</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_53" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_52"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Joint Venture Agreement with Zyl&#246;
Therapeutics, Inc.</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_54" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_53"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 22, 2021 (&#8220;Effective Date&#8221;),
the Company entered into a Joint Venture Agreement (&#8220;JV Agreement&#8221;) with Zyl&#246; Therapeutics, Inc. (&#8220;ZTI&#8221;)
pursuant to which the parties agreed to form a joint venture entity, to be named Ketamine Joint Venture, LLC (&#8220;Joint Venture&#8221;),
to, among other things, focus on the clinical development of ketamine using ZTI&#8217;s Z-pod&#8482; technology (&#8220;Venture&#8221;).
Pursuant to the JV Agreement, the Company shall act as the manager (&#8220;Manager&#8221;) of the Joint Venture. The Joint Venture shall
terminate if the development program does not meet certain specifications and milestones as set forth in the JV Agreement within 30 days
of the date set forth in the JV Agreement. Notwithstanding the foregoing, the Manager may, in its sole discretion, terminate the Joint
Venture at any time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_55" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_54"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c261" name="silo:PursuantTerms">Pursuant to the terms of the JV Agreement,
(A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall
contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and
trade secrets with respect to its Z-pod&#8482; technology for the loading and release of ketamine, (3) ketamine to be used for clinical
purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the
interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be
owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event
shall either party own more than 60% of the interest in the Joint Venture.</ix:nonNumeric> As of June 30, 2022 and as of the current date of this report,
the joint venture entity has not been formed yet.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_56" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_55"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, pursuant to the terms of the
JV Agreement, ZTI shall grant the Joint Venture a sublicense pursuant to its license agreement (the &#8220;License Agreement&#8221;)
with Albert Einstein College of Medicine dated November 27, 2017, in the event that the Company or a third party makes a request indicating
that the patented technology (the &#8220;Patented Technology&#8221;) licensed to ZTI pursuant to the License Agreement is needed to advance
the development of the Joint Venture or it is contemplated or determined that the Patented Technology will be sold. Furthermore, pursuant
to the JV Agreement, ZTI granted the Company an exclusive option to enter into a separate joint venture for the clinical development
of psilocybin using ZTI&#8217;s Z-pod&#8482; technology on the same terms and conditions set forth in the JV Agreement, which option
shall expire 24 months after the JV Effective Date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_57" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_56"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Amended Service Agreement</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_57"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 10, 2021 (&#8220;Effective Date&#8221;),
the Company entered into an Amendment Agreement (&#8220;Amended Service Agreement&#8221;) to a certain service agreement dated on September
8, 2020 with the University of Texas (&#8220;University&#8221;) at Austin whereby the University will provide advisory service and assist
the Company on identifying license and sponsored research opportunities for the Company. The Company shall pay the University $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="silo:PaymentOfUniversity" scale="0" unitRef="usd">5,000</ix:nonFraction>
per quarter starting on the Effective Date. Any cost incurred will be reimbursed only after prior written consent by the Company. The
term of the Amended Service Agreement is for 36 months unless earlier terminated by either party upon giving a written notice as defined
in the agreement. <ix:nonNumeric contextRef="c10" name="silo:AgreementDescription">In 2021, the Company paid $5,000 related to this agreement. During the six months ended June 30, 2022, the Company
paid $10,000 related to this agreement.</ix:nonNumeric></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">588,236 Shares of Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROSPECTUS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Laidlaw &amp; Company (UK) Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 1.5in">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2022</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 144 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INFORMATION NOT REQUIRED IN PROSPECTUS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 13. &#160;OTHER EXPENSES OF ISSUANCE
AND DISTRIBUTION.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the expenses
in connection with this registration statement. All of such expenses are estimates, other than the filing fees payable to the Securities
and Exchange Commission and FINRA.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.9pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount<br/> to be paid</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">SEC registration fee</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">566.65</p></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">FINRA filing fee</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,308.52</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">The Nasdaq Capital Market initial listing fee</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounting fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">325,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Printing and engraving expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Management Fee (1%)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">50-000-57,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">453,875.17-461,375.17</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All amounts are estimated except the SEC registration
fee, the FINRA filing fee, and The Nasdaq Capital Market initial listing fee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 14. &#160;INDEMNIFICATION OF DIRECTORS
AND OFFICERS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s Certificate of Incorporation
and Bylaws (collectively, the &#8220;Charter Documents&#8221;) provide that, to the fullest extent permitted under the DGCL, no director
of the Company shall be personally liable to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director.
In addition, the Company&#8217;s Charter Documents provide that the Company shall&#160;indemnify and hold harmless, to the fullest extent
permitted by applicable law, any person (a &#8220;Covered Person&#8221;) who was or is made or is threatened to be made a party or is
otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#8220;Proceeding&#8221;)
by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director or officer of
the&#160;Company&#160;or, while a director or officer of the&#160;Company, is or was serving at the request of the&#160;Company&#160;as
a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or nonprofit entity
against all liability and loss suffered and expenses (including attorneys&#8217; fees) reasonably incurred by such Covered Person.&#160;Pursuant
to the Company&#8217;s Charter Documents, the Company shall pay the expenses (including attorneys&#8217; fees) incurred by a Covered
Person in defending any Proceeding in advance of its final disposition; provided, however, that, to the extent required by applicable
law, such payment of expenses in advance of the final disposition of the Proceeding shall be made only upon receipt of an undertaking
by the Covered Person to repay all amounts advanced if it should be ultimately determined that the Covered Person is not entitled to
be indemnified pursuant to the Company&#8217;s Certificate of Incorporation.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions,
we have been informed that, in the opinion of the SEC, this indemnification is against public policy as expressed in the Securities Act
and is therefore unenforceable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 15. &#160;RECENT SALES OF UNREGISTERED
SECURITIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a list of unregistered sales
of our equity securities during the prior three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 29, 2018, pursuant to an Asset
Purchase Agreement, we issued 40,000 shares of common stock of the Company to acquire assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 4, 2018, we issued 1,400 shares
of our common stock for cash proceeds of $24,500, or $17.50 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 145; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 22, 2019, we entered into a consulting
agreement with a consultant in connection with our marketing and branding of our NFID products. The agreement ended on December 31, 2019.
For services rendered, we issued 2,000 shares of common stock of the Company to the consultant on a quarterly basis in tranches of 500
shares per quarter, commencing on March 31, 2019, and continuing on to the last day of each subsequent quarter in the year 2019. These
shares were valued on the January 22, 2019 grant date at $35,000, or $17.50 per common share, based on recent common share sales which
was amortized over the vesting period. Through December 31, 2019, the Company issued 2,000 shares of its common stock to the consultant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 15, 2019, we issued options to purchase
up to 4,000 shares of common stock to an executive officer for services rendered at an exercise price of $0.01 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 15, 2019, we issued options to
purchase up to 2,000 shares of common stock to an executive officer for services rendered at an exercise price of $0.01 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 7, 2020, we entered into advisory
agreements with certain accredited investors pursuant to which we agreed to issue an aggregate of 102,347 shares of our common stock
to the advisors for advisory services to be rendered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 10, 2020, we entered into a consulting
agreement with an accredited investor pursuant to which we agreed to issue an aggregate of 69,377 shares of our common stock, to the
consultant for consulting services to be rendered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 17, 2020, we entered into exchange
agreements with holders of our convertible promissory notes, which notes were originally issued in October 2019. Pursuant to the exchange
agreements, the holders agreed to exchange their convertible promissory notes and related warrants for an aggregate of 82,500 shares
of our common stock at a price of $4.00 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 17, 2020, we entered into exchange
agreements with the holders of our Series B Convertible Preferred Stock, which shares of Series B Convertible Preferred Stock were originally
issued in November 2019. Pursuant to the exchange agreements, the holders agreed to exchange their Series B Convertible Preferred Stock
and related warrants for an aggregate of 28,750 shares of our common stock at a price of $4.00 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Between April 9, 2020 and April 18, 2020,
we entered into subscription agreements with certain accredited investors pursuant to which we issued an aggregate of 155,287 shares
of our common stock for an aggregate of $75,644.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 17, 2020, in connection with an Employment
Agreement with the Company&#8217;s Chief Executive Officer, we issued 152,619 shares of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 28, 2020 we entered into securities
purchase agreements with certain institutions and accredited investors for the sale of an aggregate 599,875 shares of the Company&#8217;s
common stock for gross proceeds of $2,399,500.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 18, 2021, we issued a service provider
warrants to purchase up to 5,000 shares of our common stock at an exercise price of $10.00 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On February 12, 2021, we sold an aggregate
of 4,276 shares of Series C Preferred Stock and Warrants to purchase up to 285,066 shares of our common stock for gross proceeds of approximately
$4,276,000, before deducting placement agent and other offering expenses. Pursuant to the terms of the offering, we also issued the placement
agents warrants to purchase up to an aggregate of 57,013 shares of our common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 12, 2021, we converted 4,049 shares
of Series C Convertible preferred stock into 269,900 shares of common stock. The issuance was exempt under Section 3(a)(9) and/or Section
4(a)(2) of the Securities Act of 1933, as amended.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On March 31, 2022, we converted 227 shares
of Series C Convertible preferred stock into 15,167 shares of common stock. The issuance was exempt under Section 3(a)(9) and/or Section
4(a)(2) of the Securities Act of 1933, as amended.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, the foregoing
securities were offered and issued in reliance on the exemption from registration requirements under the Securities Act afforded by Section
4(a)(2) thereof and/or Rule 506 of Regulation D promulgated thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16. &#160;EXHIBITS AND FINANCIAL STATEMENT
SCHEDULES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 9%; border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt; text-align: justify"><span style="font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="vertical-align: top; width: 1%; padding: 0.25pt; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt; text-align: center"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding: 0.25pt; text-align: justify">&#160;</td>
    <td style="padding: 0.25pt; text-align: justify">&#160;</td>
    <td style="padding: 0.25pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">1.1**</span></td>
    <td style="padding: 0.25pt; text-align: justify"><span style="-keep: true">&#160;</span></td>
    <td style="padding: 0.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390022054876/ea165483ex1-1_silopharma.htm"><span style="font-size: 10pt">Form of Underwriting Agreement </span></a></td></tr>

<tr style="vertical-align: top; ">
    <td style="width: 9%"><span style="font-size: 10pt">3.1</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390012007015/def14c1212_goldswap.htm"><span style="font-size: 10pt">Certificate
    of Incorporation of Point Capital, Inc., filed as an exhibit to the Definitive Information Statement on Schedule 14C, filed with
    the Commission on December 28, 2012 and incorporated herein by reference.</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390012007015/def14c1212_goldswap.htm"><span style="font-size: 10pt">Bylaws
    of Point Capital, Inc., filed as an exhibit to the Definitive Information Statement on Schedule 14C, filed with the Commission on
    December 28, 2012 and incorporated herein by reference.</span></a></td></tr>
<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000149315213000764/ex4-2.htm"><span style="font-size: 10pt">Certificate
    of Designation of the Series A Convertible Preferred Stock, filed as an exhibit to the Current Report on Form 8-K, filed with the
    Commission on April 30, 2013 and incorporated herein by reference.</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390017005427/f10q0317ex4i_pointcapital.htm"><span style="font-size: 10pt">Amended
    and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, filed as
    an exhibit to the Quarterly Report on Form 10-Q, filed with the Commission on May 17, 2017 and incorporated herein by reference.</span></a></td></tr>
<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">3.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390019007545/def14a0419_pointcapitalinc.htm"><span style="font-size: 10pt">Amendment
    to Certificate of Incorporation for name change dated May 20, 2019, filed as an appendix to the Definitive Proxy Statement on Schedule
    14A, filed with the Commission on May 1, 2019 and incorporated herein by reference.</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020007000/f10k2019ex3-9_uppercut.htm">Certificate
    of Designation of the Series B Convertible Preferred Stock, filed as an exhibit to the Annual Report on Form 10-K filed with the
    Commission on March 20, 2020 and incorporated herein by reference.</a></span></td></tr>
<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">3.7</span></td>
    <td>&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020030221/ea127840ex3-1_silopharma.htm">Certificate
        of Amendment filed with the Delaware Secretary of State on September 24, 2020, filed as an exhibit to the Current Report on Form
        8-K filed with the Commission on October 6, 2020 and incorporated herein by reference.</a></p></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021007944/ea135066ex3-1_silopharma.htm"><span style="font-size: 10pt">Certificate
    of Designations of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (Incorporated by reference to Exhibit
    3.1 to the Company&#8217;s Current Report on Form 8-K filed on February 10, 2021)</span></a></td></tr>
<tr style="vertical-align: top; ">
    <td>3.9</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021015110/ea137577ex3-1_silopharma.htm">Certificate
    of Amendment to Certificate of Incorporation filed with the Delaware Secretary of State on March 10, 2021, filed as an exhibit to
    the Current Report on Form 8-K, filed with the Commission on March 12, 2021 and incorporated by herein by reference.</a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">4.1**</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390022054876/ea165483ex1-1_silopharma.htm"><span style="-keep: true">Form of Representative Warrant
                                    (included in Exhibit 1.1)</span></a></td></tr>
<tr style="vertical-align: top; ">
    <td style="text-align: left"><span style="-keep: true"><span style="font-size: 10pt">5.1*</span>*</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390022054876/ea165483ex5-1_silopharma.htm"><span style="font-size: 10pt">Opinion of Sheppard, Mullin, Richter &amp; Hampton, LLP</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000149315213000764/ex10-2.htm">Stock
    Purchase Agreement dated April 24, 2013 between Point Capital, Inc. and Alpha Capital Anstalt, filed as an exhibit to the Current
    Report on Form 8-K, filed with the Commission on April 30, 2013 and incorporated herein by reference.</a></span></td></tr>
<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390018017594/f8k121318ex10-1_pointcapital.htm">Corrected
    Asset Purchase Agreement with Blind Faith Concepts Holdings, Inc. dated September 28, 2018, filed as an exhibit to the Current Report
    on Form 8-K, filed with the Commission on December 20, 2018 and incorporated herein by reference.</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390018017594/f8k121318ex10-2_pointcapital.htm">Form
    of Return to Treasury Agreement, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on December 20,
    2018 and incorporated herein by reference.</a></span></td></tr>
<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390019023011/f10q0919ex10-1_uppercut.htm">Form
    of Securities Purchase Agreement, dated October 2019, between Uppercut Brands, Inc., and Investors, filed as an exhibit to the Annual
    Report on Form 10-K filed with the Commission on March 20, 2020 and incorporated herein by reference.</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1514183/000121390019023011/f10q0919ex10-2_uppercut.htm" style="-sec-extract: exhibit">Form
    of convertible note agreement with Investors dated October 2019, filed as an exhibit to the Annual Report on Form 10-K filed with
    the Commission on March 20, 2020 and incorporated herein by reference.</a></span></td></tr>
<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390019023011/f10q0919ex10-3_uppercut.htm">Form
    of Warrant, dated October 2019, filed as an exhibit to the Quarterly Report on Form 10-Q filed with the Commission on November 13,
    2019 and incorporated herein by reference.</a></span></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020007000/f10k2019ex10-7_uppercut.htm">Form
    of Securities Purchase Agreement for the purchase of Series B preferred shares, dated November 2019, between Uppercut Brands, Inc.,
    and Investors, filed as an exhibit to the Annual Report on Form 10-K filed with the Commission on March 20, 2020 and incorporated
    herein by reference.</a></span></td></tr>
<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020007000/f10k2019ex10-8_uppercut.htm">Form
    of Warrant related to Series B preferred shares, dated November 2019, between Uppercut Brands, Inc., and Investors, filed as an exhibit
    to the Annual Report on Form 10-K, filed with the Commission on March 20, 2020 and incorporated herein by reference.</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.9</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020007000/f10k2019ex10-9_uppercut.htm"><span style="font-size: 10pt">Form
    of registration rights agreement related to Series B preferred shares, dated November 2019, between Uppercut Brands, Inc., and Investors,
    filed as an exhibit to the Annual Report on Form 10-K filed with the Commission on March 20, 2020 and incorporated herein by reference.</span></a></td></tr>
<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.10</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020009770/ea120926ex10-1_uppercut.htm">Form
    of Exchange Agreement for Convertible Notes, dated as of April 15, 2020, filed as an exhibit to the Current Report on Form 8-K/A,
    filed with the Commission on April 22, 2020 and incorporated herein by reference.</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.11</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020009770/ea120926ex10-2_uppercut.htm">Form
    of Exchange Agreement for Series B Preferred Stock, dated as of April 15, 2020, filed as an exhibit to the Current Report on Form
    8-K/A, filed with the Commission on April 22, 2020 and incorporated herein by reference.</a></span></td></tr>
<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.12</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020009770/ea120926ex10-3_uppercut.htm">Form
    of Subscription Agreement, dated as of April 17, 2020, filed as an exhibit to the Current Report on Form 8-K/A, filed with the Commission
    on April 22, 2020 and incorporated herein by reference.</a></span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-size: 10pt">10.13</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020009770/ea120926ex10-4_uppercut.htm">Form
    of Consulting Agreement, dated as of April 17, 2020, filed as an exhibit to the Current Report on Form 8-K/A, filed with the Commission
    on April 22, 2020 and incorporated herein by reference.</a></span></td></tr>
<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.14</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020009770/ea120926ex10-5_uppercut.htm">Form
    of Advisory Agreement, dated as of April 17, 2020, filed as an exhibit to the Current Report on Form 8-K/A, filed with the Commission
    on April 22, 2020 and incorporated herein by reference.</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.15+</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020009770/ea120926ex10-6_uppercut.htm">Employment
    Agreement by and between the Company and Eric Weisblum, dated as of April 17, 2020, filed as an exhibit to the Current Report on
    Form 8-K/A, filed with the Commission on April 22, 2020 and incorporated herein by reference.</a></span></td></tr>
<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.16</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020010355/ea121172ex10-1_uppercut.htm"><span style="font-size: 10pt">Form
    of Securities Purchase Agreement, dated as of April 28, 2020, filed as an exhibit to the Current Report on Form 8-K, filed with the
    Commission on April 28, 2020 and incorporated herein by reference.</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.17</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020010355/ea121172ex10-2_uppercut.htm"><span style="font-size: 10pt">Form
    of Registration Rights Agreement, dated as of April 28, 2020, filed as an exhibit to the Current Report on Form 8-K, filed with the
    Commission on April 28, 2020 and incorporated herein by reference.</span></a></td></tr>
<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.18</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390020010355/ea121172ex10-3_uppercut.htm"><span style="font-size: 10pt">Form
    of Lock-Up Agreement, dated as of April 28, 2020, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission
    on April 28, 2020 and incorporated herein by reference.</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021001330/ea132847ex10-1_silo.htm">Patent
    License Agreement by and among the Company and Silo Pharma, Inc., a Florida corporation and their affiliates and subsidiaries and
    AIkido Pharma Inc., filed as an exhibit to the Current Report on Form 8-K filed with the Commission on January 11, 2021 and incorporated
    herein by reference.</a></span></td></tr>
<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.20#</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021001462/ea133115ex10-1_silopharma.htm">Sponsored
    Research Agreement by and between the Company and the University of Maryland, Baltimore, filed as an exhibit to the Current Report
    on Form 8-K filed with the Commission on January 11, 2021 and incorporated herein by reference.</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.21+</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021004937/ea134100ex10-1_silopharma.htm"><span style="font-size: 10pt">Silo
    Pharma, Inc. 2020 Omnibus Equity Incentive Plan</span>, <span style="font-size: 10pt">filed as an exhibit to the Current Report on
    Form 8-K filed with the Commission on January 28, 2021 and incorporated herein by reference.</span></a></td></tr>
<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.22+</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021004937/ea134100ex10-2_silopharma.htm"><span style="font-size: 10pt">First
    Amendment to Employment Agreement, dated January 18, 2021, by and between the Company and Eric Weisblum</span>, <span style="font-size: 10pt">filed
    as an exhibit to the Current Report on Form 8-K filed with the Commission on January 28, 2021 and incorporated herein by reference.</span></a></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">10.23</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021007944/ea135066ex10-1_silopharma.htm"><span style="font-size: 10pt">Form
    of Securities Purchase Agreement, dated as of February 9, 2021, between Silo Pharma, Inc. and the signatories thereto (Incorporated
    by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on February 10, 2021)</span></a></td></tr>
<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.24</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021007944/ea135066ex10-2_silopharma.htm"><span style="font-size: 10pt">Form
    of Warrant (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on February 10, 2021)</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.25</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021007944/ea135066ex10-3_silopharma.htm"><span style="font-size: 10pt">Form
    of Registration Rights Agreement, dated as of February 9, 2021, between Silo Pharma, Inc. and the signatories thereto (Incorporated
    by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on February 10, 2021)</span></a></td></tr>
<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.26</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021007944/ea135066ex10-4_silopharma.htm"><span style="font-size: 10pt">Form
    of Lock-Up Agreement, dated as of February 9, 2021 (Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report
    on Form 8-K filed on February 10, 2021)</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021009075/ea135511ex10-5_silopharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Placement Agent Warrant (Incorporated by reference to Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K/A filed on
    February 12, 2021)</span></a></td></tr>
<tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28#</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021009265/ea135663ex10-1_silopharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Master
    License Agreement, dated February 12, 2021, by and between the Company and the University of Maryland, Baltimore (Incorporated by
    reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on February 16, 2021)</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29#</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021009265/ea135663ex10-2_silopharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter
    of Intent, dated February 12, 2021, by and between the Company and Aikido Pharma, Inc. (Incorporated by reference to Exhibit 10.2
    to the Company&#8217;s Current Report on Form 8-K filed on February 16, 2021)</span></a></td></tr>
<tr style="vertical-align: top; ">
    <td>10.30#</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1514183/000121390021020650/ea139213ex10-1_silopharma.htm" style="-sec-extract: exhibit">Sublicense
    Agreement, dated April 6, 2021, by and between the Company and AIkido Pharma, Inc. (Incorporated by reference to Exhibit 10.1 to
    the Company&#8217;s Current Report on Form 8-K filed on April 7, 2021)</a></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.31</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021031225/ea142321ex10-1_silopharma.htm"><span style="font-size: 10pt">Sponsored
    Research Agreement dated June 1, 2021 with The Regents of the University of California, filed as Exhibit 10.1 under that certain
    Current Report on Form 8-K filed on June 7, 2021 and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.32#</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021036526/ea144103ex10-1_silopharma.htm"><span style="font-size: 10pt">Sponsored
    Research Agreement dated July 6, 2021 with the University of Baltimore Maryland, , filed as Exhibit 10.1 under that certain Current
    Report on Form 8-K filed on July 12, 2021 and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.33</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021023271/ea140001ex10-1_silopharmainc.htm"><span style="font-size: 10pt">Joint
    Venture Agreement dated April 22, 2021 with Zyl&#246; Therapeutics, Inc. filed as Exhibit 10.1 under that certain Current Report
    on Form 8-K filed on April 28, 2021 and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.34</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021054869/ea149452ex10-1_silopharma.htm"><span style="font-size: 10pt">Sponsored
    Research Agreement dated October 1, 2021 with Columbia University, filed as Exhibit 10.1 under that certain Current Report on Form
    8-K filed on October 27, 2021 and incorporated herein by reference.</span></a></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">21.1**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021009731/ea135563ex21-1_silopharma.htm"><span style="font-size: 10pt">Subsidiaries,
    filed as Exhibit 21.1 to our Annual Report on Form 10-K for the year ended December 31, 2020 filed on March 29, 2021 and incorporated
    herein by reference.</span></a></td></tr>
<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">23.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea165987ex23-1_silopharma.htm"><span style="font-size: 10pt">Consent of Salberg &amp; Company, P.A.</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">23.2**</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390022054876/ea165483ex5-1_silopharma.htm"><span style="font-size: 10pt">Consent of Sheppard, Mullin, Richter &amp; Hampton, LLP (included
    in Exhibit 5.1)</span></a></td></tr>
<tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">24.1**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390021063995/ea151630-s1_silopharma.htm#poa"><span style="font-size: 10pt">Power
    of Attorney</span></a></td></tr>

  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Instance
    Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline
    XBRL document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span>*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy
    Extension Schema Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span>*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy
    Extension Calculation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span>*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy
    Extension Definition Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span>*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy
    Extension Label Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span>*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy
    Extension Presentation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive
    Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">107</td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/1514183/000121390022051552/ea164639ex-fee_silopharma.htm">Fee Table**</a></td></tr>
  </table><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Filed herewith.</span></td></tr>
<tr style="font-size: 8pt; vertical-align: top">
    <td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>**</td>
    <td style="text-align: justify">Previously filed.</td></tr>
<tr style="font-size: 8pt; vertical-align: top">
    <td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">+</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To be filed by amendment.</span></td></tr>
<tr style="font-size: 8pt; vertical-align: top">
    <td style="font-size: 8pt">&#160;</td>
    <td style="font-size: 8pt; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>#</td>
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Portions of
                                    this exhibit (indicated by asterisks) have been redacted in compliance with Regulation&#160;S-K Item&#160;601(b)(10)(iv).</p>
</td></tr>
</table><div>
</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 17. &#160;UNDERTAKINGS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned registrant hereby undertakes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To file, during any period in which offers or sales are being made,
    a post-effective amendment to this registration statement:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To include any prospectus required by section 10(a)(3) of the Securities
    Act;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To reflect in the prospectus any facts or events arising after the
    effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the
    aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing,
    any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which
    was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of
    prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more
    than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the
    effective registration statement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(iii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To include any material information with respect to the plan of
    distribution not previously disclosed in the registration statement or any material change to such information in the registration
    statement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">That, for the purpose of determining any liability under the Securities
    Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein,
    and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To remove from registration by means of a post-effective amendment
    any of the securities being registered which remain unsold at the termination of the offering.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">That, for the purpose of determining liability under the Securities
    Act of 1933 to any purchaser, if the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of
    a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses
    filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first
    used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the
    registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or
    prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first
    use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
    statement or made in any such document immediately prior to such date of first use.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">That, for the purpose of determining liability of the registrant
    under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that
    in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting
    method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the
    following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such
    securities to such purchaser:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any preliminary prospectus or prospectus of the undersigned registrant
    relating to the offering required to be filed pursuant to Rule 424;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any free writing prospectus relating to the offering prepared by
    or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(iii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The portion of any other free writing prospectus relating to the
    offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned
    registrant; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(iv)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any other communication that is an offer in the offering made by
    the undersigned registrant to the purchaser.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy
as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other
than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the
successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with
the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as
expressed in the Act and will be governed by the final adjudication of such issue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned registrant hereby undertakes
to provide to the underwriter at the closing specified in the underwriting agreements certificates in such denominations and registered
in such names as required by the underwriter to permit prompt delivery to each purchaser.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned registrant hereby undertakes that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">For purposes of determining any liability under the Securities Act,
    the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained
    in a form of prospectus filed by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed
    to be part of this registration statement as of the time it was declared effective.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">For the purpose of determining any liability under the Securities
    Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating
    to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
    thereof.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Pursuant to the requirements of the Securities
Act of 1933, the registrant has duly caused this Amendment No. 4 to Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized in the Borough of Fort Lee, State of New Jersey, on the 20<sup>th</sup>&#160;day of September 2022.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt">&#160;</td>
    <td colspan="2" style="padding: 0.25pt; text-align: justify"><span style="font-size: 10pt"><b>SILO PHARMA, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%; padding: 0.25pt">&#160;</td>
    <td style="width: 5%; padding: 0.25pt">&#160;</td>
    <td style="width: 35%; padding: 0.25pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt"><span style="font-size: 10pt">/s/ Eric Weisblum</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">Name:&#160;&#160;</span></td>
    <td style="padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">Eric Weisblum</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">Title:</span></td>
    <td style="padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 28%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 52%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Eric Weisblum</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman, Chief Executive
    Officer, Chief Financial Officer and President</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    20, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric Weisblum</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer and Principal Financial
    and Accounting Officer)</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 20, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wayne Linsley</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 20, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Kevin Mu&#241;oz&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-size: 10pt">*By:&#160;&#160; </span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 36%"><span style="font-size: 10pt">Eric Weisblum</span></td>
    <td style="width: 60%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Eric Weisblum</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Attorney-in-fact</span></td>
    <td>&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">II-7</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>



</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentType">S-1/A</ix:nonNumeric>
<ix:nonFraction contextRef="c1" id="hidden-fact-1" name="us-gaap:ReceivablesNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-2" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-3" name="us-gaap:OtherAssetsNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-4" name="us-gaap:PrepaidExpenseNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-5" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-6" name="us-gaap:DeferredRevenueCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-7" name="us-gaap:DeferredRevenueNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-8" name="us-gaap:LongTermNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-9" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-10" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-11" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-12" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-13" name="silo:PreferredStockValueOne" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-14" name="silo:PreferredStockValueOne" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-15" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-16" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-17" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-18" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-19" name="silo:PreferredStockValueTwo" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-20" name="silo:PreferredStockValueTwo" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-21" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-22" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-23" name="us-gaap:LoansPayableCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-24" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-25" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-26" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-27" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-28" name="silo:PreferredStockValueOne" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-29" name="silo:PreferredStockValueOne" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-30" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-31" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-32" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-33" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-34" name="silo:PreferredStockValueTwo" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-35" name="silo:PreferredStockValueTwo" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-36" name="silo:LicenseFees" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-37" name="us-gaap:CostOfRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-38" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-39" name="us-gaap:OtherIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-40" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-41" name="us-gaap:InterestExpenseRelatedParty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-42" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-43" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-44" name="us-gaap:GainLossOnInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-45" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-46" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" decimals="2" id="hidden-fact-47" name="us-gaap:EarningsPerShareDiluted" unitRef="usdPershares">0.04</ix:nonFraction>
<ix:nonFraction contextRef="c11" decimals="2" id="hidden-fact-48" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.05</ix:nonFraction>
<ix:nonFraction contextRef="c10" decimals="2" id="hidden-fact-49" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" unitRef="usdPershares">0.00</ix:nonFraction>
<ix:nonFraction contextRef="c11" decimals="2" id="hidden-fact-50" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" sign="-" unitRef="usdPershares">0.01</ix:nonFraction>
<ix:nonFraction contextRef="c11" decimals="INF" id="hidden-fact-51" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="shares">65954691</ix:nonFraction>
<ix:nonFraction contextRef="c10" decimals="INF" id="hidden-fact-52" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="shares">95922218</ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-53" name="silo:BadDebtRecoveryExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-54" name="silo:OtherIncomeFromEquitySharesEarnedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-55" name="silo:OtherIncomeFromEquitySharesEarnedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-56" name="silo:OtherIncomeFromEquitySharesEarnedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-57" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-58" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-59" name="us-gaap:GainLossOnInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-60" name="us-gaap:GainLossOnInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-61" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-62" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-63" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-64" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-65" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-66" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-67" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-68" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-69" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-70" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-71" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" decimals="2" id="hidden-fact-72" name="us-gaap:EarningsPerShareDiluted" unitRef="usdPershares">0.00</ix:nonFraction>
<ix:nonFraction contextRef="c12" decimals="2" id="hidden-fact-73" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.01</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-74" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.01</ix:nonFraction>
<ix:nonFraction contextRef="c14" decimals="2" id="hidden-fact-75" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.03</ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-76" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-77" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" decimals="2" id="hidden-fact-78" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" unitRef="usdPershares">0.00</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-79" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" unitRef="usdPershares">0.00</ix:nonFraction>
<ix:nonFraction contextRef="c14" decimals="2" id="hidden-fact-80" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" unitRef="usdPershares">0.00</ix:nonFraction>
<ix:nonFraction contextRef="c14" decimals="INF" id="hidden-fact-81" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="shares">91032045</ix:nonFraction>
<ix:nonFraction contextRef="c13" decimals="INF" id="hidden-fact-82" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="shares">96857408</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="INF" id="hidden-fact-83" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="shares">99018232</ix:nonFraction>
<ix:nonFraction contextRef="c12" decimals="INF" id="hidden-fact-84" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="shares">99395304</ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-85" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-86" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-87" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-88" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-89" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-90" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-91" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-92" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-93" name="silo:CommonStockIssuedForFutureServicesShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-94" name="silo:CommonStockIssuedForFutureServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-95" name="silo:CommonStockIssuedForFutureServicesShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-96" name="silo:CommonStockIssuedForFutureServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-97" name="silo:CommonStockIssuedForFutureServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-98" name="silo:PreferredSharesExchangedForCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-99" name="silo:PreferredSharesExchangedForCommonStockShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-100" name="silo:PreferredSharesExchangedForCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-101" name="silo:PreferredSharesExchangedForCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-102" name="silo:PreferredSharesExchangedForCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-103" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-104" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-105" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-106" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-107" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-108" name="silo:CommonStockIssuedForExchangeOfNotesShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-109" name="silo:CommonStockIssuedForExchangeOfNotes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-110" name="silo:CommonStockIssuedForExchangeOfNotesShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-111" name="silo:CommonStockIssuedForExchangeOfNotes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-112" name="silo:CommonStockIssuedForExchangeOfNotes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-113" name="silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-114" name="silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-115" name="silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-116" name="silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-117" name="silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-118" name="silo:DeemedDividendOnPreferredStockExchange" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-119" name="silo:DeemedDividendOnPreferredStockExchange" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-120" name="silo:DeemedDividendOnPreferredStockExchange" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-121" name="silo:DeemedDividendOnPreferredStockExchange" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-122" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-123" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-124" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-125" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-126" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-127" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-128" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-129" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-130" name="us-gaap:StockIssuedDuringPeriodSharesOther" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-131" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-132" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-133" name="us-gaap:StockIssuedDuringPeriodSharesOther" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-134" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-135" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-136" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-137" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-138" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-139" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-140" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-141" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-142" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-143" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-144" name="silo:IssuanceOfCommonSharesForConversionOfPreferredStockinShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-145" name="silo:IssuanceOfCommonStockForConversionOfPreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-146" name="silo:IssuanceOfCommonStockForConversionOfPreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-147" name="silo:IssuanceOfCommonStockForConversionOfPreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-148" name="silo:IssuanceOfCommonStockForConversionOfPreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-149" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-150" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-151" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-152" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-153" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-154" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-155" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-156" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-157" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-158" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-159" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c42" id="hidden-fact-160" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c43" id="hidden-fact-161" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-162" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-163" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c42" id="hidden-fact-164" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-165" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-166" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c42" id="hidden-fact-167" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c43" id="hidden-fact-168" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-169" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-170" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-171" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-172" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-173" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-174" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-175" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-176" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-177" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-178" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-179" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-180" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-181" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-182" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-183" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-184" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-185" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-186" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-187" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-188" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-189" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-190" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-191" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c67" id="hidden-fact-192" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-193" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-194" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-195" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-196" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-197" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-198" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-199" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c67" id="hidden-fact-200" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-201" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-202" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-203" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-204" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c69" id="hidden-fact-205" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-206" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-207" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-208" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c79" id="hidden-fact-209" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-210" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-211" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-212" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c77" id="hidden-fact-213" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c78" id="hidden-fact-214" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-215" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-216" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-217" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-218" name="us-gaap:InventoryWriteDown" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-219" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-220" name="us-gaap:GainsLossesOnRestructuringOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-221" name="us-gaap:GainLossOnDispositionOfAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-222" name="silo:LossFromDebtExtinguishment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-223" name="us-gaap:IncreaseDecreaseInReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-224" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-225" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-226" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-227" name="us-gaap:ProceedsFromRelatedPartyDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-228" name="us-gaap:ProceedsFromNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-229" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-230" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-231" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-232" name="silo:AdvanceFromARelatedParty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-233" name="us-gaap:RepaymentsOfRelatedPartyDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-234" name="us-gaap:InterestPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-235" name="us-gaap:InterestPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-236" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-237" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-238" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-239" name="us-gaap:IncomeTaxesPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-240" name="us-gaap:IncomeTaxesPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-241" name="silo:StockIssuedForFutureServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-242" name="silo:CommonStockIssuedForPrepaidServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-243" name="silo:CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-244" name="silo:IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-245" name="silo:NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-246" name="silo:AmortizationOfPrepaidStockbasedExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-247" name="us-gaap:GainLossOnSaleOfDerivatives" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-248" name="us-gaap:GainsLossesOnRestructuringOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-249" name="silo:IncreaseDecreaseInAssetsOfDiscontinuedOperation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-250" name="us-gaap:IncreaseDecreaseInReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-251" name="us-gaap:IncreaseDecreaseInPayablesToBrokerDealers" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-252" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-253" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-254" name="silo:AdvanceFromARelatedParty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-255" name="us-gaap:RepaymentsOfRelatedPartyDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-256" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-257" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-258" name="us-gaap:IncomeTaxesPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-259" name="us-gaap:DebtConversionConvertedInstrumentAmount1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-260" name="silo:IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-261" name="us-gaap:StockIssued1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-262" name="silo:IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c89" id="hidden-fact-263" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c93" id="hidden-fact-264" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-265" name="us-gaap:InterestIncomeExpenseNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-266" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-267" name="us-gaap:AuctionMarketPreferredSecuritiesSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" decimals="INF" id="hidden-fact-268" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">19184448</ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-269" name="silo:EquityInvestmentsAtFairValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-270" name="silo:EquityInvestmentsAtFairValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-271" name="silo:EquityInvestmentsAtFairValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c101" id="hidden-fact-272" name="silo:EquityInvestmentsAtFairValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c102" id="hidden-fact-273" name="silo:EquityInvestmentsAtFairValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-274" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-275" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-276" name="silo:AdditionsofEquitySecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-277" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-278" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-279" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c87" id="hidden-fact-280" name="silo:FinanceLeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-281" name="silo:GainFromSaleOfNFIDBusiness" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-282" name="silo:AdditionalNotesReceivableIn2021" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-283" name="silo:LessNotesReceivableNetCurrentPortion" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-284" name="us-gaap:NotesReceivableNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-285" name="silo:DebtInstrumentsFaceAmount" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-286" name="silo:NotrPayableLessCurrentPortion" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-287" name="silo:NotePayableLongTermPortion" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c163" id="hidden-fact-288" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c163" id="hidden-fact-289" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c163" id="hidden-fact-290" name="silo:WeightedAverageRemainingContractualTermYearsGrantedissued" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c163" id="hidden-fact-291" name="silo:AggregateIntrinsicValueGrantedIssuedForfeited1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c165" id="hidden-fact-292" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c165" id="hidden-fact-293" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c165" id="hidden-fact-294" name="silo:WeightedAverageRemainingContractualTermYearsGrantedissued" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c165" id="hidden-fact-295" name="silo:AggregateIntrinsicValueGrantedIssuedForfeited1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c93" id="hidden-fact-296" name="silo:ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c93" id="hidden-fact-297" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c168" id="hidden-fact-298" name="silo:NumberOfWarrant" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c168" id="hidden-fact-299" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c93" id="hidden-fact-300" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c168" id="hidden-fact-301" name="silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c92" id="hidden-fact-302" name="silo:AggregateIntrinsicValueGranted" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c169" id="hidden-fact-303" name="silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c169" id="hidden-fact-304" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-305" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-306" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-307" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-308" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c190" id="hidden-fact-309" name="silo:UMBPayment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c191" id="hidden-fact-310" name="silo:UMBPayment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c206" id="hidden-fact-311" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c216" id="hidden-fact-312" name="silo:EquityInvestmentsAtFairValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c217" id="hidden-fact-313" name="silo:EquityInvestmentsAtFairValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-314" name="silo:EquityInvestmentsAtFairValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-315" name="silo:EquityInvestmentsAtFairValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-316" name="us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c87" id="hidden-fact-317" name="silo:FinanceLeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-318" name="us-gaap:ProceedsFromSaleOfProductiveAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-319" name="silo:AdditionalNotesReceivableIn2021" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-320" name="silo:LessNotesReceivableNetCurrentPortion" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-321" name="silo:LessNotesReceivableNetCurrentPortion" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c166" id="hidden-fact-322" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c242" id="hidden-fact-323" name="silo:GrantedAsIncentivesAggregateIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c242" id="hidden-fact-324" name="silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c242" id="hidden-fact-325" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c242" id="hidden-fact-326" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c242" id="hidden-fact-327" name="silo:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c242" id="hidden-fact-328" name="silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c243" id="hidden-fact-329" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c169" id="hidden-fact-330" name="silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c244" id="hidden-fact-331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c244" id="hidden-fact-332" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c244" id="hidden-fact-333" name="silo:ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c244" id="hidden-fact-334" name="silo:AggregateIntrinsicValueGranted" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c245" id="hidden-fact-335" name="silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c245" id="hidden-fact-336" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c262" id="hidden-fact-337" name="silo:MinimumAnnualRoyalty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c263" id="hidden-fact-338" name="silo:MinimumAnnualRoyalty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">true</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001514183</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="silo-20220630.xsd" xlink:type="simple"/></ix:references>
<ix:resources><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-02</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silo:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silo:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DatChatIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:AikidoPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DatChatIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">silo:PromissoryNoteReceivableAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-09-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">silo:PromissoryNoteReceivableAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">silo:PromissoryNoteReceivableAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-02</xbrli:startDate>
    <xbrli:endDate>2018-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-09-01</xbrli:startDate>
    <xbrli:endDate>2018-09-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">silo:PromissoryNoteReceivableAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-11-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">silo:PromissoryNoteReceivableAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-11-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">silo:PromissoryNoteReceivableAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-11-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">silo:PromissoryNoteReceivableAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">silo:PromissoryNoteReceivableAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementAxis">silo:PurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-09-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementAxis">silo:PurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-11-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementAxis">silo:PurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2018-11-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementAxis">silo:PurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-10-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">silo:PaycheckProtectionProgramMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYRCCyonMiwgdQ2lJYzdzUOv9fI1l/VI08eZ/jN8gtVkovQNM+Tg8ySqLg3+WC1g4h34l8wpPDRKEpvN2sEoV7GBwsfUtZ7wPjtnRwjx//zhaHDazrcKZSY+odwB4qGm1MOd/qfdmKbOaTaPPe9bPa/02wjXfGOjU12GfRhsnE31flgx8L3rlukb8GN838/Vl3diUt5XNY0SQ==] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">silo:PaycheckProtectionProgramMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">silo:PaycheckProtectionProgramMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">silo:PaycheckProtectionProgramMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">silo:PaycheckProtectionProgramMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">silo:PaycheckProtectionProgramMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2013-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-02-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-01</xbrli:startDate>
    <xbrli:endDate>2020-08-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-04-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-02-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConversionPriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCPurchaseAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-02-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCPurchaseAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-04-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:SubscriptionAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:SubscriptionAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-09</xbrli:startDate>
    <xbrli:endDate>2020-04-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-04-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:AdvisoryAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:AdvisoryAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-04-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:ConsultingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:ConsultingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-04-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:EmploymentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:EmploymentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-04-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:EmploymentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-03</xbrli:startDate>
    <xbrli:endDate>2020-08-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-04</xbrli:startDate>
    <xbrli:endDate>2020-04-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:ExchangeAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-04</xbrli:startDate>
    <xbrli:endDate>2020-04-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:ExchangeAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-04</xbrli:startDate>
    <xbrli:endDate>2020-04-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-04</xbrli:startDate>
    <xbrli:endDate>2020-04-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-01-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">silo:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">silo:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">silo:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">silo:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">silo:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">silo:OneLicensorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">silo:VendorConcentrationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-04-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypeOfAgreementAxis">silo:SublicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypeOfAgreementAxis">silo:SublicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-07-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-04-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-01-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypeOfAgreementAxis">silo:SublicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ColumbiaUniversityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-08-25</xbrli:startDate>
    <xbrli:endDate>2021-09-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ColumbiaUniversityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:JVAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentEightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementAxis">silo:KuoEmploymentAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-24</xbrli:startDate>
    <xbrli:endDate>2022-01-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-02</xbrli:startDate>
    <xbrli:endDate>2022-03-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:HomeBistroIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:AikidoPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:AikidoPharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">silo:PromissoryNoteReceivableAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-11-01</xbrli:startDate>
    <xbrli:endDate>2018-11-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementAxis">silo:PurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-12-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:LayawaySaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-12-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementAxis">silo:PurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypesOfAgreementAxis">silo:PurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConversionPriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCPurchaseAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-02-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-02-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">silo:PlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-01</xbrli:startDate>
    <xbrli:endDate>2021-12-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-01</xbrli:startDate>
    <xbrli:endDate>2021-12-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-02</xbrli:startDate>
    <xbrli:endDate>2022-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:IncentiveStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-02-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">silo:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">silo:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">silo:OneLicenseeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">silo:OneLicenseeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">silo:OneLicensorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">silo:VendorConcentrationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">silo:OneLicensorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">silo:VendorConcentrationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-01-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="silo:TypeOfAgreementAxis">silo:SublicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:AikidoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ColumbiaUniversityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:JVAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentEightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="eur">
  <xbrli:measure>iso4217:EUR</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ea165987ex23-1_silopharma.htm
<DESCRIPTION>CONSENT OF SALBERG & COMPANY, P.A.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Consent of Independent Registered Public Accounting
Firm</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hereby consent to the use of our report dated March
28, 2022 (except for the reverse stock split as discussed in footnote 11 as to which the date is September 20, 2022), on the consolidated
financial statements of SILO Pharma, Inc. (f/k/a Uppercut Brands Inc.) for the years ended December 31, 2021 and 2020, included herein
on the registration statement of SILO Pharma, Inc. on Form S-1, Amendment No. 4 and to the reference to our firm under the heading &ldquo;Experts&rdquo;
in the prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">/s/ Salberg &amp; Company, P.A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">SALBERG &amp; COMPANY, P.A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Boca Raton, Florida</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">September 20, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !1 ,\# 2(  A$! Q$!_\0
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M4J5HIIO0]:>)_=0C!V:W(+:R@LTV01A/4]S7*WG/B<?]=5KLR,UF2:'!)?\
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%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>fin_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "I!7,# 2(  A$! Q$!_\0
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M_D]_]KKI6$K-72_%'.\523LW^9[)17CZ_'6 @;] E#=P+H$?^@T[_A>MM_T
M9O\ P('_ ,31]4K?RA];H_S'KU%>.O\ '9 ?W?AUF'^U>@?^R&O3M U8:[H-
MEJ@A\D7,0?RRV[;GMG S6=2A4IJ\T73K0J.T6:E%>9ZM\4M0T2>5-1\(7MO$
MKE8Y7EPKX/KLQ^1-9O\ PO6V_P"@#-_X$#_XFK6%JM72_(EXFDG9L]>HKRS_
M (6QK#)O3P-J#1]0_F/@CU_U55%^."QSF.\\-S08Z@7.6'X%!1]4K/9?BO\
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M&Q3< 1U!;V]LU482F[11,IQ@KR9VE%>9:A\4M6T@A]3\%7UK;DX\UYSC_P!
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MX]:*E&=/XU8FG6A4^%ENBBBLS4**** "BL7Q)JU[HVE_:K#2)]4FWA?(A;!
M(/S=#QQV'>N!N?C3]BG,%YX9N[>=?O12S;6'X%:UIT9U%>*O]QE.M"#M)GK%
M%>21_&PW!*6GAFXGD'.U+G/'X(:'^-$]OAKSPI<0(>C-<'K^,8J_JE;M^*(^
MM4N_X,];HKSK3/C)X:OG$=TMW8L>-TL>Y/S7)_,5WEG>6VH6RW-I/'<0N,K)
M$P93^(K*=*</B5C6%2$_A=RS1114%A1110 4455O[V'3K">]N6VPP1F1S[ 9
MH!NQ:HK@OAWXYF\7G48KQ(HYX) \:IQ^Z;I]2,<GW%=[5SA*$N66Y$)J<>:(
M4445!84444 %%%% !1110!R_B+Q[HGA?48['4WF6:2(2C9&6&TDC^8-9'_"X
M?"?_ #VN_P#OP:X+XW?\CG:?]@]/_1DE>:5ZE'!4YTU)WU/,K8NI"HXKH?1'
M_"X?"?\ SVN_^_!H_P"%P^$_^>UW_P!^#7SO16OU"EY_>9_7JOD?1'_"X?"?
M_/:[_P"_!H_X7#X3_P">UW_WX-?.]%'U"EY_>'UZKY&EK]W#J'B/5+V#<8;F
M[EE3(P=K.2/T-9M%%=B5E8XV[NX5:T_3[O5;V*RL8'GN93A8U')_P ]35=59
MW"("S,< #DDFOH_X>>"H?"ND+-<(K:I<J&G?N@/.P>P[^I_"L,175&-^IO0H
M.K*W0Q_"?PATW3$CNM=V7]WP?)_Y8QGZ?Q?CQ[5K:[\2O#7AK-G$_P!JGB^7
M[/:*-L>.Q;H/H,GVKBOB?\0YYKJ?0-'F:.",E+JXC/,C=T![ =#Z].G7R6N:
MGAI5O?K/Y'34Q$:/N4E\SU*_^-^L2N18:;9VZ=O-+2-^A _2LD_%[Q:6!^T6
MP SQ]G&#7!T5U+#45]E'*\35?VCTJT^-?B*%@+FTL+E._P C(WY@X_2NTT/X
MRZ'J#B+4X9=-E/\ $W[R//\ O#D?B/QKP&BHG@Z,NEO0J&+JQZW/K^*6WOK5
M98GCGMY5R&4AE93[]"*X_6?A7X8U>X6X%L]D^[+_ &0A%<>FT@@?@!7BWA'Q
MOJGA*\#0.TUDQ_?6KGY6'J/1O<?CFOHW0]<L?$6EQ:A82[X9."#PRL.JL.Q%
M>=5I5,-*\7IW/0IU:>(5I+4\K^+/A/1]&\.Z?=Z9816SI<"!C'D%E*,?F]?N
M]37D%?1?Q>M_/^']S)_SPFBD_-MO_LU?.E>A@9N5+5]3AQD5&IH%>^?!#_D3
M+S_L(O\ ^BXZ\#KWSX(?\B9>?]A%_P#T7'2Q_P#!^:'@OXOR9Z71117BGL!1
M110 4444 >9?%[Q3<:5IUOHU@[)=7P)D9/O"(<8'^\>/H#71>"?!EEX4TJ-1
M&C:A(H-S<$ L6QRH/91Z?C7EWQ?G>V^(5I/MW>5:Q.H/0X=C_.O<--U&VU73
MK>_LY%DMYT#QL/0_UKKJIPH02V>YR4FIUI.6ZV+E,D1)49'4,C#!!&013Z*Y
M#K/"_BC\/K?1HO[<TB'R[1F"W%NOW8B3PR^BD\8[''KQZCX#N?M7@/1)/2U2
M/_OD;?Z5JZII\.K:5=:?<?ZFYB:-\=0".OU'6J'A+0Y/#GAFSTJ6X%P]OO!D
M P#EV;I]#BNB=;GHJ,MT_P #GA1Y*KE'9HW:***YSH"N$^*OB+^P_",EO"^V
MZO\ ,$>.H3'SG\N/JPKNZ\7;_BX?Q="_?TK2>N?NL$;_ -F?\U'M6^'BG+FE
MLM3#$2:CRQW>AYKH]_=>&?$EI>M$\<]G,&DB<%6Q_$I^HR/QKZKMKF*[M8;B
M!PT4R!T8=U(R#^5>'?&C0?L6O6^L0IB*]7;*1_ST48_5<?\ ?)KL_@_KW]J>
M%#I\KYN-.;9SWC.2OY<C\*ZL7:K2C61S89NE5E29Z+1117G'H!7#_%BVAF^'
MNH321HTD#1-&Q'*DR*I(_ D5W%<9\5?^2;:O_P!L?_1R5K0_BQ]495OX<O1G
MD7PHM(+KQ_:&= _DH\J ]-P'!_#.:^D*^=O@]_R/T/\ U[R?RKZ)KHQ_\7Y&
M&!_A?,****XCL"FD!E((R#P0:=10!\O?$'3;72/'.J6=G&([=71E0<!=R*Q
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M5P&4]01D4^BO-/0/-?BGX6TE_"5YJL%A#%?6Y1A+$@4L"Z@AL=>#G\*ZGP/
M;;P-HL;<'[(C<_[0S_6MR>&*XA:&>))(G&&1P"I'N#3E4(H50 H& !T K5U6
MZ:@^YDJ251S15U.P@U33KFQN5#PSQE&!&>HKY7T!%?Q)I:.JE6O(@0>A!<5]
M:U\E^'?^1GTK_K]A_P#1@KMP'PS7]=3DQJ]Z']=CZTK+U;0=+URV,&I64-PF
M, NOS+]&ZC\*U**\Y-IW1WM)JS/F3QYX/D\'ZVL<3N]G."]M*?O<=5)]1_45
M[#\+_%$WB/PSLO'WWMDPBD<]77'RL??''X9[UF_&RWCD\(VL[8$D5XH4]\%6
MR!^0/X5C? F.0-KC_P#+(^0/JPW_ .?QKT:DO:X7GENCSX1]EB>2.S/9:**A
MN)X[:WDGF<)%$I=V/0*!DFO-/1.;\:^,K3PAI7FNJRWDV1;P;L;CZGT4=Z\W
M\*^&M4^).I/K_B6YE;3D8B.,?*)"#RJ?W5'0D<GZY-<EJ5]>>/\ QTG)!NYU
MA@0\^5%GC\ADG\:^E-.L+?3-/M[&U0)! @1%]@*[YKZM327Q/\#A@_K$VW\*
M_$+'3[33;5;6QMHK>!.D<2!15NBBN [DK!7"^+_AGI/B.*2XM8TL=2Y(FC7"
MR'_;4=?KU^M=U15PG*#O%V(G",U:2/D_4%UKP^]UH-U-<VZ!OWUN)#Y;'J#C
MH<\'-?3N@3?:/#FF3?\ /2TB;CW0&N2^*'@S_A(M'^WV,.[4[,94*.98^Z>Y
M[C\1WKH_!Z3Q^#='CN(WCE2TC1DD7:PPH'(KJQ-6-6E&2WOK]QRX>DZ=24>E
MM#=HHHKB.T**** .#^*^NSZ+X/9+1RDU[*(-X."JD$L1^ Q^-0?!_3+6V\%1
MWT:J;F[E<S/W^5BH7Z8&<>]'QATJ74/!HN85W/93K,V!SL(*M_,'\*XOX1>,
M$TO4'T&]EVVUW)NMV/19",8^C<?B/>NZ$.;"OEWOJ<,I\N)7-M;0]REACGB:
M*5%>-P596 ((/8BO!_B'X&C\,ZU9ZGIJ%=.N9U78/^6,F<X^AY(^A]J]]JI?
MZ=::I:FUOK>.X@8AC'(,C(.17/0K.E*_0Z*U%58VZEL=****Q-@HHHH ****
M "BBN-^(_B=O#/A>62!]M[='R;<CJI(Y;\!^N*J$'.2BNI,Y*$7)]#E/B#\1
M;I;UO#OAMF-R6$4US%R^\G&R/W[$_E6OX+^&%CH\4=_K4:7NJ/\ ,5?YHX2?
M0=S[G\*Y#X-: M_K5WK=RF];,!(MW/[UNI^H'_H5>ZUUUY*BO8T_F^YRT(NK
M^]J?+R$ Q2T45Q'80SP0W,#0SQ)+$XPR2*&4CW!X->,^/_AM_8R-K_ASS8HH
M3OEMXR=T./XT/7'J.W7IT]LII 92",@\$&M:-:5*5XF56C&HK,\/^&_C+7M8
M\9VMGJ6I37$#6[H(VP!P,@G &3QU/->Y5XW;^&?^$3^-.F&V1A87QE>$ <+F
M-\I^!P?IBNW^(?B9O#'A6:X@.+N<^3;^S$<M^ R?KBM\1%5*D?9K=&-"3A"7
M/T9S?CSX@W,>H#PWX9W2ZG(_E2S1C)C8_P "_P"UZGM]>FMX0^'%AH:B^U0+
MJ&KN=[S2_,L;'^[GO_M'GZ5ROP7\/K*]YXBNEWR*Q@MRW4$C+M^H&?K7LM*O
M)4OW5/YON.C'VG[V?R\@HHHKD.HP?$'A'1O$UN4U*T5Y,86=/EE7Z-_0\>U>
M#>)O"^L?#[6X;BWN)1"6S;7D65S_ +)]#[=Z^EZR]<T6S\0:/<:;>INAF7&>
MZMV8>X-=-#$RI.SUB<]?#JHKK1G)_#SXA1^*8/L%_LCU6)<G'"S*/XE]#ZC\
M1QT] KY0GBU+PAXH= WDWUA/\KCH<=#[@C\P:^F]!U:'7=#L]3@X2XC#X_NG
MN/P.15XN@H-3ALR,+6<TX3W1!XHT*'Q'X?NM.F0,SH3$QZI(!\I'X_IFOERU
MNKC3;^&Z@8QW%O*'4^C U]?5\H:_93)X@UH10N8[:[E5R!D1CS"!D_7BMLOE
MI*+V,<='6,EN?3>@:O#KNA6>IP8"7$88CKM;H5_ Y%:E>+_!7Q'LFN?#\[\/
MF>VR>X^\OY8/X&O:*XZ]+V=1Q.RA4]I!2"BBBL34*^=OBQXC&M>*C9P/NM-/
M!A7!X,F?G/YX'_ :]B\=^)!X9\*W-XC 74G[FW'^V1U_ 9/X5\Y:OHNH:0+5
M]0BV->0"XC!.6VDGKZ'CI7HX"FN;G?R_4\_&U';D7S/=/A!I\-KX%@ND4"6[
MEDDD;N=K%!^BUZ!7#?"3_DGME_UTE_\ 0S7<UQU_XLO4ZZ'\*/H5KRTAOK*>
MTN%#13HT;@]P1@U\FZ8H.L6:E<@W" @_[PKZ[KY%TO\ Y#=E_P!?,?\ Z$*[
M<OVG_7<X\<M8_P!=CZZ'05C:WX9T?Q# 8M3L(IR1@2[<2+]&'(K9'2BO.3<7
M='H-)JS/FGQMX.N_!&KQ2V\TK6DAW6UR/E9&'8D=&'KW_EZO\,?&DGB?29+6
M^<'4;/ =^GFH>C?7L?P]:N_$_3XK_P  Z@7"[[;;/&3V(89_0L/QKRSX-2R)
MXYVK]V2TD5_IE3_,"O1;]OAG*6\3STO88A1CLSZ%HHHKS3T3GO&>OKX:\+7F
MH;@)]OEVX/>1N%_+K] :^8]]Y8WD-RWFQ7&5N(Y&4@G)RK#/7US7K/CVXD\9
M?$#3O"=HY^S6[YN&7LQ&7/\ P%>/J2*?\9/#,46E:=JMG"J):!;1U4<"/^#\
M <C\17IX5QI<L7O+^D>;B4ZMY+:/],]+\.:O'KWA^RU.+'^D1AF _A;HP_ Y
M%:U>/?!+7MT-[H4S_,A^T0 _W3PP_/!_$U[#7#7I^SJ.)VT*GM(*04445D:G
M*^//#-OXE\,W,31 W<$;2VTF/F#@9QGT/0UX+X/\77GA#6!<P[I+9\+<6^>)
M%_HP['^E?4E?*VG^&;W7)M6_LU [6*F0PC.YUW8POJ:]'!23A*$]CS\9%J<9
M0W/IK2=6L];TV&_L)EEMYAE6'Z@^AS5^OFCP'XVN/".I[)M\FFSL//BZE3_?
M7W'ZC\*^CK.\@O[.*ZM9%E@F4.CKT(-<V(H.C+R.FA756/F6:***YS<\H^-&
M@6TFC0:W%&BW<4RQ2.!@NA'&?7! _,UTGPN@C@^'^FF- IDWNY'<ESR?R%5/
MC!_R(,W_ %WC_G6A\,O^2>Z3_N-_Z&U=<I-X57[G)&*6)=NQUU>2?%_P>MS:
M?\)%8P@3PX6[51]].S_4=#[?2O6ZBEBCGA>*5 \<BE64\@@CD5A2J.G-21O5
MIJI%Q9X'\(?$L.CZ_+IMSM6+4=J)(?X)!G:/H<X^N*^@:^8/'/A>7PEXDDMX
M]_V67][:R=]I/3/J#Q^1[U[9\.O%@\4>'5\]Q_:%KB.X'=O1_P 1^N:[,934
MDJT-F<F$J.+=*6Z.SKA_BIJEKI_@>[MY]K2WF(H8SU)R"3^ &?KBNTEE2&)I
M9&"1H"S,QP !U)KQRQB?XH?$&2_G4G0=-(6-'Z/@\#'JQY/M@>E<V'BN;GEM
M'4Z*\GR\D=WH;OPH\'#1])&L7L.+^[&8]PYBC[#V)ZG\*]*I ,#%+6=2HZDG
M)FE."IQ44%%%%06%%%% !7C_ ,<K*/[/I-\%42AWB8]RN 1^7/YU[!7E/QQ_
MY >E_P#7PW_H-=&$=JT3GQ7\%E3X%JOE:TV!NW1#..<8:O7G1)$*.H9&&"",
M@BO(_@5_Q[:S_P!=(OY-7K]/%_QI!A/X*/.?&7PLTS6;62ZT>WCLM149"1X6
M*7'8CH#[C\:\G\*>*M3\%:X0?-%L)-EW:/WP<'CLP_\ K5]/5\Z?%[3H['QU
M++&-HNX4G(]^5/ZK71@ZCJ7I3U1SXJFH6JPT9]!VMS#>6D-S X>&5 Z,.A4C
M(-6*Y3X;R22_#_2&E.6$17GT!('Z 5U=<$X\LG'L=T)<T4^X4445)05Y;\8M
M=DCT^U\.V>7NKY@TB(,L4!PJX_VF_P#0:],GGCMK>2:5PD<:EW8] H&2:\@\
M$Q2>-?B-J'BBZ4_9+1L6ZMV.,(/3A>3[D&NC#Q2;J2VC^?0Y\0VTJ:W?Y'"^
M M<;P[XRL[B4[(9&^SW&[C",<<_0X/X5]/CD9%?-OQ1T'^Q/&-P\:;;:]_TB
M/TR3\P_[ZS^!%>S_  \UW^W_  =9SR/NN(1Y$_KN7C)^HP?QKHQB4XQK+J88
M1N$I4GT.KHHHKSSO"BBB@ HHHH **** ..\4?#K2?%NIQW]_=7L4L<(A MW0
M+M!)[J>?F-8O_"D/#7_/[JW_ '^C_P#C=/\ 'OQ'N_"&NP:?;V$-PDELLQ>1
MR""688X_W:Y?_A>6I?\ 0'M/^_C5W4H8IP3@]/4XJD\,I/G6OH=+_P *0\-?
M\_NK?]_H_P#XW1_PI#PU_P _NK?]_H__ (W7-?\ "\M2_P"@/:?]_&H_X7EJ
M7_0'M/\ OXU7[/&=_P 49\^$[?@SI?\ A2'AK_G]U;_O]'_\;H_X4AX:_P"?
MW5O^_P!'_P#&ZYK_ (7EJ7_0'M/^_C4?\+RU+_H#VG_?QJ/9XSO^*#GPG;\&
M><:Y8Q:9K^HV$)=H[6ZE@0M@L55BHS@#GCTK/JYJ=\VIZM>:@Z!'NIWF*CH"
M[%L?K5.O4C>RN>=*UW8[CX4Z(FL>-8))1NAL5-R0>A8$!?U(/_ :]S\7:JVA
M^$]3U%&VRPP'RSZ.?E7]2*\Y^!5N!%K=R5Y)A0'V <G^8KK?BK&[_#K4]G\)
MB9AZ@2+7DXA\^)47MH>IAUR8=R6^I\W$EB68Y)Y)-)117KGE!1110(**** "
MNW^&?BQ_#?B)()Y,:=>E8Y@3PC'[K_@>#['VKB**BI!3BXOJ7";A)21]0_$"
MV^U> =9CZXMS)_WP0W]*^7J^C_#NKIXK^&$ADE#W'V*2UN,GG>$*Y/U&&_&O
MG"N/ )Q4H/HSKQK4G&:ZH*]\^"'_ ")EY_V$7_\ 1<=>!U[Y\$/^1,O/^PB_
M_HN.KQ_\'YHG!?Q?DSTNBBBO%/8"BBB@ HHHH \L^,7A6XU.RM];LXS++9J4
MG0#),1.=P_W3G/L?:O+?#/C76O"DA&GW"M;L<O;3#=&3ZXX(/T(KZE(S7G?B
M;X2:-K4C7.GNVF7;$D^6NZ)C[IV_ CZ5WX?$P4/955H<-?#R<O:4WJ9^D?&S
M2K@!-5L9[-^\D7[U/Z$?D:[S2?%&AZX/^)9J=O<-U\L/A_\ OD\_I7@^K?"G
MQ3I>6BLTOHA_':ON/_?)PWY UQ\]O=6%UY<\,UM.G.R1"C#\\&M7A*%36G(R
M6*K4]*B/L"BOGWPA\5M4T>>.UUF1[[3R0"[\RQ#U!_B'L?P->]6MU#>VL5S;
M2++!,H='7H5(X-<-:A.B[2.VC7C55XEBBBBL38Y#XB^(_P#A'/"=Q+$^V[N?
MW%OCJ&(Y;\!D_7%4?A1X=_L7PHEU,F+O4,3/GJ$_@'Y<_P# JX?QGK%AXH^)
MUII=[>);Z/I[^5+)(^%+#F3GMD@)GVKU1?&OA90%77M. '  G6NR<)0HJ"6K
MU?Z')&<9U7)O;1$'Q T+_A(?!][:QINN8E\^W]=Z\X'U&1^->)_#'7O[#\9V
MHD?;;7G^C2>GS'Y3_P!]8Y],U[I_PF_A;_H/Z=_W_7_&OG7Q?%I]OXMOSI%S
M%-9-+YD+PGY5S\V ?8\<5M@TY0E2FM&8XII2C5B]4?55%<_X,UT>(_"ECJ#'
M,S)LG]I%X;\^OT-=!7G2BXMIGH1DI*Z"N,^*O_)-M7_[8_\ HY*[.N,^*O\
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MBV?^^:TI4W4FHHSJU%3@Y&C/XTU#Q5<W6E>$=+ANX$!CGOK[(@P>,;>IR/\
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M,W S_NJ<_C65"E[2HH]#6O4]G!LU/@_HTKP7WBB^^>ZOW98Y&ZE=V7;\6_\
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M'XA?V5)'H6KS?Z"YQ;SL>(2?X3_LG]/IT]VKDK494I<K.JC6C5CS(X'XP?\
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MF$K#$3_"",L1[GCG_&O:*RQ%H?N8[+\6:T+S_>RW?X!1117*=(4444 %%%%
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MX!_DP_0U]26MU%>VD-U VZ*9%D1O52,C]*UQT$IJ:V9G@YW@X/=$]<9\5?\
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M M%("",CD&EH **** "O*?CC_P @/2_^OAO_ $&O5J\I^./_ " ]+_Z^&_\
M0:Z,+_&B<^*_A2*WP*_X]M9_ZZ1?R:O7Z\@^!7_'MK/_ %TB_DU>OT\7_&D&
M$_@Q"BBBN8Z HJ,2QM(T8=2ZXW*#R,^M24 %<'\5/$7]B>$WMH7(N[\F&/'4
M+_&?RX_&N\KQA&_X6#\7=PR^E:5R/0A3_P"S/S]!6^'BG+FEM'4PQ$FH\L=W
MH7?#_P &]*FT:WGU>:]-Y*@=XXV5%C)&=N,$Y'?FM7_A3'A?_GKJ/_?]?_B:
M]%HH>)K-WYF"PU)*W*>=?\*8\+_\]=1_[_K_ /$UP?Q&^'5OX5M8-0TR6XDM
M'?RY4E()1B,@Y '!P?\ )KZ!K&\4:.FO^&[[3& W31'RR>SCE3^8%72Q52,T
MY2T(JX:#@U%:G!_!77_M6D7.BRN"]HWFQ#_88\C\&S^=>JU\O^"=8D\,>-+2
M>;,<8D-O< \81C@Y^AP?PKZ@!R,BGC:?)4NMF+!U.:G9[H***CDE2&,O(X1!
MU9C@"N0ZR2BD!S2T %%%% 'BOQ<\1:SI'BRV@T[4[JUA:Q1S'#(5!8O(,_7
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M>9MVR#Z,,']:[(9@_MK[CEG@%]AGRE17L/B+X*LJO/X>O"W?[+=$9_X"XX_
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MO+<_7L?Q!KMAB8RA[.LKKOU..6&E&?/2=F;FGZI9:M:BYT^[ANH3_%$X8?\
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M_P#X3?PM_P!!_3O^_P"O^-'_  F_A;_H/Z=_W_7_ !H]G/LP]I#NCH**Y_\
MX3?PM_T']._[_K_C1_PF_A;_ *#^G?\ ?]?\:/9S[,/:0[HZ"BN?_P"$W\+?
M]!_3O^_Z_P"-'_";^%O^@_IW_?\ 7_&CV<^S#VD.Z.@HKG_^$W\+?]!_3O\
MO^O^-'_";^%O^@_IW_?]?\:/9S[,/:0[HZ"BN?\ ^$W\+?\ 0?T[_O\ K_C1
M_P )OX6_Z#^G?]_U_P :/9S[,/:0[HZ"BN?_ .$W\+?]!_3O^_Z_XT?\)OX6
M_P"@_IW_ '_7_&CV<^S#VD.Z.@HKG_\ A-_"W_0?T[_O^O\ C1_PF_A;_H/Z
M=_W_ %_QH]G/LP]I#NCH**Y__A-_"W_0?T[_ +_K_C1_PF_A;_H/Z=_W_7_&
MCV<^S#VD.Z.@HKG_ /A-_"W_ $']._[_ *_XT?\ ";^%O^@_IW_?]?\ &CV<
M^S#VD.Z.@HKG_P#A-_"W_0?T[_O^O^-'_";^%O\ H/Z=_P!_U_QH]G/LP]I#
MNCH**Y__ (3?PM_T']._[_K_ (T?\)OX6_Z#^G?]_P!?\:/9S[,/:0[HZ"BN
M?_X3?PM_T']._P"_Z_XT?\)OX6_Z#^G?]_U_QH]G/LP]I#NCH**Y_P#X3?PM
M_P!!_3O^_P"O^-'_  F_A;_H/Z=_W_7_ !H]G/LP]I#NCH**Y_\ X3?PM_T'
M]._[_K_C1_PF_A;_ *#^G?\ ?]?\:/9S[,/:0[HZ"BN?_P"$W\+?]!_3O^_Z
M_P"-'_";^%O^@_IW_?\ 7_&CV<^S#VD.Z.@HKG_^$W\+?]!_3O\ O^O^-'_"
M;^%O^@_IW_?]?\:/9S[,/:0[HZ"BN?\ ^$W\+?\ 0?T[_O\ K_C1_P )OX6_
MZ#^G?]_U_P :/9S[,/:0[HZ"BN?_ .$W\+?]!_3O^_Z_XT?\)OX6_P"@_IW_
M '_7_&CV<^S#VD.Z.@HKG_\ A-_"W_0?T[_O^O\ C1_PF_A;_H/Z=_W_ %_Q
MH]G/LP]I#NCH**Y__A-_"W_0?T[_ +_K_C1_PF_A;_H/Z=_W_7_&CV<^S#VD
M.Z.@HKG_ /A-_"W_ $']._[_ *_XT?\ ";^%O^@_IW_?]?\ &CV<^S#VD.Z.
M@HKG_P#A-_"W_0?T[_O^O^-'_";^%O\ H/Z=_P!_U_QH]G/LP]I#NCH**Y__
M (3?PM_T']._[_K_ (T?\)OX6_Z#^G?]_P!?\:/9S[,/:0[HZ"BN?_X3?PM_
MT']._P"_Z_XT?\)OX6_Z#^G?]_U_QH]G/LP]I#NCH**Y_P#X3?PM_P!!_3O^
M_P"O^-'_  F_A;_H/Z=_W_7_ !H]G/LP]I#NCH**Y_\ X3?PM_T']._[_K_C
M1_PF_A;_ *#^G?\ ?]?\:/9S[,/:0[HZ"BN?_P"$W\+?]!_3O^_Z_P"-'_";
M^%O^@_IW_?\ 7_&CV<^S#VD.Z.@HKG_^$W\+?]!_3O\ O^O^-'_";^%O^@_I
MW_?]?\:/9S[,/:0[HZ"BN?\ ^$W\+?\ 0?T[_O\ K_C1_P )OX6_Z#^G?]_U
M_P :/9S[,/:0[HZ"BN?_ .$W\+?]!_3O^_Z_XT?\)OX6_P"@_IW_ '_7_&CV
M<^S#VD.Z.@HKG_\ A-_"W_0?T[_O^O\ C1_PF_A;_H/Z=_W_ %_QH]G/LP]I
M#NCH**Y__A-_"W_0?T[_ +_K_C1_PF_A;_H/Z=_W_7_&CV<^S#VD.Z.@HKG_
M /A-_"W_ $']._[_ *_XT?\ ";^%O^@_IW_?]?\ &CV<^S#VD.Z.@HKG_P#A
M-_"W_0?T[_O^O^-'_";^%O\ H/Z=_P!_U_QH]G/LP]I#NCH**Y__ (3?PM_T
M']._[_K_ (T?\)OX6_Z#^G?]_P!?\:/9S[,/:0[HZ"BN?_X3?PM_T']._P"_
MZ_XT?\)OX6_Z#^G?]_U_QH]G/LP]I#NCH*Y/QOXL7PUIRPVT3SZK>!DLX$0M
MENF3CTST[U<_X3?PM_T']._[_K_C33XT\*LX)U[3BR]#YZY%5"$D[N+9,IIJ
MRDD8WPV\&R>&=*DN[\?\32\PTHSGRU[+GU[G_P"M7=US_P#PF_A;_H8-._[_
M *_XT?\ ";^%O^@_IW_?]?\ &B:J3DY23%!TX1Y4T=!17/\ _";^%O\ H/Z=
M_P!_U_QH_P"$W\+?]!_3O^_Z_P"-3[.?9E^TAW1T%%<__P )OX6_Z#^G?]_U
M_P :/^$W\+?]!_3O^_Z_XT>SGV8>TAW1T%%<_P#\)OX6_P"@_IW_ '_7_&C_
M (3?PM_T']._[_K_ (T>SGV8>TAW1T%%<_\ \)OX6_Z#^G?]_P!?\:/^$W\+
M?]!_3O\ O^O^-'LY]F'M(=T=!17/_P#";^%O^@_IW_?]?\:/^$W\+?\ 0?T[
M_O\ K_C1[.?9A[2'='045S__  F_A;_H/Z=_W_7_ !H_X3?PM_T']._[_K_C
M1[.?9A[2'='045S_ /PF_A;_ *#^G?\ ?]?\:/\ A-_"W_0?T[_O^O\ C1[.
M?9A[2'='045S_P#PF_A;_H/Z=_W_ %_QH_X3?PM_T']._P"_Z_XT>SGV8>TA
MW1T%%<__ ,)OX6_Z#^G?]_U_QH_X3?PM_P!!_3O^_P"O^-'LY]F'M(=T=!17
M/_\ ";^%O^@_IW_?]?\ &C_A-_"W_0?T[_O^O^-'LY]F'M(=T=!14<<B31+)
M&P9& 96'0@U)4%A1110!YOX]^'%WXOUV#4+>_AMTCMEA*2(220S'/'^]7+_\
M*-U+_H,6G_?MJ[_Q1\1=)\):G'87]K>RRR0B8&W1"NTDCNPY^4UB_P#"[_#7
M_/EJW_?J/_XY7=2GBE!*"T]#BJ0PSD^=Z^IS7_"C=2_Z#%I_W[:C_A1NI?\
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M+?\ 0 T[_OPO^%'_  A'A;_H :=_WX7_  KH**/:3[L/9P[(Y_\ X0CPM_T
M-._[\+_A1_PA'A;_ * &G?\ ?A?\*Z"BCVD^[#V<.R.?_P"$(\+?] #3O^_"
M_P"%'_"$>%O^@!IW_?A?\*Z"BCVD^[#V<.R.?_X0CPM_T -._P"_"_X4?\(1
MX6_Z &G?]^%_PKH**/:3[L/9P[(Y_P#X0CPM_P! #3O^_"_X4?\ "$>%O^@!
MIW_?A?\ "N@HH]I/NP]G#LCG_P#A"/"W_0 T[_OPO^%'_"$>%O\ H :=_P!^
M%_PKH**/:3[L/9P[(Y__ (0CPM_T -._[\+_ (4?\(1X6_Z &G?]^%_PKH**
M/:3[L/9P[(Y__A"/"W_0 T[_ +\+_A1_PA'A;_H :=_WX7_"N@HH]I/NP]G#
MLCG_ /A"/"W_ $ -._[\+_A1_P (1X6_Z &G?]^%_P *Z"BCVD^[#V<.R.?_
M .$(\+?] #3O^_"_X4?\(1X6_P"@!IW_ 'X7_"N@HH]I/NP]G#LCG_\ A"/"
MW_0 T[_OPO\ A1_PA'A;_H :=_WX7_"N@HH]I/NP]G#LCG_^$(\+?] #3O\
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MM_T -._[\+_A7044>TGW8>SAV1S_ /PA'A;_ * &G?\ ?A?\*/\ A"/"W_0
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M.?\ ^$(\+?\ 0 T[_OPO^%'_  A'A;_H :=_WX7_  KH**/:3[L/9P[(Y_\
MX0CPM_T -._[\+_A1_PA'A;_ * &G?\ ?A?\*Z"BCVD^[#V<.R.?_P"$(\+?
M] #3O^_"_P"%'_"$>%O^@!IW_?A?\*Z"BCVD^[#V<.R.?_X0CPM_T -._P"_
M"_X4?\(1X6_Z &G?]^%_PKH**/:3[L/9P[(Y_P#X0CPM_P! #3O^_"_X4?\
M"$>%O^@!IW_?A?\ "N@HH]I/NP]G#LCG_P#A"/"W_0 T[_OPO^%'_"$>%O\
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MW_0 T[_OPO\ A1_PA'A;_H :=_WX7_"N@HH]I/NP]G#LCG_^$(\+?] #3O\
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MRE'V6]^AZC<>(])L]9ATB>\2._G ,<)5LL#G'.,=C5O4=1M=*L);V]F$-M$
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M3NVAOXL]>]$J=.4YSULO\_R"-2<8PCI=GJFA^+-$\2*_]EWR3,@R\9!5P/\
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M5V4**I0Y4<E:JZLN9A7OGP0_Y$R\_P"PB_\ Z+CKP.O?/@A_R)EY_P!A%_\
MT7'6./\ X/S1M@OXOR9Z71117BGL!1110 4444 %%%% !1110 4444 %%%%
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MT/PU:L/-E?>03QN<[$S^3?G7L->6V_AG6M1^,$FNW]B\6FV['R'9U(8*FQ<
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M^I_]!&[_ ._[?XT?VOJ?_01N_P#O^W^-']GR_F#Z_'^4M^+ !XQUU5& -0G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>silo-20220630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Sep 20 20:53:05 UTC 2022 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://silopharma.com/20220630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:silo="http://silopharma.com/20220630" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="silo-20220630_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="silo-20220630_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="silo-20220630_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="silo-20220630_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://silopharma.com/role/ConsolidatedBalanceSheet" id="silo_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" id="silo_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ConsolidatedIncomeStatement" id="silo_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals" id="silo_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Condensed Consolidated Statements of Operations (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ShareholdersEquityType2or3" id="silo_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ConsolidatedCashFlow" id="silo_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/OrganizationandBusiness" id="silo_r_OrganizationandBusiness">
        <link:definition>007 - Disclosure - Organization and Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/SummaryofSignificantAccountingPolicies" id="silo_r_SummaryofSignificantAccountingPolicies">
        <link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements" id="silo_r_FairValueofFinancialInstrumentsandFairValueMeasurements">
        <link:definition>009 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusiness" id="silo_r_DisposaloftheDiscontinuedOperationsoftheNfidBusiness">
        <link:definition>010 - Disclosure - Disposal of the Discontinued Operations of the Nfid Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/NotesReceivable" id="silo_r_NotesReceivable">
        <link:definition>011 - Disclosure - Notes Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/NotePayable" id="silo_r_NotePayable">
        <link:definition>012 - Disclosure - Note Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/StockholdersEquity" id="silo_r_StockholdersEquity">
        <link:definition>013 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/IncomeTaxes" id="silo_r_IncomeTaxes">
        <link:definition>014 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/Concentrations" id="silo_r_Concentrations">
        <link:definition>015 - Disclosure - Concentrations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/CommitmentsandContingencies" id="silo_r_CommitmentsandContingencies">
        <link:definition>016 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/SubsequentEvents" id="silo_r_SubsequentEvents">
        <link:definition>017 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/AccountingPoliciesByPolicy" id="silo_r_AccountingPoliciesByPolicy">
        <link:definition>018 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/SummaryofSignificantAccountingPoliciesTables" id="silo_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>019 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables" id="silo_r_FairValueofFinancialInstrumentsandFairValueMeasurementsTables">
        <link:definition>020 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessTables" id="silo_r_DisposaloftheDiscontinuedOperationsoftheNfidBusinessTables">
        <link:definition>021 - Disclosure - Disposal of the Discontinued Operations of the Nfid Business (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/NotesReceivableTables" id="silo_r_NotesReceivableTables">
        <link:definition>022 - Disclosure - Notes Receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/NotePayableTables" id="silo_r_NotePayableTables">
        <link:definition>023 - Disclosure - Note Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/StockholdersEquityTables" id="silo_r_StockholdersEquityTables">
        <link:definition>024 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/IncomeTaxesTables" id="silo_r_IncomeTaxesTables">
        <link:definition>025 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/CommitmentsandContingenciesTables" id="silo_r_CommitmentsandContingenciesTables">
        <link:definition>026 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/OrganizationandBusinessDetails" id="silo_r_OrganizationandBusinessDetails">
        <link:definition>027 - Disclosure - Organization and Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" id="silo_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>028 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable" id="silo_r_ScheduleofantidilutivenetlosspershareTable">
        <link:definition>029 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable" id="silo_r_ScheduleofreconciliationofbasicanddilutednetlosspershareTable">
        <link:definition>030 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of reconciliation of basic and diluted net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails" id="silo_r_FairValueofFinancialInstrumentsandFairValueMeasurementsDetails">
        <link:definition>031 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" id="silo_r_ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable">
        <link:definition>032 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable" id="silo_r_ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable">
        <link:definition>033 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of activity in the company&#8217;s equity investments, at fair value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessDetails" id="silo_r_DisposaloftheDiscontinuedOperationsoftheNfidBusinessDetails">
        <link:definition>034 - Disclosure - Disposal of the Discontinued Operations of the Nfid Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable" id="silo_r_ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable">
        <link:definition>035 - Disclosure - Disposal of the Discontinued Operations of the Nfid Business (Details) - Schedule of financial data of the company&#8217;s gain from sale of the NFID business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable" id="silo_r_ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable">
        <link:definition>036 - Disclosure - Disposal of the Discontinued Operations of the Nfid Business (Details) - Schedule of operating result of discontinued operations of the NFID business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/NotesReceivableDetails" id="silo_r_NotesReceivableDetails">
        <link:definition>037 - Disclosure - Notes Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofnotesreceivableTable" id="silo_r_ScheduleofnotesreceivableTable">
        <link:definition>038 - Disclosure - Notes Receivable (Details) - Schedule of notes receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/NotePayableDetails" id="silo_r_NotePayableDetails">
        <link:definition>039 - Disclosure - Note Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofinterestexpenseTable" id="silo_r_ScheduleofinterestexpenseTable">
        <link:definition>040 - Disclosure -  Note Payable (Details) - Schedule of interest expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/StockholdersEquityDetails" id="silo_r_StockholdersEquityDetails">
        <link:definition>041 - Disclosure - Stockholders&#8217; Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable" id="silo_r_ScheduleofstockoptionsactivitiesTable">
        <link:definition>042 - Disclosure - Stockholders&#8217; Equity (Details) - Schedule of stock options activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofwarrantactivitiesTable" id="silo_r_ScheduleofwarrantactivitiesTable">
        <link:definition>043 - Disclosure - Stockholders&#8217; Equity (Details) - Schedule of warrant activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/IncomeTaxesDetails" id="silo_r_IncomeTaxesDetails">
        <link:definition>044 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable" id="silo_r_ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable">
        <link:definition>045 - Disclosure - Income Taxes (Details) - Schedule of effective statutory rate and the provision for income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable_Parentheticals" id="silo_r_ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable_Parentheticals">
        <link:definition>046 - Disclosure - Income Taxes (Details) - Schedule of effective statutory rate and the provision for income taxes (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofnetdeferredtaxassetTable" id="silo_r_ScheduleofnetdeferredtaxassetTable">
        <link:definition>047 - Disclosure - Income Taxes (Details) - Schedule of net deferred tax asset</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ConcentrationsDetails" id="silo_r_ConcentrationsDetails">
        <link:definition>048 - Disclosure - Concentrations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/CommitmentsandContingenciesDetails" id="silo_r_CommitmentsandContingenciesDetails">
        <link:definition>049 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofmilestonepaymentsTable" id="silo_r_ScheduleofmilestonepaymentsTable">
        <link:definition>050 - Disclosure - Commitments and Contingencies (Details) - Schedule of milestone payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable" id="silo_r_ScheduleofUMBminimumroyaltypaymentsTable">
        <link:definition>051 - Disclosure - Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable" id="silo_r_ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable">
        <link:definition>052 - Disclosure - Commitments and Contingencies (Details) - Schedule of exclusive of value added tax to be amortized</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofshallpayUMBTable" id="silo_r_ScheduleofshallpayUMBTable">
        <link:definition>053 - Disclosure - Commitments and Contingencies (Details) - Schedule of shall pay UMB</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/SubsequentEventsDetails" id="silo_r_SubsequentEventsDetails">
        <link:definition>054 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable0" id="silo_r_ScheduleofantidilutivenetlosspershareTable0">
        <link:definition>055 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0" id="silo_r_ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0">
        <link:definition>056 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable0" id="silo_r_ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable0">
        <link:definition>057 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of activity in the company&#8217;s equity investments, at fair value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable0" id="silo_r_ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable0">
        <link:definition>058 - Disclosure - Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of financial data of the company&#8217;s gain from sale of the NFID business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable0" id="silo_r_ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable0">
        <link:definition>059 - Disclosure - Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of operating result of discontinued operations of the NFID business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofnotesreceivablenetTable" id="silo_r_ScheduleofnotesreceivablenetTable">
        <link:definition>060 - Disclosure - Notes Receivable (Details) - Schedule of notes receivable net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0" id="silo_r_ScheduleofstockoptionsactivitiesTable0">
        <link:definition>061 - Disclosure - Stockholders&#8217; Equity (Details) - Schedule of stock options activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofwarrantactivitiesTable0" id="silo_r_ScheduleofwarrantactivitiesTable0">
        <link:definition>062 - Disclosure - Stockholders&#8217; Equity (Details) - Schedule of warrant activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofmilestonepaymentsTable0" id="silo_r_ScheduleofmilestonepaymentsTable0">
        <link:definition>063 - Disclosure - Commitments and Contingencies (Details) - Schedule of milestone payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable0" id="silo_r_ScheduleofUMBminimumroyaltypaymentsTable0">
        <link:definition>064 - Disclosure - Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/ScheduleofshallpayUMBTable0" id="silo_r_ScheduleofshallpayUMBTable0">
        <link:definition>065 - Disclosure - Commitments and Contingencies (Details) - Schedule of shall pay UMB</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silopharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYRCCyonMiwgdQ2lJYzdzUOv9fI1l/VI08eZ/jN8gtVkovQNM+Tg8ySqLg3+WC1g4h34l8wpPDRKEpvN2sEoV7GBwsfUtZ7wPjtnRwjx//zhaHDazrcKZSY+odwB4qGm1MOd/qfdmKbOaTaPPe9bPa/02wjXfGOjU12GfRhsnE31flgx8L3rlukaRb5P1QozmTx8JRaSqyI5w==] CSR-->
  <xs:element name="ScheduleOfAntiDilutiveNetLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfAntiDilutiveNetLossPerShareAbstract"/>
  <xs:element name="ScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareAbstract"/>
  <xs:element name="ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract"/>
  <xs:element name="ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract"/>
  <xs:element name="ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract"/>
  <xs:element name="ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract"/>
  <xs:element name="ScheduleOfNotesReceivableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfNotesReceivableAbstract"/>
  <xs:element name="ScheduleOfInterestExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfInterestExpenseAbstract"/>
  <xs:element name="ScheduleOfStockOptionsActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfStockOptionsActivitiesAbstract"/>
  <xs:element name="ScheduleOfWarrantActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfWarrantActivitiesAbstract"/>
  <xs:element name="ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract"/>
  <xs:element name="ScheduleOfNetDeferredTaxAssetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfNetDeferredTaxAssetAbstract"/>
  <xs:element name="ScheduleOfMilestonePaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfMilestonePaymentsAbstract"/>
  <xs:element name="ScheduleOfUmbMinimumRoyaltyPaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfUmbMinimumRoyaltyPaymentsAbstract"/>
  <xs:element name="ScheduleOfExclusiveOfValueAddedTaxToBeAmortizedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortizedAbstract"/>
  <xs:element name="ScheduleOfShallPayUmbAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfShallPayUmbAbstract"/>
  <xs:element name="ScheduleOfNotesReceivableNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfNotesReceivableNetAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract12"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract16"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract17"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract18"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract19"/>
  <xs:element name="LongTermLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_LongTermLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract20"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract21"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract22"/>
  <xs:element name="UnlabeledAbstract23" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract23"/>
  <xs:element name="UnlabeledAbstract24" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract24"/>
  <xs:element name="UnlabeledAbstract25" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract25"/>
  <xs:element name="UnlabeledAbstract26" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract26"/>
  <xs:element name="UnlabeledAbstract27" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract27"/>
  <xs:element name="UnlabeledAbstract28" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract28"/>
  <xs:element name="UnlabeledAbstract29" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract29"/>
  <xs:element name="UnlabeledAbstract30" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract30"/>
  <xs:element name="UnlabeledAbstract31" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract31"/>
  <xs:element name="UnlabeledAbstract32" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract32"/>
  <xs:element name="UnlabeledAbstract33" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract33"/>
  <xs:element name="UnlabeledAbstract34" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract34"/>
  <xs:element name="UnlabeledAbstract35" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract35"/>
  <xs:element name="UnlabeledAbstract36" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract36"/>
  <xs:element name="UnlabeledAbstract37" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract37"/>
  <xs:element name="UnlabeledAbstract38" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract38"/>
  <xs:element name="DiscontinuedOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_DiscontinuedOperationsAbstract"/>
  <xs:element name="UnlabeledAbstract39" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract39"/>
  <xs:element name="UnlabeledAbstract40" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract40"/>
  <xs:element name="UnlabeledAbstract41" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract41"/>
  <xs:element name="UnlabeledAbstract42" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract42"/>
  <xs:element name="UnlabeledAbstract43" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract43"/>
  <xs:element name="UnlabeledAbstract44" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract44"/>
  <xs:element name="UnlabeledAbstract45" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract45"/>
  <xs:element name="UnlabeledAbstract46" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract46"/>
  <xs:element name="UnlabeledAbstract47" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract47"/>
  <xs:element name="UnlabeledAbstract48" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract48"/>
  <xs:element name="UnlabeledAbstract49" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract49"/>
  <xs:element name="UnlabeledAbstract50" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract50"/>
  <xs:element name="OtherIncomeExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_OtherIncomeExpenseAbstract"/>
  <xs:element name="UnlabeledAbstract51" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract51"/>
  <xs:element name="UnlabeledAbstract52" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract52"/>
  <xs:element name="UnlabeledAbstract53" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract53"/>
  <xs:element name="UnlabeledAbstract54" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract54"/>
  <xs:element name="UnlabeledAbstract55" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract55"/>
  <xs:element name="DiscontinuedOperationsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_DiscontinuedOperationsAbstract0"/>
  <xs:element name="UnlabeledAbstract56" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract56"/>
  <xs:element name="UnlabeledAbstract57" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract57"/>
  <xs:element name="UnlabeledAbstract58" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract58"/>
  <xs:element name="UnlabeledAbstract59" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract59"/>
  <xs:element name="UnlabeledAbstract60" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract60"/>
  <xs:element name="NetLossPerCommonShareAvailableToCommonStockholdersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_NetLossPerCommonShareAvailableToCommonStockholdersAbstract"/>
  <xs:element name="UnlabeledAbstract61" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract61"/>
  <xs:element name="WeightedAverageCommonSharesOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_WeightedAverageCommonSharesOutstandingAbstract"/>
  <xs:element name="UnlabeledAbstract62" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract62"/>
  <xs:element name="UnlabeledAbstract63" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract63"/>
  <xs:element name="UnlabeledAbstract64" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract64"/>
  <xs:element name="UnlabeledAbstract65" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract65"/>
  <xs:element name="UnlabeledAbstract66" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract66"/>
  <xs:element name="UnlabeledAbstract67" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract67"/>
  <xs:element name="UnlabeledAbstract68" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract68"/>
  <xs:element name="UnlabeledAbstract69" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract69"/>
  <xs:element name="UnlabeledAbstract70" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract70"/>
  <xs:element name="UnlabeledAbstract71" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract71"/>
  <xs:element name="UnlabeledAbstract72" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract72"/>
  <xs:element name="UnlabeledAbstract73" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract73"/>
  <xs:element name="UnlabeledAbstract74" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract74"/>
  <xs:element name="UnlabeledAbstract75" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract75"/>
  <xs:element name="UnlabeledAbstract76" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract76"/>
  <xs:element name="UnlabeledAbstract77" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract77"/>
  <xs:element name="UnlabeledAbstract78" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract78"/>
  <xs:element name="UnlabeledAbstract79" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract79"/>
  <xs:element name="UnlabeledAbstract80" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract80"/>
  <xs:element name="UnlabeledAbstract81" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract81"/>
  <xs:element name="UnlabeledAbstract82" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract82"/>
  <xs:element name="UnlabeledAbstract83" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract83"/>
  <xs:element name="UnlabeledAbstract84" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract84"/>
  <xs:element name="UnlabeledAbstract85" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract85"/>
  <xs:element name="UnlabeledAbstract86" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract86"/>
  <xs:element name="UnlabeledAbstract87" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract87"/>
  <xs:element name="UnlabeledAbstract88" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract88"/>
  <xs:element name="UnlabeledAbstract89" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract89"/>
  <xs:element name="UnlabeledAbstract90" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract90"/>
  <xs:element name="UnlabeledAbstract91" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract91"/>
  <xs:element name="UnlabeledAbstract92" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract92"/>
  <xs:element name="UnlabeledAbstract93" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract93"/>
  <xs:element name="UnlabeledAbstract94" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract94"/>
  <xs:element name="UnlabeledAbstract95" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract95"/>
  <xs:element name="UnlabeledAbstract96" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract96"/>
  <xs:element name="UnlabeledAbstract97" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract97"/>
  <xs:element name="UnlabeledAbstract98" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract98"/>
  <xs:element name="UnlabeledAbstract99" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract99"/>
  <xs:element name="UnlabeledAbstract100" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract100"/>
  <xs:element name="UnlabeledAbstract101" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract101"/>
  <xs:element name="UnlabeledAbstract102" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract102"/>
  <xs:element name="CashPaidDuringThePeriodForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CashPaidDuringThePeriodForAbstract"/>
  <xs:element name="UnlabeledAbstract103" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract103"/>
  <xs:element name="CashFlowsFromOperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CashFlowsFromOperatingActivitiesAbstract"/>
  <xs:element name="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract"/>
  <xs:element name="ChangeInOperatingAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ChangeInOperatingAssetsAndLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract104" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract104"/>
  <xs:element name="UnlabeledAbstract105" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract105"/>
  <xs:element name="CashFlowsFromInvestingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CashFlowsFromInvestingActivitiesAbstract"/>
  <xs:element name="UnlabeledAbstract106" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract106"/>
  <xs:element name="UnlabeledAbstract107" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract107"/>
  <xs:element name="CashFlowsFromFinancingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CashFlowsFromFinancingActivitiesAbstract"/>
  <xs:element name="UnlabeledAbstract108" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract108"/>
  <xs:element name="UnlabeledAbstract109" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract109"/>
  <xs:element name="UnlabeledAbstract110" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract110"/>
  <xs:element name="UnlabeledAbstract111" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract111"/>
  <xs:element name="UnlabeledAbstract112" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract112"/>
  <xs:element name="SupplementalDisclosureOfCashFlowInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SupplementalDisclosureOfCashFlowInformationAbstract"/>
  <xs:element name="CashPaidDuringThePeriodForAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CashPaidDuringThePeriodForAbstract0"/>
  <xs:element name="UnlabeledAbstract113" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract113"/>
  <xs:element name="NonCashInvestingAndFinancingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_NonCashInvestingAndFinancingActivitiesAbstract"/>
  <xs:element name="IncomeLossPerCommonShareBasicAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_IncomeLossPerCommonShareBasicAbstract"/>
  <xs:element name="UnlabeledAbstract114" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract114"/>
  <xs:element name="NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract"/>
  <xs:element name="UnlabeledAbstract115" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract115"/>
  <xs:element name="IncomeLossPerCommonShareDilutedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_IncomeLossPerCommonShareDilutedAbstract"/>
  <xs:element name="UnlabeledAbstract116" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract116"/>
  <xs:element name="EffectOfDilutiveSecuritiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_EffectOfDilutiveSecuritiesAbstract"/>
  <xs:element name="UnlabeledAbstract117" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract117"/>
  <xs:element name="NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract"/>
  <xs:element name="AssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_AssetsAbstract0"/>
  <xs:element name="CurrentAssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CurrentAssetsAbstract0"/>
  <xs:element name="UnlabeledAbstract118" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract118"/>
  <xs:element name="CurrentLiabilitiesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CurrentLiabilitiesAbstract0"/>
  <xs:element name="UnlabeledAbstract119" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract119"/>
  <xs:element name="UnlabeledAbstract120" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract120"/>
  <xs:element name="UnlabeledAbstract121" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UnlabeledAbstract121"/>
  <xs:element name="EquityInvestmentsAtCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_EquityInvestmentsAtCost"/>
  <xs:element name="PreferredStockValueOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_PreferredStockValueOne"/>
  <xs:element name="PreferredStockValueTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_PreferredStockValueTwo"/>
  <xs:element name="LicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_LicenseFees"/>
  <xs:element name="BadDebtRecoveryExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_BadDebtRecoveryExpense"/>
  <xs:element name="UnrealizedGainLossOnEquityInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_UnrealizedGainLossOnEquityInvestments"/>
  <xs:element name="OtherIncomeFromEquitySharesEarnedForServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_OtherIncomeFromEquitySharesEarnedForServices"/>
  <xs:element name="CommonStockIssuedForFutureServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_CommonStockIssuedForFutureServices"/>
  <xs:element name="CommonStockIssuedForFutureServicesShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CommonStockIssuedForFutureServicesShares"/>
  <xs:element name="PreferredSharesExchangedForCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_PreferredSharesExchangedForCommonStock"/>
  <xs:element name="PreferredSharesExchangedForCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PreferredSharesExchangedForCommonStockShares"/>
  <xs:element name="CommonStockIssuedForExchangeOfNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_CommonStockIssuedForExchangeOfNotes"/>
  <xs:element name="CommonStockIssuedForExchangeOfNotesShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CommonStockIssuedForExchangeOfNotesShares"/>
  <xs:element name="CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock"/>
  <xs:element name="CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares"/>
  <xs:element name="DeemedDividendOnPreferredStockExchange" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_DeemedDividendOnPreferredStockExchange"/>
  <xs:element name="IssuanceOfCommonStockForConversionOfPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_IssuanceOfCommonStockForConversionOfPreferredStock"/>
  <xs:element name="IssuanceOfCommonSharesForConversionOfPreferredStockinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares"/>
  <xs:element name="AmortizationOfPrepaidStockbasedExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_AmortizationOfPrepaidStockbasedExpense"/>
  <xs:element name="LossFromDebtExtinguishment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_LossFromDebtExtinguishment"/>
  <xs:element name="IncreaseDecreaseInAssetsOfDiscontinuedOperation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation"/>
  <xs:element name="CollectionOnNoteReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_CollectionOnNoteReceivable"/>
  <xs:element name="AdvanceFromARelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_AdvanceFromARelatedParty"/>
  <xs:element name="StockIssuedForFutureServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_StockIssuedForFutureServices"/>
  <xs:element name="CommonStockIssuedForPrepaidServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_CommonStockIssuedForPrepaidServices"/>
  <xs:element name="CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock"/>
  <xs:element name="IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree"/>
  <xs:element name="NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement"/>
  <xs:element name="IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp"/>
  <xs:element name="LiquidityPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_LiquidityPolicyTextBlock"/>
  <xs:element name="EquityInvestmentsAtFairValuePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_EquityInvestmentsAtFairValuePolicyTextBlock"/>
  <xs:element name="EquityInvestmentsAtCostPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_EquityInvestmentsAtCostPolicyTextBlock"/>
  <xs:element name="CostOfRevenuesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CostOfRevenuesPolicyTextBlock"/>
  <xs:element name="ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock"/>
  <xs:element name="ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock"/>
  <xs:element name="ScheduleOfMilestonePayments" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfMilestonePayments"/>
  <xs:element name="ScheduleOfUMBMinimumRoyaltyPayments" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfUMBMinimumRoyaltyPayments"/>
  <xs:element name="ScheduleOfExclusiveOfValueAddedTaxToBeAmortized" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized"/>
  <xs:element name="ScheduleOfShallPayUMB" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ScheduleOfShallPayUMB"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems"/>
  <xs:element name="IncomelossFromContinuingOperation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_IncomelossFromContinuingOperation"/>
  <xs:element name="IncomeLossFromDiscontinuedOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_IncomeLossFromDiscontinuedOperations"/>
  <xs:element name="NumeratorForLossFromContinuingOperationsPerCommonShareDiluted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_NumeratorForLossFromContinuingOperationsPerCommonShareDiluted"/>
  <xs:element name="NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted"/>
  <xs:element name="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
  <xs:element name="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
  <xs:element name="EquityInvestmentsAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_EquityInvestmentsAtFairValue"/>
  <xs:element name="AdditionsofEquitySecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_AdditionsofEquitySecurities"/>
  <xs:element name="FinanceLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_FinanceLeaseLiabilities"/>
  <xs:element name="NetAssetOfNFIDBusinessDisposed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_NetAssetOfNFIDBusinessDisposed"/>
  <xs:element name="ConsiderationInTheFormOfANoteReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_ConsiderationInTheFormOfANoteReceivable"/>
  <xs:element name="GainFromSaleOfNFIDBusiness" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_GainFromSaleOfNFIDBusiness"/>
  <xs:element name="AdditionalNotesReceivableIn2021" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_AdditionalNotesReceivableIn2021"/>
  <xs:element name="CollectionsOnNotesReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_CollectionsOnNotesReceivable"/>
  <xs:element name="LessNotesReceivableNetCurrentPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_LessNotesReceivableNetCurrentPortion"/>
  <xs:element name="DebtInstrumentsFaceAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_DebtInstrumentsFaceAmount"/>
  <xs:element name="NotrPayableLessCurrentPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_NotrPayableLessCurrentPortion"/>
  <xs:element name="NotePayableLongTermPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_NotePayableLongTermPortion"/>
  <xs:element name="StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable"/>
  <xs:element name="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices"/>
  <xs:element name="WeightedAverageRemainingContractualTermYearsGrantedissued" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_WeightedAverageRemainingContractualTermYearsGrantedissued"/>
  <xs:element name="AggregateIntrinsicValueGrantedIssuedForfeited1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_AggregateIntrinsicValueGrantedIssuedForfeited1"/>
  <xs:element name="NumberOfWarrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="silo_NumberOfWarrant"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue"/>
  <xs:element name="ShareBasedComponsationNumberOfWarrantsForfeited" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ShareBasedComponsationNumberOfWarrantsForfeited"/>
  <xs:element name="ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited"/>
  <xs:element name="ShareBasedComponsationNumberOfWarrantsGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ShareBasedComponsationNumberOfWarrantsGranted"/>
  <xs:element name="ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted"/>
  <xs:element name="AggregateIntrinsicValueGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_AggregateIntrinsicValueGranted"/>
  <xs:element name="ShareBasedComponsationNumberOfWarrantsExercisableinDollars" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars"/>
  <xs:element name="ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable"/>
  <xs:element name="AvailableForSalesEquitySecuritiesGrossUnrealizedGain" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain"/>
  <xs:element name="DeferredTaxAssetsCapitalLossCarryforward" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_DeferredTaxAssetsCapitalLossCarryforward"/>
  <xs:element name="DeferredTaxAssetGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_DeferredTaxAssetGross"/>
  <xs:element name="DeferredTaxAssetsValuationAllowances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_DeferredTaxAssetsValuationAllowances"/>
  <xs:element name="CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems"/>
  <xs:element name="Milestone" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_Milestone"/>
  <xs:element name="MilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_MilestonePayment"/>
  <xs:element name="CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems"/>
  <xs:element name="UMBYearDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UMBYearDescription"/>
  <xs:element name="UMBPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_UMBPayment"/>
  <xs:element name="CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems"/>
  <xs:element name="Payment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_Payment"/>
  <xs:element name="PaymentDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PaymentDescription"/>
  <xs:element name="CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems"/>
  <xs:element name="SponsoredPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_SponsoredPayment"/>
  <xs:element name="CollectionsOnNotesReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_CollectionsOnNotesReceivables"/>
  <xs:element name="GrantedAsIncentivesWeightedAverageRemainingContractualTermYears" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears"/>
  <xs:element name="GrantedAsIncentivesAggregateIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_GrantedAsIncentivesAggregateIntrinsicValue"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue"/>
  <xs:element name="YearsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_YearsDescription"/>
  <xs:element name="MinimumAnnualRoyalty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_MinimumAnnualRoyalty"/>
  <xs:element name="OrganizationandBusinessDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_OrganizationandBusinessDetailsTable"/>
  <xs:element name="promissoryNoteAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_promissoryNoteAmount"/>
  <xs:element name="AssetPurchaseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_AssetPurchaseAgreementDescription"/>
  <xs:element name="CashSPICInsuredAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_CashSPICInsuredAmount"/>
  <xs:element name="WorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_WorkingCapital"/>
  <xs:element name="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable"/>
  <xs:element name="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems"/>
  <xs:element name="EquityInvestmentsCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_EquityInvestmentsCost"/>
  <xs:element name="CompanyReceivedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CompanyReceivedShares"/>
  <xs:element name="CommonStockGrantDateFairValuePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CommonStockGrantDateFairValuePerShare"/>
  <xs:element name="GrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_GrossProceeds"/>
  <xs:element name="EquityMethodInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_EquityMethodInvestment"/>
  <xs:element name="PurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_PurchasePrice"/>
  <xs:element name="PrincipalBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_PrincipalBalance"/>
  <xs:element name="AccruedInterestReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_AccruedInterestReceivable"/>
  <xs:element name="TotalOutstandingBalanceReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_TotalOutstandingBalanceReceivable"/>
  <xs:element name="PromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_PromissoryNotes"/>
  <xs:element name="TypesOfAgreementDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_TypesOfAgreementDomain"/>
  <xs:element name="DeferredRevenueArrangementType_Domain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_DeferredRevenueArrangementType_Domain"/>
  <xs:element name="NotesReceivableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_NotesReceivableDetailsTable"/>
  <xs:element name="NotesReceivableDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_NotesReceivableDetailsLineItems"/>
  <xs:element name="RemainingBalanceOfPromissoryNoteReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_RemainingBalanceOfPromissoryNoteReceivable"/>
  <xs:element name="NotesReceivablePurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_NotesReceivablePurchasePrice"/>
  <xs:element name="NetBadDebtExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_NetBadDebtExpense"/>
  <xs:element name="BadDebtRecoveryCashPayment" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_BadDebtRecoveryCashPayment"/>
  <xs:element name="CollectedSettlementAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_CollectedSettlementAgreement"/>
  <xs:element name="RemainsCollectibleSettlementAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_RemainsCollectibleSettlementAgreement"/>
  <xs:element name="PromissoryNote" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PromissoryNote"/>
  <xs:element name="NoteReceivableNonCurrentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_NoteReceivableNonCurrentAmount"/>
  <xs:element name="DebtInstrumentIncreasesAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_DebtInstrumentIncreasesAccruedInterest"/>
  <xs:element name="PromissoryNoteAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_PromissoryNoteAgreement"/>
  <xs:element name="ReceivedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ReceivedShares"/>
  <xs:element name="AggregateOfNotesReceivablePurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_AggregateOfNotesReceivablePurchasePrice"/>
  <xs:element name="RecoveredAggregateBadDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_RecoveredAggregateBadDebt"/>
  <xs:element name="RecoveredBadDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_RecoveredBadDebt"/>
  <xs:element name="RemainsCollectibleSettlementAgreementAmountReserved" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_RemainsCollectibleSettlementAgreementAmountReserved"/>
  <xs:element name="NotePayableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_NotePayableDetailsTable"/>
  <xs:element name="NotePayableDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_NotePayableDetailsLineItems"/>
  <xs:element name="TypesOfAgreementsDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_TypesOfAgreementsDomain"/>
  <xs:element name="StockholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_StockholdersEquityDetailsTable"/>
  <xs:element name="StockholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_StockholdersEquityDetailsLineItems"/>
  <xs:element name="ConvertablePreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ConvertablePreferredStock"/>
  <xs:element name="ExchangeAgreementsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ExchangeAgreementsDescription"/>
  <xs:element name="CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares"/>
  <xs:element name="PreferredStockOutstandingDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PreferredStockOutstandingDescription"/>
  <xs:element name="WarrantsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_WarrantsTerm"/>
  <xs:element name="SubsequentFinancingPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SubsequentFinancingPercentage"/>
  <xs:element name="ObligationPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ObligationPercentage"/>
  <xs:element name="PlacementAgentWarrantsDescriptoin" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PlacementAgentWarrantsDescriptoin"/>
  <xs:element name="AggregateGrantDateFairValueOfPlacementAgentWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_AggregateGrantDateFairValueOfPlacementAgentWarrants"/>
  <xs:element name="TotalSubscriptionReceivableValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_TotalSubscriptionReceivableValue"/>
  <xs:element name="PlacementAgentFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_PlacementAgentFees"/>
  <xs:element name="InvestorInvestedAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_InvestorInvestedAmount"/>
  <xs:element name="DeemedDividend" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_DeemedDividend"/>
  <xs:element name="ConvertibleLongTermNotesPayables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_ConvertibleLongTermNotesPayables"/>
  <xs:element name="WarrantIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_WarrantIssued"/>
  <xs:element name="CommonStockServiceDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CommonStockServiceDescription"/>
  <xs:element name="PurchaseAgreementsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="silo_PurchaseAgreementsDescription"/>
  <xs:element name="PreferredStockStatedValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_PreferredStockStatedValue"/>
  <xs:element name="InvestorInvestedAmountPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_InvestorInvestedAmountPercentage"/>
  <xs:element name="NetCapitalLossCarryForward" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_NetCapitalLossCarryForward"/>
  <xs:element name="GainLossOnSaleOfCapitalLeaseNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_GainLossOnSaleOfCapitalLeaseNet"/>
  <xs:element name="AggregateEstimatedNetOperatingLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_AggregateEstimatedNetOperatingLoss"/>
  <xs:element name="DescriptionOfIncomeTaxDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_DescriptionOfIncomeTaxDescription"/>
  <xs:element name="ConcentrationsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_ConcentrationsDetailsTable"/>
  <xs:element name="ConcentrationsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ConcentrationsDetailsLineItems"/>
  <xs:element name="ConcentrationsRiskPercentage1" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ConcentrationsRiskPercentage1"/>
  <xs:element name="TypeOfAgreementDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_TypeOfAgreementDomain"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CommitmentsandContingenciesDetailsLineItems"/>
  <xs:element name="EmploymentAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_EmploymentAgreementDescription"/>
  <xs:element name="LicenseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_LicenseFee"/>
  <xs:element name="CommercialSaleTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_CommercialSaleTerm"/>
  <xs:element name="LicenseAgreementExpire" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_LicenseAgreementExpire"/>
  <xs:element name="SublicenseIncomeDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SublicenseIncomeDescription"/>
  <xs:element name="LicenseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_LicenseAgreementDescription"/>
  <xs:element name="RoyaltyPaymentsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_RoyaltyPaymentsDescription"/>
  <xs:element name="SublicenseIncomePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SublicenseIncomePercentage"/>
  <xs:element name="SublicenseAgreementAmountPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_SublicenseAgreementAmountPaid"/>
  <xs:element name="OtherDepreciationsAndAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_OtherDepreciationsAndAmortization"/>
  <xs:element name="PaymentOfSponsoredResearchAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PaymentOfSponsoredResearchAmount"/>
  <xs:element name="PrepaidExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_PrepaidExpenses"/>
  <xs:element name="NonrefundableCashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_NonrefundableCashPayment"/>
  <xs:element name="NetSalePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_NetSalePercentage"/>
  <xs:element name="LicensorShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_LicensorShare"/>
  <xs:element name="AggregateOfConvertedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_AggregateOfConvertedShares"/>
  <xs:element name="RevenueTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_RevenueTerm"/>
  <xs:element name="NumberOfVotingShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_NumberOfVotingShares"/>
  <xs:element name="ReverseStockSplitVoteDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ReverseStockSplitVoteDescription"/>
  <xs:element name="CashReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_CashReceived"/>
  <xs:element name="SecuritiesReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_SecuritiesReceived"/>
  <xs:element name="DeferredRevenueLongtermPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_DeferredRevenueLongtermPortion"/>
  <xs:element name="ConsiderationFeePayablePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ConsiderationFeePayablePercentage"/>
  <xs:element name="UpfrontLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_UpfrontLicenseFees"/>
  <xs:element name="FirstCommercialSale" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_FirstCommercialSale"/>
  <xs:element name="AgreementShallExpire" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_AgreementShallExpire"/>
  <xs:element name="RecognizedRevenues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_RecognizedRevenues"/>
  <xs:element name="SponsoredStudyAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SponsoredStudyAgreementDescription"/>
  <xs:element name="SublicenseAmountPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_SublicenseAmountPaid"/>
  <xs:element name="SponsoredResearchAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SponsoredResearchAgreementDescription"/>
  <xs:element name="CompanyPaidCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_CompanyPaidCash"/>
  <xs:element name="PursuantTerms" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PursuantTerms"/>
  <xs:element name="PaymentOfUniversity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="silo_PaymentOfUniversity"/>
  <xs:element name="DeferredRevenueLongtermPortionAmounted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_DeferredRevenueLongtermPortionAmounted"/>
  <xs:element name="AgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_AgreementDescription"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="silo_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SubsequentEventsDetailsLineItems"/>
  <xs:element name="AnnualBaseSalary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="silo_AnnualBaseSalary"/>
  <xs:element name="TotalOfSharesOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="silo_TotalOfSharesOfCommonStock"/>
  <xs:element name="TypeOfAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="silo_TypeOfAgreementAxis"/>
  <xs:element name="TypesOfAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="silo_TypesOfAgreementAxis"/>
  <xs:element name="TypesOfAgreementsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="silo_TypesOfAgreementsAxis"/>
  <xs:element name="AdvisoryAgreementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_AdvisoryAgreementsMember"/>
  <xs:element name="AikidoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_AikidoMember"/>
  <xs:element name="AikidoPharmaIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_AikidoPharmaIncMember"/>
  <xs:element name="ColumbiaUniversityMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ColumbiaUniversityMember"/>
  <xs:element name="ConsultingAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ConsultingAgreementMember"/>
  <xs:element name="DatChatIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_DatChatIncMember"/>
  <xs:element name="DrJamesKuoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_DrJamesKuoMember"/>
  <xs:element name="EmploymentAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_EmploymentAgreementMember"/>
  <xs:element name="ExchangeAgreementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_ExchangeAgreementsMember"/>
  <xs:element name="HomeBistroIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_HomeBistroIncMember"/>
  <xs:element name="IncentiveStockOptionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_IncentiveStockOptionMember"/>
  <xs:element name="JVAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_JVAgreementMember"/>
  <xs:element name="KuoEmploymentAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_KuoEmploymentAgreementMember"/>
  <xs:element name="MasterLincenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_MasterLincenseAgreementMember"/>
  <xs:element name="OmnibusEquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_OmnibusEquityIncentivePlanMember"/>
  <xs:element name="OneLicenseeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_OneLicenseeMember"/>
  <xs:element name="OneLicensorMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_OneLicensorMember"/>
  <xs:element name="PaycheckProtectionProgramMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PaycheckProtectionProgramMember"/>
  <xs:element name="PaymentEightMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PaymentEightMember"/>
  <xs:element name="PaymentFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PaymentFiveMember"/>
  <xs:element name="PaymentFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PaymentFourMember"/>
  <xs:element name="PaymentOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PaymentOneMember"/>
  <xs:element name="PaymentSevenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PaymentSevenMember"/>
  <xs:element name="PaymentSixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PaymentSixMember"/>
  <xs:element name="PaymentThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PaymentThreeMember"/>
  <xs:element name="PaymentTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PaymentTwoMember"/>
  <xs:element name="PlacementAgentWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PlacementAgentWarrantsMember"/>
  <xs:element name="PromissoryNoteReceivableAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PromissoryNoteReceivableAgreementMember"/>
  <xs:element name="PurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_PurchaseAgreementMember"/>
  <xs:element name="SecuritiesPurchaseAgreementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SecuritiesPurchaseAgreementsMember"/>
  <xs:element name="SeriesCConversionPriceMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SeriesCConversionPriceMember"/>
  <xs:element name="SeriesCConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SeriesCConvertiblePreferredStockMember"/>
  <xs:element name="SeriesCPurchaseAgreementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SeriesCPurchaseAgreementsMember"/>
  <xs:element name="StockOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_StockOptionsMember"/>
  <xs:element name="SublicenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SublicenseAgreementMember"/>
  <xs:element name="SubscriptionAgreementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_SubscriptionAgreementsMember"/>
  <xs:element name="VendorConcentrationsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_VendorConcentrationsMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="silo_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>silo-20220630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Sep 20 20:53:05 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ConsolidatedBalanceSheet" roleURI="http://silopharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ConsolidatedIncomeStatement" roleURI="http://silopharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ConsolidatedCashFlow" roleURI="http://silopharma.com/role/ConsolidatedCashFlow"/>
  <calculationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="silo_EquityInvestmentsAtCost" xlink:href="silo-20220630.xsd#silo_EquityInvestmentsAtCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="silo_EquityInvestmentsAtCost" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesNetCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LoansPayableCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermNotesPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="silo_PreferredStockValueOne" xlink:href="silo-20220630.xsd#silo_PreferredStockValueOne"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="silo_PreferredStockValueOne" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="silo_PreferredStockValueTwo" xlink:href="silo-20220630.xsd#silo_PreferredStockValueTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="silo_PreferredStockValueTwo" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="silo_LicenseFees" xlink:href="silo-20220630.xsd#silo_LicenseFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="silo_LicenseFees" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ProfessionalFees" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralInsuranceExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralInsuranceExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="silo_BadDebtRecoveryExpense" xlink:href="silo-20220630.xsd#silo_BadDebtRecoveryExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="silo_BadDebtRecoveryExpense" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="5" weight="1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYRCCyonMiwgdQ2lJYzdzUOv9fI1l/VI08eZ/jN8gtVkovQNM+Tg8ySqLg3+WC1g4h34l8wpPDRKEpvN2sEoV7GBwsfUtZ7wPjtnRwjx//zhaHDazrcKZSY+odwB4qGm1MOd/qfdmKbOaTaPPe9bPa/02wjXfGOjU12GfRhsnE31flgx8L3rlukBHCtP7EgQkbTccVkskR5Ww==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnInvestments" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="silo_UnrealizedGainLossOnEquityInvestments" xlink:href="silo-20220630.xsd#silo_UnrealizedGainLossOnEquityInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="silo_UnrealizedGainLossOnEquityInvestments" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="silo_OtherIncomeFromEquitySharesEarnedForServices" xlink:href="silo-20220630.xsd#silo_OtherIncomeFromEquitySharesEarnedForServices"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="silo_OtherIncomeFromEquitySharesEarnedForServices" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseDebt" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseRelatedParty" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="silo_AmortizationOfPrepaidStockbasedExpense" xlink:href="silo-20220630.xsd#silo_AmortizationOfPrepaidStockbasedExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="silo_AmortizationOfPrepaidStockbasedExpense" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryWriteDown" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation" xlink:href="silo-20220630.xsd#silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPayablesToBrokerDealers" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPayablesToBrokerDealers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPayablesToBrokerDealers" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnRestructuringOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnRestructuringOfDebt" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="silo_LossFromDebtExtinguishment" xlink:href="silo-20220630.xsd#silo_LossFromDebtExtinguishment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="silo_LossFromDebtExtinguishment" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="17" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfDerivatives"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfDerivatives" order="18" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromCollectionOfNotesReceivable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="silo_CollectionOnNoteReceivable" xlink:href="silo-20220630.xsd#silo_CollectionOnNoteReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="silo_CollectionOnNoteReceivable" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="silo_AdvanceFromARelatedParty" xlink:href="silo-20220630.xsd#silo_AdvanceFromARelatedParty"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="silo_AdvanceFromARelatedParty" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>silo-20220630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Sep 20 20:53:05 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ConsolidatedBalanceSheet" roleURI="http://silopharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ConsolidatedIncomeStatement" roleURI="http://silopharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ShareholdersEquityType2or3" roleURI="http://silopharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ConsolidatedCashFlow" roleURI="http://silopharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_OrganizationandBusiness" roleURI="http://silopharma.com/role/OrganizationandBusiness"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_SummaryofSignificantAccountingPolicies" roleURI="http://silopharma.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_FairValueofFinancialInstrumentsandFairValueMeasurements" roleURI="http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_DisposaloftheDiscontinuedOperationsoftheNfidBusiness" roleURI="http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusiness"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_NotesReceivable" roleURI="http://silopharma.com/role/NotesReceivable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_NotePayable" roleURI="http://silopharma.com/role/NotePayable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_StockholdersEquity" roleURI="http://silopharma.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_IncomeTaxes" roleURI="http://silopharma.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_Concentrations" roleURI="http://silopharma.com/role/Concentrations"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_CommitmentsandContingencies" roleURI="http://silopharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_SubsequentEvents" roleURI="http://silopharma.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_AccountingPoliciesByPolicy" roleURI="http://silopharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://silopharma.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_FairValueofFinancialInstrumentsandFairValueMeasurementsTables" roleURI="http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_DisposaloftheDiscontinuedOperationsoftheNfidBusinessTables" roleURI="http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_NotesReceivableTables" roleURI="http://silopharma.com/role/NotesReceivableTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_NotePayableTables" roleURI="http://silopharma.com/role/NotePayableTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_StockholdersEquityTables" roleURI="http://silopharma.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_IncomeTaxesTables" roleURI="http://silopharma.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_CommitmentsandContingenciesTables" roleURI="http://silopharma.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofantidilutivenetlosspershareTable" roleURI="http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofreconciliationofbasicanddilutednetlosspershareTable" roleURI="http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" roleURI="http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable" roleURI="http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable" roleURI="http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable" roleURI="http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofnotesreceivableTable" roleURI="http://silopharma.com/role/ScheduleofnotesreceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofinterestexpenseTable" roleURI="http://silopharma.com/role/ScheduleofinterestexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofstockoptionsactivitiesTable" roleURI="http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofwarrantactivitiesTable" roleURI="http://silopharma.com/role/ScheduleofwarrantactivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable" roleURI="http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable_Parentheticals" roleURI="http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofnetdeferredtaxassetTable" roleURI="http://silopharma.com/role/ScheduleofnetdeferredtaxassetTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofmilestonepaymentsTable" roleURI="http://silopharma.com/role/ScheduleofmilestonepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofUMBminimumroyaltypaymentsTable" roleURI="http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable" roleURI="http://silopharma.com/role/ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofshallpayUMBTable" roleURI="http://silopharma.com/role/ScheduleofshallpayUMBTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofantidilutivenetlosspershareTable0" roleURI="http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0" roleURI="http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable0" roleURI="http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable0" roleURI="http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable0" roleURI="http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofnotesreceivablenetTable" roleURI="http://silopharma.com/role/ScheduleofnotesreceivablenetTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofstockoptionsactivitiesTable0" roleURI="http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofwarrantactivitiesTable0" roleURI="http://silopharma.com/role/ScheduleofwarrantactivitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofmilestonepaymentsTable0" roleURI="http://silopharma.com/role/ScheduleofmilestonepaymentsTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofUMBminimumroyaltypaymentsTable0" roleURI="http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofshallpayUMBTable0" roleURI="http://silopharma.com/role/ScheduleofshallpayUMBTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_OrganizationandBusinessDetails" roleURI="http://silopharma.com/role/OrganizationandBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_FairValueofFinancialInstrumentsandFairValueMeasurementsDetails" roleURI="http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_DisposaloftheDiscontinuedOperationsoftheNfidBusinessDetails" roleURI="http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_NotesReceivableDetails" roleURI="http://silopharma.com/role/NotesReceivableDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_NotePayableDetails" roleURI="http://silopharma.com/role/NotePayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_StockholdersEquityDetails" roleURI="http://silopharma.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_IncomeTaxesDetails" roleURI="http://silopharma.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ConcentrationsDetails" roleURI="http://silopharma.com/role/ConcentrationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_CommitmentsandContingenciesDetails" roleURI="http://silopharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_SubsequentEventsDetails" roleURI="http://silopharma.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#DocumentAndEntityInformation" roleURI="http://silopharma.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_EquityInvestmentsAtCost" xlink:href="silo-20220630.xsd#silo_EquityInvestmentsAtCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="silo_EquityInvestmentsAtCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LoansPayableCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_LongTermLiabilitiesAbstract" xlink:href="silo-20220630.xsd#silo_LongTermLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="silo_LongTermLiabilitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PreferredStockValueOne" xlink:href="silo-20220630.xsd#silo_PreferredStockValueOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="silo_PreferredStockValueOne" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PreferredStockValueTwo" xlink:href="silo-20220630.xsd#silo_PreferredStockValueTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="silo_PreferredStockValueTwo" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestReceivableNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestReceivableNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="silo_LicenseFees" xlink:href="silo-20220630.xsd#silo_LicenseFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="silo_LicenseFees" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProfessionalFees" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralInsuranceExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralInsuranceExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_BadDebtRecoveryExpense" xlink:href="silo-20220630.xsd#silo_BadDebtRecoveryExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="silo_BadDebtRecoveryExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_OtherIncomeFromEquitySharesEarnedForServices" xlink:href="silo-20220630.xsd#silo_OtherIncomeFromEquitySharesEarnedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="silo_OtherIncomeFromEquitySharesEarnedForServices" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherIncome" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseRelatedParty" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_UnrealizedGainLossOnEquityInvestments" xlink:href="silo-20220630.xsd#silo_UnrealizedGainLossOnEquityInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="silo_UnrealizedGainLossOnEquityInvestments" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_DiscontinuedOperationsAbstract" xlink:href="silo-20220630.xsd#silo_DiscontinuedOperationsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="silo_DiscontinuedOperationsAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_DiscontinuedOperationsAbstract" xlink:to="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_DiscontinuedOperationsAbstract" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockIssuedForFutureServices" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForFutureServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="silo_CommonStockIssuedForFutureServices" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockIssuedForFutureServicesShares" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForFutureServicesShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="silo_CommonStockIssuedForFutureServicesShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PreferredSharesExchangedForCommonStock" xlink:href="silo-20220630.xsd#silo_PreferredSharesExchangedForCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="silo_PreferredSharesExchangedForCommonStock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PreferredSharesExchangedForCommonStockShares" xlink:href="silo-20220630.xsd#silo_PreferredSharesExchangedForCommonStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="silo_PreferredSharesExchangedForCommonStockShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockIssuedForExchangeOfNotes" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForExchangeOfNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="silo_CommonStockIssuedForExchangeOfNotes" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockIssuedForExchangeOfNotesShares" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForExchangeOfNotesShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="silo_CommonStockIssuedForExchangeOfNotesShares" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_DeemedDividendOnPreferredStockExchange" xlink:href="silo-20220630.xsd#silo_DeemedDividendOnPreferredStockExchange"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="silo_DeemedDividendOnPreferredStockExchange" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_IssuanceOfCommonStockForConversionOfPreferredStock" xlink:href="silo-20220630.xsd#silo_IssuanceOfCommonStockForConversionOfPreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="silo_IssuanceOfCommonStockForConversionOfPreferredStock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares" xlink:href="silo-20220630.xsd#silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AmortizationOfPrepaidStockbasedExpense" xlink:href="silo-20220630.xsd#silo_AmortizationOfPrepaidStockbasedExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="silo_AmortizationOfPrepaidStockbasedExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfDerivatives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfDerivatives" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnRestructuringOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnRestructuringOfDebt" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_LossFromDebtExtinguishment" xlink:href="silo-20220630.xsd#silo_LossFromDebtExtinguishment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="silo_LossFromDebtExtinguishment" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation" xlink:href="silo-20220630.xsd#silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPayablesToBrokerDealers" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPayablesToBrokerDealers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPayablesToBrokerDealers" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromCollectionOfNotesReceivable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CollectionOnNoteReceivable" xlink:href="silo-20220630.xsd#silo_CollectionOnNoteReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="silo_CollectionOnNoteReceivable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AdvanceFromARelatedParty" xlink:href="silo-20220630.xsd#silo_AdvanceFromARelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="silo_AdvanceFromARelatedParty" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_InterestPaid" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CashPaidDuringThePeriodForAbstract" xlink:href="silo-20220630.xsd#silo_CashPaidDuringThePeriodForAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="silo_CashPaidDuringThePeriodForAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CashPaidDuringThePeriodForAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CashPaidDuringThePeriodForAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_StockIssuedForFutureServices" xlink:href="silo-20220630.xsd#silo_StockIssuedForFutureServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="silo_StockIssuedForFutureServices" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockIssuedForPrepaidServices" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForPrepaidServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="silo_CommonStockIssuedForPrepaidServices" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp" xlink:href="silo-20220630.xsd#silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree" xlink:href="silo-20220630.xsd#silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement" xlink:href="silo-20220630.xsd#silo_NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="silo_NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/OrganizationandBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/NotesReceivable">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/NotePayable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/Concentrations">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_LiquidityPolicyTextBlock" xlink:href="silo-20220630.xsd#silo_LiquidityPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="silo_LiquidityPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_EquityInvestmentsAtFairValuePolicyTextBlock" xlink:href="silo-20220630.xsd#silo_EquityInvestmentsAtFairValuePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="silo_EquityInvestmentsAtFairValuePolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_EquityInvestmentsAtCostPolicyTextBlock" xlink:href="silo-20220630.xsd#silo_EquityInvestmentsAtCostPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="silo_EquityInvestmentsAtCostPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CostOfRevenuesPolicyTextBlock" xlink:href="silo-20220630.xsd#silo_CostOfRevenuesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="silo_CostOfRevenuesPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock" xlink:href="silo-20220630.xsd#silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock" xlink:href="silo-20220630.xsd#silo_ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="silo_ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/NotesReceivableTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/NotePayableTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/StockholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/CommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfMilestonePayments" xlink:href="silo-20220630.xsd#silo_ScheduleOfMilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="silo_ScheduleOfMilestonePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfUMBMinimumRoyaltyPayments" xlink:href="silo-20220630.xsd#silo_ScheduleOfUMBMinimumRoyaltyPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="silo_ScheduleOfUMBMinimumRoyaltyPayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized" xlink:href="silo-20220630.xsd#silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfShallPayUMB" xlink:href="silo-20220630.xsd#silo_ScheduleOfShallPayUMB"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="silo_ScheduleOfShallPayUMB" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable">
    <loc xlink:type="locator" xlink:label="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems" xlink:href="silo-20220630.xsd#silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" xlink:href="silo-20220630.xsd#silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems" xlink:to="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_StockOptionsMember" xlink:href="silo-20220630.xsd#silo_StockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="silo_StockOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable">
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="silo_IncomeLossPerCommonShareBasicAbstract" xlink:href="silo-20220630.xsd#silo_IncomeLossPerCommonShareBasicAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareAbstract" xlink:to="silo_IncomeLossPerCommonShareBasicAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_IncomelossFromContinuingOperation" xlink:href="silo-20220630.xsd#silo_IncomelossFromContinuingOperation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_IncomeLossPerCommonShareBasicAbstract" xlink:to="silo_IncomelossFromContinuingOperation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_IncomeLossFromDiscontinuedOperations" xlink:href="silo-20220630.xsd#silo_IncomeLossFromDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_IncomeLossPerCommonShareBasicAbstract" xlink:to="silo_IncomeLossFromDiscontinuedOperations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_IncomeLossPerCommonShareBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_IncomeLossPerCommonShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract" xlink:href="silo-20220630.xsd#silo_NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_IncomeLossPerCommonShareBasicAbstract" xlink:to="silo_NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_IncomeLossPerCommonShareDilutedAbstract" xlink:href="silo-20220630.xsd#silo_IncomeLossPerCommonShareDilutedAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareAbstract" xlink:to="silo_IncomeLossPerCommonShareDilutedAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_IncomeLossPerCommonShareDilutedAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NumeratorForLossFromContinuingOperationsPerCommonShareDiluted" xlink:href="silo-20220630.xsd#silo_NumeratorForLossFromContinuingOperationsPerCommonShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_IncomeLossPerCommonShareDilutedAbstract" xlink:to="silo_NumeratorForLossFromContinuingOperationsPerCommonShareDiluted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted" xlink:href="silo-20220630.xsd#silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_IncomeLossPerCommonShareDilutedAbstract" xlink:to="silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAllocatedToGeneralPartners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAllocatedToGeneralPartners"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_IncomeLossPerCommonShareDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAllocatedToGeneralPartners" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_EffectOfDilutiveSecuritiesAbstract" xlink:href="silo-20220630.xsd#silo_EffectOfDilutiveSecuritiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_IncomeLossPerCommonShareDilutedAbstract" xlink:to="silo_EffectOfDilutiveSecuritiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_EffectOfDilutiveSecuritiesAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AuctionMarketPreferredSecuritiesSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_EffectOfDilutiveSecuritiesAbstract" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesSharesOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_IncomeLossPerCommonShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract" xlink:href="silo-20220630.xsd#silo_NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_IncomeLossPerCommonShareDilutedAbstract" xlink:to="silo_NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable">
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:href="silo-20220630.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:href="silo-20220630.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_EquityInvestmentsAtFairValue" xlink:href="silo-20220630.xsd#silo_EquityInvestmentsAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="silo_EquityInvestmentsAtFairValue" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable">
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:to="us-gaap_EquityMethodInvestments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AdditionsofEquitySecurities" xlink:href="silo-20220630.xsd#silo_AdditionsofEquitySecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:to="silo_AdditionsofEquitySecurities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable">
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract"/>
    <loc xlink:type="locator" xlink:label="silo_CurrentAssetsAbstract0" xlink:href="silo-20220630.xsd#silo_CurrentAssetsAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:to="silo_CurrentAssetsAbstract0" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CurrentAssetsAbstract0" xlink:to="us-gaap_InventoryNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CurrentLiabilitiesAbstract0" xlink:href="silo-20220630.xsd#silo_CurrentLiabilitiesAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:to="silo_CurrentLiabilitiesAbstract0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_FinanceLeaseLiabilities" xlink:href="silo-20220630.xsd#silo_FinanceLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CurrentLiabilitiesAbstract0" xlink:to="silo_FinanceLeaseLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NetAssetOfNFIDBusinessDisposed" xlink:href="silo-20220630.xsd#silo_NetAssetOfNFIDBusinessDisposed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:to="silo_NetAssetOfNFIDBusinessDisposed" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ConsiderationInTheFormOfANoteReceivable" xlink:href="silo-20220630.xsd#silo_ConsiderationInTheFormOfANoteReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:to="silo_ConsiderationInTheFormOfANoteReceivable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable">
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_GainFromSaleOfNFIDBusiness" xlink:href="silo-20220630.xsd#silo_GainFromSaleOfNFIDBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="silo_GainFromSaleOfNFIDBusiness" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofnotesreceivableTable">
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfNotesReceivableAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfNotesReceivableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfNotesReceivableAbstract" xlink:to="us-gaap_NotesReceivableGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AdditionalNotesReceivableIn2021" xlink:href="silo-20220630.xsd#silo_AdditionalNotesReceivableIn2021"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesReceivableGross" xlink:to="silo_AdditionalNotesReceivableIn2021" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CollectionsOnNotesReceivable" xlink:href="silo-20220630.xsd#silo_CollectionsOnNotesReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesReceivableGross" xlink:to="silo_CollectionsOnNotesReceivable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesReceivableGross" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfNotesReceivableAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_LessNotesReceivableNetCurrentPortion" xlink:href="silo-20220630.xsd#silo_LessNotesReceivableNetCurrentPortion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="silo_LessNotesReceivableNetCurrentPortion" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfNotesReceivableAbstract" xlink:to="us-gaap_NotesReceivableNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofinterestexpenseTable">
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfInterestExpenseAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfInterestExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="silo_DebtInstrumentsFaceAmount" xlink:href="silo-20220630.xsd#silo_DebtInstrumentsFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfInterestExpenseAbstract" xlink:to="silo_DebtInstrumentsFaceAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NotrPayableLessCurrentPortion" xlink:href="silo-20220630.xsd#silo_NotrPayableLessCurrentPortion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfInterestExpenseAbstract" xlink:to="silo_NotrPayableLessCurrentPortion" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NotePayableLongTermPortion" xlink:href="silo-20220630.xsd#silo_NotePayableLongTermPortion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfInterestExpenseAbstract" xlink:to="silo_NotePayableLongTermPortion" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable">
    <loc xlink:type="locator" xlink:label="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:href="silo-20220630.xsd#silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable" xlink:href="silo-20220630.xsd#silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_StockOptionsMember" xlink:href="silo-20220630.xsd#silo_StockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="silo_StockOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" xlink:href="silo-20220630.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_WeightedAverageRemainingContractualTermYearsGrantedissued" xlink:href="silo-20220630.xsd#silo_WeightedAverageRemainingContractualTermYearsGrantedissued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="silo_WeightedAverageRemainingContractualTermYearsGrantedissued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AggregateIntrinsicValueGrantedIssuedForfeited1" xlink:href="silo-20220630.xsd#silo_AggregateIntrinsicValueGrantedIssuedForfeited1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="silo_AggregateIntrinsicValueGrantedIssuedForfeited1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofwarrantactivitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NumberOfWarrant" xlink:href="silo-20220630.xsd#silo_NumberOfWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="silo_NumberOfWarrant" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue" xlink:href="silo-20220630.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedComponsationNumberOfWarrantsForfeited" xlink:href="silo-20220630.xsd#silo_ShareBasedComponsationNumberOfWarrantsForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="silo_ShareBasedComponsationNumberOfWarrantsForfeited" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited" xlink:href="silo-20220630.xsd#silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars" xlink:href="silo-20220630.xsd#silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable" xlink:href="silo-20220630.xsd#silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedComponsationNumberOfWarrantsGranted" xlink:href="silo-20220630.xsd#silo_ShareBasedComponsationNumberOfWarrantsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="silo_ShareBasedComponsationNumberOfWarrantsGranted" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted" xlink:href="silo-20220630.xsd#silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AggregateIntrinsicValueGranted" xlink:href="silo-20220630.xsd#silo_AggregateIntrinsicValueGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="silo_AggregateIntrinsicValueGranted" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable">
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain" xlink:href="silo-20220630.xsd#silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract" xlink:to="silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofnetdeferredtaxassetTable">
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfNetDeferredTaxAssetAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfNetDeferredTaxAssetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfNetDeferredTaxAssetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_DeferredTaxAssetsCapitalLossCarryforward" xlink:href="silo-20220630.xsd#silo_DeferredTaxAssetsCapitalLossCarryforward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfNetDeferredTaxAssetAbstract" xlink:to="silo_DeferredTaxAssetsCapitalLossCarryforward" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_DeferredTaxAssetGross" xlink:href="silo-20220630.xsd#silo_DeferredTaxAssetGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfNetDeferredTaxAssetAbstract" xlink:to="silo_DeferredTaxAssetGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_DeferredTaxAssetsValuationAllowances" xlink:href="silo-20220630.xsd#silo_DeferredTaxAssetsValuationAllowances"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfNetDeferredTaxAssetAbstract" xlink:to="silo_DeferredTaxAssetsValuationAllowances" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfNetDeferredTaxAssetAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfNetDeferredTaxAssetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofmilestonepaymentsTable">
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentOneMember" xlink:href="silo-20220630.xsd#silo_PaymentOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentTwoMember" xlink:href="silo-20220630.xsd#silo_PaymentTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentThreeMember" xlink:href="silo-20220630.xsd#silo_PaymentThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentFourMember" xlink:href="silo-20220630.xsd#silo_PaymentFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentFiveMember" xlink:href="silo-20220630.xsd#silo_PaymentFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_Milestone" xlink:href="silo-20220630.xsd#silo_Milestone"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems" xlink:to="silo_Milestone" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_MilestonePayment" xlink:href="silo-20220630.xsd#silo_MilestonePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems" xlink:to="silo_MilestonePayment" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable">
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentOneMember" xlink:href="silo-20220630.xsd#silo_PaymentOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentTwoMember" xlink:href="silo-20220630.xsd#silo_PaymentTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentThreeMember" xlink:href="silo-20220630.xsd#silo_PaymentThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentFourMember" xlink:href="silo-20220630.xsd#silo_PaymentFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentFiveMember" xlink:href="silo-20220630.xsd#silo_PaymentFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_UMBYearDescription" xlink:href="silo-20220630.xsd#silo_UMBYearDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems" xlink:to="silo_UMBYearDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_UMBPayment" xlink:href="silo-20220630.xsd#silo_UMBPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems" xlink:to="silo_UMBPayment" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable">
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentOneMember" xlink:href="silo-20220630.xsd#silo_PaymentOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="silo_PaymentOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentTwoMember" xlink:href="silo-20220630.xsd#silo_PaymentTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="silo_PaymentTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentThreeMember" xlink:href="silo-20220630.xsd#silo_PaymentThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="silo_PaymentThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentFourMember" xlink:href="silo-20220630.xsd#silo_PaymentFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="silo_PaymentFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentFiveMember" xlink:href="silo-20220630.xsd#silo_PaymentFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="silo_PaymentFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_Payment" xlink:href="silo-20220630.xsd#silo_Payment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems" xlink:to="silo_Payment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentDescription" xlink:href="silo-20220630.xsd#silo_PaymentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems" xlink:to="silo_PaymentDescription" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofshallpayUMBTable">
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentSixMember" xlink:href="silo-20220630.xsd#silo_PaymentSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="silo_PaymentSixMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentSevenMember" xlink:href="silo-20220630.xsd#silo_PaymentSevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="silo_PaymentSevenMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentEightMember" xlink:href="silo-20220630.xsd#silo_PaymentEightMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="silo_PaymentEightMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SponsoredPayment" xlink:href="silo-20220630.xsd#silo_SponsoredPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems" xlink:to="silo_SponsoredPayment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentDescription" xlink:href="silo-20220630.xsd#silo_PaymentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems" xlink:to="silo_PaymentDescription" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable0">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYRCCyonMiwgdQ2lJYzdzUOv9fI1l/VI08eZ/jN8gtVkovQNM+Tg8ySqLg3+WC1g4h34l8wpPDRKEpvN2sEoV7GBwsfUtZ7wPjtnRwjx//zhaHDazrcKZSY+odwB4qGm1MOd/qfdmKbOaTaPPe9bPa/02wjXfGOjU12GfRhsnE31flgx8L3rluk2SGwGfmPYpaoiXZI8V63fA==] CSR-->
    <loc xlink:type="locator" xlink:label="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems" xlink:href="silo-20220630.xsd#silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" xlink:href="silo-20220630.xsd#silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems" xlink:to="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0">
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:href="silo-20220630.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:href="silo-20220630.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_EquityInvestmentsAtFairValue" xlink:href="silo-20220630.xsd#silo_EquityInvestmentsAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="silo_EquityInvestmentsAtFairValue" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable0">
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:to="us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AdditionsofEquitySecurities" xlink:href="silo-20220630.xsd#silo_AdditionsofEquitySecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:to="silo_AdditionsofEquitySecurities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable0">
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_FinanceLeaseLiabilities" xlink:href="silo-20220630.xsd#silo_FinanceLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="silo_FinanceLeaseLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NetAssetOfNFIDBusinessDisposed" xlink:href="silo-20220630.xsd#silo_NetAssetOfNFIDBusinessDisposed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="silo_NetAssetOfNFIDBusinessDisposed" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ConsiderationInTheFormOfANoteReceivable" xlink:href="silo-20220630.xsd#silo_ConsiderationInTheFormOfANoteReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="silo_ConsiderationInTheFormOfANoteReceivable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable0">
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofnotesreceivablenetTable">
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfNotesReceivableNetAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfNotesReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfNotesReceivableNetAbstract" xlink:to="us-gaap_NotesReceivableGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AdditionalNotesReceivableIn2021" xlink:href="silo-20220630.xsd#silo_AdditionalNotesReceivableIn2021"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesReceivableGross" xlink:to="silo_AdditionalNotesReceivableIn2021" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CollectionsOnNotesReceivables" xlink:href="silo-20220630.xsd#silo_CollectionsOnNotesReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesReceivableGross" xlink:to="silo_CollectionsOnNotesReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesReceivableGross" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfNotesReceivableNetAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_LessNotesReceivableNetCurrentPortion" xlink:href="silo-20220630.xsd#silo_LessNotesReceivableNetCurrentPortion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="silo_LessNotesReceivableNetCurrentPortion" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ScheduleOfNotesReceivableNetAbstract" xlink:to="us-gaap_NotesReceivableNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0">
    <loc xlink:type="locator" xlink:label="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:href="silo-20220630.xsd#silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable" xlink:href="silo-20220630.xsd#silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_StockOptionsMember" xlink:href="silo-20220630.xsd#silo_StockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="silo_StockOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears" xlink:href="silo-20220630.xsd#silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_GrantedAsIncentivesAggregateIntrinsicValue" xlink:href="silo-20220630.xsd#silo_GrantedAsIncentivesAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="silo_GrantedAsIncentivesAggregateIntrinsicValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:href="silo-20220630.xsd#silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:href="silo-20220630.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm" xlink:href="silo-20220630.xsd#silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue" xlink:href="silo-20220630.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofwarrantactivitiesTable0">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue" xlink:href="silo-20220630.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted" xlink:href="silo-20220630.xsd#silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AggregateIntrinsicValueGranted" xlink:href="silo-20220630.xsd#silo_AggregateIntrinsicValueGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="silo_AggregateIntrinsicValueGranted" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars" xlink:href="silo-20220630.xsd#silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable" xlink:href="silo-20220630.xsd#silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofmilestonepaymentsTable0">
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentOneMember" xlink:href="silo-20220630.xsd#silo_PaymentOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentTwoMember" xlink:href="silo-20220630.xsd#silo_PaymentTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentThreeMember" xlink:href="silo-20220630.xsd#silo_PaymentThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentFourMember" xlink:href="silo-20220630.xsd#silo_PaymentFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentFiveMember" xlink:href="silo-20220630.xsd#silo_PaymentFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_Milestone" xlink:href="silo-20220630.xsd#silo_Milestone"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems" xlink:to="silo_Milestone" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_MilestonePayment" xlink:href="silo-20220630.xsd#silo_MilestonePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems" xlink:to="silo_MilestonePayment" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable0">
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentOneMember" xlink:href="silo-20220630.xsd#silo_PaymentOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentTwoMember" xlink:href="silo-20220630.xsd#silo_PaymentTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentThreeMember" xlink:href="silo-20220630.xsd#silo_PaymentThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentFourMember" xlink:href="silo-20220630.xsd#silo_PaymentFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentFiveMember" xlink:href="silo-20220630.xsd#silo_PaymentFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="silo_PaymentFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_YearsDescription" xlink:href="silo-20220630.xsd#silo_YearsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems" xlink:to="silo_YearsDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_MinimumAnnualRoyalty" xlink:href="silo-20220630.xsd#silo_MinimumAnnualRoyalty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems" xlink:to="silo_MinimumAnnualRoyalty" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofshallpayUMBTable0">
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentSixMember" xlink:href="silo-20220630.xsd#silo_PaymentSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="silo_PaymentSixMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentSevenMember" xlink:href="silo-20220630.xsd#silo_PaymentSevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="silo_PaymentSevenMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentEightMember" xlink:href="silo-20220630.xsd#silo_PaymentEightMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="silo_PaymentEightMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SponsoredPayment" xlink:href="silo-20220630.xsd#silo_SponsoredPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems" xlink:to="silo_SponsoredPayment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentDescription" xlink:href="silo-20220630.xsd#silo_PaymentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems" xlink:to="silo_PaymentDescription" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/OrganizationandBusinessDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_OrganizationandBusinessDetailsTable" xlink:href="silo-20220630.xsd#silo_OrganizationandBusinessDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="silo_OrganizationandBusinessDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalDeferredPurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SupplementalDeferredPurchasePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_promissoryNoteAmount" xlink:href="silo-20220630.xsd#silo_promissoryNoteAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="silo_promissoryNoteAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_InvestmentInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_InvestmentMaturityDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AssetPurchaseAgreementDescription" xlink:href="silo-20220630.xsd#silo_AssetPurchaseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="silo_AssetPurchaseAgreementDescription" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInContinuingOperations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CapitalUnits" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SharesIssued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashFDICInsuredAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CashSPICInsuredAmount" xlink:href="silo-20220630.xsd#silo_CashSPICInsuredAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="silo_CashSPICInsuredAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FDICIndemnificationAssetCashPaymentsReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FDICIndemnificationAssetCashPaymentsReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FDICIndemnificationAssetCashPaymentsReceived" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryGross" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsUnappropriated" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsUnappropriated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RetainedEarningsUnappropriated" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_WorkingCapital" xlink:href="silo-20220630.xsd#silo_WorkingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="silo_WorkingCapital" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails">
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:href="silo-20220630.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" xlink:href="silo-20220630.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_DatChatIncMember" xlink:href="silo-20220630.xsd#silo_DatChatIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_DatChatIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AikidoPharmaIncMember" xlink:href="silo-20220630.xsd#silo_AikidoPharmaIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_AikidoPharmaIncMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_HomeBistroIncMember" xlink:href="silo-20220630.xsd#silo_HomeBistroIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_HomeBistroIncMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_InvestmentOwnedAtCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredSalesCommission" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredSalesCommission"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_DeferredSalesCommission" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_EquityInvestmentsCost" xlink:href="silo-20220630.xsd#silo_EquityInvestmentsCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="silo_EquityInvestmentsCost" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CompanyReceivedShares" xlink:href="silo-20220630.xsd#silo_CompanyReceivedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="silo_CompanyReceivedShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockGrantDateFairValuePerShare" xlink:href="silo-20220630.xsd#silo_CommonStockGrantDateFairValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="silo_CommonStockGrantDateFairValuePerShare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOnSaleOfInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_GainOnSaleOfInvestments" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_GrossProceeds" xlink:href="silo-20220630.xsd#silo_GrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="silo_GrossProceeds" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_EquityMethodInvestment" xlink:href="silo-20220630.xsd#silo_EquityMethodInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="silo_EquityMethodInvestment" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="silo_PurchasePrice" xlink:href="silo-20220630.xsd#silo_PurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="silo_PurchasePrice" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_LongTermDebtMaturityDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PrincipalBalance" xlink:href="silo-20220630.xsd#silo_PrincipalBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="silo_PrincipalBalance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AccruedInterestReceivable" xlink:href="silo-20220630.xsd#silo_AccruedInterestReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="silo_AccruedInterestReceivable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_TotalOutstandingBalanceReceivable" xlink:href="silo-20220630.xsd#silo_TotalOutstandingBalanceReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="silo_TotalOutstandingBalanceReceivable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PromissoryNotes" xlink:href="silo-20220630.xsd#silo_PromissoryNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="silo_PromissoryNotes" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/NotesReceivableDetails">
    <loc xlink:type="locator" xlink:label="silo_NotesReceivableDetailsLineItems" xlink:href="silo-20220630.xsd#silo_NotesReceivableDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_NotesReceivableDetailsTable" xlink:href="silo-20220630.xsd#silo_NotesReceivableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="silo_NotesReceivableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_NotesReceivableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_NotesReceivableDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_NotesReceivableDetailsTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_TypesOfAgreementAxis" xlink:href="silo-20220630.xsd#silo_TypesOfAgreementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_NotesReceivableDetailsTable" xlink:to="silo_TypesOfAgreementAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_TypesOfAgreementDomain" xlink:href="silo-20220630.xsd#silo_TypesOfAgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="silo_TypesOfAgreementAxis" xlink:to="silo_TypesOfAgreementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_TypesOfAgreementDomain_0" xlink:href="silo-20220630.xsd#silo_TypesOfAgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="silo_TypesOfAgreementAxis" xlink:to="silo_TypesOfAgreementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_NotesReceivableDetailsTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_DeferredRevenueArrangementType_Domain" xlink:href="silo-20220630.xsd#silo_DeferredRevenueArrangementType_Domain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="silo_DeferredRevenueArrangementType_Domain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_DeferredRevenueArrangementType_Domain_0" xlink:href="silo-20220630.xsd#silo_DeferredRevenueArrangementType_Domain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="silo_DeferredRevenueArrangementType_Domain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_NotesReceivableDetailsTable" xlink:to="srt_RangeAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PromissoryNoteReceivableAgreementMember" xlink:href="silo-20220630.xsd#silo_PromissoryNoteReceivableAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="silo_PromissoryNoteReceivableAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_NotesReceivableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PurchaseAgreementMember" xlink:href="silo-20220630.xsd#silo_PurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_TypesOfAgreementDomain" xlink:to="silo_PurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LayawaySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LayawaySaleMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_DeferredRevenueArrangementType_Domain" xlink:to="us-gaap_LayawaySaleMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_RemainingBalanceOfPromissoryNoteReceivable" xlink:href="silo-20220630.xsd#silo_RemainingBalanceOfPromissoryNoteReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="silo_RemainingBalanceOfPromissoryNoteReceivable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalDeferredPurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="us-gaap_SupplementalDeferredPurchasePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NotesReceivablePurchasePrice" xlink:href="silo-20220630.xsd#silo_NotesReceivablePurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="silo_NotesReceivablePurchasePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="us-gaap_InterestReceivable" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NetBadDebtExpense" xlink:href="silo-20220630.xsd#silo_NetBadDebtExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="silo_NetBadDebtExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_BadDebtRecoveryCashPayment" xlink:href="silo-20220630.xsd#silo_BadDebtRecoveryCashPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="silo_BadDebtRecoveryCashPayment" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CollectedSettlementAgreement" xlink:href="silo-20220630.xsd#silo_CollectedSettlementAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="silo_CollectedSettlementAgreement" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_RemainsCollectibleSettlementAgreement" xlink:href="silo-20220630.xsd#silo_RemainsCollectibleSettlementAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="silo_RemainsCollectibleSettlementAgreement" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PromissoryNote" xlink:href="silo-20220630.xsd#silo_PromissoryNote"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="silo_PromissoryNote" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NoteReceivableNonCurrentAmount" xlink:href="silo-20220630.xsd#silo_NoteReceivableNonCurrentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="silo_NoteReceivableNonCurrentAmount" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_DebtInstrumentIncreasesAccruedInterest" xlink:href="silo-20220630.xsd#silo_DebtInstrumentIncreasesAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="silo_DebtInstrumentIncreasesAccruedInterest" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireReceivables" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PromissoryNoteAgreement" xlink:href="silo-20220630.xsd#silo_PromissoryNoteAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="silo_PromissoryNoteAgreement" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="us-gaap_DerivativeFixedInterestRate" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ReceivedShares" xlink:href="silo-20220630.xsd#silo_ReceivedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="silo_ReceivedShares" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AggregateOfNotesReceivablePurchasePrice" xlink:href="silo-20220630.xsd#silo_AggregateOfNotesReceivablePurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="silo_AggregateOfNotesReceivablePurchasePrice" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_RecoveredAggregateBadDebt" xlink:href="silo-20220630.xsd#silo_RecoveredAggregateBadDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="silo_RecoveredAggregateBadDebt" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_RecoveredBadDebt" xlink:href="silo-20220630.xsd#silo_RecoveredBadDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="silo_RecoveredBadDebt" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="us-gaap_LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_RemainsCollectibleSettlementAgreementAmountReserved" xlink:href="silo-20220630.xsd#silo_RemainsCollectibleSettlementAgreementAmountReserved"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="silo_RemainsCollectibleSettlementAgreementAmountReserved" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="us-gaap_LongTermDebtMaturityDate" order="28" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/NotePayableDetails">
    <loc xlink:type="locator" xlink:label="silo_NotePayableDetailsLineItems" xlink:href="silo-20220630.xsd#silo_NotePayableDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_NotePayableDetailsTable" xlink:href="silo-20220630.xsd#silo_NotePayableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_NotePayableDetailsLineItems" xlink:to="silo_NotePayableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_NotePayableDetailsTable" xlink:to="dei_LegalEntityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaycheckProtectionProgramMember" xlink:href="silo-20220630.xsd#silo_PaycheckProtectionProgramMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="silo_PaycheckProtectionProgramMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotePayableDetailsLineItems" xlink:to="us-gaap_NotesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotePayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableInterestBearingInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotePayableDetailsLineItems" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotePayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotePayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotePayableDetailsLineItems" xlink:to="us-gaap_OtherNotesPayable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_NotePayableDetailsLineItems" xlink:to="us-gaap_InterestExpense" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="silo_StockholdersEquityDetailsLineItems" xlink:href="silo-20220630.xsd#silo_StockholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_StockholdersEquityDetailsTable" xlink:href="silo-20220630.xsd#silo_StockholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_StockholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_StockholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_TypesOfAgreementsAxis" xlink:href="silo-20220630.xsd#silo_TypesOfAgreementsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_StockholdersEquityDetailsTable" xlink:to="silo_TypesOfAgreementsAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_TypesOfAgreementsDomain" xlink:href="silo-20220630.xsd#silo_TypesOfAgreementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="silo_TypesOfAgreementsAxis" xlink:to="silo_TypesOfAgreementsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_TypesOfAgreementsDomain_0" xlink:href="silo-20220630.xsd#silo_TypesOfAgreementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="silo_TypesOfAgreementsAxis" xlink:to="silo_TypesOfAgreementsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PlacementAgentWarrantsMember" xlink:href="silo-20220630.xsd#silo_PlacementAgentWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="silo_PlacementAgentWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SubscriptionAgreementsMember" xlink:href="silo-20220630.xsd#silo_SubscriptionAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_TypesOfAgreementsDomain" xlink:to="silo_SubscriptionAgreementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SecuritiesPurchaseAgreementsMember" xlink:href="silo-20220630.xsd#silo_SecuritiesPurchaseAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_TypesOfAgreementsDomain" xlink:to="silo_SecuritiesPurchaseAgreementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AdvisoryAgreementsMember" xlink:href="silo-20220630.xsd#silo_AdvisoryAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_TypesOfAgreementsDomain" xlink:to="silo_AdvisoryAgreementsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ConsultingAgreementMember" xlink:href="silo-20220630.xsd#silo_ConsultingAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_TypesOfAgreementsDomain" xlink:to="silo_ConsultingAgreementMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_EmploymentAgreementMember" xlink:href="silo-20220630.xsd#silo_EmploymentAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_TypesOfAgreementsDomain" xlink:to="silo_EmploymentAgreementMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ExchangeAgreementsMember" xlink:href="silo-20220630.xsd#silo_ExchangeAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_TypesOfAgreementsDomain" xlink:to="silo_ExchangeAgreementsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SeriesCConvertiblePreferredStockMember" xlink:href="silo-20220630.xsd#silo_SeriesCConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="silo_SeriesCConvertiblePreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SeriesCConversionPriceMember" xlink:href="silo-20220630.xsd#silo_SeriesCConversionPriceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="silo_SeriesCConversionPriceMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SeriesCPurchaseAgreementsMember" xlink:href="silo-20220630.xsd#silo_SeriesCPurchaseAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="silo_SeriesCPurchaseAgreementsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_OmnibusEquityIncentivePlanMember" xlink:href="silo-20220630.xsd#silo_OmnibusEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="silo_OmnibusEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_IncentiveStockOptionMember" xlink:href="silo-20220630.xsd#silo_IncentiveStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="silo_IncentiveStockOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ConvertablePreferredStock" xlink:href="silo-20220630.xsd#silo_ConvertablePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_ConvertablePreferredStock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ExchangeAgreementsDescription" xlink:href="silo-20220630.xsd#silo_ExchangeAgreementsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_ExchangeAgreementsDescription" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PreferredStockOutstandingDescription" xlink:href="silo-20220630.xsd#silo_PreferredStockOutstandingDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_PreferredStockOutstandingDescription" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConversionBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConversionBasis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockConversionBasis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_WarrantsTerm" xlink:href="silo-20220630.xsd#silo_WarrantsTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_WarrantsTerm" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SubsequentFinancingPercentage" xlink:href="silo-20220630.xsd#silo_SubsequentFinancingPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_SubsequentFinancingPercentage" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ObligationPercentage" xlink:href="silo-20220630.xsd#silo_ObligationPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_ObligationPercentage" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PlacementAgentWarrantsDescriptoin" xlink:href="silo-20220630.xsd#silo_PlacementAgentWarrantsDescriptoin"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_PlacementAgentWarrantsDescriptoin" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AggregateGrantDateFairValueOfPlacementAgentWarrants" xlink:href="silo-20220630.xsd#silo_AggregateGrantDateFairValueOfPlacementAgentWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_AggregateGrantDateFairValueOfPlacementAgentWarrants" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_TotalSubscriptionReceivableValue" xlink:href="silo-20220630.xsd#silo_TotalSubscriptionReceivableValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_TotalSubscriptionReceivableValue" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PlacementAgentFees" xlink:href="silo-20220630.xsd#silo_PlacementAgentFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_PlacementAgentFees" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOwnershipInterestsOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherOwnershipInterestsOfferingCosts" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_InvestorInvestedAmount" xlink:href="silo-20220630.xsd#silo_InvestorInvestedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_InvestorInvestedAmount" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionContractorLiquidityCharacteristic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionContractorLiquidityCharacteristic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ConstructionContractorLiquidityCharacteristic" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AmortizationOfPrepaidStockbasedExpense" xlink:href="silo-20220630.xsd#silo_AmortizationOfPrepaidStockbasedExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_AmortizationOfPrepaidStockbasedExpense" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherAssetsCurrent" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockValue" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_DeemedDividend" xlink:href="silo-20220630.xsd#silo_DeemedDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_DeemedDividend" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ConvertibleLongTermNotesPayables" xlink:href="silo-20220630.xsd#silo_ConvertibleLongTermNotesPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_ConvertibleLongTermNotesPayables" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_WarrantIssued" xlink:href="silo-20220630.xsd#silo_WarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_WarrantIssued" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" order="41" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="42" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockServiceDescription" xlink:href="silo-20220630.xsd#silo_CommonStockServiceDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_CommonStockServiceDescription" order="43" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" order="44" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PurchaseAgreementsDescription" xlink:href="silo-20220630.xsd#silo_PurchaseAgreementsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_PurchaseAgreementsDescription" order="45" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesAuthorized" order="46" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="47" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="48" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="49" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PreferredStockStatedValue" xlink:href="silo-20220630.xsd#silo_PreferredStockStatedValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_PreferredStockStatedValue" order="50" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" order="51" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="52" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="53" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="54" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="55" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DividendsPreferredStockCash" order="56" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_InvestorInvestedAmountPercentage" xlink:href="silo-20220630.xsd#silo_InvestorInvestedAmountPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_InvestorInvestedAmountPercentage" order="57" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="58" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="59" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="60" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="61" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" order="62" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="63" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" order="64" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" order="65" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="66" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="67" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="68" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="69" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" order="70" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="71" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="72" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharePrice" order="73" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VentureCapitalGainsLossesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VentureCapitalGainsLossesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_VentureCapitalGainsLossesNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NetCapitalLossCarryForward" xlink:href="silo-20220630.xsd#silo_NetCapitalLossCarryForward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="silo_NetCapitalLossCarryForward" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_GainLossOnSaleOfCapitalLeaseNet" xlink:href="silo-20220630.xsd#silo_GainLossOnSaleOfCapitalLeaseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="silo_GainLossOnSaleOfCapitalLeaseNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AggregateEstimatedNetOperatingLoss" xlink:href="silo-20220630.xsd#silo_AggregateEstimatedNetOperatingLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="silo_AggregateEstimatedNetOperatingLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_DescriptionOfIncomeTaxDescription" xlink:href="silo-20220630.xsd#silo_DescriptionOfIncomeTaxDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="silo_DescriptionOfIncomeTaxDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/ConcentrationsDetails">
    <loc xlink:type="locator" xlink:label="silo_ConcentrationsDetailsLineItems" xlink:href="silo-20220630.xsd#silo_ConcentrationsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_ConcentrationsDetailsTable" xlink:href="silo-20220630.xsd#silo_ConcentrationsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_ConcentrationsDetailsLineItems" xlink:to="silo_ConcentrationsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_ConcentrationsDetailsTable" xlink:to="srt_MajorCustomersAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_OneLicensorMember" xlink:href="silo-20220630.xsd#silo_OneLicensorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="silo_OneLicensorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_OneLicenseeMember" xlink:href="silo-20220630.xsd#silo_OneLicenseeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="silo_OneLicenseeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_VendorConcentrationsMember" xlink:href="silo-20220630.xsd#silo_VendorConcentrationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="silo_VendorConcentrationsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ConcentrationsRiskPercentage1" xlink:href="silo-20220630.xsd#silo_ConcentrationsRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_ConcentrationsDetailsLineItems" xlink:to="silo_ConcentrationsRiskPercentage1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_TypeOfAgreementAxis" xlink:href="silo-20220630.xsd#silo_TypeOfAgreementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsTable" xlink:to="silo_TypeOfAgreementAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_TypeOfAgreementDomain" xlink:href="silo-20220630.xsd#silo_TypeOfAgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="silo_TypeOfAgreementAxis" xlink:to="silo_TypeOfAgreementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_TypeOfAgreementDomain_0" xlink:href="silo-20220630.xsd#silo_TypeOfAgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="silo_TypeOfAgreementAxis" xlink:to="silo_TypeOfAgreementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_CommitmentsandContingenciesDetailsTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SublicenseAgreementMember" xlink:href="silo-20220630.xsd#silo_SublicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_TypeOfAgreementDomain" xlink:to="silo_SublicenseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ColumbiaUniversityMember" xlink:href="silo-20220630.xsd#silo_ColumbiaUniversityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_ColumbiaUniversityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_DrJamesKuoMember" xlink:href="silo-20220630.xsd#silo_DrJamesKuoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_DrJamesKuoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AikidoMember" xlink:href="silo-20220630.xsd#silo_AikidoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="silo_AikidoMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_MasterLincenseAgreementMember" xlink:href="silo-20220630.xsd#silo_MasterLincenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="silo_MasterLincenseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_JVAgreementMember" xlink:href="silo-20220630.xsd#silo_JVAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="silo_JVAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_EmploymentAgreementDescription" xlink:href="silo-20220630.xsd#silo_EmploymentAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_EmploymentAgreementDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_LicenseFee" xlink:href="silo-20220630.xsd#silo_LicenseFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_LicenseFee" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CommercialSaleTerm" xlink:href="silo-20220630.xsd#silo_CommercialSaleTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_CommercialSaleTerm" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_LicenseAgreementExpire" xlink:href="silo-20220630.xsd#silo_LicenseAgreementExpire"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_LicenseAgreementExpire" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SublicenseIncomeDescription" xlink:href="silo-20220630.xsd#silo_SublicenseIncomeDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_SublicenseIncomeDescription" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_LicenseAgreementDescription" xlink:href="silo-20220630.xsd#silo_LicenseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_LicenseAgreementDescription" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_RoyaltyPaymentsDescription" xlink:href="silo-20220630.xsd#silo_RoyaltyPaymentsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_RoyaltyPaymentsDescription" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SublicenseIncomePercentage" xlink:href="silo-20220630.xsd#silo_SublicenseIncomePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_SublicenseIncomePercentage" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SublicenseAgreementAmountPaid" xlink:href="silo-20220630.xsd#silo_SublicenseAgreementAmountPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_SublicenseAgreementAmountPaid" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_OtherDepreciationsAndAmortization" xlink:href="silo-20220630.xsd#silo_OtherDepreciationsAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_OtherDepreciationsAndAmortization" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentOfSponsoredResearchAmount" xlink:href="silo-20220630.xsd#silo_PaymentOfSponsoredResearchAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_PaymentOfSponsoredResearchAmount" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PrepaidExpenses" xlink:href="silo-20220630.xsd#silo_PrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_PrepaidExpenses" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NonrefundableCashPayment" xlink:href="silo-20220630.xsd#silo_NonrefundableCashPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_NonrefundableCashPayment" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NetSalePercentage" xlink:href="silo-20220630.xsd#silo_NetSalePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_NetSalePercentage" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_LicensorShare" xlink:href="silo-20220630.xsd#silo_LicensorShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_LicensorShare" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AggregateOfConvertedShares" xlink:href="silo-20220630.xsd#silo_AggregateOfConvertedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_AggregateOfConvertedShares" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_RevenueTerm" xlink:href="silo-20220630.xsd#silo_RevenueTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_RevenueTerm" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_NumberOfVotingShares" xlink:href="silo-20220630.xsd#silo_NumberOfVotingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_NumberOfVotingShares" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ReverseStockSplitVoteDescription" xlink:href="silo-20220630.xsd#silo_ReverseStockSplitVoteDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_ReverseStockSplitVoteDescription" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_DeferredRevenue" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CashReceived" xlink:href="silo-20220630.xsd#silo_CashReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_CashReceived" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SecuritiesReceived" xlink:href="silo-20220630.xsd#silo_SecuritiesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_SecuritiesReceived" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceServicesRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceServicesRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_InsuranceServicesRevenue" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_DeferredRevenueLongtermPortion" xlink:href="silo-20220630.xsd#silo_DeferredRevenueLongtermPortion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_DeferredRevenueLongtermPortion" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_ConsiderationFeePayablePercentage" xlink:href="silo-20220630.xsd#silo_ConsiderationFeePayablePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_ConsiderationFeePayablePercentage" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_UpfrontLicenseFees" xlink:href="silo-20220630.xsd#silo_UpfrontLicenseFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_UpfrontLicenseFees" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_FirstCommercialSale" xlink:href="silo-20220630.xsd#silo_FirstCommercialSale"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_FirstCommercialSale" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AgreementShallExpire" xlink:href="silo-20220630.xsd#silo_AgreementShallExpire"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_AgreementShallExpire" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_RecognizedRevenues" xlink:href="silo-20220630.xsd#silo_RecognizedRevenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_RecognizedRevenues" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OtherLongTermDebt" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManagementFeePayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementFeePayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_ManagementFeePayable" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentDescription" xlink:href="silo-20220630.xsd#silo_PaymentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_PaymentDescription" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SponsoredStudyAgreementDescription" xlink:href="silo-20220630.xsd#silo_SponsoredStudyAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_SponsoredStudyAgreementDescription" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SublicenseAmountPaid" xlink:href="silo-20220630.xsd#silo_SublicenseAmountPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_SublicenseAmountPaid" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_SponsoredResearchAgreementDescription" xlink:href="silo-20220630.xsd#silo_SponsoredResearchAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_SponsoredResearchAgreementDescription" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_CompanyPaidCash" xlink:href="silo-20220630.xsd#silo_CompanyPaidCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_CompanyPaidCash" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PursuantTerms" xlink:href="silo-20220630.xsd#silo_PursuantTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_PursuantTerms" order="41" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentOfUniversity" xlink:href="silo-20220630.xsd#silo_PaymentOfUniversity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_PaymentOfUniversity" order="42" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="43" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="44" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="45" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="46" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="47" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="48" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" order="49" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="50" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" order="51" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization" order="52" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="53" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseOtherNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent" order="54" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRefundableFeesProceeds" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundableFeesProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_CustomerRefundableFeesProceeds" order="55" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RecognitionOfDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecognitionOfDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RecognitionOfDeferredRevenue" order="56" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_DeferredRevenueLongtermPortionAmounted" xlink:href="silo-20220630.xsd#silo_DeferredRevenueLongtermPortionAmounted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_DeferredRevenueLongtermPortionAmounted" order="57" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear" order="58" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AgreementDescription" xlink:href="silo-20220630.xsd#silo_AgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_AgreementDescription" order="59" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="silo_SubsequentEventsDetailsLineItems" xlink:href="silo-20220630.xsd#silo_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="silo_SubsequentEventsDetailsTable" xlink:href="silo-20220630.xsd#silo_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="silo_SubsequentEventsDetailsLineItems" xlink:to="silo_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_TypesOfAgreementAxis" xlink:href="silo-20220630.xsd#silo_TypesOfAgreementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_SubsequentEventsDetailsTable" xlink:to="silo_TypesOfAgreementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_TypesOfAgreementDomain" xlink:href="silo-20220630.xsd#silo_TypesOfAgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="silo_TypesOfAgreementAxis" xlink:to="silo_TypesOfAgreementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_TypesOfAgreementDomain_0" xlink:href="silo-20220630.xsd#silo_TypesOfAgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="silo_TypesOfAgreementAxis" xlink:to="silo_TypesOfAgreementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="silo_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_KuoEmploymentAgreementMember" xlink:href="silo-20220630.xsd#silo_KuoEmploymentAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_TypesOfAgreementDomain" xlink:to="silo_KuoEmploymentAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_AnnualBaseSalary" xlink:href="silo-20220630.xsd#silo_AnnualBaseSalary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_SubsequentEventsDetailsLineItems" xlink:to="silo_AnnualBaseSalary" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SubsequentEventDescription" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="silo_TotalOfSharesOfCommonStock" xlink:href="silo-20220630.xsd#silo_TotalOfSharesOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_SubsequentEventsDetailsLineItems" xlink:to="silo_TotalOfSharesOfCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="silo_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://silopharma.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="9" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>silo-20220630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Sep 20 20:53:05 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total Long Term Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">GROSS PROFIT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING LOSS FROM CONTINUING OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">INCOME (LOSS) FROM CONTINUING OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xml:lang="en-US">LOSS FROM DISCONTINUED OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">NET INCOME (LOSS) AVAILABLE TO COMMON STOCKHOLDERS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">NET CASH USED IN OPERATING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">NET CASH PROVIDED BY INVESTING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">NET CASH PROVIDED BY FINANCING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">NET CHANGE IN CASH AND CASH EQUIVALENTS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS - beginning of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">CASH AND CASH EQUIVALENTS - end of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US">Organization and Business [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US">Balance, beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl0" xml:lang="en-US">Balance, end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Note Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of Options, balance beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0" xml:lang="en-US">Number of Options, balance ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" xlink:href="silo-20220630.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl" xml:lang="en-US">Weighted Average Exercise Price, balance beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl0" xml:lang="en-US">Weighted Average Exercise Price, balance ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, balance beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, balance ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_NumberOfWarrant" xlink:href="silo-20220630.xsd#silo_NumberOfWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="silo_NumberOfWarrant_lbl" xml:lang="en-US">Number of Warrants, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NumberOfWarrant" xlink:to="silo_NumberOfWarrant_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="silo_NumberOfWarrant_lbl0" xml:lang="en-US">Number of Warrants, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NumberOfWarrant" xlink:to="silo_NumberOfWarrant_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Exercise Price, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue" xlink:href="silo-20220630.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xml:lang="en-US">Debt Conversion Description [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities_lbl" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities" xlink:to="us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities" xlink:to="us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, beginning balance outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Options, balance ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, balance beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, balance ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, balance beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, balance ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Warrants, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Number of Warrants, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Exercise Price, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_EquityInvestmentsAtCost" xlink:href="silo-20220630.xsd#silo_EquityInvestmentsAtCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_EquityInvestmentsAtCost_lbl" xml:lang="en-US">Equity investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquityInvestmentsAtCost" xlink:to="silo_EquityInvestmentsAtCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US">Notes receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets - current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid expense leaving a prepaid asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Assets of discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract" xlink:to="silo_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract0" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract0" xlink:to="silo_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Note receivable - non-current, including interest receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestReceivableNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestReceivableNoncurrent_lbl" xml:lang="en-US">Interest receivable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableNoncurrent" xlink:to="us-gaap_InterestReceivableNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid expenses - non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract1" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract1" xlink:to="silo_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract2" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract2" xlink:to="silo_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Note payable - current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue - current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl0" xml:lang="en-US">Deferred revenue &#8211; current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract3" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract3" xlink:to="silo_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract4" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract4" xlink:to="silo_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenue - long-term portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Note payable - long-term portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract5" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract5" xlink:to="silo_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract6" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract6" xlink:to="silo_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract7" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract7" xlink:to="silo_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitment and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract8" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract8" xlink:to="silo_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.0001 par value, 5,000,000 shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Redemption value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PreferredStockValueOne" xlink:href="silo-20220630.xsd#silo_PreferredStockValueOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PreferredStockValueOne_lbl" xml:lang="en-US">Convertible preferred stock, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredStockValueOne" xlink:to="silo_PreferredStockValueOne_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Share issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Share outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xml:lang="en-US">Preferred stock liquidation value price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract9" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract9" xlink:to="silo_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PreferredStockValueTwo" xlink:href="silo-20220630.xsd#silo_PreferredStockValueTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PreferredStockValueTwo_lbl" xml:lang="en-US">Convertible preferred stock, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredStockValueTwo" xlink:to="silo_PreferredStockValueTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract10" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract10" xlink:to="silo_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract11" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract11" xlink:to="silo_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract12" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract12" xlink:to="silo_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract13" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract13" xlink:to="silo_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract14" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract14" xlink:to="silo_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract15" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract15" xlink:to="silo_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract16" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract16" xlink:to="silo_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract17" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract17" xlink:to="silo_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US">Insurance payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract18" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract18" xlink:to="silo_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract19" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract19" xlink:to="silo_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_LongTermLiabilitiesAbstract" xlink:href="silo-20220630.xsd#silo_LongTermLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_LongTermLiabilitiesAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LongTermLiabilitiesAbstract" xlink:to="silo_LongTermLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract20" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract20" xlink:to="silo_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract21" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract21" xlink:to="silo_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract22" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract22" xlink:to="silo_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract23" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract23"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract23_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract23" xlink:to="silo_UnlabeledAbstract23_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract24" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract24"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract24_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract24" xlink:to="silo_UnlabeledAbstract24_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract25" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract25"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract25_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract25" xlink:to="silo_UnlabeledAbstract25_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract26" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract26"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract26_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract26" xlink:to="silo_UnlabeledAbstract26_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract27" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract27"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract27_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract27" xlink:to="silo_UnlabeledAbstract27_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_LicenseFees" xlink:href="silo-20220630.xsd#silo_LicenseFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_LicenseFees_lbl" xml:lang="en-US">LICENSE FEE REVENUES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LicenseFees" xlink:to="silo_LicenseFees_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract28" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract28"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract28_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract28" xlink:to="silo_UnlabeledAbstract28_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract29" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract29"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract29_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract29" xlink:to="silo_UnlabeledAbstract29_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract30" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract30"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract30_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract30" xlink:to="silo_UnlabeledAbstract30_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralInsuranceExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralInsuranceExpense_lbl" xml:lang="en-US">Insurance expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_BadDebtRecoveryExpense" xlink:href="silo-20220630.xsd#silo_BadDebtRecoveryExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_BadDebtRecoveryExpense_lbl" xml:lang="en-US">Bad debt (recovery) expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_BadDebtRecoveryExpense" xlink:to="silo_BadDebtRecoveryExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract31" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract31"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract31_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract31" xlink:to="silo_UnlabeledAbstract31_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract32" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract32"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract32_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract32" xlink:to="silo_UnlabeledAbstract32_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract33" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract33"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract33_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract33" xlink:to="silo_UnlabeledAbstract33_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER INCOME (EXPENSE):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US">Gain on forgiveness of PPP note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on debt extinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0" xml:lang="en-US">Loss on debt extinguishment (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">Net realized gain (loss) on equity investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnrealizedGainLossOnEquityInvestments" xlink:href="silo-20220630.xsd#silo_UnrealizedGainLossOnEquityInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnrealizedGainLossOnEquityInvestments_lbl" xml:lang="en-US">Net unrealized gain (loss) on equity investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnrealizedGainLossOnEquityInvestments" xlink:to="silo_UnrealizedGainLossOnEquityInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract34" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract34"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract34_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract34" xlink:to="silo_UnlabeledAbstract34_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract35" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract35"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract35_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract35" xlink:to="silo_UnlabeledAbstract35_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE PROVISION FOR INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract36" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract36"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract36_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract36" xlink:to="silo_UnlabeledAbstract36_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract37" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract37"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract37_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract37" xlink:to="silo_UnlabeledAbstract37_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract38" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract38"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract38_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract38" xlink:to="silo_UnlabeledAbstract38_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_DiscontinuedOperationsAbstract" xlink:href="silo-20220630.xsd#silo_DiscontinuedOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_DiscontinuedOperationsAbstract_lbl" xml:lang="en-US">DISCONTINUED OPERATIONS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DiscontinuedOperationsAbstract" xlink:to="silo_DiscontinuedOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_lbl" xml:lang="en-US">Gain from sale of assets of discontinued operations, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl" xml:lang="en-US">Loss from discontinued operations, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract39" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract39"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract39_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract39" xlink:to="silo_UnlabeledAbstract39_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract40" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract40"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract40_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract40" xlink:to="silo_UnlabeledAbstract40_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET INCOME (LOSS)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract41" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract41"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract41_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract41" xlink:to="silo_UnlabeledAbstract41_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract42" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract42"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract42_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract42" xlink:to="silo_UnlabeledAbstract42_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract43" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract43"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract43_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract43" xlink:to="silo_UnlabeledAbstract43_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">NET INCOME (LOSS) PER COMMON SHARE AVAILABLE TO COMMON STOCKHOLDERS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Continuing operations - basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Continuing operations - diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" xml:lang="en-US">Discontinued operations - basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" xml:lang="en-US">Discontinued operations - diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract44" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract44"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract44_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract44" xlink:to="silo_UnlabeledAbstract44_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted average common shares outstanding &#8212; basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US">Weighted average common shares outstanding, Diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract45" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract45"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract45_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract45" xlink:to="silo_UnlabeledAbstract45_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract46" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract46"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract46_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract46" xlink:to="silo_UnlabeledAbstract46_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract47" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract47"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract47_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract47" xlink:to="silo_UnlabeledAbstract47_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract48" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract48"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract48_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract48" xlink:to="silo_UnlabeledAbstract48_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract49" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract49"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract49_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract49" xlink:to="silo_UnlabeledAbstract49_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract50" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract50"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract50_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract50" xlink:to="silo_UnlabeledAbstract50_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_OtherIncomeExpenseAbstract" xlink:href="silo-20220630.xsd#silo_OtherIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_OtherIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER INCOME (EXPENSE):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OtherIncomeExpenseAbstract" xlink:to="silo_OtherIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_OtherIncomeFromEquitySharesEarnedForServices" xlink:href="silo-20220630.xsd#silo_OtherIncomeFromEquitySharesEarnedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_OtherIncomeFromEquitySharesEarnedForServices_lbl" xml:lang="en-US">Other income from equity shares earned for lock up agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OtherIncomeFromEquitySharesEarnedForServices" xlink:to="silo_OtherIncomeFromEquitySharesEarnedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract51" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract51"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract51_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract51" xlink:to="silo_UnlabeledAbstract51_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract52" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract52"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract52_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract52" xlink:to="silo_UnlabeledAbstract52_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract53" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract53"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract53_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract53" xlink:to="silo_UnlabeledAbstract53_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract54" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract54"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract54_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract54" xlink:to="silo_UnlabeledAbstract54_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract55" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract55"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract55_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract55" xlink:to="silo_UnlabeledAbstract55_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_DiscontinuedOperationsAbstract0" xlink:href="silo-20220630.xsd#silo_DiscontinuedOperationsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_DiscontinuedOperationsAbstract0_lbl" xml:lang="en-US">DISCONTINUED OPERATIONS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DiscontinuedOperationsAbstract0" xlink:to="silo_DiscontinuedOperationsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract56" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract56"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract56_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract56" xlink:to="silo_UnlabeledAbstract56_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract57" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract57"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract57_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract57" xlink:to="silo_UnlabeledAbstract57_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract58" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract58"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract58_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract58" xlink:to="silo_UnlabeledAbstract58_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract59" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract59"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract59_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract59" xlink:to="silo_UnlabeledAbstract59_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract60" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract60"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract60_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract60" xlink:to="silo_UnlabeledAbstract60_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NetLossPerCommonShareAvailableToCommonStockholdersAbstract" xlink:href="silo-20220630.xsd#silo_NetLossPerCommonShareAvailableToCommonStockholdersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_NetLossPerCommonShareAvailableToCommonStockholdersAbstract_lbl" xml:lang="en-US">NET LOSS PER COMMON SHARE AVAILABLE TO COMMON STOCKHOLDERS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NetLossPerCommonShareAvailableToCommonStockholdersAbstract" xlink:to="silo_NetLossPerCommonShareAvailableToCommonStockholdersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract61" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract61"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract61_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract61" xlink:to="silo_UnlabeledAbstract61_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_WeightedAverageCommonSharesOutstandingAbstract" xlink:href="silo-20220630.xsd#silo_WeightedAverageCommonSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_WeightedAverageCommonSharesOutstandingAbstract_lbl" xml:lang="en-US">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_WeightedAverageCommonSharesOutstandingAbstract" xlink:to="silo_WeightedAverageCommonSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract62" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract62"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract62_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract62" xlink:to="silo_UnlabeledAbstract62_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common Stock issued for cash, net of offering cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common Stock issued for cash, net of offering cost (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract63" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract63"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract63_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract63" xlink:to="silo_UnlabeledAbstract63_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockIssuedForFutureServices" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForFutureServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CommonStockIssuedForFutureServices_lbl" xml:lang="en-US">Common Stock issued for future services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForFutureServices" xlink:to="silo_CommonStockIssuedForFutureServices_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockIssuedForFutureServicesShares" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForFutureServicesShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CommonStockIssuedForFutureServicesShares_lbl" xml:lang="en-US">Common Stock issued for future services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForFutureServicesShares" xlink:to="silo_CommonStockIssuedForFutureServicesShares_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract64" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract64"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract64_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract64" xlink:to="silo_UnlabeledAbstract64_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PreferredSharesExchangedForCommonStock" xlink:href="silo-20220630.xsd#silo_PreferredSharesExchangedForCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PreferredSharesExchangedForCommonStock_lbl" xml:lang="en-US">Preferred Shares Exchanged for Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredSharesExchangedForCommonStock" xlink:to="silo_PreferredSharesExchangedForCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PreferredSharesExchangedForCommonStockShares" xlink:href="silo-20220630.xsd#silo_PreferredSharesExchangedForCommonStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PreferredSharesExchangedForCommonStockShares_lbl" xml:lang="en-US">Preferred Shares Exchanged for Common Stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredSharesExchangedForCommonStockShares" xlink:to="silo_PreferredSharesExchangedForCommonStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract65" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract65"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract65_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract65" xlink:to="silo_UnlabeledAbstract65_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Common Stock issued in connection with employment agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Common Stock issued in connection with employment agreement (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl0" xml:lang="en-US">Aggregate number of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract66" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract66"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract66_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract66" xlink:to="silo_UnlabeledAbstract66_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockIssuedForExchangeOfNotes" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForExchangeOfNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CommonStockIssuedForExchangeOfNotes_lbl" xml:lang="en-US">Common Stock issued for Exchange of Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForExchangeOfNotes" xlink:to="silo_CommonStockIssuedForExchangeOfNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockIssuedForExchangeOfNotesShares" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForExchangeOfNotesShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CommonStockIssuedForExchangeOfNotesShares_lbl" xml:lang="en-US">Common Stock issued for Exchange of Notes (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForExchangeOfNotesShares" xlink:to="silo_CommonStockIssuedForExchangeOfNotesShares_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract67" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract67"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract67_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract67" xlink:to="silo_UnlabeledAbstract67_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock_lbl" xml:lang="en-US">Common Stock issued for conversion of Redeemable Series A Preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock" xlink:to="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares_lbl" xml:lang="en-US">Common Stock issued for conversion of Redeemable Series A Preferred stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares" xlink:to="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract68" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract68"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract68_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract68" xlink:to="silo_UnlabeledAbstract68_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_DeemedDividendOnPreferredStockExchange" xlink:href="silo-20220630.xsd#silo_DeemedDividendOnPreferredStockExchange"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_DeemedDividendOnPreferredStockExchange_lbl" xml:lang="en-US">Deemed dividend on Preferred Stock Exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeemedDividendOnPreferredStockExchange" xlink:to="silo_DeemedDividendOnPreferredStockExchange_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract69" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract69"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract69_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract69" xlink:to="silo_UnlabeledAbstract69_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract70" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract70"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract70_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract70" xlink:to="silo_UnlabeledAbstract70_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract71" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract71"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract71_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract71" xlink:to="silo_UnlabeledAbstract71_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Series C preferred stock issued for cash, net of offering cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Series C preferred stock issued for cash, net of offering cost (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract72" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract72"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract72_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract72" xlink:to="silo_UnlabeledAbstract72_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Deemed dividend upon issuance of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract73" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract73"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract73_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract73" xlink:to="silo_UnlabeledAbstract73_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Common stock warrants granted for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract74" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract74"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract74_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract74" xlink:to="silo_UnlabeledAbstract74_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_IssuanceOfCommonStockForConversionOfPreferredStock" xlink:href="silo-20220630.xsd#silo_IssuanceOfCommonStockForConversionOfPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_IssuanceOfCommonStockForConversionOfPreferredStock_lbl" xml:lang="en-US">Issuance of common stock for conversion of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IssuanceOfCommonStockForConversionOfPreferredStock" xlink:to="silo_IssuanceOfCommonStockForConversionOfPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares" xlink:href="silo-20220630.xsd#silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares_lbl" xml:lang="en-US">Issuance of common stock for conversion of preferred stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares" xlink:to="silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract75" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract75"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract75_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract75" xlink:to="silo_UnlabeledAbstract75_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract76" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract76"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract76_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract76" xlink:to="silo_UnlabeledAbstract76_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract77" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract77"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract77_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract77" xlink:to="silo_UnlabeledAbstract77_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock options issued as stock based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract78" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract78"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract78_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract78" xlink:to="silo_UnlabeledAbstract78_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued for conversion of Series C preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued for conversion of Series C preferred stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract79" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract79"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract79_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract79" xlink:to="silo_UnlabeledAbstract79_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract80" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract80"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract80_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract80" xlink:to="silo_UnlabeledAbstract80_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract81" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract81"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract81_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract81" xlink:to="silo_UnlabeledAbstract81_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract82" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract82"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract82_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract82" xlink:to="silo_UnlabeledAbstract82_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Amortization of prepaid stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract83" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract83"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract83_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract83" xlink:to="silo_UnlabeledAbstract83_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract84" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract84"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract84_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract84" xlink:to="silo_UnlabeledAbstract84_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract85" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract85"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract85_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract85" xlink:to="silo_UnlabeledAbstract85_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract86" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract86"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract86_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract86" xlink:to="silo_UnlabeledAbstract86_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract87" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract87"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract87_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract87" xlink:to="silo_UnlabeledAbstract87_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract88" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract88"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract88_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract88" xlink:to="silo_UnlabeledAbstract88_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract89" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract89"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract89_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract89" xlink:to="silo_UnlabeledAbstract89_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract90" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract90"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract90_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract90" xlink:to="silo_UnlabeledAbstract90_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract91" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract91"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract91_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract91" xlink:to="silo_UnlabeledAbstract91_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract92" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract92"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract92_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract92" xlink:to="silo_UnlabeledAbstract92_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Bad debt (recovery) expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount to interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AmortizationOfPrepaidStockbasedExpense" xlink:href="silo-20220630.xsd#silo_AmortizationOfPrepaidStockbasedExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AmortizationOfPrepaidStockbasedExpense_lbl" xml:lang="en-US">Amortization of prepaid stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AmortizationOfPrepaidStockbasedExpense" xlink:to="silo_AmortizationOfPrepaidStockbasedExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silo_AmortizationOfPrepaidStockbasedExpense_lbl0" xml:lang="en-US">Recognized stock-based consulting fees (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AmortizationOfPrepaidStockbasedExpense" xlink:to="silo_AmortizationOfPrepaidStockbasedExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory write-down</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation" xlink:href="silo-20220630.xsd#silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation_lbl" xml:lang="en-US">Assets of discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation" xlink:to="silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract93" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract93"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract93_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract93" xlink:to="silo_UnlabeledAbstract93_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract94" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract94"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract94_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract94" xlink:to="silo_UnlabeledAbstract94_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl" xml:lang="en-US">Net proceeds from sale of equity investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromCollectionOfNotesReceivable_lbl" xml:lang="en-US">Collection on note receivable written off prior to 2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:to="us-gaap_ProceedsFromCollectionOfNotesReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CollectionOnNoteReceivable" xlink:href="silo-20220630.xsd#silo_CollectionOnNoteReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CollectionOnNoteReceivable_lbl" xml:lang="en-US">Collection on note receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CollectionOnNoteReceivable" xlink:to="silo_CollectionOnNoteReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract95" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract95"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract95_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract95" xlink:to="silo_UnlabeledAbstract95_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract96" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract96"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract96_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract96" xlink:to="silo_UnlabeledAbstract96_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from note payable - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayment of note payable - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from sale of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from issuance of common stock (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Net proceeds from sale of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AdvanceFromARelatedParty" xlink:href="silo-20220630.xsd#silo_AdvanceFromARelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AdvanceFromARelatedParty_lbl" xml:lang="en-US">Advance from a related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdvanceFromARelatedParty" xlink:to="silo_AdvanceFromARelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract97" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract97"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract97_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract97" xlink:to="silo_UnlabeledAbstract97_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract98" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract98"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract98_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract98" xlink:to="silo_UnlabeledAbstract98_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract99" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract99"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract99_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract99" xlink:to="silo_UnlabeledAbstract99_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract100" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract100"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract100_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract100" xlink:to="silo_UnlabeledAbstract100_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract101" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract101"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract101_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract101" xlink:to="silo_UnlabeledAbstract101_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US">Supplemental Disclosure of Cash Flow Information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Taxes paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract102" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract102"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract102_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract102" xlink:to="silo_UnlabeledAbstract102_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CashPaidDuringThePeriodForAbstract" xlink:href="silo-20220630.xsd#silo_CashPaidDuringThePeriodForAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CashPaidDuringThePeriodForAbstract_lbl" xml:lang="en-US">Cash paid during the period for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashPaidDuringThePeriodForAbstract" xlink:to="silo_CashPaidDuringThePeriodForAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract103" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract103"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract103_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract103" xlink:to="silo_UnlabeledAbstract103_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_StockIssuedForFutureServices" xlink:href="silo-20220630.xsd#silo_StockIssuedForFutureServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_StockIssuedForFutureServices_lbl" xml:lang="en-US">Common stock issued for prepaid services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_StockIssuedForFutureServices" xlink:to="silo_StockIssuedForFutureServices_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockIssuedForPrepaidServices" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForPrepaidServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CommonStockIssuedForPrepaidServices_lbl" xml:lang="en-US">Common stock issued for Exchange of Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForPrepaidServices" xlink:to="silo_CommonStockIssuedForPrepaidServices_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock_lbl" xml:lang="en-US">Common stock issued for conversion of Redeemable Series A Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock" xlink:to="silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree" xlink:href="silo-20220630.xsd#silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree_lbl" xml:lang="en-US">Increase in equity investments recorded as deferred revenue pursuant to a patent license agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree" xlink:to="silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement" xlink:href="silo-20220630.xsd#silo_NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement_lbl" xml:lang="en-US">Note receivable issued in connection with asset purchase agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement" xlink:to="silo_NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CashFlowsFromOperatingActivitiesAbstract" xlink:href="silo-20220630.xsd#silo_CashFlowsFromOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CashFlowsFromOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashFlowsFromOperatingActivitiesAbstract" xlink:to="silo_CashFlowsFromOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:href="silo-20220630.xsd#silo_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="silo_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:href="silo-20220630.xsd#silo_ChangeInOperatingAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ChangeInOperatingAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="silo_ChangeInOperatingAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPayablesToBrokerDealers" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPayablesToBrokerDealers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInPayablesToBrokerDealers_lbl" xml:lang="en-US">Insurance payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPayablesToBrokerDealers" xlink:to="us-gaap_IncreaseDecreaseInPayablesToBrokerDealers_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract104" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract104"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract104_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract104" xlink:to="silo_UnlabeledAbstract104_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract105" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract105"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract105_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract105" xlink:to="silo_UnlabeledAbstract105_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CashFlowsFromInvestingActivitiesAbstract" xlink:href="silo-20220630.xsd#silo_CashFlowsFromInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CashFlowsFromInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashFlowsFromInvestingActivitiesAbstract" xlink:to="silo_CashFlowsFromInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract106" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract106"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract106_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract106" xlink:to="silo_UnlabeledAbstract106_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract107" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract107"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract107_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract107" xlink:to="silo_UnlabeledAbstract107_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CashFlowsFromFinancingActivitiesAbstract" xlink:href="silo-20220630.xsd#silo_CashFlowsFromFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CashFlowsFromFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashFlowsFromFinancingActivitiesAbstract" xlink:to="silo_CashFlowsFromFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract108" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract108"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract108_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract108" xlink:to="silo_UnlabeledAbstract108_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract109" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract109"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract109_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract109" xlink:to="silo_UnlabeledAbstract109_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract110" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract110"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract110_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract110" xlink:to="silo_UnlabeledAbstract110_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract111" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract111"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract111_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract111" xlink:to="silo_UnlabeledAbstract111_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract112" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract112"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract112_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract112" xlink:to="silo_UnlabeledAbstract112_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:href="silo-20220630.xsd#silo_SupplementalDisclosureOfCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SupplementalDisclosureOfCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:to="silo_SupplementalDisclosureOfCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CashPaidDuringThePeriodForAbstract0" xlink:href="silo-20220630.xsd#silo_CashPaidDuringThePeriodForAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CashPaidDuringThePeriodForAbstract0_lbl" xml:lang="en-US">Cash paid during the period for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashPaidDuringThePeriodForAbstract0" xlink:to="silo_CashPaidDuringThePeriodForAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract113" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract113"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract113_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract113" xlink:to="silo_UnlabeledAbstract113_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NonCashInvestingAndFinancingActivitiesAbstract" xlink:href="silo-20220630.xsd#silo_NonCashInvestingAndFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_NonCashInvestingAndFinancingActivitiesAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NonCashInvestingAndFinancingActivitiesAbstract" xlink:to="silo_NonCashInvestingAndFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Common stock issued for conversion of Series C preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp" xlink:href="silo-20220630.xsd#silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp_lbl" xml:lang="en-US">Initial fair value of stock options issued as stock-based compensation recorded as deferred compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp" xlink:to="silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Common stock warrants granted for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl" xml:lang="en-US">Interest expense - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Total provision for income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Provision for income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Deemed dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Net realized gain on equity investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US">Net unrealized loss (gain) loss on equity investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnRestructuringOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnRestructuringOfDebt_lbl" xml:lang="en-US">Gain on forgiveness of PPP note payable and accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="us-gaap_GainsLossesOnRestructuringOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Gain from disposal of assets from discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_LossFromDebtExtinguishment" xlink:href="silo-20220630.xsd#silo_LossFromDebtExtinguishment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="silo_LossFromDebtExtinguishment_lbl" xml:lang="en-US">Loss from debt extinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LossFromDebtExtinguishment" xlink:to="silo_LossFromDebtExtinguishment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US">Interest receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayment of advance from a related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfDerivatives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_lbl" xml:lang="en-US">Equity shares earned for lock up agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfDerivatives" xlink:to="us-gaap_GainLossOnSaleOfDerivatives_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl0" xml:lang="en-US">Series B</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl1" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl2" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl0" xml:lang="en-US">Series C</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl1" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl2" xml:lang="en-US">Series C Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND BUSINESS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock" xlink:href="silo-20220630.xsd#silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of anti-dilutive net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock" xlink:to="silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_IncomeLossPerCommonShareBasicAbstract" xlink:href="silo-20220630.xsd#silo_IncomeLossPerCommonShareBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_IncomeLossPerCommonShareBasicAbstract_lbl" xml:lang="en-US">Income (loss) per common share &#8212; basic:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IncomeLossPerCommonShareBasicAbstract" xlink:to="silo_IncomeLossPerCommonShareBasicAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_IncomelossFromContinuingOperation" xlink:href="silo-20220630.xsd#silo_IncomelossFromContinuingOperation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_IncomelossFromContinuingOperation_lbl" xml:lang="en-US">Income (loss) from continuing operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IncomelossFromContinuingOperation" xlink:to="silo_IncomelossFromContinuingOperation_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_IncomeLossFromDiscontinuedOperations" xlink:href="silo-20220630.xsd#silo_IncomeLossFromDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_IncomeLossFromDiscontinuedOperations_lbl" xml:lang="en-US">Loss from discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IncomeLossFromDiscontinuedOperations" xlink:to="silo_IncomeLossFromDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract114" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract114"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract114_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract114" xlink:to="silo_UnlabeledAbstract114_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract" xlink:href="silo-20220630.xsd#silo_NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US">Net income (loss) per common share available to common stockholders&#8211; basic:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract" xlink:to="silo_NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">From continuing operations (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_lbl" xml:lang="en-US">From discontinued operations (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract115" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract115"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract115_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract115" xlink:to="silo_UnlabeledAbstract115_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_IncomeLossPerCommonShareDilutedAbstract" xlink:href="silo-20220630.xsd#silo_IncomeLossPerCommonShareDilutedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_IncomeLossPerCommonShareDilutedAbstract_lbl" xml:lang="en-US">Income (loss) per common share &#8212; diluted:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IncomeLossPerCommonShareDilutedAbstract" xlink:to="silo_IncomeLossPerCommonShareDilutedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Add: interest expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NumeratorForLossFromContinuingOperationsPerCommonShareDiluted" xlink:href="silo-20220630.xsd#silo_NumeratorForLossFromContinuingOperationsPerCommonShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_NumeratorForLossFromContinuingOperationsPerCommonShareDiluted_lbl" xml:lang="en-US">Numerator for loss from continuing operations per common share &#8212; diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NumeratorForLossFromContinuingOperationsPerCommonShareDiluted" xlink:to="silo_NumeratorForLossFromContinuingOperationsPerCommonShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted" xlink:href="silo-20220630.xsd#silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted_lbl" xml:lang="en-US">Numerator for loss from discontinuing operations per common share &#8212; diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted" xlink:to="silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAllocatedToGeneralPartners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAllocatedToGeneralPartners"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAllocatedToGeneralPartners_lbl" xml:lang="en-US">Net loss per common share &#8211; diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAllocatedToGeneralPartners" xlink:to="us-gaap_NetIncomeLossAllocatedToGeneralPartners_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract116" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract116"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract116_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract116" xlink:to="silo_UnlabeledAbstract116_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_EffectOfDilutiveSecuritiesAbstract" xlink:href="silo-20220630.xsd#silo_EffectOfDilutiveSecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_EffectOfDilutiveSecuritiesAbstract_lbl" xml:lang="en-US">Effect of dilutive securities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EffectOfDilutiveSecuritiesAbstract" xlink:to="silo_EffectOfDilutiveSecuritiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AuctionMarketPreferredSecuritiesSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesSharesOutstanding_lbl" xml:lang="en-US">Preferred shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesSharesOutstanding" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding &#8211; diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract117" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract117"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract117_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract117" xlink:to="silo_UnlabeledAbstract117_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract" xlink:href="silo-20220630.xsd#silo_NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract_lbl" xml:lang="en-US">Net loss per common share available to common stockholders &#8211; diluted:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract" xlink:to="silo_NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US">From continuing operations (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_lbl" xml:lang="en-US">From discontinued operations (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE OF FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of assets and liabilities measured at fair value on a recurring basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_EquityInvestmentsAtFairValue" xlink:href="silo-20220630.xsd#silo_EquityInvestmentsAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_EquityInvestmentsAtFairValue_lbl" xml:lang="en-US">Equity investments consisting of common stock, at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquityInvestmentsAtFairValue" xlink:to="silo_EquityInvestmentsAtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock" xlink:href="silo-20220630.xsd#silo_ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of activity in the company&#8217;s equity investments, at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock" xlink:to="silo_ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AdditionsofEquitySecurities" xlink:href="silo-20220630.xsd#silo_AdditionsofEquitySecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AdditionsofEquitySecurities_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdditionsofEquitySecurities" xlink:to="silo_AdditionsofEquitySecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized gain</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl0" xml:lang="en-US">Unrealized (loss) gain</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">DISPOSAL OF THE DISCONTINUED OPERATIONS OF THE NFID BUSINESS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US">Schedule of financial data of the company&#8217;s gain from sale of the NFID business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AssetsAbstract0" xlink:href="silo-20220630.xsd#silo_AssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AssetsAbstract0_lbl" xml:lang="en-US">Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AssetsAbstract0" xlink:to="silo_AssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CurrentAssetsAbstract0" xlink:href="silo-20220630.xsd#silo_CurrentAssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CurrentAssetsAbstract0_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CurrentAssetsAbstract0" xlink:to="silo_CurrentAssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract118" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract118"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract118_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract118" xlink:to="silo_UnlabeledAbstract118_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CurrentLiabilitiesAbstract0" xlink:href="silo-20220630.xsd#silo_CurrentLiabilitiesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CurrentLiabilitiesAbstract0_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CurrentLiabilitiesAbstract0" xlink:to="silo_CurrentLiabilitiesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract119" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract119"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract119_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract119" xlink:to="silo_UnlabeledAbstract119_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NetAssetOfNFIDBusinessDisposed" xlink:href="silo-20220630.xsd#silo_NetAssetOfNFIDBusinessDisposed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_NetAssetOfNFIDBusinessDisposed_lbl" xml:lang="en-US">Net asset of NFID business disposed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NetAssetOfNFIDBusinessDisposed" xlink:to="silo_NetAssetOfNFIDBusinessDisposed_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ConsiderationInTheFormOfANoteReceivable" xlink:href="silo-20220630.xsd#silo_ConsiderationInTheFormOfANoteReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ConsiderationInTheFormOfANoteReceivable_lbl" xml:lang="en-US">Consideration in the form of a note receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConsiderationInTheFormOfANoteReceivable" xlink:to="silo_ConsiderationInTheFormOfANoteReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xml:lang="en-US">Gain from sale of NFID business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract120" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract120"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract120_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract120" xlink:to="silo_UnlabeledAbstract120_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" xml:lang="en-US">Schedule of operating result of discontinued operations of the NFID business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xml:lang="en-US">Product sales, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl" xml:lang="en-US">Gross profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_GainFromSaleOfNFIDBusiness" xlink:href="silo-20220630.xsd#silo_GainFromSaleOfNFIDBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_GainFromSaleOfNFIDBusiness_lbl" xml:lang="en-US">Gain from sale of NFID business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_GainFromSaleOfNFIDBusiness" xlink:to="silo_GainFromSaleOfNFIDBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US">Loss from discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">NOTES RECEIVABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">Schedule of notes receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0" xml:lang="en-US">Schedule of notes receivable net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesReceivableGross_lbl" xml:lang="en-US">Principal amounts of notes receivable at beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableGross" xlink:to="us-gaap_NotesReceivableGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesReceivableGross_lbl0" xml:lang="en-US">Principal amounts of notes receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableGross" xlink:to="us-gaap_NotesReceivableGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_AdditionalNotesReceivableIn2021" xlink:href="silo-20220630.xsd#silo_AdditionalNotesReceivableIn2021"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AdditionalNotesReceivableIn2021_lbl" xml:lang="en-US">Additional notes receivable in 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdditionalNotesReceivableIn2021" xlink:to="silo_AdditionalNotesReceivableIn2021_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silo_AdditionalNotesReceivableIn2021_lbl0" xml:lang="en-US">Additional notes receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdditionalNotesReceivableIn2021" xlink:to="silo_AdditionalNotesReceivableIn2021_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Total Notes receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_LessNotesReceivableNetCurrentPortion" xlink:href="silo-20220630.xsd#silo_LessNotesReceivableNetCurrentPortion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_LessNotesReceivableNetCurrentPortion_lbl" xml:lang="en-US">Less: notes receivable, net &#8211; current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LessNotesReceivableNetCurrentPortion" xlink:to="silo_LessNotesReceivableNetCurrentPortion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesReceivableNet_lbl" xml:lang="en-US">Notes receivable &#8211; non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableNet" xlink:to="us-gaap_NotesReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">NOTE PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_lbl" xml:lang="en-US">Schedule of interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:to="us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_DebtInstrumentsFaceAmount" xlink:href="silo-20220630.xsd#silo_DebtInstrumentsFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_DebtInstrumentsFaceAmount_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DebtInstrumentsFaceAmount" xlink:to="silo_DebtInstrumentsFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NotePayableLongTermPortion" xlink:href="silo-20220630.xsd#silo_NotePayableLongTermPortion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_NotePayableLongTermPortion_lbl" xml:lang="en-US">Note payable - long term portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NotePayableLongTermPortion" xlink:to="silo_NotePayableLongTermPortion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock options activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), balance beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options, Granted/Issued/ Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Number of Options, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted/Issued/ Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_WeightedAverageRemainingContractualTermYearsGrantedissued" xlink:href="silo-20220630.xsd#silo_WeightedAverageRemainingContractualTermYearsGrantedissued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_WeightedAverageRemainingContractualTermYearsGrantedissued_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Granted/Issued/ Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_WeightedAverageRemainingContractualTermYearsGrantedissued" xlink:to="silo_WeightedAverageRemainingContractualTermYearsGrantedissued_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AggregateIntrinsicValueGrantedIssuedForfeited1" xlink:href="silo-20220630.xsd#silo_AggregateIntrinsicValueGrantedIssuedForfeited1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AggregateIntrinsicValueGrantedIssuedForfeited1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Granted/Issued/ Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateIntrinsicValueGrantedIssuedForfeited1" xlink:to="silo_AggregateIntrinsicValueGrantedIssuedForfeited1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), balance ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options, Exercisable,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrant activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedComponsationNumberOfWarrantsForfeited" xlink:href="silo-20220630.xsd#silo_ShareBasedComponsationNumberOfWarrantsForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ShareBasedComponsationNumberOfWarrantsForfeited_lbl" xml:lang="en-US">Number of Warrants, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedComponsationNumberOfWarrantsForfeited" xlink:to="silo_ShareBasedComponsationNumberOfWarrantsForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited" xlink:href="silo-20220630.xsd#silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited" xlink:to="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedComponsationNumberOfWarrantsGranted" xlink:href="silo-20220630.xsd#silo_ShareBasedComponsationNumberOfWarrantsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ShareBasedComponsationNumberOfWarrantsGranted_lbl" xml:lang="en-US">Number of Warrants, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedComponsationNumberOfWarrantsGranted" xlink:to="silo_ShareBasedComponsationNumberOfWarrantsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Granted pursuant to employment agreement, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Granted/Forfeited, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted" xlink:href="silo-20220630.xsd#silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted" xlink:to="silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted_lbl0" xml:lang="en-US">Granted/Forfeited, Weighted Average Remaining Contractual Term (Years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted" xlink:to="silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_AggregateIntrinsicValueGranted" xlink:href="silo-20220630.xsd#silo_AggregateIntrinsicValueGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AggregateIntrinsicValueGranted_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateIntrinsicValueGranted" xlink:to="silo_AggregateIntrinsicValueGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silo_AggregateIntrinsicValueGranted_lbl0" xml:lang="en-US">Granted/Forfeited, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateIntrinsicValueGranted" xlink:to="silo_AggregateIntrinsicValueGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars" xlink:href="silo-20220630.xsd#silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars_lbl" xml:lang="en-US">Number of Warrants, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars" xlink:to="silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable" xlink:href="silo-20220630.xsd#silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable" xlink:to="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of effective statutory rate and the provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income tax (benefit) liability at U.S. statutory rate of 21%</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Income tax (benefit) liability &#8211; state</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain" xlink:href="silo-20220630.xsd#silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain_lbl" xml:lang="en-US">Permanent differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain" xlink:to="silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of net deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_DeferredTaxAssetsCapitalLossCarryforward" xlink:href="silo-20220630.xsd#silo_DeferredTaxAssetsCapitalLossCarryforward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_DeferredTaxAssetsCapitalLossCarryforward_lbl" xml:lang="en-US">Net capital loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeferredTaxAssetsCapitalLossCarryforward" xlink:to="silo_DeferredTaxAssetsCapitalLossCarryforward_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_DeferredTaxAssetGross" xlink:href="silo-20220630.xsd#silo_DeferredTaxAssetGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_DeferredTaxAssetGross_lbl" xml:lang="en-US">Total deferred tax asset (liability) before valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeferredTaxAssetGross" xlink:to="silo_DeferredTaxAssetGross_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_DeferredTaxAssetsValuationAllowances" xlink:href="silo-20220630.xsd#silo_DeferredTaxAssetsValuationAllowances"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_DeferredTaxAssetsValuationAllowances_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeferredTaxAssetsValuationAllowances" xlink:to="silo_DeferredTaxAssetsValuationAllowances_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">CONCENTRATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfMilestonePayments" xlink:href="silo-20220630.xsd#silo_ScheduleOfMilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ScheduleOfMilestonePayments_lbl" xml:lang="en-US">Schedule of milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfMilestonePayments" xlink:to="silo_ScheduleOfMilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_Milestone" xlink:href="silo-20220630.xsd#silo_Milestone"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_Milestone_lbl" xml:lang="en-US">Milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_Milestone" xlink:to="silo_Milestone_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_MilestonePayment" xlink:href="silo-20220630.xsd#silo_MilestonePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_MilestonePayment_lbl" xml:lang="en-US">Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MilestonePayment" xlink:to="silo_MilestonePayment_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfUMBMinimumRoyaltyPayments" xlink:href="silo-20220630.xsd#silo_ScheduleOfUMBMinimumRoyaltyPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ScheduleOfUMBMinimumRoyaltyPayments_lbl" xml:lang="en-US">Schedule of UMB minimum royalty payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfUMBMinimumRoyaltyPayments" xlink:to="silo_ScheduleOfUMBMinimumRoyaltyPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UMBYearDescription" xlink:href="silo-20220630.xsd#silo_UMBYearDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UMBYearDescription_lbl" xml:lang="en-US">Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UMBYearDescription" xlink:to="silo_UMBYearDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UMBPayment" xlink:href="silo-20220630.xsd#silo_UMBPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UMBPayment_lbl" xml:lang="en-US">Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UMBPayment" xlink:to="silo_UMBPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized" xlink:href="silo-20220630.xsd#silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized_lbl" xml:lang="en-US">Schedule of exclusive of value added tax to be amortized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized" xlink:to="silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_Payment" xlink:href="silo-20220630.xsd#silo_Payment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_Payment_lbl" xml:lang="en-US">Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_Payment" xlink:to="silo_Payment_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentDescription" xlink:href="silo-20220630.xsd#silo_PaymentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PaymentDescription_lbl" xml:lang="en-US">Payment description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentDescription" xlink:to="silo_PaymentDescription_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silo_PaymentDescription_lbl0" xml:lang="en-US">Payment, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentDescription" xlink:to="silo_PaymentDescription_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfShallPayUMB" xlink:href="silo-20220630.xsd#silo_ScheduleOfShallPayUMB"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ScheduleOfShallPayUMB_lbl" xml:lang="en-US">Schedule of shall pay UMB</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfShallPayUMB" xlink:to="silo_ScheduleOfShallPayUMB_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SponsoredPayment" xlink:href="silo-20220630.xsd#silo_SponsoredPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SponsoredPayment_lbl" xml:lang="en-US">Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SponsoredPayment" xlink:to="silo_SponsoredPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UnlabeledAbstract121" xlink:href="silo-20220630.xsd#silo_UnlabeledAbstract121"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UnlabeledAbstract121_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract121" xlink:to="silo_UnlabeledAbstract121_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_lbl" xml:lang="en-US">Loss from discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted as incentives, Number of Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted as incentives, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears" xlink:href="silo-20220630.xsd#silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears_lbl" xml:lang="en-US">Granted as incentives, Weighted Average Remaining Contractual Term (Years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears" xlink:to="silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_GrantedAsIncentivesAggregateIntrinsicValue" xlink:href="silo-20220630.xsd#silo_GrantedAsIncentivesAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_GrantedAsIncentivesAggregateIntrinsicValue_lbl" xml:lang="en-US">Granted as incentives, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_GrantedAsIncentivesAggregateIntrinsicValue" xlink:to="silo_GrantedAsIncentivesAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted pursuant to employment agreement, Number of Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:href="silo-20220630.xsd#silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Granted pursuant to employment agreement, Weighted Average Remaining Contractual Term (Years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:href="silo-20220630.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl" xml:lang="en-US">Granted pursuant to employment agreement, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm" xlink:href="silo-20220630.xsd#silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue" xlink:href="silo-20220630.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted/Forfeited, Number of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_YearsDescription" xlink:href="silo-20220630.xsd#silo_YearsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_YearsDescription_lbl" xml:lang="en-US">Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_YearsDescription" xlink:to="silo_YearsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_MinimumAnnualRoyalty" xlink:href="silo-20220630.xsd#silo_MinimumAnnualRoyalty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_MinimumAnnualRoyalty_lbl" xml:lang="en-US">Minimum Annual Royalty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MinimumAnnualRoyalty" xlink:to="silo_MinimumAnnualRoyalty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl0" xml:lang="en-US">Sales at original cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_FinanceLeaseLiabilities" xlink:href="silo-20220630.xsd#silo_FinanceLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="silo_FinanceLeaseLiabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FinanceLeaseLiabilities" xlink:to="silo_FinanceLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xml:lang="en-US">Total operating and other non-operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CollectionsOnNotesReceivable" xlink:href="silo-20220630.xsd#silo_CollectionsOnNotesReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="silo_CollectionsOnNotesReceivable_lbl" xml:lang="en-US">Collections on notes receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CollectionsOnNotesReceivable" xlink:to="silo_CollectionsOnNotesReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl" xml:lang="en-US">Less: allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NotrPayableLessCurrentPortion" xlink:href="silo-20220630.xsd#silo_NotrPayableLessCurrentPortion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="silo_NotrPayableLessCurrentPortion_lbl" xml:lang="en-US">Less: current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NotrPayableLessCurrentPortion" xlink:to="silo_NotrPayableLessCurrentPortion_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CollectionsOnNotesReceivables" xlink:href="silo-20220630.xsd#silo_CollectionsOnNotesReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="silo_CollectionsOnNotesReceivables_lbl" xml:lang="en-US">Collections on notes receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CollectionsOnNotesReceivables" xlink:to="silo_CollectionsOnNotesReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl" xml:lang="en-US">Less: allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_StockOptionsMember" xlink:href="silo-20220630.xsd#silo_StockOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_StockOptionsMember" xlink:to="silo_StockOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentOneMember" xlink:href="silo-20220630.xsd#silo_PaymentOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PaymentOneMember_lbl" xml:lang="en-US">Payment One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentOneMember" xlink:to="silo_PaymentOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentTwoMember" xlink:href="silo-20220630.xsd#silo_PaymentTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PaymentTwoMember_lbl" xml:lang="en-US">Payment Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentTwoMember" xlink:to="silo_PaymentTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentThreeMember" xlink:href="silo-20220630.xsd#silo_PaymentThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PaymentThreeMember_lbl" xml:lang="en-US">Payment Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentThreeMember" xlink:to="silo_PaymentThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentFourMember" xlink:href="silo-20220630.xsd#silo_PaymentFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PaymentFourMember_lbl" xml:lang="en-US">Payment Four [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentFourMember" xlink:to="silo_PaymentFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentFiveMember" xlink:href="silo-20220630.xsd#silo_PaymentFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PaymentFiveMember_lbl" xml:lang="en-US">Payment Five [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentFiveMember" xlink:to="silo_PaymentFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentSixMember" xlink:href="silo-20220630.xsd#silo_PaymentSixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PaymentSixMember_lbl" xml:lang="en-US">Payment One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentSixMember" xlink:to="silo_PaymentSixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentSevenMember" xlink:href="silo-20220630.xsd#silo_PaymentSevenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PaymentSevenMember_lbl" xml:lang="en-US">Payment Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentSevenMember" xlink:to="silo_PaymentSevenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentEightMember" xlink:href="silo-20220630.xsd#silo_PaymentEightMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PaymentEightMember_lbl" xml:lang="en-US">Payment Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentEightMember" xlink:to="silo_PaymentEightMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xml:lang="en-US">Receivable Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_TypesOfAgreementAxis" xlink:href="silo-20220630.xsd#silo_TypesOfAgreementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_TypesOfAgreementAxis_lbl" xml:lang="en-US">Type of Agreement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TypesOfAgreementAxis" xlink:to="silo_TypesOfAgreementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_TypesOfAgreementsAxis" xlink:href="silo-20220630.xsd#silo_TypesOfAgreementsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_TypesOfAgreementsAxis_lbl" xml:lang="en-US">Types Of Agreements [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TypesOfAgreementsAxis" xlink:to="silo_TypesOfAgreementsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_TypeOfAgreementAxis" xlink:href="silo-20220630.xsd#silo_TypeOfAgreementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_TypeOfAgreementAxis_lbl" xml:lang="en-US">Type of Agreement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TypeOfAgreementAxis" xlink:to="silo_TypeOfAgreementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalDeferredPurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalDeferredPurchasePrice_lbl" xml:lang="en-US">Purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalDeferredPurchasePrice" xlink:to="us-gaap_SupplementalDeferredPurchasePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalDeferredPurchasePrice_lbl0" xml:lang="en-US">Aggregate purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalDeferredPurchasePrice" xlink:to="us-gaap_SupplementalDeferredPurchasePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_promissoryNoteAmount" xlink:href="silo-20220630.xsd#silo_promissoryNoteAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_promissoryNoteAmount_lbl" xml:lang="en-US">Promissory note amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_promissoryNoteAmount" xlink:to="silo_promissoryNoteAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentInterestRate_lbl" xml:lang="en-US">Bears interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentMaturityDate" xlink:to="us-gaap_InvestmentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AssetPurchaseAgreementDescription" xlink:href="silo-20220630.xsd#silo_AssetPurchaseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AssetPurchaseAgreementDescription_lbl" xml:lang="en-US">Asset purchase agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AssetPurchaseAgreementDescription" xlink:to="silo_AssetPurchaseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations_lbl" xml:lang="en-US">Cash in operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Gross proceeds issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalUnits_lbl" xml:lang="en-US">Working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnits" xlink:to="us-gaap_CapitalUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Aggregate shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Federal deposit insurance corporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CashSPICInsuredAmount" xlink:href="silo-20220630.xsd#silo_CashSPICInsuredAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CashSPICInsuredAmount_lbl" xml:lang="en-US">Securities investor protection corporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashSPICInsuredAmount" xlink:to="silo_CashSPICInsuredAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FDICIndemnificationAssetCashPaymentsReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FDICIndemnificationAssetCashPaymentsReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FDICIndemnificationAssetCashPaymentsReceived_lbl" xml:lang="en-US">FDIC cash limits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FDICIndemnificationAssetCashPaymentsReceived" xlink:to="us-gaap_FDICIndemnificationAssetCashPaymentsReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US">Inventory write-down</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsUnappropriated" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsUnappropriated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsUnappropriated_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsUnappropriated" xlink:to="us-gaap_RetainedEarningsUnappropriated_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_WorkingCapital" xlink:href="silo-20220630.xsd#silo_WorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_WorkingCapital_lbl" xml:lang="en-US">Working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_WorkingCapital" xlink:to="silo_WorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets &#8211; non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_lbl" xml:lang="en-US">Net realized gain</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentOwnedAtCost_lbl" xml:lang="en-US">Basic investment cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtCost" xlink:to="us-gaap_InvestmentOwnedAtCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredSalesCommission" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredSalesCommission"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredSalesCommission_lbl" xml:lang="en-US">Commission on sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredSalesCommission" xlink:to="us-gaap_DeferredSalesCommission_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_EquityInvestmentsCost" xlink:href="silo-20220630.xsd#silo_EquityInvestmentsCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_EquityInvestmentsCost_lbl" xml:lang="en-US">Equity investments cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquityInvestmentsCost" xlink:to="silo_EquityInvestmentsCost_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CompanyReceivedShares" xlink:href="silo-20220630.xsd#silo_CompanyReceivedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CompanyReceivedShares_lbl" xml:lang="en-US">Company received shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CompanyReceivedShares" xlink:to="silo_CompanyReceivedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet_lbl" xml:lang="en-US">Common stock grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet" xlink:to="us-gaap_InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockGrantDateFairValuePerShare" xlink:href="silo-20220630.xsd#silo_CommonStockGrantDateFairValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CommonStockGrantDateFairValuePerShare_lbl" xml:lang="en-US">Common stock grant date fair value per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockGrantDateFairValuePerShare" xlink:to="silo_CommonStockGrantDateFairValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOnSaleOfInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainOnSaleOfInvestments_lbl" xml:lang="en-US">Equity investment Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOnSaleOfInvestments" xlink:to="us-gaap_GainOnSaleOfInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_GrossProceeds" xlink:href="silo-20220630.xsd#silo_GrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_GrossProceeds_lbl" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_GrossProceeds" xlink:to="silo_GrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_EquityMethodInvestment" xlink:href="silo-20220630.xsd#silo_EquityMethodInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_EquityMethodInvestment_lbl" xml:lang="en-US">Equity investments amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquityMethodInvestment" xlink:to="silo_EquityMethodInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PurchasePrice" xlink:href="silo-20220630.xsd#silo_PurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PurchasePrice_lbl" xml:lang="en-US">Purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PurchasePrice" xlink:to="silo_PurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl" xml:lang="en-US">Bearing interest rate percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturityDate" xlink:to="us-gaap_LongTermDebtMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PrincipalBalance" xlink:href="silo-20220630.xsd#silo_PrincipalBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PrincipalBalance_lbl" xml:lang="en-US">Note receivable - non current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PrincipalBalance" xlink:to="silo_PrincipalBalance_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AccruedInterestReceivable" xlink:href="silo-20220630.xsd#silo_AccruedInterestReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AccruedInterestReceivable_lbl" xml:lang="en-US">Accrued interest receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AccruedInterestReceivable" xlink:to="silo_AccruedInterestReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_TotalOutstandingBalanceReceivable" xlink:href="silo-20220630.xsd#silo_TotalOutstandingBalanceReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_TotalOutstandingBalanceReceivable_lbl" xml:lang="en-US">Total outstanding balance receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TotalOutstandingBalanceReceivable" xlink:to="silo_TotalOutstandingBalanceReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_lbl" xml:lang="en-US">Assets of discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PromissoryNotes" xlink:href="silo-20220630.xsd#silo_PromissoryNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PromissoryNotes_lbl" xml:lang="en-US">Promissory Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PromissoryNotes" xlink:to="silo_PromissoryNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xml:lang="en-US">Principal balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_RemainingBalanceOfPromissoryNoteReceivable" xlink:href="silo-20220630.xsd#silo_RemainingBalanceOfPromissoryNoteReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_RemainingBalanceOfPromissoryNoteReceivable_lbl" xml:lang="en-US">Remaining balance of promissory note receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RemainingBalanceOfPromissoryNoteReceivable" xlink:to="silo_RemainingBalanceOfPromissoryNoteReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Accrued interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Expired term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Allowance for doubtful account and bad debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NotesReceivablePurchasePrice" xlink:href="silo-20220630.xsd#silo_NotesReceivablePurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_NotesReceivablePurchasePrice_lbl" xml:lang="en-US">Notes receivable purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NotesReceivablePurchasePrice" xlink:to="silo_NotesReceivablePurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US">Interest receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts_lbl" xml:lang="en-US">Received payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts" xlink:to="us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NetBadDebtExpense" xlink:href="silo-20220630.xsd#silo_NetBadDebtExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_NetBadDebtExpense_lbl" xml:lang="en-US">Net bad debt expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NetBadDebtExpense" xlink:to="silo_NetBadDebtExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_BadDebtRecoveryCashPayment" xlink:href="silo-20220630.xsd#silo_BadDebtRecoveryCashPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_BadDebtRecoveryCashPayment_lbl" xml:lang="en-US">Bad debt recovery cash payment, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_BadDebtRecoveryCashPayment" xlink:to="silo_BadDebtRecoveryCashPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CollectedSettlementAgreement" xlink:href="silo-20220630.xsd#silo_CollectedSettlementAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CollectedSettlementAgreement_lbl" xml:lang="en-US">Collected settlement agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CollectedSettlementAgreement" xlink:to="silo_CollectedSettlementAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_RemainsCollectibleSettlementAgreement" xlink:href="silo-20220630.xsd#silo_RemainsCollectibleSettlementAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_RemainsCollectibleSettlementAgreement_lbl" xml:lang="en-US">Remains collectible settlement agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RemainsCollectibleSettlementAgreement" xlink:to="silo_RemainsCollectibleSettlementAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PromissoryNote" xlink:href="silo-20220630.xsd#silo_PromissoryNote"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PromissoryNote_lbl" xml:lang="en-US">Promissory note interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PromissoryNote" xlink:to="silo_PromissoryNote_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NoteReceivableNonCurrentAmount" xlink:href="silo-20220630.xsd#silo_NoteReceivableNonCurrentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_NoteReceivableNonCurrentAmount_lbl" xml:lang="en-US">Note receivable non-current amounted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NoteReceivableNonCurrentAmount" xlink:to="silo_NoteReceivableNonCurrentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_DebtInstrumentIncreasesAccruedInterest" xlink:href="silo-20220630.xsd#silo_DebtInstrumentIncreasesAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_DebtInstrumentIncreasesAccruedInterest_lbl" xml:lang="en-US">Accrued interest receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DebtInstrumentIncreasesAccruedInterest" xlink:to="silo_DebtInstrumentIncreasesAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireReceivables_lbl" xml:lang="en-US">Total receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireReceivables" xlink:to="us-gaap_PaymentsToAcquireReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_PromissoryNoteAgreement" xlink:href="silo-20220630.xsd#silo_PromissoryNoteAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PromissoryNoteAgreement_lbl" xml:lang="en-US">Promissory note agreement note deposit and credit towards acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PromissoryNoteAgreement" xlink:to="silo_PromissoryNoteAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl" xml:lang="en-US">Interest rate per annum percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFixedInterestRate" xlink:to="us-gaap_DerivativeFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US">Increased interest rate per annum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ReceivedShares" xlink:href="silo-20220630.xsd#silo_ReceivedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ReceivedShares_lbl" xml:lang="en-US">Received shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ReceivedShares" xlink:to="silo_ReceivedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AggregateOfNotesReceivablePurchasePrice" xlink:href="silo-20220630.xsd#silo_AggregateOfNotesReceivablePurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AggregateOfNotesReceivablePurchasePrice_lbl" xml:lang="en-US">Aggregate of notes receivable purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateOfNotesReceivablePurchasePrice" xlink:to="silo_AggregateOfNotesReceivablePurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_RecoveredAggregateBadDebt" xlink:href="silo-20220630.xsd#silo_RecoveredAggregateBadDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_RecoveredAggregateBadDebt_lbl" xml:lang="en-US">Recovered aggregate bad debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RecoveredAggregateBadDebt" xlink:to="silo_RecoveredAggregateBadDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_RecoveredBadDebt" xlink:href="silo-20220630.xsd#silo_RecoveredBadDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_RecoveredBadDebt_lbl" xml:lang="en-US">Recovered bad debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RecoveredBadDebt" xlink:to="silo_RecoveredBadDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease_lbl" xml:lang="en-US">Bad debt allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease" xlink:to="us-gaap_LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_RemainsCollectibleSettlementAgreementAmountReserved" xlink:href="silo-20220630.xsd#silo_RemainsCollectibleSettlementAgreementAmountReserved"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_RemainsCollectibleSettlementAgreementAmountReserved_lbl" xml:lang="en-US">Remains collectible settlement agreement amount reserved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RemainsCollectibleSettlementAgreementAmountReserved" xlink:to="silo_RemainsCollectibleSettlementAgreementAmountReserved_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Received amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableInterestBearingInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate_lbl" xml:lang="en-US">Interest-bearing unsecured</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNotesPayable_lbl" xml:lang="en-US">Note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xml:lang="en-US">Authorized number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ConvertablePreferredStock" xlink:href="silo-20220630.xsd#silo_ConvertablePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ConvertablePreferredStock_lbl" xml:lang="en-US">Converted preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConvertablePreferredStock" xlink:to="silo_ConvertablePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Convertible common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US">Redemption value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ExchangeAgreementsDescription" xlink:href="silo-20220630.xsd#silo_ExchangeAgreementsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ExchangeAgreementsDescription_lbl" xml:lang="en-US">Exchange agreements, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ExchangeAgreementsDescription" xlink:to="silo_ExchangeAgreementsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares_lbl" xml:lang="en-US">Convertible preferred stock stated value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares" xlink:to="silo_CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PreferredStockOutstandingDescription" xlink:href="silo-20220630.xsd#silo_PreferredStockOutstandingDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PreferredStockOutstandingDescription_lbl" xml:lang="en-US">Preferred stock outstanding, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredStockOutstandingDescription" xlink:to="silo_PreferredStockOutstandingDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConversionBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConversionBasis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xml:lang="en-US">Preferred stock conversion, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConversionBasis" xlink:to="us-gaap_PreferredStockConversionBasis_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_WarrantsTerm" xlink:href="silo-20220630.xsd#silo_WarrantsTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_WarrantsTerm_lbl" xml:lang="en-US">Warrants term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_WarrantsTerm" xlink:to="silo_WarrantsTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SubsequentFinancingPercentage" xlink:href="silo-20220630.xsd#silo_SubsequentFinancingPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SubsequentFinancingPercentage_lbl" xml:lang="en-US">Subsequent financing, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SubsequentFinancingPercentage" xlink:to="silo_SubsequentFinancingPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ObligationPercentage" xlink:href="silo-20220630.xsd#silo_ObligationPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ObligationPercentage_lbl" xml:lang="en-US">Obligation percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ObligationPercentage" xlink:to="silo_ObligationPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PlacementAgentWarrantsDescriptoin" xlink:href="silo-20220630.xsd#silo_PlacementAgentWarrantsDescriptoin"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PlacementAgentWarrantsDescriptoin_lbl" xml:lang="en-US">Placement agent warrants, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PlacementAgentWarrantsDescriptoin" xlink:to="silo_PlacementAgentWarrantsDescriptoin_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AggregateGrantDateFairValueOfPlacementAgentWarrants" xlink:href="silo-20220630.xsd#silo_AggregateGrantDateFairValueOfPlacementAgentWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AggregateGrantDateFairValueOfPlacementAgentWarrants_lbl" xml:lang="en-US">Aggregate grant date fair value of placement agent warrants (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateGrantDateFairValueOfPlacementAgentWarrants" xlink:to="silo_AggregateGrantDateFairValueOfPlacementAgentWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl" xml:lang="en-US">Subscription receivable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_TotalSubscriptionReceivableValue" xlink:href="silo-20220630.xsd#silo_TotalSubscriptionReceivableValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_TotalSubscriptionReceivableValue_lbl" xml:lang="en-US">Total subscription receivable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TotalSubscriptionReceivableValue" xlink:to="silo_TotalSubscriptionReceivableValue_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PlacementAgentFees" xlink:href="silo-20220630.xsd#silo_PlacementAgentFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PlacementAgentFees_lbl" xml:lang="en-US">Placement agent fees (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PlacementAgentFees" xlink:to="silo_PlacementAgentFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOwnershipInterestsOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts_lbl" xml:lang="en-US">Other offering expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:to="us-gaap_OtherOwnershipInterestsOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Total net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_InvestorInvestedAmount" xlink:href="silo-20220630.xsd#silo_InvestorInvestedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_InvestorInvestedAmount_lbl" xml:lang="en-US">Investor invested amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_InvestorInvestedAmount" xlink:to="silo_InvestorInvestedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionContractorLiquidityCharacteristic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionContractorLiquidityCharacteristic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionContractorLiquidityCharacteristic_lbl" xml:lang="en-US">Liquidity damage, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionContractorLiquidityCharacteristic" xlink:to="us-gaap_ConstructionContractorLiquidityCharacteristic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_DeemedDividend" xlink:href="silo-20220630.xsd#silo_DeemedDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_DeemedDividend_lbl" xml:lang="en-US">Deemed dividend (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeemedDividend" xlink:to="silo_DeemedDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Common stock, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ConvertibleLongTermNotesPayables" xlink:href="silo-20220630.xsd#silo_ConvertibleLongTermNotesPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ConvertibleLongTermNotesPayables_lbl" xml:lang="en-US">Convertible promissory notes (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConvertibleLongTermNotesPayables" xlink:to="silo_ConvertibleLongTermNotesPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_WarrantIssued" xlink:href="silo-20220630.xsd#silo_WarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_WarrantIssued_lbl" xml:lang="en-US">Warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_WarrantIssued" xlink:to="silo_WarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Granted warrants to purchase shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommonStockServiceDescription" xlink:href="silo-20220630.xsd#silo_CommonStockServiceDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CommonStockServiceDescription_lbl" xml:lang="en-US">Warrant, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockServiceDescription" xlink:to="silo_CommonStockServiceDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xml:lang="en-US">Stock-based compensation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PurchaseAgreementsDescription" xlink:href="silo-20220630.xsd#silo_PurchaseAgreementsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PurchaseAgreementsDescription_lbl" xml:lang="en-US">Purchase agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PurchaseAgreementsDescription" xlink:to="silo_PurchaseAgreementsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesAuthorized_lbl" xml:lang="en-US">Shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesAuthorized" xlink:to="us-gaap_ExcessStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US">Designated shares of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PreferredStockStatedValue" xlink:href="silo-20220630.xsd#silo_PreferredStockStatedValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PreferredStockStatedValue_lbl" xml:lang="en-US">Preferred stock, stated value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredStockStatedValue" xlink:to="silo_PreferredStockStatedValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xml:lang="en-US">Convertible preferred stock, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrant to purchase shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Offering expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPreferredStockCash_lbl" xml:lang="en-US">Deemed dividend (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockCash" xlink:to="us-gaap_DividendsPreferredStockCash_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_InvestorInvestedAmountPercentage" xlink:href="silo-20220630.xsd#silo_InvestorInvestedAmountPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_InvestorInvestedAmountPercentage_lbl" xml:lang="en-US">Subsequent financing, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_InvestorInvestedAmountPercentage" xlink:to="silo_InvestorInvestedAmountPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares of common stock reserved and avail for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Aggregate of incentive stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock option value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Fair value of unvested stock option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xml:lang="en-US">Fair value of the unvested stock options (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl0" xml:lang="en-US">Fair value of the unvested stock option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent_lbl" xml:lang="en-US">Issuance of deferred compensation balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Employment agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US">Stock option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl0" xml:lang="en-US">Stock option (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Fair value of stock option (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl0" xml:lang="en-US">Fair value of stock option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based Compensation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Stock-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Deferred compensation balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Deferred compensation balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Grant date price per warrant (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Warrant value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Stock price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VentureCapitalGainsLossesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VentureCapitalGainsLossesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VentureCapitalGainsLossesNet_lbl" xml:lang="en-US">Company had a capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VentureCapitalGainsLossesNet" xlink:to="us-gaap_VentureCapitalGainsLossesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NetCapitalLossCarryForward" xlink:href="silo-20220630.xsd#silo_NetCapitalLossCarryForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_NetCapitalLossCarryForward_lbl" xml:lang="en-US">Net capital loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NetCapitalLossCarryForward" xlink:to="silo_NetCapitalLossCarryForward_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_GainLossOnSaleOfCapitalLeaseNet" xlink:href="silo-20220630.xsd#silo_GainLossOnSaleOfCapitalLeaseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_GainLossOnSaleOfCapitalLeaseNet_lbl" xml:lang="en-US">GainLossOnSaleOfCapitalLeasesNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_GainLossOnSaleOfCapitalLeaseNet" xlink:to="silo_GainLossOnSaleOfCapitalLeaseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AggregateEstimatedNetOperatingLoss" xlink:href="silo-20220630.xsd#silo_AggregateEstimatedNetOperatingLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AggregateEstimatedNetOperatingLoss_lbl" xml:lang="en-US">Aggregate estimated net operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateEstimatedNetOperatingLoss" xlink:to="silo_AggregateEstimatedNetOperatingLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_DescriptionOfIncomeTaxDescription" xlink:href="silo-20220630.xsd#silo_DescriptionOfIncomeTaxDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_DescriptionOfIncomeTaxDescription_lbl" xml:lang="en-US">Description of Income Tax Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DescriptionOfIncomeTaxDescription" xlink:to="silo_DescriptionOfIncomeTaxDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_lbl" xml:lang="en-US">Valuation allowance on deferred tax asset benefit, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ConcentrationsRiskPercentage1" xlink:href="silo-20220630.xsd#silo_ConcentrationsRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ConcentrationsRiskPercentage1_lbl" xml:lang="en-US">Concentration risk percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConcentrationsRiskPercentage1" xlink:to="silo_ConcentrationsRiskPercentage1_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_EmploymentAgreementDescription" xlink:href="silo-20220630.xsd#silo_EmploymentAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_EmploymentAgreementDescription_lbl" xml:lang="en-US">Employment agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EmploymentAgreementDescription" xlink:to="silo_EmploymentAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_lbl" xml:lang="en-US">Salary was increased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" xlink:to="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_LicenseFee" xlink:href="silo-20220630.xsd#silo_LicenseFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_LicenseFee_lbl" xml:lang="en-US">License fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LicenseFee" xlink:to="silo_LicenseFee_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommercialSaleTerm" xlink:href="silo-20220630.xsd#silo_CommercialSaleTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CommercialSaleTerm_lbl" xml:lang="en-US">Commercial sale term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommercialSaleTerm" xlink:to="silo_CommercialSaleTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_LicenseAgreementExpire" xlink:href="silo-20220630.xsd#silo_LicenseAgreementExpire"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_LicenseAgreementExpire_lbl" xml:lang="en-US">License agreement expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LicenseAgreementExpire" xlink:to="silo_LicenseAgreementExpire_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SublicenseIncomeDescription" xlink:href="silo-20220630.xsd#silo_SublicenseIncomeDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SublicenseIncomeDescription_lbl" xml:lang="en-US">Sublicense income, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseIncomeDescription" xlink:to="silo_SublicenseIncomeDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_LicenseAgreementDescription" xlink:href="silo-20220630.xsd#silo_LicenseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_LicenseAgreementDescription_lbl" xml:lang="en-US">License agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LicenseAgreementDescription" xlink:to="silo_LicenseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_RoyaltyPaymentsDescription" xlink:href="silo-20220630.xsd#silo_RoyaltyPaymentsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_RoyaltyPaymentsDescription_lbl" xml:lang="en-US">Royalty payments, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RoyaltyPaymentsDescription" xlink:to="silo_RoyaltyPaymentsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SublicenseIncomePercentage" xlink:href="silo-20220630.xsd#silo_SublicenseIncomePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SublicenseIncomePercentage_lbl" xml:lang="en-US">Sublicense income, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseIncomePercentage" xlink:to="silo_SublicenseIncomePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SublicenseAgreementAmountPaid" xlink:href="silo-20220630.xsd#silo_SublicenseAgreementAmountPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SublicenseAgreementAmountPaid_lbl" xml:lang="en-US">Sublicense agreement amount paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseAgreementAmountPaid" xlink:to="silo_SublicenseAgreementAmountPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_OtherDepreciationsAndAmortization" xlink:href="silo-20220630.xsd#silo_OtherDepreciationsAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_OtherDepreciationsAndAmortization_lbl" xml:lang="en-US">Recognized amortization expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OtherDepreciationsAndAmortization" xlink:to="silo_OtherDepreciationsAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentOfSponsoredResearchAmount" xlink:href="silo-20220630.xsd#silo_PaymentOfSponsoredResearchAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PaymentOfSponsoredResearchAmount_lbl" xml:lang="en-US">Payment of sponsored research amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentOfSponsoredResearchAmount" xlink:to="silo_PaymentOfSponsoredResearchAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PrepaidExpenses" xlink:href="silo-20220630.xsd#silo_PrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses &#8211; non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PrepaidExpenses" xlink:to="silo_PrepaidExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NonrefundableCashPayment" xlink:href="silo-20220630.xsd#silo_NonrefundableCashPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_NonrefundableCashPayment_lbl" xml:lang="en-US">Non-refundable cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NonrefundableCashPayment" xlink:to="silo_NonrefundableCashPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NetSalePercentage" xlink:href="silo-20220630.xsd#silo_NetSalePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_NetSalePercentage_lbl" xml:lang="en-US">Net sale percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NetSalePercentage" xlink:to="silo_NetSalePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_LicensorShare" xlink:href="silo-20220630.xsd#silo_LicensorShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_LicensorShare_lbl" xml:lang="en-US">Licensor share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LicensorShare" xlink:to="silo_LicensorShare_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AggregateOfConvertedShares" xlink:href="silo-20220630.xsd#silo_AggregateOfConvertedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AggregateOfConvertedShares_lbl" xml:lang="en-US">Aggregate of converted shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateOfConvertedShares" xlink:to="silo_AggregateOfConvertedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_RevenueTerm" xlink:href="silo-20220630.xsd#silo_RevenueTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_RevenueTerm_lbl" xml:lang="en-US">Revenue term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RevenueTerm" xlink:to="silo_RevenueTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NumberOfVotingShares" xlink:href="silo-20220630.xsd#silo_NumberOfVotingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_NumberOfVotingShares_lbl" xml:lang="en-US">Number of voting shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NumberOfVotingShares" xlink:to="silo_NumberOfVotingShares_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ReverseStockSplitVoteDescription" xlink:href="silo-20220630.xsd#silo_ReverseStockSplitVoteDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ReverseStockSplitVoteDescription_lbl" xml:lang="en-US">Reverse stock split vote, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ReverseStockSplitVoteDescription" xlink:to="silo_ReverseStockSplitVoteDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CashReceived" xlink:href="silo-20220630.xsd#silo_CashReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CashReceived_lbl" xml:lang="en-US">Cash received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashReceived" xlink:to="silo_CashReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SecuritiesReceived" xlink:href="silo-20220630.xsd#silo_SecuritiesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SecuritiesReceived_lbl" xml:lang="en-US">Securities received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SecuritiesReceived" xlink:to="silo_SecuritiesReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xml:lang="en-US">Recognized revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceServicesRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceServicesRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InsuranceServicesRevenue_lbl" xml:lang="en-US">Recognized revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceServicesRevenue" xlink:to="us-gaap_InsuranceServicesRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_DeferredRevenueLongtermPortion" xlink:href="silo-20220630.xsd#silo_DeferredRevenueLongtermPortion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_DeferredRevenueLongtermPortion_lbl" xml:lang="en-US">Revenue long term portion amounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeferredRevenueLongtermPortion" xlink:to="silo_DeferredRevenueLongtermPortion_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ConsiderationFeePayablePercentage" xlink:href="silo-20220630.xsd#silo_ConsiderationFeePayablePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ConsiderationFeePayablePercentage_lbl" xml:lang="en-US">Consideration fee payable percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConsiderationFeePayablePercentage" xlink:to="silo_ConsiderationFeePayablePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_UpfrontLicenseFees" xlink:href="silo-20220630.xsd#silo_UpfrontLicenseFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_UpfrontLicenseFees_lbl" xml:lang="en-US">Upfront license fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UpfrontLicenseFees" xlink:to="silo_UpfrontLicenseFees_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_FirstCommercialSale" xlink:href="silo-20220630.xsd#silo_FirstCommercialSale"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_FirstCommercialSale_lbl" xml:lang="en-US">First commercial sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FirstCommercialSale" xlink:to="silo_FirstCommercialSale_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AgreementShallExpire" xlink:href="silo-20220630.xsd#silo_AgreementShallExpire"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AgreementShallExpire_lbl" xml:lang="en-US">Agreement shall expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AgreementShallExpire" xlink:to="silo_AgreementShallExpire_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_RecognizedRevenues" xlink:href="silo-20220630.xsd#silo_RecognizedRevenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_RecognizedRevenues_lbl" xml:lang="en-US">Recognized revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RecognizedRevenues" xlink:to="silo_RecognizedRevenues_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYRCCyonMiwgdQ2lJYzdzUOv9fI1l/VI08eZ/jN8gtVkovQNM+Tg8ySqLg3+WC1g4h34l8wpPDRKEpvN2sEoV7GBwsfUtZ7wPjtnRwjx//zhaHDazrcKZSY+odwB4qGm1MOd/qfdmKbOaTaPPe9bPa/02wjXfGOjU12GfRhsnE31flgx8L3rlukEYrkR2oqiMiwibi4CfTWUA==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLongTermDebt_lbl" xml:lang="en-US">Deferred revenue long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebt" xlink:to="us-gaap_OtherLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManagementFeePayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementFeePayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ManagementFeePayable_lbl" xml:lang="en-US">Total fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeePayable" xlink:to="us-gaap_ManagementFeePayable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SponsoredStudyAgreementDescription" xlink:href="silo-20220630.xsd#silo_SponsoredStudyAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SponsoredStudyAgreementDescription_lbl" xml:lang="en-US">Sponsored study agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SponsoredStudyAgreementDescription" xlink:to="silo_SponsoredStudyAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SublicenseAmountPaid" xlink:href="silo-20220630.xsd#silo_SublicenseAmountPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SublicenseAmountPaid_lbl" xml:lang="en-US">Sublicense amount paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseAmountPaid" xlink:to="silo_SublicenseAmountPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SponsoredResearchAgreementDescription" xlink:href="silo-20220630.xsd#silo_SponsoredResearchAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SponsoredResearchAgreementDescription_lbl" xml:lang="en-US">Sponsored research agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SponsoredResearchAgreementDescription" xlink:to="silo_SponsoredResearchAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CompanyPaidCash" xlink:href="silo-20220630.xsd#silo_CompanyPaidCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CompanyPaidCash_lbl" xml:lang="en-US">Company paid cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CompanyPaidCash" xlink:to="silo_CompanyPaidCash_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PursuantTerms" xlink:href="silo-20220630.xsd#silo_PursuantTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PursuantTerms_lbl" xml:lang="en-US">Pursuant terms, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PursuantTerms" xlink:to="silo_PursuantTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PaymentOfUniversity" xlink:href="silo-20220630.xsd#silo_PaymentOfUniversity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PaymentOfUniversity_lbl" xml:lang="en-US">Payment of university</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentOfUniversity" xlink:to="silo_PaymentOfUniversity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization_lbl" xml:lang="en-US">Amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization" xlink:to="us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expense and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseOtherNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent_lbl" xml:lang="en-US">Prepaid expenses non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRefundableFeesProceeds" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundableFeesProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerRefundableFeesProceeds_lbl" xml:lang="en-US">Non refundable fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRefundableFeesProceeds" xlink:to="us-gaap_CustomerRefundableFeesProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RecognitionOfDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecognitionOfDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RecognitionOfDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecognitionOfDeferredRevenue" xlink:to="us-gaap_RecognitionOfDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_DeferredRevenueLongtermPortionAmounted" xlink:href="silo-20220630.xsd#silo_DeferredRevenueLongtermPortionAmounted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_DeferredRevenueLongtermPortionAmounted_lbl" xml:lang="en-US">Deferred revenue long-term portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeferredRevenueLongtermPortionAmounted" xlink:to="silo_DeferredRevenueLongtermPortionAmounted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_lbl" xml:lang="en-US">Company paid second payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AgreementDescription" xlink:href="silo-20220630.xsd#silo_AgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AgreementDescription_lbl" xml:lang="en-US">Agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AgreementDescription" xlink:to="silo_AgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AnnualBaseSalary" xlink:href="silo-20220630.xsd#silo_AnnualBaseSalary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AnnualBaseSalary_lbl" xml:lang="en-US">Annual salary amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AnnualBaseSalary" xlink:to="silo_AnnualBaseSalary_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventDescription_lbl" xml:lang="en-US">Subsequent event, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_TotalOfSharesOfCommonStock" xlink:href="silo-20220630.xsd#silo_TotalOfSharesOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_TotalOfSharesOfCommonStock_lbl" xml:lang="en-US">Total shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TotalOfSharesOfCommonStock" xlink:to="silo_TotalOfSharesOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Principles of consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_LiquidityPolicyTextBlock" xlink:href="silo-20220630.xsd#silo_LiquidityPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LiquidityPolicyTextBlock" xlink:to="silo_LiquidityPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Notes Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_EquityInvestmentsAtFairValuePolicyTextBlock" xlink:href="silo-20220630.xsd#silo_EquityInvestmentsAtFairValuePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_EquityInvestmentsAtFairValuePolicyTextBlock_lbl" xml:lang="en-US">Equity Investments, at Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquityInvestmentsAtFairValuePolicyTextBlock" xlink:to="silo_EquityInvestmentsAtFairValuePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_EquityInvestmentsAtCostPolicyTextBlock" xlink:href="silo-20220630.xsd#silo_EquityInvestmentsAtCostPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_EquityInvestmentsAtCostPolicyTextBlock_lbl" xml:lang="en-US">Equity Investments, at Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquityInvestmentsAtCostPolicyTextBlock" xlink:to="silo_EquityInvestmentsAtCostPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CostOfRevenuesPolicyTextBlock" xlink:href="silo-20220630.xsd#silo_CostOfRevenuesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_CostOfRevenuesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CostOfRevenuesPolicyTextBlock" xlink:to="silo_CostOfRevenuesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:to="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_DatChatIncMember" xlink:href="silo-20220630.xsd#silo_DatChatIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_DatChatIncMember_lbl" xml:lang="en-US">DatChat, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DatChatIncMember" xlink:to="silo_DatChatIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AikidoPharmaIncMember" xlink:href="silo-20220630.xsd#silo_AikidoPharmaIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AikidoPharmaIncMember_lbl" xml:lang="en-US">Aikido Pharma, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AikidoPharmaIncMember" xlink:to="silo_AikidoPharmaIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_HomeBistroIncMember" xlink:href="silo-20220630.xsd#silo_HomeBistroIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_HomeBistroIncMember_lbl" xml:lang="en-US">Home Bistro, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_HomeBistroIncMember" xlink:to="silo_HomeBistroIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PromissoryNoteReceivableAgreementMember" xlink:href="silo-20220630.xsd#silo_PromissoryNoteReceivableAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PromissoryNoteReceivableAgreementMember_lbl" xml:lang="en-US">Promissory Note Receivable Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PromissoryNoteReceivableAgreementMember" xlink:to="silo_PromissoryNoteReceivableAgreementMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silo_PromissoryNoteReceivableAgreementMember_lbl0" xml:lang="en-US">Promissory note receivable agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PromissoryNoteReceivableAgreementMember" xlink:to="silo_PromissoryNoteReceivableAgreementMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesReceivableMember_lbl" xml:lang="en-US">Notes Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableMember" xlink:to="us-gaap_NotesReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PurchaseAgreementMember" xlink:href="silo-20220630.xsd#silo_PurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PurchaseAgreementMember" xlink:to="silo_PurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LayawaySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LayawaySaleMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LayawaySaleMember_lbl" xml:lang="en-US">Six-monthly installments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LayawaySaleMember" xlink:to="us-gaap_LayawaySaleMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PaycheckProtectionProgramMember" xlink:href="silo-20220630.xsd#silo_PaycheckProtectionProgramMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PaycheckProtectionProgramMember_lbl" xml:lang="en-US">Paycheck Protection Program [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaycheckProtectionProgramMember" xlink:to="silo_PaycheckProtectionProgramMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_SeriesCConvertiblePreferredStockMember" xlink:href="silo-20220630.xsd#silo_SeriesCConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SeriesCConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SeriesCConvertiblePreferredStockMember" xlink:to="silo_SeriesCConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SeriesCConversionPriceMember" xlink:href="silo-20220630.xsd#silo_SeriesCConversionPriceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SeriesCConversionPriceMember_lbl" xml:lang="en-US">Series C Conversion Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SeriesCConversionPriceMember" xlink:to="silo_SeriesCConversionPriceMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SeriesCPurchaseAgreementsMember" xlink:href="silo-20220630.xsd#silo_SeriesCPurchaseAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SeriesCPurchaseAgreementsMember_lbl" xml:lang="en-US">Series C Purchase Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SeriesCPurchaseAgreementsMember" xlink:to="silo_SeriesCPurchaseAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SubscriptionAgreementsMember" xlink:href="silo-20220630.xsd#silo_SubscriptionAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SubscriptionAgreementsMember_lbl" xml:lang="en-US">Subscription Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SubscriptionAgreementsMember" xlink:to="silo_SubscriptionAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SecuritiesPurchaseAgreementsMember" xlink:href="silo-20220630.xsd#silo_SecuritiesPurchaseAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SecuritiesPurchaseAgreementsMember_lbl" xml:lang="en-US">Securities Purchase Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SecuritiesPurchaseAgreementsMember" xlink:to="silo_SecuritiesPurchaseAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AdvisoryAgreementsMember" xlink:href="silo-20220630.xsd#silo_AdvisoryAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AdvisoryAgreementsMember_lbl" xml:lang="en-US">Advisory Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdvisoryAgreementsMember" xlink:to="silo_AdvisoryAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ConsultingAgreementMember" xlink:href="silo-20220630.xsd#silo_ConsultingAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConsultingAgreementMember" xlink:to="silo_ConsultingAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_EmploymentAgreementMember" xlink:href="silo-20220630.xsd#silo_EmploymentAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_EmploymentAgreementMember_lbl" xml:lang="en-US">Employment Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EmploymentAgreementMember" xlink:to="silo_EmploymentAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ExchangeAgreementsMember" xlink:href="silo-20220630.xsd#silo_ExchangeAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ExchangeAgreementsMember_lbl" xml:lang="en-US">Exchange Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ExchangeAgreementsMember" xlink:to="silo_ExchangeAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_PlacementAgentWarrantsMember" xlink:href="silo-20220630.xsd#silo_PlacementAgentWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_PlacementAgentWarrantsMember_lbl" xml:lang="en-US">Placement Agent Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PlacementAgentWarrantsMember" xlink:to="silo_PlacementAgentWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_OmnibusEquityIncentivePlanMember" xlink:href="silo-20220630.xsd#silo_OmnibusEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_OmnibusEquityIncentivePlanMember_lbl" xml:lang="en-US">Omnibus Equity incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OmnibusEquityIncentivePlanMember" xlink:to="silo_OmnibusEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board Granted [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_IncentiveStockOptionMember" xlink:href="silo-20220630.xsd#silo_IncentiveStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_IncentiveStockOptionMember_lbl" xml:lang="en-US">Incentive Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IncentiveStockOptionMember" xlink:to="silo_IncentiveStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_OneLicensorMember" xlink:href="silo-20220630.xsd#silo_OneLicensorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_OneLicensorMember_lbl" xml:lang="en-US">One Licensee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OneLicensorMember" xlink:to="silo_OneLicensorMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="silo_OneLicensorMember_lbl0" xml:lang="en-US">One Licensor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OneLicensorMember" xlink:to="silo_OneLicensorMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_VendorConcentrationsMember" xlink:href="silo-20220630.xsd#silo_VendorConcentrationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_VendorConcentrationsMember_lbl" xml:lang="en-US">Vendor Concentrations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_VendorConcentrationsMember" xlink:to="silo_VendorConcentrationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_OneLicenseeMember" xlink:href="silo-20220630.xsd#silo_OneLicenseeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_OneLicenseeMember_lbl" xml:lang="en-US">One Licensee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OneLicenseeMember" xlink:to="silo_OneLicenseeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SublicenseAgreementMember" xlink:href="silo-20220630.xsd#silo_SublicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_SublicenseAgreementMember_lbl" xml:lang="en-US">Sublicense Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseAgreementMember" xlink:to="silo_SublicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_MasterLincenseAgreementMember" xlink:href="silo-20220630.xsd#silo_MasterLincenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_MasterLincenseAgreementMember_lbl" xml:lang="en-US">Master License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MasterLincenseAgreementMember" xlink:to="silo_MasterLincenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ColumbiaUniversityMember" xlink:href="silo-20220630.xsd#silo_ColumbiaUniversityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_ColumbiaUniversityMember_lbl" xml:lang="en-US">Columbia University [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ColumbiaUniversityMember" xlink:to="silo_ColumbiaUniversityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_JVAgreementMember" xlink:href="silo-20220630.xsd#silo_JVAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_JVAgreementMember_lbl" xml:lang="en-US">JV Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_JVAgreementMember" xlink:to="silo_JVAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_DrJamesKuoMember" xlink:href="silo-20220630.xsd#silo_DrJamesKuoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_DrJamesKuoMember_lbl" xml:lang="en-US">Dr. James Kuo [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DrJamesKuoMember" xlink:to="silo_DrJamesKuoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_AikidoMember" xlink:href="silo-20220630.xsd#silo_AikidoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_AikidoMember_lbl" xml:lang="en-US">Aikido [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AikidoMember" xlink:to="silo_AikidoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_KuoEmploymentAgreementMember" xlink:href="silo-20220630.xsd#silo_KuoEmploymentAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="silo_KuoEmploymentAgreementMember_lbl" xml:lang="en-US">Kuo Employment Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_KuoEmploymentAgreementMember" xlink:to="silo_KuoEmploymentAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" xlink:href="silo-20220630.xsd#silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" xlink:to="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems" xlink:href="silo-20220630.xsd#silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems" xlink:to="silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:href="silo-20220630.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable_lbl" xml:lang="en-US">Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:href="silo-20220630.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems_lbl" xml:lang="en-US">Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable" xlink:href="silo-20220630.xsd#silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) - Schedule of stock options activities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable" xlink:to="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:href="silo-20220630.xsd#silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) - Schedule of stock options activities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) - Schedule of milestone payments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies (Details) - Schedule of milestone payments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionNameDomain_lbl" xml:lang="en-US">Debt Conversion, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="us-gaap_DebtConversionNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) - Schedule of exclusive of value added tax to be amortized [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedTable" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedTable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems_lbl" xml:lang="en-US">Commitments and Contingencies (Details) - Schedule of exclusive of value added tax to be amortized [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) - Schedule of shall pay UMB [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems_lbl" xml:lang="en-US">Commitments and Contingencies (Details) - Schedule of shall pay UMB [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems" xlink:to="silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_OrganizationandBusinessDetailsTable" xlink:href="silo-20220630.xsd#silo_OrganizationandBusinessDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_OrganizationandBusinessDetailsTable_lbl" xml:lang="en-US">Organization and Business (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OrganizationandBusinessDetailsTable" xlink:to="silo_OrganizationandBusinessDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Organization and Business [Line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" xlink:href="silo-20220630.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable_lbl" xml:lang="en-US">Fair Value of Financial Instruments and Fair Value Measurements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" xlink:to="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:href="silo-20220630.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems_lbl" xml:lang="en-US">Fair Value of Financial Instruments and Fair Value Measurements (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xml:lang="en-US">Receivable [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_TypesOfAgreementDomain" xlink:href="silo-20220630.xsd#silo_TypesOfAgreementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_TypesOfAgreementDomain_lbl" xml:lang="en-US">TypesOfAgreement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TypesOfAgreementDomain" xlink:to="silo_TypesOfAgreementDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_DeferredRevenueArrangementType_Domain" xlink:href="silo-20220630.xsd#silo_DeferredRevenueArrangementType_Domain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_DeferredRevenueArrangementType_Domain_lbl" xml:lang="en-US">DeferredRevenueArrangementType_ [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeferredRevenueArrangementType_Domain" xlink:to="silo_DeferredRevenueArrangementType_Domain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NotesReceivableDetailsTable" xlink:href="silo-20220630.xsd#silo_NotesReceivableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NotesReceivableDetailsTable_lbl" xml:lang="en-US">Notes Receivable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NotesReceivableDetailsTable" xlink:to="silo_NotesReceivableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NotesReceivableDetailsLineItems" xlink:href="silo-20220630.xsd#silo_NotesReceivableDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NotesReceivableDetailsLineItems_lbl" xml:lang="en-US">Notes Receivable (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NotesReceivableDetailsLineItems" xlink:to="silo_NotesReceivableDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NotePayableDetailsTable" xlink:href="silo-20220630.xsd#silo_NotePayableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NotePayableDetailsTable_lbl" xml:lang="en-US">Note Payable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NotePayableDetailsTable" xlink:to="silo_NotePayableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_NotePayableDetailsLineItems" xlink:href="silo-20220630.xsd#silo_NotePayableDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NotePayableDetailsLineItems_lbl" xml:lang="en-US">Note Payable (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NotePayableDetailsLineItems" xlink:to="silo_NotePayableDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_TypesOfAgreementsDomain" xlink:href="silo-20220630.xsd#silo_TypesOfAgreementsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_TypesOfAgreementsDomain_lbl" xml:lang="en-US">TypesOfAgreements [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TypesOfAgreementsDomain" xlink:to="silo_TypesOfAgreementsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_StockholdersEquityDetailsTable" xlink:href="silo-20220630.xsd#silo_StockholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_StockholdersEquityDetailsTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_StockholdersEquityDetailsTable" xlink:to="silo_StockholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_StockholdersEquityDetailsLineItems" xlink:href="silo-20220630.xsd#silo_StockholdersEquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_StockholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_StockholdersEquityDetailsLineItems" xlink:to="silo_StockholdersEquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ConcentrationsDetailsTable" xlink:href="silo-20220630.xsd#silo_ConcentrationsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ConcentrationsDetailsTable_lbl" xml:lang="en-US">Concentrations (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConcentrationsDetailsTable" xlink:to="silo_ConcentrationsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_ConcentrationsDetailsLineItems" xlink:href="silo-20220630.xsd#silo_ConcentrationsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ConcentrationsDetailsLineItems_lbl" xml:lang="en-US">Concentrations (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConcentrationsDetailsLineItems" xlink:to="silo_ConcentrationsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_TypeOfAgreementDomain" xlink:href="silo-20220630.xsd#silo_TypeOfAgreementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_TypeOfAgreementDomain_lbl" xml:lang="en-US">TypeOfAgreement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TypeOfAgreementDomain" xlink:to="silo_TypeOfAgreementDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommitmentsandContingenciesDetailsTable" xlink:to="silo_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_CommitmentsandContingenciesDetailsLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommitmentsandContingenciesDetailsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommitmentsandContingenciesDetailsLineItems" xlink:to="silo_CommitmentsandContingenciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SubsequentEventsDetailsTable" xlink:href="silo-20220630.xsd#silo_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SubsequentEventsDetailsTable" xlink:to="silo_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="silo_SubsequentEventsDetailsLineItems" xlink:href="silo-20220630.xsd#silo_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SubsequentEventsDetailsLineItems" xlink:to="silo_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_AccruedInterestReceivable_lbl0" xml:lang="en-US">Amount of accrued interest receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AccruedInterestReceivable" xlink:to="silo_AccruedInterestReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_AdditionalNotesReceivableIn2021_lbl1" xml:lang="en-US">Additional notes receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdditionalNotesReceivableIn2021" xlink:to="silo_AdditionalNotesReceivableIn2021_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_AdditionsofEquitySecurities_lbl0" xml:lang="en-US">Additions for equity securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdditionsofEquitySecurities" xlink:to="silo_AdditionsofEquitySecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_AdvanceFromARelatedParty_lbl0" xml:lang="en-US">Advance from a related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdvanceFromARelatedParty" xlink:to="silo_AdvanceFromARelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_AggregateGrantDateFairValueOfPlacementAgentWarrants_lbl0" xml:lang="en-US">Aggregate grant date fair value of placement agent warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateGrantDateFairValueOfPlacementAgentWarrants" xlink:to="silo_AggregateGrantDateFairValueOfPlacementAgentWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_AggregateOfNotesReceivablePurchasePrice_lbl0" xml:lang="en-US">Aggregate of notes receivable purchase price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateOfNotesReceivablePurchasePrice" xlink:to="silo_AggregateOfNotesReceivablePurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_AnnualBaseSalary_lbl0" xml:lang="en-US">Annual salary amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AnnualBaseSalary" xlink:to="silo_AnnualBaseSalary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_AssetPurchaseAgreementDescription_lbl0" xml:lang="en-US">Asset Purchase Agreement Description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AssetPurchaseAgreementDescription" xlink:to="silo_AssetPurchaseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain_lbl0" xml:lang="en-US">Amount of unrealized gain before deducting unrealized loss on investment in equity securities classified as available-for-sale securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain" xlink:to="silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_BadDebtRecoveryExpense_lbl0" xml:lang="en-US">Bad debt (recovery) expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_BadDebtRecoveryExpense" xlink:to="silo_BadDebtRecoveryExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_CashSPICInsuredAmount_lbl0" xml:lang="en-US">The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Securities Investor Protection Corporation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashSPICInsuredAmount" xlink:to="silo_CashSPICInsuredAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_CollectedSettlementAgreement_lbl0" xml:lang="en-US">Amount of Collected Settlement Agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CollectedSettlementAgreement" xlink:to="silo_CollectedSettlementAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_CollectionsOnNotesReceivable_lbl0" xml:lang="en-US">Collections on notes receivables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CollectionsOnNotesReceivable" xlink:to="silo_CollectionsOnNotesReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_CommonStockGrantDateFairValuePerShare_lbl0" xml:lang="en-US">Common stock grant date fair value per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockGrantDateFairValuePerShare" xlink:to="silo_CommonStockGrantDateFairValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock_lbl0" xml:lang="en-US">Common Stock issued for conversion of Redeemable Series A Preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock" xlink:to="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock_lbl0" xml:lang="en-US">Common stock issued for conversion of Redeemable Series A Preferred Stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock" xlink:to="silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_CommonStockIssuedForExchangeOfNotes_lbl0" xml:lang="en-US">Common Stock issued for Exchange of Notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForExchangeOfNotes" xlink:to="silo_CommonStockIssuedForExchangeOfNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_CommonStockIssuedForExchangeOfNotesShares_lbl0" xml:lang="en-US">Common Stock issued for Exchange of Notes, shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForExchangeOfNotesShares" xlink:to="silo_CommonStockIssuedForExchangeOfNotesShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_CommonStockIssuedForFutureServicesShares_lbl0" xml:lang="en-US">Common Stock issued for future services, shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForFutureServicesShares" xlink:to="silo_CommonStockIssuedForFutureServicesShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_CommonStockServiceDescription_lbl0" xml:lang="en-US">Common stock service, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockServiceDescription" xlink:to="silo_CommonStockServiceDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_CompanyReceivedShares_lbl0" xml:lang="en-US">Company received shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CompanyReceivedShares" xlink:to="silo_CompanyReceivedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ConcentrationsRiskPercentage1_lbl0" xml:lang="en-US">Concentration risk percentage 1.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConcentrationsRiskPercentage1" xlink:to="silo_ConcentrationsRiskPercentage1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ConsiderationInTheFormOfANoteReceivable_lbl0" xml:lang="en-US">Consideration in the form of a note receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConsiderationInTheFormOfANoteReceivable" xlink:to="silo_ConsiderationInTheFormOfANoteReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ConvertablePreferredStock_lbl0" xml:lang="en-US">Convertable preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConvertablePreferredStock" xlink:to="silo_ConvertablePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ConvertibleLongTermNotesPayables_lbl0" xml:lang="en-US">Convertible long term notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConvertibleLongTermNotesPayables" xlink:to="silo_ConvertibleLongTermNotesPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_DebtInstrumentIncreasesAccruedInterest_lbl0" xml:lang="en-US">Increase for accrued, but unpaid interest on the debt instrument for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DebtInstrumentIncreasesAccruedInterest" xlink:to="silo_DebtInstrumentIncreasesAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_DebtInstrumentsFaceAmount_lbl0" xml:lang="en-US">Face (par) amount of debt instrument at time of issuance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DebtInstrumentsFaceAmount" xlink:to="silo_DebtInstrumentsFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_DeemedDividend_lbl0" xml:lang="en-US">The amount of deemed dividend.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeemedDividend" xlink:to="silo_DeemedDividend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_DeemedDividendOnPreferredStockExchange_lbl0" xml:lang="en-US">Deemed dividend on Preferred Stock Exchange.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeemedDividendOnPreferredStockExchange" xlink:to="silo_DeemedDividendOnPreferredStockExchange_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_DeferredRevenueLongtermPortionAmounted_lbl0" xml:lang="en-US">Deferred revenue long-term portion amounted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeferredRevenueLongtermPortionAmounted" xlink:to="silo_DeferredRevenueLongtermPortionAmounted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_DeferredTaxAssetGross_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforward.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeferredTaxAssetGross" xlink:to="silo_DeferredTaxAssetGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_DeferredTaxAssetsCapitalLossCarryforward_lbl0" xml:lang="en-US">Amount before allocation of valuation allowance of deferred tax asset attributable to deductible capital loss carryforwards.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeferredTaxAssetsCapitalLossCarryforward" xlink:to="silo_DeferredTaxAssetsCapitalLossCarryforward_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_DeferredTaxAssetsValuationAllowances_lbl0" xml:lang="en-US">Amount of deferred tax asset for which it is more likely than not that a tax benefit will not be realized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeferredTaxAssetsValuationAllowances" xlink:to="silo_DeferredTaxAssetsValuationAllowances_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_EquityInvestmentsAtCost_lbl0" xml:lang="en-US">Equity investments, at cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquityInvestmentsAtCost" xlink:to="silo_EquityInvestmentsAtCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_EquityInvestmentsCost_lbl0" xml:lang="en-US">Equity investments cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquityInvestmentsCost" xlink:to="silo_EquityInvestmentsCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_EquityMethodInvestment_lbl0" xml:lang="en-US">This item represents the carrying amount on the entity&apos;s balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity&apos;s share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquityMethodInvestment" xlink:to="silo_EquityMethodInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ExchangeAgreementsDescription_lbl0" xml:lang="en-US">The company entered into exchange agreements description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ExchangeAgreementsDescription" xlink:to="silo_ExchangeAgreementsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_FinanceLeaseLiabilities_lbl0" xml:lang="en-US">Present value of lessee&apos;s discounted obligation for lease payments from finance leases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FinanceLeaseLiabilities" xlink:to="silo_FinanceLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_FirstCommercialSale_lbl0" xml:lang="en-US">First commercial sale.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FirstCommercialSale" xlink:to="silo_FirstCommercialSale_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_GainFromSaleOfNFIDBusiness_lbl0" xml:lang="en-US">Gain from sale of NFID business.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_GainFromSaleOfNFIDBusiness" xlink:to="silo_GainFromSaleOfNFIDBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_GainLossOnSaleOfCapitalLeaseNet_lbl0" xml:lang="en-US">The net gain (loss) arising from the lessor&apos;s transactions involving the sale, transfer, or termination of financing agreements classified as capital lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_GainLossOnSaleOfCapitalLeaseNet" xlink:to="silo_GainLossOnSaleOfCapitalLeaseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears" xlink:to="silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_GrossProceeds_lbl0" xml:lang="en-US">The value of Gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_GrossProceeds" xlink:to="silo_GrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_IncomeLossFromDiscontinuedOperations_lbl0" xml:lang="en-US">Income (loss) from discontinued operations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IncomeLossFromDiscontinuedOperations" xlink:to="silo_IncomeLossFromDiscontinuedOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_IncomelossFromContinuingOperation_lbl0" xml:lang="en-US">IncomelossFromContinuingOperation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IncomelossFromContinuingOperation" xlink:to="silo_IncomelossFromContinuingOperation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree_lbl0" xml:lang="en-US">Increase in equity investments recorded as deferred revenue pursuant to a patent license agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree" xlink:to="silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp_lbl0" xml:lang="en-US">Number of shares of stock issued as of the balance sheet date, including Iniital fair value of stock options issued as stock-based compensation recorded as deferred compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp" xlink:to="silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_InvestorInvestedAmount_lbl0" xml:lang="en-US">The investor invested amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_InvestorInvestedAmount" xlink:to="silo_InvestorInvestedAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares_lbl0" xml:lang="en-US">Issuance of common stock for conversion of preferred stock (in Shares).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares" xlink:to="silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_IssuanceOfCommonStockForConversionOfPreferredStock_lbl0" xml:lang="en-US">Issuance of common stock for conversion of preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IssuanceOfCommonStockForConversionOfPreferredStock" xlink:to="silo_IssuanceOfCommonStockForConversionOfPreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_LicenseFee_lbl0" xml:lang="en-US">Fee incurred and are directly related to generating license Expenses. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LicenseFee" xlink:to="silo_LicenseFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_LicenseFees_lbl0" xml:lang="en-US">License fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LicenseFees" xlink:to="silo_LicenseFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_MinimumAnnualRoyalty_lbl0" xml:lang="en-US">The amount of minimum anual royalty.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MinimumAnnualRoyalty" xlink:to="silo_MinimumAnnualRoyalty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_NetAssetOfNFIDBusinessDisposed_lbl0" xml:lang="en-US">Net asset of NFID business disposed.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NetAssetOfNFIDBusinessDisposed" xlink:to="silo_NetAssetOfNFIDBusinessDisposed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_NetBadDebtExpense_lbl0" xml:lang="en-US">Amount of net bad debt expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NetBadDebtExpense" xlink:to="silo_NetBadDebtExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_NotesReceivablePurchasePrice_lbl0" xml:lang="en-US">NotesReceivablePurchasePrice.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NotesReceivablePurchasePrice" xlink:to="silo_NotesReceivablePurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_NumberOfWarrant_lbl1" xml:lang="en-US">Number of Warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NumberOfWarrant" xlink:to="silo_NumberOfWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted_lbl0" xml:lang="en-US">NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted" xlink:to="silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_OtherDepreciationsAndAmortization_lbl0" xml:lang="en-US">Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OtherDepreciationsAndAmortization" xlink:to="silo_OtherDepreciationsAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_OtherIncomeFromEquitySharesEarnedForServices_lbl0" xml:lang="en-US">Amount of other income from equity shares earned for services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OtherIncomeFromEquitySharesEarnedForServices" xlink:to="silo_OtherIncomeFromEquitySharesEarnedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_PaymentOfSponsoredResearchAmount_lbl0" xml:lang="en-US">Payment of sponsored research amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentOfSponsoredResearchAmount" xlink:to="silo_PaymentOfSponsoredResearchAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_PlacementAgentFees_lbl0" xml:lang="en-US">Placement agent fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PlacementAgentFees" xlink:to="silo_PlacementAgentFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_PreferredSharesExchangedForCommonStock_lbl0" xml:lang="en-US">Preferred Shares Exchanged for Common Stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredSharesExchangedForCommonStock" xlink:to="silo_PreferredSharesExchangedForCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_PreferredSharesExchangedForCommonStockShares_lbl0" xml:lang="en-US">Preferred Shares Exchanged for Common Stock, Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredSharesExchangedForCommonStockShares" xlink:to="silo_PreferredSharesExchangedForCommonStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_PreferredStockStatedValue_lbl0" xml:lang="en-US">Amount of preferred stock stated value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredStockStatedValue" xlink:to="silo_PreferredStockStatedValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_PreferredStockValueOne_lbl0" xml:lang="en-US">Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders&apos; equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredStockValueOne" xlink:to="silo_PreferredStockValueOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_PreferredStockValueTwo_lbl0" xml:lang="en-US">Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders&apos; equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredStockValueTwo" xlink:to="silo_PreferredStockValueTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_PrincipalBalance_lbl0" xml:lang="en-US">Amount of principal balance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PrincipalBalance" xlink:to="silo_PrincipalBalance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_PromissoryNoteAgreement_lbl0" xml:lang="en-US">Promissory note agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PromissoryNoteAgreement" xlink:to="silo_PromissoryNoteAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_PromissoryNotes_lbl0" xml:lang="en-US">Amount of promissory notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PromissoryNotes" xlink:to="silo_PromissoryNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_PurchaseAgreementsDescription_lbl0" xml:lang="en-US">Purchase agreement, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PurchaseAgreementsDescription" xlink:to="silo_PurchaseAgreementsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_PurchasePrice_lbl0" xml:lang="en-US">Purchase price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PurchasePrice" xlink:to="silo_PurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_PursuantTerms_lbl0" xml:lang="en-US">Pursuant Terms.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PursuantTerms" xlink:to="silo_PursuantTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ReceivedShares_lbl0" xml:lang="en-US">The company received shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ReceivedShares" xlink:to="silo_ReceivedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_RecoveredAggregateBadDebt_lbl0" xml:lang="en-US">Recovered aggregate bad debt.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RecoveredAggregateBadDebt" xlink:to="silo_RecoveredAggregateBadDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_RecoveredBadDebt_lbl0" xml:lang="en-US">The value recovered bad debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RecoveredBadDebt" xlink:to="silo_RecoveredBadDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_RemainingBalanceOfPromissoryNoteReceivable_lbl0" xml:lang="en-US">Remaining balance of promissory note receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RemainingBalanceOfPromissoryNoteReceivable" xlink:to="silo_RemainingBalanceOfPromissoryNoteReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_RemainsCollectibleSettlementAgreement_lbl0" xml:lang="en-US">Remains Collectible Settlement Agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RemainsCollectibleSettlementAgreement" xlink:to="silo_RemainsCollectibleSettlementAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_RemainsCollectibleSettlementAgreementAmountReserved_lbl0" xml:lang="en-US">Remains collectible settlement agreement amount reserved.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RemainsCollectibleSettlementAgreementAmountReserved" xlink:to="silo_RemainsCollectibleSettlementAgreementAmountReserved_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Tablular disclosure of schedule of anti-dilutive net loss per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock" xlink:to="silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized_lbl0" xml:lang="en-US">Schedule of exclusive of value added tax to be amortized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized" xlink:to="silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ScheduleOfMilestonePayments_lbl0" xml:lang="en-US">Schedule of milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfMilestonePayments" xlink:to="silo_ScheduleOfMilestonePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ScheduleOfShallPayUMB_lbl0" xml:lang="en-US">Schedule of shall pay UMB.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfShallPayUMB" xlink:to="silo_ScheduleOfShallPayUMB_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ScheduleOfUMBMinimumRoyaltyPayments_lbl0" xml:lang="en-US">Schedule of UMB minimum royalty payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfUMBMinimumRoyaltyPayments" xlink:to="silo_ScheduleOfUMBMinimumRoyaltyPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of option outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue_lbl0" xml:lang="en-US">The amount of aggregated intrinsic value for forfeited shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl0" xml:lang="en-US">The value of aggregate intrinsic value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl1" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars_lbl0" xml:lang="en-US">The number of shares into which fully or partially vested stock warrants outstanding as of the balance sheet date can be currently converted under the option plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars" xlink:to="silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ShareBasedComponsationNumberOfWarrantsForfeited_lbl0" xml:lang="en-US">The number of shares under warrants that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedComponsationNumberOfWarrantsForfeited" xlink:to="silo_ShareBasedComponsationNumberOfWarrantsForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ShareBasedComponsationNumberOfWarrantsGranted_lbl0" xml:lang="en-US">Gross number of share warrants (or share units) granted during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedComponsationNumberOfWarrantsGranted" xlink:to="silo_ShareBasedComponsationNumberOfWarrantsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted_lbl1" xml:lang="en-US">Weighted average remaining contractual term for option granted, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted" xlink:to="silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option exercisable, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable" xlink:to="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited_lbl0" xml:lang="en-US">Weighted average remaining contractual term for forfeited, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited" xlink:to="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards forfeited, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards granted, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_SponsoredPayment_lbl0" xml:lang="en-US">Amount of sponsored payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SponsoredPayment" xlink:to="silo_SponsoredPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_StockIssuedForFutureServices_lbl0" xml:lang="en-US">Common Stock issued for future services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_StockIssuedForFutureServices" xlink:to="silo_StockIssuedForFutureServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_SublicenseAmountPaid_lbl0" xml:lang="en-US">Sublicense amount paid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseAmountPaid" xlink:to="silo_SublicenseAmountPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_SublicenseIncomePercentage_lbl0" xml:lang="en-US">Percentage sublicense income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseIncomePercentage" xlink:to="silo_SublicenseIncomePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_SubsequentFinancingPercentage_lbl0" xml:lang="en-US">Subsequent financing, percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SubsequentFinancingPercentage" xlink:to="silo_SubsequentFinancingPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_TotalOfSharesOfCommonStock_lbl0" xml:lang="en-US">Number of shares of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TotalOfSharesOfCommonStock" xlink:to="silo_TotalOfSharesOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_TotalOutstandingBalanceReceivable_lbl0" xml:lang="en-US">Amount of total outstanding balance receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TotalOutstandingBalanceReceivable" xlink:to="silo_TotalOutstandingBalanceReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_TotalSubscriptionReceivableValue_lbl0" xml:lang="en-US">Total amount of subsription receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TotalSubscriptionReceivableValue" xlink:to="silo_TotalSubscriptionReceivableValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_UnrealizedGainLossOnEquityInvestments_lbl0" xml:lang="en-US">Net unrealized gain (loss) on equity investments (non-controlled/non-affiliated investments).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnrealizedGainLossOnEquityInvestments" xlink:to="silo_UnrealizedGainLossOnEquityInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_UpfrontLicenseFees_lbl0" xml:lang="en-US">Upfront license fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UpfrontLicenseFees" xlink:to="silo_UpfrontLicenseFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_WarrantIssued_lbl0" xml:lang="en-US">Warrants issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_WarrantIssued" xlink:to="silo_WarrantIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_WeightedAverageRemainingContractualTermYearsGrantedissued_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards in granted/issued/ forfeited &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_WeightedAverageRemainingContractualTermYearsGrantedissued" xlink:to="silo_WeightedAverageRemainingContractualTermYearsGrantedissued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_WorkingCapital_lbl0" xml:lang="en-US">Amount of working capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_WorkingCapital" xlink:to="silo_WorkingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="silo_promissoryNoteAmount_lbl0" xml:lang="en-US">Promissory note amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_promissoryNoteAmount" xlink:to="silo_promissoryNoteAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl0" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PlacementAgentWarrantsDescriptoin_lbl0" xml:lang="en-US">Placement Agent Warrants Descriptoin</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PlacementAgentWarrantsDescriptoin" xlink:to="silo_PlacementAgentWarrantsDescriptoin_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract103_lbl0" xml:lang="en-US">Unlabeled Abstract103</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract103" xlink:to="silo_UnlabeledAbstract103_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract102_lbl0" xml:lang="en-US">Unlabeled Abstract102</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract102" xlink:to="silo_UnlabeledAbstract102_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract101_lbl0" xml:lang="en-US">Unlabeled Abstract101</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract101" xlink:to="silo_UnlabeledAbstract101_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract100_lbl0" xml:lang="en-US">Unlabeled Abstract100</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract100" xlink:to="silo_UnlabeledAbstract100_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract107_lbl0" xml:lang="en-US">Unlabeled Abstract107</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract107" xlink:to="silo_UnlabeledAbstract107_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_RecoveredAggregateBadDebt_lbl1" xml:lang="en-US">Recovered Aggregate Bad Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RecoveredAggregateBadDebt" xlink:to="silo_RecoveredAggregateBadDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract106_lbl0" xml:lang="en-US">Unlabeled Abstract106</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract106" xlink:to="silo_UnlabeledAbstract106_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_VendorConcentrationsMember_lbl0" xml:lang="en-US">Vendor Concentrations Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_VendorConcentrationsMember" xlink:to="silo_VendorConcentrationsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract105_lbl0" xml:lang="en-US">Unlabeled Abstract105</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract105" xlink:to="silo_UnlabeledAbstract105_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract104_lbl0" xml:lang="en-US">Unlabeled Abstract104</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract104" xlink:to="silo_UnlabeledAbstract104_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfNotesReceivableAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfNotesReceivableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfNotesReceivableAbstract_lbl" xml:lang="en-US">Schedule Of Notes Receivable Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfNotesReceivableAbstract" xlink:to="silo_ScheduleOfNotesReceivableAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract109_lbl0" xml:lang="en-US">Unlabeled Abstract109</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract109" xlink:to="silo_UnlabeledAbstract109_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract108_lbl0" xml:lang="en-US">Unlabeled Abstract108</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract108" xlink:to="silo_UnlabeledAbstract108_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts_lbl0" xml:lang="en-US">Other Ownership Interests, Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:to="us-gaap_OtherOwnershipInterestsOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerRefundableFeesProceeds_lbl0" xml:lang="en-US">Customer Refundable Fees, Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRefundableFeesProceeds" xlink:to="us-gaap_CustomerRefundableFeesProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract110_lbl0" xml:lang="en-US">Unlabeled Abstract110</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract110" xlink:to="silo_UnlabeledAbstract110_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_WarrantsTerm_lbl0" xml:lang="en-US">Warrants Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_WarrantsTerm" xlink:to="silo_WarrantsTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract114_lbl0" xml:lang="en-US">Unlabeled Abstract114</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract114" xlink:to="silo_UnlabeledAbstract114_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract113_lbl0" xml:lang="en-US">Unlabeled Abstract113</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract113" xlink:to="silo_UnlabeledAbstract113_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AggregateOfNotesReceivablePurchasePrice_lbl1" xml:lang="en-US">Aggregate Of Notes Receivable Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateOfNotesReceivablePurchasePrice" xlink:to="silo_AggregateOfNotesReceivablePurchasePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract112_lbl0" xml:lang="en-US">Unlabeled Abstract112</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract112" xlink:to="silo_UnlabeledAbstract112_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract111_lbl0" xml:lang="en-US">Unlabeled Abstract111</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract111" xlink:to="silo_UnlabeledAbstract111_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract118_lbl0" xml:lang="en-US">Unlabeled Abstract118</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract118" xlink:to="silo_UnlabeledAbstract118_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract117_lbl0" xml:lang="en-US">Unlabeled Abstract117</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract117" xlink:to="silo_UnlabeledAbstract117_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract116_lbl0" xml:lang="en-US">Unlabeled Abstract116</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract116" xlink:to="silo_UnlabeledAbstract116_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract115_lbl0" xml:lang="en-US">Unlabeled Abstract115</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract115" xlink:to="silo_UnlabeledAbstract115_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract_lbl0" xml:lang="en-US">Net Loss Per Common Share Available To Common Stockholders Diluted Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract" xlink:to="silo_NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract119_lbl0" xml:lang="en-US">Unlabeled Abstract119</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract119" xlink:to="silo_UnlabeledAbstract119_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares_lbl0" xml:lang="en-US">Common Stock Issued For Conversion Of Redeemable Series Preferred Stock Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares" xlink:to="silo_CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Earnings Per Share Antidilutive Basic And Diluted Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock" xlink:to="silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PreferredSharesExchangedForCommonStock_lbl1" xml:lang="en-US">Preferred Shares Exchanged For Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredSharesExchangedForCommonStock" xlink:to="silo_PreferredSharesExchangedForCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract121_lbl0" xml:lang="en-US">Unlabeled Abstract121</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract121" xlink:to="silo_UnlabeledAbstract121_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract120_lbl0" xml:lang="en-US">Unlabeled Abstract120</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract120" xlink:to="silo_UnlabeledAbstract120_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivableNoncurrent_lbl0" xml:lang="en-US">Interest Receivable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableNoncurrent" xlink:to="us-gaap_InterestReceivableNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommonStockIssuedForFutureServices_lbl0" xml:lang="en-US">Common Stock Issued For Future Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForFutureServices" xlink:to="silo_CommonStockIssuedForFutureServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Activity In The Companys Equity Investments At Fair Value Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock" xlink:to="silo_ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_LiquidityPolicyTextBlock_lbl0" xml:lang="en-US">Liquidity Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LiquidityPolicyTextBlock" xlink:to="silo_LiquidityPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_InvestorInvestedAmountPercentage_lbl0" xml:lang="en-US">Investor Invested Amount Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_InvestorInvestedAmountPercentage" xlink:to="silo_InvestorInvestedAmountPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfInterestExpenseAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfInterestExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfInterestExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Interest Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfInterestExpenseAbstract" xlink:to="silo_ScheduleOfInterestExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_OtherIncomeFromEquitySharesEarnedForServices_lbl1" xml:lang="en-US">Other Income From Equity Shares Earned For Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OtherIncomeFromEquitySharesEarnedForServices" xlink:to="silo_OtherIncomeFromEquitySharesEarnedForServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PreferredStockOutstandingDescription_lbl0" xml:lang="en-US">Preferred Stock Outstanding Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredStockOutstandingDescription" xlink:to="silo_PreferredStockOutstandingDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CompanyReceivedShares_lbl1" xml:lang="en-US">Company Received Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CompanyReceivedShares" xlink:to="silo_CompanyReceivedShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NetSalePercentage_lbl0" xml:lang="en-US">Net Sale Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NetSalePercentage" xlink:to="silo_NetSalePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl0" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_lbl0" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized_lbl1" xml:lang="en-US">Schedule Of Exclusive Of Value Added Tax To Be Amortized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized" xlink:to="silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PreferredStockValueTwo_lbl1" xml:lang="en-US">Preferred Stock Value Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredStockValueTwo" xlink:to="silo_PreferredStockValueTwo_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted_lbl1" xml:lang="en-US">Numerator For Loss From Discontinuing Operations Per Common Share Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted" xlink:to="silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FDICIndemnificationAssetCashPaymentsReceived_lbl0" xml:lang="en-US">FDIC Indemnification Asset, Cash Payments Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FDICIndemnificationAssetCashPaymentsReceived" xlink:to="us-gaap_FDICIndemnificationAssetCashPaymentsReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SponsoredResearchAgreementDescription_lbl0" xml:lang="en-US">Sponsored Research Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SponsoredResearchAgreementDescription" xlink:to="silo_SponsoredResearchAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedAtCost_lbl0" xml:lang="en-US">Investment Owned, at Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtCost" xlink:to="us-gaap_InvestmentOwnedAtCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_EquityMethodInvestment_lbl1" xml:lang="en-US">Equity Method Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquityMethodInvestment" xlink:to="silo_EquityMethodInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_LicenseFees_lbl1" xml:lang="en-US">License Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LicenseFees" xlink:to="silo_LicenseFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPayablesToBrokerDealers_lbl0" xml:lang="en-US">Increase (Decrease) in Payable to Broker-Dealer and Clearing Organization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPayablesToBrokerDealers" xlink:to="us-gaap_IncreaseDecreaseInPayablesToBrokerDealers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfStockOptionsActivitiesAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfStockOptionsActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfStockOptionsActivitiesAbstract_lbl" xml:lang="en-US">Schedule Of Stock Options Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfStockOptionsActivitiesAbstract" xlink:to="silo_ScheduleOfStockOptionsActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_RemainsCollectibleSettlementAgreementAmountReserved_lbl1" xml:lang="en-US">Remains Collectible Settlement Agreement Amount Reserved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RemainsCollectibleSettlementAgreementAmountReserved" xlink:to="silo_RemainsCollectibleSettlementAgreementAmountReserved_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_MinimumAnnualRoyalty_lbl1" xml:lang="en-US">Minimum Annual Royalty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MinimumAnnualRoyalty" xlink:to="silo_MinimumAnnualRoyalty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_StockIssuedForFutureServices_lbl1" xml:lang="en-US">Stock Issued For Future Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_StockIssuedForFutureServices" xlink:to="silo_StockIssuedForFutureServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PaymentOneMember_lbl0" xml:lang="en-US">Payment One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentOneMember" xlink:to="silo_PaymentOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_DescriptionOfIncomeTaxDescription_lbl0" xml:lang="en-US">Description Of Income Tax Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DescriptionOfIncomeTaxDescription" xlink:to="silo_DescriptionOfIncomeTaxDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Ownership Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_MasterLincenseAgreementMember_lbl0" xml:lang="en-US">Master Lincense Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MasterLincenseAgreementMember" xlink:to="silo_MasterLincenseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AggregateGrantDateFairValueOfPlacementAgentWarrants_lbl1" xml:lang="en-US">Aggregate Grant Date Fair Value Of Placement Agent Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateGrantDateFairValueOfPlacementAgentWarrants" xlink:to="silo_AggregateGrantDateFairValueOfPlacementAgentWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US">Schedule Of Reconciliation Of Basic And Diluted Net Loss Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareAbstract" xlink:to="silo_ScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PurchaseAgreementMember_lbl0" xml:lang="en-US">Purchase Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PurchaseAgreementMember" xlink:to="silo_PurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl1" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract_lbl0" xml:lang="en-US">Net Income Loss Per Common Share Available To Common Stockholders Basic Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract" xlink:to="silo_NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnrealizedGainLossOnEquityInvestments_lbl1" xml:lang="en-US">Unrealized Gain Loss On Equity Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnrealizedGainLossOnEquityInvestments" xlink:to="silo_UnrealizedGainLossOnEquityInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SeriesCConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series CConvertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SeriesCConvertiblePreferredStockMember" xlink:to="silo_SeriesCConvertiblePreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfMilestonePaymentsAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfMilestonePaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfMilestonePaymentsAbstract_lbl" xml:lang="en-US">Schedule Of Milestone Payments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfMilestonePaymentsAbstract" xlink:to="silo_ScheduleOfMilestonePaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CashReceived_lbl0" xml:lang="en-US">Cash Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashReceived" xlink:to="silo_CashReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl1" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionContractorLiquidityCharacteristic_lbl0" xml:lang="en-US">Construction Contractor, Liquidity Characteristic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionContractorLiquidityCharacteristic" xlink:to="us-gaap_ConstructionContractorLiquidityCharacteristic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl0" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NetBadDebtExpense_lbl1" xml:lang="en-US">Net Bad Debt Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NetBadDebtExpense" xlink:to="silo_NetBadDebtExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl0" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense Other, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesReceivableNet_lbl0" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableNet" xlink:to="us-gaap_NotesReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_OtherIncomeExpenseAbstract_lbl0" xml:lang="en-US">Other Income Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OtherIncomeExpenseAbstract" xlink:to="silo_OtherIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SupplementalDisclosureOfCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Disclosure Of Cash Flow Information Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:to="silo_SupplementalDisclosureOfCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesSharesOutstanding_lbl0" xml:lang="en-US">Auction Market Preferred Securities, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesSharesOutstanding" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_DeferredRevenueLongtermPortionAmounted_lbl1" xml:lang="en-US">Deferred Revenue Longterm Portion Amounted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeferredRevenueLongtermPortionAmounted" xlink:to="silo_DeferredRevenueLongtermPortionAmounted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CashPaidDuringThePeriodForAbstract_lbl0" xml:lang="en-US">Cash Paid During The Period For Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashPaidDuringThePeriodForAbstract" xlink:to="silo_CashPaidDuringThePeriodForAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_LossFromDebtExtinguishment_lbl0" xml:lang="en-US">Loss From Debt Extinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LossFromDebtExtinguishment" xlink:to="silo_LossFromDebtExtinguishment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CollectionOnNoteReceivable_lbl0" xml:lang="en-US">Collection On Note Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CollectionOnNoteReceivable" xlink:to="silo_CollectionOnNoteReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl0" xml:lang="en-US">Interest Expense, Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl0" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_RemainsCollectibleSettlementAgreement_lbl1" xml:lang="en-US">Remains Collectible Settlement Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RemainsCollectibleSettlementAgreement" xlink:to="silo_RemainsCollectibleSettlementAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ExchangeAgreementsDescription_lbl1" xml:lang="en-US">Exchange Agreements Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ExchangeAgreementsDescription" xlink:to="silo_ExchangeAgreementsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_lbl0" xml:lang="en-US">Recorded Unconditional Purchase Obligation, to be Paid, Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_DeferredTaxAssetGross_lbl1" xml:lang="en-US">Deferred Tax Asset Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeferredTaxAssetGross" xlink:to="silo_DeferredTaxAssetGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl0" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CostOfRevenuesPolicyTextBlock_lbl0" xml:lang="en-US">Cost Of Revenues Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CostOfRevenuesPolicyTextBlock" xlink:to="silo_CostOfRevenuesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInContinuingOperations_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PaymentSevenMember_lbl0" xml:lang="en-US">Payment Seven Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentSevenMember" xlink:to="silo_PaymentSevenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AikidoMember_lbl0" xml:lang="en-US">Aikido Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AikidoMember" xlink:to="silo_AikidoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl1" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares_lbl0" xml:lang="en-US">Common Stock Issued For Conversion Of Redeemable Series APreferred Stockin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares" xlink:to="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl0" xml:lang="en-US">Gain (Loss) on Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ConsiderationInTheFormOfANoteReceivable_lbl1" xml:lang="en-US">Consideration In The Form Of ANote Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConsiderationInTheFormOfANoteReceivable" xlink:to="silo_ConsiderationInTheFormOfANoteReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AdvanceFromARelatedParty_lbl1" xml:lang="en-US">Advance From ARelated Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdvanceFromARelatedParty" xlink:to="silo_AdvanceFromARelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommonStockIssuedForExchangeOfNotesShares_lbl1" xml:lang="en-US">Common Stock Issued For Exchange Of Notes Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForExchangeOfNotesShares" xlink:to="silo_CommonStockIssuedForExchangeOfNotesShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortizedAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortizedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortizedAbstract_lbl" xml:lang="en-US">Schedule Of Exclusive Of Value Added Tax To Be Amortized Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortizedAbstract" xlink:to="silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortizedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PaymentFiveMember_lbl0" xml:lang="en-US">Payment Five Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentFiveMember" xlink:to="silo_PaymentFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VentureCapitalGainsLossesNet_lbl0" xml:lang="en-US">Venture Capital Gain (Loss), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VentureCapitalGainsLossesNet" xlink:to="us-gaap_VentureCapitalGainsLossesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_EquityInvestmentsCost_lbl1" xml:lang="en-US">Equity Investments Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquityInvestmentsCost" xlink:to="silo_EquityInvestmentsCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_DiscontinuedOperationsAbstract0_lbl0" xml:lang="en-US">Discontinued Operations Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DiscontinuedOperationsAbstract0" xlink:to="silo_DiscontinuedOperationsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_EquityInvestmentsAtFairValuePolicyTextBlock_lbl0" xml:lang="en-US">Equity Investments At Fair Value Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquityInvestmentsAtFairValuePolicyTextBlock" xlink:to="silo_EquityInvestmentsAtFairValuePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_WeightedAverageCommonSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Common Shares Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_WeightedAverageCommonSharesOutstandingAbstract" xlink:to="silo_WeightedAverageCommonSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl0" xml:lang="en-US">Preferred Stock, Convertible, Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl0" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AikidoPharmaIncMember_lbl0" xml:lang="en-US">Aikido Pharma Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AikidoPharmaIncMember" xlink:to="silo_AikidoPharmaIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PaymentEightMember_lbl0" xml:lang="en-US">Payment Eight Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentEightMember" xlink:to="silo_PaymentEightMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_OneLicensorMember_lbl1" xml:lang="en-US">One Licensor Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OneLicensorMember" xlink:to="silo_OneLicensorMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_EquityInvestmentsAtCostPolicyTextBlock_lbl0" xml:lang="en-US">Equity Investments At Cost Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquityInvestmentsAtCostPolicyTextBlock" xlink:to="silo_EquityInvestmentsAtCostPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredSalesCommission_lbl0" xml:lang="en-US">Deferred Sales Commission</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredSalesCommission" xlink:to="us-gaap_DeferredSalesCommission_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl2" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PromissoryNotes_lbl1" xml:lang="en-US">Promissory Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PromissoryNotes" xlink:to="silo_PromissoryNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl1" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl0" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SublicenseAgreementMember_lbl0" xml:lang="en-US">Sublicense Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseAgreementMember" xlink:to="silo_SublicenseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AggregateEstimatedNetOperatingLoss_lbl0" xml:lang="en-US">Aggregate Estimated Net Operating Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateEstimatedNetOperatingLoss" xlink:to="silo_AggregateEstimatedNetOperatingLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ShareBasedComponsationNumberOfWarrantsGranted_lbl1" xml:lang="en-US">Share Based Componsation Number Of Warrants Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedComponsationNumberOfWarrantsGranted" xlink:to="silo_ShareBasedComponsationNumberOfWarrantsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_LessNotesReceivableNetCurrentPortion_lbl0" xml:lang="en-US">Less Notes Receivable Net Current Portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LessNotesReceivableNetCurrentPortion" xlink:to="silo_LessNotesReceivableNetCurrentPortion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock_lbl1" xml:lang="en-US">Common Stock Issued For Conversion Of Redeemable Series APreferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock" xlink:to="silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl1" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl0" xml:lang="en-US">Notes Payable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AnnualBaseSalary_lbl1" xml:lang="en-US">Annual Base Salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AnnualBaseSalary" xlink:to="silo_AnnualBaseSalary_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_TypesOfAgreementAxis_lbl0" xml:lang="en-US">Types Of Agreement Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TypesOfAgreementAxis" xlink:to="silo_TypesOfAgreementAxis_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfAntiDilutiveNetLossPerShareAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfAntiDilutiveNetLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfAntiDilutiveNetLossPerShareAbstract_lbl" xml:lang="en-US">Schedule Of Anti Dilutive Net Loss Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfAntiDilutiveNetLossPerShareAbstract" xlink:to="silo_ScheduleOfAntiDilutiveNetLossPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_OmnibusEquityIncentivePlanMember_lbl0" xml:lang="en-US">Omnibus Equity Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OmnibusEquityIncentivePlanMember" xlink:to="silo_OmnibusEquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CashFlowsFromInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Flows From Investing Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashFlowsFromInvestingActivitiesAbstract" xlink:to="silo_CashFlowsFromInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_MilestonePayment_lbl0" xml:lang="en-US">Milestone Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_MilestonePayment" xlink:to="silo_MilestonePayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl0" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value, Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_LongTermLiabilitiesAbstract_lbl0" xml:lang="en-US">Long Term Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LongTermLiabilitiesAbstract" xlink:to="silo_LongTermLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement_lbl0" xml:lang="en-US">Note Receivable Issued In Connection With Asset Purchase Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement" xlink:to="silo_NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl1" xml:lang="en-US">Deferred Revenue, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireReceivables_lbl0" xml:lang="en-US">Payments to Acquire Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireReceivables" xlink:to="us-gaap_PaymentsToAcquireReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl0" xml:lang="en-US">Income Taxes Paid, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PaymentSixMember_lbl0" xml:lang="en-US">Payment Six Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentSixMember" xlink:to="silo_PaymentSixMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl0" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="silo_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts_lbl0" xml:lang="en-US">Allowance for Loan and Lease Loss, Recovery of Bad Debts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts" xlink:to="us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AmortizationOfPrepaidStockbasedExpense_lbl1" xml:lang="en-US">Amortization Of Prepaid Stockbased Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AmortizationOfPrepaidStockbasedExpense" xlink:to="silo_AmortizationOfPrepaidStockbasedExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization_lbl0" xml:lang="en-US">Utilities Operating Expense, Depreciation and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization" xlink:to="us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SecuritiesPurchaseAgreementsMember_lbl0" xml:lang="en-US">Securities Purchase Agreements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SecuritiesPurchaseAgreementsMember" xlink:to="silo_SecuritiesPurchaseAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CollectionsOnNotesReceivable_lbl1" xml:lang="en-US">Collections On Notes Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CollectionsOnNotesReceivable" xlink:to="silo_CollectionsOnNotesReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl0" xml:lang="en-US">Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_YearsDescription_lbl0" xml:lang="en-US">Years Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_YearsDescription" xlink:to="silo_YearsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl0" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_DeferredTaxAssetsCapitalLossCarryforward_lbl1" xml:lang="en-US">Deferred Tax Assets Capital Loss Carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeferredTaxAssetsCapitalLossCarryforward" xlink:to="silo_DeferredTaxAssetsCapitalLossCarryforward_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ColumbiaUniversityMember_lbl0" xml:lang="en-US">Columbia University Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ColumbiaUniversityMember" xlink:to="silo_ColumbiaUniversityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent_lbl0" xml:lang="en-US">Other Deferred Compensation Arrangements, Liability, Classified, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract_lbl" xml:lang="en-US">Schedule Of Assets And Liabilities Measured At Fair Value On ARecurring Basis Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:to="silo_ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CashPaidDuringThePeriodForAbstract0_lbl0" xml:lang="en-US">Cash Paid During The Period For Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashPaidDuringThePeriodForAbstract0" xlink:to="silo_CashPaidDuringThePeriodForAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainOnSaleOfInvestments_lbl0" xml:lang="en-US">Gain on Sale of Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOnSaleOfInvestments" xlink:to="us-gaap_GainOnSaleOfInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ChangeInOperatingAssetsAndLiabilitiesAbstract_lbl0" xml:lang="en-US">Change In Operating Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="silo_ChangeInOperatingAssetsAndLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl0" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_DiscontinuedOperationsAbstract_lbl0" xml:lang="en-US">Discontinued Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DiscontinuedOperationsAbstract" xlink:to="silo_DiscontinuedOperationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl0" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NotePayableLongTermPortion_lbl0" xml:lang="en-US">Note Payable Long Term Portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NotePayableLongTermPortion" xlink:to="silo_NotePayableLongTermPortion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl0" xml:lang="en-US">Interest Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Repayments of Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0" xml:lang="en-US">Employee Benefits and Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_LicenseAgreementDescription_lbl0" xml:lang="en-US">License Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LicenseAgreementDescription" xlink:to="silo_LicenseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecognitionOfDeferredRevenue_lbl0" xml:lang="en-US">Recognition of Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecognitionOfDeferredRevenue" xlink:to="us-gaap_RecognitionOfDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NetAssetOfNFIDBusinessDisposed_lbl1" xml:lang="en-US">Net Asset Of NFIDBusiness Disposed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NetAssetOfNFIDBusinessDisposed" xlink:to="silo_NetAssetOfNFIDBusinessDisposed_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl0" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfWarrantActivitiesAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfWarrantActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfWarrantActivitiesAbstract_lbl" xml:lang="en-US">Schedule Of Warrant Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfWarrantActivitiesAbstract" xlink:to="silo_ScheduleOfWarrantActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CollectionsOnNotesReceivables_lbl0" xml:lang="en-US">Collections On Notes Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CollectionsOnNotesReceivables" xlink:to="silo_CollectionsOnNotesReceivables_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock_lbl1" xml:lang="en-US">Common Stock Issued For Conversions Of Redeemable Series APreferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock" xlink:to="silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock_lbl1"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract_lbl" xml:lang="en-US">Schedule Of Activity In The Company SEquity Investments At Fair Value Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:to="silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayable_lbl0" xml:lang="en-US">Other Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl1" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree_lbl1" xml:lang="en-US">Increase In Equity Investments Recorded As Deferred Revenue Pursuant To APatent License Agree</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree" xlink:to="silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_lbl0" xml:lang="en-US">Gain (Loss) on Sale of Derivatives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfDerivatives" xlink:to="us-gaap_GainLossOnSaleOfDerivatives_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_TypesOfAgreementsAxis_lbl0" xml:lang="en-US">Types Of Agreements Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TypesOfAgreementsAxis" xlink:to="silo_TypesOfAgreementsAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl0" xml:lang="en-US">Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManagementFeePayable_lbl0" xml:lang="en-US">Management Fee Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeePayable" xlink:to="us-gaap_ManagementFeePayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PromissoryNoteReceivableAgreementMember_lbl1" xml:lang="en-US">Promissory Note Receivable Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PromissoryNoteReceivableAgreementMember" xlink:to="silo_PromissoryNoteReceivableAgreementMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PurchasePrice_lbl1" xml:lang="en-US">Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PurchasePrice" xlink:to="silo_PurchasePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl0" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_OtherDepreciationsAndAmortization_lbl1" xml:lang="en-US">Other Depreciations And Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OtherDepreciationsAndAmortization" xlink:to="silo_OtherDepreciationsAndAmortization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_lbl0" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfShallPayUmbAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfShallPayUmbAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfShallPayUmbAbstract_lbl" xml:lang="en-US">Schedule Of Shall Pay Umb Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfShallPayUmbAbstract" xlink:to="silo_ScheduleOfShallPayUmbAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain_lbl1" xml:lang="en-US">Available For Sales Equity Securities Gross Unrealized Gain</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain" xlink:to="silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NoteReceivableNonCurrentAmount_lbl0" xml:lang="en-US">Note Receivable Non Current Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NoteReceivableNonCurrentAmount" xlink:to="silo_NoteReceivableNonCurrentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AgreementShallExpire_lbl0" xml:lang="en-US">Agreement Shall Expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AgreementShallExpire" xlink:to="silo_AgreementShallExpire_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_JVAgreementMember_lbl0" xml:lang="en-US">JVAgreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_JVAgreementMember" xlink:to="silo_JVAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl0" xml:lang="en-US">Debt Instrument, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_RevenueTerm_lbl0" xml:lang="en-US">Revenue Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RevenueTerm" xlink:to="silo_RevenueTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommonStockIssuedForExchangeOfNotes_lbl1" xml:lang="en-US">Common Stock Issued For Exchange Of Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForExchangeOfNotes" xlink:to="silo_CommonStockIssuedForExchangeOfNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_IncentiveStockOptionMember_lbl0" xml:lang="en-US">Incentive Stock Option Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IncentiveStockOptionMember" xlink:to="silo_IncentiveStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PlacementAgentWarrantsMember_lbl0" xml:lang="en-US">Placement Agent Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PlacementAgentWarrantsMember" xlink:to="silo_PlacementAgentWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CurrentAssetsAbstract0_lbl0" xml:lang="en-US">Current Assets Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CurrentAssetsAbstract0" xlink:to="silo_CurrentAssetsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SublicenseIncomePercentage_lbl1" xml:lang="en-US">Sublicense Income Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseIncomePercentage" xlink:to="silo_SublicenseIncomePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_RemainingBalanceOfPromissoryNoteReceivable_lbl1" xml:lang="en-US">Remaining Balance Of Promissory Note Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RemainingBalanceOfPromissoryNoteReceivable" xlink:to="silo_RemainingBalanceOfPromissoryNoteReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_InvestorInvestedAmount_lbl1" xml:lang="en-US">Investor Invested Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_InvestorInvestedAmount" xlink:to="silo_InvestorInvestedAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AdditionalNotesReceivableIn2021_lbl2" xml:lang="en-US">Additional Notes Receivable In2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdditionalNotesReceivableIn2021" xlink:to="silo_AdditionalNotesReceivableIn2021_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SponsoredPayment_lbl1" xml:lang="en-US">Sponsored Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SponsoredPayment" xlink:to="silo_SponsoredPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PlacementAgentFees_lbl1" xml:lang="en-US">Placement Agent Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PlacementAgentFees" xlink:to="silo_PlacementAgentFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_RoyaltyPaymentsDescription_lbl0" xml:lang="en-US">Royalty Payments Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RoyaltyPaymentsDescription" xlink:to="silo_RoyaltyPaymentsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestments_lbl1" xml:lang="en-US">Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralInsuranceExpense_lbl0" xml:lang="en-US">General Insurance Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NumberOfVotingShares_lbl0" xml:lang="en-US">Number Of Voting Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NumberOfVotingShares" xlink:to="silo_NumberOfVotingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommonStockServiceDescription_lbl1" xml:lang="en-US">Common Stock Service Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockServiceDescription" xlink:to="silo_CommonStockServiceDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SeriesCPurchaseAgreementsMember_lbl0" xml:lang="en-US">Series CPurchase Agreements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SeriesCPurchaseAgreementsMember" xlink:to="silo_SeriesCPurchaseAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited_lbl1" xml:lang="en-US">Share Based Composation Weighted Average Remaining Contractual Term Years Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited" xlink:to="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl0" xml:lang="en-US">Stock Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_WarrantIssued_lbl1" xml:lang="en-US">Warrant Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_WarrantIssued" xlink:to="silo_WarrantIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CashFlowsFromOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Flows From Operating Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashFlowsFromOperatingActivitiesAbstract" xlink:to="silo_CashFlowsFromOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfShallPayUMB_lbl1" xml:lang="en-US">Schedule Of Shall Pay UMB</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfShallPayUMB" xlink:to="silo_ScheduleOfShallPayUMB_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CollectedSettlementAgreement_lbl1" xml:lang="en-US">Collected Settlement Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CollectedSettlementAgreement" xlink:to="silo_CollectedSettlementAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_DrJamesKuoMember_lbl0" xml:lang="en-US">Dr James Kuo Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DrJamesKuoMember" xlink:to="silo_DrJamesKuoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract80_lbl0" xml:lang="en-US">Unlabeled Abstract80</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract80" xlink:to="silo_UnlabeledAbstract80_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract83_lbl0" xml:lang="en-US">Unlabeled Abstract83</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract83" xlink:to="silo_UnlabeledAbstract83_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract84_lbl0" xml:lang="en-US">Unlabeled Abstract84</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract84" xlink:to="silo_UnlabeledAbstract84_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract81_lbl0" xml:lang="en-US">Unlabeled Abstract81</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract81" xlink:to="silo_UnlabeledAbstract81_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract82_lbl0" xml:lang="en-US">Unlabeled Abstract82</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract82" xlink:to="silo_UnlabeledAbstract82_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract87_lbl0" xml:lang="en-US">Unlabeled Abstract87</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract87" xlink:to="silo_UnlabeledAbstract87_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract88_lbl0" xml:lang="en-US">Unlabeled Abstract88</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract88" xlink:to="silo_UnlabeledAbstract88_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract85_lbl0" xml:lang="en-US">Unlabeled Abstract85</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract85" xlink:to="silo_UnlabeledAbstract85_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract86_lbl0" xml:lang="en-US">Unlabeled Abstract86</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract86" xlink:to="silo_UnlabeledAbstract86_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CashSPICInsuredAmount_lbl1" xml:lang="en-US">Cash SPICInsured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashSPICInsuredAmount" xlink:to="silo_CashSPICInsuredAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl0" xml:lang="en-US">Deferred Revenue, Revenue Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract89_lbl0" xml:lang="en-US">Unlabeled Abstract89</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract89" xlink:to="silo_UnlabeledAbstract89_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl0" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UMBYearDescription_lbl0" xml:lang="en-US">UMBYear Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UMBYearDescription" xlink:to="silo_UMBYearDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SubsequentFinancingPercentage_lbl1" xml:lang="en-US">Subsequent Financing Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SubsequentFinancingPercentage" xlink:to="silo_SubsequentFinancingPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AggregateIntrinsicValueGrantedIssuedForfeited1_lbl0" xml:lang="en-US">Aggregate Intrinsic Value Granted Issued Forfeited1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateIntrinsicValueGrantedIssuedForfeited1" xlink:to="silo_AggregateIntrinsicValueGrantedIssuedForfeited1_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfNetDeferredTaxAssetAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfNetDeferredTaxAssetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfNetDeferredTaxAssetAbstract_lbl" xml:lang="en-US">Schedule Of Net Deferred Tax Asset Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfNetDeferredTaxAssetAbstract" xlink:to="silo_ScheduleOfNetDeferredTaxAssetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract90_lbl0" xml:lang="en-US">Unlabeled Abstract90</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract90" xlink:to="silo_UnlabeledAbstract90_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract91_lbl0" xml:lang="en-US">Unlabeled Abstract91</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract91" xlink:to="silo_UnlabeledAbstract91_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract94_lbl0" xml:lang="en-US">Unlabeled Abstract94</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract94" xlink:to="silo_UnlabeledAbstract94_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract95_lbl0" xml:lang="en-US">Unlabeled Abstract95</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract95" xlink:to="silo_UnlabeledAbstract95_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract92_lbl0" xml:lang="en-US">Unlabeled Abstract92</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract92" xlink:to="silo_UnlabeledAbstract92_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract93_lbl0" xml:lang="en-US">Unlabeled Abstract93</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract93" xlink:to="silo_UnlabeledAbstract93_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract98_lbl0" xml:lang="en-US">Unlabeled Abstract98</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract98" xlink:to="silo_UnlabeledAbstract98_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PromissoryNoteAgreement_lbl1" xml:lang="en-US">Promissory Note Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PromissoryNoteAgreement" xlink:to="silo_PromissoryNoteAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract99_lbl0" xml:lang="en-US">Unlabeled Abstract99</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract99" xlink:to="silo_UnlabeledAbstract99_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract96_lbl0" xml:lang="en-US">Unlabeled Abstract96</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract96" xlink:to="silo_UnlabeledAbstract96_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract97_lbl0" xml:lang="en-US">Unlabeled Abstract97</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract97" xlink:to="silo_UnlabeledAbstract97_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsUnappropriated_lbl0" xml:lang="en-US">Retained Earnings, Unappropriated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsUnappropriated" xlink:to="us-gaap_RetainedEarningsUnappropriated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AggregateIntrinsicValueGranted_lbl1" xml:lang="en-US">Aggregate Intrinsic Value Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateIntrinsicValueGranted" xlink:to="silo_AggregateIntrinsicValueGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from (Repayments of) Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_WorkingCapital_lbl1" xml:lang="en-US">Working Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_WorkingCapital" xlink:to="silo_WorkingCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract61_lbl0" xml:lang="en-US">Unlabeled Abstract61</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract61" xlink:to="silo_UnlabeledAbstract61_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract62_lbl0" xml:lang="en-US">Unlabeled Abstract62</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract62" xlink:to="silo_UnlabeledAbstract62_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract60_lbl0" xml:lang="en-US">Unlabeled Abstract60</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract60" xlink:to="silo_UnlabeledAbstract60_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract65_lbl0" xml:lang="en-US">Unlabeled Abstract65</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract65" xlink:to="silo_UnlabeledAbstract65_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract66_lbl0" xml:lang="en-US">Unlabeled Abstract66</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract66" xlink:to="silo_UnlabeledAbstract66_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract63_lbl0" xml:lang="en-US">Unlabeled Abstract63</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract63" xlink:to="silo_UnlabeledAbstract63_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ShareBasedComponsationNumberOfWarrantsForfeited_lbl1" xml:lang="en-US">Share Based Componsation Number Of Warrants Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedComponsationNumberOfWarrantsForfeited" xlink:to="silo_ShareBasedComponsationNumberOfWarrantsForfeited_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract64_lbl0" xml:lang="en-US">Unlabeled Abstract64</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract64" xlink:to="silo_UnlabeledAbstract64_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract69_lbl0" xml:lang="en-US">Unlabeled Abstract69</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract69" xlink:to="silo_UnlabeledAbstract69_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_IncomeLossFromDiscontinuedOperations_lbl1" xml:lang="en-US">Income Loss From Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IncomeLossFromDiscontinuedOperations" xlink:to="silo_IncomeLossFromDiscontinuedOperations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract67_lbl0" xml:lang="en-US">Unlabeled Abstract67</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract67" xlink:to="silo_UnlabeledAbstract67_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract68_lbl0" xml:lang="en-US">Unlabeled Abstract68</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract68" xlink:to="silo_UnlabeledAbstract68_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl0" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl0" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract72_lbl0" xml:lang="en-US">Unlabeled Abstract72</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract72" xlink:to="silo_UnlabeledAbstract72_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract73_lbl0" xml:lang="en-US">Unlabeled Abstract73</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract73" xlink:to="silo_UnlabeledAbstract73_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract70_lbl0" xml:lang="en-US">Unlabeled Abstract70</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract70" xlink:to="silo_UnlabeledAbstract70_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract71_lbl0" xml:lang="en-US">Unlabeled Abstract71</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract71" xlink:to="silo_UnlabeledAbstract71_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract76_lbl0" xml:lang="en-US">Unlabeled Abstract76</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract76" xlink:to="silo_UnlabeledAbstract76_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract77_lbl0" xml:lang="en-US">Unlabeled Abstract77</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract77" xlink:to="silo_UnlabeledAbstract77_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract74_lbl0" xml:lang="en-US">Unlabeled Abstract74</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract74" xlink:to="silo_UnlabeledAbstract74_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0" xml:lang="en-US">Preferred Stock, Convertible, Shares Issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract75_lbl0" xml:lang="en-US">Unlabeled Abstract75</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract75" xlink:to="silo_UnlabeledAbstract75_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract78_lbl0" xml:lang="en-US">Unlabeled Abstract78</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract78" xlink:to="silo_UnlabeledAbstract78_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract79_lbl0" xml:lang="en-US">Unlabeled Abstract79</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract79" xlink:to="silo_UnlabeledAbstract79_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract38_lbl0" xml:lang="en-US">Unlabeled Abstract38</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract38" xlink:to="silo_UnlabeledAbstract38_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract39_lbl0" xml:lang="en-US">Unlabeled Abstract39</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract39" xlink:to="silo_UnlabeledAbstract39_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_LicensorShare_lbl0" xml:lang="en-US">Licensor Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LicensorShare" xlink:to="silo_LicensorShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_OneLicenseeMember_lbl0" xml:lang="en-US">One Licensee Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_OneLicenseeMember" xlink:to="silo_OneLicenseeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gross Profit (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract40_lbl0" xml:lang="en-US">Unlabeled Abstract40</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract40" xlink:to="silo_UnlabeledAbstract40_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ReceivedShares_lbl1" xml:lang="en-US">Received Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ReceivedShares" xlink:to="silo_ReceivedShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PreferredStockValueOne_lbl1" xml:lang="en-US">Preferred Stock Value One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredStockValueOne" xlink:to="silo_PreferredStockValueOne_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract43_lbl0" xml:lang="en-US">Unlabeled Abstract43</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract43" xlink:to="silo_UnlabeledAbstract43_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract44_lbl0" xml:lang="en-US">Unlabeled Abstract44</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract44" xlink:to="silo_UnlabeledAbstract44_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract41_lbl0" xml:lang="en-US">Unlabeled Abstract41</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract41" xlink:to="silo_UnlabeledAbstract41_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommonStockIssuedForFutureServicesShares_lbl1" xml:lang="en-US">Common Stock Issued For Future Services Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForFutureServicesShares" xlink:to="silo_CommonStockIssuedForFutureServicesShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract42_lbl0" xml:lang="en-US">Unlabeled Abstract42</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract42" xlink:to="silo_UnlabeledAbstract42_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract47_lbl0" xml:lang="en-US">Unlabeled Abstract47</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract47" xlink:to="silo_UnlabeledAbstract47_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract48_lbl0" xml:lang="en-US">Unlabeled Abstract48</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract48" xlink:to="silo_UnlabeledAbstract48_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract45_lbl0" xml:lang="en-US">Unlabeled Abstract45</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract45" xlink:to="silo_UnlabeledAbstract45_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease_lbl0" xml:lang="en-US">Loans Receivable Held-for-sale, Reconciliation to Cash Flow, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease" xlink:to="us-gaap_LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract46_lbl0" xml:lang="en-US">Unlabeled Abstract46</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract46" xlink:to="silo_UnlabeledAbstract46_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract49_lbl0" xml:lang="en-US">Unlabeled Abstract49</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract49" xlink:to="silo_UnlabeledAbstract49_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted_lbl2" xml:lang="en-US">Share Based Componsation Weighted Average Remaining Contractual Term Years Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted" xlink:to="silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentMaturityDate_lbl0" xml:lang="en-US">Investment Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentMaturityDate" xlink:to="us-gaap_InvestmentMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PaycheckProtectionProgramMember_lbl0" xml:lang="en-US">Paycheck Protection Program Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaycheckProtectionProgramMember" xlink:to="silo_PaycheckProtectionProgramMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract50_lbl0" xml:lang="en-US">Unlabeled Abstract50</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract50" xlink:to="silo_UnlabeledAbstract50_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract51_lbl0" xml:lang="en-US">Unlabeled Abstract51</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract51" xlink:to="silo_UnlabeledAbstract51_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl1" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract54_lbl0" xml:lang="en-US">Unlabeled Abstract54</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract54" xlink:to="silo_UnlabeledAbstract54_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract55_lbl0" xml:lang="en-US">Unlabeled Abstract55</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract55" xlink:to="silo_UnlabeledAbstract55_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract52_lbl0" xml:lang="en-US">Unlabeled Abstract52</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract52" xlink:to="silo_UnlabeledAbstract52_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract53_lbl0" xml:lang="en-US">Unlabeled Abstract53</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract53" xlink:to="silo_UnlabeledAbstract53_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract58_lbl0" xml:lang="en-US">Unlabeled Abstract58</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract58" xlink:to="silo_UnlabeledAbstract58_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract59_lbl0" xml:lang="en-US">Unlabeled Abstract59</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract59" xlink:to="silo_UnlabeledAbstract59_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract56_lbl0" xml:lang="en-US">Unlabeled Abstract56</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract56" xlink:to="silo_UnlabeledAbstract56_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract57_lbl0" xml:lang="en-US">Unlabeled Abstract57</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract57" xlink:to="silo_UnlabeledAbstract57_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl0" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract18" xlink:to="silo_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract19" xlink:to="silo_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract16" xlink:to="silo_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract17" xlink:to="silo_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl0" xml:lang="en-US">Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract21" xlink:to="silo_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract22" xlink:to="silo_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract20" xlink:to="silo_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract25_lbl0" xml:lang="en-US">Unlabeled Abstract25</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract25" xlink:to="silo_UnlabeledAbstract25_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract26_lbl0" xml:lang="en-US">Unlabeled Abstract26</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract26" xlink:to="silo_UnlabeledAbstract26_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract23_lbl0" xml:lang="en-US">Unlabeled Abstract23</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract23" xlink:to="silo_UnlabeledAbstract23_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract24_lbl0" xml:lang="en-US">Unlabeled Abstract24</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract24" xlink:to="silo_UnlabeledAbstract24_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract29_lbl0" xml:lang="en-US">Unlabeled Abstract29</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract29" xlink:to="silo_UnlabeledAbstract29_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract27_lbl0" xml:lang="en-US">Unlabeled Abstract27</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract27" xlink:to="silo_UnlabeledAbstract27_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract28_lbl0" xml:lang="en-US">Unlabeled Abstract28</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract28" xlink:to="silo_UnlabeledAbstract28_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl0" xml:lang="en-US">Other Operating Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract32_lbl0" xml:lang="en-US">Unlabeled Abstract32</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract32" xlink:to="silo_UnlabeledAbstract32_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract33_lbl0" xml:lang="en-US">Unlabeled Abstract33</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract33" xlink:to="silo_UnlabeledAbstract33_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract30_lbl0" xml:lang="en-US">Unlabeled Abstract30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract30" xlink:to="silo_UnlabeledAbstract30_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract31_lbl0" xml:lang="en-US">Unlabeled Abstract31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract31" xlink:to="silo_UnlabeledAbstract31_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract36_lbl0" xml:lang="en-US">Unlabeled Abstract36</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract36" xlink:to="silo_UnlabeledAbstract36_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract37_lbl0" xml:lang="en-US">Unlabeled Abstract37</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract37" xlink:to="silo_UnlabeledAbstract37_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract34_lbl0" xml:lang="en-US">Unlabeled Abstract34</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract34" xlink:to="silo_UnlabeledAbstract34_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract35_lbl0" xml:lang="en-US">Unlabeled Abstract35</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract35" xlink:to="silo_UnlabeledAbstract35_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_IncomeLossPerCommonShareBasicAbstract_lbl0" xml:lang="en-US">Income Loss Per Common Share Basic Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IncomeLossPerCommonShareBasicAbstract" xlink:to="silo_IncomeLossPerCommonShareBasicAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_LicenseFee_lbl1" xml:lang="en-US">License Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LicenseFee" xlink:to="silo_LicenseFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AssetPurchaseAgreementDescription_lbl1" xml:lang="en-US">Asset Purchase Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AssetPurchaseAgreementDescription" xlink:to="silo_AssetPurchaseAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation_lbl0" xml:lang="en-US">Increase Decrease In Assets Of Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation" xlink:to="silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ConsiderationFeePayablePercentage_lbl0" xml:lang="en-US">Consideration Fee Payable Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConsiderationFeePayablePercentage" xlink:to="silo_ConsiderationFeePayablePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesAuthorized_lbl0" xml:lang="en-US">Excess Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesAuthorized" xlink:to="us-gaap_ExcessStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PrepaidExpenses_lbl0" xml:lang="en-US">Prepaid Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PrepaidExpenses" xlink:to="silo_PrepaidExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_EquityInvestmentsAtCost_lbl1" xml:lang="en-US">Equity Investments At Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquityInvestmentsAtCost" xlink:to="silo_EquityInvestmentsAtCost_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Receivables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract10" xlink:to="silo_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares_lbl1" xml:lang="en-US">Issuance Of Common Shares For Conversion Of Preferred Stockin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares" xlink:to="silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_FirstCommercialSale_lbl1" xml:lang="en-US">First Commercial Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FirstCommercialSale" xlink:to="silo_FirstCommercialSale_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract11" xlink:to="silo_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SublicenseAgreementAmountPaid_lbl0" xml:lang="en-US">Sublicense Agreement Amount Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseAgreementAmountPaid" xlink:to="silo_SublicenseAgreementAmountPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract14" xlink:to="silo_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract15" xlink:to="silo_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract12" xlink:to="silo_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract13" xlink:to="silo_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Interest Rate Derivatives [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:to="us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_IncomelossFromContinuingOperation_lbl1" xml:lang="en-US">Incomeloss From Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IncomelossFromContinuingOperation" xlink:to="silo_IncomelossFromContinuingOperation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfUMBMinimumRoyaltyPayments_lbl1" xml:lang="en-US">Schedule Of UMBMinimum Royalty Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfUMBMinimumRoyaltyPayments" xlink:to="silo_ScheduleOfUMBMinimumRoyaltyPayments_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract2" xlink:to="silo_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract1" xlink:to="silo_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract4" xlink:to="silo_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract3" xlink:to="silo_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract0" xlink:to="silo_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract9" xlink:to="silo_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract6" xlink:to="silo_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract5" xlink:to="silo_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract8" xlink:to="silo_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract7" xlink:to="silo_UnlabeledAbstract7_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfUmbMinimumRoyaltyPaymentsAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfUmbMinimumRoyaltyPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfUmbMinimumRoyaltyPaymentsAbstract_lbl" xml:lang="en-US">Schedule Of Umb Minimum Royalty Payments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfUmbMinimumRoyaltyPaymentsAbstract" xlink:to="silo_ScheduleOfUmbMinimumRoyaltyPaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SecuritiesReceived_lbl0" xml:lang="en-US">Securities Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SecuritiesReceived" xlink:to="silo_SecuritiesReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PaymentOfSponsoredResearchAmount_lbl1" xml:lang="en-US">Payment Of Sponsored Research Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentOfSponsoredResearchAmount" xlink:to="silo_PaymentOfSponsoredResearchAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_IssuanceOfCommonStockForConversionOfPreferredStock_lbl1" xml:lang="en-US">Issuance Of Common Stock For Conversion Of Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IssuanceOfCommonStockForConversionOfPreferredStock" xlink:to="silo_IssuanceOfCommonStockForConversionOfPreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl1" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities_lbl1" xml:lang="en-US">Derivative Credit Risk Valuation Adjustment, Derivative Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities" xlink:to="us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears_lbl1" xml:lang="en-US">Granted As Incentives Weighted Average Remaining Contractual Term Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears" xlink:to="silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommercialSaleTerm_lbl0" xml:lang="en-US">Commercial Sale Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommercialSaleTerm" xlink:to="silo_CommercialSaleTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AgreementDescription_lbl0" xml:lang="en-US">Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AgreementDescription" xlink:to="silo_AgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_IncomeLossPerCommonShareDilutedAbstract_lbl0" xml:lang="en-US">Income Loss Per Common Share Diluted Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IncomeLossPerCommonShareDilutedAbstract" xlink:to="silo_IncomeLossPerCommonShareDilutedAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UnlabeledAbstract" xlink:to="silo_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_BadDebtRecoveryExpense_lbl1" xml:lang="en-US">Bad Debt Recovery Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_BadDebtRecoveryExpense" xlink:to="silo_BadDebtRecoveryExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_BadDebtRecoveryCashPayment_lbl0" xml:lang="en-US">Bad Debt Recovery Cash Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_BadDebtRecoveryCashPayment" xlink:to="silo_BadDebtRecoveryCashPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ObligationPercentage_lbl0" xml:lang="en-US">Obligation Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ObligationPercentage" xlink:to="silo_ObligationPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate_lbl0" xml:lang="en-US">Accounts Payable, Interest-Bearing, Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_DebtInstrumentsFaceAmount_lbl1" xml:lang="en-US">Debt Instruments Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DebtInstrumentsFaceAmount" xlink:to="silo_DebtInstrumentsFaceAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Option Forfeited Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm" xlink:to="silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PreferredStockStatedValue_lbl1" xml:lang="en-US">Preferred Stock Stated Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredStockStatedValue" xlink:to="silo_PreferredStockStatedValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_HomeBistroIncMember_lbl0" xml:lang="en-US">Home Bistro Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_HomeBistroIncMember" xlink:to="silo_HomeBistroIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_DeferredRevenueLongtermPortion_lbl0" xml:lang="en-US">Deferred Revenue Longterm Portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeferredRevenueLongtermPortion" xlink:to="silo_DeferredRevenueLongtermPortion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AdvisoryAgreementsMember_lbl0" xml:lang="en-US">Advisory Agreements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdvisoryAgreementsMember" xlink:to="silo_AdvisoryAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockCash_lbl0" xml:lang="en-US">Dividends, Preferred Stock, Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockCash" xlink:to="us-gaap_DividendsPreferredStockCash_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_GrossProceeds_lbl1" xml:lang="en-US">Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_GrossProceeds" xlink:to="silo_GrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0" xml:lang="en-US">Debt Instrument, Increase, Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ConvertibleLongTermNotesPayables_lbl1" xml:lang="en-US">Convertible Long Term Notes Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConvertibleLongTermNotesPayables" xlink:to="silo_ConvertibleLongTermNotesPayables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAllocatedToGeneralPartners_lbl0" xml:lang="en-US">Net Income (Loss) Allocated to General Partners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAllocatedToGeneralPartners" xlink:to="us-gaap_NetIncomeLossAllocatedToGeneralPartners_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NonCashInvestingAndFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Non Cash Investing And Financing Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NonCashInvestingAndFinancingActivitiesAbstract" xlink:to="silo_NonCashInvestingAndFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_DatChatIncMember_lbl0" xml:lang="en-US">Dat Chat Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DatChatIncMember" xlink:to="silo_DatChatIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentInterestRate_lbl0" xml:lang="en-US">Investment Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0" xml:lang="en-US">Condensed Balance Sheet [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_GrantedAsIncentivesAggregateIntrinsicValue_lbl0" xml:lang="en-US">Granted As Incentives Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_GrantedAsIncentivesAggregateIntrinsicValue" xlink:to="silo_GrantedAsIncentivesAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PromissoryNote_lbl0" xml:lang="en-US">Promissory Note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PromissoryNote" xlink:to="silo_PromissoryNote_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SubscriptionAgreementsMember_lbl0" xml:lang="en-US">Subscription Agreements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SubscriptionAgreementsMember" xlink:to="silo_SubscriptionAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NetCapitalLossCarryForward_lbl0" xml:lang="en-US">Net Capital Loss Carry Forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NetCapitalLossCarryForward" xlink:to="silo_NetCapitalLossCarryForward_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_LicenseAgreementExpire_lbl0" xml:lang="en-US">License Agreement Expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_LicenseAgreementExpire" xlink:to="silo_LicenseAgreementExpire_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NetLossPerCommonShareAvailableToCommonStockholdersAbstract_lbl0" xml:lang="en-US">Net Loss Per Common Share Available To Common Stockholders Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NetLossPerCommonShareAvailableToCommonStockholdersAbstract" xlink:to="silo_NetLossPerCommonShareAvailableToCommonStockholdersAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_TypeOfAgreementAxis_lbl0" xml:lang="en-US">Type Of Agreement Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TypeOfAgreementAxis" xlink:to="silo_TypeOfAgreementAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_lbl0" xml:lang="en-US">Supplemental Unemployment Benefits, Salary Continuation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" xlink:to="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl2" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Prices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PaymentOfUniversity_lbl0" xml:lang="en-US">Payment Of University</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentOfUniversity" xlink:to="silo_PaymentOfUniversity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl0" xml:lang="en-US">Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl0" xml:lang="en-US">Inventory Write-down</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl0" xml:lang="en-US">Derivative, Fixed Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFixedInterestRate" xlink:to="us-gaap_DerivativeFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesReceivableMember_lbl0" xml:lang="en-US">Notes Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableMember" xlink:to="us-gaap_NotesReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfMilestonePayments_lbl1" xml:lang="en-US">Schedule Of Milestone Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfMilestonePayments" xlink:to="silo_ScheduleOfMilestonePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_EquityInvestmentsAtFairValue_lbl0" xml:lang="en-US">Equity Investments At Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EquityInvestmentsAtFairValue" xlink:to="silo_EquityInvestmentsAtFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_lbl0" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl0" xml:lang="en-US">Common Stock, Share Subscribed but Unissued, Subscriptions Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGross_lbl0" xml:lang="en-US">Inventory, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NumeratorForLossFromContinuingOperationsPerCommonShareDiluted_lbl0" xml:lang="en-US">Numerator For Loss From Continuing Operations Per Common Share Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NumeratorForLossFromContinuingOperationsPerCommonShareDiluted" xlink:to="silo_NumeratorForLossFromContinuingOperationsPerCommonShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PrincipalBalance_lbl1" xml:lang="en-US">Principal Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PrincipalBalance" xlink:to="silo_PrincipalBalance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InsuranceServicesRevenue_lbl0" xml:lang="en-US">Insurance Services Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceServicesRevenue" xlink:to="us-gaap_InsuranceServicesRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NonrefundableCashPayment_lbl0" xml:lang="en-US">Nonrefundable Cash Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NonrefundableCashPayment" xlink:to="silo_NonrefundableCashPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars_lbl1" xml:lang="en-US">Share Based Componsation Number Of Warrants Exercisablein Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars" xlink:to="silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PursuantTerms_lbl1" xml:lang="en-US">Pursuant Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PursuantTerms" xlink:to="silo_PursuantTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_DeferredTaxAssetsValuationAllowances_lbl1" xml:lang="en-US">Deferred Tax Assets Valuation Allowances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeferredTaxAssetsValuationAllowances" xlink:to="silo_DeferredTaxAssetsValuationAllowances_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NotesReceivablePurchasePrice_lbl1" xml:lang="en-US">Notes Receivable Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NotesReceivablePurchasePrice" xlink:to="silo_NotesReceivablePurchasePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventDescription_lbl0" xml:lang="en-US">Subsequent Event, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_Payment_lbl0" xml:lang="en-US">Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_Payment" xlink:to="silo_Payment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SublicenseAmountPaid_lbl1" xml:lang="en-US">Sublicense Amount Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseAmountPaid" xlink:to="silo_SublicenseAmountPaid_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ConsultingAgreementMember_lbl0" xml:lang="en-US">Consulting Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConsultingAgreementMember" xlink:to="silo_ConsultingAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_KuoEmploymentAgreementMember_lbl0" xml:lang="en-US">Kuo Employment Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_KuoEmploymentAgreementMember" xlink:to="silo_KuoEmploymentAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl2" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PaymentDescription_lbl1" xml:lang="en-US">Payment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentDescription" xlink:to="silo_PaymentDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl0" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_FinanceLeaseLiabilities_lbl1" xml:lang="en-US">Finance Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_FinanceLeaseLiabilities" xlink:to="silo_FinanceLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PaymentFourMember_lbl0" xml:lang="en-US">Payment Four Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentFourMember" xlink:to="silo_PaymentFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CashFlowsFromFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Flows From Financing Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CashFlowsFromFinancingActivitiesAbstract" xlink:to="silo_CashFlowsFromFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermDebt_lbl0" xml:lang="en-US">Other Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebt" xlink:to="us-gaap_OtherLongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AdditionsofEquitySecurities_lbl1" xml:lang="en-US">Additionsof Equity Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AdditionsofEquitySecurities" xlink:to="silo_AdditionsofEquitySecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_Milestone_lbl0" xml:lang="en-US">Milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_Milestone" xlink:to="silo_Milestone_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ReverseStockSplitVoteDescription_lbl0" xml:lang="en-US">Reverse Stock Split Vote Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ReverseStockSplitVoteDescription" xlink:to="silo_ReverseStockSplitVoteDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SeriesCConversionPriceMember_lbl0" xml:lang="en-US">Series CConversion Price Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SeriesCConversionPriceMember" xlink:to="silo_SeriesCConversionPriceMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_WeightedAverageRemainingContractualTermYearsGrantedissued_lbl1" xml:lang="en-US">Weighted Average Remaining Contractual Term Years Grantedissued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_WeightedAverageRemainingContractualTermYearsGrantedissued" xlink:to="silo_WeightedAverageRemainingContractualTermYearsGrantedissued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl0" xml:lang="en-US">Proceeds from Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl0" xml:lang="en-US">Unrealized Gain (Loss) on Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl1" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl0" xml:lang="en-US">Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CurrentLiabilitiesAbstract0_lbl0" xml:lang="en-US">Current Liabilities Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CurrentLiabilitiesAbstract0" xlink:to="silo_CurrentLiabilitiesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl0" xml:lang="en-US">Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Forfeiture [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:to="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl0" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue_lbl2" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Option Outstanding Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue" xlink:to="silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_DeemedDividendOnPreferredStockExchange_lbl1" xml:lang="en-US">Deemed Dividend On Preferred Stock Exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeemedDividendOnPreferredStockExchange" xlink:to="silo_DeemedDividendOnPreferredStockExchange_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Ownership Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl0" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SponsoredStudyAgreementDescription_lbl0" xml:lang="en-US">Sponsored Study Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SponsoredStudyAgreementDescription" xlink:to="silo_SponsoredStudyAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl0" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PaymentThreeMember_lbl0" xml:lang="en-US">Payment Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentThreeMember" xlink:to="silo_PaymentThreeMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract_lbl" xml:lang="en-US">Schedule Of Effective Statutory Rate And The Provision For Income Taxes Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract" xlink:to="silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NumberOfWarrant_lbl2" xml:lang="en-US">Number Of Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NumberOfWarrant" xlink:to="silo_NumberOfWarrant_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_EffectOfDilutiveSecuritiesAbstract_lbl0" xml:lang="en-US">Effect Of Dilutive Securities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EffectOfDilutiveSecuritiesAbstract" xlink:to="silo_EffectOfDilutiveSecuritiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_EmploymentAgreementDescription_lbl0" xml:lang="en-US">Employment Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EmploymentAgreementDescription" xlink:to="silo_EmploymentAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_lbl0" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PurchaseAgreementsDescription_lbl1" xml:lang="en-US">Purchase Agreements Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PurchaseAgreementsDescription" xlink:to="silo_PurchaseAgreementsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ConvertablePreferredStock_lbl1" xml:lang="en-US">Convertable Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConvertablePreferredStock" xlink:to="silo_ConvertablePreferredStock_lbl1"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfNotesReceivableNetAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfNotesReceivableNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfNotesReceivableNetAbstract_lbl" xml:lang="en-US">Schedule Of Notes Receivable Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfNotesReceivableNetAbstract" xlink:to="silo_ScheduleOfNotesReceivableNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LayawaySaleMember_lbl0" xml:lang="en-US">Layaway Sale [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LayawaySaleMember" xlink:to="us-gaap_LayawaySaleMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl0" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_TotalOutstandingBalanceReceivable_lbl1" xml:lang="en-US">Total Outstanding Balance Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TotalOutstandingBalanceReceivable" xlink:to="silo_TotalOutstandingBalanceReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AccruedInterestReceivable_lbl1" xml:lang="en-US">Accrued Interest Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AccruedInterestReceivable" xlink:to="silo_AccruedInterestReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UMBPayment_lbl0" xml:lang="en-US">UMBPayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UMBPayment" xlink:to="silo_UMBPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_promissoryNoteAmount_lbl1" xml:lang="en-US">promissory Note Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_promissoryNoteAmount" xlink:to="silo_promissoryNoteAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AssetsAbstract0_lbl0" xml:lang="en-US">Assets Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AssetsAbstract0" xlink:to="silo_AssetsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalDeferredPurchasePrice_lbl1" xml:lang="en-US">Supplemental Deferred Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalDeferredPurchasePrice" xlink:to="us-gaap_SupplementalDeferredPurchasePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_AggregateOfConvertedShares_lbl0" xml:lang="en-US">Aggregate Of Converted Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_AggregateOfConvertedShares" xlink:to="silo_AggregateOfConvertedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl1" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable_lbl1" xml:lang="en-US">Share Based Composation Weighted Average Remaining Contractual Term Years Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable" xlink:to="silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl0" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl0" xml:lang="en-US">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract_lbl" xml:lang="en-US">Schedule Of Operating Result Of Discontinued Operations Of The Nfid Business Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalUnits_lbl0" xml:lang="en-US">Capital Units, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnits" xlink:to="us-gaap_CapitalUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_GainLossOnSaleOfCapitalLeaseNet_lbl1" xml:lang="en-US">Gain Loss On Sale Of Capital Lease Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_GainLossOnSaleOfCapitalLeaseNet" xlink:to="silo_GainLossOnSaleOfCapitalLeaseNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl0" xml:lang="en-US">Preferred Stock, Redemption Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_StockOptionsMember_lbl0" xml:lang="en-US">Stock Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_StockOptionsMember" xlink:to="silo_StockOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_EmploymentAgreementMember_lbl0" xml:lang="en-US">Employment Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_EmploymentAgreementMember" xlink:to="silo_EmploymentAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp_lbl1" xml:lang="en-US">Iniital Fair Value Of Stock Options Issued As Stockbased Compensation Recorded As Deferred Comp</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp" xlink:to="silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromCollectionOfNotesReceivable_lbl0" xml:lang="en-US">Proceeds from Collection of Notes Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:to="us-gaap_ProceedsFromCollectionOfNotesReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_lbl0" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_NotrPayableLessCurrentPortion_lbl0" xml:lang="en-US">Notr Payable Less Current Portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_NotrPayableLessCurrentPortion" xlink:to="silo_NotrPayableLessCurrentPortion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PreferredSharesExchangedForCommonStockShares_lbl1" xml:lang="en-US">Preferred Shares Exchanged For Common Stock Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PreferredSharesExchangedForCommonStockShares" xlink:to="silo_PreferredSharesExchangedForCommonStockShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_DebtInstrumentIncreasesAccruedInterest_lbl1" xml:lang="en-US">Debt Instrument Increases Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DebtInstrumentIncreasesAccruedInterest" xlink:to="silo_DebtInstrumentIncreasesAccruedInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturityDate_lbl0" xml:lang="en-US">Long-Term Debt, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturityDate" xlink:to="us-gaap_LongTermDebtMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_GainFromSaleOfNFIDBusiness_lbl1" xml:lang="en-US">Gain From Sale Of NFIDBusiness</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_GainFromSaleOfNFIDBusiness" xlink:to="silo_GainFromSaleOfNFIDBusiness_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl0" xml:lang="en-US">Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl1" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommonStockIssuedForPrepaidServices_lbl0" xml:lang="en-US">Common Stock Issued For Prepaid Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockIssuedForPrepaidServices" xlink:to="silo_CommonStockIssuedForPrepaidServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl0" xml:lang="en-US">Condensed Income Statement [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ConcentrationsRiskPercentage1_lbl1" xml:lang="en-US">Concentrations Risk Percentage1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ConcentrationsRiskPercentage1" xlink:to="silo_ConcentrationsRiskPercentage1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_TotalOfSharesOfCommonStock_lbl1" xml:lang="en-US">Total Of Shares Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TotalOfSharesOfCommonStock" xlink:to="silo_TotalOfSharesOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet_lbl0" xml:lang="en-US">Interest Rate Derivative Instruments Not Designated as Hedging Instruments at Fair Value, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet" xlink:to="us-gaap_InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_lbl0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Explanation of Change</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl1" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CompanyPaidCash_lbl0" xml:lang="en-US">Company Paid Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CompanyPaidCash" xlink:to="silo_CompanyPaidCash_lbl0"/>
    <loc xlink:type="locator" xlink:label="silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract_lbl" xml:lang="en-US">Schedule Of Financial Data Of The Company SGain From Sale Of The Nfid Business Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:to="silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_TotalSubscriptionReceivableValue_lbl1" xml:lang="en-US">Total Subscription Receivable Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_TotalSubscriptionReceivableValue" xlink:to="silo_TotalSubscriptionReceivableValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnRestructuringOfDebt_lbl0" xml:lang="en-US">Gains (Losses) on Restructuring of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="us-gaap_GainsLossesOnRestructuringOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl0" xml:lang="en-US">Cash, FDIC Insured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_RecognizedRevenues_lbl0" xml:lang="en-US">Recognized Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RecognizedRevenues" xlink:to="silo_RecognizedRevenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl1" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_DeemedDividend_lbl1" xml:lang="en-US">Deemed Dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_DeemedDividend" xlink:to="silo_DeemedDividend_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_UpfrontLicenseFees_lbl1" xml:lang="en-US">Upfront License Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_UpfrontLicenseFees" xlink:to="silo_UpfrontLicenseFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl1" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_PaymentTwoMember_lbl0" xml:lang="en-US">Payment Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_PaymentTwoMember" xlink:to="silo_PaymentTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl0" xml:lang="en-US">Proceeds from Sale of Productive Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl0" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_ExchangeAgreementsMember_lbl0" xml:lang="en-US">Exchange Agreements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_ExchangeAgreementsMember" xlink:to="silo_ExchangeAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_CommonStockGrantDateFairValuePerShare_lbl1" xml:lang="en-US">Common Stock Grant Date Fair Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_CommonStockGrantDateFairValuePerShare" xlink:to="silo_CommonStockGrantDateFairValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_RecoveredBadDebt_lbl1" xml:lang="en-US">Recovered Bad Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_RecoveredBadDebt" xlink:to="silo_RecoveredBadDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl0" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivable_lbl0" xml:lang="en-US">Interest Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl0" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableCurrent_lbl0" xml:lang="en-US">Loans Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesReceivableGross_lbl1" xml:lang="en-US">Financing Receivable, before Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableGross" xlink:to="us-gaap_NotesReceivableGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConversionBasis_lbl0" xml:lang="en-US">Preferred Stock, Conversion Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConversionBasis" xlink:to="us-gaap_PreferredStockConversionBasis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="silo_SublicenseIncomeDescription_lbl0" xml:lang="en-US">Sublicense Income Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="silo_SublicenseIncomeDescription" xlink:to="silo_SublicenseIncomeDescription_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>silo-20220630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Sep 20 20:53:05 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ConsolidatedBalanceSheet" roleURI="http://silopharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ConsolidatedIncomeStatement" roleURI="http://silopharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ShareholdersEquityType2or3" roleURI="http://silopharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ConsolidatedCashFlow" roleURI="http://silopharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_OrganizationandBusiness" roleURI="http://silopharma.com/role/OrganizationandBusiness"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_SummaryofSignificantAccountingPolicies" roleURI="http://silopharma.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_FairValueofFinancialInstrumentsandFairValueMeasurements" roleURI="http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_DisposaloftheDiscontinuedOperationsoftheNfidBusiness" roleURI="http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusiness"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_NotesReceivable" roleURI="http://silopharma.com/role/NotesReceivable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_NotePayable" roleURI="http://silopharma.com/role/NotePayable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_StockholdersEquity" roleURI="http://silopharma.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_IncomeTaxes" roleURI="http://silopharma.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_Concentrations" roleURI="http://silopharma.com/role/Concentrations"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_CommitmentsandContingencies" roleURI="http://silopharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_SubsequentEvents" roleURI="http://silopharma.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_AccountingPoliciesByPolicy" roleURI="http://silopharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://silopharma.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_FairValueofFinancialInstrumentsandFairValueMeasurementsTables" roleURI="http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_DisposaloftheDiscontinuedOperationsoftheNfidBusinessTables" roleURI="http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_NotesReceivableTables" roleURI="http://silopharma.com/role/NotesReceivableTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_NotePayableTables" roleURI="http://silopharma.com/role/NotePayableTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_StockholdersEquityTables" roleURI="http://silopharma.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_IncomeTaxesTables" roleURI="http://silopharma.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_CommitmentsandContingenciesTables" roleURI="http://silopharma.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofantidilutivenetlosspershareTable" roleURI="http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofreconciliationofbasicanddilutednetlosspershareTable" roleURI="http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" roleURI="http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable" roleURI="http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable" roleURI="http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable" roleURI="http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofnotesreceivableTable" roleURI="http://silopharma.com/role/ScheduleofnotesreceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofinterestexpenseTable" roleURI="http://silopharma.com/role/ScheduleofinterestexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofstockoptionsactivitiesTable" roleURI="http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofwarrantactivitiesTable" roleURI="http://silopharma.com/role/ScheduleofwarrantactivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable" roleURI="http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable_Parentheticals" roleURI="http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofnetdeferredtaxassetTable" roleURI="http://silopharma.com/role/ScheduleofnetdeferredtaxassetTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofmilestonepaymentsTable" roleURI="http://silopharma.com/role/ScheduleofmilestonepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofUMBminimumroyaltypaymentsTable" roleURI="http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable" roleURI="http://silopharma.com/role/ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofshallpayUMBTable" roleURI="http://silopharma.com/role/ScheduleofshallpayUMBTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofantidilutivenetlosspershareTable0" roleURI="http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0" roleURI="http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable0" roleURI="http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable0" roleURI="http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable0" roleURI="http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofnotesreceivablenetTable" roleURI="http://silopharma.com/role/ScheduleofnotesreceivablenetTable"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofstockoptionsactivitiesTable0" roleURI="http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofwarrantactivitiesTable0" roleURI="http://silopharma.com/role/ScheduleofwarrantactivitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofmilestonepaymentsTable0" roleURI="http://silopharma.com/role/ScheduleofmilestonepaymentsTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofUMBminimumroyaltypaymentsTable0" roleURI="http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ScheduleofshallpayUMBTable0" roleURI="http://silopharma.com/role/ScheduleofshallpayUMBTable0"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_OrganizationandBusinessDetails" roleURI="http://silopharma.com/role/OrganizationandBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_FairValueofFinancialInstrumentsandFairValueMeasurementsDetails" roleURI="http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_DisposaloftheDiscontinuedOperationsoftheNfidBusinessDetails" roleURI="http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_NotesReceivableDetails" roleURI="http://silopharma.com/role/NotesReceivableDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_NotePayableDetails" roleURI="http://silopharma.com/role/NotePayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_StockholdersEquityDetails" roleURI="http://silopharma.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_IncomeTaxesDetails" roleURI="http://silopharma.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_ConcentrationsDetails" roleURI="http://silopharma.com/role/ConcentrationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_CommitmentsandContingenciesDetails" roleURI="http://silopharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#silo_r_SubsequentEventsDetails" roleURI="http://silopharma.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="silo-20220630.xsd#DocumentAndEntityInformation" roleURI="http://silopharma.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityInvestmentsAtCost" xlink:href="silo-20220630.xsd#silo_EquityInvestmentsAtCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="EquityInvestmentsAtCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LoansPayableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermLiabilitiesAbstract" xlink:href="silo-20220630.xsd#silo_LongTermLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="LongTermLiabilitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredStockValueOne" xlink:href="silo-20220630.xsd#silo_PreferredStockValueOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="PreferredStockValueOne" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredStockValueTwo" xlink:href="silo-20220630.xsd#silo_PreferredStockValueTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="PreferredStockValueTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestReceivableNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestReceivableNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="LicenseFees" xlink:href="silo-20220630.xsd#silo_LicenseFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="LicenseFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProfessionalFees" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralInsuranceExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralInsuranceExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BadDebtRecoveryExpense" xlink:href="silo-20220630.xsd#silo_BadDebtRecoveryExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="BadDebtRecoveryExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIncomeFromEquitySharesEarnedForServices" xlink:href="silo-20220630.xsd#silo_OtherIncomeFromEquitySharesEarnedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="OtherIncomeFromEquitySharesEarnedForServices" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseRelatedParty" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnrealizedGainLossOnEquityInvestments" xlink:href="silo-20220630.xsd#silo_UnrealizedGainLossOnEquityInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="UnrealizedGainLossOnEquityInvestments" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="DiscontinuedOperationsAbstract" xlink:href="silo-20220630.xsd#silo_DiscontinuedOperationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="DiscontinuedOperationsAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DiscontinuedOperationsAbstract" xlink:to="us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DiscontinuedOperationsAbstract" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedForFutureServices" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForFutureServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="CommonStockIssuedForFutureServices" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedForFutureServicesShares" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForFutureServicesShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="CommonStockIssuedForFutureServicesShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredSharesExchangedForCommonStock" xlink:href="silo-20220630.xsd#silo_PreferredSharesExchangedForCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="PreferredSharesExchangedForCommonStock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredSharesExchangedForCommonStockShares" xlink:href="silo-20220630.xsd#silo_PreferredSharesExchangedForCommonStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="PreferredSharesExchangedForCommonStockShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedForExchangeOfNotes" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForExchangeOfNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="CommonStockIssuedForExchangeOfNotes" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedForExchangeOfNotesShares" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForExchangeOfNotesShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="CommonStockIssuedForExchangeOfNotesShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeemedDividendOnPreferredStockExchange" xlink:href="silo-20220630.xsd#silo_DeemedDividendOnPreferredStockExchange"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="DeemedDividendOnPreferredStockExchange" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockForConversionOfPreferredStock" xlink:href="silo-20220630.xsd#silo_IssuanceOfCommonStockForConversionOfPreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockForConversionOfPreferredStock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonSharesForConversionOfPreferredStockinShares" xlink:href="silo-20220630.xsd#silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonSharesForConversionOfPreferredStockinShares" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmortizationOfPrepaidStockbasedExpense" xlink:href="silo-20220630.xsd#silo_AmortizationOfPrepaidStockbasedExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfPrepaidStockbasedExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfDerivatives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfDerivatives" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnRestructuringOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnRestructuringOfDebt" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="LossFromDebtExtinguishment" xlink:href="silo-20220630.xsd#silo_LossFromDebtExtinguishment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="LossFromDebtExtinguishment" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInAssetsOfDiscontinuedOperation" xlink:href="silo-20220630.xsd#silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAssetsOfDiscontinuedOperation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPayablesToBrokerDealers" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPayablesToBrokerDealers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPayablesToBrokerDealers" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromCollectionOfNotesReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CollectionOnNoteReceivable" xlink:href="silo-20220630.xsd#silo_CollectionOnNoteReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="CollectionOnNoteReceivable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvanceFromARelatedParty" xlink:href="silo-20220630.xsd#silo_AdvanceFromARelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="AdvanceFromARelatedParty" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_InterestPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashPaidDuringThePeriodForAbstract" xlink:href="silo-20220630.xsd#silo_CashPaidDuringThePeriodForAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="CashPaidDuringThePeriodForAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidDuringThePeriodForAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidDuringThePeriodForAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedForFutureServices" xlink:href="silo-20220630.xsd#silo_StockIssuedForFutureServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="StockIssuedForFutureServices" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedForPrepaidServices" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForPrepaidServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="CommonStockIssuedForPrepaidServices" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp" xlink:href="silo-20220630.xsd#silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree" xlink:href="silo-20220630.xsd#silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement" xlink:href="silo-20220630.xsd#silo_NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/OrganizationandBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/NotesReceivable">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/NotePayable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/Concentrations">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiquidityPolicyTextBlock" xlink:href="silo-20220630.xsd#silo_LiquidityPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LiquidityPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityInvestmentsAtFairValuePolicyTextBlock" xlink:href="silo-20220630.xsd#silo_EquityInvestmentsAtFairValuePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="EquityInvestmentsAtFairValuePolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityInvestmentsAtCostPolicyTextBlock" xlink:href="silo-20220630.xsd#silo_EquityInvestmentsAtCostPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="EquityInvestmentsAtCostPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CostOfRevenuesPolicyTextBlock" xlink:href="silo-20220630.xsd#silo_CostOfRevenuesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="CostOfRevenuesPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock" xlink:href="silo-20220630.xsd#silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock" xlink:href="silo-20220630.xsd#silo_ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/NotesReceivableTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/NotePayableTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/StockholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/CommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfMilestonePayments" xlink:href="silo-20220630.xsd#silo_ScheduleOfMilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfMilestonePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfUMBMinimumRoyaltyPayments" xlink:href="silo-20220630.xsd#silo_ScheduleOfUMBMinimumRoyaltyPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfUMBMinimumRoyaltyPayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfExclusiveOfValueAddedTaxToBeAmortized" xlink:href="silo-20220630.xsd#silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfExclusiveOfValueAddedTaxToBeAmortized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfShallPayUMB" xlink:href="silo-20220630.xsd#silo_ScheduleOfShallPayUMB"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfShallPayUMB" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAntiDilutiveNetLossPerShareAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfAntiDilutiveNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" xlink:href="silo-20220630.xsd#silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems" xlink:href="silo-20220630.xsd#silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntiDilutiveNetLossPerShareAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="StockOptionsMember" xlink:href="silo-20220630.xsd#silo_StockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="StockOptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeLossPerCommonShareBasicAbstract" xlink:href="silo-20220630.xsd#silo_IncomeLossPerCommonShareBasicAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareAbstract" xlink:to="IncomeLossPerCommonShareBasicAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomelossFromContinuingOperation" xlink:href="silo-20220630.xsd#silo_IncomelossFromContinuingOperation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareBasicAbstract" xlink:to="IncomelossFromContinuingOperation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeLossFromDiscontinuedOperations" xlink:href="silo-20220630.xsd#silo_IncomeLossFromDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareBasicAbstract" xlink:to="IncomeLossFromDiscontinuedOperations" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract" xlink:href="silo-20220630.xsd#silo_NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareBasicAbstract" xlink:to="NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeLossPerCommonShareDilutedAbstract" xlink:href="silo-20220630.xsd#silo_IncomeLossPerCommonShareDilutedAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareAbstract" xlink:to="IncomeLossPerCommonShareDilutedAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomelossFromContinuingOperation_0" xlink:href="silo-20220630.xsd#silo_IncomelossFromContinuingOperation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareDilutedAbstract" xlink:to="IncomelossFromContinuingOperation_0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareDilutedAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumeratorForLossFromContinuingOperationsPerCommonShareDiluted" xlink:href="silo-20220630.xsd#silo_NumeratorForLossFromContinuingOperationsPerCommonShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareDilutedAbstract" xlink:to="NumeratorForLossFromContinuingOperationsPerCommonShareDiluted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted" xlink:href="silo-20220630.xsd#silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareDilutedAbstract" xlink:to="NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAllocatedToGeneralPartners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAllocatedToGeneralPartners"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAllocatedToGeneralPartners" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectOfDilutiveSecuritiesAbstract" xlink:href="silo-20220630.xsd#silo_EffectOfDilutiveSecuritiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareDilutedAbstract" xlink:to="EffectOfDilutiveSecuritiesAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectOfDilutiveSecuritiesAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AuctionMarketPreferredSecuritiesSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectOfDilutiveSecuritiesAbstract" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract" xlink:href="silo-20220630.xsd#silo_NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareDilutedAbstract" xlink:to="NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:href="silo-20220630.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
    <loc xlink:type="locator" xlink:label="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:href="silo-20220630.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:to="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EquityInvestmentsAtFairValue" xlink:href="silo-20220630.xsd#silo_EquityInvestmentsAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="EquityInvestmentsAtFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:to="us-gaap_EquityMethodInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionsofEquitySecurities" xlink:href="silo-20220630.xsd#silo_AdditionsofEquitySecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:to="AdditionsofEquitySecurities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:to="us-gaap_EquityMethodInvestments_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract"/>
    <loc xlink:type="locator" xlink:label="CurrentAssetsAbstract0" xlink:href="silo-20220630.xsd#silo_CurrentAssetsAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:to="CurrentAssetsAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAssetsAbstract0" xlink:to="us-gaap_InventoryNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentLiabilitiesAbstract0" xlink:href="silo-20220630.xsd#silo_CurrentLiabilitiesAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:to="CurrentLiabilitiesAbstract0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseLiabilities" xlink:href="silo-20220630.xsd#silo_FinanceLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentLiabilitiesAbstract0" xlink:to="FinanceLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="NetAssetOfNFIDBusinessDisposed" xlink:href="silo-20220630.xsd#silo_NetAssetOfNFIDBusinessDisposed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:to="NetAssetOfNFIDBusinessDisposed" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsiderationInTheFormOfANoteReceivable" xlink:href="silo-20220630.xsd#silo_ConsiderationInTheFormOfANoteReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:to="ConsiderationInTheFormOfANoteReceivable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="GainFromSaleOfNFIDBusiness" xlink:href="silo-20220630.xsd#silo_GainFromSaleOfNFIDBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="GainFromSaleOfNFIDBusiness" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofnotesreceivableTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfNotesReceivableAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfNotesReceivableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNotesReceivableAbstract" xlink:to="us-gaap_NotesReceivableGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalNotesReceivableIn2021" xlink:href="silo-20220630.xsd#silo_AdditionalNotesReceivableIn2021"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesReceivableGross" xlink:to="AdditionalNotesReceivableIn2021" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CollectionsOnNotesReceivable" xlink:href="silo-20220630.xsd#silo_CollectionsOnNotesReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesReceivableGross" xlink:to="CollectionsOnNotesReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesReceivableGross" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNotesReceivableAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LessNotesReceivableNetCurrentPortion" xlink:href="silo-20220630.xsd#silo_LessNotesReceivableNetCurrentPortion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="LessNotesReceivableNetCurrentPortion" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNotesReceivableAbstract" xlink:to="us-gaap_NotesReceivableNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofinterestexpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInterestExpenseAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfInterestExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentsFaceAmount" xlink:href="silo-20220630.xsd#silo_DebtInstrumentsFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInterestExpenseAbstract" xlink:to="DebtInstrumentsFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NotrPayableLessCurrentPortion" xlink:href="silo-20220630.xsd#silo_NotrPayableLessCurrentPortion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInterestExpenseAbstract" xlink:to="NotrPayableLessCurrentPortion" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="NotePayableLongTermPortion" xlink:href="silo-20220630.xsd#silo_NotePayableLongTermPortion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInterestExpenseAbstract" xlink:to="NotePayableLongTermPortion" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionsActivitiesAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfStockOptionsActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable" xlink:href="silo-20220630.xsd#silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:href="silo-20220630.xsd#silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivitiesAbstract" xlink:to="StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="StockOptionsMember" xlink:href="silo-20220630.xsd#silo_StockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="StockOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable" xlink:to="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" xlink:href="silo-20220630.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingContractualTermYearsGrantedissued" xlink:href="silo-20220630.xsd#silo_WeightedAverageRemainingContractualTermYearsGrantedissued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="WeightedAverageRemainingContractualTermYearsGrantedissued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateIntrinsicValueGrantedIssuedForfeited1" xlink:href="silo-20220630.xsd#silo_AggregateIntrinsicValueGrantedIssuedForfeited1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="AggregateIntrinsicValueGrantedIssuedForfeited1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_0" xlink:href="silo-20220630.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofwarrantactivitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantActivitiesAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfWarrantActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantActivitiesAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfWarrant" xlink:href="silo-20220630.xsd#silo_NumberOfWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOfWarrant" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue" xlink:href="silo-20220630.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedComponsationNumberOfWarrantsForfeited" xlink:href="silo-20220630.xsd#silo_ShareBasedComponsationNumberOfWarrantsForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedComponsationNumberOfWarrantsForfeited" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited" xlink:href="silo-20220630.xsd#silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfWarrant_0" xlink:href="silo-20220630.xsd#silo_NumberOfWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOfWarrant_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue_0" xlink:href="silo-20220630.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedComponsationNumberOfWarrantsExercisableinDollars" xlink:href="silo-20220630.xsd#silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedComponsationNumberOfWarrantsExercisableinDollars" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable" xlink:href="silo-20220630.xsd#silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedComponsationNumberOfWarrantsGranted" xlink:href="silo-20220630.xsd#silo_ShareBasedComponsationNumberOfWarrantsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedComponsationNumberOfWarrantsGranted" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted" xlink:href="silo-20220630.xsd#silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateIntrinsicValueGranted" xlink:href="silo-20220630.xsd#silo_AggregateIntrinsicValueGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="AggregateIntrinsicValueGranted" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvailableForSalesEquitySecuritiesGrossUnrealizedGain" xlink:href="silo-20220630.xsd#silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract" xlink:to="AvailableForSalesEquitySecuritiesGrossUnrealizedGain" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofnetdeferredtaxassetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfNetDeferredTaxAssetAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfNetDeferredTaxAssetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsCapitalLossCarryforward" xlink:href="silo-20220630.xsd#silo_DeferredTaxAssetsCapitalLossCarryforward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetAbstract" xlink:to="DeferredTaxAssetsCapitalLossCarryforward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetGross" xlink:href="silo-20220630.xsd#silo_DeferredTaxAssetGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetAbstract" xlink:to="DeferredTaxAssetGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsValuationAllowances" xlink:href="silo-20220630.xsd#silo_DeferredTaxAssetsValuationAllowances"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetAbstract" xlink:to="DeferredTaxAssetsValuationAllowances" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofmilestonepaymentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMilestonePaymentsAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfMilestonePaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMilestonePaymentsAbstract" xlink:to="CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PaymentOneMember" xlink:href="silo-20220630.xsd#silo_PaymentOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentTwoMember" xlink:href="silo-20220630.xsd#silo_PaymentTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentThreeMember" xlink:href="silo-20220630.xsd#silo_PaymentThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentThreeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentFourMember" xlink:href="silo-20220630.xsd#silo_PaymentFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentFourMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentFiveMember" xlink:href="silo-20220630.xsd#silo_PaymentFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentFiveMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable" xlink:to="CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="Milestone" xlink:href="silo-20220630.xsd#silo_Milestone"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems" xlink:to="Milestone" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePayment" xlink:href="silo-20220630.xsd#silo_MilestonePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems" xlink:to="MilestonePayment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfUmbMinimumRoyaltyPaymentsAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfUmbMinimumRoyaltyPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUmbMinimumRoyaltyPaymentsAbstract" xlink:to="CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PaymentOneMember" xlink:href="silo-20220630.xsd#silo_PaymentOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentTwoMember" xlink:href="silo-20220630.xsd#silo_PaymentTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentThreeMember" xlink:href="silo-20220630.xsd#silo_PaymentThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentThreeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentFourMember" xlink:href="silo-20220630.xsd#silo_PaymentFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentFourMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentFiveMember" xlink:href="silo-20220630.xsd#silo_PaymentFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentFiveMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable" xlink:to="CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="UMBYearDescription" xlink:href="silo-20220630.xsd#silo_UMBYearDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems" xlink:to="UMBYearDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UMBPayment" xlink:href="silo-20220630.xsd#silo_UMBPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems" xlink:to="UMBPayment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfExclusiveOfValueAddedTaxToBeAmortizedAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortizedAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExclusiveOfValueAddedTaxToBeAmortizedAbstract" xlink:to="CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PaymentOneMember" xlink:href="silo-20220630.xsd#silo_PaymentOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="PaymentOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentTwoMember" xlink:href="silo-20220630.xsd#silo_PaymentTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="PaymentTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentThreeMember" xlink:href="silo-20220630.xsd#silo_PaymentThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="PaymentThreeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentFourMember" xlink:href="silo-20220630.xsd#silo_PaymentFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="PaymentFourMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentFiveMember" xlink:href="silo-20220630.xsd#silo_PaymentFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="PaymentFiveMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedTable" xlink:to="CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="Payment" xlink:href="silo-20220630.xsd#silo_Payment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems" xlink:to="Payment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentDescription" xlink:href="silo-20220630.xsd#silo_PaymentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems" xlink:to="PaymentDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofshallpayUMBTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShallPayUmbAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfShallPayUmbAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShallPayUmbAbstract" xlink:to="CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYRCCyonMiwgdQ2lJYzdzUOv9fI1l/VI08eZ/jN8gtVkovQNM+Tg8ySqLg3+WC1g4h34l8wpPDRKEpvN2sEoV7GBwsfUtZ7wPjtnRwjx//zhaHDazrcKZSY+odwB4qGm1MOd/qfdmKbOaTaPPe9bPa/02wjXfGOjU12GfRhsnE31flgx8L3rlukMAshxNcd5JrwZ9reHAxeLQ==] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PaymentSixMember" xlink:href="silo-20220630.xsd#silo_PaymentSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="PaymentSixMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentSevenMember" xlink:href="silo-20220630.xsd#silo_PaymentSevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="PaymentSevenMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentEightMember" xlink:href="silo-20220630.xsd#silo_PaymentEightMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="PaymentEightMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable" xlink:to="CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SponsoredPayment" xlink:href="silo-20220630.xsd#silo_SponsoredPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems" xlink:to="SponsoredPayment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentDescription" xlink:href="silo-20220630.xsd#silo_PaymentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems" xlink:to="PaymentDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfAntiDilutiveNetLossPerShareAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfAntiDilutiveNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" xlink:href="silo-20220630.xsd#silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems" xlink:href="silo-20220630.xsd#silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntiDilutiveNetLossPerShareAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:href="silo-20220630.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
    <loc xlink:type="locator" xlink:label="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:href="silo-20220630.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:to="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EquityInvestmentsAtFairValue" xlink:href="silo-20220630.xsd#silo_EquityInvestmentsAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="EquityInvestmentsAtFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:to="us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionsofEquitySecurities" xlink:href="silo-20220630.xsd#silo_AdditionsofEquitySecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:to="AdditionsofEquitySecurities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract" xlink:to="us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseLiabilities" xlink:href="silo-20220630.xsd#silo_FinanceLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="FinanceLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="NetAssetOfNFIDBusinessDisposed" xlink:href="silo-20220630.xsd#silo_NetAssetOfNFIDBusinessDisposed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="NetAssetOfNFIDBusinessDisposed" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsiderationInTheFormOfANoteReceivable" xlink:href="silo-20220630.xsd#silo_ConsiderationInTheFormOfANoteReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="ConsiderationInTheFormOfANoteReceivable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofnotesreceivablenetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfNotesReceivableNetAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfNotesReceivableNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNotesReceivableNetAbstract" xlink:to="us-gaap_NotesReceivableGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalNotesReceivableIn2021" xlink:href="silo-20220630.xsd#silo_AdditionalNotesReceivableIn2021"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesReceivableGross" xlink:to="AdditionalNotesReceivableIn2021" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CollectionsOnNotesReceivables" xlink:href="silo-20220630.xsd#silo_CollectionsOnNotesReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesReceivableGross" xlink:to="CollectionsOnNotesReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesReceivableGross" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLosses" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNotesReceivableNetAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LessNotesReceivableNetCurrentPortion" xlink:href="silo-20220630.xsd#silo_LessNotesReceivableNetCurrentPortion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="LessNotesReceivableNetCurrentPortion" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNotesReceivableNetAbstract" xlink:to="us-gaap_NotesReceivableNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionsActivitiesAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfStockOptionsActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable" xlink:href="silo-20220630.xsd#silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:href="silo-20220630.xsd#silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivitiesAbstract" xlink:to="StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="StockOptionsMember" xlink:href="silo-20220630.xsd#silo_StockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="StockOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable" xlink:to="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantedAsIncentivesWeightedAverageRemainingContractualTermYears" xlink:href="silo-20220630.xsd#silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="GrantedAsIncentivesWeightedAverageRemainingContractualTermYears" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantedAsIncentivesAggregateIntrinsicValue" xlink:href="silo-20220630.xsd#silo_GrantedAsIncentivesAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="GrantedAsIncentivesAggregateIntrinsicValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:href="silo-20220630.xsd#silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:href="silo-20220630.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm" xlink:href="silo-20220630.xsd#silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue" xlink:href="silo-20220630.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofwarrantactivitiesTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantActivitiesAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfWarrantActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantActivitiesAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue" xlink:href="silo-20220630.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted" xlink:href="silo-20220630.xsd#silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateIntrinsicValueGranted" xlink:href="silo-20220630.xsd#silo_AggregateIntrinsicValueGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="AggregateIntrinsicValueGranted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue_0" xlink:href="silo-20220630.xsd#silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedComponsationNumberOfWarrantsExercisableinDollars" xlink:href="silo-20220630.xsd#silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedComponsationNumberOfWarrantsExercisableinDollars" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable" xlink:href="silo-20220630.xsd#silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofmilestonepaymentsTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfMilestonePaymentsAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfMilestonePaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMilestonePaymentsAbstract" xlink:to="CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PaymentOneMember" xlink:href="silo-20220630.xsd#silo_PaymentOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentTwoMember" xlink:href="silo-20220630.xsd#silo_PaymentTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentThreeMember" xlink:href="silo-20220630.xsd#silo_PaymentThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentThreeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentFourMember" xlink:href="silo-20220630.xsd#silo_PaymentFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentFourMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentFiveMember" xlink:href="silo-20220630.xsd#silo_PaymentFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentFiveMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable" xlink:to="CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="Milestone" xlink:href="silo-20220630.xsd#silo_Milestone"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems" xlink:to="Milestone" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePayment" xlink:href="silo-20220630.xsd#silo_MilestonePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems" xlink:to="MilestonePayment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfUmbMinimumRoyaltyPaymentsAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfUmbMinimumRoyaltyPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUmbMinimumRoyaltyPaymentsAbstract" xlink:to="CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PaymentOneMember" xlink:href="silo-20220630.xsd#silo_PaymentOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentTwoMember" xlink:href="silo-20220630.xsd#silo_PaymentTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentThreeMember" xlink:href="silo-20220630.xsd#silo_PaymentThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentThreeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentFourMember" xlink:href="silo-20220630.xsd#silo_PaymentFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentFourMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentFiveMember" xlink:href="silo-20220630.xsd#silo_PaymentFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PaymentFiveMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable" xlink:to="CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="YearsDescription" xlink:href="silo-20220630.xsd#silo_YearsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems" xlink:to="YearsDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinimumAnnualRoyalty" xlink:href="silo-20220630.xsd#silo_MinimumAnnualRoyalty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems" xlink:to="MinimumAnnualRoyalty" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ScheduleofshallpayUMBTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfShallPayUmbAbstract" xlink:href="silo-20220630.xsd#silo_ScheduleOfShallPayUmbAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShallPayUmbAbstract" xlink:to="CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PaymentSixMember" xlink:href="silo-20220630.xsd#silo_PaymentSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="PaymentSixMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentSevenMember" xlink:href="silo-20220630.xsd#silo_PaymentSevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="PaymentSevenMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentEightMember" xlink:href="silo-20220630.xsd#silo_PaymentEightMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="PaymentEightMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable" xlink:to="CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SponsoredPayment" xlink:href="silo-20220630.xsd#silo_SponsoredPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems" xlink:to="SponsoredPayment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentDescription" xlink:href="silo-20220630.xsd#silo_PaymentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems" xlink:to="PaymentDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/OrganizationandBusinessDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandBusinessDetailsTable" xlink:href="silo-20220630.xsd#silo_OrganizationandBusinessDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="OrganizationandBusinessDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDetailsTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalDeferredPurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SupplementalDeferredPurchasePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="promissoryNoteAmount" xlink:href="silo-20220630.xsd#silo_promissoryNoteAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="promissoryNoteAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_InvestmentInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_InvestmentMaturityDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AssetPurchaseAgreementDescription" xlink:href="silo-20220630.xsd#silo_AssetPurchaseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="AssetPurchaseAgreementDescription" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInContinuingOperations" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CapitalUnits" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashFDICInsuredAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashSPICInsuredAmount" xlink:href="silo-20220630.xsd#silo_CashSPICInsuredAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="CashSPICInsuredAmount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FDICIndemnificationAssetCashPaymentsReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FDICIndemnificationAssetCashPaymentsReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FDICIndemnificationAssetCashPaymentsReceived" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryGross" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsUnappropriated" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsUnappropriated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RetainedEarningsUnappropriated" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingCapital" xlink:href="silo-20220630.xsd#silo_WorkingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="WorkingCapital" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" xlink:href="silo-20220630.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:href="silo-20220630.xsd#silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DatChatIncMember" xlink:href="silo-20220630.xsd#silo_DatChatIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="DatChatIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AikidoPharmaIncMember" xlink:href="silo-20220630.xsd#silo_AikidoPharmaIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AikidoPharmaIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="HomeBistroIncMember" xlink:href="silo-20220630.xsd#silo_HomeBistroIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="HomeBistroIncMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable" xlink:to="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_InvestmentOwnedAtCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredSalesCommission" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredSalesCommission"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_DeferredSalesCommission" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityInvestmentsCost" xlink:href="silo-20220630.xsd#silo_EquityInvestmentsCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="EquityInvestmentsCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompanyReceivedShares" xlink:href="silo-20220630.xsd#silo_CompanyReceivedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="CompanyReceivedShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockGrantDateFairValuePerShare" xlink:href="silo-20220630.xsd#silo_CommonStockGrantDateFairValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="CommonStockGrantDateFairValuePerShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOnSaleOfInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="us-gaap_GainOnSaleOfInvestments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceeds" xlink:href="silo-20220630.xsd#silo_GrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="GrossProceeds" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestment" xlink:href="silo-20220630.xsd#silo_EquityMethodInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems" xlink:to="EquityMethodInvestment" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="PurchasePrice" xlink:href="silo-20220630.xsd#silo_PurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="PurchasePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_LongTermDebtMaturityDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrincipalBalance" xlink:href="silo-20220630.xsd#silo_PrincipalBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="PrincipalBalance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedInterestReceivable" xlink:href="silo-20220630.xsd#silo_AccruedInterestReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="AccruedInterestReceivable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalOutstandingBalanceReceivable" xlink:href="silo-20220630.xsd#silo_TotalOutstandingBalanceReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="TotalOutstandingBalanceReceivable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PromissoryNotes" xlink:href="silo-20220630.xsd#silo_PromissoryNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="PromissoryNotes" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/NotesReceivableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="NotesReceivableDetailsTable" xlink:href="silo-20220630.xsd#silo_NotesReceivableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="NotesReceivableDetailsLineItems" xlink:href="silo-20220630.xsd#silo_NotesReceivableDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="NotesReceivableDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PromissoryNoteReceivableAgreementMember" xlink:href="silo-20220630.xsd#silo_PromissoryNoteReceivableAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="PromissoryNoteReceivableAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsTable" xlink:to="srt_StatementScenarioAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_NotesReceivableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypesOfAgreementAxis" xlink:href="silo-20220630.xsd#silo_TypesOfAgreementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsTable" xlink:to="TypesOfAgreementAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypesOfAgreementDomain" xlink:href="silo-20220630.xsd#silo_TypesOfAgreementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfAgreementAxis" xlink:to="TypesOfAgreementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PurchaseAgreementMember" xlink:href="silo-20220630.xsd#silo_PurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfAgreementAxis" xlink:to="PurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DeferredRevenueArrangementType_Domain" xlink:href="silo-20220630.xsd#silo_DeferredRevenueArrangementType_Domain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="DeferredRevenueArrangementType_Domain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LayawaySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LayawaySaleMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_LayawaySaleMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsTable" xlink:to="srt_RangeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsTable" xlink:to="NotesReceivableDetailsLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RemainingBalanceOfPromissoryNoteReceivable" xlink:href="silo-20220630.xsd#silo_RemainingBalanceOfPromissoryNoteReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="RemainingBalanceOfPromissoryNoteReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalDeferredPurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="us-gaap_SupplementalDeferredPurchasePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NotesReceivablePurchasePrice" xlink:href="silo-20220630.xsd#silo_NotesReceivablePurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="NotesReceivablePurchasePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="us-gaap_InterestReceivable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetBadDebtExpense" xlink:href="silo-20220630.xsd#silo_NetBadDebtExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="NetBadDebtExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BadDebtRecoveryCashPayment" xlink:href="silo-20220630.xsd#silo_BadDebtRecoveryCashPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="BadDebtRecoveryCashPayment" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CollectedSettlementAgreement" xlink:href="silo-20220630.xsd#silo_CollectedSettlementAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="CollectedSettlementAgreement" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RemainsCollectibleSettlementAgreement" xlink:href="silo-20220630.xsd#silo_RemainsCollectibleSettlementAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="RemainsCollectibleSettlementAgreement" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PromissoryNote" xlink:href="silo-20220630.xsd#silo_PromissoryNote"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="PromissoryNote" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoteReceivableNonCurrentAmount" xlink:href="silo-20220630.xsd#silo_NoteReceivableNonCurrentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="NoteReceivableNonCurrentAmount" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentIncreasesAccruedInterest" xlink:href="silo-20220630.xsd#silo_DebtInstrumentIncreasesAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="DebtInstrumentIncreasesAccruedInterest" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireReceivables" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PromissoryNoteAgreement" xlink:href="silo-20220630.xsd#silo_PromissoryNoteAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="PromissoryNoteAgreement" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="us-gaap_DerivativeFixedInterestRate" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceivedShares" xlink:href="silo-20220630.xsd#silo_ReceivedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="ReceivedShares" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateOfNotesReceivablePurchasePrice" xlink:href="silo-20220630.xsd#silo_AggregateOfNotesReceivablePurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="AggregateOfNotesReceivablePurchasePrice" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecoveredAggregateBadDebt" xlink:href="silo-20220630.xsd#silo_RecoveredAggregateBadDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="RecoveredAggregateBadDebt" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecoveredBadDebt" xlink:href="silo-20220630.xsd#silo_RecoveredBadDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="RecoveredBadDebt" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="us-gaap_LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RemainsCollectibleSettlementAgreementAmountReserved" xlink:href="silo-20220630.xsd#silo_RemainsCollectibleSettlementAgreementAmountReserved"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="RemainsCollectibleSettlementAgreementAmountReserved" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesReceivableDetailsLineItems" xlink:to="us-gaap_LongTermDebtMaturityDate" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/NotePayableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="NotePayableDetailsTable" xlink:href="silo-20220630.xsd#silo_NotePayableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="NotePayableDetailsLineItems" xlink:href="silo-20220630.xsd#silo_NotePayableDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="NotePayableDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayableDetailsTable" xlink:to="dei_LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PaycheckProtectionProgramMember" xlink:href="silo-20220630.xsd#silo_PaycheckProtectionProgramMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="PaycheckProtectionProgramMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayableDetailsTable" xlink:to="NotePayableDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayableDetailsLineItems" xlink:to="us-gaap_NotesPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableInterestBearingInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayableDetailsLineItems" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayableDetailsLineItems" xlink:to="us-gaap_OtherNotesPayable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayableDetailsLineItems" xlink:to="us-gaap_InterestExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsTable" xlink:href="silo-20220630.xsd#silo_StockholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsLineItems" xlink:href="silo-20220630.xsd#silo_StockholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OmnibusEquityIncentivePlanMember" xlink:href="silo-20220630.xsd#silo_OmnibusEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="OmnibusEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncentiveStockOptionMember" xlink:href="silo-20220630.xsd#silo_IncentiveStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="IncentiveStockOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SeriesCConvertiblePreferredStockMember" xlink:href="silo-20220630.xsd#silo_SeriesCConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesCConvertiblePreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesCConversionPriceMember" xlink:href="silo-20220630.xsd#silo_SeriesCConversionPriceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesCConversionPriceMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesCPurchaseAgreementsMember" xlink:href="silo-20220630.xsd#silo_SeriesCPurchaseAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesCPurchaseAgreementsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypesOfAgreementsAxis" xlink:href="silo-20220630.xsd#silo_TypesOfAgreementsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="TypesOfAgreementsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypesOfAgreementsDomain" xlink:href="silo-20220630.xsd#silo_TypesOfAgreementsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfAgreementsAxis" xlink:to="TypesOfAgreementsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SubscriptionAgreementsMember" xlink:href="silo-20220630.xsd#silo_SubscriptionAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfAgreementsAxis" xlink:to="SubscriptionAgreementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecuritiesPurchaseAgreementsMember" xlink:href="silo-20220630.xsd#silo_SecuritiesPurchaseAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfAgreementsAxis" xlink:to="SecuritiesPurchaseAgreementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvisoryAgreementsMember" xlink:href="silo-20220630.xsd#silo_AdvisoryAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfAgreementsAxis" xlink:to="AdvisoryAgreementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultingAgreementMember" xlink:href="silo-20220630.xsd#silo_ConsultingAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfAgreementsAxis" xlink:to="ConsultingAgreementMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmploymentAgreementMember" xlink:href="silo-20220630.xsd#silo_EmploymentAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfAgreementsAxis" xlink:to="EmploymentAgreementMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeAgreementsMember" xlink:href="silo-20220630.xsd#silo_ExchangeAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfAgreementsAxis" xlink:to="ExchangeAgreementsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlacementAgentWarrantsMember" xlink:href="silo-20220630.xsd#silo_PlacementAgentWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="PlacementAgentWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="StockholdersEquityDetailsLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertablePreferredStock" xlink:href="silo-20220630.xsd#silo_ConvertablePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="ConvertablePreferredStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeAgreementsDescription" xlink:href="silo-20220630.xsd#silo_ExchangeAgreementsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="ExchangeAgreementsDescription" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares" xlink:href="silo-20220630.xsd#silo_CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredStockOutstandingDescription" xlink:href="silo-20220630.xsd#silo_PreferredStockOutstandingDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="PreferredStockOutstandingDescription" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConversionBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConversionBasis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockConversionBasis" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsTerm" xlink:href="silo-20220630.xsd#silo_WarrantsTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="WarrantsTerm" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubsequentFinancingPercentage" xlink:href="silo-20220630.xsd#silo_SubsequentFinancingPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="SubsequentFinancingPercentage" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ObligationPercentage" xlink:href="silo-20220630.xsd#silo_ObligationPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="ObligationPercentage" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlacementAgentWarrantsDescriptoin" xlink:href="silo-20220630.xsd#silo_PlacementAgentWarrantsDescriptoin"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="PlacementAgentWarrantsDescriptoin" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateGrantDateFairValueOfPlacementAgentWarrants" xlink:href="silo-20220630.xsd#silo_AggregateGrantDateFairValueOfPlacementAgentWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="AggregateGrantDateFairValueOfPlacementAgentWarrants" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalSubscriptionReceivableValue" xlink:href="silo-20220630.xsd#silo_TotalSubscriptionReceivableValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="TotalSubscriptionReceivableValue" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlacementAgentFees" xlink:href="silo-20220630.xsd#silo_PlacementAgentFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="PlacementAgentFees" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOwnershipInterestsOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherOwnershipInterestsOfferingCosts" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorInvestedAmount" xlink:href="silo-20220630.xsd#silo_InvestorInvestedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="InvestorInvestedAmount" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionContractorLiquidityCharacteristic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionContractorLiquidityCharacteristic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ConstructionContractorLiquidityCharacteristic" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmortizationOfPrepaidStockbasedExpense" xlink:href="silo-20220630.xsd#silo_AmortizationOfPrepaidStockbasedExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="AmortizationOfPrepaidStockbasedExpense" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherAssetsCurrent" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockValue" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DeemedDividend" xlink:href="silo-20220630.xsd#silo_DeemedDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="DeemedDividend" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleLongTermNotesPayables" xlink:href="silo-20220630.xsd#silo_ConvertibleLongTermNotesPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="ConvertibleLongTermNotesPayables" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantIssued" xlink:href="silo-20220630.xsd#silo_WarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="WarrantIssued" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="41.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockServiceDescription" xlink:href="silo-20220630.xsd#silo_CommonStockServiceDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="CommonStockServiceDescription" order="42.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" order="43.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseAgreementsDescription" xlink:href="silo-20220630.xsd#silo_PurchaseAgreementsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="PurchaseAgreementsDescription" order="44.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesAuthorized" order="45.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="46.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="47.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="48.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredStockStatedValue" xlink:href="silo-20220630.xsd#silo_PreferredStockStatedValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="PreferredStockStatedValue" order="49.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="51.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="52.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="53.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="54.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DividendsPreferredStockCash" order="55.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorInvestedAmountPercentage" xlink:href="silo-20220630.xsd#silo_InvestorInvestedAmountPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="InvestorInvestedAmountPercentage" order="56.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="57.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="58.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="59.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" order="61.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="62.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" order="63.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" order="64.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="65.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="66.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="67.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="68.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" order="69.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="71.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharePrice" order="72.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VentureCapitalGainsLossesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VentureCapitalGainsLossesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_VentureCapitalGainsLossesNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetCapitalLossCarryForward" xlink:href="silo-20220630.xsd#silo_NetCapitalLossCarryForward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="NetCapitalLossCarryForward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GainLossOnSaleOfCapitalLeaseNet" xlink:href="silo-20220630.xsd#silo_GainLossOnSaleOfCapitalLeaseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="GainLossOnSaleOfCapitalLeaseNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateEstimatedNetOperatingLoss" xlink:href="silo-20220630.xsd#silo_AggregateEstimatedNetOperatingLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="AggregateEstimatedNetOperatingLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfIncomeTaxDescription" xlink:href="silo-20220630.xsd#silo_DescriptionOfIncomeTaxDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="DescriptionOfIncomeTaxDescription" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/ConcentrationsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ConcentrationsDetailsTable" xlink:href="silo-20220630.xsd#silo_ConcentrationsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ConcentrationsDetailsLineItems" xlink:href="silo-20220630.xsd#silo_ConcentrationsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="ConcentrationsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VendorConcentrationsMember" xlink:href="silo-20220630.xsd#silo_VendorConcentrationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="VendorConcentrationsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="srt_MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OneLicensorMember" xlink:href="silo-20220630.xsd#silo_OneLicensorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="OneLicensorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OneLicenseeMember" xlink:href="silo-20220630.xsd#silo_OneLicenseeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="OneLicenseeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="ConcentrationsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConcentrationsRiskPercentage1" xlink:href="silo-20220630.xsd#silo_ConcentrationsRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsLineItems" xlink:to="ConcentrationsRiskPercentage1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsLineItems" xlink:href="silo-20220630.xsd#silo_CommitmentsandContingenciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MasterLincenseAgreementMember" xlink:href="silo-20220630.xsd#silo_MasterLincenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="MasterLincenseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JVAgreementMember" xlink:href="silo-20220630.xsd#silo_JVAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="JVAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ColumbiaUniversityMember" xlink:href="silo-20220630.xsd#silo_ColumbiaUniversityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ColumbiaUniversityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DrJamesKuoMember" xlink:href="silo-20220630.xsd#silo_DrJamesKuoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="DrJamesKuoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AikidoMember" xlink:href="silo-20220630.xsd#silo_AikidoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AikidoMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypeOfAgreementAxis" xlink:href="silo-20220630.xsd#silo_TypeOfAgreementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="TypeOfAgreementAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypeOfAgreementDomain" xlink:href="silo-20220630.xsd#silo_TypeOfAgreementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfAgreementAxis" xlink:to="TypeOfAgreementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SublicenseAgreementMember" xlink:href="silo-20220630.xsd#silo_SublicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfAgreementAxis" xlink:to="SublicenseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="CommitmentsandContingenciesDetailsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EmploymentAgreementDescription" xlink:href="silo-20220630.xsd#silo_EmploymentAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="EmploymentAgreementDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseFee" xlink:href="silo-20220630.xsd#silo_LicenseFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="LicenseFee" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommercialSaleTerm" xlink:href="silo-20220630.xsd#silo_CommercialSaleTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="CommercialSaleTerm" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseAgreementExpire" xlink:href="silo-20220630.xsd#silo_LicenseAgreementExpire"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="LicenseAgreementExpire" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SublicenseIncomeDescription" xlink:href="silo-20220630.xsd#silo_SublicenseIncomeDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="SublicenseIncomeDescription" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseAgreementDescription" xlink:href="silo-20220630.xsd#silo_LicenseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="LicenseAgreementDescription" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyPaymentsDescription" xlink:href="silo-20220630.xsd#silo_RoyaltyPaymentsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RoyaltyPaymentsDescription" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SublicenseIncomePercentage" xlink:href="silo-20220630.xsd#silo_SublicenseIncomePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="SublicenseIncomePercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SublicenseAgreementAmountPaid" xlink:href="silo-20220630.xsd#silo_SublicenseAgreementAmountPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="SublicenseAgreementAmountPaid" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherDepreciationsAndAmortization" xlink:href="silo-20220630.xsd#silo_OtherDepreciationsAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="OtherDepreciationsAndAmortization" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfSponsoredResearchAmount" xlink:href="silo-20220630.xsd#silo_PaymentOfSponsoredResearchAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PaymentOfSponsoredResearchAmount" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidExpenses" xlink:href="silo-20220630.xsd#silo_PrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PrepaidExpenses" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonrefundableCashPayment" xlink:href="silo-20220630.xsd#silo_NonrefundableCashPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="NonrefundableCashPayment" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetSalePercentage" xlink:href="silo-20220630.xsd#silo_NetSalePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="NetSalePercentage" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicensorShare" xlink:href="silo-20220630.xsd#silo_LicensorShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="LicensorShare" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateOfConvertedShares" xlink:href="silo-20220630.xsd#silo_AggregateOfConvertedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="AggregateOfConvertedShares" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueTerm" xlink:href="silo-20220630.xsd#silo_RevenueTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RevenueTerm" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfVotingShares" xlink:href="silo-20220630.xsd#silo_NumberOfVotingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="NumberOfVotingShares" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReverseStockSplitVoteDescription" xlink:href="silo-20220630.xsd#silo_ReverseStockSplitVoteDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="ReverseStockSplitVoteDescription" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_DeferredRevenue" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashReceived" xlink:href="silo-20220630.xsd#silo_CashReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="CashReceived" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecuritiesReceived" xlink:href="silo-20220630.xsd#silo_SecuritiesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="SecuritiesReceived" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceServicesRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceServicesRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_InsuranceServicesRevenue" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredRevenueLongtermPortion" xlink:href="silo-20220630.xsd#silo_DeferredRevenueLongtermPortion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="DeferredRevenueLongtermPortion" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsiderationFeePayablePercentage" xlink:href="silo-20220630.xsd#silo_ConsiderationFeePayablePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="ConsiderationFeePayablePercentage" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UpfrontLicenseFees" xlink:href="silo-20220630.xsd#silo_UpfrontLicenseFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="UpfrontLicenseFees" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstCommercialSale" xlink:href="silo-20220630.xsd#silo_FirstCommercialSale"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="FirstCommercialSale" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementShallExpire" xlink:href="silo-20220630.xsd#silo_AgreementShallExpire"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="AgreementShallExpire" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecognizedRevenues" xlink:href="silo-20220630.xsd#silo_RecognizedRevenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RecognizedRevenues" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OtherLongTermDebt" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManagementFeePayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementFeePayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_ManagementFeePayable" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentDescription" xlink:href="silo-20220630.xsd#silo_PaymentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PaymentDescription" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SponsoredStudyAgreementDescription" xlink:href="silo-20220630.xsd#silo_SponsoredStudyAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="SponsoredStudyAgreementDescription" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SublicenseAmountPaid" xlink:href="silo-20220630.xsd#silo_SublicenseAmountPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="SublicenseAmountPaid" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SponsoredResearchAgreementDescription" xlink:href="silo-20220630.xsd#silo_SponsoredResearchAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="SponsoredResearchAgreementDescription" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CompanyPaidCash" xlink:href="silo-20220630.xsd#silo_CompanyPaidCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="CompanyPaidCash" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PursuantTerms" xlink:href="silo-20220630.xsd#silo_PursuantTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PursuantTerms" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfUniversity" xlink:href="silo-20220630.xsd#silo_PaymentOfUniversity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PaymentOfUniversity" order="41.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="42.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="43.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="44.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="45.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="46.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="47.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" order="48.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="49.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization" order="51.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="52.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseOtherNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent" order="53.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRefundableFeesProceeds" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundableFeesProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_CustomerRefundableFeesProceeds" order="54.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RecognitionOfDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecognitionOfDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RecognitionOfDeferredRevenue" order="55.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredRevenueLongtermPortionAmounted" xlink:href="silo-20220630.xsd#silo_DeferredRevenueLongtermPortionAmounted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="DeferredRevenueLongtermPortionAmounted" order="56.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear" order="57.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementDescription" xlink:href="silo-20220630.xsd#silo_AgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="AgreementDescription" order="58.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="silo-20220630.xsd#silo_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="silo-20220630.xsd#silo_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TypesOfAgreementAxis" xlink:href="silo-20220630.xsd#silo_TypesOfAgreementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="TypesOfAgreementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypesOfAgreementDomain" xlink:href="silo-20220630.xsd#silo_TypesOfAgreementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfAgreementAxis" xlink:to="TypesOfAgreementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="KuoEmploymentAgreementMember" xlink:href="silo-20220630.xsd#silo_KuoEmploymentAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypesOfAgreementAxis" xlink:to="KuoEmploymentAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AnnualBaseSalary" xlink:href="silo-20220630.xsd#silo_AnnualBaseSalary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="AnnualBaseSalary" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SubsequentEventDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalOfSharesOfCommonStock" xlink:href="silo-20220630.xsd#silo_TotalOfSharesOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="TotalOfSharesOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="silo-20220630.xsd#silo_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336824927200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SILO PHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">AMENDMENT No. 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001514183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336823403424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,734,434<span></span>
</td>
<td class="nump">$ 9,837,001<span></span>
</td>
<td class="nump">$ 1,128,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_EquityInvestmentsAtCost', window );">Equity investments</a></td>
<td class="nump">113,012<span></span>
</td>
<td class="nump">419,995<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Notes receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">23,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets - current</a></td>
<td class="nump">99,939<span></span>
</td>
<td class="nump">145,324<span></span>
</td>
<td class="nump">241,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">33,484<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">8,947,385<span></span>
</td>
<td class="nump">10,402,320<span></span>
</td>
<td class="nump">1,426,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Note receivable - non-current, including interest receivable</a></td>
<td class="nump">63,590<span></span>
</td>
<td class="nump">61,210<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expenses - non-current</a></td>
<td class="nump">33,740<span></span>
</td>
<td class="nump">26,659<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">9,044,715<span></span>
</td>
<td class="nump">10,490,189<span></span>
</td>
<td class="nump">1,426,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">155,924<span></span>
</td>
<td class="nump">417,937<span></span>
</td>
<td class="nump">127,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Insurance payable</a></td>
<td class="nump">40,819<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable - current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue - current portion</a></td>
<td class="nump">72,102<span></span>
</td>
<td class="nump">72,102<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">268,845<span></span>
</td>
<td class="nump">490,039<span></span>
</td>
<td class="nump">141,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue - long-term portion</a></td>
<td class="nump">901,833<span></span>
</td>
<td class="nump">937,884<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable - long-term portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,246<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Long Term Liabilities</a></td>
<td class="nump">901,833<span></span>
</td>
<td class="nump">937,884<span></span>
</td>
<td class="nump">4,246<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">1,170,678<span></span>
</td>
<td class="nump">1,427,923<span></span>
</td>
<td class="nump">145,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitment and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 5,000,000 shares authorized</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">12,398,889<span></span>
</td>
<td class="nump">12,324,646<span></span>
</td>
<td class="nump">7,042,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(4,525,051)<span></span>
</td>
<td class="num">(3,262,577)<span></span>
</td>
<td class="num">(5,762,321)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">7,874,037<span></span>
</td>
<td class="nump">9,062,266<span></span>
</td>
<td class="nump">1,280,695<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">9,044,715<span></span>
</td>
<td class="nump">10,490,189<span></span>
</td>
<td class="nump">1,426,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PreferredStockValueOne', window );">Convertible preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PreferredStockValueTwo', window );">Convertible preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_EquityInvestmentsAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity investments, at cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_EquityInvestmentsAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PreferredStockValueOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PreferredStockValueOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PreferredStockValueTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PreferredStockValueTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336824569456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableNoncurrent', window );">Interest receivable (in Dollars)</a></td>
<td class="nump">$ 3,590<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Preferred stock liquidation value price (in Dollars per share)</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">1,987,906<span></span>
</td>
<td class="nump">1,972,739<span></span>
</td>
<td class="nump">1,702,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">1,987,906<span></span>
</td>
<td class="nump">1,972,739<span></span>
</td>
<td class="nump">1,702,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Preferred stock liquidation value price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">4,280<span></span>
</td>
<td class="nump">4,280<span></span>
</td>
<td class="nump">4,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Preferred stock liquidation value price (in Dollars per share)</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of noncurrent interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336821022496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_LicenseFees', window );">LICENSE FEE REVENUES:</a></td>
<td class="nump">$ 18,025<span></span>
</td>
<td class="nump">$ 18,026<span></span>
</td>
<td class="nump">$ 36,051<span></span>
</td>
<td class="nump">$ 35,213<span></span>
</td>
<td class="nump">$ 71,264<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF REVENUES</a></td>
<td class="nump">1,459<span></span>
</td>
<td class="nump">1,460<span></span>
</td>
<td class="nump">2,919<span></span>
</td>
<td class="nump">2,085<span></span>
</td>
<td class="nump">5,004<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">16,566<span></span>
</td>
<td class="nump">16,566<span></span>
</td>
<td class="nump">33,132<span></span>
</td>
<td class="nump">33,128<span></span>
</td>
<td class="nump">66,260<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation expense</a></td>
<td class="nump">100,212<span></span>
</td>
<td class="nump">54,942<span></span>
</td>
<td class="nump">227,393<span></span>
</td>
<td class="nump">167,234<span></span>
</td>
<td class="nump">395,123<span></span>
</td>
<td class="nump">755,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">248,179<span></span>
</td>
<td class="nump">270,906<span></span>
</td>
<td class="nump">444,427<span></span>
</td>
<td class="nump">942,475<span></span>
</td>
<td class="nump">1,598,367<span></span>
</td>
<td class="nump">1,173,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">105,676<span></span>
</td>
<td class="nump">98,846<span></span>
</td>
<td class="nump">275,955<span></span>
</td>
<td class="nump">147,448<span></span>
</td>
<td class="nump">693,910<span></span>
</td>
<td class="nump">26,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralInsuranceExpense', window );">Insurance expense</a></td>
<td class="nump">30,866<span></span>
</td>
<td class="nump">29,015<span></span>
</td>
<td class="nump">64,158<span></span>
</td>
<td class="nump">50,721<span></span>
</td>
<td class="nump">108,750<span></span>
</td>
<td class="nump">30,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_BadDebtRecoveryExpense', window );">Bad debt (recovery) expense, net</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(46,000)<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="num">(53,500)<span></span>
</td>
<td class="num">(148,500)<span></span>
</td>
<td class="nump">165,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">25,918<span></span>
</td>
<td class="nump">45,706<span></span>
</td>
<td class="nump">62,743<span></span>
</td>
<td class="nump">116,735<span></span>
</td>
<td class="nump">162,953<span></span>
</td>
<td class="nump">50,192<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">510,851<span></span>
</td>
<td class="nump">453,415<span></span>
</td>
<td class="nump">1,054,676<span></span>
</td>
<td class="nump">1,371,113<span></span>
</td>
<td class="nump">2,810,603<span></span>
</td>
<td class="nump">2,201,719<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS FROM CONTINUING OPERATIONS</a></td>
<td class="num">(494,285)<span></span>
</td>
<td class="num">(436,849)<span></span>
</td>
<td class="num">(1,021,544)<span></span>
</td>
<td class="num">(1,337,985)<span></span>
</td>
<td class="num">(2,744,343)<span></span>
</td>
<td class="num">(2,201,719)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expense), net</a></td>
<td class="nump">377<span></span>
</td>
<td class="num">(1,040)<span></span>
</td>
<td class="nump">792<span></span>
</td>
<td class="num">(2,389)<span></span>
</td>
<td class="nump">1,210<span></span>
</td>
<td class="nump">11,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_OtherIncomeFromEquitySharesEarnedForServices', window );">Other income from equity shares earned for lock up agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">85,733<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on forgiveness of PPP note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">19,082<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">19,082<span></span>
</td>
<td class="nump">19,082<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,036)<span></span>
</td>
<td class="num">(269,043)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expense - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,950)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(197,682)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Net realized gain (loss) on equity investments</a></td>
<td class="num">(104,700)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(104,700)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,660,483<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_UnrealizedGainLossOnEquityInvestments', window );">Net unrealized gain (loss) on equity investments</a></td>
<td class="num">(59,511)<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="num">(221,309)<span></span>
</td>
<td class="nump">68,750<span></span>
</td>
<td class="nump">248,588<span></span>
</td>
<td class="num">(9,194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(283)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(283)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(164,117)<span></span>
</td>
<td class="nump">48,042<span></span>
</td>
<td class="num">(239,767)<span></span>
</td>
<td class="nump">85,443<span></span>
</td>
<td class="nump">6,926,327<span></span>
</td>
<td class="num">(464,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE PROVISION FOR INCOME TAXES</a></td>
<td class="num">(658,402)<span></span>
</td>
<td class="num">(388,807)<span></span>
</td>
<td class="num">(1,261,311)<span></span>
</td>
<td class="num">(1,252,542)<span></span>
</td>
<td class="nump">4,181,984<span></span>
</td>
<td class="num">(2,666,269)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(24,876)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">INCOME (LOSS) FROM CONTINUING OPERATIONS</a></td>
<td class="num">(658,402)<span></span>
</td>
<td class="num">(388,807)<span></span>
</td>
<td class="num">(1,261,311)<span></span>
</td>
<td class="num">(1,252,542)<span></span>
</td>
<td class="nump">4,157,108<span></span>
</td>
<td class="num">(2,666,269)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_DiscontinuedOperationsAbstract', window );"><strong>DISCONTINUED OPERATIONS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Gain from sale of assets of discontinued operations, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,553<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(73,183)<span></span>
</td>
<td class="num">(1,163)<span></span>
</td>
<td class="num">(140,150)<span></span>
</td>
<td class="num">(254,920)<span></span>
</td>
<td class="num">(371,248)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">LOSS FROM DISCONTINUED OPERATIONS</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(73,183)<span></span>
</td>
<td class="num">(1,163)<span></span>
</td>
<td class="num">(140,150)<span></span>
</td>
<td class="num">(253,367)<span></span>
</td>
<td class="num">(371,248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td>
<td class="num">(658,402)<span></span>
</td>
<td class="num">(461,990)<span></span>
</td>
<td class="num">(1,262,474)<span></span>
</td>
<td class="num">(1,392,692)<span></span>
</td>
<td class="nump">3,903,741<span></span>
</td>
<td class="num">(3,037,517)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Deemed dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,403,997)<span></span>
</td>
<td class="num">(1,403,997)<span></span>
</td>
<td class="num">(69,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">NET INCOME (LOSS) AVAILABLE TO COMMON STOCKHOLDERS</a></td>
<td class="num">$ (658,402)<span></span>
</td>
<td class="num">$ (461,990)<span></span>
</td>
<td class="num">$ (1,262,474)<span></span>
</td>
<td class="num">$ (2,796,689)<span></span>
</td>
<td class="nump">$ 2,499,744<span></span>
</td>
<td class="num">$ (3,106,517)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET INCOME (LOSS) PER COMMON SHARE AVAILABLE TO COMMON STOCKHOLDERS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Continuing operations - basic (in Dollars per share)</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="num">$ (2.07)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations - basic (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in Shares)</a></td>
<td class="nump">1,987,906<span></span>
</td>
<td class="nump">1,937,148<span></span>
</td>
<td class="nump">1,980,365<span></span>
</td>
<td class="nump">1,820,641<span></span>
</td>
<td class="nump">1,897,315<span></span>
</td>
<td class="nump">1,319,094<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_BadDebtRecoveryExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bad debt (recovery) expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_BadDebtRecoveryExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_DiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_DiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_LicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_LicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_OtherIncomeFromEquitySharesEarnedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other income from equity shares earned for services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_OtherIncomeFromEquitySharesEarnedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_UnrealizedGainLossOnEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net unrealized gain (loss) on equity investments (non-controlled/non-affiliated investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_UnrealizedGainLossOnEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralInsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralInsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336824684944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Continuing operations - diluted</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations - diluted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Weighted average common shares outstanding, Diluted (in Shares)</a></td>
<td class="nump">99,395,304<span></span>
</td>
<td class="nump">96,857,408<span></span>
</td>
<td class="nump">99,018,232<span></span>
</td>
<td class="nump">91,032,045<span></span>
</td>
<td class="nump">95,922,218<span></span>
</td>
<td class="nump">65,954,691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336819849824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th">
<div>Series B </div>
<div>Preferred Stock</div>
</th>
<th class="th">
<div>Series C </div>
<div>Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 2,632,865<span></span>
</td>
<td class="num">$ (2,655,804)<span></span>
</td>
<td class="num">$ (22,892)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="nump">115<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">472,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common Stock issued for cash, net of offering cost</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">2,115,657<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,115,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common Stock issued for cash, net of offering cost (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">755,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommonStockIssuedForFutureServices', window );">Common Stock issued for future services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">686,878<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">686,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommonStockIssuedForFutureServicesShares', window );">Common Stock issued for future services (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">171,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PreferredSharesExchangedForCommonStock', window );">Preferred Shares Exchanged for Common Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PreferredSharesExchangedForCommonStockShares', window );">Preferred Shares Exchanged for Common Stock (in Shares)</a></td>
<td class="num">(115)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">28,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Common Stock issued in connection with employment agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">610,461<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">610,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Common Stock issued in connection with employment agreement (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">152,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommonStockIssuedForExchangeOfNotes', window );">Common Stock issued for Exchange of Notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">527,992<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">528,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommonStockIssuedForExchangeOfNotesShares', window );">Common Stock issued for Exchange of Notes (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">82,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock', window );">Common Stock issued for conversion of Redeemable Series A Preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">399,996<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares', window );">Common Stock issued for conversion of Redeemable Series A Preferred stock (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_DeemedDividendOnPreferredStockExchange', window );">Deemed dividend on Preferred Stock Exchange</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">69,000<span></span>
</td>
<td class="num">(69,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,037,517)<span></span>
</td>
<td class="num">(3,037,517)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">7,042,846<span></span>
</td>
<td class="num">(5,762,321)<span></span>
</td>
<td class="nump">1,280,695<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,702,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Series C preferred stock issued for cash, net of offering cost</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,794,102<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,794,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Series C preferred stock issued for cash, net of offering cost (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Deemed dividend upon issuance of preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,403,997<span></span>
</td>
<td class="num">(1,403,997)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock warrants granted for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">83,728<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">83,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(930,702)<span></span>
</td>
<td class="num">(930,702)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">12,324,673<span></span>
</td>
<td class="num">(8,097,020)<span></span>
</td>
<td class="nump">4,227,823<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,276<span></span>
</td>
<td class="nump">1,702,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">7,042,846<span></span>
</td>
<td class="num">(5,762,321)<span></span>
</td>
<td class="nump">1,280,695<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,702,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,392,692)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">12,324,646<span></span>
</td>
<td class="num">(8,559,010)<span></span>
</td>
<td class="nump">3,765,833<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="nump">1,972,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">7,042,846<span></span>
</td>
<td class="num">(5,762,321)<span></span>
</td>
<td class="nump">1,280,695<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,702,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Series C preferred stock issued for cash, net of offering cost</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,794,102<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,794,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Series C preferred stock issued for cash, net of offering cost (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,276<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Deemed dividend upon issuance of preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,403,997<span></span>
</td>
<td class="num">(1,403,997)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock warrants granted for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">83,728<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">83,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_IssuanceOfCommonStockForConversionOfPreferredStock', window );">Issuance of common stock for conversion of preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares', window );">Issuance of common stock for conversion of preferred stock (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(4,049)<span></span>
</td>
<td class="nump">269,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,903,741<span></span>
</td>
<td class="nump">3,903,741<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">12,324,646<span></span>
</td>
<td class="num">(3,262,577)<span></span>
</td>
<td class="nump">9,062,266<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="nump">1,972,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">12,324,673<span></span>
</td>
<td class="num">(8,097,020)<span></span>
</td>
<td class="nump">4,227,823<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,276<span></span>
</td>
<td class="nump">1,702,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock issued for conversion of Series C preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued for conversion of Series C preferred stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,049)<span></span>
</td>
<td class="nump">269,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(461,990)<span></span>
</td>
<td class="num">(461,990)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">12,324,646<span></span>
</td>
<td class="num">(8,559,010)<span></span>
</td>
<td class="nump">3,765,833<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="nump">1,972,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">12,324,646<span></span>
</td>
<td class="num">(3,262,577)<span></span>
</td>
<td class="nump">9,062,266<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="nump">1,972,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock options issued as stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">45,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock issued for conversion of Series C preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued for conversion of Series C preferred stock (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(227)<span></span>
</td>
<td class="nump">15,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(604,072)<span></span>
</td>
<td class="num">(604,072)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">12,369,653<span></span>
</td>
<td class="num">(3,866,649)<span></span>
</td>
<td class="nump">8,503,203<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,987,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">12,324,646<span></span>
</td>
<td class="num">(3,262,577)<span></span>
</td>
<td class="nump">9,062,266<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="nump">1,972,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,262,474)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">12,398,889<span></span>
</td>
<td class="num">(4,525,051)<span></span>
</td>
<td class="nump">7,874,037<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,987,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">12,369,653<span></span>
</td>
<td class="num">(3,866,649)<span></span>
</td>
<td class="nump">8,503,203<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,987,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Amortization of prepaid stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,124<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock options issued as stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,112<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(658,402)<span></span>
</td>
<td class="num">(658,402)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">$ 12,398,889<span></span>
</td>
<td class="num">$ (4,525,051)<span></span>
</td>
<td class="nump">$ 7,874,037<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,987,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock issued for conversion of Redeemable Series A Preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommonStockIssuedForExchangeOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock issued for Exchange of Notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommonStockIssuedForExchangeOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommonStockIssuedForExchangeOfNotesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock issued for Exchange of Notes, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommonStockIssuedForExchangeOfNotesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommonStockIssuedForFutureServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommonStockIssuedForFutureServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommonStockIssuedForFutureServicesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock issued for future services, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommonStockIssuedForFutureServicesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_DeemedDividendOnPreferredStockExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend on Preferred Stock Exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_DeemedDividendOnPreferredStockExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for conversion of preferred stock (in Shares).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_IssuanceOfCommonStockForConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_IssuanceOfCommonStockForConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PreferredSharesExchangedForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Shares Exchanged for Common Stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PreferredSharesExchangedForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PreferredSharesExchangedForCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Shares Exchanged for Common Stock, Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PreferredSharesExchangedForCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336821323568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (1,262,474)<span></span>
</td>
<td class="num">$ (1,392,692)<span></span>
</td>
<td class="nump">$ 3,903,741<span></span>
</td>
<td class="num">$ (3,037,517)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt (recovery) expense</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="num">(46,000)<span></span>
</td>
<td class="num">(148,500)<span></span>
</td>
<td class="nump">165,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">74,245<span></span>
</td>
<td class="nump">83,728<span></span>
</td>
<td class="nump">83,728<span></span>
</td>
<td class="nump">610,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount to interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">268,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AmortizationOfPrepaidStockbasedExpense', window );">Amortization of prepaid stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">107,970<span></span>
</td>
<td class="nump">107,970<span></span>
</td>
<td class="nump">578,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">137,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Net realized gain on equity investments</a></td>
<td class="nump">104,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,660,483)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Net unrealized loss (gain) loss on equity investments</a></td>
<td class="nump">221,309<span></span>
</td>
<td class="num">(68,750)<span></span>
</td>
<td class="num">(248,588)<span></span>
</td>
<td class="nump">9,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfDerivatives', window );">Equity shares earned for lock up agreement</a></td>
<td class="num">(85,733)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Gain on forgiveness of PPP note payable and accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(19,082)<span></span>
</td>
<td class="num">(19,082)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain from disposal of assets from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,553)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_LossFromDebtExtinguishment', window );">Loss from debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">197,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">38,304<span></span>
</td>
<td class="num">(64,047)<span></span>
</td>
<td class="num">(38,862)<span></span>
</td>
<td class="num">(144,663)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation', window );">Assets of discontinued operations</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(22,123)<span></span>
</td>
<td class="num">(24,963)<span></span>
</td>
<td class="num">(15,065)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Interest receivable</a></td>
<td class="num">(2,380)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,210)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(262,013)<span></span>
</td>
<td class="nump">65,146<span></span>
</td>
<td class="nump">291,050<span></span>
</td>
<td class="nump">72,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPayablesToBrokerDealers', window );">Insurance payable</a></td>
<td class="nump">40,819<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(36,051)<span></span>
</td>
<td class="nump">514,787<span></span>
</td>
<td class="nump">478,736<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH USED IN OPERATING ACTIVITIES</a></td>
<td class="num">(1,189,274)<span></span>
</td>
<td class="num">(841,063)<span></span>
</td>
<td class="num">(2,278,016)<span></span>
</td>
<td class="num">(1,156,996)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Net proceeds from sale of equity investments</a></td>
<td class="nump">66,707<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,020,526<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfNotesReceivable', window );">Collection on note receivable written off prior to 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CollectionOnNoteReceivable', window );">Collection on note receivable</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">69,500<span></span>
</td>
<td class="nump">164,500<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH PROVIDED BY INVESTING ACTIVITIES</a></td>
<td class="nump">86,707<span></span>
</td>
<td class="nump">69,500<span></span>
</td>
<td class="nump">7,192,526<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from note payable - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">18,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Repayment of note payable - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,115,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Net proceeds from sale of preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,794,102<span></span>
</td>
<td class="nump">3,794,102<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AdvanceFromARelatedParty', window );">Advance from a related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,366<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of advance from a related party</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,366)<span></span>
</td>
<td class="num">(2,366)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH PROVIDED BY FINANCING ACTIVITIES</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,794,102<span></span>
</td>
<td class="nump">3,794,102<span></span>
</td>
<td class="nump">2,134,633<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET CHANGE IN CASH AND CASH EQUIVALENTS:</a></td>
<td class="num">(1,102,567)<span></span>
</td>
<td class="nump">3,022,539<span></span>
</td>
<td class="nump">8,708,612<span></span>
</td>
<td class="nump">1,016,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS - beginning of the period</a></td>
<td class="nump">9,837,001<span></span>
</td>
<td class="nump">1,128,389<span></span>
</td>
<td class="nump">1,128,389<span></span>
</td>
<td class="nump">111,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS - end of the period</a></td>
<td class="nump">8,734,434<span></span>
</td>
<td class="nump">4,150,928<span></span>
</td>
<td class="nump">9,837,001<span></span>
</td>
<td class="nump">1,128,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Disclosure of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Taxes paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CashPaidDuringThePeriodForAbstract', window );"><strong>Cash paid during the period for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">25,159<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockIssuedForFutureServices', window );">Common stock issued for prepaid services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">686,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommonStockIssuedForPrepaidServices', window );">Common stock issued for Exchange of Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">528,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock', window );">Common stock issued for conversion of Redeemable Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Common stock issued for conversion of Series C preferred stock</a></td>
<td class="nump">76<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp', window );">Initial fair value of stock options issued as stock-based compensation recorded as deferred compensation</a></td>
<td class="nump">89,546<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock warrants granted for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">83,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree', window );">Increase in equity investments recorded as deferred revenue pursuant to a patent license agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 531,250<span></span>
</td>
<td class="nump">531,250<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement', window );">Note receivable issued in connection with asset purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AdvanceFromARelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance from a related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AdvanceFromARelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AmortizationOfPrepaidStockbasedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AmortizationOfPrepaidStockbasedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CashPaidDuringThePeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CashPaidDuringThePeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CollectionOnNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CollectionOnNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for conversion of Redeemable Series A Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommonStockIssuedForPrepaidServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommonStockIssuedForPrepaidServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in equity investments recorded as deferred revenue pursuant to a patent license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including Iniital fair value of stock options issued as stock-based compensation recorded as deferred compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_LossFromDebtExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_LossFromDebtExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_StockIssuedForFutureServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock issued for future services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_StockIssuedForFutureServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15743-112638<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPayablesToBrokerDealers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations incurred arising from transactions with broker-dealers, such as amounts due on margin and unsettled cash transactions; includes payables to brokers, dealers and clearing organizations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPayablesToBrokerDealers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336828485152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Organization and Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">ORGANIZATION AND BUSINESS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 &#8211; <span style="text-decoration:underline">ORGANIZATION AND BUSINESS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Silo Pharma, Inc. (formerly Uppercut Brands,
Inc.) (the &#8220;Company&#8221;) was incorporated in the State of New York on July 13, 2010, under the name Gold Swap, Inc. On January
24, 2013, the Company changed its state of incorporation from New York to Delaware.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a developmental stage biopharmaceutical
company focused on merging traditional therapeutics with psychedelic research.&#160;The Company seeks to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. The Company is focused on merging traditional therapeutics with psychedelic research for people suffering from indications
such as depression, post-traumatic stress disorder (&#8220;PTSD&#8221;), Alzheimer&#8217;s, Parkinson&#8217;s, and other rare neurological
disorders. The Company&#8217;s mission is to identify assets to license and fund the research which the Company&#8217;s believes will
be transformative to the well-being of patients and the health care industry.&#160;The Company was engaged in the development of a streetwear
apparel brand, NFID (see below).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 4, 2013, the Company filed a Form
N-54A and elected to become a business development company (&#8220;BDC&#8221;) under the Investment Company Act of 1940, as amended (the
&#8220;1940 Act&#8221;). In addition, the Company previously elected to be treated for federal income tax purpose as a regulated investment
company, (&#8220;RIC&#8221;) under Subchapter M of the Internal Revenue Code of 1986, as amended, (the &#8220;Code&#8221;). Through September
29, 2018, the Company met the definition of RIC in accordance with the guidance under Accounting Standards Codification (&#8220;ASC&#8221;)
Topic 946 &#8220;Financial Services &#8211; Investment Companies&#8221;. On September 29, 2018, the Company filed Form N-54C, Notification
of Withdrawal of Election to be Subject to Section 55 through 65 of the 1940 Act, as the Company changed the nature of its business so
as to cease to be a business development company (See Note 2 &#8211; Basis of Presentation). Additionally, since 2017, the Company has
been subject to income taxes at corporate tax rates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 21, 2019, the Company filed an amendment
to its Certificate of Incorporation with the State of Delaware to change its name from Point Capital, Inc. to Uppercut Brands, Inc. Thereafter,
on September 24, 2020, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to change its name
from Uppercut Brands, Inc. to Silo Pharma, Inc.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 8, 2020, the Company incorporated
a new wholly-owned subsidiary, Silo Pharma Inc.,&#160;in the State of Florida. The Company has also secured the domain name www.silopharma.com.
The Company has been exploring opportunities to expand the Company&#8217;s business by seeking to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. In July 2020, through the Company&#8217;s newly formed subsidiary, the Company entered into a commercial evaluation license
and option agreement with University of Maryland, Baltimore (&#8220;UMB&#8221;) (see Note 8) pursuant to which, among other things, UMB
granted the Company an exclusive, option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license to with respect
to certain technology. The option was extended and exercised on January 13, 2021. On February 12, 2021, the Company entered into a Master
License Agreement with UMB (see Note 8). The Company plans to actively pursue the acquisition and/or development of intellectual property
or technology rights to treat rare diseases, and to ultimately expand the Company&#8217;s business to focus on this new line of business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2021, the Company entered
into and closed on an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement) with NFID, LLC, a Florida limited liability company
(the &#8220;Buyer&#8221;), whereby the Buyer purchased from the Company certain assets, properties, and rights in connection with the
Company&#8217;s NFID trademark name, logos, domain, and apparel clothing and accessories for a purchase price of $60,000 in the form
of a promissory note amounting to $60,000. The promissory note bears 8% interest per annum and matures on October 1, 2023. Accordingly,
the results of operations of this component, for all periods presented, are separately reported as &#8220;discontinued operations&#8221;
on the condensed consolidated statements of operations (see Note 4).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 11, 2022, the Company stockholders
approved granting discretionary authority to the Company&#8217;s Board of Directors to amend the Company&#8217;s Certificate of Incorporation
to effect one or more consolidations of the Company&#8217;s issued and outstanding shares of common stock, pursuant to which the shares
of common stock would be combined and reclassified into one share of common stock at a ratio within the range from 1-for-5 up to 1-for-50
(the &#8220;Reverse Stock Split&#8221;), provided that, (X) that the Company shall not effect Reverse Stock Splits that, in the aggregate,
exceeds 1-for-50, and (Y) any Reverse Stock Split is completed no later than February 8, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On September 14, 2022, the Company filed a
Certificate of Amendment to the Amended and Restated Articles of Incorporation (the &#8220;Certificate of Amendment&#8221;) with the
Secretary of State of the State of Nevada to effect a 1-for-50 reverse stock split (the &#8220;Reverse Stock Split&#8221;) with respect
to the outstanding shares of the Company&#8217;s common stock. The Certificate of Amendment became effective on September 14, 2022. The
Reverse Stock Split was previously approved by the sole director and the majority of stockholders of the Company. The Reverse Stock Split
was deemed effective at the open of business on September 15, 2022. All share and per share data in the accompanying consolidated financial
statements have been retroactively restated to reflect the effect of the reverse stock split.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 &#8211; <span style="text-decoration:underline">ORGANIZATION AND BUSINESS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Silo Pharma, Inc. (formerly Uppercut Brands,
Inc.) (the &#8220;Company&#8221;) was incorporated in the State of New York on July 13, 2010 under the name Gold Swap, Inc. On January
24, 2013, the Company changed its state of incorporation from New York to Delaware.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a developmental stage biopharmaceutical
company focused on merging traditional therapeutics with psychedelic research.&#160;The Company seeks to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. The Company is focused on merging traditional therapeutics with psychedelic research for people suffering from indications
such as depression, post-traumatic stress disorder (&#8220;PTSD&#8221;), Alzheimer&#8217;s, Parkinson&#8217;s, and other rare neurological
disorders. The Company&#8217;s mission is to identify assets to license and fund the research which the Company&#8217;s believes will
be transformative to the well-being of patients and the health care industry.&#160;The Company was engaged in the development of a streetwear
apparel brand, NFID (see below).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 4, 2013, the Company filed a Form
N-54A and elected to become a business development company (&#8220;BDC&#8221;) under the Investment Company Act of 1940, as amended (the
&#8220;1940 Act&#8221;). In addition, the Company previously elected to be treated for federal income tax purpose as a regulated investment
company, (&#8220;RIC&#8221;) under Subchapter M of the Internal Revenue Code of 1986, as amended, (the &#8220;Code&#8221;). Through September
29, 2018, the Company met the definition of RIC in accordance with the guidance under Accounting Standards Codification (&#8220;ASC&#8221;)
Topic 946 &#8220;Financial Services &#8211; Investment Companies&#8221;. On September 29, 2018, the Company filed Form N-54C, Notification
of Withdrawal of Election to be Subject to Section 55 through 65 of the 1940 Act, as the Company changed the nature of its business so
as to cease to be a business development company (see Note 2 &#8211; <i>Basis of Presentation</i>). Additionally, since 2017, the Company
has been subject to income taxes at corporate tax rates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 21, 2019, the Company filed an amendment
to its Certificate of Incorporation with the State of Delaware to change its name from Point Capital, Inc. to Uppercut Brands, Inc. thereafter,
on September 24, 2020, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to change its name
from Uppercut Brands, Inc. to Silo Pharma, Inc.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 8, 2020, the Company incorporated
a new wholly-owned subsidiary, Silo Pharma Inc.,&#160;in the State of Florida. The Company has also secured the domain name <i>www.silopharma.com</i>.
The Company has been exploring opportunities to expand the Company&#8217;s business by seeking to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. In July 2020, through the Company&#8217;s newly formed subsidiary, the Company entered into a commercial evaluation license
and option agreement with University of Maryland, Baltimore (&#8220;UMB&#8221;) (see Note 10) pursuant to which, among other things,
UMB granted the Company an exclusive, option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license to with respect
to certain technology. The option was extended and exercised on January 13, 2021. On February 12, 2021, the Company entered into a Master
License Agreement with UMB (see Note 10). The Company plans to actively pursue the acquisition and/or development of intellectual property
or technology rights to treat rare diseases, and to ultimately expand the Company&#8217;s business to focus on this new line of business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2021, the Company entered
into and closed on an Asset Purchase Agreement (&#8220;Asset Purchase Agreement) with NFID, LLC, a Florida limited liability company
(&#8220;Buyer&#8221;), whereby the Buyer purchased from the Company certain assets, properties, and rights in connection with the Company&#8217;s
NFID trademark name, logos, domain, and apparel clothing and accessories for a purchase price of $60,000 in the form of a promissory
note amounting to $60,000. The promissory note bears 8% interest per annum and matures on October 1, 2023. Accordingly, the results of
operations of this component, for all periods presented, are separately reported as &#8220;discontinued operations&#8221; on the accompanying
consolidated statements of operations (see Note 4).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On September 14, 2022, the Company filed a
Certificate of Amendment to the Amended and Restated Articles of Incorporation (the &#8220;Certificate of Amendment&#8221;) with the
Secretary of State of the State of Nevada to effect a 1-for-50 reverse stock split (the &#8220;Reverse Stock Split&#8221;) with respect
to the outstanding shares of the Company&#8217;s common stock. The Certificate of Amendment became effective on September 14, 2022. The
Reverse Stock Split was previously approved by the sole director and the majority of stockholders of the Company. The Reverse Stock Split
was deemed effective at the open of business on September 15, 2022. All share and per share data in the accompanying consolidated financial
statements have been retroactively restated to reflect the effect of the reverse stock split.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336823044352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 &#8211; <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation and Principles of
Consolidation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s consolidated financial statements
include financial statements for Silo Pharma, Inc and its inactive wholly-owned subsidiary with the same name as the parent entity, Silo
Pharma, Inc, as of June 30, 2022 and during the three and nine months ended June 30, 2022. All intercompany balances and transactions
have been eliminated in consolidation. Management acknowledges its responsibility for the preparation of the accompanying unaudited condensed
consolidated financial statements which reflect all adjustments, consisting of normal recurring and non-recurring adjustments, considered
necessary in its opinion for a fair statement of its consolidated financial position and the consolidated results of its operations for
the periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America (the &#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions Article 8-03 of Regulation S-X.
Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole.
Certain information and note disclosure normally included in financial statements prepared in accordance with U.S. GAAP has been condensed
or omitted from these statements pursuant to such accounting principles and, accordingly, they do not include all the information and
notes necessary for comprehensive financial statements. These unaudited condensed consolidated financial statements should be read in
conjunction with the summary of significant accounting policies and notes to the financial statements for the year ended December 31,
2021 included in the Company&#8217;s Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 28, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with, ASC 205-20 &#8220;Discontinued
Operations&#8221; establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should
be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity&#8217;s
operations and financial results. As a result, the NFID, LLC component&#8217;s results of operations have been classified as discontinued
operations on a retrospective basis for all periods presented. Accordingly, the results of operations of this component, for all periods,
are separately reported as &#8220;discontinued operations&#8221; on the condensed consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As reflected in the accompanying condensed
consolidated financial statements, the Company generated a net loss of $1,262,474 and used cash in operations of $1,189,274 during the
six months ended June 30, 2022. Additionally, the Company has an accumulated deficit of $4,525,051 at June 30, 2022. However, as of June
30, 2022, the Company had working capital of $8,678,540.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The positive worthy capital serves to mitigate
the conditions that historically raised substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company
believes that the Company has sufficient cash to meet its obligations for a minimum of twelve months from the date of this filing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of unaudited condensed consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment.
It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at
the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one
or more future events. Accordingly, the actual results could differ significantly from estimates. Significant estimates during the six
months ended June 30, 2022 and year ended December 31, 2021 include the collectability of notes receivable, valuation of equity investments,
estimates for obsolete and slow-moving inventory, estimates of the deemed dividend, valuation allowances for deferred tax assets, the
fair value of warrants issued with debt and for services, and the fair value of shares issued for services and in settlements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash and Cash Equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid investments
with a maturity of three months or less when acquired to be cash equivalents. The Company places its cash with high credit quality financial
institutions. The Company&#8217;s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)
up to $250,000 or by the Securities Investor Protection Corporation up to $250,000. To reduce its risk associated with the failure of
such financial institutions, the Company evaluates, at least annually, the rating of the financial institutions in which it holds deposits.
At June 30, 2022 and December 31, 2021, the Company had cash in excess of FDIC limits of approximately $8,240,000, and approximately
$9,100,000, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Notes Receivable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes an allowance for losses
on notes receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical
bad debt experience, current note receivable aging, and expected future write-offs, as well as an assessment of specific identifiable
accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recognized as general
and administrative expense.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Prepaid Expenses and Other Current Assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prepaid expenses and other current assets
- current of $99,939 and $145,324 at June 30, 2022 and December 31, 2021, respectively, consist primarily of costs paid for future services
which will occur within a year. Prepaid expenses and other current assets &#8211; non-current of $33,740 and $26,659 at June 30, 2022
and December 31, 2021, respectively, consist primarily of costs paid for license fees and future services which will occur after a year.
Prepaid expenses may include prepayments in cash and equity instruments for consulting, business advisory, legal services, license fees,
research and development fees, and insurance which are being amortized over the terms of their respective agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments, at Fair Value</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Realized gain or loss is recognized when an
investment is disposed of and is computed as the difference between the Company&#8217;s carrying value and the net proceeds received
from such disposition. Realized gains and losses on investment transactions are determined by specific identification. Net unrealized
appreciation or depreciation is computed as the difference between the fair value of the investment and the cost basis of such investment.
Net unrealized gains or losses for equity investments are recognized in operations as the difference between the carrying value at the
beginning of the period and the fair value at the end of the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments, at Cost</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equity investments, at cost are comprised
mainly of non-marketable capital stock and stock warrants, are recorded at cost, as adjusted for other than temporary impairment write-downs
and are evaluated for impairment periodically.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Recognition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies ASC Topic 606, Revenue
from Contracts with Customers (&#8220;ASC 606&#8221;). ASC 606 establishes a single comprehensive model for entities to use in accounting
for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires
an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records interest and dividend
income on an accrual basis to the extent that the Company expects to collect such amounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the license and royalty income, revenue
is recognized when the Company satisfies the performance obligation based on the related license agreement. Payments received from the
licensee that are related to future periods are recorded as deferred revenue to be recognized as revenues over the term of the related
license agreement (see Note 8).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Product sales were recognized when the NFID
products were shipped to the customer and title was transferred and were recorded net of any discounts or allowances which are separately
reported as &#8220;discontinued operations&#8221; on the condensed consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cost of Revenues</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary components of cost of revenues
on license fees included the cost of the license fees. Payments made to the licensor that are related to future periods are recorded
as prepaid expense to be amortized over the term of the related license agreement (see Note 8).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary components of cost of revenues
on NFID apparel include the cost of the product, production costs, warehouse storage costs and shipping fees which are separately reported
as &#8220;discontinued operations&#8221; on the condensed consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation is accounted for
based on the requirements of ASC 718 &#8211; &#8220;Compensation &#8211; Stock Compensation&#8221;, which requires recognition in the
financial statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments
over the period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively,
the vesting period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange
for an award based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted
under Accounting Standards Update (&#8220;ASU&#8221;) 2016-09 Improvements to Employee Share-Based Payment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income tax assets and liabilities
arise from temporary differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted
tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current
or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities
not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences
are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to
be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the provisions of Financial
Accounting Standards Board (&#8220;FASB&#8221;) ASC 740-10, &#8220;Uncertainty in Income Taxes&#8221;. Certain recognition thresholds
must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax
positions that meet a &#8220;more-likely-than-not&#8221; threshold. The Company does not believe it has any uncertain tax positions as
of June 30, 2022 and December 31, 2021 that would require either recognition or disclosure in the accompanying condensed consolidated
financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 730-10, &#8220;Research
and Development-Overall,&#8221; research and development costs are expensed when incurred. During the six months ended June 30, 2022
and 2021, research and development costs were $275,955 and $147,448, respectively. During the three months ended June 30, 2022 and 2021,
research and development costs were $105,676 and $98,846, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Net Loss per Common Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per share is computed by dividing
net loss allocable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Diluted
earnings per share is computed by dividing net income available to common shareholders by the weighted average number of shares of common
stock, common stock equivalents and potentially dilutive securities outstanding during the period using the as-if converted method. Potentially
dilutive securities which included convertible preferred shares and stock options are excluded from the computation of diluted shares
outstanding if they would have an anti-dilutive impact on the Company&#8217;s net losses. The following are the potentially dilutive
shares for the six months ended June 30, 2022 and 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Series C convertible preferred stock</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-311"><span style="-keep: true">&#8212;</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">15,133</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Stock options</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">28,849</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Warrants</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">347,080</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">347,080</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">375,929</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">368,213</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, the FASB issued ASU 2020-06&#8212;<i>Debt&#8212;Debt
with Conversion and Other Options (Subtopic 470-20) and Derivatives and edging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic
815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;)</i> to simplify
the accounting for convertible instruments by removing certain separation models in Subtopic 470- 20, <i>Debt with Conversion and Other
Options</i>, for convertible instruments. Under the amendments in ASU 2020-06, the embedded conversion features no longer are separated
from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives
under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently,
a convertible debt instrument will be accounted for as a single liability measured at its amortized cost and a convertible preferred
stock will be accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation
and recognition as derivatives. By removing those separation models, the interest rate of convertible debt instruments typically will
be closer to the coupon interest rate when applying the guidance in Topic 835, Interest. The amendments in ASU 2020-06 provide financial
statement users with a simpler and more consistent starting point to perform analyses across entities. The amendments also improve the
operability of the guidance and reduce, to a large extent, the complexities in the accounting for convertible instruments and the difficulties
with the interpretation and application of the relevant guidance. To further improve the decision usefulness and relevance of the information
being provided to users of financial statements, amendments in ASU 2020-06 increased information transparency by making the following
amendments to the disclosure for convertible instruments:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Add a disclosure objective</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Add information about events or conditions that occur during the
    reporting period that cause conversion contingencies to be met or conversion terms to be significantly changed</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Add information on which party controls the conversion rights</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Align disclosure requirements for contingently convertible instruments
    with disclosure requirements for other convertible instruments</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Require that existing fair value disclosures in Topic 825, Financial
    Instruments, be provided at the individual convertible instrument level rather than in the aggregate.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, for convertible debt instruments
with substantial premiums accounted for as paid-in capital, amendments in ASU 2020-06 added disclosures about (1) the fair value amount
and the level of fair value hierarchy of the entire instrument for public business entities and (2) the premium amount recorded as paid-in
capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amendments in ASU 2020-06 are effective
for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning
after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for
fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but
no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Entities should
adopt the guidance as of the beginning of its annual fiscal year and are allowed to adopt the guidance through either a modified retrospective
method of transition or a fully retrospective method of transition. In applying the modified retrospective method, entities should apply
the guidance to transactions outstanding as of the beginning of the fiscal year in which the amendments are adopted. Transactions that
were settled (or expired) during prior reporting periods are unaffected. The cumulative effect of the change should be recognized as
an adjustment to the opening balance of retained earnings at the date of adoption. If an entity elects the fully retrospective method
of transition, the cumulative effect of the change should be recognized as an adjustment to the opening balance of retained earnings
in the first comparative period presented. The Company adopted ASU 2020-06 during the three months ended March 31, 2022 and it did not
have material impact on its condensed consolidated financial statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, the FASB issued ASU 2021-04,
Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718),
and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40). The new ASU addresses issuer&#8217;s accounting
for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities,
for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted.
The Company adopted ASU 2020-06 during the three months ended March 31, 2022 and did not have material impact on its condensed consolidated
financial statements</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management does not believe that any other
recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company&#8217;s consolidated
financial statements.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 &#8211; <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation and Principles of
Consolidation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S.
GAAP&#8221;), the instructions to Form 10-K, and the rules and regulations of the United States Securities and Exchange Commission (the
&#8220;SEC&#8221;) for financial information. The Company&#8217;s consolidated financial statements include financial statements for
Silo Pharma, Inc and its inactive wholly-owned subsidiary with the same name as the parent entity, Silo Pharma, Inc, as of December 31,
2021 and during the years ended December 31, 2021 and 2020. All intercompany transactions and balances have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with, ASC 205-20 &#8220;Discontinued
Operations&#8221; establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should
be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity&#8217;s
operations and financial results. As a result, the NFID, LLC component&#8217;s results of operations have been classified as discontinued
operations on a retrospective basis for all periods presented. Accordingly, the results of operations of this component, for all periods,
are separately reported as &#8220;discontinued operations&#8221; on the consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As reflected in the accompanying consolidated
financial statements, the Company generated a net income of $3,903,741 and used cash in operations of $2,278,016, for the year ended
December 31, 2021. Additionally, the Company has an accumulated deficit of $3,262,577 at December 31, 2021. During the year ended December
31, 2021, the Company has received gross proceeds of $7,020,526 from the sale of equity investments. As of December 31, 2021, the Company
had working capital of $9,912,281.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These events served to mitigate the conditions
that historically raised substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company believes the
proceeds received during the year ended December 31, 2021 will provide sufficient cash flows to meet its obligations for a minimum of
twelve months from the date of this filing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at
least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date
of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more
future events. Accordingly, the actual results could differ significantly from estimates. Significant estimates during the years ended
December 31, 2021 and 2020 include the collectability of notes receivable, the valuation of equity investments, estimates for obsolete
and slow-moving inventory, estimates of the deemed dividend, valuation allowances for deferred tax assets, the fair value of warrants
issued with debt and for services, and the fair value of shares issued for services and in settlements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash and Cash Equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid investments
with a maturity of three months or less when acquired to be cash equivalents. The Company places its cash with high credit quality financial
institutions. The Company&#8217;s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)
up to $250,000 and by the Securities Investor Protection Corporation (&#8220;SIPC&#8221;) up to $250,000. To reduce its risk associated
with the failure of such financial institutions, the Company evaluates, at least annually, the rating of the financial institutions in
which it holds deposits. At December 31, 2021 and 2020, the Company had cash in excess of FDIC and SIPC limits of approximately $9,100,000
and $880,000, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Notes Receivable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes an allowance for losses
on notes receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical
bad debt experience, current note receivable aging, and expected future write-offs, as well as an assessment of specific identifiable
accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recognized as general
and administrative expense.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Prepaid Expenses and Other Current Assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.65pt; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prepaid expenses and other current assets
- current of $145,324 and $241,091 at December 31, 2021 and 2020, respectively, consist primarily of costs paid for future services which
will occur within a year. Prepaid expenses and other current assets &#8211; non-current of $26,659 and $0 at December 31, 2021 and 2020,
respectively, consist primarily of costs paid for license fees and future services which will occur after a year. Prepaid expenses may
include prepayments in cash and equity instruments for consulting, business advisory, legal services, license fees, research and development
fees, and insurance which are being amortized over the terms of their respective agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments, at Fair Value</b></p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Realized gain or loss is recognized when an
investment is disposed of and is computed as the difference between the Company&#8217;s carrying value and the net proceeds received
from such disposition.&#160;&#160;Realized gains and losses on investment transactions are determined by specific identification. Net
unrealized appreciation or depreciation is computed as the difference between the fair value of the investment and the cost basis of
such investment. Net unrealized gains or losses for equity investments are recognized in operations as the difference between the carrying
value at the beginning of the period and the fair value at the end of the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Equity Investments, at Cost</b></p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equity investments, at cost are comprised
mainly of non-marketable capital stock and stock warrants, are recorded at cost, as adjusted for other than temporary impairment write-downs
and are evaluated for impairment periodically.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Recognition</b></p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies ASC Topic 606, Revenue
from Contracts with Customers (&#8220;ASC 606&#8221;). ASC 606 establishes a single comprehensive model for entities to use in accounting
for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires
an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records interest and dividend
income on an accrual basis to the extent that the Company expects to collect such amounts.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the license and royalty income, revenue
is recognized when the Company satisfies the performance obligation based on the related license agreement. Payments received from the
licensee that are related to future periods are recorded as deferred revenue to be recognized as revenues over the term of the related
license agreement (see Note 10).</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Product sales were recognized when the NFID
products were shipped to the customer and title was transferred and were recorded net of any discounts or allowances which are separately
reported as &#8220;discontinued operations&#8221; on the consolidated statements of operations.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cost of Revenues</b></p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.05pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary components of cost of revenues
on license fees included the cost of the license fees. Payments made to the licensor that are related to future periods are recorded
as prepaid expense to be amortized over the term of the related license agreement (see Note 10).</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary components of cost of revenues
on NFID apparel include the cost of the product, production costs, warehouse storage costs and shipping fees which are separately reported
as &#8220;discontinued operations&#8221; on the consolidated statements of operations.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation is accounted for
based on the requirements of ASC 718 &#8211; &#8220;Compensation &#8211; Stock Compensation&#8221;, which requires recognition in the
financial statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments
over the period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively,
the vesting period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange
for an award based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted
under Accounting Standards Update (&#8220;ASU&#8221;) 2016-09 Improvements to Employee Share-Based Payment.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Income Taxes</b></p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income tax assets and liabilities
arise from temporary differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted
tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current
or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities
not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences
are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to
be realized.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the provisions of Financial
Accounting Standards Board (&#8220;FASB&#8221;) ASC 740-10, &#8220;Uncertainty in Income Taxes&#8221;. Certain recognition thresholds
must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax
positions that meet a &#8220;more-likely-than-not&#8221; threshold. The Company does not believe it has any uncertain tax positions as
of December 31, 2021 and 2020 that would require either recognition or disclosure in the accompanying consolidated financial statements.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognized income tax expense
of $24,876 and $0 for the years ended December 31, 2021 and 2020 (see Note 8).</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 730-10, &#8220;Research
and Development-Overall,&#8221; research and development costs are expensed when incurred. During the years ended December 31, 2021 and
2020, research and development costs were $693,910 and $26,250, respectively.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Net Income (Loss) per Common Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net income (loss) per share is computed
by dividing net income (loss) allocable to common shareholders by the weighted average number of shares of common stock outstanding during
each period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted average number
of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period using the as-if
converted method. Potentially dilutive securities which include convertible preferred shares and stock options are excluded from the
computation of diluted shares outstanding if they would have an anti-dilutive impact on the Company&#8217;s net income or (loss). The
following are the potentially dilutive shares for the years ended December 31, 2021 and 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">December&#160;31,<br/> 2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">December&#160;31,<br/> 2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left"><span style="-keep: true">Series C convertible preferred stock</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; text-align: right"><span style="-keep: true">15,133</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-263"><span style="-keep: true">&#8212;</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Stock options</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Warrants</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">347,080</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-264"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">368,213</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">6,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents a reconciliation
of basic and diluted net loss per share:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the Years Ended<br/> December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="-keep: true">Income (loss) per common share &#8212; basic:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="-keep: true">Income (loss) from continuing operations</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">4,157,108</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(2,666,269</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-keep: true">Loss from discontinued operations</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(253,367</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(371,248</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Net income (loss)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">3,903,741</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(3,037,517</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Weighted average common shares outstanding &#8212; basic</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1,897,315</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1,319,094</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">Net income (loss) per common share available to common stockholders&#8211; basic:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 9pt"><span style="-keep: true">From continuing operations</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1.45</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(2.07</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"><span style="-keep: true">From discontinued operations</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(0.13</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(0.28</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="-keep: true">Income (loss) per common share &#8212; diluted:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Income (loss) from continuing operations</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">4,157,108</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(2,666,269</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">Add: interest expense, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(3,036</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-265"><span style="-keep: true">&#8212;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Numerator for loss from continuing operations per common share &#8212; diluted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,154,072</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(2,666,269</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-keep: true">Numerator for loss from discontinuing operations per common share &#8212;
    diluted</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(253,367</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(371,248</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Net loss per common share &#8211; diluted</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">3,900,705</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(3,037,517</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Weighted average common shares outstanding &#8212; basic</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,897,315</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,319,094</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">Effect of dilutive securities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt"><span style="-keep: true">Options</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,996</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-266"><span style="-keep: true">&#8212;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt"><span style="-keep: true">Preferred shares</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">15,133</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-267"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Weighted average common shares outstanding &#8211; diluted</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268"><span style="-keep: true">1,918,4448</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1,319,094</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Net loss per common share available to common stockholders &#8211; diluted:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"><span style="-keep: true">From continuing operations</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1.43</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(2.07</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"><span style="-keep: true">From discontinued operations</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(0.13</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(0.28</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company accounts
for its leases using the method prescribed by ASC 842 &#8211; <i>Lease Accounting</i>. The Company assess whether the contract is, or
contains, a lease at the inception of a contract which is based on (i) whether the contract involves the use of a distinct identified
asset, (ii) whether the Company obtain the right to substantially all the economic benefit from the use of the asset throughout the period,
and (iii) whether the Company has the right to direct the use of the asset. The Company allocates the consideration in the contract to
each lease component based on its relative stand-alone price to determine the lease payments. The Company has elected not to recognize
right-of-use (&#8220;ROU&#8221;) assets and lease liabilities for short-term leases that have a term of 12 months or less.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Operating lease ROU
assets represents the right to use the leased asset for the lease term. Operating lease liabilities are recognized based on the present
value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate,
the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value
of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included
in general and administrative expenses in the consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, the FASB issued ASU 2020-06&#8212;<i>Debt&#8212;Debt
with Conversion and Other Options (Subtopic 470-20) and Derivatives and edging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic
815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;)</i> to simplify
the accounting for convertible instruments by removing certain separation models in Subtopic 470- 20, <i>Debt with Conversion and Other
Options</i>, for convertible instruments. Under the amendments in ASU 2020-06, the embedded conversion features no longer are separated
from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives
under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently,
a convertible debt instrument will be accounted for as a single liability measured at its amortized cost and a convertible preferred
stock will be accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation
and recognition as derivatives. By removing those separation models, the interest rate of convertible debt instruments typically will
be closer to the coupon interest rate when applying the guidance in Topic 835, Interest. The amendments in ASU 2020-06 provide financial
statement users with a simpler and more consistent starting point to perform analyses across entities. The amendments also improve the
operability of the guidance and reduce, to a large extent, the complexities in the accounting for convertible instruments and the difficulties
with the interpretation and application of the relevant guidance. To further improve the decision usefulness and relevance of the information
being provided to users of financial statements, amendments in ASU 2020-06 increased information transparency by making the following
amendments to the disclosure for convertible instruments:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Add a disclosure objective</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Add information about
    events or conditions that occur during the reporting period that cause conversion contingencies to be met or conversion terms to
    be significantly changed</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Add information on which
    party controls the conversion rights</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Align disclosure requirements
    for contingently convertible instruments with disclosure requirements for other convertible instruments</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Require that existing
    fair value disclosures in Topic 825, Financial Instruments, be provided at the individual convertible instrument level rather than
    in the aggregate.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, for convertible debt instruments
with substantial premiums accounted for as paid-in capital, amendments in ASU 2020-06 added disclosures about (1) the fair value amount
and the level of fair value hierarchy of the entire instrument for public business entities and (2) the premium amount recorded as paid-in
capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The amendments in
ASU 2020-06 are effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the
SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities,
the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years.
Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those
fiscal years. Entities should adopt the guidance as of the beginning of its annual fiscal year and are allowed to adopt the guidance
through either a modified retrospective method of transition or a fully retrospective method of transition. In applying the modified
retrospective method, entities should apply the guidance to transactions outstanding as of the beginning of the fiscal year in which
the amendments are adopted. Transactions that were settled (or expired) during prior reporting periods are unaffected. The cumulative
effect of the change should be recognized as an adjustment to the opening balance of retained earnings at the date of adoption. If an
entity elects the fully retrospective method of transition, the cumulative effect of the change should be recognized as an adjustment
to the opening balance of retained earnings in the first comparative period presented. The Company is evaluating the impact of the revised
guidance and believes that it will not have a significant impact on its consolidated financial statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, the FASB issued ASU 2021-04,
Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718),
and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40). The new ASU addresses issuer&#8217;s accounting
for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities,
for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted.
The Company is evaluating the impact of the revised guidance and believes that it will not have a significant impact on its consolidated
financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management does not believe that any other
recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company&#8217;s consolidated
financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336908324928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE OF FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 &#8211; <span style="text-decoration:underline">FAIR VALUE OF FINANCIAL
INSTRUMENTS AND FAIR VALUE MEASUREMENTS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 820 - Fair Value Measurements and
Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments,
whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent
information available to the Company on June 30, 2022. Accordingly, the estimates presented in these financial statements are not necessarily
indicative of the amounts that could be realized on disposition of the financial instruments. FASB ASC 820 specifies a hierarchy of valuation
techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market
data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority
to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable
inputs (Level 3 measurement).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px">&#160;</td>
    <td style="width: 58px; text-align: justify"><span style="font-size: 10pt">Level 1 -</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inputs are unadjusted quoted prices in active markets for identical
    assets or liabilities available at the measurement date.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 2 -</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inputs are unadjusted quoted prices for similar assets and liabilities
    in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than
    quoted prices that are observable, and inputs derived from or corroborated by observable market data.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 3 -</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inputs are unobservable inputs which reflect the reporting entity&#8217;s
    own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available
    information.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company analyzes all financial instruments
with features of both liabilities and equity under the FASB&#8217;s accounting standard for such instruments. Under this standard, financial
assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts reported in the consolidated
balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair market
value based on the short-term maturity of these instruments.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments at Fair Value</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounted for certain equity investments
at fair value using level 1, level 2 and level 3 valuations. Assets and liabilities measured at fair value on a recurring basis are as
follows at June 30, 2022 and December 31, 2021:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At June 30, 2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At December 31, 2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; text-align: left">Equity investments consisting of common
    stock, at fair value</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">113,012</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-312">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-313">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">419,995</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-314">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-315">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes activity in
the Company&#8217;s equity investments, at fair value for the periods presented:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance, beginning</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">419,995</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-316">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,733</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">531,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Sales at original cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(171,407</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(359,843</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Unrealized (loss) gain</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(221,309</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">248,588</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance as of June 30, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">113,012</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">419,995</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended June 30, 2022,
the Company received 77,939 shares of Home Bistro, Inc. common stock with grant date fair value of $85,733 or $1.10 per share, in exchange
for entering into a lock up and leak out agreement which was recorded as other income from equity shares earned for services in the accompanying
condensed consolidated statement of operations. The Company measures equity securities received for services at fair value on the date
of receipt.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended June 30, 2022,
the Company sold its equity investments in Aikido Pharma, Inc. with cost of $171,407 for gross proceeds of $66,707 and the Company recorded
a net realized loss on equity investments amounting to $104,700 as reflected in the accompanying condensed consolidated statement of
operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2022 and December 31, 2021, equity
investments, at fair value consisted of common equity securities of two entities, Home Bistro, Inc. and Aikido Pharma, Inc. (see Note
8).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equity investments are carried at fair value
with unrealized gains or losses which is recorded as net unrealized gain (loss) on equity investments in the accompanying condensed consolidated
statement of operations.&#160;Realized gains and losses are determined on a specific identification basis which is recorded as net realized
gain (loss) on equity investments in the consolidated statement of operations. The Company reviews equity investments, at fair value
for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recovered.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 825-10 &#8220;Financial Instruments&#8221;
allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair
value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value
option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent
reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments at Cost</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2022 and December 31, 2021, the
Company did not have non-marketable capital stock and stock warrants, recorded at cost.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 &#8211; <span style="text-decoration:underline">FAIR VALUE OF FINANCIAL
INSTRUMENTS AND FAIR VALUE MEASUREMENTS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 820 - Fair Value Measurements and
Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments,
whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent
information available to the Company on December 31, 2021. Accordingly, the estimates presented in these financial statements are not
necessarily indicative of the amounts that could be realized on disposition of the financial instruments. FASB ASC 820 specifies a hierarchy
of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect
market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest
priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority
to unobservable inputs (Level 3 measurement).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.6in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1-&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unadjusted
    quoted prices in active markets for identical assets or liabilities available at the measurement date.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unadjusted
    quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities
    in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable
    market data.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unobservable
    inputs which reflect the reporting entity&#8217;s own assumptions on what assumptions the market participants would use in pricing
    the asset or liability based on the best available information.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company analyzes all financial instruments
with features of both liabilities and equity under the FASB&#8217;s accounting standard for such instruments. Under this standard, financial
assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts reported in the consolidated
balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair market
value based on the short-term maturity of these instruments.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments at Fair Value</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounted for certain equity investments
at fair value using level 1, level 2 and level 3 valuations. Assets and liabilities measured at fair value on a recurring basis are as
follows at December 31, 2021 and 2020:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At December 31, 2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding-left: 0.125in; text-indent: -0.125in; text-align: left; font-weight: bold">Description</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 28%; text-align: left">Equity investments consisting of common
    stock, at fair value</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">419,995</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-269">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-272">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-273">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes activity in
the Company&#8217;s equity investments, at fair value for the periods presented:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Balance, beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-274">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-275">&#160;&#160;&#160;&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; width: 76%">Additions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">531,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-276">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(359,843</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-277">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Unrealized gain</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">248,588</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-278">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Balance, end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">419,995</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-279">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2021, equity investments,
at fair value consisted of common equity securities of two entities, Home Bistro, Inc and Aikido Pharma, Inc. (see Note 10).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equity investments are carried at fair value
with unrealized gains or losses which is recorded as net unrealized gain (loss) on equity investments in the accompanying consolidated
statement of operations.&#160;Realized gains and losses are determined on a specific identification basis which is recorded as net realized
gain (loss) on equity investments in the accompanying consolidated statement of operations. The Company reviews equity investments, at
fair value for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may
not be recovered.&#160;For the year ended December 31, 2021, we recorded a net realized gain on equity investments of $6,660,483 primarily
attributed to a gain from the sale of the Company&#8217;s equity investment in DatChat, Inc. of $6,657,120 and Aikido Pharma, Inc. of
$3,363. DatChat, Inc. was a cost basis investment carried at $200 at December 31, 2020 (see below). The Company paid a commission on
the sale of DatChat, Inc. totaling $578,880 which was netted with the proceeds.</p><p style="margin: 0pt 0; font-size: 10pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 825-10 &#8220;Financial Instruments&#8221;
allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair
value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value
option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent
reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Equity Investments at Cost</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2021 and 2020, equity investments,
at cost of $0 and $200, respectively, comprised mainly of non-marketable capital stock and stock warrants, are recorded at cost, as adjusted
for other than temporary impairment write-downs and are evaluated for impairment periodically.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336822796272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disposal of the Discontinued Operations of the Nfid Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">DISPOSAL OF THE DISCONTINUED OPERATIONS OF THE NFID BUSINESS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8211; <span style="text-decoration:underline">DISPOSAL OF THE DISCONTINUED
OPERATIONS OF THE NFID BUSINESS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2021, the Company entered
into and closed on an Asset Purchase Agreement (see Note 1) with NFID, LLC, an unrelated party, a Florida limited liability company,
whereby the Company sold certain assets, properties, and rights in connection with its NFID trademark name, logos, domain, and apparel
clothing and accessories for a purchase price of $60,000 in the form of a promissory note amounting to $60,000. The promissory note bears
8% interest per annum and matures on October 1, 2023. Note receivable &#8211; non-current amounted to $60,000 as of September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 205-20 &#8220;Discontinued Operations&#8221;
establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should be reported in
discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity&#8217;s operations
and financial results. As a result, the component&#8217;s results of operations have been classified as discontinued operations on a
retrospective basis for all periods presented. Accordingly, the results of operations of this component, for all periods, are separately
reported as &#8220;discontinued operations&#8221; on the condensed consolidated statements of operations.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table set forth the selected
financial data of the Company&#8217;s gain from sale of the NFID business on September 30, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September&#160;30, <br/>
    2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 1.5pt">Inventory, net</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">58,447</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">58,447</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-317">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net asset of NFID business disposed</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">58,447</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Consideration in the form of a note receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Gain from sale of NFID business</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,553</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The summarized operating result of discontinued
operations of the NFID Business included in the Company&#8217;s condensed consolidated statements of operations for the six months ended
June 30, 2022 and 2021 is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Product sales, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-318">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">80,305</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,079</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,360</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,079</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,945</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating and other non-operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(84</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(152,095</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Loss from discontinued operations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,163</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(140,150</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8211; <span style="text-decoration:underline">DISPOSAL OF THE DISCONTINUED
OPERATIONS OF THE NFID BUSINESS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2021, the Company entered
into and closed on an Asset Purchase Agreement (see Note 1) with NFID, LLC, an unrelated party, a Florida limited liability company,
whereby the Company sold certain assets, properties, and rights in connection with its NFID trademark name, logos, domain, and apparel
clothing and accessories for a purchase price of $60,000 in the form of a promissory note for the same amount (&#8220;Note&#8221;). The
Note bears 8% interest per annum and matures on October 1, 2023. As of December 31, 2021, the Note had principal balance of $60,000 and
accrued interest receivable of $1,210 for a total outstanding receivable balance of $61,210.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 205-20 &#8220;Discontinued Operations&#8221;
establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should be reported in
discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity&#8217;s operations
and financial results. As a result, the component&#8217;s results of operations have been classified as discontinued operations on a
retrospective basis for all periods presented. Accordingly, the results of operations of this component, for all periods, are separately
reported as &#8220;discontinued operations&#8221; in the accompanying consolidated statements of operations.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2021 and 2020, assets of
discontinued operations amounted $0 and $33,484, respectively, which primarily consisted of NFID inventory.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table set forth the selected
financial data of the Company&#8217;s gain from sale of the NFID business on September 30, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September&#160;30,<br/>
    2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 1.5pt">Inventory, net</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">58,447</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">58,447</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-280">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net asset of NFID business disposed</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">58,447</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Consideration in the form of a note receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Gain from sale of NFID business</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,553</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The summarized operating result of discontinued
operations of the NFID Business included in the Company&#8217;s consolidated statements of operations for the years ended December 31,
2021 and 2020 is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Year Ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Product sales, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">119,405</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,923</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">103,824</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">182,426</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,581</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(141,503</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total operating and other non-operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(270,501</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(229,745</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain from sale of NFID business</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,533</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-281">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Loss from discontinued operations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(253,367</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(371,248</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336908324800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Receivable<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">NOTES RECEIVABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5 &#8211; <span style="text-decoration:underline">NOTES RECEIVABLE</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022 and December 31, 2021,
notes receivable, net, consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Principal amounts of notes receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">115,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">220,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Additional notes receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-319">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Collections on notes receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(164,500</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(35,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(55,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Notes receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: notes receivable, net &#8211; current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-320">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-321">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Notes receivable &#8211; non-current</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">60,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">60,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 28, 2018, the Company and Blind
Faith Concepts Holdings, Inc. (the &#8220;Seller&#8221;) executed a two-year promissory note receivable agreement with a principal balance
of $200,000 of which $100,000 was funded to the Seller in September 2018 and the remaining $100,000 was funded in October 2018. The promissory
note accrued interest at a rate of 6% per annum, and the Company was repaid in interest only payments on a quarterly basis, until the
maturity date of September 27, 2020, at which time the full principal and any interest payments was due to the Company. At the time the
promissory note receivable agreement was executed, the Company also executed a security interest and pledge agreement with the borrower
pursuant to which the borrower pledged all of the assets of its company as security for the performance of the note obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 2, 2018, the Company and Seller
entered into a promissory note agreement (&#8220;Promissory Note Agreement&#8221;) with a principal balance of $50,000. Pursuant to the
Promissory Note Agreement, the $50,000 note was a deposit and credit towards the acquisition of the assets of Lust for Life Group such
as inventory, trademarks and logos. Pursuant to the Promissory Note Agreement, since the purchase did not close within 30 days from date
of the Promissory Note, the note receivable became immediately due. Through the date of default, the outstanding principal balance accrued
interest at an interest rate of 10% per annum payable on a monthly basis. Upon default, the interest rate increased to 18% per annum.
As of December 31, 2018, the Company determined that this note receivable was doubtful and accordingly, recorded an allowance for doubtful
account and bad debt expense of $50,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, pursuant to claim purchase
agreements (&#8220;Claim Purchase Agreements&#8221;), the Company sold its notes receivable and related interest receivable balances
in the aggregate amount of $277,305 to an investor. Pursuant to the Claim Purchase Agreements, the investor agreed to pay the Company
the purchase price of $277,305 on the earlier of the payment of six-monthly installments or upon the liquidation of settlement securities
of the Seller pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended. The first installment was be made following entry
and full effectuation of a court order approving the settlement of the claim which occurred on March 6, 2020 in the United States District
Court for the District of Maryland Northern Division. Additionally, on January 6, 2020, the Company and the Seller entered into a settlement
agreement related to notes receivable. In lieu of the Company seeking default and foreclosure against the Seller pursuant to the note
agreements, the Company received 10,420 shares of the Seller&#8217;s convertible Series B Preferred Stock. Since the shares of Series
B Preferred Stock have limited marketability, no value was placed on these shares. Between April 2020 and December 2020, the Company
collected an aggregate of $30,000 on the notes receivable balance.&#160;During the year ended December 31, 2020, the Company recorded
a total allowance for doubtful account and bad debt expense of $174,376 (consisting of the principal balance of $146,500 and interest
receivable of $27,876) due to slow collection of the installment payments pursuant to the Claim Purchase Agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2021,
the Company recovered an aggregate of $7,500 bad debt previously written off during the periods between 2018 to 2020, recorded as bad
debt recovery in the accompanying consolidated statement of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2021, the
Company received $23,500 of payment and recovered $141,000 of the of the $196,500 bad debt allowance. On June 7, 2021, the Company and
the investor, entered into a settlement agreement whereby both parties agreed to settle the remaining balance of this note receivable
which was previously written off in year 2020 for a total settlement amount of $196,000 to be paid as follows; (i) an initial payment
of $46,000 upon execution of the settlement agreement and (ii) $10,000 per month for fifteen months. During the six months ended June
30, 2022, $20,000 was collected under this settlement agreement and $35,500 remains collectible under this settlement agreement and such
amount has been fully reserved as of June 30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2021, the Company executed
a note receivable agreement with NFID, LLC in connection with an Asset Purchase Agreement (see Note 4). The promissory note bears 8%
interest per annum and matures on October 1, 2023. The outstanding principal and accrued interest shall be due and payable on maturity.
As of December 31, 2021, this note receivable had outstanding principal receivable of $60,000 and accrued interest receivable of $1,210
for a total receivable balance of $61,210. As of June 30, 2022, this note receivable had outstanding principal receivable of $60,000
and accrued interest receivable of $3,590 for a total receivable balance of $63,590 which is reflected in the accompanying consolidated
balance sheet as note receivable &#8211; non-current.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>NOTE 5 &#8211; <span style="text-decoration:underline">NOTES RECEIVABLE</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 28, 2018, the Company and Blind
Faith Concepts Holdings, Inc. (the &#8220;Seller&#8221;) executed a two-year promissory note receivable agreement with a principal balance
of $200,000 of which $100,000 was funded to the Seller in September 2018 and the remaining $100,000 was funded in October 2018. The promissory
note accrued interest at a rate of 6% per annum, and the Company was repaid in interest only payments on a quarterly basis, until the
maturity date of September 27, 2020, at which time the full principal and any interest payments was due to the Company. At the time the
promissory note receivable agreement was executed, the Company also executed a security interest and pledge agreement with the borrower
pursuant to which the borrower pledged all of the assets of its company as security for the performance of the note obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 2, 2018, the Company and Blind
Faith Concepts Holdings, Inc. (the &#8220;Debtor&#8221;) entered into a promissory note agreement for the sale of a promissory note with
a principal balance of $50,000 (&#8220;Note&#8221;). The Note bore an interest rate of 10% per annum and 18% per annum in the event of
default, payable on a monthly basis. The terms of the Note also provides for the principal balance of $50,000 to be used by the Debtor
for an asset purchase transaction (&#8220;Transaction&#8221;) which is not related to the Company and for the Transaction to close within
thirty days from the issuance date of the Note otherwise the Note becomes immediately due. In December 2018, the Company determined that
the Note was not collectible and accordingly recorded an allowance for doubtful account and bad debt expense of $50,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2019, the Company and a third
party entity (&#8220;Purchaser&#8221;) entered into two separate claim purchase agreements (&#8220;Purchase Agreements&#8221;), whereby
the Company sold and the Purchaser assumed the promissory notes: (i) dated September 28, 2018 with a principal balance of $200,000 and
related accrued interest and: (ii) dated November 2, 2018 with a principal balance of $50,000 and related accrued interest (discussed
above) (collectively as &#8220;Notes&#8221;), for an aggregate purchase price of $277,305. Pursuant to the Purchase Agreements, the purchase
price is payable on the earlier of the payment of six-monthly installments or upon the liquidation of the Blind Faith Concepts Holdings,
Inc settlement securities pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended. During the year ended December 31,
2020, the Company collected an aggregate amount of $30,000 of the Notes.&#160;During the year ended December 31, 2020, the Company recorded
an allowance for doubtful account and bad debt expense of $146,500 related to the principal balance of the Notes and wrote off $27,876
of the accrued interest receivable related to the Notes, for a total bad debt expense of $174,376, due to slow collection of the installment
payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2020,
the Company recorded an aggregate bad debt expense in the amount of $174,376 and recovered an aggregate of $9,000 bad debt previously
written off during the periods between 2018 to 2020, resulting in net bad debt expense of $165,376 recorded in the accompanying consolidated
statement of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2021,
the Company recovered $148,500 of the bad debt that was previously written off during the periods between 2018 to 2020, recorded as bad
debt recovery in the accompanying consolidated statement of operations. On June 7, 2021, the Company and the investor, entered into a
settlement agreement whereby both parties agreed to settle the remaining balance of this note receivable which was previously written
off in year 2020 for a total settlement amount of $196,000 to be paid as follows; (i) an initial payment of $46,000 upon execution of
the settlement agreement and (ii) $10,000 per month for fifteen months. During the year ended, $148,500 was collected under this settlement
agreement and $47,500 remains collectible under this settlement agreement and such amount has been fully reserved as of December 31,
2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2021, the Company executed
a note receivable agreement with NFID, LLC in connection with an Asset Purchase Agreement (see Note 4). The promissory note bears 8%
interest per annum and matures on October 1, 2023. The outstanding principal and accrued interest shall be due and payable on maturity.
As of December 31, 2021, this note receivable had outstanding principal receivable of $60,000 and accrued interest receivable of $1,210
for a total receivable balance of $61,210 which is reflected in the accompanying consolidated balance sheet as note receivable &#8211;
non-current.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2021 and 2020, notes receivable,
net, consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Principal amounts of notes receivable at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">220,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">250,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify">Additional notes receivable in 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-282">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Collections on notes receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(148,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(71,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(196,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total Notes receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">Less: notes receivable, net &#8211; current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-283">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Notes receivable &#8211; non-current</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">60,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-284">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336822930240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Note Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTE PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>NOTE 6 - <span style="text-decoration:underline">NOTE PAYABLE</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>Paycheck Protection Program Funding</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 30, 2020, the Company received federal
funding in the amount of $18,900 through the Paycheck Protection Program (the &#8220;PPP&#8221;). PPP funds had certain restrictions
on use of the funding proceeds, and generally must be repaid within two years and accrued interest at a rate of 1% per annum. The PPP
loan may, under circumstances, be forgiven. No payment was due by the Company during the nine months period beginning on the date of
this note (&#8220;Deferral Period&#8221;). Commencing one month after the expiration of the Deferral Period, the Company was to pay the
lender monthly payments of principal and interest, each in equal amount required to fully amortize by the maturity date. If a payment
on this note was more than ten days late, the lender would charge a late fee of up to 5% of the unpaid portion of the regularly scheduled
payment. As of December 31, 2020, the principal balance of this note amounted to $18,900 and accrued interest of $174.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2021, the Company was notified by
the Small Business Administration that the principal and accrued interest under the PPP loan has been forgiven in full. Accordingly,
during the year ended December 31, 2021, the Company recorded a total gain on forgiveness of PPP note payable of $19,082 which consisted
of the principal balance of $18,900 and accrued interest of $182. As of December 31, 2021, the PPP note had no outstanding balance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2021 and
2020, the Company recognized $54 and $80 of interest expense, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2021 and 2020, notes payable
consisted of the following:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Principal amount</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-285">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,900</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-286">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,654</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Note payable - long term portion</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-287">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,246</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336822830640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6 &#8211; <span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Shares Authorized</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has 505,000,000 shares authorized
which consist of 500,000,000 shares of common stock and 5,000,000 shares of preferred stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Preferred Stock</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2013, the Company designated 1,000,000
shares of preferred stock as Series A Convertible Preferred Stock and in November 2019, the Company designated 2,000 shares of preferred
stock as Series B Convertible Preferred Stock. As of June 30, 2022 and December 31, 2021, there were no shares of the Series A and Series
B preferred stock issued and outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Series C Convertible Preferred Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 9, 2021, the Company filed a Certificate
of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the &#8220;Certificate of Designations&#8221;)
with the Delaware Secretary of State, designating 4,280 shares of preferred stock as Series C Convertible preferred stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Designation</span>. The Company has designated 4,280 shares of preferred stock as Series C Convertible preferred stock. Each share of Series C Convertible Preferred Stock has a par value of $0.0001 per share and a stated value of $1,000 (the &#8220;Series C Stated Value&#8221;).</span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Dividends</span><i>.&#160;</i>Holders
                                            of Series C Convertible preferred stock shall be entitled to receive dividends (on an as-if-converted-to-common-stock
                                            basis) in the same form as dividends actually paid on shares of the common stock when, as
                                            and if such dividends are paid on shares of the common stock. No other dividends shall be
                                            paid on shares of the Series C Convertible preferred stock.</span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Liquidation</span>.
                                            Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary,
                                            the holders of Series C Convertible preferred stock shall be entitled to receive the same
                                            amount that a holder of common stock would receive if the Series C Convertible preferred
                                            stock were fully converted (disregarding any conversion limitations) which amounts shall
                                            be paid&#160;pari passu&#160;with all holders of common stock.</span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Voting
                                            Rights</span>. Except as otherwise provided in the Certificate of Designations or as otherwise
                                            required by law, the Series C Convertible preferred stock shall have no voting rights. However,
                                            as long as any shares of Series C Convertible preferred stock are outstanding, the Company
                                            shall not, without the affirmative vote of the holders of a majority of the then outstanding
                                            shares of the Series C Convertible preferred stock, (a) alter or change adversely the powers,
                                            preferences or rights given to the Series C Convertible preferred stock or alter or amend
                                            the Certificate of Designations, (b) amend its Certificate of Incorporation or other charter
                                            documents in any manner that adversely affects any rights of the holders of the Series C
                                            Convertible preferred stock, (c) increase the number of authorized shares of Series C Convertible
                                            preferred stock, or (d) enter into any agreement with respect to any of the foregoing.</span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-keep: true">&#160;</span></td> <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Conversion</span>. Each share of Series C Convertible preferred stock is convertible, at any time and from time to time after the issuance date, at the option of the holder, into such number of shares of common stock determined by dividing the Series C Stated Value by the Series C Conversion Price. &#8220;Series C Conversion Price&#8221; means $15.00, subject to adjustment in the event of stock split, stock dividends, subsequent right offerings and similar recapitalization transactions.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Forced
                                            Conversion</span>. Notwithstanding anything herein to the contrary, after the date that the
                                            Company&#8217;s stockholder approval is obtained and deemed effective, the Company may deliver
                                            a written notice to all holders (the &#8220;Forced Conversion Notice Date&#8221;) to cause
                                            each holder to convert all or part of such holder&#8217;s Series C Convertible preferred
                                            stock pursuant to Section 6 (&#8220;Forced Conversion&#8221;), it being agreed that the &#8220;Conversion
                                            Date&#8221; shall be deemed to occur no later than the earlier of (i) two (2) trading days
                                            and (ii) the number of trading days comprising the standard settlement period following the
                                            Forced Conversion Notice Date; provided, however, a holder shall only be required to convert
                                            pursuant to a Forced Conversion to the extent that such conversion would not cause a holder
                                            to exceed its beneficial ownership limitation. On March 10, 2021, the Company obtained the
                                            stockholders&#8217; approval forcing the conversion of all the Series C Convertible preferred
                                            stock. On April 12, 2021, the Company notified holders of its Series C Convertible preferred
                                            stock of its election to force the conversion to its Series C Convertible preferred stock
                                            into shares of the Company&#8217;s common stock (see below for additional conversions in
                                            2022).</span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Exercisability</span><i>.&#160;</i>A holder of Series C Convertible preferred stock may not convert any portion of the Series C Convertible preferred stock to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, upon election by a holder prior to issuance, 9.99%) of the outstanding shares of the Company&#8217;s common stock after conversion, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Series C Convertible Preferred Stock
Financing</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On February 9, 2021 (the &#8220;Effectiveness
Date&#8221;), the Company entered into securities purchase agreements (collectively, the &#8220;Series C Purchase Agreements&#8221;)
with certain institutional and accredited investors for the sale of an aggregate of 4,276 shares of the Company&#8217;s Series C Convertible
Preferred Stock and warrants (the &#8220;February Warrants&#8221;) to purchase up to 285,066 shares (the &#8220;February Warrant Shares&#8221;)
of the Company&#8217;s common stock for gross proceeds of approximately $4,276,000, before deducting placement agent and other offering
expenses of $481,898 which are offset against the proceeds in additional paid in capital. The offering closed on February 12, 2021. Accordingly,
the Company recognized a total deemed dividend of $1,403,997 for the beneficial conversion feature in connection with the issuance of
these Series C Convertible preferred stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The February Warrants are exercisable for
a period of five years from the date of issuance at an exercise price of $15.00 per share. If, after a period of 180 days after the date
of issuance of the February Warrants, a registration statement covering the resale of the February Warrant Shares is not effective, the
holders may exercise the February Warrants by means of a cashless exercise.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series C Convertible preferred stock and
the February Warrants each contain a beneficial ownership limitation that restricts each of the investor&#8217;s ability to exercise
the February Warrants and convert the Series C Convertible preferred stock such that the number of shares of the Company common stock
held by each of them and their affiliates after such conversion or exercise does not exceed 4.99% (or, at the election of the Investor,
9.99%) of the Company&#8217;s then issued and outstanding shares of common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series C Purchase Agreement also provides
that until the 18 month anniversary of the Effectiveness Date, in the event of a subsequent financing (except for certain exempt issuances
as provided in the Series C Purchase Agreement) by the Company, each investor will have the right to participate in such subsequent financing
up to an amount equal to the investor&#8217;s proportionate share of the subsequent financing based on such investor&#8217;s participation
in the offering on the same terms, conditions and price provided for in the subsequent financing up to an amount equal to 50% of the
subsequent financing. In addition, pursuant to the Series C Purchase Agreement, the Company has agreed that neither it nor its subsidiaries
will enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common stock equivalents
to file any registration statement other than as contemplated pursuant to the Registration Rights Agreement (as defined below) for a
period of 90 days from the Effectiveness Date. Furthermore, subject to certain exceptions, the Company is prohibited from effecting or
entering into an agreement to effect any issuance by the Company or any of its subsidiaries of common stock or common stock equivalents
involving a Variable Rate Transaction (as defined in the Series C Purchase Agreement).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the offering, the Company
entered into separate registration rights agreements (&#8220;Registration Rights Agreements&#8221;) with the investors pursuant to which
the Company agreed to undertake to file a registration statement (the &#8220;Registration Statement&#8221;) to register the resale of
the Registrable Securities (as defined in the Registration Rights Agreement) within ten calendar days following the Effectiveness Date.
The Company agreed to use its best efforts to cause the Registration Statement covering the Registrable Securities to be declared effective
no later than the 60<sup>th</sup>&#160;calendar day following the Effectiveness Date, or in the event of a full review by the Securities
and Exchange Commission, the 90<sup>th</sup>&#160;calendar day following the Effectiveness Date, and to maintain the effectiveness of
the Registration Statement until all of the Registrable Securities have been sold or are otherwise able to be sold pursuant to Rule 144
under the Securities Act of 1933, as amended. If the Company fails to file the Registration Statement or have it declared effective by
the dates set forth above, amongst other things, the Company will be obligated to pay the investors damages in the amount of 1% of their
subscription amount, per month, until such events are satisfied. The Registration Statement was filed and declared effective in April
2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In addition, pursuant to the terms of the
offering, the Company issued Bradley Woods &amp; Co, Ltd. and Katalyst Securities LLC warrants (the &#8220;Placement Agent Warrants&#8221;)
to purchase up to an aggregate of 57,013 shares of common stock, or 10% of the shares of common stock issuable upon conversion of the
Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period
of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment. The Placement Agent
Warrants were valued at the grant date using a Black-Scholes option pricing model with the following assumptions: risk-free interest
rate of 0.50%, expected dividend yield of 0%, expected term of 5 years using the simplified method and expected volatility of 169% based
on comparable and calculated volatility. The aggregate grant date fair value of these Placement Agent Warrants amounted to approximately
$1,106,000 and was recorded against the proceeds with no net effect on the consolidated financials.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net proceeds of the offering are expected
to be used for working capital purposes and to further execute on the Company&#8217;s existing business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Conversion of Series C Convertible Preferred
Stock into Common Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On March 31, 2022, the Company notified holders
of its Series C Convertible preferred stock of its election to force the conversion to its Series C Convertible preferred stock into
shares of the Company&#8217;s common stock pursuant to the Certificate of Designations unless such conversion would cause the holder
to exceed its beneficial ownership limitation pursuant to the Certificate of Designations. On March 31, 2022, the Company converted 227
Series C Convertible preferred stock into 15,167 shares of common stock. As of June 30, 2022, there were no shares of Series C Convertible
preferred stock issued and outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Options</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 18, 2021, the Company&#8217;s board
of directors (&#8220;Board&#8221;) approved the Silo Pharma, Inc. 2020 Omnibus Equity Incentive Plan (the &#8220;2020 Plan&#8221;) to
incentivize employees, officers, directors and consultants of the Company and its affiliates. 170,000 shares of common stock are reserved
and available for issuance under the 2020 Plan, provided that certain exempt awards (as defined in the 2020 Plan), shall not count against
such share limit. The 2020 Plan provides for the grant, from time to time, at the discretion of the Board or a committee thereof, of
cash, stock options, including incentive stock options and nonqualified stock options, restricted stock, dividend equivalents, restricted
stock units, stock appreciation units and other stock or cash-based awards.&#160;The 2020 Plan shall terminate on the tenth anniversary
of the date of adoption by the Board. Subject to certain restrictions, the Board may amend or terminate the Plan at any time and for
any reason. An amendment of the 2020 Plan shall be subject to the approval of the Company&#8217;s stockholders only to the extent required
by applicable laws, rules or regulations. On March 10, 2021, the 2020 Plan was approved by the stockholders.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On December 29, 2021, the Board granted an
aggregate of 6,849 incentive stock options under the 2020 Plan, to two non-employee board members, exercisable at $7.30 per share which
expire on December 26, 2026 and vest on the first anniversary date of the grant date. These options were valued at $30,224 on the grant
date using a Binomial Lattice option pricing model with the following assumptions: risk-free interest rate of 0.75%, expected dividend
yield of 0%, expected term of 2 years using the simplified method and expected volatility of 115% based on historical volatility. The
Company recorded the fair value of the unvested stock options, in the amount of $30,224, as deferred compensation which is being amortized
over the vesting period. During the six months ended June 30, 2022, the Company amortized $15,122 of the deferred compensation which
was recorded as compensation expenses in the accompanying condensed consolidated statement of operations. As of June 30, 2022, the deferred
compensation related to this issuance had a balance of $$15,122.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 31, 2022, pursuant to an Employment
Agreement (see Note 8), an aggregate of 16,000 incentive stock options were issued under the 2020 Plan, to Dr. Kou, exercisable at $10.00
per share and expires on January 31, 2032. The stock options vest as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests
on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023. The 16,000 stock options had a fair value of $94,915 which were valued
at the grant date using a Binomial Lattice option pricing model with the following assumptions: risk-free interest rate of 1.18%, expected
dividend yield of 0%, expected term of 2 years using the simplified method and expected volatility of 117% based on historical volatility.
The Company recorded the fair value of the unvested stock options, in the amount of $59,322, as deferred compensation which is being
amortized over the vesting period. During the six months ended June 30, 2022, the Company amortized $23,540 of the deferred compensation
which was recorded as compensation expenses in the accompanying condensed consolidated statement of operations. As of June 30, 2022,
the deferred compensation related to his employment agreement had a balance of $35,782.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock option activities for the six months
ended June 30, 2022 are summarized as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number of<br/> Options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted Average<br/> Exercise<br/>
    Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted Average<br/> Remaining<br/>
    Contractual Term<br/> (Years)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Aggregate<br/> Intrinsic<br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%"><span style="-keep: true">Balance Outstanding, December 31, 2021</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">6,000</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">0.005</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">2.5</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-322"><span style="-keep: true">&#8212;</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">Granted as incentives</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,849</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">7.30</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4.5</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-323"><span style="-keep: true">&#8212;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Granted pursuant to employment agreement (see Note 8)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">16,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">10.00</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">9.6</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-324"><span style="-keep: true">&#8212;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-325"><span style="-keep: true">&#160;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-326"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-327"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-328"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Balance Outstanding, June 30, 2022</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">28,849</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">7.50</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">7.5</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-329"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Exercisable, June 30, 2022</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">12,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">5.00</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">5.8</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">6,030</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Warrants</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 18, 2021, the Company granted warrants
to purchase up to 5,000 shares of the Company&#8217;s common stock in exchange for legal services rendered. The warrants have a term
of five years from the date of grant and are exercisable at an exercise price of $10.00 per share. The warrants were valued on the grant
date at approximately $16.50 per warrant for a total of $83,728 using a Black-Scholes option pricing model with the following assumptions:
stock price of $17.50 per share (based on the quoted trading price on the date of grant), volatility of 169%, expected term of five year,
and a risk-free interest rate of 0.46%. During the year ended December 31, 2021, the Company recorded stock-based compensation of $83,728.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On February 9, 2021, the Company entered into
pursuant to securities purchase agreements with certain investors pursuant to which it sold warrants to purchase up to 285,066 shares
of the Company&#8217;s common stock and 4,276 shares of the Company&#8217;s Series C Convertible preferred stock. The February Warrants
are exercisable for a period of five years from the date of issuance at an exercise price of $15.00 per share, subject to adjustment.
If, after a period of 180 days after the date of issuance of the February Warrants, a registration statement covering the resale of the
February Warrant Shares is not effective, the holders may exercise the February Warrants by means of a cashless exercise. In addition,
pursuant to the terms of the offering, the Company issued the Placement Agent Warrants to purchase up to an aggregate of 57,013 shares
of common stock to its placement agents, or 10% of the shares of common stock issuable upon conversion of the Series C preferred stock
and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing
date of the offering at an exercise price of $17.50 per share, subject to adjustment (see Series C Convertible Preferred Stock Financing
above). Such warrants issued to various investors and to the placement agents were recorded as additional paid in capital with an offsetting
debit applied against additional paid in capital, thus these warrants have no further accounting effect within the equity section.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warrant activities for the six months ended
June 30, 2022 are summarized as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of<br/>
    Warrants</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
    Average<br/>
    Exercise<br/>
    Price</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
    Average<br/>
    Remaining<br/>
    Contractual Term<br/>
    (Years)</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/>
    Intrinsic<br/>
    Value</b></span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Outstanding, December
    31, 2021</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">347,080</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.50</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-330"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted/Forfeited</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-331"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-332"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-333"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-334"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Outstanding, June 30, 2022</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">347,080</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.50</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-335"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, June 30, 2022</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">347,080</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.50</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-336"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7 &#8211; <span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Shares Authorized</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has authorized the issuance of
5,000,000 shares of preferred stock, $0.0001 par value. The Company&#8217;s board of directors is authorized, at any time, and from time
to time, to provide for the issuance of shares of preferred stock in one or more series, and to determine the designations, preferences,
limitations and relative or other rights of the preferred stock or any series thereof.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 10, 2021, the Company filed an amendment
to its Certificate of Incorporation with the Secretary of State of Delaware to increase the authorized number of shares of common stock
of the Company from 100,000,000&#160;shares to 500,000,000 shares.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>Preferred Stock</b></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2013, 1,000,000 shares of preferred
stock were designated as Series A Convertible Preferred Stock, and in November 2019, 2,000 shares of preferred stock were designated
as Series B Convertible Preferred Stock. On February 9, 2021, 4,280 shares of preferred stock were designated as Series C Convertible
Preferred Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Conversion of Series A Redeemable Preferred
Stock into Common Shares</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On August 3, 2020, at the request of the investor,
the Company converted 4,000 Series A Preferred Stock into 40,000 shares of common stock. After such conversion, the Company reclassified
the $400,000 redemption value of the Series A Preferred Stock to additional paid in capital. Accordingly, there are no shares of Series
A Preferred Stock issued and outstanding as of December 31, 2021 and 2020. &#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b><i>Conversion of Series B Convertible Preferred
Stock into Common Shares </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 15, 2020, the Company entered into
Exchange Agreements with the holders of its Series B Preferred Stock, which shares of Series B Preferred Stock were originally issued
in November 2019. Pursuant to the Exchange Agreements, the holders agreed to exchange their 115 shares of Series B Preferred Stock with
a stated value of $115,000 and 11,500 warrants issued in connection with the Series B Preferred Stock for an aggregate of 28,750 shares
of the Company&#8217;s common stock at a price of $4.00 per share. After the exchanges, there are no shares of the Company&#8217;s Series
B Preferred Stock outstanding. The Company issued 28,750 shares of common stock which was more than the shares that would have been issued
at the original conversion price of $10.00 per share or 11,500 shares of common stock, an excess of 17,250 shares of common stock. The
excess shares were valued at a price of $4.00 per share. Consequently, in connection with this share exchange, the Company recorded a
deemed dividend on this extinguishment of $69,000 during the year ended December 31, 2020. Accordingly, there are no shares of Series
B Preferred Stock issued and outstanding as of December 31, 2021 and 2020. &#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Series C Convertible Preferred Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 9, 2021, the Company filed a Certificate
of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the &#8220;Certificate of Designations&#8221;)
with the Delaware Secretary of State, designating 4,280 shares of preferred stock as Series C Convertible Preferred Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Designation</span>. The Company has designated 4,280 shares of preferred stock as Series C Convertible Preferred Stock. Each share of Series C Convertible Preferred Stock has a par value of $0.0001 per share and a stated value of $1,000 (the &#8220;Series C Stated Value&#8221;).</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Dividends</span><i>.&#160;</i>Holders
                                            of Series C Convertible Preferred Stock shall be entitled to receive dividends (on an as-if-converted-to-common-stock
                                            basis) in the same form as dividends actually paid on shares of the common stock when, as
                                            and if such dividends are paid on shares of the common stock. No other dividends shall be
                                            paid on shares of the Series C Convertible Preferred Stock.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Liquidation</span>.
                                            Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary,
                                            the holders of Series C Convertible Preferred Stock shall be entitled to receive the same
                                            amount that a holder of common stock would receive if the Series C Convertible Preferred
                                            Stock were fully converted (disregarding any conversion limitations) which amounts shall
                                            be paid&#160;pari passu&#160;with all holders of common stock.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Voting
                                            Rights</span>. Except as otherwise provided in the Certificate of Designations or as otherwise
                                            required by law, the Series C Convertible Preferred Stock shall have no voting rights. However,
                                            as long as any shares of Series C Convertible Preferred Stock are outstanding, the Company
                                            shall not, without the affirmative vote of the holders of a majority of the then outstanding
                                            shares of the Series C Convertible Preferred Stock, (a) alter or change adversely the powers,
                                            preferences or rights given to the Series C Convertible Preferred Stock or alter or amend
                                            the Certificate of Designations, (b) amend its Certificate of Incorporation or other charter
                                            documents in any manner that adversely affects any rights of the holders of the Series C
                                            Convertible Preferred Stock, (c) increase the number of authorized shares of Series C Convertible
                                            Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Conversion</span>. Each share of Series C Convertible Preferred Stock is convertible, at any time and from time to time after the issuance date, at the option of the holder, into such number of shares of common stock determined by dividing the Series C Stated Value by the Series C Conversion Price. &#8220;Series C Conversion Price&#8221; means $15.00, subject to adjustment in the event of stock split, stock dividends, subsequent right offerings and similar recapitalization transactions.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Forced
                                            Conversion</span>. Notwithstanding anything herein to the contrary, after the date that the
                                            Company&#8217;s stockholder approval is obtained and deemed effective, the Company may deliver
                                            a written notice to all holders (the &#8220;Forced Conversion Notice Date&#8221;) to cause
                                            each holder to convert all or part of such holder&#8217;s Series C Convertible Preferred
                                            Stock pursuant to Section 6 (&#8220;Forced Conversion&#8221;), it being agreed that the &#8220;Conversion
                                            Date&#8221; shall be deemed to occur no later than the earlier of (i) two (2) trading days
                                            and (ii) the number of trading days comprising the standard settlement period following the
                                            Forced Conversion Notice Date; provided, however, a holder shall only be required to convert
                                            pursuant to a Forced Conversion to the extent that such conversion would not cause a holder
                                            to exceed its beneficial ownership limitation. On March 10, 2021, the Company obtained the
                                            stockholders&#8217; approval forcing the conversion of all the Series C Convertible Preferred
                                            Stock. On April 12, 2021, the Company notified holders of its Series C Convertible Preferred
                                            Stock of its election to force the conversion to its Series C Convertible Preferred Stock
                                            into shares of the Company&#8217;s common stock (see below).</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Exercisability</span><i>.&#160;</i>A holder of Series C Convertible Preferred Stock may not convert any portion of the Series C Convertible Preferred Stock to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, upon election by a holder prior to issuance, 9.99%) of the outstanding shares of the Company&#8217;s common stock after conversion, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Series C Convertible Preferred Stock
Financing</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On February 9, 2021 (the &#8220;Effectiveness
Date&#8221;), the Company entered into securities purchase agreements (collectively, the &#8220;Series C Purchase Agreements&#8221;)
with certain institutional and accredited investors for the sale of an aggregate of 4,276 shares of the Company&#8217;s Series C Convertible
Preferred Stock and warrants (the &#8220;February Warrants&#8221;) to purchase up to 285,066 shares (the &#8220;February Warrant Shares&#8221;)
of the Company&#8217;s common stock for gross proceeds of approximately $4,276,000, before deducting placement agent and other offering
expenses of $481,898 which are offset against the proceeds in additional paid in capital. The offering closed on February 12, 2021. Accordingly,
the Company recognized a total deemed dividend of $1,403,997 for the beneficial conversion feature in connection with the issuance of
these Series C Convertible Preferred Stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The February Warrants are exercisable for
a period of five years from the date of issuance at an exercise price of $15.00 per share. If, after a period of 180 days after the date
of issuance of the February Warrants, a registration statement covering the resale of the February Warrant Shares is not effective, the
holders may exercise the February Warrants by means of a cashless exercise.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series C Convertible Preferred Stock and
the February Warrants each contain a beneficial ownership limitation that restricts each of the investor&#8217;s ability to exercise
the February Warrants and convert the Series C Convertible Preferred Stock such that the number of shares of the Company common stock
held by each of them and their affiliates after such conversion or exercise does not exceed 4.99% (or, at the election of the Investor,
9.99%) of the Company&#8217;s then issued and outstanding shares of common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series C Purchase Agreement also provides
that until the 18 month anniversary of the Effectiveness Date, in the event of a subsequent financing (except for certain exempt issuances
as provided in the Series C Purchase Agreement) by the Company, each investor will have the right to participate in such subsequent financing
up to an amount equal to the investor&#8217;s proportionate share of the subsequent financing based on such investor&#8217;s participation
in the offering on the same terms, conditions and price provided for in the subsequent financing up to an amount equal to 50% of the
subsequent financing. In addition, pursuant to the Series C Purchase Agreement, the Company has agreed that neither it nor its subsidiaries
will enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common stock equivalents
to file any registration statement other than as contemplated pursuant to the Registration Rights Agreement (as defined below) for a
period of 90 days from the Effectiveness Date. Furthermore, subject to certain exceptions, the Company is prohibited from effecting or
entering into an agreement to effect any issuance by the Company or any of its subsidiaries of common stock or common stock equivalents
involving a Variable Rate Transaction (as defined in the Series C Purchase Agreement).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the offering, the Company
entered into separate registration rights agreements (&#8220;Registration Rights Agreements&#8221;) with the investors pursuant to which
the Company agreed to undertake to file a registration statement (the &#8220;Registration Statement&#8221;) to register the resale of
the Registrable Securities (as defined in the Registration Rights Agreement) within ten calendar days following the Effectiveness Date.
The Company agreed to use its best efforts to cause the Registration Statement covering the Registrable Securities to be declared effective
no later than the 60<sup>th</sup>&#160;calendar day following the Effectiveness Date, or in the event of a full review by the Securities
and Exchange Commission, the 90<sup>th</sup>&#160;calendar day following the Effectiveness Date, and to maintain the effectiveness of
the Registration Statement until all of the Registrable Securities have been sold or are otherwise able to be sold pursuant to Rule 144
under the Securities Act of 1933, as amended. If the Company fails to file the Registration Statement or have it declared effective by
the dates set forth above, amongst other things, the Company will be obligated to pay the investors damages in the amount of 1% of their
subscription amount, per month, until such events are satisfied. The Registration Statement was filed and declared effective in April
2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In addition, pursuant to the terms of the
offering, the Company issued Bradley Woods &amp; Co, Ltd. and Katalyst Securities LLC warrants (the &#8220;Placement Agent Warrants&#8221;)
to purchase up to an aggregate of 57,013 shares of common stock, or 10% of the shares of common stock issuable upon conversion of the
Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period
of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment. The Placement Agent
Warrants were valued at the grant date using a Black-Scholes option pricing model with the following assumptions: risk-free interest
rate of 0.50%, expected dividend yield of 0%, expected term of 5 years using the simplified method and expected volatility of $169% based
on comparable and calculated volatility. The aggregate grant date fair value of these Placement Agent Warrants amounted to approximately
$1,106,000 and was recorded against the proceeds with no net effect on the consolidated financials.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net proceeds of the offering are expected
to be used for working capital purposes and to further execute on the Company&#8217;s existing business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Conversion of Series C Convertible Preferred
Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 12, 2021, the Company notified holders
of its Series C Convertible Preferred Stock of its election to force the conversion to its Series C Convertible Preferred Stock into
shares of the Company&#8217;s common stock pursuant to the Certificate of Designations unless such conversion would cause the holder
to exceed its beneficial ownership limitation pursuant to the Certificate of Designations. On April 14, 2021, the Company converted 4,049
Series C Convertible Preferred Stock into 269,900 shares of common stock. As of December 31, 2021, there were 227 shares of the Company&#8217;s
Series C Convertible Preferred Stock issued and outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sale of Common Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Between April 9, 2020 to April 18, 2020, the
Company entered into subscription agreements with certain accredited investors pursuant to which it issued an aggregate of 155,287 shares
of the Company&#8217;s common stock for proceeds of $75,644, and subscription receivable of $2,000 or $0.50 per share, for a total of
$77,644. The Company collected the subscription receivable of $2,000 on July 6, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 28, 2020, the Company entered into
securities purchase agreements (collectively, the &#8220;April Purchase Agreements&#8221;) with certain institutions and accredited investors
for the sale of an aggregate 599,875 shares of the Company&#8217;s common stock at a price of $4.00 per share for gross proceeds of $2,399,500,
before deducting placement agent fees of $242,950 and other offering expenses of $118,460 (the &#8220;Private Placement&#8221;) for total
net proceeds of $2,038,090. The April Purchase Agreements contains customary representations, warranties and covenants of the parties,
and the closing was subject to customary closing conditions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The April Purchase Agreements also provides
that until the six month anniversary of the date of the April Purchase Agreements, in the event of a subsequent financing (except for
certain exempt issuances as provided in the April Purchase Agreements) by the Company, each investor that invested over $100,000 pursuant
to the April Purchase Agreements will have the right to participate in such subsequent financing up to an amount equal to 50% of the
subsequent financing on the same terms, conditions and price provided for in the subsequent financing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Private Placement,
the Company entered into separate Registration Rights Agreements with the investors, pursuant to which the Company agreed to undertake
to file a registration statement to register the resale of the shares underlying the Registrable Securities (as defined therein) within
30 calendar days following the closing date, and to maintain the effectiveness of the registration statement until all of such shares
of common stock have been sold or are otherwise able to be sold pursuant to Rule 144. If the Company fails to file the registration statement
or have it declared effective by the dates set forth above, amongst other things, the Company is obligated to pay the investors liquidated
damages in the amount of 1% of their subscription amount, per month, until such events are satisfied, subject to a cap of 6%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In conjunction with the Private Placement,
all officers and directors of the Company have entered into lock-up agreements pursuant to which they have agreed not to sell their shares
of common stock or common stock equivalents in the Company until the twelve-month anniversary of the closing date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock Issued for Future Services&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 17, 2020, the Company entered into
one-year advisory agreements with certain accredited investors pursuant to which it agreed to issue an aggregate of 102,347 shares of
the Company&#8217;s common stock to the advisors for advisory services to be rendered. These shares were valued at $409,387, or $4.00
per common share, based on contemporaneous common share sales which are being amortized over the term of the agreements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 17, 2020, the Company entered into
a six-month consulting agreement with an accredited investor pursuant to which it agreed to issue an aggregate of 69,377 shares of the
Company&#8217;s common stock to the consultant for consulting services to be rendered. These shares were valued at $277,508, or $4.00
per common share, based on contemporaneous common share sales which is being amortized over the term of the agreement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2021 and
2020, the Company recognized stock-based consulting fees of $107,970 and $578,924, respectively, with a remaining prepaid expense included
in prepaid expenses and other current assets of $0 and $107,970 at December 31, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock Issued for Employment Agreement</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 17, 2020, the Company entered into
an Employment Agreement with the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;) pursuant to which CEO will continue to serve
as Chief Executive Officer and Chief Financial Officer of the Company. In connection with this employment agreement, the CEO was granted
152,619 shares of the Company&#8217;s common stock. These shares were valued at $610,476, or $4.00 per common share, based on contemporaneous
common share sales. During the year ended December 31, 2020, the Company recognized stock-based compensation of $610,476.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock Issued for Conversion of
Series A and B Preferred Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On August 3, 2020, at the request of the investor,
the Company converted 4,000 Series A Preferred Stock into 40,000 shares of common stock. After such conversion, the Company reclassed
the $400,000 redemption value of the Series A Preferred Stock to additional paid in capital.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 15, 2020, the Company entered into
Exchange Agreements with the holders of its Series B Preferred Stock whereby the holders agreed to exchange their 115 shares of Series
B Preferred Stock with a stated value of $115,000 and 11,500 warrants issued in connection with the Series B Preferred Stock for an aggregate
of 28,750 shares of the Company&#8217;s common stock at a price of $4.00 per share. In connection with this share exchange, the Company
recorded a deemed dividend on this extinguishment of $69,000 during the year ended December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock Issued for Exchange of
Notes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 15, 2020, the Company entered into
Exchange Agreements with the holders of certain convertible promissory notes. Pursuant to these Exchange Agreements, the holders agreed
to exchange their convertible promissory notes of $330,000 and 33,000 warrants issued in connection with this debt for an aggregate of
82,500 shares of the Company&#8217;s common stock at a price of $4.00 per share. Consequently, the Company recorded a loss on debt extinguishment
of $198,000 during the year ended December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Options</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 18, 2021, the Company&#8217;s board
of directors (&#8220;Board&#8221;) approved the Silo Pharma, Inc. 2020 Omnibus Equity Incentive Plan (the &#8220;Plan&#8221;) to incentivize
employees, officers, directors and consultants of the Company and its affiliates. 170,000 shares of common stock are reserved and available
for issuance under the Plan, provided that certain exempt awards (as defined in the Plan), shall not count against such share limit.
The Plan provides for the grant, from time to time, at the discretion of the Board or a committee thereof, of cash, stock options, including
incentive stock options and nonqualified stock options, restricted stock, dividend equivalents, restricted stock units, stock appreciation
units and other stock or cash-based awards.&#160;The Plan shall terminate on the tenth anniversary of the date of adoption by the Board.
Subject to certain restrictions, the Board may amend or terminate the Plan at any time and for any reason. An amendment of the Plan shall
be subject to the approval of the Company&#8217;s stockholders only to the extent required by applicable laws, rules or regulations.
On March 10, 2021, the Plan was approved by the stockholders.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock option activities for the years ended
December 31, 2021 and 2020 are summarized as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number<br/> of Options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted<br/> Average<br/> Exercise<br/>
    Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted<br/> Average<br/> Remaining<br/>
    Contractual<br/> Term<br/> (Years)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Aggregate<br/> Intrinsic<br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%"><span style="-keep: true">Balance Outstanding, December 31, 2019</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">6,000</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">0.005</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">4.5</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">104,970</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Granted/Issued/ Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-288"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-289"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-290"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-291"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Balance Outstanding, December 31, 2020</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0.005</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3.5</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">127,290</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Granted/Issued/ Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-292"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-293"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-294"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-295"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Balance Outstanding, December 31, 2021</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">6,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">0.005</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">2.5</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">42,870</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Exercisable, December 31, 2021</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">6,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">0.005</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">2.5</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">42,870</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Warrants</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warrant activities for the years ended December
31, 2021 and 2020 are summarized as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of Warrants</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
    Average Exercise Price</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
    Average Remaining Contractual Term (Years)</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/>
    Intrinsic<br/>
    Value</b></span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Outstanding, December
    31, 2019</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,500</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.00</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.80</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">337,750</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(44,500</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.00</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-296"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-297"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Outstanding, December 31, 2020</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-298"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-299"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-300"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-301"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">347,080</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.50</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-302"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Outstanding, December 31, 2021</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">347,080</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.50</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-303"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, December 31, 2021</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">347,080</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.50</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-304"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 15, 2020, the Company entered into
Exchange Agreements with the holders of convertible promissory notes (see Note 5). Pursuant to these Exchange Agreements, the noteholders
agreed to exchange their convertible promissory notes of $330,000 and 33,000 warrants issued in connection with this debt for an aggregate
of 82,500 shares of the Company&#8217;s common stock at a price of $4.00 per share. After the exchanges, there are no convertible notes
outstanding. The Company issued 82,500 shares of common stock which was more than the shares that would have been issued at the original
conversion price of $4.00 per share or 33,000 shares of common stock, an excess of 49,500 shares of common stock. The excess shares were
valued at a price of $4.00 per share. Consequently, the Company recorded a loss on debt extinguishment of $198,000 during the year ended
December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 18, 2021, the Company granted warrants
to purchase up to 5,000 shares of the Company&#8217;s common stock in exchange for legal services rendered. The warrants have a term
of five years from the date of grant and are exercisable at an exercise price of $10.00 per share. The warrants were valued on the grant
date at approximately $16.50 per warrant for a total of $83,728 using a Black-Scholes option pricing model with the following assumptions:
stock price of $17.50 per share (based on the quoted trading price on the date of grant), volatility of 169%, expected term of five year,
and a risk-free interest rate of 0.46%. During the year ended December 31, 2021, the Company recorded stock-based compensation of $83,728.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On February 9, 2021, the Company entered into
pursuant to securities purchase agreements with certain investors pursuant to which it sold warrants to purchase up to 285,067 shares
of the Company&#8217;s common stock and 4,276 shares of the Company&#8217;s Series C Convertible Preferred Stock. The February Warrants
are exercisable for a period of five years from the date of issuance at an exercise price of $15.00 per share, subject to adjustment.
If, after a period of 180 days after the date of issuance of the February Warrants, a registration statement covering the resale of the
February Warrant Shares is not effective, the holders may exercise the February Warrants by means of a cashless exercise. In addition,
pursuant to the terms of the offering, the Company issued the Placement Agent Warrants to purchase up to an aggregate of 57,013 shares
of common stock to its placement agents, or 10% of the shares of common stock issuable upon conversion of the Series C Preferred Stock
and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing
date of the offering at an exercise price of $17.50 per share, subject to adjustment (see Series C Convertible Preferred Stock Financing
above). Such warrants issued to various investors and to the placement agents were recorded as additional paid in capital with an offsetting
debit applied against additional paid in capital, thus these warrants have no further accounting effect within the equity section.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336908624112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 - <span style="text-decoration:underline">INCOME TAXES</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains deferred tax assets
and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for
financial reporting purposes and the amounts used for income tax purposes. The deferred tax assets on December 31, 2021 and 2020 consist
of net operating loss carry-forwards. The net deferred tax asset has been fully offset by a valuation allowance because of the uncertainty
of the attainment of future taxable income. As of December 31, 2021 and 2020, the Company had not recorded a liability for any unrecognized
tax positions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The items accounting for the difference between
income taxes at the effective statutory rate and the provision for income taxes for the years ended December 31, 2021 and 2020 was as
follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Income tax (benefit) liability at U.S. statutory rate of 21%&#8239;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">819,786</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(637,879</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Income tax (benefit) liability &#8211; state</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">253,743</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(197,439</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,893</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">457,798</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,027,760</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">377,520</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total provision for income tax</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">24,876</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-305">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s approximate net deferred
tax asset as of December 31, 2021 and 2020 was as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Net operating loss carryforward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,647,335</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">868,338</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Net capital loss carryforward</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,707,701</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">123,932</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total deferred tax asset (liability) before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(60,366</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">992,271</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,490</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(992,271</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Provision for income tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24,876</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-306">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Net deferred tax asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-307">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-308">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">At December 31, 2021,
the Company had a capital gain of $6,660,483 which offset the prior year net capital loss carryforward $450,663 for a capital gain of
$6,209,820.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Due to the loss of
its Regulated Investment Company (&#8220;RIC&#8221;) tax status in 2017, any net tax operating losses generated as a RIC cannot be used
to offset any future taxable income. As of December 31, 2021, the Company had an aggregate estimated net operating loss carryforwards
of approximately $5,990,308 for income taxes. These net operating loss carries forwards may be available to reduce future years&#8217;
taxable income. The net loss carryforward up until 2017 in the amount of $470,204, will expire in 2037. Net loss carryforwards in the
amount of $5,520,104 from 2018 onwards can be carried over indefinitely, subject to annual usage limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Management believes
that it appears more likely than not that the Company will not realize these tax benefits due to the Company&#8217;s continuing losses
for income taxes purposes. Accordingly, the Company has provided a 100% valuation allowance on the deferred tax asset benefit related
to the U.S. net operating loss and capital loss carry forwards to reduce the asset to zero. Management will review this valuation allowance
periodically and will make adjustments as necessary.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336822829008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">CONCENTRATIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7 &#8211; <span style="text-decoration:underline">CONCENTRATIONS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Customer Concentration</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2022 and
2021, no customer accounted for over 10% of total revenues from apparel sales included in discontinued operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2022 and
2021, one licensee accounted for 100% total revenues from customer license fee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Vendor Concentrations</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2022 and
2021, one licensor accounted for 100% of the Company&#8217;s vendor license agreements (see below) related to the Company&#8217;s biopharmaceutical
operation.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9 &#8211; <span style="text-decoration:underline">CONCENTRATIONS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Customer Concentration</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 30, 2021 and
2020, no customer accounted for over 10% of total revenues from apparel sales included in discontinued operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Vendor Concentrations</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2021, one
licensor accounted for 100% of the Company&#8217;s vendor license agreements (see Note 10) related to the Company&#8217;s biopharmaceutical
operation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2020, the
Company did not have any licensor.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336822843872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 &#8211; <span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment Agreement</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Eric Weisblum</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 17, 2020, the Company entered into
an employment agreement (&#8220;Employment Agreement&#8221;) with Eric Weisblum to serve as Chief Executive Officer and Chief Financial
Officer of the Company. The term of the Employment Agreement will continue for a period of one year from the date of execution date thereof
and automatically renews for successive one-year periods at the end of each term until either party delivers written notice of their
intent not to review at least six months prior to the expiration of the then effective term. The Employment Agreement provided for a
base salary of $120,000 and 152,619 of vested shares of the Company&#8217;s common stock in April 2020. In addition, Mr. Weisblum shall
be eligible to earn a bonus, subject to the sole discretion of the Company&#8217;s Board of Directors (&#8220;Board&#8221;). The Employment
Agreement may be terminated by either the Company or Mr. Weisblum at any time and for any reason upon 60 days prior written notice. Upon
termination of the Employment Agreement, Mr. Weisblum shall be entitled to (i) any equity award that has vested prior to the termination
date, (ii) reimbursement of expenses incurred on or prior to such termination date and (iii) such employee benefits to which he may be
entitled as of the termination date (collectively, the &#8220;Accrued Amounts&#8221;). Mr. Weisblum employment may also be terminated
by the Company at any time, with cause, death or disability (as defined in the Employment Agreement). Upon the termination of the Employment
Agreement for death or disability, Mr. Weisblum shall be entitled to receive the Accrued Amounts. The Employment Agreement also contains
covenants prohibiting Mr. Weisblum from disclosing confidential information with respect to the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 18, 2021, the Company and Mr. Weisblum
entered into the first amendment (the &#8220;Amendment&#8221;) to the Employment Agreement, effective as of January 1, 2021. Pursuant
to the Amendment Mr. Weisblum&#8217;s base salary was increased from $120,000 per year to $180,000 per year and all the terms and provisions
of the Employment Agreement shall remain in full force and effect.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Dr. James Kuo </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 27, 2022, the Company and Dr. James
Kuo entered into an employment agreement (&#8220;Kuo Employment Agreement&#8221;) for Dr. Kuo to serve as the Vice President of Research
&amp; Development. The Kuo Employment Agreement shall be effective as of the date of the agreement and shall automatically renew for
a period of one year at every anniversary of the effective date, with the same terms and conditions, unless either party provides written
notice of its intention not to extend the term of the Kuo Employment Agreement at least thirty days&#8217; prior to the applicable renewal
date. Dr. Kuo shall be paid an annual base salary of $30,000. For each twelve-month period of his employment, Dr. Kuo shall be entitled
to a bonus whereby amount and terms shall be in the sole and absolute discretion of the Board of Directors (&#8220;Board&#8221;) and
shall be payable at the Company&#8217;s sole option in stock or in cash. In addition, an aggregate of 16,000 incentive stock options
were granted under the 2020 Plan to Dr. Kou, exercisable at $10.00 per share and expires on January 31, 2032. The stock options vest
as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023. The
16,000 stock options had a fair value of $94,914 which valued at grant date using Binomial Lattice option pricing model with the following
assumptions: risk-free interest rate of 1.18%, expected dividend yield of 0%, expected term of 2 years using the simplified method and
expected volatility of 117% based on calculated volatility. The Company recorded the fair value of the unvested stock options, in the
amount of $59,322, as deferred compensation which is being amortized over the vesting period. During the six months ended June 30, 2022,
the Company amortized $23,540 of the deferred compensation which was recorded as compensation expenses in the accompanying condensed
consolidated statement of operations. As of June 30, 2022, the deferred compensation had a balance of $35,782 (see Note 6).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License Agreements between the Company
and Vendors </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>University of Maryland, Baltimore -
License Agreement for Development and Use of Central Nervous System-Homing Peptides</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Commercial Evaluation License and Option
Agreement with the University of Maryland, Baltimore</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of July 15, 2020, the Company,
through its wholly-owned subsidiary, Silo Pharma, Inc. (see Note 1) and University of Maryland, Baltimore (&#8220;UMB&#8221;) (collectively
as &#8220;Parties&#8221;), entered into a commercial evaluation license and option agreement (&#8220;License Agreement&#8221;), granting
the Company an exclusive, non-sublicensable, non-transferable license to with respect to the exploration of the potential use of central
nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory
pathology. The License Agreement also granted the Company an exclusive option to negotiate and obtain an exclusive, sublicensable, royalty-bearing
license (&#8220;Exclusive Option&#8221;) to with respect to the subject technology. The License Agreement had a term of six months from
the effective date however if the Company exercises the Exclusive Option, the License Agreement shall expire at the end of the negotiation
period (as defined in the License Agreement) or upon execution of a master license agreement, whichever occurs first. The Company exercised
its Exclusive Option on January 13, 2021 and entered into a Master License Agreement on February 12, 2021. Both parties may terminate
this agreement within thirty days by giving a written notice. In July 2020, the Company paid a license fee of $10,000 to UMB pursuant
to the License Agreement which was recorded in professional fees during the year ended December 31, 2020 since the Company could not
conclude that such costs would be recoverable for this early-stage venture.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Master License Agreement with the University
of Maryland, Baltimore</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As disclosed above, effective as of February
12, 2021, the Company and University of Maryland, Baltimore (&#8220;UMB&#8221;), entered into the Master License Agreement (&#8220;Master
License Agreement&#8221;) which grants the Company an exclusive, worldwide, sublicensable, royalty-bearing license to certain intellectual
property: (i) to make, have made, use, sell, offer to sell, and import certain licensed products and: (ii) to use the invention titled,
&#8220;Central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other
neuroinflammatory pathology&#8221; and UMB&#8217;s confidential information to develop and perform certain licensed processes for the
therapeutic treatment of neuroinflammatory disease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Master License Agreement will remain in
effect on a Licensed Product-by-Licensed Product basis and country-by-country basis until the later of: (a) the last patent covered under
the Master License Agreement expires, (b) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory
exclusivity, or other legally enforceable market exclusivity, if applicable, or (c) 10 years after the first commercial sale of a Licensed
Product in that country, unless earlier terminated in accordance with the provisions of the Master License Agreement. The term of the
Master License Agreement shall expire 15 years after the Master License Agreement Effective Date in which (a) there were never any patent
rights, (b) there was never any data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally
enforceable market exclusivity or (c) there was never a first commercial sale of a Licensed Product.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may assign, sublicense, grant,
or otherwise convey any rights or obligations under the Master License Agreement to a Company affiliate, without obtaining prior written
consent from UMB provided that it meets the terms defined in the Master License Agreement. The Company may grant sublicenses of some
or all of the rights granted by the Master License Agreement, provided that there is no uncured default or breach of any material term
or condition under the Master License Agreement, by Company, at the time of the grant, and that the grant complies with the terms and
conditions of the Master License Agreement. The Company shall be and shall remain responsible for the performance by each of the Company&#8217;s
sublicensee. Any sublicense shall be consistent with and subject to the terms and conditions of the Master License Agreement and shall
incorporate terms and conditions sufficient to enable Company to comply with the Master License Agreement. The Company or Company affiliates
shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company&#8217;s sublicense income
which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first
licensed product; and (b) 15% of the Company&#8217;s sublicense income which is receivable with respect to any sublicense that is executed
after the filing of an NDA (or foreign equivalent) for the first licensed product.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Master License Agreement,
the Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty
payments depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company shall
pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the effective date; and (b)
$50,000 on or before the first anniversary of the effective date. The license fee is non-refundable and is not creditable against any
other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing,
prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid $25,000 license fee on
February 17, 2021 which was recorded as prepaid expense and is being amortized over the 15-year term. The Company recognized amortization
expense of $4,375 in 2021. During the six months ended June 30, 2022, the Company recognized amortization expense of $2,500. At December
31, 2021, prepaid expense and other current assets &#8211; current amounted $5,000 and prepaid expense &#8211; non-current amounts $15,625.
At June 30, 2022, prepaid expense and other current assets &#8211; current amounted $5,000 and prepaid expense &#8211; non-current amounts
$13,125 as reflected in the accompanying condensed consolidated balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Milestone Payment Terms</span>:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Milestone</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">50,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Receipt of New Drug Application (&#8220;NDA&#8221;) (or foreign equivalent) approval for a Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Achievement of First Commercial Sale of Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Royalty Payments Terms</span>:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.25in">&#160;</td> <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">(i)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">3% on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-size: 10pt">(ii)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">5% on sales of licensed products during the applicable calendar year for sales greater than $50,000,000; and</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-size: 10pt">(iii)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">a minimum annual royalty payments, as follows:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Years</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Minimum Annual Royalty</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prior to First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-337; font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Year of First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-338; font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">First calendar year following the First Commercial Sale</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Second calendar year following the First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Third calendar year following the First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2021, in connection with the Company&#8217;s
Sublicense Agreement with Aikido Pharma Inc. (see below - <i>Patent License Agreement with Aikido Pharma Inc.</i>), the Company paid
25% of its sublicense income to UMB, pursuant to the Master License Agreement, which amounted to $12,500. The Company recognized amortization
expense of $628 in 2021. During the six months ended June 30, 2022, the Company recognized amortization expense of $419. At December
31, 2021, prepaid expense and other current assets &#8211; current amounted $838 and prepaid expenses &#8211; non-current amounts $11,034.
At June 30, 2022, prepaid expense and other current assets &#8211; current amounted $838 and prepaid expenses &#8211; non-current amounts
$10,615 as reflected in the accompanying condensed consolidated balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>University of Maryland, Baltimore -
License Agreement for Development and Use of Joint-Homing Peptides</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Commercial Evaluation License and Option
Agreement with the University of Maryland, Baltimore</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of February 26, 2021, the Company,
through its wholly-subsidiary, Silo Pharma, Inc., and University of Maryland, Baltimore (&#8220;UMB&#8221;) (collectively as &#8220;Parties&#8221;),
entered into a commercial evaluation license and option agreement (&#8220;License Agreement&#8221;), which granted the Company an exclusive,
non-sublicensable, non-transferable license to with respect to the exploration of the potential use of joint-homing peptides for use
in the investigation and treatment of arthritogenic processes. The License Agreement also granted the Company an exclusive option to
negotiate and obtain an exclusive, sublicensable, royalty-bearing license (&#8220;Exclusive Option&#8221;) to with respect to the subject
technology. The License Agreement had a term of six months from the effective date. Both parties could have terminated the License Agreement
within thirty days by giving a written notice.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, the Company entered into
a First Amendment Agreement (&#8220;First Amendment&#8221;) with UMB to extend the term of the original License Agreement by an additional
six months such that the First Amendment was effective until February 25, 2022 however, if the Company exercises the Exclusive Option,
the License Agreement shall expire at the end of the negotiation period (as defined in the License Agreement) or upon execution of a
master license agreement, whichever occurs first. The Company paid a license fee of $10,000 to UMB in March 2021 pursuant to the License
Agreement which was recorded in professional fees during the year ended December 31, 2021, since the Company could not conclude that
such costs would be recoverable for this early-stage venture.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2022, the Parties entered into
a second amendment to the commercial evaluation and license agreement dated February 26, 2021 (&#8220;Second Amendment&#8221;). The Second
Amendment extends the term of the original license agreement until December 31, 2022. However, if the Company exercises the Exclusive
Option, the License Agreement shall expire at the end of the negotiation period (as defined in the License Agreement) or upon execution
of a master license agreement, whichever occurs first.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2022, the Parties entered into
a third amendment to the commercial evaluation and license agreement dated February 26, 2021 (&#8220;Third Amendment&#8221;). The Third
Amendment expands the scope of the license granted in the License Agreement to add additional patent rights with respect to an invention
generally known as <i>Peptide-Targeted Liposomal Delivery for Treatment Diagnosis, and Imaging of Diseases and Disorders</i>. In consideration
of the licenses granted under this Third Amendment, Company agreed to pay a one-time, non-refundable fee of $2,500 which was recorded
as research and development expense in the condensed consolidated statement of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License Agreements between the Company
and Customer</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Customer Patent License Agreement with
Aikido Pharma Inc.</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, the Company and its subsidiary
Silo Pharma, Inc., a Florida corporation, entered into a patent license agreement (&#8220;License Agreement&#8221;) (collectively, the
&#8220;Licensor&#8221;) and Aikido Pharma Inc. (&#8220;Aikido&#8221; or the &#8220;Customer&#8221;), as amended on April 12, 2021, pursuant
to which the Licensor granted Aikido an exclusive, worldwide (&#8220;Territory&#8221;), sublicensable, royalty-bearing license to certain
intellectual property: (i) to make, have made, use, provide, import, export, lease, distribute, sell, offer for sale, develop and advertise
certain licensed products and (ii) to develop and perform certain licensed processes for the treatment of cancer and symptoms caused
by cancer (&#8220;Field of Use&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The License Agreement also provided that,
if the Licensor exercised the option granted to it pursuant to its commercial evaluation license and option agreement with UMB, effective
as of July 15, 2020, it would grant Aikido a non-exclusive sublicense (&#8220;Right&#8221;) to certain UMB patent rights in the field
of neuroinflammatory diseases occurring in patients diagnosed with cancer (&#8220;Field&#8221;). Pursuant to the License Agreement, Aikido
agreed to pay the Licensor, among other things, (i) a one-time non-refundable cash payment of $500,000 and (ii) royalty payments equal
to 2% of net sales (as defined in the License Agreement) in the Field of Use in the Territory. In addition, Aikido agreed to issue the
Licensor 500 shares of Aikido&#8217;s newly designated Series M Convertible Preferred Stock which were to be converted into an aggregate
of 625,000 shares of the Aikido&#8217;s common stock. On April 12, 2021, the Company entered into an amendment to the License Agreement
(&#8220;Amended License Agreement&#8221;) with Aikido dated January 5, 2021 whereby Aikido issued an aggregate of 625,000 restricted
shares of Aikido&#8217;s common stock instead of the 500 shares of the Series M Convertible Preferred Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the License Agreement, the Company
is required to prepare file, prosecute, and maintain the licensed patents. Unless earlier terminated, the term of the license to the
licensed patents will continue until the expiration or abandonment of all issued patents and filed patent applications within the licensed
patents. The Company may terminate the License Agreement upon 30 day written notice if Aikido fails to pay any amounts due and payable
to the Company or if Aikido or any of its affiliates brings a patent challenge against the Company, assists others in bringing a legal
or administrative challenge to the validity, scope, or enforceability of or opposes any of the licensed patents (&#8220;Patent Challenge&#8221;)
against the Company (except as required under a court order or subpoena). Aikido may terminate the Agreement at any time without cause,
and without incurring any additional penalty, (i) by providing at least 30 days&#8217; prior written notice and paying the Company all
amounts due to it through such termination effective date. Either party may terminate the Agreement for material breaches that have failed
to be cured within 60 days after receiving written notice. The Company collected the non-refundable cash payment of $500,000 on January
5, 2021 which was recorded as deferred revenue to be recognized as revenues over the 15 year term of the License Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to a vote of Aikido&#8217;s stockholders
to approve a reverse split of its common stock no later than December 31, 2021 (&#8220;Reverse Stock Split Vote&#8221;), each share of
the Series M Convertible Preferred Stock shall be entitled to such number of votes equal to 20,000 shares of Aikido&#8217;s common stock.
In addition, each share of the Series M Convertible Preferred Stock shall be convertible, at any time after the earlier of (i) the date
that the Reverse Stock Split Vote is approved by Aikido&#8217;s stockholders and (ii) December 31, 2021, at the option of the holder,
into such number of shares of Aikido&#8217;s common stock determined by dividing the Stated Value by the Conversion Price. &#8220;Stated
Value&#8221; means $1,000. &#8220;Conversion Price&#8221; means $0.80, subject to adjustment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the April 12, 2021, issuance of the
common stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible
Preferred stock which was equivalent into Aikido&#8217;s 625,000 shares of common stock at a fair value of $0.85 per common share or
$531,250 based quoted trading price of Aikido&#8217;s common stock on the date of grant. The Company recorded an equity investment of
$531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license. Accordingly, the Company
recorded a total deferred revenue of $1,031,250 ($500,000 cash received and $531,250 value of equity securities received) to be recognized
as revenues over the 15-year term. The Company recognized revenue of $68,750 in 2021. During the six months ended June 30, 2022, the
Company recognized revenue of $34,375. At December 31, 2021, deferred revenue &#8211; current portion amounted $68,750 and deferred revenue
&#8211; long-term portion amounted $893,750. At June 30, 2022, deferred revenue &#8211; current portion amounted $68,750 and deferred
revenue &#8211; long-term portion amounted $859,375 as reflected in the accompanying condensed consolidated balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Right shall be to the full extent permitted
by and on terms and conditions required by UMB for a term consistent with the term of patent and technology licenses that UMB normally
grants. In the event that the Company exercises its option and executes a license with UMB to the UMB patent rights within 40 days after
the execution of such UMB license, for consideration to be agreed upon and paid by Aikido, which consideration shall in no event exceed
110% of any fee payable by the Company to UMB for the right to sublicense the UMB patent rights. The Company shall grant Aikido a nonexclusive
sublicense in the United States to the UMB patent rights in the Field, subject to the terms of any UMB license Licensor obtains, including
any royalty obligations on sublicensees required under any such sublicense. The option was exercised on January 13, 2021. Accordingly,
on April 6, 2021, the Company entered into the Sublicense Agreement with Aikido pursuant to which it granted Aikido a worldwide exclusive
sublicense to its licensed patents under the Master License Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Customer Sublicense&#160;Agreement with
Aikido Pharma Inc.</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2021 (the &#8220;Sublicense Agreement
Effective Date&#8221;), the Company entered into the Sublicense Agreement with Aikido pursuant to which the Company granted Aikido an
exclusive worldwide sublicense to (i) make, have made, use, sell, offer to sell and import the Licensed Products (as defined below) and
(ii) in connection therewith to (A) use an invention known as &#8220;Central nervous system-homing peptides in vivo and their use for
the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology&#8221; which was sublicensed to the Company
pursuant to the Master License Agreement&#160;and (B) practice certain patent rights (&#8220;Patent Rights&#8221;) for the therapeutic
treatment of neuroinflammatory disease in cancer patients. &#8220;Licensed Products&#8221; means any product, service, or process, the
development, making, use, offer for sale, sale, importation, or providing of which: (i) is covered by one or more claims of the Patent
Rights; or (ii) contains, comprises, utilizes, incorporates, or is derived from the Invention or any technology disclosed in the Patent
Rights.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Sublicense Agreement, Aikido
agreed to pay the Company (i) an upfront license fee of $50,000, (ii)&#160;the same sales-based royalty payments that the Company is
subject to under the Master License Agreement and (iii) total milestone payments of up to $1.9 million. The Sublicense Agreement shall
continue on a Licensed Product-by-Licensed Product and country-by-country basis until the later of (i) the date of expiration of the
last to expire claim of the Patent Rights covering such Licensed Product in such country, (ii) the expiration of data protection, new
chemical entity, orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity, if applicable and (iii)
10 years after the first commercial sale of a Licensed Product in that country, unless terminated earlier pursuant to the terms of the
Sublicense Agreement. Furthermore, the Sublicense Agreement shall expire 15 years after the Sublicense Agreement Effective Date with
respect to any country in which (i) there were never any Patent Rights, (ii) there was never any data protection, new chemical entity,
orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity with respect to a Licensed Product and
(ii) there was never a commercial sale of a Licensed Product, unless such agreement is earlier terminated pursuant to its terms. The
Company collected the upfront license fee of $50,000 in April 2021. The Company recognized revenue of $2,514 in 2021. During the six
months ended June 30, 2022, the Company recognized revenue of $1,676. At December 31, 2021, deferred revenue &#8211; current portion
amounted $3,352 and deferred revenue &#8211; long-term portion amounted $44,134. At June 30, 2022, deferred revenue &#8211; current portion
amounted $3,352 and deferred revenue &#8211; long-term portion amounted $42,458 as reflected in the accompanying condensed consolidated
balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sponsored Study and Research Agreements
between the Company and Vendors</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investigator-Sponsored Study Agreement
with University of Maryland, Baltimore </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, the Company entered into
an investigator-sponsored study agreement (&#8220;Sponsored Study Agreement&#8221;) with the University of Maryland, Baltimore. The research
project is a clinical study to examine a novel peptide-guided drug delivery approach for the treatment of multiple sclerosis (&#8220;MS&#8221;).
More specifically, the study is designed to evaluate (1) whether MS-1-displaying liposomes can effectively deliver dexamethasone to the
CNS and (2) whether MS-1-displaying liposomes are superior to plain liposomes, also known as free drug, in inhibiting the relapses and
progression of experimental autoimmune encephalomyelitis. Pursuant to the Sponsored Study Agreement, the research shall commence on March
1, 2021 and will continue until substantial completion, subject to renewal upon mutual written consent of the parties. The total cost
under the Sponsored Study Agreement shall not exceed $81,474 which is payable in two equal installments of $40,737 upon execution of
the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. The Company
paid $40,737 on January 13, 2021 which was recorded in prepaid expense to be amortized over the nine-month period. Currently, the project
has not been completed due to the delays cause by the Covid-19 pandemic. During the year ended December 31, 2021, the Company fully amortized
the prepaid expense of $40,737.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sponsored Research Agreement with The
Regents of the University of California</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021 (the &#8220;Effective Date&#8221;),
the Company entered into a sponsored research agreement (the &#8220;Sponsored Research Agreement&#8221;) with The Regents of the University
of California, on behalf of its San Francisco Campus (&#8220;UCSF&#8221;) pursuant to which UCSF shall conduct a study to examine psilocybin&#8217;s
effect on inflammatory activity in humans to accelerate its implementation as a potential treatment for Parkinson&#8217;s Disease, chronic
pain, and bipolar disorder. Pursuant to the Agreement, the Company shall pay UCSF a total fee of $342,850 to conduct the research over
the two-year period. The Agreement shall be effective for a period of two years from the Effective Date, subject to renewal or earlier
termination as set forth in the Sponsored Research Agreement. The Company paid the first payment of $40,000 pursuant to the payment schedule
on the Sponsored Research Agreement on June 15, 2021, second payment of $40,000 on September 9, 2021 and $20,570 on November 18, 2021,
third payment of $60,570 on March 1, 2022, which were recorded to prepaid expense and other current assets &#8211; current to be amortized
over the two-year period. In 2021, the Company amortized $92,855 of the prepaid expense. During the six months ended June 30, 2022, the
Company amortized $68,285 of the prepaid expense leaving a prepaid asset of $0 at June 30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sponsored Research Agreement with University
of Maryland, Baltimore</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, the Company and University
of Maryland, Baltimore (&#8220;UMB&#8221;) entered into a sponsored research agreement (&#8220;July 2021 Sponsored Research Agreement&#8221;)
pursuant to which UMB shall&#160;evaluate the pharmacokinetics of dexamethasone delivered to arthritic rats via liposome. The research
pursuant to the July 2021 Sponsored Research Agreement shall commence on September 1, 2021 and will continue until the substantial completion
thereof, subject to renewal upon written consent of the parties. The July 2021 Sponsored Research Agreement may be terminated by either
party upon 30 days&#8217; prior written notice to the other party. In addition, if either party commits any material breach of or defaults
with respect to any terms or conditions of the July 2021 Sponsored Research Agreement and fails to remedy such default or breach within
10 business days after written notice from the other party, the party giving notice may terminate the July 2021 Sponsored Research Agreement
as of the date of receipt of such notice by the other party. If the Company terminates the July 2021 Sponsored Research Agreement for
any reason other than an uncured material breach by UMB, the Company shall relinquish any and all rights it may have in the Results (as
defined in the July 2021 Sponsored Research Agreement) to UMB. In addition, if the July 2021 Sponsored Research Agreement is terminated
early, the Company, among other things, will pay all costs incurred and accrued by UMB as of the date of termination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the July 2021 Sponsored
Research Agreement, UMB granted the Company an option (the &#8220;Option&#8221;) to negotiate and obtain an exclusive license to any
UMB Arising IP (as defined in the July 2021 Sponsored Research Agreement) and UMB&#8217;s rights in any Joint Arising IP (as defined
in the July 2021 Sponsored Research Agreement) (collectively, the &#8220;UMB IP&#8221;). The Company may exercise the Option by giving
UMB written notice within 60 days after it receives notice from UMB of the UMB IP. Pursuant to the July 2021 Sponsored Research Agreement,
the Company shall pay UMB the fees below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Payment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 2%; text-align: center"><span style="font-size: 10pt">1</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">92,095</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 83%"><span style="font-size: 10pt">Upon execution of the July 2021 Sponsored Research Agreement</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center"><span style="font-size: 10pt">2</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">92,095</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-size: 10pt">3</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">92,095</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid the first payment of $92,095
on September 1, 2021 which was recorded to prepaid expense and other current assets &#8211; current and was amortized during the year
ended December 31, 2021. The Company paid the second payment of $50,000 on February 1, 2022 which was recorded as research and development
expense in the accompanying condensed consolidated statement of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 7, 2022, the Company and UMB amended
the July 2021 Sponsored Research Agreement whereby both parties agreed to make changes to the original project work and budget. The amendment
had no effect on the consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sponsored Research Agreement with Columbia
University</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2021, the Company entered into
a sponsored research agreement with Columbia University pursuant to which the Company has been granted an option to license certain assets
currently under development, including Alzheimer&#8217;s disease. The term of the option will commence on the effective date of this
agreement and will expire upon the earlier of (i) 90 days after the date of the Company&#8217;s receipt of a final research report for
each specific research proposal as defined in the agreement or (ii) termination of the research. If the Company elects to exercise the
option, both parties will commence negotiation of a license agreement and will execute a license agreement no later than 3 months after
the dated of the exercise of the option. Columbia University and the Company will work towards developing a therapeutic treatment for
patients suffering from Alzheimer&#8217;s disease to post-traumatic stress disorder. During a one-year period from the date of this agreement,
the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the payment schedule
as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months after the start
of the project and, (iv)10% at completion of the project. The Company paid the first payment of $430,825 in November 2021 which was recorded
to prepaid expense and other current assets &#8211; current to be amortized over the estimated project timeline of twelve months. In
2021, the Company amortized $359,021 of the prepaid expense. During the six months ended June 30, 2022, the Company amortized the remaining
prepaid expense of $71,804. As of June 30, 2022 and December 31, 2021, prepaid expense related to the sponsored research agreement were
$0 and $71,804, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Joint Venture Agreement with Zyl&#246;
Therapeutics, Inc.</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 22, 2021 (&#8220;Effective Date&#8221;),
the Company entered into a Joint Venture Agreement (&#8220;JV Agreement&#8221;) with Zyl&#246; Therapeutics, Inc. (&#8220;ZTI&#8221;)
pursuant to which the parties agreed to form a joint venture entity, to be named Ketamine Joint Venture, LLC (&#8220;Joint Venture&#8221;),
to, among other things, focus on the clinical development of ketamine using ZTI&#8217;s Z-pod&#8482; technology (&#8220;Venture&#8221;).
Pursuant to the JV Agreement, the Company shall act as the manager (&#8220;Manager&#8221;) of the Joint Venture. The Joint Venture shall
terminate if the development program does not meet certain specifications and milestones as set forth in the JV Agreement within 30 days
of the date set forth in the JV Agreement. Notwithstanding the foregoing, the Manager may, in its sole discretion, terminate the Joint
Venture at any time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the JV Agreement,
(A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall
contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and
trade secrets with respect to its Z-pod&#8482; technology for the loading and release of ketamine, (3) ketamine to be used for clinical
purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the
interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be
owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event
shall either party own more than 60% of the interest in the Joint Venture. As of June 30, 2022 and as of the current date of this report,
the joint venture entity has not been formed yet.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, pursuant to the terms of the
JV Agreement, ZTI shall grant the Joint Venture a sublicense pursuant to its license agreement (the &#8220;License Agreement&#8221;)
with Albert Einstein College of Medicine dated November 27, 2017, in the event that the Company or a third party makes a request indicating
that the patented technology (the &#8220;Patented Technology&#8221;) licensed to ZTI pursuant to the License Agreement is needed to advance
the development of the Joint Venture or it is contemplated or determined that the Patented Technology will be sold. Furthermore, pursuant
to the JV Agreement, ZTI granted the Company an exclusive option to enter into a separate joint venture for the clinical development
of psilocybin using ZTI&#8217;s Z-pod&#8482; technology on the same terms and conditions set forth in the JV Agreement, which option
shall expire 24 months after the JV Effective Date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Amended Service Agreement</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 10, 2021 (&#8220;Effective Date&#8221;),
the Company entered into an Amendment Agreement (&#8220;Amended Service Agreement&#8221;) to a certain service agreement dated on September
8, 2020 with the University of Texas (&#8220;University&#8221;) at Austin whereby the University will provide advisory service and assist
the Company on identifying license and sponsored research opportunities for the Company. The Company shall pay the University $5,000
per quarter starting on the Effective Date. Any cost incurred will be reimbursed only after prior written consent by the Company. The
term of the Amended Service Agreement is for 36 months unless earlier terminated by either party upon giving a written notice as defined
in the agreement. In 2021, the Company paid $5,000 related to this agreement. During the six months ended June 30, 2022, the Company
paid $10,000 related to this agreement.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10 &#8211; <span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment Agreement</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 17, 2020, the Company entered into
an employment agreement (&#8220;Employment Agreement&#8221;) with Eric Weisblum to serve as Chief Executive Officer and Chief Financial
Officer of the Company. The term of the Employment Agreement will continue for a period of one year from the date of execution date thereof
and automatically renews for successive one-year periods at the end of each term until either party delivers written notice of their
intent not to review at least six months prior to the expiration of the then effective term. The Employment Agreement provided for a
base salary of $120,000 and 152,619 of vested shares of the Company&#8217;s common stock in April 2020. In addition, Mr. Weisblum shall
be eligible to earn a bonus, subject to the sole discretion of the Company&#8217;s Board of Directors (&#8220;Board&#8221;). The Employment
Agreement may be terminated by either the Company or Mr. Weisblum at any time and for any reason upon 60 days prior written notice. Upon
termination of the Employment Agreement, Mr. Weisblum shall be entitled to (i) any equity award that has vested prior to the termination
date, (ii) reimbursement of expenses incurred on or prior to such termination date and (iii) such employee benefits to which he may be
entitled as of the termination date (collectively, the &#8220;Accrued Amounts&#8221;). Mr. Weisblum employment may also be terminated
by the Company at any time, with cause, death or disability (as defined in the Employment Agreement). Upon the termination of the Employment
Agreement for death or disability, Mr. Weisblum shall be entitled to receive the Accrued Amounts. The Employment Agreement also contains
covenants prohibiting Mr. Weisblum from disclosing confidential information with respect to the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 18, 2021, the Company and Mr. Weisblum
entered into the first amendment (the &#8220;Amendment&#8221;) to the Employment Agreement, effective as of January 1, 2021. Pursuant
to the Amendment Mr. Weisblum&#8217;s base salary was increased from $120,000 per year to $180,000 per year and all the terms and provisions
of the Employment Agreement shall remain in full force and effect.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License Agreements between the Company
and Vendors </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>University of Maryland, Baltimore -
License Agreement for Development and Use of Central Nervous System-Homing Peptides</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Commercial Evaluation License and Option
Agreement with the University of Maryland, Baltimore</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of July 15, 2020, the Company,
through its wholly-owned subsidiary, Silo Pharma, Inc. (see Note 1) and University of Maryland, Baltimore (&#8220;UMB&#8221;), entered
into a commercial evaluation license and option agreement (&#8220;License Agreement&#8221;), granting the Company an exclusive, non-sublicensable,
non-transferable license to with respect to the exploration of the potential use of central nervous system-homing peptides in vivo and
their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology. The License Agreement also
granted the Company an exclusive option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license (&#8220;Exclusive
Option&#8221;) to with respect to the subject technology. The License Agreement had a term of six months from the effective date however
if the Company exercises the Exclusive Option, the License Agreement shall expire at the end of the negotiation period (as defined in
the License Agreement) or upon execution of a master license agreement, whichever occurs first. The Company exercised its Exclusive Option
on January 13, 2021 and entered into a Master License Agreement on February 12, 2021. Both parties may terminate this agreement within
thirty days by giving a written notice. In July 2020, the Company paid a license fee of $10,000 to UMB pursuant to the License Agreement
which was recorded in professional fees during the year ended December 31, 2020 since the Company could not conclude that such costs
would be recoverable for this early-stage venture.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Master License Agreement with the University
of Maryland, Baltimore</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As disclosed above, effective as of February
12, 2021, the Company and University of Maryland, Baltimore (&#8220;UMB&#8221;), entered into the Master License Agreement (&#8220;Master
License Agreement&#8221;) which grants the Company an exclusive, worldwide, sublicensable, royalty-bearing license to certain intellectual
property: (i) to make, have made, use, sell, offer to sell, and import certain licensed products and: (ii) to use the invention titled,
&#8220;Central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other
neuroinflammatory pathology&#8221; and UMB&#8217;s confidential information to develop and perform certain licensed processes for the
therapeutic treatment of neuroinflammatory disease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Master License Agreement will remain in
effect on a Licensed Product-by-Licensed Product basis and country-by-country basis until the later of: (a) the last patent covered under
the Master License Agreement expires, (b) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory
exclusivity, or other legally enforceable market exclusivity, if applicable, or (c) 10 years after the first commercial sale of a Licensed
Product in that country, unless earlier terminated in accordance with the provisions of the Master License Agreement. The term of the
Master License Agreement shall expire 15 years after the Master License Agreement Effective Date in which (a) there were never any patent
rights, (b) there was never any data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally
enforceable market exclusivity or (c) there was never a first commercial sale of a Licensed Product.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may assign, sublicense, grant,
or otherwise convey any rights or obligations under the Master License Agreement to a Company affiliate, without obtaining prior written
consent from UMB provided that it meets the terms defined in the Master License Agreement. The Company may grant sublicenses of some
or all of the rights granted by the Master License Agreement, provided that there is no uncured default or breach of any material term
or condition under the Master License Agreement, by Company, at the time of the grant, and that the grant complies with the terms and
conditions of the Master License Agreement. The Company shall be and shall remain responsible for the performance by each of the Company&#8217;s
sublicensee. Any sublicense shall be consistent with and subject to the terms and conditions of the Master License Agreement and shall
incorporate terms and conditions sufficient to enable Company to comply with the Master License Agreement. The Company or Company affiliates
shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company&#8217;s sublicense income
which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first
licensed product; and (b) 15% of the Company&#8217;s sublicense income which is receivable with respect to any sublicense that is executed
after the filing of an NDA (or foreign equivalent) for the first licensed product.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Master License Agreement,
the Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty
payments depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company shall
pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the effective date; and (b)
$50,000 on or before the first anniversary of the effective date. The license fee is non-refundable and is not creditable against any
other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing,
prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid $25,000 license fee on
February 17, 2021 which was recorded as prepaid expense and is being amortized over the 15-year term. The Company recognized amortization
expense of $4,375 during the year ended December 31, 2021. At December 31, 2021, prepaid expense and other current assets &#8211; current
amounted $5,000 and prepaid expense &#8211; non-current amounts $15,625 as reflected in the accompanying consolidated balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Milestone Payment Terms:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Milestone</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">50,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Receipt of New Drug Application (&#8220;NDA&#8221;) (or foreign equivalent) approval for a Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Achievement of First Commercial Sale of Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Royalty Payments Terms:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3% on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5% on sales of licensed products during the applicable calendar year for sales greater than $50,000,000; and</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(iii)</td><td style="text-align: justify">a minimum annual
                                            royalty payments, as follows:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Minimum Annual Royalty</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Prior to First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-309; font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Year of First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-310; font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">First calendar year following the First Commercial Sale</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Second calendar year following the First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Third calendar year following the First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2021, in connection with the Company&#8217;s
Sublicense Agreement with Aikido Pharma Inc. (see below - <i>Patent License Agreement with Aikido Pharma Inc.</i>), the Company paid
25% of its sublicense income to UMB, pursuant to the Master License Agreement, which amounted to $12,500. The Company recognized amortization
expense of $628 during the year ended December 31, 2021. At December 31, 2021, prepaid expense and other current assets &#8211; current
amounted $838 and prepaid expenses &#8211; non-current amounts $11,034 as reflected in the accompanying consolidated balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>University of Maryland, Baltimore -
License Agreement for Development and Use of Joint-Homing Peptides</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Commercial Evaluation License and Option
Agreement with the University of Maryland, Baltimore</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of February 26, 2021, the Company,
through its wholly-subsidiary, Silo Pharma, Inc., and University of Maryland, Baltimore (&#8220;UMB&#8221;), entered into a commercial
evaluation license and option agreement (&#8220;License Agreement&#8221;), which granted the Company an exclusive, non-sublicensable,
non-transferable license to with respect to the exploration of the potential use of joint-homing peptides for use in the investigation
and treatment of arthritogenic processes. The License Agreement also granted the Company an exclusive option to negotiate and obtain
an exclusive, sublicensable, royalty-bearing license (&#8220;Exclusive Option&#8221;) to with respect to the subject technology. The
License Agreement had a term of six months from the effective date. Both parties could have terminated the License Agreement within thirty
days by giving a written notice.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, the Company entered into
a First Amendment Agreement (&#8220;Amended License Agreement&#8221;) with UMB to extend the term of the original License Agreement by
an additional six months such that the Amended License Agreement was effective until February 25, 2022 however, if the Company exercises
the Exclusive Option, the License Agreement shall expire at the end of the negotiation period (as defined in the License Agreement) or
upon execution of a master license agreement, whichever occurs first. The Company paid a license fee of $10,000 to UMB in March 2021
pursuant to the License Agreement which was recorded in professional fees during the year ended December 31, 2021, since the Company
could not conclude that such costs would be recoverable for this early-stage venture. Subsequent to December 31, 2021, the Company and
UMB entered into a Second Amendment Agreement (see Note 11).</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License Agreements between the Company
and Customer</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Customer Patent License Agreement with
Aikido Pharma Inc.</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, the Company and its subsidiary
Silo Pharma, Inc., a Florida corporation, entered into a patent license agreement (&#8220;License Agreement&#8221;) (collectively, the
&#8220;Licensor&#8221;) and Aikido Pharma Inc. (&#8220;Aikido&#8221; or the &#8220;Customer&#8221;), as amended on April 12, 2021, pursuant
to which the Licensor granted Aikido an exclusive, worldwide (&#8220;Territory&#8221;), sublicensable, royalty-bearing license to certain
intellectual property: (i) to make, have made, use, provide, import, export, lease, distribute, sell, offer for sale, develop and advertise
certain licensed products and (ii) to develop and perform certain licensed processes for the treatment of cancer and symptoms caused
by cancer (&#8220;Field of Use&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The License Agreement also provided that,
if the Licensor exercised the option granted to it pursuant to its commercial evaluation license and option agreement with UMB, effective
as of July 15, 2020, it would grant Aikido a non-exclusive sublicense (&#8220;Right&#8221;) to certain UMB patent rights in the field
of neuroinflammatory diseases occurring in patients diagnosed with cancer (&#8220;Field&#8221;). Pursuant to the License Agreement, Aikido
agreed to pay the Licensor, among other things, (i) a one-time non-refundable cash payment of $500,000 and (ii) royalty payments equal
to 2% of net sales (as defined in the License Agreement) in the Field of Use in the Territory. In addition, Aikido agreed to issue the
Licensor 500 shares of Aikido&#8217;s newly designated Series M Convertible Preferred Stock which were to be converted into an aggregate
of 625,000 shares of the Aikido&#8217;s common stock. On April 12, 2021, the Company entered into an amendment to the License Agreement
(&#8220;Amended License Agreement&#8221;) with Aikido dated January 5, 2021 whereby Aikido issued an aggregate of 625,000 restricted
shares of Aikido&#8217;s common stock instead of the 500 shares of the Series M Convertible Preferred Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the License Agreement, the Company
is required to prepare file, prosecute, and maintain the licensed patents. Unless earlier terminated, the term of the license to the
licensed patents will continue until the expiration or abandonment of all issued patents and filed patent applications within the licensed
patents. The Company may terminate the License Agreement upon 30 day written notice if Aikido fails to pay any amounts due and payable
to the Company or if Aikido or any of its affiliates brings a patent challenge against the Company, assists others in bringing a legal
or administrative challenge to the validity, scope, or enforceability of or opposes any of the licensed patents (&#8220;Patent Challenge&#8221;)
against the Company (except as required under a court order or subpoena). Aikido may terminate the Agreement at any time without cause,
and without incurring any additional penalty, (i) by providing at least 30 days&#8217; prior written notice and paying the Company all
amounts due to it through such termination effective date. Either party may terminate the Agreement for material breaches that have failed
to be cured within 60 days after receiving written notice. The Company collected the non-refundable cash payment of $500,000 on January
5, 2021 which was recorded as deferred revenue to be recognized as revenues over the 15 year term of the License Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to a vote of Aikido&#8217;s stockholders
to approve a reverse split of its common stock no later than December 31, 2021 only (&#8220;Reverse Stock Split Vote&#8221;), each share
of the Series M Convertible Preferred Stock shall be entitled to such number of votes equal to 20,000 shares of Aikido&#8217;s common
stock. In addition, each share of the Series M Convertible Preferred Stock shall be convertible, at any time after the earlier of (i)
the date that the Reverse Stock Split Vote is approved by Aikido&#8217;s stockholders and (ii) December 31, 2021, at the option of the
holder, into such number of shares of Aikido&#8217;s common stock determined by dividing the Stated Value by the Conversion Price. &#8220;Stated
Value&#8221; means $1,000. &#8220;Conversion Price&#8221; means $0.80, subject to adjustment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the April 12, 2021 issuance of the
common stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible
Preferred stock which was equivalent into Aikido&#8217;s 625,000 shares of common stock at a fair value of $0.85 per common share or
$531,250 based quoted trading price of Aikido&#8217;s common stock on the date of grant. The Company recorded an equity investment of
$531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license. Accordingly, the Company
recorded a total deferred revenue of $1,031,250 ($500,000 cash received and $531,250 value of equity securities received) to be recognized
as revenues over the 15-year term. The Company recognized revenue of $68,750 during the year ended December 31, 2021. At December 31,
2021, deferred revenue &#8211; current portion amounted $68,750 and deferred revenue &#8211; long-term portion amounted $893,750 as reflected
in the accompanying consolidated balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Right shall be to the full extent permitted
by and on terms and conditions required by UMB for a term consistent with the term of patent and technology licenses that UMB normally
grants. In the event that the Company exercises its option and executes a license with UMB to the UMB patent rights within 40 days after
the execution of such UMB license, for consideration to be agreed upon and paid by Aikido, which consideration shall in no event exceed
110% of any fee payable by the Company to UMB for the right to sublicense the UMB patent rights. The Company shall grant Aikido a nonexclusive
sublicense in the United States to the UMB patent rights in the Field, subject to the terms of any UMB license Licensor obtains, including
any royalty obligations on sublicensees required under any such sublicense. The option was exercised on January 13, 2021. Accordingly,
on April 6, 2021, the Company entered into the Sublicense Agreement with Aikido pursuant to which it granted Aikido a worldwide exclusive
sublicense to its licensed patents under the Master License Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Customer Sublicense&#160;Agreement with
Aikido Pharma Inc.</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2021 (the &#8220;Sublicense Agreement
Effective Date&#8221;), the Company entered into the Sublicense Agreement with Aikido pursuant to which the Company granted Aikido an
exclusive worldwide sublicense to (i) make, have made, use, sell, offer to sell and import the Licensed Products (as defined below) and
(ii) in connection therewith to (A) use an invention known as &#8220;Central nervous system-homing peptides in vivo and their use for
the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology&#8221; which was sublicensed to the Company
pursuant to the Master License Agreement&#160;and (B) practice certain patent rights (&#8220;Patent Rights&#8221;) for the therapeutic
treatment of neuroinflammatory disease in cancer patients. &#8220;Licensed Products&#8221; means any product, service, or process, the
development, making, use, offer for sale, sale, importation, or providing of which: (i) is covered by one or more claims of the Patent
Rights; or (ii) contains, comprises, utilizes, incorporates, or is derived from the Invention or any technology disclosed in the Patent
Rights.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Sublicense Agreement, Aikido
agreed to pay the Company (i) an upfront license fee of $50,000, (ii)&#160;the same sales-based royalty payments that the Company is
subject to under the Master License Agreement and (iii) total milestone payments of up to $1.9 million. The Sublicense Agreement shall
continue on a Licensed Product-by-Licensed Product and country-by-country basis until the later of (i) the date of expiration of the
last to expire claim of the Patent Rights covering such Licensed Product in such country, (ii) the expiration of data protection, new
chemical entity, orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity, if applicable and (iii)
10 years after the first commercial sale of a Licensed Product in that country, unless terminated earlier pursuant to the terms of the
Sublicense Agreement. Furthermore, the Sublicense Agreement shall expire 15 years after the Sublicense Agreement Effective Date with
respect to any country in which (i) there were never any Patent Rights, (ii) there was never any data protection, new chemical entity,
orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity with respect to a Licensed Product and
(ii) there was never a commercial sale of a Licensed Product, unless such agreement is earlier terminated pursuant to its terms. The
Company collected the upfront license fee of $50,000 in April 2021. The Company recognized revenue of $2,514 during the year ended December
31, 2021. At December 31, 2021, deferred revenue &#8211; current portion amounted $3,352 and deferred revenue &#8211; long-term portion
amounted $44,134 as reflected in the accompanying consolidated balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sponsored Study and Research Agreements
between the Company and Vendors</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investigator-Sponsored Study Agreement
with Maastricht University of the Netherlands</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 1, 2020, the Company entered into
an investigator-sponsored study agreement (&#8220;Study Agreement&#8221;) with Maastricht University of the Netherlands. The research
project is a clinical study to examine the effects of repeated low doses of psilocybin and lysergic acid diethylamide on cognitive and
emotional dysfunctions in Parkinson&#8217;s disease and to understand its mechanism of action. The Study Agreement shall terminate on
October 31, 2024, unless earlier terminated pursuant to the terms thereof. The Company shall pay a total fee of 433,885 Euros ($507,602
USD) exclusive of value added tax to be amortized over the four-year term and payment schedule as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="width: 24%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86,777 Euros ($101,520 USD)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 69%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon signing the Study Agreement and was paid in December 2020</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86,777 Euros ($101,520 USD)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtained approval from ethical committee</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86,777 Euros ($101,520 USD)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data collection has commenced</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130,166 Euros ($152,281 USD)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First half of the participants are tested</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,885 Euros ($50,760 USD)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of data collection and delivery of final report</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.4pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2020, the Company paid the first
payment of $101,520 which was recorded to prepaid expense and other current assets &#8211; current of which approximately $22,318 was
amortized in fiscal 2020. In September 2021, the Company notified Maastricht University of Netherlands for an early termination of this
agreement. Maastricht University of Netherlands has not reached the second phase which is to obtain approval from ethical committee.
The Company has no further obligation after the termination. During the year ended December 31, 2021, the Company amortized the remaining
prepaid expense of $79,202.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investigator-Sponsored Study Agreement
with University of Maryland, Baltimore </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2021, the Company entered into
an investigator-sponsored study agreement (&#8220;Sponsored Study Agreement&#8221;) with the University of Maryland, Baltimore. The research
project is a clinical study to examine a novel peptide-guided drug delivery approach for the treatment of multiple sclerosis (&#8220;MS&#8221;).
More specifically, the study is designed to evaluate (1) whether MS-1-displaying liposomes can effectively deliver dexamethasone to the
CNS and (2) whether MS-1-displaying liposomes are superior to plain liposomes, also known as free drug, in inhibiting the relapses and
progression of experimental autoimmune encephalomyelitis. Pursuant to the Sponsored Study Agreement, the research shall commence on March
1, 2021 and will continue until substantial completion, subject to renewal upon mutual written consent of the parties. The total cost
under the Sponsored Study Agreement shall not exceed $81,474 which is payable in two equal installments of $40,737 upon execution of
the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. The Company
paid $40,737 on January 13, 2021 which was recorded in prepaid expense to be amortized over the nine-month period. Currently, the project
has not been completed due to the delays cause by the Covid-19 pandemic. During the year ended December 31, 2021, the Company fully amortized
the prepaid expense of $40,737.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sponsored Research Agreement with The
Regents of the University of California</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021 (the &#8220;Effective Date&#8221;),
the Company entered into a sponsored research agreement (the &#8220;Sponsored Research Agreement&#8221;) with The Regents of the University
of California, on behalf of its San Francisco Campus (&#8220;UCSF&#8221;) pursuant to which UCSF shall conduct a study to examine psilocybin&#8217;s
effect on inflammatory activity in humans to accelerate its implementation as a potential treatment for Parkinson&#8217;s Disease, chronic
pain, and bipolar disorder. Pursuant to the Agreement, the Company shall pay UCSF a total fee of $342,850 to conduct the research over
the two-year period. The Agreement shall be effective for a period of two years from the Effective Date, subject to renewal or earlier
termination as set forth in the Sponsored Research Agreement. The Company paid the first payment of $40,000 pursuant to the payment schedule
on the Sponsored Research Agreement on June 15, 2021, second payment of $40,000 on September 9, 2021 and $20,570 on November 18, 2021
which were recorded to prepaid expense and other current assets &#8211; current to be amortized over the two-year period. During the
year ended December 31, 2021, the Company amortized $92,855 of the prepaid expense leaving a prepaid asset of $7,715 at December 31,
2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sponsored Research Agreement with University
of Maryland, Baltimore</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2021, the Company and University
of Maryland, Baltimore (&#8220;UMB&#8221;) entered into a sponsored research agreement (&#8220;July 2021 Sponsored Research Agreement&#8221;)
pursuant to which UMB shall&#160;evaluate the pharmacokinetics of dexamethasone delivered to arthritic rats via liposome.&#160;The research
pursuant to the July 2021 Sponsored Research Agreement shall commence on September 1, 2021 and will continue until the substantial completion
thereof, subject to renewal upon written consent of the parties. The July 2021 Sponsored Research Agreement may be terminated by either
party upon 30 days&#8217; prior written notice to the other party. In addition, if either party commits any material breach of or defaults
with respect to any terms or conditions of the July 2021 Sponsored Research Agreement and fails to remedy such default or breach within
10 business days after written notice from the other party, the party giving notice may terminate the July 2021 Sponsored Research Agreement
as of the date of receipt of such notice by the other party. If the Company terminates the July 2021 Sponsored Research Agreement for
any reason other than an uncured material breach by UMB, the Company shall relinquish any and all rights it may have in the Results (as
defined in the July 2021 Sponsored Research Agreement) to UMB. In addition, if the July 2021 Sponsored Research Agreement is terminated
early, the Company, among other things, will pay all costs incurred and accrued by UMB as of the date of termination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the July 2021 Sponsored
Research Agreement, UMB granted the Company an option (the &#8220;Option&#8221;) to negotiate and obtain an exclusive license to any
UMB Arising IP (as defined in the July 2021 Sponsored Research Agreement) and UMB&#8217;s rights in any Joint Arising IP (as defined
in the July 2021 Sponsored Research Agreement) (collectively, the &#8220;UMB IP&#8221;). The Company may exercise the Option by giving
UMB written notice within 60 days after it receives notice from UMB of the UMB IP. Pursuant to the July 2021 Sponsored Research Agreement,
the Company shall pay UMB the fees below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="5" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,095</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 84%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon execution of the July 2021 Sponsored Research Agreement</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,095</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,095</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid the first payment of $92,095
on September 1, 2021 which was recorded to prepaid expense and other current assets &#8211; current to be amortized over the estimated
project timeline of twelve months. During the year ended December 31, 2021, the Company fully amortized the prepaid expense of $92,095.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sponsored Research Agreement with Columbia
University</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2021, the Company entered into
a sponsored research agreement with Columbia University pursuant to which the Company has been granted an option to license certain assets
currently under development, including Alzheimer&#8217;s disease. The term of the option will commence on the effective date of this
agreement and will expire upon the earlier of (i) 90 days after the date of the Company&#8217;s receipt of a final research report for
each specific research proposal as defined in the agreement or (ii) termination of the research. If the Company elects to exercise the
option, both parties will commence negotiation of a license agreement and will execute a license agreement no later than 3 months after
the dated of the exercise of the option. Columbia University and the Company will work towards developing a therapeutic treatment for
patients suffering from Alzheimer&#8217;s disease to post-traumatic stress disorder. During a one-year period from the date of this agreement,
the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the payment schedule
as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months after the start
of the project and, (iv)10% at completion of the project. The Company paid the first payment of $430,825 in November 2021 which was recorded
to prepaid expense and other current assets &#8211; current to be amortized over the estimated project timeline of twelve months. During
the year ended December 31, 2021, the Company amortized $359,021 of the prepaid expense. As of December 31, 2021, prepaid expense related
to the sponsored research agreement was $71,804.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Joint Venture Agreement with Zyl&#246; Therapeutics, Inc.</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 22, 2021 (&#8220;Effective Date&#8221;),
the Company entered into a Joint Venture Agreement (&#8220;JV Agreement&#8221;) with Zyl&#246; Therapeutics, Inc. (&#8220;ZTI&#8221;)
pursuant to which the parties agreed to form a joint venture entity, to be named Ketamine Joint Venture, LLC (&#8220;Joint Venture&#8221;),
to, among other things, focus on the clinical development of ketamine using ZTI&#8217;s Z-pod&#8482; technology (&#8220;Venture&#8221;).
Pursuant to the JV Agreement, the Company shall act as the manager (&#8220;Manager&#8221;) of the Joint Venture. The Joint Venture shall
terminate if the development program does not meet certain specifications and milestones as set forth in the JV Agreement within 30 days
of the date set forth in the JV Agreement. Notwithstanding the foregoing, the Manager may, in its sole discretion, terminate the Joint
Venture at any time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the JV Agreement,
(A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall
contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and
trade secrets with respect to its Z-pod&#8482; technology for the loading and release of ketamine, (3) ketamine to be used for clinical
purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the
interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be
owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event
shall either party own more than 60% of the interest in the Joint Venture. As of December 31, 2021 and as of the current date of this
report, the joint venture entity has not been formed yet.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, pursuant to the terms of the
JV Agreement, ZTI shall grant the Joint Venture a sublicense pursuant to its license agreement (the &#8220;License Agreement&#8221;)
with Albert Einstein College of Medicine dated November 27, 2017, in the event that the Company or a third party makes a request indicating
that the patented technology (the &#8220;Patented Technology&#8221;) licensed to ZTI pursuant to the License Agreement is needed to advance
the development of the Joint Venture or it is contemplated or determined that the Patented Technology will be sold. Furthermore, pursuant
to the JV Agreement, ZTI granted the Company an exclusive option to enter into a separate joint venture for the clinical development
of psilocybin using ZTI&#8217;s Z-pod&#8482; technology on the same terms and conditions set forth in the JV Agreement, which option
shall expire 24 months after the JV Effective Date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Amended Service Agreement</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 10, 2021 (&#8220;Effective Date&#8221;),
the Company entered into an Amendment Agreement (&#8220;Amended Service Agreement&#8221;) to a certain service agreement dated on September
8, 2020 with the University of Texas (&#8220;University&#8221;) at Austin whereby the University will provide advisory service and assist
the Company on identifying license and sponsored research opportunities for the Company. The Company shall pay the University $5,000
per quarter starting on the Effective Date. Any cost incurred will be reimbursed only after prior written consent by the Company. The
term of the Amended Service Agreement is for 36 months unless earlier terminated by either party upon giving a written notice as defined
in the agreement. During the year ended December 31, 2021, the Company paid $5,000 related to this agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336823116928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11 &#8211; <span style="text-decoration:underline">SUBSEQUENT EVENTS</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 27, 2022, the Company and Dr. James
Kuo entered into an employment agreement (&#8220;Kuo Employment Agreement&#8221;) for Dr. Kuo to serve as the Vice President of Research
&amp; Development. The Kuo Employment Agreement shall be effective as of the date of the agreement and shall automatically renew for
a period of one year at every anniversary of the effective date, with the same terms and conditions, unless either party provides written
notice of its intention not to extend the term of the Kuo Employment Agreement at least thirty days&#8217; prior to the applicable renewal
date. Dr. Kuo shall be paid an annual base salary of $30,000. For each twelve-month period of his employment, Dr. Kuo shall be entitled
to a bonus whereby amount and terms shall be in the sole and absolute discretion of the Board of Directors (&#8220;Board&#8221;) and
shall be payable at the Company&#8217;s sole option in stock or in cash. In addition, an aggregate of 16,000 incentive stock options
was granted to Dr. Kou, at an exercise price equal to the closing price of the Company&#8217;s common stock on the date of grant (&#8220;ISOs&#8221;)
as follows: (i) 6,000 ISOs (&#8220;Initial Options&#8221;), issued under the Company&#8217;s 2020 Equity Incentive Plan (&#8220;2020
Plan&#8221;) which vest immediately, and (ii) an additional 10,000 ISOs (&#8220;Additional Options&#8221;), issued under the 2020 Plan
which shall vest ratably over two successive equal quarterly installments over the subsequent one year period as follows: 5,000 ISOs
shall vest at 9 months, and 12 months following the effective date of the Kuo Employment Agreement, which underlying Additional Options
shall be exercisable immediately upon the applicable vesting date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2022, the Company and University
of Maryland, Baltimore (&#8220;UMB&#8221;) entered into a second amendment to the commercial evaluation and license agreement dated February
26, 2021 (&#8220;Second Amendment&#8221;) (see Note 10 - <i>University of Maryland, Baltimore - License Agreement for Development and
Use of Joint-Homing Peptides</i>). The Second Amendment to extend the term of the original license agreement until December 31, 2022.
However, if the Company exercises the Exclusive Option, the License Agreement shall expire at the end of the negotiation period (as defined
in the License Agreement) or upon execution of a master license agreement, whichever occurs first.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On March 11, 2022, the Company held its special
meeting of stockholders (&#8220;Special Meeting&#8221;). A total of 1,077,199 shares of common stock constituting a quorum were represented
in person or by valid proxies at the Special Meeting. The final results for of the matter submitted to a vote of stockholders at the
Special Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on February 14, 2022,
is as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Proposal 1. At the Special Meeting, the stockholders
approved granting discretionary authority to the Company&#8217;s Board of Directors to amend the Company&#8217;s Certificate of Incorporation
to effect one or more consolidations of the Company&#8217;s issued and outstanding shares of common stock, pursuant to which the shares
of common stock would be combined and reclassified into one share of common stock at a ratio within the range from 1-for-5 up to 1-for-50
(the &#8220;Reverse Stock Split&#8221;), provided that, (X) that the Company shall not effect Reverse Stock Splits that, in the aggregate,
exceeds 1-for-50, and (Y) any Reverse Stock Split is completed no later than the first anniversary of the record date of the Special
Meeting, or February 8, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On September 14, 2022, the Company filed a
Certificate of Amendment to the Amended and Restated Articles of Incorporation (the &#8220;Certificate of Amendment&#8221;) with the
Secretary of State of the State of Nevada to effect a 1-for-50 reverse stock split (the &#8220;Reverse Stock Split&#8221;) with respect
to the outstanding shares of the Company&#8217;s common stock. The Certificate of Amendment became effective on September 14, 2022. The
Reverse Stock Split was previously approved by the sole director and the majority of stockholders of the Company. The Reverse Stock Split
was deemed effective at the open of business on September 15, 2022. All share and per share data in the accompanying consolidated financial
statements have been retroactively restated to reflect the effect of the reverse stock split.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336823377024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Principles of consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation and Principles of
Consolidation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s consolidated financial statements
include financial statements for Silo Pharma, Inc and its inactive wholly-owned subsidiary with the same name as the parent entity, Silo
Pharma, Inc, as of June 30, 2022 and during the three and nine months ended June 30, 2022. All intercompany balances and transactions
have been eliminated in consolidation. Management acknowledges its responsibility for the preparation of the accompanying unaudited condensed
consolidated financial statements which reflect all adjustments, consisting of normal recurring and non-recurring adjustments, considered
necessary in its opinion for a fair statement of its consolidated financial position and the consolidated results of its operations for
the periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America (the &#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions Article 8-03 of Regulation S-X.
Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole.
Certain information and note disclosure normally included in financial statements prepared in accordance with U.S. GAAP has been condensed
or omitted from these statements pursuant to such accounting principles and, accordingly, they do not include all the information and
notes necessary for comprehensive financial statements. These unaudited condensed consolidated financial statements should be read in
conjunction with the summary of significant accounting policies and notes to the financial statements for the year ended December 31,
2021 included in the Company&#8217;s Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 28, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with, ASC 205-20 &#8220;Discontinued
Operations&#8221; establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should
be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity&#8217;s
operations and financial results. As a result, the NFID, LLC component&#8217;s results of operations have been classified as discontinued
operations on a retrospective basis for all periods presented. Accordingly, the results of operations of this component, for all periods,
are separately reported as &#8220;discontinued operations&#8221; on the condensed consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation and Principles of
Consolidation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S.
GAAP&#8221;), the instructions to Form 10-K, and the rules and regulations of the United States Securities and Exchange Commission (the
&#8220;SEC&#8221;) for financial information. The Company&#8217;s consolidated financial statements include financial statements for
Silo Pharma, Inc and its inactive wholly-owned subsidiary with the same name as the parent entity, Silo Pharma, Inc, as of December 31,
2021 and during the years ended December 31, 2021 and 2020. All intercompany transactions and balances have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with, ASC 205-20 &#8220;Discontinued
Operations&#8221; establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should
be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity&#8217;s
operations and financial results. As a result, the NFID, LLC component&#8217;s results of operations have been classified as discontinued
operations on a retrospective basis for all periods presented. Accordingly, the results of operations of this component, for all periods,
are separately reported as &#8220;discontinued operations&#8221; on the consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As reflected in the accompanying condensed
consolidated financial statements, the Company generated a net loss of $1,262,474 and used cash in operations of $1,189,274 during the
six months ended June 30, 2022. Additionally, the Company has an accumulated deficit of $4,525,051 at June 30, 2022. However, as of June
30, 2022, the Company had working capital of $8,678,540.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The positive worthy capital serves to mitigate
the conditions that historically raised substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company
believes that the Company has sufficient cash to meet its obligations for a minimum of twelve months from the date of this filing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As reflected in the accompanying consolidated
financial statements, the Company generated a net income of $3,903,741 and used cash in operations of $2,278,016, for the year ended
December 31, 2021. Additionally, the Company has an accumulated deficit of $3,262,577 at December 31, 2021. During the year ended December
31, 2021, the Company has received gross proceeds of $7,020,526 from the sale of equity investments. As of December 31, 2021, the Company
had working capital of $9,912,281.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These events served to mitigate the conditions
that historically raised substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company believes the
proceeds received during the year ended December 31, 2021 will provide sufficient cash flows to meet its obligations for a minimum of
twelve months from the date of this filing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of unaudited condensed consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment.
It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at
the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one
or more future events. Accordingly, the actual results could differ significantly from estimates. Significant estimates during the six
months ended June 30, 2022 and year ended December 31, 2021 include the collectability of notes receivable, valuation of equity investments,
estimates for obsolete and slow-moving inventory, estimates of the deemed dividend, valuation allowances for deferred tax assets, the
fair value of warrants issued with debt and for services, and the fair value of shares issued for services and in settlements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at
least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date
of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more
future events. Accordingly, the actual results could differ significantly from estimates. Significant estimates during the years ended
December 31, 2021 and 2020 include the collectability of notes receivable, the valuation of equity investments, estimates for obsolete
and slow-moving inventory, estimates of the deemed dividend, valuation allowances for deferred tax assets, the fair value of warrants
issued with debt and for services, and the fair value of shares issued for services and in settlements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash and Cash Equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid investments
with a maturity of three months or less when acquired to be cash equivalents. The Company places its cash with high credit quality financial
institutions. The Company&#8217;s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)
up to $250,000 or by the Securities Investor Protection Corporation up to $250,000. To reduce its risk associated with the failure of
such financial institutions, the Company evaluates, at least annually, the rating of the financial institutions in which it holds deposits.
At June 30, 2022 and December 31, 2021, the Company had cash in excess of FDIC limits of approximately $8,240,000, and approximately
$9,100,000, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash and Cash Equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid investments
with a maturity of three months or less when acquired to be cash equivalents. The Company places its cash with high credit quality financial
institutions. The Company&#8217;s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)
up to $250,000 and by the Securities Investor Protection Corporation (&#8220;SIPC&#8221;) up to $250,000. To reduce its risk associated
with the failure of such financial institutions, the Company evaluates, at least annually, the rating of the financial institutions in
which it holds deposits. At December 31, 2021 and 2020, the Company had cash in excess of FDIC and SIPC limits of approximately $9,100,000
and $880,000, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Notes Receivable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Notes Receivable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes an allowance for losses
on notes receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical
bad debt experience, current note receivable aging, and expected future write-offs, as well as an assessment of specific identifiable
accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recognized as general
and administrative expense.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Notes Receivable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes an allowance for losses
on notes receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical
bad debt experience, current note receivable aging, and expected future write-offs, as well as an assessment of specific identifiable
accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recognized as general
and administrative expense.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Prepaid Expenses and Other Current Assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prepaid expenses and other current assets
- current of $99,939 and $145,324 at June 30, 2022 and December 31, 2021, respectively, consist primarily of costs paid for future services
which will occur within a year. Prepaid expenses and other current assets &#8211; non-current of $33,740 and $26,659 at June 30, 2022
and December 31, 2021, respectively, consist primarily of costs paid for license fees and future services which will occur after a year.
Prepaid expenses may include prepayments in cash and equity instruments for consulting, business advisory, legal services, license fees,
research and development fees, and insurance which are being amortized over the terms of their respective agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Prepaid Expenses and Other Current Assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.65pt; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prepaid expenses and other current assets
- current of $145,324 and $241,091 at December 31, 2021 and 2020, respectively, consist primarily of costs paid for future services which
will occur within a year. Prepaid expenses and other current assets &#8211; non-current of $26,659 and $0 at December 31, 2021 and 2020,
respectively, consist primarily of costs paid for license fees and future services which will occur after a year. Prepaid expenses may
include prepayments in cash and equity instruments for consulting, business advisory, legal services, license fees, research and development
fees, and insurance which are being amortized over the terms of their respective agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_EquityInvestmentsAtFairValuePolicyTextBlock', window );">Equity Investments, at Fair Value</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments, at Fair Value</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Realized gain or loss is recognized when an
investment is disposed of and is computed as the difference between the Company&#8217;s carrying value and the net proceeds received
from such disposition. Realized gains and losses on investment transactions are determined by specific identification. Net unrealized
appreciation or depreciation is computed as the difference between the fair value of the investment and the cost basis of such investment.
Net unrealized gains or losses for equity investments are recognized in operations as the difference between the carrying value at the
beginning of the period and the fair value at the end of the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments, at Fair Value</b></p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Realized gain or loss is recognized when an
investment is disposed of and is computed as the difference between the Company&#8217;s carrying value and the net proceeds received
from such disposition.&#160;&#160;Realized gains and losses on investment transactions are determined by specific identification. Net
unrealized appreciation or depreciation is computed as the difference between the fair value of the investment and the cost basis of
such investment. Net unrealized gains or losses for equity investments are recognized in operations as the difference between the carrying
value at the beginning of the period and the fair value at the end of the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_EquityInvestmentsAtCostPolicyTextBlock', window );">Equity Investments, at Cost</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investments, at Cost</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equity investments, at cost are comprised
mainly of non-marketable capital stock and stock warrants, are recorded at cost, as adjusted for other than temporary impairment write-downs
and are evaluated for impairment periodically.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Equity Investments, at Cost</b></p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equity investments, at cost are comprised
mainly of non-marketable capital stock and stock warrants, are recorded at cost, as adjusted for other than temporary impairment write-downs
and are evaluated for impairment periodically.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Recognition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies ASC Topic 606, Revenue
from Contracts with Customers (&#8220;ASC 606&#8221;). ASC 606 establishes a single comprehensive model for entities to use in accounting
for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires
an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records interest and dividend
income on an accrual basis to the extent that the Company expects to collect such amounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the license and royalty income, revenue
is recognized when the Company satisfies the performance obligation based on the related license agreement. Payments received from the
licensee that are related to future periods are recorded as deferred revenue to be recognized as revenues over the term of the related
license agreement (see Note 8).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Product sales were recognized when the NFID
products were shipped to the customer and title was transferred and were recorded net of any discounts or allowances which are separately
reported as &#8220;discontinued operations&#8221; on the condensed consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Recognition</b></p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies ASC Topic 606, Revenue
from Contracts with Customers (&#8220;ASC 606&#8221;). ASC 606 establishes a single comprehensive model for entities to use in accounting
for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires
an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records interest and dividend
income on an accrual basis to the extent that the Company expects to collect such amounts.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the license and royalty income, revenue
is recognized when the Company satisfies the performance obligation based on the related license agreement. Payments received from the
licensee that are related to future periods are recorded as deferred revenue to be recognized as revenues over the term of the related
license agreement (see Note 10).</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Product sales were recognized when the NFID
products were shipped to the customer and title was transferred and were recorded net of any discounts or allowances which are separately
reported as &#8220;discontinued operations&#8221; on the consolidated statements of operations.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CostOfRevenuesPolicyTextBlock', window );">Cost of Revenues</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cost of Revenues</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary components of cost of revenues
on license fees included the cost of the license fees. Payments made to the licensor that are related to future periods are recorded
as prepaid expense to be amortized over the term of the related license agreement (see Note 8).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary components of cost of revenues
on NFID apparel include the cost of the product, production costs, warehouse storage costs and shipping fees which are separately reported
as &#8220;discontinued operations&#8221; on the condensed consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cost of Revenues</b></p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.05pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary components of cost of revenues
on license fees included the cost of the license fees. Payments made to the licensor that are related to future periods are recorded
as prepaid expense to be amortized over the term of the related license agreement (see Note 10).</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary components of cost of revenues
on NFID apparel include the cost of the product, production costs, warehouse storage costs and shipping fees which are separately reported
as &#8220;discontinued operations&#8221; on the consolidated statements of operations.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation is accounted for
based on the requirements of ASC 718 &#8211; &#8220;Compensation &#8211; Stock Compensation&#8221;, which requires recognition in the
financial statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments
over the period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively,
the vesting period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange
for an award based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted
under Accounting Standards Update (&#8220;ASU&#8221;) 2016-09 Improvements to Employee Share-Based Payment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation is accounted for
based on the requirements of ASC 718 &#8211; &#8220;Compensation &#8211; Stock Compensation&#8221;, which requires recognition in the
financial statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments
over the period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively,
the vesting period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange
for an award based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted
under Accounting Standards Update (&#8220;ASU&#8221;) 2016-09 Improvements to Employee Share-Based Payment.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income tax assets and liabilities
arise from temporary differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted
tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current
or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities
not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences
are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to
be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the provisions of Financial
Accounting Standards Board (&#8220;FASB&#8221;) ASC 740-10, &#8220;Uncertainty in Income Taxes&#8221;. Certain recognition thresholds
must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax
positions that meet a &#8220;more-likely-than-not&#8221; threshold. The Company does not believe it has any uncertain tax positions as
of June 30, 2022 and December 31, 2021 that would require either recognition or disclosure in the accompanying condensed consolidated
financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Income Taxes</b></p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income tax assets and liabilities
arise from temporary differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted
tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current
or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities
not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences
are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to
be realized.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the provisions of Financial
Accounting Standards Board (&#8220;FASB&#8221;) ASC 740-10, &#8220;Uncertainty in Income Taxes&#8221;. Certain recognition thresholds
must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax
positions that meet a &#8220;more-likely-than-not&#8221; threshold. The Company does not believe it has any uncertain tax positions as
of December 31, 2021 and 2020 that would require either recognition or disclosure in the accompanying consolidated financial statements.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognized income tax expense
of $24,876 and $0 for the years ended December 31, 2021 and 2020 (see Note 8).</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">research and development costs are expensed when incurred. During the six months ended June 30, 2022
and 2021, research and development costs were $275,955 and $147,448, respectively. During the three months ended June 30, 2022 and 2021,
research and development costs were $105,676 and $98,846, respectively.<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 730-10, &#8220;Research
and Development-Overall,&#8221; research and development costs are expensed when incurred. During the years ended December 31, 2021 and
2020, research and development costs were $693,910 and $26,250, respectively.</p><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Net Loss per Common Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per share is computed by dividing
net loss allocable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Diluted
earnings per share is computed by dividing net income available to common shareholders by the weighted average number of shares of common
stock, common stock equivalents and potentially dilutive securities outstanding during the period using the as-if converted method. Potentially
dilutive securities which included convertible preferred shares and stock options are excluded from the computation of diluted shares
outstanding if they would have an anti-dilutive impact on the Company&#8217;s net losses. The following are the potentially dilutive
shares for the six months ended June 30, 2022 and 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Series C convertible preferred stock</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-311"><span style="-keep: true">&#8212;</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">15,133</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Stock options</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">28,849</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Warrants</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">347,080</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">347,080</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">375,929</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">368,213</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Net Income (Loss) per Common Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net income (loss) per share is computed
by dividing net income (loss) allocable to common shareholders by the weighted average number of shares of common stock outstanding during
each period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted average number
of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period using the as-if
converted method. Potentially dilutive securities which include convertible preferred shares and stock options are excluded from the
computation of diluted shares outstanding if they would have an anti-dilutive impact on the Company&#8217;s net income or (loss). The
following are the potentially dilutive shares for the years ended December 31, 2021 and 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">December&#160;31,<br/> 2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">December&#160;31,<br/> 2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left"><span style="-keep: true">Series C convertible preferred stock</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; text-align: right"><span style="-keep: true">15,133</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-263"><span style="-keep: true">&#8212;</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Stock options</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Warrants</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">347,080</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-264"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">368,213</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">6,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents a reconciliation
of basic and diluted net loss per share:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the Years Ended<br/> December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="-keep: true">Income (loss) per common share &#8212; basic:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="-keep: true">Income (loss) from continuing operations</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">4,157,108</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(2,666,269</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-keep: true">Loss from discontinued operations</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(253,367</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(371,248</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Net income (loss)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">3,903,741</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(3,037,517</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Weighted average common shares outstanding &#8212; basic</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1,897,315</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1,319,094</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">Net income (loss) per common share available to common stockholders&#8211; basic:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 9pt"><span style="-keep: true">From continuing operations</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1.45</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(2.07</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"><span style="-keep: true">From discontinued operations</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(0.13</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(0.28</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="-keep: true">Income (loss) per common share &#8212; diluted:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Income (loss) from continuing operations</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">4,157,108</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(2,666,269</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">Add: interest expense, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(3,036</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-265"><span style="-keep: true">&#8212;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Numerator for loss from continuing operations per common share &#8212; diluted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,154,072</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(2,666,269</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-keep: true">Numerator for loss from discontinuing operations per common share &#8212;
    diluted</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(253,367</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(371,248</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Net loss per common share &#8211; diluted</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">3,900,705</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(3,037,517</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Weighted average common shares outstanding &#8212; basic</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,897,315</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,319,094</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">Effect of dilutive securities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt"><span style="-keep: true">Options</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,996</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-266"><span style="-keep: true">&#8212;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt"><span style="-keep: true">Preferred shares</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">15,133</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-267"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Weighted average common shares outstanding &#8211; diluted</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268"><span style="-keep: true">1,918,4448</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1,319,094</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Net loss per common share available to common stockholders &#8211; diluted:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"><span style="-keep: true">From continuing operations</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1.43</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(2.07</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"><span style="-keep: true">From discontinued operations</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(0.13</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(0.28</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company accounts
for its leases using the method prescribed by ASC 842 &#8211; <i>Lease Accounting</i>. The Company assess whether the contract is, or
contains, a lease at the inception of a contract which is based on (i) whether the contract involves the use of a distinct identified
asset, (ii) whether the Company obtain the right to substantially all the economic benefit from the use of the asset throughout the period,
and (iii) whether the Company has the right to direct the use of the asset. The Company allocates the consideration in the contract to
each lease component based on its relative stand-alone price to determine the lease payments. The Company has elected not to recognize
right-of-use (&#8220;ROU&#8221;) assets and lease liabilities for short-term leases that have a term of 12 months or less.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Operating lease ROU
assets represents the right to use the leased asset for the lease term. Operating lease liabilities are recognized based on the present
value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate,
the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value
of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included
in general and administrative expenses in the consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, the FASB issued ASU 2020-06&#8212;<i>Debt&#8212;Debt
with Conversion and Other Options (Subtopic 470-20) and Derivatives and edging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic
815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;)</i> to simplify
the accounting for convertible instruments by removing certain separation models in Subtopic 470- 20, <i>Debt with Conversion and Other
Options</i>, for convertible instruments. Under the amendments in ASU 2020-06, the embedded conversion features no longer are separated
from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives
under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently,
a convertible debt instrument will be accounted for as a single liability measured at its amortized cost and a convertible preferred
stock will be accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation
and recognition as derivatives. By removing those separation models, the interest rate of convertible debt instruments typically will
be closer to the coupon interest rate when applying the guidance in Topic 835, Interest. The amendments in ASU 2020-06 provide financial
statement users with a simpler and more consistent starting point to perform analyses across entities. The amendments also improve the
operability of the guidance and reduce, to a large extent, the complexities in the accounting for convertible instruments and the difficulties
with the interpretation and application of the relevant guidance. To further improve the decision usefulness and relevance of the information
being provided to users of financial statements, amendments in ASU 2020-06 increased information transparency by making the following
amendments to the disclosure for convertible instruments:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Add a disclosure objective</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Add information about events or conditions that occur during the
    reporting period that cause conversion contingencies to be met or conversion terms to be significantly changed</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Add information on which party controls the conversion rights</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Align disclosure requirements for contingently convertible instruments
    with disclosure requirements for other convertible instruments</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Require that existing fair value disclosures in Topic 825, Financial
    Instruments, be provided at the individual convertible instrument level rather than in the aggregate.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, for convertible debt instruments
with substantial premiums accounted for as paid-in capital, amendments in ASU 2020-06 added disclosures about (1) the fair value amount
and the level of fair value hierarchy of the entire instrument for public business entities and (2) the premium amount recorded as paid-in
capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amendments in ASU 2020-06 are effective
for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning
after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for
fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but
no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Entities should
adopt the guidance as of the beginning of its annual fiscal year and are allowed to adopt the guidance through either a modified retrospective
method of transition or a fully retrospective method of transition. In applying the modified retrospective method, entities should apply
the guidance to transactions outstanding as of the beginning of the fiscal year in which the amendments are adopted. Transactions that
were settled (or expired) during prior reporting periods are unaffected. The cumulative effect of the change should be recognized as
an adjustment to the opening balance of retained earnings at the date of adoption. If an entity elects the fully retrospective method
of transition, the cumulative effect of the change should be recognized as an adjustment to the opening balance of retained earnings
in the first comparative period presented. The Company adopted ASU 2020-06 during the three months ended March 31, 2022 and it did not
have material impact on its condensed consolidated financial statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, the FASB issued ASU 2021-04,
Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718),
and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40). The new ASU addresses issuer&#8217;s accounting
for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities,
for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted.
The Company adopted ASU 2020-06 during the three months ended March 31, 2022 and did not have material impact on its condensed consolidated
financial statements</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management does not believe that any other
recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company&#8217;s consolidated
financial statements.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, the FASB issued ASU 2020-06&#8212;<i>Debt&#8212;Debt
with Conversion and Other Options (Subtopic 470-20) and Derivatives and edging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic
815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;)</i> to simplify
the accounting for convertible instruments by removing certain separation models in Subtopic 470- 20, <i>Debt with Conversion and Other
Options</i>, for convertible instruments. Under the amendments in ASU 2020-06, the embedded conversion features no longer are separated
from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives
under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently,
a convertible debt instrument will be accounted for as a single liability measured at its amortized cost and a convertible preferred
stock will be accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation
and recognition as derivatives. By removing those separation models, the interest rate of convertible debt instruments typically will
be closer to the coupon interest rate when applying the guidance in Topic 835, Interest. The amendments in ASU 2020-06 provide financial
statement users with a simpler and more consistent starting point to perform analyses across entities. The amendments also improve the
operability of the guidance and reduce, to a large extent, the complexities in the accounting for convertible instruments and the difficulties
with the interpretation and application of the relevant guidance. To further improve the decision usefulness and relevance of the information
being provided to users of financial statements, amendments in ASU 2020-06 increased information transparency by making the following
amendments to the disclosure for convertible instruments:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Add a disclosure objective</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Add information about
    events or conditions that occur during the reporting period that cause conversion contingencies to be met or conversion terms to
    be significantly changed</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Add information on which
    party controls the conversion rights</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Align disclosure requirements
    for contingently convertible instruments with disclosure requirements for other convertible instruments</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Require that existing
    fair value disclosures in Topic 825, Financial Instruments, be provided at the individual convertible instrument level rather than
    in the aggregate.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, for convertible debt instruments
with substantial premiums accounted for as paid-in capital, amendments in ASU 2020-06 added disclosures about (1) the fair value amount
and the level of fair value hierarchy of the entire instrument for public business entities and (2) the premium amount recorded as paid-in
capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The amendments in
ASU 2020-06 are effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the
SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities,
the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years.
Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those
fiscal years. Entities should adopt the guidance as of the beginning of its annual fiscal year and are allowed to adopt the guidance
through either a modified retrospective method of transition or a fully retrospective method of transition. In applying the modified
retrospective method, entities should apply the guidance to transactions outstanding as of the beginning of the fiscal year in which
the amendments are adopted. Transactions that were settled (or expired) during prior reporting periods are unaffected. The cumulative
effect of the change should be recognized as an adjustment to the opening balance of retained earnings at the date of adoption. If an
entity elects the fully retrospective method of transition, the cumulative effect of the change should be recognized as an adjustment
to the opening balance of retained earnings in the first comparative period presented. The Company is evaluating the impact of the revised
guidance and believes that it will not have a significant impact on its consolidated financial statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, the FASB issued ASU 2021-04,
Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718),
and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40). The new ASU addresses issuer&#8217;s accounting
for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities,
for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted.
The Company is evaluating the impact of the revised guidance and believes that it will not have a significant impact on its consolidated
financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management does not believe that any other
recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company&#8217;s consolidated
financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CostOfRevenuesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CostOfRevenuesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_EquityInvestmentsAtCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_EquityInvestmentsAtCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_EquityInvestmentsAtFairValuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_EquityInvestmentsAtFairValuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1D<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=SL116886442-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4549-113899<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (m)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336916200032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock', window );">Schedule of anti-dilutive net loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Series C convertible preferred stock</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-311"><span style="-keep: true">&#8212;</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">15,133</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Stock options</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">28,849</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Warrants</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">347,080</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">347,080</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">375,929</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">368,213</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">December&#160;31,<br/> 2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">December&#160;31,<br/> 2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left"><span style="-keep: true">Series C convertible preferred stock</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; text-align: right"><span style="-keep: true">15,133</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-263"><span style="-keep: true">&#8212;</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="-keep: true">Stock options</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Warrants</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">347,080</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-264"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">368,213</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">6,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of reconciliation of basic and diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the Years Ended<br/> December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="-keep: true">Income (loss) per common share &#8212; basic:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="-keep: true">Income (loss) from continuing operations</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">4,157,108</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(2,666,269</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-keep: true">Loss from discontinued operations</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(253,367</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(371,248</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Net income (loss)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">3,903,741</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(3,037,517</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Weighted average common shares outstanding &#8212; basic</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1,897,315</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1,319,094</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">Net income (loss) per common share available to common stockholders&#8211; basic:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 9pt"><span style="-keep: true">From continuing operations</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1.45</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(2.07</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"><span style="-keep: true">From discontinued operations</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(0.13</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(0.28</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify"><span style="-keep: true">Income (loss) per common share &#8212; diluted:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Income (loss) from continuing operations</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">4,157,108</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(2,666,269</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">Add: interest expense, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(3,036</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-265"><span style="-keep: true">&#8212;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Numerator for loss from continuing operations per common share &#8212; diluted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,154,072</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(2,666,269</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-keep: true">Numerator for loss from discontinuing operations per common share &#8212;
    diluted</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(253,367</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(371,248</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Net loss per common share &#8211; diluted</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">3,900,705</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(3,037,517</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Weighted average common shares outstanding &#8212; basic</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,897,315</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,319,094</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">Effect of dilutive securities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt"><span style="-keep: true">Options</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,996</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-266"><span style="-keep: true">&#8212;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt"><span style="-keep: true">Preferred shares</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">15,133</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-267"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Weighted average common shares outstanding &#8211; diluted</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268"><span style="-keep: true">1,918,4448</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1,319,094</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Net loss per common share available to common stockholders &#8211; diluted:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"><span style="-keep: true">From continuing operations</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1.43</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(2.07</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"><span style="-keep: true">From discontinued operations</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(0.13</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(0.28</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tablular disclosure of schedule of anti-dilutive net loss per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336824856160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At June 30, 2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At December 31, 2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; text-align: left">Equity investments consisting of common
    stock, at fair value</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">113,012</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-312">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-313">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">419,995</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-314">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-315">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">At December 31, 2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding-left: 0.125in; text-indent: -0.125in; text-align: left; font-weight: bold">Description</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 28%; text-align: left">Equity investments consisting of common
    stock, at fair value</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">419,995</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-269">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-271">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-272">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-273">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock', window );">Schedule of activity in the company&#8217;s equity investments, at fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance, beginning</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">419,995</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-316">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,733</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">531,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Sales at original cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(171,407</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(359,843</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Unrealized (loss) gain</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(221,309</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">248,588</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance as of June 30, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">113,012</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">419,995</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Balance, beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-274">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-275">&#160;&#160;&#160;&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; width: 76%">Additions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">531,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-276">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(359,843</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-277">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Unrealized gain</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">248,588</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-278">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Balance, end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">419,995</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-279">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336823351280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disposal of the Discontinued Operations of the Nfid Business (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of financial data of the company&#8217;s gain from sale of the NFID business</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September&#160;30, <br/>
    2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 1.5pt">Inventory, net</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">58,447</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">58,447</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-317">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net asset of NFID business disposed</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">58,447</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Consideration in the form of a note receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Gain from sale of NFID business</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,553</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September&#160;30,<br/>
    2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 1.5pt">Inventory, net</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">58,447</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">58,447</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-280">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net asset of NFID business disposed</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">58,447</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Consideration in the form of a note receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Gain from sale of NFID business</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,553</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock', window );">Schedule of operating result of discontinued operations of the NFID business</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Product sales, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-318">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">80,305</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,079</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,360</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,079</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,945</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating and other non-operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(84</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(152,095</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Loss from discontinued operations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,163</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(140,150</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Year Ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Product sales, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">119,405</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,923</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">103,824</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">182,426</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,581</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(141,503</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total operating and other non-operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(270,501</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(229,745</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain from sale of NFID business</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,533</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-281">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Loss from discontinued operations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(253,367</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(371,248</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedIncomeStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336821201232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of notes receivable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Principal amounts of notes receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">115,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">220,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Additional notes receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-319">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Collections on notes receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(164,500</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(35,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(55,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Notes receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: notes receivable, net &#8211; current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-320">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-321">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Notes receivable &#8211; non-current</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">60,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">60,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Principal amounts of notes receivable at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">220,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">250,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify">Additional notes receivable in 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-282">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Collections on notes receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(148,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(71,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(196,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total Notes receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">Less: notes receivable, net &#8211; current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-283">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Notes receivable &#8211; non-current</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">60,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-284">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336823245504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Note Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock', window );">Schedule of interest expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Principal amount</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-285">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,900</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-286">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,654</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Note payable - long term portion</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-287">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,246</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336819774400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock options activities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number of<br/> Options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted Average<br/> Exercise<br/>
    Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted Average<br/> Remaining<br/>
    Contractual Term<br/> (Years)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Aggregate<br/> Intrinsic<br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%"><span style="-keep: true">Balance Outstanding, December 31, 2021</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">6,000</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">0.005</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">2.5</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-322"><span style="-keep: true">&#8212;</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="-keep: true">Granted as incentives</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,849</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">7.30</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4.5</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-323"><span style="-keep: true">&#8212;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Granted pursuant to employment agreement (see Note 8)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">16,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">10.00</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">9.6</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-324"><span style="-keep: true">&#8212;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-325"><span style="-keep: true">&#160;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-326"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-327"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-328"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Balance Outstanding, June 30, 2022</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">28,849</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">7.50</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">7.5</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-329"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Exercisable, June 30, 2022</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">12,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">5.00</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">5.8</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">6,030</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number<br/> of Options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted<br/> Average<br/> Exercise<br/>
    Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted<br/> Average<br/> Remaining<br/>
    Contractual<br/> Term<br/> (Years)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Aggregate<br/> Intrinsic<br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%"><span style="-keep: true">Balance Outstanding, December 31, 2019</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">6,000</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">0.005</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">4.5</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">104,970</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Granted/Issued/ Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-288"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-289"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-290"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-291"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Balance Outstanding, December 31, 2020</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0.005</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3.5</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">127,290</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Granted/Issued/ Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-292"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-293"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-294"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-295"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Balance Outstanding, December 31, 2021</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">6,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">0.005</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">2.5</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">42,870</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Exercisable, December 31, 2021</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">6,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">0.005</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">2.5</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">$</span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-keep: true">42,870</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrant activities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of<br/>
    Warrants</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
    Average<br/>
    Exercise<br/>
    Price</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
    Average<br/>
    Remaining<br/>
    Contractual Term<br/>
    (Years)</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/>
    Intrinsic<br/>
    Value</b></span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Outstanding, December
    31, 2021</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">347,080</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.50</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-330"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted/Forfeited</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-331"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-332"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-333"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-334"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Outstanding, June 30, 2022</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">347,080</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.50</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-335"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, June 30, 2022</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">347,080</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.50</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-336"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of Warrants</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
    Average Exercise Price</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
    Average Remaining Contractual Term (Years)</b></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/>
    Intrinsic<br/>
    Value</b></span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Outstanding, December
    31, 2019</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,500</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.00</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.80</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">337,750</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(44,500</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.00</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-296"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-297"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Outstanding, December 31, 2020</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-298"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-299"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-300"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-301"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">347,080</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.50</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-302"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Outstanding, December 31, 2021</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">347,080</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.50</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-303"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, December 31, 2021</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">347,080</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.50</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-304"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></div></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336822910768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective statutory rate and the provision for income taxes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Income tax (benefit) liability at U.S. statutory rate of 21%&#8239;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">819,786</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(637,879</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Income tax (benefit) liability &#8211; state</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">253,743</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(197,439</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,893</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">457,798</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,027,760</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">377,520</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total provision for income tax</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">24,876</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-305">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of net deferred tax asset</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Net operating loss carryforward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,647,335</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">868,338</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Net capital loss carryforward</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,707,701</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">123,932</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total deferred tax asset (liability) before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(60,366</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">992,271</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,490</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(992,271</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Provision for income tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24,876</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-306">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Net deferred tax asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-307">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-308">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336824862896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfMilestonePayments', window );">Schedule of milestone payments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Milestone</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">50,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Receipt of New Drug Application (&#8220;NDA&#8221;) (or foreign equivalent) approval for a Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Achievement of First Commercial Sale of Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Milestone</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">50,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Receipt of New Drug Application (&#8220;NDA&#8221;) (or foreign equivalent) approval for a Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Achievement of First Commercial Sale of Licensed Product</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfUMBMinimumRoyaltyPayments', window );">Schedule of UMB minimum royalty payments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Years</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Minimum Annual Royalty</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prior to First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-337; font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Year of First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-338; font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">First calendar year following the First Commercial Sale</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Second calendar year following the First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Third calendar year following the First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Minimum Annual Royalty</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Prior to First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-309; font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Year of First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-310; font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">First calendar year following the First Commercial Sale</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Second calendar year following the First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Third calendar year following the First Commercial Sale</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized', window );">Schedule of exclusive of value added tax to be amortized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="width: 24%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86,777 Euros ($101,520 USD)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 69%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon signing the Study Agreement and was paid in December 2020</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86,777 Euros ($101,520 USD)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtained approval from ethical committee</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86,777 Euros ($101,520 USD)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data collection has commenced</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130,166 Euros ($152,281 USD)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First half of the participants are tested</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,885 Euros ($50,760 USD)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of data collection and delivery of final report</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.4pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfShallPayUMB', window );">Schedule of shall pay UMB</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Payment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 2%; text-align: center"><span style="font-size: 10pt">1</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">92,095</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 83%"><span style="font-size: 10pt">Upon execution of the July 2021 Sponsored Research Agreement</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center"><span style="font-size: 10pt">2</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">92,095</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-size: 10pt">3</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">92,095</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="5" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payment</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,095</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 84%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon execution of the July 2021 Sponsored Research Agreement</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,095</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,095</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of exclusive of value added tax to be amortized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfShallPayUMB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of shall pay UMB.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfShallPayUMB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfUMBMinimumRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of UMB minimum royalty payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfUMBMinimumRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336824963664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Business [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalDeferredPurchasePrice', window );">Purchase price</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_promissoryNoteAmount', window );">Promissory note amount</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Bears interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentMaturityDate', window );">Maturity date</a></td>
<td class="text">Oct.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AssetPurchaseAgreementDescription', window );">Asset purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On September 30, 2021, the Company entered
into and closed on an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement) with NFID, LLC, a Florida limited liability company
(the &#8220;Buyer&#8221;), whereby the Buyer purchased from the Company certain assets, properties, and rights in connection with the
Company&#8217;s NFID trademark name, logos, domain, and apparel clothing and accessories for a purchase price of $60,000 in the form
of a promissory note amounting to $60,000. The promissory note bears 8% interest per annum and matures on October 1, 2023. Accordingly,
the results of operations of this component, for all periods presented, are separately reported as &#8220;discontinued operations&#8221;
on the condensed consolidated statements of operations (see Note 4).&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AssetPurchaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Purchase Agreement Description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AssetPurchaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_promissoryNoteAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Promissory note amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_promissoryNoteAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity date of investment, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalDeferredPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalDeferredPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336824659152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 18, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,262,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,903,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInContinuingOperations', window );">Cash in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,189,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,278,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (4,525,051)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,525,051)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,262,577)<span></span>
</td>
<td class="num">$ (5,762,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,020,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnits', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,912,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Aggregate shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal deposit insurance corporation</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CashSPICInsuredAmount', window );">Securities investor protection corporation</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FDICIndemnificationAssetCashPaymentsReceived', window );">FDIC cash limits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100,000<span></span>
</td>
<td class="nump">880,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">99,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,324<span></span>
</td>
<td class="nump">241,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,659<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,876<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">693,910<span></span>
</td>
<td class="nump">26,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsUnappropriated', window );">Accumulated deficit</a></td>
<td class="nump">4,525,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,525,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_WorkingCapital', window );">Working capital</a></td>
<td class="nump">8,678,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,678,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other current assets &#8211; non-current</a></td>
<td class="nump">33,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development cost</a></td>
<td class="nump">$ 105,676<span></span>
</td>
<td class="nump">$ 98,846<span></span>
</td>
<td class="nump">$ 275,955<span></span>
</td>
<td class="nump">$ 147,448<span></span>
</td>
<td class="nump">$ 693,910<span></span>
</td>
<td class="nump">$ 26,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CashSPICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Securities Investor Protection Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CashSPICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.16(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FDICIndemnificationAssetCashPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decreases to the indemnification asset due to cash payments received relating to loss sharing agreements with the Federal Deposit Insurance Corporation (FDIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FDICIndemnificationAssetCashPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsUnappropriated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A segregation of retained earnings which is available for dividend distribution. Earnings not paid out as dividends but instead reinvested in the core business or used to pay off debt. Unappropriated profit is part of shareholder equity. Also called cumulative distributions or earned surplus or accumulated earnings or unappropriated profit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsUnappropriated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336821182032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive net loss per share</a></td>
<td class="nump">375,929<span></span>
</td>
<td class="nump">368,213<span></span>
</td>
<td class="nump">368,213<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,080<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive net loss per share</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15,133<span></span>
</td>
<td class="nump">15,133<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=silo_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=silo_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=silo_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336821354672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of reconciliation of basic and diluted net loss per share - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_IncomeLossPerCommonShareBasicAbstract', window );"><strong>Income (loss) per common share &#8212; basic:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_IncomelossFromContinuingOperation', window );">Income (loss) from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,157,108<span></span>
</td>
<td class="num">$ (2,666,269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_IncomeLossFromDiscontinuedOperations', window );">Loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(253,367)<span></span>
</td>
<td class="num">(371,248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,903,741<span></span>
</td>
<td class="num">$ (3,037,517)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding &#8212; basic (in Shares)</a></td>
<td class="nump">1,987,906<span></span>
</td>
<td class="nump">1,937,148<span></span>
</td>
<td class="nump">1,980,365<span></span>
</td>
<td class="nump">1,820,641<span></span>
</td>
<td class="nump">1,897,315<span></span>
</td>
<td class="nump">1,319,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract', window );"><strong>Net income (loss) per common share available to common stockholders&#8211; basic:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">From continuing operations (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="num">$ (2.07)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">From discontinued operations (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_IncomeLossPerCommonShareDilutedAbstract', window );"><strong>Income (loss) per common share &#8212; diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_IncomelossFromContinuingOperation', window );">Income (loss) from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,157,108<span></span>
</td>
<td class="num">$ (2,666,269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Add: interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,036)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NumeratorForLossFromContinuingOperationsPerCommonShareDiluted', window );">Numerator for loss from continuing operations per common share &#8212; diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,154,072<span></span>
</td>
<td class="num">(2,666,269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted', window );">Numerator for loss from discontinuing operations per common share &#8212; diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(253,367)<span></span>
</td>
<td class="num">(371,248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAllocatedToGeneralPartners', window );">Net loss per common share &#8211; diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,705<span></span>
</td>
<td class="num">$ (3,037,517)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding &#8212; basic (in Shares)</a></td>
<td class="nump">1,987,906<span></span>
</td>
<td class="nump">1,937,148<span></span>
</td>
<td class="nump">1,980,365<span></span>
</td>
<td class="nump">1,820,641<span></span>
</td>
<td class="nump">1,897,315<span></span>
</td>
<td class="nump">1,319,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_EffectOfDilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,996<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AuctionMarketPreferredSecuritiesSharesOutstanding', window );">Preferred shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,133<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding &#8211; diluted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,184,448<span></span>
</td>
<td class="nump">1,319,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Net loss per common share available to common stockholders &#8211; diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">From continuing operations (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
<td class="num">$ (2.07)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare', window );">From discontinued operations (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_EffectOfDilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_EffectOfDilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_IncomeLossFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (loss) from discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_IncomeLossFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_IncomeLossPerCommonShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_IncomeLossPerCommonShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_IncomeLossPerCommonShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_IncomeLossPerCommonShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_IncomelossFromContinuingOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>IncomelossFromContinuingOperation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_IncomelossFromContinuingOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NumeratorForLossFromContinuingOperationsPerCommonShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NumeratorForLossFromContinuingOperationsPerCommonShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AuctionMarketPreferredSecuritiesSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of auction market preferred securities shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AuctionMarketPreferredSecuritiesSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAllocatedToGeneralPartners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of net income allocated to general partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAllocatedToGeneralPartners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336821340992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems', window );"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Net realized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,660,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_EquityInvestmentsCost', window );">Equity investments cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet', window );">Common stock grant date fair value</a></td>
<td class="nump">$ 85,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommonStockGrantDateFairValuePerShare', window );">Common stock grant date fair value per share (in Dollars per share)</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_DatChatIncMember', window );">DatChat, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems', window );"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Net realized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,657,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Basic investment cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredSalesCommission', window );">Commission on sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">578,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_AikidoPharmaIncMember', window );">Aikido Pharma, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems', window );"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Net realized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainOnSaleOfInvestments', window );">Equity investment Sold</a></td>
<td class="nump">$ 171,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_GrossProceeds', window );">Gross proceeds</a></td>
<td class="nump">66,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_EquityMethodInvestment', window );">Equity investments amount</a></td>
<td class="nump">$ 104,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_HomeBistroIncMember', window );">Home Bistro, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems', window );"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CompanyReceivedShares', window );">Company received shares (in Shares)</a></td>
<td class="nump">77,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommonStockGrantDateFairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock grant date fair value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommonStockGrantDateFairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CompanyReceivedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company received shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CompanyReceivedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_EquityInvestmentsCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity investments cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_EquityInvestmentsCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_EquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_EquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of Gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredSalesCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of advanced commission payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredSalesCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126966630&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_DatChatIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_DatChatIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_AikidoPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_AikidoPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_HomeBistroIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_HomeBistroIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336821145824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_EquityInvestmentsAtFairValue', window );">Equity investments consisting of common stock, at fair value</a></td>
<td class="nump">$ 113,012<span></span>
</td>
<td class="nump">$ 419,995<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_EquityInvestmentsAtFairValue', window );">Equity investments consisting of common stock, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_EquityInvestmentsAtFairValue', window );">Equity investments consisting of common stock, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_EquityInvestmentsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_EquityInvestmentsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336819477184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of activity in the company&#8217;s equity investments, at fair value - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract', window );"><strong>Schedule Of Activity In The Company SEquity Investments At Fair Value Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Balance, beginning of the year</a></td>
<td class="nump">$ 419,995<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AdditionsofEquitySecurities', window );">Additions</a></td>
<td class="nump">85,733<span></span>
</td>
<td class="nump">531,250<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales</a></td>
<td class="num">(171,407)<span></span>
</td>
<td class="num">(359,843)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain</a></td>
<td class="num">$ (221,309)<span></span>
</td>
<td class="nump">248,588<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Balance, end of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 419,995<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AdditionsofEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions for equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AdditionsofEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336821230768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disposal of the Discontinued Operations of the Nfid Business (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PurchasePrice', window );">Purchase price</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Bearing interest rate percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturityDate', window );">Maturity date</a></td>
<td class="text">Oct.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PrincipalBalance', window );">Note receivable - non current</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AccruedInterestReceivable', window );">Accrued interest receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_TotalOutstandingBalanceReceivable', window );">Total outstanding balance receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Assets of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 33,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PromissoryNotes', window );">Promissory Notes</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AccruedInterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AccruedInterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PrincipalBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PrincipalBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of promissory notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_TotalOutstandingBalanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of total outstanding balance receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_TotalOutstandingBalanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity date of long-term debt, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336822247344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disposal of the Discontinued Operations of the Nfid Business (Details) - Schedule of financial data of the company&#8217;s gain from sale of the NFID business<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CurrentAssetsAbstract0', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">$ 58,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets</a></td>
<td class="nump">58,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CurrentLiabilitiesAbstract0', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_FinanceLeaseLiabilities', window );">Total liabilities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NetAssetOfNFIDBusinessDisposed', window );">Net asset of NFID business disposed</a></td>
<td class="nump">58,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ConsiderationInTheFormOfANoteReceivable', window );">Consideration in the form of a note receivable</a></td>
<td class="num">(60,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain from sale of NFID business</a></td>
<td class="num">$ (1,553)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ConsiderationInTheFormOfANoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration in the form of a note receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ConsiderationInTheFormOfANoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CurrentAssetsAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CurrentAssetsAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CurrentLiabilitiesAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CurrentLiabilitiesAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_FinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_FinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NetAssetOfNFIDBusinessDisposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net asset of NFID business disposed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NetAssetOfNFIDBusinessDisposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336821195136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disposal of the Discontinued Operations of the Nfid Business (Details) - Schedule of operating result of discontinued operations of the NFID business - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract', window );"><strong>Schedule Of Operating Result Of Discontinued Operations Of The Nfid Business Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Product sales, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 80,305<span></span>
</td>
<td class="nump">$ 119,405<span></span>
</td>
<td class="nump">$ 40,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of sales</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">68,360<span></span>
</td>
<td class="nump">103,824<span></span>
</td>
<td class="nump">182,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss', window );">Gross profit (loss)</a></td>
<td class="num">(1,079)<span></span>
</td>
<td class="nump">11,945<span></span>
</td>
<td class="nump">15,581<span></span>
</td>
<td class="num">(141,503)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Total operating and other non-operating expenses</a></td>
<td class="num">$ (84)<span></span>
</td>
<td class="num">$ (152,095)<span></span>
</td>
<td class="num">(270,501)<span></span>
</td>
<td class="num">(229,745)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_GainFromSaleOfNFIDBusiness', window );">Gain from sale of NFID business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,533<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (253,367)<span></span>
</td>
<td class="num">$ (371,248)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_GainFromSaleOfNFIDBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain from sale of NFID business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_GainFromSaleOfNFIDBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336816028240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Receivable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2023</div></th>
<th class="th"><div>Jun. 07, 2021</div></th>
<th class="th"><div>Nov. 02, 2018</div></th>
<th class="th"><div>Dec. 29, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 02, 2018</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NotesReceivableDetailsLineItems', window );"><strong>Notes Receivable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 174,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 26,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalDeferredPurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,590<span></span>
</td>
<td class="nump">1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts', window );">Received payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,500<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NetBadDebtExpense', window );">Net bad debt expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_BadDebtRecoveryCashPayment', window );">Bad debt recovery cash payment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On June 7, 2021, the Company and the investor, entered into a
settlement agreement whereby both parties agreed to settle the remaining balance of this note receivable which was previously written
off in year 2020 for a total settlement amount of $196,000 to be paid as follows; (i) an initial payment of $46,000 upon execution of
the settlement agreement and (ii) $10,000 per month for fifteen months.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CollectedSettlementAgreement', window );">Collected settlement agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_RemainsCollectibleSettlementAgreement', window );">Remains collectible settlement agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">47,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PromissoryNote', window );">Promissory note interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NoteReceivableNonCurrentAmount', window );">Note receivable non-current amounted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_DebtInstrumentIncreasesAccruedInterest', window );">Accrued interest receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireReceivables', window );">Total receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,590<span></span>
</td>
<td class="nump">61,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PromissoryNoteAgreement', window );">Promissory note agreement note deposit and credit towards acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rate per annum percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Increased interest rate per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ReceivedShares', window );">Received shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AggregateOfNotesReceivablePurchasePrice', window );">Aggregate of notes receivable purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_RecoveredAggregateBadDebt', window );">Recovered aggregate bad debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_RecoveredBadDebt', window );">Recovered bad debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease', window );">Bad debt allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_RemainsCollectibleSettlementAgreementAmountReserved', window );">Remains collectible settlement agreement amount reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_LayawaySaleMember', window );">Six-monthly installments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NotesReceivableDetailsLineItems', window );"><strong>Notes Receivable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalDeferredPurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 277,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_TypesOfAgreementAxis=silo_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NotesReceivableDetailsLineItems', window );"><strong>Notes Receivable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,500<span></span>
</td>
<td class="nump">146,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful account and bad debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,376<span></span>
</td>
<td class="nump">174,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalDeferredPurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 277,305<span></span>
</td>
<td class="nump">277,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NotesReceivablePurchasePrice', window );">Notes receivable purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,876<span></span>
</td>
<td class="nump">$ 27,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AggregateOfNotesReceivablePurchasePrice', window );">Aggregate of notes receivable purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Notes Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NotesReceivableDetailsLineItems', window );"><strong>Notes Receivable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 27,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts', window );">Received payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NotesReceivableDetailsLineItems', window );"><strong>Notes Receivable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PromissoryNote', window );">Promissory note interest</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=silo_PromissoryNoteReceivableAgreementMember', window );">Promissory Note Receivable Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NotesReceivableDetailsLineItems', window );"><strong>Notes Receivable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_RemainingBalanceOfPromissoryNoteReceivable', window );">Remaining balance of promissory note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Accrued interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful account and bad debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=silo_PromissoryNoteReceivableAgreementMember', window );">Promissory Note Receivable Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NotesReceivableDetailsLineItems', window );"><strong>Notes Receivable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Accrued interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=silo_PromissoryNoteReceivableAgreementMember', window );">Promissory Note Receivable Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NotesReceivableDetailsLineItems', window );"><strong>Notes Receivable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Accrued interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AggregateOfNotesReceivablePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate of notes receivable purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AggregateOfNotesReceivablePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_BadDebtRecoveryCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_BadDebtRecoveryCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CollectedSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Collected Settlement Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CollectedSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_DebtInstrumentIncreasesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_DebtInstrumentIncreasesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NetBadDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net bad debt expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NetBadDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NoteReceivableNonCurrentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NoteReceivableNonCurrentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NotesReceivableDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NotesReceivableDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NotesReceivablePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>NotesReceivablePurchasePrice.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NotesReceivablePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PromissoryNoteAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Promissory note agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PromissoryNoteAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ReceivedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The company received shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ReceivedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_RecoveredAggregateBadDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recovered aggregate bad debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_RecoveredAggregateBadDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_RecoveredBadDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value recovered bad debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_RecoveredBadDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_RemainingBalanceOfPromissoryNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining balance of promissory note receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_RemainingBalanceOfPromissoryNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_RemainsCollectibleSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remains Collectible Settlement Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_RemainsCollectibleSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_RemainsCollectibleSettlementAgreementAmountReserved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remains collectible settlement agreement amount reserved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_RemainsCollectibleSettlementAgreementAmountReserved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recovery of loans and lease receivables which had previously been fully or partially written-off as bad debts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for bad debt, of increase (decrease) in loan receivables held-for-sale that are not part of a disposal group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity date of long-term debt, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of all receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalDeferredPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalDeferredPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_LayawaySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_LayawaySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_TypesOfAgreementAxis=silo_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_TypesOfAgreementAxis=silo_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=silo_PromissoryNoteReceivableAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=silo_PromissoryNoteReceivableAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336821229168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Receivable (Details) - Schedule of notes receivable - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfNotesReceivableAbstract', window );"><strong>Schedule Of Notes Receivable Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Principal amounts of notes receivable at beginning of the year</a></td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 115,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AdditionalNotesReceivableIn2021', window );">Additional notes receivable in 2021</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CollectionsOnNotesReceivable', window );">Collections on notes receivables</a></td>
<td class="num">(148,500)<span></span>
</td>
<td class="num">(30,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket', window );">Less: allowance for doubtful accounts</a></td>
<td class="num">(71,500)<span></span>
</td>
<td class="num">(196,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Total Notes receivable, net</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">23,500<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_LessNotesReceivableNetCurrentPortion', window );">Less: notes receivable, net &#8211; current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(23,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Notes receivable &#8211; non-current</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AdditionalNotesReceivableIn2021">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional notes receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AdditionalNotesReceivableIn2021</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CollectionsOnNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collections on notes receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CollectionsOnNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_LessNotesReceivableNetCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_LessNotesReceivableNetCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfNotesReceivableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfNotesReceivableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 79<br> -URI https://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922352-210448<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 80<br> -URI https://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922355-210448<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (2)<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1404<br> -Paragraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336824643920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NotePayableDetailsLineItems', window );"><strong>Note Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=silo_PaycheckProtectionProgramMember', window );">Paycheck Protection Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NotePayableDetailsLineItems', window );"><strong>Note Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Received amount</a></td>
<td class="nump">$ 18,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Interest-bearing unsecured</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,900<span></span>
</td>
<td class="nump">18,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NotePayableDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NotePayableDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableInterestBearingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=29642582&amp;loc=d3e27881-108397<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 25<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=29642582&amp;loc=d3e27862-108397<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableInterestBearingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=silo_PaycheckProtectionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=silo_PaycheckProtectionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336824627824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note Payable (Details) - Schedule of interest expense - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfInterestExpenseAbstract', window );"><strong>Schedule Of Interest Expense Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_DebtInstrumentsFaceAmount', window );">Principal amount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NotrPayableLessCurrentPortion', window );">Less: current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(14,654)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NotePayableLongTermPortion', window );">Note payable - long term portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_DebtInstrumentsFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_DebtInstrumentsFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NotePayableLongTermPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NotePayableLongTermPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NotrPayableLessCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NotrPayableLessCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfInterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfInterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336801419136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 14, 2021</div></th>
<th class="th"><div>Feb. 09, 2021</div></th>
<th class="th"><div>Aug. 03, 2020</div></th>
<th class="th"><div>Aug. 03, 2020</div></th>
<th class="th"><div>Apr. 18, 2020</div></th>
<th class="th"><div>Apr. 15, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 29, 2021</div></th>
<th class="th"><div>Jan. 18, 2021</div></th>
<th class="th"><div>Apr. 28, 2020</div></th>
<th class="th"><div>Apr. 17, 2020</div></th>
<th class="th"><div>Apr. 15, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 10, 2021</div></th>
<th class="th"><div>Jul. 06, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Apr. 30, 2013</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ConvertablePreferredStock', window );">Converted preferred stock</a></td>
<td class="nump">4,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Convertible common stock</a></td>
<td class="nump">269,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Redemption value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ExchangeAgreementsDescription', window );">Exchange agreements, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On April 15, 2020, the Company entered into
Exchange Agreements with the holders of its Series B Preferred Stock, which shares of Series B Preferred Stock were originally issued
in November 2019. Pursuant to the Exchange Agreements, the holders agreed to exchange their 115 shares of Series B Preferred Stock with
a stated value of $115,000 and 11,500 warrants issued in connection with the Series B Preferred Stock for an aggregate of 28,750 shares
of the Company&#8217;s common stock at a price of $4.00 per share. After the exchanges, there are no shares of the Company&#8217;s Series
B Preferred Stock outstanding. The Company issued 28,750 shares of common stock which was more than the shares that would have been issued
at the original conversion price of $10.00 per share or 11,500 shares of common stock, an excess of 17,250 shares of common stock. The
excess shares were valued at a price of $4.00 per share. Consequently, in connection with this share exchange, the Company recorded a
deemed dividend on this extinguishment of $69,000 during the year ended December 31, 2020. Accordingly, there are no shares of Series
B Preferred Stock issued and outstanding as of December 31, 2021 and 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred stock conversion, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Series C Convertible preferred stock and
the February Warrants each contain a beneficial ownership limitation that restricts each of the investor&#8217;s ability to exercise
the February Warrants and convert the Series C Convertible preferred stock such that the number of shares of the Company common stock
held by each of them and their affiliates after such conversion or exercise does not exceed 4.99% (or, at the election of the Investor,
9.99%) of the Company&#8217;s then issued and outstanding shares of common stock.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Series C Convertible Preferred Stock and
the February Warrants each contain a beneficial ownership limitation that restricts each of the investor&#8217;s ability to exercise
the February Warrants and convert the Series C Convertible Preferred Stock such that the number of shares of the Company common stock
held by each of them and their affiliates after such conversion or exercise does not exceed 4.99% (or, at the election of the Investor,
9.99%) of the Company&#8217;s then issued and outstanding shares of common stock.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_WarrantsTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SubsequentFinancingPercentage', window );">Subsequent financing, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ObligationPercentage', window );">Obligation percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PlacementAgentWarrantsDescriptoin', window );">Placement agent warrants, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition, pursuant to the terms of the
offering, the Company issued Bradley Woods & Co, Ltd. and Katalyst Securities LLC warrants (the &#8220;Placement Agent Warrants&#8221;)
to purchase up to an aggregate of 57,013 shares of common stock, or 10% of the shares of common stock issuable upon conversion of the
Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period
of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition, pursuant to the terms of the
offering, the Company issued Bradley Woods & Co, Ltd. and Katalyst Securities LLC warrants (the &#8220;Placement Agent Warrants&#8221;)
to purchase up to an aggregate of 57,013 shares of common stock, or 10% of the shares of common stock issuable upon conversion of the
Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period
of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AggregateGrantDateFairValueOfPlacementAgentWarrants', window );">Aggregate grant date fair value of placement agent warrants (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,106,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,115,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable', window );">Subscription receivable (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_TotalSubscriptionReceivableValue', window );">Total subscription receivable (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_InvestorInvestedAmount', window );">Investor invested amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionContractorLiquidityCharacteristic', window );">Liquidity damage, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">If the Company fails to file the Registration Statement or have it declared effective by
the dates set forth above, amongst other things, the Company will be obligated to pay the investors damages in the amount of 1% of their
subscription amount, per month, until such events are satisfied.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">If the Company fails to file the registration statement
or have it declared effective by the dates set forth above, amongst other things, the Company is obligated to pay the investors liquidated
damages in the amount of 1% of their subscription amount, per month, until such events are satisfied, subject to a cap of 6%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AmortizationOfPrepaidStockbasedExpense', window );">Recognized stock-based consulting fees (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 107,970<span></span>
</td>
<td class="nump">$ 107,970<span></span>
</td>
<td class="nump">$ 578,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other current assets (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">107,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Redemption value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_DeemedDividend', window );">Deemed dividend (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (197,682)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ConvertibleLongTermNotesPayables', window );">Convertible promissory notes (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_WarrantIssued', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Aggregate number of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PurchaseAgreementsDescription', window );">Purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On February 9, 2021, the Company entered into
pursuant to securities purchase agreements with certain investors pursuant to which it sold warrants to purchase up to 285,066 shares
of the Company&#8217;s common stock and 4,276 shares of the Company&#8217;s Series C Convertible preferred stock. The February Warrants
are exercisable for a period of five years from the date of issuance at an exercise price of $15.00 per share, subject to adjustment.
If, after a period of 180 days after the date of issuance of the February Warrants, a registration statement covering the resale of the
February Warrant Shares is not effective, the holders may exercise the February Warrants by means of a cashless exercise. In addition,
pursuant to the terms of the offering, the Company issued the Placement Agent Warrants to purchase up to an aggregate of 57,013 shares
of common stock to its placement agents, or 10% of the shares of common stock issuable upon conversion of the Series C preferred stock
and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing
date of the offering at an exercise price of $17.50 per share, subject to adjustment (see Series C Convertible Preferred Stock Financing
above). Such warrants issued to various investors and to the placement agents were recorded as additional paid in capital with an offsetting
debit applied against additional paid in capital, thus these warrants have no further accounting effect within the equity section.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,020,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_InvestorInvestedAmountPercentage', window );">Subsequent financing, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Expired term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 26,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Employment agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Kou, exercisable at $10.00
per share and expires on January 31, 2032. The stock options vest as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests
on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense', window );">Deferred compensation balance (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_WarrantsTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Common stock, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company issued 82,500 shares of common stock which was more than the shares that would have been issued at the original
conversion price of $4.00 per share or 33,000 shares of common stock, an excess of 49,500 shares of common stock. The excess shares were
valued at a price of $4.00 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Granted warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommonStockServiceDescription', window );">Warrant, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The warrants were valued on the grant
date at approximately $16.50 per warrant for a total of $83,728 using a Black-Scholes option pricing model with the following assumptions:
stock price of $17.50 per share (based on the quoted trading price on the date of grant), volatility of 169%, expected term of five year,
and a risk-free interest rate of 0.46%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based Compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Grant date price per warrant (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Warrant value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=silo_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AggregateGrantDateFairValueOfPlacementAgentWarrants', window );">Aggregate grant date fair value of placement agent warrants (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,106,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Authorized number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Authorized number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_TypesOfAgreementsAxis=silo_SubscriptionAgreementsMember', window );">Subscription Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable', window );">Subscription receivable (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_TypesOfAgreementsAxis=silo_SecuritiesPurchaseAgreementsMember', window );">Securities Purchase Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,399,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PlacementAgentFees', window );">Placement agent fees (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 242,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOwnershipInterestsOfferingCosts', window );">Other offering expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Total net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,038,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_TypesOfAgreementsAxis=silo_AdvisoryAgreementsMember', window );">Advisory Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 409,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_TypesOfAgreementsAxis=silo_ConsultingAgreementMember', window );">Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 277,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_TypesOfAgreementsAxis=silo_EmploymentAgreementMember', window );">Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 610,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AmortizationOfPrepaidStockbasedExpense', window );">Recognized stock-based consulting fees (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">610,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_TypesOfAgreementsAxis=silo_ExchangeAgreementsMember', window );">Exchange Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Common stock, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On April 15, 2020, the Company entered into
Exchange Agreements with the holders of certain convertible promissory notes. Pursuant to these Exchange Agreements, the holders agreed
to exchange their convertible promissory notes of $330,000 and 33,000 warrants issued in connection with this debt for an aggregate of
82,500 shares of the Company&#8217;s common stock at a price of $4.00 per share. Consequently, the Company recorded a loss on debt extinguishment
of $198,000 during the year ended December 31, 2020.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Share outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Redemption value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Designated shares of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred stock conversion, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On April 15, 2020, the Company entered into
Exchange Agreements with the holders of its Series B Preferred Stock whereby the holders agreed to exchange their 115 shares of Series
B Preferred Stock with a stated value of $115,000 and 11,500 warrants issued in connection with the Series B Preferred Stock for an aggregate
of 28,750 shares of the Company&#8217;s common stock at a price of $4.00 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Share outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Designated shares of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,280<span></span>
</td>
<td class="nump">4,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ConvertablePreferredStock', window );">Converted preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Convertible common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Share outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=silo_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares', window );">Convertible preferred stock stated value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PreferredStockOutstandingDescription', window );">Preferred stock outstanding, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A holder of Series C Convertible Preferred Stock may not convert any portion of the Series C Convertible Preferred Stock to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, upon election by a holder prior to issuance, 9.99%) of the outstanding shares of the Company&#8217;s common stock after conversion, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Share outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PurchaseAgreementsDescription', window );">Purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On February 9, 2021, the Company entered into
pursuant to securities purchase agreements with certain investors pursuant to which it sold warrants to purchase up to 285,067 shares
of the Company&#8217;s common stock and 4,276 shares of the Company&#8217;s Series C Convertible Preferred Stock. The February Warrants
are exercisable for a period of five years from the date of issuance at an exercise price of $15.00 per share, subject to adjustment.
If, after a period of 180 days after the date of issuance of the February Warrants, a registration statement covering the resale of the
February Warrant Shares is not effective, the holders may exercise the February Warrants by means of a cashless exercise. In addition,
pursuant to the terms of the offering, the Company issued the Placement Agent Warrants to purchase up to an aggregate of 57,013 shares
of common stock to its placement agents, or 10% of the shares of common stock issuable upon conversion of the Series C Preferred Stock
and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing
date of the offering at an exercise price of $17.50 per share, subject to adjustment (see Series C Convertible Preferred Stock Financing
above). Such warrants issued to various investors and to the placement agents were recorded as additional paid in capital with an offsetting
debit applied against additional paid in capital, thus these warrants have no further accounting effect within the equity section.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Designated shares of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PreferredStockStatedValue', window );">Preferred stock, stated value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Convertible preferred stock, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A holder of Series C Convertible preferred stock may not convert any portion of the Series C Convertible preferred stock to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, upon election by a holder prior to issuance, 9.99%) of the outstanding shares of the Company&#8217;s common stock after conversion, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Deemed dividend (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,403,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=silo_SeriesCConversionPriceMember', window );">Series C Conversion Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=silo_SeriesCPurchaseAgreementsMember', window );">Series C Purchase Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred stock conversion, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On February 9, 2021 (the &#8220;Effectiveness
Date&#8221;), the Company entered into securities purchase agreements (collectively, the &#8220;Series C Purchase Agreements&#8221;)
with certain institutional and accredited investors for the sale of an aggregate of 4,276 shares of the Company&#8217;s Series C Convertible
Preferred Stock and warrants (the &#8220;February Warrants&#8221;) to purchase up to 285,066 shares (the &#8220;February Warrant Shares&#8221;)
of the Company&#8217;s common stock for gross proceeds of approximately $4,276,000, before deducting placement agent and other offering
expenses of $481,898 which are offset against the proceeds in additional paid in capital. The offering closed on February 12, 2021. Accordingly,
the Company recognized a total deemed dividend of $1,403,997 for the beneficial conversion feature in connection with the issuance of
these Series C Convertible Preferred Stock.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SubsequentFinancingPercentage', window );">Subsequent financing, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 481,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board Granted [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Aggregate of incentive stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Fair value of unvested stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Fair value of the unvested stock options (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent', window );">Issuance of deferred compensation balance (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silo_OmnibusEquityIncentivePlanMember', window );">Omnibus Equity incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved and avail for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silo_IncentiveStockOptionMember', window );">Incentive Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.18%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Fair value of the unvested stock options (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock option (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based Compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AggregateGrantDateFairValueOfPlacementAgentWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate grant date fair value of placement agent warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AggregateGrantDateFairValueOfPlacementAgentWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AmortizationOfPrepaidStockbasedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AmortizationOfPrepaidStockbasedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommonStockServiceDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock service, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommonStockServiceDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ConvertablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ConvertablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ConvertibleLongTermNotesPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible long term notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ConvertibleLongTermNotesPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ExchangeAgreementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The company entered into exchange agreements description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ExchangeAgreementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_InvestorInvestedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The investor invested amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_InvestorInvestedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_InvestorInvestedAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_InvestorInvestedAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PlacementAgentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Placement agent fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PlacementAgentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PlacementAgentWarrantsDescriptoin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PlacementAgentWarrantsDescriptoin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PreferredStockOutstandingDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PreferredStockOutstandingDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PreferredStockStatedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of preferred stock stated value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PreferredStockStatedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PurchaseAgreementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase agreement, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PurchaseAgreementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_StockholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_StockholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SubsequentFinancingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsequent financing, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SubsequentFinancingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_TotalSubscriptionReceivableValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of subsription receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_TotalSubscriptionReceivableValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_WarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_WarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_WarrantsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_WarrantsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionContractorLiquidityCharacteristic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of liquidity characteristic of construction contractor's asset and liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 910<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126937589&amp;loc=SL119991581-234733<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionContractorLiquidityCharacteristic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of conversion terms for preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20015-108363<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of excess stock shares permitted to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the liabilities, classified as other, for deferred compensation arrangements payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOwnershipInterestsOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of offering costs allocated to the other unit holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB TOPIC 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOwnershipInterestsOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=silo_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=silo_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_TypesOfAgreementsAxis=silo_SubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_TypesOfAgreementsAxis=silo_SubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_TypesOfAgreementsAxis=silo_SecuritiesPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_TypesOfAgreementsAxis=silo_SecuritiesPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_TypesOfAgreementsAxis=silo_AdvisoryAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_TypesOfAgreementsAxis=silo_AdvisoryAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_TypesOfAgreementsAxis=silo_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_TypesOfAgreementsAxis=silo_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_TypesOfAgreementsAxis=silo_EmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_TypesOfAgreementsAxis=silo_EmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_TypesOfAgreementsAxis=silo_ExchangeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_TypesOfAgreementsAxis=silo_ExchangeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=silo_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=silo_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=silo_SeriesCConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=silo_SeriesCConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=silo_SeriesCPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=silo_SeriesCPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silo_OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silo_OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silo_IncentiveStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silo_IncentiveStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336824666832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - Schedule of stock options activities - Stock Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems', window );"><strong>Stockholders&#8217; Equity (Details) - Schedule of stock options activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options, balance beginning</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices', window );">Weighted Average Exercise Price, balance beginning</a></td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="nump">$ 0.005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years), balance beginning</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, balance beginning</a></td>
<td class="nump">$ 42,870<span></span>
</td>
<td class="nump">$ 127,290<span></span>
</td>
<td class="nump">$ 104,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Granted/Issued/ Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted/Issued/ Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_WeightedAverageRemainingContractualTermYearsGrantedissued', window );">Weighted Average Remaining Contractual Term (Years), Granted/Issued/ Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AggregateIntrinsicValueGrantedIssuedForfeited1', window );">Aggregate Intrinsic Value, Granted/Issued/ Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options, balance ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices', window );">Weighted Average Exercise Price, balance ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="nump">$ 0.005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), balance ending</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, balance ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,870<span></span>
</td>
<td class="nump">$ 127,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable,</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 6,030<span></span>
</td>
<td class="nump">$ 42,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AggregateIntrinsicValueGrantedIssuedForfeited1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AggregateIntrinsicValueGrantedIssuedForfeited1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_WeightedAverageRemainingContractualTermYearsGrantedissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards in granted/issued/ forfeited 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_WeightedAverageRemainingContractualTermYearsGrantedissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=silo_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=silo_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336821475216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - Schedule of warrant activities - Warrants [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NumberOfWarrant', window );">Number of Warrants, beginning balance</a></td>
<td class="nump">347,080<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">44,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, beginning balance</a></td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years), beginning balance</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 337,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedComponsationNumberOfWarrantsForfeited', window );">Number of Warrants, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited', window );">Weighted Average Remaining Contractual Term (Years), Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate Intrinsic Value, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NumberOfWarrant', window );">Number of Warrants, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,080<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), ending balance</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">4 years 1 month 13 days<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars', window );">Number of Warrants, Exercisable</a></td>
<td class="nump">347,080<span></span>
</td>
<td class="nump">347,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable', window );">Weighted Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">4 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedComponsationNumberOfWarrantsGranted', window );">Number of Warrants, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted', window );">Weighted Average Remaining Contractual Term (Years), Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">4 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AggregateIntrinsicValueGranted', window );">Aggregate Intrinsic Value, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AggregateIntrinsicValueGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AggregateIntrinsicValueGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NumberOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NumberOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of option outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock warrants outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedComponsationNumberOfWarrantsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under warrants that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedComponsationNumberOfWarrantsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedComponsationNumberOfWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share warrants (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedComponsationNumberOfWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for forfeited, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336824942240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VentureCapitalGainsLossesNet', window );">Company had a capital</a></td>
<td class="nump">$ 6,660,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NetCapitalLossCarryForward', window );">Net capital loss carryforward</a></td>
<td class="nump">450,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_GainLossOnSaleOfCapitalLeaseNet', window );">GainLossOnSaleOfCapitalLeasesNet</a></td>
<td class="nump">6,209,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AggregateEstimatedNetOperatingLoss', window );">Aggregate estimated net operating loss</a></td>
<td class="nump">$ 5,990,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_DescriptionOfIncomeTaxDescription', window );">Description of Income Tax Description</a></td>
<td class="text">The net loss carryforward up until 2017 in the amount of $470,204, will expire in 2037. Net loss carryforwards in the
amount of $5,520,104 from 2018 onwards can be carried over indefinitely, subject to annual usage limits.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange', window );">Valuation allowance on deferred tax asset benefit, description</a></td>
<td class="text">Accordingly, the Company has provided a 100% valuation allowance on the deferred tax asset benefit related
to the U.S. net operating loss and capital loss carry forwards to reduce the asset to zero.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AggregateEstimatedNetOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AggregateEstimatedNetOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_DescriptionOfIncomeTaxDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_DescriptionOfIncomeTaxDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_GainLossOnSaleOfCapitalLeaseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net gain (loss) arising from the lessor's transactions involving the sale, transfer, or termination of financing agreements classified as capital lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_GainLossOnSaleOfCapitalLeaseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NetCapitalLossCarryForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NetCapitalLossCarryForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of and reason for the change during the period in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VentureCapitalGainsLossesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on venture capital activities. Includes venture capital revenue, fair value adjustments, interest and dividends, investment gain (loss) and fee or other income from venture capital activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VentureCapitalGainsLossesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336828022000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of effective statutory rate and the provision for income taxes - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract', window );"><strong>Schedule Of Effective Statutory Rate And The Provision For Income Taxes Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax (benefit) liability at U.S. statutory rate of 21%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 819,786<span></span>
</td>
<td class="num">$ (637,879)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">Income tax (benefit) liability &#8211; state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,743<span></span>
</td>
<td class="num">(197,439)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain', window );">Permanent differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,893)<span></span>
</td>
<td class="nump">457,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,027,760)<span></span>
</td>
<td class="nump">377,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 24,876<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain before deducting unrealized loss on investment in equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336828269712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of effective statutory rate and the provision for income taxes (Parentheticals)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract', window );"><strong>Schedule Of Effective Statutory Rate And The Provision For Income Taxes Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336819574480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of net deferred tax asset - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfNetDeferredTaxAssetAbstract', window );"><strong>Schedule Of Net Deferred Tax Asset Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,647,335<span></span>
</td>
<td class="nump">$ 868,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_DeferredTaxAssetsCapitalLossCarryforward', window );">Net capital loss carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,707,701)<span></span>
</td>
<td class="nump">123,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_DeferredTaxAssetGross', window );">Total deferred tax asset (liability) before valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,366)<span></span>
</td>
<td class="nump">992,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_DeferredTaxAssetsValuationAllowances', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,490<span></span>
</td>
<td class="num">(992,271)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,876<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_DeferredTaxAssetGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_DeferredTaxAssetGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_DeferredTaxAssetsCapitalLossCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowance of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_DeferredTaxAssetsCapitalLossCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_DeferredTaxAssetsValuationAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_DeferredTaxAssetsValuationAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfNetDeferredTaxAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfNetDeferredTaxAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336820960432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=silo_OneLicenseeMember', window );">One Licensee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ConcentrationsRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ConcentrationsRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | One Licensee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ConcentrationsRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=silo_VendorConcentrationsMember', window );">Vendor Concentrations [Member] | One Licensor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ConcentrationsRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ConcentrationsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ConcentrationsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ConcentrationsRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration risk percentage 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ConcentrationsRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=silo_OneLicenseeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=silo_OneLicenseeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=silo_VendorConcentrationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=silo_VendorConcentrationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=silo_OneLicensorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=silo_OneLicensorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336816780416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 06, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 12, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 05, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 27, 2022</div></th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 17, 2020</div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_EmploymentAgreementDescription', window );">Employment agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Employment Agreement provided for a
base salary of $120,000 and 152,619 of vested shares of the Company&#8217;s common stock in April 2020. In addition, Mr. Weisblum shall
be eligible to earn a bonus, subject to the sole discretion of the Company&#8217;s Board of Directors (&#8220;Board&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_LicenseFee', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommercialSaleTerm', window );">Commercial sale term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_LicenseAgreementExpire', window );">License agreement expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SublicenseIncomeDescription', window );">Sublicense income, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company or Company affiliates
shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company&#8217;s sublicense income
which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first
licensed product; and (b) 15% of the Company&#8217;s sublicense income which is receivable with respect to any sublicense that is executed
after the filing of an NDA (or foreign equivalent) for the first licensed product.<span></span>
</td>
<td class="text">The Company or Company affiliates
shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company&#8217;s sublicense income
which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first
licensed product; and (b) 15% of the Company&#8217;s sublicense income which is receivable with respect to any sublicense that is executed
after the filing of an NDA (or foreign equivalent) for the first licensed product.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_LicenseAgreementDescription', window );">License agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty
payments depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company shall
pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the effective date; and (b)
$50,000 on or before the first anniversary of the effective date. The license fee is non-refundable and is not creditable against any
other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing,
prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid $25,000 license fee on
February 17, 2021 which was recorded as prepaid expense and is being amortized over the 15-year term. The Company recognized amortization
expense of $4,375 in 2021. During the six months ended June 30, 2022, the Company recognized amortization expense of $2,500. At December
31, 2021, prepaid expense and other current assets &#8211; current amounted $5,000 and prepaid expense &#8211; non-current amounts $15,625.
At June 30, 2022, prepaid expense and other current assets &#8211; current amounted $5,000 and prepaid expense &#8211; non-current amounts
$13,125 as reflected in the accompanying condensed consolidated balance sheets.<span></span>
</td>
<td class="text">the Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty
payments depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company shall
pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the effective date; and (b)
$50,000 on or before the first anniversary of the effective date. The license fee is non-refundable and is not creditable against any
other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing,
prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid $25,000 license fee on
February 17, 2021 which was recorded as prepaid expense and is being amortized over the 15-year term. The Company recognized amortization
expense of $4,375 during the year ended December 31, 2021. At December 31, 2021, prepaid expense and other current assets &#8211; current
amounted $5,000 and prepaid expense &#8211; non-current amounts $15,625 as reflected in the accompanying consolidated balance sheets.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_RoyaltyPaymentsDescription', window );">Royalty payments, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Royalty Payments Terms:&#160;&#160;(i)3% on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and&#160;&#160;&#160;&#160;(ii)5% on sales of licensed products during the applicable calendar year for sales greater than $50,000,000; and<span></span>
</td>
<td class="text">(i)3% on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_OtherDepreciationsAndAmortization', window );">Recognized amortization expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PaymentOfSponsoredResearchAmount', window );">Payment of sponsored research amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PrepaidExpenses', window );">Prepaid expenses &#8211; non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NonrefundableCashPayment', window );">Non-refundable cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NetSalePercentage', window );">Net sale percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_LicensorShare', window );">Licensor share (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AggregateOfConvertedShares', window );">Aggregate of converted shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_RevenueTerm', window );">Revenue term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NumberOfVotingShares', window );">Number of voting shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ReverseStockSplitVoteDescription', window );">Reverse stock split vote, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition, each share of the Series M Convertible Preferred Stock shall be convertible, at any time after the earlier of (i) the date
that the Reverse Stock Split Vote is approved by Aikido&#8217;s stockholders and (ii) December 31, 2021, at the option of the holder,
into such number of shares of Aikido&#8217;s common stock determined by dividing the Stated Value by the Conversion Price. &#8220;Stated
Value&#8221; means $1,000. &#8220;Conversion Price&#8221; means $0.80, subject to adjustment.Prior to the April 12, 2021, issuance of the
common stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible
Preferred stock which was equivalent into Aikido&#8217;s 625,000 shares of common stock at a fair value of $0.85 per common share or
$531,250 based quoted trading price of Aikido&#8217;s common stock on the date of grant. The Company recorded an equity investment of
$531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license.<span></span>
</td>
<td class="text">In addition, each share of the Series M Convertible Preferred Stock shall be convertible, at any time after the earlier of (i)
the date that the Reverse Stock Split Vote is approved by Aikido&#8217;s stockholders and (ii) December 31, 2021, at the option of the
holder, into such number of shares of Aikido&#8217;s common stock determined by dividing the Stated Value by the Conversion Price. &#8220;Stated
Value&#8221; means $1,000. &#8220;Conversion Price&#8221; means $0.80, subject to adjustment.Prior to the April 12, 2021 issuance of the
common stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible
Preferred stock which was equivalent into Aikido&#8217;s 625,000 shares of common stock at a fair value of $0.85 per common share or
$531,250 based quoted trading price of Aikido&#8217;s common stock on the date of grant. The Company recorded an equity investment of
$531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,031,250<span></span>
</td>
<td class="nump">$ 1,031,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CashReceived', window );">Cash received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SecuritiesReceived', window );">Securities received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">531,250<span></span>
</td>
<td class="nump">531,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Recognized revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,375<span></span>
</td>
<td class="nump">68,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Recognized revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_DeferredRevenueLongtermPortion', window );">Revenue long term portion amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 859,375<span></span>
</td>
<td class="nump">$ 893,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ConsiderationFeePayablePercentage', window );">Consideration fee payable percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_UpfrontLicenseFees', window );">Upfront license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_FirstCommercialSale', window );">First commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AgreementShallExpire', window );">Agreement shall expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_RecognizedRevenues', window );">Recognized revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue &#8211; current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,102<span></span>
</td>
<td class="nump">72,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Deferred revenue long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeePayable', window );">Total fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 433,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PaymentDescription', window );">Payment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In December 2020, the Company paid the first
payment of $101,520 which was recorded to prepaid expense and other current assets &#8211; current of which approximately $22,318 was
amortized in fiscal 2020. In September 2021, the Company notified Maastricht University of Netherlands for an early termination of this
agreement. Maastricht University of Netherlands has not reached the second phase which is to obtain approval from ethical committee.
The Company has no further obligation after the termination. During the year ended December 31, 2021, the Company amortized the remaining
prepaid expense of $79,202.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SponsoredStudyAgreementDescription', window );">Sponsored study agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The total cost
under the Sponsored Study Agreement shall not exceed $81,474 which is payable in two equal installments of $40,737 upon execution of
the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. The Company
paid $40,737 on January 13, 2021 which was recorded in prepaid expense to be amortized over the nine-month period. Currently, the project
has not been completed due to the delays cause by the Covid-19 pandemic. During the year ended December 31, 2021, the Company fully amortized
the prepaid expense of $40,737.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SublicenseAmountPaid', window );">Sublicense amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 342,850<span></span>
</td>
<td class="nump">$ 342,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SponsoredResearchAgreementDescription', window );">Sponsored research agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company paid the first payment of $40,000 pursuant to the payment schedule
on the Sponsored Research Agreement on June 15, 2021, second payment of $40,000 on September 9, 2021 and $20,570 on November 18, 2021,
third payment of $60,570 on March 1, 2022, which were recorded to prepaid expense and other current assets &#8211; current to be amortized
over the two-year period. In 2021, the Company amortized $92,855 of the prepaid expense. During the six months ended June 30, 2022, the
Company amortized $68,285 of the prepaid expense leaving a prepaid asset of $0 at June 30, 2022.<span></span>
</td>
<td class="text">The Company paid the first payment of $40,000 pursuant to the payment schedule
on the Sponsored Research Agreement on June 15, 2021, second payment of $40,000 on September 9, 2021 and $20,570 on November 18, 2021
which were recorded to prepaid expense and other current assets &#8211; current to be amortized over the two-year period. During the
year ended December 31, 2021, the Company amortized $92,855 of the prepaid expense leaving a prepaid asset of $7,715 at December 31,
2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense leaving a prepaid asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 241,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,939<span></span>
</td>
<td class="nump">$ 145,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CompanyPaidCash', window );">Company paid cash</a></td>
<td class="nump">$ 92,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PaymentOfUniversity', window );">Payment of university</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense', window );">Deferred compensation balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expense and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="nump">$ 838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseOtherNoncurrent', window );">Prepaid expenses non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,615<span></span>
</td>
<td class="nump">11,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerRefundableFeesProceeds', window );">Non refundable fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecognitionOfDeferredRevenue', window );">Deferred revenue current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,750<span></span>
</td>
<td class="nump">68,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_DeferredRevenueLongtermPortionAmounted', window );">Deferred revenue long-term portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,458<span></span>
</td>
<td class="nump">$ 893,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear', window );">Company paid second payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AgreementDescription', window );">Agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In 2021, the Company paid $5,000 related to this agreement. During the six months ended June 30, 2022, the Company
paid $10,000 related to this agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation', window );">Salary was increased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation', window );">Salary was increased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_TypeOfAgreementAxis=silo_SublicenseAgreementMember', window );">Sublicense Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SublicenseIncomePercentage', window );">Sublicense income, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SublicenseAgreementAmountPaid', window );">Sublicense agreement amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_OtherDepreciationsAndAmortization', window );">Recognized amortization expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_RecognizedRevenues', window );">Recognized revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,676<span></span>
</td>
<td class="nump">2,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue &#8211; current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecognitionOfDeferredRevenue', window );">Deferred revenue current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_ColumbiaUniversityMember', window );">Columbia University [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SponsoredResearchAgreementDescription', window );">Sponsored research agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">If the Company elects to exercise the
option, both parties will commence negotiation of a license agreement and will execute a license agreement no later than 3 months after
the dated of the exercise of the option. Columbia University and the Company will work towards developing a therapeutic treatment for
patients suffering from Alzheimer&#8217;s disease to post-traumatic stress disorder. During a one-year period from the date of this agreement,
the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the payment schedule
as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months after the start
of the project and, (iv)10% at completion of the project. The Company paid the first payment of $430,825 in November 2021 which was recorded
to prepaid expense and other current assets &#8211; current to be amortized over the estimated project timeline of twelve months. In
2021, the Company amortized $359,021 of the prepaid expense. During the six months ended June 30, 2022, the Company amortized the remaining
prepaid expense of $71,804. As of June 30, 2022 and December 31, 2021, prepaid expense related to the sponsored research agreement were
$0 and $71,804, respectively.<span></span>
</td>
<td class="text">If the Company elects to exercise the
option, both parties will commence negotiation of a license agreement and will execute a license agreement no later than 3 months after
the dated of the exercise of the option. Columbia University and the Company will work towards developing a therapeutic treatment for
patients suffering from Alzheimer&#8217;s disease to post-traumatic stress disorder. During a one-year period from the date of this agreement,
the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the payment schedule
as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months after the start
of the project and, (iv)10% at completion of the project. The Company paid the first payment of $430,825 in November 2021 which was recorded
to prepaid expense and other current assets &#8211; current to be amortized over the estimated project timeline of twelve months. During
the year ended December 31, 2021, the Company amortized $359,021 of the prepaid expense. As of December 31, 2021, prepaid expense related
to the sponsored research agreement was $71,804.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense leaving a prepaid asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_DrJamesKuoMember', window );">Dr. James Kuo [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_EmploymentAgreementDescription', window );">Employment agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">James
Kuo entered into an employment agreement (&#8220;Kuo Employment Agreement&#8221;) for Dr. Kuo to serve as the Vice President of Research
& Development. The Kuo Employment Agreement shall be effective as of the date of the agreement and shall automatically renew for
a period of one year at every anniversary of the effective date, with the same terms and conditions, unless either party provides written
notice of its intention not to extend the term of the Kuo Employment Agreement at least thirty days&#8217; prior to the applicable renewal
date. Dr. Kuo shall be paid an annual base salary of $30,000. For each twelve-month period of his employment, Dr. Kuo shall be entitled
to a bonus whereby amount and terms shall be in the sole and absolute discretion of the Board of Directors (&#8220;Board&#8221;) and
shall be payable at the Company&#8217;s sole option in stock or in cash. In addition, an aggregate of 16,000 incentive stock options
were granted under the 2020 Plan to Dr. Kou, exercisable at $10.00 per share and expires on January 31, 2032. The stock options vest
as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Stock option (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.18%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Fair value of the unvested stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense', window );">Deferred compensation balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_AikidoMember', window );">Aikido [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecognitionOfDeferredRevenue', window );">Deferred revenue current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_DeferredRevenueLongtermPortionAmounted', window );">Deferred revenue long-term portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silo_MasterLincenseAgreementMember', window );">Master License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_UpfrontLicenseFees', window );">Upfront license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silo_JVAgreementMember', window );">JV Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PursuantTerms', window );">Pursuant terms, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the terms of the JV Agreement,
(A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall
contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and
trade secrets with respect to its Z-pod&#8482; technology for the loading and release of ketamine, (3) ketamine to be used for clinical
purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the
interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be
owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event
shall either party own more than 60% of the interest in the Joint Venture.<span></span>
</td>
<td class="text">Pursuant to the terms of the JV Agreement,
(A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall
contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and
trade secrets with respect to its Z-pod&#8482; technology for the loading and release of ketamine, (3) ketamine to be used for clinical
purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the
interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be
owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event
shall either party own more than 60% of the interest in the Joint Venture.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AggregateOfConvertedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AggregateOfConvertedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AgreementShallExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AgreementShallExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommercialSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommercialSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommitmentsandContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommitmentsandContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CompanyPaidCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CompanyPaidCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ConsiderationFeePayablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ConsiderationFeePayablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_DeferredRevenueLongtermPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_DeferredRevenueLongtermPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_DeferredRevenueLongtermPortionAmounted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred revenue long-term portion amounted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_DeferredRevenueLongtermPortionAmounted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_EmploymentAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_EmploymentAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_FirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>First commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_FirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_LicenseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_LicenseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_LicenseAgreementExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_LicenseAgreementExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fee incurred and are directly related to generating license Expenses. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_LicensorShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_LicensorShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NetSalePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NetSalePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NonrefundableCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NonrefundableCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NumberOfVotingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NumberOfVotingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_OtherDepreciationsAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_OtherDepreciationsAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PaymentOfSponsoredResearchAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of sponsored research amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PaymentOfSponsoredResearchAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PaymentOfUniversity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PaymentOfUniversity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PursuantTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pursuant Terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PursuantTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_RecognizedRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_RecognizedRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_RevenueTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_RevenueTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ReverseStockSplitVoteDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ReverseStockSplitVoteDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_RoyaltyPaymentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_RoyaltyPaymentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SecuritiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SecuritiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SponsoredResearchAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SponsoredResearchAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SponsoredStudyAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SponsoredStudyAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SublicenseAgreementAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SublicenseAgreementAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SublicenseAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublicense amount paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SublicenseAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SublicenseIncomeDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SublicenseIncomeDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SublicenseIncomePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage sublicense income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SublicenseIncomePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_UpfrontLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_UpfrontLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundableFeesProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from customers for revenue related transactions that are refundable to the customers and do not meet the criteria for revenue recognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundableFeesProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20015-108363<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from insurance services, including net premiums earned, gain on sale of insurance block, agency management fees and insurance contract fees and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.1,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the unpaid portion of the fee payable to the managing member or general partner for management of the fund or trust.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseOtherNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseOtherNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecognitionOfDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecognitionOfDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recorded unconditional purchase obligation to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability for agreement to continue an employee's salary after termination of employment (but before retirement) including death, disability, or other event. For example, a company may agree to continue a disabled employee's salary for six months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense for depreciation and amortization of regulated operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_TypeOfAgreementAxis=silo_SublicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_TypeOfAgreementAxis=silo_SublicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_ColumbiaUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_ColumbiaUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_DrJamesKuoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_DrJamesKuoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_AikidoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_AikidoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silo_MasterLincenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silo_MasterLincenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silo_JVAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silo_JVAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336824457248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of milestone payments - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentOneMember', window );">Payment One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of milestone payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_Milestone', window );">Milestone</a></td>
<td class="text">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product<span></span>
</td>
<td class="text">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestonePayment', window );">Payment</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentTwoMember', window );">Payment Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of milestone payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_Milestone', window );">Milestone</a></td>
<td class="text">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product<span></span>
</td>
<td class="text">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestonePayment', window );">Payment</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentThreeMember', window );">Payment Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of milestone payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_Milestone', window );">Milestone</a></td>
<td class="text">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product<span></span>
</td>
<td class="text">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestonePayment', window );">Payment</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentFourMember', window );">Payment Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of milestone payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_Milestone', window );">Milestone</a></td>
<td class="text">Receipt of New Drug Application (&#8220;NDA&#8221;) (or foreign equivalent) approval for a Licensed Product<span></span>
</td>
<td class="text">Receipt of New Drug Application (&#8220;NDA&#8221;) (or foreign equivalent) approval for a Licensed Product<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestonePayment', window );">Payment</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentFiveMember', window );">Payment Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of milestone payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_Milestone', window );">Milestone</a></td>
<td class="text">Achievement of First Commercial Sale of Licensed Product<span></span>
</td>
<td class="text">Achievement of First Commercial Sale of Licensed Product<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestonePayment', window );">Payment</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_Milestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_Milestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336821303904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentOneMember', window );">Payment One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_UMBYearDescription', window );">Year</a></td>
<td class="text">Prior to First Commercial Sale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_UMBPayment', window );">Payment</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentTwoMember', window );">Payment Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_UMBYearDescription', window );">Year</a></td>
<td class="text">Year of First Commercial Sale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_UMBPayment', window );">Payment</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentThreeMember', window );">Payment Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_UMBYearDescription', window );">Year</a></td>
<td class="text">First calendar year following the First Commercial Sale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_UMBPayment', window );">Payment</a></td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentFourMember', window );">Payment Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_UMBYearDescription', window );">Year</a></td>
<td class="text">Second calendar year following the First Commercial Sale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_UMBPayment', window );">Payment</a></td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentFiveMember', window );">Payment Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_UMBYearDescription', window );">Year</a></td>
<td class="text">Third calendar year following the First Commercial Sale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_UMBPayment', window );">Payment</a></td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_UMBPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_UMBPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_UMBYearDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_UMBYearDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336815985216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of exclusive of value added tax to be amortized<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentOneMember', window );">Payment One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of exclusive of value added tax to be amortized [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_Payment', window );">Payment</a></td>
<td class="nump">$ 101,520<span></span>
</td>
<td class="nump">&#8364; 86,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PaymentDescription', window );">Payment description</a></td>
<td class="text">Upon signing the Study Agreement and was paid in December 2020<span></span>
</td>
<td class="text">Upon signing the Study Agreement and was paid in December 2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentTwoMember', window );">Payment Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of exclusive of value added tax to be amortized [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_Payment', window );">Payment</a></td>
<td class="nump">$ 101,520<span></span>
</td>
<td class="nump">&#8364; 86,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PaymentDescription', window );">Payment description</a></td>
<td class="text">Obtained approval from ethical committee<span></span>
</td>
<td class="text">Obtained approval from ethical committee<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentThreeMember', window );">Payment Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of exclusive of value added tax to be amortized [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_Payment', window );">Payment</a></td>
<td class="nump">$ 101,520<span></span>
</td>
<td class="nump">&#8364; 86,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PaymentDescription', window );">Payment description</a></td>
<td class="text">Data collection has commenced<span></span>
</td>
<td class="text">Data collection has commenced<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentFourMember', window );">Payment Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of exclusive of value added tax to be amortized [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_Payment', window );">Payment</a></td>
<td class="nump">$ 152,281<span></span>
</td>
<td class="nump">&#8364; 130,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PaymentDescription', window );">Payment description</a></td>
<td class="text">First half of the participants are tested<span></span>
</td>
<td class="text">First half of the participants are tested<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentFiveMember', window );">Payment Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of exclusive of value added tax to be amortized [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_Payment', window );">Payment</a></td>
<td class="nump">$ 50,760<span></span>
</td>
<td class="nump">&#8364; 43,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PaymentDescription', window );">Payment description</a></td>
<td class="text">Completion of data collection and delivery of final report<span></span>
</td>
<td class="text">Completion of data collection and delivery of final report<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_Payment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_Payment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336819766656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of shall pay UMB - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentSixMember', window );">Payment One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of shall pay UMB [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SponsoredPayment', window );">Payment</a></td>
<td class="nump">$ 92,095<span></span>
</td>
<td class="nump">$ 92,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PaymentDescription', window );">Payment description</a></td>
<td class="text">Upon execution of the July 2021 Sponsored Research Agreement<span></span>
</td>
<td class="text">Upon execution of the July 2021 Sponsored Research Agreement<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentSevenMember', window );">Payment Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of shall pay UMB [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SponsoredPayment', window );">Payment</a></td>
<td class="nump">$ 92,095<span></span>
</td>
<td class="nump">$ 92,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PaymentDescription', window );">Payment description</a></td>
<td class="text">Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement<span></span>
</td>
<td class="text">Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentEightMember', window );">Payment Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of shall pay UMB [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SponsoredPayment', window );">Payment</a></td>
<td class="nump">$ 92,095<span></span>
</td>
<td class="nump">$ 92,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PaymentDescription', window );">Payment description</a></td>
<td class="text">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement<span></span>
</td>
<td class="text">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SponsoredPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sponsored payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SponsoredPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336828272368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 11, 2022</div></th>
<th class="th"><div>Jan. 27, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_TotalOfSharesOfCommonStock', window );">Total shares of common stock</a></td>
<td class="nump">1,077,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">At the Special Meeting, the stockholders
approved granting discretionary authority to the Company&#8217;s Board of Directors to amend the Company&#8217;s Certificate of Incorporation
to effect one or more consolidations of the Company&#8217;s issued and outstanding shares of common stock, pursuant to which the shares
of common stock would be combined and reclassified into one share of common stock at a ratio within the range from 1-for-5 up to 1-for-50
(the &#8220;Reverse Stock Split&#8221;), provided that, (X) that the Company shall not effect Reverse Stock Splits that, in the aggregate,
exceeds 1-for-50, and (Y) any Reverse Stock Split is completed no later than the first anniversary of the record date of the Special
Meeting, or February 8, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_TypesOfAgreementAxis=silo_KuoEmploymentAgreementMember', window );">Kuo Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AnnualBaseSalary', window );">Annual salary amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent event, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">For each twelve-month period of his employment, Dr. Kuo shall be entitled
to a bonus whereby amount and terms shall be in the sole and absolute discretion of the Board of Directors (&#8220;Board&#8221;) and
shall be payable at the Company&#8217;s sole option in stock or in cash. In addition, an aggregate of 16,000 incentive stock options
was granted to Dr. Kou, at an exercise price equal to the closing price of the Company&#8217;s common stock on the date of grant (&#8220;ISOs&#8221;)
as follows: (i) 6,000 ISOs (&#8220;Initial Options&#8221;), issued under the Company&#8217;s 2020 Equity Incentive Plan (&#8220;2020
Plan&#8221;) which vest immediately, and (ii) an additional 10,000 ISOs (&#8220;Additional Options&#8221;), issued under the 2020 Plan
which shall vest ratably over two successive equal quarterly installments over the subsequent one year period as follows: 5,000 ISOs
shall vest at 9 months, and 12 months following the effective date of the Kuo Employment Agreement, which underlying Additional Options
shall be exercisable immediately upon the applicable vesting date.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AnnualBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual salary amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AnnualBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_TotalOfSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_TotalOfSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_TypesOfAgreementAxis=silo_KuoEmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_TypesOfAgreementAxis=silo_KuoEmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336819572272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive net loss per share</a></td>
<td class="nump">375,929<span></span>
</td>
<td class="nump">368,213<span></span>
</td>
<td class="nump">368,213<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive net loss per share</a></td>
<td class="nump">28,849<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive net loss per share</a></td>
<td class="nump">347,080<span></span>
</td>
<td class="nump">347,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive net loss per share</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15,133<span></span>
</td>
<td class="nump">15,133<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336824512656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_EquityInvestmentsAtFairValue', window );">Equity investments consisting of common stock, at fair value</a></td>
<td class="nump">$ 113,012<span></span>
</td>
<td class="nump">$ 419,995<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_EquityInvestmentsAtFairValue', window );">Equity investments consisting of common stock, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_EquityInvestmentsAtFairValue', window );">Equity investments consisting of common stock, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_EquityInvestmentsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_EquityInvestmentsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336824572000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of activity in the company&#8217;s equity investments, at fair value - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract', window );"><strong>Schedule Of Activity In The Company SEquity Investments At Fair Value Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities', window );">Beginning balance</a></td>
<td class="nump">$ 419,995<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AdditionsofEquitySecurities', window );">Additions</a></td>
<td class="nump">85,733<span></span>
</td>
<td class="nump">531,250<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales at original cost</a></td>
<td class="num">(171,407)<span></span>
</td>
<td class="num">(359,843)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized (loss) gain</a></td>
<td class="num">(221,309)<span></span>
</td>
<td class="nump">248,588<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities', window );">Ending balance</a></td>
<td class="nump">$ 113,012<span></span>
</td>
<td class="nump">$ 419,995<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AdditionsofEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions for equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AdditionsofEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of credit risk valuation adjustment to derivative liabilities to properly reflect the credit quality of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336827999984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of financial data of the company&#8217;s gain from sale of the NFID business<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">$ 58,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets</a></td>
<td class="nump">58,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_FinanceLeaseLiabilities', window );">Total liabilities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_NetAssetOfNFIDBusinessDisposed', window );">Net asset of NFID business disposed</a></td>
<td class="nump">58,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ConsiderationInTheFormOfANoteReceivable', window );">Consideration in the form of a note receivable</a></td>
<td class="num">(60,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain from sale of NFID business</a></td>
<td class="num">$ (1,553)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ConsiderationInTheFormOfANoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration in the form of a note receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ConsiderationInTheFormOfANoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_FinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_FinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_NetAssetOfNFIDBusinessDisposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net asset of NFID business disposed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_NetAssetOfNFIDBusinessDisposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336827978992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of operating result of discontinued operations of the NFID business - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract', window );"><strong>Schedule Of Operating Result Of Discontinued Operations Of The Nfid Business Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Product sales, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 80,305<span></span>
</td>
<td class="nump">$ 119,405<span></span>
</td>
<td class="nump">$ 40,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of sales</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">68,360<span></span>
</td>
<td class="nump">103,824<span></span>
</td>
<td class="nump">182,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss', window );">Gross profit (loss)</a></td>
<td class="num">(1,079)<span></span>
</td>
<td class="nump">11,945<span></span>
</td>
<td class="nump">15,581<span></span>
</td>
<td class="num">(141,503)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Total operating and other non-operating expenses</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(152,095)<span></span>
</td>
<td class="num">$ (270,501)<span></span>
</td>
<td class="num">$ (229,745)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Loss from discontinued operations</a></td>
<td class="num">$ (1,163)<span></span>
</td>
<td class="num">$ (140,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336801407792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Receivable (Details) - Schedule of notes receivable net - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ScheduleOfNotesReceivableNetAbstract', window );"><strong>Schedule Of Notes Receivable Net Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Principal amounts of notes receivable</a></td>
<td class="nump">$ 115,500<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AdditionalNotesReceivableIn2021', window );">Additional notes receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CollectionsOnNotesReceivables', window );">Collections on notes receivables</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="num">(164,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLosses', window );">Less: allowance for doubtful accounts</a></td>
<td class="num">(35,500)<span></span>
</td>
<td class="num">(55,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Total Notes receivable, net</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">23,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_LessNotesReceivableNetCurrentPortion', window );">Less: notes receivable, net &#8211; current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(23,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Notes receivable &#8211; non-current</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AdditionalNotesReceivableIn2021">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional notes receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AdditionalNotesReceivableIn2021</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CollectionsOnNotesReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CollectionsOnNotesReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_LessNotesReceivableNetCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_LessNotesReceivableNetCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ScheduleOfNotesReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ScheduleOfNotesReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (3)<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (c)<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 79<br> -URI https://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922352-210448<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 80<br> -URI https://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922355-210448<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (2)<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1404<br> -Paragraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336816682608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - Schedule of stock options activities - Stock Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems', window );"><strong>Stockholders&#8217; Equity (Details) - Schedule of stock options activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, beginning balance outstanding</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, balance beginning</a></td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years), balance beginning</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, balance beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted as incentives, Number of Options</a></td>
<td class="nump">6,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice', window );">Granted as incentives, Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears', window );">Granted as incentives, Weighted Average Remaining Contractual Term (Years)</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_GrantedAsIncentivesAggregateIntrinsicValue', window );">Granted as incentives, Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted pursuant to employment agreement, Number of Options</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted pursuant to employment agreement, Weighted Average Exercise Price</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Granted pursuant to employment agreement, Weighted Average Remaining Contractual Term (Years)</a></td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue', window );">Granted pursuant to employment agreement, Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (Years), Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue', window );">Aggregate Intrinsic Value, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, balance ending</a></td>
<td class="nump">28,849<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, balance ending</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), balance ending</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, balance ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable,</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 6,030<span></span>
</td>
<td class="nump">$ 42,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_GrantedAsIncentivesAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_GrantedAsIncentivesAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregated intrinsic value for forfeited shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards forfeited, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could acquire or could have acquired the underlying shares with respect to any other type of change in shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=silo_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=silo_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336821448624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - Schedule of warrant activities - Warrants [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, beginning balance</a></td>
<td class="nump">347,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, beginning balance</a></td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years), beginning balance</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 337,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted/Forfeited, Number of Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted/Forfeited, Weighted Average Exercise Price</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted', window );">Granted/Forfeited, Weighted Average Remaining Contractual Term (Years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">4 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_AggregateIntrinsicValueGranted', window );">Granted/Forfeited, Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, ending balance</a></td>
<td class="nump">347,080<span></span>
</td>
<td class="nump">347,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, ending balance</a></td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), ending balance</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">4 years 1 month 13 days<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars', window );">Number of Warrants, Exercisable</a></td>
<td class="nump">347,080<span></span>
</td>
<td class="nump">347,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable', window );">Weighted Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">4 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_AggregateIntrinsicValueGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_AggregateIntrinsicValueGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of option outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock warrants outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336816002464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of milestone payments - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentOneMember', window );">Payment One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of milestone payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_Milestone', window );">Milestone</a></td>
<td class="text">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product<span></span>
</td>
<td class="text">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestonePayment', window );">Payment</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentTwoMember', window );">Payment Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of milestone payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_Milestone', window );">Milestone</a></td>
<td class="text">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product<span></span>
</td>
<td class="text">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestonePayment', window );">Payment</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentThreeMember', window );">Payment Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of milestone payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_Milestone', window );">Milestone</a></td>
<td class="text">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product<span></span>
</td>
<td class="text">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestonePayment', window );">Payment</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentFourMember', window );">Payment Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of milestone payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_Milestone', window );">Milestone</a></td>
<td class="text">Receipt of New Drug Application (&#8220;NDA&#8221;) (or foreign equivalent) approval for a Licensed Product<span></span>
</td>
<td class="text">Receipt of New Drug Application (&#8220;NDA&#8221;) (or foreign equivalent) approval for a Licensed Product<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestonePayment', window );">Payment</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentFiveMember', window );">Payment Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of milestone payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_Milestone', window );">Milestone</a></td>
<td class="text">Achievement of First Commercial Sale of Licensed Product<span></span>
</td>
<td class="text">Achievement of First Commercial Sale of Licensed Product<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MilestonePayment', window );">Payment</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_Milestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_Milestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336824613312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentOneMember', window );">Payment One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_YearsDescription', window );">Years</a></td>
<td class="text">Prior to First Commercial Sale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MinimumAnnualRoyalty', window );">Minimum Annual Royalty</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentTwoMember', window );">Payment Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_YearsDescription', window );">Years</a></td>
<td class="text">Year of First Commercial Sale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MinimumAnnualRoyalty', window );">Minimum Annual Royalty</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentThreeMember', window );">Payment Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_YearsDescription', window );">Years</a></td>
<td class="text">First calendar year following the First Commercial Sale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MinimumAnnualRoyalty', window );">Minimum Annual Royalty</a></td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentFourMember', window );">Payment Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_YearsDescription', window );">Years</a></td>
<td class="text">Second calendar year following the First Commercial Sale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MinimumAnnualRoyalty', window );">Minimum Annual Royalty</a></td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=silo_PaymentFiveMember', window );">Payment Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_YearsDescription', window );">Years</a></td>
<td class="text">Third calendar year following the First Commercial Sale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_MinimumAnnualRoyalty', window );">Minimum Annual Royalty</a></td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_MinimumAnnualRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of minimum anual royalty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_MinimumAnnualRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_YearsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_YearsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=silo_PaymentFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=silo_PaymentFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140336801177136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of shall pay UMB - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentSixMember', window );">Payment One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of shall pay UMB [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SponsoredPayment', window );">Payment</a></td>
<td class="nump">$ 92,095<span></span>
</td>
<td class="nump">$ 92,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PaymentDescription', window );">Payment description</a></td>
<td class="text">Upon execution of the July 2021 Sponsored Research Agreement<span></span>
</td>
<td class="text">Upon execution of the July 2021 Sponsored Research Agreement<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentSevenMember', window );">Payment Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of shall pay UMB [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SponsoredPayment', window );">Payment</a></td>
<td class="nump">$ 92,095<span></span>
</td>
<td class="nump">$ 92,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PaymentDescription', window );">Payment description</a></td>
<td class="text">Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement<span></span>
</td>
<td class="text">Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentEightMember', window );">Payment Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems', window );"><strong>Commitments and Contingencies (Details) - Schedule of shall pay UMB [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_SponsoredPayment', window );">Payment</a></td>
<td class="nump">$ 92,095<span></span>
</td>
<td class="nump">$ 92,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_silo_PaymentDescription', window );">Payment description</a></td>
<td class="text">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement<span></span>
</td>
<td class="text">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_PaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_PaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silo_SponsoredPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sponsored payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silo_SponsoredPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=silo_PaymentEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>ea165987-s1a4_silopharma_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:silo="http://silopharma.com/20220630"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="silo-20220630.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2021-09-02</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silo:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silo:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DatChatIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:AikidoPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DatChatIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">silo:PromissoryNoteReceivableAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-28</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">silo:PromissoryNoteReceivableAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">silo:PromissoryNoteReceivableAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-02</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">silo:PromissoryNoteReceivableAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-02</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">silo:PromissoryNoteReceivableAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-02</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">silo:PromissoryNoteReceivableAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-02</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">silo:PromissoryNoteReceivableAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">silo:PromissoryNoteReceivableAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementAxis">silo:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-28</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementAxis">silo:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-02</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementAxis">silo:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-11-02</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementAxis">silo:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-07</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-01</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">silo:PaycheckProtectionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">silo:PaycheckProtectionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">silo:PaycheckProtectionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">silo:PaycheckProtectionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">silo:PaycheckProtectionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">silo:PaycheckProtectionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-10</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-10</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-04-30</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-09</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-15</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-09</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-09</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-14</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-18</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-09</startDate>
            <endDate>2020-04-18</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2020-04-18</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2020-07-06</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-28</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-28</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:AdvisoryAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-17</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:AdvisoryAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-17</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-17</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-04-15</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:ExchangeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-04-15</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementsAxis">silo:ExchangeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2021-01-18</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-04-15</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2020-04-15</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-04-15</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-18</instant>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-18</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">silo:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">silo:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">silo:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">silo:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">silo:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">silo:OneLicensorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">silo:VendorConcentrationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypeOfAgreementAxis">silo:SublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypeOfAgreementAxis">silo:SublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-06</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-12</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-05</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypeOfAgreementAxis">silo:SublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ColumbiaUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2021-08-25</startDate>
            <endDate>2021-09-01</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ColumbiaUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:JVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementAxis">silo:KuoEmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-24</startDate>
            <endDate>2022-01-27</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-02</startDate>
            <endDate>2022-03-11</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:HomeBistroIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:AikidoPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:AikidoPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">silo:PromissoryNoteReceivableAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-02</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementAxis">silo:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:LayawaySaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementAxis">silo:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypesOfAgreementAxis">silo:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-09</instant>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">silo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-09</endDate>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">silo:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-18</instant>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-29</endDate>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-29</instant>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-29</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2022-01-02</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:IncentiveStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2021-02-09</instant>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">silo:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">silo:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">silo:OneLicenseeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">silo:OneLicenseeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">silo:OneLicensorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">silo:VendorConcentrationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">silo:OneLicensorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">silo:VendorConcentrationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-27</endDate>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:DrJamesKuoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="silo:TypeOfAgreementAxis">silo:SublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:MasterLincenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:AikidoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <instant>2022-02-01</instant>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">silo:ColumbiaUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silo:JVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">silo:PaymentFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">silo:PaymentEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:AmendmentDescription contextRef="c0">AMENDMENT No. 4</dei:AmendmentDescription>
    <dei:EntityRegistrantName contextRef="c0">SILO PHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0">false</dei:EntityEmergingGrowthCompany>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="0" unitRef="usd">9837001</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" unitRef="usd">1128389</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <silo:EquityInvestmentsAtCost contextRef="c1" decimals="0" unitRef="usd">419995</silo:EquityInvestmentsAtCost>
    <silo:EquityInvestmentsAtCost contextRef="c2" decimals="0" unitRef="usd">200</silo:EquityInvestmentsAtCost>
    <us-gaap:ReceivablesNetCurrent contextRef="c2" decimals="0" unitRef="usd">23500</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c1" decimals="0" unitRef="usd">145324</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" unitRef="usd">241091</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c2" decimals="0" unitRef="usd">33484</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="0" unitRef="usd">10402320</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="0" unitRef="usd">1426664</us-gaap:AssetsCurrent>
    <us-gaap:InterestReceivableNoncurrent contextRef="c1" decimals="0" unitRef="usd">1210</us-gaap:InterestReceivableNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c1" decimals="0" unitRef="usd">61210</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c1" decimals="0" unitRef="usd">26659</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:Assets contextRef="c1" decimals="0" unitRef="usd">10490189</us-gaap:Assets>
    <us-gaap:Assets contextRef="c2" decimals="0" unitRef="usd">1426664</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c1" decimals="0" unitRef="usd">417937</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c2" decimals="0" unitRef="usd">127069</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c2" decimals="0" unitRef="usd">14654</us-gaap:NotesPayableCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c1" decimals="0" unitRef="usd">72102</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="0" unitRef="usd">490039</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="0" unitRef="usd">141723</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c1" decimals="0" unitRef="usd">937884</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:LongTermNotesPayable contextRef="c2" decimals="0" unitRef="usd">4246</us-gaap:LongTermNotesPayable>
    <us-gaap:LiabilitiesNoncurrent contextRef="c1" decimals="0" unitRef="usd">937884</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c2" decimals="0" unitRef="usd">4246</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c1" decimals="0" unitRef="usd">1427923</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c2" decimals="0" unitRef="usd">145969</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c1" decimals="4" unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c2" decimals="4" unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c1" decimals="0" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c3" decimals="4" unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c4" decimals="4" unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">2000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c4" decimals="0" unitRef="shares">2000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockRedemptionPricePerShare contextRef="c3" decimals="0" unitRef="usdPershares">1000</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare contextRef="c4" decimals="0" unitRef="usdPershares">1000</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c5" decimals="4" unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c6" decimals="4" unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c5" decimals="0" unitRef="shares">4280</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c6" decimals="0" unitRef="shares">4280</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c5" decimals="0" unitRef="shares">227</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c5" decimals="0" unitRef="shares">227</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockRedemptionPricePerShare contextRef="c5" decimals="0" unitRef="usdPershares">1000</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare contextRef="c6" decimals="0" unitRef="usdPershares">1000</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c1" decimals="4" unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c2" decimals="4" unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c1" decimals="0" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c1" decimals="0" unitRef="shares">1972739</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c1" decimals="0" unitRef="shares">1972739</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="0" unitRef="shares">1702839</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="0" unitRef="shares">1702839</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c1" decimals="0" unitRef="usd">197</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" unitRef="usd">170</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c1" decimals="0" unitRef="usd">12324646</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="0" unitRef="usd">7042846</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="0" unitRef="usd">-3262577</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="0" unitRef="usd">-5762321</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="0" unitRef="usd">9062266</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" unitRef="usd">1280695</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="0" unitRef="usd">10490189</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="0" unitRef="usd">1426664</us-gaap:LiabilitiesAndStockholdersEquity>
    <silo:LicenseFees contextRef="c10" decimals="0" unitRef="usd">71264</silo:LicenseFees>
    <us-gaap:CostOfRevenue contextRef="c10" decimals="0" unitRef="usd">5004</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c10" decimals="0" unitRef="usd">66260</us-gaap:GrossProfit>
    <us-gaap:ShareBasedCompensation contextRef="c10" decimals="0" unitRef="usd">395123</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c11" decimals="0" unitRef="usd">755993</us-gaap:ShareBasedCompensation>
    <us-gaap:ProfessionalFees contextRef="c10" decimals="0" unitRef="usd">1598367</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c11" decimals="0" unitRef="usd">1173717</us-gaap:ProfessionalFees>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c10" decimals="0" unitRef="usd">693910</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c11" decimals="0" unitRef="usd">26250</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralInsuranceExpense contextRef="c10" decimals="0" unitRef="usd">108750</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense contextRef="c11" decimals="0" unitRef="usd">30191</us-gaap:GeneralInsuranceExpense>
    <silo:BadDebtRecoveryExpense contextRef="c10" decimals="0" unitRef="usd">-148500</silo:BadDebtRecoveryExpense>
    <silo:BadDebtRecoveryExpense contextRef="c11" decimals="0" unitRef="usd">165376</silo:BadDebtRecoveryExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c10" decimals="0" unitRef="usd">162953</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c11" decimals="0" unitRef="usd">50192</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c10" decimals="0" unitRef="usd">2810603</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c11" decimals="0" unitRef="usd">2201719</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c10" decimals="0" unitRef="usd">-2744343</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c11" decimals="0" unitRef="usd">-2201719</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c10" decimals="0" unitRef="usd">1210</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c11" decimals="0" unitRef="usd">11543</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherIncome contextRef="c11" decimals="0" unitRef="usd">3000</us-gaap:OtherIncome>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c10" decimals="0" unitRef="usd">19082</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:InterestExpenseDebt contextRef="c10" decimals="0" unitRef="usd">3036</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c11" decimals="0" unitRef="usd">269043</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseRelatedParty contextRef="c11" decimals="0" unitRef="usd">224</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c11" decimals="0" unitRef="usd">-2950</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c11" decimals="0" unitRef="usd">-197682</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnInvestments contextRef="c10" decimals="0" unitRef="usd">6660483</us-gaap:GainLossOnInvestments>
    <silo:UnrealizedGainLossOnEquityInvestments contextRef="c10" decimals="0" unitRef="usd">248588</silo:UnrealizedGainLossOnEquityInvestments>
    <silo:UnrealizedGainLossOnEquityInvestments contextRef="c11" decimals="0" unitRef="usd">-9194</silo:UnrealizedGainLossOnEquityInvestments>
    <us-gaap:NonoperatingIncomeExpense contextRef="c10" decimals="0" unitRef="usd">6926327</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c11" decimals="0" unitRef="usd">-464550</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c10" decimals="0" unitRef="usd">4181984</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c11" decimals="0" unitRef="usd">-2666269</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c10" decimals="0" unitRef="usd">24876</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c10" decimals="0" unitRef="usd">4157108</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c11" decimals="0" unitRef="usd">-2666269</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax contextRef="c10" decimals="0" unitRef="usd">1553</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="c10" decimals="0" unitRef="usd">-254920</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="c11" decimals="0" unitRef="usd">-371248</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c10" decimals="0" unitRef="usd">-253367</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c11" decimals="0" unitRef="usd">-371248</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss contextRef="c10" decimals="0" unitRef="usd">3903741</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c11" decimals="0" unitRef="usd">-3037517</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="c10" decimals="0" unitRef="usd">1403997</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="c11" decimals="0" unitRef="usd">69000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c10" decimals="0" unitRef="usd">2499744</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c11" decimals="0" unitRef="usd">-3106517</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic contextRef="c10" decimals="2" unitRef="usdPershares">1.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c11" decimals="2" unitRef="usdPershares">-2.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare contextRef="c10" decimals="2" unitRef="usdPershares">-0.13</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare contextRef="c11" decimals="2" unitRef="usdPershares">-0.28</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c10" decimals="INF" unitRef="shares">1897315</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c11" decimals="INF" unitRef="shares">1319094</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding contextRef="c15" decimals="0" unitRef="shares">115</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="c17" decimals="0" unitRef="shares">472084</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="0" unitRef="usd">47</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="0" unitRef="usd">2632865</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="0" unitRef="usd">-2655804</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="0" unitRef="usd">-22892</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c23" decimals="0" unitRef="shares">755162</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c23" decimals="0" unitRef="usd">76</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c24" decimals="0" unitRef="usd">2115657</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c11" decimals="0" unitRef="usd">2115733</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <silo:CommonStockIssuedForFutureServicesShares contextRef="c23" decimals="0" unitRef="shares">171724</silo:CommonStockIssuedForFutureServicesShares>
    <silo:CommonStockIssuedForFutureServices contextRef="c23" decimals="0" unitRef="usd">17</silo:CommonStockIssuedForFutureServices>
    <silo:CommonStockIssuedForFutureServices contextRef="c24" decimals="0" unitRef="usd">686878</silo:CommonStockIssuedForFutureServices>
    <silo:CommonStockIssuedForFutureServices contextRef="c11" decimals="0" unitRef="usd">686895</silo:CommonStockIssuedForFutureServices>
    <silo:PreferredSharesExchangedForCommonStockShares contextRef="c21" decimals="0" unitRef="shares">-115</silo:PreferredSharesExchangedForCommonStockShares>
    <silo:PreferredSharesExchangedForCommonStockShares contextRef="c23" decimals="0" unitRef="shares">28750</silo:PreferredSharesExchangedForCommonStockShares>
    <silo:PreferredSharesExchangedForCommonStock contextRef="c23" decimals="0" unitRef="usd">3</silo:PreferredSharesExchangedForCommonStock>
    <silo:PreferredSharesExchangedForCommonStock contextRef="c24" decimals="0" unitRef="usd">-3</silo:PreferredSharesExchangedForCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan contextRef="c23" decimals="0" unitRef="shares">152619</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan contextRef="c23" decimals="0" unitRef="usd">15</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan contextRef="c24" decimals="0" unitRef="usd">610461</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan contextRef="c11" decimals="0" unitRef="usd">610476</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <silo:CommonStockIssuedForExchangeOfNotesShares contextRef="c23" decimals="0" unitRef="shares">82500</silo:CommonStockIssuedForExchangeOfNotesShares>
    <silo:CommonStockIssuedForExchangeOfNotes contextRef="c23" decimals="0" unitRef="usd">8</silo:CommonStockIssuedForExchangeOfNotes>
    <silo:CommonStockIssuedForExchangeOfNotes contextRef="c24" decimals="0" unitRef="usd">527992</silo:CommonStockIssuedForExchangeOfNotes>
    <silo:CommonStockIssuedForExchangeOfNotes contextRef="c11" decimals="0" unitRef="usd">528000</silo:CommonStockIssuedForExchangeOfNotes>
    <silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares contextRef="c23" decimals="0" unitRef="shares">40000</silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares>
    <silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock contextRef="c23" decimals="0" unitRef="usd">4</silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock>
    <silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock contextRef="c24" decimals="0" unitRef="usd">399996</silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock>
    <silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock contextRef="c11" decimals="0" unitRef="usd">400000</silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock>
    <silo:DeemedDividendOnPreferredStockExchange contextRef="c24" decimals="0" unitRef="usd">69000</silo:DeemedDividendOnPreferredStockExchange>
    <silo:DeemedDividendOnPreferredStockExchange contextRef="c25" decimals="0" unitRef="usd">-69000</silo:DeemedDividendOnPreferredStockExchange>
    <us-gaap:NetIncomeLoss contextRef="c25" decimals="0" unitRef="usd">-3037517</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c11" decimals="0" unitRef="usd">-3037517</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c28" decimals="0" unitRef="shares">1702839</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="0" unitRef="usd">170</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c29" decimals="0" unitRef="usd">7042846</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="0" unitRef="usd">-5762321</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" unitRef="usd">1280695</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c32" decimals="0" unitRef="shares">4276</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c34" decimals="0" unitRef="usd">3794102</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c10" decimals="0" unitRef="usd">3794102</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c34" decimals="0" unitRef="usd">1403997</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c35" decimals="0" unitRef="usd">-1403997</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c34" decimals="0" unitRef="usd">83728</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c10" decimals="0" unitRef="usd">83728</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <silo:IssuanceOfCommonSharesForConversionOfPreferredStockinShares contextRef="c32" decimals="0" unitRef="shares">-4049</silo:IssuanceOfCommonSharesForConversionOfPreferredStockinShares>
    <silo:IssuanceOfCommonSharesForConversionOfPreferredStockinShares contextRef="c33" decimals="0" unitRef="shares">269900</silo:IssuanceOfCommonSharesForConversionOfPreferredStockinShares>
    <silo:IssuanceOfCommonStockForConversionOfPreferredStock contextRef="c33" decimals="0" unitRef="usd">27</silo:IssuanceOfCommonStockForConversionOfPreferredStock>
    <silo:IssuanceOfCommonStockForConversionOfPreferredStock contextRef="c34" decimals="0" unitRef="usd">-27</silo:IssuanceOfCommonStockForConversionOfPreferredStock>
    <us-gaap:NetIncomeLoss contextRef="c35" decimals="0" unitRef="usd">3903741</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c10" decimals="0" unitRef="usd">3903741</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c37" decimals="0" unitRef="shares">227</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="c38" decimals="0" unitRef="shares">1972739</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c38" decimals="0" unitRef="usd">197</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c39" decimals="0" unitRef="usd">12324646</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c40" decimals="0" unitRef="usd">-3262577</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="0" unitRef="usd">9062266</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c10" decimals="0" unitRef="usd">3903741</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c11" decimals="0" unitRef="usd">-3037517</us-gaap:NetIncomeLoss>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c10" decimals="0" unitRef="usd">-148500</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c11" decimals="0" unitRef="usd">165376</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c10" decimals="0" unitRef="usd">83728</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c11" decimals="0" unitRef="usd">610476</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c11" decimals="0" unitRef="usd">268125</us-gaap:AmortizationOfDebtDiscountPremium>
    <silo:AmortizationOfPrepaidStockbasedExpense contextRef="c10" decimals="0" unitRef="usd">107970</silo:AmortizationOfPrepaidStockbasedExpense>
    <silo:AmortizationOfPrepaidStockbasedExpense contextRef="c11" decimals="0" unitRef="usd">578924</silo:AmortizationOfPrepaidStockbasedExpense>
    <us-gaap:InventoryWriteDown contextRef="c11" decimals="0" unitRef="usd">137947</us-gaap:InventoryWriteDown>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c10" decimals="0" unitRef="usd">6660483</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c10" decimals="0" unitRef="usd">248588</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c11" decimals="0" unitRef="usd">-9194</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="c10" decimals="0" unitRef="usd">19082</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c10" decimals="0" unitRef="usd">1553</us-gaap:GainLossOnDispositionOfAssets>
    <silo:LossFromDebtExtinguishment contextRef="c11" decimals="0" unitRef="usd">-197682</silo:LossFromDebtExtinguishment>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c10" decimals="0" unitRef="usd">38862</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c11" decimals="0" unitRef="usd">144663</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <silo:IncreaseDecreaseInAssetsOfDiscontinuedOperation contextRef="c10" decimals="0" unitRef="usd">-24963</silo:IncreaseDecreaseInAssetsOfDiscontinuedOperation>
    <silo:IncreaseDecreaseInAssetsOfDiscontinuedOperation contextRef="c11" decimals="0" unitRef="usd">-15065</silo:IncreaseDecreaseInAssetsOfDiscontinuedOperation>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="c10" decimals="0" unitRef="usd">1210</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c10" decimals="0" unitRef="usd">291050</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c11" decimals="0" unitRef="usd">72525</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c10" decimals="0" unitRef="usd">478736</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c10" decimals="0" unitRef="usd">-2278016</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c11" decimals="0" unitRef="usd">-1156996</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c10" decimals="0" unitRef="usd">7020526</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable contextRef="c10" decimals="0" unitRef="usd">7500</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <silo:CollectionOnNoteReceivable contextRef="c10" decimals="0" unitRef="usd">164500</silo:CollectionOnNoteReceivable>
    <silo:CollectionOnNoteReceivable contextRef="c11" decimals="0" unitRef="usd">39000</silo:CollectionOnNoteReceivable>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c10" decimals="0" unitRef="usd">7192526</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c11" decimals="0" unitRef="usd">39000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c11" decimals="0" unitRef="usd">35000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromNotesPayable contextRef="c11" decimals="0" unitRef="usd">18900</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c11" decimals="0" unitRef="usd">-35000</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c11" decimals="0" unitRef="usd">2115733</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="c10" decimals="0" unitRef="usd">3794102</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <silo:AdvanceFromARelatedParty contextRef="c10" decimals="0" unitRef="usd">2366</silo:AdvanceFromARelatedParty>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c10" decimals="0" unitRef="usd">2366</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c10" decimals="0" unitRef="usd">3794102</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c11" decimals="0" unitRef="usd">2134633</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c10" decimals="0" unitRef="usd">8708612</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c11" decimals="0" unitRef="usd">1016637</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" unitRef="usd">1128389</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c20" decimals="0" unitRef="usd">111752</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="0" unitRef="usd">9837001</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" unitRef="usd">1128389</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c11" decimals="0" unitRef="usd">224</us-gaap:InterestPaidNet>
    <silo:StockIssuedForFutureServices contextRef="c11" decimals="0" unitRef="usd">686895</silo:StockIssuedForFutureServices>
    <silo:CommonStockIssuedForPrepaidServices contextRef="c11" decimals="0" unitRef="usd">528000</silo:CommonStockIssuedForPrepaidServices>
    <silo:CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock contextRef="c11" decimals="0" unitRef="usd">400000</silo:CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock>
    <silo:IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree contextRef="c10" decimals="0" unitRef="usd">531250</silo:IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree>
    <silo:NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement contextRef="c10" decimals="0" unitRef="usd">60000</silo:NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 1 &#x2013; &lt;span style="text-decoration:underline"&gt;ORGANIZATION AND BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Silo Pharma, Inc. (formerly Uppercut Brands,
Inc.) (the &#x201c;Company&#x201d;) was incorporated in the State of New York on July 13, 2010 under the name Gold Swap, Inc. On January
24, 2013, the Company changed its state of incorporation from New York to Delaware.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is a developmental stage biopharmaceutical
company focused on merging traditional therapeutics with psychedelic research.&#160;The Company seeks to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. The Company is focused on merging traditional therapeutics with psychedelic research for people suffering from indications
such as depression, post-traumatic stress disorder (&#x201c;PTSD&#x201d;), Alzheimer&#x2019;s, Parkinson&#x2019;s, and other rare neurological
disorders. The Company&#x2019;s mission is to identify assets to license and fund the research which the Company&#x2019;s believes will
be transformative to the well-being of patients and the health care industry.&#160;The Company was engaged in the development of a streetwear
apparel brand, NFID (see below).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 4, 2013, the Company filed a Form
N-54A and elected to become a business development company (&#x201c;BDC&#x201d;) under the Investment Company Act of 1940, as amended (the
&#x201c;1940 Act&#x201d;). In addition, the Company previously elected to be treated for federal income tax purpose as a regulated investment
company, (&#x201c;RIC&#x201d;) under Subchapter M of the Internal Revenue Code of 1986, as amended, (the &#x201c;Code&#x201d;). Through September
29, 2018, the Company met the definition of RIC in accordance with the guidance under Accounting Standards Codification (&#x201c;ASC&#x201d;)
Topic 946 &#x201c;Financial Services &#x2013; Investment Companies&#x201d;. On September 29, 2018, the Company filed Form N-54C, Notification
of Withdrawal of Election to be Subject to Section 55 through 65 of the 1940 Act, as the Company changed the nature of its business so
as to cease to be a business development company (see Note 2 &#x2013; &lt;i&gt;Basis of Presentation&lt;/i&gt;). Additionally, since 2017, the Company
has been subject to income taxes at corporate tax rates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 21, 2019, the Company filed an amendment
to its Certificate of Incorporation with the State of Delaware to change its name from Point Capital, Inc. to Uppercut Brands, Inc. thereafter,
on September 24, 2020, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to change its name
from Uppercut Brands, Inc. to Silo Pharma, Inc.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 8, 2020, the Company incorporated
a new wholly-owned subsidiary, Silo Pharma Inc.,&#160;in the State of Florida. The Company has also secured the domain name &lt;i&gt;www.silopharma.com&lt;/i&gt;.
The Company has been exploring opportunities to expand the Company&#x2019;s business by seeking to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. In July 2020, through the Company&#x2019;s newly formed subsidiary, the Company entered into a commercial evaluation license
and option agreement with University of Maryland, Baltimore (&#x201c;UMB&#x201d;) (see Note 10) pursuant to which, among other things,
UMB granted the Company an exclusive, option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license to with respect
to certain technology. The option was extended and exercised on January 13, 2021. On February 12, 2021, the Company entered into a Master
License Agreement with UMB (see Note 10). The Company plans to actively pursue the acquisition and/or development of intellectual property
or technology rights to treat rare diseases, and to ultimately expand the Company&#x2019;s business to focus on this new line of business.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 30, 2021, the Company entered
into and closed on an Asset Purchase Agreement (&#x201c;Asset Purchase Agreement) with NFID, LLC, a Florida limited liability company
(&#x201c;Buyer&#x201d;), whereby the Buyer purchased from the Company certain assets, properties, and rights in connection with the Company&#x2019;s
NFID trademark name, logos, domain, and apparel clothing and accessories for a purchase price of $60,000 in the form of a promissory
note amounting to $60,000. The promissory note bears 8% interest per annum and matures on October 1, 2023. Accordingly, the results of
operations of this component, for all periods presented, are separately reported as &#x201c;discontinued operations&#x201d; on the accompanying
consolidated statements of operations (see Note 4).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On September 14, 2022, the Company filed a
Certificate of Amendment to the Amended and Restated Articles of Incorporation (the &#x201c;Certificate of Amendment&#x201d;) with the
Secretary of State of the State of Nevada to effect a 1-for-50 reverse stock split (the &#x201c;Reverse Stock Split&#x201d;) with respect
to the outstanding shares of the Company&#x2019;s common stock. The Certificate of Amendment became effective on September 14, 2022. The
Reverse Stock Split was previously approved by the sole director and the majority of stockholders of the Company. The Reverse Stock Split
was deemed effective at the open of business on September 15, 2022. All share and per share data in the accompanying consolidated financial
statements have been retroactively restated to reflect the effect of the reverse stock split.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:SupplementalDeferredPurchasePrice contextRef="c86" decimals="0" unitRef="usd">60000</us-gaap:SupplementalDeferredPurchasePrice>
    <silo:promissoryNoteAmount contextRef="c86" decimals="0" unitRef="usd">60000</silo:promissoryNoteAmount>
    <us-gaap:InvestmentInterestRate contextRef="c87" decimals="2" unitRef="pure">0.08</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentMaturityDate contextRef="c87">2023-10-01</us-gaap:InvestmentMaturityDate>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 2 &#x2013; &lt;span style="text-decoration:underline"&gt;SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Basis of Presentation and Principles of
Consolidation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S.
GAAP&#x201d;), the instructions to Form 10-K, and the rules and regulations of the United States Securities and Exchange Commission (the
&#x201c;SEC&#x201d;) for financial information. The Company&#x2019;s consolidated financial statements include financial statements for
Silo Pharma, Inc and its inactive wholly-owned subsidiary with the same name as the parent entity, Silo Pharma, Inc, as of December 31,
2021 and during the years ended December 31, 2021 and 2020. All intercompany transactions and balances have been eliminated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with, ASC 205-20 &#x201c;Discontinued
Operations&#x201d; establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should
be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity&#x2019;s
operations and financial results. As a result, the NFID, LLC component&#x2019;s results of operations have been classified as discontinued
operations on a retrospective basis for all periods presented. Accordingly, the results of operations of this component, for all periods,
are separately reported as &#x201c;discontinued operations&#x201d; on the consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Liquidity&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As reflected in the accompanying consolidated
financial statements, the Company generated a net income of $3,903,741 and used cash in operations of $2,278,016, for the year ended
December 31, 2021. Additionally, the Company has an accumulated deficit of $3,262,577 at December 31, 2021. During the year ended December
31, 2021, the Company has received gross proceeds of $7,020,526 from the sale of equity investments. As of December 31, 2021, the Company
had working capital of $9,912,281.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;These events served to mitigate the conditions
that historically raised substantial doubt about the Company&#x2019;s ability to continue as a going concern. The Company believes the
proceeds received during the year ended December 31, 2021 will provide sufficient cash flows to meet its obligations for a minimum of
twelve months from the date of this filing.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at
least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date
of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more
future events. Accordingly, the actual results could differ significantly from estimates. Significant estimates during the years ended
December 31, 2021 and 2020 include the collectability of notes receivable, the valuation of equity investments, estimates for obsolete
and slow-moving inventory, estimates of the deemed dividend, valuation allowances for deferred tax assets, the fair value of warrants
issued with debt and for services, and the fair value of shares issued for services and in settlements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers all highly liquid investments
with a maturity of three months or less when acquired to be cash equivalents. The Company places its cash with high credit quality financial
institutions. The Company&#x2019;s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;)
up to $250,000 and by the Securities Investor Protection Corporation (&#x201c;SIPC&#x201d;) up to $250,000. To reduce its risk associated
with the failure of such financial institutions, the Company evaluates, at least annually, the rating of the financial institutions in
which it holds deposits. At December 31, 2021 and 2020, the Company had cash in excess of FDIC and SIPC limits of approximately $9,100,000
and $880,000, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Notes Receivable&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes an allowance for losses
on notes receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical
bad debt experience, current note receivable aging, and expected future write-offs, as well as an assessment of specific identifiable
accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recognized as general
and administrative expense.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.65pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Prepaid expenses and other current assets
- current of $145,324 and $241,091 at December 31, 2021 and 2020, respectively, consist primarily of costs paid for future services which
will occur within a year. Prepaid expenses and other current assets &#x2013; non-current of $26,659 and $0 at December 31, 2021 and 2020,
respectively, consist primarily of costs paid for license fees and future services which will occur after a year. Prepaid expenses may
include prepayments in cash and equity instruments for consulting, business advisory, legal services, license fees, research and development
fees, and insurance which are being amortized over the terms of their respective agreements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Equity Investments, at Fair Value&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Realized gain or loss is recognized when an
investment is disposed of and is computed as the difference between the Company&#x2019;s carrying value and the net proceeds received
from such disposition.&#160;&#160;Realized gains and losses on investment transactions are determined by specific identification. Net
unrealized appreciation or depreciation is computed as the difference between the fair value of the investment and the cost basis of
such investment. Net unrealized gains or losses for equity investments are recognized in operations as the difference between the carrying
value at the beginning of the period and the fair value at the end of the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Equity Investments, at Cost&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Equity investments, at cost are comprised
mainly of non-marketable capital stock and stock warrants, are recorded at cost, as adjusted for other than temporary impairment write-downs
and are evaluated for impairment periodically.&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company applies ASC Topic 606, Revenue
from Contracts with Customers (&#x201c;ASC 606&#x201d;). ASC 606 establishes a single comprehensive model for entities to use in accounting
for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires
an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures.&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company records interest and dividend
income on an accrual basis to the extent that the Company expects to collect such amounts.&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the license and royalty income, revenue
is recognized when the Company satisfies the performance obligation based on the related license agreement. Payments received from the
licensee that are related to future periods are recorded as deferred revenue to be recognized as revenues over the term of the related
license agreement (see Note 10).&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Product sales were recognized when the NFID
products were shipped to the customer and title was transferred and were recorded net of any discounts or allowances which are separately
reported as &#x201c;discontinued operations&#x201d; on the consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Cost of Revenues&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.05pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The primary components of cost of revenues
on license fees included the cost of the license fees. Payments made to the licensor that are related to future periods are recorded
as prepaid expense to be amortized over the term of the related license agreement (see Note 10).&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The primary components of cost of revenues
on NFID apparel include the cost of the product, production costs, warehouse storage costs and shipping fees which are separately reported
as &#x201c;discontinued operations&#x201d; on the consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Stock-based compensation is accounted for
based on the requirements of ASC 718 &#x2013; &#x201c;Compensation &#x2013; Stock Compensation&#x201d;, which requires recognition in the
financial statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments
over the period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively,
the vesting period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange
for an award based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted
under Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-09 Improvements to Employee Share-Based Payment.&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred income tax assets and liabilities
arise from temporary differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted
tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current
or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities
not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences
are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to
be realized.&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company follows the provisions of Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 740-10, &#x201c;Uncertainty in Income Taxes&#x201d;. Certain recognition thresholds
must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax
positions that meet a &#x201c;more-likely-than-not&#x201d; threshold. The Company does not believe it has any uncertain tax positions as
of December 31, 2021 and 2020 that would require either recognition or disclosure in the accompanying consolidated financial statements.&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognized income tax expense
of $24,876 and $0 for the years ended December 31, 2021 and 2020 (see Note 8).&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 730-10, &#x201c;Research
and Development-Overall,&#x201d; research and development costs are expensed when incurred. During the years ended December 31, 2021 and
2020, research and development costs were $693,910 and $26,250, respectively.&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Net Income (Loss) per Common Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic net income (loss) per share is computed
by dividing net income (loss) allocable to common shareholders by the weighted average number of shares of common stock outstanding during
each period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted average number
of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period using the as-if
converted method. Potentially dilutive securities which include convertible preferred shares and stock options are excluded from the
computation of diluted shares outstanding if they would have an anti-dilutive impact on the Company&#x2019;s net income or (loss). The
following are the potentially dilutive shares for the years ended December 31, 2021 and 2020:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;&lt;span style="-keep: true"&gt;Series C convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="-keep: true"&gt;15,133&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-263"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;347,080&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-264"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;368,213&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table presents a reconciliation
of basic and diluted net loss per share:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;For the Years Ended&lt;br/&gt; December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="-keep: true"&gt;Income (loss) per common share &#x2014; basic:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="-keep: true"&gt;Income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;4,157,108&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;(2,666,269&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;Loss from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;(253,367&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;(371,248&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;3,903,741&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(3,037,517&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Weighted average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;1,897,315&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;1,319,094&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Net income (loss) per common share available to common stockholders&#x2013; basic:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="-keep: true"&gt;From continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;1.45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(2.07&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"&gt;&lt;span style="-keep: true"&gt;From discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(0.13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(0.28&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="-keep: true"&gt;Income (loss) per common share &#x2014; diluted:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;4,157,108&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;(2,666,269&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Add: interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;(3,036&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-265"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Numerator for loss from continuing operations per common share &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;4,154,072&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;(2,666,269&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;Numerator for loss from discontinuing operations per common share &#x2014;
    diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;(253,367&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;(371,248&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Net loss per common share &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;3,900,705&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(3,037,517&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Weighted average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;1,897,315&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;1,319,094&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 10pt"&gt;&lt;span style="-keep: true"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;5,996&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-266"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;span style="-keep: true"&gt;Preferred shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;15,133&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-267"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Weighted average common shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-268"&gt;&lt;span style="-keep: true"&gt;1,918,4448&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;1,319,094&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Net loss per common share available to common stockholders &#x2013; diluted:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"&gt;&lt;span style="-keep: true"&gt;From continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;1.43&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(2.07&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"&gt;&lt;span style="-keep: true"&gt;From discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(0.13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(0.28&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;The Company accounts
for its leases using the method prescribed by ASC 842 &#x2013; &lt;i&gt;Lease Accounting&lt;/i&gt;. The Company assess whether the contract is, or
contains, a lease at the inception of a contract which is based on (i) whether the contract involves the use of a distinct identified
asset, (ii) whether the Company obtain the right to substantially all the economic benefit from the use of the asset throughout the period,
and (iii) whether the Company has the right to direct the use of the asset. The Company allocates the consideration in the contract to
each lease component based on its relative stand-alone price to determine the lease payments. The Company has elected not to recognize
right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities for short-term leases that have a term of 12 months or less.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Operating lease ROU
assets represents the right to use the leased asset for the lease term. Operating lease liabilities are recognized based on the present
value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate,
the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value
of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included
in general and administrative expenses in the consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In August 2020, the FASB issued ASU 2020-06&#x2014;&lt;i&gt;Debt&#x2014;Debt
with Conversion and Other Options (Subtopic 470-20) and Derivatives and edging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic
815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU 2020-06&#x201d;)&lt;/i&gt; to simplify
the accounting for convertible instruments by removing certain separation models in Subtopic 470- 20, &lt;i&gt;Debt with Conversion and Other
Options&lt;/i&gt;, for convertible instruments. Under the amendments in ASU 2020-06, the embedded conversion features no longer are separated
from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives
under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently,
a convertible debt instrument will be accounted for as a single liability measured at its amortized cost and a convertible preferred
stock will be accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation
and recognition as derivatives. By removing those separation models, the interest rate of convertible debt instruments typically will
be closer to the coupon interest rate when applying the guidance in Topic 835, Interest. The amendments in ASU 2020-06 provide financial
statement users with a simpler and more consistent starting point to perform analyses across entities. The amendments also improve the
operability of the guidance and reduce, to a large extent, the complexities in the accounting for convertible instruments and the difficulties
with the interpretation and application of the relevant guidance. To further improve the decision usefulness and relevance of the information
being provided to users of financial statements, amendments in ASU 2020-06 increased information transparency by making the following
amendments to the disclosure for convertible instruments:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Add a disclosure objective&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Add information about
    events or conditions that occur during the reporting period that cause conversion contingencies to be met or conversion terms to
    be significantly changed&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Add information on which
    party controls the conversion rights&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Align disclosure requirements
    for contingently convertible instruments with disclosure requirements for other convertible instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Require that existing
    fair value disclosures in Topic 825, Financial Instruments, be provided at the individual convertible instrument level rather than
    in the aggregate.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Additionally, for convertible debt instruments
with substantial premiums accounted for as paid-in capital, amendments in ASU 2020-06 added disclosures about (1) the fair value amount
and the level of fair value hierarchy of the entire instrument for public business entities and (2) the premium amount recorded as paid-in
capital.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;The amendments in
ASU 2020-06 are effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the
SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities,
the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years.
Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those
fiscal years. Entities should adopt the guidance as of the beginning of its annual fiscal year and are allowed to adopt the guidance
through either a modified retrospective method of transition or a fully retrospective method of transition. In applying the modified
retrospective method, entities should apply the guidance to transactions outstanding as of the beginning of the fiscal year in which
the amendments are adopted. Transactions that were settled (or expired) during prior reporting periods are unaffected. The cumulative
effect of the change should be recognized as an adjustment to the opening balance of retained earnings at the date of adoption. If an
entity elects the fully retrospective method of transition, the cumulative effect of the change should be recognized as an adjustment
to the opening balance of retained earnings in the first comparative period presented. The Company is evaluating the impact of the revised
guidance and believes that it will not have a significant impact on its consolidated financial statements.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2021, the FASB issued ASU 2021-04,
Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718),
and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40). The new ASU addresses issuer&#x2019;s accounting
for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities,
for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted.
The Company is evaluating the impact of the revised guidance and believes that it will not have a significant impact on its consolidated
financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management does not believe that any other
recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company&#x2019;s consolidated
financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Basis of Presentation and Principles of
Consolidation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S.
GAAP&#x201d;), the instructions to Form 10-K, and the rules and regulations of the United States Securities and Exchange Commission (the
&#x201c;SEC&#x201d;) for financial information. The Company&#x2019;s consolidated financial statements include financial statements for
Silo Pharma, Inc and its inactive wholly-owned subsidiary with the same name as the parent entity, Silo Pharma, Inc, as of December 31,
2021 and during the years ended December 31, 2021 and 2020. All intercompany transactions and balances have been eliminated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with, ASC 205-20 &#x201c;Discontinued
Operations&#x201d; establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should
be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity&#x2019;s
operations and financial results. As a result, the NFID, LLC component&#x2019;s results of operations have been classified as discontinued
operations on a retrospective basis for all periods presented. Accordingly, the results of operations of this component, for all periods,
are separately reported as &#x201c;discontinued operations&#x201d; on the consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <silo:LiquidityPolicyTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Liquidity&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As reflected in the accompanying consolidated
financial statements, the Company generated a net income of $3,903,741 and used cash in operations of $2,278,016, for the year ended
December 31, 2021. Additionally, the Company has an accumulated deficit of $3,262,577 at December 31, 2021. During the year ended December
31, 2021, the Company has received gross proceeds of $7,020,526 from the sale of equity investments. As of December 31, 2021, the Company
had working capital of $9,912,281.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;These events served to mitigate the conditions
that historically raised substantial doubt about the Company&#x2019;s ability to continue as a going concern. The Company believes the
proceeds received during the year ended December 31, 2021 will provide sufficient cash flows to meet its obligations for a minimum of
twelve months from the date of this filing.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</silo:LiquidityPolicyTextBlock>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c10" decimals="0" unitRef="usd">3903741</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetCashProvidedByUsedInContinuingOperations contextRef="c10" decimals="0" unitRef="usd">2278016</us-gaap:NetCashProvidedByUsedInContinuingOperations>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="0" unitRef="usd">-3262577</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c10" decimals="0" unitRef="usd">7020526</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CapitalUnits contextRef="c1" decimals="0" unitRef="usd">9912281</us-gaap:CapitalUnits>
    <us-gaap:SharesIssued contextRef="c1" decimals="0" unitRef="shares">12</us-gaap:SharesIssued>
    <us-gaap:UseOfEstimates contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at
least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date
of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more
future events. Accordingly, the actual results could differ significantly from estimates. Significant estimates during the years ended
December 31, 2021 and 2020 include the collectability of notes receivable, the valuation of equity investments, estimates for obsolete
and slow-moving inventory, estimates of the deemed dividend, valuation allowances for deferred tax assets, the fair value of warrants
issued with debt and for services, and the fair value of shares issued for services and in settlements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers all highly liquid investments
with a maturity of three months or less when acquired to be cash equivalents. The Company places its cash with high credit quality financial
institutions. The Company&#x2019;s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;)
up to $250,000 and by the Securities Investor Protection Corporation (&#x201c;SIPC&#x201d;) up to $250,000. To reduce its risk associated
with the failure of such financial institutions, the Company evaluates, at least annually, the rating of the financial institutions in
which it holds deposits. At December 31, 2021 and 2020, the Company had cash in excess of FDIC and SIPC limits of approximately $9,100,000
and $880,000, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount contextRef="c1" decimals="0" unitRef="usd">250000</us-gaap:CashFDICInsuredAmount>
    <silo:CashSPICInsuredAmount contextRef="c1" decimals="0" unitRef="usd">250000</silo:CashSPICInsuredAmount>
    <us-gaap:FDICIndemnificationAssetCashPaymentsReceived contextRef="c10" decimals="0" unitRef="usd">9100000</us-gaap:FDICIndemnificationAssetCashPaymentsReceived>
    <us-gaap:FDICIndemnificationAssetCashPaymentsReceived contextRef="c11" decimals="0" unitRef="usd">880000</us-gaap:FDICIndemnificationAssetCashPaymentsReceived>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Notes Receivable&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes an allowance for losses
on notes receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical
bad debt experience, current note receivable aging, and expected future write-offs, as well as an assessment of specific identifiable
accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recognized as general
and administrative expense.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.65pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Prepaid expenses and other current assets
- current of $145,324 and $241,091 at December 31, 2021 and 2020, respectively, consist primarily of costs paid for future services which
will occur within a year. Prepaid expenses and other current assets &#x2013; non-current of $26,659 and $0 at December 31, 2021 and 2020,
respectively, consist primarily of costs paid for license fees and future services which will occur after a year. Prepaid expenses may
include prepayments in cash and equity instruments for consulting, business advisory, legal services, license fees, research and development
fees, and insurance which are being amortized over the terms of their respective agreements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c1" decimals="0" unitRef="usd">145324</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c2" decimals="0" unitRef="usd">241091</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:InventoryGross contextRef="c1" decimals="0" unitRef="usd">26659</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="c2" decimals="0" unitRef="usd">0</us-gaap:InventoryGross>
    <silo:EquityInvestmentsAtFairValuePolicyTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Equity Investments, at Fair Value&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Realized gain or loss is recognized when an
investment is disposed of and is computed as the difference between the Company&#x2019;s carrying value and the net proceeds received
from such disposition.&#160;&#160;Realized gains and losses on investment transactions are determined by specific identification. Net
unrealized appreciation or depreciation is computed as the difference between the fair value of the investment and the cost basis of
such investment. Net unrealized gains or losses for equity investments are recognized in operations as the difference between the carrying
value at the beginning of the period and the fair value at the end of the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</silo:EquityInvestmentsAtFairValuePolicyTextBlock>
    <silo:EquityInvestmentsAtCostPolicyTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Equity Investments, at Cost&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Equity investments, at cost are comprised
mainly of non-marketable capital stock and stock warrants, are recorded at cost, as adjusted for other than temporary impairment write-downs
and are evaluated for impairment periodically.&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</silo:EquityInvestmentsAtCostPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company applies ASC Topic 606, Revenue
from Contracts with Customers (&#x201c;ASC 606&#x201d;). ASC 606 establishes a single comprehensive model for entities to use in accounting
for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires
an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures.&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company records interest and dividend
income on an accrual basis to the extent that the Company expects to collect such amounts.&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the license and royalty income, revenue
is recognized when the Company satisfies the performance obligation based on the related license agreement. Payments received from the
licensee that are related to future periods are recorded as deferred revenue to be recognized as revenues over the term of the related
license agreement (see Note 10).&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Product sales were recognized when the NFID
products were shipped to the customer and title was transferred and were recorded net of any discounts or allowances which are separately
reported as &#x201c;discontinued operations&#x201d; on the consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <silo:CostOfRevenuesPolicyTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Cost of Revenues&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.05pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The primary components of cost of revenues
on license fees included the cost of the license fees. Payments made to the licensor that are related to future periods are recorded
as prepaid expense to be amortized over the term of the related license agreement (see Note 10).&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The primary components of cost of revenues
on NFID apparel include the cost of the product, production costs, warehouse storage costs and shipping fees which are separately reported
as &#x201c;discontinued operations&#x201d; on the consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</silo:CostOfRevenuesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Stock-based compensation is accounted for
based on the requirements of ASC 718 &#x2013; &#x201c;Compensation &#x2013; Stock Compensation&#x201d;, which requires recognition in the
financial statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments
over the period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively,
the vesting period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange
for an award based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted
under Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-09 Improvements to Employee Share-Based Payment.&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred income tax assets and liabilities
arise from temporary differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted
tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current
or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities
not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences
are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to
be realized.&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company follows the provisions of Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 740-10, &#x201c;Uncertainty in Income Taxes&#x201d;. Certain recognition thresholds
must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax
positions that meet a &#x201c;more-likely-than-not&#x201d; threshold. The Company does not believe it has any uncertain tax positions as
of December 31, 2021 and 2020 that would require either recognition or disclosure in the accompanying consolidated financial statements.&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognized income tax expense
of $24,876 and $0 for the years ended December 31, 2021 and 2020 (see Note 8).&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c10" decimals="0" unitRef="usd">24876</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c11" decimals="0" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 730-10, &#x201c;Research
and Development-Overall,&#x201d; research and development costs are expensed when incurred. During the years ended December 31, 2021 and
2020, research and development costs were $693,910 and $26,250, respectively.&lt;/p&gt;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c10" decimals="0" unitRef="usd">693910</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c11" decimals="0" unitRef="usd">26250</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Net Income (Loss) per Common Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic net income (loss) per share is computed
by dividing net income (loss) allocable to common shareholders by the weighted average number of shares of common stock outstanding during
each period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted average number
of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period using the as-if
converted method. Potentially dilutive securities which include convertible preferred shares and stock options are excluded from the
computation of diluted shares outstanding if they would have an anti-dilutive impact on the Company&#x2019;s net income or (loss). The
following are the potentially dilutive shares for the years ended December 31, 2021 and 2020:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;&lt;span style="-keep: true"&gt;Series C convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="-keep: true"&gt;15,133&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-263"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;347,080&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-264"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;368,213&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table presents a reconciliation
of basic and diluted net loss per share:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;For the Years Ended&lt;br/&gt; December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="-keep: true"&gt;Income (loss) per common share &#x2014; basic:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="-keep: true"&gt;Income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;4,157,108&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;(2,666,269&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;Loss from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;(253,367&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;(371,248&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;3,903,741&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(3,037,517&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Weighted average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;1,897,315&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;1,319,094&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Net income (loss) per common share available to common stockholders&#x2013; basic:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="-keep: true"&gt;From continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;1.45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(2.07&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"&gt;&lt;span style="-keep: true"&gt;From discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(0.13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(0.28&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="-keep: true"&gt;Income (loss) per common share &#x2014; diluted:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;4,157,108&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;(2,666,269&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Add: interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;(3,036&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-265"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Numerator for loss from continuing operations per common share &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;4,154,072&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;(2,666,269&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;Numerator for loss from discontinuing operations per common share &#x2014;
    diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;(253,367&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;(371,248&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Net loss per common share &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;3,900,705&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(3,037,517&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Weighted average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;1,897,315&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;1,319,094&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 10pt"&gt;&lt;span style="-keep: true"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;5,996&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-266"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;span style="-keep: true"&gt;Preferred shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;15,133&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-267"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Weighted average common shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-268"&gt;&lt;span style="-keep: true"&gt;1,918,4448&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;1,319,094&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Net loss per common share available to common stockholders &#x2013; diluted:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"&gt;&lt;span style="-keep: true"&gt;From continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;1.43&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(2.07&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"&gt;&lt;span style="-keep: true"&gt;From discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(0.13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(0.28&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <silo:ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock contextRef="c10">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;&lt;span style="-keep: true"&gt;Series C convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;span style="-keep: true"&gt;15,133&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-263"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;347,080&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-264"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;368,213&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</silo:ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c88" decimals="INF" unitRef="shares">15133</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c90" decimals="INF" unitRef="shares">6000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c91" decimals="INF" unitRef="shares">6000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c92" decimals="INF" unitRef="shares">347080</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c10" decimals="INF" unitRef="shares">368213</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c11" decimals="INF" unitRef="shares">6000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c10">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;For the Years Ended&lt;br/&gt; December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="-keep: true"&gt;Income (loss) per common share &#x2014; basic:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="-keep: true"&gt;Income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;4,157,108&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;(2,666,269&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;Loss from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;(253,367&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;(371,248&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;3,903,741&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(3,037,517&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Weighted average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;1,897,315&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;1,319,094&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Net income (loss) per common share available to common stockholders&#x2013; basic:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="-keep: true"&gt;From continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;1.45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(2.07&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"&gt;&lt;span style="-keep: true"&gt;From discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(0.13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(0.28&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="-keep: true"&gt;Income (loss) per common share &#x2014; diluted:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;4,157,108&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;(2,666,269&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Add: interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;(3,036&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-265"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Numerator for loss from continuing operations per common share &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;4,154,072&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;(2,666,269&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;Numerator for loss from discontinuing operations per common share &#x2014;
    diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;(253,367&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;(371,248&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Net loss per common share &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;3,900,705&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(3,037,517&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Weighted average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;1,897,315&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;1,319,094&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 10pt"&gt;&lt;span style="-keep: true"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;5,996&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-266"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;span style="-keep: true"&gt;Preferred shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;15,133&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-267"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Weighted average common shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-268"&gt;&lt;span style="-keep: true"&gt;1,918,4448&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;1,319,094&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-keep: true"&gt;Net loss per common share available to common stockholders &#x2013; diluted:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"&gt;&lt;span style="-keep: true"&gt;From continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;1.43&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(2.07&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"&gt;&lt;span style="-keep: true"&gt;From discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(0.13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;(0.28&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <silo:IncomelossFromContinuingOperation contextRef="c10" decimals="0" unitRef="usd">4157108</silo:IncomelossFromContinuingOperation>
    <silo:IncomelossFromContinuingOperation contextRef="c11" decimals="0" unitRef="usd">-2666269</silo:IncomelossFromContinuingOperation>
    <silo:IncomeLossFromDiscontinuedOperations contextRef="c10" decimals="0" unitRef="usd">-253367</silo:IncomeLossFromDiscontinuedOperations>
    <silo:IncomeLossFromDiscontinuedOperations contextRef="c11" decimals="0" unitRef="usd">-371248</silo:IncomeLossFromDiscontinuedOperations>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c10" decimals="0" unitRef="usd">3903741</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c11" decimals="0" unitRef="usd">-3037517</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c10" decimals="INF" unitRef="shares">1897315</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c11" decimals="INF" unitRef="shares">1319094</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare contextRef="c10" decimals="2" unitRef="usdPershares">1.45</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare contextRef="c11" decimals="2" unitRef="usdPershares">-2.07</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare contextRef="c10" decimals="2" unitRef="usdPershares">-0.13</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare contextRef="c11" decimals="2" unitRef="usdPershares">-0.28</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <silo:IncomelossFromContinuingOperation contextRef="c10" decimals="0" unitRef="usd">4157108</silo:IncomelossFromContinuingOperation>
    <silo:IncomelossFromContinuingOperation contextRef="c11" decimals="0" unitRef="usd">-2666269</silo:IncomelossFromContinuingOperation>
    <us-gaap:InterestIncomeExpenseNet contextRef="c10" decimals="0" unitRef="usd">-3036</us-gaap:InterestIncomeExpenseNet>
    <silo:NumeratorForLossFromContinuingOperationsPerCommonShareDiluted contextRef="c10" decimals="0" unitRef="usd">4154072</silo:NumeratorForLossFromContinuingOperationsPerCommonShareDiluted>
    <silo:NumeratorForLossFromContinuingOperationsPerCommonShareDiluted contextRef="c11" decimals="0" unitRef="usd">-2666269</silo:NumeratorForLossFromContinuingOperationsPerCommonShareDiluted>
    <silo:NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted contextRef="c10" decimals="0" unitRef="usd">-253367</silo:NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted>
    <silo:NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted contextRef="c11" decimals="0" unitRef="usd">-371248</silo:NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted>
    <us-gaap:NetIncomeLossAllocatedToGeneralPartners contextRef="c10" decimals="0" unitRef="usd">3900705</us-gaap:NetIncomeLossAllocatedToGeneralPartners>
    <us-gaap:NetIncomeLossAllocatedToGeneralPartners contextRef="c11" decimals="0" unitRef="usd">-3037517</us-gaap:NetIncomeLossAllocatedToGeneralPartners>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c10" decimals="INF" unitRef="shares">1897315</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c11" decimals="INF" unitRef="shares">1319094</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c10" decimals="INF" unitRef="shares">5996</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:AuctionMarketPreferredSecuritiesSharesOutstanding contextRef="c1" decimals="INF" unitRef="shares">15133</us-gaap:AuctionMarketPreferredSecuritiesSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c11" decimals="INF" unitRef="shares">1319094</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare contextRef="c10" decimals="2" unitRef="usdPershares">1.43</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare contextRef="c11" decimals="2" unitRef="usdPershares">-2.07</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare contextRef="c10" decimals="2" unitRef="usdPershares">-0.13</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare contextRef="c11" decimals="2" unitRef="usdPershares">-0.28</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;The Company accounts
for its leases using the method prescribed by ASC 842 &#x2013; &lt;i&gt;Lease Accounting&lt;/i&gt;. The Company assess whether the contract is, or
contains, a lease at the inception of a contract which is based on (i) whether the contract involves the use of a distinct identified
asset, (ii) whether the Company obtain the right to substantially all the economic benefit from the use of the asset throughout the period,
and (iii) whether the Company has the right to direct the use of the asset. The Company allocates the consideration in the contract to
each lease component based on its relative stand-alone price to determine the lease payments. The Company has elected not to recognize
right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities for short-term leases that have a term of 12 months or less.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Operating lease ROU
assets represents the right to use the leased asset for the lease term. Operating lease liabilities are recognized based on the present
value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate,
the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value
of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included
in general and administrative expenses in the consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In August 2020, the FASB issued ASU 2020-06&#x2014;&lt;i&gt;Debt&#x2014;Debt
with Conversion and Other Options (Subtopic 470-20) and Derivatives and edging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic
815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU 2020-06&#x201d;)&lt;/i&gt; to simplify
the accounting for convertible instruments by removing certain separation models in Subtopic 470- 20, &lt;i&gt;Debt with Conversion and Other
Options&lt;/i&gt;, for convertible instruments. Under the amendments in ASU 2020-06, the embedded conversion features no longer are separated
from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives
under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently,
a convertible debt instrument will be accounted for as a single liability measured at its amortized cost and a convertible preferred
stock will be accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation
and recognition as derivatives. By removing those separation models, the interest rate of convertible debt instruments typically will
be closer to the coupon interest rate when applying the guidance in Topic 835, Interest. The amendments in ASU 2020-06 provide financial
statement users with a simpler and more consistent starting point to perform analyses across entities. The amendments also improve the
operability of the guidance and reduce, to a large extent, the complexities in the accounting for convertible instruments and the difficulties
with the interpretation and application of the relevant guidance. To further improve the decision usefulness and relevance of the information
being provided to users of financial statements, amendments in ASU 2020-06 increased information transparency by making the following
amendments to the disclosure for convertible instruments:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Add a disclosure objective&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Add information about
    events or conditions that occur during the reporting period that cause conversion contingencies to be met or conversion terms to
    be significantly changed&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Add information on which
    party controls the conversion rights&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Align disclosure requirements
    for contingently convertible instruments with disclosure requirements for other convertible instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Require that existing
    fair value disclosures in Topic 825, Financial Instruments, be provided at the individual convertible instrument level rather than
    in the aggregate.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Additionally, for convertible debt instruments
with substantial premiums accounted for as paid-in capital, amendments in ASU 2020-06 added disclosures about (1) the fair value amount
and the level of fair value hierarchy of the entire instrument for public business entities and (2) the premium amount recorded as paid-in
capital.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;The amendments in
ASU 2020-06 are effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the
SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities,
the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years.
Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those
fiscal years. Entities should adopt the guidance as of the beginning of its annual fiscal year and are allowed to adopt the guidance
through either a modified retrospective method of transition or a fully retrospective method of transition. In applying the modified
retrospective method, entities should apply the guidance to transactions outstanding as of the beginning of the fiscal year in which
the amendments are adopted. Transactions that were settled (or expired) during prior reporting periods are unaffected. The cumulative
effect of the change should be recognized as an adjustment to the opening balance of retained earnings at the date of adoption. If an
entity elects the fully retrospective method of transition, the cumulative effect of the change should be recognized as an adjustment
to the opening balance of retained earnings in the first comparative period presented. The Company is evaluating the impact of the revised
guidance and believes that it will not have a significant impact on its consolidated financial statements.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2021, the FASB issued ASU 2021-04,
Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718),
and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40). The new ASU addresses issuer&#x2019;s accounting
for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities,
for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted.
The Company is evaluating the impact of the revised guidance and believes that it will not have a significant impact on its consolidated
financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management does not believe that any other
recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company&#x2019;s consolidated
financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 3 &#x2013; &lt;span style="text-decoration:underline"&gt;FAIR VALUE OF FINANCIAL
INSTRUMENTS AND FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;FASB ASC 820 - Fair Value Measurements and
Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments,
whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent
information available to the Company on December 31, 2021. Accordingly, the estimates presented in these financial statements are not
necessarily indicative of the amounts that could be realized on disposition of the financial instruments. FASB ASC 820 specifies a hierarchy
of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect
market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest
priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority
to unobservable inputs (Level 3 measurement).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.6in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1-&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs are unadjusted
    quoted prices in active markets for identical assets or liabilities available at the measurement date.&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs are unadjusted
    quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities
    in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable
    market data.&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs are unobservable
    inputs which reflect the reporting entity&#x2019;s own assumptions on what assumptions the market participants would use in pricing
    the asset or liability based on the best available information.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company analyzes all financial instruments
with features of both liabilities and equity under the FASB&#x2019;s accounting standard for such instruments. Under this standard, financial
assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The carrying amounts reported in the consolidated
balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair market
value based on the short-term maturity of these instruments.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Equity Investments at Fair Value&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounted for certain equity investments
at fair value using level 1, level 2 and level 3 valuations. Assets and liabilities measured at fair value on a recurring basis are as
follows at December 31, 2021 and 2020:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;At December 31, 2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;At December 31, 2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-left: 0.125in; text-indent: -0.125in; text-align: left; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 28%; text-align: left"&gt;Equity investments consisting of common
    stock, at fair value&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;419,995&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-269"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-270"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-271"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-272"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-273"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes activity in
the Company&#x2019;s equity investments, at fair value for the periods presented:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Balance, beginning of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-274"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-275"&gt;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; width: 76%"&gt;Additions&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;531,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-276"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Sales&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(359,843&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-277"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Unrealized gain&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;248,588&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-278"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Balance, end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;419,995&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-279"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At December 31, 2021, equity investments,
at fair value consisted of common equity securities of two entities, Home Bistro, Inc and Aikido Pharma, Inc. (see Note 10).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Equity investments are carried at fair value
with unrealized gains or losses which is recorded as net unrealized gain (loss) on equity investments in the accompanying consolidated
statement of operations.&#160;Realized gains and losses are determined on a specific identification basis which is recorded as net realized
gain (loss) on equity investments in the accompanying consolidated statement of operations. The Company reviews equity investments, at
fair value for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may
not be recovered.&#160;For the year ended December 31, 2021, we recorded a net realized gain on equity investments of $6,660,483 primarily
attributed to a gain from the sale of the Company&#x2019;s equity investment in DatChat, Inc. of $6,657,120 and Aikido Pharma, Inc. of
$3,363. DatChat, Inc. was a cost basis investment carried at $200 at December 31, 2020 (see below). The Company paid a commission on
the sale of DatChat, Inc. totaling $578,880 which was netted with the proceeds.&lt;/p&gt;&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ASC 825-10 &#x201c;Financial Instruments&#x201d;
allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair
value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value
option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent
reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Equity Investments at Cost&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At December 31, 2021 and 2020, equity investments,
at cost of $0 and $200, respectively, comprised mainly of non-marketable capital stock and stock warrants, are recorded at cost, as adjusted
for other than temporary impairment write-downs and are evaluated for impairment periodically.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c10">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;At December 31, 2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;At December 31, 2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-left: 0.125in; text-indent: -0.125in; text-align: left; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 28%; text-align: left"&gt;Equity investments consisting of common
    stock, at fair value&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;419,995&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-269"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-270"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-271"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-272"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-273"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <silo:EquityInvestmentsAtFairValue contextRef="c97" decimals="0" unitRef="usd">419995</silo:EquityInvestmentsAtFairValue>
    <silo:ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock contextRef="c10">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Balance, beginning of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-274"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-275"&gt;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; width: 76%"&gt;Additions&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;531,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-276"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Sales&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(359,843&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-277"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Unrealized gain&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;248,588&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-278"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Balance, end of the year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;419,995&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-279"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</silo:ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock>
    <silo:AdditionsofEquitySecurities contextRef="c10" decimals="0" unitRef="usd">531250</silo:AdditionsofEquitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c10" decimals="0" unitRef="usd">359843</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c10" decimals="0" unitRef="usd">248588</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:EquityMethodInvestments contextRef="c1" decimals="0" unitRef="usd">419995</us-gaap:EquityMethodInvestments>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c10" decimals="0" unitRef="usd">6660483</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c94" decimals="0" unitRef="usd">6657120</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="c95" decimals="0" unitRef="usd">3363</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:InvestmentOwnedAtCost contextRef="c96" decimals="0" unitRef="usd">200</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:DeferredSalesCommission contextRef="c96" decimals="0" unitRef="usd">578880</us-gaap:DeferredSalesCommission>
    <silo:EquityInvestmentsCost contextRef="c10" decimals="0" unitRef="usd">0</silo:EquityInvestmentsCost>
    <silo:EquityInvestmentsCost contextRef="c11" decimals="0" unitRef="usd">200</silo:EquityInvestmentsCost>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 4 &#x2013; &lt;span style="text-decoration:underline"&gt;DISPOSAL OF THE DISCONTINUED
OPERATIONS OF THE NFID BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 30, 2021, the Company entered
into and closed on an Asset Purchase Agreement (see Note 1) with NFID, LLC, an unrelated party, a Florida limited liability company,
whereby the Company sold certain assets, properties, and rights in connection with its NFID trademark name, logos, domain, and apparel
clothing and accessories for a purchase price of $60,000 in the form of a promissory note for the same amount (&#x201c;Note&#x201d;). The
Note bears 8% interest per annum and matures on October 1, 2023. As of December 31, 2021, the Note had principal balance of $60,000 and
accrued interest receivable of $1,210 for a total outstanding receivable balance of $61,210.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ASC 205-20 &#x201c;Discontinued Operations&#x201d;
establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should be reported in
discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity&#x2019;s operations
and financial results. As a result, the component&#x2019;s results of operations have been classified as discontinued operations on a
retrospective basis for all periods presented. Accordingly, the results of operations of this component, for all periods, are separately
reported as &#x201c;discontinued operations&#x201d; in the accompanying consolidated statements of operations.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2021 and 2020, assets of
discontinued operations amounted $0 and $33,484, respectively, which primarily consisted of NFID inventory.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table set forth the selected
financial data of the Company&#x2019;s gain from sale of the NFID business on September 30, 2021:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;September&#160;30,&lt;br/&gt;
    2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 1.5pt"&gt;Inventory, net&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;58,447&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;58,447&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-280"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net asset of NFID business disposed&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;58,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Consideration in the form of a note receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(60,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Gain from sale of NFID business&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,553&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The summarized operating result of discontinued
operations of the NFID Business included in the Company&#x2019;s consolidated statements of operations for the years ended December 31,
2021 and 2020 is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Year Ended&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Product sales, net&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;119,405&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;40,923&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cost of sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;103,824&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;182,426&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross profit (loss)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,581&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(141,503&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total operating and other non-operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(270,501&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(229,745&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain from sale of NFID business&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,533&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-281"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Loss from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(253,367&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(371,248&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <silo:PurchasePrice contextRef="c86" decimals="0" unitRef="usd">60000</silo:PurchasePrice>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate contextRef="c87" decimals="2" unitRef="pure">0.08</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:LongTermDebtMaturityDate contextRef="c87">2023-10-01</us-gaap:LongTermDebtMaturityDate>
    <silo:PrincipalBalance contextRef="c10" decimals="0" unitRef="usd">60000</silo:PrincipalBalance>
    <silo:AccruedInterestReceivable contextRef="c10" decimals="0" unitRef="usd">1210</silo:AccruedInterestReceivable>
    <silo:TotalOutstandingBalanceReceivable contextRef="c10" decimals="0" unitRef="usd">61210</silo:TotalOutstandingBalanceReceivable>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent contextRef="c1" decimals="0" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent contextRef="c2" decimals="0" unitRef="usd">33484</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="c10">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;September&#160;30,&lt;br/&gt;
    2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 1.5pt"&gt;Inventory, net&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;58,447&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;58,447&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-280"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net asset of NFID business disposed&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;58,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Consideration in the form of a note receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(60,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Gain from sale of NFID business&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,553&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:InventoryNet contextRef="c87" decimals="0" unitRef="usd">58447</us-gaap:InventoryNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c87" decimals="0" unitRef="usd">58447</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <silo:NetAssetOfNFIDBusinessDisposed contextRef="c86" decimals="0" unitRef="usd">58447</silo:NetAssetOfNFIDBusinessDisposed>
    <silo:ConsiderationInTheFormOfANoteReceivable contextRef="c86" decimals="0" unitRef="usd">-60000</silo:ConsiderationInTheFormOfANoteReceivable>
    <us-gaap:GainLossOnSaleOfOtherAssets contextRef="c86" decimals="0" unitRef="usd">-1553</us-gaap:GainLossOnSaleOfOtherAssets>
    <srt:ScheduleOfCondensedIncomeStatementTableTextBlock contextRef="c10">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Year Ended&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Product sales, net&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;119,405&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;40,923&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cost of sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;103,824&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;182,426&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross profit (loss)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,581&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(141,503&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total operating and other non-operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(270,501&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(229,745&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain from sale of NFID business&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,533&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-281"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Loss from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(253,367&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(371,248&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedIncomeStatementTableTextBlock>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c10" decimals="0" unitRef="usd">119405</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c11" decimals="0" unitRef="usd">40923</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="c10" decimals="0" unitRef="usd">103824</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="c11" decimals="0" unitRef="usd">182426</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef="c10" decimals="0" unitRef="usd">15581</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef="c11" decimals="0" unitRef="usd">-141503</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c10" decimals="0" unitRef="usd">270501</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c11" decimals="0" unitRef="usd">229745</us-gaap:OtherOperatingIncomeExpenseNet>
    <silo:GainFromSaleOfNFIDBusiness contextRef="c10" decimals="0" unitRef="usd">1533</silo:GainFromSaleOfNFIDBusiness>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c10" decimals="0" unitRef="usd">-253367</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c11" decimals="0" unitRef="usd">-371248</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;b&gt;NOTE 5 &#x2013; &lt;span style="text-decoration:underline"&gt;NOTES RECEIVABLE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 28, 2018, the Company and Blind
Faith Concepts Holdings, Inc. (the &#x201c;Seller&#x201d;) executed a two-year promissory note receivable agreement with a principal balance
of $200,000 of which $100,000 was funded to the Seller in September 2018 and the remaining $100,000 was funded in October 2018. The promissory
note accrued interest at a rate of 6% per annum, and the Company was repaid in interest only payments on a quarterly basis, until the
maturity date of September 27, 2020, at which time the full principal and any interest payments was due to the Company. At the time the
promissory note receivable agreement was executed, the Company also executed a security interest and pledge agreement with the borrower
pursuant to which the borrower pledged all of the assets of its company as security for the performance of the note obligations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 2, 2018, the Company and Blind
Faith Concepts Holdings, Inc. (the &#x201c;Debtor&#x201d;) entered into a promissory note agreement for the sale of a promissory note with
a principal balance of $50,000 (&#x201c;Note&#x201d;). The Note bore an interest rate of 10% per annum and 18% per annum in the event of
default, payable on a monthly basis. The terms of the Note also provides for the principal balance of $50,000 to be used by the Debtor
for an asset purchase transaction (&#x201c;Transaction&#x201d;) which is not related to the Company and for the Transaction to close within
thirty days from the issuance date of the Note otherwise the Note becomes immediately due. In December 2018, the Company determined that
the Note was not collectible and accordingly recorded an allowance for doubtful account and bad debt expense of $50,000.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 20, 2019, the Company and a third
party entity (&#x201c;Purchaser&#x201d;) entered into two separate claim purchase agreements (&#x201c;Purchase Agreements&#x201d;), whereby
the Company sold and the Purchaser assumed the promissory notes: (i) dated September 28, 2018 with a principal balance of $200,000 and
related accrued interest and: (ii) dated November 2, 2018 with a principal balance of $50,000 and related accrued interest (discussed
above) (collectively as &#x201c;Notes&#x201d;), for an aggregate purchase price of $277,305. Pursuant to the Purchase Agreements, the purchase
price is payable on the earlier of the payment of six-monthly installments or upon the liquidation of the Blind Faith Concepts Holdings,
Inc settlement securities pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended. During the year ended December 31,
2020, the Company collected an aggregate amount of $30,000 of the Notes.&#160;During the year ended December 31, 2020, the Company recorded
an allowance for doubtful account and bad debt expense of $146,500 related to the principal balance of the Notes and wrote off $27,876
of the accrued interest receivable related to the Notes, for a total bad debt expense of $174,376, due to slow collection of the installment
payments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2020,
the Company recorded an aggregate bad debt expense in the amount of $174,376 and recovered an aggregate of $9,000 bad debt previously
written off during the periods between 2018 to 2020, resulting in net bad debt expense of $165,376 recorded in the accompanying consolidated
statement of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2021,
the Company recovered $148,500 of the bad debt that was previously written off during the periods between 2018 to 2020, recorded as bad
debt recovery in the accompanying consolidated statement of operations. On June 7, 2021, the Company and the investor, entered into a
settlement agreement whereby both parties agreed to settle the remaining balance of this note receivable which was previously written
off in year 2020 for a total settlement amount of $196,000 to be paid as follows; (i) an initial payment of $46,000 upon execution of
the settlement agreement and (ii) $10,000 per month for fifteen months. During the year ended, $148,500 was collected under this settlement
agreement and $47,500 remains collectible under this settlement agreement and such amount has been fully reserved as of December 31,
2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 30, 2021, the Company executed
a note receivable agreement with NFID, LLC in connection with an Asset Purchase Agreement (see Note 4). The promissory note bears 8%
interest per annum and matures on October 1, 2023. The outstanding principal and accrued interest shall be due and payable on maturity.
As of December 31, 2021, this note receivable had outstanding principal receivable of $60,000 and accrued interest receivable of $1,210
for a total receivable balance of $61,210 which is reflected in the accompanying consolidated balance sheet as note receivable &#x2013;
non-current.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2021 and 2020, notes receivable,
net, consisted of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Principal amounts of notes receivable at beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;220,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Additional notes receivable in 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-282"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Collections on notes receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(148,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(71,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(196,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total Notes receivable, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"&gt;Less: notes receivable, net &#x2013; current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-283"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Notes receivable &#x2013; non-current&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-284"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:NotesAndLoansReceivableNetCurrent contextRef="c103" decimals="0" unitRef="usd">200000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent contextRef="c104" decimals="0" unitRef="usd">100000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <silo:RemainingBalanceOfPromissoryNoteReceivable contextRef="c105" decimals="0" unitRef="usd">100000</silo:RemainingBalanceOfPromissoryNoteReceivable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c103" decimals="2" unitRef="pure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c106">2020-09-27</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesAndLoansReceivableNetCurrent contextRef="c107" decimals="0" unitRef="usd">50000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c108" decimals="2" unitRef="pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c109" decimals="2" unitRef="pure">0.18</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesAndLoansReceivableNetCurrent contextRef="c110" decimals="0" unitRef="usd">50000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c111" decimals="0" unitRef="usd">50000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:NotesAndLoansReceivableNetCurrent contextRef="c112" decimals="0" unitRef="usd">200000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent contextRef="c113" decimals="0" unitRef="usd">50000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:SupplementalDeferredPurchasePrice contextRef="c114" decimals="0" unitRef="usd">277305</us-gaap:SupplementalDeferredPurchasePrice>
    <silo:NotesReceivablePurchasePrice contextRef="c115" decimals="0" unitRef="usd">30000</silo:NotesReceivablePurchasePrice>
    <us-gaap:NotesAndLoansReceivableNetCurrent contextRef="c115" decimals="0" unitRef="usd">146500</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:InterestReceivable contextRef="c115" decimals="0" unitRef="usd">27876</us-gaap:InterestReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c115" decimals="0" unitRef="usd">174376</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:NotesAndLoansReceivableNetCurrent contextRef="c2" decimals="0" unitRef="usd">174376</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:AllowanceForLoanAndLeaseLossRecoveryOfBadDebts contextRef="c11" decimals="0" unitRef="usd">9000</us-gaap:AllowanceForLoanAndLeaseLossRecoveryOfBadDebts>
    <silo:NetBadDebtExpense contextRef="c11" decimals="0" unitRef="usd">165376</silo:NetBadDebtExpense>
    <us-gaap:AllowanceForLoanAndLeaseLossRecoveryOfBadDebts contextRef="c10" decimals="0" unitRef="usd">148500</us-gaap:AllowanceForLoanAndLeaseLossRecoveryOfBadDebts>
    <silo:BadDebtRecoveryCashPayment contextRef="c116">On June 7, 2021, the Company and the investor, entered into a
settlement agreement whereby both parties agreed to settle the remaining balance of this note receivable which was previously written
off in year 2020 for a total settlement amount of $196,000 to be paid as follows; (i) an initial payment of $46,000 upon execution of
the settlement agreement and (ii) $10,000 per month for fifteen months.</silo:BadDebtRecoveryCashPayment>
    <silo:CollectedSettlementAgreement contextRef="c10" decimals="0" unitRef="usd">148500</silo:CollectedSettlementAgreement>
    <silo:RemainsCollectibleSettlementAgreement contextRef="c10" decimals="0" unitRef="usd">47500</silo:RemainsCollectibleSettlementAgreement>
    <silo:PromissoryNote contextRef="c117" decimals="2" unitRef="pure">0.08</silo:PromissoryNote>
    <silo:NoteReceivableNonCurrentAmount contextRef="c1" decimals="0" unitRef="usd">60000</silo:NoteReceivableNonCurrentAmount>
    <silo:DebtInstrumentIncreasesAccruedInterest contextRef="c10" decimals="0" unitRef="usd">1210</silo:DebtInstrumentIncreasesAccruedInterest>
    <us-gaap:PaymentsToAcquireReceivables contextRef="c10" decimals="0" unitRef="usd">61210</us-gaap:PaymentsToAcquireReceivables>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c10">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Principal amounts of notes receivable at beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;220,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Additional notes receivable in 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-282"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Collections on notes receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(148,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(71,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(196,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total Notes receivable, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt"&gt;Less: notes receivable, net &#x2013; current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-283"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Notes receivable &#x2013; non-current&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-284"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:NotesReceivableGross contextRef="c1" decimals="0" unitRef="usd">220000</us-gaap:NotesReceivableGross>
    <us-gaap:NotesReceivableGross contextRef="c2" decimals="0" unitRef="usd">250000</us-gaap:NotesReceivableGross>
    <silo:AdditionalNotesReceivableIn2021 contextRef="c1" decimals="0" unitRef="usd">60000</silo:AdditionalNotesReceivableIn2021>
    <silo:CollectionsOnNotesReceivable contextRef="c1" decimals="0" unitRef="usd">148500</silo:CollectionsOnNotesReceivable>
    <silo:CollectionsOnNotesReceivable contextRef="c2" decimals="0" unitRef="usd">30000</silo:CollectionsOnNotesReceivable>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket contextRef="c10" decimals="0" unitRef="usd">71500</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket contextRef="c11" decimals="0" unitRef="usd">196500</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c1" decimals="0" unitRef="usd">60000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c2" decimals="0" unitRef="usd">23500</us-gaap:OtherReceivablesNetCurrent>
    <silo:LessNotesReceivableNetCurrentPortion contextRef="c2" decimals="0" unitRef="usd">-23500</silo:LessNotesReceivableNetCurrentPortion>
    <us-gaap:NotesReceivableNet contextRef="c1" decimals="0" unitRef="usd">60000</us-gaap:NotesReceivableNet>
    <us-gaap:DebtDisclosureTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;b&gt;NOTE 6 - &lt;span style="text-decoration:underline"&gt;NOTE PAYABLE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;b&gt;Paycheck Protection Program Funding&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 30, 2020, the Company received federal
funding in the amount of $18,900 through the Paycheck Protection Program (the &#x201c;PPP&#x201d;). PPP funds had certain restrictions
on use of the funding proceeds, and generally must be repaid within two years and accrued interest at a rate of 1% per annum. The PPP
loan may, under circumstances, be forgiven. No payment was due by the Company during the nine months period beginning on the date of
this note (&#x201c;Deferral Period&#x201d;). Commencing one month after the expiration of the Deferral Period, the Company was to pay the
lender monthly payments of principal and interest, each in equal amount required to fully amortize by the maturity date. If a payment
on this note was more than ten days late, the lender would charge a late fee of up to 5% of the unpaid portion of the regularly scheduled
payment. As of December 31, 2020, the principal balance of this note amounted to $18,900 and accrued interest of $174.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In April 2021, the Company was notified by
the Small Business Administration that the principal and accrued interest under the PPP loan has been forgiven in full. Accordingly,
during the year ended December 31, 2021, the Company recorded a total gain on forgiveness of PPP note payable of $19,082 which consisted
of the principal balance of $18,900 and accrued interest of $182. As of December 31, 2021, the PPP note had no outstanding balance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2021 and
2020, the Company recognized $54 and $80 of interest expense, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At December 31, 2021 and 2020, notes payable
consisted of the following:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Principal amount&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-285"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,900&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-286"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,654&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Note payable - long term portion&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-287"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,246&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:NotesPayable contextRef="c118" decimals="0" unitRef="usd">18900</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c119" decimals="2" unitRef="pure">0.01</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:AccountsPayableInterestBearingInterestRate contextRef="c118" decimals="2" unitRef="pure">0.05</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c120" decimals="0" unitRef="usd">18900</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c121" decimals="0" unitRef="usd">174</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:OtherNotesPayable contextRef="c122" decimals="0" unitRef="usd">19082</us-gaap:OtherNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c122" decimals="0" unitRef="usd">18900</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c123" decimals="0" unitRef="usd">182</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:InterestExpense contextRef="c10" decimals="0" unitRef="usd">54</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c11" decimals="0" unitRef="usd">80</us-gaap:InterestExpense>
    <us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock contextRef="c10">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Principal amount&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-285"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,900&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-286"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,654&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Note payable - long term portion&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-287"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,246&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock>
    <silo:DebtInstrumentsFaceAmount contextRef="c2" decimals="0" unitRef="usd">18900</silo:DebtInstrumentsFaceAmount>
    <silo:NotrPayableLessCurrentPortion contextRef="c2" decimals="0" unitRef="usd">14654</silo:NotrPayableLessCurrentPortion>
    <silo:NotePayableLongTermPortion contextRef="c2" decimals="0" unitRef="usd">4246</silo:NotePayableLongTermPortion>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 7 &#x2013; &lt;span style="text-decoration:underline"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Shares Authorized&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has authorized the issuance of
5,000,000 shares of preferred stock, $0.0001 par value. The Company&#x2019;s board of directors is authorized, at any time, and from time
to time, to provide for the issuance of shares of preferred stock in one or more series, and to determine the designations, preferences,
limitations and relative or other rights of the preferred stock or any series thereof.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 10, 2021, the Company filed an amendment
to its Certificate of Incorporation with the Secretary of State of Delaware to increase the authorized number of shares of common stock
of the Company from 100,000,000&#160;shares to 500,000,000 shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;b&gt;Preferred Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In April 2013, 1,000,000 shares of preferred
stock were designated as Series A Convertible Preferred Stock, and in November 2019, 2,000 shares of preferred stock were designated
as Series B Convertible Preferred Stock. On February 9, 2021, 4,280 shares of preferred stock were designated as Series C Convertible
Preferred Stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Conversion of Series A Redeemable Preferred
Stock into Common Shares&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On August 3, 2020, at the request of the investor,
the Company converted 4,000 Series A Preferred Stock into 40,000 shares of common stock. After such conversion, the Company reclassified
the $400,000 redemption value of the Series A Preferred Stock to additional paid in capital. Accordingly, there are no shares of Series
A Preferred Stock issued and outstanding as of December 31, 2021 and 2020. &#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Conversion of Series B Convertible Preferred
Stock into Common Shares &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On April 15, 2020, the Company entered into
Exchange Agreements with the holders of its Series B Preferred Stock, which shares of Series B Preferred Stock were originally issued
in November 2019. Pursuant to the Exchange Agreements, the holders agreed to exchange their 115 shares of Series B Preferred Stock with
a stated value of $115,000 and 11,500 warrants issued in connection with the Series B Preferred Stock for an aggregate of 28,750 shares
of the Company&#x2019;s common stock at a price of $4.00 per share. After the exchanges, there are no shares of the Company&#x2019;s Series
B Preferred Stock outstanding. The Company issued 28,750 shares of common stock which was more than the shares that would have been issued
at the original conversion price of $10.00 per share or 11,500 shares of common stock, an excess of 17,250 shares of common stock. The
excess shares were valued at a price of $4.00 per share. Consequently, in connection with this share exchange, the Company recorded a
deemed dividend on this extinguishment of $69,000 during the year ended December 31, 2020. Accordingly, there are no shares of Series
B Preferred Stock issued and outstanding as of December 31, 2021 and 2020. &#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Series C Convertible Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 9, 2021, the Company filed a Certificate
of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the &#x201c;Certificate of Designations&#x201d;)
with the Delaware Secretary of State, designating 4,280 shares of preferred stock as Series C Convertible Preferred Stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Designation&lt;/span&gt;. The Company has designated 4,280 shares of preferred stock as Series C Convertible Preferred Stock. Each share of Series C Convertible Preferred Stock has a par value of $0.0001 per share and a stated value of $1,000 (the &#x201c;Series C Stated Value&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration:underline"&gt;Dividends&lt;/span&gt;&lt;i&gt;.&#160;&lt;/i&gt;Holders
                                            of Series C Convertible Preferred Stock shall be entitled to receive dividends (on an as-if-converted-to-common-stock
                                            basis) in the same form as dividends actually paid on shares of the common stock when, as
                                            and if such dividends are paid on shares of the common stock. No other dividends shall be
                                            paid on shares of the Series C Convertible Preferred Stock.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration:underline"&gt;Liquidation&lt;/span&gt;.
                                            Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary,
                                            the holders of Series C Convertible Preferred Stock shall be entitled to receive the same
                                            amount that a holder of common stock would receive if the Series C Convertible Preferred
                                            Stock were fully converted (disregarding any conversion limitations) which amounts shall
                                            be paid&#160;pari passu&#160;with all holders of common stock.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration:underline"&gt;Voting
                                            Rights&lt;/span&gt;. Except as otherwise provided in the Certificate of Designations or as otherwise
                                            required by law, the Series C Convertible Preferred Stock shall have no voting rights. However,
                                            as long as any shares of Series C Convertible Preferred Stock are outstanding, the Company
                                            shall not, without the affirmative vote of the holders of a majority of the then outstanding
                                            shares of the Series C Convertible Preferred Stock, (a) alter or change adversely the powers,
                                            preferences or rights given to the Series C Convertible Preferred Stock or alter or amend
                                            the Certificate of Designations, (b) amend its Certificate of Incorporation or other charter
                                            documents in any manner that adversely affects any rights of the holders of the Series C
                                            Convertible Preferred Stock, (c) increase the number of authorized shares of Series C Convertible
                                            Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Conversion&lt;/span&gt;. Each share of Series C Convertible Preferred Stock is convertible, at any time and from time to time after the issuance date, at the option of the holder, into such number of shares of common stock determined by dividing the Series C Stated Value by the Series C Conversion Price. &#x201c;Series C Conversion Price&#x201d; means $15.00, subject to adjustment in the event of stock split, stock dividends, subsequent right offerings and similar recapitalization transactions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration:underline"&gt;Forced
                                            Conversion&lt;/span&gt;. Notwithstanding anything herein to the contrary, after the date that the
                                            Company&#x2019;s stockholder approval is obtained and deemed effective, the Company may deliver
                                            a written notice to all holders (the &#x201c;Forced Conversion Notice Date&#x201d;) to cause
                                            each holder to convert all or part of such holder&#x2019;s Series C Convertible Preferred
                                            Stock pursuant to Section 6 (&#x201c;Forced Conversion&#x201d;), it being agreed that the &#x201c;Conversion
                                            Date&#x201d; shall be deemed to occur no later than the earlier of (i) two (2) trading days
                                            and (ii) the number of trading days comprising the standard settlement period following the
                                            Forced Conversion Notice Date; provided, however, a holder shall only be required to convert
                                            pursuant to a Forced Conversion to the extent that such conversion would not cause a holder
                                            to exceed its beneficial ownership limitation. On March 10, 2021, the Company obtained the
                                            stockholders&#x2019; approval forcing the conversion of all the Series C Convertible Preferred
                                            Stock. On April 12, 2021, the Company notified holders of its Series C Convertible Preferred
                                            Stock of its election to force the conversion to its Series C Convertible Preferred Stock
                                            into shares of the Company&#x2019;s common stock (see below).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration:underline"&gt;Exercisability&lt;/span&gt;&lt;i&gt;.&#160;&lt;/i&gt;A holder of Series C Convertible Preferred Stock may not convert any portion of the Series C Convertible Preferred Stock to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, upon election by a holder prior to issuance, 9.99%) of the outstanding shares of the Company&#x2019;s common stock after conversion, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Series C Convertible Preferred Stock
Financing&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On February 9, 2021 (the &#x201c;Effectiveness
Date&#x201d;), the Company entered into securities purchase agreements (collectively, the &#x201c;Series C Purchase Agreements&#x201d;)
with certain institutional and accredited investors for the sale of an aggregate of 4,276 shares of the Company&#x2019;s Series C Convertible
Preferred Stock and warrants (the &#x201c;February Warrants&#x201d;) to purchase up to 285,066 shares (the &#x201c;February Warrant Shares&#x201d;)
of the Company&#x2019;s common stock for gross proceeds of approximately $4,276,000, before deducting placement agent and other offering
expenses of $481,898 which are offset against the proceeds in additional paid in capital. The offering closed on February 12, 2021. Accordingly,
the Company recognized a total deemed dividend of $1,403,997 for the beneficial conversion feature in connection with the issuance of
these Series C Convertible Preferred Stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;The February Warrants are exercisable for
a period of five years from the date of issuance at an exercise price of $15.00 per share. If, after a period of 180 days after the date
of issuance of the February Warrants, a registration statement covering the resale of the February Warrant Shares is not effective, the
holders may exercise the February Warrants by means of a cashless exercise.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Series C Convertible Preferred Stock and
the February Warrants each contain a beneficial ownership limitation that restricts each of the investor&#x2019;s ability to exercise
the February Warrants and convert the Series C Convertible Preferred Stock such that the number of shares of the Company common stock
held by each of them and their affiliates after such conversion or exercise does not exceed 4.99% (or, at the election of the Investor,
9.99%) of the Company&#x2019;s then issued and outstanding shares of common stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Series C Purchase Agreement also provides
that until the 18 month anniversary of the Effectiveness Date, in the event of a subsequent financing (except for certain exempt issuances
as provided in the Series C Purchase Agreement) by the Company, each investor will have the right to participate in such subsequent financing
up to an amount equal to the investor&#x2019;s proportionate share of the subsequent financing based on such investor&#x2019;s participation
in the offering on the same terms, conditions and price provided for in the subsequent financing up to an amount equal to 50% of the
subsequent financing. In addition, pursuant to the Series C Purchase Agreement, the Company has agreed that neither it nor its subsidiaries
will enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common stock equivalents
to file any registration statement other than as contemplated pursuant to the Registration Rights Agreement (as defined below) for a
period of 90 days from the Effectiveness Date. Furthermore, subject to certain exceptions, the Company is prohibited from effecting or
entering into an agreement to effect any issuance by the Company or any of its subsidiaries of common stock or common stock equivalents
involving a Variable Rate Transaction (as defined in the Series C Purchase Agreement).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the offering, the Company
entered into separate registration rights agreements (&#x201c;Registration Rights Agreements&#x201d;) with the investors pursuant to which
the Company agreed to undertake to file a registration statement (the &#x201c;Registration Statement&#x201d;) to register the resale of
the Registrable Securities (as defined in the Registration Rights Agreement) within ten calendar days following the Effectiveness Date.
The Company agreed to use its best efforts to cause the Registration Statement covering the Registrable Securities to be declared effective
no later than the 60&lt;sup&gt;th&lt;/sup&gt;&#160;calendar day following the Effectiveness Date, or in the event of a full review by the Securities
and Exchange Commission, the 90&lt;sup&gt;th&lt;/sup&gt;&#160;calendar day following the Effectiveness Date, and to maintain the effectiveness of
the Registration Statement until all of the Registrable Securities have been sold or are otherwise able to be sold pursuant to Rule 144
under the Securities Act of 1933, as amended. If the Company fails to file the Registration Statement or have it declared effective by
the dates set forth above, amongst other things, the Company will be obligated to pay the investors damages in the amount of 1% of their
subscription amount, per month, until such events are satisfied. The Registration Statement was filed and declared effective in April
2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;In addition, pursuant to the terms of the
offering, the Company issued Bradley Woods &amp;amp; Co, Ltd. and Katalyst Securities LLC warrants (the &#x201c;Placement Agent Warrants&#x201d;)
to purchase up to an aggregate of 57,013 shares of common stock, or 10% of the shares of common stock issuable upon conversion of the
Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period
of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment. The Placement Agent
Warrants were valued at the grant date using a Black-Scholes option pricing model with the following assumptions: risk-free interest
rate of 0.50%, expected dividend yield of 0%, expected term of 5 years using the simplified method and expected volatility of $169% based
on comparable and calculated volatility. The aggregate grant date fair value of these Placement Agent Warrants amounted to approximately
$1,106,000 and was recorded against the proceeds with no net effect on the consolidated financials.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The net proceeds of the offering are expected
to be used for working capital purposes and to further execute on the Company&#x2019;s existing business.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Conversion of Series C Convertible Preferred
Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On April 12, 2021, the Company notified holders
of its Series C Convertible Preferred Stock of its election to force the conversion to its Series C Convertible Preferred Stock into
shares of the Company&#x2019;s common stock pursuant to the Certificate of Designations unless such conversion would cause the holder
to exceed its beneficial ownership limitation pursuant to the Certificate of Designations. On April 14, 2021, the Company converted 4,049
Series C Convertible Preferred Stock into 269,900 shares of common stock. As of December 31, 2021, there were 227 shares of the Company&#x2019;s
Series C Convertible Preferred Stock issued and outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Sale of Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;Between April 9, 2020 to April 18, 2020, the
Company entered into subscription agreements with certain accredited investors pursuant to which it issued an aggregate of 155,287 shares
of the Company&#x2019;s common stock for proceeds of $75,644, and subscription receivable of $2,000 or $0.50 per share, for a total of
$77,644. The Company collected the subscription receivable of $2,000 on July 6, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On April 28, 2020, the Company entered into
securities purchase agreements (collectively, the &#x201c;April Purchase Agreements&#x201d;) with certain institutions and accredited investors
for the sale of an aggregate 599,875 shares of the Company&#x2019;s common stock at a price of $4.00 per share for gross proceeds of $2,399,500,
before deducting placement agent fees of $242,950 and other offering expenses of $118,460 (the &#x201c;Private Placement&#x201d;) for total
net proceeds of $2,038,090. The April Purchase Agreements contains customary representations, warranties and covenants of the parties,
and the closing was subject to customary closing conditions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The April Purchase Agreements also provides
that until the six month anniversary of the date of the April Purchase Agreements, in the event of a subsequent financing (except for
certain exempt issuances as provided in the April Purchase Agreements) by the Company, each investor that invested over $100,000 pursuant
to the April Purchase Agreements will have the right to participate in such subsequent financing up to an amount equal to 50% of the
subsequent financing on the same terms, conditions and price provided for in the subsequent financing.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the Private Placement,
the Company entered into separate Registration Rights Agreements with the investors, pursuant to which the Company agreed to undertake
to file a registration statement to register the resale of the shares underlying the Registrable Securities (as defined therein) within
30 calendar days following the closing date, and to maintain the effectiveness of the registration statement until all of such shares
of common stock have been sold or are otherwise able to be sold pursuant to Rule 144. If the Company fails to file the registration statement
or have it declared effective by the dates set forth above, amongst other things, the Company is obligated to pay the investors liquidated
damages in the amount of 1% of their subscription amount, per month, until such events are satisfied, subject to a cap of 6%.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In conjunction with the Private Placement,
all officers and directors of the Company have entered into lock-up agreements pursuant to which they have agreed not to sell their shares
of common stock or common stock equivalents in the Company until the twelve-month anniversary of the closing date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock Issued for Future Services&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On April 17, 2020, the Company entered into
one-year advisory agreements with certain accredited investors pursuant to which it agreed to issue an aggregate of 102,347 shares of
the Company&#x2019;s common stock to the advisors for advisory services to be rendered. These shares were valued at $409,387, or $4.00
per common share, based on contemporaneous common share sales which are being amortized over the term of the agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On April 17, 2020, the Company entered into
a six-month consulting agreement with an accredited investor pursuant to which it agreed to issue an aggregate of 69,377 shares of the
Company&#x2019;s common stock to the consultant for consulting services to be rendered. These shares were valued at $277,508, or $4.00
per common share, based on contemporaneous common share sales which is being amortized over the term of the agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2021 and
2020, the Company recognized stock-based consulting fees of $107,970 and $578,924, respectively, with a remaining prepaid expense included
in prepaid expenses and other current assets of $0 and $107,970 at December 31, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock Issued for Employment Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On April 17, 2020, the Company entered into
an Employment Agreement with the Company&#x2019;s Chief Executive Officer (&#x201c;CEO&#x201d;) pursuant to which CEO will continue to serve
as Chief Executive Officer and Chief Financial Officer of the Company. In connection with this employment agreement, the CEO was granted
152,619 shares of the Company&#x2019;s common stock. These shares were valued at $610,476, or $4.00 per common share, based on contemporaneous
common share sales. During the year ended December 31, 2020, the Company recognized stock-based compensation of $610,476.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock Issued for Conversion of
Series A and B Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On August 3, 2020, at the request of the investor,
the Company converted 4,000 Series A Preferred Stock into 40,000 shares of common stock. After such conversion, the Company reclassed
the $400,000 redemption value of the Series A Preferred Stock to additional paid in capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On April 15, 2020, the Company entered into
Exchange Agreements with the holders of its Series B Preferred Stock whereby the holders agreed to exchange their 115 shares of Series
B Preferred Stock with a stated value of $115,000 and 11,500 warrants issued in connection with the Series B Preferred Stock for an aggregate
of 28,750 shares of the Company&#x2019;s common stock at a price of $4.00 per share. In connection with this share exchange, the Company
recorded a deemed dividend on this extinguishment of $69,000 during the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock Issued for Exchange of
Notes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On April 15, 2020, the Company entered into
Exchange Agreements with the holders of certain convertible promissory notes. Pursuant to these Exchange Agreements, the holders agreed
to exchange their convertible promissory notes of $330,000 and 33,000 warrants issued in connection with this debt for an aggregate of
82,500 shares of the Company&#x2019;s common stock at a price of $4.00 per share. Consequently, the Company recorded a loss on debt extinguishment
of $198,000 during the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock Options&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On January 18, 2021, the Company&#x2019;s board
of directors (&#x201c;Board&#x201d;) approved the Silo Pharma, Inc. 2020 Omnibus Equity Incentive Plan (the &#x201c;Plan&#x201d;) to incentivize
employees, officers, directors and consultants of the Company and its affiliates. 170,000 shares of common stock are reserved and available
for issuance under the Plan, provided that certain exempt awards (as defined in the Plan), shall not count against such share limit.
The Plan provides for the grant, from time to time, at the discretion of the Board or a committee thereof, of cash, stock options, including
incentive stock options and nonqualified stock options, restricted stock, dividend equivalents, restricted stock units, stock appreciation
units and other stock or cash-based awards.&#160;The Plan shall terminate on the tenth anniversary of the date of adoption by the Board.
Subject to certain restrictions, the Board may amend or terminate the Plan at any time and for any reason. An amendment of the Plan shall
be subject to the approval of the Company&#x2019;s stockholders only to the extent required by applicable laws, rules or regulations.
On March 10, 2021, the Plan was approved by the stockholders.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Stock option activities for the years ended
December 31, 2021 and 2020 are summarized as follows:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;Number&lt;br/&gt; of Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt;
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt;
    Contractual&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;&lt;span style="-keep: true"&gt;Balance Outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;0.005&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;104,970&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;Granted/Issued/ Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-288"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-289"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-290"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-291"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;Balance Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;0.005&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;127,290&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;Granted/Issued/ Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-292"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-293"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-294"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-295"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Balance Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;0.005&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;42,870&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Exercisable, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;0.005&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;42,870&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Warrant activities for the years ended December
31, 2021 and 2020 are summarized as follows:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
    of Warrants&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
    Average Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
    Average Remaining Contractual Term (Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;br/&gt;
    Intrinsic&lt;br/&gt;
    Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance Outstanding, December
    31, 2019&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;44,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.80&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;337,750&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(44,500&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-296"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-297"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-298"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-299"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-300"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-301"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;347,080&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.50&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.12&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-302"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;347,080&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.50&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.12&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-303"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable, December 31, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;347,080&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.50&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.12&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-304"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On April 15, 2020, the Company entered into
Exchange Agreements with the holders of convertible promissory notes (see Note 5). Pursuant to these Exchange Agreements, the noteholders
agreed to exchange their convertible promissory notes of $330,000 and 33,000 warrants issued in connection with this debt for an aggregate
of 82,500 shares of the Company&#x2019;s common stock at a price of $4.00 per share. After the exchanges, there are no convertible notes
outstanding. The Company issued 82,500 shares of common stock which was more than the shares that would have been issued at the original
conversion price of $4.00 per share or 33,000 shares of common stock, an excess of 49,500 shares of common stock. The excess shares were
valued at a price of $4.00 per share. Consequently, the Company recorded a loss on debt extinguishment of $198,000 during the year ended
December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On January 18, 2021, the Company granted warrants
to purchase up to 5,000 shares of the Company&#x2019;s common stock in exchange for legal services rendered. The warrants have a term
of five years from the date of grant and are exercisable at an exercise price of $10.00 per share. The warrants were valued on the grant
date at approximately $16.50 per warrant for a total of $83,728 using a Black-Scholes option pricing model with the following assumptions:
stock price of $17.50 per share (based on the quoted trading price on the date of grant), volatility of 169%, expected term of five year,
and a risk-free interest rate of 0.46%. During the year ended December 31, 2021, the Company recorded stock-based compensation of $83,728.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On February 9, 2021, the Company entered into
pursuant to securities purchase agreements with certain investors pursuant to which it sold warrants to purchase up to 285,067 shares
of the Company&#x2019;s common stock and 4,276 shares of the Company&#x2019;s Series C Convertible Preferred Stock. The February Warrants
are exercisable for a period of five years from the date of issuance at an exercise price of $15.00 per share, subject to adjustment.
If, after a period of 180 days after the date of issuance of the February Warrants, a registration statement covering the resale of the
February Warrant Shares is not effective, the holders may exercise the February Warrants by means of a cashless exercise. In addition,
pursuant to the terms of the offering, the Company issued the Placement Agent Warrants to purchase up to an aggregate of 57,013 shares
of common stock to its placement agents, or 10% of the shares of common stock issuable upon conversion of the Series C Preferred Stock
and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing
date of the offering at an exercise price of $17.50 per share, subject to adjustment (see Series C Convertible Preferred Stock Financing
above). Such warrants issued to various investors and to the placement agents were recorded as additional paid in capital with an offsetting
debit applied against additional paid in capital, thus these warrants have no further accounting effect within the equity section.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c1" decimals="0" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c1" decimals="4" unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased contextRef="c124" decimals="0" unitRef="shares">100000000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased contextRef="c125" decimals="0" unitRef="shares">500000000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c126" decimals="0" unitRef="shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c127" decimals="0" unitRef="shares">2000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c128" decimals="0" unitRef="shares">4280</us-gaap:PreferredStockSharesAuthorized>
    <silo:ConvertablePreferredStock contextRef="c129" decimals="0" unitRef="shares">4000</silo:ConvertablePreferredStock>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c129" decimals="0" unitRef="shares">40000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="c129" decimals="0" unitRef="usd">400000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <silo:ExchangeAgreementsDescription contextRef="c130">On April 15, 2020, the Company entered into
Exchange Agreements with the holders of its Series B Preferred Stock, which shares of Series B Preferred Stock were originally issued
in November 2019. Pursuant to the Exchange Agreements, the holders agreed to exchange their 115 shares of Series B Preferred Stock with
a stated value of $115,000 and 11,500 warrants issued in connection with the Series B Preferred Stock for an aggregate of 28,750 shares
of the Company&#x2019;s common stock at a price of $4.00 per share. After the exchanges, there are no shares of the Company&#x2019;s Series
B Preferred Stock outstanding. The Company issued 28,750 shares of common stock which was more than the shares that would have been issued
at the original conversion price of $10.00 per share or 11,500 shares of common stock, an excess of 17,250 shares of common stock. The
excess shares were valued at a price of $4.00 per share. Consequently, in connection with this share exchange, the Company recorded a
deemed dividend on this extinguishment of $69,000 during the year ended December 31, 2020. Accordingly, there are no shares of Series
B Preferred Stock issued and outstanding as of December 31, 2021 and 2020.</silo:ExchangeAgreementsDescription>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c131" decimals="0" unitRef="shares">4280</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c132" decimals="0" unitRef="shares">4280</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c132" decimals="4" unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <silo:CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares contextRef="c133" decimals="0" unitRef="shares">1000</silo:CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c134" decimals="2" unitRef="usdPershares">15</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <silo:PreferredStockOutstandingDescription contextRef="c133">A holder of Series C Convertible Preferred Stock may not convert any portion of the Series C Convertible Preferred Stock to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, upon election by a holder prior to issuance, 9.99%) of the outstanding shares of the Company&#x2019;s common stock after conversion, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%.</silo:PreferredStockOutstandingDescription>
    <us-gaap:PreferredStockConversionBasis contextRef="c135">On February 9, 2021 (the &#x201c;Effectiveness
Date&#x201d;), the Company entered into securities purchase agreements (collectively, the &#x201c;Series C Purchase Agreements&#x201d;)
with certain institutional and accredited investors for the sale of an aggregate of 4,276 shares of the Company&#x2019;s Series C Convertible
Preferred Stock and warrants (the &#x201c;February Warrants&#x201d;) to purchase up to 285,066 shares (the &#x201c;February Warrant Shares&#x201d;)
of the Company&#x2019;s common stock for gross proceeds of approximately $4,276,000, before deducting placement agent and other offering
expenses of $481,898 which are offset against the proceeds in additional paid in capital. The offering closed on February 12, 2021. Accordingly,
the Company recognized a total deemed dividend of $1,403,997 for the beneficial conversion feature in connection with the issuance of
these Series C Convertible Preferred Stock.&#160;</us-gaap:PreferredStockConversionBasis>
    <silo:WarrantsTerm contextRef="c10">P5Y</silo:WarrantsTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c1" decimals="2" unitRef="usdPershares">15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PreferredStockConversionBasis contextRef="c10">The Series C Convertible Preferred Stock and
the February Warrants each contain a beneficial ownership limitation that restricts each of the investor&#x2019;s ability to exercise
the February Warrants and convert the Series C Convertible Preferred Stock such that the number of shares of the Company common stock
held by each of them and their affiliates after such conversion or exercise does not exceed 4.99% (or, at the election of the Investor,
9.99%) of the Company&#x2019;s then issued and outstanding shares of common stock.&#160;</us-gaap:PreferredStockConversionBasis>
    <silo:SubsequentFinancingPercentage contextRef="c136" decimals="2" unitRef="pure">0.50</silo:SubsequentFinancingPercentage>
    <silo:ObligationPercentage contextRef="c10" decimals="2" unitRef="pure">0.01</silo:ObligationPercentage>
    <silo:PlacementAgentWarrantsDescriptoin contextRef="c10">In addition, pursuant to the terms of the
offering, the Company issued Bradley Woods &amp; Co, Ltd. and Katalyst Securities LLC warrants (the &#x201c;Placement Agent Warrants&#x201d;)
to purchase up to an aggregate of 57,013 shares of common stock, or 10% of the shares of common stock issuable upon conversion of the
Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period
of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment.</silo:PlacementAgentWarrantsDescriptoin>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c10" decimals="4" unitRef="pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c10" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c10">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c10" decimals="2" unitRef="pure">1.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <silo:AggregateGrantDateFairValueOfPlacementAgentWarrants contextRef="c10" decimals="0" unitRef="usd">1106000</silo:AggregateGrantDateFairValueOfPlacementAgentWarrants>
    <silo:ConvertablePreferredStock contextRef="c137" decimals="0" unitRef="shares">4049</silo:ConvertablePreferredStock>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c137" decimals="0" unitRef="shares">269900</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c132" decimals="0" unitRef="shares">227</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:SharesIssued contextRef="c138" decimals="0" unitRef="shares">155287</us-gaap:SharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c139" decimals="0" unitRef="usd">75644</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="c138" decimals="0" unitRef="usd">2000</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c138" decimals="2" unitRef="usdPershares">0.5</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <silo:TotalSubscriptionReceivableValue contextRef="c140" decimals="0" unitRef="usd">77644</silo:TotalSubscriptionReceivableValue>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="c141" decimals="0" unitRef="usd">2000</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:SharesIssued contextRef="c142" decimals="0" unitRef="shares">599875</us-gaap:SharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c142" decimals="2" unitRef="usdPershares">4</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c143" decimals="0" unitRef="usd">2399500</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <silo:PlacementAgentFees contextRef="c142" decimals="0" unitRef="usd">242950</silo:PlacementAgentFees>
    <us-gaap:OtherOwnershipInterestsOfferingCosts contextRef="c142" decimals="0" unitRef="usd">118460</us-gaap:OtherOwnershipInterestsOfferingCosts>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c143" decimals="0" unitRef="usd">2038090</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <silo:InvestorInvestedAmount contextRef="c10" decimals="0" unitRef="usd">100000</silo:InvestorInvestedAmount>
    <silo:SubsequentFinancingPercentage contextRef="c10" decimals="2" unitRef="pure">0.50</silo:SubsequentFinancingPercentage>
    <us-gaap:ConstructionContractorLiquidityCharacteristic contextRef="c10">If the Company fails to file the registration statement
or have it declared effective by the dates set forth above, amongst other things, the Company is obligated to pay the investors liquidated
damages in the amount of 1% of their subscription amount, per month, until such events are satisfied, subject to a cap of 6%.</us-gaap:ConstructionContractorLiquidityCharacteristic>
    <us-gaap:SharesIssued contextRef="c144" decimals="0" unitRef="shares">102347</us-gaap:SharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c145" decimals="0" unitRef="usd">409387</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c144" decimals="2" unitRef="usdPershares">4</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharesIssued contextRef="c146" decimals="0" unitRef="shares">69377</us-gaap:SharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c147" decimals="0" unitRef="usd">277508</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c146" decimals="2" unitRef="usdPershares">4</us-gaap:CommonStockParOrStatedValuePerShare>
    <silo:AmortizationOfPrepaidStockbasedExpense contextRef="c10" decimals="0" unitRef="usd">107970</silo:AmortizationOfPrepaidStockbasedExpense>
    <silo:AmortizationOfPrepaidStockbasedExpense contextRef="c11" decimals="0" unitRef="usd">578924</silo:AmortizationOfPrepaidStockbasedExpense>
    <us-gaap:OtherAssetsCurrent contextRef="c1" decimals="0" unitRef="usd">0</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c2" decimals="0" unitRef="usd">107970</us-gaap:OtherAssetsCurrent>
    <us-gaap:SharesIssued contextRef="c148" decimals="0" unitRef="shares">152619</us-gaap:SharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c149" decimals="0" unitRef="usd">610476</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c148" decimals="2" unitRef="usdPershares">4</us-gaap:CommonStockParOrStatedValuePerShare>
    <silo:AmortizationOfPrepaidStockbasedExpense contextRef="c150" decimals="0" unitRef="usd">610476</silo:AmortizationOfPrepaidStockbasedExpense>
    <silo:ConvertablePreferredStock contextRef="c151" decimals="0" unitRef="shares">4000</silo:ConvertablePreferredStock>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c151" decimals="0" unitRef="shares">40000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:PreferredStockValue contextRef="c152" decimals="0" unitRef="usd">400000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockConversionBasis contextRef="c153">On April 15, 2020, the Company entered into
Exchange Agreements with the holders of its Series B Preferred Stock whereby the holders agreed to exchange their 115 shares of Series
B Preferred Stock with a stated value of $115,000 and 11,500 warrants issued in connection with the Series B Preferred Stock for an aggregate
of 28,750 shares of the Company&#x2019;s common stock at a price of $4.00 per share.</us-gaap:PreferredStockConversionBasis>
    <silo:DeemedDividend contextRef="c2" decimals="0" unitRef="usd">69000</silo:DeemedDividend>
    <us-gaap:DebtInstrumentDescription contextRef="c154">On April 15, 2020, the Company entered into
Exchange Agreements with the holders of certain convertible promissory notes. Pursuant to these Exchange Agreements, the holders agreed
to exchange their convertible promissory notes of $330,000 and 33,000 warrants issued in connection with this debt for an aggregate of
82,500 shares of the Company&#x2019;s common stock at a price of $4.00 per share. Consequently, the Company recorded a loss on debt extinguishment
of $198,000 during the year ended December 31, 2020.&#160;</us-gaap:DebtInstrumentDescription>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c155" decimals="0" unitRef="usd">198000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:SharesIssued contextRef="c156" decimals="0" unitRef="shares">170000</us-gaap:SharesIssued>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c10">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;Number&lt;br/&gt; of Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt;
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt;
    Contractual&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;&lt;span style="-keep: true"&gt;Balance Outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;0.005&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;104,970&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;Granted/Issued/ Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-288"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-289"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-290"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-291"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;Balance Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;0.005&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;127,290&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;Granted/Issued/ Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-292"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-293"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-294"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-295"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Balance Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;0.005&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;42,870&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Exercisable, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;0.005&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;42,870&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c162" decimals="INF" unitRef="shares">6000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices contextRef="c162" decimals="3" unitRef="usdPershares">0.005</silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c163">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c162" decimals="0" unitRef="usd">104970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c164" decimals="INF" unitRef="shares">6000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices contextRef="c164" decimals="3" unitRef="usdPershares">0.005</silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c163">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c164" decimals="0" unitRef="usd">127290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c166" decimals="INF" unitRef="shares">6000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices contextRef="c166" decimals="3" unitRef="usdPershares">0.005</silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c165">P2Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c166" decimals="0" unitRef="usd">42870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c166" decimals="INF" unitRef="shares">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c166" decimals="3" unitRef="usdPershares">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c165">P2Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c166" decimals="0" unitRef="usd">42870</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c10">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
    of Warrants&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
    Average Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
    Average Remaining Contractual Term (Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;br/&gt;
    Intrinsic&lt;br/&gt;
    Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance Outstanding, December
    31, 2019&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;44,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.80&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;337,750&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(44,500&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-296"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-297"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-298"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-299"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-300"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-301"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;347,080&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.50&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.12&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-302"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;347,080&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.50&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.12&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-303"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable, December 31, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;347,080&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.50&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.12&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-304"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <silo:NumberOfWarrant contextRef="c167" decimals="INF" unitRef="shares">44500</silo:NumberOfWarrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c167" decimals="2" unitRef="usdPershares">10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c93">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue contextRef="c167" decimals="0" unitRef="usd">337750</silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue>
    <silo:ShareBasedComponsationNumberOfWarrantsForfeited contextRef="c93" decimals="INF" unitRef="shares">-44500</silo:ShareBasedComponsationNumberOfWarrantsForfeited>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="c93" decimals="2" unitRef="usdPershares">10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <silo:ShareBasedComponsationNumberOfWarrantsGranted contextRef="c92" decimals="INF" unitRef="shares">347080</silo:ShareBasedComponsationNumberOfWarrantsGranted>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c92" decimals="2" unitRef="usdPershares">15.5</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <silo:ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted contextRef="c92">P4Y1M13D</silo:ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted>
    <silo:NumberOfWarrant contextRef="c169" decimals="INF" unitRef="shares">347080</silo:NumberOfWarrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c169" decimals="2" unitRef="usdPershares">15.5</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c92">P4Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <silo:ShareBasedComponsationNumberOfWarrantsExercisableinDollars contextRef="c92" decimals="INF" unitRef="shares">347080</silo:ShareBasedComponsationNumberOfWarrantsExercisableinDollars>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c169" decimals="2" unitRef="usdPershares">15.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <silo:ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable contextRef="c92">P4Y1M13D</silo:ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable>
    <silo:ConvertibleLongTermNotesPayables contextRef="c157" decimals="0" unitRef="usd">330000</silo:ConvertibleLongTermNotesPayables>
    <silo:WarrantIssued contextRef="c157" decimals="0" unitRef="shares">33000</silo:WarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan contextRef="c157" decimals="0" unitRef="shares">82500</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c158" decimals="2" unitRef="usdPershares">4</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DebtInstrumentDescription contextRef="c159">The Company issued 82,500 shares of common stock which was more than the shares that would have been issued at the original
conversion price of $4.00 per share or 33,000 shares of common stock, an excess of 49,500 shares of common stock. The excess shares were
valued at a price of $4.00 per share.</us-gaap:DebtInstrumentDescription>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c93" decimals="0" unitRef="usd">198000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c160" decimals="0" unitRef="shares">5000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <silo:WarrantsTerm contextRef="c161">P5Y</silo:WarrantsTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c160" decimals="2" unitRef="usdPershares">10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <silo:CommonStockServiceDescription contextRef="c92">The warrants were valued on the grant
date at approximately $16.50 per warrant for a total of $83,728 using a Black-Scholes option pricing model with the following assumptions:
stock price of $17.50 per share (based on the quoted trading price on the date of grant), volatility of 169%, expected term of five year,
and a risk-free interest rate of 0.46%.</silo:CommonStockServiceDescription>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c10" decimals="0" unitRef="usd">83728</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <silo:PurchaseAgreementsDescription contextRef="c131">On February 9, 2021, the Company entered into
pursuant to securities purchase agreements with certain investors pursuant to which it sold warrants to purchase up to 285,067 shares
of the Company&#x2019;s common stock and 4,276 shares of the Company&#x2019;s Series C Convertible Preferred Stock. The February Warrants
are exercisable for a period of five years from the date of issuance at an exercise price of $15.00 per share, subject to adjustment.
If, after a period of 180 days after the date of issuance of the February Warrants, a registration statement covering the resale of the
February Warrant Shares is not effective, the holders may exercise the February Warrants by means of a cashless exercise. In addition,
pursuant to the terms of the offering, the Company issued the Placement Agent Warrants to purchase up to an aggregate of 57,013 shares
of common stock to its placement agents, or 10% of the shares of common stock issuable upon conversion of the Series C Preferred Stock
and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing
date of the offering at an exercise price of $17.50 per share, subject to adjustment (see Series C Convertible Preferred Stock Financing
above). Such warrants issued to various investors and to the placement agents were recorded as additional paid in capital with an offsetting
debit applied against additional paid in capital, thus these warrants have no further accounting effect within the equity section.</silo:PurchaseAgreementsDescription>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 8 - &lt;span style="text-decoration:underline"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company maintains deferred tax assets
and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for
financial reporting purposes and the amounts used for income tax purposes. The deferred tax assets on December 31, 2021 and 2020 consist
of net operating loss carry-forwards. The net deferred tax asset has been fully offset by a valuation allowance because of the uncertainty
of the attainment of future taxable income. As of December 31, 2021 and 2020, the Company had not recorded a liability for any unrecognized
tax positions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The items accounting for the difference between
income taxes at the effective statutory rate and the provision for income taxes for the years ended December 31, 2021 and 2020 was as
follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Income tax (benefit) liability at U.S. statutory rate of 21%&#x202f;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;819,786&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(637,879&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Income tax (benefit) liability &#x2013; state&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;253,743&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(197,439&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,893&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;457,798&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,027,760&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;377,520&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total provision for income tax&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;24,876&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-305"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s approximate net deferred
tax asset as of December 31, 2021 and 2020 was as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Net operating loss carryforward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,647,335&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;868,338&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Net capital loss carryforward&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,707,701&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;123,932&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total deferred tax asset (liability) before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(60,366&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;992,271&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(992,271&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Provision for income tax&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;24,876&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-306"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-307"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-308"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;At December 31, 2021,
the Company had a capital gain of $6,660,483 which offset the prior year net capital loss carryforward $450,663 for a capital gain of
$6,209,820.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Due to the loss of
its Regulated Investment Company (&#x201c;RIC&#x201d;) tax status in 2017, any net tax operating losses generated as a RIC cannot be used
to offset any future taxable income. As of December 31, 2021, the Company had an aggregate estimated net operating loss carryforwards
of approximately $5,990,308 for income taxes. These net operating loss carries forwards may be available to reduce future years&#x2019;
taxable income. The net loss carryforward up until 2017 in the amount of $470,204, will expire in 2037. Net loss carryforwards in the
amount of $5,520,104 from 2018 onwards can be carried over indefinitely, subject to annual usage limits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Management believes
that it appears more likely than not that the Company will not realize these tax benefits due to the Company&#x2019;s continuing losses
for income taxes purposes. Accordingly, the Company has provided a 100% valuation allowance on the deferred tax asset benefit related
to the U.S. net operating loss and capital loss carry forwards to reduce the asset to zero. Management will review this valuation allowance
periodically and will make adjustments as necessary.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c10">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Income tax (benefit) liability at U.S. statutory rate of 21%&#x202f;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;819,786&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(637,879&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Income tax (benefit) liability &#x2013; state&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;253,743&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(197,439&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,893&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;457,798&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,027,760&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;377,520&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total provision for income tax&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;24,876&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-305"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c10" decimals="2" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c11" decimals="2" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c10" decimals="0" unitRef="usd">819786</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c11" decimals="0" unitRef="usd">-637879</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c10" decimals="0" unitRef="usd">253743</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c11" decimals="0" unitRef="usd">-197439</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <silo:AvailableForSalesEquitySecuritiesGrossUnrealizedGain contextRef="c10" decimals="0" unitRef="usd">-20893</silo:AvailableForSalesEquitySecuritiesGrossUnrealizedGain>
    <silo:AvailableForSalesEquitySecuritiesGrossUnrealizedGain contextRef="c11" decimals="0" unitRef="usd">457798</silo:AvailableForSalesEquitySecuritiesGrossUnrealizedGain>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c10" decimals="0" unitRef="usd">-1027760</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c11" decimals="0" unitRef="usd">377520</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c10" decimals="0" unitRef="usd">24876</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c10">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Net operating loss carryforward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,647,335&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;868,338&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Net capital loss carryforward&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,707,701&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;123,932&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total deferred tax asset (liability) before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(60,366&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;992,271&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(992,271&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Provision for income tax&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;24,876&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-306"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-307"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-308"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c1" decimals="0" unitRef="usd">1647335</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c2" decimals="0" unitRef="usd">868338</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <silo:DeferredTaxAssetsCapitalLossCarryforward contextRef="c1" decimals="0" unitRef="usd">-1707701</silo:DeferredTaxAssetsCapitalLossCarryforward>
    <silo:DeferredTaxAssetsCapitalLossCarryforward contextRef="c2" decimals="0" unitRef="usd">123932</silo:DeferredTaxAssetsCapitalLossCarryforward>
    <silo:DeferredTaxAssetGross contextRef="c1" decimals="0" unitRef="usd">-60366</silo:DeferredTaxAssetGross>
    <silo:DeferredTaxAssetGross contextRef="c2" decimals="0" unitRef="usd">992271</silo:DeferredTaxAssetGross>
    <silo:DeferredTaxAssetsValuationAllowances contextRef="c1" decimals="0" unitRef="usd">35490</silo:DeferredTaxAssetsValuationAllowances>
    <silo:DeferredTaxAssetsValuationAllowances contextRef="c2" decimals="0" unitRef="usd">-992271</silo:DeferredTaxAssetsValuationAllowances>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c10" decimals="0" unitRef="usd">24876</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:VentureCapitalGainsLossesNet contextRef="c10" decimals="0" unitRef="usd">6660483</us-gaap:VentureCapitalGainsLossesNet>
    <silo:NetCapitalLossCarryForward contextRef="c1" decimals="0" unitRef="usd">450663</silo:NetCapitalLossCarryForward>
    <silo:GainLossOnSaleOfCapitalLeaseNet contextRef="c10" decimals="0" unitRef="usd">6209820</silo:GainLossOnSaleOfCapitalLeaseNet>
    <silo:AggregateEstimatedNetOperatingLoss contextRef="c10" decimals="0" unitRef="usd">5990308</silo:AggregateEstimatedNetOperatingLoss>
    <silo:DescriptionOfIncomeTaxDescription contextRef="c10">The net loss carryforward up until 2017 in the amount of $470,204, will expire in 2037. Net loss carryforwards in the
amount of $5,520,104 from 2018 onwards can be carried over indefinitely, subject to annual usage limits.</silo:DescriptionOfIncomeTaxDescription>
    <us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange contextRef="c10">Accordingly, the Company has provided a 100% valuation allowance on the deferred tax asset benefit related
to the U.S. net operating loss and capital loss carry forwards to reduce the asset to zero.</us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 9 &#x2013; &lt;span style="text-decoration:underline"&gt;CONCENTRATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Customer Concentration&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the years ended December 30, 2021 and
2020, no customer accounted for over 10% of total revenues from apparel sales included in discontinued operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Vendor Concentrations&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended December 31, 2021, one
licensor accounted for 100% of the Company&#x2019;s vendor license agreements (see Note 10) related to the Company&#x2019;s biopharmaceutical
operation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended December 31, 2020, the
Company did not have any licensor.&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <silo:ConcentrationsRiskPercentage1 contextRef="c170" decimals="2" unitRef="pure">0.10</silo:ConcentrationsRiskPercentage1>
    <silo:ConcentrationsRiskPercentage1 contextRef="c171" decimals="2" unitRef="pure">0.10</silo:ConcentrationsRiskPercentage1>
    <silo:ConcentrationsRiskPercentage1 contextRef="c172" decimals="2" unitRef="pure">1</silo:ConcentrationsRiskPercentage1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 10 &#x2013; &lt;span style="text-decoration:underline"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Employment Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On April 17, 2020, the Company entered into
an employment agreement (&#x201c;Employment Agreement&#x201d;) with Eric Weisblum to serve as Chief Executive Officer and Chief Financial
Officer of the Company. The term of the Employment Agreement will continue for a period of one year from the date of execution date thereof
and automatically renews for successive one-year periods at the end of each term until either party delivers written notice of their
intent not to review at least six months prior to the expiration of the then effective term. The Employment Agreement provided for a
base salary of $120,000 and 152,619 of vested shares of the Company&#x2019;s common stock in April 2020. In addition, Mr. Weisblum shall
be eligible to earn a bonus, subject to the sole discretion of the Company&#x2019;s Board of Directors (&#x201c;Board&#x201d;). The Employment
Agreement may be terminated by either the Company or Mr. Weisblum at any time and for any reason upon 60 days prior written notice. Upon
termination of the Employment Agreement, Mr. Weisblum shall be entitled to (i) any equity award that has vested prior to the termination
date, (ii) reimbursement of expenses incurred on or prior to such termination date and (iii) such employee benefits to which he may be
entitled as of the termination date (collectively, the &#x201c;Accrued Amounts&#x201d;). Mr. Weisblum employment may also be terminated
by the Company at any time, with cause, death or disability (as defined in the Employment Agreement). Upon the termination of the Employment
Agreement for death or disability, Mr. Weisblum shall be entitled to receive the Accrued Amounts. The Employment Agreement also contains
covenants prohibiting Mr. Weisblum from disclosing confidential information with respect to the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 18, 2021, the Company and Mr. Weisblum
entered into the first amendment (the &#x201c;Amendment&#x201d;) to the Employment Agreement, effective as of January 1, 2021. Pursuant
to the Amendment Mr. Weisblum&#x2019;s base salary was increased from $120,000 per year to $180,000 per year and all the terms and provisions
of the Employment Agreement shall remain in full force and effect.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;License Agreements between the Company
and Vendors &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;University of Maryland, Baltimore -
License Agreement for Development and Use of Central Nervous System-Homing Peptides&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Commercial Evaluation License and Option
Agreement with the University of Maryland, Baltimore&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective as of July 15, 2020, the Company,
through its wholly-owned subsidiary, Silo Pharma, Inc. (see Note 1) and University of Maryland, Baltimore (&#x201c;UMB&#x201d;), entered
into a commercial evaluation license and option agreement (&#x201c;License Agreement&#x201d;), granting the Company an exclusive, non-sublicensable,
non-transferable license to with respect to the exploration of the potential use of central nervous system-homing peptides in vivo and
their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology. The License Agreement also
granted the Company an exclusive option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license (&#x201c;Exclusive
Option&#x201d;) to with respect to the subject technology. The License Agreement had a term of six months from the effective date however
if the Company exercises the Exclusive Option, the License Agreement shall expire at the end of the negotiation period (as defined in
the License Agreement) or upon execution of a master license agreement, whichever occurs first. The Company exercised its Exclusive Option
on January 13, 2021 and entered into a Master License Agreement on February 12, 2021. Both parties may terminate this agreement within
thirty days by giving a written notice. In July 2020, the Company paid a license fee of $10,000 to UMB pursuant to the License Agreement
which was recorded in professional fees during the year ended December 31, 2020 since the Company could not conclude that such costs
would be recoverable for this early-stage venture.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Master License Agreement with the University
of Maryland, Baltimore&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As disclosed above, effective as of February
12, 2021, the Company and University of Maryland, Baltimore (&#x201c;UMB&#x201d;), entered into the Master License Agreement (&#x201c;Master
License Agreement&#x201d;) which grants the Company an exclusive, worldwide, sublicensable, royalty-bearing license to certain intellectual
property: (i) to make, have made, use, sell, offer to sell, and import certain licensed products and: (ii) to use the invention titled,
&#x201c;Central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other
neuroinflammatory pathology&#x201d; and UMB&#x2019;s confidential information to develop and perform certain licensed processes for the
therapeutic treatment of neuroinflammatory disease.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Master License Agreement will remain in
effect on a Licensed Product-by-Licensed Product basis and country-by-country basis until the later of: (a) the last patent covered under
the Master License Agreement expires, (b) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory
exclusivity, or other legally enforceable market exclusivity, if applicable, or (c) 10 years after the first commercial sale of a Licensed
Product in that country, unless earlier terminated in accordance with the provisions of the Master License Agreement. The term of the
Master License Agreement shall expire 15 years after the Master License Agreement Effective Date in which (a) there were never any patent
rights, (b) there was never any data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally
enforceable market exclusivity or (c) there was never a first commercial sale of a Licensed Product.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company may assign, sublicense, grant,
or otherwise convey any rights or obligations under the Master License Agreement to a Company affiliate, without obtaining prior written
consent from UMB provided that it meets the terms defined in the Master License Agreement. The Company may grant sublicenses of some
or all of the rights granted by the Master License Agreement, provided that there is no uncured default or breach of any material term
or condition under the Master License Agreement, by Company, at the time of the grant, and that the grant complies with the terms and
conditions of the Master License Agreement. The Company shall be and shall remain responsible for the performance by each of the Company&#x2019;s
sublicensee. Any sublicense shall be consistent with and subject to the terms and conditions of the Master License Agreement and shall
incorporate terms and conditions sufficient to enable Company to comply with the Master License Agreement. The Company or Company affiliates
shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company&#x2019;s sublicense income
which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first
licensed product; and (b) 15% of the Company&#x2019;s sublicense income which is receivable with respect to any sublicense that is executed
after the filing of an NDA (or foreign equivalent) for the first licensed product.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the Master License Agreement,
the Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty
payments depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company shall
pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the effective date; and (b)
$50,000 on or before the first anniversary of the effective date. The license fee is non-refundable and is not creditable against any
other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing,
prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid $25,000 license fee on
February 17, 2021 which was recorded as prepaid expense and is being amortized over the 15-year term. The Company recognized amortization
expense of $4,375 during the year ended December 31, 2021. At December 31, 2021, prepaid expense and other current assets &#x2013; current
amounted $5,000 and prepaid expense &#x2013; non-current amounts $15,625 as reflected in the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Milestone Payment Terms:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Milestone&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Receipt of New Drug Application (&#x201c;NDA&#x201d;) (or foreign equivalent) approval for a Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Achievement of First Commercial Sale of Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Royalty Payments Terms:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(i)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3% on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5% on sales of licensed products during the applicable calendar year for sales greater than $50,000,000; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(iii)&lt;/td&gt;&lt;td style="text-align: justify"&gt;a minimum annual
                                            royalty payments, as follows:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Minimum Annual Royalty&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Prior to First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-309; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Year of First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-310; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;First calendar year following the First Commercial Sale&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Second calendar year following the First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Third calendar year following the First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In April 2021, in connection with the Company&#x2019;s
Sublicense Agreement with Aikido Pharma Inc. (see below - &lt;i&gt;Patent License Agreement with Aikido Pharma Inc.&lt;/i&gt;), the Company paid
25% of its sublicense income to UMB, pursuant to the Master License Agreement, which amounted to $12,500. The Company recognized amortization
expense of $628 during the year ended December 31, 2021. At December 31, 2021, prepaid expense and other current assets &#x2013; current
amounted $838 and prepaid expenses &#x2013; non-current amounts $11,034 as reflected in the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;University of Maryland, Baltimore -
License Agreement for Development and Use of Joint-Homing Peptides&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Commercial Evaluation License and Option
Agreement with the University of Maryland, Baltimore&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective as of February 26, 2021, the Company,
through its wholly-subsidiary, Silo Pharma, Inc., and University of Maryland, Baltimore (&#x201c;UMB&#x201d;), entered into a commercial
evaluation license and option agreement (&#x201c;License Agreement&#x201d;), which granted the Company an exclusive, non-sublicensable,
non-transferable license to with respect to the exploration of the potential use of joint-homing peptides for use in the investigation
and treatment of arthritogenic processes. The License Agreement also granted the Company an exclusive option to negotiate and obtain
an exclusive, sublicensable, royalty-bearing license (&#x201c;Exclusive Option&#x201d;) to with respect to the subject technology. The
License Agreement had a term of six months from the effective date. Both parties could have terminated the License Agreement within thirty
days by giving a written notice.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 6, 2021, the Company entered into
a First Amendment Agreement (&#x201c;Amended License Agreement&#x201d;) with UMB to extend the term of the original License Agreement by
an additional six months such that the Amended License Agreement was effective until February 25, 2022 however, if the Company exercises
the Exclusive Option, the License Agreement shall expire at the end of the negotiation period (as defined in the License Agreement) or
upon execution of a master license agreement, whichever occurs first. The Company paid a license fee of $10,000 to UMB in March 2021
pursuant to the License Agreement which was recorded in professional fees during the year ended December 31, 2021, since the Company
could not conclude that such costs would be recoverable for this early-stage venture. Subsequent to December 31, 2021, the Company and
UMB entered into a Second Amendment Agreement (see Note 11).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;License Agreements between the Company
and Customer&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Customer Patent License Agreement with
Aikido Pharma Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 5, 2021, the Company and its subsidiary
Silo Pharma, Inc., a Florida corporation, entered into a patent license agreement (&#x201c;License Agreement&#x201d;) (collectively, the
&#x201c;Licensor&#x201d;) and Aikido Pharma Inc. (&#x201c;Aikido&#x201d; or the &#x201c;Customer&#x201d;), as amended on April 12, 2021, pursuant
to which the Licensor granted Aikido an exclusive, worldwide (&#x201c;Territory&#x201d;), sublicensable, royalty-bearing license to certain
intellectual property: (i) to make, have made, use, provide, import, export, lease, distribute, sell, offer for sale, develop and advertise
certain licensed products and (ii) to develop and perform certain licensed processes for the treatment of cancer and symptoms caused
by cancer (&#x201c;Field of Use&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The License Agreement also provided that,
if the Licensor exercised the option granted to it pursuant to its commercial evaluation license and option agreement with UMB, effective
as of July 15, 2020, it would grant Aikido a non-exclusive sublicense (&#x201c;Right&#x201d;) to certain UMB patent rights in the field
of neuroinflammatory diseases occurring in patients diagnosed with cancer (&#x201c;Field&#x201d;). Pursuant to the License Agreement, Aikido
agreed to pay the Licensor, among other things, (i) a one-time non-refundable cash payment of $500,000 and (ii) royalty payments equal
to 2% of net sales (as defined in the License Agreement) in the Field of Use in the Territory. In addition, Aikido agreed to issue the
Licensor 500 shares of Aikido&#x2019;s newly designated Series M Convertible Preferred Stock which were to be converted into an aggregate
of 625,000 shares of the Aikido&#x2019;s common stock. On April 12, 2021, the Company entered into an amendment to the License Agreement
(&#x201c;Amended License Agreement&#x201d;) with Aikido dated January 5, 2021 whereby Aikido issued an aggregate of 625,000 restricted
shares of Aikido&#x2019;s common stock instead of the 500 shares of the Series M Convertible Preferred Stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the License Agreement, the Company
is required to prepare file, prosecute, and maintain the licensed patents. Unless earlier terminated, the term of the license to the
licensed patents will continue until the expiration or abandonment of all issued patents and filed patent applications within the licensed
patents. The Company may terminate the License Agreement upon 30 day written notice if Aikido fails to pay any amounts due and payable
to the Company or if Aikido or any of its affiliates brings a patent challenge against the Company, assists others in bringing a legal
or administrative challenge to the validity, scope, or enforceability of or opposes any of the licensed patents (&#x201c;Patent Challenge&#x201d;)
against the Company (except as required under a court order or subpoena). Aikido may terminate the Agreement at any time without cause,
and without incurring any additional penalty, (i) by providing at least 30 days&#x2019; prior written notice and paying the Company all
amounts due to it through such termination effective date. Either party may terminate the Agreement for material breaches that have failed
to be cured within 60 days after receiving written notice. The Company collected the non-refundable cash payment of $500,000 on January
5, 2021 which was recorded as deferred revenue to be recognized as revenues over the 15 year term of the License Agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;With respect to a vote of Aikido&#x2019;s stockholders
to approve a reverse split of its common stock no later than December 31, 2021 only (&#x201c;Reverse Stock Split Vote&#x201d;), each share
of the Series M Convertible Preferred Stock shall be entitled to such number of votes equal to 20,000 shares of Aikido&#x2019;s common
stock. In addition, each share of the Series M Convertible Preferred Stock shall be convertible, at any time after the earlier of (i)
the date that the Reverse Stock Split Vote is approved by Aikido&#x2019;s stockholders and (ii) December 31, 2021, at the option of the
holder, into such number of shares of Aikido&#x2019;s common stock determined by dividing the Stated Value by the Conversion Price. &#x201c;Stated
Value&#x201d; means $1,000. &#x201c;Conversion Price&#x201d; means $0.80, subject to adjustment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Prior to the April 12, 2021 issuance of the
common stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible
Preferred stock which was equivalent into Aikido&#x2019;s 625,000 shares of common stock at a fair value of $0.85 per common share or
$531,250 based quoted trading price of Aikido&#x2019;s common stock on the date of grant. The Company recorded an equity investment of
$531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license. Accordingly, the Company
recorded a total deferred revenue of $1,031,250 ($500,000 cash received and $531,250 value of equity securities received) to be recognized
as revenues over the 15-year term. The Company recognized revenue of $68,750 during the year ended December 31, 2021. At December 31,
2021, deferred revenue &#x2013; current portion amounted $68,750 and deferred revenue &#x2013; long-term portion amounted $893,750 as reflected
in the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Right shall be to the full extent permitted
by and on terms and conditions required by UMB for a term consistent with the term of patent and technology licenses that UMB normally
grants. In the event that the Company exercises its option and executes a license with UMB to the UMB patent rights within 40 days after
the execution of such UMB license, for consideration to be agreed upon and paid by Aikido, which consideration shall in no event exceed
110% of any fee payable by the Company to UMB for the right to sublicense the UMB patent rights. The Company shall grant Aikido a nonexclusive
sublicense in the United States to the UMB patent rights in the Field, subject to the terms of any UMB license Licensor obtains, including
any royalty obligations on sublicensees required under any such sublicense. The option was exercised on January 13, 2021. Accordingly,
on April 6, 2021, the Company entered into the Sublicense Agreement with Aikido pursuant to which it granted Aikido a worldwide exclusive
sublicense to its licensed patents under the Master License Agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Customer Sublicense&#160;Agreement with
Aikido Pharma Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 6, 2021 (the &#x201c;Sublicense Agreement
Effective Date&#x201d;), the Company entered into the Sublicense Agreement with Aikido pursuant to which the Company granted Aikido an
exclusive worldwide sublicense to (i) make, have made, use, sell, offer to sell and import the Licensed Products (as defined below) and
(ii) in connection therewith to (A) use an invention known as &#x201c;Central nervous system-homing peptides in vivo and their use for
the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology&#x201d; which was sublicensed to the Company
pursuant to the Master License Agreement&#160;and (B) practice certain patent rights (&#x201c;Patent Rights&#x201d;) for the therapeutic
treatment of neuroinflammatory disease in cancer patients. &#x201c;Licensed Products&#x201d; means any product, service, or process, the
development, making, use, offer for sale, sale, importation, or providing of which: (i) is covered by one or more claims of the Patent
Rights; or (ii) contains, comprises, utilizes, incorporates, or is derived from the Invention or any technology disclosed in the Patent
Rights.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the Sublicense Agreement, Aikido
agreed to pay the Company (i) an upfront license fee of $50,000, (ii)&#160;the same sales-based royalty payments that the Company is
subject to under the Master License Agreement and (iii) total milestone payments of up to $1.9 million. The Sublicense Agreement shall
continue on a Licensed Product-by-Licensed Product and country-by-country basis until the later of (i) the date of expiration of the
last to expire claim of the Patent Rights covering such Licensed Product in such country, (ii) the expiration of data protection, new
chemical entity, orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity, if applicable and (iii)
10 years after the first commercial sale of a Licensed Product in that country, unless terminated earlier pursuant to the terms of the
Sublicense Agreement. Furthermore, the Sublicense Agreement shall expire 15 years after the Sublicense Agreement Effective Date with
respect to any country in which (i) there were never any Patent Rights, (ii) there was never any data protection, new chemical entity,
orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity with respect to a Licensed Product and
(ii) there was never a commercial sale of a Licensed Product, unless such agreement is earlier terminated pursuant to its terms. The
Company collected the upfront license fee of $50,000 in April 2021. The Company recognized revenue of $2,514 during the year ended December
31, 2021. At December 31, 2021, deferred revenue &#x2013; current portion amounted $3,352 and deferred revenue &#x2013; long-term portion
amounted $44,134 as reflected in the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Sponsored Study and Research Agreements
between the Company and Vendors&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Investigator-Sponsored Study Agreement
with Maastricht University of the Netherlands&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 1, 2020, the Company entered into
an investigator-sponsored study agreement (&#x201c;Study Agreement&#x201d;) with Maastricht University of the Netherlands. The research
project is a clinical study to examine the effects of repeated low doses of psilocybin and lysergic acid diethylamide on cognitive and
emotional dysfunctions in Parkinson&#x2019;s disease and to understand its mechanism of action. The Study Agreement shall terminate on
October 31, 2024, unless earlier terminated pursuant to the terms thereof. The Company shall pay a total fee of 433,885 Euros ($507,602
USD) exclusive of value added tax to be amortized over the four-year term and payment schedule as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Payment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;86,777 Euros ($101,520 USD)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 69%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon signing the Study Agreement and was paid in December 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;86,777 Euros ($101,520 USD)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Obtained approval from ethical committee&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;86,777 Euros ($101,520 USD)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Data collection has commenced&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;130,166 Euros ($152,281 USD)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First half of the participants are tested&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;43,885 Euros ($50,760 USD)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Completion of data collection and delivery of final report&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.4pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2020, the Company paid the first
payment of $101,520 which was recorded to prepaid expense and other current assets &#x2013; current of which approximately $22,318 was
amortized in fiscal 2020. In September 2021, the Company notified Maastricht University of Netherlands for an early termination of this
agreement. Maastricht University of Netherlands has not reached the second phase which is to obtain approval from ethical committee.
The Company has no further obligation after the termination. During the year ended December 31, 2021, the Company amortized the remaining
prepaid expense of $79,202.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Investigator-Sponsored Study Agreement
with University of Maryland, Baltimore &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 5, 2021, the Company entered into
an investigator-sponsored study agreement (&#x201c;Sponsored Study Agreement&#x201d;) with the University of Maryland, Baltimore. The research
project is a clinical study to examine a novel peptide-guided drug delivery approach for the treatment of multiple sclerosis (&#x201c;MS&#x201d;).
More specifically, the study is designed to evaluate (1) whether MS-1-displaying liposomes can effectively deliver dexamethasone to the
CNS and (2) whether MS-1-displaying liposomes are superior to plain liposomes, also known as free drug, in inhibiting the relapses and
progression of experimental autoimmune encephalomyelitis. Pursuant to the Sponsored Study Agreement, the research shall commence on March
1, 2021 and will continue until substantial completion, subject to renewal upon mutual written consent of the parties. The total cost
under the Sponsored Study Agreement shall not exceed $81,474 which is payable in two equal installments of $40,737 upon execution of
the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. The Company
paid $40,737 on January 13, 2021 which was recorded in prepaid expense to be amortized over the nine-month period. Currently, the project
has not been completed due to the delays cause by the Covid-19 pandemic. During the year ended December 31, 2021, the Company fully amortized
the prepaid expense of $40,737.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Sponsored Research Agreement with The
Regents of the University of California&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 1, 2021 (the &#x201c;Effective Date&#x201d;),
the Company entered into a sponsored research agreement (the &#x201c;Sponsored Research Agreement&#x201d;) with The Regents of the University
of California, on behalf of its San Francisco Campus (&#x201c;UCSF&#x201d;) pursuant to which UCSF shall conduct a study to examine psilocybin&#x2019;s
effect on inflammatory activity in humans to accelerate its implementation as a potential treatment for Parkinson&#x2019;s Disease, chronic
pain, and bipolar disorder. Pursuant to the Agreement, the Company shall pay UCSF a total fee of $342,850 to conduct the research over
the two-year period. The Agreement shall be effective for a period of two years from the Effective Date, subject to renewal or earlier
termination as set forth in the Sponsored Research Agreement. The Company paid the first payment of $40,000 pursuant to the payment schedule
on the Sponsored Research Agreement on June 15, 2021, second payment of $40,000 on September 9, 2021 and $20,570 on November 18, 2021
which were recorded to prepaid expense and other current assets &#x2013; current to be amortized over the two-year period. During the
year ended December 31, 2021, the Company amortized $92,855 of the prepaid expense leaving a prepaid asset of $7,715 at December 31,
2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Sponsored Research Agreement with University
of Maryland, Baltimore&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 6, 2021, the Company and University
of Maryland, Baltimore (&#x201c;UMB&#x201d;) entered into a sponsored research agreement (&#x201c;July 2021 Sponsored Research Agreement&#x201d;)
pursuant to which UMB shall&#160;evaluate the pharmacokinetics of dexamethasone delivered to arthritic rats via liposome.&#160;The research
pursuant to the July 2021 Sponsored Research Agreement shall commence on September 1, 2021 and will continue until the substantial completion
thereof, subject to renewal upon written consent of the parties. The July 2021 Sponsored Research Agreement may be terminated by either
party upon 30 days&#x2019; prior written notice to the other party. In addition, if either party commits any material breach of or defaults
with respect to any terms or conditions of the July 2021 Sponsored Research Agreement and fails to remedy such default or breach within
10 business days after written notice from the other party, the party giving notice may terminate the July 2021 Sponsored Research Agreement
as of the date of receipt of such notice by the other party. If the Company terminates the July 2021 Sponsored Research Agreement for
any reason other than an uncured material breach by UMB, the Company shall relinquish any and all rights it may have in the Results (as
defined in the July 2021 Sponsored Research Agreement) to UMB. In addition, if the July 2021 Sponsored Research Agreement is terminated
early, the Company, among other things, will pay all costs incurred and accrued by UMB as of the date of termination.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the terms of the July 2021 Sponsored
Research Agreement, UMB granted the Company an option (the &#x201c;Option&#x201d;) to negotiate and obtain an exclusive license to any
UMB Arising IP (as defined in the July 2021 Sponsored Research Agreement) and UMB&#x2019;s rights in any Joint Arising IP (as defined
in the July 2021 Sponsored Research Agreement) (collectively, the &#x201c;UMB IP&#x201d;). The Company may exercise the Option by giving
UMB written notice within 60 days after it receives notice from UMB of the UMB IP. Pursuant to the July 2021 Sponsored Research Agreement,
the Company shall pay UMB the fees below:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="5" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Payment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;92,095&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 84%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon execution of the July 2021 Sponsored Research Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;92,095&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;92,095&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company paid the first payment of $92,095
on September 1, 2021 which was recorded to prepaid expense and other current assets &#x2013; current to be amortized over the estimated
project timeline of twelve months. During the year ended December 31, 2021, the Company fully amortized the prepaid expense of $92,095.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Sponsored Research Agreement with Columbia
University&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 1, 2021, the Company entered into
a sponsored research agreement with Columbia University pursuant to which the Company has been granted an option to license certain assets
currently under development, including Alzheimer&#x2019;s disease. The term of the option will commence on the effective date of this
agreement and will expire upon the earlier of (i) 90 days after the date of the Company&#x2019;s receipt of a final research report for
each specific research proposal as defined in the agreement or (ii) termination of the research. If the Company elects to exercise the
option, both parties will commence negotiation of a license agreement and will execute a license agreement no later than 3 months after
the dated of the exercise of the option. Columbia University and the Company will work towards developing a therapeutic treatment for
patients suffering from Alzheimer&#x2019;s disease to post-traumatic stress disorder. During a one-year period from the date of this agreement,
the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the payment schedule
as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months after the start
of the project and, (iv)10% at completion of the project. The Company paid the first payment of $430,825 in November 2021 which was recorded
to prepaid expense and other current assets &#x2013; current to be amortized over the estimated project timeline of twelve months. During
the year ended December 31, 2021, the Company amortized $359,021 of the prepaid expense. As of December 31, 2021, prepaid expense related
to the sponsored research agreement was $71,804.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Joint Venture Agreement with Zyl&#xf6; Therapeutics, Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 22, 2021 (&#x201c;Effective Date&#x201d;),
the Company entered into a Joint Venture Agreement (&#x201c;JV Agreement&#x201d;) with Zyl&#xf6; Therapeutics, Inc. (&#x201c;ZTI&#x201d;)
pursuant to which the parties agreed to form a joint venture entity, to be named Ketamine Joint Venture, LLC (&#x201c;Joint Venture&#x201d;),
to, among other things, focus on the clinical development of ketamine using ZTI&#x2019;s Z-pod&#x2122; technology (&#x201c;Venture&#x201d;).
Pursuant to the JV Agreement, the Company shall act as the manager (&#x201c;Manager&#x201d;) of the Joint Venture. The Joint Venture shall
terminate if the development program does not meet certain specifications and milestones as set forth in the JV Agreement within 30 days
of the date set forth in the JV Agreement. Notwithstanding the foregoing, the Manager may, in its sole discretion, terminate the Joint
Venture at any time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the terms of the JV Agreement,
(A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall
contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and
trade secrets with respect to its Z-pod&#x2122; technology for the loading and release of ketamine, (3) ketamine to be used for clinical
purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the
interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be
owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event
shall either party own more than 60% of the interest in the Joint Venture. As of December 31, 2021 and as of the current date of this
report, the joint venture entity has not been formed yet.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Furthermore, pursuant to the terms of the
JV Agreement, ZTI shall grant the Joint Venture a sublicense pursuant to its license agreement (the &#x201c;License Agreement&#x201d;)
with Albert Einstein College of Medicine dated November 27, 2017, in the event that the Company or a third party makes a request indicating
that the patented technology (the &#x201c;Patented Technology&#x201d;) licensed to ZTI pursuant to the License Agreement is needed to advance
the development of the Joint Venture or it is contemplated or determined that the Patented Technology will be sold. Furthermore, pursuant
to the JV Agreement, ZTI granted the Company an exclusive option to enter into a separate joint venture for the clinical development
of psilocybin using ZTI&#x2019;s Z-pod&#x2122; technology on the same terms and conditions set forth in the JV Agreement, which option
shall expire 24 months after the JV Effective Date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Amended Service Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 10, 2021 (&#x201c;Effective Date&#x201d;),
the Company entered into an Amendment Agreement (&#x201c;Amended Service Agreement&#x201d;) to a certain service agreement dated on September
8, 2020 with the University of Texas (&#x201c;University&#x201d;) at Austin whereby the University will provide advisory service and assist
the Company on identifying license and sponsored research opportunities for the Company. The Company shall pay the University $5,000
per quarter starting on the Effective Date. Any cost incurred will be reimbursed only after prior written consent by the Company. The
term of the Amended Service Agreement is for 36 months unless earlier terminated by either party upon giving a written notice as defined
in the agreement. During the year ended December 31, 2021, the Company paid $5,000 related to this agreement.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <silo:EmploymentAgreementDescription contextRef="c173">The Employment Agreement provided for a
base salary of $120,000 and 152,619 of vested shares of the Company&#x2019;s common stock in April 2020. In addition, Mr. Weisblum shall
be eligible to earn a bonus, subject to the sole discretion of the Company&#x2019;s Board of Directors (&#x201c;Board&#x201d;).</silo:EmploymentAgreementDescription>
    <us-gaap:SupplementalUnemploymentBenefitsSalaryContinuation contextRef="c174" decimals="0" unitRef="usd">120000</us-gaap:SupplementalUnemploymentBenefitsSalaryContinuation>
    <us-gaap:SupplementalUnemploymentBenefitsSalaryContinuation contextRef="c175" decimals="0" unitRef="usd">180000</us-gaap:SupplementalUnemploymentBenefitsSalaryContinuation>
    <silo:LicenseFee contextRef="c176" decimals="0" unitRef="usd">10000</silo:LicenseFee>
    <silo:CommercialSaleTerm contextRef="c10">P10Y</silo:CommercialSaleTerm>
    <silo:LicenseAgreementExpire contextRef="c10">P15Y</silo:LicenseAgreementExpire>
    <silo:SublicenseIncomeDescription contextRef="c10">The Company or Company affiliates
shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company&#x2019;s sublicense income
which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first
licensed product; and (b) 15% of the Company&#x2019;s sublicense income which is receivable with respect to any sublicense that is executed
after the filing of an NDA (or foreign equivalent) for the first licensed product.</silo:SublicenseIncomeDescription>
    <silo:LicenseAgreementDescription contextRef="c10">the Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty
payments depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company shall
pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the effective date; and (b)
$50,000 on or before the first anniversary of the effective date. The license fee is non-refundable and is not creditable against any
other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing,
prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid $25,000 license fee on
February 17, 2021 which was recorded as prepaid expense and is being amortized over the 15-year term. The Company recognized amortization
expense of $4,375 during the year ended December 31, 2021. At December 31, 2021, prepaid expense and other current assets &#x2013; current
amounted $5,000 and prepaid expense &#x2013; non-current amounts $15,625 as reflected in the accompanying consolidated balance sheets.</silo:LicenseAgreementDescription>
    <silo:ScheduleOfMilestonePayments contextRef="c10">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Milestone&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Receipt of New Drug Application (&#x201c;NDA&#x201d;) (or foreign equivalent) approval for a Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Achievement of First Commercial Sale of Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</silo:ScheduleOfMilestonePayments>
    <silo:Milestone contextRef="c190">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product</silo:Milestone>
    <silo:MilestonePayment contextRef="c190" decimals="0" unitRef="usd">50000</silo:MilestonePayment>
    <silo:Milestone contextRef="c191">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product</silo:Milestone>
    <silo:MilestonePayment contextRef="c191" decimals="0" unitRef="usd">100000</silo:MilestonePayment>
    <silo:Milestone contextRef="c192">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product</silo:Milestone>
    <silo:MilestonePayment contextRef="c192" decimals="0" unitRef="usd">250000</silo:MilestonePayment>
    <silo:Milestone contextRef="c193">Receipt of New Drug Application (&#x201c;NDA&#x201d;) (or foreign equivalent) approval for a Licensed Product</silo:Milestone>
    <silo:MilestonePayment contextRef="c193" decimals="0" unitRef="usd">500000</silo:MilestonePayment>
    <silo:Milestone contextRef="c194">Achievement of First Commercial Sale of Licensed Product</silo:Milestone>
    <silo:MilestonePayment contextRef="c194" decimals="0" unitRef="usd">1000000</silo:MilestonePayment>
    <silo:RoyaltyPaymentsDescription contextRef="c10">(i)3% on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and</silo:RoyaltyPaymentsDescription>
    <silo:ScheduleOfUMBMinimumRoyaltyPayments contextRef="c10">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Minimum Annual Royalty&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Prior to First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-309; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Year of First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-310; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;First calendar year following the First Commercial Sale&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Second calendar year following the First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Third calendar year following the First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</silo:ScheduleOfUMBMinimumRoyaltyPayments>
    <silo:UMBYearDescription contextRef="c190">Prior to First Commercial Sale</silo:UMBYearDescription>
    <silo:UMBYearDescription contextRef="c191">Year of First Commercial Sale</silo:UMBYearDescription>
    <silo:UMBYearDescription contextRef="c192">First calendar year following the First Commercial Sale</silo:UMBYearDescription>
    <silo:UMBPayment contextRef="c192" decimals="0" unitRef="usd">25000</silo:UMBPayment>
    <silo:UMBYearDescription contextRef="c193">Second calendar year following the First Commercial Sale</silo:UMBYearDescription>
    <silo:UMBPayment contextRef="c193" decimals="0" unitRef="usd">25000</silo:UMBPayment>
    <silo:UMBYearDescription contextRef="c194">Third calendar year following the First Commercial Sale</silo:UMBYearDescription>
    <silo:UMBPayment contextRef="c194" decimals="0" unitRef="usd">100000</silo:UMBPayment>
    <silo:SublicenseIncomePercentage contextRef="c177" decimals="2" unitRef="pure">0.25</silo:SublicenseIncomePercentage>
    <silo:SublicenseAgreementAmountPaid contextRef="c177" decimals="0" unitRef="usd">12500</silo:SublicenseAgreementAmountPaid>
    <silo:OtherDepreciationsAndAmortization contextRef="c178" decimals="0" unitRef="usd">628</silo:OtherDepreciationsAndAmortization>
    <silo:PaymentOfSponsoredResearchAmount contextRef="c10" decimals="0" unitRef="usd">838</silo:PaymentOfSponsoredResearchAmount>
    <silo:PrepaidExpenses contextRef="c1" decimals="0" unitRef="usd">11034</silo:PrepaidExpenses>
    <silo:LicenseFee contextRef="c179" decimals="0" unitRef="usd">10000</silo:LicenseFee>
    <silo:NonrefundableCashPayment contextRef="c10" decimals="0" unitRef="usd">500000</silo:NonrefundableCashPayment>
    <silo:NetSalePercentage contextRef="c10" decimals="2" unitRef="pure">0.02</silo:NetSalePercentage>
    <silo:LicensorShare contextRef="c10" decimals="0" unitRef="shares">500</silo:LicensorShare>
    <silo:AggregateOfConvertedShares contextRef="c10" decimals="0" unitRef="shares">625000</silo:AggregateOfConvertedShares>
    <silo:AggregateOfConvertedShares contextRef="c180" decimals="0" unitRef="shares">625000</silo:AggregateOfConvertedShares>
    <silo:LicensorShare contextRef="c180" decimals="0" unitRef="shares">500</silo:LicensorShare>
    <silo:NonrefundableCashPayment contextRef="c181" decimals="0" unitRef="usd">500000</silo:NonrefundableCashPayment>
    <silo:RevenueTerm contextRef="c181">P15Y</silo:RevenueTerm>
    <silo:NumberOfVotingShares contextRef="c10" decimals="0" unitRef="shares">20000</silo:NumberOfVotingShares>
    <silo:ReverseStockSplitVoteDescription contextRef="c10">In addition, each share of the Series M Convertible Preferred Stock shall be convertible, at any time after the earlier of (i)
the date that the Reverse Stock Split Vote is approved by Aikido&#x2019;s stockholders and (ii) December 31, 2021, at the option of the
holder, into such number of shares of Aikido&#x2019;s common stock determined by dividing the Stated Value by the Conversion Price. &#x201c;Stated
Value&#x201d; means $1,000. &#x201c;Conversion Price&#x201d; means $0.80, subject to adjustment.Prior to the April 12, 2021 issuance of the
common stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible
Preferred stock which was equivalent into Aikido&#x2019;s 625,000 shares of common stock at a fair value of $0.85 per common share or
$531,250 based quoted trading price of Aikido&#x2019;s common stock on the date of grant. The Company recorded an equity investment of
$531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license.</silo:ReverseStockSplitVoteDescription>
    <us-gaap:DeferredRevenue contextRef="c1" decimals="0" unitRef="usd">1031250</us-gaap:DeferredRevenue>
    <silo:CashReceived contextRef="c1" decimals="0" unitRef="usd">500000</silo:CashReceived>
    <silo:SecuritiesReceived contextRef="c1" decimals="0" unitRef="usd">531250</silo:SecuritiesReceived>
    <silo:RevenueTerm contextRef="c10">P15Y</silo:RevenueTerm>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c10" decimals="0" unitRef="usd">68750</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:InsuranceServicesRevenue contextRef="c10" decimals="0" unitRef="usd">68750</us-gaap:InsuranceServicesRevenue>
    <silo:DeferredRevenueLongtermPortion contextRef="c1" decimals="0" unitRef="usd">893750</silo:DeferredRevenueLongtermPortion>
    <silo:ConsiderationFeePayablePercentage contextRef="c10" decimals="2" unitRef="pure">1.10</silo:ConsiderationFeePayablePercentage>
    <silo:UpfrontLicenseFees contextRef="c10" decimals="0" unitRef="usd">50000</silo:UpfrontLicenseFees>
    <silo:UpfrontLicenseFees contextRef="c182" decimals="-5" unitRef="usd">1900000</silo:UpfrontLicenseFees>
    <silo:FirstCommercialSale contextRef="c10">P10Y</silo:FirstCommercialSale>
    <silo:AgreementShallExpire contextRef="c10">P15Y</silo:AgreementShallExpire>
    <silo:UpfrontLicenseFees contextRef="c183" decimals="0" unitRef="usd">50000</silo:UpfrontLicenseFees>
    <silo:RecognizedRevenues contextRef="c10" decimals="0" unitRef="usd">2514</silo:RecognizedRevenues>
    <us-gaap:DeferredRevenueCurrent contextRef="c184" decimals="0" unitRef="usd">3352</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OtherLongTermDebt contextRef="c1" decimals="0" unitRef="usd">44134</us-gaap:OtherLongTermDebt>
    <us-gaap:ManagementFeePayable contextRef="c1" decimals="0" unitRef="eur">433885</us-gaap:ManagementFeePayable>
    <us-gaap:ManagementFeePayable contextRef="c1" decimals="0" unitRef="usd">507602</us-gaap:ManagementFeePayable>
    <silo:ScheduleOfExclusiveOfValueAddedTaxToBeAmortized contextRef="c10">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Payment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;86,777 Euros ($101,520 USD)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 69%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon signing the Study Agreement and was paid in December 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;86,777 Euros ($101,520 USD)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Obtained approval from ethical committee&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;86,777 Euros ($101,520 USD)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Data collection has commenced&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;130,166 Euros ($152,281 USD)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First half of the participants are tested&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;43,885 Euros ($50,760 USD)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Completion of data collection and delivery of final report&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.4pt"&gt;&#160;&lt;/p&gt;</silo:ScheduleOfExclusiveOfValueAddedTaxToBeAmortized>
    <silo:Payment contextRef="c195" decimals="0" unitRef="eur">86777</silo:Payment>
    <silo:Payment contextRef="c195" decimals="0" unitRef="usd">101520</silo:Payment>
    <silo:PaymentDescription contextRef="c195">Upon signing the Study Agreement and was paid in December 2020</silo:PaymentDescription>
    <silo:Payment contextRef="c196" decimals="0" unitRef="eur">86777</silo:Payment>
    <silo:Payment contextRef="c196" decimals="0" unitRef="usd">101520</silo:Payment>
    <silo:PaymentDescription contextRef="c196">Obtained approval from ethical committee</silo:PaymentDescription>
    <silo:Payment contextRef="c197" decimals="0" unitRef="eur">86777</silo:Payment>
    <silo:Payment contextRef="c197" decimals="0" unitRef="usd">101520</silo:Payment>
    <silo:PaymentDescription contextRef="c197">Data collection has commenced</silo:PaymentDescription>
    <silo:Payment contextRef="c198" decimals="0" unitRef="eur">130166</silo:Payment>
    <silo:Payment contextRef="c198" decimals="0" unitRef="usd">152281</silo:Payment>
    <silo:PaymentDescription contextRef="c198">First half of the participants are tested</silo:PaymentDescription>
    <silo:Payment contextRef="c199" decimals="0" unitRef="eur">43885</silo:Payment>
    <silo:Payment contextRef="c199" decimals="0" unitRef="usd">50760</silo:Payment>
    <silo:PaymentDescription contextRef="c199">Completion of data collection and delivery of final report</silo:PaymentDescription>
    <silo:PaymentDescription contextRef="c185">In December 2020, the Company paid the first
payment of $101,520 which was recorded to prepaid expense and other current assets &#x2013; current of which approximately $22,318 was
amortized in fiscal 2020. In September 2021, the Company notified Maastricht University of Netherlands for an early termination of this
agreement. Maastricht University of Netherlands has not reached the second phase which is to obtain approval from ethical committee.
The Company has no further obligation after the termination. During the year ended December 31, 2021, the Company amortized the remaining
prepaid expense of $79,202.&#160;</silo:PaymentDescription>
    <silo:SponsoredStudyAgreementDescription contextRef="c181">The total cost
under the Sponsored Study Agreement shall not exceed $81,474 which is payable in two equal installments of $40,737 upon execution of
the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. The Company
paid $40,737 on January 13, 2021 which was recorded in prepaid expense to be amortized over the nine-month period. Currently, the project
has not been completed due to the delays cause by the Covid-19 pandemic. During the year ended December 31, 2021, the Company fully amortized
the prepaid expense of $40,737.</silo:SponsoredStudyAgreementDescription>
    <silo:SublicenseAmountPaid contextRef="c10" decimals="0" unitRef="usd">342850</silo:SublicenseAmountPaid>
    <silo:SponsoredResearchAgreementDescription contextRef="c10">The Company paid the first payment of $40,000 pursuant to the payment schedule
on the Sponsored Research Agreement on June 15, 2021, second payment of $40,000 on September 9, 2021 and $20,570 on November 18, 2021
which were recorded to prepaid expense and other current assets &#x2013; current to be amortized over the two-year period. During the
year ended December 31, 2021, the Company amortized $92,855 of the prepaid expense leaving a prepaid asset of $7,715 at December 31,
2021.</silo:SponsoredResearchAgreementDescription>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c186" decimals="0" unitRef="usd">7715</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <silo:ScheduleOfShallPayUMB contextRef="c10">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="5" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Payment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;92,095&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 84%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon execution of the July 2021 Sponsored Research Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;92,095&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;92,095&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</silo:ScheduleOfShallPayUMB>
    <silo:SponsoredPayment contextRef="c200" decimals="0" unitRef="usd">92095</silo:SponsoredPayment>
    <silo:PaymentDescription contextRef="c200">Upon execution of the July 2021 Sponsored Research Agreement</silo:PaymentDescription>
    <silo:SponsoredPayment contextRef="c201" decimals="0" unitRef="usd">92095</silo:SponsoredPayment>
    <silo:PaymentDescription contextRef="c201">Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement</silo:PaymentDescription>
    <silo:SponsoredPayment contextRef="c202" decimals="0" unitRef="usd">92095</silo:SponsoredPayment>
    <silo:PaymentDescription contextRef="c202">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement</silo:PaymentDescription>
    <silo:CompanyPaidCash contextRef="c187" decimals="0" unitRef="usd">92095</silo:CompanyPaidCash>
    <silo:OtherDepreciationsAndAmortization contextRef="c10" decimals="0" unitRef="usd">92095</silo:OtherDepreciationsAndAmortization>
    <silo:SponsoredResearchAgreementDescription contextRef="c188">If the Company elects to exercise the
option, both parties will commence negotiation of a license agreement and will execute a license agreement no later than 3 months after
the dated of the exercise of the option. Columbia University and the Company will work towards developing a therapeutic treatment for
patients suffering from Alzheimer&#x2019;s disease to post-traumatic stress disorder. During a one-year period from the date of this agreement,
the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the payment schedule
as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months after the start
of the project and, (iv)10% at completion of the project. The Company paid the first payment of $430,825 in November 2021 which was recorded
to prepaid expense and other current assets &#x2013; current to be amortized over the estimated project timeline of twelve months. During
the year ended December 31, 2021, the Company amortized $359,021 of the prepaid expense. As of December 31, 2021, prepaid expense related
to the sponsored research agreement was $71,804.</silo:SponsoredResearchAgreementDescription>
    <silo:PursuantTerms contextRef="c189">Pursuant to the terms of the JV Agreement,
(A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall
contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and
trade secrets with respect to its Z-pod&#x2122; technology for the loading and release of ketamine, (3) ketamine to be used for clinical
purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the
interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be
owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event
shall either party own more than 60% of the interest in the Joint Venture.</silo:PursuantTerms>
    <silo:PaymentOfUniversity contextRef="c10" decimals="0" unitRef="usd">5000</silo:PaymentOfUniversity>
    <silo:CompanyPaidCash contextRef="c10" decimals="0" unitRef="usd">5000</silo:CompanyPaidCash>
    <us-gaap:SubsequentEventsTextBlock contextRef="c10">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 11 &#x2013; &lt;span style="text-decoration:underline"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On January 27, 2022, the Company and Dr. James
Kuo entered into an employment agreement (&#x201c;Kuo Employment Agreement&#x201d;) for Dr. Kuo to serve as the Vice President of Research
&amp;amp; Development. The Kuo Employment Agreement shall be effective as of the date of the agreement and shall automatically renew for
a period of one year at every anniversary of the effective date, with the same terms and conditions, unless either party provides written
notice of its intention not to extend the term of the Kuo Employment Agreement at least thirty days&#x2019; prior to the applicable renewal
date. Dr. Kuo shall be paid an annual base salary of $30,000. For each twelve-month period of his employment, Dr. Kuo shall be entitled
to a bonus whereby amount and terms shall be in the sole and absolute discretion of the Board of Directors (&#x201c;Board&#x201d;) and
shall be payable at the Company&#x2019;s sole option in stock or in cash. In addition, an aggregate of 16,000 incentive stock options
was granted to Dr. Kou, at an exercise price equal to the closing price of the Company&#x2019;s common stock on the date of grant (&#x201c;ISOs&#x201d;)
as follows: (i) 6,000 ISOs (&#x201c;Initial Options&#x201d;), issued under the Company&#x2019;s 2020 Equity Incentive Plan (&#x201c;2020
Plan&#x201d;) which vest immediately, and (ii) an additional 10,000 ISOs (&#x201c;Additional Options&#x201d;), issued under the 2020 Plan
which shall vest ratably over two successive equal quarterly installments over the subsequent one year period as follows: 5,000 ISOs
shall vest at 9 months, and 12 months following the effective date of the Kuo Employment Agreement, which underlying Additional Options
shall be exercisable immediately upon the applicable vesting date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 28, 2022, the Company and University
of Maryland, Baltimore (&#x201c;UMB&#x201d;) entered into a second amendment to the commercial evaluation and license agreement dated February
26, 2021 (&#x201c;Second Amendment&#x201d;) (see Note 10 - &lt;i&gt;University of Maryland, Baltimore - License Agreement for Development and
Use of Joint-Homing Peptides&lt;/i&gt;). The Second Amendment to extend the term of the original license agreement until December 31, 2022.
However, if the Company exercises the Exclusive Option, the License Agreement shall expire at the end of the negotiation period (as defined
in the License Agreement) or upon execution of a master license agreement, whichever occurs first.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On March 11, 2022, the Company held its special
meeting of stockholders (&#x201c;Special Meeting&#x201d;). A total of 1,077,199 shares of common stock constituting a quorum were represented
in person or by valid proxies at the Special Meeting. The final results for of the matter submitted to a vote of stockholders at the
Special Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on February 14, 2022,
is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Proposal 1. At the Special Meeting, the stockholders
approved granting discretionary authority to the Company&#x2019;s Board of Directors to amend the Company&#x2019;s Certificate of Incorporation
to effect one or more consolidations of the Company&#x2019;s issued and outstanding shares of common stock, pursuant to which the shares
of common stock would be combined and reclassified into one share of common stock at a ratio within the range from 1-for-5 up to 1-for-50
(the &#x201c;Reverse Stock Split&#x201d;), provided that, (X) that the Company shall not effect Reverse Stock Splits that, in the aggregate,
exceeds 1-for-50, and (Y) any Reverse Stock Split is completed no later than the first anniversary of the record date of the Special
Meeting, or February 8, 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On September 14, 2022, the Company filed a
Certificate of Amendment to the Amended and Restated Articles of Incorporation (the &#x201c;Certificate of Amendment&#x201d;) with the
Secretary of State of the State of Nevada to effect a 1-for-50 reverse stock split (the &#x201c;Reverse Stock Split&#x201d;) with respect
to the outstanding shares of the Company&#x2019;s common stock. The Certificate of Amendment became effective on September 14, 2022. The
Reverse Stock Split was previously approved by the sole director and the majority of stockholders of the Company. The Reverse Stock Split
was deemed effective at the open of business on September 15, 2022. All share and per share data in the accompanying consolidated financial
statements have been retroactively restated to reflect the effect of the reverse stock split.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <silo:AnnualBaseSalary contextRef="c203" decimals="0" unitRef="usd">30000</silo:AnnualBaseSalary>
    <us-gaap:SubsequentEventDescription contextRef="c203">For each twelve-month period of his employment, Dr. Kuo shall be entitled
to a bonus whereby amount and terms shall be in the sole and absolute discretion of the Board of Directors (&#x201c;Board&#x201d;) and
shall be payable at the Company&#x2019;s sole option in stock or in cash. In addition, an aggregate of 16,000 incentive stock options
was granted to Dr. Kou, at an exercise price equal to the closing price of the Company&#x2019;s common stock on the date of grant (&#x201c;ISOs&#x201d;)
as follows: (i) 6,000 ISOs (&#x201c;Initial Options&#x201d;), issued under the Company&#x2019;s 2020 Equity Incentive Plan (&#x201c;2020
Plan&#x201d;) which vest immediately, and (ii) an additional 10,000 ISOs (&#x201c;Additional Options&#x201d;), issued under the 2020 Plan
which shall vest ratably over two successive equal quarterly installments over the subsequent one year period as follows: 5,000 ISOs
shall vest at 9 months, and 12 months following the effective date of the Kuo Employment Agreement, which underlying Additional Options
shall be exercisable immediately upon the applicable vesting date.</us-gaap:SubsequentEventDescription>
    <silo:TotalOfSharesOfCommonStock contextRef="c204" decimals="0" unitRef="shares">1077199</silo:TotalOfSharesOfCommonStock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c205">At the Special Meeting, the stockholders
approved granting discretionary authority to the Company&#x2019;s Board of Directors to amend the Company&#x2019;s Certificate of Incorporation
to effect one or more consolidations of the Company&#x2019;s issued and outstanding shares of common stock, pursuant to which the shares
of common stock would be combined and reclassified into one share of common stock at a ratio within the range from 1-for-5 up to 1-for-50
(the &#x201c;Reverse Stock Split&#x201d;), provided that, (X) that the Company shall not effect Reverse Stock Splits that, in the aggregate,
exceeds 1-for-50, and (Y) any Reverse Stock Split is completed no later than the first anniversary of the record date of the Special
Meeting, or February 8, 2023.</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c7" decimals="0" unitRef="usd">8734434</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="0" unitRef="usd">9837001</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <silo:EquityInvestmentsAtCost contextRef="c7" decimals="0" unitRef="usd">113012</silo:EquityInvestmentsAtCost>
    <silo:EquityInvestmentsAtCost contextRef="c1" decimals="0" unitRef="usd">419995</silo:EquityInvestmentsAtCost>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c7" decimals="0" unitRef="usd">99939</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c1" decimals="0" unitRef="usd">145324</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c7" decimals="0" unitRef="usd">8947385</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="0" unitRef="usd">10402320</us-gaap:AssetsCurrent>
    <us-gaap:InterestReceivableNoncurrent contextRef="c7" decimals="0" unitRef="usd">3590</us-gaap:InterestReceivableNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c7" decimals="0" unitRef="usd">63590</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c1" decimals="0" unitRef="usd">61210</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c7" decimals="0" unitRef="usd">33740</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c1" decimals="0" unitRef="usd">26659</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:Assets contextRef="c7" decimals="0" unitRef="usd">9044715</us-gaap:Assets>
    <us-gaap:Assets contextRef="c1" decimals="0" unitRef="usd">10490189</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c7" decimals="0" unitRef="usd">155924</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c1" decimals="0" unitRef="usd">417937</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LoansPayableCurrent contextRef="c7" decimals="0" unitRef="usd">40819</us-gaap:LoansPayableCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c7" decimals="0" unitRef="usd">72102</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c1" decimals="0" unitRef="usd">72102</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c7" decimals="0" unitRef="usd">268845</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="0" unitRef="usd">490039</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c7" decimals="0" unitRef="usd">901833</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c1" decimals="0" unitRef="usd">937884</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c7" decimals="0" unitRef="usd">901833</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c1" decimals="0" unitRef="usd">937884</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c7" decimals="0" unitRef="usd">1170678</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c1" decimals="0" unitRef="usd">1427923</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c7" decimals="4" unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c1" decimals="4" unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c7" decimals="0" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c1" decimals="0" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c8" decimals="4" unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c3" decimals="4" unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c8" decimals="0" unitRef="shares">2000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">2000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockRedemptionPricePerShare contextRef="c7" decimals="0" unitRef="usdPershares">1000</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare contextRef="c1" decimals="0" unitRef="usdPershares">1000</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c9" decimals="4" unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c5" decimals="4" unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c9" decimals="0" unitRef="shares">4280</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c5" decimals="0" unitRef="shares">4280</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c9" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c9" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c5" decimals="0" unitRef="shares">227</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c5" decimals="0" unitRef="shares">227</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockRedemptionPricePerShare contextRef="c9" decimals="0" unitRef="usdPershares">1000</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare contextRef="c5" decimals="0" unitRef="usdPershares">1000</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c7" decimals="4" unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c1" decimals="4" unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c7" decimals="0" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c1" decimals="0" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c7" decimals="0" unitRef="shares">1987906</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c7" decimals="0" unitRef="shares">1987906</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c1" decimals="0" unitRef="shares">1972739</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c1" decimals="0" unitRef="shares">1972739</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c7" decimals="0" unitRef="usd">199</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c1" decimals="0" unitRef="usd">197</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c7" decimals="0" unitRef="usd">12398889</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c1" decimals="0" unitRef="usd">12324646</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c7" decimals="0" unitRef="usd">-4525051</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="0" unitRef="usd">-3262577</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="0" unitRef="usd">7874037</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="0" unitRef="usd">9062266</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c7" decimals="0" unitRef="usd">9044715</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="0" unitRef="usd">10490189</us-gaap:LiabilitiesAndStockholdersEquity>
    <silo:LicenseFees contextRef="c12" decimals="0" unitRef="usd">18025</silo:LicenseFees>
    <silo:LicenseFees contextRef="c13" decimals="0" unitRef="usd">18026</silo:LicenseFees>
    <silo:LicenseFees contextRef="c0" decimals="0" unitRef="usd">36051</silo:LicenseFees>
    <silo:LicenseFees contextRef="c14" decimals="0" unitRef="usd">35213</silo:LicenseFees>
    <us-gaap:CostOfRevenue contextRef="c12" decimals="0" unitRef="usd">1459</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c13" decimals="0" unitRef="usd">1460</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="0" unitRef="usd">2919</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c14" decimals="0" unitRef="usd">2085</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c12" decimals="0" unitRef="usd">16566</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c13" decimals="0" unitRef="usd">16566</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" unitRef="usd">33132</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c14" decimals="0" unitRef="usd">33128</us-gaap:GrossProfit>
    <us-gaap:ShareBasedCompensation contextRef="c12" decimals="0" unitRef="usd">100212</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c13" decimals="0" unitRef="usd">54942</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">227393</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c14" decimals="0" unitRef="usd">167234</us-gaap:ShareBasedCompensation>
    <us-gaap:ProfessionalFees contextRef="c12" decimals="0" unitRef="usd">248179</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c13" decimals="0" unitRef="usd">270906</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c0" decimals="0" unitRef="usd">444427</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c14" decimals="0" unitRef="usd">942475</us-gaap:ProfessionalFees>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c12" decimals="0" unitRef="usd">105676</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c13" decimals="0" unitRef="usd">98846</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="usd">275955</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c14" decimals="0" unitRef="usd">147448</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralInsuranceExpense contextRef="c12" decimals="0" unitRef="usd">30866</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense contextRef="c13" decimals="0" unitRef="usd">29015</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense contextRef="c0" decimals="0" unitRef="usd">64158</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense contextRef="c14" decimals="0" unitRef="usd">50721</us-gaap:GeneralInsuranceExpense>
    <silo:BadDebtRecoveryExpense contextRef="c13" decimals="0" unitRef="usd">-46000</silo:BadDebtRecoveryExpense>
    <silo:BadDebtRecoveryExpense contextRef="c0" decimals="0" unitRef="usd">-20000</silo:BadDebtRecoveryExpense>
    <silo:BadDebtRecoveryExpense contextRef="c14" decimals="0" unitRef="usd">-53500</silo:BadDebtRecoveryExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c12" decimals="0" unitRef="usd">25918</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c13" decimals="0" unitRef="usd">45706</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="usd">62743</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c14" decimals="0" unitRef="usd">116735</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c12" decimals="0" unitRef="usd">510851</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c13" decimals="0" unitRef="usd">453415</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" unitRef="usd">1054676</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c14" decimals="0" unitRef="usd">1371113</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c12" decimals="0" unitRef="usd">-494285</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c13" decimals="0" unitRef="usd">-436849</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-1021544</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c14" decimals="0" unitRef="usd">-1337985</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c12" decimals="0" unitRef="usd">377</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c13" decimals="0" unitRef="usd">-1040</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c0" decimals="0" unitRef="usd">792</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c14" decimals="0" unitRef="usd">-2389</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <silo:OtherIncomeFromEquitySharesEarnedForServices contextRef="c0" decimals="0" unitRef="usd">85733</silo:OtherIncomeFromEquitySharesEarnedForServices>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c13" decimals="0" unitRef="usd">19082</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c14" decimals="0" unitRef="usd">19082</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnInvestments contextRef="c12" decimals="0" unitRef="usd">-104700</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c0" decimals="0" unitRef="usd">-104700</us-gaap:GainLossOnInvestments>
    <silo:UnrealizedGainLossOnEquityInvestments contextRef="c12" decimals="0" unitRef="usd">-59511</silo:UnrealizedGainLossOnEquityInvestments>
    <silo:UnrealizedGainLossOnEquityInvestments contextRef="c13" decimals="0" unitRef="usd">30000</silo:UnrealizedGainLossOnEquityInvestments>
    <silo:UnrealizedGainLossOnEquityInvestments contextRef="c0" decimals="0" unitRef="usd">-221309</silo:UnrealizedGainLossOnEquityInvestments>
    <silo:UnrealizedGainLossOnEquityInvestments contextRef="c14" decimals="0" unitRef="usd">68750</silo:UnrealizedGainLossOnEquityInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c12" decimals="0" unitRef="usd">-283</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="0" unitRef="usd">-283</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c12" decimals="0" unitRef="usd">-164117</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c13" decimals="0" unitRef="usd">48042</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="0" unitRef="usd">-239767</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c14" decimals="0" unitRef="usd">85443</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c12" decimals="0" unitRef="usd">-658402</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c13" decimals="0" unitRef="usd">-388807</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" unitRef="usd">-1261311</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c14" decimals="0" unitRef="usd">-1252542</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c12" decimals="0" unitRef="usd">-658402</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c13" decimals="0" unitRef="usd">-388807</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c0" decimals="0" unitRef="usd">-1261311</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c14" decimals="0" unitRef="usd">-1252542</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="c13" decimals="0" unitRef="usd">-73183</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="c0" decimals="0" unitRef="usd">-1163</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="c14" decimals="0" unitRef="usd">-140150</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c13" decimals="0" unitRef="usd">-73183</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c0" decimals="0" unitRef="usd">-1163</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c14" decimals="0" unitRef="usd">-140150</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss contextRef="c12" decimals="0" unitRef="usd">-658402</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="0" unitRef="usd">-461990</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-1262474</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c14" decimals="0" unitRef="usd">-1392692</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="c14" decimals="0" unitRef="usd">1403997</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c12" decimals="0" unitRef="usd">-658402</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c13" decimals="0" unitRef="usd">-461990</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c0" decimals="0" unitRef="usd">-1262474</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c14" decimals="0" unitRef="usd">-2796689</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic contextRef="c12" decimals="2" unitRef="usdPershares">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c13" decimals="2" unitRef="usdPershares">-0.2</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">-0.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c14" decimals="2" unitRef="usdPershares">-1.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare contextRef="c13" decimals="2" unitRef="usdPershares">-0.04</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare contextRef="c0" decimals="2" unitRef="usdPershares">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare contextRef="c14" decimals="2" unitRef="usdPershares">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c12" decimals="INF" unitRef="shares">1987906</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c13" decimals="INF" unitRef="shares">1937148</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="INF" unitRef="shares">1980365</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c14" decimals="INF" unitRef="shares">1820641</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding contextRef="c37" decimals="0" unitRef="shares">227</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="c38" decimals="0" unitRef="shares">1972739</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c38" decimals="0" unitRef="usd">197</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c39" decimals="0" unitRef="usd">12324646</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c40" decimals="0" unitRef="usd">-3262577</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="0" unitRef="usd">9062266</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c44" decimals="0" unitRef="usd">45009</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c45" decimals="0" unitRef="usd">45009</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c42" decimals="0" unitRef="shares">-227</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c43" decimals="0" unitRef="shares">15167</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c43" decimals="0" unitRef="usd">2</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c44" decimals="0" unitRef="usd">-2</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:NetIncomeLoss contextRef="c46" decimals="0" unitRef="usd">-604072</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c45" decimals="0" unitRef="usd">-604072</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c49" decimals="0" unitRef="shares">1987906</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c49" decimals="0" unitRef="usd">199</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c50" decimals="0" unitRef="usd">12369653</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c51" decimals="0" unitRef="usd">-3866649</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c52" decimals="0" unitRef="usd">8503203</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c56" decimals="0" unitRef="usd">15112</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c12" decimals="0" unitRef="usd">15112</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c56" decimals="0" unitRef="usd">14124</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c12" decimals="0" unitRef="usd">14124</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c57" decimals="0" unitRef="usd">-658402</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c12" decimals="0" unitRef="usd">-658402</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c60" decimals="0" unitRef="shares">1987906</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c60" decimals="0" unitRef="usd">199</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c61" decimals="0" unitRef="usd">12398889</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c62" decimals="0" unitRef="usd">-4525051</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="0" unitRef="usd">7874037</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c28" decimals="0" unitRef="shares">1702839</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="0" unitRef="usd">170</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c29" decimals="0" unitRef="usd">7042846</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="0" unitRef="usd">-5762321</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" unitRef="usd">1280695</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c64" decimals="0" unitRef="shares">4276</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c66" decimals="0" unitRef="usd">3794102</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c68" decimals="0" unitRef="usd">3794102</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c66" decimals="0" unitRef="usd">1403997</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c67" decimals="0" unitRef="usd">-1403997</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c66" decimals="0" unitRef="usd">83728</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c68" decimals="0" unitRef="usd">83728</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:NetIncomeLoss contextRef="c67" decimals="0" unitRef="usd">-930702</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c68" decimals="0" unitRef="usd">-930702</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c70" decimals="0" unitRef="shares">4276</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="c71" decimals="0" unitRef="shares">1702839</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c71" decimals="0" unitRef="usd">170</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c72" decimals="0" unitRef="usd">12324673</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c73" decimals="0" unitRef="usd">-8097020</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c74" decimals="0" unitRef="usd">4227823</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c76" decimals="0" unitRef="shares">-4049</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c77" decimals="0" unitRef="shares">269900</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c77" decimals="0" unitRef="usd">27</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c78" decimals="0" unitRef="usd">-27</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:NetIncomeLoss contextRef="c79" decimals="0" unitRef="usd">-461990</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="0" unitRef="usd">-461990</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c81" decimals="0" unitRef="shares">227</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="c82" decimals="0" unitRef="shares">1972739</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c82" decimals="0" unitRef="usd">197</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c83" decimals="0" unitRef="usd">12324646</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c84" decimals="0" unitRef="usd">-8559010</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c85" decimals="0" unitRef="usd">3765833</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-1262474</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c14" decimals="0" unitRef="usd">-1392692</us-gaap:NetIncomeLoss>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c0" decimals="0" unitRef="usd">-20000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c14" decimals="0" unitRef="usd">-46000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">74245</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c14" decimals="0" unitRef="usd">83728</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <silo:AmortizationOfPrepaidStockbasedExpense contextRef="c14" decimals="0" unitRef="usd">107970</silo:AmortizationOfPrepaidStockbasedExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c0" decimals="0" unitRef="usd">-104700</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c0" decimals="0" unitRef="usd">-221309</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c14" decimals="0" unitRef="usd">68750</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:GainLossOnSaleOfDerivatives contextRef="c0" decimals="0" unitRef="usd">85733</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="c14" decimals="0" unitRef="usd">19082</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c0" decimals="0" unitRef="usd">-38304</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c14" decimals="0" unitRef="usd">64047</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <silo:IncreaseDecreaseInAssetsOfDiscontinuedOperation contextRef="c14" decimals="0" unitRef="usd">-22123</silo:IncreaseDecreaseInAssetsOfDiscontinuedOperation>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="c0" decimals="0" unitRef="usd">2380</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="0" unitRef="usd">-262013</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c14" decimals="0" unitRef="usd">65146</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInPayablesToBrokerDealers contextRef="c0" decimals="0" unitRef="usd">40819</us-gaap:IncreaseDecreaseInPayablesToBrokerDealers>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c0" decimals="0" unitRef="usd">-36051</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c14" decimals="0" unitRef="usd">514787</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" unitRef="usd">-1189274</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c14" decimals="0" unitRef="usd">-841063</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c0" decimals="0" unitRef="usd">66707</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <silo:CollectionOnNoteReceivable contextRef="c0" decimals="0" unitRef="usd">20000</silo:CollectionOnNoteReceivable>
    <silo:CollectionOnNoteReceivable contextRef="c14" decimals="0" unitRef="usd">69500</silo:CollectionOnNoteReceivable>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" unitRef="usd">86707</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c14" decimals="0" unitRef="usd">69500</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="c14" decimals="0" unitRef="usd">3794102</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <silo:AdvanceFromARelatedParty contextRef="c14" decimals="0" unitRef="usd">2366</silo:AdvanceFromARelatedParty>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c14" decimals="0" unitRef="usd">2366</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c14" decimals="0" unitRef="usd">3794102</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="0" unitRef="usd">-1102567</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c14" decimals="0" unitRef="usd">3022539</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="0" unitRef="usd">9837001</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" unitRef="usd">1128389</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c7" decimals="0" unitRef="usd">8734434</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c85" decimals="0" unitRef="usd">4150928</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c14" decimals="0" unitRef="usd">224</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c0" decimals="0" unitRef="usd">25159</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c0" decimals="0" unitRef="usd">76</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <silo:IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp contextRef="c0" decimals="0" unitRef="usd">89546</silo:IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp>
    <us-gaap:StockIssued1 contextRef="c14" decimals="0" unitRef="usd">83728</us-gaap:StockIssued1>
    <silo:IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree contextRef="c14" decimals="0" unitRef="usd">531250</silo:IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 1 &#x2013; &lt;span style="text-decoration:underline"&gt;ORGANIZATION AND BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Silo Pharma, Inc. (formerly Uppercut Brands,
Inc.) (the &#x201c;Company&#x201d;) was incorporated in the State of New York on July 13, 2010, under the name Gold Swap, Inc. On January
24, 2013, the Company changed its state of incorporation from New York to Delaware.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is a developmental stage biopharmaceutical
company focused on merging traditional therapeutics with psychedelic research.&#160;The Company seeks to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. The Company is focused on merging traditional therapeutics with psychedelic research for people suffering from indications
such as depression, post-traumatic stress disorder (&#x201c;PTSD&#x201d;), Alzheimer&#x2019;s, Parkinson&#x2019;s, and other rare neurological
disorders. The Company&#x2019;s mission is to identify assets to license and fund the research which the Company&#x2019;s believes will
be transformative to the well-being of patients and the health care industry.&#160;The Company was engaged in the development of a streetwear
apparel brand, NFID (see below).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 4, 2013, the Company filed a Form
N-54A and elected to become a business development company (&#x201c;BDC&#x201d;) under the Investment Company Act of 1940, as amended (the
&#x201c;1940 Act&#x201d;). In addition, the Company previously elected to be treated for federal income tax purpose as a regulated investment
company, (&#x201c;RIC&#x201d;) under Subchapter M of the Internal Revenue Code of 1986, as amended, (the &#x201c;Code&#x201d;). Through September
29, 2018, the Company met the definition of RIC in accordance with the guidance under Accounting Standards Codification (&#x201c;ASC&#x201d;)
Topic 946 &#x201c;Financial Services &#x2013; Investment Companies&#x201d;. On September 29, 2018, the Company filed Form N-54C, Notification
of Withdrawal of Election to be Subject to Section 55 through 65 of the 1940 Act, as the Company changed the nature of its business so
as to cease to be a business development company (See Note 2 &#x2013; Basis of Presentation). Additionally, since 2017, the Company has
been subject to income taxes at corporate tax rates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 21, 2019, the Company filed an amendment
to its Certificate of Incorporation with the State of Delaware to change its name from Point Capital, Inc. to Uppercut Brands, Inc. Thereafter,
on September 24, 2020, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to change its name
from Uppercut Brands, Inc. to Silo Pharma, Inc.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 8, 2020, the Company incorporated
a new wholly-owned subsidiary, Silo Pharma Inc.,&#160;in the State of Florida. The Company has also secured the domain name www.silopharma.com.
The Company has been exploring opportunities to expand the Company&#x2019;s business by seeking to acquire and/or develop intellectual
property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs,
such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological
disorders. In July 2020, through the Company&#x2019;s newly formed subsidiary, the Company entered into a commercial evaluation license
and option agreement with University of Maryland, Baltimore (&#x201c;UMB&#x201d;) (see Note 8) pursuant to which, among other things, UMB
granted the Company an exclusive, option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license to with respect
to certain technology. The option was extended and exercised on January 13, 2021. On February 12, 2021, the Company entered into a Master
License Agreement with UMB (see Note 8). The Company plans to actively pursue the acquisition and/or development of intellectual property
or technology rights to treat rare diseases, and to ultimately expand the Company&#x2019;s business to focus on this new line of business.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 30, 2021, the Company entered
into and closed on an Asset Purchase Agreement (the &#x201c;Asset Purchase Agreement) with NFID, LLC, a Florida limited liability company
(the &#x201c;Buyer&#x201d;), whereby the Buyer purchased from the Company certain assets, properties, and rights in connection with the
Company&#x2019;s NFID trademark name, logos, domain, and apparel clothing and accessories for a purchase price of $60,000 in the form
of a promissory note amounting to $60,000. The promissory note bears 8% interest per annum and matures on October 1, 2023. Accordingly,
the results of operations of this component, for all periods presented, are separately reported as &#x201c;discontinued operations&#x201d;
on the condensed consolidated statements of operations (see Note 4).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 11, 2022, the Company stockholders
approved granting discretionary authority to the Company&#x2019;s Board of Directors to amend the Company&#x2019;s Certificate of Incorporation
to effect one or more consolidations of the Company&#x2019;s issued and outstanding shares of common stock, pursuant to which the shares
of common stock would be combined and reclassified into one share of common stock at a ratio within the range from 1-for-5 up to 1-for-50
(the &#x201c;Reverse Stock Split&#x201d;), provided that, (X) that the Company shall not effect Reverse Stock Splits that, in the aggregate,
exceeds 1-for-50, and (Y) any Reverse Stock Split is completed no later than February 8, 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On September 14, 2022, the Company filed a
Certificate of Amendment to the Amended and Restated Articles of Incorporation (the &#x201c;Certificate of Amendment&#x201d;) with the
Secretary of State of the State of Nevada to effect a 1-for-50 reverse stock split (the &#x201c;Reverse Stock Split&#x201d;) with respect
to the outstanding shares of the Company&#x2019;s common stock. The Certificate of Amendment became effective on September 14, 2022. The
Reverse Stock Split was previously approved by the sole director and the majority of stockholders of the Company. The Reverse Stock Split
was deemed effective at the open of business on September 15, 2022. All share and per share data in the accompanying consolidated financial
statements have been retroactively restated to reflect the effect of the reverse stock split.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <silo:AssetPurchaseAgreementDescription contextRef="c0">On September 30, 2021, the Company entered
into and closed on an Asset Purchase Agreement (the &#x201c;Asset Purchase Agreement) with NFID, LLC, a Florida limited liability company
(the &#x201c;Buyer&#x201d;), whereby the Buyer purchased from the Company certain assets, properties, and rights in connection with the
Company&#x2019;s NFID trademark name, logos, domain, and apparel clothing and accessories for a purchase price of $60,000 in the form
of a promissory note amounting to $60,000. The promissory note bears 8% interest per annum and matures on October 1, 2023. Accordingly,
the results of operations of this component, for all periods presented, are separately reported as &#x201c;discontinued operations&#x201d;
on the condensed consolidated statements of operations (see Note 4).&#160;</silo:AssetPurchaseAgreementDescription>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 2 &#x2013; &lt;span style="text-decoration:underline"&gt;SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Basis of Presentation and Principles of
Consolidation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s consolidated financial statements
include financial statements for Silo Pharma, Inc and its inactive wholly-owned subsidiary with the same name as the parent entity, Silo
Pharma, Inc, as of June 30, 2022 and during the three and nine months ended June 30, 2022. All intercompany balances and transactions
have been eliminated in consolidation. Management acknowledges its responsibility for the preparation of the accompanying unaudited condensed
consolidated financial statements which reflect all adjustments, consisting of normal recurring and non-recurring adjustments, considered
necessary in its opinion for a fair statement of its consolidated financial position and the consolidated results of its operations for
the periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America (the &#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions Article 8-03 of Regulation S-X.
Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole.
Certain information and note disclosure normally included in financial statements prepared in accordance with U.S. GAAP has been condensed
or omitted from these statements pursuant to such accounting principles and, accordingly, they do not include all the information and
notes necessary for comprehensive financial statements. These unaudited condensed consolidated financial statements should be read in
conjunction with the summary of significant accounting policies and notes to the financial statements for the year ended December 31,
2021 included in the Company&#x2019;s Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 28, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with, ASC 205-20 &#x201c;Discontinued
Operations&#x201d; establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should
be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity&#x2019;s
operations and financial results. As a result, the NFID, LLC component&#x2019;s results of operations have been classified as discontinued
operations on a retrospective basis for all periods presented. Accordingly, the results of operations of this component, for all periods,
are separately reported as &#x201c;discontinued operations&#x201d; on the condensed consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Liquidity&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As reflected in the accompanying condensed
consolidated financial statements, the Company generated a net loss of $1,262,474 and used cash in operations of $1,189,274 during the
six months ended June 30, 2022. Additionally, the Company has an accumulated deficit of $4,525,051 at June 30, 2022. However, as of June
30, 2022, the Company had working capital of $8,678,540.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The positive worthy capital serves to mitigate
the conditions that historically raised substantial doubt about the Company&#x2019;s ability to continue as a going concern. The Company
believes that the Company has sufficient cash to meet its obligations for a minimum of twelve months from the date of this filing.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of unaudited condensed consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment.
It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at
the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one
or more future events. Accordingly, the actual results could differ significantly from estimates. Significant estimates during the six
months ended June 30, 2022 and year ended December 31, 2021 include the collectability of notes receivable, valuation of equity investments,
estimates for obsolete and slow-moving inventory, estimates of the deemed dividend, valuation allowances for deferred tax assets, the
fair value of warrants issued with debt and for services, and the fair value of shares issued for services and in settlements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers all highly liquid investments
with a maturity of three months or less when acquired to be cash equivalents. The Company places its cash with high credit quality financial
institutions. The Company&#x2019;s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;)
up to $250,000 or by the Securities Investor Protection Corporation up to $250,000. To reduce its risk associated with the failure of
such financial institutions, the Company evaluates, at least annually, the rating of the financial institutions in which it holds deposits.
At June 30, 2022 and December 31, 2021, the Company had cash in excess of FDIC limits of approximately $8,240,000, and approximately
$9,100,000, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Notes Receivable&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes an allowance for losses
on notes receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical
bad debt experience, current note receivable aging, and expected future write-offs, as well as an assessment of specific identifiable
accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recognized as general
and administrative expense.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Prepaid expenses and other current assets
- current of $99,939 and $145,324 at June 30, 2022 and December 31, 2021, respectively, consist primarily of costs paid for future services
which will occur within a year. Prepaid expenses and other current assets &#x2013; non-current of $33,740 and $26,659 at June 30, 2022
and December 31, 2021, respectively, consist primarily of costs paid for license fees and future services which will occur after a year.
Prepaid expenses may include prepayments in cash and equity instruments for consulting, business advisory, legal services, license fees,
research and development fees, and insurance which are being amortized over the terms of their respective agreements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Equity Investments, at Fair Value&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Realized gain or loss is recognized when an
investment is disposed of and is computed as the difference between the Company&#x2019;s carrying value and the net proceeds received
from such disposition. Realized gains and losses on investment transactions are determined by specific identification. Net unrealized
appreciation or depreciation is computed as the difference between the fair value of the investment and the cost basis of such investment.
Net unrealized gains or losses for equity investments are recognized in operations as the difference between the carrying value at the
beginning of the period and the fair value at the end of the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Equity Investments, at Cost&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Equity investments, at cost are comprised
mainly of non-marketable capital stock and stock warrants, are recorded at cost, as adjusted for other than temporary impairment write-downs
and are evaluated for impairment periodically.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company applies ASC Topic 606, Revenue
from Contracts with Customers (&#x201c;ASC 606&#x201d;). ASC 606 establishes a single comprehensive model for entities to use in accounting
for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires
an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company records interest and dividend
income on an accrual basis to the extent that the Company expects to collect such amounts.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the license and royalty income, revenue
is recognized when the Company satisfies the performance obligation based on the related license agreement. Payments received from the
licensee that are related to future periods are recorded as deferred revenue to be recognized as revenues over the term of the related
license agreement (see Note 8).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Product sales were recognized when the NFID
products were shipped to the customer and title was transferred and were recorded net of any discounts or allowances which are separately
reported as &#x201c;discontinued operations&#x201d; on the condensed consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Cost of Revenues&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The primary components of cost of revenues
on license fees included the cost of the license fees. Payments made to the licensor that are related to future periods are recorded
as prepaid expense to be amortized over the term of the related license agreement (see Note 8).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The primary components of cost of revenues
on NFID apparel include the cost of the product, production costs, warehouse storage costs and shipping fees which are separately reported
as &#x201c;discontinued operations&#x201d; on the condensed consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Stock-based compensation is accounted for
based on the requirements of ASC 718 &#x2013; &#x201c;Compensation &#x2013; Stock Compensation&#x201d;, which requires recognition in the
financial statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments
over the period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively,
the vesting period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange
for an award based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted
under Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-09 Improvements to Employee Share-Based Payment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred income tax assets and liabilities
arise from temporary differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted
tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current
or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities
not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences
are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to
be realized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company follows the provisions of Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 740-10, &#x201c;Uncertainty in Income Taxes&#x201d;. Certain recognition thresholds
must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax
positions that meet a &#x201c;more-likely-than-not&#x201d; threshold. The Company does not believe it has any uncertain tax positions as
of June 30, 2022 and December 31, 2021 that would require either recognition or disclosure in the accompanying condensed consolidated
financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 730-10, &#x201c;Research
and Development-Overall,&#x201d; research and development costs are expensed when incurred. During the six months ended June 30, 2022
and 2021, research and development costs were $275,955 and $147,448, respectively. During the three months ended June 30, 2022 and 2021,
research and development costs were $105,676 and $98,846, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Net Loss per Common Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic loss per share is computed by dividing
net loss allocable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Diluted
earnings per share is computed by dividing net income available to common shareholders by the weighted average number of shares of common
stock, common stock equivalents and potentially dilutive securities outstanding during the period using the as-if converted method. Potentially
dilutive securities which included convertible preferred shares and stock options are excluded from the computation of diluted shares
outstanding if they would have an anti-dilutive impact on the Company&#x2019;s net losses. The following are the potentially dilutive
shares for the six months ended June 30, 2022 and 2021:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-keep: true"&gt;Series C convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-311"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;15,133&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;28,849&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;347,080&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;347,080&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;375,929&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;368,213&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In August 2020, the FASB issued ASU 2020-06&#x2014;&lt;i&gt;Debt&#x2014;Debt
with Conversion and Other Options (Subtopic 470-20) and Derivatives and edging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic
815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU 2020-06&#x201d;)&lt;/i&gt; to simplify
the accounting for convertible instruments by removing certain separation models in Subtopic 470- 20, &lt;i&gt;Debt with Conversion and Other
Options&lt;/i&gt;, for convertible instruments. Under the amendments in ASU 2020-06, the embedded conversion features no longer are separated
from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives
under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently,
a convertible debt instrument will be accounted for as a single liability measured at its amortized cost and a convertible preferred
stock will be accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation
and recognition as derivatives. By removing those separation models, the interest rate of convertible debt instruments typically will
be closer to the coupon interest rate when applying the guidance in Topic 835, Interest. The amendments in ASU 2020-06 provide financial
statement users with a simpler and more consistent starting point to perform analyses across entities. The amendments also improve the
operability of the guidance and reduce, to a large extent, the complexities in the accounting for convertible instruments and the difficulties
with the interpretation and application of the relevant guidance. To further improve the decision usefulness and relevance of the information
being provided to users of financial statements, amendments in ASU 2020-06 increased information transparency by making the following
amendments to the disclosure for convertible instruments:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Add a disclosure objective&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Add information about events or conditions that occur during the
    reporting period that cause conversion contingencies to be met or conversion terms to be significantly changed&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Add information on which party controls the conversion rights&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Align disclosure requirements for contingently convertible instruments
    with disclosure requirements for other convertible instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Require that existing fair value disclosures in Topic 825, Financial
    Instruments, be provided at the individual convertible instrument level rather than in the aggregate.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Additionally, for convertible debt instruments
with substantial premiums accounted for as paid-in capital, amendments in ASU 2020-06 added disclosures about (1) the fair value amount
and the level of fair value hierarchy of the entire instrument for public business entities and (2) the premium amount recorded as paid-in
capital.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The amendments in ASU 2020-06 are effective
for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning
after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for
fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but
no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Entities should
adopt the guidance as of the beginning of its annual fiscal year and are allowed to adopt the guidance through either a modified retrospective
method of transition or a fully retrospective method of transition. In applying the modified retrospective method, entities should apply
the guidance to transactions outstanding as of the beginning of the fiscal year in which the amendments are adopted. Transactions that
were settled (or expired) during prior reporting periods are unaffected. The cumulative effect of the change should be recognized as
an adjustment to the opening balance of retained earnings at the date of adoption. If an entity elects the fully retrospective method
of transition, the cumulative effect of the change should be recognized as an adjustment to the opening balance of retained earnings
in the first comparative period presented. The Company adopted ASU 2020-06 during the three months ended March 31, 2022 and it did not
have material impact on its condensed consolidated financial statements.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2021, the FASB issued ASU 2021-04,
Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718),
and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40). The new ASU addresses issuer&#x2019;s accounting
for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities,
for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted.
The Company adopted ASU 2020-06 during the three months ended March 31, 2022 and did not have material impact on its condensed consolidated
financial statements&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management does not believe that any other
recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company&#x2019;s consolidated
financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Basis of Presentation and Principles of
Consolidation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s consolidated financial statements
include financial statements for Silo Pharma, Inc and its inactive wholly-owned subsidiary with the same name as the parent entity, Silo
Pharma, Inc, as of June 30, 2022 and during the three and nine months ended June 30, 2022. All intercompany balances and transactions
have been eliminated in consolidation. Management acknowledges its responsibility for the preparation of the accompanying unaudited condensed
consolidated financial statements which reflect all adjustments, consisting of normal recurring and non-recurring adjustments, considered
necessary in its opinion for a fair statement of its consolidated financial position and the consolidated results of its operations for
the periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America (the &#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions Article 8-03 of Regulation S-X.
Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole.
Certain information and note disclosure normally included in financial statements prepared in accordance with U.S. GAAP has been condensed
or omitted from these statements pursuant to such accounting principles and, accordingly, they do not include all the information and
notes necessary for comprehensive financial statements. These unaudited condensed consolidated financial statements should be read in
conjunction with the summary of significant accounting policies and notes to the financial statements for the year ended December 31,
2021 included in the Company&#x2019;s Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 28, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with, ASC 205-20 &#x201c;Discontinued
Operations&#x201d; establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should
be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity&#x2019;s
operations and financial results. As a result, the NFID, LLC component&#x2019;s results of operations have been classified as discontinued
operations on a retrospective basis for all periods presented. Accordingly, the results of operations of this component, for all periods,
are separately reported as &#x201c;discontinued operations&#x201d; on the condensed consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <silo:LiquidityPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Liquidity&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As reflected in the accompanying condensed
consolidated financial statements, the Company generated a net loss of $1,262,474 and used cash in operations of $1,189,274 during the
six months ended June 30, 2022. Additionally, the Company has an accumulated deficit of $4,525,051 at June 30, 2022. However, as of June
30, 2022, the Company had working capital of $8,678,540.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The positive worthy capital serves to mitigate
the conditions that historically raised substantial doubt about the Company&#x2019;s ability to continue as a going concern. The Company
believes that the Company has sufficient cash to meet its obligations for a minimum of twelve months from the date of this filing.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</silo:LiquidityPolicyTextBlock>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c0" decimals="0" unitRef="usd">1262474</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetCashProvidedByUsedInContinuingOperations contextRef="c0" decimals="0" unitRef="usd">1189274</us-gaap:NetCashProvidedByUsedInContinuingOperations>
    <us-gaap:RetainedEarningsUnappropriated contextRef="c7" decimals="0" unitRef="usd">4525051</us-gaap:RetainedEarningsUnappropriated>
    <silo:WorkingCapital contextRef="c7" decimals="0" unitRef="usd">8678540</silo:WorkingCapital>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of unaudited condensed consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment.
It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at
the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one
or more future events. Accordingly, the actual results could differ significantly from estimates. Significant estimates during the six
months ended June 30, 2022 and year ended December 31, 2021 include the collectability of notes receivable, valuation of equity investments,
estimates for obsolete and slow-moving inventory, estimates of the deemed dividend, valuation allowances for deferred tax assets, the
fair value of warrants issued with debt and for services, and the fair value of shares issued for services and in settlements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers all highly liquid investments
with a maturity of three months or less when acquired to be cash equivalents. The Company places its cash with high credit quality financial
institutions. The Company&#x2019;s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;)
up to $250,000 or by the Securities Investor Protection Corporation up to $250,000. To reduce its risk associated with the failure of
such financial institutions, the Company evaluates, at least annually, the rating of the financial institutions in which it holds deposits.
At June 30, 2022 and December 31, 2021, the Company had cash in excess of FDIC limits of approximately $8,240,000, and approximately
$9,100,000, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount contextRef="c7" decimals="0" unitRef="usd">250000</us-gaap:CashFDICInsuredAmount>
    <silo:CashSPICInsuredAmount contextRef="c7" decimals="0" unitRef="usd">250000</silo:CashSPICInsuredAmount>
    <us-gaap:FDICIndemnificationAssetCashPaymentsReceived contextRef="c0" decimals="0" unitRef="usd">8240000</us-gaap:FDICIndemnificationAssetCashPaymentsReceived>
    <us-gaap:FDICIndemnificationAssetCashPaymentsReceived contextRef="c10" decimals="0" unitRef="usd">9100000</us-gaap:FDICIndemnificationAssetCashPaymentsReceived>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Notes Receivable&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes an allowance for losses
on notes receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical
bad debt experience, current note receivable aging, and expected future write-offs, as well as an assessment of specific identifiable
accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recognized as general
and administrative expense.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Prepaid expenses and other current assets
- current of $99,939 and $145,324 at June 30, 2022 and December 31, 2021, respectively, consist primarily of costs paid for future services
which will occur within a year. Prepaid expenses and other current assets &#x2013; non-current of $33,740 and $26,659 at June 30, 2022
and December 31, 2021, respectively, consist primarily of costs paid for license fees and future services which will occur after a year.
Prepaid expenses may include prepayments in cash and equity instruments for consulting, business advisory, legal services, license fees,
research and development fees, and insurance which are being amortized over the terms of their respective agreements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c7" decimals="0" unitRef="usd">99939</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c1" decimals="0" unitRef="usd">145324</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="c7" decimals="0" unitRef="usd">33740</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="c1" decimals="0" unitRef="usd">26659</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <silo:EquityInvestmentsAtFairValuePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Equity Investments, at Fair Value&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Realized gain or loss is recognized when an
investment is disposed of and is computed as the difference between the Company&#x2019;s carrying value and the net proceeds received
from such disposition. Realized gains and losses on investment transactions are determined by specific identification. Net unrealized
appreciation or depreciation is computed as the difference between the fair value of the investment and the cost basis of such investment.
Net unrealized gains or losses for equity investments are recognized in operations as the difference between the carrying value at the
beginning of the period and the fair value at the end of the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</silo:EquityInvestmentsAtFairValuePolicyTextBlock>
    <silo:EquityInvestmentsAtCostPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Equity Investments, at Cost&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Equity investments, at cost are comprised
mainly of non-marketable capital stock and stock warrants, are recorded at cost, as adjusted for other than temporary impairment write-downs
and are evaluated for impairment periodically.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</silo:EquityInvestmentsAtCostPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company applies ASC Topic 606, Revenue
from Contracts with Customers (&#x201c;ASC 606&#x201d;). ASC 606 establishes a single comprehensive model for entities to use in accounting
for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires
an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company records interest and dividend
income on an accrual basis to the extent that the Company expects to collect such amounts.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the license and royalty income, revenue
is recognized when the Company satisfies the performance obligation based on the related license agreement. Payments received from the
licensee that are related to future periods are recorded as deferred revenue to be recognized as revenues over the term of the related
license agreement (see Note 8).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Product sales were recognized when the NFID
products were shipped to the customer and title was transferred and were recorded net of any discounts or allowances which are separately
reported as &#x201c;discontinued operations&#x201d; on the condensed consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <silo:CostOfRevenuesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Cost of Revenues&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The primary components of cost of revenues
on license fees included the cost of the license fees. Payments made to the licensor that are related to future periods are recorded
as prepaid expense to be amortized over the term of the related license agreement (see Note 8).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The primary components of cost of revenues
on NFID apparel include the cost of the product, production costs, warehouse storage costs and shipping fees which are separately reported
as &#x201c;discontinued operations&#x201d; on the condensed consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</silo:CostOfRevenuesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Stock-based compensation is accounted for
based on the requirements of ASC 718 &#x2013; &#x201c;Compensation &#x2013; Stock Compensation&#x201d;, which requires recognition in the
financial statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments
over the period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively,
the vesting period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange
for an award based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted
under Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-09 Improvements to Employee Share-Based Payment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred income tax assets and liabilities
arise from temporary differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted
tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current
or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities
not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences
are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to
be realized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company follows the provisions of Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 740-10, &#x201c;Uncertainty in Income Taxes&#x201d;. Certain recognition thresholds
must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax
positions that meet a &#x201c;more-likely-than-not&#x201d; threshold. The Company does not believe it has any uncertain tax positions as
of June 30, 2022 and December 31, 2021 that would require either recognition or disclosure in the accompanying condensed consolidated
financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">research and development costs are expensed when incurred. During the six months ended June 30, 2022
and 2021, research and development costs were $275,955 and $147,448, respectively. During the three months ended June 30, 2022 and 2021,
research and development costs were $105,676 and $98,846, respectively.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="usd">275955</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c14" decimals="0" unitRef="usd">147448</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c12" decimals="0" unitRef="usd">105676</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c13" decimals="0" unitRef="usd">98846</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Net Loss per Common Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic loss per share is computed by dividing
net loss allocable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Diluted
earnings per share is computed by dividing net income available to common shareholders by the weighted average number of shares of common
stock, common stock equivalents and potentially dilutive securities outstanding during the period using the as-if converted method. Potentially
dilutive securities which included convertible preferred shares and stock options are excluded from the computation of diluted shares
outstanding if they would have an anti-dilutive impact on the Company&#x2019;s net losses. The following are the potentially dilutive
shares for the six months ended June 30, 2022 and 2021:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-keep: true"&gt;Series C convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-311"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;15,133&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;28,849&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;347,080&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;347,080&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;375,929&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;368,213&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <silo:ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-keep: true"&gt;Series C convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-311"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;15,133&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;28,849&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;347,080&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-keep: true"&gt;347,080&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;375,929&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;368,213&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</silo:ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c207" decimals="INF" unitRef="shares">15133</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c208" decimals="INF" unitRef="shares">28849</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c209" decimals="INF" unitRef="shares">6000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c210" decimals="INF" unitRef="shares">347080</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c211" decimals="INF" unitRef="shares">347080</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c0" decimals="INF" unitRef="shares">375929</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c14" decimals="INF" unitRef="shares">368213</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In August 2020, the FASB issued ASU 2020-06&#x2014;&lt;i&gt;Debt&#x2014;Debt
with Conversion and Other Options (Subtopic 470-20) and Derivatives and edging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic
815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU 2020-06&#x201d;)&lt;/i&gt; to simplify
the accounting for convertible instruments by removing certain separation models in Subtopic 470- 20, &lt;i&gt;Debt with Conversion and Other
Options&lt;/i&gt;, for convertible instruments. Under the amendments in ASU 2020-06, the embedded conversion features no longer are separated
from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives
under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently,
a convertible debt instrument will be accounted for as a single liability measured at its amortized cost and a convertible preferred
stock will be accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation
and recognition as derivatives. By removing those separation models, the interest rate of convertible debt instruments typically will
be closer to the coupon interest rate when applying the guidance in Topic 835, Interest. The amendments in ASU 2020-06 provide financial
statement users with a simpler and more consistent starting point to perform analyses across entities. The amendments also improve the
operability of the guidance and reduce, to a large extent, the complexities in the accounting for convertible instruments and the difficulties
with the interpretation and application of the relevant guidance. To further improve the decision usefulness and relevance of the information
being provided to users of financial statements, amendments in ASU 2020-06 increased information transparency by making the following
amendments to the disclosure for convertible instruments:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Add a disclosure objective&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Add information about events or conditions that occur during the
    reporting period that cause conversion contingencies to be met or conversion terms to be significantly changed&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Add information on which party controls the conversion rights&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Align disclosure requirements for contingently convertible instruments
    with disclosure requirements for other convertible instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Require that existing fair value disclosures in Topic 825, Financial
    Instruments, be provided at the individual convertible instrument level rather than in the aggregate.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Additionally, for convertible debt instruments
with substantial premiums accounted for as paid-in capital, amendments in ASU 2020-06 added disclosures about (1) the fair value amount
and the level of fair value hierarchy of the entire instrument for public business entities and (2) the premium amount recorded as paid-in
capital.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The amendments in ASU 2020-06 are effective
for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning
after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for
fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but
no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Entities should
adopt the guidance as of the beginning of its annual fiscal year and are allowed to adopt the guidance through either a modified retrospective
method of transition or a fully retrospective method of transition. In applying the modified retrospective method, entities should apply
the guidance to transactions outstanding as of the beginning of the fiscal year in which the amendments are adopted. Transactions that
were settled (or expired) during prior reporting periods are unaffected. The cumulative effect of the change should be recognized as
an adjustment to the opening balance of retained earnings at the date of adoption. If an entity elects the fully retrospective method
of transition, the cumulative effect of the change should be recognized as an adjustment to the opening balance of retained earnings
in the first comparative period presented. The Company adopted ASU 2020-06 during the three months ended March 31, 2022 and it did not
have material impact on its condensed consolidated financial statements.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2021, the FASB issued ASU 2021-04,
Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718),
and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40). The new ASU addresses issuer&#x2019;s accounting
for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities,
for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted.
The Company adopted ASU 2020-06 during the three months ended March 31, 2022 and did not have material impact on its condensed consolidated
financial statements&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management does not believe that any other
recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company&#x2019;s consolidated
financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 3 &#x2013; &lt;span style="text-decoration:underline"&gt;FAIR VALUE OF FINANCIAL
INSTRUMENTS AND FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;FASB ASC 820 - Fair Value Measurements and
Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments,
whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent
information available to the Company on June 30, 2022. Accordingly, the estimates presented in these financial statements are not necessarily
indicative of the amounts that could be realized on disposition of the financial instruments. FASB ASC 820 specifies a hierarchy of valuation
techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market
data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority
to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable
inputs (Level 3 measurement).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify; width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 58px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 1 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Inputs are unadjusted quoted prices in active markets for identical
    assets or liabilities available at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 2 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Inputs are unadjusted quoted prices for similar assets and liabilities
    in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than
    quoted prices that are observable, and inputs derived from or corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 3 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Inputs are unobservable inputs which reflect the reporting entity&#x2019;s
    own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available
    information.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company analyzes all financial instruments
with features of both liabilities and equity under the FASB&#x2019;s accounting standard for such instruments. Under this standard, financial
assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The carrying amounts reported in the consolidated
balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair market
value based on the short-term maturity of these instruments.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Equity Investments at Fair Value&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounted for certain equity investments
at fair value using level 1, level 2 and level 3 valuations. Assets and liabilities measured at fair value on a recurring basis are as
follows at June 30, 2022 and December 31, 2021:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;At June 30, 2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;At December 31, 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; text-align: left"&gt;Equity investments consisting of common
    stock, at fair value&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;113,012&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-312"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-313"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;419,995&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-314"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-315"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes activity in
the Company&#x2019;s equity investments, at fair value for the periods presented:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Balance, beginning&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;419,995&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-316"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85,733&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;531,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Sales at original cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(171,407&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(359,843&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Unrealized (loss) gain&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(221,309&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;248,588&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance as of June 30, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;113,012&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;419,995&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the six months ended June 30, 2022,
the Company received 77,939 shares of Home Bistro, Inc. common stock with grant date fair value of $85,733 or $1.10 per share, in exchange
for entering into a lock up and leak out agreement which was recorded as other income from equity shares earned for services in the accompanying
condensed consolidated statement of operations. The Company measures equity securities received for services at fair value on the date
of receipt.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the six months ended June 30, 2022,
the Company sold its equity investments in Aikido Pharma, Inc. with cost of $171,407 for gross proceeds of $66,707 and the Company recorded
a net realized loss on equity investments amounting to $104,700 as reflected in the accompanying condensed consolidated statement of
operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At June 30, 2022 and December 31, 2021, equity
investments, at fair value consisted of common equity securities of two entities, Home Bistro, Inc. and Aikido Pharma, Inc. (see Note
8).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Equity investments are carried at fair value
with unrealized gains or losses which is recorded as net unrealized gain (loss) on equity investments in the accompanying condensed consolidated
statement of operations.&#160;Realized gains and losses are determined on a specific identification basis which is recorded as net realized
gain (loss) on equity investments in the consolidated statement of operations. The Company reviews equity investments, at fair value
for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recovered.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ASC 825-10 &#x201c;Financial Instruments&#x201d;
allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair
value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value
option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent
reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Equity Investments at Cost&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At June 30, 2022 and December 31, 2021, the
Company did not have non-marketable capital stock and stock warrants, recorded at cost.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;At June 30, 2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;At December 31, 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; text-align: left"&gt;Equity investments consisting of common
    stock, at fair value&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;113,012&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-312"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-313"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;419,995&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-314"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-315"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <silo:EquityInvestmentsAtFairValue contextRef="c215" decimals="0" unitRef="usd">113012</silo:EquityInvestmentsAtFairValue>
    <silo:EquityInvestmentsAtFairValue contextRef="c97" decimals="0" unitRef="usd">419995</silo:EquityInvestmentsAtFairValue>
    <silo:ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Balance, beginning&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;419,995&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-316"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85,733&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;531,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Sales at original cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(171,407&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(359,843&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Unrealized (loss) gain&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(221,309&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;248,588&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance as of June 30, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;113,012&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;419,995&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</silo:ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock>
    <us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities contextRef="c1" decimals="0" unitRef="usd">419995</us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities>
    <silo:AdditionsofEquitySecurities contextRef="c0" decimals="0" unitRef="usd">85733</silo:AdditionsofEquitySecurities>
    <silo:AdditionsofEquitySecurities contextRef="c10" decimals="0" unitRef="usd">531250</silo:AdditionsofEquitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c0" decimals="0" unitRef="usd">171407</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c10" decimals="0" unitRef="usd">359843</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c0" decimals="0" unitRef="usd">-221309</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c10" decimals="0" unitRef="usd">248588</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities contextRef="c7" decimals="0" unitRef="usd">113012</us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities>
    <us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities contextRef="c1" decimals="0" unitRef="usd">419995</us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities>
    <silo:CompanyReceivedShares contextRef="c212" decimals="0" unitRef="shares">77939</silo:CompanyReceivedShares>
    <us-gaap:InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet contextRef="c7" decimals="0" unitRef="usd">85733</us-gaap:InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet>
    <silo:CommonStockGrantDateFairValuePerShare contextRef="c0" decimals="2" unitRef="usdPershares">1.1</silo:CommonStockGrantDateFairValuePerShare>
    <us-gaap:GainOnSaleOfInvestments contextRef="c213" decimals="0" unitRef="usd">171407</us-gaap:GainOnSaleOfInvestments>
    <silo:GrossProceeds contextRef="c213" decimals="0" unitRef="usd">66707</silo:GrossProceeds>
    <silo:EquityMethodInvestment contextRef="c214" decimals="0" unitRef="usd">104700</silo:EquityMethodInvestment>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 4 &#x2013; &lt;span style="text-decoration:underline"&gt;DISPOSAL OF THE DISCONTINUED
OPERATIONS OF THE NFID BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 30, 2021, the Company entered
into and closed on an Asset Purchase Agreement (see Note 1) with NFID, LLC, an unrelated party, a Florida limited liability company,
whereby the Company sold certain assets, properties, and rights in connection with its NFID trademark name, logos, domain, and apparel
clothing and accessories for a purchase price of $60,000 in the form of a promissory note amounting to $60,000. The promissory note bears
8% interest per annum and matures on October 1, 2023. Note receivable &#x2013; non-current amounted to $60,000 as of September 30, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ASC 205-20 &#x201c;Discontinued Operations&#x201d;
establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should be reported in
discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity&#x2019;s operations
and financial results. As a result, the component&#x2019;s results of operations have been classified as discontinued operations on a
retrospective basis for all periods presented. Accordingly, the results of operations of this component, for all periods, are separately
reported as &#x201c;discontinued operations&#x201d; on the condensed consolidated statements of operations.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table set forth the selected
financial data of the Company&#x2019;s gain from sale of the NFID business on September 30, 2021:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September&#160;30, &lt;br/&gt;
    2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 1.5pt"&gt;Inventory, net&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;58,447&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;58,447&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-317"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net asset of NFID business disposed&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;58,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Consideration in the form of a note receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(60,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Gain from sale of NFID business&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,553&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The summarized operating result of discontinued
operations of the NFID Business included in the Company&#x2019;s condensed consolidated statements of operations for the six months ended
June 30, 2022 and 2021 is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Six Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Product sales, net&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-318"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;80,305&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cost of sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,079&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68,360&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross profit (loss)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,079&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,945&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total operating and other non-operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(84&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(152,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Loss from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,163&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(140,150&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <silo:PurchasePrice contextRef="c86" decimals="0" unitRef="usd">60000</silo:PurchasePrice>
    <silo:PromissoryNotes contextRef="c87" decimals="0" unitRef="usd">60000</silo:PromissoryNotes>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate contextRef="c87" decimals="2" unitRef="pure">0.08</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:LongTermDebtMaturityDate contextRef="c87">2023-10-01</us-gaap:LongTermDebtMaturityDate>
    <silo:PrincipalBalance contextRef="c86" decimals="0" unitRef="usd">60000</silo:PrincipalBalance>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September&#160;30, &lt;br/&gt;
    2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 1.5pt"&gt;Inventory, net&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;58,447&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;58,447&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-317"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net asset of NFID business disposed&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;58,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Consideration in the form of a note receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(60,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Gain from sale of NFID business&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,553&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:InventoryNet contextRef="c87" decimals="0" unitRef="usd">58447</us-gaap:InventoryNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c87" decimals="0" unitRef="usd">58447</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <silo:NetAssetOfNFIDBusinessDisposed contextRef="c86" decimals="0" unitRef="usd">58447</silo:NetAssetOfNFIDBusinessDisposed>
    <silo:ConsiderationInTheFormOfANoteReceivable contextRef="c86" decimals="0" unitRef="usd">-60000</silo:ConsiderationInTheFormOfANoteReceivable>
    <us-gaap:GainLossOnSaleOfOtherAssets contextRef="c86" decimals="0" unitRef="usd">-1553</us-gaap:GainLossOnSaleOfOtherAssets>
    <srt:ScheduleOfCondensedIncomeStatementTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Six Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Product sales, net&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-318"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;80,305&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cost of sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,079&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68,360&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross profit (loss)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,079&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,945&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total operating and other non-operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(84&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(152,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Loss from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,163&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(140,150&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedIncomeStatementTableTextBlock>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c14" decimals="0" unitRef="usd">80305</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="c0" decimals="0" unitRef="usd">1079</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="c14" decimals="0" unitRef="usd">68360</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef="c0" decimals="0" unitRef="usd">-1079</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef="c14" decimals="0" unitRef="usd">11945</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c0" decimals="0" unitRef="usd">84</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c14" decimals="0" unitRef="usd">152095</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="c0" decimals="0" unitRef="usd">-1163</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="c14" decimals="0" unitRef="usd">-140150</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 5 &#x2013; &lt;span style="text-decoration:underline"&gt;NOTES RECEIVABLE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of June 30, 2022 and December 31, 2021,
notes receivable, net, consisted of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Principal amounts of notes receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;115,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;220,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Additional notes receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-319"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Collections on notes receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(164,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(35,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(55,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Notes receivable, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Less: notes receivable, net &#x2013; current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-320"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-321"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Notes receivable &#x2013; non-current&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 28, 2018, the Company and Blind
Faith Concepts Holdings, Inc. (the &#x201c;Seller&#x201d;) executed a two-year promissory note receivable agreement with a principal balance
of $200,000 of which $100,000 was funded to the Seller in September 2018 and the remaining $100,000 was funded in October 2018. The promissory
note accrued interest at a rate of 6% per annum, and the Company was repaid in interest only payments on a quarterly basis, until the
maturity date of September 27, 2020, at which time the full principal and any interest payments was due to the Company. At the time the
promissory note receivable agreement was executed, the Company also executed a security interest and pledge agreement with the borrower
pursuant to which the borrower pledged all of the assets of its company as security for the performance of the note obligations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 2, 2018, the Company and Seller
entered into a promissory note agreement (&#x201c;Promissory Note Agreement&#x201d;) with a principal balance of $50,000. Pursuant to the
Promissory Note Agreement, the $50,000 note was a deposit and credit towards the acquisition of the assets of Lust for Life Group such
as inventory, trademarks and logos. Pursuant to the Promissory Note Agreement, since the purchase did not close within 30 days from date
of the Promissory Note, the note receivable became immediately due. Through the date of default, the outstanding principal balance accrued
interest at an interest rate of 10% per annum payable on a monthly basis. Upon default, the interest rate increased to 18% per annum.
As of December 31, 2018, the Company determined that this note receivable was doubtful and accordingly, recorded an allowance for doubtful
account and bad debt expense of $50,000.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2019, pursuant to claim purchase
agreements (&#x201c;Claim Purchase Agreements&#x201d;), the Company sold its notes receivable and related interest receivable balances
in the aggregate amount of $277,305 to an investor. Pursuant to the Claim Purchase Agreements, the investor agreed to pay the Company
the purchase price of $277,305 on the earlier of the payment of six-monthly installments or upon the liquidation of settlement securities
of the Seller pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended. The first installment was be made following entry
and full effectuation of a court order approving the settlement of the claim which occurred on March 6, 2020 in the United States District
Court for the District of Maryland Northern Division. Additionally, on January 6, 2020, the Company and the Seller entered into a settlement
agreement related to notes receivable. In lieu of the Company seeking default and foreclosure against the Seller pursuant to the note
agreements, the Company received 10,420 shares of the Seller&#x2019;s convertible Series B Preferred Stock. Since the shares of Series
B Preferred Stock have limited marketability, no value was placed on these shares. Between April 2020 and December 2020, the Company
collected an aggregate of $30,000 on the notes receivable balance.&#160;During the year ended December 31, 2020, the Company recorded
a total allowance for doubtful account and bad debt expense of $174,376 (consisting of the principal balance of $146,500 and interest
receivable of $27,876) due to slow collection of the installment payments pursuant to the Claim Purchase Agreements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2021,
the Company recovered an aggregate of $7,500 bad debt previously written off during the periods between 2018 to 2020, recorded as bad
debt recovery in the accompanying consolidated statement of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2021, the
Company received $23,500 of payment and recovered $141,000 of the of the $196,500 bad debt allowance. On June 7, 2021, the Company and
the investor, entered into a settlement agreement whereby both parties agreed to settle the remaining balance of this note receivable
which was previously written off in year 2020 for a total settlement amount of $196,000 to be paid as follows; (i) an initial payment
of $46,000 upon execution of the settlement agreement and (ii) $10,000 per month for fifteen months. During the six months ended June
30, 2022, $20,000 was collected under this settlement agreement and $35,500 remains collectible under this settlement agreement and such
amount has been fully reserved as of June 30, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 30, 2021, the Company executed
a note receivable agreement with NFID, LLC in connection with an Asset Purchase Agreement (see Note 4). The promissory note bears 8%
interest per annum and matures on October 1, 2023. The outstanding principal and accrued interest shall be due and payable on maturity.
As of December 31, 2021, this note receivable had outstanding principal receivable of $60,000 and accrued interest receivable of $1,210
for a total receivable balance of $61,210. As of June 30, 2022, this note receivable had outstanding principal receivable of $60,000
and accrued interest receivable of $3,590 for a total receivable balance of $63,590 which is reflected in the accompanying consolidated
balance sheet as note receivable &#x2013; non-current.&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Principal amounts of notes receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;115,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;220,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Additional notes receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-319"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Collections on notes receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(164,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(35,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(55,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Notes receivable, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Less: notes receivable, net &#x2013; current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-320"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-321"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Notes receivable &#x2013; non-current&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:NotesReceivableGross contextRef="c7" decimals="0" unitRef="usd">115500</us-gaap:NotesReceivableGross>
    <us-gaap:NotesReceivableGross contextRef="c1" decimals="0" unitRef="usd">220000</us-gaap:NotesReceivableGross>
    <silo:AdditionalNotesReceivableIn2021 contextRef="c1" decimals="0" unitRef="usd">60000</silo:AdditionalNotesReceivableIn2021>
    <silo:CollectionsOnNotesReceivables contextRef="c7" decimals="0" unitRef="usd">20000</silo:CollectionsOnNotesReceivables>
    <silo:CollectionsOnNotesReceivables contextRef="c1" decimals="0" unitRef="usd">164500</silo:CollectionsOnNotesReceivables>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses contextRef="c7" decimals="0" unitRef="usd">35500</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses contextRef="c1" decimals="0" unitRef="usd">55500</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c7" decimals="0" unitRef="usd">60000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c1" decimals="0" unitRef="usd">60000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:NotesReceivableNet contextRef="c7" decimals="0" unitRef="usd">60000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet contextRef="c1" decimals="0" unitRef="usd">60000</us-gaap:NotesReceivableNet>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c103" decimals="0" unitRef="usd">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c104" decimals="0" unitRef="usd">100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c218" decimals="0" unitRef="usd">100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c103" decimals="2" unitRef="pure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c106">2020-09-27</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesAndLoansReceivableNetCurrent contextRef="c107" decimals="0" unitRef="usd">50000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <silo:PromissoryNoteAgreement contextRef="c219" decimals="0" unitRef="usd">50000</silo:PromissoryNoteAgreement>
    <us-gaap:DerivativeFixedInterestRate contextRef="c7" decimals="2" unitRef="pure">0.10</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease contextRef="c0" decimals="2" unitRef="pure">0.18</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c111" decimals="0" unitRef="usd">50000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:SupplementalDeferredPurchasePrice contextRef="c220" decimals="0" unitRef="usd">277305</us-gaap:SupplementalDeferredPurchasePrice>
    <us-gaap:SupplementalDeferredPurchasePrice contextRef="c221" decimals="0" unitRef="usd">277305</us-gaap:SupplementalDeferredPurchasePrice>
    <silo:ReceivedShares contextRef="c0" decimals="0" unitRef="shares">10420</silo:ReceivedShares>
    <silo:AggregateOfNotesReceivablePurchasePrice contextRef="c222" decimals="0" unitRef="usd">30000</silo:AggregateOfNotesReceivablePurchasePrice>
    <silo:AggregateOfNotesReceivablePurchasePrice contextRef="c185" decimals="0" unitRef="usd">30000</silo:AggregateOfNotesReceivablePurchasePrice>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c223" decimals="0" unitRef="usd">174376</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:NotesAndLoansReceivableNetCurrent contextRef="c223" decimals="0" unitRef="usd">146500</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:InterestReceivable contextRef="c223" decimals="0" unitRef="usd">27876</us-gaap:InterestReceivable>
    <silo:RecoveredAggregateBadDebt contextRef="c10" decimals="0" unitRef="usd">7500</silo:RecoveredAggregateBadDebt>
    <us-gaap:AllowanceForLoanAndLeaseLossRecoveryOfBadDebts contextRef="c224" decimals="0" unitRef="usd">23500</us-gaap:AllowanceForLoanAndLeaseLossRecoveryOfBadDebts>
    <silo:RecoveredBadDebt contextRef="c10" decimals="0" unitRef="usd">141000</silo:RecoveredBadDebt>
    <us-gaap:LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease contextRef="c10" decimals="0" unitRef="usd">196500</us-gaap:LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease>
    <silo:BadDebtRecoveryCashPayment contextRef="c116">On June 7, 2021, the Company and
the investor, entered into a settlement agreement whereby both parties agreed to settle the remaining balance of this note receivable
which was previously written off in year 2020 for a total settlement amount of $196,000 to be paid as follows; (i) an initial payment
of $46,000 upon execution of the settlement agreement and (ii) $10,000 per month for fifteen months.</silo:BadDebtRecoveryCashPayment>
    <silo:RemainsCollectibleSettlementAgreement contextRef="c0" decimals="0" unitRef="usd">20000</silo:RemainsCollectibleSettlementAgreement>
    <silo:RemainsCollectibleSettlementAgreementAmountReserved contextRef="c0" decimals="0" unitRef="usd">35500</silo:RemainsCollectibleSettlementAgreementAmountReserved>
    <silo:PromissoryNote contextRef="c86" decimals="2" unitRef="pure">0.08</silo:PromissoryNote>
    <us-gaap:LongTermDebtMaturityDate contextRef="c87">2023-10-01</us-gaap:LongTermDebtMaturityDate>
    <us-gaap:NotesAndLoansReceivableNetCurrent contextRef="c1" decimals="0" unitRef="usd">60000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:InterestReceivable contextRef="c1" decimals="0" unitRef="usd">1210</us-gaap:InterestReceivable>
    <us-gaap:PaymentsToAcquireReceivables contextRef="c10" decimals="0" unitRef="usd">61210</us-gaap:PaymentsToAcquireReceivables>
    <us-gaap:NotesAndLoansReceivableNetCurrent contextRef="c7" decimals="0" unitRef="usd">60000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:InterestReceivable contextRef="c7" decimals="0" unitRef="usd">3590</us-gaap:InterestReceivable>
    <us-gaap:PaymentsToAcquireReceivables contextRef="c0" decimals="0" unitRef="usd">63590</us-gaap:PaymentsToAcquireReceivables>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 6 &#x2013; &lt;span style="text-decoration:underline"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Shares Authorized&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has 505,000,000 shares authorized
which consist of 500,000,000 shares of common stock and 5,000,000 shares of preferred stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Preferred Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In April 2013, the Company designated 1,000,000
shares of preferred stock as Series A Convertible Preferred Stock and in November 2019, the Company designated 2,000 shares of preferred
stock as Series B Convertible Preferred Stock. As of June 30, 2022 and December 31, 2021, there were no shares of the Series A and Series
B preferred stock issued and outstanding.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Series C Convertible Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 9, 2021, the Company filed a Certificate
of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the &#x201c;Certificate of Designations&#x201d;)
with the Delaware Secretary of State, designating 4,280 shares of preferred stock as Series C Convertible preferred stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Designation&lt;/span&gt;. The Company has designated 4,280 shares of preferred stock as Series C Convertible preferred stock. Each share of Series C Convertible Preferred Stock has a par value of $0.0001 per share and a stated value of $1,000 (the &#x201c;Series C Stated Value&#x201d;).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="text-align: justify; width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Dividends&lt;/span&gt;&lt;i&gt;.&#160;&lt;/i&gt;Holders
                                            of Series C Convertible preferred stock shall be entitled to receive dividends (on an as-if-converted-to-common-stock
                                            basis) in the same form as dividends actually paid on shares of the common stock when, as
                                            and if such dividends are paid on shares of the common stock. No other dividends shall be
                                            paid on shares of the Series C Convertible preferred stock.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="text-align: justify; width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Liquidation&lt;/span&gt;.
                                            Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary,
                                            the holders of Series C Convertible preferred stock shall be entitled to receive the same
                                            amount that a holder of common stock would receive if the Series C Convertible preferred
                                            stock were fully converted (disregarding any conversion limitations) which amounts shall
                                            be paid&#160;pari passu&#160;with all holders of common stock.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="text-align: justify; width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Voting
                                            Rights&lt;/span&gt;. Except as otherwise provided in the Certificate of Designations or as otherwise
                                            required by law, the Series C Convertible preferred stock shall have no voting rights. However,
                                            as long as any shares of Series C Convertible preferred stock are outstanding, the Company
                                            shall not, without the affirmative vote of the holders of a majority of the then outstanding
                                            shares of the Series C Convertible preferred stock, (a) alter or change adversely the powers,
                                            preferences or rights given to the Series C Convertible preferred stock or alter or amend
                                            the Certificate of Designations, (b) amend its Certificate of Incorporation or other charter
                                            documents in any manner that adversely affects any rights of the holders of the Series C
                                            Convertible preferred stock, (c) increase the number of authorized shares of Series C Convertible
                                            preferred stock, or (d) enter into any agreement with respect to any of the foregoing.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 24px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Conversion&lt;/span&gt;. Each share of Series C Convertible preferred stock is convertible, at any time and from time to time after the issuance date, at the option of the holder, into such number of shares of common stock determined by dividing the Series C Stated Value by the Series C Conversion Price. &#x201c;Series C Conversion Price&#x201d; means $15.00, subject to adjustment in the event of stock split, stock dividends, subsequent right offerings and similar recapitalization transactions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="text-align: justify; width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Forced
                                            Conversion&lt;/span&gt;. Notwithstanding anything herein to the contrary, after the date that the
                                            Company&#x2019;s stockholder approval is obtained and deemed effective, the Company may deliver
                                            a written notice to all holders (the &#x201c;Forced Conversion Notice Date&#x201d;) to cause
                                            each holder to convert all or part of such holder&#x2019;s Series C Convertible preferred
                                            stock pursuant to Section 6 (&#x201c;Forced Conversion&#x201d;), it being agreed that the &#x201c;Conversion
                                            Date&#x201d; shall be deemed to occur no later than the earlier of (i) two (2) trading days
                                            and (ii) the number of trading days comprising the standard settlement period following the
                                            Forced Conversion Notice Date; provided, however, a holder shall only be required to convert
                                            pursuant to a Forced Conversion to the extent that such conversion would not cause a holder
                                            to exceed its beneficial ownership limitation. On March 10, 2021, the Company obtained the
                                            stockholders&#x2019; approval forcing the conversion of all the Series C Convertible preferred
                                            stock. On April 12, 2021, the Company notified holders of its Series C Convertible preferred
                                            stock of its election to force the conversion to its Series C Convertible preferred stock
                                            into shares of the Company&#x2019;s common stock (see below for additional conversions in
                                            2022).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="text-align: justify; width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Exercisability&lt;/span&gt;&lt;i&gt;.&#160;&lt;/i&gt;A holder of Series C Convertible preferred stock may not convert any portion of the Series C Convertible preferred stock to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, upon election by a holder prior to issuance, 9.99%) of the outstanding shares of the Company&#x2019;s common stock after conversion, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Series C Convertible Preferred Stock
Financing&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On February 9, 2021 (the &#x201c;Effectiveness
Date&#x201d;), the Company entered into securities purchase agreements (collectively, the &#x201c;Series C Purchase Agreements&#x201d;)
with certain institutional and accredited investors for the sale of an aggregate of 4,276 shares of the Company&#x2019;s Series C Convertible
Preferred Stock and warrants (the &#x201c;February Warrants&#x201d;) to purchase up to 285,066 shares (the &#x201c;February Warrant Shares&#x201d;)
of the Company&#x2019;s common stock for gross proceeds of approximately $4,276,000, before deducting placement agent and other offering
expenses of $481,898 which are offset against the proceeds in additional paid in capital. The offering closed on February 12, 2021. Accordingly,
the Company recognized a total deemed dividend of $1,403,997 for the beneficial conversion feature in connection with the issuance of
these Series C Convertible preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;The February Warrants are exercisable for
a period of five years from the date of issuance at an exercise price of $15.00 per share. If, after a period of 180 days after the date
of issuance of the February Warrants, a registration statement covering the resale of the February Warrant Shares is not effective, the
holders may exercise the February Warrants by means of a cashless exercise.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Series C Convertible preferred stock and
the February Warrants each contain a beneficial ownership limitation that restricts each of the investor&#x2019;s ability to exercise
the February Warrants and convert the Series C Convertible preferred stock such that the number of shares of the Company common stock
held by each of them and their affiliates after such conversion or exercise does not exceed 4.99% (or, at the election of the Investor,
9.99%) of the Company&#x2019;s then issued and outstanding shares of common stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Series C Purchase Agreement also provides
that until the 18 month anniversary of the Effectiveness Date, in the event of a subsequent financing (except for certain exempt issuances
as provided in the Series C Purchase Agreement) by the Company, each investor will have the right to participate in such subsequent financing
up to an amount equal to the investor&#x2019;s proportionate share of the subsequent financing based on such investor&#x2019;s participation
in the offering on the same terms, conditions and price provided for in the subsequent financing up to an amount equal to 50% of the
subsequent financing. In addition, pursuant to the Series C Purchase Agreement, the Company has agreed that neither it nor its subsidiaries
will enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common stock equivalents
to file any registration statement other than as contemplated pursuant to the Registration Rights Agreement (as defined below) for a
period of 90 days from the Effectiveness Date. Furthermore, subject to certain exceptions, the Company is prohibited from effecting or
entering into an agreement to effect any issuance by the Company or any of its subsidiaries of common stock or common stock equivalents
involving a Variable Rate Transaction (as defined in the Series C Purchase Agreement).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the offering, the Company
entered into separate registration rights agreements (&#x201c;Registration Rights Agreements&#x201d;) with the investors pursuant to which
the Company agreed to undertake to file a registration statement (the &#x201c;Registration Statement&#x201d;) to register the resale of
the Registrable Securities (as defined in the Registration Rights Agreement) within ten calendar days following the Effectiveness Date.
The Company agreed to use its best efforts to cause the Registration Statement covering the Registrable Securities to be declared effective
no later than the 60&lt;sup&gt;th&lt;/sup&gt;&#160;calendar day following the Effectiveness Date, or in the event of a full review by the Securities
and Exchange Commission, the 90&lt;sup&gt;th&lt;/sup&gt;&#160;calendar day following the Effectiveness Date, and to maintain the effectiveness of
the Registration Statement until all of the Registrable Securities have been sold or are otherwise able to be sold pursuant to Rule 144
under the Securities Act of 1933, as amended. If the Company fails to file the Registration Statement or have it declared effective by
the dates set forth above, amongst other things, the Company will be obligated to pay the investors damages in the amount of 1% of their
subscription amount, per month, until such events are satisfied. The Registration Statement was filed and declared effective in April
2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;In addition, pursuant to the terms of the
offering, the Company issued Bradley Woods &amp;amp; Co, Ltd. and Katalyst Securities LLC warrants (the &#x201c;Placement Agent Warrants&#x201d;)
to purchase up to an aggregate of 57,013 shares of common stock, or 10% of the shares of common stock issuable upon conversion of the
Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period
of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment. The Placement Agent
Warrants were valued at the grant date using a Black-Scholes option pricing model with the following assumptions: risk-free interest
rate of 0.50%, expected dividend yield of 0%, expected term of 5 years using the simplified method and expected volatility of 169% based
on comparable and calculated volatility. The aggregate grant date fair value of these Placement Agent Warrants amounted to approximately
$1,106,000 and was recorded against the proceeds with no net effect on the consolidated financials.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The net proceeds of the offering are expected
to be used for working capital purposes and to further execute on the Company&#x2019;s existing business.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Conversion of Series C Convertible Preferred
Stock into Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On March 31, 2022, the Company notified holders
of its Series C Convertible preferred stock of its election to force the conversion to its Series C Convertible preferred stock into
shares of the Company&#x2019;s common stock pursuant to the Certificate of Designations unless such conversion would cause the holder
to exceed its beneficial ownership limitation pursuant to the Certificate of Designations. On March 31, 2022, the Company converted 227
Series C Convertible preferred stock into 15,167 shares of common stock. As of June 30, 2022, there were no shares of Series C Convertible
preferred stock issued and outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock Options&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On January 18, 2021, the Company&#x2019;s board
of directors (&#x201c;Board&#x201d;) approved the Silo Pharma, Inc. 2020 Omnibus Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;) to
incentivize employees, officers, directors and consultants of the Company and its affiliates. 170,000 shares of common stock are reserved
and available for issuance under the 2020 Plan, provided that certain exempt awards (as defined in the 2020 Plan), shall not count against
such share limit. The 2020 Plan provides for the grant, from time to time, at the discretion of the Board or a committee thereof, of
cash, stock options, including incentive stock options and nonqualified stock options, restricted stock, dividend equivalents, restricted
stock units, stock appreciation units and other stock or cash-based awards.&#160;The 2020 Plan shall terminate on the tenth anniversary
of the date of adoption by the Board. Subject to certain restrictions, the Board may amend or terminate the Plan at any time and for
any reason. An amendment of the 2020 Plan shall be subject to the approval of the Company&#x2019;s stockholders only to the extent required
by applicable laws, rules or regulations. On March 10, 2021, the 2020 Plan was approved by the stockholders.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On December 29, 2021, the Board granted an
aggregate of 6,849 incentive stock options under the 2020 Plan, to two non-employee board members, exercisable at $7.30 per share which
expire on December 26, 2026 and vest on the first anniversary date of the grant date. These options were valued at $30,224 on the grant
date using a Binomial Lattice option pricing model with the following assumptions: risk-free interest rate of 0.75%, expected dividend
yield of 0%, expected term of 2 years using the simplified method and expected volatility of 115% based on historical volatility. The
Company recorded the fair value of the unvested stock options, in the amount of $30,224, as deferred compensation which is being amortized
over the vesting period. During the six months ended June 30, 2022, the Company amortized $15,122 of the deferred compensation which
was recorded as compensation expenses in the accompanying condensed consolidated statement of operations. As of June 30, 2022, the deferred
compensation related to this issuance had a balance of $$15,122.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On January 31, 2022, pursuant to an Employment
Agreement (see Note 8), an aggregate of 16,000 incentive stock options were issued under the 2020 Plan, to Dr. Kou, exercisable at $10.00
per share and expires on January 31, 2032. The stock options vest as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests
on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023. The 16,000 stock options had a fair value of $94,915 which were valued
at the grant date using a Binomial Lattice option pricing model with the following assumptions: risk-free interest rate of 1.18%, expected
dividend yield of 0%, expected term of 2 years using the simplified method and expected volatility of 117% based on historical volatility.
The Company recorded the fair value of the unvested stock options, in the amount of $59,322, as deferred compensation which is being
amortized over the vesting period. During the six months ended June 30, 2022, the Company amortized $23,540 of the deferred compensation
which was recorded as compensation expenses in the accompanying condensed consolidated statement of operations. As of June 30, 2022,
the deferred compensation related to his employment agreement had a balance of $35,782.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Stock option activities for the six months
ended June 30, 2022 are summarized as follows:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;Number of&lt;br/&gt; Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;Weighted Average&lt;br/&gt; Exercise&lt;br/&gt;
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;Weighted Average&lt;br/&gt; Remaining&lt;br/&gt;
    Contractual Term&lt;br/&gt; (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;&lt;span style="-keep: true"&gt;Balance Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;0.005&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-322"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;Granted as incentives&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;6,849&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;7.30&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-323"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;Granted pursuant to employment agreement (see Note 8)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;16,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-324"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-325"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-326"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-327"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-328"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Balance Outstanding, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;28,849&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;7.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-329"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Exercisable, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;12,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;6,030&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock Warrants&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On January 18, 2021, the Company granted warrants
to purchase up to 5,000 shares of the Company&#x2019;s common stock in exchange for legal services rendered. The warrants have a term
of five years from the date of grant and are exercisable at an exercise price of $10.00 per share. The warrants were valued on the grant
date at approximately $16.50 per warrant for a total of $83,728 using a Black-Scholes option pricing model with the following assumptions:
stock price of $17.50 per share (based on the quoted trading price on the date of grant), volatility of 169%, expected term of five year,
and a risk-free interest rate of 0.46%. During the year ended December 31, 2021, the Company recorded stock-based compensation of $83,728.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On February 9, 2021, the Company entered into
pursuant to securities purchase agreements with certain investors pursuant to which it sold warrants to purchase up to 285,066 shares
of the Company&#x2019;s common stock and 4,276 shares of the Company&#x2019;s Series C Convertible preferred stock. The February Warrants
are exercisable for a period of five years from the date of issuance at an exercise price of $15.00 per share, subject to adjustment.
If, after a period of 180 days after the date of issuance of the February Warrants, a registration statement covering the resale of the
February Warrant Shares is not effective, the holders may exercise the February Warrants by means of a cashless exercise. In addition,
pursuant to the terms of the offering, the Company issued the Placement Agent Warrants to purchase up to an aggregate of 57,013 shares
of common stock to its placement agents, or 10% of the shares of common stock issuable upon conversion of the Series C preferred stock
and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing
date of the offering at an exercise price of $17.50 per share, subject to adjustment (see Series C Convertible Preferred Stock Financing
above). Such warrants issued to various investors and to the placement agents were recorded as additional paid in capital with an offsetting
debit applied against additional paid in capital, thus these warrants have no further accounting effect within the equity section.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Warrant activities for the six months ended
June 30, 2022 are summarized as follows:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
    of&lt;br/&gt;
    Warrants&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
    Average&lt;br/&gt;
    Exercise&lt;br/&gt;
    Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
    Average&lt;br/&gt;
    Remaining&lt;br/&gt;
    Contractual Term&lt;br/&gt;
    (Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;br/&gt;
    Intrinsic&lt;br/&gt;
    Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance Outstanding, December
    31, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;347,080&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.50&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-330"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted/Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-331"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-332"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-333"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-334"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance Outstanding, June 30, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;347,080&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.50&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.6&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-335"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable, June 30, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;347,080&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.50&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.6&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-336"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ExcessStockSharesAuthorized contextRef="c7" decimals="0" unitRef="shares">505000000</us-gaap:ExcessStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c7" decimals="0" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c7" decimals="0" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockConvertibleSharesIssuable contextRef="c126" decimals="0" unitRef="shares">1000000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable contextRef="c127" decimals="0" unitRef="shares">2000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockSharesIssued contextRef="c225" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c225" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockConvertibleSharesIssuable contextRef="c131" decimals="0" unitRef="shares">4280</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable contextRef="c226" decimals="0" unitRef="shares">4280</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c226" decimals="4" unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <silo:PreferredStockStatedValue contextRef="c227" decimals="0" unitRef="usd">1000</silo:PreferredStockStatedValue>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c228" decimals="2" unitRef="usdPershares">15</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion contextRef="c227">A holder of Series C Convertible preferred stock may not convert any portion of the Series C Convertible preferred stock to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, upon election by a holder prior to issuance, 9.99%) of the outstanding shares of the Company&#x2019;s common stock after conversion, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%.</us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c135" decimals="0" unitRef="shares">4276</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="c229" decimals="0" unitRef="shares">285066</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c135" decimals="0" unitRef="usd">4276000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DeferredOfferingCosts contextRef="c229" decimals="0" unitRef="usd">481898</us-gaap:DeferredOfferingCosts>
    <us-gaap:DividendsPreferredStockCash contextRef="c230" decimals="0" unitRef="usd">1403997</us-gaap:DividendsPreferredStockCash>
    <silo:WarrantsTerm contextRef="c0">P5Y</silo:WarrantsTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c7" decimals="2" unitRef="usdPershares">15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PreferredStockConversionBasis contextRef="c0">The Series C Convertible preferred stock and
the February Warrants each contain a beneficial ownership limitation that restricts each of the investor&#x2019;s ability to exercise
the February Warrants and convert the Series C Convertible preferred stock such that the number of shares of the Company common stock
held by each of them and their affiliates after such conversion or exercise does not exceed 4.99% (or, at the election of the Investor,
9.99%) of the Company&#x2019;s then issued and outstanding shares of common stock.&#160;</us-gaap:PreferredStockConversionBasis>
    <silo:InvestorInvestedAmountPercentage contextRef="c0" decimals="2" unitRef="pure">0.50</silo:InvestorInvestedAmountPercentage>
    <us-gaap:ConstructionContractorLiquidityCharacteristic contextRef="c0">If the Company fails to file the Registration Statement or have it declared effective by
the dates set forth above, amongst other things, the Company will be obligated to pay the investors damages in the amount of 1% of their
subscription amount, per month, until such events are satisfied.</us-gaap:ConstructionContractorLiquidityCharacteristic>
    <silo:PlacementAgentWarrantsDescriptoin contextRef="c0">In addition, pursuant to the terms of the
offering, the Company issued Bradley Woods &amp; Co, Ltd. and Katalyst Securities LLC warrants (the &#x201c;Placement Agent Warrants&#x201d;)
to purchase up to an aggregate of 57,013 shares of common stock, or 10% of the shares of common stock issuable upon conversion of the
Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period
of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment.</silo:PlacementAgentWarrantsDescriptoin>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c231" decimals="4" unitRef="pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c231" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c231">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c231" decimals="2" unitRef="pure">1.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <silo:AggregateGrantDateFairValueOfPlacementAgentWarrants contextRef="c231" decimals="0" unitRef="usd">1106000</silo:AggregateGrantDateFairValueOfPlacementAgentWarrants>
    <silo:ConvertablePreferredStock contextRef="c232" decimals="0" unitRef="shares">227</silo:ConvertablePreferredStock>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c232" decimals="0" unitRef="shares">15167</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c233" decimals="0" unitRef="shares">170000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c234" decimals="0" unitRef="shares">6849</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c235" decimals="2" unitRef="usdPershares">7.3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c236">2026-12-26</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c234" decimals="0" unitRef="usd">30224</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c234" decimals="4" unitRef="pure">0.0075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c234" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c234">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="c234" decimals="2" unitRef="pure">1.15</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="c234" decimals="0" unitRef="shares">30224</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense contextRef="c237" decimals="0" unitRef="usd">15122</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent contextRef="c238" decimals="0" unitRef="usd">15122</us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="c239">Kou, exercisable at $10.00
per share and expires on January 31, 2032. The stock options vest as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests
on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="c240" decimals="0" unitRef="shares">16000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c240" decimals="0" unitRef="usd">94915</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c240" decimals="4" unitRef="pure">0.0118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c240" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c240">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c240" decimals="2" unitRef="pure">1.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense contextRef="c240" decimals="0" unitRef="usd">59322</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c240" decimals="0" unitRef="usd">23540</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense contextRef="c0" decimals="0" unitRef="usd">35782</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;Number of&lt;br/&gt; Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;Weighted Average&lt;br/&gt; Exercise&lt;br/&gt;
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;Weighted Average&lt;br/&gt; Remaining&lt;br/&gt;
    Contractual Term&lt;br/&gt; (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;&lt;span style="-keep: true"&gt;Balance Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;0.005&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-keep: true"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-322"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;Granted as incentives&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;6,849&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;7.30&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-323"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;Granted pursuant to employment agreement (see Note 8)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;16,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-keep: true"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-324"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-325"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-326"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-327"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-328"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Balance Outstanding, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;28,849&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;7.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-329"&gt;&lt;span style="-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;Exercisable, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-keep: true"&gt;12,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-keep: true"&gt;6,030&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c166" decimals="INF" unitRef="shares">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c166" decimals="3" unitRef="usdPershares">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c242">P2Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c242" decimals="INF" unitRef="shares">6849</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice contextRef="c242" decimals="2" unitRef="usdPershares">7.3</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice>
    <silo:GrantedAsIncentivesWeightedAverageRemainingContractualTermYears contextRef="c242">P4Y6M</silo:GrantedAsIncentivesWeightedAverageRemainingContractualTermYears>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c242" decimals="INF" unitRef="shares">16000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c242" decimals="2" unitRef="usdPershares">10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <silo:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="c242">P9Y7M6D</silo:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c243" decimals="INF" unitRef="shares">28849</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c243" decimals="2" unitRef="usdPershares">7.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c242">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c243" decimals="INF" unitRef="shares">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c243" decimals="2" unitRef="usdPershares">5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c242">P5Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c243" decimals="0" unitRef="usd">6030</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c160" decimals="0" unitRef="shares">5000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <silo:WarrantsTerm contextRef="c161">P5Y</silo:WarrantsTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c160" decimals="2" unitRef="usdPershares">10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="c161" decimals="2" unitRef="usdPershares">16.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c161" decimals="0" unitRef="usd">83728</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:SharePrice contextRef="c160" decimals="2" unitRef="usdPershares">17.5</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c161" decimals="2" unitRef="pure">1.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c161">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c161" decimals="4" unitRef="pure">0.0046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c92" decimals="0" unitRef="usd">83728</us-gaap:AllocatedShareBasedCompensationExpense>
    <silo:PurchaseAgreementsDescription contextRef="c241">On February 9, 2021, the Company entered into
pursuant to securities purchase agreements with certain investors pursuant to which it sold warrants to purchase up to 285,066 shares
of the Company&#x2019;s common stock and 4,276 shares of the Company&#x2019;s Series C Convertible preferred stock. The February Warrants
are exercisable for a period of five years from the date of issuance at an exercise price of $15.00 per share, subject to adjustment.
If, after a period of 180 days after the date of issuance of the February Warrants, a registration statement covering the resale of the
February Warrant Shares is not effective, the holders may exercise the February Warrants by means of a cashless exercise. In addition,
pursuant to the terms of the offering, the Company issued the Placement Agent Warrants to purchase up to an aggregate of 57,013 shares
of common stock to its placement agents, or 10% of the shares of common stock issuable upon conversion of the Series C preferred stock
and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing
date of the offering at an exercise price of $17.50 per share, subject to adjustment (see Series C Convertible Preferred Stock Financing
above). Such warrants issued to various investors and to the placement agents were recorded as additional paid in capital with an offsetting
debit applied against additional paid in capital, thus these warrants have no further accounting effect within the equity section.&#160;</silo:PurchaseAgreementsDescription>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
    of&lt;br/&gt;
    Warrants&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
    Average&lt;br/&gt;
    Exercise&lt;br/&gt;
    Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
    Average&lt;br/&gt;
    Remaining&lt;br/&gt;
    Contractual Term&lt;br/&gt;
    (Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;br/&gt;
    Intrinsic&lt;br/&gt;
    Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance Outstanding, December
    31, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;347,080&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.50&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-330"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted/Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-331"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-332"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-333"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-334"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance Outstanding, June 30, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;347,080&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.50&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.6&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-335"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable, June 30, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;347,080&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.50&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.6&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-336"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c169" decimals="INF" unitRef="shares">347080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c169" decimals="2" unitRef="usdPershares">15.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c244">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c245" decimals="INF" unitRef="shares">347080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c245" decimals="2" unitRef="usdPershares">15.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c244">P3Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <silo:ShareBasedComponsationNumberOfWarrantsExercisableinDollars contextRef="c244" decimals="INF" unitRef="shares">347080</silo:ShareBasedComponsationNumberOfWarrantsExercisableinDollars>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c245" decimals="2" unitRef="usdPershares">15.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <silo:ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable contextRef="c244">P3Y7M6D</silo:ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 7 &#x2013; &lt;span style="text-decoration:underline"&gt;CONCENTRATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Customer Concentration&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the six months ended June 30, 2022 and
2021, no customer accounted for over 10% of total revenues from apparel sales included in discontinued operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the six months ended June 30, 2022 and
2021, one licensee accounted for 100% total revenues from customer license fee.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Vendor Concentrations&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the six months ended June 30, 2022 and
2021, one licensor accounted for 100% of the Company&#x2019;s vendor license agreements (see below) related to the Company&#x2019;s biopharmaceutical
operation.&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <silo:ConcentrationsRiskPercentage1 contextRef="c246" decimals="2" unitRef="pure">0.10</silo:ConcentrationsRiskPercentage1>
    <silo:ConcentrationsRiskPercentage1 contextRef="c251" decimals="2" unitRef="pure">0.10</silo:ConcentrationsRiskPercentage1>
    <silo:ConcentrationsRiskPercentage1 contextRef="c247" decimals="2" unitRef="pure">1</silo:ConcentrationsRiskPercentage1>
    <silo:ConcentrationsRiskPercentage1 contextRef="c248" decimals="2" unitRef="pure">1</silo:ConcentrationsRiskPercentage1>
    <silo:ConcentrationsRiskPercentage1 contextRef="c249" decimals="2" unitRef="pure">1</silo:ConcentrationsRiskPercentage1>
    <silo:ConcentrationsRiskPercentage1 contextRef="c250" decimals="2" unitRef="pure">1</silo:ConcentrationsRiskPercentage1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 8 &#x2013; &lt;span style="text-decoration:underline"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Employment Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Eric Weisblum&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On April 17, 2020, the Company entered into
an employment agreement (&#x201c;Employment Agreement&#x201d;) with Eric Weisblum to serve as Chief Executive Officer and Chief Financial
Officer of the Company. The term of the Employment Agreement will continue for a period of one year from the date of execution date thereof
and automatically renews for successive one-year periods at the end of each term until either party delivers written notice of their
intent not to review at least six months prior to the expiration of the then effective term. The Employment Agreement provided for a
base salary of $120,000 and 152,619 of vested shares of the Company&#x2019;s common stock in April 2020. In addition, Mr. Weisblum shall
be eligible to earn a bonus, subject to the sole discretion of the Company&#x2019;s Board of Directors (&#x201c;Board&#x201d;). The Employment
Agreement may be terminated by either the Company or Mr. Weisblum at any time and for any reason upon 60 days prior written notice. Upon
termination of the Employment Agreement, Mr. Weisblum shall be entitled to (i) any equity award that has vested prior to the termination
date, (ii) reimbursement of expenses incurred on or prior to such termination date and (iii) such employee benefits to which he may be
entitled as of the termination date (collectively, the &#x201c;Accrued Amounts&#x201d;). Mr. Weisblum employment may also be terminated
by the Company at any time, with cause, death or disability (as defined in the Employment Agreement). Upon the termination of the Employment
Agreement for death or disability, Mr. Weisblum shall be entitled to receive the Accrued Amounts. The Employment Agreement also contains
covenants prohibiting Mr. Weisblum from disclosing confidential information with respect to the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 18, 2021, the Company and Mr. Weisblum
entered into the first amendment (the &#x201c;Amendment&#x201d;) to the Employment Agreement, effective as of January 1, 2021. Pursuant
to the Amendment Mr. Weisblum&#x2019;s base salary was increased from $120,000 per year to $180,000 per year and all the terms and provisions
of the Employment Agreement shall remain in full force and effect.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Dr. James Kuo &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;On January 27, 2022, the Company and Dr. James
Kuo entered into an employment agreement (&#x201c;Kuo Employment Agreement&#x201d;) for Dr. Kuo to serve as the Vice President of Research
&amp;amp; Development. The Kuo Employment Agreement shall be effective as of the date of the agreement and shall automatically renew for
a period of one year at every anniversary of the effective date, with the same terms and conditions, unless either party provides written
notice of its intention not to extend the term of the Kuo Employment Agreement at least thirty days&#x2019; prior to the applicable renewal
date. Dr. Kuo shall be paid an annual base salary of $30,000. For each twelve-month period of his employment, Dr. Kuo shall be entitled
to a bonus whereby amount and terms shall be in the sole and absolute discretion of the Board of Directors (&#x201c;Board&#x201d;) and
shall be payable at the Company&#x2019;s sole option in stock or in cash. In addition, an aggregate of 16,000 incentive stock options
were granted under the 2020 Plan to Dr. Kou, exercisable at $10.00 per share and expires on January 31, 2032. The stock options vest
as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023. The
16,000 stock options had a fair value of $94,914 which valued at grant date using Binomial Lattice option pricing model with the following
assumptions: risk-free interest rate of 1.18%, expected dividend yield of 0%, expected term of 2 years using the simplified method and
expected volatility of 117% based on calculated volatility. The Company recorded the fair value of the unvested stock options, in the
amount of $59,322, as deferred compensation which is being amortized over the vesting period. During the six months ended June 30, 2022,
the Company amortized $23,540 of the deferred compensation which was recorded as compensation expenses in the accompanying condensed
consolidated statement of operations. As of June 30, 2022, the deferred compensation had a balance of $35,782 (see Note 6).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;License Agreements between the Company
and Vendors &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;University of Maryland, Baltimore -
License Agreement for Development and Use of Central Nervous System-Homing Peptides&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Commercial Evaluation License and Option
Agreement with the University of Maryland, Baltimore&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective as of July 15, 2020, the Company,
through its wholly-owned subsidiary, Silo Pharma, Inc. (see Note 1) and University of Maryland, Baltimore (&#x201c;UMB&#x201d;) (collectively
as &#x201c;Parties&#x201d;), entered into a commercial evaluation license and option agreement (&#x201c;License Agreement&#x201d;), granting
the Company an exclusive, non-sublicensable, non-transferable license to with respect to the exploration of the potential use of central
nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory
pathology. The License Agreement also granted the Company an exclusive option to negotiate and obtain an exclusive, sublicensable, royalty-bearing
license (&#x201c;Exclusive Option&#x201d;) to with respect to the subject technology. The License Agreement had a term of six months from
the effective date however if the Company exercises the Exclusive Option, the License Agreement shall expire at the end of the negotiation
period (as defined in the License Agreement) or upon execution of a master license agreement, whichever occurs first. The Company exercised
its Exclusive Option on January 13, 2021 and entered into a Master License Agreement on February 12, 2021. Both parties may terminate
this agreement within thirty days by giving a written notice. In July 2020, the Company paid a license fee of $10,000 to UMB pursuant
to the License Agreement which was recorded in professional fees during the year ended December 31, 2020 since the Company could not
conclude that such costs would be recoverable for this early-stage venture.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Master License Agreement with the University
of Maryland, Baltimore&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As disclosed above, effective as of February
12, 2021, the Company and University of Maryland, Baltimore (&#x201c;UMB&#x201d;), entered into the Master License Agreement (&#x201c;Master
License Agreement&#x201d;) which grants the Company an exclusive, worldwide, sublicensable, royalty-bearing license to certain intellectual
property: (i) to make, have made, use, sell, offer to sell, and import certain licensed products and: (ii) to use the invention titled,
&#x201c;Central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other
neuroinflammatory pathology&#x201d; and UMB&#x2019;s confidential information to develop and perform certain licensed processes for the
therapeutic treatment of neuroinflammatory disease.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Master License Agreement will remain in
effect on a Licensed Product-by-Licensed Product basis and country-by-country basis until the later of: (a) the last patent covered under
the Master License Agreement expires, (b) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory
exclusivity, or other legally enforceable market exclusivity, if applicable, or (c) 10 years after the first commercial sale of a Licensed
Product in that country, unless earlier terminated in accordance with the provisions of the Master License Agreement. The term of the
Master License Agreement shall expire 15 years after the Master License Agreement Effective Date in which (a) there were never any patent
rights, (b) there was never any data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally
enforceable market exclusivity or (c) there was never a first commercial sale of a Licensed Product.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company may assign, sublicense, grant,
or otherwise convey any rights or obligations under the Master License Agreement to a Company affiliate, without obtaining prior written
consent from UMB provided that it meets the terms defined in the Master License Agreement. The Company may grant sublicenses of some
or all of the rights granted by the Master License Agreement, provided that there is no uncured default or breach of any material term
or condition under the Master License Agreement, by Company, at the time of the grant, and that the grant complies with the terms and
conditions of the Master License Agreement. The Company shall be and shall remain responsible for the performance by each of the Company&#x2019;s
sublicensee. Any sublicense shall be consistent with and subject to the terms and conditions of the Master License Agreement and shall
incorporate terms and conditions sufficient to enable Company to comply with the Master License Agreement. The Company or Company affiliates
shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company&#x2019;s sublicense income
which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first
licensed product; and (b) 15% of the Company&#x2019;s sublicense income which is receivable with respect to any sublicense that is executed
after the filing of an NDA (or foreign equivalent) for the first licensed product.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the Master License Agreement,
the Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty
payments depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company shall
pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the effective date; and (b)
$50,000 on or before the first anniversary of the effective date. The license fee is non-refundable and is not creditable against any
other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing,
prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid $25,000 license fee on
February 17, 2021 which was recorded as prepaid expense and is being amortized over the 15-year term. The Company recognized amortization
expense of $4,375 in 2021. During the six months ended June 30, 2022, the Company recognized amortization expense of $2,500. At December
31, 2021, prepaid expense and other current assets &#x2013; current amounted $5,000 and prepaid expense &#x2013; non-current amounts $15,625.
At June 30, 2022, prepaid expense and other current assets &#x2013; current amounted $5,000 and prepaid expense &#x2013; non-current amounts
$13,125 as reflected in the accompanying condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Milestone Payment Terms&lt;/span&gt;:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Milestone&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Receipt of New Drug Application (&#x201c;NDA&#x201d;) (or foreign equivalent) approval for a Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Achievement of First Commercial Sale of Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Royalty Payments Terms&lt;/span&gt;:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify; width: 0.25in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;(i)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;3% on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;5% on sales of licensed products during the applicable calendar year for sales greater than $50,000,000; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;(iii)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a minimum annual royalty payments, as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Years&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Minimum Annual Royalty&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prior to First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-337; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Year of First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-338; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;First calendar year following the First Commercial Sale&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Second calendar year following the First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Third calendar year following the First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In April 2021, in connection with the Company&#x2019;s
Sublicense Agreement with Aikido Pharma Inc. (see below - &lt;i&gt;Patent License Agreement with Aikido Pharma Inc.&lt;/i&gt;), the Company paid
25% of its sublicense income to UMB, pursuant to the Master License Agreement, which amounted to $12,500. The Company recognized amortization
expense of $628 in 2021. During the six months ended June 30, 2022, the Company recognized amortization expense of $419. At December
31, 2021, prepaid expense and other current assets &#x2013; current amounted $838 and prepaid expenses &#x2013; non-current amounts $11,034.
At June 30, 2022, prepaid expense and other current assets &#x2013; current amounted $838 and prepaid expenses &#x2013; non-current amounts
$10,615 as reflected in the accompanying condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;University of Maryland, Baltimore -
License Agreement for Development and Use of Joint-Homing Peptides&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Commercial Evaluation License and Option
Agreement with the University of Maryland, Baltimore&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective as of February 26, 2021, the Company,
through its wholly-subsidiary, Silo Pharma, Inc., and University of Maryland, Baltimore (&#x201c;UMB&#x201d;) (collectively as &#x201c;Parties&#x201d;),
entered into a commercial evaluation license and option agreement (&#x201c;License Agreement&#x201d;), which granted the Company an exclusive,
non-sublicensable, non-transferable license to with respect to the exploration of the potential use of joint-homing peptides for use
in the investigation and treatment of arthritogenic processes. The License Agreement also granted the Company an exclusive option to
negotiate and obtain an exclusive, sublicensable, royalty-bearing license (&#x201c;Exclusive Option&#x201d;) to with respect to the subject
technology. The License Agreement had a term of six months from the effective date. Both parties could have terminated the License Agreement
within thirty days by giving a written notice.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 6, 2021, the Company entered into
a First Amendment Agreement (&#x201c;First Amendment&#x201d;) with UMB to extend the term of the original License Agreement by an additional
six months such that the First Amendment was effective until February 25, 2022 however, if the Company exercises the Exclusive Option,
the License Agreement shall expire at the end of the negotiation period (as defined in the License Agreement) or upon execution of a
master license agreement, whichever occurs first. The Company paid a license fee of $10,000 to UMB in March 2021 pursuant to the License
Agreement which was recorded in professional fees during the year ended December 31, 2021, since the Company could not conclude that
such costs would be recoverable for this early-stage venture.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 28, 2022, the Parties entered into
a second amendment to the commercial evaluation and license agreement dated February 26, 2021 (&#x201c;Second Amendment&#x201d;). The Second
Amendment extends the term of the original license agreement until December 31, 2022. However, if the Company exercises the Exclusive
Option, the License Agreement shall expire at the end of the negotiation period (as defined in the License Agreement) or upon execution
of a master license agreement, whichever occurs first.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 30, 2022, the Parties entered into
a third amendment to the commercial evaluation and license agreement dated February 26, 2021 (&#x201c;Third Amendment&#x201d;). The Third
Amendment expands the scope of the license granted in the License Agreement to add additional patent rights with respect to an invention
generally known as &lt;i&gt;Peptide-Targeted Liposomal Delivery for Treatment Diagnosis, and Imaging of Diseases and Disorders&lt;/i&gt;. In consideration
of the licenses granted under this Third Amendment, Company agreed to pay a one-time, non-refundable fee of $2,500 which was recorded
as research and development expense in the condensed consolidated statement of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;License Agreements between the Company
and Customer&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Customer Patent License Agreement with
Aikido Pharma Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 5, 2021, the Company and its subsidiary
Silo Pharma, Inc., a Florida corporation, entered into a patent license agreement (&#x201c;License Agreement&#x201d;) (collectively, the
&#x201c;Licensor&#x201d;) and Aikido Pharma Inc. (&#x201c;Aikido&#x201d; or the &#x201c;Customer&#x201d;), as amended on April 12, 2021, pursuant
to which the Licensor granted Aikido an exclusive, worldwide (&#x201c;Territory&#x201d;), sublicensable, royalty-bearing license to certain
intellectual property: (i) to make, have made, use, provide, import, export, lease, distribute, sell, offer for sale, develop and advertise
certain licensed products and (ii) to develop and perform certain licensed processes for the treatment of cancer and symptoms caused
by cancer (&#x201c;Field of Use&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The License Agreement also provided that,
if the Licensor exercised the option granted to it pursuant to its commercial evaluation license and option agreement with UMB, effective
as of July 15, 2020, it would grant Aikido a non-exclusive sublicense (&#x201c;Right&#x201d;) to certain UMB patent rights in the field
of neuroinflammatory diseases occurring in patients diagnosed with cancer (&#x201c;Field&#x201d;). Pursuant to the License Agreement, Aikido
agreed to pay the Licensor, among other things, (i) a one-time non-refundable cash payment of $500,000 and (ii) royalty payments equal
to 2% of net sales (as defined in the License Agreement) in the Field of Use in the Territory. In addition, Aikido agreed to issue the
Licensor 500 shares of Aikido&#x2019;s newly designated Series M Convertible Preferred Stock which were to be converted into an aggregate
of 625,000 shares of the Aikido&#x2019;s common stock. On April 12, 2021, the Company entered into an amendment to the License Agreement
(&#x201c;Amended License Agreement&#x201d;) with Aikido dated January 5, 2021 whereby Aikido issued an aggregate of 625,000 restricted
shares of Aikido&#x2019;s common stock instead of the 500 shares of the Series M Convertible Preferred Stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the License Agreement, the Company
is required to prepare file, prosecute, and maintain the licensed patents. Unless earlier terminated, the term of the license to the
licensed patents will continue until the expiration or abandonment of all issued patents and filed patent applications within the licensed
patents. The Company may terminate the License Agreement upon 30 day written notice if Aikido fails to pay any amounts due and payable
to the Company or if Aikido or any of its affiliates brings a patent challenge against the Company, assists others in bringing a legal
or administrative challenge to the validity, scope, or enforceability of or opposes any of the licensed patents (&#x201c;Patent Challenge&#x201d;)
against the Company (except as required under a court order or subpoena). Aikido may terminate the Agreement at any time without cause,
and without incurring any additional penalty, (i) by providing at least 30 days&#x2019; prior written notice and paying the Company all
amounts due to it through such termination effective date. Either party may terminate the Agreement for material breaches that have failed
to be cured within 60 days after receiving written notice. The Company collected the non-refundable cash payment of $500,000 on January
5, 2021 which was recorded as deferred revenue to be recognized as revenues over the 15 year term of the License Agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;With respect to a vote of Aikido&#x2019;s stockholders
to approve a reverse split of its common stock no later than December 31, 2021 (&#x201c;Reverse Stock Split Vote&#x201d;), each share of
the Series M Convertible Preferred Stock shall be entitled to such number of votes equal to 20,000 shares of Aikido&#x2019;s common stock.
In addition, each share of the Series M Convertible Preferred Stock shall be convertible, at any time after the earlier of (i) the date
that the Reverse Stock Split Vote is approved by Aikido&#x2019;s stockholders and (ii) December 31, 2021, at the option of the holder,
into such number of shares of Aikido&#x2019;s common stock determined by dividing the Stated Value by the Conversion Price. &#x201c;Stated
Value&#x201d; means $1,000. &#x201c;Conversion Price&#x201d; means $0.80, subject to adjustment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Prior to the April 12, 2021, issuance of the
common stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible
Preferred stock which was equivalent into Aikido&#x2019;s 625,000 shares of common stock at a fair value of $0.85 per common share or
$531,250 based quoted trading price of Aikido&#x2019;s common stock on the date of grant. The Company recorded an equity investment of
$531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license. Accordingly, the Company
recorded a total deferred revenue of $1,031,250 ($500,000 cash received and $531,250 value of equity securities received) to be recognized
as revenues over the 15-year term. The Company recognized revenue of $68,750 in 2021. During the six months ended June 30, 2022, the
Company recognized revenue of $34,375. At December 31, 2021, deferred revenue &#x2013; current portion amounted $68,750 and deferred revenue
&#x2013; long-term portion amounted $893,750. At June 30, 2022, deferred revenue &#x2013; current portion amounted $68,750 and deferred
revenue &#x2013; long-term portion amounted $859,375 as reflected in the accompanying condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Right shall be to the full extent permitted
by and on terms and conditions required by UMB for a term consistent with the term of patent and technology licenses that UMB normally
grants. In the event that the Company exercises its option and executes a license with UMB to the UMB patent rights within 40 days after
the execution of such UMB license, for consideration to be agreed upon and paid by Aikido, which consideration shall in no event exceed
110% of any fee payable by the Company to UMB for the right to sublicense the UMB patent rights. The Company shall grant Aikido a nonexclusive
sublicense in the United States to the UMB patent rights in the Field, subject to the terms of any UMB license Licensor obtains, including
any royalty obligations on sublicensees required under any such sublicense. The option was exercised on January 13, 2021. Accordingly,
on April 6, 2021, the Company entered into the Sublicense Agreement with Aikido pursuant to which it granted Aikido a worldwide exclusive
sublicense to its licensed patents under the Master License Agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Customer Sublicense&#160;Agreement with
Aikido Pharma Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 6, 2021 (the &#x201c;Sublicense Agreement
Effective Date&#x201d;), the Company entered into the Sublicense Agreement with Aikido pursuant to which the Company granted Aikido an
exclusive worldwide sublicense to (i) make, have made, use, sell, offer to sell and import the Licensed Products (as defined below) and
(ii) in connection therewith to (A) use an invention known as &#x201c;Central nervous system-homing peptides in vivo and their use for
the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology&#x201d; which was sublicensed to the Company
pursuant to the Master License Agreement&#160;and (B) practice certain patent rights (&#x201c;Patent Rights&#x201d;) for the therapeutic
treatment of neuroinflammatory disease in cancer patients. &#x201c;Licensed Products&#x201d; means any product, service, or process, the
development, making, use, offer for sale, sale, importation, or providing of which: (i) is covered by one or more claims of the Patent
Rights; or (ii) contains, comprises, utilizes, incorporates, or is derived from the Invention or any technology disclosed in the Patent
Rights.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the Sublicense Agreement, Aikido
agreed to pay the Company (i) an upfront license fee of $50,000, (ii)&#160;the same sales-based royalty payments that the Company is
subject to under the Master License Agreement and (iii) total milestone payments of up to $1.9 million. The Sublicense Agreement shall
continue on a Licensed Product-by-Licensed Product and country-by-country basis until the later of (i) the date of expiration of the
last to expire claim of the Patent Rights covering such Licensed Product in such country, (ii) the expiration of data protection, new
chemical entity, orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity, if applicable and (iii)
10 years after the first commercial sale of a Licensed Product in that country, unless terminated earlier pursuant to the terms of the
Sublicense Agreement. Furthermore, the Sublicense Agreement shall expire 15 years after the Sublicense Agreement Effective Date with
respect to any country in which (i) there were never any Patent Rights, (ii) there was never any data protection, new chemical entity,
orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity with respect to a Licensed Product and
(ii) there was never a commercial sale of a Licensed Product, unless such agreement is earlier terminated pursuant to its terms. The
Company collected the upfront license fee of $50,000 in April 2021. The Company recognized revenue of $2,514 in 2021. During the six
months ended June 30, 2022, the Company recognized revenue of $1,676. At December 31, 2021, deferred revenue &#x2013; current portion
amounted $3,352 and deferred revenue &#x2013; long-term portion amounted $44,134. At June 30, 2022, deferred revenue &#x2013; current portion
amounted $3,352 and deferred revenue &#x2013; long-term portion amounted $42,458 as reflected in the accompanying condensed consolidated
balance sheets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Sponsored Study and Research Agreements
between the Company and Vendors&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Investigator-Sponsored Study Agreement
with University of Maryland, Baltimore &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 5, 2021, the Company entered into
an investigator-sponsored study agreement (&#x201c;Sponsored Study Agreement&#x201d;) with the University of Maryland, Baltimore. The research
project is a clinical study to examine a novel peptide-guided drug delivery approach for the treatment of multiple sclerosis (&#x201c;MS&#x201d;).
More specifically, the study is designed to evaluate (1) whether MS-1-displaying liposomes can effectively deliver dexamethasone to the
CNS and (2) whether MS-1-displaying liposomes are superior to plain liposomes, also known as free drug, in inhibiting the relapses and
progression of experimental autoimmune encephalomyelitis. Pursuant to the Sponsored Study Agreement, the research shall commence on March
1, 2021 and will continue until substantial completion, subject to renewal upon mutual written consent of the parties. The total cost
under the Sponsored Study Agreement shall not exceed $81,474 which is payable in two equal installments of $40,737 upon execution of
the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. The Company
paid $40,737 on January 13, 2021 which was recorded in prepaid expense to be amortized over the nine-month period. Currently, the project
has not been completed due to the delays cause by the Covid-19 pandemic. During the year ended December 31, 2021, the Company fully amortized
the prepaid expense of $40,737.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Sponsored Research Agreement with The
Regents of the University of California&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 1, 2021 (the &#x201c;Effective Date&#x201d;),
the Company entered into a sponsored research agreement (the &#x201c;Sponsored Research Agreement&#x201d;) with The Regents of the University
of California, on behalf of its San Francisco Campus (&#x201c;UCSF&#x201d;) pursuant to which UCSF shall conduct a study to examine psilocybin&#x2019;s
effect on inflammatory activity in humans to accelerate its implementation as a potential treatment for Parkinson&#x2019;s Disease, chronic
pain, and bipolar disorder. Pursuant to the Agreement, the Company shall pay UCSF a total fee of $342,850 to conduct the research over
the two-year period. The Agreement shall be effective for a period of two years from the Effective Date, subject to renewal or earlier
termination as set forth in the Sponsored Research Agreement. The Company paid the first payment of $40,000 pursuant to the payment schedule
on the Sponsored Research Agreement on June 15, 2021, second payment of $40,000 on September 9, 2021 and $20,570 on November 18, 2021,
third payment of $60,570 on March 1, 2022, which were recorded to prepaid expense and other current assets &#x2013; current to be amortized
over the two-year period. In 2021, the Company amortized $92,855 of the prepaid expense. During the six months ended June 30, 2022, the
Company amortized $68,285 of the prepaid expense leaving a prepaid asset of $0 at June 30, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Sponsored Research Agreement with University
of Maryland, Baltimore&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 6, 2021, the Company and University
of Maryland, Baltimore (&#x201c;UMB&#x201d;) entered into a sponsored research agreement (&#x201c;July 2021 Sponsored Research Agreement&#x201d;)
pursuant to which UMB shall&#160;evaluate the pharmacokinetics of dexamethasone delivered to arthritic rats via liposome. The research
pursuant to the July 2021 Sponsored Research Agreement shall commence on September 1, 2021 and will continue until the substantial completion
thereof, subject to renewal upon written consent of the parties. The July 2021 Sponsored Research Agreement may be terminated by either
party upon 30 days&#x2019; prior written notice to the other party. In addition, if either party commits any material breach of or defaults
with respect to any terms or conditions of the July 2021 Sponsored Research Agreement and fails to remedy such default or breach within
10 business days after written notice from the other party, the party giving notice may terminate the July 2021 Sponsored Research Agreement
as of the date of receipt of such notice by the other party. If the Company terminates the July 2021 Sponsored Research Agreement for
any reason other than an uncured material breach by UMB, the Company shall relinquish any and all rights it may have in the Results (as
defined in the July 2021 Sponsored Research Agreement) to UMB. In addition, if the July 2021 Sponsored Research Agreement is terminated
early, the Company, among other things, will pay all costs incurred and accrued by UMB as of the date of termination.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the terms of the July 2021 Sponsored
Research Agreement, UMB granted the Company an option (the &#x201c;Option&#x201d;) to negotiate and obtain an exclusive license to any
UMB Arising IP (as defined in the July 2021 Sponsored Research Agreement) and UMB&#x2019;s rights in any Joint Arising IP (as defined
in the July 2021 Sponsored Research Agreement) (collectively, the &#x201c;UMB IP&#x201d;). The Company may exercise the Option by giving
UMB written notice within 60 days after it receives notice from UMB of the UMB IP. Pursuant to the July 2021 Sponsored Research Agreement,
the Company shall pay UMB the fees below:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Payment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 2%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;92,095&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 83%"&gt;&lt;span style="font-size: 10pt"&gt;Upon execution of the July 2021 Sponsored Research Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;92,095&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;92,095&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company paid the first payment of $92,095
on September 1, 2021 which was recorded to prepaid expense and other current assets &#x2013; current and was amortized during the year
ended December 31, 2021. The Company paid the second payment of $50,000 on February 1, 2022 which was recorded as research and development
expense in the accompanying condensed consolidated statement of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 7, 2022, the Company and UMB amended
the July 2021 Sponsored Research Agreement whereby both parties agreed to make changes to the original project work and budget. The amendment
had no effect on the consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Sponsored Research Agreement with Columbia
University&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 1, 2021, the Company entered into
a sponsored research agreement with Columbia University pursuant to which the Company has been granted an option to license certain assets
currently under development, including Alzheimer&#x2019;s disease. The term of the option will commence on the effective date of this
agreement and will expire upon the earlier of (i) 90 days after the date of the Company&#x2019;s receipt of a final research report for
each specific research proposal as defined in the agreement or (ii) termination of the research. If the Company elects to exercise the
option, both parties will commence negotiation of a license agreement and will execute a license agreement no later than 3 months after
the dated of the exercise of the option. Columbia University and the Company will work towards developing a therapeutic treatment for
patients suffering from Alzheimer&#x2019;s disease to post-traumatic stress disorder. During a one-year period from the date of this agreement,
the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the payment schedule
as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months after the start
of the project and, (iv)10% at completion of the project. The Company paid the first payment of $430,825 in November 2021 which was recorded
to prepaid expense and other current assets &#x2013; current to be amortized over the estimated project timeline of twelve months. In
2021, the Company amortized $359,021 of the prepaid expense. During the six months ended June 30, 2022, the Company amortized the remaining
prepaid expense of $71,804. As of June 30, 2022 and December 31, 2021, prepaid expense related to the sponsored research agreement were
$0 and $71,804, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Joint Venture Agreement with Zyl&#xf6;
Therapeutics, Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 22, 2021 (&#x201c;Effective Date&#x201d;),
the Company entered into a Joint Venture Agreement (&#x201c;JV Agreement&#x201d;) with Zyl&#xf6; Therapeutics, Inc. (&#x201c;ZTI&#x201d;)
pursuant to which the parties agreed to form a joint venture entity, to be named Ketamine Joint Venture, LLC (&#x201c;Joint Venture&#x201d;),
to, among other things, focus on the clinical development of ketamine using ZTI&#x2019;s Z-pod&#x2122; technology (&#x201c;Venture&#x201d;).
Pursuant to the JV Agreement, the Company shall act as the manager (&#x201c;Manager&#x201d;) of the Joint Venture. The Joint Venture shall
terminate if the development program does not meet certain specifications and milestones as set forth in the JV Agreement within 30 days
of the date set forth in the JV Agreement. Notwithstanding the foregoing, the Manager may, in its sole discretion, terminate the Joint
Venture at any time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the terms of the JV Agreement,
(A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall
contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and
trade secrets with respect to its Z-pod&#x2122; technology for the loading and release of ketamine, (3) ketamine to be used for clinical
purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the
interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be
owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event
shall either party own more than 60% of the interest in the Joint Venture. As of June 30, 2022 and as of the current date of this report,
the joint venture entity has not been formed yet.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Furthermore, pursuant to the terms of the
JV Agreement, ZTI shall grant the Joint Venture a sublicense pursuant to its license agreement (the &#x201c;License Agreement&#x201d;)
with Albert Einstein College of Medicine dated November 27, 2017, in the event that the Company or a third party makes a request indicating
that the patented technology (the &#x201c;Patented Technology&#x201d;) licensed to ZTI pursuant to the License Agreement is needed to advance
the development of the Joint Venture or it is contemplated or determined that the Patented Technology will be sold. Furthermore, pursuant
to the JV Agreement, ZTI granted the Company an exclusive option to enter into a separate joint venture for the clinical development
of psilocybin using ZTI&#x2019;s Z-pod&#x2122; technology on the same terms and conditions set forth in the JV Agreement, which option
shall expire 24 months after the JV Effective Date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Amended Service Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 10, 2021 (&#x201c;Effective Date&#x201d;),
the Company entered into an Amendment Agreement (&#x201c;Amended Service Agreement&#x201d;) to a certain service agreement dated on September
8, 2020 with the University of Texas (&#x201c;University&#x201d;) at Austin whereby the University will provide advisory service and assist
the Company on identifying license and sponsored research opportunities for the Company. The Company shall pay the University $5,000
per quarter starting on the Effective Date. Any cost incurred will be reimbursed only after prior written consent by the Company. The
term of the Amended Service Agreement is for 36 months unless earlier terminated by either party upon giving a written notice as defined
in the agreement. In 2021, the Company paid $5,000 related to this agreement. During the six months ended June 30, 2022, the Company
paid $10,000 related to this agreement.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <silo:EmploymentAgreementDescription contextRef="c173">The Employment Agreement provided for a
base salary of $120,000 and 152,619 of vested shares of the Company&#x2019;s common stock in April 2020. In addition, Mr. Weisblum shall
be eligible to earn a bonus, subject to the sole discretion of the Company&#x2019;s Board of Directors (&#x201c;Board&#x201d;).</silo:EmploymentAgreementDescription>
    <us-gaap:SupplementalUnemploymentBenefitsSalaryContinuation contextRef="c252" decimals="0" unitRef="usd">120000</us-gaap:SupplementalUnemploymentBenefitsSalaryContinuation>
    <us-gaap:SupplementalUnemploymentBenefitsSalaryContinuation contextRef="c253" decimals="0" unitRef="usd">180000</us-gaap:SupplementalUnemploymentBenefitsSalaryContinuation>
    <silo:EmploymentAgreementDescription contextRef="c254">James
Kuo entered into an employment agreement (&#x201c;Kuo Employment Agreement&#x201d;) for Dr. Kuo to serve as the Vice President of Research
&amp; Development. The Kuo Employment Agreement shall be effective as of the date of the agreement and shall automatically renew for
a period of one year at every anniversary of the effective date, with the same terms and conditions, unless either party provides written
notice of its intention not to extend the term of the Kuo Employment Agreement at least thirty days&#x2019; prior to the applicable renewal
date. Dr. Kuo shall be paid an annual base salary of $30,000. For each twelve-month period of his employment, Dr. Kuo shall be entitled
to a bonus whereby amount and terms shall be in the sole and absolute discretion of the Board of Directors (&#x201c;Board&#x201d;) and
shall be payable at the Company&#x2019;s sole option in stock or in cash. In addition, an aggregate of 16,000 incentive stock options
were granted under the 2020 Plan to Dr. Kou, exercisable at $10.00 per share and expires on January 31, 2032. The stock options vest
as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023.</silo:EmploymentAgreementDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="c255" decimals="0" unitRef="shares">16000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c255" decimals="0" unitRef="usd">94914</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c255" decimals="4" unitRef="pure">0.0118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c255" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c255">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c255" decimals="2" unitRef="pure">1.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense contextRef="c255" decimals="0" unitRef="usd">59322</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c255" decimals="0" unitRef="usd">23540</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense contextRef="c255" decimals="0" unitRef="usd">35782</us-gaap:DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense>
    <silo:LicenseFee contextRef="c176" decimals="0" unitRef="usd">10000</silo:LicenseFee>
    <silo:CommercialSaleTerm contextRef="c0">P10Y</silo:CommercialSaleTerm>
    <silo:LicenseAgreementExpire contextRef="c0">P15Y</silo:LicenseAgreementExpire>
    <silo:SublicenseIncomeDescription contextRef="c0">The Company or Company affiliates
shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company&#x2019;s sublicense income
which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first
licensed product; and (b) 15% of the Company&#x2019;s sublicense income which is receivable with respect to any sublicense that is executed
after the filing of an NDA (or foreign equivalent) for the first licensed product.</silo:SublicenseIncomeDescription>
    <silo:LicenseAgreementDescription contextRef="c0">the Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty
payments depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company shall
pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the effective date; and (b)
$50,000 on or before the first anniversary of the effective date. The license fee is non-refundable and is not creditable against any
other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing,
prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid $25,000 license fee on
February 17, 2021 which was recorded as prepaid expense and is being amortized over the 15-year term. The Company recognized amortization
expense of $4,375 in 2021. During the six months ended June 30, 2022, the Company recognized amortization expense of $2,500. At December
31, 2021, prepaid expense and other current assets &#x2013; current amounted $5,000 and prepaid expense &#x2013; non-current amounts $15,625.
At June 30, 2022, prepaid expense and other current assets &#x2013; current amounted $5,000 and prepaid expense &#x2013; non-current amounts
$13,125 as reflected in the accompanying condensed consolidated balance sheets.</silo:LicenseAgreementDescription>
    <silo:ScheduleOfMilestonePayments contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Milestone&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Receipt of New Drug Application (&#x201c;NDA&#x201d;) (or foreign equivalent) approval for a Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Achievement of First Commercial Sale of Licensed Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</silo:ScheduleOfMilestonePayments>
    <silo:Milestone contextRef="c262">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product</silo:Milestone>
    <silo:MilestonePayment contextRef="c262" decimals="0" unitRef="usd">50000</silo:MilestonePayment>
    <silo:Milestone contextRef="c263">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product</silo:Milestone>
    <silo:MilestonePayment contextRef="c263" decimals="0" unitRef="usd">100000</silo:MilestonePayment>
    <silo:Milestone contextRef="c264">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product</silo:Milestone>
    <silo:MilestonePayment contextRef="c264" decimals="0" unitRef="usd">250000</silo:MilestonePayment>
    <silo:Milestone contextRef="c265">Receipt of New Drug Application (&#x201c;NDA&#x201d;) (or foreign equivalent) approval for a Licensed Product</silo:Milestone>
    <silo:MilestonePayment contextRef="c265" decimals="0" unitRef="usd">500000</silo:MilestonePayment>
    <silo:Milestone contextRef="c266">Achievement of First Commercial Sale of Licensed Product</silo:Milestone>
    <silo:MilestonePayment contextRef="c266" decimals="0" unitRef="usd">1000000</silo:MilestonePayment>
    <silo:RoyaltyPaymentsDescription contextRef="c0">Royalty Payments Terms:&#160;&#160;(i)3% on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and&#160;&#160;&#160;&#160;(ii)5% on sales of licensed products during the applicable calendar year for sales greater than $50,000,000; and</silo:RoyaltyPaymentsDescription>
    <silo:ScheduleOfUMBMinimumRoyaltyPayments contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Years&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Minimum Annual Royalty&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prior to First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-337; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Year of First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-338; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;First calendar year following the First Commercial Sale&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Second calendar year following the First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Third calendar year following the First Commercial Sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</silo:ScheduleOfUMBMinimumRoyaltyPayments>
    <silo:YearsDescription contextRef="c262">Prior to First Commercial Sale</silo:YearsDescription>
    <silo:YearsDescription contextRef="c263">Year of First Commercial Sale</silo:YearsDescription>
    <silo:YearsDescription contextRef="c264">First calendar year following the First Commercial Sale</silo:YearsDescription>
    <silo:MinimumAnnualRoyalty contextRef="c264" decimals="0" unitRef="usd">25000</silo:MinimumAnnualRoyalty>
    <silo:YearsDescription contextRef="c265">Second calendar year following the First Commercial Sale</silo:YearsDescription>
    <silo:MinimumAnnualRoyalty contextRef="c265" decimals="0" unitRef="usd">25000</silo:MinimumAnnualRoyalty>
    <silo:YearsDescription contextRef="c266">Third calendar year following the First Commercial Sale</silo:YearsDescription>
    <silo:MinimumAnnualRoyalty contextRef="c266" decimals="0" unitRef="usd">100000</silo:MinimumAnnualRoyalty>
    <silo:SublicenseIncomePercentage contextRef="c177" decimals="2" unitRef="pure">0.25</silo:SublicenseIncomePercentage>
    <silo:SublicenseAgreementAmountPaid contextRef="c177" decimals="0" unitRef="usd">12500</silo:SublicenseAgreementAmountPaid>
    <silo:OtherDepreciationsAndAmortization contextRef="c178" decimals="0" unitRef="usd">628</silo:OtherDepreciationsAndAmortization>
    <us-gaap:UtilitiesOperatingExpenseDepreciationAndAmortization contextRef="c256" decimals="0" unitRef="usd">419</us-gaap:UtilitiesOperatingExpenseDepreciationAndAmortization>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c1" decimals="0" unitRef="usd">838</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="c1" decimals="0" unitRef="usd">11034</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c7" decimals="0" unitRef="usd">838</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="c7" decimals="0" unitRef="usd">10615</us-gaap:PrepaidExpenseOtherNoncurrent>
    <silo:LicenseFee contextRef="c179" decimals="0" unitRef="usd">10000</silo:LicenseFee>
    <us-gaap:CustomerRefundableFeesProceeds contextRef="c0" decimals="0" unitRef="usd">2500</us-gaap:CustomerRefundableFeesProceeds>
    <silo:NonrefundableCashPayment contextRef="c0" decimals="0" unitRef="usd">500000</silo:NonrefundableCashPayment>
    <silo:NetSalePercentage contextRef="c0" decimals="2" unitRef="pure">0.02</silo:NetSalePercentage>
    <silo:LicensorShare contextRef="c0" decimals="0" unitRef="shares">500</silo:LicensorShare>
    <silo:AggregateOfConvertedShares contextRef="c0" decimals="0" unitRef="shares">625000</silo:AggregateOfConvertedShares>
    <silo:AggregateOfConvertedShares contextRef="c181" decimals="0" unitRef="shares">625000</silo:AggregateOfConvertedShares>
    <silo:LicensorShare contextRef="c181" decimals="0" unitRef="shares">500</silo:LicensorShare>
    <silo:NonrefundableCashPayment contextRef="c181" decimals="0" unitRef="usd">500000</silo:NonrefundableCashPayment>
    <silo:RevenueTerm contextRef="c181">P15Y</silo:RevenueTerm>
    <silo:NumberOfVotingShares contextRef="c10" decimals="0" unitRef="shares">20000</silo:NumberOfVotingShares>
    <silo:ReverseStockSplitVoteDescription contextRef="c0">In addition, each share of the Series M Convertible Preferred Stock shall be convertible, at any time after the earlier of (i) the date
that the Reverse Stock Split Vote is approved by Aikido&#x2019;s stockholders and (ii) December 31, 2021, at the option of the holder,
into such number of shares of Aikido&#x2019;s common stock determined by dividing the Stated Value by the Conversion Price. &#x201c;Stated
Value&#x201d; means $1,000. &#x201c;Conversion Price&#x201d; means $0.80, subject to adjustment.Prior to the April 12, 2021, issuance of the
common stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible
Preferred stock which was equivalent into Aikido&#x2019;s 625,000 shares of common stock at a fair value of $0.85 per common share or
$531,250 based quoted trading price of Aikido&#x2019;s common stock on the date of grant. The Company recorded an equity investment of
$531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license.</silo:ReverseStockSplitVoteDescription>
    <us-gaap:DeferredRevenue contextRef="c7" decimals="0" unitRef="usd">1031250</us-gaap:DeferredRevenue>
    <silo:CashReceived contextRef="c7" decimals="0" unitRef="usd">500000</silo:CashReceived>
    <silo:SecuritiesReceived contextRef="c7" decimals="0" unitRef="usd">531250</silo:SecuritiesReceived>
    <silo:RevenueTerm contextRef="c0">P15Y</silo:RevenueTerm>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c10" decimals="0" unitRef="usd">68750</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c0" decimals="0" unitRef="usd">34375</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:RecognitionOfDeferredRevenue contextRef="c10" decimals="0" unitRef="usd">68750</us-gaap:RecognitionOfDeferredRevenue>
    <silo:DeferredRevenueLongtermPortionAmounted contextRef="c10" decimals="0" unitRef="usd">893750</silo:DeferredRevenueLongtermPortionAmounted>
    <us-gaap:RecognitionOfDeferredRevenue contextRef="c0" decimals="0" unitRef="usd">68750</us-gaap:RecognitionOfDeferredRevenue>
    <silo:DeferredRevenueLongtermPortion contextRef="c7" decimals="0" unitRef="usd">859375</silo:DeferredRevenueLongtermPortion>
    <silo:ConsiderationFeePayablePercentage contextRef="c0" decimals="2" unitRef="pure">1.10</silo:ConsiderationFeePayablePercentage>
    <silo:UpfrontLicenseFees contextRef="c0" decimals="0" unitRef="usd">50000</silo:UpfrontLicenseFees>
    <silo:UpfrontLicenseFees contextRef="c257" decimals="-5" unitRef="usd">1900000</silo:UpfrontLicenseFees>
    <silo:FirstCommercialSale contextRef="c0">P10Y</silo:FirstCommercialSale>
    <silo:AgreementShallExpire contextRef="c0">P15Y</silo:AgreementShallExpire>
    <silo:UpfrontLicenseFees contextRef="c183" decimals="0" unitRef="usd">50000</silo:UpfrontLicenseFees>
    <silo:RecognizedRevenues contextRef="c178" decimals="0" unitRef="usd">2514</silo:RecognizedRevenues>
    <silo:RecognizedRevenues contextRef="c256" decimals="0" unitRef="usd">1676</silo:RecognizedRevenues>
    <us-gaap:RecognitionOfDeferredRevenue contextRef="c258" decimals="0" unitRef="usd">3352</us-gaap:RecognitionOfDeferredRevenue>
    <silo:DeferredRevenueLongtermPortionAmounted contextRef="c258" decimals="0" unitRef="usd">44134</silo:DeferredRevenueLongtermPortionAmounted>
    <us-gaap:RecognitionOfDeferredRevenue contextRef="c256" decimals="0" unitRef="usd">3352</us-gaap:RecognitionOfDeferredRevenue>
    <silo:DeferredRevenueLongtermPortionAmounted contextRef="c0" decimals="0" unitRef="usd">42458</silo:DeferredRevenueLongtermPortionAmounted>
    <silo:SponsoredStudyAgreementDescription contextRef="c181">The total cost
under the Sponsored Study Agreement shall not exceed $81,474 which is payable in two equal installments of $40,737 upon execution of
the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. The Company
paid $40,737 on January 13, 2021 which was recorded in prepaid expense to be amortized over the nine-month period. Currently, the project
has not been completed due to the delays cause by the Covid-19 pandemic. During the year ended December 31, 2021, the Company fully amortized
the prepaid expense of $40,737.</silo:SponsoredStudyAgreementDescription>
    <silo:SublicenseAmountPaid contextRef="c0" decimals="0" unitRef="usd">342850</silo:SublicenseAmountPaid>
    <silo:SponsoredResearchAgreementDescription contextRef="c0">The Company paid the first payment of $40,000 pursuant to the payment schedule
on the Sponsored Research Agreement on June 15, 2021, second payment of $40,000 on September 9, 2021 and $20,570 on November 18, 2021,
third payment of $60,570 on March 1, 2022, which were recorded to prepaid expense and other current assets &#x2013; current to be amortized
over the two-year period. In 2021, the Company amortized $92,855 of the prepaid expense. During the six months ended June 30, 2022, the
Company amortized $68,285 of the prepaid expense leaving a prepaid asset of $0 at June 30, 2022.</silo:SponsoredResearchAgreementDescription>
    <silo:ScheduleOfShallPayUMB contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Payment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 2%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;92,095&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 83%"&gt;&lt;span style="font-size: 10pt"&gt;Upon execution of the July 2021 Sponsored Research Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;92,095&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;92,095&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</silo:ScheduleOfShallPayUMB>
    <silo:SponsoredPayment contextRef="c267" decimals="0" unitRef="usd">92095</silo:SponsoredPayment>
    <silo:PaymentDescription contextRef="c267">Upon execution of the July 2021 Sponsored Research Agreement</silo:PaymentDescription>
    <silo:SponsoredPayment contextRef="c268" decimals="0" unitRef="usd">92095</silo:SponsoredPayment>
    <silo:PaymentDescription contextRef="c268">Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement</silo:PaymentDescription>
    <silo:SponsoredPayment contextRef="c269" decimals="0" unitRef="usd">92095</silo:SponsoredPayment>
    <silo:PaymentDescription contextRef="c269">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement</silo:PaymentDescription>
    <silo:CompanyPaidCash contextRef="c187" decimals="0" unitRef="usd">92095</silo:CompanyPaidCash>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear contextRef="c259" decimals="0" unitRef="usd">50000</us-gaap:RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear>
    <silo:SponsoredResearchAgreementDescription contextRef="c260">If the Company elects to exercise the
option, both parties will commence negotiation of a license agreement and will execute a license agreement no later than 3 months after
the dated of the exercise of the option. Columbia University and the Company will work towards developing a therapeutic treatment for
patients suffering from Alzheimer&#x2019;s disease to post-traumatic stress disorder. During a one-year period from the date of this agreement,
the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the payment schedule
as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months after the start
of the project and, (iv)10% at completion of the project. The Company paid the first payment of $430,825 in November 2021 which was recorded
to prepaid expense and other current assets &#x2013; current to be amortized over the estimated project timeline of twelve months. In
2021, the Company amortized $359,021 of the prepaid expense. During the six months ended June 30, 2022, the Company amortized the remaining
prepaid expense of $71,804. As of June 30, 2022 and December 31, 2021, prepaid expense related to the sponsored research agreement were
$0 and $71,804, respectively.</silo:SponsoredResearchAgreementDescription>
    <silo:PursuantTerms contextRef="c261">Pursuant to the terms of the JV Agreement,
(A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall
contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and
trade secrets with respect to its Z-pod&#x2122; technology for the loading and release of ketamine, (3) ketamine to be used for clinical
purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the
interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be
owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event
shall either party own more than 60% of the interest in the Joint Venture.</silo:PursuantTerms>
    <silo:PaymentOfUniversity contextRef="c0" decimals="0" unitRef="usd">5000</silo:PaymentOfUniversity>
    <silo:AgreementDescription contextRef="c10">In 2021, the Company paid $5,000 related to this agreement. During the six months ended June 30, 2022, the Company
paid $10,000 related to this agreement.</silo:AgreementDescription>
    <dei:DocumentType contextRef="c0" id="hidden-fact-0">S-1/A</dei:DocumentType>
    <us-gaap:ReceivablesNetCurrent
      contextRef="c1"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="c1"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c2"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="c2"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c1"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredRevenueCurrent
      contextRef="c2"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="c2"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermNotesPayable
      contextRef="c1"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c1"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c1"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:PreferredStockValueOne
      contextRef="c3"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:PreferredStockValueOne
      contextRef="c4"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c3"
      id="hidden-fact-15"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c4"
      id="hidden-fact-16"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c3"
      id="hidden-fact-17"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c4"
      id="hidden-fact-18"
      unitRef="shares"
      xsi:nil="true"/>
    <silo:PreferredStockValueTwo
      contextRef="c5"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:PreferredStockValueTwo
      contextRef="c6"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c6"
      id="hidden-fact-21"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c6"
      id="hidden-fact-22"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:LoansPayableCurrent
      contextRef="c1"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c7"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c1"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c7"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c1"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:PreferredStockValueOne
      contextRef="c8"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:PreferredStockValueOne
      contextRef="c3"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c8"
      id="hidden-fact-30"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c3"
      id="hidden-fact-31"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c8"
      id="hidden-fact-32"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c3"
      id="hidden-fact-33"
      unitRef="shares"
      xsi:nil="true"/>
    <silo:PreferredStockValueTwo
      contextRef="c9"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:PreferredStockValueTwo
      contextRef="c5"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:LicenseFees
      contextRef="c11"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="c11"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c11"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="c10"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c11"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="c10"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="c10"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c10"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnInvestments
      contextRef="c11"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c11"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="c11"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c10"
      decimals="2"
      id="hidden-fact-47"
      unitRef="usdPershares">0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c11"
      decimals="2"
      id="hidden-fact-48"
      unitRef="usdPershares">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c10"
      decimals="2"
      id="hidden-fact-49"
      unitRef="usdPershares">0.00</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c11"
      decimals="2"
      id="hidden-fact-50"
      unitRef="usdPershares">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c11"
      decimals="INF"
      id="hidden-fact-51"
      unitRef="shares">65954691</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c10"
      decimals="INF"
      id="hidden-fact-52"
      unitRef="shares">95922218</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <silo:BadDebtRecoveryExpense
      contextRef="c12"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:OtherIncomeFromEquitySharesEarnedForServices
      contextRef="c12"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:OtherIncomeFromEquitySharesEarnedForServices
      contextRef="c13"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:OtherIncomeFromEquitySharesEarnedForServices
      contextRef="c14"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c12"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c0"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnInvestments
      contextRef="c13"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnInvestments
      contextRef="c14"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c13"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c14"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c12"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c13"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c14"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="c12"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="c12"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="c12"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="c13"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="c0"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c13"
      decimals="2"
      id="hidden-fact-72"
      unitRef="usdPershares">0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c12"
      decimals="2"
      id="hidden-fact-73"
      unitRef="usdPershares">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-74"
      unitRef="usdPershares">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c14"
      decimals="2"
      id="hidden-fact-75"
      unitRef="usdPershares">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c12"
      id="hidden-fact-76"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c12"
      id="hidden-fact-77"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c13"
      decimals="2"
      id="hidden-fact-78"
      unitRef="usdPershares">0.00</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c0"
      decimals="2"
      id="hidden-fact-79"
      unitRef="usdPershares">0.00</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c14"
      decimals="2"
      id="hidden-fact-80"
      unitRef="usdPershares">0.00</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c14"
      decimals="INF"
      id="hidden-fact-81"
      unitRef="shares">91032045</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c13"
      decimals="INF"
      id="hidden-fact-82"
      unitRef="shares">96857408</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c0"
      decimals="INF"
      id="hidden-fact-83"
      unitRef="shares">99018232</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c12"
      decimals="INF"
      id="hidden-fact-84"
      unitRef="shares">99395304</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:StockholdersEquity
      contextRef="c15"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c16"
      id="hidden-fact-86"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c16"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c21"
      id="hidden-fact-88"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c21"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c22"
      id="hidden-fact-90"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c22"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c25"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:CommonStockIssuedForFutureServicesShares
      contextRef="c21"
      id="hidden-fact-93"
      unitRef="shares"
      xsi:nil="true"/>
    <silo:CommonStockIssuedForFutureServices
      contextRef="c21"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:CommonStockIssuedForFutureServicesShares
      contextRef="c22"
      id="hidden-fact-95"
      unitRef="shares"
      xsi:nil="true"/>
    <silo:CommonStockIssuedForFutureServices
      contextRef="c22"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:CommonStockIssuedForFutureServices
      contextRef="c25"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:PreferredSharesExchangedForCommonStock
      contextRef="c21"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:PreferredSharesExchangedForCommonStockShares
      contextRef="c22"
      id="hidden-fact-99"
      unitRef="shares"
      xsi:nil="true"/>
    <silo:PreferredSharesExchangedForCommonStock
      contextRef="c22"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:PreferredSharesExchangedForCommonStock
      contextRef="c25"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:PreferredSharesExchangedForCommonStock
      contextRef="c11"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="c21"
      id="hidden-fact-103"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="c21"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="c22"
      id="hidden-fact-105"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="c22"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="c25"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:CommonStockIssuedForExchangeOfNotesShares
      contextRef="c21"
      id="hidden-fact-108"
      unitRef="shares"
      xsi:nil="true"/>
    <silo:CommonStockIssuedForExchangeOfNotes
      contextRef="c21"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:CommonStockIssuedForExchangeOfNotesShares
      contextRef="c22"
      id="hidden-fact-110"
      unitRef="shares"
      xsi:nil="true"/>
    <silo:CommonStockIssuedForExchangeOfNotes
      contextRef="c22"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:CommonStockIssuedForExchangeOfNotes
      contextRef="c25"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares
      contextRef="c21"
      id="hidden-fact-113"
      unitRef="shares"
      xsi:nil="true"/>
    <silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock
      contextRef="c21"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares
      contextRef="c22"
      id="hidden-fact-115"
      unitRef="shares"
      xsi:nil="true"/>
    <silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock
      contextRef="c22"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock
      contextRef="c25"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:DeemedDividendOnPreferredStockExchange
      contextRef="c21"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:DeemedDividendOnPreferredStockExchange
      contextRef="c22"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:DeemedDividendOnPreferredStockExchange
      contextRef="c23"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:DeemedDividendOnPreferredStockExchange
      contextRef="c11"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c21"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c22"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c23"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c24"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c26"
      id="hidden-fact-126"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c26"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c27"
      id="hidden-fact-128"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c27"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c31"
      id="hidden-fact-130"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c31"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c32"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c33"
      id="hidden-fact-133"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c33"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c35"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="c31"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="c32"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="c33"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="c10"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c31"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c32"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c33"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c35"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:IssuanceOfCommonSharesForConversionOfPreferredStockinShares
      contextRef="c31"
      id="hidden-fact-144"
      unitRef="shares"
      xsi:nil="true"/>
    <silo:IssuanceOfCommonStockForConversionOfPreferredStock
      contextRef="c31"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:IssuanceOfCommonStockForConversionOfPreferredStock
      contextRef="c32"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:IssuanceOfCommonStockForConversionOfPreferredStock
      contextRef="c35"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:IssuanceOfCommonStockForConversionOfPreferredStock
      contextRef="c10"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c31"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c32"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c33"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c34"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c36"
      id="hidden-fact-153"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c36"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c37"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c36"
      id="hidden-fact-156"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c36"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c37"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c41"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c42"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c43"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c41"
      id="hidden-fact-162"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c41"
      id="hidden-fact-163"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c42"
      id="hidden-fact-164"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c46"
      id="hidden-fact-165"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c41"
      id="hidden-fact-166"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c42"
      id="hidden-fact-167"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c43"
      id="hidden-fact-168"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c44"
      id="hidden-fact-169"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c47"
      id="hidden-fact-170"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c48"
      id="hidden-fact-171"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c53"
      id="hidden-fact-172"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c54"
      id="hidden-fact-173"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c55"
      id="hidden-fact-174"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c57"
      id="hidden-fact-175"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c53"
      id="hidden-fact-176"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c54"
      id="hidden-fact-177"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c55"
      id="hidden-fact-178"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c57"
      id="hidden-fact-179"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c53"
      id="hidden-fact-180"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c54"
      id="hidden-fact-181"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c55"
      id="hidden-fact-182"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c56"
      id="hidden-fact-183"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c58"
      id="hidden-fact-184"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c59"
      id="hidden-fact-185"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c26"
      id="hidden-fact-186"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c27"
      id="hidden-fact-187"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c27"
      id="hidden-fact-188"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c63"
      id="hidden-fact-189"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c64"
      id="hidden-fact-190"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c65"
      id="hidden-fact-191"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c67"
      id="hidden-fact-192"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="c63"
      id="hidden-fact-193"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="c64"
      id="hidden-fact-194"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="c65"
      id="hidden-fact-195"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="c68"
      id="hidden-fact-196"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c63"
      id="hidden-fact-197"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c64"
      id="hidden-fact-198"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c65"
      id="hidden-fact-199"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c67"
      id="hidden-fact-200"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c63"
      id="hidden-fact-201"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c64"
      id="hidden-fact-202"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c65"
      id="hidden-fact-203"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c66"
      id="hidden-fact-204"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c69"
      id="hidden-fact-205"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c70"
      id="hidden-fact-206"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c75"
      id="hidden-fact-207"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c76"
      id="hidden-fact-208"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c79"
      id="hidden-fact-209"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c13"
      id="hidden-fact-210"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c75"
      id="hidden-fact-211"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c76"
      id="hidden-fact-212"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c77"
      id="hidden-fact-213"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c78"
      id="hidden-fact-214"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c80"
      id="hidden-fact-215"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c81"
      id="hidden-fact-216"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c10"
      id="hidden-fact-217"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryWriteDown
      contextRef="c10"
      id="hidden-fact-218"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="c11"
      id="hidden-fact-219"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="c11"
      id="hidden-fact-220"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="c11"
      id="hidden-fact-221"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:LossFromDebtExtinguishment
      contextRef="c10"
      id="hidden-fact-222"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="c11"
      id="hidden-fact-223"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="c11"
      id="hidden-fact-224"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="c11"
      id="hidden-fact-225"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable
      contextRef="c11"
      id="hidden-fact-226"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="c10"
      id="hidden-fact-227"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c10"
      id="hidden-fact-228"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="c10"
      id="hidden-fact-229"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c10"
      id="hidden-fact-230"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="c11"
      id="hidden-fact-231"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:AdvanceFromARelatedParty
      contextRef="c11"
      id="hidden-fact-232"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="c11"
      id="hidden-fact-233"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="c10"
      id="hidden-fact-234"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="c11"
      id="hidden-fact-235"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c10"
      id="hidden-fact-236"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c11"
      id="hidden-fact-237"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c10"
      id="hidden-fact-238"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c10"
      id="hidden-fact-239"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c11"
      id="hidden-fact-240"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:StockIssuedForFutureServices
      contextRef="c10"
      id="hidden-fact-241"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:CommonStockIssuedForPrepaidServices
      contextRef="c10"
      id="hidden-fact-242"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock
      contextRef="c10"
      id="hidden-fact-243"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree
      contextRef="c11"
      id="hidden-fact-244"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement
      contextRef="c11"
      id="hidden-fact-245"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:AmortizationOfPrepaidStockbasedExpense
      contextRef="c0"
      id="hidden-fact-246"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="c14"
      id="hidden-fact-247"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="c0"
      id="hidden-fact-248"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:IncreaseDecreaseInAssetsOfDiscontinuedOperation
      contextRef="c0"
      id="hidden-fact-249"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="c14"
      id="hidden-fact-250"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPayablesToBrokerDealers
      contextRef="c14"
      id="hidden-fact-251"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="c14"
      id="hidden-fact-252"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="c0"
      id="hidden-fact-253"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:AdvanceFromARelatedParty
      contextRef="c0"
      id="hidden-fact-254"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="c0"
      id="hidden-fact-255"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c0"
      id="hidden-fact-256"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-257"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c14"
      id="hidden-fact-258"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="c14"
      id="hidden-fact-259"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp
      contextRef="c14"
      id="hidden-fact-260"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="c0"
      id="hidden-fact-261"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree
      contextRef="c0"
      id="hidden-fact-262"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c89"
      id="hidden-fact-263"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c93"
      id="hidden-fact-264"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="c11"
      id="hidden-fact-265"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c11"
      id="hidden-fact-266"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:AuctionMarketPreferredSecuritiesSharesOutstanding
      contextRef="c2"
      id="hidden-fact-267"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c10"
      decimals="INF"
      id="hidden-fact-268"
      unitRef="shares">19184448</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <silo:EquityInvestmentsAtFairValue
      contextRef="c98"
      id="hidden-fact-269"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:EquityInvestmentsAtFairValue
      contextRef="c99"
      id="hidden-fact-270"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:EquityInvestmentsAtFairValue
      contextRef="c100"
      id="hidden-fact-271"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:EquityInvestmentsAtFairValue
      contextRef="c101"
      id="hidden-fact-272"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:EquityInvestmentsAtFairValue
      contextRef="c102"
      id="hidden-fact-273"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c2"
      id="hidden-fact-274"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c20"
      id="hidden-fact-275"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:AdditionsofEquitySecurities
      contextRef="c11"
      id="hidden-fact-276"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="c11"
      id="hidden-fact-277"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="c11"
      id="hidden-fact-278"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c2"
      id="hidden-fact-279"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:FinanceLeaseLiabilities
      contextRef="c87"
      id="hidden-fact-280"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:GainFromSaleOfNFIDBusiness
      contextRef="c11"
      id="hidden-fact-281"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:AdditionalNotesReceivableIn2021
      contextRef="c2"
      id="hidden-fact-282"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:LessNotesReceivableNetCurrentPortion
      contextRef="c1"
      id="hidden-fact-283"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesReceivableNet
      contextRef="c2"
      id="hidden-fact-284"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:DebtInstrumentsFaceAmount
      contextRef="c1"
      id="hidden-fact-285"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:NotrPayableLessCurrentPortion
      contextRef="c1"
      id="hidden-fact-286"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:NotePayableLongTermPortion
      contextRef="c1"
      id="hidden-fact-287"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c163"
      id="hidden-fact-288"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c163"
      id="hidden-fact-289"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <silo:WeightedAverageRemainingContractualTermYearsGrantedissued contextRef="c163" id="hidden-fact-290" xsi:nil="true"/>
    <silo:AggregateIntrinsicValueGrantedIssuedForfeited1
      contextRef="c163"
      id="hidden-fact-291"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c165"
      id="hidden-fact-292"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c165"
      id="hidden-fact-293"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <silo:WeightedAverageRemainingContractualTermYearsGrantedissued contextRef="c165" id="hidden-fact-294" xsi:nil="true"/>
    <silo:AggregateIntrinsicValueGrantedIssuedForfeited1
      contextRef="c165"
      id="hidden-fact-295"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited contextRef="c93" id="hidden-fact-296" xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="c93"
      id="hidden-fact-297"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:NumberOfWarrant
      contextRef="c168"
      id="hidden-fact-298"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c168"
      id="hidden-fact-299"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c93" id="hidden-fact-300" xsi:nil="true"/>
    <silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue
      contextRef="c168"
      id="hidden-fact-301"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:AggregateIntrinsicValueGranted
      contextRef="c92"
      id="hidden-fact-302"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue
      contextRef="c169"
      id="hidden-fact-303"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c169"
      id="hidden-fact-304"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c11"
      id="hidden-fact-305"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c11"
      id="hidden-fact-306"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c1"
      id="hidden-fact-307"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c2"
      id="hidden-fact-308"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:UMBPayment
      contextRef="c190"
      id="hidden-fact-309"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:UMBPayment
      contextRef="c191"
      id="hidden-fact-310"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c206"
      id="hidden-fact-311"
      unitRef="shares"
      xsi:nil="true"/>
    <silo:EquityInvestmentsAtFairValue
      contextRef="c216"
      id="hidden-fact-312"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:EquityInvestmentsAtFairValue
      contextRef="c217"
      id="hidden-fact-313"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:EquityInvestmentsAtFairValue
      contextRef="c98"
      id="hidden-fact-314"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:EquityInvestmentsAtFairValue
      contextRef="c99"
      id="hidden-fact-315"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities
      contextRef="c2"
      id="hidden-fact-316"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:FinanceLeaseLiabilities
      contextRef="c87"
      id="hidden-fact-317"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="c0"
      id="hidden-fact-318"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:AdditionalNotesReceivableIn2021
      contextRef="c7"
      id="hidden-fact-319"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:LessNotesReceivableNetCurrentPortion
      contextRef="c7"
      id="hidden-fact-320"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:LessNotesReceivableNetCurrentPortion
      contextRef="c1"
      id="hidden-fact-321"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c166"
      id="hidden-fact-322"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:GrantedAsIncentivesAggregateIntrinsicValue
      contextRef="c242"
      id="hidden-fact-323"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
      contextRef="c242"
      id="hidden-fact-324"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c242"
      id="hidden-fact-325"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c242"
      id="hidden-fact-326"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <silo:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm contextRef="c242" id="hidden-fact-327" xsi:nil="true"/>
    <silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue
      contextRef="c242"
      id="hidden-fact-328"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c243"
      id="hidden-fact-329"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue
      contextRef="c169"
      id="hidden-fact-330"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c244"
      id="hidden-fact-331"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c244"
      id="hidden-fact-332"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <silo:ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted contextRef="c244" id="hidden-fact-333" xsi:nil="true"/>
    <silo:AggregateIntrinsicValueGranted
      contextRef="c244"
      id="hidden-fact-334"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue
      contextRef="c245"
      id="hidden-fact-335"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c245"
      id="hidden-fact-336"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:MinimumAnnualRoyalty
      contextRef="c262"
      id="hidden-fact-337"
      unitRef="usd"
      xsi:nil="true"/>
    <silo:MinimumAnnualRoyalty
      contextRef="c263"
      id="hidden-fact-338"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c0">0001514183</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( (>+-%4'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "'BS153(]*/NX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>NLTT$%&7"X@32$A, G&+'&^+:-HH,6KW]J1EZX3@ 3C&_O/Y
ML^0&@\(^TG/L T5VE*Y&WW9)8=B( W-0  D/Y$TJ<Z++S5T?O>'\C'L(!C_,
MGD!6U35X8F,-&YB 15B(0C<6%48RW,<3WN*"#Y^QG6$6@5KRU'&"NJQ!Z&EB
M.(YM Q? !&.*/GT7R"[$N?HG=NZ ."7'Y);4, SEL)IS>8<:WIX>7^9U"]<E
M-AU2_I6<XF.@C3A/?EW=W6\?A):5E$5U6\AJ*VLE;]1Z_3ZY_O"["/O>NIW[
MQ\9G0=W K[O07U!+ P04    " "'BS15F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M (>+-%5]WS?* 0,  &()   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MC9;;<MHP$(9?1>/.]"K!!P@A*7B&4UK:0!E(VVO%7HPGLN1*<@AOWY4-#IUQ
M!!=@'79_?;LZ]G="OJ@M@"9O&>-JX&RUSN]=5T5;R*AJB1PX]FR$S*C&JDQ<
ME4N@<>F4,3?PO*Z;T90[8;]L6\JP+PK-4@Y+2521953N1\#$;N#XSK%AE29;
M;1K<L)_3!-:@?^5+B36W5HG3#+A*!2<2-@-GZ-^/_, XE!:_4]BIDS(QH3P+
M\6(JLWC@>(8(&$3:2%#\O,(8&#-*R/'W(.K48QK'T_)1_:$,'H-YI@K&@OU)
M8[T=.#V'Q+"A!=,KL?L&AX!NC%XDF"K_R:ZR[70<$A5*B^S@C 19RJLO?3LD
MXL0A"#YP" X.92+<:J"2<D(U#?M2[(@TUJAF"F6HI3?"I=S,REI+[$W13X<3
M$1689$V&/"93KE.])S->S39FK>]J',28NM%!<%0)!A\(=LE<<+U5*!9#_+^_
MBW U87 D' 56P>\%;Y&V=T4"+P@L>NTZXG:IUSX7\4F8Y!&-R$Q#IIHBK@0[
MS8)FW]RKG$8P<'!C*)"OX(2?/_E=[XL%MU/C=FSJX6%.5I"D2DN*W N:01.E
M76<]>_Q)EM^&J_GPBLP6XY:%[:9FN[%JUJE\VN>-2';W];7O#BT8W1JC:]49
M(D-<<CPPFC1QV/VU+,""<5MCW%Z(,0$5R33_: .=D9E/%Q/\/9&%:)&.!:Q7
M@_4N64)C1).4X;J/X8W\@'T3FUW)\SS_QN_XO;8%ZZ[&NKL$ZR%E(,F8:DB$
M;&2RRRP$OZ91A.>\1(VXTK/@^=[[T>A= KC.*&-D5"CL5HWGPQF=,^O+/SFK
M_4N IAG().4)^8H*>DO&(LLI;TS=&<$-9<J*%KRC!9>@S7@D9"YD>:I>D;7&
M*2$"IU<4N/AP#8JX\: XHSZ9-D&Z)]>>24EYN2L2F;&J&[!NK1\0P^K:?#>O
M7A]S:C*J"(,-NGJM6SRY9'6A5Q4M\O(2?18:K^2RN,5'$$AC@/T;(?2Q8@:H
MGU7A/U!+ P04    " "'BS15])E^UE0'  "0*   &    'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;*U:77.;.!3]*QJWT]F=26(D\9DFGDD@N\UNVF9C=W?V
MD8 <,P7D@NRT^^M7 @(&A&RG/+0!^^K .;K2/5QS\4RSK_F*$ :^)W&:7TY6
MC*W/I],\6)'$S\_HFJ3\FR7-$I_QT^QIFJ\SXH?%H"2>(DTSIXD?I9/91?'9
M?3:[H!L61RFYST"^21(_^W%-8OI\.8&3EP\>HJ<5$Q],9Q=K_XG,"?NROL_X
MV;1&":.$I'E$4Y"1Y>7D"IY[V!0#BHB_(_*<[QP#0>61TJ_BY#:\G&CBCDA,
M B8@?/YG2UP2QP*)W\>W"G127U,,W#U^0?^M(,_)//HY<6G\3Q2RU>7$GH"0
M+/U-S![H\P=2$3($7D#CO/@?/)>QICX!P29G-*D&\SM(HK3\ZW^OA-@9 (<&
MH&H .G0 K@;@0P?HU0"]4*:D4NC@^<R?763T&60BFJ.)@T+,8C2G'Z5BWN<L
MX]]&?!R;N30-^2R2$/"CG,91Z#-^<NW'?AH0,!? .3@%7^8>^.7MKQ=3QB\J
MADZ#Z@+7Y070P 7^V*1G &LG &D(28:[ZN$>"?AP6 R'DN'>X<.U]O I5ZJ6
M"]5RH0(/#\GUY>'AYM,"7,WG-XOYN4R.$D"7 XAE?)ZO_8!<3O@ZS4FV)9/9
MNS?0U-[+Q!D3S!L)K"4<KH7#*O29Z^<KX*<A",0!^;:)MGY,4I;+)"RAC )*
M;%S;F6UA7<?ZQ72[JTX_SK&QI6FP'>?UXR!$-K:=.J[%2:\YZ4I.-YP%^P&B
M=$MRE@R1*3',UL6Q!E&'2S],AX[C&!TJ_3"^P\MI&#4-0TGC$V4DYWMX0/B<
M/,;D!*2$R9@H88[-[%>  5E2&WU!L#$DB5E+8BHEN<_(VH]"0+ZOQ>:8%YE+
MV8ID?$_.,C[5P,_S<F>L/I )9O;NC<\H=CHSWX^"NH%1)]F]?AC2H>9 .5.K
M9FHIF5Z5-.@2A%$>T)1%Z8;O_]Q79+XHS-*45D(>FPBO ),F@M73!V/=UN7R
MV+4\ME*>!65^#-QJSDNQ9(K8O8O;CFYAN[-\W7X<U'0-8:1U9EL2J"/3- ?X
M.#4?9^]:WUGJ/'U3FIY6*7S"M[(@WH11^L2/&.%ZLYU@&6^G=YLF-IP.&5<2
M!1'L4E;>^4&)T)($:HT%THY;[2U5I)9'DR2;I7=Y2\+X'!J=#<!3W]XKF.^8
M/WA >@^G=36\M8-INF[!;EY+ GEB.QJT>V0ED:K,AHTU@X=YL[O;J^O;N]O%
M[8W<H,%1'=JH:-Y8:&T)&Y,&U2[M*@CHAOL8L/9_%/N#J'M^$&2B)KPL#ZFF
MN#^KAN%TBY@KB=.AY6"KFR42/&1IYH!C@XUE@VK/=IOFFZQXM*DH2ME(S)AF
MPV[A5E_JB-+U&J#]L][X/[C? -8S7AL:L*:9< !2@4:U@J]!D^O8-X-0-XVA
MG:5Q@U!M!SVR)%R3D!?#+>'^Z$"1^H[-XE6O:_P/"_/4M_B*(M$X1*BVB&T/
M=!?YCU$<L6A@(^C;,&3:MMXK&/TX7BZTKCGV)'&0[Q@(#\QI8^R@K:P6=Y\_
M_0X6-P\?]]<+I44\.MG'1//&0FN+V+A)J+:3DH41T_3IE'O'1+DT^HY0> 6,
MNUDBB<.6;7>?C=2W>?SB0(UW1&KOV-D[#V*OACRZ1?3S[K%J#_7=JHYT4[[0
M4.,QT2$>\XX+ Q9"F#T;"))93DEJR.)DJ2&)4[#:Z0,JG=@+JSU<D*3WPUV,
M97?)2 )U9#D(=]G( @UGR!>AQOFA/?TYFB11T<0J/)];= *>2!H,45/"'9YU
M[EA W@A ;>T:3XET92F9+SZ[?W[X?.?=/,S?O;$1M-Z#F[^^W"[^E3>(1W)[
ME7YCHGECH;65;)PH4CM1_B1>%92<T>#K"7BKG6F:!OD.FX&M'V_("3!.^"?B
M'\A7?B9Z<QNVHEGT'PFE:H]D+MVQ@+P1@-KR-CX6J7VL6.0T+;4MY90J)FE(
M.MUG'VE0]RE.%F0-M&91XT?1GI9E&$:BM/+]5[1M3J,4!/XZXONQE(W$0"+L
MV':W,^'*(WFMV*D6%:]^I*7IR!XL*XTK1>I^(W\ WR2;N/@-+B3+*(BD_2?4
M;P^>Z@8R- -V24DB,3*18?4F2Q)I6"978*#%C!J;B-0VL2R6<Y%V*QJ'),OK
M;;+X"45*L6_]+-O2M6ZKP)4$.IJ)D-F;M7X@1+9F[OS&TOYIJS&!6&T">V:@
MJ*''\<5]]R5OM4D"!UIMLDA5JPTWG@ZK/=V<9(+EM? )6\*-KG"_S>9=,)>2
M5,(>6_I&1?/&0FM+VAA*K.Y>'FDB\*A-S%'1O+'0VDKN_-*\S\HV.;GN&HK!
MJJ<&/<(GC 7DC0#45K QM%C=)*V6MWOT\A[5V8Z*YHV%UI:T<;;8&'5YC]I@
M'17-&PNMK61C8O$^$_NJY?WS[=-*RY& O!& 2@6G.V]_B7?U/OK94Y3F("9+
MCJR=67R^LO+UM_*$T77Q0M@C98PFQ>&*^-RFB #^_9)2]G(BWC&K7T*<_0]0
M2P,$%     @ AXLT52B&[;\\!   X1<  !@   !X;"]W;W)K<VAE971S+W-H
M965T,RYX;6R]6&N/HS84_2L6K:I9:3M@\B"9)I$ZL:INI4K11MM^]H"36 .8
MM9UDVU]?&Q@>@3&0TLZ'"89SCWTNYMXCKZZ,OXH3(1)\B\)8K*V3E,F3;0O_
M1"(L'EE"8O7DP'B$I1KRHRT23G"0!D6A[3K.W(XPC:W-*KVWXYL5.\N0QF3'
M@3A'$>9_/9.07=<6M-YN?*;'D]0W[,TJP4>R)_)+LN-J9!<L 8U(+"B+ 2>'
MM?4S?$)N&I B_J#D*BK70$MY8>Q5#SX%:\O1*R(A\:6FP.KG0K8D##636L?7
MG-0JYM2!U>LW]E]2\4K,"Q9DR\(_:2!/:VMA@8 <\#F4G]GU5Y(+FFD^GX4B
M_0^N&78^LX!_%I)%>;!:043C[!=_RQ-1"8#3=P+</,#M&S#) R9] Z9YP#3-
M3"8ES0/"$F]6G%T!UVC%IB_29*;12CZ-]7O?2ZZ>4A4G-UL6!^HMD@"H*\%"
M&F"I!L\XQ+%/P%X3"_"PPYS$\D0D]7$H/H ?P9<] @_??UC94JU"<]E^/N-S
M-J/[SHR_G>-','$^ M=QW9;PK3D<$5^%PS0<MH2C_N%./=Q6J2ORYQ;Y<U.^
MZ3M\GV)).!%2?0,^H1?\$A+P0&. 6!AB+EKSDS'.4D;]75XVD]E2+>92S4(3
M!%UX T+&M>F2\202[).UI6J"(/Q"K,T/W\&Y\Y-!^:10/C$JWZD/E'"N-HO:
MI/[K1Y!@#BXX/-<2 !*BJLQ);9_65&13>!65SJ/C./ F&?U@J!-6$SHMA$Z'
M"4WE"(#/\L0X_9L$;<HRSGEE+3,G_;N1UA.'NG$U<;-"W&R(.!#2KV== W1-
MSEYFPJD_Y)7.FANWJ;H/"!E7?N?NGA=YF1OSLF51I%+P+[;VO-_6[@=#G;":
M2J]0Z0U0V6M?>^_MP\8[[HU$?9 U?8M"WV*X/BK$N5W;HK$.N%QX2V=^HZP-
MY[G>9'FCJP7G.>ZB@JNI6A:JEL-5*4\G)(X#&A_;I"U[2FO#M4EKP9FD0:?T
M(XY1W)YPJN0\:S]R(5Q2W5'+*K77HEM-AY&V?[7(/<B8;&@LMGI**Q8/_O>=
M.I^CLY[UQ*%N7%UM:<B@V9'=UZYSTNJ&=ILEK1<*=:'JPDJ_!0<:KLYZ9B9L
MWW>@]7,8B0B-0%3/7FGBX'TNKJ-NFEF'I' D(C0"43V%I56$_[=7-$\XN&CW
M<I5=J'IR2K\(S88Q[UO;P7W+2#LX!6.RH;'8ZBDMS2DTN]-Q^I;7LV_UPZ%N
M7%UM:56AV:O>V;>:'G/J+AI]JP\*=:'JPDJW"LUV]8Z^U727#45-B.MZMX*,
M"QM>*MW2Q;IF%WMGM\E93<);($WAYM7=(;STFNX@KSE"C\@G[#A0Z(5"7:A,
MM%TY3M6'W[]C?J2Q "$YJ##GT5/Q/#M/S@:2)>D)ZPN3DD7IY8G@@' -4,\/
MC,FW@3ZT+4[U-_\ 4$L#!!0    ( (>+-%4.2!&)"0P  &Y*   8    >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&ULK5QM4]LZ&OTK&G9GA\X4L%XLVRPP _%+
MV6T)0VCOG=G9#R81(=/$YMJ&MOOK5W9,'$N/1:#JAY(X1T?)T:.7YTCVR8^\
M^%X^"%&AGZME5I[N/535X_'143E]$*NT/,P?128_N<^+55K)M\7\J'PL1#IK
M"JV61\1Q^-$J761[9R?-M>OB["1_JI:+3%P7J'Q:K=+BUX58YC].]_#>RX6;
MQ?RAJB\<G9T\IG,Q$=77Q^M"OCO:L,P6*Y&5BSQ#A;@_W3O'QPFC=8$&\6TA
M?I1;KU']4^[R_'O]YG)VNN?4WT@LQ;2J*5+YYUF,Q')9,\GO\5=+NK>ILRZX
M_?J%/6Y^O/PQ=VDI1OGRC\6L>CC=\_?03-RG3\OJ)O_Q2;0_R*WYIOFR;/Y'
M/]98S]U#TZ>RRE=M8?D-5HML_3?]V0JQ50 /%2!M :(68 ,%:%N [EH#:PNP
M76MPVP*N6H /%.!M ;YK#5Y;P&L::ZUNTS1A6J5G)T7^ Q4U6K+5+YKV;4K+
M%EED=2A.JD)^NI#EJK-1GLUD8(D9DJ_*?+F8I95\,ZGD'QEQ58GR>S1^%$5:
M1TZ)#M#728CV__[AY*B2U=<D1].VJHMU562@*HJ^Y%GU4*)(5CD#RH?F\ORU
M\K&Y/"8&@B.IVT8\\B+>!3$R_NLI.T34^8B(0PCPA4:[%\>0'K]7>_1[M<?F
MXJ&8RN)XL'BR>W''T!1T$\>TX:,#?)?9-%^)+F[1?\[ORJJ0(]U_H4A=DS&8
MK![^C\O'="I.]^3X7HKB6>R=_>-OF#O_A%K9)EEHDRRR21;;)$LLD?5BA6UB
MA9G8SSY?CJ*K283B*$(WT;?HZFLT.8:B9$WC-C3UG/Y\AGV'N"='S]O-#Z-X
M'Q7J*,H=%_=1$8!R":9]5*RC/$PXZZ,2HPBPQ,B@KKM1US6J.QI/;M$XWB@+
M";MFX-N2,3=0=(5 W%%DU4$DP I3!( <7VG&6 >YCJ-J:OSI;]>4;S3E1DV3
MF_%D@JYOQO'E+:0GUZ7B+E="<+03*M11E&)*%$E!%/$53744YT1MP\3XV]\N
MJK<1U3-.&>/KZ.;\]O(J0=&?U_6   \"GLVIPB99:),LLDD6VR1++)'U8L3?
MQ(AO'LSRE4SZRF;QB\3/^K6 @L37NY8CUT5*KQGI,)<%3$&%.HH0CP;*+! !
M=7*/4&7(BG48#5Q,%+9$AWFN&VQ5VM,OV.@7&/6[+O)[4=9Y:[I$]T*4D'B!
M_GN9CSUU/@!@GA,XZOBEPYC\1SQ%/1TF&X)YZJR@P[ ;^)0K= F PQ[UL ?K
MAYTN/W.,"M[(F$Z+Z0-*LYG,L9_%,G^L%[A@_N4 8>AR3YT( %S@^TQ5$H 1
MSPU<1:,(JI9YC*FS 8#C 0VP.A] ]7+B.@-2;J6ZV"CE958^%6DV%::>W'+T
M^HOC:W,I ".!@UU50AW&&79]54$=YCH>P:J .@P[ON=J D*_ 0=X0$#2"4B,
M EZD=0C>56B_$-/\612_/KQ(^1%E HY)(^5.LWNK.-%^U(%<#SKJBA#"$4?#
M11#.I:Z*BR$<9KX&3 "@7%_1K=[7E[U+;;$Q&SJ;B*6\-/^(YB(3A1Q(ZZ$@
MG:T6V:).<6LO[Z49P/&UI>_%JAM@7PUI'<9<3QM? 1@G'E-G)P"&Y?Q$U0$6
MPG$2N.K\!.!<&=-D0-PN%\3F9/ VKZ2B^=KARN9F(9G^'60'5+.X$8!C+F7Z
MZ*#CY'C-M $[@H!R<L%:9@@ B8\=[FAR D#B8&\K=^H+VJ5_V)S_=<OJSW72
M$M^,OZ#1^$I>^5I?;#\>7X&)(=:SL(-ZA:1F:R,02+G/ E5C (CETLQE3!49
M0E+J!5JJ""%E%V!4[04)B#3JW*6$F)O3E]M/T0VZO!J-OT1HOTUA/H I#'Y'
MAC6<PUAE"ZVR15;98JMLB2VV?KQTV2XV)DIR]5,)R5NAQ=HJW6]'N@_#4[>G
M+R,\3^V(.DCV+Z;-RCK,"U13 >(BU _4[J?#,-%7D0!*]OJ!A 9W&2$VIX3C
MZD$4+R+>%_D*B;^>%M4O5#ZD4E\D5^N9F*'[O$#+?/H=/3VB=%X(,;AH-U;W
ME@62):(0Z[F@[WI4F^$MU1>_A\C0S2RQ]<.C2WBQ.>/=#@^PN8W%WSP6VV0+
MK;)%5MGB][!!T99@/56GV]E!?R>PR].).4]/TD6&\JSN]W.Y(,]$V6R=7E]?
MHRRO!'I,?Z5W2S DS,QO& $(D(@'CJ_Z2[;JBW:K+]X-EECX6OVVZXP!\IHQ
MT$Z-!E_ 3/'6?FN5+;3*%EEEBXGN11Q0AW*U\0$8X8$S-%^3SK0@9M-";5QT
M@ JQ;$XY/*9%]0ML['>8%H;&MLD66F6+K++%[V$#!VD"F3B$#<1"YZ00LY,2
MYX58S&LG?_J09G,A5V@EF.F;>=X< %9/"%AEBZRRQ>]A@P- MWL.2##D 9/.
M[B&O[/WG];R<K6U,\;.V?)X6Y</0XMS,]N8XL,D66F6+K++%[V&#XT#WJ0YP
MX'%_P/@CG4]%S#[5E:CD1) N%_^3,\&\7KWMUZ/!ASHZVHQND3W+B:,Y!@<&
M!V@M,4]UAD?F;_*&S&S7&B-;-<9 C9QSA_FJTV6AQGY#=D88,1^.J!OR*?O-
MIM1/*ARX@8M59Q? 47UO(83H",'444^F $"N;^C$ (PPW_5]M1& >@,<#,V;
MG7=$S-[1.JDUK8XAYT:-D9&YEK?T@UVJBVQ5%[^':-B@L,76;\O.OR)F_ZK=
M\-AVL396(-BTNAMT@#G#6'4" 2#S'>UT \1'J!S2U1UZ .B[3+788P#& \*I
MNN.?0!4SSMS!147G^1"SY_-BPM<;'A\,.Q[H(HK'-U%]D.O;Y41>0?+MBX5_
M>_XG?%B.Z(;% 7=]YJBG2R @]7W?\=0F ("8<$S5\2Z"D2YQU6:- 23#/@Y\
M]0@=1$EX?2YL8$N$=AX,-7LPUT7^O&ANDJC=US:XJ_0GO)MG)GN#[6*+*+1%
M%-DBBJENW1S(F4?=H$PL5-AO\\Z[H:]X-SOV/3 " -,![%D0$.Q9$!#N63 2
MZED DF'7PXXZ^T.4YI[5F2B4&#<;P\M)JVH4;HD*[C92J^:)5;;0*EMDE2VV
MRI;88NL'S-;M&&:GI;'#F]VQ,EV*V@E/RU*L;R>:+<IIGLG4^TDNU_/-O47-
M/F3]N1RQP;BR>].&W;LV[-ZV8?>^#>"$C:N=KWE/G<81O+-DZ Z63!,J[PT,
M2V;#B )F@T>QFEB$$ YCKN8?((PY6$OO(*"<" *B[FE#0.IALG74LM\(G1M"
MS6Y(=U9G8*@'A;?D,HPHX&N PD/^!R \! .%AX[GN%0_W@L!C<)W[@5]Q;V(
M;E%O#0,*#>3U\$(% #*.@T!U*""@7*@0YJG'HD DE1F6>GPC!I T<*C'L*HF
M0$DET!TZ+DT[IX*:G8JP/F@QDR/)\V(F,N@NT0LSPUNBUI:=88LHHM!A'.;0
M(/#4MMH5F4!('@SNF-/.B*!F(T*+?'3^[?SR\_G%9YD,C^4J_LL7F2%/;L>C
M?W\:?PZC&W@,6E?BOMXU "#<-0#@0-< D,0+.->.+ %(PJ36ZB'$!**DV.'#
M7:-S*6A@7,/K>LO!?2/SI_.;Z-4&@-?[5D^T6&4+K;)%5MEBJVR)+;;^';6=
M]<+,ULMHO6ZK3U#GVT\+N$O+Q13MRV0@S)?+M"B1_'1]5 Z<Z=IJ_.WX=P[5
MLV>C%A;T8:K5").I-\I&$ P?JK?#Q !,HI2SP0E$1@Z=@=[+.I^#F7V.$%X;
MOT?B=YSO .>_EDB15[UG-FQAVT.:NETUP*3>0 3#U$/P"0PC TLUUID@S&R"
M_!%=)I]NY:KX_)M<%2=1;^R<H/'7V\GM^55X>97 =Y-;]46LLH56V2*K;+%5
MML066S^&.E^$F7V1BTUGG33'A>$>"F3L@>]I]SJ.0*#,2]1;[T*8T:%<O9</
M OK$X>H:/@:!@4S:M $1 %(<.-JNY-'64VQ6HI@W#R@JT31_RJK3YN$.FZN;
MAR"=-X_^4:Y?X.,1!JZ'^#B"KL?X.%D_^JBK=OTDIB]I,5_(078I[N57< [K
M1Q<5ZX<;K=]4^6/S;)V[O*KR5?/R0:0S4=0 ^?E]GE<O;^H*-H^8.OL_4$L#
M!!0    ( (>+-%5NSO[9<@,  ,X,   8    >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&ULK5=K;]HP%/TK5C9-J]0V[_ 8()7G.FE:M6K;AVD?W,2 U21FMH'N
MW^_:25-(34 J7XA]<\ZYSO&-<^EM&7\42T(D>LK27/2MI92KKFV+>$DR+*[9
MBN1P9\YXAB5,^<(6*TYPHDE9:GN.$]D9IKDUZ.G8'1_TV%JF-"=W'(EUEF'^
M;TA2MNU;KO4<^$X72ZD"]J"WP@MR3^2/U1V'F5VI)#0CN: L1YS,^]:-VYU%
M"J\!/RG9BITQ4D_RP-BCFMPF?<M1"R(IB:52P'#9D!%)4R4$R_A;:EI52D7<
M'3^K3_6SP[,\8$%&+/U%$[GL6VT+)62.UZG\SK:?2?D\H=*+62KT+]H6V!:
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MQXU3+2JZ0E5+L-34=+AYX+P=70W:M-HUQD05[3'R6#U66$)K!K O[E(WT._
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MIR[R)1Z[5-[*=5'6:*%4.4B\:!<1P/$#O3-\DX*H@Y76,LX)CT;T(M?RE7F
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MLTP$PAR.U96?2OKL$FS<)=I3C$K?U/XZ6Y"-?M3(B)8-FZ%0P"[ YB#FK".
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MUN#NT0.!\0 *%I&I#B9:FJ^(F>AKK;V-NF&@4$--%87=EVA$(Y6CD.#\!MB
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M<%O.B!A9G%"N#"57$TML[&B.3'%$UVYNU";82,8H,$K'1AF%'JV#2RPM>!V
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M?^0BBW."JS0E[IR>?*_/?GA=3RN*_(Y.>IU![TB+^0*H'#&MB[%B3/+JE9N
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M1JXKQP=Y3,8&@<BFSJ?P6@6)<0J.#/'D,U(MT]6BS6DR%,:L4+ B9SA'*+D
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M*4SJT0*S;E$J4=8#+"%E  \,8B!"J(L:"%OK7T X#<*(6LU9Z-+C0NFE%K'
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M8NV _0KE<\.N9,[S#?*C]^7CY!T%7;C>^I\L_?^0O*OQS[7<9[TH9$F4))L
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M#?.AX#G 99G2.:JU6#3@-D-Q-S,TM=##UTK17IHSP]%>B&VQ"-HL ;$OJ"W
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M+:F&6'*J[X3P?XL0!G\ (?P&&KAP-Y!C@&NE'JR5^C86^#=(>_[W5I@$-W/
M.#X*^]$ 3Z!21TGO-0>,>N$PZ;-XF(3]Y& C#8P'X6 8$QE#G",7YV\F@LEA
M!-F8V&"2'(6'_<%79!;F>KVVVKZ*.R:#'NCL8<,>>X>X&_O#U^RQ^:[77?D*
M77(]<Q_G*:48(LT'Z7:W_?Y_X3Y[=U^.-_\\^#75,P'[!9]"--H_''0:)K5<
M6%6Y;]H39:TJW>.<@T9I.H#W4X7J]PLRT/Y7Y/QW4$L#!!0    ( (>+-%4]
MY39LW0P   XQ   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;.U;6V_;
M1A9^YZ\8N.["!E19E'R+G1APG'2;(DV,..T^+/9A1(ZD02B..D-*\;_?<\Y<
M>)6LIMGV80,$%D7-G#GWRT?F^4;I3V8A1,$^+[/<O#A8%,7JZN3$) NQY&:H
M5B*'7V9*+WD!7_7\Q*RTX"EM6F8GX]'H_&3)97YP\YSNW>N;YZHL,IF+>\U,
MN5QR_?A29&KSXB ^\#<^R/FBP!LG-\]7?"X>1/'KZE[#MY- )95+D1NI<J;%
M[,7!;7QU=XKK:<%O4FQ,[9JA)%.E/N&7-^F+@Q$R)#*1%$B!P\=:W(DL0T+
MQN^.YD$X$C?6KSWU'TEVD&7*C;A3V;]D6BQ>'%P>L%3,>)D5']3F)^'D.4-Z
MB<H,_64;NW8\.6!):0JU=)N!@Z7,[2?_[/10VW YVK)A[#:,]]TP<1LF)*CE
MC,1ZQ0M^\URK#=.X&JCA!>F&=H,T,D<K/A0:?I6PK[AYIPIAV >1"+GFTTP\
M/RF *OYVDC@*+RV%\18*Y^P7E1<+PU[GJ4A[]M_MWA^/=Q X 7&"3&,OT\OQ
M3HH_E_F0348#-AZ-QWT,[=[^2B2P/:;M\0YV)D'%$Z(WV4*O4JYA_[Z=FD*#
M[_ZG3]&6SFD_'8SG*[/BB7AQ  %KA%Z+@YM_?!>?CZ[[A/Q*Q!HBGP:13W=1
MOWGW_N/K!_;A]=WK-[_=OGS[ND_8IRFP,_:/[R['<7S-V@39K6%JQL#2(EB:
M\3QE8#RQG H=##B(<G)Q':PP8+DH!BQ1D(I,(5(D5"P$FZD,<IK,YU=1H%LG
M%]UKF2=RQ3/&EZK,"V*A39T=LC@^&YR-1G U'H\&H]$HNDU3B5D+MG;6DXCC
M:W9NET(^<BD.R.>=Y88=69KLF!W%YZ=TT''T5AASQ3@*P/,$9=$L5>6TF)7
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MI %I'9!:(>" R#^J' %+CEIA?T*Z6QD2A@]1R794<- @@$+S-E@G4"@O>*V
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MAFLU6SF ]RN#F-J%.-A=U&?_ E!+ P04    " "'BS15(6L> .(:  #>BP
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M,VMP2H>6O,1:( $S+$$KE#0C/'20+/ =,5BS)%=7*5HF P'DMY/H2]5I>IJ
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M 7UM/;7>XD!"HO#CIP_]*!Z<LB/6#P=^TN_AJ-F+$[^?#-CQKU23=!B>.M7
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MH"P#= 5652+D<A(D%(LF(<!,SI29+@RQ1H"N<^)PPYCG A-M\@RD&E]&4<*
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MR1H"ZO:+P_C%X% ),_3Q%"%"@&22T1 [?)?FQ0)9X=^3FF\AGR-<E E^ORA
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MUXP6=/4CV)IPVF12%/?/2721KJ>1S%2*4&!">/8*)!RF-2\<AK<]W(]'Q_3
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M<@:O[N\=C[:8$>H_ZF*)0Z(]H"X6].M< M\J\0'X?E84M?X#)T MFY;W]G\
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MI@!<)9XJ  -WF6^2#+>"VXOD(DJ*9EDX%[;I6/XF+Q.+T0@'KQV #P1<:<8
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M>5G3$A"+:6YB7038UN/L.S4+8#CED@^YH3M8:;Y.*EIUD:]QV:7R1JZ+LHX
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M$!PJQJKL)5"2&N2+14D7%Y<*PQL9"KC<TEQ]XB&C?BI1?:O@$PXL+$=P%&Y
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MLH/H>TWTO6/:IP]4K_)2>%HR8[#FH>!LS@6WG) H*B+FP"PL'%B;BL=4'*C
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MB%5_9+8I[;_?M1,R)E&TE]C7ON?XW!L?3[;:/-H*P)%G*92=TLJY>AQ%MJA
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ME=H098>)O$O&MF8%3"G:P()Y IJ?G2;#^/J(S*R3F1UCSQ?HNG*#$O6*<.4
M3W $GM&#%@YI/<IV6"MV%N023.CN?G R-UP5O&:",*DWRI$WY.QTE";I-<Z2
M4>\JCD\^@[5CO)G& ";4V@1S[=+.DZPWO,S(Q4GH=]WV^RT16JT)EB,[R#YW
MUDNS(3G4OFCO:DLPZV!@2PHOK[GEW6KW1MPTUOB;WCPP]\RLN;)$P JA<?_=
M)26F,6T3.%T'HRRU0]N%:87O'!B?@/LKC36U@3^@>SGS/U!+ P04    " "'
MBS15D-5KU^X#   ?#0  &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6RU
M5UMOVS84?O>O(-2A2P!#HFZ^)+8!QTVW#F@7)-V*8=@#+1W;0B11):DX^?<[
MI&35<10E;K<7B:+X?>=^=#39<G$K-P"*W&=I+J?61JGBS'%DM(&,29L7D..;
M%1<94_@HUHXL!+#8@++4\2@=.!E+<FLV,7M78C;AI4J3'*X$D666,?%P 2G?
M3BW7VFU<)^N-TAO.;%*P-=R ^J.X$OCD-"QQDD$N$YX3 :NI-7?/%J$^;P[\
MF<!6[JV)MF3)^:U^^!!/+:H5@A0BI1D8WNY@ 6FJB5"-KS6GU8C4P/WUCOV]
ML1UM63()"YY^26*UF5HCB\2P8F6JKOGV5ZCM,0I&/)7F2K;567]HD:B4BF<U
M&#7(DKRZL_O:#WN $7T&X-4 [[4 OP;XQM!*,V/6.Z;8;"+XE@A]&MGTPOC&
MH-&:)-=1O%$"WR:(4[,;Q:/;#4]C$/+MFY'G#L_)Y=<R40_DY#-;IB!/)XY"
M0?JX$]6D%Q6I]PSI@'SDN=I(<IG'$+?@%]UXU^L@<-#"QDQO9^:%U\GX6YG;
MQ*=]XE'/:U.H&_X.(H2[!NYVJ.,W7O<-G_\*K_^\\_<GKH#\/5]*)3"Y_VES
M>\4:M+/J@C^3!8M@:F%%2Q!W8,W>OG$']+S-Y/^([)$#@L8!01?[[ :[45RF
M0/B*2.T,P@M=UK*JZT0E(-L<T,G:KO.G,EN"T(*^F)J&F,SO0&"+>KHQ7Z\%
MK)F"W@5+61X!^;U44K$\3O)UGV :@"';I0(9]"FEY"=";4I#XMDAKDT9>>>]
M7P3+-3F3)$&J7/<KB8A1,,930]NG)&@%%*60)2Z)X@2R(N4/V#858:@;F-6)
M!*C2971*W)T.KE:"C.W!'B6VNA4DFK3>.;RW&XKE DVY$&_4Z!Q2?=D3<'D/
M(DJD[A2',->K%0NU7J$]PB7JBF:W9>/W1[:)XK=P'A5&=WP0QBHJ+@WZXR'=
M1<7Y(&6)-_*B2[M=>YA#M!9>B?91M.L-^][X?Q?<GKR!UQ^AT8_">@R2=#2'
ML&D.X:N;PY8)[887VD(G7U?R]/;:0N^P+?2.; N]QC]^,.S3D2G*4-=,8+M/
MZ]SYP8 ^KK9#D?ZC/M!1IIW UE+],6]7 95/O5SK".1*)%%+%*Y!3Z5H.EG@
M<*"_D25+R6<0&3GY"YB0IT<&"@L_"/KA7O,,;.,(WQ_VAR'=ZYXG]<'3^N!W
MEOI+<=Y] 78Q:;+'.[:V6S+0>RX?CD6WUKBS-X-F(-9F-)<DXF6NJG&TV6VF
M_[D9>IUOQZM?AX],K!,<!5)8(93:0TPX48WCU8/BA9EHEUSA?&R6&_R# :$/
MX/L5QV]C_: %-/]$LW\!4$L#!!0    ( (>+-%7"\ B+>0,  #((   9
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M.,)]]_;-, S]X\OIV+T%Q_LN+G4Q87FN)#6:@E-J'4<)QUNT<V$UGSMW[-I
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MK*@O5S194%XU4)\_,B9?;BJ!_5'IZ?]02P,$%     @ AXLT50$[).S& P
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M0'Z_Y%R\'A0--*_(S/X%4$L#!!0    ( (>+-%4K)3!)R 0   P<   9
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M%$31!OE)MSR%3,M#*P\WR-/MY4%;[NOT-#F*FAQ%EM=[@7<.2Z H1'<74$Q
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ML0,G>_O&'WD?^KS]G63Y;R)[Y'O4^1X-L6=7F.KC"6=H"6O"&&%K<]3,\7H
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M]"X2+4XT55[34'QKZYXE5[J*LI\;71B#,!/T^(IS=6B8!;I2._L'4$L#!!0
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M2&V$:B*J2:@FK[7;=DUJER2R4175-%334<U -1/5+%2S4<U!-1?5/%3S42U
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MJ#9"-1'5)%2344U!-175-%334<U -1/5+%2SUUHCY+/7KDMH!@BJ>:CFHUJ
M:B&J1936K$N[I)#BQY/JTGLA_]W+GUV-2&V$:B*J2:@FHYJ":BJJ::BFHYJ!
M:B:J6:AF'_G6>']R! ==#Q?5/%3S42U M1#5(DIKUJA=3LAM]W#Z$T/^NY6S
M*Q4:$X)J(JI)J":CFH)J*JIIJ*:CFH%J)JI9J&:OM2.3(SAHHRZJ>:CFHUJ
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M^2%Y?B/H(CLVGE A:)Q=SH$$P)2!')]2*MYNU 3EORK&_P%02P,$%     @
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M$MOI=F:G3$C:S\*^!L_:$I4$)/^^\@.7@'')1%_ DN\Y]UKG6+(TWE'VDZ\
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M20QQTOZ)15[0CX[OSX]7>V/TH#5Z\.Z+^O01KK.YDW/M/6P2%IN$)29AZ?^
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MQO+S2RGL^7^/$K:683]6ODB\I<1Q()_R>$&O21U3L[JX)RZN0VN2-8U2[D7
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MMXX$NMJ1X'C\=PY_J!\!E&9 :2:49D%I-I3F0&DNE.9!:3Z4-J]I)U4"ZFZ
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M0&DNE.9!:7Y-V[<XTVX&@V-G_',O#*#E"U$T603T5@34EJC>[V>N8=2<BU4
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MGBKA?BBZZ0*;X]TCWI8D"992,.(5LE,B_:_:ZR'M)$G2CZ\W#=D6%=G1.76
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M =$@@  I^H041PL]CKE0[!\()K;2?IK5;+_PZ2KWB1SP"1-TJ]T()?J8!/L
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M6@Y+5/9.QC@04=](ZX;BI;FC+;C"&Y]Y7.$E'H0&X/<EQW2:AK[VM?\61'\
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M\IC,(Y4PXO'?+%+S@=-S2 13NHC5/5^]AR*A,\T7\EB:3[(JQGH."1=2\:0
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MRKU@G\^D-,\#-T%S2C/\#U!+ P04    " "'BS15H8S\&G8#  "B$   &0
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M4XR6.&C:?L.$#D+NM/;<AIV[@(F';O$_OWXCI=,@:\435%4ZZ&6%:(HU\FU
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MR+P'M]Y'P>H]%33_/1W\!5!+ P04    " "'BS15EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( (>+-%5JY^Q>H 0
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M:8(<D1!+ IHLZE>E2!(IL22@RV),)(F46!+093$FS$K>P1FAR]C10[^QOX6
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M?POKCU>\J>X-ZS>[)2]YT<];K[JFN?3'[M1'S>O]:M7]2MN+?P%02P,$%
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M^6S\(]KB!5!+ 0(4 Q0    ( (>+-%4'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ AXLT54R/2C[N
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ AXLT59E<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "'BS15?=\WR@$#  !B"0
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ AXLT5?29?M94!P  D"@  !@              ("!1 L  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( (>+-%4HANV_/ 0
M .$7   8              " @<X2  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " "'BS15#D@1B0D,  !N2@  &               @(%
M%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ AXLT56[.
M_MER P  S@P  !@              ("!?R,  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( (>+-%6.RTUAP@T  )"$   8
M  " @2<G  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "'
MBS154WXSXF<,  ##3@  &               @($?-0  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ AXLT50#6E3XF#   M3   !@
M         ("!O$$  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( (>+-%7XDU^%VQX  .:/   8              " @1A.  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "'BS15HLZKV48,  "*,0
M&0              @($I;0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( (>+-%6)!)'%= <  "$9   9              " @:9Y  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ AXLT53WE-FS=
M#   #C$  !D              ("!48$  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " "'BS15R+=MF!\%  "T"P  &0
M@(%EC@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( (>+
M-%4A:QX XAH  -Z+   9              " @;N3  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ AXLT52=CI[&<!@  Z \  !D
M         ("!U*X  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " "'BS15>N!J/E0#  #>"0  &0              @(&GM0  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( (>+-%5S#OPOK2\  ,T,
M 0 9              " @3*Y  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ AXLT5?$"5:Z5"   \10  !D              ("!%ND
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "'BS15KW5(
MVB0@  "QG   &0              @('B\0  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( (>+-%6W?H +=P0  )<-   9
M  " @3T2 0!X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
MAXLT54_2A32Z P  W0H  !D              ("!ZQ8! 'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " "'BS15MJ'NA1L$  #K"P  &0
M            @('<&@$ >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( (>+-%5XLM'U+ ,  #P)   9              " @2X? 0!X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ AXLT55_W5V-A @
M104  !D              ("!D2(! 'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " "'BS15D-5KU^X#   ?#0  &0              @($I
M)0$ >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( (>+-%7"
M\ B+>0,  #((   9              " @4XI 0!X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ AXLT53&\3A+R!   \!(  !D
M     ("!_BP! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M" "'BS15PMZ6+6$$  !V#   &0              @($G,@$ >&PO=V]R:W-H
M965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( (>+-%4";6B\:@8  #8M   9
M              " @;\V 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L!
M A0#%     @ AXLT50$[).S& P  TA8  !D              ("!8#T! 'AL
M+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "'BS15+F+3 :H&
M   N,P  &0              @(%=00$ >&PO=V]R:W-H965T<R]S:&5E=#,Q
M+GAM;%!+ 0(4 Q0    ( (>+-%4K)3!)R 0   P<   9              "
M@3Y( 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ AXLT
M5>O_^9PP P  *Q$  !D              ("!/4T! 'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " "'BS15P5(>IV\#  !V"P  &0
M        @(&D4 $ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( (>+-%5!'*0ZH0,  ,T.   9              " @4I4 0!X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ AXLT5=124"(% P  :@@
M !D              ("!(E@! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " "'BS150X5)!M4#   D#@  &0              @(%>6P$
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( (>+-%6<_, :
M4A(  +\C 0 9              " @6I? 0!X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ AXLT58_?7\Z' P  YPP  !D
M ("!\W$! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "'
MBS15**0F@7,#  "B#P  &0              @(&Q=0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( (>+-%6U6%OT;0(  ,8&   9
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M970T-2YX;6Q02P$"% ,4    " "'BS15*I(.]NH#  "N$@  &0
M    @(&&T0$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M (>+-%4.31C'> (   T&   9              " @:?5 0!X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ AXLT57=#/J_C P  ;A0  !D
M             ("!5M@! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    " "'BS15SVW)4HD#   6%P  &0              @(%PW $ >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( (>+-%5[M1=X$B@
M )#! 0 9              " @3#@ 0!X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ AXLT5<"#\LEI!   MA@  !D              ("!
M>0@" 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " "'BS15
M:\+L5WL#  !B$0  &0              @($9#0( >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( (>+-%7O] 8D@@0  !H8   9
M      " @<L0 @!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ AXLT5:&,_!IV P  HA   !D              ("!A!4" 'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " "'BS15_=!,!^0%   #$0
M&0              @($Q&0( >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( (>+-%4;$=>:S ,  +,6   9              " @4P? @!X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ AXLT5>O_^9PP
M P  *Q$  !D              ("!3R," 'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    " "'BS15.BVQS'L#  !6"P  &0
M@(&V)@( >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( (>+
M-%5#C^-[ P,  &H(   9              " @6@J @!X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ AXLT57YYP/^K P  N0P  !D
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M=#8T+GAM;%!+ 0(4 Q0    ( (>+-%7;8.7XC ,  +$1   9
M  " @3]$ @!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @
MAXLT5:&,_!IV P  HA   !D              ("! D@" 'AL+W=O<FMS:&5E
M=',O<VAE970V-BYX;6Q02P$"% ,4    " "'BS15H%G:\5T#  !*%0  #0
M            @ &O2P( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( (>+-%67
MBKL<P    !,"   +              "  3=/ @!?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( (>+-%5JY^Q>H 0  .TK   /              "  2!0 @!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " "'BS15'M^97AP"   ])P  &@
M        @ 'M5 ( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " "'BS15I7\.<>X!  "0)@  $P              @ %!5P( 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     2@!* #T4  !@60(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>270</ContextCount>
  <ElementCount>487</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Operations (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Changes in Stockholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/OrganizationandBusiness</Role>
      <ShortName>Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements</Role>
      <ShortName>Fair Value of Financial Instruments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Disposal of the Discontinued Operations of the Nfid Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusiness</Role>
      <ShortName>Disposal of the Discontinued Operations of the Nfid Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Notes Receivable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://silopharma.com/role/NotesReceivable</Role>
      <ShortName>Notes Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/NotePayable</Role>
      <ShortName>Note Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Concentrations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/Concentrations</Role>
      <ShortName>Concentrations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://silopharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silopharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables</Role>
      <ShortName>Fair Value of Financial Instruments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Disposal of the Discontinued Operations of the Nfid Business (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessTables</Role>
      <ShortName>Disposal of the Discontinued Operations of the Nfid Business (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusiness</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Notes Receivable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://silopharma.com/role/NotesReceivableTables</Role>
      <ShortName>Notes Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silopharma.com/role/NotesReceivable</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/NotePayableTables</Role>
      <ShortName>Note Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silopharma.com/role/NotePayable</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silopharma.com/role/StockholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silopharma.com/role/IncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silopharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Organization and Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/OrganizationandBusinessDetails</Role>
      <ShortName>Organization and Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/OrganizationandBusiness</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of reconciliation of basic and diluted net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of reconciliation of basic and diluted net loss per share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value of Financial Instruments and Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable</Role>
      <ShortName>Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of activity in the company???s equity investments, at fair value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable</Role>
      <ShortName>Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of activity in the company???s equity investments, at fair value</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Disposal of the Discontinued Operations of the Nfid Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessDetails</Role>
      <ShortName>Disposal of the Discontinued Operations of the Nfid Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Disposal of the Discontinued Operations of the Nfid Business (Details) - Schedule of financial data of the company???s gain from sale of the NFID business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable</Role>
      <ShortName>Disposal of the Discontinued Operations of the Nfid Business (Details) - Schedule of financial data of the company???s gain from sale of the NFID business</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Disposal of the Discontinued Operations of the Nfid Business (Details) - Schedule of operating result of discontinued operations of the NFID business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable</Role>
      <ShortName>Disposal of the Discontinued Operations of the Nfid Business (Details) - Schedule of operating result of discontinued operations of the NFID business</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Notes Receivable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://silopharma.com/role/NotesReceivableDetails</Role>
      <ShortName>Notes Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/NotesReceivableTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Notes Receivable (Details) - Schedule of notes receivable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://silopharma.com/role/ScheduleofnotesreceivableTable</Role>
      <ShortName>Notes Receivable (Details) - Schedule of notes receivable</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/NotesReceivableTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/NotePayableDetails</Role>
      <ShortName>Note Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/NotePayableTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure -  Note Payable (Details) - Schedule of interest expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofinterestexpenseTable</Role>
      <ShortName>Note Payable (Details) - Schedule of interest expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/NotePayableTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Stockholders??? Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders??? Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Stockholders??? Equity (Details) - Schedule of stock options activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable</Role>
      <ShortName>Stockholders??? Equity (Details) - Schedule of stock options activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Stockholders??? Equity (Details) - Schedule of warrant activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofwarrantactivitiesTable</Role>
      <ShortName>Stockholders??? Equity (Details) - Schedule of warrant activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Income Taxes (Details) - Schedule of effective statutory rate and the provision for income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of effective statutory rate and the provision for income taxes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Income Taxes (Details) - Schedule of effective statutory rate and the provision for income taxes (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable_Parentheticals</Role>
      <ShortName>Income Taxes (Details) - Schedule of effective statutory rate and the provision for income taxes (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Income Taxes (Details) - Schedule of net deferred tax asset</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofnetdeferredtaxassetTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of net deferred tax asset</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Concentrations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ConcentrationsDetails</Role>
      <ShortName>Concentrations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/Concentrations</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Commitments and Contingencies (Details) - Schedule of milestone payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofmilestonepaymentsTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of milestone payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Commitments and Contingencies (Details) - Schedule of exclusive of value added tax to be amortized</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of exclusive of value added tax to be amortized</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Commitments and Contingencies (Details) - Schedule of shall pay UMB</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofshallpayUMBTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of shall pay UMB</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/SubsequentEvents</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable0</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0</Role>
      <ShortName>Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of activity in the company???s equity investments, at fair value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable0</Role>
      <ShortName>Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of activity in the company???s equity investments, at fair value</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of financial data of the company???s gain from sale of the NFID business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable0</Role>
      <ShortName>Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of financial data of the company???s gain from sale of the NFID business</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of operating result of discontinued operations of the NFID business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable0</Role>
      <ShortName>Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of operating result of discontinued operations of the NFID business</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Notes Receivable (Details) - Schedule of notes receivable net</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://silopharma.com/role/ScheduleofnotesreceivablenetTable</Role>
      <ShortName>Notes Receivable (Details) - Schedule of notes receivable net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/NotesReceivableTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Stockholders??? Equity (Details) - Schedule of stock options activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0</Role>
      <ShortName>Stockholders??? Equity (Details) - Schedule of stock options activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Stockholders??? Equity (Details) - Schedule of warrant activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofwarrantactivitiesTable0</Role>
      <ShortName>Stockholders??? Equity (Details) - Schedule of warrant activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Commitments and Contingencies (Details) - Schedule of milestone payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofmilestonepaymentsTable0</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of milestone payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable0</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ea165987-s1a4_silopharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>065 - Disclosure - Commitments and Contingencies (Details) - Schedule of shall pay UMB</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/ScheduleofshallpayUMBTable0</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of shall pay UMB</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 18 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:EarningsPerShareDiluted, us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare, us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  ea165987-s1a4_silopharma.htm 18784, 18785, 18786, 18787, 18788, 18789, 18809, 18810, 18811, 18812, 18815, 18816, 18817, 18818, 18819, 18820, 18821, 19005</Log>
  </Logs>
  <InputFiles>
    <File doctype="S-1/A" original="ea165987-s1a4_silopharma.htm">ea165987-s1a4_silopharma.htm</File>
    <File>ea165987ex23-1_silopharma.htm</File>
    <File>silo-20220630.xsd</File>
    <File>silo-20220630_cal.xml</File>
    <File>silo-20220630_def.xml</File>
    <File>silo-20220630_lab.xml</File>
    <File>silo-20220630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>fin_001.jpg</File>
    <File>image_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="4">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="1117">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="9">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea165987-s1a4_silopharma.htm": {
   "axisCustom": 3,
   "axisStandard": 19,
   "contextCount": 270,
   "dts": {
    "calculationLink": {
     "local": [
      "silo-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "silo-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ea165987-s1a4_silopharma.htm"
     ]
    },
    "labelLink": {
     "local": [
      "silo-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "silo-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "silo-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 678,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 242,
    "http://silopharma.com/20220630": 96,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 341
   },
   "keyCustom": 177,
   "keyStandard": 310,
   "memberCustom": 37,
   "memberStandard": 20,
   "nsprefix": "silo",
   "nsuri": "http://silopharma.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://silopharma.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements",
     "role": "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements",
     "shortName": "Fair Value of Financial Instruments and Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Disposal of the Discontinued Operations of the Nfid Business",
     "role": "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusiness",
     "shortName": "Disposal of the Discontinued Operations of the Nfid Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Notes Receivable",
     "role": "http://silopharma.com/role/NotesReceivable",
     "shortName": "Notes Receivable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Note Payable",
     "role": "http://silopharma.com/role/NotePayable",
     "shortName": "Note Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Stockholders\u2019 Equity",
     "role": "http://silopharma.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Income Taxes",
     "role": "http://silopharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Concentrations",
     "role": "http://silopharma.com/role/Concentrations",
     "shortName": "Concentrations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Commitments and Contingencies",
     "role": "http://silopharma.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Subsequent Events",
     "role": "http://silopharma.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Accounting Policies, by Policy (Policies)",
     "role": "http://silopharma.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c7",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://silopharma.com/role/ConsolidatedBalanceSheet",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c7",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "silo:ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "silo:ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Tables)",
     "role": "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables",
     "shortName": "Fair Value of Financial Instruments and Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Disposal of the Discontinued Operations of the Nfid Business (Tables)",
     "role": "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessTables",
     "shortName": "Disposal of the Discontinued Operations of the Nfid Business (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Notes Receivable (Tables)",
     "role": "http://silopharma.com/role/NotesReceivableTables",
     "shortName": "Notes Receivable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Note Payable (Tables)",
     "role": "http://silopharma.com/role/NotePayableTables",
     "shortName": "Note Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "role": "http://silopharma.com/role/StockholdersEquityTables",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Income Taxes (Tables)",
     "role": "http://silopharma.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "silo:ScheduleOfMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://silopharma.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "silo:ScheduleOfMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c86",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SupplementalDeferredPurchasePrice",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Organization and Business (Details)",
     "role": "http://silopharma.com/role/OrganizationandBusinessDetails",
     "shortName": "Organization and Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c86",
      "decimals": "0",
      "lang": null,
      "name": "silo:promissoryNoteAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c7",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestReceivableNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)",
     "role": "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c7",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestReceivableNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "silo:ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share",
     "role": "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "silo:ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c92",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "silo:IncomelossFromContinuingOperation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of reconciliation of basic and diluted net loss per share",
     "role": "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of reconciliation of basic and diluted net loss per share",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": "0",
      "lang": null,
      "name": "silo:IncomeLossFromDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details)",
     "role": "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails",
     "shortName": "Fair Value of Financial Instruments and Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c215",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "silo:EquityInvestmentsAtFairValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis",
     "role": "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
     "shortName": "Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "silo:ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of activity in the company\u2019s equity investments, at fair value",
     "role": "http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable",
     "shortName": "Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of activity in the company\u2019s equity investments, at fair value",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c86",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "silo:PurchasePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Disposal of the Discontinued Operations of the Nfid Business (Details)",
     "role": "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessDetails",
     "shortName": "Disposal of the Discontinued Operations of the Nfid Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c86",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "silo:PurchasePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c87",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Disposal of the Discontinued Operations of the Nfid Business (Details) - Schedule of financial data of the company\u2019s gain from sale of the NFID business",
     "role": "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable",
     "shortName": "Disposal of the Discontinued Operations of the Nfid Business (Details) - Schedule of financial data of the company\u2019s gain from sale of the NFID business",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c14",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleOfProductiveAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Disposal of the Discontinued Operations of the Nfid Business (Details) - Schedule of operating result of discontinued operations of the NFID business",
     "role": "http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable",
     "shortName": "Disposal of the Discontinued Operations of the Nfid Business (Details) - Schedule of operating result of discontinued operations of the NFID business",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": "0",
      "lang": null,
      "name": "silo:GainFromSaleOfNFIDBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Notes Receivable (Details)",
     "role": "http://silopharma.com/role/NotesReceivableDetails",
     "shortName": "Notes Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c7",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:NotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesReceivableGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Notes Receivable (Details) - Schedule of notes receivable",
     "role": "http://silopharma.com/role/ScheduleofnotesreceivableTable",
     "shortName": "Notes Receivable (Details) - Schedule of notes receivable",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c1",
      "decimals": "0",
      "lang": null,
      "name": "silo:CollectionsOnNotesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c12",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "silo:LicenseFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://silopharma.com/role/ConsolidatedIncomeStatement",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c12",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "silo:LicenseFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Note Payable (Details)",
     "role": "http://silopharma.com/role/NotePayableDetails",
     "shortName": "Note Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "silo:DebtInstrumentsFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure -  Note Payable (Details) - Schedule of interest expense",
     "role": "http://silopharma.com/role/ScheduleofinterestexpenseTable",
     "shortName": "Note Payable (Details) - Schedule of interest expense",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "silo:DebtInstrumentsFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c7",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Stockholders\u2019 Equity (Details)",
     "role": "http://silopharma.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders\u2019 Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c137",
      "decimals": "0",
      "lang": null,
      "name": "silo:ConvertablePreferredStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c166",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Stockholders\u2019 Equity (Details) - Schedule of stock options activities",
     "role": "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable",
     "shortName": "Stockholders\u2019 Equity (Details) - Schedule of stock options activities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c162",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c169",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "silo:NumberOfWarrant",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Stockholders\u2019 Equity (Details) - Schedule of warrant activities",
     "role": "http://silopharma.com/role/ScheduleofwarrantactivitiesTable",
     "shortName": "Stockholders\u2019 Equity (Details) - Schedule of warrant activities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c167",
      "decimals": "INF",
      "lang": null,
      "name": "silo:NumberOfWarrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:VentureCapitalGainsLossesNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Income Taxes (Details)",
     "role": "http://silopharma.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:VentureCapitalGainsLossesNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Income Taxes (Details) - Schedule of effective statutory rate and the provision for income taxes",
     "role": "http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable",
     "shortName": "Income Taxes (Details) - Schedule of effective statutory rate and the provision for income taxes",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Income Taxes (Details) - Schedule of effective statutory rate and the provision for income taxes (Parentheticals)",
     "role": "http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable_Parentheticals",
     "shortName": "Income Taxes (Details) - Schedule of effective statutory rate and the provision for income taxes (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c10",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Income Taxes (Details) - Schedule of net deferred tax asset",
     "role": "http://silopharma.com/role/ScheduleofnetdeferredtaxassetTable",
     "shortName": "Income Taxes (Details) - Schedule of net deferred tax asset",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "silo:ConcentrationsRiskPercentage1",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c248",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "silo:ConcentrationsRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Concentrations (Details)",
     "role": "http://silopharma.com/role/ConcentrationsDetails",
     "shortName": "Concentrations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "silo:ConcentrationsRiskPercentage1",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c248",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "silo:ConcentrationsRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Condensed Consolidated Statements of Operations (Parentheticals)",
     "role": "http://silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "shortName": "Condensed Consolidated Statements of Operations (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c173",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "silo:EmploymentAgreementDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://silopharma.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c173",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "silo:EmploymentAgreementDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "silo:ScheduleOfMilestonePayments",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c262",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "silo:Milestone",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Commitments and Contingencies (Details) - Schedule of milestone payments",
     "role": "http://silopharma.com/role/ScheduleofmilestonepaymentsTable",
     "shortName": "Commitments and Contingencies (Details) - Schedule of milestone payments",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "silo:ScheduleOfUMBMinimumRoyaltyPayments",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c190",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "silo:UMBYearDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments",
     "role": "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable",
     "shortName": "Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "silo:ScheduleOfUMBMinimumRoyaltyPayments",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c190",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "silo:UMBYearDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "silo:ScheduleOfExclusiveOfValueAddedTaxToBeAmortized",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c195",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "silo:Payment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Commitments and Contingencies (Details) - Schedule of exclusive of value added tax to be amortized",
     "role": "http://silopharma.com/role/ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable",
     "shortName": "Commitments and Contingencies (Details) - Schedule of exclusive of value added tax to be amortized",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "silo:ScheduleOfExclusiveOfValueAddedTaxToBeAmortized",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c195",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "silo:Payment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "silo:ScheduleOfShallPayUMB",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c267",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "silo:SponsoredPayment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Commitments and Contingencies (Details) - Schedule of shall pay UMB",
     "role": "http://silopharma.com/role/ScheduleofshallpayUMBTable",
     "shortName": "Commitments and Contingencies (Details) - Schedule of shall pay UMB",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c204",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "silo:TotalOfSharesOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Subsequent Events (Details)",
     "role": "http://silopharma.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c204",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "silo:TotalOfSharesOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "silo:ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share",
     "role": "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable0",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "silo:ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c208",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c215",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "silo:EquityInvestmentsAtFairValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis",
     "role": "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0",
     "shortName": "Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "silo:ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "057 - Disclosure - Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of activity in the company\u2019s equity investments, at fair value",
     "role": "http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable0",
     "shortName": "Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of activity in the company\u2019s equity investments, at fair value",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "silo:ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c7",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c87",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "058 - Disclosure - Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of financial data of the company\u2019s gain from sale of the NFID business",
     "role": "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable0",
     "shortName": "Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of financial data of the company\u2019s gain from sale of the NFID business",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c17",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Condensed Consolidated Statements of Changes in Stockholders\u2019 Equity (Unaudited)",
     "role": "http://silopharma.com/role/ShareholdersEquityType2or3",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders\u2019 Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c17",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c14",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleOfProductiveAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "059 - Disclosure - Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of operating result of discontinued operations of the NFID business",
     "role": "http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable0",
     "shortName": "Disposal of the Discontinued Operations of the NFID Business (Details) - Schedule of operating result of discontinued operations of the NFID business",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c7",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesReceivableGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060 - Disclosure - Notes Receivable (Details) - Schedule of notes receivable net",
     "role": "http://silopharma.com/role/ScheduleofnotesreceivablenetTable",
     "shortName": "Notes Receivable (Details) - Schedule of notes receivable net",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c7",
      "decimals": "0",
      "lang": null,
      "name": "silo:CollectionsOnNotesReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c166",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061 - Disclosure - Stockholders\u2019 Equity (Details) - Schedule of stock options activities",
     "role": "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0",
     "shortName": "Stockholders\u2019 Equity (Details) - Schedule of stock options activities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c242",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c169",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "062 - Disclosure - Stockholders\u2019 Equity (Details) - Schedule of warrant activities",
     "role": "http://silopharma.com/role/ScheduleofwarrantactivitiesTable0",
     "shortName": "Stockholders\u2019 Equity (Details) - Schedule of warrant activities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c245",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "silo:ScheduleOfMilestonePayments",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c262",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "silo:Milestone",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "063 - Disclosure - Commitments and Contingencies (Details) - Schedule of milestone payments",
     "role": "http://silopharma.com/role/ScheduleofmilestonepaymentsTable0",
     "shortName": "Commitments and Contingencies (Details) - Schedule of milestone payments",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "silo:ScheduleOfUMBMinimumRoyaltyPayments",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c262",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "silo:YearsDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "064 - Disclosure - Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments",
     "role": "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable0",
     "shortName": "Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "silo:ScheduleOfUMBMinimumRoyaltyPayments",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c262",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "silo:YearsDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "silo:ScheduleOfShallPayUMB",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c267",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "silo:SponsoredPayment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "065 - Disclosure - Commitments and Contingencies (Details) - Schedule of shall pay UMB",
     "role": "http://silopharma.com/role/ScheduleofshallpayUMBTable0",
     "shortName": "Commitments and Contingencies (Details) - Schedule of shall pay UMB",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://silopharma.com/role/ConsolidatedCashFlow",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Organization and Business",
     "role": "http://silopharma.com/role/OrganizationandBusiness",
     "shortName": "Organization and Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://silopharma.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea165987-s1a4_silopharma.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 64,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description",
        "terseLabel": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://silopharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://silopharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://silopharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://silopharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://silopharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://silopharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://silopharma.com/role/NotePayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://silopharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://silopharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://silopharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://silopharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://silopharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://silopharma.com/role/NotePayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_AccruedInterestReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued interest receivable.",
        "label": "Accrued Interest Receivable",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "AccruedInterestReceivable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_AdditionalNotesReceivableIn2021": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional notes receivable.",
        "label": "Additional Notes Receivable In2021",
        "terseLabel": "Additional notes receivable in 2021",
        "verboseLabel": "Additional notes receivable"
       }
      }
     },
     "localname": "AdditionalNotesReceivableIn2021",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofnotesreceivableTable",
      "http://silopharma.com/role/ScheduleofnotesreceivablenetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_AdditionsofEquitySecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions for equity securities.",
        "label": "Additionsof Equity Securities",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsofEquitySecurities",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable",
      "http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_AdvanceFromARelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance from a related party.",
        "label": "Advance From ARelated Party",
        "terseLabel": "Advance from a related party"
       }
      }
     },
     "localname": "AdvanceFromARelatedParty",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_AdvisoryAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advisory Agreements Member",
        "terseLabel": "Advisory Agreements [Member]"
       }
      }
     },
     "localname": "AdvisoryAgreementsMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_AggregateEstimatedNetOperatingLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Estimated Net Operating Loss",
        "terseLabel": "Aggregate estimated net operating loss"
       }
      }
     },
     "localname": "AggregateEstimatedNetOperatingLoss",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_AggregateGrantDateFairValueOfPlacementAgentWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate grant date fair value of placement agent warrants.",
        "label": "Aggregate Grant Date Fair Value Of Placement Agent Warrants",
        "terseLabel": "Aggregate grant date fair value of placement agent warrants (in Dollars)"
       }
      }
     },
     "localname": "AggregateGrantDateFairValueOfPlacementAgentWarrants",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_AggregateIntrinsicValueGranted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value Granted",
        "terseLabel": "Aggregate Intrinsic Value, Granted",
        "verboseLabel": "Granted/Forfeited, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueGranted",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_AggregateIntrinsicValueGrantedIssuedForfeited1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value Granted Issued Forfeited1",
        "terseLabel": "Aggregate Intrinsic Value, Granted/Issued/ Forfeited"
       }
      }
     },
     "localname": "AggregateIntrinsicValueGrantedIssuedForfeited1",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_AggregateOfConvertedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Of Converted Shares",
        "terseLabel": "Aggregate of converted shares (in Shares)"
       }
      }
     },
     "localname": "AggregateOfConvertedShares",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "silo_AggregateOfNotesReceivablePurchasePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate of notes receivable purchase price.",
        "label": "Aggregate Of Notes Receivable Purchase Price",
        "terseLabel": "Aggregate of notes receivable purchase price"
       }
      }
     },
     "localname": "AggregateOfNotesReceivablePurchasePrice",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_AgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement Description",
        "terseLabel": "Agreement, description"
       }
      }
     },
     "localname": "AgreementDescription",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_AgreementShallExpire": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement Shall Expire",
        "terseLabel": "Agreement shall expire"
       }
      }
     },
     "localname": "AgreementShallExpire",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "silo_AikidoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aikido Member",
        "terseLabel": "Aikido [Member]"
       }
      }
     },
     "localname": "AikidoMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_AikidoPharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aikido Pharma Inc Member",
        "terseLabel": "Aikido Pharma, Inc. [Member]"
       }
      }
     },
     "localname": "AikidoPharmaIncMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_AmortizationOfPrepaidStockbasedExpense": {
     "auth_ref": [],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization Of Prepaid Stockbased Expense",
        "terseLabel": "Amortization of prepaid stock-based compensation",
        "verboseLabel": "Recognized stock-based consulting fees (in Dollars)"
       }
      }
     },
     "localname": "AmortizationOfPrepaidStockbasedExpense",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_AnnualBaseSalary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual salary amount.",
        "label": "Annual Base Salary",
        "terseLabel": "Annual salary amount"
       }
      }
     },
     "localname": "AnnualBaseSalary",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_AssetPurchaseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement Description.",
        "label": "Asset Purchase Agreement Description",
        "terseLabel": "Asset purchase agreement, description"
       }
      }
     },
     "localname": "AssetPurchaseAgreementDescription",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_AvailableForSalesEquitySecuritiesGrossUnrealizedGain": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain before deducting unrealized loss on investment in equity securities classified as available-for-sale securities.",
        "label": "Available For Sales Equity Securities Gross Unrealized Gain",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "AvailableForSalesEquitySecuritiesGrossUnrealizedGain",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_BadDebtRecoveryCashPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bad Debt Recovery Cash Payment",
        "terseLabel": "Bad debt recovery cash payment, description"
       }
      }
     },
     "localname": "BadDebtRecoveryCashPayment",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_BadDebtRecoveryExpense": {
     "auth_ref": [],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bad debt (recovery) expense.",
        "label": "Bad Debt Recovery Expense",
        "terseLabel": "Bad debt (recovery) expense, net"
       }
      }
     },
     "localname": "BadDebtRecoveryExpense",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_CashPaidDuringThePeriodForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid During The Period For Abstract",
        "terseLabel": "Cash paid during the period for:"
       }
      }
     },
     "localname": "CashPaidDuringThePeriodForAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_CashReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received",
        "terseLabel": "Cash received"
       }
      }
     },
     "localname": "CashReceived",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_CashSPICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Securities Investor Protection Corporation.",
        "label": "Cash SPICInsured Amount",
        "terseLabel": "Securities investor protection corporation"
       }
      }
     },
     "localname": "CashSPICInsuredAmount",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_CollectedSettlementAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Collected Settlement Agreement.",
        "label": "Collected Settlement Agreement",
        "terseLabel": "Collected settlement agreement"
       }
      }
     },
     "localname": "CollectedSettlementAgreement",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_CollectionOnNoteReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Collection On Note Receivable",
        "terseLabel": "Collection on note receivable"
       }
      }
     },
     "localname": "CollectionOnNoteReceivable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_CollectionsOnNotesReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collections on notes receivables.",
        "label": "Collections On Notes Receivable",
        "negatedLabel": "Collections on notes receivables"
       }
      }
     },
     "localname": "CollectionsOnNotesReceivable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofnotesreceivableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_CollectionsOnNotesReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Collections On Notes Receivables",
        "negatedLabel": "Collections on notes receivables"
       }
      }
     },
     "localname": "CollectionsOnNotesReceivables",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofnotesreceivablenetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_ColumbiaUniversityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Columbia University Member",
        "terseLabel": "Columbia University [Member]"
       }
      }
     },
     "localname": "ColumbiaUniversityMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_CommercialSaleTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Sale Term",
        "terseLabel": "Commercial sale term"
       }
      }
     },
     "localname": "CommercialSaleTerm",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "silo_CommitmentsandContingenciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Line Items]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsLineItems",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Line Items]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsLineItems",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable",
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Table]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsScheduleofUMBminimumroyaltypaymentsTable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable",
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) - Schedule of exclusive of value added tax to be amortized [Line Items]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedLineItems",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) - Schedule of exclusive of value added tax to be amortized [Table]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsScheduleofexclusiveofvalueaddedtaxtobeamortizedTable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) - Schedule of milestone payments [Line Items]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsLineItems",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable",
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) - Schedule of milestone payments [Table]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsScheduleofmilestonepaymentsTable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable",
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) - Schedule of shall pay UMB [Line Items]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsScheduleofshallpayUMBLineItems",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofshallpayUMBTable",
      "http://silopharma.com/role/ScheduleofshallpayUMBTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) - Schedule of shall pay UMB [Table]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsScheduleofshallpayUMBTable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofshallpayUMBTable",
      "http://silopharma.com/role/ScheduleofshallpayUMBTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_CommitmentsandContingenciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsTable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_CommonStockGrantDateFairValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock grant date fair value per share.",
        "label": "Common Stock Grant Date Fair Value Per Share",
        "terseLabel": "Common stock grant date fair value per share (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockGrantDateFairValuePerShare",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock issued for conversion of Redeemable Series A Preferred stock.",
        "label": "Common Stock Issued For Conversion Of Redeemable Series APreferred Stock",
        "terseLabel": "Common Stock issued for conversion of Redeemable Series A Preferred stock"
       }
      }
     },
     "localname": "CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStock",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Issued For Conversion Of Redeemable Series APreferred Stockin Shares",
        "terseLabel": "Common Stock issued for conversion of Redeemable Series A Preferred stock (in Shares)"
       }
      }
     },
     "localname": "CommonStockIssuedForConversionOfRedeemableSeriesAPreferredStockinShares",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "silo_CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Issued For Conversion Of Redeemable Series Preferred Stock Shares",
        "terseLabel": "Convertible preferred stock stated value"
       }
      }
     },
     "localname": "CommonStockIssuedForConversionOfRedeemableSeriesPreferredStockShares",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "silo_CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued for conversion of Redeemable Series A Preferred Stock.",
        "label": "Common Stock Issued For Conversions Of Redeemable Series APreferred Stock",
        "terseLabel": "Common stock issued for conversion of Redeemable Series A Preferred Stock"
       }
      }
     },
     "localname": "CommonStockIssuedForConversionsOfRedeemableSeriesAPreferredStock",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_CommonStockIssuedForExchangeOfNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock issued for Exchange of Notes.",
        "label": "Common Stock Issued For Exchange Of Notes",
        "terseLabel": "Common Stock issued for Exchange of Notes"
       }
      }
     },
     "localname": "CommonStockIssuedForExchangeOfNotes",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_CommonStockIssuedForExchangeOfNotesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock issued for Exchange of Notes, shares.",
        "label": "Common Stock Issued For Exchange Of Notes Shares",
        "terseLabel": "Common Stock issued for Exchange of Notes (in Shares)"
       }
      }
     },
     "localname": "CommonStockIssuedForExchangeOfNotesShares",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "silo_CommonStockIssuedForFutureServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Issued For Future Services",
        "terseLabel": "Common Stock issued for future services"
       }
      }
     },
     "localname": "CommonStockIssuedForFutureServices",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_CommonStockIssuedForFutureServicesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock issued for future services, shares.",
        "label": "Common Stock Issued For Future Services Shares",
        "terseLabel": "Common Stock issued for future services (in Shares)"
       }
      }
     },
     "localname": "CommonStockIssuedForFutureServicesShares",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "silo_CommonStockIssuedForPrepaidServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Issued For Prepaid Services",
        "terseLabel": "Common stock issued for Exchange of Notes"
       }
      }
     },
     "localname": "CommonStockIssuedForPrepaidServices",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_CommonStockServiceDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock service, description.",
        "label": "Common Stock Service Description",
        "terseLabel": "Warrant, description"
       }
      }
     },
     "localname": "CommonStockServiceDescription",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_CompanyPaidCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Paid Cash",
        "terseLabel": "Company paid cash"
       }
      }
     },
     "localname": "CompanyPaidCash",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_CompanyReceivedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Company received shares.",
        "label": "Company Received Shares",
        "terseLabel": "Company received shares (in Shares)"
       }
      }
     },
     "localname": "CompanyReceivedShares",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "silo_ConcentrationsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations (Details) [Line Items]"
       }
      }
     },
     "localname": "ConcentrationsDetailsLineItems",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_ConcentrationsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations (Details) [Table]"
       }
      }
     },
     "localname": "ConcentrationsDetailsTable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_ConcentrationsRiskPercentage1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration risk percentage 1.",
        "label": "Concentrations Risk Percentage1",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationsRiskPercentage1",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silo_ConsiderationFeePayablePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration Fee Payable Percentage",
        "terseLabel": "Consideration fee payable percentage"
       }
      }
     },
     "localname": "ConsiderationFeePayablePercentage",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silo_ConsiderationInTheFormOfANoteReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consideration in the form of a note receivable.",
        "label": "Consideration In The Form Of ANote Receivable",
        "terseLabel": "Consideration in the form of a note receivable"
       }
      }
     },
     "localname": "ConsiderationInTheFormOfANoteReceivable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable",
      "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_ConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreement Member",
        "terseLabel": "Consulting Agreement [Member]"
       }
      }
     },
     "localname": "ConsultingAgreementMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_ConvertablePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertable preferred stock.",
        "label": "Convertable Preferred Stock",
        "terseLabel": "Converted preferred stock"
       }
      }
     },
     "localname": "ConvertablePreferredStock",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "silo_ConvertibleLongTermNotesPayables": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible long term notes payable.",
        "label": "Convertible Long Term Notes Payables",
        "terseLabel": "Convertible promissory notes (in Dollars)"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayables",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_CostOfRevenuesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost Of Revenues Policy Text Block",
        "terseLabel": "Cost of Revenues"
       }
      }
     },
     "localname": "CostOfRevenuesPolicyTextBlock",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "silo_CurrentAssetsAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets Abstract0",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "CurrentAssetsAbstract0",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_CurrentLiabilitiesAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities Abstract0",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract0",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_DatChatIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dat Chat Inc Member",
        "terseLabel": "DatChat, Inc. [Member]"
       }
      }
     },
     "localname": "DatChatIncMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_DebtInstrumentIncreasesAccruedInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.",
        "label": "Debt Instrument Increases Accrued Interest",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "DebtInstrumentIncreasesAccruedInterest",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_DebtInstrumentsFaceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instruments Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentsFaceAmount",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofinterestexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_DeemedDividend": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deemed dividend.",
        "label": "Deemed Dividend",
        "terseLabel": "Deemed dividend (in Dollars)"
       }
      }
     },
     "localname": "DeemedDividend",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_DeemedDividendOnPreferredStockExchange": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed dividend on Preferred Stock Exchange.",
        "label": "Deemed Dividend On Preferred Stock Exchange",
        "terseLabel": "Deemed dividend on Preferred Stock Exchange"
       }
      }
     },
     "localname": "DeemedDividendOnPreferredStockExchange",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_DeferredRevenueArrangementType_Domain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredRevenueArrangementType_ [Domain]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementType_Domain",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_DeferredRevenueLongtermPortion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue Longterm Portion",
        "terseLabel": "Revenue long term portion amounts"
       }
      }
     },
     "localname": "DeferredRevenueLongtermPortion",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_DeferredRevenueLongtermPortionAmounted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred revenue long-term portion amounted.",
        "label": "Deferred Revenue Longterm Portion Amounted",
        "terseLabel": "Deferred revenue long-term portion"
       }
      }
     },
     "localname": "DeferredRevenueLongtermPortionAmounted",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_DeferredTaxAssetGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforward.",
        "label": "Deferred Tax Asset Gross",
        "terseLabel": "Total deferred tax asset (liability) before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetGross",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofnetdeferredtaxassetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_DeferredTaxAssetsCapitalLossCarryforward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowance of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets Capital Loss Carryforward",
        "terseLabel": "Net capital loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforward",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofnetdeferredtaxassetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_DeferredTaxAssetsValuationAllowances": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax asset for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowances",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowances",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofnetdeferredtaxassetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_DescriptionOfIncomeTaxDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Income Tax Description",
        "terseLabel": "Description of Income Tax Description"
       }
      }
     },
     "localname": "DescriptionOfIncomeTaxDescription",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_DiscontinuedOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations Abstract",
        "terseLabel": "DISCONTINUED OPERATIONS:"
       }
      }
     },
     "localname": "DiscontinuedOperationsAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "silo_DrJamesKuoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr James Kuo Member",
        "terseLabel": "Dr. James Kuo [Member]"
       }
      }
     },
     "localname": "DrJamesKuoMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_EffectOfDilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect Of Dilutive Securities Abstract",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "EffectOfDilutiveSecuritiesAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_EmploymentAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employment Agreement Description",
        "terseLabel": "Employment agreement, description"
       }
      }
     },
     "localname": "EmploymentAgreementDescription",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_EmploymentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employment Agreement Member",
        "terseLabel": "Employment Agreement [Member]"
       }
      }
     },
     "localname": "EmploymentAgreementMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_EquityInvestmentsAtCost": {
     "auth_ref": [],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity investments, at cost.",
        "label": "Equity Investments At Cost",
        "terseLabel": "Equity investments"
       }
      }
     },
     "localname": "EquityInvestmentsAtCost",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_EquityInvestmentsAtCostPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Investments At Cost Policy Text Block",
        "terseLabel": "Equity Investments, at Cost"
       }
      }
     },
     "localname": "EquityInvestmentsAtCostPolicyTextBlock",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "silo_EquityInvestmentsAtFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Investments At Fair Value",
        "terseLabel": "Equity investments consisting of common stock, at fair value"
       }
      }
     },
     "localname": "EquityInvestmentsAtFairValue",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
      "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_EquityInvestmentsAtFairValuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Investments At Fair Value Policy Text Block",
        "terseLabel": "Equity Investments, at Fair Value"
       }
      }
     },
     "localname": "EquityInvestmentsAtFairValuePolicyTextBlock",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "silo_EquityInvestmentsCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity investments cost.",
        "label": "Equity Investments Cost",
        "terseLabel": "Equity investments cost"
       }
      }
     },
     "localname": "EquityInvestmentsCost",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_EquityMethodInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investment",
        "terseLabel": "Equity investments amount"
       }
      }
     },
     "localname": "EquityMethodInvestment",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_ExchangeAgreementsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The company entered into exchange agreements description.",
        "label": "Exchange Agreements Description",
        "terseLabel": "Exchange agreements, description"
       }
      }
     },
     "localname": "ExchangeAgreementsDescription",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_ExchangeAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange Agreements Member",
        "terseLabel": "Exchange Agreements [Member]"
       }
      }
     },
     "localname": "ExchangeAgreementsMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments and Fair Value Measurements (Details) [Line Items]"
       }
      }
     },
     "localname": "FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsLineItems",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis [Line Items]"
       }
      }
     },
     "localname": "FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
      "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of assets and liabilities measured at fair value on a recurring basis [Table]"
       }
      }
     },
     "localname": "FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
      "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments and Fair Value Measurements (Details) [Table]"
       }
      }
     },
     "localname": "FairValueofFinancialInstrumentsandFairValueMeasurementsDetailsTable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_FinanceLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance leases.",
        "label": "Finance Lease Liabilities",
        "negatedLabel": "Total liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilities",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable",
      "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_FirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First commercial sale.",
        "label": "First Commercial Sale",
        "terseLabel": "First commercial sale"
       }
      }
     },
     "localname": "FirstCommercialSale",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "silo_GainFromSaleOfNFIDBusiness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain from sale of NFID business.",
        "label": "Gain From Sale Of NFIDBusiness",
        "terseLabel": "Gain from sale of NFID business"
       }
      }
     },
     "localname": "GainFromSaleOfNFIDBusiness",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_GainLossOnSaleOfCapitalLeaseNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net gain (loss) arising from the lessor's transactions involving the sale, transfer, or termination of financing agreements classified as capital lease.",
        "label": "Gain Loss On Sale Of Capital Lease Net",
        "terseLabel": "GainLossOnSaleOfCapitalLeasesNet"
       }
      }
     },
     "localname": "GainLossOnSaleOfCapitalLeaseNet",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_GrantedAsIncentivesAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted As Incentives Aggregate Intrinsic Value",
        "terseLabel": "Granted as incentives, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "GrantedAsIncentivesAggregateIntrinsicValue",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_GrantedAsIncentivesWeightedAverageRemainingContractualTermYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Granted As Incentives Weighted Average Remaining Contractual Term Years",
        "terseLabel": "Granted as incentives, Weighted Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "GrantedAsIncentivesWeightedAverageRemainingContractualTermYears",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "silo_GrossProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of Gross proceeds.",
        "label": "Gross Proceeds",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "GrossProceeds",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_HomeBistroIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Home Bistro Inc Member",
        "terseLabel": "Home Bistro, Inc. [Member]"
       }
      }
     },
     "localname": "HomeBistroIncMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_IncentiveStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Stock Option Member",
        "terseLabel": "Incentive Stock Option [Member]"
       }
      }
     },
     "localname": "IncentiveStockOptionMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_IncomeLossFromDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (loss) from discontinued operations.",
        "label": "Income Loss From Discontinued Operations",
        "terseLabel": "Loss from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperations",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_IncomeLossPerCommonShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Loss Per Common Share Basic Abstract",
        "terseLabel": "Income (loss) per common share \u2014 basic:"
       }
      }
     },
     "localname": "IncomeLossPerCommonShareBasicAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_IncomeLossPerCommonShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Loss Per Common Share Diluted Abstract",
        "terseLabel": "Income (loss) per common share \u2014 diluted:"
       }
      }
     },
     "localname": "IncomeLossPerCommonShareDilutedAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_IncomelossFromContinuingOperation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IncomelossFromContinuingOperation.",
        "label": "Incomeloss From Continuing Operation",
        "terseLabel": "Income (loss) from continuing operations"
       }
      }
     },
     "localname": "IncomelossFromContinuingOperation",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_IncreaseDecreaseInAssetsOfDiscontinuedOperation": {
     "auth_ref": [],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Assets Of Discontinued Operation",
        "terseLabel": "Assets of discontinued operations"
       }
      }
     },
     "localname": "IncreaseDecreaseInAssetsOfDiscontinuedOperation",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in equity investments recorded as deferred revenue pursuant to a patent license agreement.",
        "label": "Increase In Equity Investments Recorded As Deferred Revenue Pursuant To APatent License Agree",
        "terseLabel": "Increase in equity investments recorded as deferred revenue pursuant to a patent license agreement"
       }
      }
     },
     "localname": "IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including Iniital fair value of stock options issued as stock-based compensation recorded as deferred compensation.",
        "label": "Iniital Fair Value Of Stock Options Issued As Stockbased Compensation Recorded As Deferred Comp",
        "terseLabel": "Initial fair value of stock options issued as stock-based compensation recorded as deferred compensation"
       }
      }
     },
     "localname": "IniitalFairValueOfStockOptionsIssuedAsStockbasedCompensationRecordedAsDeferredComp",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_InvestorInvestedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The investor invested amount.",
        "label": "Investor Invested Amount",
        "terseLabel": "Investor invested amount (in Dollars)"
       }
      }
     },
     "localname": "InvestorInvestedAmount",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_InvestorInvestedAmountPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Invested Amount Percentage",
        "terseLabel": "Subsequent financing, percentage"
       }
      }
     },
     "localname": "InvestorInvestedAmountPercentage",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silo_IssuanceOfCommonSharesForConversionOfPreferredStockinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for conversion of preferred stock (in Shares).",
        "label": "Issuance Of Common Shares For Conversion Of Preferred Stockin Shares",
        "terseLabel": "Issuance of common stock for conversion of preferred stock (in Shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonSharesForConversionOfPreferredStockinShares",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "silo_IssuanceOfCommonStockForConversionOfPreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for conversion of preferred stock.",
        "label": "Issuance Of Common Stock For Conversion Of Preferred Stock",
        "terseLabel": "Issuance of common stock for conversion of preferred stock"
       }
      }
     },
     "localname": "IssuanceOfCommonStockForConversionOfPreferredStock",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_JVAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JVAgreement Member",
        "terseLabel": "JV Agreement [Member]"
       }
      }
     },
     "localname": "JVAgreementMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_KuoEmploymentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kuo Employment Agreement Member",
        "terseLabel": "Kuo Employment Agreement [Member]"
       }
      }
     },
     "localname": "KuoEmploymentAgreementMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_LessNotesReceivableNetCurrentPortion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Less Notes Receivable Net Current Portion",
        "terseLabel": "Less: notes receivable, net \u2013 current portion"
       }
      }
     },
     "localname": "LessNotesReceivableNetCurrentPortion",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofnotesreceivableTable",
      "http://silopharma.com/role/ScheduleofnotesreceivablenetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_LicenseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement Description",
        "terseLabel": "License agreement, description"
       }
      }
     },
     "localname": "LicenseAgreementDescription",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_LicenseAgreementExpire": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement Expire",
        "terseLabel": "License agreement expire"
       }
      }
     },
     "localname": "LicenseAgreementExpire",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "silo_LicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fee incurred and are directly related to generating license Expenses. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License Fee",
        "terseLabel": "License fee"
       }
      }
     },
     "localname": "LicenseFee",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_LicenseFees": {
     "auth_ref": [],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License fees.",
        "label": "License Fees",
        "terseLabel": "LICENSE FEE REVENUES:"
       }
      }
     },
     "localname": "LicenseFees",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_LicensorShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensor Share",
        "terseLabel": "Licensor share (in Shares)"
       }
      }
     },
     "localname": "LicensorShare",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "silo_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity Policy Text Block",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "silo_LongTermLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Liabilities Abstract",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "localname": "LongTermLiabilitiesAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_LossFromDebtExtinguishment": {
     "auth_ref": [],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss From Debt Extinguishment",
        "negatedLabel": "Loss from debt extinguishment"
       }
      }
     },
     "localname": "LossFromDebtExtinguishment",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_MasterLincenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Master Lincense Agreement Member",
        "terseLabel": "Master License Agreement [Member]"
       }
      }
     },
     "localname": "MasterLincenseAgreementMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_Milestone": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone",
        "terseLabel": "Milestone"
       }
      }
     },
     "localname": "Milestone",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable",
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payment",
        "terseLabel": "Payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable",
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_MinimumAnnualRoyalty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of minimum anual royalty.",
        "label": "Minimum Annual Royalty",
        "terseLabel": "Minimum Annual Royalty"
       }
      }
     },
     "localname": "MinimumAnnualRoyalty",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_NetAssetOfNFIDBusinessDisposed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net asset of NFID business disposed.",
        "label": "Net Asset Of NFIDBusiness Disposed",
        "terseLabel": "Net asset of NFID business disposed"
       }
      }
     },
     "localname": "NetAssetOfNFIDBusinessDisposed",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable",
      "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_NetBadDebtExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net bad debt expense.",
        "label": "Net Bad Debt Expense",
        "terseLabel": "Net bad debt expense"
       }
      }
     },
     "localname": "NetBadDebtExpense",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_NetCapitalLossCarryForward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Capital Loss Carry Forward",
        "terseLabel": "Net capital loss carryforward"
       }
      }
     },
     "localname": "NetCapitalLossCarryForward",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss Per Common Share Available To Common Stockholders Basic Abstract",
        "terseLabel": "Net income (loss) per common share available to common stockholders\u2013 basic:"
       }
      }
     },
     "localname": "NetIncomeLossPerCommonShareAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Share Available To Common Stockholders Diluted Abstract",
        "terseLabel": "Net loss per common share available to common stockholders \u2013 diluted:"
       }
      }
     },
     "localname": "NetLossPerCommonShareAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_NetSalePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sale Percentage",
        "terseLabel": "Net sale percentage"
       }
      }
     },
     "localname": "NetSalePercentage",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silo_NonrefundableCashPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrefundable Cash Payment",
        "terseLabel": "Non-refundable cash payment"
       }
      }
     },
     "localname": "NonrefundableCashPayment",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_NotePayableDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable (Details) [Line Items]"
       }
      }
     },
     "localname": "NotePayableDetailsLineItems",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotePayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_NotePayableDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable (Details) [Table]"
       }
      }
     },
     "localname": "NotePayableDetailsTable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotePayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_NotePayableLongTermPortion": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable Long Term Portion",
        "terseLabel": "Note payable - long term portion"
       }
      }
     },
     "localname": "NotePayableLongTermPortion",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofinterestexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Receivable Issued In Connection With Asset Purchase Agreement",
        "terseLabel": "Note receivable issued in connection with asset purchase agreement"
       }
      }
     },
     "localname": "NoteReceivableIssuedInConnectionWithAssetPurchaseAgreement",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_NoteReceivableNonCurrentAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Receivable Non Current Amount",
        "terseLabel": "Note receivable non-current amounted"
       }
      }
     },
     "localname": "NoteReceivableNonCurrentAmount",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_NotesReceivableDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Receivable (Details) [Line Items]"
       }
      }
     },
     "localname": "NotesReceivableDetailsLineItems",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_NotesReceivableDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Receivable (Details) [Table]"
       }
      }
     },
     "localname": "NotesReceivableDetailsTable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_NotesReceivablePurchasePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NotesReceivablePurchasePrice.",
        "label": "Notes Receivable Purchase Price",
        "terseLabel": "Notes receivable purchase price"
       }
      }
     },
     "localname": "NotesReceivablePurchasePrice",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_NotrPayableLessCurrentPortion": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notr Payable Less Current Portion",
        "negatedLabel": "Less: current portion"
       }
      }
     },
     "localname": "NotrPayableLessCurrentPortion",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofinterestexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_NumberOfVotingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Voting Shares",
        "terseLabel": "Number of voting shares (in Shares)"
       }
      }
     },
     "localname": "NumberOfVotingShares",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "silo_NumberOfWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Warrants.",
        "label": "Number Of Warrant",
        "periodEndLabel": "Number of Warrants, ending balance",
        "periodStartLabel": "Number of Warrants, beginning balance"
       }
      }
     },
     "localname": "NumberOfWarrant",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "silo_NumeratorForLossFromContinuingOperationsPerCommonShareDiluted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Numerator For Loss From Continuing Operations Per Common Share Diluted",
        "terseLabel": "Numerator for loss from continuing operations per common share \u2014 diluted"
       }
      }
     },
     "localname": "NumeratorForLossFromContinuingOperationsPerCommonShareDiluted",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted.",
        "label": "Numerator For Loss From Discontinuing Operations Per Common Share Diluted",
        "terseLabel": "Numerator for loss from discontinuing operations per common share \u2014 diluted"
       }
      }
     },
     "localname": "NumeratorForLossFromDiscontinuingOperationsPerCommonShareDiluted",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_ObligationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obligation Percentage",
        "terseLabel": "Obligation percentage"
       }
      }
     },
     "localname": "ObligationPercentage",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silo_OmnibusEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Omnibus Equity Incentive Plan Member",
        "terseLabel": "Omnibus Equity incentive Plan [Member]"
       }
      }
     },
     "localname": "OmnibusEquityIncentivePlanMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_OneLicenseeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Licensee Member",
        "terseLabel": "One Licensee [Member]"
       }
      }
     },
     "localname": "OneLicenseeMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_OneLicensorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Licensor Member",
        "terseLabel": "One Licensee [Member]",
        "verboseLabel": "One Licensor [Member]"
       }
      }
     },
     "localname": "OneLicensorMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_OrganizationandBusinessDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Business (Details) [Table]"
       }
      }
     },
     "localname": "OrganizationandBusinessDetailsTable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_OtherDepreciationsAndAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.",
        "label": "Other Depreciations And Amortization",
        "terseLabel": "Recognized amortization expenses"
       }
      }
     },
     "localname": "OtherDepreciationsAndAmortization",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_OtherIncomeFromEquitySharesEarnedForServices": {
     "auth_ref": [],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 8.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other income from equity shares earned for services.",
        "label": "Other Income From Equity Shares Earned For Services",
        "terseLabel": "Other income from equity shares earned for lock up agreement"
       }
      }
     },
     "localname": "OtherIncomeFromEquitySharesEarnedForServices",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_PaycheckProtectionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paycheck Protection Program Member",
        "terseLabel": "Paycheck Protection Program [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotePayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_Payment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment",
        "terseLabel": "Payment"
       }
      }
     },
     "localname": "Payment",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_PaymentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Description",
        "terseLabel": "Payment description",
        "verboseLabel": "Payment, description"
       }
      }
     },
     "localname": "PaymentDescription",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable",
      "http://silopharma.com/role/ScheduleofshallpayUMBTable",
      "http://silopharma.com/role/ScheduleofshallpayUMBTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_PaymentEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Eight Member",
        "terseLabel": "Payment Three [Member]"
       }
      }
     },
     "localname": "PaymentEightMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofshallpayUMBTable",
      "http://silopharma.com/role/ScheduleofshallpayUMBTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_PaymentFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Five Member",
        "terseLabel": "Payment Five [Member]"
       }
      }
     },
     "localname": "PaymentFiveMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable",
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable0",
      "http://silopharma.com/role/ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable",
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable",
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_PaymentFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Four Member",
        "terseLabel": "Payment Four [Member]"
       }
      }
     },
     "localname": "PaymentFourMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable",
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable0",
      "http://silopharma.com/role/ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable",
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable",
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_PaymentOfSponsoredResearchAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of sponsored research amount.",
        "label": "Payment Of Sponsored Research Amount",
        "terseLabel": "Payment of sponsored research amount"
       }
      }
     },
     "localname": "PaymentOfSponsoredResearchAmount",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_PaymentOfUniversity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Of University",
        "terseLabel": "Payment of university"
       }
      }
     },
     "localname": "PaymentOfUniversity",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_PaymentOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment One Member",
        "terseLabel": "Payment One [Member]"
       }
      }
     },
     "localname": "PaymentOneMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable",
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable0",
      "http://silopharma.com/role/ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable",
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable",
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_PaymentSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Seven Member",
        "terseLabel": "Payment Two [Member]"
       }
      }
     },
     "localname": "PaymentSevenMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofshallpayUMBTable",
      "http://silopharma.com/role/ScheduleofshallpayUMBTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_PaymentSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Six Member",
        "terseLabel": "Payment One [Member]"
       }
      }
     },
     "localname": "PaymentSixMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofshallpayUMBTable",
      "http://silopharma.com/role/ScheduleofshallpayUMBTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_PaymentThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Three Member",
        "terseLabel": "Payment Three [Member]"
       }
      }
     },
     "localname": "PaymentThreeMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable",
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable0",
      "http://silopharma.com/role/ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable",
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable",
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_PaymentTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Two Member",
        "terseLabel": "Payment Two [Member]"
       }
      }
     },
     "localname": "PaymentTwoMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable",
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable0",
      "http://silopharma.com/role/ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable",
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable",
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_PlacementAgentFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement agent fees.",
        "label": "Placement Agent Fees",
        "terseLabel": "Placement agent fees (in Dollars)"
       }
      }
     },
     "localname": "PlacementAgentFees",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_PlacementAgentWarrantsDescriptoin": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrants Descriptoin",
        "terseLabel": "Placement agent warrants, description"
       }
      }
     },
     "localname": "PlacementAgentWarrantsDescriptoin",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_PlacementAgentWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrants Member",
        "terseLabel": "Placement Agent Warrants [Member]"
       }
      }
     },
     "localname": "PlacementAgentWarrantsMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_PreferredSharesExchangedForCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Shares Exchanged for Common Stock.",
        "label": "Preferred Shares Exchanged For Common Stock",
        "terseLabel": "Preferred Shares Exchanged for Common Stock"
       }
      }
     },
     "localname": "PreferredSharesExchangedForCommonStock",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_PreferredSharesExchangedForCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Shares Exchanged for Common Stock, Shares.",
        "label": "Preferred Shares Exchanged For Common Stock Shares",
        "terseLabel": "Preferred Shares Exchanged for Common Stock (in Shares)"
       }
      }
     },
     "localname": "PreferredSharesExchangedForCommonStockShares",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "silo_PreferredStockOutstandingDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Outstanding Description",
        "terseLabel": "Preferred stock outstanding, description"
       }
      }
     },
     "localname": "PreferredStockOutstandingDescription",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_PreferredStockStatedValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of preferred stock stated value.",
        "label": "Preferred Stock Stated Value",
        "terseLabel": "Preferred stock, stated value (in Dollars)"
       }
      }
     },
     "localname": "PreferredStockStatedValue",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_PreferredStockValueOne": {
     "auth_ref": [],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value One",
        "terseLabel": "Convertible preferred stock, value"
       }
      }
     },
     "localname": "PreferredStockValueOne",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_PreferredStockValueTwo": {
     "auth_ref": [],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value Two",
        "terseLabel": "Convertible preferred stock, value"
       }
      }
     },
     "localname": "PreferredStockValueTwo",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_PrepaidExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses",
        "terseLabel": "Prepaid expenses \u2013 non-current"
       }
      }
     },
     "localname": "PrepaidExpenses",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_PrincipalBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of principal balance.",
        "label": "Principal Balance",
        "terseLabel": "Note receivable - non current"
       }
      }
     },
     "localname": "PrincipalBalance",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_PromissoryNote": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note",
        "terseLabel": "Promissory note interest"
       }
      }
     },
     "localname": "PromissoryNote",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silo_PromissoryNoteAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory note agreement.",
        "label": "Promissory Note Agreement",
        "terseLabel": "Promissory note agreement note deposit and credit towards acquisition"
       }
      }
     },
     "localname": "PromissoryNoteAgreement",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_PromissoryNoteReceivableAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note Receivable Agreement Member",
        "terseLabel": "Promissory Note Receivable Agreement [Member]",
        "verboseLabel": "Promissory note receivable agreement [Member]"
       }
      }
     },
     "localname": "PromissoryNoteReceivableAgreementMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_PromissoryNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of promissory notes.",
        "label": "Promissory Notes",
        "terseLabel": "Promissory Notes"
       }
      }
     },
     "localname": "PromissoryNotes",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement Member",
        "terseLabel": "Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_PurchaseAgreementsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase agreement, description.",
        "label": "Purchase Agreements Description",
        "terseLabel": "Purchase agreement, description"
       }
      }
     },
     "localname": "PurchaseAgreementsDescription",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_PurchasePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price.",
        "label": "Purchase Price",
        "terseLabel": "Purchase price"
       }
      }
     },
     "localname": "PurchasePrice",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_PursuantTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pursuant Terms.",
        "label": "Pursuant Terms",
        "terseLabel": "Pursuant terms, description"
       }
      }
     },
     "localname": "PursuantTerms",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_ReceivedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The company received shares.",
        "label": "Received Shares",
        "terseLabel": "Received shares (in Shares)"
       }
      }
     },
     "localname": "ReceivedShares",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "silo_RecognizedRevenues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recognized Revenues",
        "terseLabel": "Recognized revenues"
       }
      }
     },
     "localname": "RecognizedRevenues",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_RecoveredAggregateBadDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovered aggregate bad debt.",
        "label": "Recovered Aggregate Bad Debt",
        "terseLabel": "Recovered aggregate bad debt"
       }
      }
     },
     "localname": "RecoveredAggregateBadDebt",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_RecoveredBadDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value recovered bad debt",
        "label": "Recovered Bad Debt",
        "terseLabel": "Recovered bad debt"
       }
      }
     },
     "localname": "RecoveredBadDebt",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_RemainingBalanceOfPromissoryNoteReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining balance of promissory note receivable.",
        "label": "Remaining Balance Of Promissory Note Receivable",
        "terseLabel": "Remaining balance of promissory note receivable"
       }
      }
     },
     "localname": "RemainingBalanceOfPromissoryNoteReceivable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_RemainsCollectibleSettlementAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remains Collectible Settlement Agreement.",
        "label": "Remains Collectible Settlement Agreement",
        "terseLabel": "Remains collectible settlement agreement"
       }
      }
     },
     "localname": "RemainsCollectibleSettlementAgreement",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_RemainsCollectibleSettlementAgreementAmountReserved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remains collectible settlement agreement amount reserved.",
        "label": "Remains Collectible Settlement Agreement Amount Reserved",
        "terseLabel": "Remains collectible settlement agreement amount reserved"
       }
      }
     },
     "localname": "RemainsCollectibleSettlementAgreementAmountReserved",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_RevenueTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Term",
        "terseLabel": "Revenue term"
       }
      }
     },
     "localname": "RevenueTerm",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "silo_ReverseStockSplitVoteDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Stock Split Vote Description",
        "terseLabel": "Reverse stock split vote, description"
       }
      }
     },
     "localname": "ReverseStockSplitVoteDescription",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_RoyaltyPaymentsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Payments Description",
        "terseLabel": "Royalty payments, description"
       }
      }
     },
     "localname": "RoyaltyPaymentsDescription",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Activity In The Company SEquity Investments At Fair Value Abstract"
       }
      }
     },
     "localname": "ScheduleOfActivityInTheCompanySEquityInvestmentsAtFairValueAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "silo_ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Activity In The Companys Equity Investments At Fair Value Table Text Block",
        "terseLabel": "Schedule of activity in the company\u2019s equity investments, at fair value"
       }
      }
     },
     "localname": "ScheduleOfActivityInTheCompanysEquityInvestmentsAtFairValueTableTextBlock",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "silo_ScheduleOfAntiDilutiveNetLossPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Anti Dilutive Net Loss Per Share Abstract"
       }
      }
     },
     "localname": "ScheduleOfAntiDilutiveNetLossPerShareAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "silo_ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Assets And Liabilities Measured At Fair Value On ARecurring Basis Abstract"
       }
      }
     },
     "localname": "ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "silo_ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tablular disclosure of schedule of anti-dilutive net loss per share.",
        "label": "Schedule Of Earnings Per Share Antidilutive Basic And Diluted Table Text Block",
        "terseLabel": "Schedule of anti-dilutive net loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareAntidilutiveBasicAndDilutedTableTextBlock",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "silo_ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Effective Statutory Rate And The Provision For Income Taxes Abstract"
       }
      }
     },
     "localname": "ScheduleOfEffectiveStatutoryRateAndTheProvisionForIncomeTaxesAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of exclusive of value added tax to be amortized.",
        "label": "Schedule Of Exclusive Of Value Added Tax To Be Amortized",
        "terseLabel": "Schedule of exclusive of value added tax to be amortized"
       }
      }
     },
     "localname": "ScheduleOfExclusiveOfValueAddedTaxToBeAmortized",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "silo_ScheduleOfExclusiveOfValueAddedTaxToBeAmortizedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Exclusive Of Value Added Tax To Be Amortized Abstract"
       }
      }
     },
     "localname": "ScheduleOfExclusiveOfValueAddedTaxToBeAmortizedAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "silo_ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Data Of The Company SGain From Sale Of The Nfid Business Abstract"
       }
      }
     },
     "localname": "ScheduleOfFinancialDataOfTheCompanySGainFromSaleOfTheNfidBusinessAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "silo_ScheduleOfInterestExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Interest Expense Abstract"
       }
      }
     },
     "localname": "ScheduleOfInterestExpenseAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "silo_ScheduleOfMilestonePayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of milestone payments.",
        "label": "Schedule Of Milestone Payments",
        "terseLabel": "Schedule of milestone payments"
       }
      }
     },
     "localname": "ScheduleOfMilestonePayments",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "silo_ScheduleOfMilestonePaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Milestone Payments Abstract"
       }
      }
     },
     "localname": "ScheduleOfMilestonePaymentsAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "silo_ScheduleOfNetDeferredTaxAssetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Net Deferred Tax Asset Abstract"
       }
      }
     },
     "localname": "ScheduleOfNetDeferredTaxAssetAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "silo_ScheduleOfNotesReceivableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Notes Receivable Abstract"
       }
      }
     },
     "localname": "ScheduleOfNotesReceivableAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "silo_ScheduleOfNotesReceivableNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Notes Receivable Net Abstract"
       }
      }
     },
     "localname": "ScheduleOfNotesReceivableNetAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "silo_ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Operating Result Of Discontinued Operations Of The Nfid Business Abstract"
       }
      }
     },
     "localname": "ScheduleOfOperatingResultOfDiscontinuedOperationsOfTheNfidBusinessAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "silo_ScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Reconciliation Of Basic And Diluted Net Loss Per Share Abstract"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfBasicAndDilutedNetLossPerShareAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "silo_ScheduleOfShallPayUMB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of shall pay UMB.",
        "label": "Schedule Of Shall Pay UMB",
        "terseLabel": "Schedule of shall pay UMB"
       }
      }
     },
     "localname": "ScheduleOfShallPayUMB",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "silo_ScheduleOfShallPayUmbAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Shall Pay Umb Abstract"
       }
      }
     },
     "localname": "ScheduleOfShallPayUmbAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "silo_ScheduleOfStockOptionsActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stock Options Activities Abstract"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsActivitiesAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "silo_ScheduleOfUMBMinimumRoyaltyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of UMB minimum royalty payments.",
        "label": "Schedule Of UMBMinimum Royalty Payments",
        "terseLabel": "Schedule of UMB minimum royalty payments"
       }
      }
     },
     "localname": "ScheduleOfUMBMinimumRoyaltyPayments",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "silo_ScheduleOfUmbMinimumRoyaltyPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Umb Minimum Royalty Payments Abstract"
       }
      }
     },
     "localname": "ScheduleOfUmbMinimumRoyaltyPaymentsAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "silo_ScheduleOfWarrantActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warrant Activities Abstract"
       }
      }
     },
     "localname": "ScheduleOfWarrantActivitiesAbstract",
     "nsuri": "http://silopharma.com/20220630",
     "xbrltype": "stringItemType"
    },
    "silo_SecuritiesPurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreements Member",
        "terseLabel": "Securities Purchase Agreements [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementsMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_SecuritiesReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Received",
        "terseLabel": "Securities received"
       }
      }
     },
     "localname": "SecuritiesReceived",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_SeriesCConversionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series CConversion Price Member",
        "terseLabel": "Series C Conversion Price [Member]"
       }
      }
     },
     "localname": "SeriesCConversionPriceMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_SeriesCConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series CConvertible Preferred Stock Member",
        "terseLabel": "Series C Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesCConvertiblePreferredStockMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_SeriesCPurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series CPurchase Agreements Member",
        "terseLabel": "Series C Purchase Agreements [Member]"
       }
      }
     },
     "localname": "SeriesCPurchaseAgreementsMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of option outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Option Outstanding Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, ending balance",
        "periodStartLabel": "Aggregate Intrinsic Value, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of aggregated intrinsic value for forfeited shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of aggregate intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value",
        "terseLabel": "Granted pursuant to employment agreement, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Prices",
        "periodEndLabel": "Weighted Average Exercise Price, balance ending",
        "periodStartLabel": "Weighted Average Exercise Price, balance beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "silo_ShareBasedComponsationNumberOfWarrantsExercisableinDollars": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock warrants outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Componsation Number Of Warrants Exercisablein Dollars",
        "terseLabel": "Number of Warrants, Exercisable"
       }
      }
     },
     "localname": "ShareBasedComponsationNumberOfWarrantsExercisableinDollars",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "silo_ShareBasedComponsationNumberOfWarrantsForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under warrants that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Componsation Number Of Warrants Forfeited",
        "terseLabel": "Number of Warrants, Forfeited"
       }
      }
     },
     "localname": "ShareBasedComponsationNumberOfWarrantsForfeited",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "silo_ShareBasedComponsationNumberOfWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share warrants (or share units) granted during the period.",
        "label": "Share Based Componsation Number Of Warrants Granted",
        "terseLabel": "Number of Warrants, Granted"
       }
      }
     },
     "localname": "ShareBasedComponsationNumberOfWarrantsGranted",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "silo_ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Componsation Weighted Average Remaining Contractual Term Years Granted",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Granted",
        "verboseLabel": "Granted/Forfeited, Weighted Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedComponsationWeightedAverageRemainingContractualTermYearsGranted",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Composation Weighted Average Remaining Contractual Term Years Exercisable",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Exercisable"
       }
      }
     },
     "localname": "ShareBasedComposationWeightedAverageRemainingContractualTermYearsExercisable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "silo_ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for forfeited, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Composation Weighted Average Remaining Contractual Term Years Forfeited",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Forfeited"
       }
      }
     },
     "localname": "ShareBasedComposationWeightedAverageRemainingContractualTermYearsForfeited",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards forfeited, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Option Forfeited Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionForfeitedWeightedAverageRemainingContractualTerm",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "silo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term",
        "terseLabel": "Granted pursuant to employment agreement, Weighted Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "silo_SponsoredPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sponsored payment.",
        "label": "Sponsored Payment",
        "terseLabel": "Payment"
       }
      }
     },
     "localname": "SponsoredPayment",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofshallpayUMBTable",
      "http://silopharma.com/role/ScheduleofshallpayUMBTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_SponsoredResearchAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsored Research Agreement Description",
        "terseLabel": "Sponsored research agreement, description"
       }
      }
     },
     "localname": "SponsoredResearchAgreementDescription",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_SponsoredStudyAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsored Study Agreement Description",
        "terseLabel": "Sponsored study agreement, description"
       }
      }
     },
     "localname": "SponsoredStudyAgreementDescription",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_StockIssuedForFutureServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock issued for future services.",
        "label": "Stock Issued For Future Services",
        "terseLabel": "Common stock issued for prepaid services"
       }
      }
     },
     "localname": "StockIssuedForFutureServices",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_StockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Member",
        "terseLabel": "Stock Options [Member]"
       }
      }
     },
     "localname": "StockOptionsMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable",
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable",
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_StockholdersEquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsLineItems",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) - Schedule of stock options activities [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsScheduleofstockoptionsactivitiesLineItems",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable",
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) - Schedule of stock options activities [Table]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsScheduleofstockoptionsactivitiesTable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable",
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_StockholdersEquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) [Table]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsTable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_SublicenseAgreementAmountPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublicense Agreement Amount Paid",
        "terseLabel": "Sublicense agreement amount paid"
       }
      }
     },
     "localname": "SublicenseAgreementAmountPaid",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_SublicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublicense Agreement Member",
        "terseLabel": "Sublicense Agreement [Member]"
       }
      }
     },
     "localname": "SublicenseAgreementMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_SublicenseAmountPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublicense amount paid.",
        "label": "Sublicense Amount Paid",
        "terseLabel": "Sublicense amount paid"
       }
      }
     },
     "localname": "SublicenseAmountPaid",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_SublicenseIncomeDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublicense Income Description",
        "terseLabel": "Sublicense income, description"
       }
      }
     },
     "localname": "SublicenseIncomeDescription",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_SublicenseIncomePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage sublicense income.",
        "label": "Sublicense Income Percentage",
        "terseLabel": "Sublicense income, percentage"
       }
      }
     },
     "localname": "SublicenseIncomePercentage",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silo_SubscriptionAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreements Member",
        "terseLabel": "Subscription Agreements [Member]"
       }
      }
     },
     "localname": "SubscriptionAgreementsMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_SubsequentEventsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsLineItems",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_SubsequentEventsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsTable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_SubsequentFinancingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsequent financing, percentage.",
        "label": "Subsequent Financing Percentage",
        "terseLabel": "Subsequent financing, percentage"
       }
      }
     },
     "localname": "SubsequentFinancingPercentage",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareLineItems",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable",
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofantidilutivenetlosspershareTable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable",
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_TotalOfSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock.",
        "label": "Total Of Shares Of Common Stock",
        "terseLabel": "Total shares of common stock"
       }
      }
     },
     "localname": "TotalOfSharesOfCommonStock",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "silo_TotalOutstandingBalanceReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of total outstanding balance receivable.",
        "label": "Total Outstanding Balance Receivable",
        "terseLabel": "Total outstanding balance receivable"
       }
      }
     },
     "localname": "TotalOutstandingBalanceReceivable",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_TotalSubscriptionReceivableValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of subsription receivable.",
        "label": "Total Subscription Receivable Value",
        "terseLabel": "Total subscription receivable (in Dollars)"
       }
      }
     },
     "localname": "TotalSubscriptionReceivableValue",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_TypeOfAgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type Of Agreement Axis",
        "terseLabel": "Type of Agreement [Axis]"
       }
      }
     },
     "localname": "TypeOfAgreementAxis",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_TypeOfAgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TypeOfAgreement [Domain]"
       }
      }
     },
     "localname": "TypeOfAgreementDomain",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_TypesOfAgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types Of Agreement Axis",
        "terseLabel": "Type of Agreement [Axis]"
       }
      }
     },
     "localname": "TypesOfAgreementAxis",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails",
      "http://silopharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_TypesOfAgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TypesOfAgreement [Domain]"
       }
      }
     },
     "localname": "TypesOfAgreementDomain",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails",
      "http://silopharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_TypesOfAgreementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types Of Agreements Axis",
        "terseLabel": "Types Of Agreements [Axis]"
       }
      }
     },
     "localname": "TypesOfAgreementsAxis",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_TypesOfAgreementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TypesOfAgreements [Domain]"
       }
      }
     },
     "localname": "TypesOfAgreementsDomain",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_UMBPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "UMBPayment",
        "terseLabel": "Payment"
       }
      }
     },
     "localname": "UMBPayment",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_UMBYearDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UMBYear Description",
        "terseLabel": "Year"
       }
      }
     },
     "localname": "UMBYearDescription",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_UnrealizedGainLossOnEquityInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 7.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net unrealized gain (loss) on equity investments (non-controlled/non-affiliated investments).",
        "label": "Unrealized Gain Loss On Equity Investments",
        "terseLabel": "Net unrealized gain (loss) on equity investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnEquityInvestments",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_UpfrontLicenseFees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront license fees.",
        "label": "Upfront License Fees",
        "terseLabel": "Upfront license fees"
       }
      }
     },
     "localname": "UpfrontLicenseFees",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_VendorConcentrationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor Concentrations Member",
        "terseLabel": "Vendor Concentrations [Member]"
       }
      }
     },
     "localname": "VendorConcentrationsMember",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silo_WarrantIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued.",
        "label": "Warrant Issued",
        "terseLabel": "Warrants issued"
       }
      }
     },
     "localname": "WarrantIssued",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "silo_WarrantsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Term",
        "terseLabel": "Warrants term"
       }
      }
     },
     "localname": "WarrantsTerm",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "silo_WeightedAverageRemainingContractualTermYearsGrantedissued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards in granted/issued/ forfeited 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Term Years Grantedissued",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Granted/Issued/ Forfeited"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermYearsGrantedissued",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "silo_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of working capital.",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silo_YearsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Years Description",
        "terseLabel": "Years"
       }
      }
     },
     "localname": "YearsDescription",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "silo_promissoryNoteAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory note amount.",
        "label": "promissory Note Amount",
        "terseLabel": "Promissory note amount"
       }
      }
     },
     "localname": "promissoryNoteAmount",
     "nsuri": "http://silopharma.com/20220630",
     "presentation": [
      "http://silopharma.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leader of board of directors.",
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Board Granted [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r188",
      "r328",
      "r329",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://silopharma.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r264",
      "r303",
      "r341",
      "r343",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r511",
      "r568",
      "r570",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/NotesReceivableDetails",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r264",
      "r303",
      "r341",
      "r343",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r511",
      "r568",
      "r570",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/NotesReceivableDetails",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r188",
      "r328",
      "r329",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://silopharma.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r240",
      "r245",
      "r246",
      "r247",
      "r248",
      "r264",
      "r303",
      "r331",
      "r341",
      "r343",
      "r376",
      "r377",
      "r378",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r511",
      "r568",
      "r570",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/NotesReceivableDetails",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r240",
      "r245",
      "r246",
      "r247",
      "r248",
      "r264",
      "r303",
      "r331",
      "r341",
      "r343",
      "r376",
      "r377",
      "r378",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r511",
      "r568",
      "r570",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/NotesReceivableDetails",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r132",
      "r342",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.",
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r132",
      "r137",
      "r244",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "auth_ref": [
      "r122",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.",
        "label": "Condensed Balance Sheet [Table Text Block]",
        "terseLabel": "Schedule of financial data of the company\u2019s gain from sale of the NFID business"
       }
      }
     },
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": {
     "auth_ref": [
      "r122",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.",
        "label": "Condensed Income Statement [Table Text Block]",
        "terseLabel": "Schedule of operating result of discontinued operations of the NFID business"
       }
      }
     },
     "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r132",
      "r137",
      "r244",
      "r342",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r189",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableInterestBearingInterestRate": {
     "auth_ref": [
      "r460",
      "r461",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables.",
        "label": "Accounts Payable, Interest-Bearing, Interest Rate",
        "terseLabel": "Interest-bearing unsecured"
       }
      }
     },
     "localname": "AccountsPayableInterestBearingInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotePayableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r37",
      "r475"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r384",
      "r385",
      "r386",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket": {
     "auth_ref": [
      "r316",
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned.",
        "label": "Adjustments to Additional Paid in Capital, Fair Value",
        "negatedLabel": "Less: allowance for doubtful accounts"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalMarkToMarket",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofnotesreceivableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r345",
      "r387",
      "r388"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Amortization of prepaid stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based Compensation (in Dollars)",
        "verboseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r43",
      "r198",
      "r216",
      "r218",
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful account and bad debt"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForLoanAndLeaseLossRecoveryOfBadDebts": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recovery of loans and lease receivables which had previously been fully or partially written-off as bad debts.",
        "label": "Allowance for Loan and Lease Loss, Recovery of Bad Debts",
        "terseLabel": "Received payment"
       }
      }
     },
     "localname": "AllowanceForLoanAndLeaseLossRecoveryOfBadDebts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r86",
      "r102",
      "r284",
      "r462"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount to interest expense"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable",
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r25",
      "r118",
      "r179",
      "r182",
      "r186",
      "r214",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r423",
      "r426",
      "r446",
      "r473",
      "r475",
      "r528",
      "r550"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r17",
      "r47",
      "r118",
      "r214",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r423",
      "r426",
      "r446",
      "r473",
      "r475"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet",
      "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r10",
      "r11",
      "r13",
      "r236",
      "r238"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Assets of discontinued operations"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AuctionMarketPreferredSecuritiesSharesOutstanding": {
     "auth_ref": [
      "r33",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of auction market preferred securities shares outstanding.",
        "label": "Auction Market Preferred Securities, Shares Outstanding",
        "terseLabel": "Preferred shares (in Shares)"
       }
      }
     },
     "localname": "AuctionMarketPreferredSecuritiesSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Principles of consolidation"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Organization and Business [Line items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Total assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable",
      "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Business [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalUnits": {
     "auth_ref": [
      "r578"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.",
        "label": "Capital Units, Value",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "CapitalUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r15",
      "r22",
      "r104"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r96",
      "r104",
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS - end of the period",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS - beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r96",
      "r451"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "NET CHANGE IN CASH AND CASH EQUIVALENTS:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "Federal deposit insurance corporation"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r31",
      "r33",
      "r34",
      "r115",
      "r118",
      "r142",
      "r146",
      "r151",
      "r154",
      "r156",
      "r162",
      "r163",
      "r164",
      "r214",
      "r250",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r300",
      "r301",
      "r305",
      "r309",
      "r316",
      "r446",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet",
      "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable",
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable0",
      "http://silopharma.com/role/ShareholdersEquityType2or3",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Warrant to purchase shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Granted warrants to purchase shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r326",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r57",
      "r534",
      "r556"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitment and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r249",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares of common stock reserved and avail for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r124",
      "r125",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of subscription receivable from investors who have been allocated common stock.",
        "label": "Common Stock, Share Subscribed but Unissued, Subscriptions Receivable",
        "terseLabel": "Subscription receivable (in Dollars)"
       }
      }
     },
     "localname": "CommonStockShareSubscribedButUnissuedSubscriptionsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r34",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r34",
      "r475"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock value"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r170",
      "r171",
      "r188",
      "r444",
      "r445",
      "r576",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "CONCENTRATIONS"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/Concentrations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r170",
      "r171",
      "r188",
      "r444",
      "r445",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionContractorLiquidityCharacteristic": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of liquidity characteristic of construction contractor's asset and liability.",
        "label": "Construction Contractor, Liquidity Characteristic",
        "terseLabel": "Liquidity damage, description"
       }
      }
     },
     "localname": "ConstructionContractorLiquidityCharacteristic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r107",
      "r108",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Convertible common stock"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "auth_ref": [
      "r32",
      "r33",
      "r317",
      "r319",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of conversion terms for preferred stock.",
        "label": "Preferred Stock, Convertible, Terms",
        "terseLabel": "Convertible preferred stock, description"
       }
      }
     },
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r82",
      "r118",
      "r214",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r446"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "COST OF REVENUES"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r169",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRefundableFeesProceeds": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from customers for revenue related transactions that are refundable to the customers and do not meet the criteria for revenue recognition.",
        "label": "Customer Refundable Fees, Proceeds",
        "terseLabel": "Non refundable fees"
       }
      }
     },
     "localname": "CustomerRefundableFeesProceeds",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionByUniqueDescriptionAxis": {
     "auth_ref": [
      "r107",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.",
        "label": "Debt Conversion Description [Axis]"
       }
      }
     },
     "localname": "DebtConversionByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofexclusiveofvalueaddedtaxtobeamortizedTable",
      "http://silopharma.com/role/ScheduleofshallpayUMBTable",
      "http://silopharma.com/role/ScheduleofshallpayUMBTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r107",
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Common stock issued for conversion of Series C preferred stock"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r114",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r278",
      "r285",
      "r286",
      "r288",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "NOTE PAYABLE"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotePayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r117",
      "r122",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r291",
      "r292",
      "r293",
      "r294",
      "r465",
      "r529",
      "r530",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable",
      "http://silopharma.com/role/ScheduleofUMBminimumroyaltypaymentsTable0",
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable",
      "http://silopharma.com/role/ScheduleofmilestonepaymentsTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r263",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price per share (in Dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentDescription": {
     "auth_ref": [
      "r26",
      "r28",
      "r317",
      "r529",
      "r530",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.",
        "label": "Debt Instrument, Description",
        "terseLabel": "Common stock, description"
       }
      }
     },
     "localname": "DebtInstrumentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r261",
      "r291",
      "r292",
      "r463",
      "r465",
      "r466"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal balance",
        "verboseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotePayableDetails",
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.",
        "label": "Debt Instrument, Increase, Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotePayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r54",
      "r281",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotePayableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.",
        "label": "Debt Instrument, Interest Rate, Increase (Decrease)",
        "terseLabel": "Increased interest rate per annum"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r54",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Accrued interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r55",
      "r264",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity date",
        "verboseLabel": "Expired term"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans).",
        "label": "Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense",
        "terseLabel": "Deferred compensation balance (in Dollars)",
        "verboseLabel": "Deferred compensation balance"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": {
     "auth_ref": [
      "r330",
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement.",
        "label": "Deferred Compensation Arrangement with Individual, Compensation Expense",
        "terseLabel": "Fair value of the unvested stock options (in Dollars)",
        "verboseLabel": "Fair value of the unvested stock option"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r102",
      "r119",
      "r403",
      "r409",
      "r410",
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Offering expenses (in Dollars)"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred revenue arrangement.",
        "label": "Deferred Revenue Arrangement Type [Axis]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue - current portion",
        "verboseLabel": "Deferred revenue \u2013 current portion"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenue - long-term portion"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.",
        "label": "Deferred Revenue, Revenue Recognized",
        "terseLabel": "Recognized revenues"
       }
      }
     },
     "localname": "DeferredRevenueRevenueRecognized1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredSalesCommission": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of advanced commission payments.",
        "label": "Deferred Sales Commission",
        "terseLabel": "Commission on sales"
       }
      }
     },
     "localname": "DeferredSalesCommission",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofnetdeferredtaxassetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r401",
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofnetdeferredtaxassetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of credit risk valuation adjustment to derivative liabilities to properly reflect the credit quality of the entity.",
        "label": "Derivative Credit Risk Valuation Adjustment, Derivative Liabilities",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed interest rate related to the interest rate derivative.",
        "label": "Derivative, Fixed Interest Rate",
        "terseLabel": "Interest rate per annum percentage"
       }
      }
     },
     "localname": "DerivativeFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": {
     "auth_ref": [
      "r3",
      "r5",
      "r7",
      "r12"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.",
        "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax",
        "terseLabel": "Gain from sale of assets of discontinued operations, net of tax"
       }
      }
     },
     "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r72",
      "r559"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "terseLabel": "Loss from discontinued operations, net of tax"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share",
        "terseLabel": "From discontinued operations (in Dollars per share)"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share",
        "terseLabel": "From discontinued operations (in Dollars per share)"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r12",
      "r393",
      "r408",
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Loss from discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r9",
      "r13"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable",
      "http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": {
     "auth_ref": [
      "r9",
      "r13"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)",
        "terseLabel": "Gross profit (loss)"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable",
      "http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r10",
      "r236",
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "terseLabel": "Assets of discontinued operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r14",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "DISPOSAL OF THE DISCONTINUED OPERATIONS OF THE NFID BUSINESS"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsPreferredStockCash": {
     "auth_ref": [
      "r322",
      "r546"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Preferred Stock, Cash",
        "terseLabel": "Deemed dividend (in Dollars)"
       }
      }
     },
     "localname": "DividendsPreferredStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "NET INCOME (LOSS) PER COMMON SHARE AVAILABLE TO COMMON STOCKHOLDERS:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r74",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r139",
      "r142",
      "r154",
      "r155",
      "r156",
      "r159",
      "r160",
      "r436",
      "r437",
      "r541",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Continuing operations - basic (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r74",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r142",
      "r154",
      "r155",
      "r156",
      "r159",
      "r160",
      "r436",
      "r437",
      "r541",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Continuing operations - diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r157",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r394",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable_Parentheticals"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employee Benefits and Share-Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r65",
      "r66",
      "r67",
      "r124",
      "r125",
      "r126",
      "r128",
      "r134",
      "r136",
      "r161",
      "r215",
      "r316",
      "r322",
      "r384",
      "r385",
      "r386",
      "r405",
      "r406",
      "r435",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r468",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable",
      "http://silopharma.com/role/ShareholdersEquityType2or3",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r23",
      "r180",
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "periodEndLabel": "Balance, end of the year",
        "periodStartLabel": "Balance, beginning of the year"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ExcessStockSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of excess stock shares permitted to be issued.",
        "label": "Excess Stock, Shares Authorized",
        "terseLabel": "Shares authorized"
       }
      }
     },
     "localname": "ExcessStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_FDICIndemnificationAssetCashPaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decreases to the indemnification asset due to cash payments received relating to loss sharing agreements with the Federal Deposit Insurance Corporation (FDIC).",
        "label": "FDIC Indemnification Asset, Cash Payments Received",
        "terseLabel": "FDIC cash limits"
       }
      }
     },
     "localname": "FDICIndemnificationAssetCashPaymentsReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r276",
      "r291",
      "r292",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r439",
      "r483",
      "r484",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
      "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r276",
      "r332",
      "r333",
      "r338",
      "r340",
      "r439",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
      "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r276",
      "r291",
      "r292",
      "r332",
      "r333",
      "r338",
      "r340",
      "r439",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
      "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r276",
      "r291",
      "r292",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r439",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
      "http://silopharma.com/role/ScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": {
     "auth_ref": [
      "r441",
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings",
        "terseLabel": "Net realized gain"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r217",
      "r221",
      "r222",
      "r223",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r287",
      "r314",
      "r433",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLosses": {
     "auth_ref": [
      "r43",
      "r194",
      "r216",
      "r218",
      "r220",
      "r532",
      "r596",
      "r598",
      "r599"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable, Allowance for Credit Loss",
        "negatedLabel": "Less: allowance for doubtful accounts"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofnotesreceivablenetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r447",
      "r448",
      "r449",
      "r450"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r102",
      "r235",
      "r237"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedLabel": "Gain from disposal of assets from discontinued operations"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "terseLabel": "Gain on forgiveness of PPP note payable"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r84",
      "r102",
      "r204"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "terseLabel": "Net realized gain (loss) on equity investments"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfDerivatives": {
     "auth_ref": [
      "r102",
      "r543"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.",
        "label": "Gain (Loss) on Sale of Derivatives",
        "negatedLabel": "Equity shares earned for lock up agreement"
       }
      }
     },
     "localname": "GainLossOnSaleOfDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of other assets.",
        "label": "Gain (Loss) on Disposition of Other Assets",
        "terseLabel": "Gain from sale of NFID business"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable",
      "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainOnSaleOfInvestments": {
     "auth_ref": [
      "r77",
      "r78",
      "r102",
      "r537",
      "r563"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale.",
        "label": "Gain on Sale of Investments",
        "terseLabel": "Equity investment Sold"
       }
      }
     },
     "localname": "GainOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r102",
      "r295",
      "r296"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Loss on debt extinguishment",
        "verboseLabel": "Loss on debt extinguishment (in Dollars)"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnRestructuringOfDebt": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.",
        "label": "Gains (Losses) on Restructuring of Debt",
        "negatedLabel": "Gain on forgiveness of PPP note payable and accrued interest"
       }
      }
     },
     "localname": "GainsLossesOnRestructuringOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralInsuranceExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).",
        "label": "General Insurance Expense",
        "terseLabel": "Insurance expense"
       }
      }
     },
     "localname": "GeneralInsuranceExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r79",
      "r118",
      "r179",
      "r181",
      "r184",
      "r185",
      "r187",
      "r214",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r446"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "GROSS PROFIT"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r80",
      "r103",
      "r129",
      "r130",
      "r131",
      "r132",
      "r152",
      "r156",
      "r421"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "INCOME (LOSS) FROM CONTINUING OPERATIONS"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r70",
      "r179",
      "r181",
      "r184",
      "r185",
      "r187",
      "r526",
      "r538",
      "r545",
      "r564"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE PROVISION FOR INCOME TAXES"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r68",
      "r74",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r142",
      "r154",
      "r155",
      "r437",
      "r535",
      "r539",
      "r541",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "From continuing operations (in Dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r68",
      "r74",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r142",
      "r154",
      "r155",
      "r156",
      "r437",
      "r541",
      "r558",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "From continuing operations (in Dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r12",
      "r13",
      "r416",
      "r559"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Loss from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r12",
      "r422"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "LOSS FROM DISCONTINUED OPERATIONS"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r72",
      "r74",
      "r146",
      "r154",
      "r155",
      "r541",
      "r559",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Discontinued operations - basic (in Dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r146",
      "r154",
      "r155",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Discontinued operations - diluted"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r71",
      "r102",
      "r177",
      "r213",
      "r536",
      "r557"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Net realized gain on equity investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r120",
      "r395",
      "r396",
      "r400",
      "r407",
      "r413",
      "r417",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r121",
      "r135",
      "r136",
      "r178",
      "r393",
      "r408",
      "r414",
      "r565"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes",
        "terseLabel": "Total provision for income tax",
        "verboseLabel": "Provision for income tax"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement",
      "http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable",
      "http://silopharma.com/role/ScheduleofnetdeferredtaxassetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r391",
      "r392",
      "r396",
      "r397",
      "r399",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax (benefit) liability at U.S. statutory rate of 21%"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "Income tax (benefit) liability \u2013 state"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofeffectivestatutoryrateandtheprovisionforincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r99",
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPayablesToBrokerDealers": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations incurred arising from transactions with broker-dealers, such as amounts due on margin and unsettled cash transactions; includes payables to brokers, dealers and clearing organizations.",
        "label": "Increase (Decrease) in Payable to Broker-Dealer and Clearing Organization",
        "terseLabel": "Insurance payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInPayablesToBrokerDealers",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Interest receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r156",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Options (in Shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InsuranceServicesRevenue": {
     "auth_ref": [
      "r566"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from insurance services, including net premiums earned, gain on sale of insurance block, agency management fees and insurance contract fees and commissions.",
        "label": "Insurance Services Revenue",
        "terseLabel": "Recognized revenue"
       }
      }
     },
     "localname": "InsuranceServicesRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r69",
      "r176",
      "r459",
      "r464",
      "r544"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotePayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r86",
      "r282",
      "r290",
      "r293",
      "r294"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 10.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 11.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.",
        "label": "Interest Expense, Related Party",
        "negatedLabel": "Interest expense - related party"
       }
      }
     },
     "localname": "InterestExpenseRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Add: interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income (expense), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r95",
      "r98",
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all derivatives not designated as hedging instruments.",
        "label": "Interest Rate Derivative Instruments Not Designated as Hedging Instruments at Fair Value, Net",
        "terseLabel": "Common stock grant date fair value"
       }
      }
     },
     "localname": "InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of noncurrent interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable, Noncurrent",
        "terseLabel": "Interest receivable (in Dollars)"
       }
      }
     },
     "localname": "InterestReceivableNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r16",
      "r44",
      "r475"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable",
      "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentInterestRate": {
     "auth_ref": [
      "r206",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of interest on investment.",
        "label": "Investment Interest Rate",
        "terseLabel": "Bears interest rate"
       }
      }
     },
     "localname": "InvestmentInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_InvestmentMaturityDate": {
     "auth_ref": [
      "r205",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity date of investment, in YYYY-MM-DD format.",
        "label": "Investment Maturity Date",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "InvestmentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_InvestmentOwnedAtCost": {
     "auth_ref": [
      "r577"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of the investment.",
        "label": "Investment Owned, at Cost",
        "terseLabel": "Basic investment cost"
       }
      }
     },
     "localname": "InvestmentOwnedAtCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LayawaySaleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of deferred revenue by arrangement wherein a retail customer pays installments of cash over a period of time, which will generally be taken into income upon delivery to the customer, and typically upon payment of the final installment.",
        "label": "Layaway Sale [Member]",
        "terseLabel": "Six-monthly installments [Member]"
       }
      }
     },
     "localname": "LayawaySaleMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r51",
      "r118",
      "r183",
      "r214",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r424",
      "r426",
      "r427",
      "r446",
      "r473",
      "r474"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r42",
      "r118",
      "r214",
      "r446",
      "r475",
      "r531",
      "r554"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r53",
      "r118",
      "r214",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r424",
      "r426",
      "r427",
      "r446",
      "r473",
      "r474",
      "r475"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet",
      "http://silopharma.com/role/ScheduleoffinancialdataofthecompanysgainfromsaleoftheNFIDbusinessTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r28",
      "r29",
      "r118",
      "r214",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r424",
      "r426",
      "r427",
      "r446",
      "r473",
      "r474"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total Long Term Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "NOTES RECEIVABLE"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LoansPayableCurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.",
        "label": "Loans Payable, Current",
        "terseLabel": "Insurance payable"
       }
      }
     },
     "localname": "LoansPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for bad debt, of increase (decrease) in loan receivables held-for-sale that are not part of a disposal group.",
        "label": "Loans Receivable Held-for-sale, Reconciliation to Cash Flow, Period Increase (Decrease)",
        "terseLabel": "Bad debt allowance"
       }
      }
     },
     "localname": "LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturityDate": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity date of long-term debt, in YYYY-MM-DD format.",
        "label": "Long-Term Debt, Maturity Date",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "LongTermDebtMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessDetails",
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.",
        "label": "Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate",
        "terseLabel": "Bearing interest rate percentage"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingVariableInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/DisposaloftheDiscontinuedOperationsoftheNfidBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Note payable - long-term portion"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ManagementFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of the unpaid portion of the fee payable to the managing member or general partner for management of the fund or trust.",
        "label": "Management Fee Payable",
        "terseLabel": "Total fee"
       }
      }
     },
     "localname": "ManagementFeePayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gain",
        "verboseLabel": "Unrealized (loss) gain"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable",
      "http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInContinuingOperations": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.",
        "label": "Net Cash Provided by (Used in) Continuing Operations",
        "terseLabel": "Cash in operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "NET CASH PROVIDED BY INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r96",
      "r100",
      "r103"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r13",
      "r62",
      "r63",
      "r67",
      "r73",
      "r103",
      "r118",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r135",
      "r136",
      "r152",
      "r179",
      "r181",
      "r184",
      "r185",
      "r187",
      "r214",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r437",
      "r446",
      "r540",
      "r560"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "NET INCOME (LOSS)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow",
      "http://silopharma.com/role/ConsolidatedIncomeStatement",
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAllocatedToGeneralPartners": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of net income allocated to general partners.",
        "label": "Net Income (Loss) Allocated to General Partners",
        "terseLabel": "Net loss per common share \u2013 diluted"
       }
      }
     },
     "localname": "NetIncomeLossAllocatedToGeneralPartners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r62",
      "r63",
      "r67",
      "r135",
      "r136",
      "r425",
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132",
      "r139",
      "r140",
      "r153",
      "r156",
      "r179",
      "r181",
      "r184",
      "r185",
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r141",
      "r147",
      "r148",
      "r149",
      "r150",
      "r153",
      "r156"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "NET INCOME (LOSS) AVAILABLE TO COMMON STOCKHOLDERS"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "OTHER INCOME (EXPENSE):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r190",
      "r191",
      "r533"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Principal balance"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r28",
      "r530",
      "r551"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Received amount"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotePayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Note payable - current portion"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableGross": {
     "auth_ref": [
      "r36",
      "r200",
      "r216",
      "r222",
      "r224",
      "r226",
      "r227",
      "r595",
      "r596",
      "r597"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.",
        "label": "Financing Receivable, before Allowance for Credit Loss",
        "terseLabel": "Principal amounts of notes receivable at beginning of the year",
        "verboseLabel": "Principal amounts of notes receivable"
       }
      }
     },
     "localname": "NotesReceivableGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofnotesreceivableTable",
      "http://silopharma.com/role/ScheduleofnotesreceivablenetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Notes Receivable [Member]",
        "terseLabel": "Notes Receivable [Member]"
       }
      }
     },
     "localname": "NotesReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesReceivableNet": {
     "auth_ref": [
      "r190",
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.",
        "label": "Financing Receivable, after Allowance for Credit Loss",
        "terseLabel": "Notes receivable \u2013 non-current"
       }
      }
     },
     "localname": "NotesReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofnotesreceivableTable",
      "http://silopharma.com/role/ScheduleofnotesreceivablenetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "OPERATING EXPENSES:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r179",
      "r181",
      "r184",
      "r185",
      "r187"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING LOSS FROM CONTINUING OPERATIONS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r123",
      "r138",
      "r175",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND BUSINESS"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/OrganizationandBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r46",
      "r475"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets (in Dollars)"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Note receivable - non-current, including interest receivable"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the liabilities, classified as other, for deferred compensation arrangements payable after one year or the operating cycle, if longer.",
        "label": "Other Deferred Compensation Arrangements, Liability, Classified, Noncurrent",
        "terseLabel": "Issuance of deferred compensation balance (in Dollars)"
       }
      }
     },
     "localname": "OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r567"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermDebt": {
     "auth_ref": [
      "r28",
      "r530",
      "r551"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt classified as other.",
        "label": "Other Long-Term Debt",
        "terseLabel": "Deferred revenue long-term"
       }
      }
     },
     "localname": "OtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 9.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNotesPayable": {
     "auth_ref": [
      "r28",
      "r530",
      "r551"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term notes payable classified as other.",
        "label": "Other Notes Payable",
        "terseLabel": "Note payable"
       }
      }
     },
     "localname": "OtherNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotePayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedLabel": "Total operating and other non-operating expenses"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable",
      "http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOwnershipInterestsOfferingCosts": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of offering costs allocated to the other unit holders.",
        "label": "Other Ownership Interests, Offering Costs",
        "terseLabel": "Other offering expenses (in Dollars)"
       }
      }
     },
     "localname": "OtherOwnershipInterestsOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r45",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid expense and other current assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Total Notes receivable, net"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofnotesreceivableTable",
      "http://silopharma.com/role/ScheduleofnotesreceivablenetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r390"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Other Research and Development Expense",
        "terseLabel": "Research and development cost"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireReceivables": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the purchase of all receivables.",
        "label": "Payments to Acquire Receivables",
        "terseLabel": "Total receivable"
       }
      }
     },
     "localname": "PaymentsToAcquireReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockConversionBasis": {
     "auth_ref": [
      "r33",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.",
        "label": "Preferred Stock, Conversion Basis",
        "terseLabel": "Preferred stock conversion, description"
       }
      }
     },
     "localname": "PreferredStockConversionBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion of preferred stock.",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "terseLabel": "Designated shares of preferred stock"
       }
      }
     },
     "localname": "PreferredStockConvertibleSharesIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "auth_ref": [],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "negatedLabel": "Deemed dividend"
       }
      }
     },
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r33",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "auth_ref": [
      "r299",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.",
        "label": "Preferred Stock, Redemption Price Per Share",
        "terseLabel": "Preferred stock liquidation value price (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockRedemptionPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r33",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "verboseLabel": "Share issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "verboseLabel": "Share outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r33",
      "r475"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value, 5,000,000 shares authorized",
        "verboseLabel": "Redemption value (in Dollars)"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets - current",
        "verboseLabel": "Prepaid expense leaving a prepaid asset"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "auth_ref": [
      "r25",
      "r527",
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "terseLabel": "Prepaid expenses and other current assets \u2013 non-current"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Prepaid Expense, Noncurrent",
        "terseLabel": "Prepaid expenses - non-current"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseOtherNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Prepaid Expense Other, Noncurrent",
        "terseLabel": "Prepaid expenses non-current"
       }
      }
     },
     "localname": "PrepaidExpenseOtherNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollectionOfNotesReceivable": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Collection of Notes Receivable",
        "terseLabel": "Collection on note receivable written off prior to 2019"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfNotesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from sale of common stock",
        "verboseLabel": "Proceeds from issuance of common stock (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Net proceeds from sale of preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Warrant value (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Total net proceeds (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from note payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds from Related Party Debt",
        "terseLabel": "Proceeds from note payable - related party"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "auth_ref": [],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.",
        "label": "Proceeds from (Repayments of) Related Party Debt",
        "terseLabel": "Repayment of note payable - related party"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "negatedLabel": "Sales",
        "negatedTerseLabel": "Sales at original cost"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable",
      "http://silopharma.com/role/ScheduleofactivityinthecompanysequityinvestmentsatfairvalueTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "terseLabel": "Net proceeds from sale of equity investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Product sales, net"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable",
      "http://silopharma.com/role/ScheduleofoperatingresultofdiscontinuedoperationsoftheNFIDbusinessTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r580",
      "r581"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r75",
      "r219"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Bad debt (recovery) expense"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r475",
      "r555",
      "r579"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Notes receivable, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RecognitionOfDeferredRevenue": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Recognition of Deferred Revenue",
        "terseLabel": "Deferred revenue current portion"
       }
      }
     },
     "localname": "RecognitionOfDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recorded unconditional purchase obligation to be paid in remainder of current fiscal year.",
        "label": "Recorded Unconditional Purchase Obligation, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Company paid second payment"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r339",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r339",
      "r469",
      "r472",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments of Related Party Debt",
        "negatedLabel": "Repayment of advance from a related party"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r390",
      "r512",
      "r586"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development cost"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement",
      "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r39",
      "r322",
      "r475",
      "r553",
      "r574",
      "r575"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet",
      "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r124",
      "r125",
      "r126",
      "r128",
      "r134",
      "r136",
      "r215",
      "r384",
      "r385",
      "r386",
      "r405",
      "r406",
      "r435",
      "r571",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsUnappropriated": {
     "auth_ref": [
      "r38",
      "r116",
      "r552"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A segregation of retained earnings which is available for dividend distribution. Earnings not paid out as dividends but instead reinvested in the core business or used to pay off debt. Unappropriated profit is part of shareholder equity. Also called cumulative distributions or earned surplus or accumulated earnings or unappropriated profit.",
        "label": "Retained Earnings, Unappropriated",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsUnappropriated",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Gross proceeds issued",
        "verboseLabel": "Gross proceeds (in Dollars)"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails",
      "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of aggregate shares"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of notes receivable",
        "verboseLabel": "Schedule of notes receivable net"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of net deferred tax asset"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of basic and diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective statutory rate and the provision for income taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/FairValueofFinancialInstrumentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.",
        "label": "Schedule of Interest Rate Derivatives [Table Text Block]",
        "terseLabel": "Schedule of interest expense"
       }
      }
     },
     "localname": "ScheduleOfInterestRateDerivativesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotePayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r354",
      "r369",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock options activities"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r326",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of warrant activities"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r31",
      "r33",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock [Member]",
        "verboseLabel": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r31",
      "r33",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Convertible Preferred Stock [Member]",
        "netLabel": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock",
        "verboseLabel": "Series B"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet",
      "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://silopharma.com/role/ShareholdersEquityType2or3",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [
      "r31",
      "r33",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C preferred stock.",
        "label": "Series C Preferred Stock [Member]",
        "netLabel": "Series C Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Convertible Preferred Stock",
        "verboseLabel": "Series C"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet",
      "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable",
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable0",
      "http://silopharma.com/role/ShareholdersEquityType2or3",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r348",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description",
        "terseLabel": "Employment agreement, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted/Forfeited, Number of Warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Warrants, ending balance",
        "periodStartLabel": "Number of Warrants, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Exercise Price, ending balance",
        "periodStartLabel": "Weighted Average Exercise Price, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date price per warrant (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options, Exercisable,"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable",
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable",
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Number of Options, Granted/Issued/ Forfeited",
        "verboseLabel": "Number of Options, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable",
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted pursuant to employment agreement, Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted as incentives, Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, balance ending",
        "periodStartLabel": "Aggregate Intrinsic Value, balance beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options, balance ending",
        "periodStartLabel": "Number of Options, beginning balance outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, balance ending",
        "periodStartLabel": "Weighted Average Exercise Price, balance beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, balance ending",
        "periodStartLabel": "Aggregate Intrinsic Value, balance beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "terseLabel": "Stock option",
        "verboseLabel": "Stock option (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted/Issued/ Forfeited",
        "verboseLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable",
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "netLabel": "Granted/Forfeited, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "verboseLabel": "Granted pursuant to employment agreement, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could acquire or could have acquired the underlying shares with respect to any other type of change in shares reserved for issuance.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted as incentives, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock": {
     "auth_ref": [
      "r344",
      "r346",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence.",
        "label": "Share-Based Payment Arrangement, Forfeiture [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationForfeituresPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.",
        "label": "Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Stock price (in Dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Aggregate Intrinsic Value, Forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable",
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), balance ending",
        "verboseLabel": "Weighted Average Remaining Contractual Term (Years), ending balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable",
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Number of Options, balance ending",
        "periodStartLabel": "Number of Options, balance beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, ending balance",
        "periodStartLabel": "Weighted Average Exercise Price, beginning balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), balance beginning",
        "verboseLabel": "Weighted Average Remaining Contractual Term (Years), beginning balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable",
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of stock option (in Dollars)",
        "verboseLabel": "Fair value of stock option"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Fair value of unvested stock option"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable",
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Aggregate shares (in Shares)",
        "verboseLabel": "Shares of common stock"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails",
      "http://silopharma.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r111",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r31",
      "r33",
      "r34",
      "r115",
      "r118",
      "r142",
      "r146",
      "r151",
      "r154",
      "r156",
      "r162",
      "r163",
      "r164",
      "r214",
      "r250",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r300",
      "r301",
      "r305",
      "r309",
      "r316",
      "r446",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet",
      "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable",
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable0",
      "http://silopharma.com/role/ShareholdersEquityType2or3",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r60",
      "r65",
      "r66",
      "r67",
      "r124",
      "r125",
      "r126",
      "r128",
      "r134",
      "r136",
      "r161",
      "r215",
      "r316",
      "r322",
      "r384",
      "r385",
      "r386",
      "r405",
      "r406",
      "r435",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r468",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable",
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable",
      "http://silopharma.com/role/ScheduleofstockoptionsactivitiesTable0",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable0",
      "http://silopharma.com/role/ShareholdersEquityType2or3",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet",
      "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r161",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet",
      "http://silopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of preferred stock and warrants for common stock issued.",
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "terseLabel": "Deemed dividend upon issuance of preferred stock"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r107",
      "r108",
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Common stock warrants granted for services"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r59",
      "r279",
      "r316",
      "r317",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Common stock issued for conversion of Series C preferred stock (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r33",
      "r34",
      "r316",
      "r322",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan",
        "terseLabel": "Common Stock issued in connection with employment agreement (in Shares)",
        "verboseLabel": "Aggregate number of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r33",
      "r34",
      "r316",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Common Stock issued for cash, net of offering cost (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Series C preferred stock issued for cash, net of offering cost (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r33",
      "r34",
      "r316",
      "r322",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Aggregate of incentive stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r60",
      "r316",
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Common stock issued for conversion of Series C preferred stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r33",
      "r34",
      "r316",
      "r322",
      "r389"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Employee Stock Ownership Plan",
        "terseLabel": "Common Stock issued in connection with employment agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Common stock warrants granted for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r33",
      "r34",
      "r316",
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Common Stock issued for cash, net of offering cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Series C preferred stock issued for cash, net of offering cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r33",
      "r34",
      "r322",
      "r370"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock options issued as stock based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture",
        "terseLabel": "Stock-based compensation (in Dollars)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r60",
      "r316",
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock option value (in Dollars)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "terseLabel": "Authorized number of shares"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r34",
      "r40",
      "r41",
      "r118",
      "r201",
      "r214",
      "r446",
      "r475"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet",
      "http://silopharma.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r116",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r322",
      "r327",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventDescription": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.",
        "label": "Subsequent Event, Description",
        "terseLabel": "Subsequent event, description"
       }
      }
     },
     "localname": "SubsequentEventDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r458",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r458",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r476",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental Disclosure of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalDeferredPurchasePrice": {
     "auth_ref": [
      "r107",
      "r108",
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.",
        "label": "Supplemental Deferred Purchase Price",
        "terseLabel": "Purchase price",
        "verboseLabel": "Aggregate purchase price"
       }
      }
     },
     "localname": "SupplementalDeferredPurchasePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/NotesReceivableDetails",
      "http://silopharma.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for agreement to continue an employee's salary after termination of employment (but before retirement) including death, disability, or other event. For example, a company may agree to continue a disabled employee's salary for six months.",
        "label": "Supplemental Unemployment Benefits, Salary Continuation",
        "terseLabel": "Salary was increased"
       }
      }
     },
     "localname": "SupplementalUnemploymentBenefitsSalaryContinuation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.",
        "label": "Temporary Equity, Accretion to Redemption Value, Adjustment",
        "terseLabel": "Redemption value (in Dollars)"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r192",
      "r193",
      "r196",
      "r197",
      "r199",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Notes Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r287",
      "r314",
      "r433",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://silopharma.com/role/ConsolidatedCashFlow": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Net unrealized loss (gain) loss on equity investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r172",
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense for depreciation and amortization of regulated operation.",
        "label": "Utilities Operating Expense, Depreciation and Amortization",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "UtilitiesOperatingExpenseDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of and reason for the change during the period in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Explanation of Change",
        "terseLabel": "Valuation allowance on deferred tax asset benefit, description"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetExplanationOfChange",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VentureCapitalGainsLossesNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on venture capital activities. Includes venture capital revenue, fair value adjustments, interest and dividends, investment gain (loss) and fee or other income from venture capital activities.",
        "label": "Venture Capital Gain (Loss), Net",
        "terseLabel": "Company had a capital"
       }
      }
     },
     "localname": "VentureCapitalGainsLossesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant [Member]",
        "verboseLabel": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable",
      "http://silopharma.com/role/ScheduleofantidilutivenetlosspershareTable0",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable",
      "http://silopharma.com/role/ScheduleofwarrantactivitiesTable0",
      "http://silopharma.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Weighted average common shares outstanding, Diluted (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r141",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding \u2013 diluted (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r139",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in Shares)",
        "verboseLabel": "Weighted average common shares outstanding \u2014 basic (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement",
      "http://silopharma.com/role/ScheduleofreconciliationofbasicanddilutednetlosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://silopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(4)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "79",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "80",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3)(ii))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(m)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126966630&loc=d3e41228-113958"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=29642582&loc=d3e27862-108397"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=29642582&loc=d3e27881-108397"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991581-234733"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.13(h))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4)(ii))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.1,4)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r587": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r588": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r589": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r591": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r592": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r593": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r594": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r595": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1404"
  },
  "r596": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(1)"
  },
  "r597": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(2)"
  },
  "r598": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(3)"
  },
  "r599": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1405"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "11",
   "Subsection": "03"
  },
  "r601": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001213900-22-057479-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-22-057479-xbrl.zip
M4$L#!!0    ( .M1/E6SU2K8##D$ )A,)0 <    96$Q-C4Y.#<M<S%A-%]S
M:6QO<&AA<FUA+FAT;>Q]:7?;2)+M=_P*//=TC^L<B-;BM1:_(TMRE:9M22/)
M55WO2Q\02)(H@P ;BV36KW^QY0(0E 1;6TGL,]-MD2"0R(R,C.7&C1__[Y=I
MZI^IHDSR[*?_WABL_[>OLBB/DVS\TW]OG^SL[__W_WWK_3BIX#*X-"N_CZOB
MIR>3JII]_^S9^?GYX,NP2 =Y,7X&7SRKYC/U;'-]<WUM?6-M<^.)_";Y4G7_
M)LG2)%/_>G?\X5E5A%DYRHMI6,%8Y":;:QN;SDW62A4U;@1_#\;YV87WV7BQ
MMOYZ;<L,!J[\W#V:S?7UK6?X]3 LE;X\5HFYFJ[4SX0O<)1V?&7^?'/CU06W
MEBOT#\HDS<W5^,=L$L*P!U$^I1NOO]Q:U]?BC9*+;IV559A%9M1PCUD9V5_(
MWX4J\[J(5(D/L1.[[,8;6\[,FJ&4S8&<;^EA;#S[U\</)]%$3<.U]H#J<@V%
MHS0_'87ED'ZHOVE,9EE4BU?"AXV+OJ07S,B_/L!"NM,7M]91KGSYC+]T!CH.
MPUGG./&+Y@C*KYB*+PL2*+_;>//FS3/Z5BY=?A%NR"=O?YRH,'[K^?B?'ZND
M2M5;_\=G_ _/^W&JJM"/\JQ2&<QFI;Y4S^AW/MYU3?VG3LY^>K+#WZ^=PAH\
M>09[_1G?],=A'L_?_A@G9WY9S5/UTY,17/F]O[$^J_S39*I*_T"=^\?Y-,P"
M_B#P3U21C)[0KW  S_!_?YSUO<$/_C0LQDGVO8^7KO_@X]#7PC09PT<1#%85
M\(RAONW:9Z5FW_M54:LG;[=+?Y2D*O;/DVKB5Q,%MXSJ(JD2>%Z8Q?[>EV@2
M9F/E[>33:5*BXO/A_T[4K%+3H2K\S?7 QS4>_/AL^/;'9S-YFZ]_&7?T13*>
M5/K]UJI\1N]H/ACF595/Z3-\P[?':IR4H-%0E?DG50A#A-?W#O*!O[6UM;;Y
M<N/%UF9SG'J@_V=MS7^?J#3^WC^N4[5V%(Z5O[;66-'&,!8'\0-,8EQ-\"W7
M__YD01;6RN1/!5_B^(=Y$:N"[_0N#://_B9,3)FG26R^U/?E[S?T]T_>_N-O
M&R_7?Y!Q+XS^V<+P;UJT]'C:4_K53[MPH9>)]]M/!_NG>[O^R>GVZ=Y)]R+?
M\HA.]G8^'>^?[N^=^-L'N_[>OW9^V3[X><_;.?SX<?_D9/_PX%X,\[?MDU_V
M#WX^/3P(_-W!S@"V\XOG;^[!T,I9F'7LH%>XV[70X377.<Z+E6CRY?LLSP[J
M*?PDXK/B2W6L1C\]B<#VR,(I/!$,G>^W0>_$J'MV51D5R0P5TG(=_''O8!?^
M_]1'1?6<)[[QI-M[P>';*K\'*S]\^_[P^*/?D "T9M>2+VN3)(X57,S_NS8*
MHVIM_<G;D[4-(PUW/OZ+)!=>3@LOCO.Z!?CKIOMX[^?]D]/C[5-02JQ"42"]
M3P>[>\<_#@LP=$Y_V?-=A;9SZA^^]S?>;&VMYKOO<*^J1O8R,$[GVJK)J@/X
MAD^6_0^'_M$OV\<?MP-__V!G<,-*XZM>\NW3O2^P.>E]_'SDV_?PPM(O9RI*
M1@F8GDGF)U7I@YU9P"^_@]>XZZ%_P\%3A<-4P9W2=!;&%!=X DN*?\,/(OUW
M[W=Q+$MC($9YFH:S$@:F__4$_)FJP/^*]2.ZC<G!"VMNGJFB2J(PU;, \V6>
MM[7Y]Z\280XH_/1$@A#?EVB+SXK\#&5!98LROI]%>3'+V70GRWTGK[.JF._D
ML5J^(AO:\M]5:7@>%JJQQ]O;H8H;4R,+9.:&9F5Q/OAK,R7+9D3+1>LA-S7_
METW(YNNMYXW)>%0O_VIM:_WYRZVMU^TI@/\J%C=)YRB^XLF@\DAV_;SP<W"F
M"_\/\*7+.(G((\U',D]XH(+:<T2>?E&,PRSYD_X6+=B]=LL6J<?*7.,;'Q4)
M*-8Y^MM9'!:QOY_%->CY)$SY17?2L"Q!U4?\IKBC?=B40Z/K_PION3\X'IP,
M_+WI+,WGJN WVP<#M+)O!N;[PAN)P#VC<^&;8R-7,>'OPFOZ.J/SQ<MU_V2>
MGL%XM\]45JO .ZD3V#Y;,,I[8%4.W^YEXU2=YWD,0IR,1F7@'?R/O_[JY;(H
MTBT/[^FKC=??^<_7U]?>K&]MW(,AP4;9CN-"E1P\K%2J9I,\4UY&^QVMP%D!
MBB^9A:FOOJBHKI(S- YA#ZGROIM^]]"3 !%%^^LWE93#M)[> Q$8OMV9)&KD
M[YG5/:35+>[%V%8JYP&J''2+ S^TBL<SBL>WBB<<PT_0,_%+59R!1-YW=7./
M#NN=?(8)H2K__M8BD7]=']S#[&)Q@0WZA'.0CJ$JMWZQ@7FC&POM'B<88XG]
M[8'_ODA4C#?B;&CW?_;*_YBL'H_XQH;V<Z'&.3@1QP-_)RPR-0]N\^DG$S6;
MP<P$_L<Z31.X"TX5?.O_(YR"R_ +_'>59S2*#Q^.;FE46^OPZ^BS&H'@PE".
MTO#/\)8>C3__/2\^!_[![W#;C8W-6WKPT\V-S>_\ER^VUEZ_6K<',GI22_;,
M!FS&EL=VJ8^XY%;/7]_H]GL7%H6J*G\W.0KS-+\O6^\$1%UE?R8AW 2.S_>J
M4%FD;E'.-S9>OQ!K#,]I!"%L4\@N+.]&W->W7MZJN+_9 FNJ+>X4.,"CY!9#
M!W^!L_W&EF)[-BOR+\D4PW>[%,,;^8AYP<V F5S\^ZC(9WFI8N\D! .CRDE6
MC^IAFD3?X^+QV+=+O\SSS ]+<';#"$]_M$?"$1XH^ LU&JF(7*-8'E1-DM(O
M7/1*J=$K@YN>@S_JLDI&\_NT+&9(^V"V9W.M%4H+31HJ,.-DQD!AQ1Y,&4WB
M^[R8^F%!JS.DR )^C9"ET(]5&L[QCX(2%DE6YS7<*BSA=[.Z*.L0EAE^AP@:
M__G&"[_.8EDR!Q6U'9$L8.8S\$%U1I_IBA'8?_DYC,H;YE\&_N)DCL)IDLZ_
MOPP,]H^_O7GU_.6MS_3]7'R[I(D&JL'ZZ&5'ER_!W1*FGB,;Z.*%&2\]2LGB
MTK[<?#K\;NGJ=JXJ&/Q?**:5PJ.[1,+=O9[9O8[_23L_+-($_K0:H'O3TSN0
MR'/NE-_D6Z7J^4JJ%J4J]$&E5VMV14*-W?%8X#K%)[I)\?';XN.MQ.=AB4^\
M$I]'*CY9C-E"Y0_GLL[PJ\_^^411NA@GO; P&9*O%&X+8A5%*E6P4B!2*%A%
M@&=<UZ=^EF=KG5^4TY B"86:Y46%8H5U#F1@T8D)BX]O,/;'17Y>3?2W ^]$
M*1I:K$9)1B=NB2?:/_[V>G-S_8=E Z2O-W[0EUUZP=+AR74>;@"Y=LE0]1V3
MC/?:QN9P;5,?OAK*CAMFX#_=H>G/,_7=C0<U9?GEPR3#M#%<.'B19'_I2.>E
M<<ZN&.??EZ;K.Z=,(T_P=Q>GZ3]TR^$R?(%YR;]?67U<2=TMA*,6]5_W2+9Z
MC,2]^W;/-^[SG&M\8P.]N51B>LA';R2:(K@931/J80PZ=^'1WN,%.W+!90MP
MT*5PKXI"NXV%>+E4]+Y"W$Z6J>E^S[CRLGT_2KZH>(VP\@OK1(-Y5Y=)ILKR
M)N>M8Q6_0:!!A>)]?WJRV4<97K8R>]V'XLVNRRA,RXZ%T6/YF8:RPR.Y20VS
M?(%N/H!Z8^?[38;5EIE[ 5A/QDCU'",U&;7L4W\2ECYHO0B57I:3BU.7;"K"
M8\$/PG@-%AB3S>C/8(1Y3-X%/BN=X\.I\!!MT S>*$>U<I:4I$2S,(N2,,43
M';' &%HK!6.(D=7\+(E;_M6)8J#EJZ?A=T\WOWOZ[CMM^[7<I94G\^U#&KX]
M;4F#*A2X->0 EXLA;2<HALYF'4TD_%W0_Y88+Y^&<XS:9BH"=8Z@4EA4BMI2
MA4 K;HXRD;9%LIS @4 G,$]+Z(_J@GPKZYB?3Q)XN!0@@+Y.Y^S[XJ##ZJ)@
MO-P>[Z<XGC]4(,IN2#\AKPQL9JQA9ND6L>0!O0;9!*GT+HHJPTS0:%4<X/0L
MOFCGJ!:&TICFL.PH[_6,3V3+>^'Q4=6.FY9A$B^^1T +%BN8B"F<P .; WD4
M.Z,K8W;7=<2F3GA)';&I,[[+.N(;J!F^VI+@Z_P /_Q/C6D]N+]]-TKT\@^6
M+-7&9@=DZJ6S#$OK'%Q4@3/<QC281R\;RA!4SN>UH8+C$T8^HS=QA_>R8W0X
MY*]_N"L-=R8(8"KG!6PF%;,1>.TG6)(9^A-4WJ3]9X5*$U!I< 1Y8&G@45'5
M)<9[T<PAXT6A3LUB?62Q&HT'/MRR;*0J\0+\%5P$PA!?KLV7$C)X+B&#H[%Q
M7$;KXPB:;^ OOH%.CY%J5WRB-4>-CTHJ?3U*<930J1!FGOGIL)XO_A(/P$Q.
M5#R]&B4PYWARTFOQ31"-B;ET><X,#Y(*S,G!-2-++Y:$VSFS;AUFT5UN?O+I
MW?_L[9SZIX?^SN''HP][6/,;^+O;Q)ZP=W2Z]_'=WC'R>GC(ZW$;"W%C3!+V
M5!B^/3K>^[#_<?]@^_AW_^CX\.0()N'3=1-%7(8R<>L'[A8V/86MG((G_\0O
MBP@<^BDH^'^OKV\,_IB-GSR[S3DY2=+</R(RI\#?SZ);V?N7;)(7KU\'FULO
M_1,8EBHU%HA89?+H\W51W?12%G_)G7<5J[TQ\7)XF0,+CC'VS'+)2*:4.T.9
M\5R9\9_BUY(=VFEF@^"0D2\<49,O*4(@J\V34)HECWC)2UQR_+OU"",.^E:!
M%]+1&I9E/:70!"+#'"!*D40$]_JOUX,7ZWC8^?2P]K,&M^O+=X>M;EDB?E/^
M),3T^6R6)@SSH5QW7A>M=<C(=3X(RSC\C[\3SI(J3/V/8?%957X]PU+:&HV*
M*BF1&H3K;B4DQ983+M?&JQ_04@&+!7Z,#Z(X-E@P,.)PX.^/%A^L32?$"9ZI
MV,,PEOXEH<^6#"KPSS$. $86VXX9" >A#,G2M-GU@YP$IZ"X001B! ;C& RZ
MC*,2.!Z:'"DVI3L.E:?',[AA37'+QM(55,5AQPJ!%5J %*=SC#O&=FF\P].=
M_WWG_PK?U;#A1%S<#4T7&*5@T1GE?#K,4Z- ]C\<#K1>0>\A#<M*4B$@M:2>
M>)NC>+1E"'DOS+4B,SRP!J7:QDNF5///X?J6KA@@\H1^.*L+!*.6!C]JM2:)
M'&\G445A6QEYRY01>3 8 JI!@KLUF%5<(H0V!!3#7]6Y J&MI01THG@RSVES
M^2'#5ZJ$D"4T"O8JC">%.M2/DY*"OEKOR[I2(!H6CL9!(RW('P[HHHOU;HU1
MY6I2Y/5XDM=5>\X\QT^3 #B7IC(2!SRIM'7'6U;38@L\C%U]2@)\L7#EI(2]
MQA:_4.""16E#+S8[4_#C@I"^O.]$BD 7QX)F:8JE+V(9:+GT^LBE#+QYI+=E
MM5#1PN^^24)EQ\)#AS0MG;-[>V#RVSXEAF_W:9WQ51.Q 9R81.E/DO$$ _TP
MEW5*,^>)=.3I&08\Z H0K'&A:%*+I(1E^SVO01SS.HWA3(8%K#%;@(=XH@\(
MO(YU70TG=U&%24;/C(GZ;:ABYS!!KE <H9PFQ_!3[SVL'$BG/E2&"EXVDY,+
MHWS^BPX-[W,<$.;F,ZE/>%J44"P(!!-.!K!T2M6:A6MCZ+SB@MR(KWOI4P_V
M]D]_V3OVVWQE#@&C;PD8O8/#8_CN=^8\<W]@K_%_V8;?'QT='_ZZM^O#];O[
M)_;/]_BDD\9/X9*C[9,3^/;3$?P<1[*] ]]N[_R.WVWO[OWO)_HW_G;_Q(E&
M##P<R_'>T3'<\N"4Z=A.#^D6.X<'I\<8O(!?;/L[QQ3+^  W>;]W<+)W/P)F
M][KREH,BB\6W/8L%.YF3NG_AP#Q,%+^9*A@N4B)]%>/1$2@8BE6T"8^^8?3W
M^7U/<W"POOU=39'=95(#8@<#'\/1G,5KDI+XV\[.WM[[]TNKN5^]OA2R>-1U
M2%_T2J;H]2KUK!N7/O^_KO"LURVT('$RZ\<O^^_K&?QU777A*_2X?0]QL5)Q
MR1)\TN8JKK\V+]F>B$R&I_2?;GS7M59=[W#1>UUM%K[ELWY/>G;-6_"R_5;D
MD5)QR4@EB1R**:6^S%0&_O25I_D;MM9]6X9.(6_@YAZ607&%O,D3MCI^>B(H
MC,L8/1:5QWJ282)E\?/!)D58:4OCA%\"R3Q6(\38E=:S;:B*BV@$%O[35BOB
MQKH^,X:$_OWO?Q/R2*'$H$M.SNK3UX/UOW_GAHI,U#8M\W[C0"^+HKPPDEJ)
M2SPK5 D/:OBUSM!*'!("P<"U@BE26.L)5Z[-55CXYV&! +!^T^$Z2Z%3J[DD
M!Z#^@RXV_.@%3(2I2NZ\MM<P"!>@L0?&&*#P&5:[)M-A70BNLC$=A*1DE]/\
M;(TS)K'19X->0]G/3%6M$T4TJS4+YS!1L*/ ,66P@C*%\,?-]3.3M8%3U6]9
MX&Z@Z$OR>%EA8[P$[MHQ34_5ERBM8S:?VE>/BGR*1',%>,?J:X;ASK<D#OP<
M- #LTC2O&,U(].[?^0PKE#1!DN&@]'A58^_V&L0RDV!@E?6]T-3?\KBOR!(2
M_H5JUQ"$/,:M3V'NYR]X@#$(*B\,B*#7UG'NOJ]G^&>8.=7DOF1_N[=VP%)5
MFZAA9Z@M\%-D(UM8>[V> 3XU0E%JR1/,3T*T![<>7[Z#&+"[**BP\)ACS&]R
MIA,PM B>LV1%J7>5F7)FT V'>5U=[)BX_^V;SC5_;7C+4F3%AS")T_!<6*ST
MAGGZZ9_?^1^JV\%8W=F[HW0UZ%6:*+BK2PG_-X.A'O*4]<'-;JYPLW>*F[T7
M C-\N_WN\--I.X;]\+:(4[V_F&FO,W/.2[&<7];CL2K!%2$.^'.P/ .P2$=,
MK$;GF^1_*FO&M(OA75!<^ZO]#X?MS\Y5^Q,86T?=?%X7^CH:$55-M?%W OXM
M*<^%^Y#\B;(>EDF<A 6GDAZJ3=(\*702CQ=8EPQA^CE,TM(KU#@LR/5H^"2<
MXL4,M;;:3:)9G,:&6\ED5IJJ2I=1"7B"TXOPL\3-;SJ2H^%,7C/?["0N00'&
M"V>@OK]C];I(>#*EW,<X^4QY?BG5=E12C9!UD;'?\ T\?/X.6-7O$WC01PRP
M[=O;VV2GF\6<8[Z27Y,<*YW3?+#2=J 20_NA]0!XCX4F/<,]R-SH11F YP!N
M+::* ^8R+H-6R*3D8C'KL&)]UF=%=W.OY"PQS+:SRBE(<II4]-@P<U>AK[2Q
M]PN/AP=65B]F51=226C:Z.F!/Y1"[L!]/L*=PB\@IV>$^7$3\HBE2RN/2B5(
M>/+SC"XL<XF.<$'??$9F(-]"[TC\J:FRF+:G(L"'NB-RZE'A]]S=@V)77#7H
MS9OC(GB B/=E.[<-_KR]9/GMI>A=JV%W=Q\3V]L?_/T#[/-&:>Y[D;^^H<<U
M='$*>RRC_R)9<)4N;I00T3M>LF!I"):)-C,6F)($2=!+7U+6LUG*K)$()T7^
M<XR.#!$>%=;5)"^2/R6.Q^73I 1H#\0)'3^\WQQ>/6=XC Q<$AI%P!9CD]RS
M3,9[80G00NE/6YDPK,^3VMQE!5MF$D1]=DX+,79%45U(16S._)+L)XHJ#GE=
M^#/^]ZC(F0 4RVF].(]J"M3<6N#@KG;JZ?'V[M['[>-_,GZ&_O0/MC]>>W_5
M>[5;VS:@A')+@A0K1.Q)H3C(/%8'5DR P"@O@6ACU@H/P10S-X2D+7*0<#A?
MT_"<]W(HNZ!]&)@K-<[7_#VB'2T69/L\;ICG?OL=,$&CU8O[(H%NAN#+G_05
ML7G0*)\15\-L3JE#VB^\35C_)#BS'/:6M_&<T?*RP8<)LCK02"BO<YZ!:3+P
M3_(4=2&S0< )"7?+,&SJS#+9J,Z R&4I)&^TN/,1'PGSK\*"3 )]GL,X7CVG
M*I#3CP+G+O%DK[@ZWO',M!+#E6/RBMR0801:F9V'\\ WRDA;QP;@#]H*WC^0
MI(B'@$$X_)D/HUH4$A"'@.P\/<,:5(B)-PWM="Z'I0*?K)#;8U)HZ70]>/6T
M?[#[Z>3T^'=23JBF]DZQC''[(2NG3QQN,)$%(Y]Q<'53 KX$ER)COW51 R7<
MP,WZH(Q2IJB[)+DPZT5L5V2KZ_R;1C/G0OC"Z&G\S,MG6/909^!B!'@*&RRV
M.VC*J]CDHAD06L]3?A@<VN=8L S_2U>;L7(2)A0X=X:65@F:()J BJN+,S5G
MPHNR@J$JFH*X)KT]Q!KFI(C]65A4HCP5?[2&'\W]$EP+5 _T0)X =^NCB94/
M>;8;KP-.&LR1H1<Q2L/K7"AF%8$I-B:;N2D]6(]BJ-)$G;%R&F+6/$U0-;!&
M<\<5A9DVGPJV]"R]B3,"S[6)-#6/JJ00Q'U)5HVQFBDJ%8/W.D/!Q7(MAZ4;
M#*>01]PUA^C=XKU @LR/<4I(,3(CD((IR:=)Q(;?C%<47Q,/62SPHA7+2]5>
MMY-DFJ0AW"5@!S1C/#R-7V0@L *#KED4EI)8%3&U0K.XSC+QY>+$DRS3T#J$
M]W.6GZ<J'IN36X\@X.0Z6\VPW'H^/(K^S-VIUM/76!-GO\K+&D&']38;C-8C
M8;(FA,JRM9+K]-H,"YA*>"^05!^1%/I(]Y)JV2L/_(\6 6 V)ST65M$FWGE/
M@IR$9R&L#!M%1O#XW+M@>G"_NC)@7HG.[4:T"E;0W$BOG8-26'B/L 3OAECY
MT1+#$KI9D80H]+_DYS@9@2M]%$&U[]EM@?FCFFK+0"_2P,B8T1IT\3L=WW%>
M%RX *^X/6" <9X949DA0CR]&KPB;A/^]I.3 5<6\0:Y8@^"W:A"6>)]T3\_>
M4Z6E8F]N\0?VU=E@-$Y38TLAU479177A+Z&Z(%32R=Y.X+&&P7H=-(7@?S7U
MAA.>F>*9@PQ&(WX_D'_VP2GV(WVG'?E%67#E3?&A1D6AJ,:MDTQ/YT7U^'9E
M5\AUB7O?-<%:[:9\[)HYH84CWC->5M#@(DSR7*F;\SK'2;?*$3PDAU?+;)6<
M.^A.H?AM.M>"85DJ/._SXCP$'?\ASRF">Z))3$I=)'EW=MA=<0IMK7*C]YU3
MZ-KC)-OO/NQA.0_6Z.P=G-Z+'.B]J,596I.1JA%Q#6P@%K;%0+!F/KZH/?B;
M]>NH$+B\/N62ENAOOK9).4H_C>8@'W2V*6^"XGO4GWSS'%\Z^M"?%$@)^[<0
M*6.>O+79?QK+R:>/X([__N.SL+,^YZ+UZ-/U^^)!;BR9T)N8KIZ@_*]L;7[W
M4M%8]\W+5N!X_^2?-(KWVSNGA\<G9D'"NY"'%RMYN%EYV+IL!3Z=[-$@X* $
MA0'#VKUCD=A:7\G$S<K$\\N68'?_U_W=O8-=&LG1X8?]G=]7,O&P9>+%94NP
MLWVT?[K]8?__"3#@3L5A94;<L#B\O%Q%?/AT#P1A<R4(-RL(KRY;@H_;!]L_
M[WT$!UMBKNQM[.Z?['QBI@Y,!,)%'WX_V3]!,^/]_L'VP<[^]@?TS!EU1-<<
M[YU\^G!*EQP>[1V3GKEK6V1K)5\W*U^O+UN"=Y].]@_V3NY8$)Z_7@G"S0K"
MFZLKFCMV65^M1.%&16%C_=*>2O_:VP'KXU?V7)$P>^_@Y![8I2]7Q\4-B\;&
MY5KB=.\8; L:R:?!R<!_O[<+Q@3"FD%0]OS3[7^AW7&R][^?]@YV]DZ0R>O@
M\&"-KOWE\ -<?"($8B19VP>_:\.&Z,? 6#DY/=SYYQU+VBIP=L.2=FD@5;CE
M?N?HV6\'(#>_[!]1PFGO^'1[_\!_MW>P]WZ?+%W^7C!Q]^,<>_EF)4(W*T*7
MQEY%4&@@QWL?V.,!(3H1?^@#M7\X/=Z&TVV'OJ0O=O>/]S!V#RIM=P^.OEU4
M9'<K3*]6 ;H;%J9+@[:?0 Z.?T.VRX.?[U@85N&Y&Q:&2Z.UNWLG.\?[1Z@S
M=';'<J'>L72LSIT;EHY+@[<?]GX6"QG,9;"7[U@B7K]<2<3-2L2E4=R]?QV!
M+;*2@P<N!Y=&6W_[9>^8HRJ_'W[R=[8/,%H//LOA\5ZS+G@E)P]93BX-QJ+G
M\2\:!G6L.S@Y_+#/S>IL=H?8VS\R\O(NQ>7]6K<]>A,MR.]-$]7G/_B'C)C_
M'A\@78)_\'\-T_IN>JQ>_;T7E_AJY+"-"=%3\8-_.I_!&W_(SU5!C_O!/PBG
MBJ?L(,>)2!H(:/U+FJ*_+&+;&9Y6#U2_^KW_8O <Q]-4&O(A+VC'2EIH+1&H
MWS1J&EXC])/XIR>"9275<6-0<8N4M2A9QHK#.&[A56^*2R0APKU1GJ;Y.5:"
M4).S8LYM5[BTN51<>[:D_/&B:B(FORA]I)3EFD%=O)-52:&J.=<$*G^:4PT:
MLC.UBC'Q#I;#Q73;+3U3Y7+1  ;^?N7'N=(-@&G0OO2";SR'*G2DE94M0-)\
M.S"(I2Q'7F>O&4O>Q._:J+%RZ[VP3+<B6N!255C=6$VD<*>CTJO-%O9QH6[1
MVTW*J.;^PCCL[2Q,YR617"&GD\SCCF:VHFN.I2()+CFD\F \%,RCJ# +WKUK
M%:1BEYF+88J5H5V(O4O693DGF^9C*T#+)D1:<@D?VX4L:I9!K8NK;;'79*M$
M\(J4:X;&83X !9S<C&;H*)JZ2=6@[]OLWM?H>/>"J5B)<II;61.;[\8:R/':
MBW6OP)I,[#,]2Y-*-]C*Z\H4QBVAI8%#=U1P&TB4-[[HG&0)N9M(CX"89$)E
M9JKNS//H+OQ4*D=-4ZX^=>Y*Y;?(]\<W)CN:ZH$U,7:F\+&5?S[)4W4IRSC7
M^!(E1J%W'])P&!9KHA<N/9D$>0_>7'8^^/=5@C5 M@64JS'DZ?A[JA2B^F6'
M*KLYO=Q[<V;+ZS7?>N Y0^U8&'<@O+&%?TM^4W*_-<WLP0^BPFBF+8I1D/ %
MHR@GJKT4=L9VVF2K$VZS;K8#>S,X*>3CY$R1;B4-1*7T8^(L)]'#/_$UM/3Y
MO:7/$Z)H+M%=SMA@Q"F<NAS?!=*EY.[\E?R60E^V* Y<Y6T5OTR#USD-9DX7
M7UL841:$?W#SN@A,"*V.;OQ1P[>'9\A[H\YOS/JZ51W[FZ+J<6P#!X*=S_!,
MY?,5[/5ADL_HJ(E437ZNITD11GE4ZY:("I\RYK:IHMA08L,9_4B*M&?E/)HH
M9.>.#+\&=8' IQ,W?25R)0-ATKLL/^.> &#?UY4TGO# *2AP9X3^&;(6,<,1
MESO#VBB7-E..>2SO-A7O5/0M/1_E?2<J3&&44I^?6<-OJ.8Y6Y!<TSVK=0='
M#S12-6""2N+^XN+_",PN&G$&R\+SD&B"(*6$&DB_@!1&XZ.C"6QIE8V%)2"/
M0]!6.]23D7C1:J)"$BX,FM+SO$CCM2@-R]*;*M0,J9E:HK;(B,@16S'D,RIV
M)TY';("!5*1H7(;Q64B6C- +ZMO@F[LKAG6?W +RKRWMQ[@,8)XJI.\_=83T
MK_]JO^%IK3Z3=$5DM6I]+QNJP2KF-;C"5#3)\C0?SS67%)7\IU*Q7V<)G2.&
M74$+&7H,N!=0XOV".#QX:A?\BYKM E>DXJ(>@PG 9QB<NB48MM$<I-WR/\QR
M9+Y"<W^H,C5*F )B3CX2G4EH@LF6CO"QTI.3FMP0:RD3/S3WN%!OXD,R51?X
MWJ3:8N3^C(E@3-32M2@YHBF;J7R&YE2MNPYH!B+#.R3SX+GCGN5EM09/K-%6
M@4U8D<[0X_2?BKMP='JR:QK)^T=A\3G)2F;*17<L<'@M"E9#]JU]YZVQ*[:0
M92"S#S*88506I(NHR;B_ M.(,5?&J-9,P_I=F3[E7&G:%--U%]XB*\7J.C-]
M7Y"/:4WS/H+* @G3I@PJ6*T9P\)RNSP )71D1)WZC@OE*WDM<'SE59ZAL$4^
M'@AUE&3Y6&6>A#&PV0B3X<&DP6\2X=DM\ZF03//Y,:W+29'G4UC68^X7;-B+
M-(\5\M..79%%2K^.W6BM/] 9(!_(4DW#<9:Y8B<;3^049@#/VBE8E'C@\<Z8
M$K%FYR[HO5,=F?5^FR1(58!GH-!)X1A.\)5J^&*?O.**6',L%<D.+&>!?$:Q
M?Z*_+OUML&/UEMHYV;8[RKY<1G174^H"#,,?YC%:'IY"0E1\!$5P[-Q91<7Z
MBR(7;#&7Q*]DWMS9HLTI< V95A]HQHWF.7MPNZ!.O>UX"M8"K#+;+_IMWN^:
MMZ%KZ9?X W\//:&(F8ZV0<RBN?G1[I[]$;V#H5EM:G0KRZ"$4W@\ZE(M8R,A
M):0C@CF91[ ^!7'SZ ,A"2MP1-Q7_>OO\=/&\=6<*#XWD*5+%MM;6&S+Y!8K
M< II1844UXD"A!$2.";1&KI\L"7(">:)-R1=*9)TQ0JO=$QAA5QG^F)DTP*G
MO/3RH9C/;3G6(Q;N7[  P*A%.P")\&B\24.:R_ET5N5(83^B7NH^*@W8CMPG
M.\<H&FD%,$$3^1E:H[(U/!PSJ0<D)><>2Q5:(T@WEGSQ84*J"<N6.QOZ^-!L
M3GHJ\.PJ\1@WH]+10G(V&ELPS+Z0.R&MU#WW_N<P5)@TL@CPVK/0]#< D=<,
M:^1-,WV?H0AT1R,='A:F&-2+)?VC<['*4[X)*5L4B*9-9"POYQW.)^2DLQ:@
M,\7:)49](JDQN/H/8)?I)H+@-H&[2OLC-K%GL<GT$F+4BSVF0B$5&H;M07Q#
M$XJ#>U:UC5(9,GC;J<'9T(:34MO$- XT</@<CQ*RG)"*D.\SA],";L-<U$G9
M((J=J'3&URF7>J[KP63:.QR9CM?.T; <M^1#T*"-=H(@_)2?X<2&Y9$#^R,_
M#[QS(P>5D(>CSK"V*C8AI"DR4=I/VJ>AT,$[4+_)E$[6CV$Q3V%F [NJK;O^
MD<,__#/X%*G4Z([_;Y[FGNM.<FA>M)PP&%/7-O%6N@F>R>ZUOIB;#R*M0Z<I
MFE>H6:31&8W?R(>7@>)/[7'+X8_%MHP%V80PE:UWLP>),>E;D[>3I["=DM"=
MP5E=E+7DJI@ 4C^'CC#38B^S??7,VN@9 >UM;'],<66&O)-M+?$8&H;$=OKG
M1(%@%89(4?Q/N@N[2P@MJ2-4HG2XH.5LS$<Q@?^IJA T)KN3%' );4C?-,DT
MY-48I'\(&PR4YRP-,PX82%B;5I+I_!Q-XS4#"7KZNX6X,YZP+$H@C4KKE(D4
M4Z(5U-D^W4$#KR!7W,LE1(^AM31A1G-]U6VNB -WN";DS,O!&T0V=,><^T!J
M7MP[2,U7 V76+D+*;!?A,(D643(;2U$R:RN8S(W 9"X4W268MY?"9.>2OYN.
MI=^RB1=%2B9*1KDH9\V1XP32R!#R4'K;99E'"5GR=!I@B.R=*)SKR_]\]0SJ
MZ7.F#D9S=YW/&QR/EW4^7_+"7>W0N>WY\H[HG6MX(=SR'W][\_+5FQ\:D,M+
MFJE?@DEF1L:K_H?BHH(N<1NI"<+%-GP2QEX\ FLY%W,+D.%P?$A!.;?W3I^A
M1.#+8\0)+<THQ+A.G'"NC7R3/"5325+7E-B5SP+*@A<)F+;-8:$-(._6:R3<
MU NIPC.T/:SQQ5;$P%TM[T>W?_6W'_O]=]IJG]W%/MO1(<8^@H6YIH;URI%J
ME8VK";M=W/(>O0/J!%]*\*"9,D:3LT6>WFL8>5V! X&1HOV1B96"80R.FVDH
MI?>[=2:Q&T-,D2;.(L\P$)YAN(-,\C2<JSCHIWRH6P/NV:@N=.<N>3#1\(+E
M$!+KN?8^F?$>P2U#WI"\N]%-'&,T'.,;Q(5_!J_2;S"2[.'(-@Y-IXSL0Q$>
M@) 5D)0_%0,!+YPEC(WP@LU[#648$DJQP'!CF*:Z&P -*(P)V8(<ZPQY<3V4
ME69::::WVUD_:5LBO.>*=IU-VKMF@.Q'I]=#9'-9)M75:QBFJYAL91W.ESZT
M10*;&X.<MOF>!!G-1N4&*$I"9J,0K >R6/I9(=C$8&X"=*7J'%B@NUQ%>5D)
M:&Z6)I3?N^RGO89##<':6UY2W1JHW(A1.-;/(EK9)'8&O09Q(DV#,2<0N,D"
MAN?@G_A'@<V]&.E8NJG/+M$H.0W:5U O2)F*J&!.D06@Y%XZG8_'#JE)F>HF
M$?U.3XG U7!;'76G_CP.G@F==Y@ $F ZWVY(/+#9$348,5NE<QNA%#DM0S#V
M4=0S#6.C$;I6"87ADJJ?&LD=(<0I3[(:;K$ZD58GTMO#NM]&UXK=.8W(*92:
ME4Y]$KAH -T]:6XRH-+(J>=1@,]!W8MX;5;"<I^$ \S\!R(2(L49!2=79M7D
M@I';:QARY$H+YK%.%%I(IP;0-. >F1J'$DQ/LE%:"RX$S^R(_(I\U%?YELH^
M=+6O5_OZ[=Z9ZG=T)B/=9N\*SI/V\!8<N\#USL0$[2?+V%AZG!/<#S;PV+&7
MY.1J>I2%0IQ]X*@5>Y@V4<Q?%?ABGY]\8?@'IH#Q.!_A6Z(1*YZGL4H; R/W
M5[=R7NW(Q[XC]_LI]7/&%]L(A\KP8+4(6&V^-F-$@:X"D,Q\"_^A1EC!4_:.
MOFCS,>CR6#3@VS@]UL_AEGCD )K^<<9GZC<*J=M;[:757NJ;2>%.J%A[TXP3
M(@RK\XCS.;<KO5NQK7KT68HMT4##TG,\&6"62]7/*X0?E5@1FNI-(]4Z7!V'
M-V?\TF(\TQJ5.>]\[-4)YQ(=/"4X="B(/8UH)XZ[VE>K?860Y*_Q?ZRP.B[,
M%>Q(,A2Y#;&?<XPD5H@EZQ?=&.G6X"$_FZ(^$;I]NA4N#L5!Q=J*.]OO&Q\.
M$Z9<B%J?48S1&\T$F1_6U21W>LWJ8H4,FV47U!46Q!O3EV$,=B)JG$(ETV$-
MYR*=TRF>V=Q3O,\@L%J7P:#H"*]<P=6F[G]8<OX DY!XQN4EXX\QF"[-@^-P
M&E*A&[;K3E*,MT1IF$QU%1GN-8D2V2M(]'LG'BA:0I0H>'9C/3L]7$GU(94B
M\;-7DKZ2]+=[64@40'U$C(L4Z91R$P\H>4F&A=H<6J.NUTD$+LY<@A%EQ<4G
MI9/SYG.(@#82$.E[DO&]7=OORE$9_BGZ6V3OAL;GTAY7O\B'I+"S519[M<V^
M+6>P+ &J@^[.%F0L/UPP26:"K['!=626\IV"W[Z)BQ%70%&4!$MJ83,3QPP"
MQHMX#>D0YOXLG".JA<=7PFHKBW&1@&8 RJ" _TWG??,%6,W-OPQ0:U"1Y4C%
M6-(E]0AH"O(K4DGSJ AK+B4+A[6D)0-_!*^@Y.#CC_JYP]H:=2ENDK,P8M4F
MA#YS>1CG5)TQ=:8Q37%J/_\!G&R0O.6/)QC40BB,0ZZ4Z&?7'DP$XS;/TJ0W
MV(E=:# F^)7/E2C241@IG<@BU\$$@5>*<*4(^[O+!O>B#0:0X"G\KUO>%$C=
M$UD1NK#*V6#=-34] S\HW$Y(-IF"D#!>31OLLLU4I0F<*&&Y$ON5V']%)J,K
M5T8A3"?%)R 91^29C<'PA5 @5DH"&SPU?09C:M!<%ALZ_XD.B<*KA4.G1F'>
MA#+T<5*VD3G&LFG8+?W/'KP7OUI>N.=/"NZWJ8_#4D^B.7%Y/U?&^6IS7E-J
M9!8F2 U;3D#2B:TD=LK6LYPJ04GR9U0%TKBN 4%=R>%*#K_AD"C4E*!DXAU*
MGKM0J/70*'*1%8ZN'*+W.,V1FT24NO(/3W?^]UV_<?!IP]HWF2:,Z-5&$=82
M%_EG5:S%X \)MUF)&00J?#),J(:>S/ZPURC<$BKS"+A?TGB(;#KX),]BS$ER
M^&FU_5;;KW>,IL%K;#:44T0 0\ ]YY_E:.F@4 ^0"(/2;E@<!3*83QL432VL
M8[] B75(+H>>$#\N,]6N9'\E^V_?DQ723^$B.Y/T 4">DDC9<E:K<'E?6("A
M4Y1KZF&%'I9PQQDRY/;+ )PC(2LX$5W%M$Z$GXMPZ0(K_%0!#/[\36Z"ZZQ#
MOT$"YIV\F.4$+M^W4<[[68U_@]PM3$6?17HR8FTRG%"<&40,G_![7GQ&VI3_
MJ<$UW]A"KOR-]8%_")^$68UVQ>9S^G"+K2TJ:HE%.N4^]B&X!\C^TK=&J=P%
M]_@<Y)0)1$%808W/D.CP"VPN(MS),;NF2H\"S#D1F&.)Y8N7Z_[)/#V#&=T^
M4UFM8 KJ!)ZY!?,8^'M(&7>._(8[:3(:P00=_(^__NKEUJ9)15<J5;-)GAEJ
M_*3TG[[:>/V=_WQ]?>W-^M;&';/"7$#4\O+Q<+)LKCA9;IV3Y45;ASF=A%S6
ME>O1F!<]#7O4'[Y_OW=,+7]OX9F-37E#1IIC?YF=1Y#+60D2JO_U9%G+OTXS
M3>ZYA;>4P;+AU?LX$JH$U^S/D7-7X!-#9+%LV!$]AK>Q.+K60!K-6EJ'8H\>
M>O*\EV^N:3I>O'X=;&Z]E(X;2YHS7C #2SL:VFFXH%/@=5U[;6/M(3MPR ]5
MHVM),L5. <S8QAROQ,N6:V+GB];[6H7G.@1C,WCQZF6P\7Q3-V-YNAF\?/D\
MV'KUVK2Z8<.?DA;GX#" P4XC,:U4.'YCZ0UG=0&V5-G@]M'WRBB?_=W@!D3P
M$C/E>N7R\H==U/6T4\=<QW)B?Q;X29H+3^2,W8-;$LAEVNPZWNRT)8*"!>-:
M0)$]9D7&O!88SF"\/W_AQ^&\=-M""*5RP\5MZ,:%7E@A1TJE[-;L<G), S^5
M3B8T##,^:L*0E%2O'Z"-@[I"\X'#]D#T*3_HC.^6-]8-6:FI:G'9-KE.@;JF
M_?%M:W_7^^83K\<1\A^I^$+[X 8FY1MMWJ5^<C]<9,D\I)R/Y9J@BAFA8$9,
M/MDYZ'0Y+$%"OV@2T_]Z/MAXX4_A.V+=[0DD6[C7ZRU]KZZ#:.$0ZM)_^M3I
MR<U$1WO,-.^ZE4O7!B\-MC41[FV*&\MTQG:^I.:V7QI]%L[)BB>[E3UZ_/@F
M!&:QE=A-/>G4-GD4,G!2TK5 DEW!HS%T"!]UEA$TOE,(&KA09>S3D6-'F+$A
M^L//A&O>-^$CK9)+I%S0QP+B\ 2<40O$&,X63-4YP5"].VCP?/Y8ZN#2D/10
M3@\#3CKF3]P1FBF8VA!H<(:TFQGXO^3GW%1+\TEG3"K$_<(82.+,6<=&/73G
MBMABJ,-)8X!N3]62SSIL?P.K.6!9.%%*M^9D)4F#T(I2M^CDDY=HROF%*R5,
MY3-WO@SQN^Z@L5R[##A \2C/O1NP@B\^_G8%[^ ?87W5_+J.O^NR^[2JP#X0
M#.F(592&U#8H:T,VV"#D/L>-!J$\4/=^DHE/%Y00%N2$9V&2DNI%\E%+N22
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MG$E3%IR[Z:QBT.8880Y:L]F?80<9TQ++^"5T4&@3LLIUF1J^C.Z7VKJ/USS
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ME0*\,>:KD9,WZ6)N)=*?N8!"1TNSB-+DH8R*9*CZ^5N6U&WEJC]. 0ZSGMR
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M( T<3 O&4J#<1+2_[KNI^0NV2;TQS9.5E58*2/CHY,($M&W&1=R*3P[24<&
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MD3(J3TY?LC#";[-$:ZGX7" 5G&G7#.<;6=1]RWY5>T*$O;8S38EH.$)JP;$
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M"XEOT"2WARB0ZG!\$ !W;^21;N[?-?FB( V9OB:+L_ ]IWY_^^;=:VTY%;I
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M* 8-[6%[T]4?OKAH&\:C8SBOF QY_8YLU(-4T15*F0 3;^+# %;T4T"Y?DT
M%T*9,-M2FW/UM2PH(6<U;7'\$90@INMC)0< X@SM#.><*-:-/=N*/8C<4H:Y
M!4IQF <$TL-H[BFL^\ >M<O,@K-"EXL$/2$'$3,[J,Y]OYM>C:4AG=YUU+MH
MVXJ(<95A.19,Q$U(47/YE&>1\*;Q07I$[AV]B !ID:%\Z9I)>SK PB?K4&H;
M,8VM6!D1;-*&86!^)*/.*2=YLQY 3Y^SAHO*%-=E:SK1:^RF6G*&-J<(-R%N
M<G5@H\C[Z)Q-(A"HJN:J.&;$BG9S&=$K7$^M]WIG*^;)<H5$#2=6&-KJ#@?N
MJ3N]J868@K,I8+&HYSV$SJ(<G51K6:VILA"=Q$UXJ+]ZR^B[0>=R %.HK]@<
MH16%NZ 9ZPA:810P=Q<E]X9"+Q4$"6W(ZVKX(>P&V_%<V^5_0U&A13E/;8,X
M:!WHHZKJN6.A6WDZ-Z(:":@DB37-:$5+GPD(IH]O9RNWR,*!38(.*[+)A3OU
M5,IWR) %W"5"S, \3L*#5=KT!1-B$MZF!=_#E3;5%9-BZU3W#G'U&"!35;'H
M3=7X$'6H]9ONK#KA,DR"OI+5*W4&FQ:&.G?6I> 3.DK/ .7DG:"# ':,,B\)
M#8W@U%OM:5SD%6/K4#,0B;0MS$;'Z;C'D3-B&!R)& =YB_'.H*$%2%<^<S/!
M7>-@HF/T,<*IGL)>9O(,-E19)7/7)*XK)']8T&(Q'EML4.IS2$C&J*B4>L";
MH2;%Z9 @8'+@J1UXOG?86D/#\5N:L&$,UW0<(\>CYA97 -"AQ& N;7E*:NY(
MAV\[;\I9P=6[_*0V@Y%D5MEO1/-TMC/=X8FX 4%]I5DI <YP#*Z\^+:HI^0^
MCA6S764C4XO17,9.!) &ETE%8_81U1,W)<IS*=#4=S<(-/7@%C3U%Q'A&#1E
M2WXD[.".&5C2B88I.$3A(Y6T[PNGA>NMD*/L,>#W)33P.IB@9U4!Y#.',-DE
MX!B0>[?BTW?TV;OND4U9*:IK)H2/GW?.$5;."9I#OR/Q 4>=7#ZRF=SA(9>3
MRYGV54D:7 R])AVPMUJ?-204S0GB?,T5!3V/3SR% S46QDG"G7E%.)+=@Y24
M12^5@S:H.'#NWE?UV;V3^LPPY;%MX"3JK&[>PZCOVQW%:X(I5W9&.K:F!+97
M!MJRG:]V]W*,W?G(Z9P*CYHOR0A:Y4O = P^;437%7XS-0?ISR$&*A\52#L0
ML@:1J<8%)8^';\W$DM\JK5!<4Y8HQ6!?+?/3FD/.DCBXMEY/',"!.<YUM?!Y
MW8$YW[(A!Z\AB?7:4'3/3FI=$XLQ'<#S46$^J?  41<R%M.%M@4H1M'WTZE=
MJ:FS?$HAOP;<'Q[LGT),DOH*:5Z?$[T# H[T'=0>A:(?,O!VUY!9I015K"XX
M5Q<)OL9M2/X*]IS"MYG89%NLEO?"*(67?,85>O,3"N/%C%$<W(/+2<[6,"(>
M17HR7QZ\T"/,5VS-N#.\#Z1GO(T8V,%*:/_ILP?%>FVW3>CQ#1]&JK9YW7B>
M.9"T3;CZ0Q10&;8;5]9/H@F]')/"!;'&GO27YM"([Z1IZZHJXL T?%J_%9*]
MPQ49B(8\47JK'J3G"\ IV$I21;T@ODZT+CE5=(9 5U#TC$M<<P[$WA37R+"=
M3?6''S#+):([C;Y@;CE)88N,2-YBKW0@KAU7-$=(<((M-%P)Y1:IZ3=*;0=C
MQ0>R@7*EOSA5T(8Q>XI2DP. Z-I,&C+W:P*#Y95/11K?^-J;J#&I/\>81Y!]
M>*$)&%%V9;L'1((7FE[A/YFX&0 ,A)A]''%1NL$CNYNLG4'0=DX]:<0M$YK'
MK0E76S)$IR7Z(>^3"&HAM0Q:B :6^HD111%T:Y$G7,XG"$'25&77:UIEL@"B
MCQ);<3*O6+H#5.KBJF/R;=UV\U-@S)5)I&$2D(:C''NH#_9UD+K:VM"]=0]I
ME\X0=?>4R]+],LPTOE(FV4? PA1K:0,ID&2@0(#/-*O!Z@*@CL'\!M:7MACL
MW[&K8/D:)+(Y6K=D$A#F28P,PC+FSAQP'%,@<J)&5J!N2BCCGD:UK@P_;<CU
MVF8^6IM0N'A8T;J3'<"P*SI!X^CRY =Z]E'#OG@]=57D$[CC8--W"L1HRK8(
MT),=:?^((66"^-1[BK<%,]<?2![QOHD]H&B:P)0[5B?:J2D4AP7BNGM:;8,D
MW&TGI1LC2$)@Z10+F\""S"#?!HE4K:J, Z%:P2)157N *6;<<P"',\]?PYZ1
MR.6MK-T$60.AKEK!$Q;5?I6% (FQ#]788_IQ\[1;8;H)PE0N8Z(X<K8;U5CN
M6'-F/[.@D0^78P0L9<%XLNAWU#/W3=NCO"/(HX 3E[Z/B*#0QA[6[G+QF5R,
M05BX 3N8N2&]TX)RCG""JE_O]MGQ :3MMGKPIHC\*&;,W$V>N])GKCP$!J.0
M*%61_JLN"9U)^'C)=?7"3#OI< @Q7? B46MSX^KT+H>\>'*#D!</;Y$77ZO0
MOM#X D"/NY-L[LQ*X@@JG6">0+V1L,PP[J,P7L9Z"1.DL>N;)A<P.&*7!+;?
M= 'L/]VE)1DV[; =@G?2A)HZSAN5[CBO:(N3[_.<5#Q#Z5NTW;'9)7=.N)F<
M2\Y9\T@\NYKU\L='25!FH/\8?]B6D(>RN/YI!LW[T7QY.F&J;R= @\WE!5Z?
M4=&E9'D(R+$K"2$I9+1E-^M65FZ'1;VAE %%=H8PO/K%2U!6@K)^X2+/M83Y
M,JL:EZ$PE-?CW;F/'P&X:ZKUE*V^% PM4I14%W)2Y!0\<-.]KB6589F)FG(=
MS5$==5R1:K(EM]8MA>0[7VW;3OHNG%)PWUDF6B[OD?48 ./&$ZV\,.5"TVTO
MM>Z9^#]\N0DIGIILLGK^7G@HS2ZKFYCR&4_W'.7(/'*5BK/%* (O:V9XELT>
MU/Y;0!A%N9+@]5*95+75HL8V!\S:U&LU+ GEK!\P-VC19$*>#K[?D!F:-$+C
MJR5T7*;#V!#A,_A\;4JYVKJ9,B4[8S;8Q'=-=GLL]_2@+0O1.:]94P&D;?CA
M3K)*NCZ"\+[W6'$GWL>H![5D%/[3#I+?(P;Y !WW-K-446,N!9=35KU/VHR:
M$T3 K(%<T#2XYY:C/$JB+-<R$;R>&V?JW:Q#31"'?%!%-<I^R9)1J6(H*/+T
M:1,1QG80]MYA#B'U#W$!7AU0?D;JH4^@9O:=3CDM+-&XSW?-&L(I=FPDT2I>
M^\/QUQIEFZ,N.L$P\[/#L$C>4F3@M>2L!LBG=%":Y6T)A.* 6%PJQPW;P[HH
MF .W*8^1YAPU[?)-S0"A"6RPB2>EUB5V__T;56MA80.$XT)+3"<E2A114I-)
M8P**ZIABD'%T*)D\W%D+[A'S:?&5\=L+)U  6LWFL2>^J)7B2IRG99P2C>)&
M*9]0GDTGI)Y/X4A3KR@1S"[W(Q[ <H.2V8G+[89=G2P#2[4(?HV:6D8X5J$[
MU WH4_@'RK&V,,NB6;9T,GTTU8G50ED*] CKFC/8KX&\<E:L2K>>4SW7VM04
M$X3V;$QH%%K7Q M/I8HE&52D7<( 87;A*P2]P86MH;:8+( AC"3" S/_CWMJ
MSJW!^XZ.1=LJ.W1Q -@$9GQ-^D51/45C)=,9O27B>8-IO*0D*_II G<[T8QM
ML&MV5E=[2(]AWX:A+NW.J5YVL55#2<(4RYB[=?>KDFC\D7]C6@.7%1<A%[+A
MN+7XCCG:.3L16(L&^].+HXS.()("U,R3)#=YU;I?%-7<,_:PJ])J7 7=2]D4
M0G<&Z2R!TX>(9@,#HIU']L^(+-U[%32[J3N[.L(?XY EUA$M+[ W:V($GJB\
M6XIP+UN%P,V<XI927!J!&D7DG9UB2$Z$ <Q-DB]2,.L(S+P2EW 3K9@UA%I4
M>0*)Y^[P6K$V'=!%C6"WMM A 6B-V0>8*<^BM>,V>R-2FFQ81REL%>9,CB9O
M7$4NSNAJFTCG,^LZD7/K#VUM9'2CSF=S&D2R:IAVJ'-;.='U6+6<1V(7S2FY
M^ A!*"PW2YVM2KQN^ANG>+<S"KT#:9=W73Y_S[T7BPZ%0!*6V&HM09M9CY^@
MQE[&!/ZKY09C$XP%D0,5:'% $G"SSOCI5=799IQJNVV[8JU'UQR<V-"A5)R,
M"SH$!\@\;NH*$2J+DC3O^($#&^A\AW-^F%/5[E0]A=*Z0DJK$\O:B3 VG=AS
M]SW. <#QVU-9-WXD35_%AV_(6"LC%T#FDU^N'^NAHRV%T4L)E7-50Q8AR]$D
MH^\6]1G)LS/I%V>Y],ZHEQU^%@U%HW.6#)UJ'1='D*;I.U"2-SW<&!9_$7QJ
M_[$JPGQ0M#,\R]W@3KNF$;"I^WO>N@78G+@5X&IY &RYI&7OQU)4BKI[D)%5
M3'RD_4;>\8/-A  -[<K-BK@*Q-RS)HF$<7W;I4*Z!=%981M,1WLYO<A>3O;N
MY=C@B&97X?U%#K$+/G%DV AID03K+V!.9=@TT&O _W((2Q5<((1S4T2E5'T#
M)H:H638F+]0Q<(!U4H%BX:./^D*\7NZ\4"WVU5;H/[U!>>)'MWGBKUUV9S'T
M!!<MG+9GY?<]\% KI^*^^?MK'&._E:W;W[\%>GXJR_Q1M* 'B%RYC?BE#51;
M>!K5R;I37T)Y"=?3T[_>%UOKY@=?3.I5J94N&J0UUS_%2O*CW*F&P"VB466L
M,H4[R[;($G,JF=1,L?"GD_AJ)O\9[#":>Y\-/9= _67C[)@_BK*=K?HU6P;/
M3\IBF;[4E4JXZW2C=40HU(/;R(-!</J7YL _13-YRC*0K@LEB@H#SF)/P=/K
MFADRM:'><[S&530D)YK\%'%!L_!]?+O.'$%JG#.O\,1/G,_N)N]_>O=\+A2;
M2I('<?';5&TF3C5.V$U"R][4RP)L=&YT,*0HQAYB,5&B+_,DZVIT&;(DI=]0
M]M7XR9QF0!Z$?_24GOIK3H(BC%"U;+9'Q'/I3WU#GTA)U<RG84'[2J/4VE3.
MU2(Q$)ZDO$T<-.,N>/3L;CNX3"[@K'@4S\Z2RU$_H0PR!%F*EF!%97L294E
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M>!!A\N5&*W0DHEJ6;Q\?.'MG0SB($P%P"+\8Y8::>=D6%[@M2RPQL? 7%!\
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MHR&D@QK)"%>8=VI72/@I5^UZ9FHEQVZS\E#1 ).= TPO/$ >&169T%"CPHF
MUI##U_)WH6:-#E\$/>#4=*Q6I)D.?L:= .8%+>)/!J]#A!?#4R'%A:@T/R1Z
M83BL/RC8K(@W+49,]CWJLRC[J]/K SHZ,H8ZCFS6MI-2@I)/+?,-O-@W1:/&
M<Y-$<Y/NFAL*8^$8RUNG!&=E/>S=0&F+?%[TRG<D,:11"#!R!S@DAVV>A.A^
M9J)1W+^@HOQW3< F"3>[$<"RE]"PQF7A[M#[.]H_GJ8>726TF+M5!4'XCF'#
MI2SQG;+"?K1ZD).%%\N7A3090QTD[7<.,D&H$EOU 79!F6]C:MYD,W%W ?,D
MML>VFZ-9(75]T5&J,_I[!:3L6W*/.8$> [7B1'Q(W1E^-;4];/]C9S>X;1+%
MO/6@&F>D;X3VB:%7: JP2'0QSHJ)GD#(H6:*=59(N1S7DK[F*OF/6''UE$:=
M!IU!U3?*\$)-R=IH<$Q%Y4&HDW2;4U2;HD4&3==XI'XZ C!MNE^\+>L-^/8I
M9%6$A)A OWCL@AEBPMQCIOIX#"ESL_S@\/!!7'@L%1_QY;[L> *%]@>14KWM
M&J)L_*T DI6N>BZ1G>1-Z!9Q1%UE."<1%>"R.:P5S7X!0(I85$J5$'@1!S".
M*!))J39_<+CS"BSOB5!Y^2LX6+<<*QXVZ[$P$J#:/^&Y4]O'DO]C/@H&U,D'
M!GJYI?N2)(IEE'0A.R7N(24J?BT5Y #2RO&C_3(JQ.>%U5]49V0TF!LPE0N2
M5RNZS.W!O@G<Z1;10DM;:]C' M18$.J4>'W<::^H6[)B8TA@I^W() >XQ"/[
M3@#+\H%PU&'IS8BH'W9MP ^8UB<\W?+5GFK>K;1S"=8W,-CA@UR)%YNP3::%
M'NU?)P2_!(]>W2P"B/JM[-M'AX\\M<18C9A@1S+U<*U7<K^>N^.!^QU?_[/R
M#P8@>H-B(^Q'Y,%=:&)!KFNNS*+^U9?3:(Q 56Y!_ENBQ-0J,(P!6PIMI>I2
M >WQ[4+E 5*AJ,V1L!%YUY<X%^EYI$47W.XK%(P8)29M22[\-0?IT8J8DHY/
M2*-LW.^9O-->;.JV)H3:F"+.!'=W;"A2>*Q%E$(F&>)/D:F1I=%HS;/\T:-,
MZN P)FUGH)T!0BTV)/M8&)>:50F;5<:I"PY/N8H.#JD\$0&32#M_N(0)S KM
M.AM->T<Q5'!Z)#SE?D&(8(3JJ>=:CL<3X?N-V1H_;;$<9H>*8OW,&([H.=B^
MMM-R2)'3H6"T>R3#N;A%R8=PWG+ID<+1YH3/-4>*@?^U[D%*&":ED^HS"\%T
M)@AM=VS1<S0\PQU>0H6N26&%"C^G[^9;V73NK#/PI!TB>VVAWY?#3]R_0?B)
M)[?XB:]5: <F-Q5?4X$*'7\+MICM>9"<JZ2<3FJ**'<@9<7DNGD%"(_L13%G
M L6']T&@>-^"]P.7L!3^?)_>*>^B?8.3:P+J%<=-H8V]E^FB[_2@D2-1%7-?
M2;Q>+J&A\3/4*S&GVW (]/%:ISS1I3P!]?X&YXBD6 BJIMZ*T":4/'#?W5VR
MQGS$4966=M#D1EOB)%6].10.TC].&'!H#(L.!:(XR:A2/!<&NI&) AC&KF92
MW#F _<&,0YF:)X>UL*2*$3K,D,?EEO ,#H4KYE^=!%HFZ=HP-I24U83KLD22
M\!AI1<JD%&@(*%FQB<>HM3#L!ZR68W*>@S AMMG.XRI.NC%6,1@=PK(9&?\2
M/DTNDTR?8**^"C5SU2?D[.^C[D2H$GDM]7S7&3'/#BT% K5%(22?V6J!<0Z8
MH$3L*Z3761%61:>5&JU6EIA*2%$:6V]#DRF^E<"&O\^TVKL1%0HRTS[A,8R'
MA\E/PN1[X];4UDPM GX7%:,&3=&W6NGJ+^?\/C(]-J5??-AHS'$P6E]+G3*:
M+)>F HJPHD8I.+HXE\Y!9I4MG[7MI=G1WJ%#8.8<JO1>@B_DQ(11$UX=$%I4
M>IQ ;?JD<]J^,4UV/:E)VO%@?*L:_]SH=N3OE>D"?"R=:;_=H&UXI\1+&'-;
MQMX-7?Y#>J+-P)%I+]Z[22==WU>&;\5F\X4HU\N'-"%O0]>?!5%(NC_7C%<B
MYA/;;)1Z1EL^!4 I,%K^)FEVP"6+$GX,M8!2)D9G?M\&HM.]JW:0_G?=H\8&
MQR!Q*X5J9H$B: ^%85AB?E*#&I,FTEE8<V66!Q)Q]&H/JA#)F%1(22Q2%A"!
MR5W41:O-PT&FZK8+>:UJ%:PP(+ _L"QKQ^9Q4&6@WT!H895;LK.H>A>H=U?C
MFNNI&_U9Y*W"XSX'3?F@Q6AHE><F%;MR5*^RHJ#(0LM-I![_N>![&(9]D+YT
MUAU1D8SN+ML0CR+EMA+4Q[['98EO)49=K-JE$J(O!7;$YJS7^ESON/+/GC<E
MC+$LNIQ!0QX)@PYW=,?$F'VP:E@@JS6Y*X]=D<C89SQMOS!#B< NV'S7A@9B
MD0^F3RHH]RUM^EE65CP5BS9%\%*)=[U2R#2RMUS5.6 D"X-:#=#O$/&$^O#K
MSFQ[I:&U#$XP&*]$N,?4<,,0J#:(DS@U0YOU?INHRB:K+@<%JBS)'$,<%]UA
MS?@2X0R9\*ZPEGIVAW<1_7'>H/D)SP6GKGQ3(8/<T>7 D2RHR1BNFO@NBD26
M)JV/*CAM]]QC[\&I!V$AR<H/Z3_TC"_E9*3@ VP/<L4F\(-\+#"NQJ3)A\X9
MA3E:B5)%#J"& BS>G[$U$-X!Q=LD_1\3B5MA4FB_EM..4+P'252B5]H=1^ H
MT%CI"INHL.W"21@=@86:_E/<:\3@,@>,=&+#A0N2"%5NF,;V:O@+'!$:H]C9
MO#&O&('JYTEK$R=GFEGY&19+,LH]VNEC: *6G:0)!_KC,YSWG^]H5[U/-B ^
MUQ*_KC4@Q%&;,4R6&J+$L;8I9])*T 1R_&:1S>UN^.-TZM:M@K*,[Z LHU3@
MP&'L;#N!+78]WSK#3M5^J>P7S.KZO5S-K#RZR*O A0H8,+N==&IA5'FYD!0G
M=(^-+\3O%G2QNY 8A4E$#*H:#P@U Z1@<=*MW,P5P$-2%DH+ J;AN\R1YP>*
MD"%M\W5(J7D1Y ] /-)=ME7W=+&?%2[]D6N9M">Q[T2"?9"#\)C%YO'3I]F#
MA]_)@Y+A6CF?HY>:[6ACL"+:.V;WJ&^?'CRV;/]8"*52(KWC]Z>MPOCVX<'3
MA[HTY%YU1!]$YZ]9>M-Y8/CM7+_$D*@S6$)MZ$G TX:CE!P^IF2I-])UJ&'5
M[9L<)?7&TZ1XL;9:-G1)TC<L+-Q\J) FM ?W. !XW9"#$MF_9^5]H9<*/&O4
MXNN*]<M%\GH/;E!>[^EM7F_'N7QU31YYF?'2MV]>/G]U]'/ZZ^MW+]/?7O['
MT6\O7OWZ'^E/KW_[P_UX[^?7K_^+_OWVW=&[E[^\_/7=VZL<WY5'?YFY"P&X
MGNLXB=I(*U_OK9Q*%1==,CT)[$PA"10:?.9$,;PM''-K3V!@(YA%J%O2N7W!
M" B .2N-3.U\&^%\(B0/.TXX%^UOEZG[$DI24M4 ^</^6Q3!$W\HB"'WO/7=
MR;Z_3SPQP5E3.2-#:FFY6%:CM&RIG/>U;":LMIX.5[NYVMIEP>W\J] "JQDW
MC"/K,I%"BA@.VS6< I60E<1L.?A]T:[5NZ-_A+<![QT8Z'"()^2?2)9S>_Y7
M$[,_"FNU_D,.MM#QUC<MDK_()PQ_K3$ _7WB?^_D<'@Q0Y;:X:\)^+.>>"6O
MP>ARSB\/?^NF=O@K"7X,AT;UB\-+/:)U] <6K?&O(0W#7_/V&_Z6;([A(!!0
MT.O$S_9$.1X)*/T&M<JN=5X^\<RXB6D*9H//TEQ1>0B*N*V[9]EE@PI$_:QN
M%I??,']VHZ1FH_#V2,[9'A.;8B<E;ZCV=FO0=/=HYC@VYJ2 _S5%MH=R\]!'
M)=[$%3(,U]5K?'?>0ALZ3*2U##\:SJ L/H"XM(L<D,VH*)CE+>).DWU :??T
M)R$GT_WPB[.Z:LV1\6J1+9[DJ?OE%H'MHBL[+3)J\DVY<"K<LYH:$H8#3!*?
MF>Z[R"6<JGOM.-O0:8/QPD=OXN2.J(.$]IE,0D4 1*=\SPH%^L*_\^WJL26%
M!6T JM"-+_7([OE"8U9MY99," 9FVK/'D-.A_9\T[6!'7/<&^#;!]&C*:B4U
MKP!C?T[C9;NE0#"J1!Z!<P=M74QI B8A.4<2NHFSW:B#>=G,^S6Y>'/!-O=M
M.VU%*)(5?CZ_*/IV2;"-/Y])/)7APTQ&./(6<#>I,L+4P.^V6*ZK8AC8D0W-
M%^(6>RS4O+5&&*34*OT8.Z[JWD.NHC.D*98K9E\Y=PD$YJ_MK;+DS&>S!VE#
M0V?@J1-7%(7ESJK,($#ELX;?L&YVR^AY@[26LL_3ST_HLR%E$-\#H^BXQ2)9
M8AY5[FRT57[F%(Q JX'4X^:+MOA(@CXHBG.KY+071]&75+(^A$(KBTLH.-AO
ME/\A49N.N&.JVA34 36QH4X3H2QQORI!8P?&S><8-Z+=-(*%M)P>;G9.4Z&P
MC;6-F54 0R*MQ^@.4T'&X;X@6C=AQQ(CX]CU$N3$HG8B'#Q*XK_0;M*3'ELE
M*,% 5IHJ66E.$;P3)VN=8DZD#($MJ[!2@9QS^/B2 OV(S_HG0]9\/W./\I6%
MONP&!@?5KAT\XIU(^,SP/<#.9(I8@CZ[[%QM.,('9RY5&O#P!H40G]V&$#]6
M9/$_>5HN_L\W^?]_>/B0Q"W_^^<.-O[^]F7Z^J?TS6^OG[]\^>(ZAQ)WY_V.
M6B9<@%*5[)(I*4[/R3&=DUVZ0%K)H$93#>^8UHQ3F.$BT8%*#J>$4^9?YLTH
M8B/Y@"<ZD^/;1P?W'Z=KZK0(KI6)3!,P8E&^:5>VB081#6WG.Y\^#.\43_97
M<Z,ZLH3\T&_VT\%1+=OOBRVA!2=!>=42_PG:(<=WK N] /F$D^DUZZ+T#KY5
MH#3RE"$<?.ETU97AJTTMRB3>.)G JR]KSS46\Y=YUC)&(L4@9^YJ(0#H0%V@
MG=ZON'SBB\QUA.QVEAT5L'B(7/()8-[IQ\*\DPO!O.TW4=G9'KAW>A[<FP'8
M'%J2B*FS-&V_)^;&/*X[I<6?>C[&'/7,O*ZNS)%W2W<XA='9DNS'KIL3S["T
M \:^]#%W(Y;,EN#;!'NPAGC-7IHCJ+L3EX2I/5JE/!*P'/E&XKI$G#B" 0.@
MW3VR(K(6PNY/=)W ^>U<J;[5!TZH)NT(DR5,C!=89&-ZQ,P(^IQ!A7FE7"H]
MNVIH\LAZ3 )B?<NQB$$9@483$(BE8_ (U?[NC:LMRK8O4>.27K[&A9D-(U0'
MEHZ;>_&Z)?_J%\?J@Y91NT!#[+/C;;N+&[[XUAO8U8^NQJY^\>J?KUZ\_/5%
M^N;USZ^>__=U!M2-3X NM%ZE&!S@8JQ_3$]4$KL2639+G<DE.$'[6YOD KU1
M.1U5:)S4'0$BI/0FGT!.!J5:H:8E[N$J;<LNV,>5IYUFPWT]>GD1[HWA %,]
M89.)"?![$TVS18^,^]8J>KALC#+@R1NHRRG5,I4I3'9D"M5@&Y$J<5!54S6,
MN9@<*[C32^ &#5C[,^@%_.^CIQ0HF*2ZP2]+D(!\G]Y[\&@0);@X-NS1S0GL
M/#R\#>S\"6S8X,QY?#5GSO.C-Z_>'?W\ZO\>O7OU^M=K',IY9QDE4FX3T%(O
M">XF-E6$"]4+*RSN*95#X_UG7Q7IPT/P5SQP:O/[3^Z [E=.YQ7R\R?.B]5J
M0Q#<ZOC_?'/X#?[=;O*Y_OO2(SPK%]T)77KX;UX)S=V\YIO6[57]Z1O:7?_>
M-?I\4%L[BUB_P6WC;V0#=@N]2![MM.R''U(9M)N*@P>/:0IHB/?:\G\+'F<0
MH&[QL4^*PGP3[WGVW9-G 8$\\;[S7G&1\.+HO5SV O@_U9;]D-H1N/]I,,=_
MPSI_"<&[%;F_HLA-'9"D-"^Z'/N"XG6%45[T_W)R 5,D$Z5\TMF\QZ:/G:0]
M$;6V[2X&T5;2QH-X^V6&,:K_ #NO,Z(6'U<$<JE!F,A^H-YUKQ]&3P:?O2=4
MSS'O2PTBQ,<G8^/M(#C>7C0Z?JE![(FD?[6*[S/:+*9 QHLCZ]F2&)?S?D%E
MJ=(-)G5+W_L6RD!N[V 8&=HTQC3:'XXSI!@T3HI<:<$:!83DQ)K>&<$'%-CM
M\-F^=<9"6VQXKHL1^D(F 7VV_B5,7Q[GD-AIB\!XDDOZG>EUWLC6&@**W_;K
M-<6M WW[J_! O98^1Z[_9<RP_X)!=E1R1Q<>5?EJV^)CS5.?1UCTWX(__5K]
M:3\RTZD6T80I2E!=[*KN - 1,K=BU19G5&.;C#$H7ZM3_6=,BIVVP<"&N/A9
MM]^D8-]S;%7(4.^MBF5'!_3]!X_+:OC=\:^'GMG.,U8GRIB"X<6P <X*2L;0
MZ%8+;XH$/YE"!)=[@?\\-YWTV__SS8-O]KQQ*MIP@6C%S@&IH_7OL^9O?X>W
MM>/K)S]5#",[Q-OIM0/ZM>@PLQB&ZL/;&?Z$,WPD)^753JK:27]E]75ERXS\
M];ZWW?E=3:V[GV?P_T[__XD^]E)?]O%#^2L/_6IVR:THW []:Y!B=XZY<^NX
M<=[\@LSDNG'C.Y[=>7#X*'OP\&GVX/'CNQ]['HBE_=VC?]OWT<_S]F2'(E53
M_=\^[=D_?OIY9WI\1-#7[WOUM_L_Y]FE7WBNX#S-GCQ\E#UZ^.A/3N3EOF_O
MR7V[9A=<LT?9_4??9?<?'MZNV5]FS>X_R)X^/<P>?_?%-MK%]?M?PDZ9."4_
M2I(__KC]9$.ZG9#;"?FK6&KG^,3G?=U;0^\F4>_T)7CD;D7@=D_<3LA?^[A_
M;E/BF[P1#L)O#P\.#P_O?Y\^/CS,#OG_/25@WYW43?F_A5,D][-G3Y]DSPZ_
MP_BTWHPX9Q?28<T3#D[AJ?[Z\G'_V;/;W>*?]/AV,L*3'CQ^^J7UQJ<P+BZ<
M%3CO2XX"0RA@_Y339W3"7W^MG>_X\-E3YS_>;H!A$.3PR?W;.0F"\EWV^-&C
M[-EWNR)#7Y%-\>EV_GS>KWOIK(8FK-U??R7O/,H>/WB<'3[^%.(]S#;^!>?C
MWNTNOPK9^(L>_N]J*A6[SK&$)]G3)X^RPX=/;O?!A=,@-W%.G*EX^. PN__=
M9Q*4K]("X.W_LW0/5VK+ZZP.GF6'SLY[<O_QK>C?JH-]ZN!A=O_98?;TT6<2
ME,DZBJ\2 W[EY%XO\_E)^NW]@\-#PM"C=U9Z1[MHW?4$&EP%E%RT%4S*+<ZF
MGBAT&%(+18W(M;@B\(84-"CE#^&J5/<#E=B?YBNT@TL&C$G$;@#BI!:%KB@.
MP"_:"?4J'8#NB!MVE^IP!M5%CQ_=SQZX.;FC/]W->!(\E21HB#R'M6_40Z2/
M"^ZK@_;O+??N0M=$J3>AYMQ4Z#W)1],4:S1PX&*P-1>2#"F];,E2\M$E2SS:
M@_0M$\*OMADOP-3JN2'?CR/A+"'G3$4JM&67;2GT9^0HN8P<#9FW/JT<)=\^
M>?H DW5'?[H[YDN[?G0G$\(PZ*=H>C"5I@^83Z7L;"YVX;0*TWT4'U 7)'5$
M6OCU_1>;_.M1/;R_Q/?/H:<N\F3\=9D[-;7]_KRY^#.%QI/']WA(G[.N^.&C
M)]GAT\-/4=R+$F*2,U"/><I*HE#67J:H(<Q3!D:@XV?1T,GD+X9BONPHOKW_
M.-+B*!^T:F^/4?8I;;+O#I[=M+K^VYWYV7;F@Z?.07GV>3>F]".\8"7X%]\L
M'_MB^?][AP>C8,JT]^2\K _.9]'V!@DJK,]H\MP5Q+GG=!@5_Y;$]H4^E..*
M<D,:+XT7P/8OC0\^@VD@TSL"Q^[XQ$,&)%]3!37@\OC3/".?@U;DZEE$<F?T
M%O><C-Y;ELMN>RFMTA3H/R,ZI=VLRDZ;:D?:A@E&V+Y^Z_9- =O\_F,VDW^8
M5C7G*!H_%==)3D?R8.1OKYSNO_&JY'3O:ZHZ.F= 6V[\)^V#:_K<8Q2AR58^
MJT\'AMS% NT7F>K+S.[E5F+O<?:E/N Z:"XC4)>UA8:<^AI.82&,>C'W&R:M
MMIV5(_:C8%M=:A2L&=$1B*)Q,8._ITR]6D*>3]F>^?$-HN"\?TO!.47!N>M<
M'G!O?N>^XDKXGG_^_:I8-[]4Y//5DGKGFGX#DUQ4K*RF6Z.@^:Y31V>54XLG
MY0;LS@T]39FHT%:>&JO6MM>CDMQ+SREBC2NZLZ*(DC?#:/NF:!(.L@O_<V0U
M*KV23= 005M'73&1-*CK]P*4#^'ZJ2>5:_?RDO,JH4M;H+S_AV_\G)S_@J:@
M9K7<LXU&YT/]4W/-D7O_0(GIK]!5$W]:A5Q\)L33BT1(V:9BV*-O,S;4EV=R
MO_+<(87Z3=ON7:OG\R/)CG6*!6^"<?:,I#!.T'FD$=FLWSX\>/:=D1+.)R"Z
M,IU'2"+CM^*6&-0CPHKC^1]T$<'DGG93@MA0/B\(W-0M4P*JK(%\Q652+0?I
M$?;?L7L0Y0$M\V0R7)1S&SWY#-]',4>:*602QY#E#*G+2U T3LG7GAQH-GF#
MD[1DG)_>)0Z3$HN\)3>E(#W\;4 \06 ?'7SWA/>Q_WYJ_E&V5I#R*O'*,^1
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MD'E$-4LH\"+$%JI8D=4I+\_ BPRI*VDI<V@6S@4;ASHF8R&93$O##Z64)TU
M\2B_*AVO#0$#G#EN\#8N.>V\I@UXKJ<DIC"CVHO #^." ?2UO&[5 F(K73ZD
MTF*?%GI<*[34$=:3.G$I5RBVEAGV*BWL7HYHT=>5,5%K,]6UJ]2Z:7--/::H
MLF*YL;'9L?]VE?-K,8E%:'K!@CB525Z%/>LBFIP-6V9+;K7SJAWTNH.@->K@
M.NHHHY2R=$(I<XD4%)A6 IX4DOB%ZBP5%M*@MOB1#D,7?&1$;F#?1G2PB1'E
MEV=8BLX=(I*SZOZ"B6J6L&"IJ4I@Y DIRGR^T;O^1I_@#E@,T^9;L0M!$CFH
M/KZR!@9#00*"/:GO16KVNJU@U.GC>5.N(N((VGOK[C>R];8C32J6G\XU)SK7
M[("KZ8[\(L(CDR$JB9&2<<F<N^./W]--K4#_JD7'VE3T:DQ%.U9!#R) Q'5\
M4D4!5G-2^%N284P- 69$+'.XM2^VDXZH_R16?2%8/P)-4: Q)XPC=J)P"VC-
M$$3U91PJ/HNDH2(=>*-2RY'3:S[**DM3^H]:9EISC00AHE6>JD6UZN*D%]^2
MNYAKL81Z)\K.G!@HV$/1%>*.T?80<*J'^ ,K;F/4,O5S4@(0DRZJLP=XK<FE
MDIPL\)KMG6JE8^%J=8C5XZ 7+4V24&HB!AC:.-_& =,J^F9V>-8Q'N,S-_K*
M[98+GZ>L<_=Q'U/S4VI^3+&HLQ [E7M5Y,M:!21S.R2C0EW-/IYZ$X1Q4O!6
MS".07X1)E/?BPV4]G(SSVBW3:\4R"DN4T*K=HD6@]U+#D>5JW (WO=9L^5[H
M)@7AWY;Q2=\A;Y"(OKLSKGVH%U#L0D!,[>/=G.[0.6%$\Z;8XGJ%]Y6W=D)E
MM"28V*S)D8^QA<Z%KP(N]&M.)<5+IU,NKNXWZ5]OX>M4>_IF"S\4P&N507?X
M^+A2@;S&KEOU"7*2%62_D<Q R&N<DD/$3?; $LM7?/I05E:WUC+VJ]D@-WL(
MR_>V+C^HZ?,@[I2M JJE '6%!V[LUDK7X7[B>TYR:JCJ?_A<AX%NNFGE'@>*
M0U+B&XYOU[]I5_8XP&EOD?1ZXJ-K->/X\-D@ ?_@ ^QX55(C90H/\"8EW>5,
M2G9_X#B7\9*/\"4C"[0LP?NMLMT/G^F]QBE@E^!, CNO.L-!T!GUZ_.KB@+>
M=11H;#2/.T%KW-^L(TEYL;M"JI$!O^8)WJL^(] SNV.*E'_NM8T&FGNX$=Z-
M(H!K';P=)!)-QYBL76_>0("HX_[T(J2^_DI;*UBU,BO(;Z9A ZO9>?20-:E-
M4(_C9X1Z[+^@'AL!=QZ%V_R%S)1SRBHIR>W47[Z!Q\)&I."^* >:\W_X1ZMU
M.LC%#ZJSCIYO' %C9MELS],?)"-O+_<AV^%OV8X 23Z)*(8EN)U3,&_>YSA5
MJIAF<.E\ ?:2+K!Y<_I>0Q)J/%_X<RD5$E9KTDV"6ALWTFZ%MMSJK$0-*"55
M<[$"XA;<EG(:<1=E7+ 7H].)7R_%#PA:L!HJ.T'/RI %A?,/0%?D&16OAFJ>
MQ00\[23,K?@F4E:P3SK&3A,7O (A6E<((9!/L;+PF#^PO\SB[ ERMFM_F/;[
MA$> QS,!R:BF]L$JP*DL)+=TE_JTUX!)W4X_QIRB/0N-54663K?7"4;]%@]G
ME)R6'6?0G<B75YD=Z.5/*7=8F=@UK]SA6^+"Y,YGY?95;C:C-H9 606W;8QL
M?L4(U/++^P[3K\>&6SF^4@DA9Z5WUKFRF3KM?77<*Y:B?J%C:XXM6_-5IQ7T
MAW2!QOJT1]8%"LMC'CG0=U#=HW?OEN>#9?F;02(\'=-[ECT<52%F?V,PU6U4
M8@84L,BIZ5)R7(I.BME-,T6^KV>)O[EGB5?;LT2KL(^GQI^E$6(:Q)XH[Y=7
M%%,C%R 3.Q0ZC(L(8' ^*.+Q\?2H?03Z89&$:VXSP,'9PIN&J9%CU+*<%EX*
M]JHROJBN(Z.&,V]]&PTY [404:@2\W0)MS>4OP<>=5S0M7)GL%%$3T(%QNE%
M/(F7"C&/4("%JGPC_+\@48"N[Q"Q&Y.R3?R3U3*+YW,49>_ .%^ K,_FZPA!
MOT55_YADG^>H$B?VS 79V^+.]3'GS;'F^8J:<*K I82</3?D+/%TRKJ3+L3
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M7]WC#X5Z1%UO_XH,I? E=;.Y-FDCD?UP0LE;6J6,?\5*C21CVZR(:KY+G=Z
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M'LWEK*3V[<-@..(:2??B<#K%JB)U<6.; BRZ7M\V*5S+A2>'T63C1(:IJ*6
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M6I0!C)6G5V,;+W*B9(\8%^NM/;_[Q<FZ7F FV\:>NP)1,L0\-GN+H<T7&5Q
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MS!UHZI8WJ,ZLFX"]=!9/XS#!8!/5BE!!-FH&50%;+80RI>E$1R#P&PSG$AH
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MXYUC<(2N&$ 6GSD4C+[AYQ72].R=,KO]3PN6?==94')FI6D6KE0!W*+S#*Q
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MLX'9\3_X*0O7/EC>:?C:R?+Z< \/&A XT(#0R>,*+D!R @;?\2[-BV2PQ%S
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MSPK2=%&])8FV/S6!&[314S,C*L\ 5@,$VMG:WHM,]MD&?:A(SRKKV4^3Q'M
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MZ]:W^P?TH:/83WWV;3V0_1*+*F.VWQ%=_$':-@5T!1Q==/E'=0EZ($V$B.F
M]$L4?MC<IU-]D,0764XM:3C\I*O&31-S.L_$R:.NB[JS(![U)37HB>!_X7W8
M)+.ZQ I(F ]\6J9J."OKDENH&;+P<G-J N@X/LSU)YLO<,-#_QM?);!^CIOB
M>#/N)UL'*6@]V/^%QWK"0:V.P-/[I'^97,39=%BI,?(;#_=@[L-=2YUS9G.8
MO]5\?@9EX:(-75A&4Q%J#$/PN#3B8MTUG 3Y_M;0D:,.YXD6-1XW%:#6<F@%
MKR7")"K4>8Y18(%OE[[+O["_>82:!UP\;,>U[]0O<YC#^#[O3O_W$T>?4XPT
M49,ZXWQX-7*:[D*:?)&OR<1CV-K8;A6XN9=P,R;])?J$V'[SYDWWEZ WL5]5
MBLM>6;\F<:8#)EKAAC,4;K LA1O.5+A!<P&WMF9\-IVH%(R#*6T<(/9;*Z>D
M[]>\) IJ[X3B3_>\^P#>O'/#F^%@R_O4_,$]!3]@E;7[<AHDO8$$87]PA3%#
M;#N.G-=4!?TA+N(1\DCBUOHGMKB8R&@"'6MH&0TEFV"5CS-.SA!-+A8M\KG>
MF _T0_.T!@F+G3/$)"S$0Z0OT/)3AG^-1^.?>:2T.NX(),9WPV%(%?^Z:M-Y
MR6E9J7P<PY;O=QV*C=0+SE..71/1=-"');WCG_EE!BL[_@R.K/-M[6>B#/]K
MG-T!4R6!M@IN/@O'Z-8G?2%QH3Z^"EO\]&,JI:5V2(LFA+QM?[6EN;;W=P"_
M(Y $"+WM6/&DNX:<$^T@4]"$C!#QVG64TL@1R;:ZZ_*H9X]%V#QU&,-^46"=
M.?-+]%1UC1KTU"U2-'BCIRP[1\0#%]*!5DE=)XI3DD4:@(6IGE0-+A1UL#,$
ME[&=0*[$Q!2RIMO0$XKVCXA<JZ"QFL>+B"Z7T3XM_#Z$TY',JW,_<7>4#ON9
M5=V911C9ZY^!7!]G5WEZ93B"#H3KY3=U 4?3!]N9JC&NQ1T #\%%81H?4?\3
M(B8T<N?D+HK "&%/\2E,D\5TZ'!+2K/D]N^2<WJ,K03 J!:/@[4K,\?B?>"W
M4"=;=';! 2CJ<=4G+%N)C\_PWV[;+OWT8"UW6**+& ?G]$"&Z\GR&:H,_(]U
MM)QEW$XMLGPI=8VE3M1V'S.3WS'\-MS=VEX;KK-IK%O9A6<;_WH&&^+,])]$
M>SLI<["S"5-Z/P-Y6)#H!G8@_ EDJ5:T,8C CY+V:$W;5IQAK*>";%I. "4E
M]0#.I*,G&-YCODXYB4\DE(R)E3 <YY7B-I0NM1?!"!Q>,.J7(4Q=TN ';6IR
MVPEDR58UI@BQ*29A3\O-G\E _V=>7H:?<G05)N'[PQ\_7&X>;M+9#'\\N(R+
ME&9OI K8)<N'8';.?*-P;HE1Z-89(QQO9IW4 ,Z!H= %2+-7I!"K]'I]0%I5
MN+!@[O^WX#U>)7EAH\ME._[B )VHO,B2&,8-+WQ78.JN[.>&:/3W@[-WIF-,
M\"O9$M21,Y9FFB!Z8_WVI"3&23 JAD/]0O^Q_T9><'1.]X?#. &9:KKQORKB
MNDM0QQ-+.X:5WA]*VY4RI.E!?-L)1B%*UY/$H4I:6!,+XAUC.S>2B^Y/4'=+
M4[V*[N. E5Z&I!1Z4@<(/<Q9.XOJ?IN3W401Z/VJJC-S@-/ [)3TP2PM*4]G
MJ>#?[I\<&OK6W^(>AII@:\MN2\K28=S#:_$:&E3N6&U@:$W _LKA4P,B8A2N
MWB1-,2"%HFB;D98PFC_S\66A:*W'>5G!%-08ONLC/)0:F\@XHW"$T1;]8VE:
MKTN358PF.W\DC56!^]S3 R&A):;DC-NUF"YDHF;X1R1[S7+XA8U/E3K<5C)Q
M<3]!'?0K?'IJ9HDD4+>L8*+.1)CFQF62YOU)+\D"1HDR6^VH3BNDZ;>C=F9F
M%/^!]J9">G@"7-IIZ"7C'$-<^H_X(?W+(L]@SL9Q(I]%DU5.1N,J'R$CJVS9
M ;%C!A_B B,;#B(>Q $;RSS=@/JM<N([SR@G_GJ5$W^L0MMFGH3<QB$I=$-R
M/H%9Q]WE#*;3C0Y//EE*(>F6%"[IJB-JU/Q;,E1H_,I)_5%W81=F>+@MN+T!
M4%*367VNO*_3JU@"SB;)X1ZJ,-P/NH/&'SF?EH<8?7V/Y$HX87JB G3J>:;D
MX;<?'![;.O@]12[% 7AL]'$A9W9;,C4>)0$B>)$,?3IGBX%]O"0R3)>>K>'F
M1B5F378Q!<@Q3<"_)(^1$B"][MPN,1630W<0%Z!SLMB:4R>6MWUZD)M@%N&7
MWFRRG# [^6']V7TQ09W!"QA@G@<.O4E@^;TP@NY?W;"].+)3A4<C/&1G)\!9
M!:%7G?>-7]VQ)C!CF)!Y0_/M)V+&+CB0LC+<D"SS,AJ.=5F:,K&V*ZWEI=&5
MM$1BOR1((2ULEUT>IC&Z"FJD[ BKW8/OT!"4/!_;PP;CN$&!+?,QV9=$52SS
MA\:$,$8]YNUL#[;6<J"36!HI[/>1R7KBR<J3M1_ R4\L?\"Y*D;ES^'_<+Y'
MX.U_^S'YY2D'>=];C[LCC<5Q4^*3H[++#!ZC:?(<XCB7,3KR^/= 61L.NM)I
M.#C $@<)T#Y9&?MTJ1C! -N6JN*N+Q5%\/PX=\:XCS)@'^?2K<:*= I21!(I
M D%']>I*CK/R,YQ%Y+.IC/MBM .T,0@.CRB'X,U4C)0HL<27&+AQB)0'1JRM
M:7A&C@_XWWB5CTTS7H;!)=!0I/Y/15V#&.;]&B$3MK6+J$J=Y-1U@UD9]UDI
M!>Y<V!BH3:82Q[1NUZ<CGW66@-FK)P=]:V?6?-_)@9PLB9'W<:@\7C.3V?HM
M820 MCXI:XRDJ*>N_LX=L"5:#$9.->DGB9M,D/PN2,T\)7J>^%^4-ZC*QMZV
M]*;8NZ6L0GL_$7BB>8XFJ(1C=&(A0:9[Y)[0?2O=;(5Y:!0X 7_-WJ^^]-.Z
M9&CB&<91[3C)*: ?5>E!3<W@<H[H<'(MJ:B=89+U:PH(8C'"*).6R*1$9!Q!
M@[O5ZY_93O#*8R&%IQ^K*T,*5#BZFZ#3\">-KTM;P-_41$[S\7*J_;G;A(CM
MK0D^[<D>/ WCYMA4D3SU38VT:;BM4[#B44J+.F5Q."<[MQS$_Q>>47>']]PW
MY+??#HS7Q'\WCI-T&&=8D%N(8X5XA-53& =&)" UL_H#G#[V2F(:!/?8="4U
MF#X7&SL&Q9L&3MX&#]H=C,<Y3. Z0BB9UFTP8<2P8:W\SK'$R),4T:\UQTYD
M;9+8E$!=6&:6OF9FP62I.R^;PKID+C 9'9HFVO#:!)$SWTAET(=I@T6.G30E
M]KZ"60#)V-]XX307/=+]0/:Q@\SOYO>-*8O<FB)JKI5G8'#H_F*,!3!=ZLQ7
M!/H>T^Q]:+I8Y&-PC77,/*Z:L]E*TZS91Q"_,,A5Z?3/\L X?.%U7J?4P$45
M0U4H&P127["1<"E-#ZPL_E$/+G1* &E'2#?G-8<NFJ8=B\+R00^/.C3\XAF%
MAM^L0L./56A/VQUPM$M)]57Q9\1-A5A<JJYUK9"K0Z>!+5*\2NXG>COB?:+%
M9S3C)>-98]*^J:^22/LDE59VJ)KHL$-K51&V%1^ 3Q23%KU0K:CFTE*$YN=G
M-)759OB62 BH#""Q[7/H*%1TFE%0%#LZ20DO]6GRR:7ZV"JNH( FOLMU&QW6
M)HJ*@9V:)MK+MIF[-N!DEX-+Y=VV*35/'%<,2 5M9.K!LOQ/>J];$H(HI>DC
MR>F8RNVDD?,_*;GG*LZ0.0*=1JY\&N(+"H/L,=169T<'QI#6IA)E>^&#G".4
M[!)I7:BSI?QM>IHZPD96Z"AJU.>>B)IOBWI"NC!4^BI<-]YSR,S!BZ,4_\:3
M5G,F&N\%5P_/=Y+N(?E4)/I)T:]'G$X&4>T :F,;-)RD5%W%+*'Z(^6SD\+;
M9JYLD!2HC%+(R#UVG0E=3D>X!'PZK"P(N,&8".M-'QT9,*03&"D%HR:C&&$C
M0;"A>HQ9X[:%="&^$_\7_B"21:/9^5D0@$$#$4P"(UT,W=>YWILW'YLBGE93
MWK>!_V"0,0[>&VK")PT _GTLH;G6"JQ3J< B11@TQ9SGB6QN4-2@CI+R4IIE
M&B2P=2-^8K\A\I@^6>CG8(J43C'YD#6-=4[8Y)=6U2YR&",7X$$4! 0Z=V_2
MOY:;>TI.6PH:8,P;S@'I[=(ULJ"-PQ+TZ!!U<Y&#]HLK"60F4MV62O6-T6N4
MX[0TA*35[(=%,]_OS$Q@.30QC(-OQ\HR_"0.-4DR37\T3T:;ST!'JITE/*4\
M=3/*Z3>@3G#2TOSZR;H6XHV/\7S 4R8<8Z_:#9@#)IC$V:K!E\L#TY"'PGP9
M]Y_$@^\"/7&*%H*&K@N>9.[#3AW4$0K,]!>ZS)$:R2O%/EV#V3CJXL?UMT\P
M!]&J9TM*O$&H^JR3W37$QCQ$[&SC)-@H!(I18,4H*?5;!FYV@LN?, :H,A*O
MCE'I_'P%BTAV"$^M$)M0AT"R[;BPM Q-6@-V7^ &:BH?>]H0=HI=W'IL@J!X
MLQ4.XHE&KVJ+P8P$,R>Z\J9]])$Q;NYIA%I, P,P\$87SAS=D]WF'#]M;+6E
M1TX?QLXY;U,R7"BFJQ*XY3:>D4'/.3%2PA;]M+10+_TR(1=)4UL_9,NPF_J"
M5?FXLS^3)N:>:G!P<QNBSENG6:+]![]Y^>I-:Q.7CGOF)J-V7R/$W3"_/[,%
MI#T6+^8,:N9G3DDKK&.A@> UU]0B=LB9..P'7I;Z=M\EFTJ2HZ>I"@H:2&C$
MOPF<493QO/CYYI813ZICQ$I@9[^&+7XK914:2BE+2SBL,T&:FQ@ C0%M05\@
MQVFLY;!7#RY4M9*SE9PU%",K0\&O$.-#)'*F S[D9Y1TM-(8,$C$5Q@B0M%R
M'/O,ZV*EXU:R-[^.8X$1'2<\ETZ$U<V+XCA$GJ(6W:CCE+8B<"5U*ZGK/EGC
M 7BC<=^48\>6Z9GJX QY.([$2&9<"MTGZ[L.FVXEGROYO+U\6O^#!-(2S/8M
MBWLY*2LU(G]D)3TKZ>F6'J[W+)+R,X*Y<X9<VA)YS)K@(*8ZT'=H08>1>IRG
M23_1>0 J436!>N\X;[HLG'.P>73;#F7S<<CRHX8)[3X?F-#+K15,Z$$CTS,B
MLQT0(02OT+ZFJ@V+0 D,M*)1\]5LD(GYI5(,,\:A4KLF)WM@$)H.)!NK+3HP
MGPQ*0: )8W I'\79,P^<NQD>Z80#0WUT;#!5K9R?7:4EE+&-!SF25H77!0XF
MTZE-!)52%HR!I?25=77)&2!&/$PG/5MFB3.DG-V>->OAS%EW\K+P74;%PQ-2
MG&&3'YXBW[=KY(<[F=AH:DGMX4$E-$\W6].2L6!Q(!A22<5+!,(*Y@%A^<T5
M^#E4=-PJ$ WZ2%@Y*JV=25M+?&GF8)82NK9-*1\!>V%B?7)G^WD)/7G&3-R7
MOP$=C)B PC:7 ^)YH'Q>>Z;\:1=$V"JG%HR 1;F8#%[PD!F\50+O\?DU-FK#
MT1,"@Q;4!TQ)@;I!$M')2(,@;85B)54J+0D_G_S1*PYK0BP/CDY7P9J56':X
MVY0LD;9&UD1L>-8T!LMNZ\FBY.JLS.&Q6DTVN D><D<.RI7\K>3/?4VF+O(J
ML0!,1Q[=N@(D<R'SS&K%=I6W"BFN9&R&CKO,K]L+"AP]1D/0T4&IM2!>>542
M #@F/[OU,12G=+@\[8WPF!\ED+E1\>&//0<RU*+E(XD;+H\4^U:1"G;S[ABJ
M"&\;JF@W\9^TSS_+J[&N?S!__97NY81_HJ<8VO!^HQ][QVR'W2&ZX-;!HH[/
MLU&@><)SGJ%CHG1!1Y0N[([2N609$O$HO9!'>ZV(LMO![!<A"PMF?R<M@(&]
M>Z&.8:,$B3_#<D,T0BO$)CSC+8$38HD(=W/7&$O;U'GQE>8NN>>P1V*V9>*3
MNC^=IA[PC;>JA7D.X9XY)L0!=P==X.[PX<#=*UOTD=FB?AC(AV(W6-UU;KNE
MEXQ;D'Z+D)+++5_DH]SPR0NU'/Y(]54K-WTEMMYKU%6<UE836A2%)UYBRSL%
M XQVQ"Y=S6HH$G@;J'0*3O4YS\\D6H7KRSQ5*YE<R:3[&BQJ(3)(G=%C@2'>
M>G$*=*)/%PP;<1RH,BEHV4;)%Q1'=!O!5U=(6YOTL9DB41Y&DO,E6BJOV9P;
MYQP8%EVME'7]C&9J'M9@!HA 9QS:]ZL/5\*]$FZOK$'7R2,1L<JF=2U3D0F-
M57*5#.!RCHX:"T WA-4D9-(>E=ABA>/3/&\E?ROY:[5300.:LS^2PU_DB^@G
MB$*.!4_D:8I1LLUM^@!V:Q^[?)3B6NE PH&P*#Q:@7P4*,J]9X2BW%ZA*)^%
M%IU?:2Y 1]Y))3IZSSN+G1-83ERG9>80(T!7<1\QA*(HN2WW-9SN?6REI)S\
M)9)'/1+5MY*E^Y,E)R79E8Z42AGP72Z*>-2 \DC1PX J\@_R#-O_K5+?ST=H
MR!>U,9GNM+8VO2SQL-% W(S5R;Y@7Q57\EI3X*X@IBH>,%$?^,NV:4$CHHBP
MH(RL1YL]-\P4S1&WU?L\\_3XC-3XYK)SX].6_(\..=;S2)??*BL4M +HY\RB
MO\>F7LQHVIY&]]+),^BS6_E46U+EM_HT[F=KBX9MMS-X:NSB\=MHP<.+.AFH
M%+N>=&5\EX2BOQU\^NN',!M&'QZC0Y7F_<]<ZW/, 460 SS.DC%=ON3D*XYY
MZ>T'3I!2K9W_-6A)B='>X*9);D]QV\&,>U<T!+Y%<Q+9<1O8@Y[=8)$,B#^$
MM@NA7>%(QJU@BT6E5SI&\)#7&?<=#HF^K6#"QY:/N;[,[69W&.O:3DQN,-W\
M!"+G;/V,S="=V1L>WOX(V/DT&?@EZ@J[""E%A;&Z_SO^49/PZD<+R?^]' UZ
M2[DHC?O9'?0F;7B_U5V;Q (GI7D$6K"_3$K;!]F=IM>D#]X+IL![K6)ENO<=
MMALL?9E@TQ:K[TRPH@ENX+-0WK7$E5'@<[>;/C]$$=0'JWA 1QFWK;+/^7WS
M;#,<*LS?I"ZK*/:X,6G)-INZV3.#SN5@GJ_0^!#F 4W!_KJ*DY1&(]G4YMQ=
MJUZ95-A\$O2*M'DF[4%]>01?5837,26E K/[;AX+:3Z^3'Z#Z8)29;C4M@K2
M:"DTYWM(BHOW9);3=PX-10VQ]:<7<'V%6+ZD[*=YR<TF#:5I;[+ )0KL$CT)
M/=1BG_W#V%5/60=U:J .^/#--K*K@5H%R#%86]3(C:HA$+F[7XZ&;K;3>=(*
M+Y]16F%GE5:XC?@X0_I;'":#OW\7_W=K&V_X,?[E7G8ZRP"-Z.A_CPY^/S_^
M]U%X</K^P]')V?[Y\>G)4X>?.FS7=/9)=Y;2M"AT6&@""^WS;':JNJ-$!#8S
M*S+A-RQ 7A-*3W!++7:2R)$IJ:!TS/E9(CUHN"=L4GG76)8Q?<V@-A6$Q-[.
M<(1#U6?WZ\5V%.YL[6S3L^ ?6^$:A2-BW5PCBT?4BJWQ;MU4;ED!IF7'!CKD
M_PR+ 8J)#[X_1Z%8QAYP!C)+-=Q_B-^<)WW8&?&X!+6K_W53])\5\'0"H'%
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MXJFK-ZW>=)]O6JR?L<!=?UALAO]25TD6OJ__^I>=W>V?\S_G!ET^!<CTRT[
M_C(]@V\1O[H:^VKLJPJ,IID;[2U)G<RR:9_L]+[JG-X'!-8O+=W[-3VJMK"5
MR<V.S<);GCQHTZJ/2B,Z?B*@X_=[IE'3_]5Q42'_J@ )AHH0N(A1DA!K)'!B
MQH$@!M:!P!+D\7O:[5V/<DVK+/^S^3@:Q?=D?LS1FF*1 )RM35O#.37W*[%^
M_&VMK%B#"+),$B":AC$4S+%(,4FK""KWGL$+4#:MP7^7UBB/#O,VMT#/JG]Z
M_8SJGW97]4]?#?&B_\1A,OC[=_%_M[:W4=[B7^YE+":'VOOE_?[YT<?C_=_"
MWS?/-L-W1X=''_=_XR$>GQR<OC\*SO?_-SPX/3D[^I_?CTX.CL["\]/PY/1D
M@V[X]?0WN.,L/'T7GO]Z!->]_[!_\A]!Y)[AS^]/3\*S\].#?RVQ9*J!"06-
M_="8T 0AG64]&DD-3$4%![ (6+5$,SE4L+D)H][/1XBH_(+8]5*V$C?NR3.>
M]<L\'2!\T47Z$\9R73\[O\[@@LMDS*#,I!SG93*KD(7K:@*NJ^G553C(X:4$
MU:R+<5X01KZGL-T>W)DJJJZ(TTF9$(I2 Z;'>258>_T!"7X64\P7*HTKP9X6
MJLH1]X_=^61:$D9P#X):ER5,M;@4P43IA9>'']65PEJM@WQ 9M+VF]<OH]#V
M[2*$*#ZH]0Y8582'UP76S%S4J8P27CJJTPLJPZ"!UDBN#X\=C)(L*2O\FBL5
M%G6*L!.:WS_J04+4$@/5Y_%&-".VA(3*1K@P3'<YB^OJ,F<B?UT#U+^,LPL<
M-JQ6F?2H9*PJ\EA7F@1ECL^D:HJR3JE]XES",TB&0W@Y5G!P]5J.2'F#XB79
MV0Q!F?-7A3+_[K,CV"94H9,709KW.U=873DM4IM2EH_-I;8(" 0,/ARK6:S4
M<GF)*[18KE,*<2V6$_64RH("OY#*BG15GD@(J"33  O'J2=[0E\9E[#J,9Y0
M?3"C8.(O8'XS+E7RGG&=URD#EN$6,"5%H+ <!SZ]AEU!5P1X10D[/TXR[$AI
MQHV5*P7*MH]%GEX?@YKFI7A6>M)1 53N8S0/^ BPW*6>LJ A;'&14(D/[4^Z
M*(VO61O!5&ME*7*+"\=B^T<-]\%^Y3)!^#7?[^VCBV18<<$&WXP+A@^/0O6E
MK\:F("5-1DE%S=2HS+*YH[2Z<LH2*_Q<K$^JRY+JR:8^=GI7Q>-Q"DZ,E"W&
M6%B"Q71Y83HI8C5HT@<55H3]I.C7(^SCUE=ZE^GKF<I9:QNGXA&KH+32!A6
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MT!Z[L>5F+LL%M@2L3!!>T*O3% X,2@5PP*LU2Q5/=#B+\F1PQP7'O0O*KOC
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M!3.\P#2!-%[F:5GW>?=L++,,W?-V,R099:_6L@]IB8U]#=\4X <36Y/I02/
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M25DU!0N.^OZ/>7B6I'GX 81D%$>@Z_J;4;@'ZN!LDE[!9.P3RQD,N4Y 7;V
M*8C"H^PB5==Y/@@/TF0XA \Z^6>X]>KEBYTE!E&^8JEN55(ACC)&Z.-Q"6_0
M__)J*&YCH<VNMF"'=+K@@K[Q6B47EQ5>E [F\N$[C<$3#:+8%Q %:*ZW]AP[
M18WF@>MGCD3FT7K3FWM3E1S>ZQLKY!9QP/SB;__^W<YWLP(0BYZ/FBS6?/BW
M7O'C+Z(T^=^NYJ3?<%'#-3&4M\Y0ZW2T#/EV,_2@2W#3W+8NR(U^N#>@#^9
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M9%=Y>N7PV]D;0(5R"P;\/8*]V-CY?GN'[0_0F1;X)=D7C?:J<NJ>0.V@\6#
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MT6NSAVAA""X\I4R^\(S )%27I84G*1@8%8)ZY3]!.[4 0^D2RO6.X10*AS0
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M(K;&(@YQQGQV\!_8.&X>F6B7TNRL8484@VG(%L2&E:OHX:\#=44X?CG\)7:
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MA98DQ>6$0,A]0FF8K5RX,Z&?Q["H+F7.V=$!+7@CHPM_"HY$S^$^E UZ)F&
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M8+GXT[&N,B"H6@N[ME,Y$5[F2VL#$FJ=I0IC;B#>J>\-7$"HA-9IZ5YAN9\
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MM1"VJA9[('6'\)@XLB2K"[.OP7:%E]VG ).H3%A(S/31VG$Y<DGS51BM;CQ
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M[I 7*$-X(HJY46?'XZ&/L3HJBM#[=]DI@VEX7M\"D (W[KM_\LX#N ,0U@-
MX@C"<\Q0I)3N./2#8G ,@9[ %X^V"JXEL>]=:I;3Z'4@Z"!0;_D\0\C:P:KR
M)7Y\)"$MU#[E<UQHOZCY#4F'51ZN-@X!0J.4+9=+!<$!V1$Q#+ 7,;$2^2ZB
M>P+"8 1A&@LDS[TGT*' 6$;+C>#G>0D95;6(R:Y8:E,T+8,;;33^=8#C@?G
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MP>=<QS-6AN0VOA%^HXUCCP52'[S"_CUVQ=%VT!1=;9<)R N#*0'7\ $.@@\
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MBK*%\'[^1XO'384KA2.D\1X!=+D+X)+9;\T=-HRQ%^2\<?*=_X0O0+,Q9(\
MAYEEKS[RDL>PSXM9^*:++C!?F]C(C;N4D4G=MHP8]Q,Y(I)>J<0VSA6G0-)_
M'G94!8/II8(3125QF>E58$8*CD)R 2/G10!:0QKU= 9BRO&=R=V+'*R9QL2J
MME)9ZU:9M>YDCT :V!M+!B/(8(K]W$L7=#Q1JX\;2^!MB22LGOZ1I!J,IE%*
M@HI28IN;4Z1Y\\][MXX"A:$Z>LY<C< ]L"%A#GME:<:1YU.29A@&'C-PA!$T
M8!3<ERVA[(<2:I 0\IA8^_<DT. -:>";+0:^H2"<:3]:ZH'P*&^D/PF,XMPR
M2'YQ7Q=K]]0\&N[URAF,R"V:K' PL$] ;Q*1DVD'2[)G3X/=RZOQ/5'GQKE5
MJI0IAH.-N&A8.IE*?N 3])>SX.7VJ/195E(!L&%UVX5B84-WFA(+\@;41WLT
M&28^%45SO93+QE!UV9B#A=$RL?:!K=J/^:@]09 ^;)W:T'GWS-+E.W\ON V(
M\QAK[C5<?DV^9X:I"%(0&Y9MOEVZ^=82-S\/#)M?H;8-=FH;K-=O0YFQ77"P
MTF:WG3>[K1373+EW=N?=80P5JV,_XK88483]6T:%@"G2U'A7HAM(J<9-N(IT
M.4/-2AEJRMR<PS:KX"H(EE*66=8DLUYGDMG&)%NA299EH3*S#%7-NFPRE-SO
MT"!;1E+\^!TEQ9LF*?YVF)O2$JAYT.?8_XKELMD"80AO6/FJ/YY++JFV+7(4
M'++"4+8\/T+<B=P0=#<R\+%."LT+[6YH/'1*)S]6S[:75TEY1552A:9T+F)%
M:-O"2](!M[%"4ZMG8EL5>!'10%A^HFA/9LX@!^C(H*B>T0_UVB<J#'!?]#8.
MNE<F[,;6X#,-):[+U1)\K)0G+-OL)><)2]/%",.JE"VE:9@X#";0!&Z)9?+[
MB.!=,<<XTZRH%) K*E)Z"/IT3M40JP,NNH>67H^6Q9QMA8C<YRN,:/KB?1C^
M ?X5)K!ZH6RYTN"C.2P??[_ '4DG1(_CX*@ 9NWCNI$FUK,+(8.^QR?.XSQY
MBE'C1?JOP0@(0X2'&D,OLMB)S @ZP;T:<9BUP%@1KH;TXXO*6V,PDOZV5 Z;
M;RY_)RB5)Y%1TH%DQ_"ZZ:H4[5Q@':T?_X%[R2M%,$(=J_J7=!Z?*OP.UBQQ
MUR_@4YWQ>%$?V O/Z"<B!V/C#U^ZL@2ZHTJ@@:QW,NT;#JPK#6.,%(7]'0Z_
M:Y]*B/%3PG&4C<9K&QF[+3JUB)1<H>H"#*$W.0(0,C-:;RX%.B*8I1#'=/3%
M)]3O[?^'?Q*/F144#@;BKTD"5XEJ,O@[C![<0+N>8'XAE?F#R2@F9)BPCEXL
M_:B2D$]]G\HE0'R+AB=FY&Q:NA:7^7YT]%R'HVK/&6O%?)JAJBS30.L%S");
MQZ1')UM.C<QVT&.42%7T0Y*6A#DH)5H+!9D0-54Q.\TSN?=(5++'4BK,TX;U
M<3L CL4?T+T ZD5-SY!]Q+,ZAWGZ"C[#VV#%AS(QY!VU\7I.68H4FG QA*"=
M3+W%%N/%4\*W//4E%^/H+YEM-2C7IJ(/0X[@$ P@/F'?,]\!;0O.#*DN#'WY
M^<Y?K*UBWUJE]N:T @=X$TRW33/_LC3D]]4,*=YARHT32S>B$B88O 3,J&XA
MWU&@1PD#.?$$4=BA.I^P-7A/&K;W0L!-,&.IQ9$VS MPZDMZ=E3/,,;\\^\M
M&FLTZU+L*!,UR+6IK*CUZ#[Q$:[JN.0CW+)3ODJLGG]1QG+%(L;"0;=$);1.
M^ O),*Y:7OHDJ7I:$3T1O@ 4Z/F#XL-7S#=0L21?E2WQ 72H/MMH22]K%[ZL
M4\(>N/.\5TAW.ZBG)[/;E)?6\]ZBVE99BP?V[YG0)">V=K#!DV<:TJ)6;_T,
M" ] B%MJKY-0VV7-=0?02.>-5>\6!;^J6>3Z\Z>4KJ665M#.+A!6I),@4V"C
ML"]UM@[$RY4EU-N!\:DU"$*QT>/'O6:JWN@=Q=C09"JP'J<T*%,/WX1*C%64
MH%K].532ZDZ9:BQ2%>$@"<2.YF;GB*K$/0VR ]L"V0[VF.HF[9** X-SQ*O'
M<&T3%?GG (\2O"0U%%H6"_,P $'Z:/DQ6IRE%H=G/YA2;6?+JA]<Y3W.'DF7
M (&8 -LG-2,"%CL)>(@9$:+TD</<HK+T1JV>&T4O=#@PL, Q3TA^\A.&18XP
MFNU%1J]A?]2=/W/MS9:C3Y33W< ^EE B0).L\W0L(<HR3J+F&^K?9%K'1!_E
M-*L"H*>@[%]99K))4M13,F[J6[FW@]OKQH.V#G\$E9[]7,9'5V3IV_/($SV$
MAWFP?Y1,DE3GQI!]-XQ+8V7D>6.V2BO=+)B"2"W%N9%26E\$<4S6LL!Q C*Q
M:>6L5%I -LF89?OBI[\K@7E.C;Q4%9SO=<Z(+BLGNJCL&Z6!G.F%5@FV]8+)
M G),&F82:H.@[#^A<, !XS&Y5%@6\,*/,S5]9*?1@V10T+:'"MJ6(Y6/H=GY
M,QUT%R)ELLI.;36%3_GTEQ$"V>&0^]+^]\_<MQ%>-M0MI_QLN#HGB_6J7D>W
MU/<ZZE9V[E;(\^S,3H8)YOBUE]-\1-@(/YA@TS0UA#.GD8DII(C"<R?&!T^9
M44 GD;03)]&3CQ8W)SX8Y@F$X"(1N"G!!,CI%U$Z4_9B:LEV:LGL=8<>8'2F
M9_+ K8J@"*JL&S9H[^LT*M.P.Y)[3%H.*:;MYJ(C*L >A()3*9\YC4LY"UCY
M?9.O#9\7,G+A=GV6I9Z%4V,H7PRB6-V$O5,"_B"S>/NNJ+9G ED,"1.N=E8N
MNEK-G'3?"%4:?\^DA:]DZ#V(98 U!+4QE$W[!#1=P/5P(RMS(RH I7UT\D29
MRL.T-WZL2G)S$Y]0.NGK%&%@2X5PL"DBP3F?N(%"'DQ*["@"3.-$(4XK(I'^
M9D)V:E.OD+VM, 7E):&YBZ8MZFUA2F_3'.L>0I#RG@N2'\+_0IQ<@4Z)"12?
M!#ZTZ3P@R(RE7:/#?1)]LS1UBJ@"L7<(,,$UJ>\QZ(]VD S IX-G'F'_">CW
MV!)C=XEP!(()TRIX8>$,MEL?6M>Z'9RY"@9.WE'!0,L4#&PMTU;/'=VY/S 2
MQ*O WFGF!_OM=*=?>&JRYQ!'A?_A63C.^X%W*$H,8F@9%#&VO'<&,<L(_2@M
M2*=*7T?N#W\T&6EMD- Z&%%$(<@&[D1=FJ4YOO]FID[<]S4_3X_K57&)"S+C
M$Z89!69S(BH,G'0TS9K2*<-1;OJ3'D4@J',/B@RII!5]Z730DA(S*B@T\<HC
ME[S> (TQ,7RU*&R2S;%#A(3V[47DP+R', //!6_#*_,1X8<;T$B+22S+)NE%
M>%;^1:L3KA@#=D22FZCF\(H"?D-TO(=,2/9?N*E5H4_* 46.A2L]3"2*V#X/
M5:L*8UE?HL5/<',H*H&OR"2EJACEG7&/U-G*Q[L3WN?O6MYC@A6H+SS=0YU0
M:"L(Q"FJ@!"88(H%(NI.\R!L#R4,,SA+["'8(*G6-+DP_-@J.@F[:ZU4%_P=
M"2*+E0+IZA\A&RS"*'V7.J$X@%WBFO/V0QTQ#D&K&"L/$W*&TUB_FN0E*"\>
M*"09SMQCR#))L2O3G&D=E1;T>0RL3((H7]L,CJ@GF@E*\HT"^$\DJ!@E\)%,
M1 U?"/J7.4HN_R#U.I9"*H8["6A7]K/*+UAI];=E#CI7.Y8K5"-I=9)%'F*%
MZ!H>7?B77 J+B9PBZ,LY@*6[5/'PY%EG</D>8XI':M--I\#)&";O"PN[.7H<
M#H_0 [*0_.A!J9G*N9$KC3GRCVL$3TX/4%UCVHGM"HR;X,4Y _O9XXCP:C_'
MD0?!*<NU!VR? @P6@09E>X!,J1D8@C<1.B&7SF1\I-\!_>BTQ3 U>8--?_QB
MO%D*811A\WE\SL43Q3,=O-P2N4$T]F%DAAL3TH<7F5!8MQ?$),9Y:Q=/J+%;
MB(&IVD/[DTAH9.A9%%:!&B@G)\<5O)0T%YF<<6..1ZE5!?#R$1I3#L(M_];6
M,\X=1KM*KO?1[?-,0:7WO/<\Q/[M3:A_B6I+^(E,[3N&=VGW5"TFYX>^I2Z5
M##)5+L+86(B?A'@2)QP$E+P!1HT$HT4QQVU'.<*>*&A&<1XJQD(<2>\/K!V=
MC$>\O RFS_KA)(9@#S3S5",&Z/+'\-D>30A<5D#(JBNHZ8\]B(^F=0LWAK="
M6@'THO'HEXPDJ;H@%5/"L&7)S7B),O\93^6-!)N4O F9H;14P)06M:45$1)F
MYDK?4=9I&:TP[7<4V3HTD:V5,#?^CVO[_;]]</^O5C\"'G2_K&1]Q"4X>N%;
M]Y?.-_NWSMU=]^9V'?,6Q+,WX*\PN]?O:\D\?0P S^F,F 7 *Z9@KI0L:D%U
MJ$V;DL;R&"+\?4KJ@Y!GU[)?W#YZXS'Z []-ALRC=.P;IB]P_ID[&G^V?V7_
MF\#4]6_7#K[7O\+H#_77@4#CMQ T'<RO!!)'90^5#0#/.,&+E@ #S(+_^"ZC
M&;,ZSGD'$GOBRF6[QE[31H=D&/YX/0S?_=_K[LW=KK.ZRBU#U7;>=B,D?W\8
M6JD!6'N#G__XV;6_CP'>B?F67YGG!1$G^/*C9#4R?FE4WQFS2[&JNEFG839H
M460_K9$1B\8H'Q(LIT@@:@#Y$ZK?BNQ06J4[9'=ZX">'3\1Q[.N#S@$4>O0]
M'!J(HW@>Q)B%\>2>N:?"](3S.O"CD:-J;U0L LQ L"#A HBL>3\@^(@9/^WG
M:"9-H)H))\V)G=SHZ)W,^3E9S_GY_=?N3=?^U]5W^[1S:9]?7)[9OUW==*V+
MR_.K&Z9'+JXNMVL>Y_(/EYC*-/!IQ$,P<8<.H$HRSRD:TN V/G[3XHR,@:$?
M+_H!5#-=_  KV51^ CCTMGM*CH%X&J ;P!/[J6LPM?Z@!D0H]YW]XYS=ENAS
MNU^W5&+C5I5_='HP7[$ AR'5-TC0'4(EBAOYL0QW3;#Z+O6!FED"Q0(XWW,H
M<Q'Z*^<:)4M>2/6)//KW?B)[1HLO/X"WMP>3J)#$5N9M]9E[Z,DI"E5X=[:[
M4##D4:>O1D$J>2E_'ROU/@@APZ&QQ5YC\80>WBAYVUT];_\*)QA/@$0/;VX9
MOTPAA&,QBCU[ .P2ZSLKPZ)S'DB)_</.FKS'-:F7&]G7?1-"RBX!%"2BS[EU
MFT0>S"Z]/.@R/?6[&S\R-DK@AF<'IS!J\K#5/K"OB6]Z.(E/G&AVG_V36FV?
M_6._UFS64/%B%9+.QNZ]B/[2\%XM.9%=GP7K(VD"#X!X*1Q(!)^] ,D>L",8
M^PF/K?+SFJ,5#J34#ZZDG5,BS51N%]MA(ZIP1]:FU&$4!GX/8]YYP:=3/+U*
M/I%VP+0SE 1SEO2_/";)^-///S\_/Q^P WSP$#Y1_%,P$5/H&(&;1!9);65G
MD+!D&[C_=UV4%WS_#T<(]]RW)_M_UP@AOJ6#3,(H\.-'K8\>*A1Y1(A>HM[<
M<Q'%K'ZXUY>-$ZD!2RGI#TA)F.1\A*IH$=?3*??LW0/--B@@ECDK<)ZH3+OV
MCJ(R1SL=E2DBYKQ,-(/L%<,R[?58V<RL[OZO?7<%!G;G\O2B\\V^O>O<=7_K
M7J[7=TTES.'.^['_'X]NG_-0ECV FV]9?L->N5:8N&Y=_]IA?@KS:2]/#][&
MLB4/6%D>V/#*EVX++IMR=YVOW[K6U;E]>G5Y5YUL,V5W?H&K,XP_5"]:^7YV
M<=<]*Y098G7+YABYR!6^?NZ>U(?>8U;^&)K"@X>_?:A]P'^SU^N)?\_]W&>_
MGSQ^0BA3J>M[X1";X1@C\+\^@!+[:Q*)^S\!D VS807#$$NP&S#CX"$"$Q5N
M$D:?[.CA?J]1:SF-YHG3.#S\^(&KPZ2?VER1+]BO'=0;AW[PV>9ON3_T!IA'
MX!_S];;K/WT %?7(O,^_??COP?_5:O6BLS%P1_[PY=,L*N3.T0W:L;A49FE>
M:!&W&Q5QXRY'1X7,SOUH)/D--&;2S[VOH/A/BG\*KBHZCOR7)S\M\TW/]QMR
MQ6P=['^BBIN]V%9FMZ^QS)<ZU4+!N,BO[A"S'K>/S$&-.:IB<1P70K=E>SC?
MCBUWFYJOW*95G\GL1C8_?+%7N).WJ7#^E0@#*)"+?V&DOCLE4J_ML+U56\P7
MU=KL26RM]"2F]X^@ C#7J)7LQ=R3)P"6E]=M[3;N[.&V'][#=1[>4RA@.A^&
MS[MT>(\V>WB/EKJ!EV'BQ;B\)+3UW626CLBOJCW=YFTY3F_+SVA.+S>C*>RY
MF5[!JURM+?4(<ON997/V1AFK?:H#^_URFD>GFT#+LZO+3J9F;VMWU(YVE9<O
M7,UR5EBV+!G>7+DW5OB^,R(44ES=DM/&Q I[6LPU1$K(%%KM_S,)/+M90Y70
ML/>^!UBCX/4_%E9AU$D8Y=EFVA:4,<3\\1AFMM=*[/9-D[XQE?0SS6RJ"<?T
MK?_#'K%G/?+Z&")L>INXYJ[K^[7QG:G/\*C>P/EI5MO$ZJ;VWAEB:'A![T45
M/]WA7O]&>TS&V1O8WK*XQJ;WK#7'GN4MY+=ZVOBSF\TW?-H.\Q8Q;>-LVWC1
MK2@B.>/QUA2S-F=W;BR<7\(Q<R6VZY]M/G7Y$SR55Q"\R6SW^:O2W?72;/<.
M)+NW(07SZOW\JS^"OOSD;Q^8NQ7UV#/] &S;@W^/'Z0#QIV)H^/:^,=G^]&#
M'E?F6]3'/S[\O/&J;"WA+U(I:TCX4Y(EDV"Q*B18=KC4EH_Z B0' 9TEZC,+
M>LS#P:>U+0TJYVV]<GY7]Z!JZOEJ[ =8@$@%:%,B8KM**0$&PPT;ZC+H]:CZ
M%(ZKWI)AW7-O/B9O'MH<+KY=V7,T8^S! S@<IE;CBE-02U)ZC@P:8S^V)68:
MIII%TBTBLK04II(HIRDN<)IXZ^U>'YVFA$(0V)<[D$8[ML#RHL;D.:1.$@&N
MQJ>VE?25*#1:L>P S$][#Z)P$G !"[!Y?SLO !:0H;,Z8N1D5^N","Y#XFE'
M@A).;Z@1Z)& @ Y(#U3PKEKG><5Y//5^&I:AE:I+G[VCVE E=6?1U\VG6*KM
MI&)>]M'T';*HUZ?B#A$P()3_ B<0.(#25^/(9R\YAMKV!R]@"R%D7X \5PWG
MWP-?>GZX[,Z(/;3GOGL)^]6-?=HB+FMW7)[>X=2RV<<.$"PX4L$84/WO_:'6
MXIFM_F>+<1]X?\C5),K^RH\)RQO.<DQ#X%-Z+7N[E$PO7)[$6T T2- -A @%
M8!QN29^:WLDFJ[VY_2<$@F8'7@&<"N*0$WSG7NH,,4W!)>#U:>?JJ](14#J?
M002Y]U(-=45M0>+YQ1 K]O>#VP-[X,%HA:&E-=' D 0%)Z[-/YA0"Q5(J@>
MJ-"&UNEM2G"%K()G:QCY<2P0'9 Z\&X[*R-^)RSU"2*;*48JV 0\"HB#0[-!
M!AIU[#L<R**^%9@KV)/Q+* B8#H.8:OS3LD^[[4B7" =LL.-XTF$SZ9F%([9
M8553F,!]HG]!:DG86-G+(T% .!0-4^TAHD4-(K:L='N<3[UF&CO#Y!;/89]&
M[.78LYX!O_6!'7]"OZ%WI,G;\(X"?C8*V#($OBT.5RD MSFP.[%LRU([XA3@
M[%B<;@C^#0:3'&8TQ_,X;I3"/^8HZ33:&,45'U*3D5B>P%8*V"56B52<Y[61
MW]B?8.(\>U)6"H@N_OB=/8I7^NGCC<R<E<C&"7M>?P*3--$"C8$VA./%9_@5
M<KI"()AQ:&8<"4<_OH!TIM9C"QAWIN\X5B'P#Z[KP+[%<8GJ8OENW@^7 'D<
M&Z?A,8V2@%+SV5+$M!&MS4LA&Y',!D2981@C0?R@VCN29N9$1M1$M1K :703
M-?VSR+B<Q'P>!5.* <ZL802&N:) ^MC"T3?W+YHI@(B*HF<P\P@X"6#&<^L^
MU697X4U^AZ;W(<RNX*#1\LTL,5+"U27JO;3R- ]DW8=I2RW@4[ %>HS '137
MOQ$HQNZ;P79/O#CI*8$& AW:DX"/7,4Y/1:H'O&URXXV6I0 9(7LRKL6N1<G
ME5XU;<V-A,A+/Q<1#E,6I/ZUF,! SX)O +34XV:;R^BT5__('7I;887%'+9>
MB YZ.'\YDI[:Z* 95D; +.+&1R9#GL+A$[>?/#XQDCF@/8#.8G8!BC@^WLM_
M(K19ZN#^P7:C_Z .M(:Q)0#@(M+Z3 D6[]6.JD,HV/LY_EE ='#I 3@=5@JG
M8XW+6?O[WW:^?>W>_))Z]ZO?KCN7_UK[NXL0)!_6Z<96D;&'C DS"P!:SF[4
MZNV_^E\.UHI?^^'+U[#GVC<N]L.?#\.(G> U/CVE<?;_\+SQ)SN))DS'_.9&
MS!!JG(B**IK(9PFK.X))&+$8JA<S-Q8'2X.HF@ DTWJ5T?17X>;6$ ;9,$_%
M?8C<\:.%4Z3#!&*G=KV.,=)0&]C>IW'<L]\CL[JJKS5MP;<0",2(8H,7;WQ\
M\\I]:K:T.!G8:+0/[<O?V;D5LX&_#I_Z!XYU.P'L@T:K1B'MH\]VZA1]LYO-
M5K.^?]QLG&SV#:X?P\!CJOWPB"GW=OMP_Z1Q7+/$HN]"9DZ?,[^?77%R=/31
M/KWN[)\<UM1KG;L_]%_7VU#EOLD70D )TG&]\(!9!6*I%H!=_'^IKS:[4B;*
M?Z,S=(GV,UC+<1PR6T=,,01D.>84,?WP3W)TF#_38=>]Q,Q8$CMP4Q2 A"#2
MDM7$0F_(^.:4!O@1OGA'C)KLVU<(K1K;OX?1L/\,7I9X,_[;S@7[-:,%W!/=
M+?(I_C%Q(0Z\5K3F;1[9TVZ\HZ*BABDJ6C^@X>L+C0C.P=;A'*S.Y9E]^_WK
M[<791>?F7S-A\T2O[4+U/8N\P>G5Y>W5MXNSSEWWS/K:^=:Y/.W:M[]VN^L!
M^9@I@U;45E/:29/JN*G6:*\*8:>8EAGT [A6E9-BH>LS+T*[#X?]:49J_DZR
M.I6]!'SZMP^-#Z6WKE OG'J<2++38YMU9S7O8*CQJH;R%?">*MB6*@*4X_(V
M898"YHV#BVP3M1H5OF_ARQ4\<GGLNR,$K:V7H/.?@*4=\L[M;3?=W3CO^2K:
MK7GY::77KW^!2Y5HI]]O;KJ7=S;MU*>W18FM7^!J 1%$'V_CI_2YA/:@S+P"
MWO53S@90.2B+/"$)].0.4Y6^:5&E-26_:@>RM\F_P+0;_V7ZJHXRM\.Y6]/N
M]U?_QZ<@#,XC/CT+2B?8[V^@0:I7_V#WO9X_<H<Q6LB$B/JW#_Z/Y%,P&>WW
M0TQRP@4?[(#YH7_[,(GW'UQW_ FHV@GZ\)^N(FDG.76C".J(T1UGRH?Q@X?W
MG@0^/742,RG?=DZ:QTZMQA1P>H%?9NW*?.2<JH3?T4XW-K;3=:?>.'&:)^WU
M[_3"@!ZO%SI=,>#IR8N348&T68CCEG8"-BI*8G\8?B)"72@Z,<8*XZ2<GUKU
MMM-N'U;EIH5)M6L;]0I)\+J-:M1J:]JD-6 SO5X28/<QGXM'\X$#+WDS/*;%
MC?=CK[?O_]A_]/OLS3_9]-]]F)6WGP5R3#UT7SX/@W7F@*Y,5=](+HLOO>24
M"JFFG-"F<[B%AW3I1_ :9G+Z?9R9$\2>/D)!%)M!"6P2V_OB@QWGL04,?T[,
M+M&2&8970,@.TF\FQ]5;ATZST3+*>_VR8:%]:[3J3JU=V5E[8_J\)#@YEXPA
M0D*=*E19A5#M/8$J3MG).$]@=#%_=':D=VF</=^CYC0JID:PIAL5TW9T&>_]
M'G=M[1*+CM35X,R/QV'L#G]A!WU\@3T6C/9GVC&36&<S!5FSZ;1.*NN?U;#1
M:RRA=Z#X*M_IO5@"JR3(^E1L<?],:GUW8>(.;7YV;3KV;W_[5F6 5S6U:TZK
MUF#6]KH<O-W;I(5UU^Q-<EJ-(^?H:%T>D5$]1O5LFB!;I7H@.JL%9^U]FQW"
M?1X$<GA'+PZ&A'H0:"K6+F;.WE]6)>4O^/-42.\R#'JSY4FC/E/>OT%^7!65
MM1A(%?(>5:+O.Q <%3WXYL;2 LN*-LL6MKD]_ES0.25:3%QA6R+85<X]V&B'
ME0L83/!I8R'#[!RDC8<,5V/L[(XB,2;Y-A!DY=JR-5U 40"H,/!3=CQGW/&5
M(H_=U>Z'$V9M+Z>6;ZZ';#BB-#V4U*XY]>HU? 6[M4(%:'AAV8&K)4:L5L$*
M1JMNH1(Q!%FB5EVX/>G;1>?KQ;>+NXONK8WMQG=7IW__]>K;6??F5LX/^L?W
MB[M_F4TT7+UQV?N:Q8G^+HW5E]/DM;-[9PBR/46I'8$A.'9?"*48D*Y[O6CB
MJ:#AIG:OS(;=#G>%4^Z:"-<)^ATBVS??18!TWYN=>6W5CYUV\WCW8OFKW[I%
MO(ME;%V]<>S4CBK[HF]*W[VBN40*D'T%G0HPV-KHA6V7_16CNX>FRV0;#C%V
M-/$37*'BWSDZW.;REO*3N(RR\#,QZ <@.8/)[$,Z-1VQXTF>M5L28G=N:'-F
M,O-QPZG7&B8/N/5YP".3!]P1)6;<X3?K#L\MG])UX)I+8 3@YG3D7$YUN^;4
MFJ90YLWQQP+>P%R>>ZON'#>:;Z7]RJABHXIW015/S1->7?YBWW5O?C-I%,.L
MVR52EQ0C+0C!#$.F56 ZTIN+E&XZ1%*E6KK=/'9.JC=9[_!AK!BM.'[S;1++
M"YAF,AJS3NI[-O4K<M?)ML7"WO>NK=]!8T?HCIT@/6TSQ85W&JTCXZ!MLU8Q
M-N\V$&01U2G.#3SVDUT[:!SZ01'.]2LCJ'#B;3CR)H:Z=3'4%1C01DMO"XLL
M)XQ:A46,FC9:R1!D.SS<"@K9J.$M4\/3&]R.G?:FLU2&-3:E?J>C%[>K%QX;
MM?MNM(PAR(;2EZ?A:.3C/ KLGSE%1-@'+^BQ@VSOQ9YG8T"Y7OOX9O:K8EBW
M/<=#WUE%?-6A%;7-DM!(\BT47(8@&Y+DY0WJIAK%<.SFY6IJ<7-,GN'%)W$2
M]OYPYL$+;<T+:D=/NH4'7;O1572;N(G7Q_%\UUYT^^A&I7D_]GT,W\?S>%@;
M6F#MH%8\-S+S@3UV(_L);N[8*X02U%X*WR#N3)+',/+_X_4+7V9^.J]M28<.
MHRS\7P7BTF]L5][YS<BDJM;AU)EFQL"N0L)Y9A!O6753U11M2AWLUP[J<.%4
M.\>+P#?]"@<>EP.%3N/Y]$1S"\3PU 6VMF"!2]<3S>W3$ZV-+*DQGX[H>S$[
M,+"%G^WTN9@F.W+-_M,NSO5[3KLX5VXY[>*3#U^"4$J5@O^(M_3C&)!;<+3@
M)(D3]@?@QKN)?>;UO-&]%]G-NF,W:HTZ7L3^J#DV^^788^1Z\H8O]MX<IWZ1
MS;[Q^MYH# ^XCOS>:@[]9M97K\B98[8;^!M[Z/\Y\?LX/(J$P,X%"NN;0V'?
M!>JUWD!QMHD/FFC+]D=;UF]DGRYB9!]N@0T[=8%'6[# I1O9A]MG9!]M9$E,
M=I^\ULA>(X$OT.Q]/7&7O)PK97I/=V$:1=!_6=J"G5[956CD D;3+F[D_8KU
M>1)+(_J*/(FEG3CC22S5%IY:<V \B1E'?FJY@?$DWIOA; BR19[$6-QHY$8/
M?L#OLR]NM#)'!>K7PF#EV6%ZS+:FAI>SNFW*"VMOM!5)X=>NYY#RP:_-"<]P
M199)X$7]D&6NI:H34G?:QPWGN! PK= 561=W+$K,9:ZE.C&/:PWGI!(QE^9H
M2?TU?LM*?0T' X7YE,Z*]@XB\:]I@Y9SV&9MT/&ZQAYO-994AYF!\.[NT(81
MLNQW=L\=^XD[W'$F6V1<AZ39-2/917!*!)LVW\%I-EK.4?4&9R,3ECBB8][M
M.G9J+:9XU[9;VX=9U>GU)J/)$)P61O:!W_/-?.\*'+RW*HESXR6N'WC]KAL%
MC-JQMC]GM#TZ-T/>A*TLR]9-IW'4< Z/*QLF2VCWS$:,#=O,S38+2+ZEL,VA
M<WP$^JLH$+$>MC'!WBV,;1J";",N!WH^C^&0B:=8]IS].?&3%R.(-^<PZ+M"
MNS$%*LNI,7';.-HP%I+AD+7Z*/-P2!WJ:)RC]J&![3!*R!!DDUJY-2=6%@;=
M%];1,Y[Z2OG+[FKWP\G]T)M/-)2-9YWK(=N H-4)^G.)X9H#TX'J)Z^&3VJM
M5$\;+ED)F-:\7.*T&D?.T=&KL4^7P21""/Z< %0VUG=]L>#_\=HL62LR"$5T
MT+[S1TQ>77K/]DTX<@.'/G!L*$0??+:IJN23#9?6T@OL>8SHD5K(6#SP]4_+
MWUZL8#\)Q[@*^8$@'(8X;ST/1I"'(T:,%TB%!H 9;B4AL 8:@!CC'/B!&_1\
M)JQCJ-0 ]*7X8"DK7R^=*CPM_YS_VM^WSWUOV/]D7[L/[,C=>G].O*#G?;+;
MS<\VYM'8X^W]??Y#E!/T6ZU24-^/>J-@0X[@LUGVN%ZY].I=/]_77TJ\SF?[
M[F7,WJ03L</<^VQ?LB-.KWP9PLLU]1_]+'Z%KXW9</'"902XCSSWC_U[C\D5
M=M\QDE)?[E'!<H%0^6(M_AH:8Q0_7%\OO(?:HA(>.EH."^FR!VZ\'_O_\416
M(2-_2KFZ:'?GY?09?/#7^R^W%]^N[.M?.S>_=1S[XO+TP.I<GMFWW[_>7IQ=
M=&[^]=>?[PL6B?_CVGZ?O=__U6K0;_BS^V4S;W!Z=7E[]>WBK'/7/;-N[]A_
M?NM>WMW:5^?VU77WIG-WP2XH?HV5['Z9N$+=PJX:#KD*0VT(_V:<T!/_3JM]
MY@X.W7',>$?\]=E^]OO)(Y"P]E-U<GZH9.2_WLU,<?NS!W8(W'38?Z6)Q5X7
M/OW;AZ,/I;>N</A2CSL/(SMY].Q_>6X4V]V@GX,P6=);5':J5D#O5T1&5[ -
ME?18Z8+T6JSY0C9FX[(;UUCGQD'=W'HW;/<)6MNU$[ P_5?ZP.U?X&K+Y;AU
M<7STTWQ>];>+T^[E;=<^[W;MF^X_NY??\T-%,\^H_[18_$7>9CF1%GZ[]D]+
MC;S5Y@^JQ/XP_/3-9_(C]LZ]:?#DQW6G43UR\DIZ396Z;W(K*[;O-7,80]7;
M]Y9'Z]<$Z$U.Q"2)WDZ%]MQFVNG5[1VX]T+/F,3\!K24ZBB(DZL!'Q9<KJH
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ML]KQ5. &(IFT45P!,LNXD]JD"D>AX;0/*T?+3/YX:YAFD9#J@DQS"-93XZU
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MG_O>L/_)OG8?V-F\]?Z<>$'/^V2W#S_;"(')'F7O[_,?HD"AWVJ^G$[M>J.
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M;A-69L1>(J-7FIET+>@*T2ADYY(R^>#9R!+,J0TZKS!XX=E% US\ 30_9HZ
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MJ6DI\-KZ*5R'TW:-BCU\D"&\'BR8@@A-3.11_)WJ;O0^_CTY!T4]QZ]YLS!
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M]7A;Z)"RE^<('G(8U/6VX"'EJ>O-X4..O4YY@\9ZR8Z4K=JGM1TIDU/[SH*
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M(YAP #Y5"[% "4&+C'&\$T]IS;&TR?1G!*Y36G,L=4%_0XCOJCTR!<%&ZMM
M&UE13X\::M65],LXK!OCJ.??[9UZ-J.J\DP7)UDGE;@2TNL85EL@&?;FFLF5
M"*24F5R:>60 OY+]9A#;$CU=/G4?F #;<PBU YX_G41!4]F4CI>S<&\4_?0*
M%J')O5J^ZA#B9V10^QF)(!:W_"10KI!-@!F:_CSA_O+MD,':7P7WI6Y6'-A
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ME?%[BOI,/5?^Z@IH6=Z%%1,&IR)WAC\4))]*]0!IECK'.$, >VTEI@/?X<6
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MMK \A0+M0*J:;3&(@O9'@BAH'R$*-@W:E7[=RA/-CV:@'=$,WA;-H,0YK@@
M;U>MO"BO5G8K]39EF0@9!F^FC:!_)",!DP#*'N?%6U@)*S,:FK6$QG[]:S@V
MW6<6-X&_8L'0MTDY4^  ZNTT. "UP: FAU(:RL>Q"+%M5)H1*HZ6)8\3KS-;
M5-N6G^2N"L^W8:.HBIZK<=JBMVJY\7W*/(W$'./NATP^"G^V?;U>;^>:&2Q:
M,W7J!FG%"NY?X.O441 UR#JAU.JOIN^;N%%""4WI(J;HQ<NOHJ9)"^UZ&UWC
MO%T3$UV(U$0!4=4(X5@"4^P>SYLFGHFVAS2$-%%X53O?CR!3RTY[E]"\EV>O
MJ-N)L*W<C<1*%DTGI<ND4I>.;1U%Q(::@E(U^MA\8;SF4Q"),)HE]2B6E[(-
M]5IB'S!Z*DXM?4+H+<4=$B6>]7.CD3EY6JXF'A:/$$$3M5CK3@2X=4!:8X@&
M3RK1V&+<Z,RR"E4U] W!#\ \;8NA$23*_H%GP,',[& <M=/L4*-E/5]I;*V0
M7;9,'67MLJ6>G%NWT\KHD-48;]L7=O4-DIYJ5?LWTWS1BW2S"]5DSUS2]4TR
MU;:1JI:=W[ <*$G)<%#S&32ZW%$*#!7+*SDP^B//<,';_EU)AXGE\4KB2*#Z
M+&11*&\-),Z+%HG@*&UB.:O"B'-V@#^M]LTUWR8=K' @*"/PLQ0,VYG#B^K"
M1N;$=N9?5@]>@*6^K4-L^WQ@@TS*>J.ZPE&E.G1%%>FGKZM*-$#DT@.+I56-
MUO27J!H,X!KP":71COK7__4_+SKG%S&%A%9BZ(7G<Y-GY@16I%4K7$=,)ZD*
M8^JI$I!=PUTV0-;81^ZB7YO2&,S-X2E7-\X'S0'ID=RU?4MLC>P/ BQ9MBK7
MK*T$7(D(Y:&U0JNZ)47\QO/5R%@<4^:GDD8^ZQ-9EM>K"NCHO/F6\@A!!,&F
MWEXJ.8D+3@ZHWWH95KU!-FN]61V;SV4<)9 "5O/[C%/0EH5 S78__36E[K9V
MMMS*@I<K;:!;+(F.=2 &I=^56X8(TSV0L[*_GL7VR=\X@5 X)^__\C+;J$\[
MF+EVZ'"OF0 )C3P*@?X9R![=5,&I/3J-LA" 4DZY4^249Q47F>' #.S@1.*.
M!L"XB+6A:(G?"TQE1LY!BABC\R7AJ%IP)S$X +/8/E%^W(B'[Y77^BS'&PG'
MDJ?MQU^5&UIH%NGORJF_QW2L$1>MFHF^D5:_?2Z\04YQO77DPN^."W^WX?"M
MA"9?Z!;_G!*7G.M./) !K"$(/&?&?2$^'!QY04]GTP5O.T9.&#&3%WC<Y0X*
M'Q/!Y*]&H=DL!&TVEP:231?CKQS'EGSYIIC/<B" G/SR/78>[E=H$DJ\B8/H
MQGETG^%X,/+B<]=TE&-'H02E7.M$1"MD^VO:J6+RCHL4S@3!NK'A5]#+^>_D
MI<*]5TXL(6IVS>;%AT"L# =M  =(M\H/E/=O4+]0;Q]Y_[OC_7_WT/=;Z$)S
M1W;D\[G^-61PP!C=0B[^:@=,%IM:4LM=X;"FVD[ENX6F$L&$#T#XF*]&;O51
M<'R*K[H>2![R@/,BU#/];]XK@V\6DSNP" )&02\.UJHNAMM7SX<<17&P,!%M
M*#0-OC#7"PT*J,*8O$9R-++1?X*"YL4+H\15A>^:<.G^Z1&FNO@C_+^KSJKH
M1 KJ](;^V3P!:8!!>Z *D<%@6BB6F,-AWZ=P-'Y0[&244F0<5Y0:<PAED5J1
MZXR04N7DJ+*UL%ZRXA[ X@<G?-CUE;)1V33"U<.,"DW$\H8<+@QO)Y(JL ^7
M\B105XEV&RB&#4-.S,GJ;(5FU+TK-(G59# \25;XQF6]2JWOZAM6:#9+,X -
M_FR=\#0AGD:&VV#*O!N>JR" 677QUP@-%/0J#S-#/K;NLM,E[B!$M4'Y5+WS
MSD-4N0@J9:2*PEEEIY-7:8K#";$65#S>8P?2'K.IY; "Y)'$\= %CH?2I25"
M[[ HC"_3PJ9J>P].HP9G7^3H6X>.$ -ZD$9%SCV9+Y4:TI#-6!;62T;D R:!
MG2U%1!:?$%$1?<),4 ;7!85:VVH(I!Q,/".:4'J55#+F56^?I82 #-CEP3^E
M1(C*C*02#"HEST;C>QU,'1N4-+'QTH]*8X@4.2YVX1M -G ,/'<D -O<,7WT
M&O B(OO?G,.%/FP@GTFP\Q#3FXF>W5C-&Y1;UL^/5O.[LYIO/']8T!>7(C.
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M(N&O]^JCV&/1HH7MHBAS\GU!J*P>#%\0;I*3\?<".Z/FSZ)B(GJ(C*''F]/
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M R.B@C*Y$C^:NG\RK.P3ETW!0.*[QRB!QX.N "V+#Y@UL6LYO>)%X_X0PKM
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MH5<DR<H6WC6K;!A5-/(?"(Y;P2K0DX_SQBL.YXL/L6DX+MHX[5KVH2&X; E
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MX7^(I\:;UB(37I+G(MFE5DMTJ35=0)/E.T!<UCAL$9LW_6 E %9,/]"V,_U
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MZL!2>!W7B'D3=\D R.L4^F"4'!9)FW>8I*;Z2^1-H(;[:AM!:4A-D9JUO(%
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M)A1UJ$0U4640ST[7G-6G(&V)N%!@_TG'4_*%CNI$&RIJ]<^MAM'MTP-AD<N
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MR37+FR70KULP[<59M"[:LOT"G;I":[?A_W(WKC^L.[_NQ9^RI1O7,MJ#2CI
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M?)0?M1-U[828]J$EQ-1H*X*V3HVV8T1;B58V-=KVA[82;5CJR,\KUI]J@-0
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M3<P2TYQJ$_-P%+:MI5*DZF;>-?-OIJ"5G?F^:XV6/D[R>W#NV,)QL>W*)?S
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MWF#>B?? _C,S7,-C?>:\&$/&O7X/;&@_6?06<@ N<?4UM&JM43J\TY^9->"
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M;M'P@>>/OPK+17W"?T0FN<N<%V.X -1Z@/M>>I.2+:LUH&6.F'PE*^5@I36
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M[<1Q9-@;I.A@K;R"&6&#_#ZS7RW,*)T-7&-DZ X(]!#K$.=H?'OG?4@WINT
MC:(VWS.J$Z9K@TD]G#GBFAK!FN#;=/9>7U_/T6#E%OXY7 ?GROP+Z-9@/Z8X
M -HH4YBXAX%5@X?UX$_25EFP@.0=-^!6/5F<I5V_MEW?$WY"R5E<78G; 6 M
M\XUB\7-L%69'"M.0=DL)'L %8&Z3OL8P$9.+ V$%*V1ITRD+4C^XK/PN]^$-
M:?D-AC')N/P"RS(F-I!?:HO?OWWQ566R.DG5Z7R(9)J080W$GMC(=63;>\]
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M<\Y@AU$MK@M3\@.#*([T/QEZ=?AR>66.Z\XFTY!<U;DKA/L'I%E/%3?DY1<
M2OA56;DD?8\AYS9Y>6A3*"29\!UO3LPE.%5E6$Y.1Q'3X:YZPEMQ10TFMK"
M7T)A6?XE<N62\P)CI:3D!&1(():LZ(RXAO^8C9[P@7.E1_GLL :3Z:Z'?F87
MM,L!%EN"*F^ "A_<$G(LN<P@D50/[C5$^? $<U)#!'I@:#B@E^*M-I3W#OL!
M5Q_NBJ>DH9\F@K*AU06!5 HZ  ]1' 6H@G>5/]LA.=$E)@*WLRST;(,I,@$B
M4^&L#2JEK,P8SP@K!?>$_&+S#B>=UY1*OQ-__\A N+$PE;&V&2]!?XO.U="!
M#^U<:)]!_U>2]7]BCP2GO!IVR@NO%)6_2@V!(M6<48;,>.&EQ$$)-?QY$7Y?
M4X)9XGUO#S"U6I0JNZ;]>C:QJ6(<OV.!(@,4"KXA=E.D3(,<1?RR47A0T'KL
M5\X38ZK@%>#^"/$BZ_W0+(KVW?&[;XCB&)(:(X9ZDC6*M.$(RN'G.O?P1/90
M,RWY#9Z'82'?>J:/]WT VLI^I$8W3RDUNGG,J=&'F-!_&DG.<XM=DLZ\096U
MFC.KM9+1@$%'6]<:X3_8<@,D-HK@C.Y\:=>D>EFAY@X.35<*_1":Q$G:/7E3
MHZM)AD]6;MD*6K%42UT*-CX;3\^@"9KDIHJT-N+Y2KQZ7RAH//M2*("@E9A8
M2?;ZS"P)2R01(LDSPX(E+R"G#$7:)#U((^%$U"&\PO#4_X#^2EF4?CT99BB!
MWL[CD[%0M"*=1!H\+L]JDM]1.02L2TA.H@SO1D!77C%RDJD]_#-%\B_#59(2
MB/$JP*A4>+UP85YK9!@<K\<GS-M]+FMP3>@,BZYJV"*QUE ""X>-A#_=.Z!O
M\XF'%US0VL@EC0OKWZ^],.  K!D<S88<1<XQW#]1(;>'Y-8/\G9 K3:YI<S!
MJ,*Y< %SS"&5</V?M'-I=^J4+.1']'696QNU!B,,!THZMPB!L["2D^"<D<_<
M<Z7KQ1A."];28NA !I:P*)R'S)!+.,@)3_/ X,8/B0946,2)\^:(32P?+I3
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M(8HT0$H:KM]6?!B=W="?'4GMV12QM4?HS$'Q+^LF?@CP./E&)]@0O\LM!M-
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M7UOHG,S;JT]U@XCC+]FVS#?0FMX$3@(VYOO/3'?@K_ YH5YC,R[/,*G9ST1
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MNY&>[J=L++ TO@)[.P:2?8KB3W.L'SH7F4O-POEPR2[O,65LT)LH)\"]<_U
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M"=?.>4B2%.Q5_:$S!K=I")KW+=MQ*FY"8236$]?(!]23_",*54?RY6C$!*.
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M78U'<_PHNH?/U/CN#?>3!)ZQ.[_*"=8T!*4M0Q8C /M1KML]-6^57%S@7-(
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M8XD$3>^W.4(N!'X(EP#L_2EL\=7)MW/@ G49/"K.2*FV8(7B@J7V4N*++,D
MV]R^4_A[!#0P<W-ZEH O2U&UN\I6;+%0\U--(8=9*.0(QP:7:H:1.9)[)ZI^
MX&FL!\%*O>8";Z<W6-Z2(Y,@1RXJSP;+"C^!&\YNJLQNGD]_!5"!]>9C5YF
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MW?F<T;<!2HHWJ!><T<@(_KR0FK5SS!Q-V.@"R<,7J&!ZF#@E<89D,K+1A ?
M(*3>C*GQ.5 6LL<VQM9F(UL;S6PMV;@TPS;L)>7&R[D8UBQ4L[=8J:;[)ZCF
M$\S9FU!3WCSA_+,,R2/W<*\C8>Z\!R[L)98E%H+?L&Z3:&G)M6>$W!E*C9Q,
M_,!72?31/!6.+U*O]#IA2E2A0 U6FY']+NN\25KYJ3GU/*&E<EIXP>'3+(-T
M<G!::48,$F-)-/60&BB%A%03-) ^/E$F6_<>JS!C/D9P38:@B&(E,:99>A,7
MU$$D*P;V073@(:)IP9AXLG!I. U56]""YA9.37JXI<.,2K7%0GBOA?HJOF<B
M8%I/@$XD)=Q5>8.1E3>T$_.2Q"J;/BO-$'H(^B-A.#]S<7A23:4;!FO1!5$J
MTN^-;,>\ _,$WZ0^R%Z*?.0GJ;*Q:1+Y\ONJ"HY%2\P68_@A7(FSB%*&*X=*
MYH@ZX8O3X(4D;R5UT#)"HC]D)*\GZX)[4$?J5Z0XA^E-O1*6@E;97SJ=B:B
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M'[47<P#7!#URMM@/F9234C2QYO2EE,RRU</'^3(U9X^^S!T].!WBZ"6C:*8
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MF6+M"]6]R-!)%BZ!YV7$0^)@LAIAC&0=C0"4RN%**L1I\R3X]ZT'1(E58$,
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MOZ3H:O\UNKHR%[UL+_M&%:G^$RM245$CXMNA0KTBU:JH4F7>;38T<TZADGG
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M7 :85'-+#B(3"C J36XA" W\QK&=: &S1Y&QYW59.4:'\_'%0H+J'[ADH[A
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M#@,ZPX%OZ)8. ]@ST/@^;C$-G7F@2-J_2,,"=+=K.K^#4<2P@%#@W0K9PV)
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MB3]VAGM=7Y$+G0Y>IK&Z".Z.PG&#@1^Z[2+O@=/YZZVWWH-20&N+OFYWCN[
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MM=FVK-X62F']0&'A% K=6==JC0.%A2J[E$2MEK6H)/J04+%'JS71,M\=#)S
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M8@M6]1I>S0X?Z7F+^(63CE>SZ]*O'5J3P+=F9'USXOGK8!(,R?#"=:;LL)/
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M.H8[U>2*A/4*J 9;E*(-:W_O^E =KU2@+M-R5^\Z/J5@1\HR-HJ^@Z4(GUB
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MI+85!J-PLDWYFEOH776Z@3]"[*@>P59X)M9&#6I)^)J>,F&9;H774AA\!)G
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MK/9KS;])Z+MK9W4/==?57U!+ P04    " #K43Y5$0&TH9^0  !4K   "P
M &9I;E\P,#$N:G!GG+L'5%/1MBZ\ 1%!(2"$)A 5*8J(4J0(1$5 0$4ZTB*@
M(D1 >B?T)D60HK1(DTY$>HUT$)%.E!YZ)X$  4+RQW//O>^<^[__CO?^G;$R
MQMQ[9>\UUYI[SN^;:X;RFS(+L&JJ::@!-#0TP'/J!Z!, "K F=.G&4[3GV%@
M8&!D/,-TCH/YW-FSYWC.LX,X^'DA OR\?'P7K]P0N7CYNB ?GZCLU>LW;TE+
M2T-$Y)7D)!5O2$E+_KT)#2,CX[FSY[B9F;DE+_%=DOR_/BC? ;8S0"&]"QW-
M98"6C8:.C8;2#D  @(:>YA\'\,^#AI;N%/UIAC.,3&>I':I8 5H:.CK:4W3T
M]*=.4:_Z4:\#I]CHSU^Z=>\TNXXEPV4G#LG ^*PS@O?+6\"Z@[@K4E;.08Q,
MG%S</+Q"PB*B5Z])R]R6E9-74'F@JJ;^4$-33]_ T,CXF8GUBY>O;%[;VKFX
MNKE[>'IY!X>$AH5'1$8E?$A,2D[Y^"DU.R<W[TM^06'1MXK*JNJ:VKKZUK;V
MCLZN[IX?0\,CHV.8WW_&L7/S"XM+RRNK:_B=7<+>_@'Q\.BO7C0 '<U_'O];
MO=BH>M&>.D5WBN&O7C2T'G\[L)VBOW3K]/E[.@R63NR7)0//<-R/SRIO8124
MTL6!K9P'F3BO2&.%\']5^X=F_V>*!?W_TNR_%/M?>HT#Y^AHJ(M'QP9 @2I\
MZOX6II.SD'YRH/!K=#Q?=([RBW2\A<L)JA QH+9-I@ U1$P5Z0'1HYA8T\X*
M^VWV3)W#O9B1O>'T)$_<2T7?UCHH45=9B (@IT2HO34H0.?Z[S9,=J&J1G'F
M8V\9<[6YC%BZ8Y@N!?@<,W-" 1SQ.?\FE5$ ,D=<)&+Y@/I;]! "7P_%/B2F
MD!&NR.,3$0IPH;2Y7.4P96]'<A^,3J( ,*D ,F8$O2+H00$0$Z37_RK T10@
M5' .=G@RA-@F($D.<?]];"M'': E&*9;*=1Q$8'Y.0NMVI,X.C-% 6;V*0#O
MOTL..=8W/A5.&3_I'AK_B:M[E'2]1']>;CZJV%2(JTA-O"K+Y7]0J\A5;]$\
M]&<O<OPHY>24 P78/D;$0/Y5T"M]+-96WUE[[-JG,+=@0S_(TK)G_9WT6.1'
MTE187=HW,0H 7X,1V!JHT[))ED;\BR S\<>7!Z_T(RRCQ%[I006G(\F5[6@,
M21*=TN9;O_V) I39&RNJTH]>N 9&JGFA]IOS*,"]"^AC\LR\^K\*%@D4@*[J
M*5H8]<IT("?P!'YC=W8FJC3QH^&O;?Y3>K/(XPV)W2PK4>7BHT.ZK&>N-N!_
MM8O!?Q5&,XS:3,8B*< E\1M+?Q#+.9>N4@"_<W%CWXK=>H7<K+E^9GSZOYXO
M'V1+6F29[R6/*[L:4N\.:'*=NP3,?%]@ HR:?5DI0+SD+KE5@@)DSY<I.FO&
M]?%["D_!/BC=B!)%<>^U1HE^IOU'$PO!^(NN')DO_Y8FOAI%552JPG]L$:8F
M3VB*0X1D7Q?'RW<R[=AXJ'KEDX1F6+<07O#9[KD(PK/TK1--"G MQP,OU9'*
M-E7FJ=4;+K?+^@UULA<&&ZLRMFT"-Q->X5E-9[9L2@8M?/)]+7%]4VF]KAA.
MEXL]H?/734^&&B%=X"F3R0XO6^:?S/57XU^H1+]\V'TB=G4X75G(^J%^")G+
MN8-#YZFQCJKT^R(-.;J$QX!"U"Z:@?1 ^0H^-O_+S4A[0-RJ;5NRL*6_3+UO
MTR+22#>]L/D9&U-\:N/]*-&"ZZ)%WC$='6493DJEA0V9TM??,S"]4/ZDR+2K
MA8XV4C#KY-=N33%T<8_5Z+[BO1-4F:_II@QVD1^-@4;L>8MUAW?=<;_(3&NE
M?6\_D *T8URPVJQV)B>5NVN\IXXTLV!BOSYXI+(XW[V6:QV;TZ2_HO\%)61E
M:9$^E?TK(4JTY'%0E%@8WB;63>+LC"0%:)5P\<@OT-L?26'L7LY.M\Z_8G#_
M?%KEP_01\(*'M-%[:H^]:NJBGYLALD*)J>4,G1<F1B4L9X]["[KHYS]%,)#I
M>$J;"Y\YH 4E2G5]I$8+4)=3YLVJ*PX]IL&9OP] SBK^:K?,6<+Q-FW>[<6G
MAGKS?T[2N +W$3.GXOHY\L**P1YL7>R:3WHR%CE&G^NS.H-4="85XTU_X!^\
MC-=/BF8]^UZ.1_$<8>FKK'!V8[$^L:;H=<69/8G39B;)OV9NKP3\)BA;,#^E
MNI%M"J [0]9&[->O&FOVF4MT\&V#->[('F;VJ'H>D=P" M%W$V7?W@B$'#'?
M(7.5UIP KRC ][]S.+BG.?,#8II#ZD+I6"A0 /[WD"FBVT=$E3<#N1L^7,EL
M#*]G3BZXM*/Z\Q[IVT3U<O5;J6<C6;JIC8.NZ_=S*I\5JGIEEN*UG@Z*),E
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MI5^040:M##5R38LV'VZAII+E+Q2:_W$GF5* >ZA[&->"JCZ6W4=I(;417_Q
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ME^$KVZAG_^T-=C<(R7HB/;1K(W2U4\_MPH[Z';S'/?(H+KXY4LHIOR95R5V
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MK+GF?.:<ZUUKOM)_S'I1M-)I7E"?EN6T]R "C[$QSPJZ]W(.GXBI%$1$+^F
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MN9T5P M[W(,EJ9SHEF@[_\EF7%=?)MU+>;>,*[$;@]O[JMU!H@/$9_3P<EX
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M>/4:"<Q363_9U]^8;F:)LL#9CLIK\,VEJ9RPRM8W7#USM1GLI\D?.;4-V-C
M%W>KK4L6,95-C%-XD.FKYIE6UL%#JE_40QE]^".":@[XW;_'=..6[@H29.;(
MKE:ZJY]7NCNBQH>/&O!3*'?9YMH\?VJWSRZ9=5Z!T]7\I!X9!@8&2W!#6))K
M[1I^X,E]Z?8E8_ =XAO/4(>CP^Q@"X_F5"O[HLG;S";_'/WVR\L;?YY"R#!H
M[W*E!,T"=M"LLDZ<L\Y/7FJS%\J_8.\#Z]*+V0N+VLZ$K&0\G$-:R=1-6%DL
M%KTDB?\=1W($.9YM;%DN@<\CO^C5UB?Y97/:]IL<\G*^"CF>,>+.A_^0_(B<
MWTEGFB@-8PZR;WDLF?03**O5TR8I1AU873^)XFXL-G7'.:6"PMA)<F"#Q4>6
MI-JY&J D^0VO-/+X3!M-Z]F7.KHT0=U9C(_4NMH&Z-(S5*9*A<WWHCOG](/(
MM.G?#!E<"ZU,T=9!F1.$PF#=R.LN9@(X-D90Z)RAN0,V'DG,I5C8Q#"XW]8B
M/:4"PFGV_!YZ_.!2E$5WILM3NND=^4LTOESS4X3DL3]%LIE*' INU($=F8Z&
M7ARP3L0GX[9)"E''&1C9HJD?KHG@UP+?\X6?6.@$%A1]-' M;Z-QS=:>T%C*
M'7Y32KJRL$>Q"&BLB6U-W%Y52JI[,@G9RJN1D,XRWOHY3#[4Y%D8)G1AN7OW
M1ZMHVX[SX;9A%);TJ$X-XAT+D)#7]=\P +JBG-7QV3H;=L="3U5Y9)J@X3J^
M@EC%D!3ECDZR2=3^1E/:XZ 5C_/>3UFAJ\PG)V4_ILY&6SF<[^-F/7IP; J7
M?MFZ4&1[Y[P;R_N_Q@V6_2)?!T[R=+AQ/H2L&Y&OORBIJTN^H'H=9:NQO@[:
M<)_V>SJR]S %^KZ;T\T[:'@]=9JT#&4^^H')H]+%]\4F%8&LDO\YZQTT#J((
M#,]V6;HD,,( EJH*.9OQMA^J0SP+%^9_I'Z;I.!=[#QRU,"#F97D+/46JCXZ
M468LZQ W,NAL9JY#!)<S_=2VYKIB8PT@<].F!FKN$'HA1(K.JG_JZ??8VS^2
MOZ-"SB3[.=.MU+O+CR2IB^$-_<?+_@6MDA@9A3Z!^4NT8.1&T=#A2WL\L4^_
M)M,)$3@:7[014\7N'V P_B(.MEYQ<DVF/_ME+DB' EG?935>.7XEN.):_ZUU
M*H:0\?#U\>6/7VDW)P\?7-Z1 8M54+:EB8TV#D@Z:]4D573O$&_=*JV??*:5
MEYEKYTE763@5I"A,CQI6*Q++@YIFZU4M9KF35^*CW@@)[(G'[W%$ HD$R5\7
MKT;Y/%YE\#8#GD_R+\$HPJ=OKVHU3PB*XFI(_,$]NFC17WN=4Y.T/)0O5F:-
M9KU?*)2-L.LNXF3T<!EX]U"5$4'FV6>)37L:B/.S! _T+=,<<K839WU_? A8
MY*,A?B>=QA6<9I4[RP6-JM2!\RBMR&2?%'_=F=I4X=-1?9>K&G?D5>UD0E(&
M^PEG*!CK)<F#],IX5?!UX\*2X<,A]4'52:M-_ ='IN3U%<5*/8"/"AH9LG&B
M96\G_4BC/B(.7(&/=H2)E#DVV&,^G^%DHOBT29?=PA\Z3/(,N#.] _;7%TQD
MJZ=\240K<MFZ6FFH<34.*ZM>B;[F-VKM]R)Y_'C2KNSAUM3C%*A.-QUX6#40
M]V(ZHZ;UFJQPIL@D>$^]73H!2[X/!-2P(7)PZ?I*?U-KRS7E*FH>F[XQ7@UR
MN:\2^><KC&XW6V8[CGRXRX2[$(J6F9:$7PM":) CR&)MYS/OQWT/2E_@<D05
M20*8,WQTHK#BN46U2UWMZF+H$EYJ]9X,"VY[^678Y;[ML+!XT&&/-QN;+\.^
M^29*1%!5YS(63SLUOOC7EGR);?4L=X)S@5%O(1G>V[555KI;!R#RH]($ET2Q
MKH3YSU\#8,SOQ)9Y!0_]F)#OTY].LC0V3CM4\_UV0]YEI-K*G'J'!/YX]W%2
M\+;WZCL,8,;NE:#^\Q\'IWXOW[--%K-8_#B6?#ITM(@>$R]6CK-FOA7W4O2.
M=O*Q@4E@1&ZO^9B/6M&,L,E";-]YM\!)F7R8'N-+=^Y^ *<"/IUKJ5AL@-]J
MW?1]991*ER](K7JR<C<"OW+)X5,0G3<0!%:YB._TNI>]O$1":^6N&Q:8.,W1
MO8Z[;GH@*4YS^>.7ZQ*Q33I3^15#_H<*!2*M$W.I(J_P:<+0,^YA2XO0K'V=
ME&SBUG21*H1E<FS_-D/Q W\)26$SY/0$< 1-O5<\H-BFBL<]Y2WIA)[/ZG](
MZ75-97:A"\ZVB=O6M]57*U@PJ8][-?V24FKF!+7#P:[;)'S$'E]HIZ4HB,!I
M=?2H'K2J9B,J!#"R$2N:' BOCIR548^>^KK#ED(S?M=XY% 91.@Y46AA ))4
M8/9+KPI!>UR5:7M4E'HW;4&/VFK")>^:'WDNG2ZSY].R1QRF=;G#N)86'G8]
M7L PF(:=2[E1C+#^[S9SW+FK)0TC>4^W;#A((6W@CRVEF_F)SFUMDWRYR_$G
M2(L5N\>/QGN$RSN;R'VZ@(FH-PEBQ&^'%@NC!4HJOSIL#6M:WE)F!;@*MB(;
M5OP2LN:4'?+4Z-$Y';;,BBZ.&3JF/0R?-[?U-F&"ZV>4^HC@7%\@=>0!^L,@
MJKA@1.(N[)!(;,#J/<.ZEZ$AD!_4\1,%R$F@LET23NSX6%FIFH202))%&I0A
MDZTF7#W5 C7K8I/-?X\]<E(?XD.N;AL?YL]BO=C>,O"706?Y/4DEC? J>37;
MHZ+3/T5:3*HW^V!(WY4XD'IX37?.TEW:3_<#-Y0!?5$]"L#-//D/HVK"E"Y/
MXW6L^O6G0HH]%/6/N!.56,-J9!VI'XO@!BM@ ")E"O"6[N!HD7T?^8]'L3VS
MRQKQZ"/'"TA_DY7FV ?!"*&J"2[&ND ,@" B%:@Q#W0T=B]$/1H]8.;)MQ46
M\D3?)U/)WNZ5_BZXY6L993W[J^+@DZ\QE,TX?F0'VOS$0V5?6+%4O^ D(=+J
MZ!U[8C8"U.[E8UZ:.>U$%#NG\!NT\JD%ZFBVK'75;._'V_QCXN:^C<Y!/-S@
M185%_.OZNA93E/1.#!HG8^K7I_8>8\M!,@2/NE:T@18"-U2*W; T-F=[USZO
M.#AV[:)Z-5M\%9*YN?MVD1]I4X#4)V^HB2TK =!N:'6\_(-F.1F6N[BZOF^6
M/VM376QO9H\EY#&1F&?7[&[:L0]^$I3PRJZ1O'2,)F2W'=TCQLLK$_9TEV!J
ME29C&7WI95Q]*)4N];94U"K0BV$O^YB^8JRI>^Q@$3TKGJ*<G7S_GH[2'_[8
M/3M_!&[;-;%.0NGS"Y-7WZ-5NOU7AJ]2S>"/O74^QL/]CKJ^FW3I.AJ47_RH
M5(AL6:V%C(P7GWHUHTPXR'D<0 NV6Z?)[-"@5"_?KQ2. I6?,N7Y^2P?$SAY
M)U<9*MH^P!LD>XT;XO,":2*9>FP[>[<N<;3/$VI&;1VV\]K=Q'1\>ZP,6PV&
M#6=V,<27'":!C!F_$30RC43O7D+\OBSN)DZC@4CWSE?C1C.>NEQ3*S.--=+&
M/8A[#:9AD5E[NQREU^JBIKG4QV-NEAL917JV4S\V00W!.Z0H#1%3#&!*T*TQ
MH1F_*K<G+<<C<6,RY,7[BY;#7 NTMJL4T*,V,PH%]B&M8S!U&/:0AIIOO[D2
MN!I_KLU^&K("D6]HJ"ZOMHLH#LT,\NKC"-) )A]A )2H=U75X:K21. <P]0O
M;@-7E1B "[ 1#(*^DB)L<^=->HM@R/99+7Z'<U%NNWT"#O&C&IEA^:*FG&\<
M-Y_!5[$CT"HMPYY]ZB%>O89>8_/VW$KBV7"4QG/A4JX27R+9<?PM@0R7YYQ9
M8+.<'QR6#)$\-NZ0)X_2C\ZY^ YEMTWUU%AM>21%/2!QM)M,(+[0YYWRDBY^
M8<3]')C@S' 7"7&'*:*'6A1KQX6!\6A]&>>A^;-33:19RZC@H!WZ+C8U#+L?
M=]F)#[E !N[%(YC*5I.W\L/4&8:*ZD5W3),S)%DMK:W13\9<KTREOOL2]J\R
M<_@,H(_2%5?UJ];B48^BV5#[/)V4%+\;R[[C60+A+!RH(A20V$?O(9Z/KT\Y
M1&8/K%NRKAXQ=:/'*)466V"X),7?LOST#6M8T#U]92IV_U/!]68VQ.!FV :8
MR(.;FMOXM<[*_CV 9ML#D.Q.#_P4^JV9_,^\TJ_=^J'"$K'4_70GTJ,U=-6?
M[7JU8(@M5^6NDKTIL..1?_SACE_ECVU-=^-C%"[+FQ\U[2VDJ7!6?_O&)^;F
M,267J1VDO\5N74^>G1]>$O6'<[ -:28]KQ$,)*/D5)=;42]TR/.@U7A4'\:=
M+81@DZ@0Q@7*QB-U<>":AE55M2UC'YF5UFO9.&FCA6/P+"Y/1"ZGE0M03-63
MI_<=! F]-=+2O@>DY;]C%:$>)M= X]K04579K3--8LMI6:.8A+ORXTY+O:NI
M=F)%MN*>Z85O%Y^.,B(H0\J>]_$2]!WQH2GI"E$(#0^SCF,/=Y"WGJM!TTN*
M>:B3DQG5EF2Q5^WA $?7GIM!LE"<E D<$F0UU6A% 7$F99SK'70CUM:2YKV,
M/T(+GNPP=OH_O*M-!?@$*+E2(U8OGS@4I+73BCZ %Z;+IC9+)\&FFVRF_H0?
M5,9O17XZD8RSJ]6-0CDU!J8Q]AG2!AZS6-!KJX\(G+:AHKPFKRL6WQH:R#NS
M-,9ER2=+-P9&9\_KIK2T&>"'+=H-.FND*ZZG[L^#ZD0')9YGW3\>G&T+B]PD
M4H+VF^"<<H#+;?7M1"@9K+]KI>NI?'8\Z=GAF-X=N"DAV'0,[&W1K,9RID[$
M!4SD2]9B6O5"">1?9X.ZKGHREN;IZJBW%9YJ;;**2':%:#.1W^<*<TW367HY
M]M$5/U\['&_ R3$^&G#.&GXA=']V<8=M]0I1ZYCQVME$!OD%%H/U-Z[)P] J
MBJCY1K?]8"7_O4PXAX@/\2C?4&&!%?K6S3*I @V4AL_=JX6)0(V]2O_7J&>Z
M_P\[BN2#>(<"/24&:BT&(I7T'=\>E;$R_DJD3/*'/#7QSOJT;-(I.K8>6/B)
MG?4KBM&71XTEX62]&(!G*#VHKI3];SG,C+JFW9(.:Y%^8K9=KLVQB;$*4XV_
MJ@#0 :2I:Q> H.QP0"J[4G/S-,H6?,,_B/YC/_/P1&,<T6VC^=IAR4VN8"VI
MOG0(IY6FWBZ#@GE2D%)6L+U_Y)XDU6=RQ5%^CB6._KEEO[@'E6)-1R1#*EGH
M@ 80/M(+3#2C;"]5[E[HX-L_S9S!:9;9)S@:GL#6;"U9617).UIX9U6PN4;L
M9O&.*+.,'KENYK!NHPN+,8P;B4W7DX*C;@U?GQK7B3W_J13!I/ [!]?00ETL
M<CK%$$57/<$=>1D2ZLI12*P;?S?T,A6K.HW B[5]LPQ2:G6Z6-VZ"+A5%U_[
M.-+KX'6SG6=U T2':4/VPMQ/<%]P/0HNK73GN5C3):]H'QXXL[2BPX^R<82;
M/@]!CL[^.+KWECMZ.5]2=LC+$>)5(I<K*MJ&*E&GUP[4>MI"JFHRM=\HF6UH
M*_RQ*/8)>\YR@UD0P]ITM _UA"F(W$1.(KS"J./KT+T-PCC<9B+'/;N?V)2^
M"[KSR&B'X<F$%>=>FP'N.]:#4N?/DD5E*#9Z>M$(G8DW,K(Z%R),\.)\=I*\
ME?7B(\8?4/9P%3$>@8F"4N<.*9HZ.#S-<IJGZMD\89C+7&.C5;[@Z#1=G'K?
M_&Z$O6T)>4+IEHXQXUC>^.'* MF78* G;05/%GFQ_/W*@^ QV]\7H"X&ZB9X
M:3E+T,JZWPF__U'_]V7(CKANBP\_!A#GG8,!U"Y=TNJ$A$MPF:XTL964:16S
M+9#UG6<[:%S+OX4?1#<#1[B>5R4-46S7_)ZI<>P3[1'9-7)%L$.9T\]%G\$6
MV*'0$CL->?)NM[L>93T<M<SUH]!',N/MOQI#B=EI+05.9^TF)61S!J V]E9$
MN<[Y%;Q/[<Q"6O=/!+%E<'O<6,[[<YKN;,Y()Y.US>-[]9_&\N^S#:*B/[PH
M%#F2I\[ .:75,E)5]R3_F..:0):N)_-X=?O:;L:N'P. *6W']C-_T6N.+'N\
M;_CEE*KTO./RY>73;]7..[KZ7S@>/:T3]6%84N'CS\=.Y.$([TX.4Q^S'7;&
M+*<$>VD(Q9[E?E%.N.6IF3-\/>9]:WNI+->;_O5D9;&1W:L,4%.D9&._=DA^
M[3EN\E"4O+JMFN%8)=WR2AJ$ 2FZDO+M5 %^_7OH;"S+^UV/E &1"N0]/YC8
MZ_S!Q1PL..49,N4!SV_.Q@TW>KZ C,$@7U*#52UM@Y[":,*^\8JMFT,]::;&
M/(@&W0 ]EX6G;')J]VWR9)QK'M\=;M$T+BRUB;>]U$K\9$LI1+3FAYZ'M>+F
MV0WWM''Q*].H1EFB=3XJMP> ZAY/J]-HP;@]F_Y#6[)T2VUI;G.@*8?G<]_O
M@.VUCU3I;N]F).W(^24<DJ]#X.**3.=>T*-JKYB0RP?;*+[E;92@RY%PJ"#M
M%K405U/'.F5L+]UQMS1-R:M"K?A4X^9 V*2^79PJ2+.DA(=\5]B+.*14$)\#
MMRGY";K$1>-ZHT>$'G'I"IW%&W3JRAFWW=2*M^V] "L@$JO,5J:F?I@Y>SK]
M26:*8[ES/8(+@[QZ<*G?O:':)+6X8N!>$_=V<I;RJE>I3_. (WU< B=KVYBE
M=IHKB]%3X!<3A)O1ZRO5JG2^X)CARW$#U4<J[]U?%.U.*M,KCM4["F9IEVJ;
M91"KN(QON(M*ARX^!1%YZ(.YC6JF93H^WKH(]JI9%K]<J6OQWYB[HM3L8)T=
M[%V4CK <K8$/[50XP]W&7]?91:F:3)1NF [T5=9L.%]H.?I05E5^&S1=P;_2
M\^(,!Y@B2]G',PO%?&9;F(2*Q8I\ZF]<LLC+/OO/]M39+\,!%W@W2=[7]7G_
MB:ODNILT\EE)QD,;_EU]S1G9@OGMO=_WD__ ?HK[$@I:[G7.J<IM+H55\[[U
M.-=0=0JRL/C^%8S/.X"#7$,+[K4026@ 0U%\MY4?"T\5,:8I7T3C$B(ATX+#
MD  :S8;&RRY49(_X9QGGPQAGT)?EP82T]F&SLAV=7SP*:EDA*WS&0?J5[)JO
MG29=R]O4TZRUG%05QS8+=(-0A@B=8JG,2YQ992M3VGOS7O-FV59Y2P[&S8LM
M639)8MHA,Z55XE'R'8^>UN*X$3MX05<@#[87.<?ETXX2GLUE?^=K%EBZ\V6Z
MR6FD\($K#Y?N:>&X/FFA^NAHJD.["=E.<E>$35)B&2>%]6WCXVB\VT*G(H=;
MHF6OBVC4$VQ^V,38G&F$+@>]*#CP'2X4]/M1LBI:)Z]'J<(?^2B^ 4O]%<\%
M>*KVF5ZERH*+]/15!FJ9SQ]$ZHH,W=]N*Y"&<<.7K@G$0.A[/6C!U1;:EC5G
M;![[TPN\U<<QR#&:ZQ^YG+=>MSG9W4_JJ&JVLX14;13& .2(L(6.?SD&$ 6$
M)WDXH(/I63$ '#,,@.9")7S\2DSZ]V\,H)(%57!9@WYT2(@!C'1@"7#Y WA5
M$<6R2(LMDD*4,8#6/QA =_.;'Y"]+0Q @'C_/IA=L!'T7)>!<\HJ^&4<&X^5
MN>OC8C:WQP%B7W;UGFL8!VK'*1*D+;2'/\M3TM7(1,E@TZ@ 13N?L3D>5,,\
M:ALB.^]W1Y='_E46=;&R84&_AGM$^0&-=/>"E(]B\?;1;(OG.ZGW?DP!T@33
MGKD>%3)39U'BVM7?YW(,SEJNX9_ *A?JX:OIMU.;Z8EJS8IX(C3WO#C6TSAZ
M&)A'W2(D=58'3"XLV(Y)@0I#T@2ZF=8MM//D$,-Q6?J-2A'I\PYPE)-6ZV1T
ML68IU:S3DMQ,,66G,=6X!"@_14UA7DA@O;]10G$2=$%6SQIV B9IV[!Q'QV2
M&5 \-_(K\B2O,$P_89G)+EY(]<Y>AU!ZJ%^UZY=7UETL^U0UM=(IM8Q$KV(
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MC3R=0DV57_,7=K]=AH.8M@U>\$:RLWU(1OW.95/1FG>W24_)\FB10_#%NC3
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M+B&0MU7H$:*A-%])]<&_-KVV1\Y@=AHB(0Z[*ONU0Q,.[4'(TP@D7.[CDH?
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M-HT[C)57'/ \OL@@G)'Y[6&;W[^G>SL&R$I[V/?.EWBNQH#%MC-75MGM9S&
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M09<:X(=\5\N&"[H^Z?<P*Q<,0%-N91@5/W!XN4V)#N8PPU+K$>-6QNDF$!W
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M^V",D"T34H\M9-YZSO,NYSWO>;?O?3Y_7=>YS_F<Z[K/N<DSY$7@C*X.0@<
M@4# [9\'(,\!F@ M-34--14M#0T-'1TM/2.$B9&!@9&+C9T%PLM]GH^7FX>'
M7UA2C%_PHA /C[C\A8N7I>7DY,Z+*:HHR"A+RLK)_+H$1$='Q\C "&5B@LH(
M\ C(_,\AMP.LM( 1, (&"0(4K" P*XC<!9P' ! 5Z(\ ?P9$ ::DHJ:AI:-G
M^-F /0-0@,!@"DHP%14EY<]JT,\Z0,E*Q28@K4[-;F1/(^@%D7D1ETTKI%'5
MP8$<VQ&6=? .IJ,_RPGEXA81%1._("$'OR*OH'A54TM;Y_H-A*ZQB2G*S-S"
MTM'ICO-=%U<WGX>^?OZ/ AZ'O P-"_\M AV?D)B4G/(Z-2TG-R^_H+ (4UQ=
M4XNMJV]H;'K7V=7=T]O7/S ^,3F%GYZ9)2Q]7%Y975O_M$'Z^NWWW;W]@\/O
M1[^\0  8]-?\2R_6GUX4E)1@2II?7B *_U\-K)14 M+4;.I&-/9>[((R+V@A
M&G'951UT0K+('0X'[S'ZL\)R2R)??ZG]8?;?B07_7V9_$_N[%P%@!(-^#@_,
M"J@!!T?B.<_I_Y$8"R0_UWO.9K[@-SP\B[O9S^_P/U>'\H^"7@7D<\0J&>8Z
MFYAE=JI=9;9E):F8S6%=K>8[?2GT*2.%/0:JWX3HE\!V!?3EW?-VD<YIX\4K
M50 H'O'I J=7UPM\+B)N/HGY8]NCF.#JY%,;9XUD1L<:X_ F7KM9M<.* :P
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M+67&*]QJN[,G"WP5['*,@TC&W6Y[+=8;R(':FXBX0A(-T79?\QIY:&C$NOB
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M(5H;;15KHPW1VFBK6!MMB-9&6\7::$.T-MHJUD8;HK715HD M"'JY+:*3NY
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MVQ&+>!W$AS[6JET*ODB\63I9S"2Z13,6Y/,/LDM]+(+%F*77)GGN"&U8?VS
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MV/J-[?'HC.&X2UY]$*+^]@DAI5 R]^V',THAF2WP$G$6_C]02P,$%     @
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MC8K[XI[SYO&"/_"]/V_8;]>.CHXJ]M^^O$JUH!=9L;7*]YOKOC*!!BAKB)H
M*1R :L?4?GB-%6#:3$;:51*^P?^O[+Y6YH_*M7JY47N_H.J>PUNI=$*P#GMP
M5+(M/S:74WBZ1S5CJG.#[&<3 D?\F8[+G,'JQT:5%_%O_N0G^=G"B&)=4SGW
M9T#G5>E/(#3W2KSHNU[[I1+\@^D$$ -P\2K\KRO"KRN?LC"PS=JD ?LF^[,!
M40H;UPNH9$-D"]#)I8[GR0U\^=*QS#9- ;IBZ7:+NF:&^$R$"Q,B%:JND;S
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M5U+.*R.QN$]"S$J(@RU7QFU(3^AVR:QVT.PE><HS-*#*AJ(^)#--B;G_EZC
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MXM<U_R$PRK&&S02"C@V>5#@<SUKGSO1_4$L#!!0    ( .M1/E55;Z^-B68
M )1N!@ 5    <VEL;RTR,#(R,#8S,%]D968N>&UL[;UK<^0VLB;\?7]%;[]?
M=N-$3[O;9X['$S.[4;KU:$:MTDIJ^_AL;#BH(JJ*-HLL\Z)6^=>_ $E4D44
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MNHXK_YT%A1-E0?\R"P8UU[IY&;L6Z(DTE[_*-P5^KQ[)"M!E9K*A=-IH\U4
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M8NPL&^*T8R4M6;\Q*I0Q'F[M? "N^=<OPS$.3A$CX<1E.UQ/N[4=]@:6:\[
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M+DS@9X@2@GVW C6S9Q)F:U70CXJF7[Y00R)(R5T2+#13409CQMD5'\&0'DR
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M74&H_A$I>3R'D 9)6T,#A T<#U$'.2QUU]]5I+]"K%Q&76)P4OW[Y#8"V3P
M[J.3\^CD/#HYCT[.HY/S:*2 GIQ')^?19# ].8^FY3RB9B;+[;X@Z2()BF(
M6I */G,8981\V1)AI*&);61AXEZJ_;F[&")\Z$V\2VX28EX689[271HOGUF*
MON?[181]%C\1;Q,G&<OI&RKL2(L9/,^3(?D!PI,,I.,$C)&',=FM)RL_E8FD
MG(8[G;/6)PF[C9[MOD3!;SFI'0U(KJQNFF@V#;QORWQ/'E_?-42 U0>O21[5
M]R4DX][WI;W^Y5(S<X=!B@G%&R85E'-O&*BL=)OE_3&=9"JE<'*2(0-Z<I)A
M 7MRDH%C>G*2@2.*ZB0S\<HT7#)C]\CTO-T=NV9@$X>KT4U=DX+/)N*:A)&&
MR$TY.I]9NO;"<.OMOGP^ZU$ T@3<&D4\]Y>0B-6Q:$D5QY'5(H!WM>GOL5()
MVLHOU887P/MT\CTY\CW)-@N.A^GD8#HYF$X.IO$XF!Z"%_,[T>&CZ?A#:A-%
M=3 ]D&<264!:^VQ:_I#&A+O7JBVNEZPZO#FN]<^FA6MCP@A^I@?6\B!.]NTO
MM%!M?32!#!XM^[>-!MY2_N-<X+6@M[VF.[BE>W2R?A#FK/QE1#+*4TK-\90U
M$BELYV_>5AS\[;^_>_?F__[X^8<__[__^Y^+;?[R4_3G[_W?OWM>_;2+OESD
M7S]]EWS_W;\^_O+E<9>&WSTO?O\F_&?VGBK3?_[^W;>_OGQ8W&3?_-?5U<>'
M?[U_?CD[_^F;9_\A^>G^_'P71Y^#KRO__WP,__G3[_[O7^;/WR^O/X3O?[C^
MYB_DO][_<ON75?;#K_'S_[G]_&^/J[_L'GZ[67W[;S^>?UC]^_K;?P__\G5[
M=W'_K\OM\^W']#+^X;M/9U_3Y9?LO[[[>O=+%MU__>7E_?O?U]X_+KS?D\6_
M_NOAIW^+_:]G__[;I\V'SW/__6]+?_.OI[GWZ-W=D>^?[KSWWWS\^LM_+C_-
M?_GRX>.GY?TZC2Z__; ,5R]_N?DV"?-?/SY\^OIIN;G[:>O%P7_^U_5??OB/
M;Y>SO__]_[TY?[A_]\ZFV&:^V7C)+EX^!*LH6 8+*I?98A'GQ5J\B\- N!H5
MTC/S@&#2MVH7!,Z/OML$BS;:#5KL4!E@21W.&BQQ]7?#V-S[BK8,;-BJH<]#
M%B]^1?"\R.G@W?OTW"W(^Z_1V4P.-I+WI4X(Q>\B((!IWF@Y73K7=%TF(H2P
M@JW:M,#=*Q)Y.'2K])2&GA/%1AJSV@X^="^Y9,]6U,"\HI-@K>7RK"R*OKST
M$M9*+KTC2=E\;B<> $%Y8G**= <<G>Y%E3;TB[&::30G>B<YO#  +<4^P([M
M7C*&N<\H<@<_-O0D[_0<&9GP\<ZER\TVC'>$%(=@V=)6Y#KMWQ)%2L=) I:I
MSFNT-9%#AE9RM&I]BB*:YMAN7=\V\CC"!CB]<&]9DH1R<GZ75 6\"^FCR$-%
MR65@H?QZU[AVJG!"NGCVU-:S#;,!QV5&5SRY*C0WD),+6("Z[]^#/P84E?Z]
MR \#[RD(B\EMB)?F=']XV=(+DB)H,8[H7.CD$SJW)R\-TOI+@;&K]XH.6_2]
MCI=70>1%BX"U0N7)\XR;_5]\+GDI?MZ6J27S9H[R\7!KEX#NFG]]-_PX.$4T
M,\1N>]?3ECOY77,&F!=L<WCO)W>VV__S'P%)J#C7NQOR3$($)Y<F4>=E[T:R
M-MHGMJ[4< ((A9-N\X'BMS*C/4B@H<*+9;:[A!+6PQC+.V7$!KBKREC8#GU6
M XD:SQ>UIW@=45L_+5C^@'+%5E%R><6VTFM"28H@1/-.B:A^'$QP'U^KX#X:
MN+3@!/?M8(+[]K4*[EO]8%R;N^;E;WF0[:XCUD>^X'>6[;G0N@(J!W 8,.K:
MVI7?T=20:QV'@SN=6.MURC05PIK0WV^]:)>28A[!81XU. [>)O.PPGT[S%E%
M]3IZ7)/SDNJ#"CW+CN?V='HDER7!L\=<E.=T'079?9#^>NB%NV]A?_BSF\/J
M ]:FO5AQ5_$0<)DT4Z+Z" ;VAEK,<^;[!:9IO"SG=/!I:RUSU??.BB, "Z\;
M*-!ZXGRMW"7Q@A _96\*#UY(9I'_V<L8S=U\^=E+?J5G"56#,H'UWKGF])T]
M >%L5@L!=%I1-@M!1.I+E! O9*4B/E%H;HI^\Z#2UR3JT 1#DKHNVKIMY(<V
MII;<'*7VHQ<O:Q;5BO+.\$L]]G?T%[=7UQ=/>4I-R;3^@-?#IMK;PA>4^'Q9
M$P<#CF^DXA>WR\ _JXA;6E9]J?6XCI8=T<^I14Z7EIC]_N_R0AJ.DA/!9=QX
M5!>CB>6H94HAHK_>%1WM0676&-JEMT"Y0.O8-\'HA-P&;[X$Z#IYHHN'H7!/
MM=(J8AKUVJ?D@V7 ]$_)]&Q!53<UC^EY6S-_Z>_HW=HO_P18:@@,3D+V&()!
ML85KY'!UKH+0:U2\*EQ1RKV5<R WQ$OE3@=9.(CD6[=QH-U+\Q ^(9L\]$%7
M4*/ZO-B3\R6S\_AJN C2+1M;"_&.(9S&0QO@WH4$?#NP\SA* SIHH5*+:\E5
MG&SH3>4VS@A5L21X-JCAIC>6@]NWA2RTD0%_D.#,\BO</"K5Y9S>A!(4LT)%
MR:5]H"<N+;QT"ML.?0..M\7RBE8)2?,PBY=^D"Z*DAXY\:M?%HX\^16XSQUX
MSLG?%^3GRXL:^?F>/-0EN#<YVQB(8_?8?$E_XN?,%T-0MI,&0?<>2"CIJQR1
M(J2QRA06AZ07?DKB?'L=L2AW.C?AG,[C-*/S^A3'?OH0ASZP]/MP\CJ712_9
M(.4>&?!$_R1-Z4)>!AF"_[H'(Z/P:3M>,"WAP!9KXQP5ML1^JI2E>$,N7[8D
M2@F\;ZZ#V!@>FS&DWH6QSD.&I2IHL_[HO5PNEV0AFQJ\%K#@X34K !N1=/9:
M<&'E1_2^F";["V-$LEKWQ3[V.[N(IH>;*',>V%GFBH$LW:!'(Q9*&GC'"$F,
M035VBZ6^TL5(@;YN-,)"O/"(XG5$H?U@%$,C&\-=/6+5>FM%QD@A@$?]/ Y#
MJK *_1<=4=7M]Z :P:$K30ORCOECE=VI'B#8D<2IS<(P_LJ<VE=Q4H:T,7,1
M/!;)A++;YX N^5EAB1)65-B%M75#-6KE#<2PN\6$G+^IF9TJ*L@02BO?4'.N
MS6!%\8ZU"M(LMJPUD+MCIGLE[C6?'B0XJ9QMNKBVU^%2.JE-(H)II*6O4U;Q
M)2[J(J55$D) TF;5:^.+!!MS'8=TPFD9@]BN("XD>V-6KKD_&:NJS+9D#8HO
M]R,Q=(UE,'$?2BGWQ-AQQ>2291::$D=%W"UBU60A+2SK7;-V)\@.$99'%B.+
M<]@=T4*I3R"F@9^:KE,C6;6*&R7VQ#BAQ%$*:8$7$I!*91SEDGL)1K?UE-VY
M6%983 T:^@@^<WM]56[[Y@EU-%NL8.VR2JE'AV)<T:52YLJQ0HJK8D&<[0Y_
M4K5=F7WU$K_B;YYG:>9%[*7K-L>H@0C.GZM+,:@E@R@^G)(>@(S^2%B;*^+/
MGDGBK<CE"S4;@I3<)<&"C'?U*;EV>0\=^[I4BUOSZFNW7I^Z)_!D/(%[P@1"
M?\[Z8+%;?NZ%CR39?,18NP//P.%+%MXR'GH5Z 1]NM2_UY3A@-J4"T&=D3%I
MW",^G46IC5W!'LNS.Q[!D:WYB57W3J^C.Y($L8_Q/(_!X>ELUQ%CM>C^//C]
M)NW:*.SUI/B+ZVB1L-RB"U+^+Y_!F.Q1Y-FXJSGB9B5C+XYJU?^'8M4;^TJ*
M[<421BE++,7TF:2:ML=/Q$OTGD?ZTG@U.A$&\6H9? <7PB-@:;9:)63E941E
MO^G+6S;<*U$1QBA6,OS+R*VF41M,KT<O8 FO6F7?C\Y,:C(Z)9/(@/-7HMN<
M")V[E6&S\/LZ:"H-KWE<ZSTZ#<O2:W&Y.1$G7Y3 KY6@2M_"7$-EX)4HP0$D
MQ5<7;&!Q7YZOXF1)@BQ/R%B-0A&')\M01XQ\Q76631S>0!3P.R4KT93]5Z(E
MW8F?+V7E,\30]F(UBU$9C,8\O8H &#?2Y(M2^4PQO,'8V%R#6XMRZJ_CR15;
M1'Q10;T"0 4O5 J9Q4UK;I /&*?VP#-X+?=IIZN +VGYBX:3JT]M+J,,5FWS
M]RK.:D3Q\86F>G9QO-+&=,L!XOIT&;<5-U^OR@<<P-.^^&DZR[-UG+"JTU\B
M2K^67W 7>GON2Q[OV91K\ZEF.*H@UN%G]<>P"ARL%AZ_#9Q?!VCU-,WU$9NX
MQXS^,=8LC$SY,AQ7YS[*/'M@ ,B=YQB>AUZ:SI<_E@//DWNV3UNH ZWM#F+V
MT0K"@04I\#@SV"?"#Y(&;R:Y^GY1H=0[B?V4PVZ5PZZ_@D%3U$])ZJ<D]5.2
M.EZ2.B=8[6>4QMG-L4>>QRX!!*>8AO7MG3<QW#>6+N+Y']=>5)F,MW'1X)#X
MXW(7&O/MM)6,N>4RH$"1"K4/,(.C.W81BG1!%:2D _P45FOWE%SV=1GE.M98
M!6BM?DXY\I/)D>^YAD>7 C]\D(5F CQ.C(4ZJWT*RPE9!!HYZ^,ZQL>9E67*
MML-*WF,ZC2596HHHL5..UFO*T4)<DP@I6*HXL][G:EQ-P20!NLK:L3A(^U";
M\,G9"^3.9'.+-2#)BC81;,<0$[&:M=# 314_17Q.(>+3W86L3T"G*FP)Z. H
M'7-[1.KL!M%%'(:Z-4IZ#/\*C@8]&,&3LD_QD^.-GW1P<[(-CX1L\W*T/\PM
MIQKW-HJG'T%W;6/ZJ:&>,'>G3KLVD$YA@9,S=V11?^IT:0=Q?YL@)&D61V1;
MSJ=GSQP*W";(BH&\R#\O6I"N2+0(2-J*RVR1;@FGH_$?""G+[-Y>U/5;Z "0
M&2IZ$$'^M3:)_='NWTS'TD"]($_9P:.+$( H((!H]NDUSX';'XVVQP(H=4(2
M >1VZVT(2EBBE S:BX=6:*)\U<H%4L=(0RR00@&/2U2*Q6EL8C_):,4D&A^'
ME34TCXA!SYS61^YN(%U[?7\2M2<*KG_J=!Z_QN: 'CZ:#J"UB>I$S-H#2@&T
M6*/US]RZ5(R!K4^X.S[+%M>K.$_,8:U]Y?(QU133^F1!6V@TB 3/%@NU]M6D
M$*U-MC/ QAC1S]S U$+R\->NBLH@W:)J,,!; /O!*XF:0<T_<E2$ AOP/28:
M ;(.G$!?/I]MZ+";?)/$.R^DX[6=0:@>$BD#>"XA#9*VI@8(&S@^H@YR6 JO
MO[-(?X58.8VZQ. DB?7D. +9/  .I)/[Z.0^.KF/3NZCD_MHI(">W$<G]]%D
M,#VYCZ;E/BIBABY(NDB"(M!#"]#61Q-P;5A<LMK88+B6"IYF491[X7W)F:9[
M2?"ANUIER*(0PZ2;DCVTSRE=>V%()T4G6@\Y0G6VU&CB.9:$1*S.1DNJ.)ZC
M%@&\?=3?6Z02M)5_J TO0#B1[07VG%5D2-A-[VSW)0I^RTE- 2.YB;IIHMD+
M\'XCV68YO@!K (WHISA01W4>"<FX=QYI+W*YT,S\29!B0G$G207EW)T$*BO=
MHFG6-Z.'X,7\8G3XR*U31*44CF]%M8FB>ID>R#.)+""M?>;>*6($;'W"W6O5
M%M=+EK%@CFO]LVGAVI@P@K/I@>4LQLD^>4,+U=9'$[C(:]F_;33PEK*I]T3P
MF<-.$.#0BU#1N:@/=D^?)RLO"GXO$J#HE,_RE,XEY;-]:VDN\6%FB]_R(.6L
MHA0$5Y*R/>_4J.C?NW7&&?!Z;2*>_1+6PL)9SLU#OMV6-+SP@BQ)PM1<GBS6
M'E(Z=R<]MR>QKF@-\(,N;%RLJBWE.DCIJ;2[C3,RV\2YYBDM_-!I_JG1;A+/
M6R]:T'AS7!<%/9EPK^EN3.B_[[T,>D=(B+A\53+=!#*<@$M&MLE]]K(\8:U,
M,,72(#)-L31Q B[,6.S+69J2C"N^V2HAQ,::[1YE&J>#+B2=10F'>V_*-QLO
MV<7+AV 5!<M@X479;+%@ZI6:\'=Q&-2,>%NSMCW@["DMBDX ;UX%(<L0TUM"
M=1M%B]S$5/Q9E@1/><9LM\?X-HZ8M49A#,LJJ(4&!)Z1.7V'=4"[Y5Q74Q;0
M(CTF4$[.O71]E\3/ =T\9[LO=-#KJ+S'YI2#^98DA2$/?0LSH>Q6!1K+5A]1
M6*\*9^&>Z:R(^)=>PLK<4-V]R#=Y2$]"GQKL= ;06U6#X&3VI@YX2,;W@Q>2
M^;)H6T>72TJ73[E0[LF"!,_$GT>/B5<VJCNV+OK?4HUH.[T]F<G3$%0- ]Y*
MMN?>-J 7YB\4*? &=_6A75KK9H)I(@(:FM>HVI1>IVE^7/X5IC06'WHZH#<1
MT3'&+59ZNKZZN#Z_CM(\(;[(40.PY$4TW#V_FJY\(4(XA;$9L8<[I3AD(6#"
M+\<.LFK2W46G;19\*4J?;,I;9($(NP@79F 5FLE/&^!]8$1Z,B:8&: :=:QM
MI'J7D*T7^)<OK-H?F45^T6ZAX /Z %>2FM+=1XU9=_5F6]=H1'^]^Y30RS2"
M2[0V^&1VT#$H:!66^0-0Z<YX]%XJV9^1B"($?>QW41O[V:2-6G<%8AMA%;OQ
MGJ2$3FQ-=^<%>29AO"W":TH&@.6E07 R6TH'/(UZP3 >G2^1M]TF\38)O%9G
M"W!OSA&Q"=W]NV#3JKQK;G+_&">_LO+2Y057R]8^^F3TNT(X3PXG["5>950P
M;WE.-2GX!5.3Z&LQSNHX<BDJ^H99ZK#A#IY7<N9H'C=*C\%@[ZG[7J_Q\BJ(
MO&@1>&&M6YT7^?N_^$P\=B\O?EY[8+50M?V(WAAE^D'1LLES[4=;/_P0@@Z:
M-U2<_ >\!/:G&PCD_:,<[51M\5YUYR79KO:ZD9[MZK]!2 <T(.PX)Q!P0S4U
MMC[R:-7)ZZ10<@,%!# M(:W$0/,U+Y.;=EX@C&S $P(ETG&8" @M&]T\0.-C
M]L++SM<>"\XQR*UJ?>3.#27?^?MCK3U%'3UD'AT9_!KX\5UA(YK!*?YRU)A*
M)HNR1/\1;\A90 ^JV Q6T7<.+T(:J IG"IOZMW]QXF?]+<DN2!(\>UGP3(J[
M\4W@/05AD.TJ,\"?L] 1>EFF=[@S+PW2+U'\E)+DN>SMM,V+MREZGZ8?%4]7
MG^C<6)P?G428^\SIR]U1T(^!;B;A,/D.P?1WO2*@=48[,G[^-2+^+#N/P2-V
MQ30<Y<0BK@T)ECBJB;\5L3BVM,@V3>M7&N"7M6,JKW-S2S&%COXK)G+Y6TZ5
MQ6'1I.VM)SFSQ5^^G@VE@D<C9<>J;-;6BW8\>*2,AM,2A?C+5R8*"3R=88+6
M9](A=>YPQM8F<ANSY*%@%3%3<9;^@_BK(BEB_P>SK'Y.@Q]GP.RY*R^(>AA"
M"[$S#M*J6EX<%3'@GUC'5Y84N*=Y1Y)BH>NJ 8V17,0#8RL&'0"[XRLM-06S
MF.=1&<I?.RF -[R,RNLT@J28:@14FF_!(A#M+HD7A/AZ)V[SB]<E Q$DG>&1
MEH;G9Y*M8_\@80/+L_7IJU-L,HBZ R8'>U>_"%+6R#Z,E]F:T/]8E)F$Q#\D
M$A:_NET&@F(\5E=.(1$6A%"Q0E=NOL7*9#:E;I>]KZCX(JL[-:*:+982.A29
M$M9K@7^)O(FCU2-)-JS:&S43%JQHS(J<$8_YRGZ@_[=TD:%5&C&G[] EWD.H
M/?#&<CC664$L6B(E\WH$*2QE A9B7.H#NCX6P=8+S[R0'JZ:"O'X(X?E3_OJ
MP];\@0OYE,^$BP7]V-_OO\+-HAV:)?_::41V7^@5H'2[ (U%\!AG7CC/LS2C
M)F/Q7E/(VU 4W:-,VSS00$G')VAK?!Y8+%_(* ?"&541S<U0YG.4>' HKB:I
M(L%% ^_ANVL4R=-S,!Q_,VDUV@) *]=YF!MLP=%!>?2+^!8/UKKA*R7?-8;-
M"A2/J1]YK?I^X(AJ38CW:T\Y=3<1T _K.,FX ?U(/T (=A;30-+P>E'-&HNP
M60U$B!)T0*"4'$IPLHR*\PAEY9I4BL6@\RVH9,!#DU6R<1B?W%<RFO'(1F=*
MDOW\D-$;?]%48D$B+PEB725&/ZY)@_[701+R<1'W!ZCR4B #WQN&T:I(?(G2
M+5D$RX#X^GJK2Q+2L?%>6I2ZJG/9[24@1P4\GEQ%3D]%]1.#$]W47Q)Z6JE'
M5=NTV+$WL5=<5*IWN6AUV,)GN\._D8RP7JS@W?A0S+5^L",5K6R20DHW$Y!
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MIY&[9@'@9R_-2'(31-9J53V"PUV/^5BUEU$'?ACJ^9\_V(BI_97+U3^(; 1
MP5K/C$C9'+U@;W^*&R8==@SASCKI$U30A8O.<6#WOIAOMV4\@A=^J6HV%_56
M2$3!R]('+_2273F9,GD.^NW0G(')B;@/V!A)V%5LZ!71B^&I_?GDH&_-%]YK
MQ;EC%?&]D.72L[:)FN9_ZS.'A<?Z1D4= Z"1+VV[=/=:\O)E&R1&R_CX4V>5
ML@!6= N&[ESE'FZ$,MW:]+Q6?3])[)6 \"J,@ (XEK6I %3?3U( 2D!X12I
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M]!^$\ 0I &H+R3P>\O+I6A!4B:+7KOW@>F[LHH&.-0, Q-ENHB%UP$O#8-F
M3Z<R2W!6J7S>2_/=8!R'9I 2#-/2@(F%D$6N __1PK?U\RB9I$DN#I_45JM%
MD@S'(9!\(>:&$?) "^5[TGL98W7U&?/-U+.C:+%9QL'ZY\D75S?U^7 JN&MA
M!T_ "5P\.'Q!/[."C44_M/Y%/OUWSAL G-%*L#*?B%>;OO@4> ;/\A1X#G[D
MS'[9N?&K=F9I (#0-IIH"(5'^?,__N'L8/_TSU8RK"1+0*0)GV!59F$N]_W?
M-._[%H5NX&#6#./NN[_'V/X+VR.6G&*7W]@6[PT@ Y--GOE.]RW>E]GBM\?(
M^WJTHHGO#"[_6L%I/Y-=-"@F2K)JE67[SH@EI2RA.<H8?VL*C;<3XWT(@RBZ
M#8.-J_O!5I[9M#I>@LWAFP]WB^72NKU;7,U7L)HX@P)EXM>7HBYC%EOBF7']
MQ]F7+?(C[>^OYOSFI4@#!Z'8"+*O+91^#JEX<^E39@?V A4/?S[9W%\'S^@:
M<]I0/%&"\/YO4$Q1(,%AB\7M[&ZRFM]\L*Z)>+BZ6WRTIHL;_)M[\LOTSXN;
M)?0U(J <DUMJ*Z\^=CKQS$W@!]594T[4S#E\./IUV58.XB(C%B_Q$PHMEWYO
M?9V*F&]@;YM6\I791[QLU==]P8M7&+5IX./I=QA"RJR!KUL(20 T+I/:<>*P
MUOQFNO@XL[XF NH;20D%P&?R1"XSG.2N]!!?50B7;K1.@""G@'&#XL5F97^9
MQ''H/NQB^\%#J^ .;8.0WKQX@/87F3Z\( Q9VK#G,'UQ&U_.ERF[SRY9W [.
MZAI8BG\B^NZLLH</@R@PF;S8KI< F0;/SX%??I)>NMXN+H)-=&D#G>$;E^B=
M4>3P^LUL956%_.339'X]N;B>6:L%%O8?/RYNK.5J,?W[]XOKR]D=M*A7YHV*
MJJ&T>STN@N63C=E@L8M)E!X)9]3M8FC,#V;GKF/"8;S4!&M][?I6,N8;6(LW
MCT(54RQS<9KM37*V;A8F F\"<Y_?U#;O]7#PI6[#Q(!)XH0#'_\S&M(QS(2E
M^YJ0<@VS,.$<RN13J_BV[B$&<I-(T(_I)^8NO8]) L53.WJZ#8,7UT'.Q>M]
MA)RYGQL_)NO8?1DBXJ0#8/.F4'GD!(K(=++\WKI?8EU[?F,5UK')=#7_-%_-
M9R/0/3J2OJ9T=-DB12LK!\K<?T$1!'NR (^&/1G(M;'G[=WBT_P2L^C%CYA+
M/\V6?!8=#X<*J"_!H;Q=TLNA5ZZ/%14 #F4!'@V',I#KPJ%7\YO)S?0-<*B
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M3(<#2$ Q/!"'0!M6O'C?@$@^/S$1H\HX<">!+&'K K!]'[0;["6\?U*8L3R
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MH"A;+6=O@VKO.1J(>%$U ']$SP\HU,Q7(D@ D3]\;'@Y,DG(YH65!C>ZQ-#
MK^<-$0'43LM*0%#+%F@.#Y=P_+5@Q/+"9E3Y+>W\W@!:8=QCWUE.U_PTU$Z
M]:]DW+^AH^&T4F1?>]\"3YT<!XK"B46:-T^9 ^7V=,G$4V,W'QL2U,W'Q$9\
M\TW'?O,):=GD*?X60-U\7(P$-]_TM[3S0#<?%Q_!S2<\#4U1^^9) W$%<I$1
M7('3_P!:J%]Z!FX[_C5G]I[K<,$)NC+!1W/QN41T?REQ1ZF#TR"LT9S?O/K3
MP$&<]P/9IJN5+)5^E\QU*5J%)HY#W;ZV1TH:S/VIO24Y:8,PA1B6\6:L0G2X
M+2:R,1899,U]*QT&+4JD"%EFH_;E]W*2Q+;K(V=FA[[K/T:#\!,'B'E)PT:$
MQT+K]>YYE[@]+M'&7;N@QFDQI:HN#^XJ%87/(GRT??=7&CR#=>PH\%R'_N/"
MCMQHL<'77D1*]]!?[2*71(%=HF@=NC1%=N([>#-)LCE&YQ8/7F-5:H6^Q!=>
MH\ME;V8;%E>(;O:#KHC#_(N[#Y.;^7_3TE+6Y.;2NKA?SF]FRR7LV]8((Y;/
MTO![K^Q_7+J/OHO%DNW'YDZ7)%"(8R*'&K?<VL>/D[L?27FUY?S#S?QJ/IW<
MK*S)=+JXOZ%U\F\7U_/I?+:$UA^ZD;WRA)7?(+6R:LOU$W)VQ!6:73VW*%P2
MG^\$PW)<;T><H^3DK/'!N"3_1LZ*!'MPV)57!E #',,5/S2@S./<=&8:M('G
M>I=-5G13VZ(P<;T#ENG0R!M%T4!-F]I#?RX#6J+U+J25H&9?UM[.00X)SB3E
M/G;)!<' DY;@T?U\TX*3^6>>#K1YNKSLP8!X$.IDH<K#4=N&]JE4PSVC'>Z!
M_FJ+(A8 1E)%5"5NAZS/IIL4=<*_>2 STA!E)YES9$>C)_-4E)\>VZI8'"U+
MEL2 4E-@ :Y+#4FYF8R7,)- BM]]GA0$^)HPVC>4T]9I22<R@_7'/YP=[!_\
M.>%.T*JSG6A8[@\ON36J:3L)!"]-_Y@F&4XD!RW+<.K 5Z)9C/=P;T5)BJ-H
MS/(Z'\Q._(+B)@FJU3BI;3MZBB>:053*D\LGCSI*)\%$1NO:RF#4GA76DCD(
M)XK:Z<601"T[H6R$ND%Q 63R8KL>O3Z#DN_K*? <3"\J_32K=5VAF_<X=,10
MD.'OED4<L/M3D>IE?4QE8S05:E?MX[L_ACZ^^V^AC^^^3!_???4^OA7FJ2I9
M[:S4K7Z[%DC&;"GZ<):51$WUW<Y@6'&0_Z4$AJKW^TWUWGA->)U,5)2*U[;Y
MZN5,JM<^0VTDB%& %"_-EW)7Z%!E!:4QY!R%*^XKP_K:]:W+P//LL&1(^0;2
MDJ+($OSJ3W*[IAAOP-14)919?/@6FY7]94CVUHN;>>;7BK_H:'!>4&V' Z;/
MPA ,5VG&H'W7-2G#QZK*\/$8E.'CMZ ,'\LHP\?*1.6I&ZD]6XNIN3Z76856
M$JM^UN;4 _(=H(^\(R5;#<ZL_>FC528%1Q)H:<D7+)^TJX\<,,8=TCQ,^"''
MW^6E[;("0-\2CQITR% ;Y5BEXYF+5O57W.R>R7T6A%=!V*) -ME7[IW>"X+9
MMFM]4.4]R[,YTZ(:F16;_3QIDX%@1FXM?%(\Q7MOM%H8' MNH=P-R/"=@!BV
M2?5$MR/?.^6IE5A_%+ROPC5"]N^\Y>KJ0M7 []&/D;,*/B ?@_5($2;\@^Y2
M2;)0C2L3DH@)S*YY6$Z3?_<9_#L&SU KU?D>(?$.J2HBC(?7B>H#^&0,#^"3
MM_  /FG()NY*5![ L\T&K>/%YK(1Z]CI[2LQC=D[LQTA7K4U.I $^.4AKU$^
M]CLP[4Z>3CF?2&Y!+U=)F+:=+]V T22.0_=A%R?>FBQZBY0.I+4$)Z3GX",:
MJ"]&7X1,O6;TH<Q+0ML6%N-DSF^@[S=]_-*H@]I_!]6/P62W)EO]T0Y_1G%1
MQ" _;0D^BUT<Q;;O8-U1,]=WAV\^/:$KBJV5+=)JF$SNALA#4.6!2LZ!TB[U
MR"_X ;F/3\3(^8*5Q$>$'ST/*$PO# QX8+[M"MV\NZ\CAARFS6:Q[&2:RALD
MLH)B@OJ#9#3LK<@H9>96V4M-;KI3U5?*Z1A>*:=OX95RVM ^N2M1C%GK&!*D
MXL#K#\4TN_3&N+/)I"U K2["8&/4]#!-.3Y-PW;W:B#<8HLOBU.(T+0*? "G
M8T<4M4>GC: G80?.Z!RAUMB['LJGAJB> ;E=-W;&SX+F!0P2K/96P]7:SM(0
M>]_CI%W9;OC)]G:( ,77^BX<KL:-&);Q4R!$A\?3D_F=]6ER?3\C%6VNYC>3
MF^E\<FW-;Y:KN_N/LYO5DE9U*GWW<399WM_-Z-] 'VI2I"ZS:OL&::E?D(-)
M^NY-?.?:M1]<C]HU/B*;P'5(4TC2Z O?.K1"E*&J!CIP ZA[KA-_F?(X26=(
M4N_ *Z:WGM/Y+3NV-A@1ZX5@0IJ:DKY'*42:K@+>M6T0;F272=!%$B6/'FT7
M5.KO.XES=.1\>:()C&>UB[ 1-TPJ-6PFRCS>X9@J\YO*N_7;*N>")KG+D*YP
M[[5MC%)J>\'#DW7LOE (JR=$BMW8_FLD MJK&%E?:,;Y4AOJ,K(WA8!9VHJ?
MJ &9 *&FEM,_1XP.Y5RNABM=IHF?& 7,=!! Z;!DU86C8). *WPU4NPO&F^X
M)(T E98JT4 -H64)D/-+VPI[Z+F)QXXP53'GO1\BVW-_14[6ZDZS BL)%**:
MJ!QJ'+XJ/K0>\9>PIK5NE"TK@QWV0/M1E^C0(X\>JUE/B49I:M!_!JGV>H2)
M).WG;>]#&.RVT=PGE02Q/LHN+%.\QH=Z__9&!\*BV0MCCKRYG"]O%\O)-3'V
MK+Z?6?C?TP4I6WP_N[06M[,[6L=[F?WYYFK.+.@-9,K4PE(UVV7_758),0[C
MDDHW#7R')$\Y%[9'6BDOGQ"*N]N#\*2ELX#_59R#[O ,:F1=<9-X0VQ<'P]V
M;<]R[-@FOV&])(@83[) , N@["O*\P]IA7:0$%A5YJ#:G])N=A?TB9:9&'Q2
M?^^>W#.@-L9T%$$-/D_?IU^!EI3D;&ZAXC,6HF)"F^["D,2(*M"2,]3P:XZ-
M!:\U5/)Q:N$%);!XXW,Z"Y;7XQ5'; 4^_O/K$'G9I:DA:O84X+F)_NDGU:1K
MD&B&)AFJ@0JUQ2C&TV0=1Z;!\P.^&XD^<X?6P:-/E/XYOB-B=^.2>R%EL_4O
M.S=$3M66C_^V>\:_I)]H9IH!$#3/>OH7P6'@51!CW2:18<!J^7"<53X' ^VL
MIIC;,ZG;DCEP!#&W9V\AYO:L<2]R5Z(H(LN,P@RD[2WC6!",&Q882/!*'!=?
M@J0"2A"F+")X"U/- $[U+L:TG91CYG@8#9F%2HN:[+%X $Y7%A&CKC!S5ZLQ
M)?Q<5?"?CT'PG[\%P7\N(_C/^R1;4'U@L2%VG[PQ'[4+RA98$4\!D"8A0$>0
M T'526(%JUC 2, K'0F:VR!!HW+B0ML&*-E)2%2-D\>WKI[051 ^+S:3FR!&
M6!E%[@M10.7N!LFYS)81D,2*VW2[-#H+WMC@"6A0A^7C.4B07#H)'#=UI&-Q
MK738'77'6>: 6_A+FUAP%W@7PT%>W")(YI_. FPX_/:A8;UG6^Y!7L429"SK
MKFVKU_-./9!37)D#X=65 YZN.B9UY:"ICG)7TI6H;,].DFFQC.V8UG<PX384
M@S3)*0KX27@/TZP>_Q'?5]'.2^OCL--^A$Y#TR^E'APB\!VV;V<//\1M&*P1
M<FB:4"+[\&\<4AOB!0UR[4D -&Z3:<>)6R*$?D9OP*A601;@UI,G9OGRDUQ]
MO^S+(LQ#'.4Q#:(X6FP^!($3+0//T<Q]?3"!C4'JABSWC1!1:4KY%915-; $
M-Y!(8:O,,#?^)(KPX=JX\0 QNCT0@8C;54>7]R ):1$)^EFC^]JX69S#&(H<
MSMHNM0+)Y%U47 ME<X[42T8PW&@A;SX>O=^VQM\\[23)7SXMRU9N)2G3K#++
M+M<>V](!-'!)$#%VO?N:PA?_D*,\O^Z'Q ;UN)>O QM/%L0H6H6V@R:^0ZTZ
MA:700-R[&@X0M[$2ICQGQF(U6UIWL^EL_FER<3T#CI#IQ0@5#[?R'BF+VG+>
MX3K8^7$"GV*"X5\E<=;^8X'#\"4,NF-B7!#W0%;"/D5<*1&T+T4CA[#+"JCM
MW "R2R+!K"?6K*PS$<'KK8+^X\F^IQKT1:$4D]*7BV;!Q01AT$@NPH-K5G3Q
M;F])B.DS)0:3">W8>D"/KN^GA2:('?P5V2&H.!(1M-)#@K<;NN\*">G!PX4E
M%J1( UU\IB\1]A3-!5G6N^W59I[[^%CN2]D,VN8P:CAH0::E6 %FDL:A=7V+
MC!Q!&8,6(C5*&8CVP&12N2Q2K-,KH,QOBR)]<L?KCQK\($]#.C7?S ) ICMC
M\%$19H#<U)BHWD020/:W4Z]\ [2L6S$O]1I%48TUBXEO@Y PK]1E(#61T1M!
M!B.>:0\/_:XA=RC+Y(6LUVG<]S:9"=+0W(6(N6B2WAYEBTAS]F'?"WD2)>QS
M@9],69=!.2_Y@?\NY2?@QRJ?9@)MM-+*5LDQBQYB Z5-.%! 7*IL7 1F6NMV
M\F/=1 OB*Q73JN((%2Q2@YTU:ZM\9\?H$H68%TD<C*GRL'+0(0O 2F$H842M
M]]^&YD!%#F ;T>0W226RF)R N1_%X8[6&KRRUVA"C1%2.A5_M.D88RXFDF8Q
MP"=;*PERC4B\2*64*7Q/WMJOA)>N _]QA<+G+CJU8+C9[NI</ 2*CK5-1ECO
M+ \/LC"(9Y:R;#Y'JI4H17Z4>.'J=UBI%4Q2=)) &EX#DH=K^E4OC1GOOEHM
MIG__?G%].;M;_M'>!M&?K=D_[N>K'R'3L3N3N7)%==H1=1M2<146S3!)L5Q\
MT],H#XI'VC4TJZAK2,521L@X]_9&64(-HV7)K2#MWYK6?G:!@X/U<0];/>NU
MGST.!0'[4 =;:@Y[\5I\DK6._6R'3HI4J6-AK<'A'7JV7>(')*V42([3SO;(
MO7*@^Q0!K # 50NPS+9VGNEX*Y_ *LU@D2FLKW]$=AA]\ZWUD!0;++S#X&\K
M.,:O"  @L@*XM(&6RO*YJ;%P'MB0,C.L4^4_FX$5P@$J&#=NVB;&%QR,KX)P
M@]R8-(J:^[<H= /=&6%#8 AA^QU@';QW..VF3)3'=.BWU@<,!3/3^WD4[?!_
MK'0RH*(E!IBO<2H'V'F(2OT#K85U+S#8B,$VOS..PF;W?**(4(JZXU2[:F9?
M4+AV(W0;NFMD6ICK1A_ $V-XB;(/DVR014=)70DC/=P#L7BGDS\$$37;KW3<
M)@,L4^H)4F?6-Z*O_$8Y<T^M(9KD$X8^*5-IY%)A).4F4Y_=<'%1941UFIS&
M]0#0PQZYPZ[?#JN6.YT\/H;HT8[1'$-Q_<A=TW:"*8!DH_-MEHRM[S:EV5#[
M3KCQ(N^S2:Q\%HM.,T)]I >1BTCP[IO6SY33P_B4BGWB4)$\4/M#O X,K^ -
M>B\4ECF$]P)1.R6\0@;#\CK-OJH$?8-^"\6E:O-;)$S+<%K\SK\ 1 5S6Y0P
M3LR<(W-:-/$S'MRB>P7RSHK2T&_AKY<AN$RGD9F]T0-:F.7Q&9-A61/6;]%S
M*+DV54-R:?K?RFG5;I332"'-[T/ZVVBRBY^"D/0*N_<=%)8B[6XQ,T05+.[(
MHDH8IVL85<2;^56-YAUI?.DZWY9,63(BU1SLM+2KZS!T[^H8&.#)436MC=@F
M54=T-")#QVJZ&WS99WTT1UTG+P[TV&:10/E %L'WS!24'VR"81PMPCLB'B(#
M>2 =\8!,NNV(JT3>Q^=D[ @S/M38@Y/HH;!O*BF9504]2 ]=\EY>;#)XN2=&
MREG7=4[#;N>.Z+6:9[(1["A TWXY18+FCCF5W5%U%-=@):"Z^*Q[\64?<&;;
MZ^E#7.>39(3<KH&#> >A[Z8#)-\E]T8IA9_6S%H]V7Z6*\AVPG]"4>-(P3T7
M>J["? 5GF(5V?V: QY% LX;.-X@&XFFZ13DW=AI9HU&!RV8T77RE$W8=M+=T
M!&3E.B52=E3=RANC6/NZ=Z@MQ>%-IEETP/P-9EC(KZYG<L6X_6'ZV5=KH'I'
M*KW![(EN*V3%0*5\9FUW8;0CYJ(XL-#SU@LH+,O&ES'%Y%NKA65'8(']CV'5
M/7W:^GG"K#Z*1\2H^WQ&?9]KX_(<^3L_#DXOI?0>MAZFD(O10UE7@68RA$<O
MZ@,D!($F5VCGH)8W@NJ6&XRSUH^]0&T02N-V)AJ/072LG*/<IT68-J0AE<RX
M-4.,CG*V&(22T(%"DGE@AM\ODAA)"@XND2 M3-K)HY@"+6>K*H5TN/YEX'E8
MBFBT8#*G'XD6)(-K!^,F*Z9H''=3%YIW-'5R]TP'RW:__TKHF/%7EP$:38G6
MB?G@4;1OSF?-X"-]7NOZSO?LM;ZROPQ?QUL("B(Q1800AY_G-]/%QYFUFOQS
MMH1VR,J0KMD<7;!<#=U-9IL-(A%_* =&6E3<(;(<UW,IGQNJPZV "D1$<P]\
M)<(P43:I%<5VO,,D?+5"HNS:OD,;NF[#X,6-\-36)@@MEX*V8OM+*5X3-%Q3
MG:'8$9N*NZP:EEQ J4#(?SU+FM-<(!]MW'@27R$'"W]OF1&K@N50\E@+;N;]
MJ%KQY\G[_$!87S\D$WUC84 /&%K\2EHDW_]I^:?ZX<('[V#__P?UG@[">,S;
M1-ON*X8YR)QH&N8S<7[:13'U/V@^24HHF#\P*FCR[I@*PT->%7W(7^9GY<U1
M9%O.^2$;BR:^<XT'>_DW2#?'=H4^&NG.PU!-?F>M+(G\!N5B16Z0$,C"#5/)
M19F\V*Y'-*2K(%S:'DH37Y9HO0MIH@]M\W[OA\CV2"+G!_R*E3/YJTQL."M%
M!4=>MSG\EK=]$N;BN%CVA @S201;+*X'90M;M.H.*036MK#^](D$',S]2X2W
M-T0._F 212B.B'4\B4GPO. SJ:1D1KQV0<ATP9S^*'/X/)D!/RVMEVR(96=C
M1F-#Z<TY$J*XZU[J:(_6@$6N@O3^<XVUG>V&!:@9IA.J$A88TGW=2>>D>HA-
M9H6N#M&//]BFE>X[IVI5:4!:;/';,G;]QVM\MTSM,'S=!"$)*-.M-W>!#-.A
M6QH_GEL2\VN0#;(\/,I:EX8!,ZX"Y:N]O;MMCUKX2P/*U-ZZL>W584AIQ=*3
MF>^N+(>8@,_6R0@!EYGON]R-=*4VS!UV0ZTI=Q4 5:.5."@9:=33S$2!PQBK
M@+!$\\JTOL[?[=]8#PCO)Q)JE-"L4R$0ET^*G= D:YJZI!J7,"<"91H61AP>
M^B1Z:4 SAHA$?'G"6[RRT[8! 4ODH;4E @) NV?A(;B61.KZ&'2>$J&$RDVV
M2E4U>TIP([$GA.WNW.CGX6-$I$":-HW((,4S?BQNIK.;U=UD-5_<@$>,="%H
MF;.D-T#=8C$-GI_=Q*N"GXTDY DKY<A?XX>C":[K!-P\_W5!C\N)'S_.5Q\Q
M,RZMR<VEA3ES-;_Y,+N9SN%#F=2H7V71SGO4G5F3V+W<X/'1]5 4!SY*4]@D
M@YX%XTW7V.*C(F'9>L[&6-MT$&A1AG:R%.&7+>M6K?&1SR;%",779NM4Y7 Y
M-,[_#NJ,:NQE3KTJ_HJGN$[X;A3+!AE]#]6A\_R*R5_'0;S:[C9I6%Z+V@NX
M.,SW'R\^NK[[O'N^"UYM+WY5E,O\>8P7T6G'24)0X[%86-/!5IB,9HAL.('=
M2C>&X!;OAXJ!#<](0NLO4;0.79J'+L4VC&'&<Y.:.'"X@GP%>4GS]S@G,6<M
M2KE >*XNXKWTN>F#7H"6E^H Q..)\QKZ2B5NBQ#M+VMO%[DO^$>:QCAQ'&K4
M6 47:/(<A#$)&^DHTN7F!%._I="3"??/YB'_(,9Q9-ED*FK)B@/K ?\[FPZV
M=((:M1D7@?S6J6KU741(17Z8XZ1NLL,TL7E2HZ'[J1.GZZW-&&;\UF[B(*:?
MY11?0MX#_"VO4U9PB6O9W[8B 6PT6(4!TB^_Y>SQF]EBU8H=I9+V3[;GX<GQ
ME=[QCBV/-)O'S$)!XK:,R-?D)41>2)#58$2;S[CRZJM4)#E)R _"O "7'+7K
M@\P2N@9]Q!80WNX6Y&2M13T#=_<0H5]V>)[9"WD%#Q;2R84#$;3)0X9W]N\O
MEK-_W,]N5M;L$W&$P-8W;2-9)<I2N%2UQ[%/_X6<R4-$ZPOL'^Q+R0#F0.,/
M9@82'++#F;A$6UR\G7DK44PL(^XNZO[:(2<-;R0IS5^2!+?%AOEWS6)"#0>0
M@%D53#F,1F+]+$)^RRF-RJ)IL;B'S##KQ1:5,!/E'0-KEUVM)\J(G 3OW\O"
M\"WVZF6L@W-8LM+/=D2J3N!IW!<4?6LU^FF/O+*S.N?I;,#+V_;A3EQ;"5^:
M*DV_F/OK$.&O+E'RW[?83Z#G:MY@CX%^*^YVYG_+E;3UG .MU;4UD%;%P9,2
M?X+%5$;Z+A7/I)XF?6$8MP'W1+CG.>M4(]GXZTD3P^0/+1U[K?329@#F5&Q5
M97+>=(;=4/*8=6-<B1J](V#.%IJ*^%"T2SWJ(NA5*T?]9/H-O)9:SD1[CQS!
MVVF,JI,2\PWW:NKC2NG9$STEL>1M).>H,8L22'=!8\OK?3)[:EXPQ8^-,W2U
M/+)9ZO;ORMY7_BAH@H,B -KO7>]:>I_?=@44MCSY,+S'*5<^ &UZ-=55%Q1Y
M&Y 1W;R=<3+?,L#<XG1V%0!OI W)L;JN5B4"]E"J>PB=%-4=/@0 5RL?NMED
MO\'6H:63_5N[-5MY2MN5*=[W'I4!5?%*RGC._2@.=]3+0-T(JR?;'[6QJ"O:
MQDZGZ96)=>!R1[1F8ZI1>^ T,ZP6 Y,*;51U8*K?=,U_: PRJD76H0NR%8'B
M/X0[FPMYYCK4M)TTF77B^UAS2E-:I2C)'&C:',="@EM=($E$3KZUTH\A_8RB
MK2\EK'-6J!BE>1L&:X2<Z KC0<ID3WSGHQV3$MFOB\U'._P9Q:1>:E$V6_.%
MVAV^_J;O1$UT1'=C9R1Y@=^D#CGD):9,[?)MI+8;.OUB5<JMVE0;)819V5F4
M?J393A"ZCZZ/Q<8ZB*!K*,/1=$_)6GV%-PXOZIH$^I3*,DM=,KRQPS$7]ZKA
MH"(L)NH5WT%>-"T4R.\:T1)5:_E1!32O=IP4J$];-.FO^]@"3*-V(G^7B'$2
MLD]1#IMTS0O(1)8?^.^*WZ-D(K#V'=VH7!9 $MNB%/,T#3R/]%,B\8;^31"C
MZ ZMD?LBW597. & W!'APRNY5PRQ A^S#!YDA?DH4%DD0Y]<(+6N754JE7II
MK8*)X[@$ANW=VJXS]],*VN067 7)7:A93G4&;Y;O5-'DI2>A*/JN*(A,&WXZ
MP>XAWNP\RUZO@QU4/:B^[% 6:$J;I?9FQR<AO+5?R2D@>SO=A2$&>TMJCDB:
M8<0S&'QQM6,C9*IU\JFU3;Z%%&Q21,DE6_N2%>L+BD2FG,XMGL$T;PBQT7#_
MC>H";*KD[<M7=\DDZC[6OHHI\QKO5T$X#1$68B2W5+L1J MDF*NO X9O]M93
MH'_YPNNZ18K>^#A8_YPZ+SXBXB"2<Z,WAQG/L6GBP&UJBS_,8J>M?R7?_AO0
M6\W=\\+-S%Z;JCZ>.OQ8!.XM;*IS0X3K5S#@A18EWS"H#R(;F 0IG_[FFK3'
M;0JJ;'&Q8%EQ,V\R:V_?Q-;N];GD;3>D\1MS?[N+HVOT@KS]0<Z9")+Y1&0!
M-MP+&W]B[8^$2R3H5KF,6Y:KZ"UD37M@C'L.1L4]!Q+<<S!B[CGHQCT'PW#/
MH3'N.1P5]QQ*<,_AB+GGL!OW'*IS3[G*Y,)''93^QB"CP45UZ"U%5?%WP.06
M;G2]WF=U66ION72JU>>@.U&+01!$S:&W$!5_-R*B-C:Z3M3JLOH1%1-1X:R6
MAT$50B[AT$9>\N4('NC\/6]0N+8V)9]J.M<5WO[N%"Z-@BE.7B#00EWR(?/]
M#47?YH;7R5M;6\]BYE?NB\(1+HT"(G".0!N!28."41&XL>$- E?7UI/ 2_=+
M=_H6@R!NWASZFU*G&AM=IVMU6;UNWB76MWT%LI:&0=V\)1S4%"LX C<WO4'B
MVN+Z7+TSDO38G<;E85 T+N'PMK0KQI[725Q?FZK[8T:3_Q$J>54&,9/PX0!4
M4><B(_22!6/PDDG3K6PF$:]7E77ND$=\V;=V&+^N0MN/["1:X.*U_)?)%U>W
M#[\#8.UJH2=@*WF\.'R6?F;1[ZQ_D2]AN:P[B<MLUW$_%$V]RZ<@C$GB_25Z
MB%=XP  <QX:A62D5L183 9ZT(M^^HY4@R-??6N3[!C<!%4@3T*J:ALI;K[H_
M<I)&OM!8INL \^/$=QBA)(0]LY\'XJ=>J.B_,$6<UP=5KIC+/F2S)D08K@;>
MJ(3D]MVUSBI[&/_/'<G1EN56/*#$J?A?!9=6YS(@Y2H N3J8';M1[*YMS_J(
M;-+;GJKN3;EF5&MG;3O5U1M+4GJ$$9Z(%IM)5I>K25W.,XPYT'2.- L)7MH1
M$03!QLJ_K1/6]%-,M//Y8XR[P*Z.1\PMA,'I),LU\NW0#32=9/:\ [S)>2>;
MB0"W5UWR">2=T$J,['SS%Z;:QPAM4!@BYX[8;W:H5'5C(#U$ J#NZC B7:,=
M'0[;9 .M=*15&CHB]5>>OI7N0W*[HF"@=Y#[/]?HT?9F?NRV/M4CM/[38_#R
M'H]*> O_4+ 4:RX3O,. RXUTP5]9R6? :H-@XPGE>6M23,RIWU*1LA81#:$1
M=M,AHA8E(K(6)2TB@CWX[=O/526B*M65'KRD+M-0+]C*W(:T"29P7E4^\@U/
M]H,\,5G4J+P9&ZOJ[IS#6LG*C4G'W+GON"^NL[,]37HD>UZ#>B03 9XD(-^2
M]T3Q=9,-#.N40L)D.B5_D8HZY32@+3>2GH1W;O3SQ>M (D$$R:@=7H (-VVS
M-,(B0T9CF9*@7UF(M*U=X6'ZT?XI"*>[* Z>\4VM29HP)C5CUV0#Y_%%^@VP
M%B$D0B8Y.(M2C=LA7*-J>&+9G<QJC)J,3E#JHHS=B6-V4M05:]VVA_*C<: 8
MUA\Y:/!L4OG7%OV<>35 .-/$)!/T4N^G9-9\'*[_>!MX[MI%4=;.>QAO&0N0
M01<L'PO>"R0?8&4C,->D8T YIYUR#%\6;^%]9,YVZU$!9GN9D>L6D^S)'J@G
M;BL\D(YJ;5CQ8M?2;ZQMI6,LC"22)&15)LFL&R*U6PHS5KIWT0E@RR$.C.EA
M./JHY(=3#6:+$72C* A?B8M\\DPDC)1^R1QHVK')0H)W3/-/:34@RZ8?0]HC
M15N?:YC<%2J:(>;^"TIJE,U]O+?XYSM\3C0+> X0\VFX;$0X'')!2JI;;OJA
MA9_NH/V_Q90J2PC!*GMS2582^')(+JD @>22,B*\(O+I)Y93Y@^@"T5,)S:/
M--:HDIP]B2(49[=0_O[MV@JB?1;C*0NM*/$>&61<H6Z4&O@YQ5BXA 9I>N47
MC]Q&J,:LWZ X*?A+JH--XCAT'W:TW/@JN,%+(9V\ L^C98$3B:99]G2';[P[
M3V<4.9R)Y[$\/ 7HRT29WF49IK8C/9J88X!3.WK"JN.+ZR#GXO4^0J24:T!>
MX3L,**U>'?BZ#71=($,\ECO@QS/IX^%8V<HJG)=;AL/P9U=*USBSTW8HV_I(
MHX;%AN8/X<DC#"SU,-'H9>0L_%*"AVZS32?8 .EDG1#D-B7#LL7:IKTQ+/ST
MVI6Z!D+8#%0H7K$?=-X5W5>=C*FG*Y(LLT^-=E]CZ7*)+P3(EN9P5-Q3%S)I
MJ?)[WXVUQR:4IS;_TBN#YU7A#,*?B:M@G7P*&W/ ($0ER*"^'.74/9LT^Z2R
M3O>E49[:/,'+X%O;QD;T8RHWDG'P8H-!F$:7R/+R-/OA9"1W#05F$ZUD8X.-
MA;7WY\"W(B+'8%TE'7=V3_FI2Q3#J\OY=.Z37"F'96+7(%99,$S%!PNQX)RZ
M*T1N,,]RT#:(W!B_!/ 86B5]'83;(+G<8&L@"@E7%<.\=:MV<, 3+F^%+,/K
MW, <:310G(D"+Z0C;RZ'&8 8*(.0Z&]QTN^ PPH #1M$]"@:-7 7KJR))5SE
MH&??W;CKI 4PL<O1QV92@"3*-$#-(J43:./&L2[8\200G@)K>=&3Y;G/;@S>
M0$V%UI4:K%VWI(=A[#9$6]MUTFYM$]^AO=PH./W=8@6@($Q?(H2XOF<Z)._5
M5VKFE[4OLNEX\+ZB[62MMA!MV0IEP4?<53[^\RM]TP_@>"Q-;EQX5>%S>";_
MR/J,;TCTS@D^0S6W$A.E[F6LK:R'E,FB71*C_\K^DC+:!?+1QM6M0[=!,ZU-
MM^##91ORM17;7S)I,Y)<VQ8BLA)M12M7CW:D,NH.10@OX@G+K$M2K#S8TF)N
M"1S-C"4!T+@(:L>)6S,F&4.O,*<856^+#<!I\H1M=*%MWXD>8NP.Q;;K(V=F
MA[[K/T;WOKW%CYQMZ)+:6YJ9K048@%=&C!$_9GOWO$NJL#GXT*]=Z)[K<E2L
MEEUK7;A2+9K40IT:?Z7, K4A9O. JL [FMU-/_79FYN_\1EK4;^)1.HS"6A(
MG@8&WU,EH&-[616H]7UC67_\P]G!_OZ?:1_U]$\C?G<U&4'V!5;;,G4C5-;<
MY0;%ERAT7^S8?4$4QK5K/[B>&[^FE<"<!7%(8J#XC%S8D8ME7O 0H9#654MZ
MP^"_8[SP(&JA^( E)(GFP:J>MW.(RI=)2]WF+)A%0!PCF*4*HL]"9'ONK_@F
M?\2CP<ULH-S,;)IDGDZ][#))&/'B,U9M)O$TT!Z;R89A^OG-Q(*7.8!)LDX]
M&(S'$&A@.(-.[+CP^C+5]9KL_4YB5J)I\$P26/2'H_&@0(A<#B[<*A?9!Z0W
M>617^I$#FF@X]&*99E@+56MA,?MEA^5<P8914Z)P'C7LD49]G4P4.%1/OBU)
MB:@J)DR_=(0;GS]X^"M4(S?FF:WMOV:.J"3,0LZUS1QIUK7-0H%_R,FW6/E)
M/A9'%QGW:(O(4'BTN>OMH4 4&6J%TC/WHSC<4?ZZ"4B2B?OH$R/))/H>.8\T
MHC__8!*7%2?MNH=F]  ,;KK7(+C%LE NZY%V+B<I<=8&#[5>R%AP=]4PK%95
MGP;8:R6K8$(.&B#\@1"#I/?E,]^BD!Y>64$K,9/A1F]22"ESJK5%82*@RU'C
MQ6^_ ;NE.Y&U++@E=ZN'7X.\,1=^$IA>4A T2V0>% @UGX.+K,)G+0//@;9_
MM%"M+-Q$RU73_FA8P&V:H"$EC*HCC*<#5\!+I0Q!5I1@;F\N%)IK4;IH$K;^
MB.*GP"FXHL.+K3'4\%7"QD+^U09?.41,@MK;C;E0Y2ZB_+)0O#Z$8(6=FN [
M5G "Z#O(*P;$68MJ3L)UX#]F79VP.D JE=J/B!1 P<KI)_R_B5UYL (QW>$;
MCY#IC**@J@QQ;%?JRA#-,IT1,K=4F0W*6H+:1O70.\L !RQ/PP4#RHKJ%6J
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MPDR!MU02N"6M6]M^*A=&5<8@T?6SM CB8J"_'LM)X:$':CK2LP8)&RMLOM9
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M?&P&1VQT-$?U^&PQ3$388WAC6P;C>1UT8VNF7>ZZ1LI=ULB7[AJ9V"+IY\[
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MQVBKA:;T F!M(5\PI!M1,W4-MPWDA=@FD,8$"=TPB\7J\^W=S=6V3#)LME-
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M1GFU73,W2;G)2W.P\V<(A*2A<EVW%)BW:-> ,K#3I$C#A04AY,)1^7IP!YM
M1O!-/0D40@5Z,,"IH]"@8[V.2M\:_AB(8UN?D!;"02C&CM#%?H5!C2>+%<?
M-A5!:&PL?ZCPX"'XWIZVRFH=6?Z/%?+K @+QB)JM&NYELW!YCPOI07:3I%M+
M]LNNXP:7W4ZSUPE[#VP.\;!=0(#C#?B&EPF;X#P#ZTM1)?]K=9LT]Q"_>A Y
M2HIG> Y!P$19-?&88$MGV1>8Q:="5"?80\EX-)$"'E!)UOR3AJ$CP*:%]DDA
MN<\QX6F^3I;D/?0* #KM^ @:KAGT#NSEI[)V'"7@_V"F$V/N)%C/'+>9&F(^
M$-%2O!^!]-._2E@D;<+\H]0Q*E"QF<D<TR&I%43 (P54*8?0KI?H(,:%V/GW
M++1RL?JR@>HOU)M3$BDL7^R&9MZ/.B9$3U3PKIJ" OZ%UT>9(C W5OC64MLE
M0FR&A_M. 97P!@AU[BK3#>3Y/^@:FR/;HSSPFJ%$UH9*2X2SR-=F)UG=GQYF
M,A1<R'>"&Y&JE ;P9JJ2L_MF!LAOQIL$O)B&4#Q2F*%]+6T7P)<*3.G4D=NO
M9'2=9R7MS#SI@0]$$U$6(6G)]_Z$;,^'>=0SATI0FZ@ SX(L H'J0OZ=Y5G1
MP! K3D_2L?LSJ7E))IZ^4:P8\IS@P;,BU0O&+]Z)E#1(C^/^% C/QE&Y+=[J
M$45EJKKJ TLM^YF"K/Y_"*?<(P,'058;((QSIQMG1BEG]#8I9! %F.90?P'Q
MI5)2UTZ2D4:L2<E+2WQ+JI>$>P5?\C3&1<EC>)G&'/1]HU\-/8NXO6B\ZU'J
M7!Z_Y?]O ?^_!=RL!I<%7"\:_PN8+(!D T70:/"8RSW(>XAXL]"77YL #;=U
M% 9P3-Z322>0T?,&&ZBW+DW3G$%N:B)$P_!;2X6&[19J0VCS\G0<;$J;-ON#
M(MEW)M_#ZU"@V$K5/I=4Z[IR8;V\39#8WIEN(T<503_Q0=X[+N['6@9J#=50
M3->[&"?A4ZP#TG&Q-C_\1:P_;16:I<U\=2SM4N.?I6YX[3(J@Q&SW3]_>^#:
MS3CMWGD,3B\<UX\0'BUA8G?=@1S-XMDB0D+"JB!&4G3,MQ'M_8JLY]/#^R:_
MLJBE('@_#=;W<EQAM'=6<[<N5_LA_%?6DOIQ\.L1ZL0:52W4 N'[%XHKJ1IQ
M#>.2[^<IFU\I"BC2(EK.E3UY9R3U[J_L&49X/10:Y.;$ETF*C+VSP!-:O)HC
M@80 EY( RT: ]9-!Q/ 6?+SI"[1-_SCQZG@8X*#]LGS!\1: -S[PH!Q1(G.>
M54D,04A$_[F*RF0YSV(>E/0(1\HC_EY=I1;W)[3:IE'+0 BA ?R+##>N2MZ+
MC]"P58J8JJD^ZGL=[($ORKK8&Z]]'PK2Q+\OTVU)9KE84<OG/(XI/NAC?H5Y
M9)+Y0/@B21Z+@03F+D81C$515*L<<%,C,5Y8?74@\3:INS,OG(0_)2GD6V:8
MA[X8'W2R-->B4PW+%O00MU!C$8^!\G"B($=#FI+)?/UTY2*$$IJ# !#I$/)-
MK:7 PGB%SJ#W()D%S\KA^3A#-@+I7"<B\10DW98()Q$C=1;Y]'#$^SN<7IE7
MW03]>9,H>?76-.%SG0. %DOT7S0@6G=951!-+5G6812Z! ,!%__&H<!II#(D
M>$) G0)?N\UB7*0499?Y8LE5!Z!%S G['2 (A;&61K]R%V\SJ8!*SX$8JZZM
M@TK0OPET1WH@QWV%$RB06JH$]:<^UB8^&BS/NO-%26O+LM%U]M8?;(69&;7O
M)=8GDA!&X%U)HIAVA)I[6O?,?:'5QUMC2NXLLQ]X1=F8LO=%U2\![]KFCA1)
M1W$''_$#O^JHNZ\TW:T*'B:[&*.*W[7/%(<1 \!IAJ+EO[9)P5*%>'*(,!K1
M@T[4A6-W,&LF(22A#?ETV(>))V[O?>$.$W/XPS'G%'9R+4L^6["I)-E-GJ86
MJ%:*\MO%[Z) \FQIKK9I^@9Q@)NH@)H$Y!\<6XDMNF_\F[)N9\7[HFO\J=8M
MR7@,]06&;%:T?BV'7<E#V-VS-H=++K2Z9YKQK5"[!BTP)NAZ[=#:0M]P01?'
M$J<IU 1D<"T-6"\%;Z%7"JRO" [%;<IRZY9L,;&W1M0 2T/"Y"L\8,H-7K(L
M25K7HX$@EJ"F-U#;ESG3R.KO/5:GN19K<8Q<@!UQAKVH39/DL,5&)'D*]MM9
M<\UB@]AD]J-MEE3E.W[[ME:<IFCN1 7.>3%2W"U.!C9QB#D.0:"6YN^D=[GA
MD/,%,6WP\6DLQQ'"<ERJHY=!\)MR^/RE:W_/D/JX&7G:RSGX@MY):GUK>@]+
M(H2[8%<B>I7#H:NZ-O)-?#'_<&O966_<>1$$>S8K8,>J8>!);QBH*7 D^S!E
M47Z4M1]F\?N3KGZ'^%Y=H:Z#\70*+2WH)OH15/L?;/\,E.N^M\^H9>7_J2N0
M=3@!_<E]#;@0#ZT(?,AV"%#%J*4PQ#$%5CM6YH <K;=;\&[VX73)*"<BPYWJ
MF[2W#I$K@ 0L=*G2Z&5"@&?R]HEC@+-5?A\EYBC*NJV( -B0UF'YKYF^RG<C
MC?Z/G'HJ#(OMGCPHH?VS.<FR;H'*AO\,LRY@O(Z1#@OW]22'.(VV3R7^UY8T
MN17U+?L%T71JJF+.P"C-^P6U ]H(TDFDC_P0#\+'O(I2&I-)AF_58QA2XTBN
M7Q'V=C;3HTBDC_0 >X1-J?$?\T2O_O2W1ENJ8(B6#UIXGJ>0_=9+H$%*O2SQ
M?XG3B<&N%L !S93L(5940$TT'[E@2CZ"5D1A9&0A3"^B7D[X]J!^S0H<I9!C
MT=0<5BK9V>H<;.L!6I6?<VTQP9^R/'M/G]V0!A;_ _X9K59)FO XS;IIP.I-
M3BQ1Q#N D=YEO"'4U54&;<BHO&5=>R<\,JHZ=Y7S!O+\'W;<3<[>44:#E @L
M8._&L.QMS5CAK(:> $P=[MA-[ +8R2*8U/[^?[#/_$,*)9^HB=#[JAHK,G4%
M[B9\WR?M'WGQ-\PNVD!)S7XU]!MKCY:L0T")M2:NBD%#5XAW6 -501'8[,#K
M7; Y%6K=-Y=UTU=X;:9QWR:AUC0YFV.<_#4G,HA!#@Y@9W5;)#4.8VXP35WF
ML)V\ RQI'8\92E4+SUTH!6)*>6*&EZO1ZVG/NKX/DOH&A)CK(TM9[XZ,V+OB
M893,UXS^BUPZ3R6]9(Y^.3$JS*(MDAJ'/&)TD]>\54P4^CAB3%,X'L+DXXDQ
M^=B%R<?AF7PTA,E'$V/RD0N3C\(S^9<A3/YE8DS^Q87)O_AC\K9\_QQ%F[^^
M;#<;!A<4I==1^7*;YM_N,O:L@@  /C>SCZ3ICJ _@@&0- +Z4XSQWZ'>Y -I
ME24UBDU[?A\-V2,70_;(Q<3VR(7+'KGP?!!9D2%UZ0X-'&:#XD^ZH!L9DO$'
M1<+<?_'((8O[?,CB/I_8XCYW6=SGGA?W[^3-!F5W,O %\]J0GS#X6$VL9CU0
MNPMB?<*]C\QT*%SO(WG_GM<A2_QLR!(_F]@2/W-9XF?A%<G3(4P^G1B33UV8
M?!I D=PQ[?]WFL\^SV(HRKT$-,(<?B1EX-07DAN4$OW:>_HY)$\)27,"H"6Y
MG2@K22<V0WQJ,\0F1YT!8GJ0G@P_GJ$/<G97<^?7LT1TFL&5WU#RT:K381=+
MVR*9MP5 :P3GA>XL:7#*.C7,NT^'EP*O6)_WQ[\<'_]R?O++S]_+^-\<1_%I
M,>V=#;!,M[T$%-UB1>L\E:CI6A^?4X"AZQ&5!H3.QHB0]];ED'OK<F+WUJ7+
MO7497CGX=0B3?YT8DW]U8?*O_I4#6HQZ\2W#1?F2;,B13!Z8954N5BM<4+]S
M:0Z'HGU1W1G5O<G]S/LC.D 8_]@0$G57H3MK/-T*8F*?<066KOLB?TUB'%^]
M?25W\5VVV.""@KK,EU7RFE0)+ON,A!#01FV#8BQ0NWZ"X5"2O4/UB*@94F\U
M#"#6X5S0"7DL+[VXY\0DK[=EE:]Q\8!7VRR&FP^BOLB<*::H,6F']T)--P3]
M9DCT#*WYVNG2B<N%$R$]IT=#7"%'$W.%'+FX0HX\ND+DH+S2FO0J8@*@4<#D
M#WFN"B]50L*Y(XZ&6%J.)F9I.7*QM!QYM+28IC DC.)H8F$41RYA%$>^PRAJ
MXX'R%E0*"VI!O&L;D.YM7!=1I&,$\P@YTJB(9Q!O?!HR-.MF2.S+T<1B7XY<
M8E^.PL>^' V)?3F:6.S+D4OLRU'XV)>C(5:)HXE9)8Y<K!)''JT2IBD,"9XX
MFECPQ)%+\,21Q^ )\9::I]2@SNN:*C9_,.!GI9,3IW;.-&Z"&>+] PEC&)&Z
MI^80]@1U31\-B;XXFECTQ9%+],61[^@+S12&^/^/)N;_/W+Q_Q_Y]O]_QA6D
MC=[C@B?9TR)XKU&2TFIWN91Z_Y*G,2Y*7@W/Q:H)(R,R-!+0-131N!X=/>9(
M!K7A'T#\"QHWF7<Q[LP>1>9[8GC(73C$T78T,4?;D8NC[<BWHTT2>HV'=$TK
M#I109&GU@&.,UQ&M7UHD8&O%*UP4Y%J$+O9R[RW8*#8ZNF4Q:GQ\>(<W7T#L
M$ZC^!N_*OA)2FOO@DB+]_;'>JS?"X#*I 6SVYGZJ1_R!W$\6+@QP/_7RTI^/
M8T_U:K5/""E010Q.[VQ^64OC(_H!\J.XOJ(?V3U./H+H5R91ZW)R=8*/O#D9
MFM.)'DP?OB]?X#'(#K46B))N+4A'/L./JOOS&Z.Y24+> VY$*L(<PANO9SFD
M#S17SK6H-'27D<-FVU0H-UH2H;]TG<]0/01JQI@A-DH(B_I00G6']# FA70_
M'P\Q^1Y/S.1[[&+R/0YO\CT>XN,_GIB/_]C%QW\<(-U1Q%<U7JO/A#A6!,W$
M;]%'<N+-4-,M='B+C23=.=//@I:=T2DZNC[#DA+ ?I*,/#-X<%.>E51S**%J
M0?I;D6\WBJ[*PJ6!&27A!N7$*BJ?*#OXT/^ ..I_X+0JQ4]H9#6-JA[[=;]W
MX+#)&:*NY5%0,PS-3! #(3:2[@T3XDH<MR1:-^,(UOG21W6OZQ%HUY+9@O5&
MHGNP (%^RIQ,#4;4:^\O2_[*?;O+'E\P.%FB[*U4P 3GU6V4%#191'WG:%/@
MI?>E^ 112Q&47!1?0>PS2/H.FE<(OL2R@RSOS'#/S!T99GEL[D44OH_OYJBY
MRY;I%@!AM2<3#=E>K'[+\[C\DJ=&Q+SV>3U#]:A(?\K/6)@[()S1L1$,'MCQ
MN0-;#"?];ESV=>Q_3,ABC<ERO<_39/G6>TC4[1'KH+<H>=_K)C*4K6NGUW-F
M@NP[8H=&+TR)U(/C0?(3>5Y51?*TK>CQ6^7H/@(]>"*ZDYE0W>;I8XO/6Y>=
MXGG!_B2//E:'H1=S7_1#HB,WZJ"F:U!DUSZZE(WCQ@@/QY98)3KWSGQ;O>0%
MH"R;81];OK*9L)\V/4,_@^UTZ?:+"R>\ZAB[UF#ZG/-%UL%WI1"N-U&%:W7J
MX#GSU$#")C-#-30PGX_(F.^&0(=9./ZXKCVT/<M\]]1W83_BH6DC4]]-HX1Y
M&AIFXY#Z7AL'>==)I;[WB$KS,+,QPILQG*;$LMI!MX0LILMPGU949-2L(!L4
M="<9RQIF@R 812A\PO%'!Z(&%\72XE]D0RA6I#><75X1>5NWK%1,Q0$&N1NA
M(_4.#XSL3)W%3]O'$H\1O]P*P[P"PH5LVEV\,1*ME=BI ,9*=?8Z^Z2)1H^<
M_HRK+U'J4 D. I>@I>'Q$R!4M#UOA;\&RCR^;B3;\\VV8'7.DCRF"I ^POZW
M(B^--GI^6; !9\Q4.]-KOW)2PA->Y05&O*;PML!A@\A&,L5H8QC+7Z^/J6X\
M$X]=,DE:C0R;B1BPD!8@ Q4ZT5@)]G.\M3!-YF6)J[+?O<XT-=9:ZU</!>;2
M)4#'= NEGHVB6B,YTPHA'!\T0VT3<F8O5H_1=[)L:)@?73L6EX76,<'U[)\^
MTBIEP$NC#P,NM7R%R!=G=*^QD$OZU2#JPT'XY^S%WDU WEYD4ICH]V6Z+8GV
MM%C10W\>QQ 0^OTQOX*J*D4E;&>]H;AB(/@'\X'2L6!E0-[,%4;U>.&JW@ZC
MV_*P'L W_Z&T<*DS-^NWW"%TEK[%N-OZ6Q[4'J^GH>?%U2;5IW8Z%O;2X:V\
M!].M]DG](T&5&A[=^V>_7W7*D+[!7$K[3(6I1_R!4F$L7-"M@;&\]/IV:6L%
MUTPE()-K@M^<M#6-5M:,)44/6A2Q,*(>2+].SJ-8Z"\I>;N&:>3%;5ZHRE]W
MFE(>K?2HTUW2];C4L$VSDV_;RGA;\FKN<O?-&\30M"-W5+O47MCM^4$'QQ3\
M!_;\URB%@+@'<D85">!=PR_F6=S^@=22F67()B@PN<QN,/N3*J%@:!:I00]1
MA3^L5MA\8\"X,W9G2,//4/-EQ)I !'+GA^T>;$I(S G])&;U;H;JB=4)60BF
MAMC<PMX[?N6@.\M"K 2O]]WMS=WU71;C=9:LDB73RL"F0F]JIH>5PFAO6J@P
M!NH,PJQ*?/F*@6JG1>A;;@C5NF4QG&L^GSK),YL64:&72XAY F,Q! \2U:H_
MIKKIC9KN2/1'?S;ADX&U4C<ZM:^1 1SRZ)WZLB&W8$Z>RN1$P801+_/G F/'
MNK5U9R1ZH[J[P6,;(#["A4+5E./.%X_;K(F6!PCQ>%Y!6+0]N)+*@K8FEW9%
M8\J#OO:U).A5>B.M/@,:6'S%)UR]P+4JIF32R'G4"6LNY7^$=.3J*5!6O(U0
M#TL<BDI_((<BI(0L\V*3,PW]2T4TE6LX+HNWZSPV/GY95]3J.T.T-Z*I_G0$
M!$.$.HT<*90%,X@I/G?%QV0) 6. DV[:"KP)18</9M&7YJDL>(4&OV:^KHY^
MEQ$M#O(2RL?\JLC_QL4-)CI]88Q6T#RM4)(A/@ID-[!AWK-QZ)/M.B67&34*
M%,]1EOQO%/)Z'LP)@^5G"!M];9*B^NM3DB7K[=I>8)$W0G^R9D'R3Y3)MK:*
MGI+F1A@35,PBX5A(L]F0ZQA;W#.83V7:<4X.@<8\ I*-(-OGIQ1P["9&C7O4
M@3T>M6HICYE%@$DQFB[IW"(]9B9'K 95LFT4:4U.O1SPN(L>\#I*LO(Z3U-,
MU@9%JJLJ5HZ[?H6QQ"IXG!6O9@,Y'PI)8Z%F,.FQRM/.Q'A!'ZPCZ%>VVF@>
M^M6!.B="*YL1R@V(ZB:+X@'271PL2>((S5<M#-9V%B@,/4-U?1?R/F##HS^[
M>?G_'3I;:2R#M":HW;CMS5W&U8UYEFVC]"%_B]+JS;3#A?[$&B/>.NC^U4U?
MV:!F&OU%>?4 =VA#NESA2P*H)4.@2_II]X>XQHWWBPS;GPHB?(<T#%Z!O3MG
M-01+2Y1'+4(RTT*>&X0'/$;?'8S:4A.6\4>C*B!,<1HY2+V$*;)P9(7?Y&=]
M9@'/8UMOTOP-8_9,$,4R[XF8G,XE-B#W0#?*N1A5O*WJ$J,P<'#<A^&\T%[Q
MN[#5ZP*8QW$":R]*[Z,DOLNNHTU21:G]"&PZ(>CU/LD0[Z<:4 )I;%:Z=")S
M8(3OF-4Q">H"SDG EY8T5^+Q)<K$.U]?HIW5=C]@F&N-Q57/#+$<E(K,35A8
M9JBIXE;/3R2 L2F&?@F$$8SVD FY1GR%RW^*R#>+CTE&G03UF[G'FDL[(=%+
M,C!T%;8 SQ(;0>K[I)]\G_ZF>F&H0!>+%;G!EMRR0?XG7K']Y1KI6 @&DZ'Y
MB,Y7#XCHB+6E(*#6-X(!BDQ',]%S.J$HD\U1*7K#W)N*XJ*'/HH]3*%X$S6Z
MD[6'=%E!&^-V>< PX21-(O86Z #]-Z5\6$F <>Z8D1\)D-PV;J8.SIOVP/ 3
MM=)$JYX4KTW1=>V$\^SLME(T'I\=>.W1:"!JVCI>]W5M7^,][]TNHR= -<_8
M"/7Z#M3!LG6\3P[YB35"W50\<#UDZ0Y_)T[X5+K(IFSR:@84>&-[VR$WC=O6
M1I;5XV=J<'_X7MBD[- ],M]O6>X"1RED-_\6)1G,?9$I2,^F3=UT1M";+8Q%
MIH'3#B=M)P(5:0Y@B]=P8FX+=H0U;FSA,P%L_*<"<!PX0M]$D^[$M=/OR]+
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M2L?$2^C$@"58-Z1D(01SBUCIT5@K>JGW?%<9*H3J(N9MJ>R6,JO:M(.0-\\
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M\38(&@59\=V9RJS54S$^S.8A*?\&E_M7,IL"L/5T,"Y[BK.Q?\OG;K7.Q/#
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M2"V-<;:DV8PE]TNM 5!&#(18$WB-=WXH]PB=D;4+;[16E]V9':(,CW)A2HI
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M(Y='Q0GM1[3^K--9MHU2F.V7*(T*,[8K;4>MFXBU#(>9T)VS:F+6$N4QNPU
M5\K%JG8\S+\G1O6#MJ5@TK6?!9H'2W'3S5WAL)G H3:?#BCFG"@M-)TJ>847
M(K@#R(N#;JF1T*HN(P8!5'68F .,*HR"Q##46  #P3N4G?+3P%H8)6 -9JHK
MSSS&E4AO)'J^N]7DX/8!]JH*'?W=H<#TME"I].FC6ZRSY&E;BN2.)3EUR"*
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M+*CP\S4 TC4.FP[X,S#L9Q_9BNQ&L2U8%,GY@!B'\RG%.)P[Q#B<3R'&X7R
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M3BDX\M0A./)T"MG4IP/<KZ=3<K^>.KA?3Z?@?CT=$ 9S.J4PF%.',)C3,!5
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M7_\>DX&S*GK&5S@J:&I3D4#(EPLX/ STG@80P% T5HX/AOAH2 PGX:)(K28
M"S>8&3K5<B1'/68LWQ=X$R4Q+WW>5+ZP8#]">\0[R,4_0AO.M708S.86FGWH
M^D0/^Q1]3];;'L<S;Q2\#%-KLEV-4D-)L/?2\0#/YO&4/)O'#I[-XRE@A1\/
M,(D?3\DD?NQ@$C^>@DG\>$#\P_&4XA^.'>(?COW&/]2)VTVRV7U4+(HO5010
MJF#U(?>R%2-(3L4C2DI4(, +HOVY)8R,H ((A4AK[R=2=QTZ\R8@RNSQ %?G
M\91<G<<.KL[C*;@ZCP<\68^G]&0]=GBR'D_AR7H\P-5Y/"57Y[&#J_-X"J[.
MXP$A)\=3"CDY=@@Y.9Y"R,GQ -/A\91,A\<.IL/C*9@.CP<8MHZG9-@Z=C!L
M'4\A&?IX@(/A>$H.AF,'!\.Q7P>#WJ0RS^)%]8(+5MGVNK&N&*(Q98L2!9"B
MO1'K/D/7D[,O:0GL-S59^.(U<8A.HH:AOLN6^1H+:Y@9YIH)I4&O9OW03[SG
M.T@7JL*X0=T(TPG(A14!WSTG ZPM)U.RMIPX6%M.IF!M.1F@E9],22L_<=#*
M3Z:@E9\,L&>=3,F>=>)@SSJ90C[/R0"K]\F4K-XG#E;ODRE8O4\&6$=.IF0=
M.7&PCIQ,P3IR,N#=<S*E=\^)P[OG9 KOGI,!UI&3*5E'3ARL(R=3L(Z<#+!2
MGTS)2GWB8*4^"6"E9OHX@'??XX+[*3A@0[(4$S,GS-/WR4<*ATY>+L*1(X Q
MDF4MC(#IVTXD*M(9P!A?OG@.O7^+C=C#O 4B34(B5C835=C:I<%G'NL'40D2
M''&LXHT].$1;>*@IIB/*#TTEL]A(G^Y9WL,,_X6GKOK+%ET9RA9))97OLJI(
M,K)%:Z#P0U>>:E6OKC^O5)X* NER*+[J%M2!A>CKD*66PWLRW N9Y_RYP'3N
M-[A<%@F=J&E-T8Y(]$1U5R3U#:>0])*EG-2.C/!GNNLB'-YES,H+J1::VB06
MI87A28IQR*;EAG"T6!F*OH157X:0K5-DAK,M2*WM@><&J_ITEQ%5; L_+*FE
M^?$ERK35[#J(8Q14# "2ZN0T%RU@Y&7!"W%)<^4.F(K,UE;$4(&2H].FJ%3Z
M H<_UCVS;Q'N]5XZS/KRJ?#6G[[+-N1V_8A?<7IL5WF;107*#/2:(=H/'4]%
MS;50I9-_+Q-\2F37 IT?ON-BF90\J4%2DHSVZ7VJNM+7K:INL#/H()PU'BH'
ME.,/]?RB1UTISD$?"Y%]4;XH 78W7T$%CQ5.H,1%&2*3XS </<1K2R<SCY"$
MUV0*2<Q5SEN,R0QA+S097.98<:DCV+D0[RHEMX5[9?62I6CGCHSP>AY\^+[$
M92DAGLVWU4M>0)%UDUA8EP[:6],MM&',3)#6--9'OT^- 1(;!U0!AN:]M7Y#
MR,! AX[_5I(]'E+MT#(CS',GO"YHK:C.E)7C1DN2S^6L6B/JT+#K:)-44>K@
M=.K6 P%%H(F:X^.@/\5(H1\L[C3K=L-0CGF#>A;O8X$Z#54Z\](8A5K;0.KV
M:%XAZ!'NOC:0H&P;*ZGRW9RW)TW^'55Y8=@+3967LKL 7@J\8O25A$!*W"HJ
MGRB%O#NA]/CX'SBM2O&3]_"3G[^7\;_9ON!SMVN^#SS3K ZII6[C!L'I-4JG
M#=*K)S$L=L> @,"C*04$'CD$!!X%" @$S-^(T+)82:$ )7EM$OW]%1<E4=X7
MJS98<)+9"U"*(<'I( =.E+0,93,N_+Z#IYQDFK*4_AT3XWFB.BEVY:_/Q7";
M%&4%\P0;3I1";2Z3D&E3U+1%T#B@,TDS=4461O+"'FD#(G"/IA2!>^00@7L4
M( +WR_8I9<$XM7-WOLZW675/'@A&(U[=27)PLVX(^H5\^U@)4F3@0'[8]3X@
MEO1H2K&D1PZQI$=3B"4]&A!+>C2E6-(CAUC2HRD@'AP-R*TZFE)NU9%#;M71
M%'*KC@;D5AU-*;?JR"&WZLAO;M6^7"N2#TKVKQPZ#E'Z;.,8^Y&=8!H^'L(3
M9A271TOSKNYD7B'1L:BB=34^V1?C%5^,3^I:%$M15+,<4@<S".R>?\ZK6F@
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MYSH-SMXAV&O38J\+^%IP]@Z(L_IE6NQU"+3Z)3A[!V A7TZ+O0Y@R)?!V3L
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M&+%XVMT)A$Q[^BX*9.-)+V=233Q1'-QCA3*;[J.X?=?-<[75Z:[A+'G=SJ0
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MR** I5[]>?=@RPA,YLPH@JQZ5K@=72SP9195H:=%A"_\@9$4!&$ 'RR6 8+
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ML^0P/-&2J6U1Y- 0@[2:&  7<BY+%PR9 /2JRTI5;ACBH/,ETN3#'&'3D!0
M;4BQ6A/7/^!.Y;$X;[OJ==M5^;!N9/2QA>\Q2>CD?==5K8$'3"%!0%.#I7@>
MX#3(Z-&E'6*24- +'.2_]I&0')TY(RLQF0XK]L WG;B ;;XFVP#8H7C5-J,L
M*E/Z-L8X1 -U@I(@?<=![<<!'$A\ !@#J;:W]>?FL6TVS;H26KH"SQ33((]#
MH1(D;P1)4[G;)JI2GW+HLHDP,Y1QM:H$MM<14L$F^W@I%XPS4C6B!S%FR4:V
M&6WJ)^NL%@:8C?*4-I>A0J R''_>/6Q5X)D*VKGB-B\M7"?!=#%AC4ZGHD64
MP[QXMN4DWVH"-#OO1%]][(M?Q#^@_@7<R/\'4$L#!!0    ( .M1/E6H/UEW
M86@  //,!@ 5    <VEL;RTR,#(R,#8S,%]P<F4N>&UL[;UI<^0XDB#Z?7]%
M;KTO[]E8=59F34]WM77O6NC*5K=2H=%1-3UK:V50$!%B%8.,XJ%4U*]_ $A$
M\ !)' Z"4,IL=SI+$N$.=X?#W>''7__WRS9Z]XS3+$SBOWWSX0_???,.QZLD
M"./-W[YYN/MV<7=Z>?G-__Y?[][]C[_^SV^_??<)QSA%.0[>/>[?G2;;W=TJ
M?'>?HCA;)^GVW?^;;_^_=]^^>\KSW5_>O__RY<L?5N1OLE68XBPITA7.Z _>
M??LM69 O>9IBNN!?WMT7^-T=WKW[^!WY?W_YX_=_^>Z/[Q[N3\E_?/Q8?O(_
M_AJ%\:^/*,/O"-YQ]K=O:I!>'M/H#TFZ>?_QN^^^?\__\)OR+__R0G_0^/LO
MW[.__O###S^\9[\]_&D6BOZ0+/OA_7]]OKI;/>$M^C:,LQS%*PH@"_^2L1]>
M)2N4,TJ.XO6N]R_H?WW+_^Q;^J-O/WS\]OL/?WC)@F]*NKU[]]<TB? M7K]C
MF/\EW^_PW[[)PNTNH@BQGSVE>$U_%B7?4@I^]Q_??T>7^'_H3WY.?SY-XBR)
MPH#2_@1%="MW3QCGW[RC2S_<7AXV03_8/:%TBRCSWM-?O^_]^OW_LHW@SS<H
MQ7'^A/-PA:+,#-_V8G;0OR1':HOO<O+O+8&FCG)[@?=VY* %QIC2(^L![N*.
M8(&?DB@@JNS\MR+,]_=DD8])^KT<U@/?4RS!*7V*LJ>+*/FB3M/#ER7U8%!;
MIAL4A[\SY87BX*3(PAAGDASO^Y@@",/;8KM%Z3Y9WX6;.%P3V8GSQ6J5%'%.
MKJD;0IA5B"5QE5P+"O4+%*8_HJC R?HB),19A2BZ)!='6M#SD!%J'?[B,T99
MD;)S(KD7W<4A!><LS'9)AJ)D38XU^8]50@E9X&"YHW9"2 67_NIZ'2I*E=;*
M@!KE.LEQ=HM7.'Q&C_0K&:3;'T&2FJY]@_9JR/ /P)3879ZL?FTH2LF#U_T.
MZI"5M\P]>I%5 O4/(+7[BARO2C2E]7K]&TCC8[L-<ZX&3MG1V1##7EI/#BT
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M6Y^HUIDF(E#%K>_^\)W)@<$I30:^X=QF$#[C[2-.H8_, *2:X,R=$X,$TS]
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MIGI/APE7QQ1ENR&7 4#SC[L,40G.)]0Z1&5Z5E9EI! 3F?PD)>9/%V7HDZ8
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M*96#[MABD6Y8HTQ5'TO9NGU&#$/SKZ2=S8'WXKR8^D@.[FA.=,BT$?*L 0X
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MXO.%3IS5',K,7H&'W$%SBH)-:+;V]%>78A>/?PWX3FX)L(.C_/+7I+WK/IP
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M$MSE**TU\U)A]"((0O9\D*Q+]([OTE+2.?2]\Q *!/,&">2T=>5-FJPP#EA
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M(L+V2"204HI61F]B>ME>!@33<!U2=53M;$6T-7U';;RNDM\56_)#]B? O+6
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MD8J,?1U*1(NKD*4-;W4-K[RNP9U03UV[T/$0YA =FZ:.;#@^YH',V20_: D
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M]*=0'-"G=V(W8N)TX:S3Z+2''#+( X!1U,-&$#O/WO8V=S6?/I:C\DG/.X3
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MR:WE)/:EQBMILKCH*LVWPJ,FR[C4UTOB_*56S)\A2&[M&#EV2E$,K$6UB_A
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M3DF-F"!2R . 4;2XC2!V#HV]S5W-IUYB5#ZIZH 0&'<Y^&?X,3]&WRR440@
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M1.Y6.$9IF,BJ-_)Q[:B0_SH>D_YU71T02;4V0! '$Z@9-A42#W&VPZMP'>)
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M;H08B%9CR.:VU3I4BK[54*C=I3JBIXC*5;TOI=/RT2%IX$\\0A8 -#M4X4&
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MCK-$8O_0XXXDNT@$SR%M J3%C]Z/Y\F%_KVZ&0M![+"LB/(PWNA,INW_VE&
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M.4("N"'F2IV%'J-PPVBER [AAUX$[,1;!IQ3;OZ@RZVA1+*L97P5/Y2;!#7
M)I-;Z=?6UQCL H5I&2LB;FL9.LINP^S7BQ1CB]V^[>/K@X4T(?? YJQ;ZB>H
MLD/:0W:5X^",-L3!<3!W^13B^]7*IYA[<(/D]>7S<7R'CRH[I(X/M =A$5$O
M;*0I&,9E<=* G-6S]F-"^[)%A+:^Z,H6QAYX49,RD(LH0"12<X3Y)VH!TZ&5
M![27:[&5+.4HZ*P[_ZBR%K5XH@Q$2!(J2;(6$)\@2[(.;?Y,EJ8;9ZQ&"!1H
M4DR)5/E":>,6X$M[9]P>:,)YI!&&%/!(\_PE*XR#[()LBJ*%8AHRK;TP@Y_
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MW&A151ZT=@]EF.IS0<[!4V"&\RYBVBP1]CMRH*%*E7E*,$I1=$E,RI=_XCW
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M87)M82YH=&U02P$"%  4    " #K43Y5;$]S^<<"  "U"@  '0
M    @ %&.00 96$Q-C4Y.#=E>#(S+3%?<VEL;W!H87)M82YH=&U02P$"%  4
M    " #K43Y5$0&TH9^0  !4K   "P              @ %(/ 0 9FEN7S P
M,2YJ<&=02P$"%  4    " #K43Y5&= POL<+  "M#   #0
M@ $0S00 :6UA9V5?,# Q+FIP9U!+ 0(4 !0    ( .M1/E5F'1,C620  !;U
M 0 1              "  0+9! !S:6QO+3(P,C(P-C,P+GAS9%!+ 0(4 !0
M   ( .M1/E7$1>JN\0P  #*6   5              "  8K]! !S:6QO+3(P
M,C(P-C,P7V-A;"YX;6Q02P$"%  4    " #K43Y556^OC8EF  "4;@8 %0
M            @ &N"@4 <VEL;RTR,#(R,#8S,%]D968N>&UL4$L! A0 %
M  @ ZU$^50C<FEU&"P$ N7P- !4              ( !:G$% '-I;&\M,C R
M,C V,S!?;&%B+GAM;%!+ 0(4 !0    ( .M1/E6H/UEW86@  //,!@ 5
M          "  >-\!@!S:6QO+3(P,C(P-C,P7W!R92YX;6Q02P4&      D
,"0!4 @  =^4&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
